<SEC-DOCUMENT>0001420720-23-000045.txt : 20230927
<SEC-HEADER>0001420720-23-000045.hdr.sgml : 20230927
<ACCEPTANCE-DATETIME>20230927160158
ACCESSION NUMBER:		0001420720-23-000045
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		146
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230927
DATE AS OF CHANGE:		20230927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iBio, Inc.
		CENTRAL INDEX KEY:			0001420720
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262797813
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35023
		FILM NUMBER:		231284750

	BUSINESS ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737
		BUSINESS PHONE:		302 355-0650

	MAIL ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	iBioPharma, Inc.
		DATE OF NAME CHANGE:	20080806

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	InB:Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20071210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ibio-20230630x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.3.0.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 9/27/2023 5:26:22 PM -->
      <!-- iXBRL Library version: 1.0.8528.25195 -->
      <!-- iXBRL Service Job ID: be313000-77aa-4105-ba7c-7965b8de084c -->

  <html xmlns:ibio="http://www.ibioinc.com/20230630" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_9TX3NNNRy0W_FzlFVjryTg">12245000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_LvpfSz29Z0-veCoAJrAqsQ">8721000</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityCentralIndexKey" id="Tc_qJvxE-6pbUyNvTldIukVBQ_2_1">0001420720</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:CurrentFiscalYearEndDate" id="Tc_2glO0_FEdkWLG5WBZlQMYA_3_1">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:DocumentFiscalYearFocus" id="Tc_L4fGRKc_UEWjh3u5KVPTwA_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_k0WmJqdSH028QAoInQdBTw_5_1">FY</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_FffZNwmc2E6Z5H9UGIqZPg">12245000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_fxymUTMtv0yzaYqtx0x1Eg">8721000</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityFilerCategory" id="Hidden_W7kAKHbkB0qlIFztIdEZZg">Non-accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntitySmallBusiness" id="Hidden_z5fi3FYiC0Sje7OERl8DoA">true</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" xs:nil="true" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" name="us-gaap:PreferredStockValue" id="Hidden_uFvV_eO1B0iDE-lKD_tAZQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" xs:nil="true" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" name="us-gaap:PreferredStockValue" id="Hidden_xc77VMaqY0C4oB8D5qP6Yg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_PSGT3Zxau0menl4RCH0N3Q">2.39</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_-eod8074fkioAk0b2mm6UA">3.39</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_LuCOlpKQOUuSt-yj6PnmyA">2.92</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_o1v8rmdOQ068c6OAx2PQXg">2.39</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_8u14s749302L6GMFbCXKCQ">5.31</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_do79_3DIF0SwBQdVF3GLSA">5.78</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_C1BZAkhphkSP6NLYZ6XiZg">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_6s-44Ts3DkK4VQjk-RCW4A">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_AI8GxgTdWkG2tUl-e2so6Q" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" id="Hidden_0UtmYiIXKka_hRPj17MXuA">2600000</ix:nonFraction><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_WTIXjTIUo0WsYIlTKeDT7A" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_uabS_NI-Z06ict9nQUkf0w">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_yedw2vciQ0GGT6sdYzn5Tg" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_9YJQTd2bdk-gA4FmiAYIkg">P15Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_0pwc1NvoEE2aEZVFYLQxng" name="ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm" id="Hidden_1lNt1UglOEOd6nh1BKY2Rg">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA" name="ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" id="Hidden_YMSx4gGHzEiJmUbTbVGKZg">P24M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA" name="ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" id="Hidden_SYAPHltUpUekE3X9uPDPUg">P24M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA" name="ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" id="Hidden_CQT6G5UgS0uV_qC3r8ildA">P18M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA" name="ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" id="Hidden_0Ap6AYAnBkSKK9C3lFNv3w">P18M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" id="Hidden_vEQqufD90USP1VGzaUl2Uw">400000</ix:nonFraction><ix:nonNumeric contextRef="Duration_2_20_2023_To_2_20_2023_KDi-T4qNR0iJnz_Le3NQ_g" name="ibio:PeriodForPaymentFromIssuanceOfAtMarketFacility" id="Hidden_sMGyGM4rm0etbg7foCVLZw">P5D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_vDIIL2z8l0Kc9hg2BTNjnQ" decimals="4" name="ibio:DebtInstrumentPaidInKindInterestRate" id="Hidden_HmO8mI3b8UikyAnwMIet_Q">0.0300</ix:nonFraction><ix:nonNumeric contextRef="Duration_9_18_2023_To_9_18_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_WyyCJT9CnEeJevuU_YtSMQ" name="ibio:ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" id="Hidden_v7l5jYByc026hKF0AEadYQ">P1D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_-VsXEX2vkE-Ouo9lo2p2sg" name="ibio:BaseRentAbatementInFirstYearPeriod" id="Hidden_3yjQiksPYkaMOne7lIAO3w">P2M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_m-QTr2a_uU6kouKEDBmRAg" name="ibio:BaseRentAbatementInFirstYearPeriod" id="Hidden_coC25BjKxUC8oCpGfnMVKg">P5M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_NSsLunwOnk-e7VxuFTCjbw">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_SIzvssG14kSIBSMx9LhFKg">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_E34AVy54BU-rs9CUNflyRg">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_tOoXZBADJEadNjNS6JvQtQ" decimals="0" name="ibio:NumberOfDaysOptionToPurchaseAdditionalShares" id="Hidden_sSHbFN61YUW0p-uuiWxmGw">30</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_IJ_L-uKjmUGPDD1rWyktvg" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Hidden_CLcT6POV_06On0uZXB8YcQ">1.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_TBHg74MkiUewy0H-HarEhw" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Hidden_uJKhf1drZEWLizl1NaG14A">0.50</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_VSCcaFQWPEqZ6HuNP22L4g">2.39</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_szGXjMD-xEyf9K1Eh278Xw">3.39</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_KWCju4zEm0OFrF28ztSNUw">2.92</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_g9LgYZJp_E2abMmTXdVUKg">2.39</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_NyTbTzFAwU-jeS3gdyqc7A">5.31</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" sign="-" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_GSNMn7paDkWrRL314FWinw">5.78</ix:nonFraction><ix:nonNumeric contextRef="Duration_12_9_2020_To_12_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_uJ16IRXhB067Ywy6LTJl-A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_LToFWvo-BkiblBBqRkPxFg">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_0OdVFTQWiE-Lr_bsSKBPmA">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_mpImJhbCfEK69FYXeZdXCQ">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_z9rBFPXNl0qc-K8BGo9Big">P10Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_PoQNhovghEC-LFK4CiyRQQ" decimals="0" name="us-gaap:SettlementAssetsCurrent" id="Hidden_jYLIaZRQbkaIs4FnEH9rdg">5100000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DwOwJATaWkOBScq2_qtADg" decimals="0" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" id="Hidden_kXKwXnCsRkauOXx5_TATcQ">900000</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UksXtGeVpEqIW93JXYx-jA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_jBumV3Rkt02i3MRw82WE7Q">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:AmendmentFlag" id="Narr_bpulpr2GX0edOpmjesUgFg">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ibio-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_rZ1rHQ0ZHUSWW77arLucKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_M0zc34V5Q0m5WCVOKFey5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C3bH4V8Ib0S8XH9UELJ_gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_8k_8F3ieCk6zFGf27VtTEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_AZyAVySM7UKPZ8RTjixNPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OBOy6kxRiU-oe0ymEhUYpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_SFHPA8kiYE6ZzTtqaqm52A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember__ZIfD-ddyUWPf60tnoVcmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_gsFictXunUazEpdpJkg4ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3j_LUG_w402t7idvNDSjIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_16_2023_To_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_iUI1PTAMS0mokeLZNB2Fjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-16</xbrli:startDate><xbrli:endDate>2023-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mX_BARMd50iV5vznznteBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_I49KgjiFbkiWuxK9AUMMTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_43N1IQqzkEqJ13LA3fBcnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-07</xbrli:startDate><xbrli:endDate>2022-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mHPAoRsEt0Gat8eBQF4yqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_84atjSQ3lkqV3dHvpF-GGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qeC92PWuXk6kis_CsVZ_CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sN_Hnjg5ykm1YYIBPdZ-vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_GVb0po6fo0GQxDi2ozIWyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rCT3Y6oqDkaJvtijpVT8fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_TEPezL3XWkKqi_B0FPpBFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kAxEI4glK0KksnZbo4Dl-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_K3rvxXz_kEOX2nxI7ySCQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TzGVANYEDkKQtb1ZjhZ9Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QblOI1ljmUWLbXeZ7kzXTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_D0mHT9ezdE2X0uInsc1A0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3umrq38u0aybR_OiS3qMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_FzOe7EM0YEaXLo9qcItmHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_E7yiwtNsC0mz-2dHsOptEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_ygGJi-7VwkSgwUh8hFlAmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_ac-7x3LW9E6Qyh9TSY9ZPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_sM74qrP0cUKZ4Ya1U1gVYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_QgG8WNbPyUmBAvmup53SMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_DhwMK66Jc0W1ZHFYrQtkXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_JqlBsxB3WEy25nmRrsywXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_xtVTtCXFJ0G4QbVCIxGD0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_2Y54sBBMcUylpJ4aaoVljQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9AU5LSHRJ0uhtE7EOzns8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SHgrCz-qZEG92jvNuUFSAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_xCmsPvHt_0-4XRMWv2OvcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ZsC7M5TDO06bqBrcL1vesg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_6_30_2021_uOAx-6C-q0ysOGltI-sj8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rm5qrexyo0mItmFx_ydLbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9bo96afqQUqvQatv96XUtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PlanNameAxis_ibio_OmnibusIncentivePlanMember_joWgB2aWOEyl8YJ2QrOPgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UksXtGeVpEqIW93JXYx-jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_u3o7OY19vkGgjeV5Z4Mo1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nKpGtSGxbEyiWH4EXHdW8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HfFb1iTZDEK4b5gZPeFNew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_a-ruAN-Fp0aT8KVbiaSHbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_ibio_InterimChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HhEQxy6pnUCpQsZ0aKHI-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Mr.RobertLutzMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SVjgzLilBkyuvpaaJZlWoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Mr.RobertLutzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-11</xbrli:startDate><xbrli:endDate>2022-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dpjHIDhP7ESwXkYz03k_Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Dr.MartinBrennerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-11</xbrli:startDate><xbrli:endDate>2022-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2023_To_6_22_2023_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kqjXeqU8mEmZuO4mrfyDSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-22</xbrli:startDate><xbrli:endDate>2023-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_XbzQngOnPkuMI19LjLTR6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_YvKXv6XQlUSg6GU05Ezz1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Mz-O4KcM5kmuLTNfOTFLBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_G3Cg20_u1k-sLeLr-GIKSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_26_2023_To_6_26_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_A3-mdp0Omkera-zLt8EKJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Dr.MartinBrennerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-26</xbrli:startDate><xbrli:endDate>2023-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_4UJTvMaPYUmEsDKWssS5fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_igEZn9PhVEiylIxh6caSLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Dr.MartinBrennerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_10_2022_To_11_10_2022_srt_TitleOfIndividualAxis_ibio_Mr.IsettMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lgDtxmNOk0-1j1MhUErEmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Mr.IsettMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-29</xbrli:startDate><xbrli:endDate>2022-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_N5IDTAkcGkqXFW4wZwmQCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9Cz54lZIsEqkhtb-zVdBsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_XZG8-Y3yAUK2kmzzd5QisA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_VGPTPTFClUWUEjRTn7IMzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_sbtMBgPfE0GQWHaJX1zw5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CSnFR5tK_UmMcPFIliPY2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ibio_IsettMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_e88Xq6AsD0WbXCbo4ZpVbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:IsettMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_BoardOfDirectorsOfficersAndEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_3f1m_cPO-0Ki-AKnAQsaNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:BoardOfDirectorsOfficersAndEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_9_2020_To_12_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_uJ16IRXhB067Ywy6LTJl-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-09</xbrli:startDate><xbrli:endDate>2020-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_9_2020_To_12_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_TS5Xb__b0USUWuxhMopskw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-09</xbrli:startDate><xbrli:endDate>2020-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Ng3EGcHwDUSSHJ0vzePC6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_PoQNhovghEC-LFK4CiyRQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_3_2023_To_9_26_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_UNfYWTucIEGpRkg5uUnc2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-03</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_E1rZVhR8okSSqW6gfMvzJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_KNMSVlZ63keio6WMZ-FPmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_m5xJ-VdP5EGewGg_SkDIbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j-fx3hLA50uNFaaqQkekIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_pojHavUPcEas5qPQYCAHRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_TZN5AIYJp0-6KjjZaFqg6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_56vZG9jEekWgY4y74laSeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_F9D1CtdJIUGZ_NarVuJabA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_9NVLwycAS06AXqdN0JVz6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_w4qDIzxgXUiJo3l8Fvo9Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_lYOxtlA7SECAFRsqcF-SfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_WTIXjTIUo0WsYIlTKeDT7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_yedw2vciQ0GGT6sdYzn5Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_-LP9qePrKEKSRn6V__dvKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_3cd_ntn9tk-FS9Dj6nY5OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_eQjpKMv4a0WIG8KhXwtaAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_6o-7lqfD3E6XYI9oPMTzMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_0UI15QK8_EKkODArRfq0rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_n8A-vIkPIk-D3alQ6Tlk4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_rnZo30pQDUukbPb7XP4wQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Eqhm6X_g3kW4sI5yXUWYdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sF1HRLA4G0Wy2T1ygJ69aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_-HXRfzZt7EeeqOAod_TF_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_AI8GxgTdWkG2tUl-e2so6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-30</xbrli:startDate><xbrli:endDate>2023-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_10_2023_To_2_10_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_GuaranteedAuctionProceedsMember_atQz6mAuyUK6kUqxRjzLBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:GuaranteedAuctionProceedsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-10</xbrli:startDate><xbrli:endDate>2023-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5qaPdrZ830G5d8zR_8zrkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_t8lePepQ2kKL5ThSHCVZjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_l9rVfdViGkK2f-fdYObPPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2023_To_3_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_GhYBtnMX2kWlAFeWO0dmuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-17</xbrli:startDate><xbrli:endDate>2023-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2023_To_2_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_KnJIktsPp0-EQ6aH9Z2wWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_QFHntIxLBEO846_F3J6DgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_HvdB1ZWYLEujtiGbTKuLOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_1C24-uZb10SvLErWVqmo3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_-uulEswf2EOU3Yjcrnq5ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_8uq-EWtWF0WoADmNPR7Tfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-31</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_xoNlaRhK6ku3VdMk_jLIIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-23</xbrli:startDate><xbrli:endDate>2017-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_olBr2CcxoUyuzZH0lS6s3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_9whzlfUgsUeBm5EBeEsgEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_rv5XUgdp7EGs6FYMQwZaCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:PppLoanCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_0YcPqwpOjkuyZyE_8SFtfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_j1xUG58p10iMMcwJJ-ZzWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_pjd-weRrSUC1EbGtOeMjCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_srt_CounterpartyNameAxis_ibio_EasternAffiliateMember_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_UjXKotGel0yQY9BFBXctgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:EasternAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_XdqoL_rkxkCM1xpi2PlAeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:PppLoanCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_26_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_dm18S2OvJ0Sy2-xaPQ94EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_2umbQoBSEk60AzYnxpGopg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_OXGEMBaf90uzpnugexjTyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_1SxKBjeXXku5LCaQyLli3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_SecondEasternAffiliateMember_DgnY7nozKk6LLsBoViwjXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:SecondEasternAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_14_2022_To_8_14_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_TbCIxSxD_ka6X8lcCqL-Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-14</xbrli:startDate><xbrli:endDate>2022-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_MeaCIqKJOEawOzUh7Pp-PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_tLpytXewLUGWxGC9zN2FKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_YzbY9GLiGE2-ktZqZfwryg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_z9FbEXk9g0ql9OZ20V-ejg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DA4mNb1HCESUnEtjTHgS3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_OUSYNzx-3kmj7vrVQcR-fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_6Fl1dC8ctUaESD30gx10sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bdlOYYhGck24BhiEx8F8Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_G00b6C-z9kKKm4HpP4CcHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2008_80RUzZ4LGECu9HWLvLycUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2008-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lw4nMpzng0qzbfkprZhULg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember__jVFiqLstUOWmy568nqUUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_2RUbpio7FEeipqf0K7mQCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:DateOfAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_nz1JdBks80Cs0AMppzhnXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_CU79tDBZJ0-os-9D7HXbbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_CreditAgreementWithWoodforestNationalBankMember_2dAEJVyuAUOVNF-AXyg-lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsNotSoldOnOrBeforeDecember12023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CreditAgreementWithWoodforestNationalBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_ip8TzvFk80eYolQL5zegdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_X5uA0-qoeEeIkEVG5KZZjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Wllg_X7FK0iPGlaGUB08bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_gu1NRcCf3UK-cY9abE950Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_kGxSOxgACUGRePau63QWAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_r68Y0EmbuEeMR0WnlD99_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RSn4_RfPj0SPtSJMEmhzUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8w4IUbsDIki_jJ-9mVfRmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8Im5yjRmNUarH6CaeVLVOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ldHkHQ1HnEC1Bn3XAgpiXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_7hZGnl4YaECwuy-_woxKIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_br7oNpaVRECbzfYrlkkvkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_O9UHa1q5u0uVaR1ViiQn-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_TBHg74MkiUewy0H-HarEhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_iwp_hRW6o0erhC__pkGDFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_IJ_L-uKjmUGPDD1rWyktvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_Zw6WafGCsUCnHKMzdWedpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_oMAsA2QZvk2xKNG3oHvjzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_m9_bmICRfkK3AwOGcAYudw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_i1SOU2raCEu41QFjJywLPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_6d6Raa3cZUiRPuWmRc-WaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_uUlIkQW2oEq35oK92beemA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_ibio_RubrycTheraputicsInc.Member_a0DlE4N_I0GxjgfDV7eBFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_UDQEaykRk0-p2VWL-WDKDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_JyKBqBRPyU6zhBnwdkIH9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionFixedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_qGJJOjg520eitr0OnzDv_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_03q0Za05A0K0e2L2ZORfzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionPrepaidExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_aQUPv9G7qESYPE20QdAeDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_s69drdBtfkiXxiX5xIaWhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_3_2022_x45ryYnU3UWbXnPzJBxuug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_2Unp8yCqvUWviC4g1sxLBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cUS-0Y50wkGSIGh6RCynOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_vveLDkXdfkmYnuPBTD5qQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Ak8TEYVQm0SAkhapZ3V0_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_17hKRS8vdUK0th6qBY6JZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_OAl5YM-9vUiYev8izSQcBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember__JoTwj7JekqGkccr8jaLLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-cLI1L4-PUeoHAyAedVjig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_L1pakgn-HEqXSQrFTkRD1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_lUPOZKyWjkGiiwoG4yyWyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7JFoPwEFAEm9j_JAvuBOqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_F6t0DfzkFkyMeMWVv6D4Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_18_2023_To_9_18_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_WyyCJT9CnEeJevuU_YtSMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j4x0PspL1UuXk5bJ7v3ZFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_GMLt8Z0kCUWGHfk9AJSpeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_0ZWSZA9Kr0KCCrEbl4ckpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_X8mbSSFy70ubOrSPbND4oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_aSOPBLDfl0qZrWSm0hH1mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_TkpAIuZ6B0q3R1zaoy1iDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HptY7B29EUeK8ToPssBmJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9KRNjiJqDUK-i_ivBqGgvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QsKwNCPfTEOZYuRBlUxk8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_20_2023_To_2_20_2023_KDi-T4qNR0iJnz_Le3NQ_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-20</xbrli:startDate><xbrli:endDate>2023-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_utNLNmYSRU-7gHrqgVWwQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_20_2023_To_2_20_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_kHwI2oYS2kqmmWDijalKcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-20</xbrli:startDate><xbrli:endDate>2023-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_49sQrs8MA0CP9gEl5c6S8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_ExcessAuctionProceedsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_2ZiYX-syC0ai3JUx-2X5gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ExcessAuctionProceedsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ibio:AuctionSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-30</xbrli:startDate><xbrli:endDate>2023-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_ibio_FourCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y8MwivQ9ekC2NZNY1aglKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ibio:FourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_ibio_EightCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_6zllRl-74kWHjjUok5X3fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ibio:EightCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_sAVoKqkVwEuYlSh556L0JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-23</xbrli:startDate><xbrli:endDate>2017-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_tOoXZBADJEadNjNS6JvQtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XheyQ-Fl9UOlWW6gNyl5VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_1_2021_94fR0DLTmEC12g7MPaQqxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_U6Pc1fTlZUCT-CsKaG5_qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_oxMyEE3vMkKthpi_lTkUeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Lh5bPHn7wEyfg1z7EBU_sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_ushJsRuZQEyiUOY_3efaUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:PurchaseAndSaleAgreementWithMajesticRealtyCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cDhv992H80uLjlrOUmMXpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_Nj1rBi5mf0-4KTZgTQfTXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_yQtckMjz-Eqm8XRVYD1YnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibio:IbioCmoPreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_12_2022_To_10_12_2022_L-VOkowDDUifCXu94CAHuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-12</xbrli:startDate><xbrli:endDate>2022-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_12_2022_JPfG9ZEqqUa0LmbfHdCHIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_nbd9NMQisEiyfXHpBgaVUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_7qBiEha-vECXgWze-i-g6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_LDEVyL3h-0GVW39rjQJBaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_dZg1WhqNY0uE1A0c9lHl3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_i3ZFj12p9UazqqscbySntw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldOnOrBeforeJune302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_vDIIL2z8l0Kc9hg2BTNjnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_nNBE8O_Yc0GrXHryQ3ARjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ni7O9yqrp0G3jZAhtH1cdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsNotSellOnOrBeforeDecember12023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_0UIjDWk4GkapKTIJmMsJJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldOnOrBeforeJune302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_9TjCBbgA7UyTlQwWmTS87Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_GcE4nP69ekilykVs1dNbZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_EbZx7U23KkqqedJKnH3P9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_GmkcutYho0qIygUE-r1Kyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_bMRwgJhi-EeZTQrY-DJ9ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_N0d1OE5sOk6a6vFBAShgiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:OccurrenceOfSpecificMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_4NB7YEQHAUqVr8MzcB_kuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_NCgEbLSz3ky2W-1HFoSejQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_CQLMvmW4IEONf8twopcH1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:PrincipalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_0pwc1NvoEE2aEZVFYLQxng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:NoBiosimilarProductHasBeenApprovedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_YH7c7zxS4Um37Nlh67R2QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_65MqqZL2kUWg5zU9Y4i3kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_Dw9k-bulX0-p0mYFE2o_Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_odmv-ki5qUWWcb8GBFn57Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Fy-Gf6u-0EitjXayqqPTHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DwOwJATaWkOBScq2_qtADg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_xiBf2oc6W0C50iTxTcBcmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember__8CY_8OqkkmBwgmzP9GZVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_gQzJcEQS6U-ffQ0wp3xFOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedLegalFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_-VsXEX2vkE-Ouo9lo2p2sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_m-QTr2a_uU6kouKEDBmRAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_90XItF3zBE20jmvLFm1lDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ibio:AuctionSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_dj-dsQcEtkq53NmB8lZZ7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-16</xbrli:startDate><xbrli:endDate>2022-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KaGEDjN0e0GNLqwZeqxNuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfOutstandingPrincipalAmountReducedTo10000000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_JHTUWvDAy0mSeOtQy7guzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AMSxbpHjr0eHHzhd2SU4ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_PideCfI-jEiSzj_q8lGFBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lIakFT-JPkmRV8rez2kjQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_UWTbx3EXRkCgwv1m35o82A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_Dv8esl-yyEqZRtO2EUMxYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_26_2023_3j1VawjkGU6vNhxNJ-WHFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_acre_scgUJO-cMUuybvEVKZVJgQ"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_position_oflWAv0coEqkT6ZpEJ9RSQ"><xbrli:measure>ibio:position</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_item_hCBMRpViQ0aEEJdOwEy49g"><xbrli:measure>ibio:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ"><xbrli:measure>ibio:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_customer_bk92zj7mYE-AcFFVra0SUg"><xbrli:measure>ibio:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_DabM02qyekqEwyzN94-Wtg"><xbrli:measure>ibio:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6ca10d68_cf2b_4628_bc5d_bedf2d8988b2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:DocumentType" id="Narr_pW0EZhbHFkqvJOLQrUdUCA"><b style="font-size:9pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><a id="_0b0f02de_ac57_44af_83c9_232875649b59"></a><a id="Tc_pBXg_n0AB0SMZqfN9kO9Sg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.05831909%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:96.6%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:DocumentAnnualReport" id="Tc_rc47N1-AYEmyIO_PVcTsuA_1_1"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">For the fiscal&#160;year ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:DocumentPeriodEndDate" id="Narr_kcAg6BFwmkm80vbYc92u-g"><span style="font-size:9pt;">June&#160;30,&#160;2023</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_70f8d103_4cb5_4784_991a_fcb6db92c705"></a><a id="Tc_ZecBmni6vEWR2_efonQxBw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.05831909%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:DocumentTransitionReport" id="Tc_DWKCj03ISkii02eAoDG7Bg_1_1"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">For the transition period from ___ to ___</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission file number </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityFileNumber" id="Narr_r_rEuqJ_4E2S-YFqsM5oqw"><b style="font-size:9pt;font-weight:bold;">001-35023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityRegistrantName" id="Narr_92V9bpFdwUWJPhjCtBmLXA"><b style="font-weight:bold;">iBio,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_d4830278_2f25_4dc3_9aa5_02e954e58148"></a><a id="Tc_RLGC8c0U5E2JHMmbbPsBRQ_2_0"></a><a id="Tc_dWAY__PmRkmXJkkNFwHhRw_2_1"></a><a id="Tc_cjSZS6vNokKLZIxyuGSZaw_4_0"></a><a id="Tc_vp58Gz7niEKHySknJxPnGg_5_0"></a><a id="Tc_FOaLwrhdqkGyy5eRCj6u5Q_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_qt4TZS3q8EStkl0BzJ6IuA_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityTaxIdentificationNumber" id="Tc_ybYlvHh2RkCJPpkWZEARzA_1_1"><b style="font-size:8pt;font-weight:bold;">26-2797813</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityAddressAddressLine1" id="Narr_CZy8GWqa10KmTE3VzUTC0Q"><b style="font-size:8pt;font-weight:bold;">8800 HSC Parkway</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityAddressCityOrTown" id="Narr_oAAwg509lkec6UOdU8B7WQ"><b style="font-size:8pt;font-weight:bold;">Bryan</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityAddressStateOrProvince" id="Narr_3JkCyJ0yS0uqt1zv2E1U3A"><b style="font-size:8pt;font-weight:bold;">TX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityAddressPostalZipCode" id="Tc_cV_Ol7zKtEGfMr1VaHXGBQ_4_1"><b style="font-size:8pt;font-weight:bold;">77807-1107</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:CityAreaCode" id="Narr_fQE2xkEYrki2w5gBucwp7g"><b style="font-size:8pt;font-weight:bold;">302</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:LocalPhoneNumber" id="Narr_kk7upLdpcEe4WFXn5ObKvg"><b style="font-size:8pt;font-weight:bold;">355-0650</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_802b3962_d3ed_47dc_8b4b_eb7610987190"></a><a id="Tc_iH7_bzXQ9EyNwx_OaLFD4Q_1_0"></a><a id="Tc_VvObqsIMU02Koupf7Pa3ww_1_2"></a><a id="Tc_N18FXzVYrEOfMAltR5IEPw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.95%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:Security12bTitle" id="Tc_nacG919HZEOBctgWDgNSoQ_2_0"><span style="font-size:8pt;">Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:TradingSymbol" id="Tc_9fTlfcsHPUKxllLJMnme9A_2_2"><span style="font-size:8pt;">IBIO</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:SecurityExchangeName" id="Tc_JbtEXcJlS0KbXjeyKMydLg_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:&#160;&#160;&#160;&#160; <b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes </span><span style="font-family:Times New Roman;font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_XkQ2OFCdW028NxqBDHVRiQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:Times New Roman;font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;&#160;&#160;Yes </span><span style="font-family:Times New Roman;font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityVoluntaryFilers" id="Narr_PMfN4ef8R0qRica_5jUOHg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:Times New Roman;font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityCurrentReportingStatus" id="Narr_yfS1EzCa5UqsykuwnN1X_A"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:Times New Roman;font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> No </span><span style="font-family:Times New Roman;font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityInteractiveDataCurrent" id="Narr_FoAaIFaXLEeYVoQBjM4Xqg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:Times New Roman;font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> No </span><span style="font-family:Times New Roman;font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p><a id="_9b4ab6e4_33ce_4043_aa7e_b8f16cf47607"></a><a id="Tc_VxUrFP41PE6HHh3Jp9wprQ_1_0"></a><a id="Tc_2XWWC18EWkW7c51BRD54sQ_1_1"></a><a id="Tc_vYc5dXZVVkKPv2d3abeY7w_1_2"></a><a id="Tc_-xZ-lWAux0G3vPhTEbxy8g_1_3"></a><a id="Tc_-ktbQfxIpEa3OprQ8s188Q_2_1"></a><a id="Tc_3lao9-zOW0KOX11zD7aqIQ_2_2"></a><a id="Tc_CIMLtFEz_kWlJe-0ju6p6Q_3_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9723;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9723;</span></p></td></tr><tr><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_W7kAKHbkB0qlIFztIdEZZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Non-accelerated filer</span></span></p></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:Times New Roman;">&#8999;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_z5fi3FYiC0Sje7OERl8DoA;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;font-style:normal;font-weight:normal;">&#9746;</span></span></p></td></tr><tr><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityEmergingGrowthCompany" id="Tc_lEHQF680B0GxhIV7CQu1bQ_3_1"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <span style="font-family:Times New Roman;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;&#160;&#160;<span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:EntityShellCompany" id="Narr_AG2FJFWPoEeR2Gq_dq27hw"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:Times New Roman;font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_12_31_2022_Dv8esl-yyEqZRtO2EUMxYg" decimals="0" name="dei:EntityPublicFloat" id="Narr_6YnJz-wE9kaaiymYMXmGXQ">5,435,812</ix:nonFraction> as of December&#160;31, 2022, based upon the closing sale price on the NYSE American of $0.44 per share reported for such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_9_26_2023_3j1VawjkGU6vNhxNJ-WHFQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_aWJf8B4Qjkazrwlayk9GAg">27,586,499</ix:nonFraction> shares of the registrant&#8217;s common stock issued and outstanding as of September 26, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">DOCUMENTS INCORPORATED BY REFERENCE:</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Certain portions of the Definitive Proxy Statement to be used in connection with the Registrant&#8217;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6d31dfac_7fcd_4bfa_915e_976cea4ca065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">IBIO,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Part1"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:7.99%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1A"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1A"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1B"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1B"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_765972"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_765972"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Part2"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7_Management_Discussion"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7_Management_Discussion"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7A"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7A"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9A"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9A"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_9633"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_9633"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item 9C</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Part3"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Part4"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">94</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">94</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e94ee4a3_02d0_4eb0_97e1_7436b3a9dc30"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless the context requires otherwise, references in this Annual Report for the fiscal year ended June 30, 2023 (this &#8220;Annual Report&#8221;) to &#8220;iBio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms mean iBio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain statements in this Annual Report, including, without limitation, statements under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; include forward-looking statements as defined in Section&#160;27A of the Securities Act of 1933 (the &#8220;Securities Act&#8221;), Section&#160;21E of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), the Private Securities Litigation Reform Act of 1995 (the &#8220;PSLRA&#8221;) or in releases made by the Securities and Exchange Commission (the &#8220;SEC&#8221;), all as may be amended from time to time. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the &#8220;safe harbor&#8221; provisions of such laws. All statements contained in this Annual Report, other than statements that are purely historical, are forward-looking statements. Forward looking-statements can be identified by, among other things, the use of forward-looking language, such as the words &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;potential,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; or &#8220;scheduled to,&#8221; or other similar words, the negative of these terms, other variations of these terms or comparable language, or by discussion of strategy or intentions. Forward-looking statements are based upon management&#8217;s present expectations, objectives, anticipations, plans, hopes, beliefs, intentions or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements, including the risks and uncertainties set forth in Item&#160;1A of this Annual Report and in other securities filings by the Company. These risks and uncertainties should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. As such, no assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this Annual Report is as of June&#160;30, 2023, unless otherwise indicated. The Company does not intend to update this information to reflect events after the date of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Copies of this Annual Report, our Quarterly Reports on Form&#160;10-Q, our Current Reports on Form&#160;8-K and our other reports filed with the SEC can be obtained free of charge as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC on our website at <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">http://www.ibioinc.com/</span> or directly from the SEC&#8217;s website at <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">http://www.sec.gov/</span>. Our website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bb97b9a2_3a0a_4ca8_94d6_d858ebd9a046"></a><a id="Part1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;I</b></p><a id="Item1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1. Business.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (also referred to as &quot;we&quot;, &quot;us&quot;, &quot;our&quot;, &quot;iBio&quot;, or the &quot;Company&quot;) is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, iBio made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. (&quot;RubrYc&quot;). This acquisition commenced our transition to an AI-enabled biotech company and led to the divestiture of our Contract Development and Manufacturing Organization (CDMO) business. This strategic decision allowed us to focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key features of iBio&#8217;s technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. &#160;Another integral part of iBio&#8217;s technology stack is the machine learning (ML) based antibody-optimizing StableHu&#8482; technology. When coupled with our mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio also developed the EngageTx&#8482; platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of our antibody products. By incorporating EngageTx into iBio&#8217;s own development initiatives, the Company&#8217;s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to our potential partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">iBio&#8217;s scientific team, composed of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in our San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows us to quickly translate scientific discoveries into potential therapeutic applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Artificial Intelligence in Antibody Discovery and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company&#8217;s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Key Achievements in Fiscal Year 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Transformation to an AI-powered biotech</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completed construction of a state-of-the-art lab and commenced operations at San Diego research and development (R&amp;D) center.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Acquired substantially all of RubrYc&#8217;s assets and integrated key RubrYc AI team members with iBio&#8217;s existing ML </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">biopharmaceutical </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scientists.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Epitope steering AI platform patent issued with broad set of allowed claims.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filed five provisional patents for the Company&#8217;s PD-1 agonist antibodies, chemokine receptor 8 (CCR8) antibodies, epidermal growth factor receptor variant III (EGFRvIII) antibodies, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">anti-MU16 antibodies, and TROP2 antibodies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Developed next gen T-cell engager antibody panel EngageTx.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Business Development</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Forged research collaboration with </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">National Institute of Allergy and Infectious Diseases, a component of National Institutes of Health</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pipeline</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advanced IBIO-101 into IND enabling stage</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expanded pre-clinical pipeline with MUC16 and TROP2 bispecific</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio is a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of discovery. Our core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through iBio&#8217;s innovative platform, we champion a culture of innovation by swiftly identifying novel targets, forging strategic collaborations with the goal of to enhancing efficiency, diversifying pipelines, and accelerating preclinical processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, iBio&#8217;s groundbreaking EngageTx technology enables us to precisely target bi-specific molecules. With the ability to navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release, our goal is to enhance agility and bolster preclinical safety assessments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our strategic approach to fulfilling iBio&#8217;s mission is outlined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Elevate Epitope Discovery:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> iBio is one of the leaders in the field with our patented AI-engine uncovering &quot;hard to develop&quot; molecules. Our unparalleled epitope engine stands out by allowing the ability to target select regions of a protein potentially removing the lengthy trial and error out of mAb discovery. &#160;This capability can improve the probability of success of drug discovery while at the same time, can reduce costs commonly caused by having an iterative process. iBio&#8217;s epitope engine, is engineered to match its target, refined for stability and optimized for water solubility; allowing us to identify new drug candidates that have failed or have been abandoned due to their complexity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Capital efficient business approach:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> iBio&#8217;s strategic business approach is structured around the following pillars of value creation:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Strategic Collaborations</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: We have leveraged our platform and pipeline by forming strategic partnerships. We &#160;aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, rich array of fast follower molecules within the Company&#8217;s pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into our, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Developing and advancing our in-house programs cost effectively</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Clinical advancement is crucial for drug discovery. We are actively looking for opportunities to progress our internal preclinical programs, with a focal point on oncology, steadily reinforcing our pre-clinical pipeline.</span><span style="color:#374151;font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;background:#f7f7f8;"> &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tech Licensing in Diverse Therapeutic Areas:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In pursuit of adding value, iBio is exploring partnerships in diverse therapeutic domains such as CNS or vaccines. Our intention is to license the AI tech stack, extending its benefits to our partners and amplifying its biological impact and insights. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This strategic approach enables us to capitalize on the value of our meticulously curated data while empowering collaborations and innovations, while at the same time allowing iBio to focus on both the platform and our core therapeutic area, oncology.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Focused Investment in advancing the platform:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> iBio maintains a focused commitment to invest in our platform, continually unlocking the potential of biology through AI and machine learning. &#160;The pinnacle of being on the forefront of Machine learning advancing algorithms, and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In essence, we believe that we are sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:214.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AI-Technology Platform </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio&#39;s technology stack is a multi-layered, AI-powered system designed to significantly enhance the probability of success to discover and develop antibodies against hard-to-drug pathophysiologically relevant proteins. This platform comprises four key components, each playing a crucial role in the discovery and optimization of precision antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing us to engineer antibodies with high specificity and efficacy. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing StableHu AI technology, coupled with mammalian display technology. This combination speeds up the Lead Optimization process and potentially minimizes downstream risks, with the goal of making the overall development process more efficient and cost-effective. Finally, our EngageTx platform forms the fourth layer. It provides an optimized next-generation CD3 T-cell engager antibody panel characterized by a wide range of potencies, Non-Human Primate (NHP) cross-reactivity, increased humanness of the antibodies, and retained tumor cell killing capacity with reduced cytokine release. &#160;Each layer of the tech stack is designed to work synergistically, enabling us to rapidly advance antibodies from concept to in vivo proof-of-concept (POC).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230630x10k001.jpg" alt="Graphic" style="display:inline-block;height:214.4pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Figure 1: iBio&#8217;s Technology Stack</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AI Epitope Steering Technology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Epitopes, the small regions on large drug target proteins, play a crucial role in eliciting a desired biological function when targeted with antibodies. However, traditional approaches to epitope-specific antibody discovery often face significant challenges. For instance, dominant-epitope antibodies, which typically exhibit low or no efficacy, can overwhelm traditional discovery methods. This inundation can make it difficult to identify and isolate the more effective antibodies targeting less dominant epitopes. &#160;Additionally, these traditional methods often yield low or even zero discovery results when it comes to high-value, therapeutically challenging epitopes. These are the epitopes that, despite their potential therapeutic value, are particularly difficult to target due to their complex structure or location on the protein. &#160;Another challenge lies in the limited availability of epitope-stabilizing immunogen scaffolds suitable for epitope grafting. These scaffolds are crucial for maintaining the structure of the epitope during the antibody discovery process, and their scarcity can further complicate the discovery of effective antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio&#8217;s Epitope steering technology is designed to address these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, we believe we can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of our antibody discovery process. &#160;iBio&#8217;s AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from na&#239;ve or immunized libraries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The application of engineered epitopes extends to a wide array of complex and hard-to-drug protein structures (as depicted in Figure 2). This broad applicability not only has the potential to unlock high-value targets in the field of immuno-oncology (I/O), but it could also be transformative in various other disease areas such as immunology and pain </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:211.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">management. Furthermore, the potential use of this approach in vaccine development could open up new avenues for disease prevention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k002.jpg" alt="Graphic" style="display:inline-block;height:211.65pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 2: iBio&#8217;s patented epitope steering technology</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Na&#239;ve Human Antibody Library</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, iBio has extracted a diverse array of Complementarity-Determining Region (CDR) sequences. Subsequently, iBio has meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from our library.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">StableHu</span><sup style="font-size:7.5pt;line-height:100%;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;">TM</sup><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> AI Antibody-Optimizing Technology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Antibody optimization is a pivotal step in the development of therapeutic antibodies. It refines an antibody&#39;s properties to enhance its efficacy, safety, and manufacturability. This process includes humanization, which alters non-human antibodies to mimic human antibodies, thereby reducing the risk of immune reactions when used in therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:198.55pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">When paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k003.jpg" alt="Graphic" style="display:inline-block;height:198.55pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Figure 3: StableHu</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">TM</sup><i style="font-style:italic;"> Antibody Optimization Technology</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-variant:small-caps;font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EngageTx CD3-Based T-Cell Engager Panel</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CD3-based T-cell engagers potentially offer significant clinical benefits in cancer treatment. They have the potential to effectively target and eliminate a wide range of tumor types, including those resistant to other therapies. By recruiting and activating the body&#39;s own T-cells to specifically target cancer cells, they can overcome some mechanisms of immune evasion, potentially leading to improved patient outcomes. &#160;However, first-generation T-cell engaging bispecific antibodies often face challenges related to safety and efficacy. They can cause severe side effects, such as cytokine release syndrome due to overactivation of the immune system. Additionally, they may lack specificity, which can lead to off-target effects and damage to healthy tissues. The lack of non-human primate (NHP) cross-reactivity also prevents safety assessment in higher species.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To address these issues, iBio used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized our StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows us to pair the panel with a wide variety of tumor-targeting antibodies. &#160;Importantly, iBio was able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to our StableHu technology, reduces the risk of immunogenicity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:190.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Furthermore, our StableHu technology enabled the Company to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k004.jpg" alt="Graphic" style="display:inline-block;height:190.9pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Figure 4: CD3-Based T-Cell Engager Panel EngageTx</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">TM</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-variant:small-caps;font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Modalities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Epitope steering, a technology iBio is pioneering, has the potential to positively impact various areas of medicine. In the field of immuno-oncology, it can be used to develop antibodies targeting specific cancer antigens, potentially enhancing the efficacy of treatments like checkpoint inhibitors and CAR-T therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The technology also holds promise in the realm of systemic secreted and cell-surface therapeutics. Here, epitope steering can be applied to the development of antibodies, circulating immune modulation factors, secreted enzymes, and transmembrane proteins. This could be particularly beneficial in treating diseases such as heart failure, infectious diseases, and rare genetic conditions. &#160;In the context of localized regenerative therapeutics, epitope steering could potentially be used to develop treatments that target specific damaged or diseased tissues. This approach could be particularly beneficial in the treatment of cardiovascular diseases. &#160;Intratumoral immuno-oncology is another area where epitope steering could make a significant impact. It could potentially be used to develop treatments that alter the tumor microenvironment to favor an immune response against tumors, potentially enhancing the efficacy of treatments that use immune-stimulatory proteins. &#160;The potential of epitope steering extends to cancer vaccine development as well. The ability to target specific epitopes could be beneficial in the development of vaccines, particularly those that aim to increase the number and antitumor activity of a patient&#39;s T cells. &#160;Finally, epitope steering could be used to develop treatments for a wide range of diseases, including those in the immune-oncology space, immunology, pain, and potentially in vaccine development. This is particularly relevant for complex and hard-to-drug protein structures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pre-Clinical Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">iBio is currently in the process of building and advancing its preclinical pipeline. The focus of this pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging iBio&#8217;s technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:172.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">on the learnings of competitors, iBio&#39;s programs are primarily adopting a fast follower strategy. This approach allows iBio to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k005.jpg" alt="Graphic" style="display:inline-block;height:171.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Figure 5: iBio&#8217;s Preclinical Therapeutics Pipeline</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Immuno-Oncology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;">There have been notable advances in the field of oncology in recent years, and arguably none more important than the advent of immunotherapies. The Company has established its own AI drug discovery and drug development capabilities in San Diego, California, has built a pipeline of nine immuno-oncology programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IBIO-101</span></p><a id="_Hlk83419975"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In August 2021, the Company signed a worldwide exclusive licensing agreement with RubrYc to develop and commercialize RTX-003 (now referred to as IBIO-101), an anti-CD25 monoclonal antibody [mAb]. In September 2022, the Company acquired exclusive ownership rights to IBIO-101. &#160;IBIO-101 is a second-generation anti-CD25 mAb that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T [Treg] cells to inhibit the growth of solid tumors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Targeting depletion of Treg cells&#160;to control tumors emerged as an area of interest in oncology over the past several years. Since Treg cells express interleukin-2 R&#945; (&#8220;IL-2R&#945;&#8221; or &#8220;CD25&#8221;), it was envisioned mAbs could be developed that bind CD25 and thereby trigger depletion by Natural Killer cells, resulting in stimulation of anti-tumor immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Unfortunately, while first-generation mAbs successfully bound CD25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> cells, they also interfered with interleukin-2 [IL-2] signaling to T effector [Teff] cells to activate their cancer cell killing effects. The result was a failure of first-gen anti-CD25 mAbs as cancer immunotherapies, since their favorable anti-Treg effects were negated by their unfavorable impact on Teff cells.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:216pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k006.jpg" alt="Graphic" style="display:inline-block;height:215.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Figure 6: Mechanism of action of first and 2</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">nd</sup><i style="font-style:italic;"> generation Treg depleting antibodies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In vitro characterization of IBIO-101 demonstrated potent binding to recombinant CD25 while preserving IL-2 signaling. Further assessment of IBIO-101 showed selective Treg depletion and sparing of Teffs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k007.jpg" alt="Graphic" style="display:inline-block;height:213.55pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Figure 7: In vitro characterization of IBIO-101</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In a humanized mouse disease model, IBIO-101, when used as a monotherapy, effectively demonstrated its mechanism of action by significantly enhancing the Treg/Teff ratio, resulting in the suppression of tumor growth. When paired with an anti-PD-1 checkpoint inhibitor in the same model, the combined treatment of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to either anti-PD-1 or IBIO-101 used independently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:255pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k008.jpg" alt="Graphic" style="display:inline-block;height:254.8pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Figure 8: IBIO-101 monotherapy in a humanized mouse model leads to increased Treg/Teff ratio, resulting in the suppression of tumor growth</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k009.jpg" alt="Graphic" style="display:inline-block;height:173.7pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:310.55pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:12pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Figure 9: Combination Therapy of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to anti-PD-1 or IBIO-101 alone</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">iBio has progressed IBIO-101 to the IND-enabling phase and entrusted its Chemistry, Manufacturing, and Controls (CMC) development to a reputable Contract Research Organization (CRO). In the initial stages of this process, IBIO-101 has exhibited promising attributes for CMC progression. Notably, we&#39;ve pinpointed optimal cell lines for master cell bank creation and have set in place a CMC methodology to produce IBIO-101 in compliance with cGMP standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k010.jpg" alt="Graphic" style="display:inline-block;height:219.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:438.8pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:12pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Figure 10: IBIO-101 has shown favorable characteristics for CMC development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company continues to advance our IL-2 sparing anti-CD25 antibody, IBIO-101, and anticipates moving the program from IND-enabling stage to an IND filing during the calendar year 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:192.55pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TROP-2 x CD3 Bispecific</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio has identified highly potent, fully human TROP-2 (Trophoblast Cell Surface Antigen 2) monoclonal antibodies, which have been formatted into bispecific TROP-2 x CD3 molecules using the Company&#8217;s T-cell engager antibody panel, EngageTx. TROP-2 is highly expressed in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers and is closely linked to metastasis and tumor growth. TROP-2 antibody drug conjugates have been developed to deliver toxic payloads to these cancer cells but could risk harming healthy cells and cause adverse effects. The Company&#8217;s bispecific approach has the potential to increase the therapeutic window, while promoting a robust and long-lasting anti-tumor response. Combining the bispecific TROP-2 approach with immunotherapies like checkpoint inhibitors can potentially lead to improved clinical outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:12pt;text-align:center;margin:0pt;"><img src="ibio-20230630x10k011.jpg" alt="Graphic" style="display:inline-block;height:192.55pt;width:405.15pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Figure 11: Proposed mechanism of action of iBio&#8217;s TROP-2 x CD3 bispecific antibodies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:274.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using EngageTx, iBio&#8217;s lead TROP-2 x CD3 bispecific antibody was engineered to potently kill tumor cells while limiting the release of cytokines, like Interferon Gamma (IFNg), Interleukin 2 (IL-2) and Tumor Necrosis Factor Alpha (TNFa), all of which have the potential to cause cytokine release syndrome. When compared to a bispecific molecule engineered with iBio&#8217;s TROP-2 binding arm and a first generation CD3 engager, SP34, the Company&#8217;s lead TROP-2 x CD3 bispecific antibody showed a markedly reduced cytokine release profile, potentially indicating a decreased risk for cytokine release syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ibio-20230630x10k012.jpg" alt="Graphic" style="display:inline-block;height:274.6pt;width:355.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 12: iBio&#8217;s TROP-2 x CD3 lead antibody shows reduced cytokine release while retaining tumor cell killing potential</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">When tested in a humanized mouse model of squamous cell carcinoma, iBio&#8217;s lead TROP-2 x CD3 bi-specific antibody demonstrated a significant 36 percent reduction in tumor size within just 14 days after tumor implantation, and after only a single dose.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:252pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ibio-20230630x10k013.jpg" alt="Graphic" style="display:inline-block;height:252pt;width:447.2pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 13: iBio&#8217;s lead TROP-2 x CD3 molecule showed a 36% reduction in tumor size in an animal model engrafted with human peripheral blood mononuclear immune cells (PBMC) and human tumor cells</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MUC16</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreas cancers. Specifically, MUC16 is a large extracellular protein expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to effectively target and destroy the cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k014.jpg" alt="Graphic" style="display:inline-block;height:247pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:468pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:250.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Figure 14: MUC16 structure and mechanisms to evade anti-cancer therapy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Using the Company&#8217;s patented epitope steering AI platform, iBio&#39;s innovative approach to this challenge allows its new mAbs to bind to a specific region of MUC16 that is not shed or glycosylated, circumventing both tumor evasion mechanisms and potentially providing a powerful tool in the fight against cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k015.jpg" alt="Graphic" style="display:inline-block;height:250.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:12pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Figure 15: iBio&#8217;s epitope steering approach and immunization strategy to target the non-shed MUC16 region</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">During its immunization and screening campaign, iBio identified several hits that specifically bound to the non-shed region of MUC16 while no binding to the shed fragment of MUC16 was observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k016.jpg" alt="Graphic" style="display:inline-block;height:212.55pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:213.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:12pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Figure 16: iBio&#8217;s hit molecules bind to the non-shed but not the shed region of MUC16</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Establishing antibodies with the ability to bind to a recombinant version of their target protein represents a vital initial step in the<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span>validation process. &#160;However, it&#39;s crucial to ensure such antibodies maintain their binding affinity in a whole cell context, specifically when the target protein is expressed on a cell&#39;s surface. To best predict therapeutic efficacy, it&#39;s recommended to utilize tumor cells as a means to demonstrate and confirm this cell binding capability. During pre-clinical studies, iBio&#8217;s MUC16 molecule has demonstrated binding to MUC16 on OVCAR-3 ovarian cancer cells as shown below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k017.jpg" alt="Graphic" style="display:inline-block;height:213.25pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Figure 17: iBio&#8217;s MUC16 molecule shows binding to MUC16 on human ovarian cancer cells</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:225.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">Another critical step in antibody optimization is the humanization of molecules originally raised in mice or other species. Humanization efforts of antibodies carry the risk of, among other things, losing binding strength. After engineering the leading MUC16 molecule with a fully human framework, the MUC16 molecule retained potent binding to the engineered epitope and maintained binding to human OVCAR-3 ovarian cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ibio-20230630x10k018.jpg" alt="Graphic" style="display:inline-block;height:225.35pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 18: iBio&#8217;s humanized MUC16 molecule retains binding to the engineered epitope and human tumor cell lines</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EGFRvIII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:12pt;text-align:justify;margin:0pt;">EGFRvIII is a specific variant of the EGFR protein, unique to tumor cells. Unlike the more common EGFR, EGFRvIII is not found in healthy cells, making it an attractive target for therapeutic interventions. This variant is most prominently associated with glioblastoma, a type of brain cancer and head and neck cancer, but can also be present in certain cases of breast, lung, and ovarian cancers, among others. In our pursuit of innovative treatments, iBio is exploring antibody therapeutics that specifically target EGFRvIII, aiming to address these cancer types without affecting healthy cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Leveraging our patented AI-enabled epitope steering engine, we&#39;ve specifically directed antibodies to target a unique epitope found exclusively on EGFRvIII, and not on the wildtype receptor, EGFR. Through this precision approach, iBio has designed tumor-specific molecules aimed at selectively targeting cancer cells while preserving healthy ones, potentially offering patients a more focused and safer therapeutic solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:236.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k019.jpg" alt="Graphic" style="display:inline-block;height:204.4pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Figure 19: Tumor epitope specific antibodies target tumor cells while sparing healthy cells</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">iBio&#39;s hit molecules have demonstrated strong binding to the tumor-specific EGFRvIII protein without targeting the wildtype EGFR. &#160;Additionally, these molecules have effectively eliminated tumor cells, while sparing healthy ones, in in vitro cell killing tests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="ibio-20230630x10k020.jpg" alt="Graphic" style="display:inline-block;height:236.2pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Figure 20: In vitro characterization of iBio&#8217;s hit molecules demonstrates selective binding to EGFRvIII leading to tumor-specific cell killing while sparing healthy cells</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:236.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio&#8217;s lead anti-EGFRvIII antibody was specially engineered to enhance its ability to attack cancer cells and has proven effective in a mouse model for head and neck cancer. In preclinical studies, iBio&#8217;s anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k021.jpg" alt="Graphic" style="display:inline-block;height:236.05pt;width:466.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 21: iBio&#8217;s lead molecule demonstrates efficacy in a mouse model for head and neck cancer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CCR8</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">GPCRs are one of the most successful therapeutic target classes, with approximately one-third of all approved drugs targeting these proteins.&#160;Compared to small molecule-based GPCR drugs, antibody-based GPCR therapeutics potentially offer several potential advantages, including superior selectivity, extended mechanisms of action, and longer half-life. However, GPCRs are intricate, multi-membrane spanning receptors, making clinically relevant regions difficult to identify and target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;">The chemokine receptor CCR8 is a GPCR which is predominantly expressed on Tregs, which play a role in suppressing immune responses. In the context of cancer, Tregs can inhibit the body&#39;s natural immune response against tumor cells, promoting cancer progression. Anti-CCR8 antibodies are being explored as a therapeutic strategy to deplete these Tregs in the tumor environment. By targeting and reducing Tregs using anti-CCR8 antibodies, the hope is to enhance the body&#39;s immune response against cancer cells, offering a promising avenue for cancer treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">Aiming directly at CCR8 is believed to be a safer approach because it focuses on specific suppressive Treg cells in the tumor environment without affecting other immune cells and functions. It&#39;s important to make sure antibodies are fine-tuned to CCR8 and don&#39;t mistakenly target a similar receptor, CCR4. This is because CCR4 is found in many immune cells, and accidentally targeting it could potentially lead to unwanted side effects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:214.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ibio-20230630x10k022.jpg" alt="Graphic" style="display:inline-block;height:214.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 22: Proposed mechanism of action for selective anti-CCR8 antibodies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;">Using its unique AI-driven technology, iBio successfully identified molecules targeting CCR8, addressing some of the hurdles often faced when creating therapies that target GPCR with antibodies. iBio&#39;s specialized anti-CCR8 antibody has shown strong attachment to cells expressing CCR8 and effectively disrupted the CCR8 signaling process, resulting in the efficient elimination of Tregs derived from primary human immune cells. Notably, iBio&#39;s CCR8-focused molecule did not attach to cells overproducing CCR4, highlighting its precision in targeting only CCR8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k023.jpg" alt="Graphic" style="display:inline-block;height:214.75pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 23: Selective binding to CCR8 and inhibition of the CCR8 signaling pathway by iBio&#8217;s lead molecule leads to potent killing of Tregs derived from primary human immune cells</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:240pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio&#8217;s CCR8 antibody has proven effective in a mouse model for colon cancer. Preclinical studies show iBio&#8217;s anti-CCR8 molecule inhibited tumor growth and achieved a 22 percent reduction in tumor size compared to its pre-treatment dimensions. &#160;iBio specifically engineered the anti-CCR8 molecule as a high Antibody-Dependent Cellular Cytotoxicity (ADCC) antibody to enhance its ability to attack cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k024.jpg" alt="Graphic" style="display:inline-block;height:239.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 24: iBio&#8217;s lead CCR8 antibody inhibited tumor growth and achieved a 22 percent tumor regression in a humanized mouse model for colon cancer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Autoimmune</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PD-1 Agonist</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">Programmed cell death protein 1 (PD-1) is a pivotal player in the immune system, acting as a type of &quot;off switch&quot; that helps keep the cells from attacking other cells in the body. By agonizing or enhancing the signaling of PD-1, it&#39;s possible to temper the immune response, making it particularly valuable in the treatment of autoimmune diseases. In conditions where the immune system mistakenly wages war on the body&#39;s own cells, such as in autoimmune diabetes or lupus, therapies that target PD-1 can potentially reduce the severity of these autoimmune reactions. This approach offers a promising avenue for providing relief to patients suffering from these debilitating conditions. The figures below depict the mechanism of action of antagonistic and agonistic PD-1 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio purchased the global rights to a partnership-ready PD-1 agonistic mAb intended to treat serious autoimmune disorders. While the goal in immuno-oncology is to remove immune tolerance towards cancer cells, in autoimmune diseases the opposite is the case, because autoimmune diseases can result from deficits in peripheral and/or central tolerance mechanisms which presents an opportunity for therapeutic intervention. Specifically, agonism or stimulation of inhibitory receptors like PD-1 or CTLA4, which mediate peripheral tolerance is a promising approach to treat autoimmune diseases. Unlike PD-1 antagonists used in immuno-oncology, PD-1 agonists are difficult to find. RubrYc used its AI Discovery Platform to discover PD-1. PD-1 is currently in the late-discovery stage, having undergone extensive screening and <i style="font-style:italic;">in vitro</i> characterization, and we anticipate it will be advanced into <i style="font-style:italic;">in vivo</i> models as IBIO-102, in the near future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:210pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ibio-20230630x10k025.jpg" alt="Graphic" style="display:inline-block;height:209.35pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 25: A PD-1 antagonist antibody worsens autoimmunity and increases systemic inflammation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ibio-20230630x10k026.jpg" alt="Graphic" style="display:inline-block;height:207.55pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 26: A PD-1 agonist antibody improves autoimmunity, reduces inflammation in diseased tissue and maintains a low inflammatory status in healthy tissue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio has harnessed the power of three core components of its technology stack to discover PD-1 agonists: the epitope steering engine, the proprietary naive human antibody library, and the StableHu antibody optimizer. Engineering the resulting agonist antibodies into both bivalent and tetravalent formats has led to potent PD-1 agonists.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:217.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ibio-20230630x10k027.jpg" alt="Graphic" style="display:inline-block;height:217pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 27: iBio&#8217;s bi- and tetravalent PD-1 antibodies potently agonize PD-1 in vitro</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, in preclinical studies, iBio&#39;s PD-1 agonists have been evaluated using a primary T-cell assay. Our top-performing molecules showed a significant decrease in the proinflammatory cytokine IL-2 and reduced expression of the T-cell activation marker CD96. Both of these outcomes are indicative of the desired dampening of T-cell activation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ibio-20230630x10k028.jpg" alt="Graphic" style="display:inline-block;height:208.95pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 28: iBio&#8217;s most promising PD-1 antibodies demonstrate suppression of T-cell activation in primary human cells</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio&#8217;s PD-1 agonist is currently in the late-discovery stage and we anticipate it will be advanced into <i style="font-style:italic;">in vivo</i> models as IBIO-102, in the near future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fibrosis </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fibrosis is a pathological&#160;disorder&#160;in which&#160;connective tissue&#160;replaces normal&#160;parenchymal tissue&#160;to the extent that it goes unchecked, leading to considerable tissue remodeling and the formation of permanent&#160;scar tissue. Fibrosis can occur in many tissues within the body, including the lungs (e.g., idiopathic pulmonary fibrosis [&#8220;IPF&#8221;] and skin (e.g., systemic scleroderma [&#8220;SSc&#8217;].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IBIO-100</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our preclinical anti-fibrotic program, IBIO-100, is design and based upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we had a license to the patents relevant for the continued development of the molecule from the university. &#160;After careful consideration, in February 2023, we terminated all efforts on IBIO-100 anti-fibrotic program and provided a six (6) month notice of termination of the license agreement to the University of Pittsburgh, as required by the license agreement. Pursuant to the license agreement with the University of Pittsburgh, our financial obligations for the management of the patents under the license ceased on August 14, 2023, and at such time, transitioned back to the University of Pittsburgh and the Medical University of South Carolina.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;">As part of this decision, we completed the pre-clinical cancer studies we were conducting in collaboration with University of Texas Southwestern using E4 endostatin peptide, which is derived from IBIO-100. After the conclusion of the pre-clinical studies, we determined not to further pursue this oncology program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Digital Infrastructure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">iBio is a firm believer in the transformative power of digital technologies, including robotics, automation, artificial intelligence (AI), machine learning (ML), and cloud computing. These technologies are integral to operationalizing our strategy, accelerating our learning curve, and executing at scale. As such, the Company has made substantial investments in these areas. &#160;iBio&#8217;s aspiration is to digitize our operations to the greatest extent possible, harnessing the potential of digital technology to maximize our impact on human health. As the Company continues to grow, we remain committed to further investing in our digital infrastructure to support our ambitious goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Strategic Alliances, Collaborations, and Joint Ventures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio has formed collaborations and strategic alliances to gain access to funding, capabilities, technical resources and intellectual property to further its development efforts, commercialize its technology and to generate revenues, including through the use of our patented epitope-steering AI-engine and our EngageTX platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">National Institute of Allergy and Infectious Diseases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June 12, 2023, iBio entered into a research collaboration with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a component of the National Institutes of Health (&#8220;NIH&#8221;), to investigate the potential of the patented AI-driven epitope steering platform for the development of a vaccine for Lassa fever, which currently there is no vaccine available. &#160;Based on the viral epitopes identified by researchers at NIAID&#8217;s Vaccine Research Center (&#8220;VRC&#8221;), the Company will work with the VRC to determine if using the platform to steer immunity toward these epitopes offers advantages over other vaccine development approaches. Should the collaboration be successful, researchers at the VRC may assess promising candidates in both <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> studies, and potentially advance a lead candidate to a Phase 1 clinical trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Several agreements with RubrYc Therapeutics, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">On August 23, 2021, we entered into a series of agreements with RubrYc described in more detail below:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.3pt 0pt 0pt;"><i style="font-style:italic;">Collaboration and License Agreement: </i> iBio entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 campaign. &#160;During the term of the RTX-003 License Agreement, RubrYc granted us an exclusive worldwide sublicensable royalty-bearing license under the patents controlled by RubrYc that cover the RTX-003 antibodies. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022, including RubrYc&#8217;s immune-oncology antibodies in its RTX-003 campaign.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Collaboration, Option and License Agreement: </i>iBio entered into a collaboration agreement (the &#8220;Collaboration Agreement&#8221;) with RubrYc to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. In addition, RubrYc granted the Company an exclusive option to obtain a worldwide sublicensable commercial license with respect to each of the lead product candidates resulting from such collaboration programs (the &#8220;Selected Compounds&#8221;). With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Stock Purchase Agreement:</i> In connection with the entry into the Collaboration Agreement and RTX-003 License Agreement, iBio also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby we purchased 1,909,563 shares of RubrYc&#8217;s Series A-2 preferred stock &#8220;Series A-2 Preferred&#8221;) for $5,000,000 and acquired an additional 954,782 shares of RubrYc&#8217;s Series A-2 Preferred. In connection with the Stock Purchase Agreement, iBio entered into the RubrYc Therapeutics, Inc. Second Amended and Restated Investors&#8217; Rights Agreement (the &#8220;Investors&#8217; Rights Agreement&#8221;), RubrYc Therapeutics, Inc. Second Amended and Restated Voting Agreement (the &#8220;Voting Agreement&#8221;) and the RubrYc Therapeutics, Inc. Second Amended and Restated Right of First Refusal and Co-Sale Agreement (the &#8220;Right of First Refusal and Co-Sale Agreement&#8221;).  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The rights, preferences of and privileges of the RubrYc Series A-2 Preferred Stock (&#8220;Series A-2 Preferred&#8221;) are set forth in the Third Amended and Restated Certificate of Incorporation of RubrYc Therapeutics, Inc. (the &#8220;Amended RubrYc COI&#8221;), and include a preferential eight percent (8%) dividend, senior rights on liquidation, the right to elect a Series A-2 Preferred director for as long as we hold at least 1,500,000 shares of RubrYc stock, the right to vote on an as-converted basis, certain anti-dilution and other protective provisions, the right to convert the Series A-2 Preferred into shares of RubrYc common stock at our option, and mandatory conversion of the Series A-2 Preferred into shares of RubrYc common stock upon (a) the closing of a firm-commitment underwritten public offering to the public pursuant to an effective registration statement under the Securities Act of 1933, as amended, for shares of RubrYc common stock at a per share price of at least five (5) times the Series A-2 Original Issue Price (as defined in the Amended RubrYc COI) and resulting in at least $30,000,000 of gross proceeds to RubrYc or (b) such other date, time or event, specified by vote or written consent of the majority of the aggregate voting power, on an as-converted basis, of the RubrYc Series A preferred stock (&#8220;Series A Preferred&#8221; and together with the Series A-2 Preferred, the &#8220;Senior Preferred Stock&#8221;) and Series A-2 Preferred. The Right of First Refusal and Co-Sale Agreement gives RubrYc the right of first refusal on stock sales by key holders, generally defined as founders, and a second right of first refusal and a co-sale right to specified other investors, including certain holders of Senior Preferred Stock and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Investors&#8217; Rights Agreement provides the holders of Senior Preferred Stock with, among things: (i)&#160;demand registration rights, under specified circumstances; (ii)&#160;piggyback registration rights in the event of a company registered offering; (iii)&#160;lock-up and market-standoff obligations following a registered underwritten public offering; (iv)&#160;preemptive rights on company offered securities; and (v)&#160;additional protective covenants that require the approval at least two of the three directors elected by the holders of the Senior Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Pursuant to the Voting Agreement, certain RubrYc stockholders are contractually obligated to, among other things, vote for and maintain the authorized number of directors at five members, one of which the Company has the contractual right to elect subject to the conditions set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Purchase Agreement:</i> On September 16, 2022, iBio entered into an asset purchase agreement (the &#8220;Purchase Agreement&#8221;) with RubrYc in order to acquire substantially all of its assets, including the AI Drug Discovery Platform, RTX-003 (IBIO-101), all Selected Compounds, three additional immune-oncology candidates, a PD-1 agonist, in addition to lab and technology equipment. &#160;On September 19, 2022, in connection with the closing of the acquisition, the Company entered into a termination agreement (the &#8220;Termination Agreement&#8221;) with RubrYc in order terminate the RTX-003 License Agreement and the Collaboration Agreement, which terminated any and all future milestone payments or royalty obligations we had under those agreements. &#160;Under the terms of the Purchase Agreement, upon closing of the acquisition, the Company made an upfront payment of approximately $1,000,000 by issuing 102,354 (post reverse split effected in October 2022) shares of our common stock, par value $.001 per share (the &#8220;Common Stock&#8221;) to RubrYc. &#160;RubrYc is also eligible to receive up to $5,000,000 in development milestone over the period of five years from the date of the Purchase Agreement, which can be paid in shares of our Common Stock or cash, at our sole discretion. &#160;In addition, we had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101 (RTX-003), in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">License with University of Pittsburgh (&#8220;Univ. of Pitt&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 14, 2014 (the &#8220;Effective Date&#8221;), we entered into an exclusive worldwide License Agreement with Univ. of Pitt, which was amended on August 11, 2016, December 2, 2020 and February 8, 2022 (the &#8220;Exclusive License Agreement&#8221;) covering all of the U.S. and foreign patents and patent applications and related intellectual property owned by Univ. of Pitt pertinent to the use of endostatin peptides for the treatment of human and veterinary fibrosis (the &#8220;Field&#8221;). We paid an initial license fee of $20,000 and we were required to pay all of Univ. of Pitt&#8217;s patent prosecution costs that were incurred prior to, totaling $30,627, and subsequent to the Effective Date. On each anniversary date through the fourth anniversary we were to pay license fees ranging from $25,000 and $100,000, and upon the execution of the amendment in February, 2022, $10,000 starting on the eighth anniversary and on each subsequent anniversary date until the first commercial sale of the licensed technology. &#160;On February 14, 2023, we provided notification to the Univ. of Pitt terminating the License Agreement. Pursuant to the termination of the license agreement with the Univ. of Pitt, our financial obligations for the management of the patents under the license ceased on August 14, 2023, and at or about such time, we transitioned back the management of the patents under the license to the Univ. of Pitt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Facility Purchase from Eastern Capital Limited </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On November 1, 2021, we purchased the manufacturing facility (the &#8220;Facility&#8221;) previously operated under a lease from two affiliates of Eastern Capital Limited (the &#8220;Eastern Affiliates&#8221;). We also acquired the approximate 30% equity interest (after conversion) in iBio CDMO LLC (&#8220;iBio CDMO&#8221;) held by the Eastern Affiliates, who became the lessee under the ground lease agreement with the Board of Regents of the Texas A&amp;M University System (the &#8220;Ground Lease Agreement&#8221;) for the land upon which the Facility is located and terminated the Sublease iBio had entered into with the Eastern Affiliates. As a result, iBio CDMO and its intellectual property are now wholly owned by iBio. The total purchase price for the Facility, the termination of the Sublease and other agreements among the parties, and the equity described below was $28,750,000, which was paid $28,000,000 in cash and by the issuance to Bryan Capital Investors LLC, an affiliate of the Eastern Affiliates a five-year warrant to purchase 51,583 shares of our Common Stock at an exercise price of $33.25 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In connection with the purchase of the Facility, iBio CDMO entered into a Credit Agreement, dated November 1, 2021 (the &#8220;Credit Agreement&#8221;), with Woodforest National Bank (&#8220;Woodforest&#8221;) pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a Term Note (the &#8220;Term Note&#8221;). The Term Loan was advanced in full on the closing date. <span style="font-style:italic;font-weight:bold;"> </span>The Term Loan originally bared an interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. &#160;Principal on the Term Loan was originally payable on November 1, 2023,<span style="font-style:italic;font-weight:bold;"> </span>subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">for mandatory prepayment upon certain circumstances. The Term Loan is secured by a lien on all of the assets of iBio CDMO and we guaranteed payments of the obligations owed under the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The Credit Agreement contains customary events of default (which are in some cases subject to certain exceptions, thresholds, notice requirements and grace periods), including, but not limited to, nonpayment of principal or interest, failure to perform or observe covenants, breaches of representations and warranties, cross-defaults with certain other indebtedness, certain bankruptcy-related events or proceedings, final monetary judgments or orders and certain change of control events. The Credit Agreement also contains negative covenants which included a prohibition on the incurrence of Debt (as defined in the Credit Agreement) except Permitted Debt (as defined in the Credit Agreement) and Liens (as defined in the Credit Agreement), and termination of the Ground Lease Agreement and affirmative covenants that have been amended and originally included delivery of audited financial statements within 120 days of the year end without a &#8220;going concern&#8221; or like qualification. In addition, the Credit Agreement originally provided that the Company must maintain unrestricted cash of no less than $10,000,000 (the &#8220;Liquidity Covenant&#8221;), which amount has been amended to $1,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement (the &#8220;First Amendment&#8221;) to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the First Amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer USA, Inc. (&#8220;Fraunhofer&#8221;) as part of our legal settlement with them (the &#8220;Fraunhofer Settlement Funds&#8221;) (see Note 19 &#8211; Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the First Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company&#8217;s unrestricted cash decreased below the required $7,500,000, did not comply with the Liquidity Covenant at the time. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#8220;Second Amendment&#8221;), which as amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which as amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company was in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed the Company to retain $2,000,000 million of the $5,100,000 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 million being held in a Company account at Woodforest. &#160;In addition, the Company was obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), pursuant to which Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the Maturity Date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk145834820"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 15, 2023, iBio CDMO entered into a purchase and sale agreement, dated as of September 15, 2023 (the &#8220;Purchase and Sale Agreement&#8221;) with Majestic Realty Co., a California corporation (&#8220;Majestic Realty&#8221;), pursuant to which iBio CDMO agreed to sell to Majestic Realty for a purchase price of $17,250,000 its Facility located in Bryan, TX consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;M University System (together, the &#8220;Ground Lease&#8221;), related to 21.401 acres in Brazos County, Texas land (the &#8220;Land&#8221;); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the &#8220;Improvements&#8221;); (iii) all iBio CDMO&#8217;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the &#8220;Personal Property&#8221;); (iii) all iBio CDMO&#8217;s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the &#8220;Contracts&#8221;); and (iv) all iBio CDMO&#8217;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the &#8220;Intangibles&#8221;; and together with the Ground Lease, Improvements and Personal Property, collectively, the &#8220;Property&#8221;). The closing of the sale of the Property is to occur, with time being of the essence, on December 1, 2023 or such other date as mutually agreed. &#160;Pursuant to the terms of the Purchase and Sale Agreement , Majestic Realty deposited with a title company (the &#8220;Escrow Agent&#8221;) $200,000 as an earnest money deposit. Majestic Realty will also be afforded access to the Property to conduct a due diligence review of its condition. The closing is subject to certain closing conditions, including: (i) Majestic Realty&#8217;s delivery to iBio CDMO and the Escrow Agent of written notice of its approval of the condition of the Property on or before 5:00 p.m. Central time on October 16, 2023 (the &#8220;Due Diligence Deadline&#8221;); (ii) Majestic Realty obtaining the approval of The Board of Regents of the Texas A&amp;M University System of Majestic Realty&#8217;s purchase from it of the fee interest in the Land on or before 5:00 p.m. Central time on November 13, 2023; and (iii) the delivery at closing by the title company of a title policy to Majestic Realty in the amount of the Purchase Price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#8220;Sixth Amendment&#8221;), to amend the Credit Agreement to: (i) set the maturity date of the term loan to the&#160;<i style="font-style:italic;">earlier of </i>(a) December 31, 2023, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement, (ii) provided that iBio CDMO will, immediately upon receipt of the proceeds of the sale of the Property, apply the net proceeds to satisfy all outstanding obligations under the term loan, and to the extent such net proceeds are sufficient, to pay off the term loan, and (iii) change the annual filing requirement solely for the fiscal year ending June 30, 2023, such that the filing is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">acceptable with or without a &#8220;going concern&#8221; designation; provided that (y) iBio CDMO shall deliver an executed copy of the Purchase and Sale Agreement for the sale of the Facility within one business day after entry into the Sixth Amendment, and (z) if the Facility is not sold on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Facility is a life science building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the land until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. The Facility has been listed for sale since November 2022 and remarketed starting July 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently own 95 patents. Of the 95 patents, 24 are U.S. and 71 are international. Since July 1, 2022, we have primarily focused our intellectual property estate on our preclinical assets filing 10 provisional patents in the U.S. and foreign countries, including for chemokine receptor 8 (CCR8) antibodies, epidermal growth factor receptor variant III (EGFRvIII) antibodies, anti-MUC16 antibodies, TROP2 antibodies, CD3 antibodies, and recently filed a provisional patent for our high-efficiency, conditionally-activated antibodies. &#160;We now have 18 U.S., 2 Patent Cooperation Treaty, and 32 international applications pending. International patents and applications include numerous foreign countries including Australia, Brazil, Canada, China, Hong Kong, India, Japan, Korea, and several countries in Europe. &#160;In the U.S. our patents expire between 2023 and 2036. &#160;Outside the U.S. these patents expire between 2023 and 2036. &#160;The 8 patents expiring in 2023 in the U.S. and overseas are related to virus-induced gene silencing in plants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Included in the 95 patents are 30 U.S. and foreign applications that we acquired &#160;from RubrYc for novel antibodies, scaffold technology, and a machine learning apparatus for engineering meso-scale peptides, including 1 allowed application. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the plant portfolio, we exclusively own the right to use certain intellectual property acquired by or developed at Fraunhofer for human health and certain veterinary and diagnostic applications. We also own intellectual property developed or acquired independently of Fraunhofer as part of the plant portfolio. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the second quarter of Fiscal 2023, we re-evaluated our business strategy and reviewed our product portfolio. &#160;After such review, we identified intellectual property, patent and licenses with a net book value of approximately $565 that will no longer be utilized and therefore they were fully impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to patents and patent applications that we own, our plant focused patent estate relies on trade secrets and know-how, which we are currently seeking a partner to out-license such proprietary technology and processes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success will depend in part on our ability to obtain and maintain patent protection for our technologies and preclinical assets. Our policy is to seek to protect our proprietary rights, by among other methods, filing patent applications in the U.S. and foreign jurisdictions to cover certain aspects of our technology. We continue to prepare patent applications relating to our expanding technology in the U.S. and abroad.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The technology and products covered by our issued and pending patent applications are summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Technology and Product Patents (U.S.)</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Virus-induced gene silencing in plants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Transient expression of foreign genes in plants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Production of foreign nucleic acids and polypeptides in sprout systems</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Production of pharmaceutically active proteins in sprouted seedlings</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Systems and method for clonal expression in plants</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recombinant carrier molecule for expression, delivery and purification of target polypeptides</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Influenza antigens, vaccine compositions, and related methods</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Plague antigens, vaccine compositions, and related methods</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Influenza therapeutic antibodies</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Trypanosomiasis vaccine</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Anthrax antigens, vaccine compositions, and related methods</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Use of endostatin peptides for the treatment of fibrosis</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pending Technology Patent Applications (U.S. and International)</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Activation of transgenes in plants by viral vectors</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Transient expression of proteins in plants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Thermostable carrier molecule</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">In vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> deglycosylation of recombinant proteins in plants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Scaffold technology</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Machine learning apparatus for engineering meso-scale peptides</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Methods of making conditionally-activated antibodies</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pending Product Patent Applications (U.S. and International)</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibodies</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Influenza vaccines</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Influenza therapeutic antibodies</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Anthrax vaccines</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Plague vaccines</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HPV vaccines</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Trypanosomiasis vaccine</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Malaria vaccines</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">COVID-19 vaccines</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibodies against chemokine receptor 8 (CCR8)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibodies against epidermal growth factor receptor variant III (EGFRvIII)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibodies against </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MUC16</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibodies against </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">TROP2</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibodies against </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CD3</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">High-efficiency, conditionally-activated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">antibodies</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we or our collaborators may develop based on the use of our technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">While we believe that the potential advantages of our new technologies will enable us to compete effectively against other providers of technology for biologic product development and manufacturing, many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through arrangements with large and established companies, and this may reduce the value of our technologies for the purposes of establishing license agreements. In addition, these third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to rely upon licensees, collaborators or customers for support in advancing certain of our drug candidates and intend to rely on additional work with our collaborators during our efforts to commercialize our product candidates. Our licensees, collaborators or customers may be conducting multiple product development efforts within the same disease areas that are the subjects of their agreements with us. Agreements with collaborators may not preclude them from pursuing development efforts using a different approach from that which is the subject of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are currently approved vaccines and therapies for many of the diseases and conditions addressed by the product candidates our partners and collaborators may be developing or manufacturing or in our own pipeline. Technological developments in our field of research and development occur at a rapid rate and we expect competition to intensify as advances in this field are made. We will be required to continue to devote substantial resources and efforts to our research and development activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a biopharmaceutical company with a focus on cancer therapeutics, we compete with a broad range of companies. At the highest level, our therapeutics can be seen as both a complement and a potential competitor to any oncology therapy, most notably chemotherapy, radiotherapy, biologics and small molecule drugs. Not only do we compete with companies engaged in various cancer treatments including radiotherapy and chemotherapy, but we also compete with various companies that have developed or are trying to develop immunology vaccines for the treatment of cancer. Certain of our competitors have substantially greater capital resources, large customer bases, broader product lines, sales forces, greater marketing and management resources, larger research and development staffs with extensive facilities and equipment than we do and have more established reputations as well as global distribution channels. Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Bristol-Myers Squibb Company, Merck&#160;&amp; Co.,&#160;Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca plc), Johnson&#160;&amp; Johnson, Pfizer&#160;Inc., Merck KGaA and Sanofi SA, and more established biotechnology companies such as Genentech,&#160;Inc. (a member of the Roche Group), Amgen&#160;Inc., Gilead Sciences,&#160;Inc. and its subsidiary Kite Pharma,&#160;Inc., and competing cancer immunotherapy companies such as, Bluebird Bio,&#160;Inc., Transgene SA, Bausch Health Companies, Lumos Pharma, Agenus&#160;Inc., Aduro Biotech,&#160;Inc., Advaxis,&#160;Inc., ImmunoCellular Therapeutics,&#160;Ltd., IMV&#160;Inc., Oxford BioMedica plc, Bavarian Nordic A/S, Celldex Therapeutics,&#160;Inc., as well as tech enabled drug discovery companies such as Recursion, Abcellera Biologics, Inc., Cellarity, BenevolentAI, and others, some of which have substantially greater financial, technical, sales, marketing, and human resources than we do. These companies might succeed in obtaining regulatory approval for competitive products more rapidly than we can for our products. In addition, competitors might develop technologies and products that are less expensive, safer or more effective than those being developed by us or that would render our technology obsolete. In addition, the pharmaceutical and biotechnology industry is characterized by rapid technological change. Because our research approach integrates many technologies, it may be difficult for us to remain current with the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Our competitors may render our technologies obsolete by advancing their existing technological approaches or developing new or different approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our research and development functions are focused on the creation of new products and services, as well as enhancements to our existing offerings, both of which are necessary to maintain our competitive position. Our research and development activities take place primarily at our facilities in San Diego. iBio has leased lab and office space in San Diego for the purpose of conducting research. For the Fiscal year 2023, iBio spent $10.3 million in R&amp;D related activities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Suppliers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We outsource certain functions and supplies to third parties such as Charles River Laboratories, Sartorius AG, Fisher Scientific, Lonza Sales AG, and Twist Bioscience Corporation. While we rely on our outsourcing partners to perform their contracted functions, we are continuing to build internal capabilities. Our suppliers are generally available to meet our demands and supply requirements, but our items are long lead time items that have been exacerbated by the current macro environment due to increased demand. &#160;We continue to mitigate the risks through inventory management, relationship management and evaluation of alternative sources when possible. Refer to Item&#160;1A, &#8220;Risk Factors,&#8221; for a description of risks associated with our reliance on suppliers and outsourcing partners.<span style="color:#ff0000;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation and Product Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug products. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Drug Approval Process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of the vaccine and therapeutic products developed from our technologies will require regulatory approval by governmental agencies prior to commercialization. In particular, pharmaceutical drugs and vaccines are subject to rigorous preclinical testing and clinical trials and other pre-marketing approval requirements by the FDA and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations, also govern or impact the manufacturing, safety, labeling, storage, record-keeping and marketing of vaccines and pharmaceutical products. The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of substantial resources. Regulatory approval, if and when obtained for any of our product candidates, may be limited in scope, which may significantly limit the indicated uses for which our product candidates may be marketed. Further, FDA approved vaccines and drugs are subject to ongoing oversight and discovery of previously unknown problems may result in restrictions on their manufacture, sale or use, or in their withdrawal from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of pre-clinical laboratory tests and animal studies according to good laboratory practices (&#8220;GLP&#8221;) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;) application which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices (&#8220;GCPs&#8221;) and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of a New Drug Application or NDA or Biologics License Application (&#8220;BLA&#8221;) for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the NDA or BLA based on results of pre-clinical testing and clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product candidates are produced, to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential FDA audit of the pre-clinical trial and clinical trial sites that generated the data in support of the NDA or BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA or licensure of the BLA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical Tests</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before any product candidates with potential immunization or therapeutic value may be tested in human subjects, we must satisfy stringent government requirements for preclinical studies. Preclinical testing includes both <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> laboratory evaluation and characterization of the safety and efficacy of the product candidate. &#8220;<i style="font-style:italic;">In vitro</i>&#8221; refers to tests conducted with cells in culture and &#8220;<i style="font-style:italic;">in vivo</i>&#8221; refers to tests conducted in animals. The conduct of the preclinical tests must comply with federal regulations and requirements including GLP. Preclinical testing results obtained from studies in several animal species, as well as data from <i style="font-style:italic;">in vitro</i> studies, are submitted to the FDA as part of an IND application and are reviewed by the FDA prior to the commencement of human clinical trials. These preclinical data must provide an adequate basis for evaluating both the safety and the scientific rationale for the initial clinical trials. In the case of vaccine candidates, animal immunogenicity and immune protection tests must establish a sound scientific basis to believe that the product candidate may be beneficial when administered to humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">IND</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An IND becomes effective automatically 30&#160;days after receipt by the FDA unless the FDA raises concern or questions about the conduct of the clinical trials as outlined in the IND prior to that time. In such an event, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials may proceed. For additional information on the most recent FDA regulations and guidance on vaccine and therapeutic product testing and approval, visit its website at http://www.fda.gov. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to potential safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical Trails</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules&#160;that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations composing the good clinical practice requirements, including the requirement that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional review board (the &#8220;IRB&#8221;) at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Human clinical trials involving biological products are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The biological product is initially introduced into a small number of closely monitored healthy human volunteers and tested for safety. In the case of some products for severe or life-threatening diseases, especially </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the targeted disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 3</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Clinical trials generally enroll a large number of volunteers and are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or <i style="font-style:italic;">in vitro</i> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar&#160;days after the sponsor&#8217;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to subjects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many other countries in which we might choose to develop drugs or run clinical trials have similar rules and regulation. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union or other foreign countries, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NDA/BLA:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Once clinical trials of a product candidate are completed, FDA approval of an NDA or BLA must be obtained before commercial marketing of the product. The NDA or BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the NDA or BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:31.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Approval Requirements: &#160; </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any products for which we receive FDA approvals will be subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses, known as &#8216;off-label&#8217; use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other U.S. Healthcare Laws and Compliance Requirement</span><i style="font-style:italic;">: </i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, for instance the Office of Inspector General, the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, research, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the physician payment transparency laws, the privacy and security provisions of HIPAA, as amended by Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and similar state laws, each as amended. &#160;Once commercialized, we could be liable to ensure full compliance with the law.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">Coverage, Pricing and Reimbursement  </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. This is dictated by third-party payors&#8217; coverage and establish adequate reimbursement levels for such products. The marketability of any product candidate for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Regulation: </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, the approval process varies between countries and jurisdictions and can involve </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Orphan Drug Act </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the name of the sponsor, identity of the drug or biologic and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not shorten the duration of the regulatory review or approval process, but does provide certain advantages, such as a waiver of Prescription Drug User Fee Act, or PDUFA, fees, enhanced access to FDA staff and potential waiver of pediatric research requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug or biologic for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application user fee. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accelerated Approval</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">There are a variety of pathways under which applicants may seek expedited approval from FDA, including fast track, breakthrough therapy, priority review and accelerated approval. &#160;The FDA accelerated approval program provides for early approval of drugs based on a drug on a clinical trial(s) showing that the drug meets a surrogate or an intermediate clinical endpoint rather than a clinical benefit endpoint. Accelerated approval is possible for drugs for serious conditions that fill an unmet medical need. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A surrogate endpoint used for accelerated approval is a marker, such as a laboratory measurement, that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Likewise, an intermediate clinical endpoint is a measure of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on irreversible morbidity and mortality. Because it sometimes can take many years for a drug trial to show a clinical benefit, the use of a surrogate endpoint or an intermediate clinical endpoint can significantly shorten the time required to complete clinical trials and obtain FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a drug receives an accelerated approval, the company that sponsored the application must conduct a post-approval trial to confirm the anticipated clinical benefit. These trials are known as Phase 4 or post-approval confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Healthcare Regulations and Healthcare Reform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Healthcare regulation and pricing (included drug pricing) is complex, extensive, and dynamic around the world. In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. We expect that there will continue to be a number of federal and state proposals to implement government pricing controls and limit the growth of healthcare costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We anticipate that current and future U.S. legislative healthcare reforms may result in additional downward pressure on the price that we receive for any approved product, if covered, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">U.S. Patent-Term Extension</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Depending upon the timing, duration and specifics of FDA approval of our current product candidates or any future product candidate, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch Waxman Act. The Hatch Waxman Act permits extension of the patent term of up to five years as compensation for patent term lost during FDA regulatory review process. Patent term extension, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term extension period is generally one half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension (and only those patent claims covering the approved drug, a method for using it or a method for manufacturing it may be extended), and the application for the extension must be submitted prior to the expiration of the patent. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension. In the future, we may apply for extension of a patent term for our currently owned patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. However, there can be no assurance that the USPTO will grant us any requested patent term extension, either for the length we request or at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Human Capital/Employees </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of June 30, 2023, we had 23 employees in iBio and 3 employees in iBio CDMO that are maintaining the Facility until it is sold, all of which are full time employees. Our employees are not represented by any union and are not the subject of a collective bargaining agreement. We consider our relations with our employees to be good. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our success depends upon our ability to attract, develop, retain and motivate key personnel. Our management and scientific teams possess considerable experience in drug discovery, research and development, manufacturing, clinical and regulatory affairs, and iBio directly benefits from this experience and industry knowledge. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate that we will need to identify, attract, train and retain other highly skilled personnel to pursue our development program. Hiring for such personnel is competitive, and there can be no assurance that we will be able to retain our key employees or attract, assimilate or retain the qualified personnel necessary for the development of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have no collective bargaining agreements with our employees and have not experienced any work stoppages. We consider our relations with our employees to be good. Management believes that it has sufficient human capital to operate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">its business successfully currently and will need to attract new talent to the organization in order to achieve its plans for growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competitive Pay and Benefits. Our compensation programs are designed to align the compensation of our employees with our performance and to provide the proper incentives to attract, retain and motivate employees to achieve superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance. Specifically: &#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we provide employee wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we engage nationally recognized outside compensation and benefits consulting firms to independently evaluate the effectiveness of our executive compensation and benefit programs and to provide benchmarking against our peers within the industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we align our executives&#8217; long-term equity compensation with our shareholders&#8217; interests by linking realizable pay with stock performance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">annual increases and incentive compensation are based on merit, which is communicated to employees at the time of hiring and documented through our talent management process as part of our annual review procedures and upon internal transfer and/or promotion; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencing January 1, 2018, we established the iBio, Inc. 401(k) Plan. Eligible employees may participate in the 401(k) Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. We will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#8217;s compensation. In addition, we may make qualified non-elective contributions at our discretion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We were incorporated under the laws of the State of Delaware on April&#160;17, 2008, under the name iBioPharma,&#160;Inc. We engaged in a merger with InB:Biotechnologies,&#160;Inc., a New Jersey corporation on July&#160;25, 2008, and changed our name to iBio,&#160;Inc. on August&#160;10, 2009.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our principal executive offices are located at 8800 Health Science Center Parkway, Bryan, Texas and our telephone number is (979) 446-0027. Our website address is www.ibioinc.com. The information contained on, or accessible through, our website does not constitute part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On October 7, 2022, we effected a reverse stock split at a ratio of one-for-twenty five (1:25) shares of our common stock. As a result of the reverse stock split, every twenty five (25) shares of the Company&#39;s common stock either issued and outstanding or held by us in our treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of our common stock. The reverse split also applied to common stock issuable upon the exercise of our outstanding stock options. The reverse stock split did not affect the par value of our common stock or the shares of our common stock that we are authorized to issue under our Certificate of Incorporation, as amended. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. All share and per share amounts of common stock presented in this Annual Report have been retroactively adjusted to reflect the one-for-twenty five reverse stock split.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our website address is www.ibioinc.com. We file Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, proxy statements and other materials with the SEC. We are subject to the informational requirements of the Exchange Act and file or furnish reports, proxy statements and other information with the SEC. Such reports and other information filed by the Company with the SEC are available free of charge on our website at <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.ibioinc.com</span>. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report, and you should not consider information on our website to be part of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The SEC also maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2b19e4cb_3161_4b7d_b14a_6e97ab98a37e"></a><a id="Item1A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1A. Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Risk Factors </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business faces significant risks and uncertainties of which investors should be aware before making a decision to invest in our common stock. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. The following is a summary of the more significant risks relating to the Company. A more detailed description of our risk factors is set forth below under the caption &#8220;Detailed Risk Factors.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;margin:0pt;">&#8226; We have a limited operating history developing vaccines and therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;margin:0pt;">&#8226; We are evaluating potential options to extend our cash runway that could impact our future operations and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;margin:0pt;">&#8226; Substantial doubt exists related to our ability to operate as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.35pt;text-align:justify;text-indent:-9.35pt;margin:0pt;">&#8226; We have incurred and expect to continue to incur significant losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We anticipate that our expenses will increase in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We need additional funding to fully execute our business plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; The actual amount of funds we will need to operate is subject to many risk factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Raising additional capital may cause dilution to our existing stockholders and/or restrict our operations or rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; There can be no assurance that the sale of the Property will be completed in a timely manner or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Failure to complete the sale of the Property is expected to negatively impact our stock price and our future business and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; If the sale of the Property is not complete, we will have incurred substantial expenses without realizing the expected benefits of the sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; The unaudited pro forma financial information included as an exhibit to our Current Report on Form 8-K filed with the SEC on September 21, 2023 is for illustrative purposes and although we do not expect actual results to differ materially from the preliminary estimates, our actual financial position or result of operations after the anticipated sale may differ from the estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; A default under the terms of the Credit Agreement could result in action against our pledged assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; The Credit Agreement requires that we pay a significant amount of cash to the lender.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Covenant restrictions in the Credit Agreement may limit our ability to operate our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Potential use of government funding for R&amp;D programs may impose conditions limiting our ability to take certain actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Development and Commercialization of Our Technologies and Product Candidates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We have a limited operating history developing precision antibodies and have no significant source of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We are reliant on a limited number of product candidates that involve significant clinical testing before seeking regulatory approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We may fail to capitalize on particular technology or product candidates that we expend our limited resources on. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; There can be no guarantee that we will be able to successfully develop and commercialize product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We may not be successful in our efforts to use iBio technologies to build a pipeline of product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Clinical trials are very expensive, time-consuming and difficult to design and implement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We or our clients, collaborators or licensees are dependent upon successful preclinical and clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; If we, or our clients and collaborators, are not able to obtain required regulatory approvals, we, or our clients and collaborators, will not be able to commercialize our, or third-party, product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Alternative technologies may supersede our technologies or make them noncompetitive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Our clinical product candidates may exhibit undesirable side effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Our failure to receive or maintain regulatory approval for product candidates could negatively impact our revenue and profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Product liability lawsuits could cause us to incur substantial liabilities and to limit product commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Any manufacturing problems experienced by our only third-party contract manufacturer could result in a delay or interruption in the supply of our clinical product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Dependence on Third Parties</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; If we are unable to establish new collaborations and maintain both new and existing collaborations, or if these collaborations are not successful, our business could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226;<span style="font-style:italic;font-weight:bold;"> </span>If third parties on whom we or our licensees will rely for the conduct of preclinical and clinical studies do not perform as required, we may not be able to obtain regulatory approval for or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Our inability to obtain materials or supplies may adversely impact our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Any claims beyond our insurance coverage limits may result in substantial costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We may be subject to various litigation claims and legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Intellectual Property</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; If we or our licensors are unable to obtain and maintain sufficient patent protection for our technology and products, our ability to successfully commercialize our technology and products may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We may become involved in lawsuits to protect or enforce our patents or other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Patent terms may be inadequate to protect our competitive position for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; If we are unable to protect our trade secrets, our business and competitive position would be harmed<span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We may be subject to claims challenging the inventorship of our patent filings and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We may not be able to protect our intellectual property rights throughout the world.</p><a id="_Hlk81917490"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; If we should fail to comply with various patents laws, our patent protection could be reduced or eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Changes in patent law could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to iBio&#8217;s Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We recently identified and remediated material weaknesses in our internal controls, and we cannot provide assurances that these weaknesses will not occur in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; The loss of one or more of our executive officers or key employees could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; A failure to have an appropriately skilled and adequate workforce could adversely impact the ability of our R&amp;D facility to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; A natural disaster, unfavorable weather conditions or other disruptions at laboratory would adversely affect our business and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; If we are unable to protect the confidentiality of our customers&#8217; proprietary information, we may be subject to claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We may face integration risks and additional costs if we acquire companies, products or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Our Common Stock </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Our stockholders will experience dilution from the issuance of the development milestone payments if paid in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We are subject to compliance under the NYSE American continued listing standards of the NYSE American Company Guide, the failure of which can result in our delisting from the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Provisions in our certificate of incorporation, bylaws and under Delaware law could discourage a takeover.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Our bylaws provide that the Delaware Court of Chancery is the exclusive forum for certain disputes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We do not anticipate paying cash dividends for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; The issuance of preferred stock could adversely affect the rights of the holders of shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Changes in general economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We rely extensively on our information technology systems and are vulnerable to damage and interruptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Holders of our warrants have no rights as common stockholders until they exercise their warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; The market price of our common stock has been and may continue to be volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; Reports published by securities or industry analysts, could adversely affect our common stock price and trading volume.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;">&#8226; We are subject to<span style="font-style:italic;font-weight:bold;"> </span>reduced disclosure requirements applicable to smaller reporting companies<span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt;"><b style="font-weight:bold;">Detailed Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business faces many risks. Past experience may not be indicative of future performance, and as noted elsewhere in this Annual Report, we have included forward-looking statements about our business, plans and prospects that are subject to change. Forward-looking statements are particularly located in, but not limited to, the sections &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; In addition to the other risks or uncertainties contained in this Annual Report, the risks described below may affect our operating results, financial condition and cash flows. If any of these risks occur, either alone or in combination with other factors, our business, financial condition or operating results could be adversely affected, and the trading price of our common stock may decline. Moreover, readers should note this is not an exhaustive list of the risks we face; some risks are unknown or not quantifiable, and other risks that we currently perceive as immaterial may ultimately prove more significant than expected. Statements about plans, predictions or expectations should not be construed to be assurances of performance or promises to take a given course of action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a limited operating history developing vaccines and therapeutics, which may limit the ability of investors to make an informed investment decision.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We commenced independent operations in 2008, and our operations to date have included organizing and staffing our company, business planning, raising capital, acquiring and developing our proprietary technologies, identifying potential product candidates and undertaking, through third parties, preclinical trials and clinical trials of product candidates derived from our technologies. During the past year, we shifted our focus away from generating revenue as a CDMO service provider to the development of vaccines and therapeutics for commercialization. Our current focus is on immune-oncology therapeutics. &#160;The current vaccines and therapeutics being developed are all in preclinical development. Certain vaccine candidates using iBio&#8217;s technologies have previously been evaluated by other organizations in Phase 1 clinical trials; however, all of our vaccine and therapeutic protein product candidates are still in preclinical development. Neither we nor our collaborators have completed any other clinical trials for any vaccine or therapeutic protein product candidate produced using iBio technology. As a result, we have not yet demonstrated our ability to successfully complete any Phase 2 or pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any conclusion you reach about our future success or viability may not be as predictive as it might be if we had a longer operating history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we receive regulatory approval for the sale of any of our product candidates, we do not know when we will begin to generate significant revenue from such product candidates, if at all. Our ability to generate revenue depends on a number of factors, including our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">set an acceptable price for our products and obtain coverage and adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales, marketing, manufacturing and distribution systems; add operational, financial and management information systems and personnel, including personnel to support our clinical, manufacturing and planned future clinical development and commercialization efforts and operations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture commercial quantities of product candidates at acceptable cost levels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieve broad market acceptance of our product candidates in the medical community and with third-party payors and consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract and retain an experienced management and advisory team;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launch commercial sales of our products, whether alone or in collaboration with others; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with development and manufacturing product candidates, we are unable to predict if we will generate significant revenue. If we cannot successfully execute on any of the factors listed above, our business may not succeed, and we may never generate significant revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are reviewing potential options to extend our cash runway. This review could impact our future operations and financial position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact our liquidity. &#160;In an effort to improve liquidity and our runway, we have placed our CDMO business and Facility on the market for sale and recently entered into an agreement for the sale of the CDMO Facility, reduced our work force and ceased operations of our CDMO, thereby reducing annual spend on expenses by approximately 67% and generating cash savings of approximately 64% from first quarter Fiscal year 2023 compared to the fourth quarter Fiscal year 2023. Potential options being considered&#160;to further increase liquidity, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from the capital markets, grant revenue or collaborations, or a combination thereof. However, we anticipate that our expenses will increase as we continue our research and development activities and conduct clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our cash, cash equivalents and restricted cash of $7.6 million as of June 30, 2023, is not anticipated to be sufficient to support our operations for at least 12 months from the date of the filing of this Annual Report unless we reduce our burn rate further, sell the CDMO Facility for amounts above its term note payable, or raise additional capital. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our near and long-term business plans. In fact, our current cash, cash equivalents and restricted cash as of June 30, 2023, is not anticipated to be sufficient to support operations through the second quarter of Fiscal 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 1pt 0pt 0pt;">There can be no assurance that all of the conditions set forth in the Purchase and Sale Agreement will be met and that we will be able to close on the sale of the CDMO Facility or that if we are able to do so that we do so on favorable terms or that we will be able to do so before the maturity date of the Term Loan or that the exploration of potential options will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. If we determine to change our business strategy, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or projected by our management. Because of the significant uncertainty regarding our future plans, we are not able to accurately predict the impact of a potential change in our business strategy and future funding requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.45pt;margin:0pt;"><span style="font-size:8.45pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our historical operating results indicate substantial doubt exists related to our ability to operate as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have incurred net losses and used significant cash in operating activities since inception, and we expect to continue to generate operating losses for the foreseeable future. As of June 30, 2023, we have an accumulated deficit of $288.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We held cash, cash equivalents and restricted cash of $7.6 million as of June 30, 2023. Based on current trends and activities, there is significant doubt that we can continue as a going concern beyond the second quarter of Fiscal 2024. We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact our liquidity. Potential options being considered&#160;to increase liquidity include focusing product development on a select number of product candidates, the sale of the CDMO Facility, the sale or out-licensing of certain product candidates or parts of the business, raising money from capital markets, grant revenue or collaborations, or a combination thereof. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our longer-term business plan. We believe based on input from expert advisors, that it is likely we will be able to implement one or more options that will extend our cash runway for 12 months or more from the date of the filing of this Annual Report. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:8.7pt;text-align:justify;margin:0pt;"><span style="font-size:8.7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Our consolidated audited financial statements as of and for the year ended June 30, 2023 have been prepared under the assumption that we will continue as a going concern for the next 12 months. Our management concluded that our recurring losses from operations and the fact that we have&#160;not generated significant revenue or positive cash flows from operations raise substantial doubt about our ability to continue as a going concern for the next 12 months after issuance of our financial </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">statements. Our auditors also included an explanatory paragraph in its report on our financial statements as of and for the year ended June 30, 2023 with respect to this uncertainty.&#160;</span>If we continue to experience operating losses, and we are not able to generate additional liquidity through a capital raise or other cash infusion, we might need to secure additional sources of funds, which may or may not be available to us. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to further scale back or discontinue the development of our product candidates or other research and development initiatives or initiate steps to cease operations or liquidate our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since our inception. We expect to incur losses during our next fiscal&#160;year, we do not anticipate generating significant revenue for several years and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since our 2008 spinoff from Integrated BioPharma, we have incurred operating losses and negative cash flows from operations. Our comprehensive net loss was approximately ($64.8) million and ($50.5) million for the years ended June 30, 2023 and 2022, respectively. As of June&#160;30, 2023, we had an accumulated deficit of approximately ($288.9) million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have financed our operations primarily through the sale of common stock, preferred stock and warrants. We devoting substantially all of our efforts to research and development, including the development and validation of our technologies, and the development of a proprietary therapeutic products against oncology. We have not completed development of or commercialized any vaccine or therapeutic product candidates. We expect to continue to incur significant expenses and may incur operating losses for at least the next&#160;year. We anticipate that our expenses and losses will increase substantially if we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue the research and development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to discover or license in additional product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our product development and manufacturing efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our future profitability and cash flow in large part depends on our research and development programs, including our AI platform, and our ability to successfully develop, partner or commercialize our product candidates and to a lesser extent, which is not anticipated for several years. Our cash position is expected to limit the number of product candidates that we seek to develop. This will require us, alone or with our licensees and collaborators, to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling those products for which regulatory approval is obtained or establishing collaborations with parties willing and able to provide necessary capital or other value. We may never succeed in these activities. We may never generate revenues that are significant or large enough to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our existing product candidates are in various stages of development and will require extensive additional clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide us with any revenue. As a result, even if we successfully develop, achieve regulatory approval and commercialize our products, we may be unable to generate revenue for many&#160;years, if at all. We do not anticipate that we will generate revenue from product sales for at least several&#160;years, if at all. If we are unable to generate revenue from product sales, we will not become profitable, and we may be unable to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would diminish the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We anticipate that our expenses will increase in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Although we have recently reduced expenses, we expect our research and development expenses to increase significantly in light of the acquisition of the assets of RubrYc as our product candidates advance in clinical development, and as we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">add more employees. As part of the regulatory process, we must conduct clinical trials for each product candidate to demonstrate safety and efficacy to the satisfaction of the FDA and other regulatory authorities. The number and design of the clinical trials that will be required varies depending upon product candidate, the condition being evaluated, and the trial results themselves. Therefore, it is difficult to accurately estimate the cost of the clinical trials. Clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time consuming. We estimate that clinical trials of our product candidates will take at least several years to complete. Because of numerous risks and uncertainties involved in our business, the timing or amount of increased development expenses cannot be accurately predicted, and our expenses could increase beyond expectations if we are required by the FDA, or comparable non-U.S. regulatory authorities, to perform studies or clinical trials in addition to those we currently anticipate. We anticipate that further product development is also expected to increase expenses, including but not limited to the expected initiation of IND-enabling studies IBIO-101 and the additional studies that will be required to support development of our immuno-oncology programs. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, as we expand our business, we will need to retain additional employees with the necessary skills including employees for our continued expansion of drug discovery capabilities in San Diego, California. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if any of our product candidates are approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of and the related commercial-scale manufacturing requirements for our product candidates. As a result, we expect to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of future expenses or when, or if, we will be able to achieve or maintain profitability. These losses have had and will continue to have an adverse effect on our financial position and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We need additional funding to fully execute our business plan, which funding may not be available on commercially acceptable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate the commercialization of our development and manufacturing services and efforts for our product development programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Even if we are able to consummate the sale of the Facility, we will need additional capital to fully implement our near term and long-term business, operating and development plans as we do not anticipate that any of our product candidates will generate revenue in the next few years, if at all. To the extent that we initiate or continue clinical development without securing collaborator or licensee funding, our research and development expenses could increase substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">When we elect to raise additional funds or additional funds are required, we may raise such funds from time to time through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. Additional equity or debt financing or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. We currently have no committed sources of funding. &#160;Our <span style="background:#ffffff;">purchase agreement that we entered into on August 4, 2023 (the &#8220;Purchase Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), allows us to sell shares of common stock to Lincoln Park only if certain conditions are met and there can be no guarantee that we will meet such conditions. </span>The Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) that we entered into with Cantor Fitzgerald &amp; Co. (&quot;Cantor Fitzgerald&quot;) in November 25, 2020 also has certain requirements that we must meet in order to sell securities pursuant to the Sales Agreement. There can be no assurance that we will meet the requirements to be able to sell securities pursuant to the Purchase Agreement or the Sales Agreement, of if we meet the requirements that we will be able to raise sufficient funds on favorable terms. In addition,<span style="background:#ffffff;"> &#160;we will not be eligible to sell securities pursuant our registration statement on Form S-3, including pursuant to the Sales Agreement, from the date of the filing of this Annual Report until March 1, 2024 due to our late filing of our Quarterly Report on Form 10-Q for the quarter ended December 31, 2022. &#160;There can be no assurances that we will be able to raise the funds needed, especially in light of the fact that our ability to sell securities registered on our registration statement on Form S-3 after we regain eligibility to use a registration statement on Form S-3 will be limited until such time the market value of our voting securities held by non-affiliates is $75 million or more. </span>If we are unable to raise capital in sufficient amounts when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">commercialization efforts and our ability to generate revenues and achieve or sustain profitability will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly liquidate assets or cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The actual amount of funds we will need to operate is subject to many risk factors, some of which are beyond our control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control therefore we are unable to determine this amount with certainty. These factors include the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of our research activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of our research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of our preclinical and clinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of the development efforts of parties with whom we have entered into research and development agreements and amount of funding received from partners and collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve our milestones under licensing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with manufacturing related services to produce materials for use in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs incurred to screen and enroll patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of regulatory approvals.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We have based our estimate on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. Additionally, we may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Until such time as we can generate substantial development, manufacturing, license or product revenues, we expect to finance our cash needs through a combination of equity offerings, collaborations, strategic alliances, service contracts, manufacturing contracts, facility build-out and technology transfer contracts, licensing and other arrangements. Sources of funds may not be available or, if available, may not be available on terms satisfactory to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences, which are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, our business, operating results, financial condition and prospects could be materially and adversely affected, and we may be unable to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">To the extent that we raise additional capital through a public or private offering and sale of equity securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Sales of our common stock offered through current or future equity offerings may result in substantial dilution to our stockholders. The sale of a substantial number of shares of our common stock to investors, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</p><a id="_Hlk145834025"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">There can be no assurance that the sale of the Property will &#160;be completed in a timely manner or at all</span><span style="font-style:italic;font-weight:bold;">. If the sale is not completed by December 31, 2023, it is unlikely iBio CDMO would have sufficient funding to pay the Term Loan with Woodforest for which we are a guarantor.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Although we have entered into a Purchase and Sale Agreement for the sale of the Property, there can be no assurance that the sale of the Property will &#160;be completed in a timely manner or at all. &#160;The closing of the sale is subject to many conditions</p><a id="_Hlk145876813"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">including: (i) Majestic Realty&#8217;s delivery to iBio CDMO and the Escrow Agent of written notice of its approval of the condition of the Property (the &#8220;Property Approval Notice&#8221;) on or before 5:00 p.m. Central time on October 16, 2023 ; (ii) Majestic Realty obtaining the approval of The Board of Regents of the Texas A&amp;M University System of Majestic Realty&#8217;s purchase from it of the fee interest in the Land on or before 5:00 p.m. Central time on November 13, 2023; and (iii) the delivery at closing by the title company of a title policy to Majestic Realty in the amount of the purchase price. &#160;None of the mentioned closing conditions are within our control. We cannot guarantee that these conditions will be satisfied. The conditions to the closing of the sale of the Property may not be fulfilled in a timely manner or at all, and, accordingly, the sale may not be completed. &#160;If the closing is not consummated prior to the December 31, 2023 maturity date of the Term &#160;Loan it is unlikely that we will have sufficient funds the repay the Term Loan on its maturity date, the outstanding balance of which is $12,688,817 as of September 15, 2023. Our failure to make such payments when due could result in our loss of the Facility. Any action to proceed against our assets would likely have a serious disruptive effect on our business operations, especially if the Facility or our other assets were foreclosed upon or our guarantee were enforced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Failure to complete the sale of the Property could negatively impact our stock price and our future business and financial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Majestic Realty&#8217;s obligation to complete the sale of the Property is subject to the satisfaction or waiver of a number of conditions set forth in the Purchase and Sale Agreement. There can be no assurance that the conditions to complete the sale will be satisfied or waived or that the sale will be completed. If the sale is not completed for any reason, our ongoing business may be materially and adversely affected and, without realizing any of the benefits of having completed the sale, we would be subject to a number of risks, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience negative reactions from the financial markets, including negative impacts on the trading price of our common stock, which could affect its ability to secure sufficient financing in the future on attractive terms (or at all); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will be required to pay our transaction-related expenses incurred in connection with the Purchase and Sale Agreement whether or not the sale is completed; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">matters related to the sale of the Property may require substantial commitments of time and resources by our management, which could otherwise have been devoted to other opportunities that may have been beneficial to us.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In addition, we could be subject to litigation related to any failure to complete the sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">If the sale of the Property is not completed, we cannot assure our stockholders that the risks described above will not materialize and will not materially and adversely affect our business, financial condition, financial results and common stock prices.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the sale of the Property is not completed, we will have incurred substantial expenses without realizing the expected benefits of the sale. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:10pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">We have incurred substantial expenses in connection with the negotiation and completion of the transactions contemplated by the Purchase and Sale Agreement. If the sale of the Property is not completed, we would have to recognize these expenses without realizing the expected benefits of the sale</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The unaudited pro forma financial information included as an exhibit to this Current Report on Form 8-K is for illustrative purposes. Our actual financial position or results of operations after the anticipated sale may differ materially.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The unaudited pro forma financial information included as an exhibit to our Current Report on Form 8-K filed with the SEC on September 21, 2023<span style="font-style:italic;font-weight:bold;"> </span>and incorporated by reference herein is presented for illustrative purposes only and is not necessarily indicative of what our actual financial position or results of operations would have been had the sale been completed on the dates indicated. The unaudited pro forma financial information reflects adjustments, which are based upon estimates.<span style="font-family:'Arial','Helvetica','sans-serif';"> </span>The information upon which these adjustments and assumptions have been made is preliminary, and these kinds of adjustments and assumptions are difficult to make with complete accuracy. Moreover, the pro forma financial information does not reflect all costs that are expected to be incurred by us. Accordingly, the final accounting adjustments may differ materially from such pro forma information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The failure to comply with the terms of the Credit Agreement, as amended, could result in a default under the terms of the&#160;Credit Agreement, as amended,&#160;and,&#160;if&#160;uncured,&#160;it&#160;could potentially result in action against our pledged assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">There is no assurance that we will generate sufficient revenue or raise sufficient capital to be able to make the required principal payment under the Term Loan that iBio CDMO entered into with Woodforest. The Term Loan with Woodforest is secured by (a) a leasehold deed of trust on our Facility, and (b) a first lien on all assets of iBio CDMO including the Facility. &#160;We have also guaranteed the payment of all iBio CDMO&#8217;s obligations under the Credit Agreement. &#160;The Term Loan matures the earlier of December 31, 2023, or the acceleration of maturity of the Term Loan pursuant to the Credit Agreement. &#160;If we or iBio CDMO fail to comply with the terms of the Term Loan and/or the related agreements, including the affirmative and negative covenants contained therein, Woodforest National Bank could declare a default and if the default were to remain uncured, Woodforest National Bank would have the right to proceed against any or all of the collateral securing their Term Loan. Our failure to make such payments when due could result in our loss of the Facility. Any action to proceed against our assets would likely have a serious disruptive effect on our business operations, especially if the Facility or our other assets were foreclosed upon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Credit Agreement, as amended, requires that we pay a significant amount of cash to the lender. Our ability to generate sufficient cash to make all required payments under the Credit Agreement, as amended, depends on many factors beyond our control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;">Our ability to make payments on and to refinance the Term Loan, to fund planned capital expenditures and to maintain sufficient working capital depends on our ability to raise capital and generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. We cannot assure you that our business will generate sufficient cash flow from operations or from other sources in an amount sufficient to enable us to service our debt or to fund our other liquidity needs. To date, we have generated minimal revenue and have financed a significant portion our capital needs from sales of our equity and most recently the Term Loan. &#160;There can be no assurance that financing options will be available to us when needed to make payments under the Term Loan or if available, that they will be on favorable terms. If our cash flow and capital resources are insufficient to allow us to make payments due under the Term Loan, we may need to seek additional capital or restructure or refinance all or a portion of the Term Loan on or before the maturity thereof, any of which could have a material adverse effect on our business, financial condition or results of operations. Although we plan to explore potential longer-term financing options for our Facility, including, but not limited to, the sale of the Facility, we cannot assure you that we will be able to enter consummate the sale prior to the maturity date of the Term Loan or refinance the Term Loan on commercially reasonable terms or at all. If we are unable to generate sufficient cash flow to repay or refinance our debt on favorable terms, it could significantly adversely affect our financial condition. Our ability to restructure or refinance the Term Loan will depend on the condition of the capital markets and our financial condition. Any refinancing of the Term Loan could </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;">be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. There can be no assurance that we will be able to obtain any financing when needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Covenant restrictions in the Credit Agreement, as amended, may limit our ability to operate our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Credit Agreement contains, and our future indebtedness agreements may contain covenants that restrict our ability to finance future operations or capital needs or to engage in other business activities. The Credit Agreement, as amended, currently requires maintaining $1,000,000 of unrestricted cash and cash equivalents and restricts our ability to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur, assume or guarantee additional Debt (as defined in the Credit Agreement);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">repurchase capital stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make other restricted payments including, without limitation, paying dividends and making investments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell or otherwise dispose of assets.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">As of the date of this filing, iBio is in compliance with this covenant in the Credit Agreement, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">In order to develop certain of our product candidates we will rely upon government funding. Any government funding for our R&amp;D programs may impose requirements that limit our ability to take certain actions, and subject us to potential financial penalties, which could materially and adversely affect our business, financial condition and results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have applied for government grants to support some of our research and development activities for our product candidates. &#160;If we do not obtain the grants we applied for or other grants, we currently do not anticipate developing certain of our product candidates. &#160;Even if we obtain grant funding, the terms of the grant funding may be restrictive. Often government grants include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to potentially require repayment of all or a portion of the grant award proceeds, in certain cases with interest, in the event we violate certain covenants pertaining to various matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Risks Related to the Development and Commercialization of Our Technologies and Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have&#160;a limited operating history developing precision antibodies,&#160;no products approved for commercial sale, have no significant source of revenue and may never generate significant revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">We are a pre-clinical-stage biopharmaceutical company that recently began to focus on leveraging the power of Artificial Intelligence (AI) for the development of precision antibodies. Prior to August 23, 2021, when we entered into a series of agreements with RubrYc, we were focused on our CDMO business<i style="font-style:italic;">. </i>We have never generated any product revenue from the development of precision antibodies, do not expect to generate revenue in the near future and&#160;do not have any products approved for sale. Our operations to date have been primarily focused on developing our product candidates. We have not yet successfully conducted any clinical trials of any antibodies we have developed. Consequently, predictions about our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;">future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our existing product candidates are in very early stages of development and will require extensive additional clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide us with any revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have a limited number of product candidates in early stages of pre-clinical development and are dependent on the success of these product candidates, which requires significant clinical testing before seeking regulatory approval. If our product candidates do not receive regulatory approval or are not successfully commercialized, our business may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently in preclinical development of multiple product candidates as potential treatments across multiple therapeutic areas; however, we announced we are evaluating potential options to extend our cash runway and may change the focus of our resources. It is possible that we may never be able to develop a marketable product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that a substantial portion of our efforts and expenditures over the next few&#160;years will be devoted to our product candidates in the immune-oncology field. Accordingly, our business currently depends heavily on the successful development, regulatory approval and commercialization of these product candidates, which may not receive regulatory approval or be successfully commercialized even if regulatory approval is received. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of product candidates are and will remain subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries that each have differing regulations. We are not permitted to market any product in the United States unless and until we receive approval from the FDA, or in any foreign countries unless and until we receive the requisite approval from regulatory authorities in such countries. We have never submitted an NDA or BLA to the FDA or comparable applications to other regulatory authorities and do not expect to be in a position to do so for the foreseeable future. Obtaining approval of an NDA or BLA is an extensive, lengthy, expensive, and inherently uncertain process, and the FDA may delay, limit or deny approval of its product for many reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, our focus is limited to the development of multiple product candidates. As a result, we may forego or delay pursuit of opportunities with other technologies or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending and the spending of our clients and collaborators may not yield any commercially viable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have based our research and development efforts largely on our technologies and product candidates derived from such technologies. Notwithstanding our large investment to date and anticipated future expenditures in these technologies, we have not yet developed, and may never successfully develop, any marketed products using these technologies. As a result, we may fail to address or develop product candidates based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also may not be successful in our efforts to identify or discover additional product candidates using our technologies. Research programs to identify new product candidates require substantial technical, financial, and human resources. These research programs may initially show promise in identifying potential product candidates yet fail to yield product candidates for clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular technology or product candidate and fail to capitalize on technologies or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Because we have limited financial and managerial resources, we focus on specific product candidates derived from or enhanced by our technologies or that have been identified and partially developed by our clients or collaborators. As a result, we may forego or delay pursuit of opportunities with other technologies or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commercial products or profitable market opportunities. Our spending and the spending of our clients and collaborators may not yield any commercially viable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have based our research and development efforts largely on our technologies and product candidates derived from such technologies. Notwithstanding our large investment to date and anticipated future expenditures in these technologies, we have not yet developed, and may never successfully develop, any marketed products using these technologies. As a result, we may fail to address or develop product candidates based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also may not be successful in our efforts to identify or discover additional product candidates using our technologies. Research programs to identify new product candidates require substantial technical, financial, and human resources. These research programs may initially show promise in identifying potential product candidates yet fail to yield product candidates for clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements on terms less favorable to us than possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We, our clients and collaborators, are very early in our development efforts. If we or our clients and collaborators are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our vaccine and therapeutic protein product candidates are still in preclinical development. Our ability to generate product sales revenues for our own products, which we do not expect will occur for many&#160;years, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical studies and clinical trials with positive results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity, which may exceed patent exclusivity, for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers for commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully maintaining existing collaborations and entering into new ones throughout the development process as appropriate, from preclinical studies through to commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the products, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other products;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for any products we successfully develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protecting our rights in our intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the products following approval.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to use iBio technologies to build a pipeline of product candidates and develop marketable products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">While we believe that data we and our collaborators have obtained from preclinical studies of iBio technology-derived and iBio technology-enhanced product candidates has validated these technologies, our technologies have not yet, and may never lead to, approvable or marketable products. Even if we are successful in further validating our technologies and continuing to build&#160;our pipeline, the potential product candidates that we identify may not be suitable for clinical development for many possible reasons, including harmful side effects, limited efficacy or other characteristics that indicate that such product candidates are unlikely to be products that will receive marketing approval and achieve market acceptance.&#160;If we and our collaborators do not successfully develop and commercialize product candidates based upon our technologies, we will not obtain product or collaboration revenues in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials are very expensive, time-consuming, and difficult to design and implement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. We estimate that clinical trials for our product candidates would take at least several&#160;years to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining an IND application with the FDA or foreign equivalent to commence clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identification of, and acceptable arrangements with, one or more clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining IRB or EC approval to commence clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining IBC approval for use of a genetically modified organism;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination of dosing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of effectiveness during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected rates of patient recruitment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to monitor patients adequately during or after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lower than expected rates of patient completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain supply of our drug candidate in a timely manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of medical investigators to follow our clinical protocols; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unwillingness of the FDA or foreign equivalent, IRBs/ECs, or IBCs to permit the clinical trials to be initiated.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In addition, we, IRBs/ECs or the FDA or foreign equivalent may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs/ECs or the FDA or foreign equivalent finds deficiencies in our submissions or conduct of our trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neither we nor our clients, collaborators or potential licensees will be able to commercialize product candidates based on our technologies and services if preclinical studies do not produce successful results or clinical trials do not demonstrate safety and efficacy in humans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Preclinical and clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and has an uncertain outcome. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily predict final results. We and our licensees may experience numerous unforeseen events during, or as a result of, preclinical testing and the clinical trial process that could delay or prevent the commercialization of product candidates based on our iBio technologies, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical or clinical trials may produce negative or inconclusive results, which may require additional preclinical testing, additional clinical trials or the abandonment of projects that we expect to be promising. For example, promising animal data may be obtained about the anticipated efficacy of a therapeutic protein product candidate and then human tests may not result in such an effect. In addition, unexpected safety concerns may be encountered that would require further testing even if the therapeutic protein product candidate produced an otherwise favorable response in human subjects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Initial clinical results may not be supported by further or more extensive clinical trials. For example, a licensee may obtain data that suggest a desirable immune response from a product candidate in a small human study, but when tests are conducted on larger numbers of people, the same extent of immune response may not occur. If the immune response generated by a product candidate is too low or occurs in too few treated individuals, then the product candidate will have no commercial value.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enrollment in any clinical trials that we or our licensee&#8217;s conduct may be slower than projected, resulting in significant delays. The cost of conducting a clinical trial increases as the time required to enroll adequate numbers of human subjects to obtain meaningful results increases. Enrollment in a clinical trial can be a slower-than-anticipated process because of competition from other clinical trials, because the study is not of interest to qualified subjects, or because the stringency of requirements for enrollment limits the number of people who are eligible to participate in the clinical trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We or our potential licensees might have to suspend or terminate clinical trials if the participating subjects are being exposed to unacceptable health risks. Animal tests do not always adequately predict potential safety risks to human subjects. The risk of any candidate product is unknown until it is tested in human subjects, and if subjects experience adverse events during the clinical trial, the trial may have to be suspended and modified or terminated entirely.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Regulators or institutional review boards may suspend or terminate clinical research for various reasons, including safety concerns or noncompliance with regulatory requirements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any regulatory approval ultimately obtained may be limited or subject to restrictions or post-approval commitments that render the product not commercially viable.</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The effects of iBio technology-derived or iBio technology-enhanced product candidates may not be the desired effects or may include undesirable side effects.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant clinical trial delays could allow our competitors to bring products to market before we or our licensees do and impair our ability to commercialize our technologies and product candidates based on our technologies. Poor clinical trial results or delays may make it impossible to license a product candidate, or reduce its attractiveness to prospective licensees, so that we will be unable to successfully develop and commercialize such a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Clinical trials are risky, lengthy, and expensive. We will incur substantial expense for, and devote significant time and resources to, preclinical testing and clinical trials, yet we cannot be certain that these tests and trials will demonstrate that a product candidate is effective and well-tolerated or will ever support its approval and commercial sale. For example, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">clinical trials require adequate supplies of clinical trial material and sufficient patient enrollment to power the trial. Delays in patient enrollment can result in increased costs and longer development times. Even if we, or a licensee or collaborator, if applicable, successfully complete clinical trials for our clinical product candidate, we or they might not file the required regulatory submissions in a timely manner and may not receive marketing approval for the clinical product candidate. We cannot assure you that our clinical product candidate will successfully progress further through the drug development process or will ultimately result in an approved and commercially viable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we, or our clients and collaborators, are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we, or our clients and collaborators, will not be able to develop or commercialize our, or third-party, product candidates or will not be able to do so as soon as anticipated, and our ability to generate revenue will be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and by similar regulatory authorities outside the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to engage in any clinical trials for any of our product candidates and there is no assurance that we will conduct successful clinical trials or obtain approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third parties to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use in such a restrictive manner that it is not possible to obtain commercial viability for such product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many&#160;years. If additional clinical trials are required for certain jurisdictions, these trials can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved, and may ultimately be unsuccessful. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review process for each submitted product application, may cause delays in the review and approval of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept a marketing application as deficient or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the FDA and other regulatory authorities have approved plant-based therapeutics in the past, consistent with the oversight of all products, the FDA is monitoring whether these plant-based therapeutics pose any health and human safety risks. While they have not issued any regulation to date that is averse to plant-based vaccines or therapeutics, it is possible that the FDA and other regulatory authorities could issue regulations in the future that could adversely affect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product candidate, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">efficacy and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and current GCP requirements for any clinical trials that we conduct post-approval. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval. If our clinical product candidate receives marketing approval, the accompanying label may limit the approved use of our product, which could limit sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alternative technologies may supersede our technologies or make them noncompetitive, which would harm our ability to generate future revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The manufacture of precision antibodies and use of artificial intelligence to do so is intensely competitive. There are currently extensive research efforts in this field, which result in rapid technological progress that can render existing technologies obsolete or economically noncompetitive. If our competitors succeed in developing more effective technologies or render our technologies obsolete or noncompetitive, our business will suffer. Many universities, public agencies and established pharmaceutical, biotechnology, and other life sciences companies with substantially greater resources than we have are developing and using technologies and are actively engaging in the development of products similar to or competitive with our technologies and products. To remain competitive, we must continue to invest in new technologies and improve existing technologies. To make such renewing investment we will need to obtain additional financing and/or collaborations. If we are unable to secure such financing, we will not have sufficient resources to continue such investment. In addition, they also have significantly greater experience in the discovery and development of products, as well as in obtaining regulatory approvals of those products in the United States and in foreign countries. Our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our competitors may devise methods and processes for protein expression that are faster, more efficient or less costly than that which can be achieved using iBio technologies. There has been and continues to be substantial academic and commercial research effort devoted to the development of such methods and processes. If successful competitive methods are developed, it may undermine the commercial basis for iBio products and our technologies and related services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For our cancer product candidates, not only will we compete with companies engaged in various cancer treatments including radiotherapy and chemotherapy, but we will also compete with various companies that have developed or are trying to develop immunology vaccines for the treatment of cancer. Certain of our competitors have substantially greater capital resources, large customer bases, broader product lines, sales forces, greater marketing and management resources, larger research and development staffs with extensive facilities and equipment than we do and have more established reputations as well as global distribution channels. Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Bristol-Myers Squibb Company, Merck&#160;&amp; Co.,&#160;Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca plc), Johnson&#160;&amp; Johnson, Pfizer&#160;Inc., MerckKGaA and Sanofi SA, and more established biotechnology companies such as Genentech,&#160;Inc. (a member of the Roche Group), Amgen&#160;Inc., Gilead Sciences,&#160;Inc. and its subsidiary Kite Pharma,&#160;Inc., and competing cancer immunotherapy companies such as, Bluebird Bio,&#160;Inc., Transgene SA, Bausch Health Companies, Lumos Pharma, Agenus&#160;Inc., Aduro Biotech,&#160;Inc., Advaxis,&#160;Inc., ImmunoCellular Therapeutics,&#160;Ltd., IMV&#160;Inc., Oxford BioMedica plc, Bavarian Nordic A/S, Celldex Therapeutics,&#160;Inc., as well as tech enabled drug discovery companies such as Recursion, Abcellera Biologics, Inc., Cellarity, and BenevolentAI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products, which may delay or preclude its development or regulatory approval or limit its use if ever approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Throughout the drug development process, we must continually demonstrate the activity, safety, and tolerability of our product candidates in order to obtain regulatory approval to further advance our clinical development, or to eventually market it. Even if any of our product candidates demonstrate adequate biologic activity and clear clinical benefit, any </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">unacceptable side effects or adverse events, when administered alone or in the presence of other pharmaceutical products, may outweigh these potential benefits. We may observe adverse or serious adverse events or drug-drug interactions in preclinical studies or clinical trials of our clinical product candidate, which could result in the delay or termination of its development, prevent regulatory approval, or limit its market acceptance if it is ultimately approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Adverse events caused by any of our product candidates or generally by plant-based therapeutics could cause reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. If an unacceptable frequency or severity of adverse events are reported in any clinical trials we may conduct for our product candidates, our ability to obtain regulatory approval for such clinical product candidate may be negatively impacted. In addition, adverse events caused by any product candidate administered in combination with our product candidates could cause similar interruptions and delays, even though not caused by our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, if any of our products are approved and then cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the clinical product candidate or impose restrictions on its distribution or other risk management measures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for injuries sustained by patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could elect to discontinue the sale of the clinical product candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected clinical product candidate and could substantially increase the costs of commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face the risk of product liability exposure in connection with the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced resources of our management to pursue our business strategy; and</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any products that we may develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to commencing human clinical trials, we will seek to obtain product liability insurance coverage. Such insurance coverage is expensive and may not be available in coverage amounts we seek or at all. If we obtain such coverage, we may in the future be unable to maintain such coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">For our clinical product candidates, we currently rely on one third-party contract manufacturer. Any manufacturing problems experienced by us could result in a delay or interruption in the supply of our clinical product candidate until the problem is cured or until we locate and qualify an alternative source of manufacturing and supply.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently do not manufacture any of our clinical product candidates and currently rely upon one third-party manufacturer to manufacture such product candidates. If we were to experience any prolonged disruption for our manufacturing, we could be forced to seek additional third-party manufacturing contracts, thereby increasing our development costs and negatively impacting our timelines and any commercialization costs. Although we believe there are other manufacturers that could manufacture our product candidates, they may not do so on favorable term. In addition, if we change manufacturers at any point once we commence clinical trials &#160;or after approval of a product candidate, we will be required to demonstrate comparability between the product manufactured by the old manufacturer and the product manufactured by the new manufacturer. If we are unable to do so we may need to conduct additional clinical trials with product manufactured by the new manufacturer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we or any outsourced manufacturer of our products are not able to manufacture sufficient quantities of our clinical product candidate, our development activities would be impaired. In addition, any manufacturing facility where any of our clinical product candidates are manufactured will be subject to ongoing, periodic inspection by the FDA or other comparable regulatory agencies to ensure compliance with current Good Manufacturing Practice, or cGMP. Any failure to follow and document the manufacturer&#8217;s adherence to such cGMP regulations or other regulatory requirements may lead to significant delays in the availability of clinical bulk drug substance and finished product for clinical trials, which may result in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for our clinical product candidate. We also may encounter problems with the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieving adequate or clinical-grade materials that meet FDA or other comparable regulatory agency standards or specifications with consistent and acceptable production yield and costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failing to develop an acceptable formulation to support late-stage clinical trials for, or the commercialization of, our clinical product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being unable to increase the scale of or the capacity for, or reformulate the form of our clinical product candidate, which may cause us to experience a shortage in supply or cause the cost to manufacture our clinical product candidate to increase;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot assure you that we will be able to manufacture our clinical product candidate at a suitable commercial scale, or that we will be able to find alternative manufacturers acceptable to us that can do so;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our facility closing as a result of regulatory sanctions, pandemic or a natural disaster;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shortages of qualified personnel, raw materials or key contractors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failing to obtain FDA approval for commercial scale manufacturing; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ongoing compliance with cGMP regulations and other requirements of the FDA or other comparable regulatory agencies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we encounter any of these problems or are otherwise delayed, or if the cost of manufacturing is not economically feasible or we cannot find another third-party manufacturer, we may not be able to produce our clinical product candidate in a sufficient quantity to meet future demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These risks are likely to be exacerbated by our limited experience with our current products and manufacturing processes. If demand for our products materializes, we may have to invest additional resources to purchase materials, hire and train employees, and enhance our manufacturing processes or those of third-party manufacturers. It may not be possible for us to manufacture our clinical product candidate at a cost or in quantities sufficient to make its clinical product candidate commercially viable. Any of these factors may affect our ability to manufacture our products and could reduce gross margins and profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Reliance on third-party manufacturers and suppliers entails risks to which we would not be subject if we manufacture our clinical product candidate ourselves, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third parties for regulatory compliance and quality assurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing agreements by the third parties because of factors beyond our control or the insolvency of any of these third parties or other financial difficulties, labor unrest, natural disasters or other factors adversely affecting their ability to conduct their business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possibility of termination or non-renewal of the agreements by the third parties, at a time that is costly or inconvenient for us, because of our breach of the manufacturing agreement or based on their own business priorities.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If we rely on a third-party contract manufacturer or its suppliers fail to deliver the required commercial quantities of our clinical product candidate required for our clinical trials and, if approved, for commercial sale, on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers or suppliers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality, and on a timely basis, we would likely be unable to meet demand for our products and would have to delay or terminate our pre-clinical or clinical trials, and we would lose potential revenue. It may also take significant time to establish an alternative source of supply for our clinical product candidate and to have any such new source approved by the FDA or any applicable foreign regulatory authorities. Furthermore, any of the above factors could cause the delay or suspension of initiation or completion of clinical trials, regulatory submissions or required approvals of our clinical product candidate, cause it to incur higher costs and could prevent us from commercializing our clinical product candidate successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish new collaborations and maintain both new and existing collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our current business plan contemplates that we will in the future derive revenues or payments from collaborators and licensees that successfully utilize iBio technologies in connection with the production, development and commercialization of vaccines and therapeutic protein product candidates. Our realization of these revenues and payments including dependence on existing collaborations, and any future collaborations we enter into, is subject to a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and, if successful, commercialization of product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, which divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we would potentially lose the right to pursue further development or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may learn about our technology and use this knowledge to compete with us in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of collaborators&#8217; preclinical or clinical studies could produce results that harm or impair other products using our technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there may be conflicts between different collaborators that could negatively affect those collaborations and others; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our collaborations do not result in the successful development and commercialization of products or if one or more of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. There can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We seek to establish and collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of iBio technology-produced and iBio technology-enhanced product candidates. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration depends, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of several factors. If we fail to reach agreements </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development or the development of one or more of our other product candidates, or increase our expenditures and undertake additional development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product portfolio and our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If third parties on whom we or our licensees will rely for the conduct of preclinical studies and clinical trials do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business may suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited resources dedicated to designing, conducting, and managing our preclinical studies and clinical trials. We do not have the ability to independently conduct the preclinical studies and clinical trials required to obtain regulatory approval for our product candidates. We have not yet contracted with any third parties to conduct clinical trials of product candidates we develop independently of collaborators. We will depend on licensees or on independent clinical investigators, contract research organizations and other third-party service providers to conduct the clinical trials of our product candidates. We will rely on these vendors and individuals to perform many facets of the clinical development process on our behalf, including conducting preclinical studies and will rely on them for the recruitment of sites and subjects for participation in our clinical trials, maintenance of good relations with the clinical sites, and ensuring that these sites are conducting our trials in compliance with the trial protocol and applicable regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will rely heavily on these parties for successful execution of our clinical trials but will not control many aspects of their activities. For example, the investigators participating in our clinical trials will not be our employees. However, we will be responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The failure of these third parties to carry out their obligations could delay or prevent the development, approval and commercialization of our product candidates. If these third parties fail to perform satisfactorily, or do not adequately fulfill their obligations under the terms of our agreements with them, we may not be able to enter into alternative arrangements without undue delay or additional expenditures, and therefore the preclinical studies and clinical trials of our clinical product candidate may be delayed or prove unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:12pt;text-align:justify;margin:0pt;">Further, the FDA, the EMA, or similar regulatory authorities in other countries, may inspect some of the clinical sites participating in our clinical trials or our third-party vendors&#8217; sites to determine if our clinical trials are being conducted according to good clinical practices, or GCPs, or similar regulations. If we or a regulatory authority determine that our third-party vendors are not in compliance with or have not conducted our clinical trials according to applicable regulations, we may be forced to exclude certain data from the results of the trial, or delay, repeat or terminate such clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to supply the raw materials needed to operate our research and development activities and do not have any long-term commitments from such suppliers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We currently rely on third parties for the raw materials needed to operate our research and development activities. We do not have any long-term commitments from any raw material suppliers and therefore cannot guarantee that there will be adequate supply of our raw materials. Natural disasters or other disruptions at any of our suppliers&#8217; facilities may impair or delay the delivery of our products. Influenza or other pandemics, such as the coronavirus, could disrupt production of our products, reduce demand for certain of our products, or disrupt the marketplace in the food service or retail environment with consequent material adverse effects on our results of operations. To the extent we are unable to, or cannot, financially mitigate the likelihood or potential impact of such events, or effectively manage such events if they occur, particularly when a product is sourced from a single location, there could be a material adverse effect on our business and results of operations, and additional resources could be required to restore our supply chain. Although we believe we have sufficient supply of our other raw materials at this time, due to supply chain shortages, we may not be able to obtain such materials </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">in the future is our current suppliers should be unable to satisfy our needs. Such suppliers may not be able to provide us with engines in a timely manner due to supply chain shortages and even if other suppliers are able to fulfill our needs they may not be able to do so at the same price as we currently pay for such materials, which could result in lower profit margins or us increasing the price of our services in order to maintain profit margins which could adversely impact demand for our services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any claims beyond our insurance coverage limits, or that are otherwise not covered by our insurance, may result in substantial costs and a reduction in our available capital resources.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We maintain property insurance, employer&#8217;s liability insurance, product liability insurance, general liability insurance, business interruption insurance, and directors&#8217; and officers&#8217; liability insurance, among others. Although we maintain what we believe to be adequate insurance coverage, potential claims may exceed the amount of insurance coverage or may be excluded under the terms of the policy, which could cause an adverse effect on our business, financial condition and results from operations. Generally, we would be at risk for the loss of inventory that is not within customer specifications. These amounts could be significant. In addition, in the future we may not be able to obtain adequate insurance coverage, or we may be required to pay higher premiums and accept higher deductibles in order to secure adequate insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to various litigation claims and legal proceedings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We, as well as certain of our directors and officers, may be subject to claims or lawsuits during the ordinary course of business. Regardless of the outcome, these lawsuits may result in significant legal fees and expenses and could divert management&#8217;s time and other resources. If the claims contained in these lawsuits are successfully asserted against us, we could be liable for damages and be required to alter or cease certain of our business practices. Any of these outcomes could cause our business, financial performance and cash position to be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or our licensors are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates, and by maintenance of our trade secrets through proper procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States and we may fail to seek or obtain patent protection in all major markets. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions, nor can we know whether those from whom we license patents were the first to make the inventions claimed or were the first to file. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. PTO, or become involved in opposition, derivation, reexamination, <i style="font-style:italic;">inter partes</i> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if our pending or future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and ultimately unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could adversely affect us and our collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.8pt 12pt 0pt;">While no such litigation has been brought against us and we have not been held by any court to have infringed a third party&#8217;s intellectual property rights, we cannot guarantee that our technology, products or use of our products do not infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November&#160;29, 2000, and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing date, which is referred to as the priority date. Therefore, patent applications covering our products or technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the U.S. PTO </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and similar bodies in other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In spite of our efforts, our licensors might allege that we have materially breached our obligations under such license agreements and might therefore attempt to terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of our lead products or other product candidates that we may identify. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also seek to enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship of our patent filings and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Many of our employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies. These employees typically executed proprietary rights, non-disclosure and non-competition agreements in connection with their previous employers. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, while we require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our licensors or collaborators might not have been the first to make the inventions covered by an issued patent or pending patent application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our licensors or collaborators might not have been the first to file patent applications covering an invention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our or our licensors&#8217; technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pending patent applications may not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop or in-license additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file a patent application for certain trade secrets or know-how, and a third party may subsequently obtain a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we should fail to comply with various patent laws our patent protection could be reduced or eliminated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law, including recent patent reform legislation, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September&#160;2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March&#160;2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our product candidates or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to iBio&#8217;s Operations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">We recently identified and remediated material weaknesses in our internal controls, and we cannot provide assurances additional material weaknesses will not occur in the future</span><span style="background:#ffffff;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud.<span style="background:#ffffff;"> During the preparation of the Quarterly Report for the quarter ended March 31, 2023, we identified a material weakness in our controls relating to accounting for stock-based compensation expense relating to the vesting of severed employees&#8217; awards. &#160;If our internal control over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results, prevent fraud, or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.</span> <span style="background:#ffffff;">In addition, a material weakness will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are designed and operating effectively. As of June 30, 2023, management believes that significant progress has been made in enhancing internal controls and has concluded that the enhanced controls are operating effectively. &#160;Therefore, as of June 30, 2023, the material weakness described in Item 4 Controls and Procedures in our Quarterly Report on Form 10-Q for quarter ended March 31, 2023 has been fully remediated. &#160;Although the material weakness has been remediated, there can be no assurance that the internal control over financial reporting, as modified, will enable us to identify or avoid material weaknesses in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. As a growing company, implementing and maintaining effective controls may require more resources, and we may encounter internal control integration difficulties. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have experienced turnover in our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our success depends largely upon the continued services of our key executive officers. We have in the past and may in the future experience changes in our executive management team resulting from the departure of executives, which may be disruptive to our business. To continue to develop our pipeline and execute our strategy, we also must attract and retain highly skilled personnel in our industry.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A failure by iBio to hire and retain an appropriately skilled and adequate workforce could adversely impact the ability to operate and function efficiently.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">iBio&#8217;s operations will depend, in part, on our ability to attract and retain an appropriately skilled and sufficient workforce to operate our R&amp;D facility. These employees may voluntarily terminate their employment with us at any time. The R&amp;D facility is located in San Diego, California, a growing biotechnology hub and competition for skilled workers will continue to increase as the industry undergoes further growth in the area. There can be no assurance that we will be able to retain key personnel, or to attract and retain additional qualified employees especially in light of our cash position. Our inability to attract and retain key personnel as we grow in two locations may have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of our laboratory space in San Diego is critical to our success. A natural disaster or other disruptions at our laboratory would adversely affect our business, financial condition, and results of operations</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We currently conduct all of our pre-clinical research at our laboratory in San Diego using specialized equipment that we have purchased. &#160;Any natural disaster or other serious disruption to our facility due to fire, flood, earthquake, or any other unforeseen circumstance would adversely affect our business, financial condition, and results of operations. Although we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">do believe that we could find alternative space in the case of a natural disaster, there can be no assurance that we will find suitable space near the location of our employees or that our equipment will survive a natural disaster. The occurrence of any disruption at our laboratory, even for a short period of time, may have an adverse effect on our research and development operations, during and after the period of the disruption. Although we maintain property, casualty, and business interruption insurance of the types and in the amounts that we believe are customary for the industry, we are not fully insured against all potential natural disasters or other disruptions to our laboratory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to grow our business operations as demand increases and increase the number of our employees to accommodate such potential growth, which may cause us to experience periods of rapid growth and expansion. This potential future growth could create a strain on our organizational, administrative and operational infrastructure, including manufacturing operations, quality control, technical support and other administrative functions. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As our commercial operations and sales volume grow, we will need to continue to increase our capacity for manufacturing, customer service, billing and general process improvements and expand our internal quality assurance program, among other things. We may also need to purchase additional equipment, some of which can take several&#160;months or more to procure, set up and validate, and increase our manufacturing, maintenance, software and computing capacity to meet increased demand. These increases in scale, expansion of personnel, purchase of equipment or process enhancements may not be successfully implemented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our partners&#8217; or collaborators&#8217; proprietary information, we may be subject to claims.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The research and development processes developed by us or our partners&#8217; or collaborators&#8217; products are subject to trade secret protection, patents or other intellectual property protections owned or licensed by such partners. While we make significant efforts to protect our partners&#8217; proprietary and confidential information, including requiring our employees to enter into agreements protecting such information, if any of our employees breaches the non-disclosure provisions in such agreements, or if our partners make claims that their proprietary information has been disclosed, our reputation may suffer damage and we may become subject to legal proceedings that could require us to incur significant expenses and divert our management&#8217;s time, attention and resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we acquire companies, products or technologies, we may face integration risks and costs associated with those acquisitions that could negatively impact our business, results from operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are presented with appropriate opportunities, we may acquire or make investments in complementary companies, products or technologies. We may not realize the anticipated benefit of any acquisition or investment. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology with our products, diversion of our management&#8217;s attention from other business concerns, the potential loss of key employees or customers of the acquired business, and impairment charges if future acquisitions are not as successful as we originally anticipate. In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating to acquired intangible assets. Any failure to successfully integrate other companies, products, or technologies that we may acquire may have a material adverse effect on our business and results of operations. Furthermore, we may have to incur debt or issue equity securities to pay for any additional future acquisitions or investments, the issuance of which could be dilutive to our existing stockholders.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our stockholders will experience substantial dilution from the issuance of the development milestone payments if paid in equity and may not realize a benefit from the acquisition of substantially all of the assets RubrYc commensurate with the ownership dilution they will experience in connection therewith.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have the option to pay the contingent development milestone consideration owed to the RubrYc shareholders in shares of our common stock. Our stockholders will experience substantial dilution from the issuance of shares of common stock to pay the contingent development milestone consideration, should we elect to pay such development milestones in shares of common stock in lieu of cash. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">iBio is subject to compliance under the NYSE American continued listing standards of the NYSE American Company Guide, the failure of which can result in delisting from the NYSE American.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to maintain its listing with NYSE American, we must remain in compliance with the continued listing standards as set forth in the NYSE American Company Guide (the &#8220;Company Guide&#8221;), including the listing standard set forth in Section&#160;1003 of the Guide, which applies if a listed company has stockholders&#8217; equity below certain threshold amounts and has sustained losses from continuing operations and/or net losses in its five most recent fiscal&#160;years. In the past, we have received notification of noncompliance with the continued listing requirements, which to date have been remediated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will continue to meet all of the Exchange&#8217;s continued listing standards, or exemptions therefrom, in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our certificate of incorporation, bylaws and under Delaware law could discourage a takeover that stockholders may consider favorable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provisions of our certificate of incorporation, bylaws and provisions of applicable Delaware law may discourage, delay or prevent a merger or other change in control that a stockholder may consider favorable. Pursuant to our certificate of incorporation, our Board of Directors may issue additional shares of common stock or preferred stock. Any additional issuance of common stock could have the effect of impeding or discouraging the acquisition of control of us by means of a merger, tender offer, proxy contest or otherwise, including a transaction in which our stockholders would receive a premium over the market price for their shares, and thereby protect the continuity of our management. Specifically, if in the due exercise of its fiduciary obligations, the Board of Directors were to determine that a takeover proposal was not in our best interest, shares could be issued by our Board of Directors without stockholder approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diluting the voting or other rights of the proposed acquirer or insurgent stockholder group,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">putting a substantial voting bloc in institutional or other hands that might undertake to support the incumbent Board of Directors, or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effecting an acquisition that might complicate or preclude the takeover.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation also allows our Board of Directors to fix the number of directors in the by-laws. Our certificate of incorporation does not contemplate cumulative voting in the election of directors and thus, under Delaware law, cumulative voting in the election of directors is not permitted. Our Board of Directors is divided into three classes, each of which serves for a staggered term of three&#160;years. This division of our Board of Directors could have the effect of impeding an attempt to take over our company or change or remove management, since only one class will be elected annually. Thus, only approximately one-third of the existing Board of Directors could be replaced at any election of directors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">The effect of these provisions may be to delay or prevent a tender offer or takeover attempt that a stockholder may determine to be in his, her or its best interest, including attempts that might result in a premium over the market price for the shares held by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our Second Amended and Restated Bylaws provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders</span>&#8217;<span style="font-style:italic;font-weight:bold;">&#160;ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our Second Amended and Restated Bylaws provides that the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on behalf of the Company, any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#8217;s stockholders, any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or any action asserting a claim governed by the internal affairs doctrine. The federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended and the forum selection provision does not apply to claims arising exclusively under the Exchange Act or the Investment Company Act, or any other claim for which the federal courts have exclusive jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">This forum selection provision may limit a stockholder&#8217;s ability to bring certain claims in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. If a court were to find this forum selection provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The issuance of preferred stock could adversely affect the rights of the holders of shares of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Board of Directors is authorized to issue up to 1,000,000 shares of preferred stock without any further action on the part of our stockholders. Our Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Our Board of Directors may, at any time, designate a new series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock, and the right to the redemption of the shares, together with a premium, before the redemption of our common stock and authorize the issuance of such series of preferred stock, which may have a material adverse effect on the rights of the holders of our common stock. In addition, our Board of Directors, without further stockholder approval, may, at any time, issue large blocks of preferred stock. In addition, the ability of our Board of Directors to designate and issue shares of preferred stock without any further action on the part of our stockholders may impede a takeover of our company and may prevent a transaction that is favorable to our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not anticipate paying cash dividends for the foreseeable future, and therefore investors should not buy our stock if they wish to receive cash dividends.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">We have never declared or paid any cash dividends or distributions on our capital stock. We currently intend to retain our future earnings to support operations and to finance expansion and therefore we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in general economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;">The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values could impact our business in the future. We and our third-party contract manufacturers, contract research organizations, and any clinical sites that may conduct our clinical trials in the future may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;">which there are shortages because of ongoing efforts to address the outbreak.&#160;These minor disruptions have had an immaterial effect on business, which we have been able to address with minimal impact to our business operations to date. Further, although we have not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing manufacturing of our drug candidates or services providers, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;">Our operations and performance depend on global, regional and U.S. economic and geopolitical conditions. &#160;Russia&#8217;s invasion and military attacks on Ukraine have triggered significant sanctions from U.S. and European leaders. &#160;Resulting changes in U.S. trade policy could trigger retaliatory actions by Russia, its allies and other affected countries, including China, resulting in a &#8220;trade war.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;">The<span style="letter-spacing:1.5pt;">&#160;</span>above<span style="letter-spacing:1.5pt;">&#160;</span>factors,<span style="letter-spacing:1.5pt;">&#160;</span>including<span style="letter-spacing:1.5pt;">&#160;</span>a<span style="letter-spacing:1.5pt;">&#160;</span>number<span style="letter-spacing:1.5pt;">&#160;</span>of<span style="letter-spacing:1.5pt;">&#160;</span>other<span style="letter-spacing:1.5pt;">&#160;</span>economic<span style="letter-spacing:1.5pt;">&#160;</span>and<span style="letter-spacing:1.5pt;">&#160;</span>geopolitical<span style="letter-spacing:1.5pt;">&#160;</span>factors<span style="letter-spacing:1.5pt;">&#160;</span>both<span style="letter-spacing:1.5pt;">&#160;</span>in<span style="letter-spacing:1.5pt;">&#160;</span>the<span style="letter-spacing:1.5pt;">&#160;</span>U.S.<span style="letter-spacing:1.5pt;">&#160;</span>and<span style="letter-spacing:1.5pt;">&#160;</span>abroad,<span style="letter-spacing:1.5pt;">&#160;</span>could ultimately have material adverse effects on our business, financial condition, results of operations or cash flows, including the<span style="letter-spacing:-0.05pt;">&#160;</span>following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effects of significant changes in economic, monetary and fiscal policies in the U.S. and abroad including currency fluctuations, inflationary pressures and significant income tax changes;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply chain disruptions;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a global or regional economic slowdown in any of our market segments;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in government policies and regulations affecting the Company or its significant customers;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">industrial policies in various countries that favor domestic industries over multinationals or that restrict foreign companies altogether;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new or stricter trade policies and tariffs enacted by countries, such as China, in response to changes in U.S. trade policies and tariffs;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">postponement of spending, in response to tighter credit, financial market volatility and other factors;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rapid material escalation of the cost of regulatory compliance and litigation;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties protecting intellectual property; </span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">longer payment cycles;</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">credit risks and other challenges in collecting accounts receivable; and</span></td><td style="width:5.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:20.15pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of each of the foregoing on outsourcing and procurement arrangements.</span></td><td style="width:5.05pt;"></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely extensively on our information technology systems and are vulnerable to damage and interruption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We rely on our information technology systems and infrastructure to process transactions, summarize results and manage our business, including maintaining client and supplier information. Additionally, we utilize third parties, including cloud providers, to store, transfer and process data. Our information technology systems, as well as the systems of our suppliers and other partners, whose systems we do not control, are vulnerable to outages and an increasing risk of continually evolving deliberate intrusions to gain access to company sensitive information. Likewise, data security incidents and breaches by employees and others with or without permitted access to our systems pose a risk that sensitive data may be exposed to unauthorized persons or to the public. A cyber-attack or other significant disruption involving our information technology systems, or those of our vendors, suppliers and other partners, could also result in disruptions in critical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">systems, corruption or loss of data and theft of data, funds or intellectual property. &#160;A security breach of any kind, including physical or electronic break-ins, computer viruses and attacks by hackers, employees or others, could expose us to risks of data loss, litigation, government enforcement actions, regulatory penalties and costly response measures, and could seriously disrupt our operations. We may be unable to prevent outages or security breaches in our systems. &#160;We remain potentially vulnerable to additional known or yet unknown threats as, in some instances, we, our suppliers and our other partners may be unaware of an incident or its magnitude and effects. &#160;We also face the risk that we expose our vendors or partners to cybersecurity attacks. &#160;Any or all of the foregoing could harm our reputation and adversely affect our results of operations and our business reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Holders of our warrants issued in our offerings have no rights as common stockholders until they exercise their warrants and acquire our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Until the holders of the warrants we issued in our offerings acquire shares of our common stock by exercising their warrants, the holders of the warrants have no rights as a stockholder with respect to the shares of common stock underlying their securities. Upon exercise of the warrants they will be entitled to the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Whether the outstanding warrants will have any value will depend on the market conditions for, and the price of, our common stock, which conditions will depend on factors related and unrelated to the success of our clinical development program, and cannot be predicted at this time. If our common stock price does not increase to an amount sufficiently above the exercise price of the warrants during the periods the warrants are exercisable, holders of warrants will be unable to recover any of their investment in the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because there is no established public trading market for any of our warrants we issued, the liquidity of each such security is limited. We do not expect a market to develop, nor do we intend to apply to list the warrants on any securities exchange. Upon exercise of the warrants, our stockholders will experience dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our common stock has been and may continue to be volatile and adversely affected by various factors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future. By way of example, on September 11, 2023, the price of our common stock closed at $0.28 per share while on April 19, 2023, our stock price closed at $1.30 per share. We may incur rapid and substantial decreases in our stock price in the foreseeable future that are unrelated to our operating performance or prospects. The stock market in general and the market for biotechnology and pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock. The market price of our common stock could fluctuate significantly in response to various factors and events, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>investor reaction to our business strategy;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the success of competitive products or technologies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our continued compliance with the listing standards of the NYSE American;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>results of our preclinical and clinical trials;</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>variations in our financial results or those of companies that are perceived to be similar to us;</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products;</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our ability or inability to raise additional capital and the terms on which we raise it;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>declines in the market prices of stocks generally;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>trading volume of our common stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>sales of our common stock by us or our stockholders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>announcements of licensing or other business development initiatives;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>general economic, industry and market conditions; and</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">other events or factors, including those resulting from such events, or the prospect of such events, including war, terrorism and other international conflicts, public health issues including health epidemics or pandemics, and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere, could disrupt our operations, disrupt the operations of our suppliers or result in political or economic instability.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Since the stock price of our common stock has fluctuated in the past, has been recently volatile and may be volatile in the future, investors in our common stock could incur substantial losses. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. There can be no guarantee that our stock price will remain at current prices or that future sales of our common stock will not be at prices lower than those sold to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reports published by securities or industry analysts, including projections in those reports that exceed our actual results, could adversely affect our common stock price and trading volume.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Securities research analysts, including those affiliated with our underwriters from prior offerings, establish and publish their own periodic projections for our business. These projections may vary widely from one another and may not accurately predict the results we actually achieve. Our stock price may decline if our actual results do not match securities research analysts&#8217; projections. Similarly, if one or more of the analysts who writes reports on us downgrades our stock or publishes inaccurate or unfavorable research about our business or if one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, our stock price or trading volume could decline. While we expect securities research analyst coverage to continue going forward, if no securities or industry analysts begin to cover us, the trading price for our stock and the trading volume could be adversely affected<span style="font-style:italic;font-weight:bold;">.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a &#8220;smaller reporting company&#8221;, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a &quot;smaller reporting company&quot; as defined in Rule 12b-2 promulgated under the Exchange Act. We may remain a smaller reporting company until we have a non-affiliate public float in excess of $250 million or annual revenues in excess of $100 million and a non-affiliate public float in excess of $700 million, each as determined on an annual basis. For so long as we remain smaller reporting company, we are permitted and may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exemption from compliance with the auditor attestation requirement of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, on the design and effectiveness of our internal controls over financial reporting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scaled reporting and disclosure requirements including about our executive compensation arrangements.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot predict whether investors will find our common stock less attractive if we rely on such exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the market price of our common stock may be more volatile.</p><a id="_a811ef61_8af2_486c_be6e_203d283ce71a"></a><a id="Item1B"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1B. Unresolved Staff Comments.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_b1fbe298_1fbf_44c8_af8a_c84a67213a01"></a><a id="Item2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;2. Properties.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Facility</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time conducted business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 15, 2023, iBio CDMO entered into a Purchase and Sale Agreement with Majestic Realty, pursuant to which iBio CDMO agreed to sell the Property to Majestic Realty for a purchase price of $17,250,000. The closing of the sale of the Property is to occur, with time being of the essence, on December 1, 2023 or such other date as mutually agreed. &#160;Pursuant to the terms of the Purchase and Sale Agreement, Majestic Realty deposited with a title company $200,000 as an earnest money deposit. Majestic Realty will also be afforded access to the Property to conduct a due diligence review of its condition. The closing is subject to certain closing conditions, including: (i) Majestic Realty&#8217;s delivery to iBio CDMO and the Escrow Agent of written notice of its approval of the condition of the Property on or before 5:00 p.m. Central time on October 16, 2023; (ii) Majestic Realty obtaining the approval of The Board of Regents of the Texas A&amp;M University System of Majestic Realty&#8217;s purchase from it of the fee interest in the Land on or before 5:00 p.m. Central time on November 13, 2023; and (iii) the delivery at closing by the title company of a title policy to Majestic Realty in the amount of the Purchase Price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Biopharmaceutical R&amp;D Facility</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 11, 2021, iBio entered into a lease with SAN DIEGO INSPIRE 4, LLC for approximately 11,383 square feet of lab and office space at 11750 Sorrento Valley Road in San Diego, CA. The lease recently commenced in September 2022. The lease is for seven years and four months. The lease is triple net with Base Rent starting at $4.50 per month per square foot escalating approximately 3.0 percent per year during the lease term. iBio will use the facility primarily for R&amp;D associated with its AI Drug Discovery Platform and our biologic product portfolio.</p><a id="_56718de0_85e4_4504_b564_080fb2509874"></a><a id="Item3LegalProceedings_765972"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;3. Legal Proceedings.</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Lawsuits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;background:#ffffff;">We are not currently subject to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Litigation, regardless of the outcome, could have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_061435dd_efdb_4cec_8c0a_2064689c72e6"></a><a id="Item4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;4. Mine Safety Disclosures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cd6f7065_cf47_4626_b0b9_7752b0856d09"></a><a id="Part2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><a id="Item5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is traded on the NYSE American under the trading symbol &#8220;IBIO.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 12, 2023, there were 27 stockholders of record of our common stock, one of which was Cede &amp; Co., a nominee for Depository Trust Company, or DTC. All of the shares of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede &amp; Co. as one stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. Dividends on our common stock cannot be declared or paid or set aside for payment or other distribution unless all accrued dividends on all outstanding shares of Preferred Tracking Stock are paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no sales of unregistered securities other than as set forth in documents previously filed by the Company with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company completed a reverse stock split at a ratio of one-for-twenty five (1:25) shares of the Company&#39;s common stock. The effective date of the reverse stock split was October 7, 2022. All share and per share amounts of common stock presented have been retroactively adjusted to reflect the one-for-twenty five reverse stock split.</p><a id="_7b887d48_ebf2_420a_aa2a_294fac4e16da"></a><a id="Item6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;6. [Reserved]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_85946c52_2c94_432e_99b6_863550b46a81"></a><a id="Item7_Management_Discussion"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;7. </b><b style="font-weight:bold;">Management&#8217;s Discussion </b><b style="font-weight:bold;">and Analysis of Financial Condition and Results of Operations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following discussion of our financial condition and results of operations should be read together with our financial statements and the notes thereto and other information included elsewhere in this Annual Report. Unless the context requires otherwise, references in this Report to &#8220;iBio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; and similar terms mean iBio, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of discovery. Our core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through our innovative platform, we champion a culture of innovation by identifying novel targets, forging strategic collaborations to enhance efficiency, diversify pipelines, and with the goal of accelerating preclinical processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, our groundbreaking EngageTx technology enables us to target bi-specific molecules. With the ability to navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release, our goal is to enhance agility and bolster preclinical safety assessments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our strategic approach to fulfilling our mission is outlined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Elevate Epitope Discovery:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We believe we lead the field with our patented AI-engine uncovering &quot;hard to develop&quot; molecules. Our unparalleled epitope engine stands out by allowing the ability to target select regions of a protein, potentially removing the lengthy trial and error out of mAb discovery. &#160;This capability is expected to improve probability of success while at the same time, reduces costs commonly caused by having an iterative process. Our epitope engine is engineered to match its target, refined for stability and optimized for water solubility; allowing us to identify new drug candidates that have failed or have been abandoned due to their complexity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Capital efficient business approach:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our strategic business approach is structured around the following pillars of value creation:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Strategic Collaborations</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: We are leveraging our platform and pipeline by forming strategic partnerships. Our aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, a rich array of fast follower molecules within our pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into our platform, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Developing and advancing our in-house programs cost effectively</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Clinical advancement is crucial for drug discovery. We are actively looking for opportunities to progress our internal pre-clinical programs, with a focal point on oncology, steadily reinforcing our pre-clinical pipeline.</span><span style="color:#374151;font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;background:#f7f7f8;"> &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tech Licensing in Diverse Therapeutic Areas:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In pursuit of adding value, we are exploring partnerships in diverse therapeutic domains such as CNS or vaccines. Our intention is to license the AI tech stack, extending its benefits to our partners and amplifying its biological impact and insights. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This strategic approach enables us to capitalize on the value of our meticulously curated data while empowering collaborations and innovations, while at the same time allowing us to focus on both the platform and our core therapeutic area, oncology.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Unwavering Investment in advancing the platform:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We maintain an unwavering commitment to invest in our platform, continually unlocking the potential of biology through AI and machine learning. &#160;The pinnacle of being on the forefront of machine learning advancing algorithms, and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In essence, we are sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AI-Technology Platform </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our platform comprises four key components, each playing a crucial role in the discovery and optimization of precision antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing us to engineer antibodies with high specificity and efficacy. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing StableHu AI technology, coupled with mammalian display technology. Finally, our EngageTx platform forms the fourth layer. Each layer of the tech stack is designed to work synergistically, enabling us to rapidly advance antibodies from concept to in vivo proof-of-concept (POC).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AI Epitope Steering Technology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our epitope steering technology is designed to address these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, we can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of our antibody discovery process. &#160;Our AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from na&#239;ve or immunized libraries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Na&#239;ve Human Antibody Library</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, we have extracted a diverse array of Complementarity-Determining Region (CDR) sequences. Subsequently, we have meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from our library.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">StableHu</span><sup style="font-size:7.5pt;line-height:100%;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;">TM</sup><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> AI Antibody-Optimizing Technology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our proprietary StableHu technology is instrumental in the optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:172.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">When paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EngageTx CD3-Based T-Cell Engager Panel</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized our StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows us to pair the panel with a wide variety of tumor-targeting antibodies. &#160;Importantly, we were able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to our StableHu technology, reduces the risk of immunogenicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 10pt 0pt;">Furthermore, our StableHu technology enabled us to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pre-Clinical Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">We are currently in the process of building and advancing our preclinical pipeline. The focus of our pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging our technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize on the learnings of competitors, our programs are primarily adopting a fast follower strategy. This approach allows us to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k005.jpg" alt="Graphic" style="display:inline-block;height:171.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 15, 2023, iBio CDMO entered into the Purchase and Sale Agreement with Majestic Realty Co., pursuant to which iBio CDMO agreed to sell to Majestic Realty for a purchase price of $17,250,000 its Facility located in Bryan, TX consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;M University System (together, the &#8220;Ground Lease&#8221;), related to 21.401 acres in Brazos County, Texas land (the &#8220;Land&#8221;); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the &#8220;Improvements&#8221;); (iii) all iBio CDMO&#8217;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the &#8220;Personal Property&#8221;); (iii) all iBio CDMO&#8217;s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the &#8220;Contracts&#8221;); and (iv) all iBio CDMO&#8217;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the &#8220;Intangibles&#8221;; and together with the Ground Lease, Improvements and Personal Property, collectively, the &#8220;Property&#8221;). The closing of the sale of the Property is to occur, with time being of the essence, on December 1, 2023 or such other date as mutually agreed. &#160;Pursuant to the terms of the Purchase and Sale Agreement, Majestic Realty deposited with a title company (the &#8220;Escrow Agent&#8221;) $200,000 as an earnest money deposit. Majestic Realty will also be afforded access to the Property to conduct a due diligence review of its condition. The closing is subject to certain closing conditions, including: (i) Majestic Realty&#8217;s delivery to iBio CDMO and the Escrow Agent of written notice of its approval of the condition of the Property on or before 5:00 p.m. Central time on October 16, 2023; (ii) Majestic Realty obtaining the approval of The Board of Regents of the Texas A&amp;M University System of Majestic Realty&#8217;s purchase from it of the fee interest in the Land on or before 5:00 p.m. Central time on November 13, 2023; and (iii) the delivery at closing by the title company of a title policy to Majestic Realty in the amount of the Purchase Price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Revenue from the CDMO operations is now included in discontinued operations and not broken out separately on the financial statements. Our ongoing business is primarily focused on i) development of our pipeline for which we do not expect revenue for many years, if at all, and ii) on our AI-driven discovery platform for which to date we have not generated any material revenue. We may have revenue with the AI-driven discovery platform in the future. During the year ended June 30, 2023, we reported no revenue. Revenue for the year ended June 30, 2022 was mainly related to a licensing agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses for Fiscal year ended June 30, 2023 and Fiscal year ended June 30, 2022 were approximately $10.3 million and $9.8 million, respectively, an increase of approximately $0.5 million or 5%. The increase primarily related to the increase in activities related to our internal pipeline including IBIO-101, CCR8, and EGFRvIII, and the expansion of our AI-driven discovery platform to include an increased spend of approximately $1.7 million on lab supplies, lab equipment/maintenance, and facility rent for the San Diego facility and an increase of approximately $0.6 million in R&amp;D personnel at the San Diego center. &#160;This increase was partially offset by a reduction of approximately $1.8 million in spend on consultants and contracted services. iBio&#160;anticipates&#160;R&amp;D expenses in Fiscal year ended June 30, 2024 will be close to those of Fiscal year ended June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses relating to CDMO operations are captured separately under discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses (&#8220;G&amp;A&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">G&amp;A expenses for Fiscal year ended June 30 2023 and Fiscal year ended June 30 2022 were approximately $19.0 million and $21.8 million, respectively, a decrease of ($2.8) million or (13)%. G&amp;A expenses principally include officer and employee salaries and benefits, depreciation and amortization, professional fees, consulting services, operational costs and other costs associated with being a publicly traded company. The decrease is primarily attributable to a reduction in intangible asset impairment charges and related amortization of ($1.5) million, a reduction of legal fees expense of ($0.8) million, a reduction in profession/consulting fees and outside services of ($0.8) million, and reduced travel of ($0.2) million. The decrease was partially offset by an increase of ($0.5) million for IT security and related costs. iBio&#160;expects&#160;G&amp;A expenses to continue to decrease in Fiscal year ended June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">G&amp;A expenses relating to CDMO operations are captured separately under discontinued operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Total Operating Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total operating expenses, consisting primarily of R&amp;D and G&amp;A expenses, for Fiscal year ended June 30, 2023 were approximately $29.3 million, compared to approximately $31.6 million for Fiscal ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Income (Expense)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other income (expense) for Fiscal year ended June 30, 2023 and Fiscal year ended June 30, 2022 was approximately $0.03 million and $0.2 million, a decrease of approximately ($0.2) million. The minimal increase in interest income was offset by interest expenses and loss on sale of debt securities for a total other income (expense) of approximately $0.03 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Loss Available to iBio, Inc. Stockholders from Continuing Operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations for Fiscal year ended June 30, 2023 was approximately ($29.3) million, or ($2.39) per share, compared to approximately ($29.6) million, or ($3.39) per share, in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Discontinued Operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 2, 2022, we announced our plans to divest our contract development and manufacturing organization (iBio CDMO, LLC) in order to complete our transformation into an AI-driven, precision antibody drug discovery and development company. In conjunction with the restructuring, we completed a workforce reduction of approximately 60% and discontinued the CDMO operations. CDMO operations are reported as discontinued operations on our financial statements. Losses for Discontinued Operations for 2023 and 2022 were approximately ($35.7) million and ($20.8) million, respectively, an increase of ($14.9) million, or 72%. &#160;This increase was primarily due to the impairment of fixed assets ($17.9) million, impairment of consumable inventory of ($4.9) million, and ($3.1) million of personnel restructuring related charges including severance, benefits and the acceleration of stock compensation awards. &#160;This increase in expense was offset by the decrease of Facility related expenses of ($4.5) million, personnel costs of ($3.6) million, consultant/outside services of ($1.5) million, the gain on sale of fixed assets of ($0.8) million and the ($0.6) million forgiveness of the PPP loan in Fiscal year 2022, which did not reoccur in Fiscal year 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Total Net Loss Available to iBio, Inc. Stockholders </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net loss available to iBio, Inc. stockholders from both continuing and discontinued operations for Fiscal year ended June 30, 2023 was approximately ($65.0) million, or ($5.31) per share, compared to approximately ($50.4) million, or ($5.78) per share, in Fiscal year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company&#39;s ability to continue as a going concern. Our management concluded that our recurring losses from operations and the fact that we have not generated significant revenue or positive cash flows from operations raise substantial doubt about our ability to continue as a going concern for the next 12 months after issuance of our financial statements. Our auditors also included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended June 30, 2023 with respect to this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In an effort to remain a going concern and increase cash reserves, we completed a public offering in December 2022, reduced our work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of our CDMO Facility thereby reducing annual spend on expenses by approximately 67% and generating cash savings of approximately 64% from first quarter Fiscal year 2023 compared to fourth quarter Fiscal year 2023. Additionally, we have executed the Purchase and Sale Agreement for the sale of the CDMO Facility, which sale if consummated will allow us to pay all outstanding amounts under the Term Loan; however, the consummation of the sale </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">is subject to closing conditions for which there can be no assurance that they will be met or the closing will occur in a timely manner, if at all . If the closing is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely that we will have sufficient funds the repay the Term Loan on its maturity date, which Term Loan has an outstanding balance of which is $12.7 million as of September 26, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal 2023, we completed at-the-market offerings and sold 175,973 shares of our common stock, par value $.001 per share (the &#8220;Common Stock&#8221;) for net proceeds of approximately $1.2 million. During the second quarter of Fiscal 2023, we completed a public offering and raised gross proceeds of approximately $3.5 million selling an aggregate of 3,365,385 shares of its Common Stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,870,192 shares of Common Stock and Series B warrants to purchase up to 3,870,192 shares of Common Stock. Subsequently after the public offering, during the third quarter of Fiscal 2023, 341,300 Class A Warrants and 1,704,916 Class B Warrants were exercised for total proceeds of $2,128,000. Also, during the third quarter of Fiscal 2023, we completed at-the-market offerings and sold 1,375,906 shares of Common Stock for which we received approximately $2.0 million. In the fourth quarter of Fiscal 2023, an additional 76,300 Class B Warrants were exercised with total proceeds of approximately $79,000. Also, during the fourth quarter of Fiscal 2023, we completed at-the-market offerings and sold 4,230,992 shares of Common Stock of which we received approximately $3.3 million and holds a subscription receivable for $204,000 at June 30, 2023 for proceeds received on July 6, 2023. (See Note 17 &#8211; Stockholder&#8217;s Equity for more information.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to June 30, 2023, we completed at-the-market offerings and sold 3,419,795 shares of Common Stock which we received approximately $1.7 million. We also sold 3,622,834 shares of Common Stock under our Purchase Agreement with Lincoln Park and received approximately $1.2 million in proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our cash, cash equivalents and restricted cash of approximately $7.6 million</span>&#160;<span style="font-size:10pt;">as of June&#160;30,&#160;2023, is not anticipated to be sufficient to support operations through the second quarter of Fiscal 2024,</span><b style="font-size:10pt;font-weight:bold;">&#160;</b><span style="font-size:10pt;">unless we further reduce our burn rate, consummate the sale of the Facility for amounts above the debt on the Facility, or increase our capital as described above. Regardless of whether we are able to reduce our burn rate or sell or out-license certain assets or parts of the business, we will need to raise additional capital in order to fully execute our longer-term business plan. It is our goal to implement one or more potential options described herein to allow us to have a cash runway for at least 12 months from the date of the filing of this Annual Report. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our liquidity and operations could also be impacted by our obligations under the Woodforest Credit Agreement. As described below and in detail in Note 6 - Significant Transactions, to avoid violating the Liquidity Covenant associated with the parent guarantee of the debt, we need to pay off the debt through the sale of the Facility or we need to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Woodforest Debt </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 11, 2022, we and Woodforest entered into the First Amendment to the Credit Agreement pursuant to which the Credit Agreement was amended to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days &#160;upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (see Item 3 &#8211; Legal Proceedings for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast (vi) reduce the liquidity covenant in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ending June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, iBio&#8217;s unrestricted cash decreased below the required $7,500,000, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#8220;Second Amendment&#8221;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, iBio, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed iBio to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow us until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether we are in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, we agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by us for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest we are required to make from the proceeds of sales of our common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest we are required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed us to retain $2,000,000 million of the $5,100,000 million that we received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 million being held in our account at Woodforest. &#160;In addition, we are obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, iBio, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in our account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from our account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the Maturity Date.&#160; We also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the Maturity Date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#8220;Sixth Amendment&#8221;), to amend the Credit Agreement to: (i) set the maturity date of the term loan to the&#160;<i style="font-style:italic;">earlier of</i>&#160;(a) December 31, 2023, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement, (ii) provided that iBio CDMO will, immediately upon receipt of the proceeds of the sale of the Property, apply the net proceeds to satisfy all outstanding obligations under the term loan, and to the extent such net proceeds are sufficient, to pay off the term loan, and (iii) change the annual filing requirement solely for the fiscal year ending June 30, 2023, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation; provided that (y) iBio CDMO shall deliver an executed copy of the Purchase and Sale Agreement for the sale of the Facility within one business day after entry into the Sixth </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amendment, and (z) if the Facility is not sold on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cantor Fitzgerald Underwriting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On November 25, 2020, we entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&quot;Cantor Fitzgerald&quot;) to sell shares of Common Stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022, and June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 5,782,871 shares of Common Stock. We received net proceeds of approximately $6.4 million during the Fiscal year 2023 and hold a subscription receivable for $204,000 at June 30, 2023 for proceeds received on July 6, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">In Fiscal year 2022, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 175,973 shares of Common Stock. We received net proceeds of approximately $1.2 million. (See Note 17 - Stockholders&#8217; Equity for more detail.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Wainwright Underwriting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 6, 2022, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;). Pursuant to the Underwriting Agreement, we agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#8220;Offering&#8221;) (i) 1,530,769 shares of the Company&#8217;s Common Stock, (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 1,834,616 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#8220;Series A Warrants&#8221;) to purchase up to 3,365,385 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#8220;Series B Warrants&#8221; and together with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to 3,365,385 shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Wainwright acted as the sole book-running manager for the Offering. We paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, we granted Wainwright a 30-day option to purchase up to an additional 504,807 shares of Common Stock and/or Common Warrants to purchase up to an additional 1,009,614 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 504,807 Series A Warrants and 504,807 Series B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#8220;Representative&#8217;s Warrants&#8221;) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 201,923 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs. During the year ended June 30, 2023, 341,300 Class A Warrants and 1,781,216 Class B Warrants were exercised. The total proceeds from Class A and B Warrants exercised during the year ended June 30, 2023 was $2,207,000. (See Note 17 - Stockholders&#8217; Equity for more detail.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 12, 2022, we entered into a securities purchase agreement with a certain accredited investor for the issuance and sale of 1,000 shares of Series 2022 Convertible Preferred Stock, $0.001 par value per share (the &#8220;Preferred Stock&#8221;), at a price of $0.27 per share. The Preferred Stock permitted the holder to vote at the Special Meeting, on the Reverse Stock Split proposal, with the holders of the common stock as a single class, with each share of Preferred Stock being entitled to 200,000 votes per share, provided that any votes cast by the Preferred Stock with respect to the Proposal must be voted in the same proportion as the aggregate shares of common stock are voted on the Proposal. Pursuant to the terms of the preferred stock, our Board of Directors converted the Preferred Stock to common stock at a conversion ratio of 1:1 on July 19, 2022. (See Note 17 - Stockholders&#8217; Equity for more detail.)</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bryan Capital</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 3, 2021, as part of consideration for the purchase of the Bryan site and other rights, iBio issued a warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share to affiliates of Eastern Capital Limited. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also, as part of the consideration for the purchase of the Bryan site and other rights, iBio entered into a $22,375,000 Senior Secured Term Loan with Woodforest National Bank. The loan bears interest at 5.25% plus a payment in kind adjustment dependent on when the Facility is sold and original maturity date of November 1, 2023. &#160;See Note 14 &#8211; Debt for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Lincoln Park Stock Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 4, 2023, iBio entered into a purchase agreement, dated as of August 4, 2023 (the &#8220;Purchase Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to&#160;<span style="background:#ffffff;">which, under the terms and subject to the satisfaction of specified conditions set forth therein,&#160;we</span> may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, we entered into a registration rights agreement, dated as of August 4, 2023 (the &#8220;Registration Rights Agreement&#8221;), with Lincoln Park, pursuant to which we agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by us to Lincoln Park under the Purchase Agreement. We cannot sell any shares of Common Stock to Lincoln Park under the Purchase Agreement unless all of the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase Agreement, including that the resale registration statement that we are required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the &#8220;Commencement Date&#8221;). &#160;The registration statement was declared effective on August 11, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at our discretion, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10 million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, we may, at our discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.15, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to 100,000 shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a &#8220;Regular Purchase&#8221;);&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the maximum number of shares we may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 150,000 shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00, and (ii) 200,000 shares, if the closing sale price of the Common Stock on the applicable purchase date is not below $2.00;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that Lincoln Park&#8217;s maximum purchase commitment in any single Regular Purchase may not exceed $500,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, provided that we have directed Lincoln Park to purchase the maximum amount of shares that we are then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.20, then in addition to such Regular Purchase, we may, in our sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an &#8220;accelerated purchase,&#8221; and one or more &#8220;additional accelerated purchases&#8221; on the business day immediately following the purchase date for such Regular Purchase,&#160;<span style="background:#ffffff;">as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable,</span>&#160;calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We will control the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park is obligated to make purchases as we direct, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Actual sales of shares of Common Stock to Lincoln Park will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, market prices of the Common Stock from time to time during the term of the Purchase Agreement and determinations by us as to the appropriate sources of funding for iBio and its operations. The net proceeds under the Purchase Agreement to iBio will depend on the frequency and prices at which we sell shares of Common Stock to Lincoln Park. We expect that any proceeds received by us from such sales to Lincoln Park will be used for working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As consideration for Lincoln Park&#8217;s commitment to purchase shares of Common Stock at our direction pursuant to the Purchase Agreement, we issued 211,473 shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Initial Commitment Shares&#8221;) and agreed to issue 211,474 additional shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Additional Commitment Shares&#8221; and, collectively with the Initial Commitment Shares, the &#8220;Commitment Shares&#8221;) at such time as we have received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, if any, that we elect, in our sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement. (See Note 17 - Stockholders&#8217; Equity for more detail.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Between August 16, 2023 and September 15, 2023, Lincoln Park purchased pursuant to the Purchase Agreement 3,622,834 shares of Common Stock. The Company received net proceeds of approximately $1.2 million during the first quarter of Fiscal 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Operating Activities</i></p><a id="_Hlk83424276"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In fiscal year 2023, net cash used in operating activities was ($30.4) million, compared to net cash used in operating activities of ($37.5) million in 2022.&#160; The decrease in net cash was primarily used to support our ongoing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Provided by (Used in) Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In fiscal year 2023, net cash provided by investing activities was $7.0 million, which primarily consisted of redemption and sales of debt securities of $10.8 million and the sale of fixed asset of $2.6 million, partially offset by the purchase of ($5.7) million of fixed assets and ($0.7) million for certain assets acquired from RubrYc. Offset by proceeds from the sales of fixed assets. In fiscal year 2022, our net cash used in investing activities was ($5.1) million, which primarily consisted of the purchase of RubrYc equity and acquisition of intangible assets related to our license of IBIO-101, and purchases of fixed assets, offset by the net redemption of debt securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Provided by (Used in) Financing Activities</i></p><a id="_Hlk83426123"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In fiscal year 2023, net cash provided by financing activities was $2.3 million, compared to net cash used in financing activities of ($6.1) million in 2022.&#160; Net cash generated from financing activities in 2023 primarily related to proceeds from sales of common stock offset by payments made towards term note payable while the net cash spent in 2022 mainly &#160;related to the purchase of the Facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Funding Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant losses and negative cash flows from operations since our spin-off from Integrated BioPharma in August&#160;2008. As of June&#160;30,&#160;2023, our accumulated deficit was approximately ($288.9) million, and we used approximately ($21.1) million of net cash in fiscal year 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to fund our future business operations using cash on hand, through proceeds realized in connection with the commercialization of our technologies, through proceeds from the sale of the CDMO Facility, through potential proceeds from the sale or out-licensing of assets, and through proceeds from the sale of additional equity or other securities. However, there can be no assurance that we will be successful in implementing these plans, many of which will take several years before we realize proceeds. The Term Loan with Woodforest and the Guaranty requires we maintain an unrestricted cash balance of $1.0 million, which limits our ability to use our funds for operations. If we should default on the Credit Agreement and Woodforest does not waive the default, and if Woodforest makes a demand for the acceleration of all payments due to this default, it could result in all obligations that are guaranteed being due and payable immediately without further notice. We cannot be certain that such funding will be available on favorable terms or available at all. If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPEs), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of June&#160;30,&#160;2023, we were not involved in any SPE transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A critical accounting policy is one that is both important to the portrayal of a company&#8217;s financial condition and results of operations and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are presented in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). All applicable U.S. GAAP accounting standards effective as of June&#160;30,&#160;2023, have been taken into consideration in preparing the consolidated financial statements. The preparation of consolidated financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Some of those estimates are subjective and complex, and, consequently, actual results could differ from those estimates. We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ from our estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Critical accounting estimates are those estimates made in accordance with U.S. GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on the financial condition or results of operations of the Company. The following accounting estimate had a material impact on the results of operations of the Company for the year ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Fixed Assets </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We monitor fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although we base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On November 3, 2022, we announced we are seeking to divest our contract development and manufacturing organization (iBio CDMO) in order to complete our transformation into an antibody discovery and development company. Through the process of seeking to divest its contract development and manufacturing organization, we have entered into a Purchase </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and Sale Agreement for the Facility. The decision to divest triggered a quantitative impairment analysis of our CDMO fixed assets of the Facility totaling $22.65 million and machinery and equipment totaling $13.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We utilized a market approach in the second quarter of Fiscal 2023, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility, the machinery and equipment. &#160;We recorded an impairment charge of $6.3 million for the facility and $11.3 million for the machinery and equipment in the quarter ended December 31, 2022. The key assumption in the valuation analysis is the expected sale price of $21.1 million for the Facility and the associated machinery and equipment less approximate costs to sell of $2.7 million. In the first quarter of Fiscal 2024, we entered into an agreement for the sale of the Facility for $17.25 million, and an additional impairment of $0.3 million was recorded in Fiscal 2023 to reflect the agreed upon sales price less estimated costs to sell. &#160;The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $16.1 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2021, the &#8220;Company, entered into an Auction Sale Agreement (the &#8220;Auction Sale Agreement&#8221;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#8220;Auctioneers&#8221;) for the sale at public auction of equipment and other tangible personal property (the &#8220;Equipment&#8221;) located at the Facility. &#160;The Auctioneer guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. &#160;In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland was paid a fixed amount of $0.2 million for expenses, which was approximately $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We may have to record a further, potentially material, impairment to the fair value of this asset group if we do not realize a sale transaction for the expected amount of $17.25 million less costs to sell in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Indefinite-Lived Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, we perform an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in our business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although we base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the fourth quarter of Fiscal 2023, we performed our annual impairment testing of the IBIO-101 therapeutic technology (or &#8220;IP&#8221;), classified as an indefinite-lived intangible asset, which had a carrying amount of $5 million at June 30, 2023. We engaged a third party to perform valuation assistance with estimating the fair value of IBIO-101 and preparing a market capitalization reconciliation. The Multi-Period Excess Earnings Method (&#8220;MPEEM&#8221;) under the income approach was utilized to value the indefinite-lived asset. &#160;The MPEEM determines the value of a specified asset by calculating the present value of future earnings attributed to the asset. Since IBIO-101 is currently in its pre-clinical development phase, a probability of success was applied to the cash flows to account for the probability of reaching each step of development. The MPEEM requires that charges for the use of other contributory assets be subtracted under the theory that the owner of the subject asset does not own the other contributory assets and would have to rent/lease them in order to earn the cash flows related to the subject asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The resulting probability of success adjusted &#8220;excess earnings&#8221; were discounted to the present value using a 13% discount rate, which was based on iBio&#8217;s weighted average cost of capital. &#160;The sum of the discounted excess earnings and the present value of the tax benefit related to amortization of the IBIO-101 indefinite-lived intangible indicated that the fair value was $7.1 million as of the April 1, 2023, valuation date. Given that the carrying amount of the asset was $5 million at June 30, 2023, it was concluded that no impairment existed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We will continue to monitor the value of the IP, since we believe it is at risk for impairment. The primary impairment indicators that may arise in the near future are (1) any sustained decline in our common stock market price and (2) FDA decisions on similar competing technologies that are applying for Phase 1 approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We continue to operate in a highly competitive environment, rising interest rates (and cost of capital) and experience liquidity challenges. Accordingly, we may have to adjust our cash flow projections and valuation assumptions in the near future to account for market trends and any changes to our research and development plans. Any such future adjustments may lead to material future impairments in the IP and other related assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Our remaining critical accounting estimates remain consistent with the information disclosed in the same section in our last annual report on Form 10-K for the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the aforementioned critical accounting estimates, the following accounting policies and estimates have been highlighted as significant because changes to certain judgments and assumptions inherent in these policies could affect our consolidated financial statements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue recognition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">legal and contractual contingencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research and development expenses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share-based compensation expenses.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ from our estimates. See Note&#160;4 &#8211; Summary of Significant Accounting Policies - for a complete discussion of our significant accounting policies and estimates.</p><a id="_2f5ddcf9_0e05_49b5_8a4d_e3e0e82ff344"></a><a id="Item7A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information under this Item&#160;is not required to be provided by smaller reporting companies.</p><a id="_62403a28_f9fe_461b_958a_ee010ce312c5"></a><a id="Item8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;8. Financial Statements and Supplementary Data.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial statements and notes thereto appear on pages&#160;F-1 to F-44 of this Annual Report.</p><a id="_1a3d81e8_db86_419e_a523_0cb206e97f7c"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_533d47b9_618a_40bb_aea7_b99651813327"></a><a id="Item9A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9A. Controls and Procedures. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Our management, under the direction of our Chief Executive Officer (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer) have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, as amended), as of June 30, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are also designed to ensure that such </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">information is accumulated and communicated to management to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Based on our evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June&#160;30,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Report on Internal Control over Financial Reporting </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">It is the responsibility of the management of iBio to establish and maintain effective internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under the Exchange Act). Internal control over financial reporting is designed to provide reasonable assurance to iBio&#8217;s management and board of directors regarding the preparation of reliable financial statements for external purposes in accordance with generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio&#8217;s internal control over financial reporting includes those policies and procedures that: (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of iBio; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of iBio are being made only in accordance with authorizations of management and directors of iBio; and (iii)&#160;provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of iBio&#8217;s assets that could have a material effect on the financial statements of iBio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Management has performed an assessment of the effectiveness of iBio&#8217;s internal control over financial reporting as of June&#160;30, 2023, based upon criteria set forth in Internal Control&#160;- Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO Framework).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on this assessment, management has concluded that our internal control over financial reporting was effective as of June&#160;30,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control Over Financial Reporting </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We remediated the material weakness relating to our internal controls over the accounting for stock-based compensation, as described below. Except as otherwise described herein, there were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the quarter ended June&#160;30,&#160;2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.<br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Remediation of Material Weakness in Internal Controls over Accounting for Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We strengthened our internal controls over accounting for stock-based compensation through designing and implementing additional procedures and controls over stock-based compensation. Management believes that significant progress has been made in enhancing internal controls as of June 30, 2023 and has concluded that the enhanced controls are operating effectively. The material weakness described in in Item 4 Controls and Procedures in our Quarterly Report on Form 10-Q for the nine months ended March 31, 2023 has been fully remediated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Annual Report does not include an attestation report by CohnReznick LLP (&quot;CohnReznick&quot;), our independent registered public accounting firm, regarding internal control over financial reporting. As a smaller reporting company, our internal control over financial reporting was not subject to audit by our independent registered public accounting firm pursuant to rules&#160;of the SEC that permit us to provide only management&#8217;s report.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_878641f1_6bfe_4d49_976f_c598d1c0d5ad"></a><a id="Item9BOtherInformation_9633"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9B. Other Information.</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3d003854_8d33_4c12_a75e_694e7d4cc56d"></a><a id="_Hlk83475322"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item </b><b style="font-weight:bold;">9C. Disclosure Regarding </b><b style="font-weight:bold;">Foreign Jurisdictions That Prevent Inspections.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d55219ea_de60_491e_bffb_99d34bfe07e2"></a><a id="Part3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain information required by Part&#160;III is omitted from this Annual Report because we intend to file our definitive proxy statement for our 2023 Annual Meeting of Stockholders, pursuant to regulation 14A of the Exchange Act, not later than 120&#160;days after the end of the fiscal&#160;year covered by this Annual Report and certain information to be included in the definitive proxy statement is incorporated herein by reference.</b></p><a id="Item10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;10. Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Information required by this Item&#160;that will appear under the headings &#8220;Governance,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Delinquent Section&#160;16(a)&#160;Reports&#8221; in the definitive proxy statement to be filed with the SEC relating to our 2023 Annual Meeting of Stockholders is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have adopted a written code of business conduct and ethics within the meaning of Item&#160;406 of SEC Regulation S-K, which applies to all of our employees, including our principal executive officer and our chief financial officer, a copy of which can be found on our website at www.ibioinc.com. If we make any waivers or substantive amendments to the code of ethics that are applicable to our principal executive officer or our chief financial officer, we will disclose the nature of such waiver or amendment in a Current Report on Form&#160;8-K in a timely manner. No waivers from any provision of our policy have been granted.</p><a id="_577210fb_a020_4813_a53e_3563d1123b71"></a><a id="Item11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;11. Executive Compensation </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Information required by this Item&#160;that will appear under the heading &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; in the definitive proxy statement to be filed with the SEC relating to our 2023 Annual Meeting of Stockholders is incorporated herein by reference.</p><a id="_7add7a57_7b90_4b2b_ad55_c6b68ace1234"></a><a id="Item12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Information required by this Item&#160;that will appear under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in the definitive proxy statement to be filed with the SEC relating to our 2023 Annual Meeting of Stockholders is incorporated herein by reference.</p><a id="_a95cd449_a333_4333_8b69_f92242463d80"></a><a id="Item13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Information required by this Item&#160;that will appear under the headings &#8220;Certain Relationships and Related Transactions&#8221; and &#8220;Independence of Board&#8221; in the definitive proxy statement to be filed with the SEC relating to our 2023 Annual Meeting of Stockholders is incorporated herein by reference.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3b7351dc_4cbd_436f_ac51_8ff5291bb13b"></a><a id="Item14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;14. Principal Accountant Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Information required by this Item&#160;that will appear under the heading &#8220;Independent Auditor Fees and Other Matters&#8221; in the definitive proxy statement to be filed with the SEC relating to our 2023 Annual Meeting of Stockholders is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4f56ecf1_8fde_4ca1_9603_78163b461dfb"></a><a id="Part4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;IV</b></p><a id="Item15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;15. Exhibits and Financial Statement Schedules. </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits and Index</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A list of the financial statements filed as part of this Annual Report is set forth in the index to financial statements at page&#160;F-1 and is incorporated herein by reference.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An exhibit index is incorporated by reference or filed with this Annual Report is provided below:</span></td></tr></table><div style="margin-top:12pt;"><a id="_fb9a88cd_3e21_4842_8a04_5ad605886e82"></a><a id="Item16"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16. Form&#160;10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not Applicable</p><a id="_e3152bf1_9f60_443c_9089_70aa3db4138e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465920129557/tm2036971d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Controlled Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;Sales Agreement, dated as of November 25, 2020, by and between iBio, Inc. and Cantor Fitzgerald &amp; Co. (incorporated herein by reference to Exhibit Number 1.1 to the Company&#8217;s registration statement on Form S-3 (File No. 333-250973) filed by the Company with the Securities and Exchange Commission on November 25, 2020 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.2</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/ibio-20221206xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Underwriting Agreement, dated December 6, 2022, by and between iBio, Inc. and H.C. Wainwright &amp; Co., LLC (incorporated herein by reference to the Company&#8217;s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on December 8, 2022 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418027689/tv493469_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of iBio, Inc., Certificate of Merger, Certificate of Ownership and Merger, Certificate of Amendment of the Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed by the Company with the Securities and Exchange Commission on May 11, 2018 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418009023/tv484918_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q filed by the Company with the Securities and Exchange Commission on February 14, 2018 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418033574/tv496218_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to the Company&#8217;s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on June 8, 2018 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420417011007/v460437_3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation, Preferences and Rights of the iBio CMO Preferred Tracking Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 24, 2017 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418035914/tv497273_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2018 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418035914/tv497273_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation, Preferences and Rights of the Series B Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2018 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465919057346/tm1921411d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation, Preferences and Rights of the Series C Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2019 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465922009994/tm224794d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on August 14, 2009 &#8211; Commission File No. 000-53125)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.9</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418035914/tv497273_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Certificate of Designation of Preferences, Rights and Limitations of Series 2022 Convertible Preferred Stock</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2022 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.10</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000018/ibio-20220509xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of Series 2022 Convertible Preferred Stock (incorporated herein by reference to the Company&#8217;s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on May 12, 2022 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.11</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000062/ibio-20221007xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to the Company&#8217;s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on October 7, 2022 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072008000013/exhibit4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Form 10-12G filed with the Securities and Exchange Commission on July 11, 2008 &#8211; &#160;Commission File No. 000-53125)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837021012819/ibio-20210630ex4109a055a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities of iBio, Inc. (incorporated by reference to Exhibit 4.10 to the Annual Report on Form 10-K for the year ended June 30, 2021- Commission File No. 000-53125)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Term Note of IBIO CDMO LLC (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">iBio, Inc. Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/ibio-20221206xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2022 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/ibio-20221206xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series A Warrants (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2022 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/ibio-20221206xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series B Warrants (incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2022 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000094/ibio-20221206xex4d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Representative&#8217;s Warrants (incorporated herein by reference to Exhibit 4.4 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2022 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072008000010/exhibit10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Technology Transfer Agreement, dated as of January 1, 2004, between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. as amended (incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Form 10-12G filed with the Securities and Exchange Commission on June 18, 2008 &#8211; Commission File No. 000-53125)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2+</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420413053105/v355527_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Ratification dated September 6, 2013 of Terms of Settlement by and between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2013, filed with the Securities and Exchange Commission on September 30, 2013 &#8211; &#160;Commission File No. 001-35023).</span></a>&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420416083497/v430583_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Limited Liability Company Agreement of iBio CDMO LLC, dated January 13, 2016, between the Company, Bryan Capital Investors LLC and iBio CDMO LLC (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 22, 2016 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420416083497/v430583_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated January 13, 2016, between the Company and iBio CDMO LLC (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 22, 2016 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420417011007/v460437_10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to the Amended and Restated Limited Liability Company Agreement of iBio CDMO LLC, dated February 23, 2017 (incorporated herein by reference to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2017 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420419017417/tv517790_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Directors and Officer Indemnification Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2019 &#160;&#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420419041659/tv527664_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2018 Omnibus Equity Incentive Plan, effective December 18, 2018 (incorporated herein by reference to Exhibit 10.13 to the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on August 26, 2019 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465920006289/tv536232-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2018 Omnibus Equity Incentive Plan, effective December 18, 2018 (incorporated herein by reference to Appendix B to the Company&#8217;s Definitive Proxy Statement filed with the Securities and Exchange Commission on January 23, 2020 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837021012819/ibio-20210630ex1020d8652.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated January 18, 2021, by and between iBio, Inc. and Martin B. Brenner (incorporated by reference to Exhibit 10.20 to the Annual Report on Form 10-K for the year ended June 30, 2021- Commission File No. 000-53125)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465920121027/tm2034104d2_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (incorporated by reference to Appendix B to the Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on November 3, 2020 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921003052/tm212012d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Non-Qualified Stock Option Agreement for Employees under the iBio,&#160;Inc. 2020 Omnibus Incentive Plan &#160;(incorporated herein by reference to Exhibit 10.2 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 &#8211; Commission File No. 333-252027)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921003052/tm212012d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Non-Qualified Stock Option Agreement for Non-Employee Directors (Initial Grant) under the iBio,&#160;Inc. 2020 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 &#8211; Commission File No. 333-252027)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921003052/tm212012d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Non-Qualified Stock Option Agreement for Non-Employee Directors (Annual Grant) under the iBio,&#160;Inc. 2020 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 &#8211; Commission File No. 333-252027)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921003052/tm212012d1_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Unit Award Agreement for Employees under the iBio,&#160;Inc. 2020 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 &#8211; Commission File No. 333-252027)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921003053/tm212012d2_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Unit Award Agreement for Employees under the iBio,&#160;Inc. 2018 Omnibus Equity Incentive Plan, as amended and restated (incorporated herein by reference to Exhibit 10.2 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921022960/tm216721d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated February 15, 2021, by and between iBio, Inc. and Robert Lutz, Effective March 4, 2021 (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 16, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24++</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921023996/tm216632d1_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement between the Company and University of Pittsburgh dated January 14, 2014 (incorporated herein by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q filed by the Company with the Securities and Exchange Commission on February 16, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25++</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921023996/tm216632d1_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Exclusive License Agreement between the Company and the University of Pittsburgh dated August 11, 2016 (incorporated herein by reference to Exhibit 10.7 to the Quarterly Report on Form 10-Q filed by the Company with the Securities and Exchange Commission on February 16, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:center;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921023996/tm216632d1_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Exclusive License Agreement between the Company and the University of Pittsburgh dated November 2, 2020 (incorporated herein by reference to Exhibit 10.8 to the Quarterly Report on Form 10-Q filed by the Company with the Securities and Exchange Commission on February 16, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921062463/tm2114740d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated as of April 30, 2021, by and between iBio, Inc. and Thomas F. Isett (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on May 6, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921078867/tm2119311d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Director Offer Letter (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on June 9, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:center;margin:0pt;">10.29++**</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921110011/tm2126053d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration, Option and License Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.30++**</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921110011/tm2126053d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31++**</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921110011/tm2126053d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Stock Purchase Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.32++**</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921110011/tm2126053d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Second Amended and Restated Investor Rights Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33++**</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921110011/tm2126053d1_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Voting Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors(incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.34++**</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921110011/tm2126053d1_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Right of First Refusal and Co-Sale Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors(incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.35++</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837021012819/ibio-20210630ex1020d8652.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated December 23, 2020 and effective as of January 18, 2021, by and between iBio, Inc. and Martin B. Brenner (incorporated herein by reference to Exhibit 10.20 to the Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission on September 28, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.36</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837021012819/ibio-20210630ex1031161e4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Confidential Settlement and Mutual Release with Fraunhofer USA, Inc. dated May 4, 2021 (incorporated herein by reference to Exhibit 10.31 to the Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission on September 28, 2021 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:center;margin:0pt;">10.37</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Purchase and Sale Agreement, dated November 1, 2021, by and among College Station Investors LLC, Bryan Capital Investors LLC, iBio CDMO LLC and iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.38</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Equity Purchase Agreement dated November 1, 2021 by and between Bryan Capital Investors LLC and iBio, Inc. (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.39</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit Agreement, dated November 1, 2021 by and, between iBio CDMO LLC with Woodforest National Bank (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.40</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-4.htm">Guaranty Agreement, dated November 1, 2021, by iBio, Inc. for the benefit of Woodforest National Bank</a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-4.htm">(incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.41</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Leasehold Deed of Trust, Assignment of Leases and Rents, Security Agreement and UCC Financing Statement for Fixture Filing by iBio CDMO LLC as grantor to the trustee for the benefit of Woodforest National Bank (incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.42</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Security Agreement, dated November 1, 2021 by iBio CDMO LLC for the benefit of Woodforest National Bank(incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.43</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Environmental Indemnity Agreement, dated November 1, 2021 by iBio CDMO LLC and iBio, Inc. in favor of Woodforest National Bank (incorporated herein by reference to Exhibit 10.7 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211; &#160;Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.44</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465921134395/tm2131788d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Ground Lease Agreement (included as Exhibit A to The Purchase and Sale Agreement, dated November 1, 2021 by and among College Station Investors LLC, Bryan Capital Investors LLC, iBio CDMO LLC and iBio, Inc. filed as Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 &#8211;  Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.46</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000018/ibio-20220509xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.47</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000018/ibio-20220509xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Irrevocable Proxy for Voting Control (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.48</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000024/ibio-20220331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Exclusive License Agreement, dated February 3, 2022, by and between University of Pittsburgh and iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2022&#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.49</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000049/ibio-20220916xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement dated September 16, 2022, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.50*++</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000064/ibio-20220630xex10d51.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Credit Agreement entered into as of October 11, 2022, by and between iBio CDMO LLC with Woodforest National Bank (incorporated herein by reference to Exhibit 10.51 to the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on October 11, 2022&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.51</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837022017874/ibio-20220930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Termination Agreement and Release dated September 19, 2022, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.52</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837022017874/ibio-20220930xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease dated September 10, 2021, by and between iBio, Inc., and San Diego Inspire 4, LLC (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.53&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837022017874/ibio-20220930xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Unit Award Agreement dated November 10, 2022, by and between iBio, Inc. and Thomas Isett (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.54&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/ibio-20221201xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation Agreement and General Release, dated December 1, 2022, by and between iBio, Inc. and Thomas Isett (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2022, &#8211;File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.55&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/ibio-20230120xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter by and between iBio, Inc. and Felipe Duran dated January 23, 2023 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 25, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.56</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000009/ibio-20221231xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Credit Agreement dated February 9, 2023, by and between iBio, Inc. and Woodforest National Bank (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.57&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000009/ibio-20221231xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Special Incentive Bonus Agreement dated January 26, 2023, by and between iBio, Inc. and Martin Brenner (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.58&#8224;</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000009/ibio-20221231xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Special Incentive Bonus Agreement dated January 26, 2023, by and between iBio, Inc. and Felipe Duran (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.59</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000017/ibio-20230220xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Credit Agreement dated February 21, 2023 between iBio CDMO LLC and Woodforest National Bank and Third Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2023 &#8211; File No. 000 35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.60</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000022/ibio-20230324xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Credit Agreement dated March 24, 2023, between iBio CDMO LLC and Woodforest National Bank and Fourth Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2023 &#8211; File No. 000 35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.61</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837023009707/ibio-20230331xex10d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Auction Sale Agreement between iBio, Inc. and Holland Industrial Group, Federal Equipment Company and Capital Recovery Group LLC dated as of February 10, 2023 (incorporated herein by reference to Exhibit 10.7 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.62</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000155837023009707/ibio-20230331xex10d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to the Credit Agreement dated May 10, 2023, between iBio CDMO LLC and Woodforest National Bank and Fifth Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.8 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.63</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465923087894/tm2322878d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Purchase Agreement by and between the Registrant and Lincoln Park Capital Fund, LLC, dated August 4, 2023 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2023&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.64</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465923087894/tm2322878d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement by and between the Registrant and Lincoln Park Capital Fund, LLC, dated August 4, 2023 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2023&#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230630xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of Registrant</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230630xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of the Independent Registered Public Accounting Firm</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Financial Officer and Principal Accounting Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:87.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230630xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Financial Officer and Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.06%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:15.65pt;"><td style="vertical-align:top;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Inline XBRL Instance Document*</p></td></tr><tr style="height:13.95pt;"><td style="vertical-align:top;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document *</p></td></tr><tr style="height:15.65pt;"><td style="vertical-align:top;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document *</p></td></tr><tr style="height:13.95pt;"><td style="vertical-align:top;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document *</p></td></tr><tr style="height:15.65pt;"><td style="vertical-align:top;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document *</p></td></tr><tr style="height:13.95pt;"><td style="vertical-align:top;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document *</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:95.81%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12.6pt;"><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;*</p></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Filed herewith.</p></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Management contract or compensatory plan or arrangement required to be identified pursuant to Item&#160;15(a)(3)&#160;of this Annual Report.</p></td></tr><tr style="height:16.8pt;"><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">+</p></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Certain portions of this exhibit have been omitted subject to a confidential treatment request.</p></td></tr><tr style="height:16.8pt;"><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">++</p></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">Certain portions of this exhibit indicated therein by [**] have been omitted in accordance with Item 601(b)(10) of Regulation S-K. The Company agrees to furnish unredacted copies of these Exhibits to the SEC upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*&#160;*Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_492620fc_a815_49b3_a9bf_3a49447784e6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio,&#160;Inc.</span></p></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">(Registrant)</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">Dated:&#160; September 27, 2023</p></td><td style="vertical-align:top;width:54.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Chief Executive Officer </p></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Felipe Duran</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:54.56%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Martin Brenner</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Chief Executive </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">September 27, 2023</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Martin Brenner</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Officer and Chief Scientific Officer (Principal Executive Officer)</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/ Felipe Duran</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Chief Financial Officer </p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">September 27, 2023</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Felipe Duran</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Officer (Principal Financial Officer and Principal Accounting Officer)</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/Linda Armstrong</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">September 27, 2023</p></td></tr><tr style="height:12.15pt;"><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Linda Armstrong</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/Alexandra Kropotova</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">September 27, 2023</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Alexandra Kropotova</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/William Clark</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">September 27, 2023</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">William Clark</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/Evert Schimmelpennink</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">September 27, 2023</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Evert Schimmelpennink</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/James T. Hill</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">September 27, 2023</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">General James T. Hill, USA (Retired)</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:38.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">/s/Gary Sender</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">September 27, 2023</p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Gary Sender</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_174c2da5_8602_47f0_b1a1_2992b78c85f4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Annual Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">iBio,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Statement Index</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> &#8211; PCAOB ID <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:AuditorFirmId" id="Narr_eePoY7LmDkyLwP19J6qcWw">596</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:11.11%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial Statements:</p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BalanceSheet"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets&#160;&#8211; June&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ComprehensiveLoss"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss&#160;&#8211; Fiscal&#160;years ended June&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Equity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity&#160;&#8211; Fiscal&#160;years ended June&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-8</p></td></tr><tr><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CashFlow"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows&#160;&#8211; Fiscal&#160;years ended June&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-9</p></td></tr><tr><td style="vertical-align:top;width:88.88%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Notes_to_Consolidated"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-11</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e8c077d7_b1a1_4533_b4cd_b25dd8e9c047"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Board of Directors and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders of iBio, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of iBio, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of June 30, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2023 and 2022, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and negative cash flows from operating activities for the years ended June 30, 2023 and 2022 and has an accumulated deficit as of June 30, 2023. &#160;These matters, among others, raise substantial doubt about its ability to continue as a going concern. Management&#39;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&quot;PCAOB&quot;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Asset Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Critical Audit Matter Description</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed in the notes to the consolidated financial statements, on September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;). The Company accounted for this agreement as an asset purchase and allocated the consideration to the various assets acquired. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The financial reporting for the terms of the Asset Purchase Agreement (the &#8220;Agreement&#8221;) involved significant estimation by management in its determination of the fair value of the assets acquired and the related fair value allocation of the Agreement. &#160;Given these factors, the related audit effort in evaluating management&#8217;s judgments of the fair value of the assets acquired and related fair value allocation related to the Agreement was challenging, subjective, and complex and required a high degree of auditor judgment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">How the Critical Audit Matter was addressed in the Audit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our principal audit procedures related to the Company&#8217;s financial reporting for the Agreement included, among others:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We obtained an understanding of and evaluated the design and implementation of controls that address the risk of material misstatement for the financial reporting for asset acquisitions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated management&#8217;s significant accounting policies related to asset acquisitions for reasonableness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the reasonableness of the assets acquired included within the Agreement. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We verified the total consideration included among the terms of the Agreement. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We involved our valuation specialists to assist in testing the Company&#8217;s methodology and significant assumptions used to fair value the assets acquired.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We utilized our valuation specialists who performed sensitivity analyses of the significant assumptions to evaluate the change in the fair value allocation of the assets acquired resulting from changes in the assumptions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the Company&#8217;s allocation of total consideration to the assets acquired. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the Company&#8217;s relevant financial statement presentation and disclosures for consistency with our knowledge of the terms of the Agreement and with accounting standards. &#160;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Acquired License Impairment Assessment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As disclosed in the notes to the consolidated financial statements, the Company acquired an indefinite-lived license of approximately $5.003 million. This asset is assessed for impairment at least annually and upon the occurrence of a triggering event. &#160;The impairment test for indefinite life licenses consists of comparing the fair value, which is estimated using the income approach, to its carrying value. &#160;If the carrying value exceeds the fair value, an impairment loss is recognized in an amount equal to such excess. &#160;The determination of the fair value is primarily based on discounted future cash flows projected to be generated from the license, including the estimates of future revenue, future development costs, the probability of success in various phases of development programs, and potential post-launch cash flows. Changes in these assumptions could have a significant impact on either the fair value, the amount of any impairment charges, or both. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Significant judgment is exercised by management when developing the fair value measurement of the license. &#160;Given these factors, the related audit effort in evaluating management&#8217;s judgments of the fair value of the acquired license was challenging, subjective, and complex and required a high degree of auditor judgment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">How the Critical Audit Matter was addressed in the Audit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our principal audit procedures related to the Company&#8217;s financial reporting relating to potential impairment of the license included, among others:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We obtained an understanding and evaluated the design and implementation of internal controls over the Company&#8217;s process for indefinite-lived intangible impairment assessments. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated management&#8217;s significant accounting policies related to impairment of the acquired license intangible for reasonableness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We tested management&#8217;s process for developing the fair value of the license. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Through the use of internal valuation specialists, we assessed the appropriateness and consistency of the discounted cash flow analyses model.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We involved our valuation specialists to assist in testing the Company&#8217;s methodology and significant assumptions used amongst the Company&#8217;s impairment assessment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We involved our valuation specialists to assist in testing the Company&#8217;s market capitalization reconciliation associated with the Company&#8217;s impairment assessment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We utilized our valuation specialists who performed sensitivity analyses of the significant assumptions to evaluate the Company&#8217;s impairment assessment resulting from changes in the assumptions.</span><span style="display:inline-block;width:30.05pt;"></span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the significant assumptions related to future revenue, future development costs, and the probability of success in various phases of development programs as well as post launch cash flows. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In evaluating management&#8217;s significant assumptions for reasonableness, we considered consistency with external market and industry data and evidence obtained in other areas of the audit. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We assessed the sensitivity of changes in estimating the fair value in comparison to the carrying value for reasonableness. &#160;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Assets Held for Sale </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As disclosed in the notes to the consolidated financial statements, the Company has Assets Held for Sale of approximately $18.065 million. &#160;Assets held for sale shall be measured at the lower of its carrying amount or fair value less costs to sell. &#160;A loss shall be recognized for any initial or subsequent write-down to fair value less costs to sell. The determination of fair value less costs to sell is based on a combination of appraisal of the respective building and associated land, discussions with the Company engaged brokers and estimated closing costs on any potential sale of the assets held for sale. Changes in the assumptions could have a significant impact on either the fair value, the amount of any impairment charges, or both. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Significant judgment is exercised by management when developing the fair value less costs to sell analysis related to the assets held for sale. Given these factors, the related audit effort in evaluating management&#8217;s judgments of the fair value less costs to sell was challenging, subjective and complex and required a high degree of auditor judgement. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">How the Critical Audit Matter was addressed in the Audit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our principal audit procedures related to the Company&#8217;s financial reporting relating to impairment of the assets held for sale included, among others:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We obtained an understanding and evaluated the design and implementation of internal controls over the Company&#8217;s process for impairment assessments regarding assets held for sale. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated management&#8217;s significant accounting policies related to impairment of the Company&#8217;s assets held for sale.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We tested management&#8217;s process for developing the fair value estimates regarding the assets held for sale. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We involved our valuation specialists to assist in testing the Company&#8217;s methodology and significant assumptions used to estimate fair value of the assets held for sale. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We tested management&#8217;s process for developing the estimated costs to sell the assets held for sale. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In evaluating management&#8217;s significant assumptions for reasonableness, we considered consistency with external market data and evidence obtained in other areas of the audit.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">/s/ </span><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:AuditorName" id="Narr_sSeky8nxPEWmCESbcsnqhA"><span style="font-size:10pt;">CohnReznick LLP</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have served as the Company&#39;s auditor since 2010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="dei:AuditorLocation" id="Narr_cP_wYxJbQEqciPdu6tGZzQ"><span style="font-size:10pt;">Holmdel, New Jersey</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">September 27, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3d3d2f75_6f66_458f_8c4a_217ac98672ac"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">iBio,&#160;Inc. and Subsidiaries</p><a id="BalanceSheet"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In Thousands, except share and per share amounts)</b></p><a id="_67646706_6c59_4c60_93c1_8db8b61d5de9"></a><a id="Tc_Z9gT_D8g0k2FIVZiK71nVg_2_2"></a><a id="Tc_P5kJohz-Q06rwHeD-ZGaOA_2_5"></a><a id="Tc_PV7CJleaI02Zp3hxa7Oxbg_4_0"></a><a id="Tc_7lkah0Gi5UucdhQR01vuYg_5_0"></a><a id="Tc_fJCCSH-250mJLEccRwC3Ug_6_0"></a><a id="Tc_W1Mtij5l40qH3eU0qXsBpQ_6_2"></a><a id="Tc_bVwGM1cdvU2ShKf0rOlCWw_6_5"></a><a id="Tc_yzRh4WdziUyx88lFNN2V_w_7_0"></a><a id="Tc_ASfDXff-nECY0F2b5MkpUA_7_6"></a><a id="Tc_gA-OOL-jo0yGyh3uFWl5Xw_8_0"></a><a id="Tc_KOGrC32LUEWouTY3NzRRkw_8_3"></a><a id="Tc_W2hCSn5pyEKbTldkjU2THg_9_0"></a><a id="Tc_q248Vscq9Eqc8r5Yyoh30A_9_3"></a><a id="Tc_OETg3Q5Bnk-lz-5EXyq8Aw_10_0"></a><a id="Tc_KHsFd2R5OkeapoxhntAoBg_10_6"></a><a id="Tc_Bh3F-PUgqEiA_Eu76v-qrA_11_0"></a><a id="Tc_QCN-Xjb2L0WZgk2PjAdw6Q_11_3"></a><a id="Tc_HGKOwB041kCCBR_Ee8Kyng_12_0"></a><a id="Tc_sbMoHYoWQUuLhthHlQgCjQ_13_0"></a><a id="Tc_YXwqsXIwzkSUFcu22oLofQ_14_0"></a><a id="Tc_ywh_JaZ9C0uJRkzDMyzHlQ_16_0"></a><a id="Tc_YyX0OyEOcUKWO1P-ZCdWEw_17_0"></a><a id="Tc_2IoVK-5mrUOv74N6sBNAWQ_18_0"></a><a id="Tc_gaoNWCJEzUelxMWS00uX5w_18_6"></a><a id="Tc_LluUNp6zmkqZltQhT4O4wA_19_0"></a><a id="Tc_enEa_7aOckWNitj3FNk6vQ_20_0"></a><a id="Tc_HaPfnsJM-06Ebr00CVi88w_21_0"></a><a id="Tc_s-VsTVH4d0WuhshV2j3ezA_22_0"></a><a id="Tc_MG1L6W7Wn0G-DCEh-9DNrw_23_0"></a><a id="Tc_eZ63dvJ0I0OxcjldbnfSRg_23_3"></a><a id="Tc_YD46-AEBRUaVE4LfsjYDuw_24_0"></a><a id="Tc_t1QBE4sigEKUq4HRonmvBQ_24_3"></a><a id="Tc_4soij57mTkqFAko-ft3wkw_25_0"></a><a id="Tc_ORPDzqtn10C4m-J1ciQ49Q_25_2"></a><a id="Tc_vY5gaUHgTEe72iFsBn_lcQ_25_5"></a><a id="Tc_-BoycuI05UyIAnfD0MukmA_27_0"></a><a id="Tc_M2QHLZwHDkahVbVVgT13zg_28_0"></a><a id="Tc__7iP-ftHGUy9fxBCJoa7dg_29_0"></a><a id="Tc_3RuAFx3ik06wGJZG7mpq1g_29_2"></a><a id="Tc_DnFVQCU2-0OwBMBPZRIgsQ_29_5"></a><a id="Tc_AszHdBwrwU-8w1cG5cTnsg_30_0"></a><a id="Tc_0rED_1vVikuAgY_WAdbj0w_31_0"></a><a id="Tc_YgfZeXfQ0U20hx73GyCatA_31_6"></a><a id="Tc_ERf10mWHFkS8XLu40-X4Tw_32_0"></a><a id="Tc_Fpc1JchnbEO6ONEBi3_1mg_33_0"></a><a id="Tc_tlcFKHShnUSWZvK7mO8Jrw_33_6"></a><a id="Tc_MwcETA_1dke4Gj0gyjp3Yw_34_0"></a><a id="Tc_oMUAUPc7LEyGzpLpwJpcFw_35_0"></a><a id="Tc_GnASYqlQM02xbgp5kWVx5g_35_3"></a><a id="Tc_06oxBd2lmEGhBXIpF_qKWQ_36_0"></a><a id="Tc_NA44fHFLgUunZDTiDXQxFA_37_0"></a><a id="Tc_1Qb5ibNIa0-a53eaVsqKGA_39_0"></a><a id="Tc_wZ7iLANjr0-dIP2E8X5BEg_39_6"></a><a id="Tc_5zq6t9m2ikCplkYXVjhnLg_40_0"></a><a id="Tc_KUShr1Scv06oiNbx1jxswQ_41_0"></a><a id="Tc_BaA-TvsBY0Kxoi6KjELvjg_41_6"></a><a id="Tc_7e4A7FGoHUagkB02I9iRkw_42_0"></a><a id="Tc_WNuEcH7X4EyiFqGQH6UrWQ_42_6"></a><a id="Tc_DafLzirN1kyHZ_k_wAZjZQ_43_0"></a><a id="Tc_0b3N20wNPkWsEScChFw8IQ_43_3"></a><a id="Tc_EOtmkJJgNkSlktZ8QD0Gwg_45_0"></a><a id="Tc_QMTN7EZjyEq76P2kXbd1hA_47_0"></a><a id="Tc_k1SqDFo-pkSKuH_iMMVZww_48_0"></a><a id="Tc_NnUGHvtpJkmrNulS-O1jjw_49_0"></a><a id="Tc_OiUnjyavmEKpHry2O8enDQ_50_0"></a><a id="Tc_HCuFsSvanUetm-pQSDYiVA_51_0"></a><a id="Tc_igU6_9kU-Eatq6q92TbfAA_51_3"></a><a id="Tc_jAHO_ULee0eN39_0kchxZw_52_0"></a><a id="Tc_LhGvaqPAp0m76IQpRy6OVg_53_0"></a><a id="Tc_4qoYZ1gS_EqnGlXA9LFEcw_54_0"></a><a id="Tc_GXpw4LiMmUuSpg78wysdiw_54_2"></a><a id="Tc_OY7azvS3rEiKUlbhewFsRg_54_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_HW2Zh_CdcUmINkqJKOmJRg_6_3">4,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_sJX8uAX3JEixJ61u-Ri9Qw_6_6">22,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_srA1-T9CrE-vBRCnG6k-eg_7_3">3,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Investments in debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_Ygqv6edVi0SlYWBp8IY87Q_8_6">10,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts receivable - trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_T5Ged7M890ODX5dT_DMc4w_9_6">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Subscription receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:SubscriptionReceivableCurrent" scale="3" id="Tc_6gbIy2_ny0-DGBKWzLyz-A_10_3">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Settlement receivable - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SettlementAssetsCurrent" scale="3" id="Tc_V9VAhJ7FVkKvQOYIo_C-7Q_11_6">5,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_g6qmK0TpmUidZSKO-MpZkQ_12_3">664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_YlPHmmIUJky75NOJ4JEewA_12_6">1,549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Current assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="Tc_lD7vbYcQCUqZEeasH56FSg_13_3">18,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="Tc_FlJxWmtvkU6AWrFKxN4kpg_13_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_6uvMeshRB0WT6ZEPiI_9pQ_14_3">26,259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_z509ppTA70Kr1dD9soC1qQ_14_6">45,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_5tLyWGbcaki8ghwGcq7ccg_16_3">253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_gBfvjw3EOUOLcl3EAv582w_16_6">5,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Promissory note receivable and accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest" scale="3" id="Tc_-_69FtYLwkaDXUIBohy9yQ_17_3">1,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest" scale="3" id="Tc_EJLc5zI_JEyqR4qyWJ7OsA_17_6">1,631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right-of-use assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_-Az0_iQZl0uTLmFnkqBb8A_18_3">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_BVckeON6jEyn0id7-upU-w_19_3">2,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_mUPRRtcZc0GVgvQYWyMnCA_19_6">3,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets, net of accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_HLS0mrBVBkeraNawF4tJ7A_20_3">4,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_AC8PkjhVm0e5pXQ8wtBukg_20_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_q_2X03U4MUCnbzJNp5Aadg_21_3">5,388</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_UfvrpHA94kyeaNKIKxjo3w_21_6">4,851</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc_XK8KoXofQkyLxny1PKVnpA_22_3">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc_ZTiNPhTTEEORMBMg1omVhA_22_6">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="Tc_BT-OzuWgZkqED8kV3QW1wA_23_6">74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="Tc__XdKiv0rw02gsD4-iDdO2A_24_6">37,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_OL_2GZsdd0iD2skNIFnOIg_25_3">41,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_6RlWUz45zkKcYkZj5rY-0Q_25_6">99,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities and Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_TOnn5eE4SEmYuIMK3gtqqQ_29_3">1,849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_w7qPYUf9aEWQGtobYCeQGw_29_6">4,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_c4qZCLvCgESd83r22tTdOQ_30_3">4,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_X2e-3qhm7EildyOdLFLCRA_30_6">3,764</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease obligations - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_uI8pMK9O6keSM3faoSLlBQ_31_3">272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_oZNXhTPRmkyrHGghya41ug_32_3">389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_YpM1i3sMoUGX23Whi5FaqQ_32_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Equipment financing payable - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingPayableCurrent" scale="3" id="Tc_tp5rbaqqVkaL-ZMAGoDKSQ_33_3">160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Term note payable - net of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_2h8204qxoky1ELYw43OLng_34_3">12,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_8KDS6eTsF0-WyySn-931JA_34_6">22,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_e0TymSofhUyU3KE-K5xgMQ_35_6">100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Current liabilities related to assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_yR2oTW2Q3UaOUjMhScF9Yg_36_3">1,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_Ta9SJK7oYE2zE6b2C2ApXg_36_6">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Current Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_5m80TbrjAUOa2OUBAbOysA_37_3">21,582</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_P0M07FSGKkqGiC_ZR0RbRw_37_6">30,436</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease obligations - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_sS29Zc1eXEKaojZG1b7d1Q_39_3">351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligation - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_wm-SKk8IYk6fXiY4vww7KA_40_3">3,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_laRiXyTtfUCyK6A477Mtkg_40_6">3,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equipment financing payable - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingPayableNoncurrent" scale="3" id="Tc_u_I2cS1K5kKNv5ZtLSszlQ_41_3">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedLiabilitiesNoncurrent" scale="3" id="Tc_-qj73e8Xj0-65s2pVn5a1g_42_3">527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent liabilities related to assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_fueHJfE3ZUip91ZMnT6YTw_43_6">1,971</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_892naxQSc0yrp8HLeWD1Vw_45_3">25,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_PhUDp_uYYU68N6WLgTDb3A_45_6">35,921</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Series 2022 Convertible Preferred Stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_iYCCUz6sRESmGczh4J0oJw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_yQ5XqH9_GEKr283m3eZNVg">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_UF4dBSyzYkSZ9DV0LCTQbQ"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Y_OhJf7rNUugpGOHrR99OA">1,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_LveuaG8c6Um0fu5ZnuTwLA"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_evGtdH66L0el-K33ESGCfQ">0</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_esGAZvKj3kqLxFaN0KP3NQ"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_7Hft50asqU6mr6wCM4gubQ">1,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2023 and 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_uFvV_eO1B0iDE-lKD_tAZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xc77VMaqY0C4oB8D5qP6Yg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Common Stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_tQ5hEIJhZE6D4CpVG8Fhjg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_w6JFMAg4Skq00zQI5ttXhQ">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_FwwdYLrkUkOJOBpMnk1xZg"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_MhCFtV4NeU2CDdvkwh5MIA">275,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June 30, 2023 and 2022; <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_wV3lXrwc30SHLN3HF_UeUA"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr__mR1_MNgo0OiB70vQoikQg">20,310,077</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_b_nAG08jLUaefKKLFSKJVQ"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_ZH6lE-kOT0WaMCXRUEEsQQ">8,727,158</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2023 and June 30,&#160;2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_JX5RR4fUok6x0ZWUZqa65A_49_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_bfqwe_fLjka8le-tWyEgrw_49_6">9</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_7U_X3BDZjEmpMMap69Ohcw_50_3">304,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_yWh42IoTpUW4A8c0hxajFA_50_6">287,619</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_5tOAW5PS1EWgHEfmscviEg_51_6">213</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_SdN2mH7T3kuqTY8juCisJw_52_3">288,940</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_i9-fam8yHEe4jBEmrX5UxA_52_6">223,930</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Stockholders&#8217; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NIOM7FvMN0u3RVxTNy9OPw_53_3">15,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hIdxJRB780yXmwUA3zQ89A_53_6">63,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Liabilities and Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_YNZoDq9xa06yLfrISCsVxA_54_3">41,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ep5Dcn7vZEu8X7sYa4EvGw_54_6">99,406</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f9343d0c_1e88_4c76_935b_199e945b7fdd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><a id="ComprehensiveLoss"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In Thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_90aebe5f_aed7_4466_bb49_93930b2bac61"></a><a id="Tc_JF_z9hzW-kSqjU6ad27Ulg_1_2"></a><a id="Tc_3VXe8xqBVUSnIdCu1VRh3Q_2_2"></a><a id="Tc_yCr0_GTNV0-_NhAmEt-jeg_3_2"></a><a id="Tc_DcUUgd3NAkGVimjnWqynuQ_3_5"></a><a id="Tc_6rV8sQitxk-aNmc7LZxjUw_5_0"></a><a id="Tc_LWkoIMtxrkmNcBcEr4pDhA_5_2"></a><a id="Tc_D7xGEDxAeE-UIw2JaPkJkQ_5_3"></a><a id="Tc_CqKXfjcYWESctRsLrE5RVg_5_5"></a><a id="Tc_fKlYMOZ2jUKSi_MsEPVKfg_7_0"></a><a id="Tc_LpNVZ2omNUS3d8zzDjqKHQ_8_0"></a><a id="Tc_2_P0L-QezkuO0KY6pMsugw_9_0"></a><a id="Tc_MMGs65W6_U2tz9IV-vklLQ_10_0"></a><a id="Tc_OGKBIh57DU-6rJYK1ivC6A_12_0"></a><a id="Tc_AP_aCYwZ30ecnW1ta6ZMRA_14_0"></a><a id="Tc_EtsbTor18kqIG-hRMU6NkQ_15_0"></a><a id="Tc_MLvYWdgGhECssv_FF5_vkg_15_6"></a><a id="Tc_Ijm4G57leEGtqusOPPIcRw_16_0"></a><a id="Tc_a9bsDMWN4k2x6ujCFbJAWA_17_0"></a><a id="Tc_Lw7cgIevl0miM2mmE8K8GQ_17_6"></a><a id="Tc_5qsGd297DkCeIiwJ1BNAIg_18_0"></a><a id="Tc_HjDQndLOj0-SIC14MNNzFA_18_3"></a><a id="Tc_dY9z2T0pyEC6EzTrMzQ2Zg_19_0"></a><a id="Tc_lRELcLXvu0W58gu0y6xsTw_21_0"></a><a id="Tc_vqvQ1CXbgUiPodTjY5y9sw_22_0"></a><a id="Tc_AVEpZO5hnEuvlayGh0u-Gg_22_3"></a><a id="Tc_1cAQcFkXi0y1uUiAc2VB2A_23_0"></a><a id="Tc_5BSqKAXfckesP_nuE7cRbA_25_0"></a><a id="Tc_aRYjh5gt4UWasO2NEVSzLQ_25_3"></a><a id="Tc_lWT9-lns8ESO5RqPo3YdSA_26_0"></a><a id="Tc_6ZF2QSxsrkKS5VlLe4xjUg_28_0"></a><a id="Tc_EttYgSyZiEKzA9VMCXQAJg_30_0"></a><a id="Tc_V1BBtvmMo0ydVxM8kDxQlw_30_2"></a><a id="Tc_wvtZHFWB00q6ETfWjn9ROA_30_5"></a><a id="Tc_aaSA3-ZI0E2xt2ldoZ_RDg_32_0"></a><a id="Tc_sAG_bA04LUaj9Fo-ABNIVg_33_0"></a><a id="Tc_9yPG8iMPvEO_fgh_Mzq3QQ_33_2"></a><a id="Tc_Vf1pwa9A2UudYUj6nQIu-g_33_5"></a><a id="Tc_LoZs0iqif0OL2BSUL3bEiw_34_0"></a><a id="Tc_Y2QYb11f20mq4ls21w1dcQ_35_0"></a><a id="Tc_sB-AfvnKvE2hUfjDMC4xcA_35_6"></a><a id="Tc_R_Cy67BXN0e79AbXIjCCvQ_37_0"></a><a id="Tc_B5L43m-G4EOkZJ9xUgz0RA_37_2"></a><a id="Tc_l_IycU1zbEmgNXvWbDGD4A_37_5"></a><a id="Tc_hEB0YK62ZUuDT2J9SRY4VQ_39_0"></a><a id="Tc_2loz_cO2BECFCpbR3wlogw_40_0"></a><a id="Tc__o3ubS_SJ02P4j_mSzlXaw_41_0"></a><a id="Tc_pykuMkji40iqT5kSeMIV3w_43_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-8tnqA4_sEqkKGZD7W_uBA_5_6">1,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_sQgrv1udg0qc473TEU2HKg_8_3">10,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ZNNSBUsT7UivVpO1dy0c9w_8_6">9,827</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Pj2FIcCP2UWchyCgxKOBwQ_9_3">19,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_JBb-z07ySUe5_FxmHblvkA_9_6">21,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_SQFN_lJGk0GsxPfVdzIN8A_10_3">29,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_RXwQSx3aI0Ol36EuSb04mg_10_6">31,581</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_I5pWbEpI1UyzFOJ-fpxX6w_12_3">29,343</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_L_7CuUndckuSe-9yBv8QKg_12_6">29,697</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_W45Rhy12JEGQRc_mQ3mppw_15_3">83</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_wWPU-crKiEqy2_Oze8WHug_16_3">213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_AQisFl6X0EKRcn-hHMrjLw_16_6">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" sign="-" scale="3" id="Tc_keIdyHRQnU2EDNqCZCY-cA_17_3">98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Royalty income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="Tc_HZll7FXWZUWS8KxZ0HFPSQ_18_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_mAG25rPEtEO6D25pIIOcRg_19_3">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_SPgr5hZg0067GidogaDR6g_19_6">184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Consolidated net loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_3fjV_NkHGE-8CHLuakwY-Q_21_3">29,311</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_pHBLBO-1CEqz4ENIhgjtkg_21_6">29,513</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" sign="-" scale="3" id="Tc_c3oDDd5l1EW3TxG7CKE-Rw_22_6">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_ZEUoBa8mb0K5deJD62AgnQ_23_3">29,311</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_-lk1CYUkC0eHBOXyIdVtEw_23_6">29,512</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock dividends - iBio CDMO Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_Z3kOHG_JyEO__65LpZSVGQ_25_6">88</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:NetLossAvailableToStockholdersFromContinuingOperations" sign="-" scale="3" id="Tc_nmfl2wvydEKhwKsV1DDDUg_26_3">29,311</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:NetLossAvailableToStockholdersFromContinuingOperations" sign="-" scale="3" id="Tc_-S47DGD7w0a3fjH0wBFuiw_26_6">29,600</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_CHICDavBtkK1ZSLVWtcsUw_28_3">35,699</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_qf6TuYoDL0W_xmx7vR3y9w_28_6">20,791</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_83bdq1glhUi9c5hSBvAF5w_30_3">65,010</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_4EtRScCXr0KE1H6HM_RNxQ_30_6">50,391</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_lIdP0S2rdUSzw4owNJ5Hig_33_3">65,010</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_HHOsyP_i-UmpLFLf1DcdBg_33_6">50,304</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive income (loss) - unrealized gain (loss) on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_gGYP91Oyp02z7Apn2TjUZw_34_3">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_ih3sYLJBxk2dyt5Dsq9BUA_34_6">150</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive income - foreign currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_gM6QsDl1ZE-n1vl5viT2mA_35_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_EbuakRM4rEWd7d22pIncPA_37_3">64,797</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Uuj8Tee2q0qHd5O2hjvQcQ_37_6">50,454</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PSGT3Zxau0menl4RCH0N3Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_x4amxarUG02YFrMnjeVv2A_39_3">2.39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-eod8074fkioAk0b2mm6UA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_4ry-cnPeiU6WgptUFoWV2w_39_6">3.39</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_LuCOlpKQOUuSt-yj6PnmyA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_7VmJDIdKQ0-s1HQ4kM7GAA_40_3">2.92</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_o1v8rmdOQ068c6OAx2PQXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_4wVWNWtHTkW8xP_YXzFSkQ_40_6">2.39</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_8u14s749302L6GMFbCXKCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_XqAq4vMxT0uFSr6_BhP64w_41_3">5.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_do79_3DIF0SwBQdVF3GLSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc__1EelJXkOkii6MZBOwhjqQ_41_6">5.78</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_iP1gSwzv1EuxU-G3a5ZX2A_43_3">12,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_32e8-Ncp8E2tatYBLql6ZQ_43_6">8,721</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a0323e26_3801_4d88_8455_ff0078c41ee0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><a id="Equity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Years Ended June&#160;30, 2023 and 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In Thousands)</b></p><a id="_a8d0119d_d42a_4beb_9135_c6ade76e45e7"></a><a id="Tc_Bzs70-NWhkat4Gxy9zyImg_1_16"></a><a id="Tc_uYQkU9euNUumw7V3mP4EbA_2_13"></a><a id="Tc_V33uHJgzsUKwfFRn91hPZg_2_16"></a><a id="Tc_VXpz2PjwAUKnwBz9RBrsIQ_3_2"></a><a id="Tc_VVZOb92lhEWdWvF5eee5Cg_3_8"></a><a id="Tc_RQ6hk5Lfn0WpeAeFJNppyA_3_13"></a><a id="Tc_W1PSuo3qekm33F-nJPSGfw_3_16"></a><a id="Tc_ZcrHDOfgjUKa3pS_GCCaZg_3_19"></a><a id="Tc_SgGX3QeSEUmLyR1fzgd0VQ_3_22"></a><a id="Tc_d4umCOOgb0qD3Foq4uzpsQ_4_2"></a><a id="Tc_lY3GZXaMb06-lTwamJ8xBA_4_5"></a><a id="Tc__DfoVlwY4UybBod5FmVueQ_4_8"></a><a id="Tc_CwZATn2i-0OZcQvILn7nyA_4_10"></a><a id="Tc_e-8vj6rIo062il8WcfbSig_4_13"></a><a id="Tc_9HKUxxSyuk2i6IDqsGD_Vg_4_16"></a><a id="Tc_hL6PKiYXS0mXT1PAr7EMwA_4_19"></a><a id="Tc_EI4fPh5xB0Spa3kjrjHB8g_4_22"></a><a id="Tc__wZ_HWYR7E-AMj_y-RZ-9Q_4_25"></a><a id="Tc_An90Nlpj-U-l2lxp1xkf6A_6_0"></a><a id="Tc_KRS81zEPJEKD9U7DSOWcwA_6_3"></a><a id="Tc_O1_Qjtan9kqXYRQwFfEQ5w_6_5"></a><a id="Tc_dZrCQywoJ0qrdK4WP0cBvg_6_6"></a><a id="Tc_jQR5pMmwA06-IwhwrwmvUw_6_10"></a><a id="Tc_5dqPvgwaTU-sSngl_qqDiA_6_13"></a><a id="Tc_13aNcWi1IkyE14wCyP2T6g_6_16"></a><a id="Tc_lXxwumvSOk-g-YsTsf0G1Q_6_19"></a><a id="Tc_Gf1QjMOVPUGSFZd4VB3JwQ_6_22"></a><a id="Tc_wbLnOM5WYUeWDaVI_I0wuw_6_25"></a><a id="Tc_zyckruJNtkuBl49SfULMCQ_8_0"></a><a id="Tc_c6ErxDPDyEeF3OoMlfjlDw_8_6"></a><a id="Tc_lAMlcbJRmk6ZD6YaDuFkdg_8_8"></a><a id="Tc_QrwdiMGLekG36e3bdDNCqA_8_11"></a><a id="Tc_PWv-11iANE2V-g4UMSsFfA_8_14"></a><a id="Tc_pDepKboPfEeqU_oqwMAMbA_8_17"></a><a id="Tc_M1qVwqMEFk2a0ZFaR9xdmw_8_20"></a><a id="Tc_qHmSq09OXU-HPdHNlSDVAA_8_23"></a><a id="Tc_ygsBvQS970ayvYJn7e_KIA_8_26"></a><a id="Tc_L9vflsP790CwtdHxveZSSQ_9_0"></a><a id="Tc_QN9a2cY3C0Goeme3t_UxfA_9_3"></a><a id="Tc_NDLbrMjWZkOxG4oxZOjw8Q_9_6"></a><a id="Tc_QXc9WJOI50OcEXxqLzg1Cw_9_11"></a><a id="Tc_1TlMl3Ilq0uD8b40hpxUSA_9_14"></a><a id="Tc_McCixauuT0W_l8n9cZ8J_Q_9_17"></a><a id="Tc_XNlz4ADXPUO8_6-hF4yzmg_9_20"></a><a id="Tc_nwbCloskwU6Tic7Vlp-SFg_9_23"></a><a id="Tc_HzkWLcdLIUmrqkNulqazmA_9_26"></a><a id="Tc_CiY4D6-5NU-baji6fpAWzA_10_0"></a><a id="Tc_KNHGSJeiM0agDzTKeNjAag_10_3"></a><a id="Tc_CkirlRGuS0-JRJYyOMh0eQ_10_6"></a><a id="Tc_OZopJCOkFkWK7PNE9qzmyg_10_8"></a><a id="Tc_KWm-Xjh4o0uXVfNFW0JoEg_10_11"></a><a id="Tc_7BhoMav6-Uer8u2gtr7N-g_10_17"></a><a id="Tc_jGZwpFlgx0WjFpyF77Q4mw_10_20"></a><a id="Tc_bh5APuTjW0yVOEHjXYghWw_10_23"></a><a id="Tc_vQKByMfcEUWhNE6nhBiF8Q_11_0"></a><a id="Tc_alH-VWeJJkqHUABQDAVxoA_11_3"></a><a id="Tc_3GbLPyOcAEqCFh6_WOZSaQ_11_6"></a><a id="Tc_fM1yock76kCRkMFtrDyimg_11_8"></a><a id="Tc_f36naDhze0iPx0Nbvch6UQ_11_11"></a><a id="Tc_2xjG5hXZz0e-uZMiBEv-uQ_11_17"></a><a id="Tc_iOD0LZlz70C8MvIDkGNyeg_11_20"></a><a id="Tc_PSNZFo0h70CreMDwNgDSew_12_0"></a><a id="Tc_p77hgeQRs0WcBU09UOnThw_12_3"></a><a id="Tc_KGO63WomI0-uJEz7n1tDtA_12_6"></a><a id="Tc_Ce1SlhJk0kaMAIH61WaSBQ_12_11"></a><a id="Tc_VTgnt6ssskuapn-fb4RYwg_12_17"></a><a id="Tc_X05dN_MPIEyFFLEbNTnbCA_12_20"></a><a id="Tc_rnQXfT_0sEKxXZ1sOL63Yw_12_23"></a><a id="Tc_SJFAamh1MU-aeVc0kGJ3AQ_13_0"></a><a id="Tc_6AG4KUrWYk62GJqfqyoZOg_13_3"></a><a id="Tc_J8Yi2Tj9o0OIACQpaEL8mQ_13_6"></a><a id="Tc_fhUMLYC7o0u46hkEZqLxUQ_13_8"></a><a id="Tc_jcpR6wULCEGYHCBbdoVwoA_13_11"></a><a id="Tc_rIXO9w9M0U67iWMfhW-sxQ_13_17"></a><a id="Tc_dRqEdjJySkye-SxivTpiBg_13_20"></a><a id="Tc_0K4wlMUNz0GDWzYLbu7nVg_13_23"></a><a id="Tc_7jekU4siZUmITwg3g-9Bkw_14_0"></a><a id="Tc_fIeROL4jy0iXk7dM4mk3Fg_14_3"></a><a id="Tc_Iy3PZLh4s06QkRjzbY3Q1g_14_6"></a><a id="Tc_2JHJfFCerE6-oRuNwlSJpQ_14_8"></a><a id="Tc_n3DD5BFf6E2PrQeV6kt8pA_14_11"></a><a id="Tc_NDkhF0_TLEGRRIsSjzwICA_14_14"></a><a id="Tc_BFaTeC4x2U-e-f39sS22BA_14_20"></a><a id="Tc_NrOTDCr5CES2axfr7KcGIg_14_23"></a><a id="Tc_yggUnPbeVkuEJZ_Ee3tzyQ_15_0"></a><a id="Tc_jZEvOan4qUCy26Zhk9Uxpw_15_3"></a><a id="Tc_IFpnQeYR5UuPazttXJ65Jg_15_6"></a><a id="Tc_wuMfiIsiI0ya-eGTCAtrXw_15_8"></a><a id="Tc_p_9ljUu1W06AmeK87y7dTg_15_11"></a><a id="Tc_hLyzNZbgtEi_STxZhgb4Cg_15_14"></a><a id="Tc_HVwlLmc4R0-6tZFSqNP5WA_15_17"></a><a id="Tc_Ow6m8jCMgU6FIpKbqebofA_16_0"></a><a id="Tc_UG0yNm83Z0GLO5Fb1odQpQ_16_6"></a><a id="Tc_2-WRX_wRm0utgw3EVea1tQ_16_23"></a><a id="Tc_sNvVfg9oOU2mt_O3WHSlqQ_18_0"></a><a id="Tc_Wx2QybREB06g6psUQWSLNg_18_3"></a><a id="Tc_HgfKbwNZwU62bbi1Xb8yhQ_18_6"></a><a id="Tc_5LtC1TxYPEi8FagnC3ivng_18_17"></a><a id="Tc_eQjRaA0N4ECIhRzwCsdZNw_18_20"></a><a id="Tc_-bZjFA0UK02TAPTP2Uu61A_18_23"></a><a id="Tc_ume4SkZaX0-qYzbDcYSQlQ_19_0"></a><a id="Tc_ZJC-_3Qd20eH_eSVdnFdFw_19_3"></a><a id="Tc_In8POYl9AEWPvU_RvB5Lpg_19_6"></a><a id="Tc_zvGBSMdXME6DVfdNM6HTHw_19_8"></a><a id="Tc_oWZyjXnf6Eqvkh5fFWMh4Q_19_11"></a><a id="Tc_nDIamYjDfEqKFS0YrXsS-g_19_17"></a><a id="Tc_lJnG9ltt5UKknbUtgexD0Q_19_20"></a><a id="Tc_Z_baAoVZA0WqRMBIh2PPAg_19_23"></a><a id="Tc_v4B26OqFBUCy8SxRw5Hckg_20_0"></a><a id="Tc_aR07SztDd0u36R_c9Nz5SA_20_3"></a><a id="Tc_K0E9BMXE_k6-sRphDbwHtg_20_6"></a><a id="Tc_9wc4KHDiR0ekAQLBt57ntQ_20_11"></a><a id="Tc_nJpmZnnqGkaovFcew5XK8Q_20_17"></a><a id="Tc_9UYysBiBn0-Ixfi5OxT44w_20_20"></a><a id="Tc_YdBy0sXlRUy77bt62L3XgQ_20_23"></a><a id="Tc_jNC_hZ_W30yZFWt5nke6mQ_21_0"></a><a id="Tc_YtV9Bwkp8kOu3qWwySWFZw_21_3"></a><a id="Tc_dZE4GuhW-0-5YOR9T0V7AA_21_6"></a><a id="Tc_ftNORi33RkW1UEL7KtoR1A_21_11"></a><a id="Tc_cUmHzmu0KU-8BJz6TruJ_w_21_17"></a><a id="Tc_-R1f-TKIiEqzC9WYFBsDqg_21_20"></a><a id="Tc_Z1B3oUxTD0um8TPseD9y5Q_21_23"></a><a id="Tc_CqpUr1-NEEuJyBNJM-P9hw_22_0"></a><a id="Tc_5VIpl0_9_UOEF4ueYMTBkQ_22_3"></a><a id="Tc_O8Gw_iouykSQ6gjlOBzlxA_22_6"></a><a id="Tc_OZGSNxxKI0GUBjXbCce7BQ_22_11"></a><a id="Tc_LExO-gW2rkmTpoIgGNuPJg_22_14"></a><a id="Tc_N8SC2E5R00-B3_v9S3jw6w_22_17"></a><a id="Tc_EKRnfo6Adk6a8PCuKnRU6g_22_20"></a><a id="Tc_7LxBw6FhrU2twKQjwZLdcA_22_23"></a><a id="Tc_ANLBpCNN8EmzauiRruuyUg_22_26"></a><a id="Tc_eDCnBrtWGUew5pELgtC3iQ_23_0"></a><a id="Tc_Ll1gTuIPC0qo-mum0gw3xw_23_6"></a><a id="Tc_of3_KfLIHkmUHBxErIzcPA_23_8"></a><a id="Tc_RHHpZomSpU-SIRFss_7WAw_23_11"></a><a id="Tc_uqvjXbeKFEuBOClv56t8eg_23_14"></a><a id="Tc_LYa68p1PVU6AASp1gx9IZA_23_17"></a><a id="Tc_Lacm9rijXU6KzSs3HpIKRQ_23_20"></a><a id="Tc_zcmXE5whpkiLoT2pvg3cwQ_23_23"></a><a id="Tc_8nT1S_cvaEeObF04obyHBg_23_26"></a><a id="Tc_7tTJSXpvQkeeN1vvqBdbag_24_0"></a><a id="Tc_xAzEeEUaS0G8aU6ozFXQpw_24_3"></a><a id="Tc__mjSDr50C0Gk62uMGyoDEQ_24_6"></a><a id="Tc_PSIWSNOt90O9QPbhfBlx-g_24_8"></a><a id="Tc_AQzmuSQ8AE2iRqSmvMdePQ_24_11"></a><a id="Tc_iKMTS6Tc30SMcBHLl3dfTQ_24_17"></a><a id="Tc_k9dzS0cpkUKSnDLH6So7vA_24_20"></a><a id="Tc_F_LXn2vlVEaLktHhIU9WbQ_24_23"></a><a id="Tc_h0sBz-Tx_Ui7FKBKq1SMrw_25_0"></a><a id="Tc_xHOHjIzyW0Ktc_UgRg8jgQ_25_3"></a><a id="Tc_qHg-RNp2MkaeQllV4Y-Q3w_25_6"></a><a id="Tc_LTR_QdO5nEafoAEru7Wi_w_25_8"></a><a id="Tc_Eoz26HcIO0KY2N5GA9XWQg_25_11"></a><a id="Tc_H35_NSKRpU6EULRJ-OfqeQ_25_14"></a><a id="Tc_9OJzb1aHwUu8jyhouZh75A_25_20"></a><a id="Tc_9wmzn1RHRUKwh7G_gNe-Jg_25_23"></a><a id="Tc_s1u1f9P7RU6t-nt93FaFmA_26_0"></a><a id="Tc_-zUWTzjxuUiU1xBGavOuSw_26_3"></a><a id="Tc_1aQJAjpAB0ayoQccGWEGIg_26_6"></a><a id="Tc_7WzB0r4MfEW3i7RqcXLBMQ_26_8"></a><a id="Tc_CImhqU5bP0-IaVcfPXQeBw_26_11"></a><a id="Tc_NFSgAQcJC0mPz2SPMrtFug_26_14"></a><a id="Tc_RtEp4YYaL0mOjwk1c9ioOw_26_20"></a><a id="Tc_nsJLgPmEM0mbV_Ju_mOT0w_26_23"></a><a id="Tc_4tVdRZLfTE64fLu_ljkCzg_27_0"></a><a id="Tc_cA3LItRxak-Wvv2HLqua9w_27_3"></a><a id="Tc_ldh5rsSQfEevVN252GJh7A_27_6"></a><a id="Tc_D_52s40Ds0O-a3HR8JWZeQ_27_8"></a><a id="Tc_5G-UfjvpGECj7XB_gBFEdA_27_11"></a><a id="Tc_wbAx6_nDxEWnJh4q2n9E4Q_27_14"></a><a id="Tc_NwZgsKL830Sp8Tv9lQ91ew_27_20"></a><a id="Tc_uY9IQ9gwMk2ka-YFiMu18Q_27_23"></a><a id="Tc_FJ_XuY6_DU-ktLPmH6kEYg_28_0"></a><a id="Tc_YhmeYSo9UE6WMJnWH0UNXg_28_3"></a><a id="Tc_MGjM6xqKY0mKadmEq3aeBQ_28_6"></a><a id="Tc_tzj2W5e-GUak3HgeLBDFmw_28_8"></a><a id="Tc_r3Iwo1_U80WM6srlkVxO9Q_28_11"></a><a id="Tc_7ADPpkqq9kaTzTr2AfAmkA_28_14"></a><a id="Tc_CcSNVYsjRUCC6o4Xhn-34w_28_17"></a><a id="Tc_C9cBwIgo-EKjsBWhhakS5w_28_23"></a><a id="Tc_rGnBucfGaEa9VYcHb1uJXQ_29_0"></a><a id="Tc_JXC0bgAbKUmYg7QvduAlYg_29_3"></a><a id="Tc_HhkOT7P4s0G_41YhZmXi8A_29_5"></a><a id="Tc_Wbj6MPQTukqeBHa6scpzpg_29_6"></a><a id="Tc_IhcsxiY4okiEdj9ET4jz5Q_29_10"></a><a id="Tc_75sJ5D6MLEGqkz18wc3DIQ_29_13"></a><a id="Tc_ghjSBbwbNEKxQMMrfhHshQ_29_16"></a><a id="Tc_e8zfyQi4IUyRm5kGLB4uZQ_29_17"></a><a id="Tc_1Deal5-VtkOfbn8CoJD9Gw_29_19"></a><a id="Tc_J3Jtck9d-UmhH4-CebKplg_29_22"></a><a id="Tc_CCLc4B6C7kS4uBwaeU1Aug_29_23"></a><a id="Tc_ShMAaPFpUkSYqG83vUBCMA_29_25"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Noncontrolling</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of July 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3umrq38u0aybR_OiS3qMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_URuqxq2tDUmd2OwxBRf-tg_6_8">8,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3umrq38u0aybR_OiS3qMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_3iNAbjFTSkyibvpF_u95Vw_6_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kAxEI4glK0KksnZbo4Dl-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_sYUw9evQJUuttBnm6Qyw0A_6_14">282,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_K3rvxXz_kEOX2nxI7ySCQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_D8ywOOY2O06LWQEg0YMj7g_6_17">63</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rCT3Y6oqDkaJvtijpVT8fA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_uPZJupSFPkWazlj48bXd3w_6_20">173,627</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_TEPezL3XWkKqi_B0FPpBFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Lsq47X-pCkSB9G2fji4kBg_6_23">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_3mhJIU4qPU-C62UjRmqJWQ_6_26">108,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Sale of preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_I49KgjiFbkiWuxK9AUMMTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_rmW3kXdeykKVG2E7Txaylw_8_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3j_LUG_w402t7idvNDSjIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_FDK0H6MP-kaSpwYhKKDM1Q_9_8">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Warrant issued for Transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_8LUBPPWrPkaUycvg2uitXg_10_14">967</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_JHNI8YMJU0W8sH7psis6eg_10_26">967</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Acquisition of remaining portion of iBio CDMO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg" decimals="-3" format="ixt:numdotdecimal" name="ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" scale="3" id="Tc_HNvkVPxJnUq3FCnjF_JrRw_11_14">68</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lIakFT-JPkmRV8rez2kjQg" decimals="-3" format="ixt:numdotdecimal" name="ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" sign="-" scale="3" id="Tc_DflYA79yK0SxvDavNNP8EA_11_23">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" scale="3" id="Tc_3nL9T0G5LU2OItogkHZ8Qg_11_26">50</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3j_LUG_w402t7idvNDSjIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_WBeU_LZmE0CgHMWO5qtthg_12_8">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_wmpDIuXVHkCF47tErMvF2A_12_14">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_-pFg43vmIEKJTAXrJyY2kw_12_26">77</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_gobArSPwrkC8Z-c-AeEnhA_13_14">4,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_QXSZSznV90iqzTnuaj2Erw_13_26">4,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized loss on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lw4nMpzng0qzbfkprZhULg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_96zNJsFLPECGrtb1mAsASA_14_17">150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_lonk3hX_ikyvPyqIb1n3Ug_14_26">150</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sF1HRLA4G0Wy2T1ygJ69aA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_P6BrWMDb6EOUSNI-mIeRzA_15_20">50,303</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lIakFT-JPkmRV8rez2kjQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_mXzPEA4BT0yTozbLAV1p4Q_15_23">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_361iXLBTo0KyWic1JW_YPg_15_26">50,304</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QblOI1ljmUWLbXeZ7kzXTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_eET4-0vMOUq5KGgptk-ekg_16_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_D0mHT9ezdE2X0uInsc1A0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_M1zmXS1w4kSUnikzIHtQlA_16_8">8,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_D0mHT9ezdE2X0uInsc1A0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_bYUgREt8jEu9b6QtePZo0Q_16_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sN_Hnjg5ykm1YYIBPdZ-vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_kleoSPe-sE-qa68sjaSYSg_16_14">287,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_GVb0po6fo0GQxDi2ozIWyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_3B0WKD_yMkWbdv867W6r-A_16_17">213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qeC92PWuXk6kis_CsVZ_CQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_CGzqBdWkn0WpFnDWLwwcxQ_16_20">223,930</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_EAraov8BxkyCPjzjIJNvEw_16_26">63,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Capital raises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesCapitalRaise" scale="3" id="Tc_I1OzDUlcEkOXPknNoIhSkg_18_8">11,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_aK9dKZFpikarLMhKNjsRHw_18_11">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_2ulH7Al0x0ePm1YVGJLdTQ_18_14">12,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_knPvVWmTSUikNYCev-epVw_18_26">12,327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Costs to raise capital </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_xvGFzAx8CUO2hXxNifXEGg_19_14">636</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_IpzHFXvgHUOzZo7tD_R5iQ_19_26">636</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Asset acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A" decimals="-3" format="ixt:numdotdecimal" name="ibio:AssetAcquisitionInShares" scale="3" id="Tc_zIkPSnJgJ0Kb6bR3fzp89Q_20_8">102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg" decimals="-3" format="ixt:numdotdecimal" name="ibio:AssetAcquisitionValue" scale="3" id="Tc_2s6gygN070miGpaOB4IFcA_20_14">650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:AssetAcquisitionValue" scale="3" id="Tc_XMAqjWAMQU2wSx_KpKWDHw_20_26">650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Payments for fractional shares resulting from reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A" decimals="-3" format="ixt:numdotdecimal" name="ibio:FractionalShareIssuedAfterReverseStockSplitShares" sign="-" scale="3" id="Tc_ZVyJ7KdBPEmOFaf-nMxMfA_21_8">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg" decimals="-3" format="ixt:numdotdecimal" name="ibio:FractionalShareIssuedAfterReverseStockSplitValue" sign="-" scale="3" id="Tc__H2Q5dDQnEuBwCPKSY48tw_21_14">39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:FractionalShareIssuedAfterReverseStockSplitValue" sign="-" scale="3" id="Tc_Pua2SPrdyEKBiBXldNl9GQ_21_26">39</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_LiVh_ZGE2EqRdGaGYO5U4A_22_8">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_43N1IQqzkEqJ13LA3fBcnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_e9dzIf-yy02dfzgBncVtHQ_23_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_P4j24UJ4Lkirv2irAWUe0A_24_14">4,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_17_tK_5FXk-PctEQB0pQ-A_24_26">4,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QsKwNCPfTEOZYuRBlUxk8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_Tw3wn72QdEqKVHgAWUlUgw_25_17">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_TE6T74ul10y2ZfL3lz6VpQ_25_26">33</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Reclassification adjustment for loss on available-for-sale debt securities realized in net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QsKwNCPfTEOZYuRBlUxk8g" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" scale="3" id="Tc_cUxxLS-_nUuQIURedLw1OA_26_17">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" scale="3" id="Tc_wDxWavqmNUWTtJ1061m-Qg_26_26">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QsKwNCPfTEOZYuRBlUxk8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="Tc_SwfWarEG7060mwrG0pN8Tg_27_17">159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="Tc_hjt_5aa8Ake_YS88SCDt5g_27_26">159</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Eqhm6X_g3kW4sI5yXUWYdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_oXUHrhGikUuFLjyNB7lY-A_28_20">65,010</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_XMHC3h2Ngkyvirh62R3djw_28_26">65,010</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TzGVANYEDkKQtb1ZjhZ9Kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_KnKICKl1oUeLkddbVVqZkw_29_8">20,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TzGVANYEDkKQtb1ZjhZ9Kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_XdRo1N_PLE-kriTUKqVwsA_29_11">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_84atjSQ3lkqV3dHvpF-GGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_KheEPVcxw0yrxPRf16-5HQ_29_14">304,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mHPAoRsEt0Gat8eBQF4yqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_jOlNeafLt0uepFgX4UrZQw_29_20">288,940</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_-GWDCQ0-rkS-RDPIVVQgHg_29_26">15,381</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d90b3ed2_6eb5_43a8_b120_bb65ab56d298"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><a id="CashFlow"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In Thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_28182dcb_02a5_45fa_9e37_873a84a50db5"></a><a id="Tc_t55GaSV7z0CD2f6TKAN-3Q_1_2"></a><a id="Tc_cDyW75Ebw0G71kn0ttEAHA_2_2"></a><a id="Tc_Gu44nTlvak26u3NBznTUrw_3_2"></a><a id="Tc_QEWrkp8iPkyIwJOzRYKGfA_3_5"></a><a id="Tc_h9WBFWyWs0K-_eD-iSd9Jw_5_0"></a><a id="Tc_Sn2a3tyJr067zAHlR3WcTA_6_0"></a><a id="Tc_jHuew-Bpdk2srBCPV1Y33w_6_2"></a><a id="Tc_UESyPOwx_0GmKymvUJD5cg_6_5"></a><a id="Tc_e2fTwT8GZUuRSelO_fFCUw_7_0"></a><a id="Tc_8AjYlQZz3UyqWNW1c11HpQ_8_0"></a><a id="Tc_cRftkOjlVkScBXUvHuChVQ_9_0"></a><a id="Tc_fgMXwQQm9kCcYTkIp_gBkw_10_0"></a><a id="Tc_Y48HiCUOSU6oaJmBIltd6A_11_0"></a><a id="Tc_x66Tag9j60qesrbM2JRTUw_12_0"></a><a id="Tc_wiI0ohcGe0WD7AqdQGcLfg_13_0"></a><a id="Tc_QXovh_rGF0S7U8wUYlkd0w_13_6"></a><a id="Tc_dd4boZjZO0WtY2iBgz-DYg_14_0"></a><a id="Tc_x16wbWBzQkmy-rLkOCNBTg_15_0"></a><a id="Tc_UNbPwg6Z0kWX0-_WVM339g_16_0"></a><a id="Tc_bGYDRQ4PTUek_0M5mywNJA_16_6"></a><a id="Tc_UP2tQAtCJ0SINtpkNYa6Yg_17_0"></a><a id="Tc_NcEvCj5J00SB_GOF3U0CHA_18_0"></a><a id="Tc_ddsgQuJ980SRvkSI_rnb3A_18_6"></a><a id="Tc_bz8iz9kfGkOrhsWtbw5U0w_19_0"></a><a id="Tc_SEyRLHYBZUKRyxaW_h6GhA_19_6"></a><a id="Tc_-rcdipnjJUOpnFLqhOMl6w_20_0"></a><a id="Tc_b_Nym-9Abka0gM-kJWtxzQ_20_6"></a><a id="Tc_d2FV36vpoEipLWNapvmzXA_21_0"></a><a id="Tc_pMcSW58S6UWmR7a9DE9Ttw_21_6"></a><a id="Tc_nacVty8YVk-RY6iTy-z3tA_22_0"></a><a id="Tc_wZCK-ivzGkGo1h3cBOK6xA_22_3"></a><a id="Tc_OKEFrBxoAEGRHzypuPb8dg_23_0"></a><a id="Tc_4RTbtZB6iUy7BngxTxFPOw_23_3"></a><a id="Tc_RElzGiD-B0OOLRxy-SLxLA_24_0"></a><a id="Tc_lHtnC43AE0mJY9O_Nfytlw_24_3"></a><a id="Tc__Q43PK5Bq06YPUGGLMlqOw_25_0"></a><a id="Tc_XoOGrbU57ki0cC-O6Fz96Q_26_0"></a><a id="Tc_rD38cUTIbkCqf2GN6UmW-A_27_0"></a><a id="Tc_dQ0v-x_W8kGwXs6RL6L_4g_28_0"></a><a id="Tc_irhiSpl3j0yuCuYfCVYOYw_29_0"></a><a id="Tc_DkbeQmo8T0i8tZ_HbE7M2A_30_0"></a><a id="Tc_v3pgZ1vAlUSDsfUc-AODIg_31_0"></a><a id="Tc_tLR8Q_nsDUORFqWVjghhhw_32_0"></a><a id="Tc_IsLPfguZ60Od9Y7iPh5wxg_33_0"></a><a id="Tc_X1nzi-iE8EqOqY7n0uqjTg_34_0"></a><a id="Tc_iHT_osTUc0-aRLk-6R0LcQ_34_6"></a><a id="Tc_lFZXqfn1REGUd5oDAr5fRg_35_0"></a><a id="Tc_d9rQ-6OppEaKhWNDI_qhIw_36_0"></a><a id="Tc_vfOaozMe3EGH-ahGh0eKkQ_37_0"></a><a id="Tc_Eljxyn0rkE-hHOZOl4MneA_39_0"></a><a id="Tc_B8rkC6eNX0yFSFn1G2hLTw_40_0"></a><a id="Tc_Ghrbj3ySMECeZnL_yDZZfA_40_3"></a><a id="Tc_UupNd8iXFkmO7_SSvFmkWA_41_0"></a><a id="Tc_xfwxLZa6dEyLDgJDl-2_yA_42_0"></a><a id="Tc_M2_lAmw22kK_7Y5Qv6ruOQ_42_6"></a><a id="Tc_xtSnFFmspUyBgT424pR4Pw_43_0"></a><a id="Tc_uB5B7lWrSUW2RXPMyScFxw_43_3"></a><a id="Tc_OPDLSaxTt0OH8G-u47sicQ_44_0"></a><a id="Tc__mwAM4uLD0yoAfekXKaf1g_44_3"></a><a id="Tc_jm3Y1prJDUKFVrGzwhCwAA_45_0"></a><a id="Tc_v7tsXftbnEiD8DmRK-HRKQ_46_0"></a><a id="Tc_4TBEROZ0vkeWCb_ZbsyzoQ_46_6"></a><a id="Tc_kJHBQH39fEqOTyQX4MqFPQ_47_0"></a><a id="Tc_fpjgMJItMEyyxmzUzKybhg_47_6"></a><a id="Tc_hfPNNTbJ_kSyhpQT8uC74Q_49_0"></a><a id="Tc_uFrxaMbuy0anpbbcgV0m1A_51_0"></a><a id="Tc_GDOTTXj-JkKnsZJFrotoKw_52_0"></a><a id="Tc_lZOH4YQcJkay5Y2Kb_UVHA_52_6"></a><a id="Tc_OATe-TpMg0KLZbTe5wTzlg_53_0"></a><a id="Tc_Ad4KDTKNaUSioFG3lCXcig_53_6"></a><a id="Tc_qTJM7itUOEOPASCtSOLJwA_54_0"></a><a id="Tc_o5_zUI3OqU-gygE5Cs2KYg_54_3"></a><a id="Tc_XjzHPQeX90m9wVCYgYaL9g_55_0"></a><a id="Tc_M0Yn5lOMYUeLRkz76DNkpQ_55_6"></a><a id="Tc_J-ELEB_qQUCKoecJMGVphA_56_0"></a><a id="Tc_CQqpbfFpnkO58oPG1bMHcA_56_6"></a><a id="Tc_RKp4CAZhtEyVy-mswP1v3Q_57_0"></a><a id="Tc_wKe6NX6dYkqyfN1UNeDHng_57_6"></a><a id="Tc_WOT5R4iRGEeKI5-5lOCNqQ_58_0"></a><a id="Tc_z-DS9wISmkqEbycmd7BusQ_58_3"></a><a id="Tc_1OZ9bJ5loUeOBptDBZBf6Q_59_0"></a><a id="Tc_PyqdWFJeekieaXUaiXl6Mg_60_0"></a><a id="Tc_kotOMtmz3U2YWE2WLBz9PA_61_0"></a><a id="Tc_0BqLjY6iG0arCu4Qec6J9w_63_0"></a><a id="Tc_ZlKWetPk5EixsLpMcipyZg_63_6"></a><a id="Tc_dxeV0bslNk6k7zLh1odejw_65_0"></a><a id="Tc_mUw2yuweiEStrbWCT6Q92g_66_0"></a><a id="Tc_jY6kHRfgFkeB0s2g2zCZQw_67_0"></a><a id="Tc_uGg4-KN7IUOpl0edcsasQQ_67_2"></a><a id="Tc_LbKBYAYec0a4dZzpcq8vnA_67_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_N2BpWPx5bkafNfEMJE-8xA_6_3">65,010</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_POj6qCyKRkijQpGIBOs4EQ_6_6">50,304</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Hosp_ec_cUGAgicTGc7wow_8_3">4,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_lSzvWp3Hd0aOJPGmW3u_9g_8_6">4,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_IBX6xFMcTUau_7CsMkgUBA_9_3">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_FsPD37-6N0-AcXgr__H7IQ_9_6">401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_GxCoJ0riaESeCgctDc2DTA_10_3">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_tDcZ6mae00O4XBMEsOyrQg_10_6">599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Amortization of operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_rackOmLG60WgG1ATwmdsAw_11_3">356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_3qwvQ9Fl8k6uTElYJT2c0A_11_6">516</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Depreciation of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_neaecdELN0iDLASGZ0huvA_12_3">674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_-YDSJt2JLkWMuCmj2FWw1g_12_6">2,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="3" id="Tc_AJRNiun_0EWhXTiWBhXQUA_13_3">773</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Accrued interest receivable on promissory note receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" scale="3" id="Tc_kCPEjlVYgU214FQyT_G0EQ_14_3">75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" scale="3" id="Tc_UVD_IHiQL0-7jb6Ghg1Ovg_14_6">75</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Amortization of premiums on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_LTx9sBBTF0mlLh7F5h9GlQ_15_3">67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_utqcEgdPPEK7EIjT5oMO8Q_15_6">312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" sign="-" scale="3" id="Tc_AVRYMj7Sj0SJ1ne7wSxR5A_16_3">98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Amortization of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredFinancingCostsAmortizationExpense" scale="3" id="Tc_VpWV5WtzEE2eBep-8fFpEA_17_3">242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredFinancingCostsAmortizationExpense" scale="3" id="Tc_GijSoqHrR024x-BAEFlBUg_17_6">107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInInventoryReserve" scale="3" id="Tc_pEc4uyLA-EqADDcyfoFsJw_18_3">4,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Impairment of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Tc_J34rDr7HFk2h_wRDKBKu-w_19_3">17,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Impairment of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_lM1swXuclE2r2G244c8UNA_20_3">565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Gain on disposition of finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" scale="3" id="Tc_gcqCuQpu9kGzLiGLAgxkEw_21_3">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Forgiveness of note payable and accrued interest - SBA loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan" scale="3" id="Tc_q19xFE7BGUqG66gmsuzzXQ_22_6">607</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Settlement of revenue contract</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:SettlementOfRevenueContract" scale="3" id="Tc_Gq0d78DFukCtoPyHDx1fsA_23_6">84</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Impairment of investment in equity security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfInvestments" scale="3" id="Tc_3ikuTPSz_EipNY-9xKioaA_24_6">1,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accounts receivable - trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_Aj7_Ly1V_k2LVnNcpXftJQ_26_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_IiUmdQQREkKYR2SGut1SYg_26_6">886</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Settlement receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInSettlementAssets" sign="-" scale="3" id="Tc_kyCzLh6FO0iMbxDKKuXbiA_27_3">5,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInSettlementAssets" sign="-" scale="3" id="Tc_3HEV9yUiuEukaEBQ1ZJZcQ_27_6">5,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" scale="3" id="Tc_8TqCvyHvYkecSWpUS0eL3w_28_3">1,015</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" scale="3" id="Tc_rcvCCcZscEmyX9R8IWuBDQ_28_6">3,873</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_ZslbRkb6SkifMBELPr4Mog_29_3">885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_b-mDmGGUyUaAPQUluS8Qig_29_6">307</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_Ff8sPKIaLkKVumRcuhGlfg_30_3">74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_ePrmt4y9tUOM-YM_i73fgg_30_6">74</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Security deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" sign="-" scale="3" id="Tc_cLW2_IDktkmlO96RJs6rgA_31_3">21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" sign="-" scale="3" id="Tc_Emv8QOedjkKYGddn_xqP7w_31_6">5</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_zRAnXCqkGkCF7Xo3Nia2_w_32_3">625</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_dm5IsFeKhkiZIy-27R4PlA_32_6">1,239</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_NejoUzz-T0y7j2zev4_wig_33_3">145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_XzT6vWdPUkW81t2G7hUjyw_33_6">1,443</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accrued expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent" scale="3" id="Tc_ZrbzcizqXEe6d5oR-zNB8A_34_3">527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_FIhKycmALkivfiphZmRlSg_35_3">101</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_BkAHpriEkUqTnuIF-Y_n7A_35_6">15</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_WkptxgXSV0iixGE7eg20cA_36_3">100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_Z_ZUeuoOxkeFnDiR9e3ssg_36_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;"><span style="white-space:pre-wrap;">     Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_OhcC-uUpS0OWxBeFE5A3iQ_37_3">30,436</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_6UiNMb8FdE-uNyS6dN1OHw_37_6">37,480</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Purchases of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_6vaHx6wdtkC0zF2mFlHhTA_40_6">5,355</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Redemption of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_Mol-9pWUSEKzoUWQ4k07nA_41_3">4,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_VfQJm0XknEWwK3KJwk-L9A_41_6">13,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="Tc_mz6XEKqJf06M7Q3-zWm3gg_42_3">6,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Purchase of equity security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="3" id="Tc_1wiqSPZ5n0q_1jOmd0bqiQ_43_6">1,760</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Additions to intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_QyGb1twtP06uHQd1DD-dPA_44_6">4,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Purchases of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_2n4S68PXA0CihwCeokhYng_45_3">5,738</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_8eg2PJKj00mOasATuQzgfQ_45_6">7,330</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Sales proceeds for fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_1hk6LoVd9UqDbYQ1UdafTQ_46_3">2,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Payment for RubrYc asset acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="Tc_iX44H8vSXEac2sEms0L-FQ_47_3">692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;"><span style="white-space:pre-wrap;">     Net cash provided by (used in) investing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_RvEZvc0Wh02fEoSqUNunUg_49_3">7,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_PB8VReMorE6M0dMJZF3WRA_49_6">5,127</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Proceeds from sales of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromIssuanceOfPreferredAndCommonStock" scale="3" id="Tc_1AzKaY8iY0agzcRKabuXug_52_3">11,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Payments for fractional shares after reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentsForFractionalSharesAfterReverseStockSplit" scale="3" id="Tc_zyvCzqYUfUKtwbqWjaG2LQ_53_3">39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Acquisition of noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="Tc_wfJ9jsxMcUyNbGcC7UxjZw_54_6">50</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Proceeds from equipment financing loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromEquipmentFinancingLoan" scale="3" id="Tc_WjbEs6SAPEC-IK4-00daKw_55_3">500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Payment of equipment financing loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentOfEquipmentFinancingLoan" scale="3" id="Tc_rAR-cnNhlUSfKgzLUxEagw_56_3">99</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Payment of term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_ecPVD2r6xUuUoOEoE94ifg_57_3">9,318</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_VYyHv-2MTEqF3d8gXnoniw_58_6">77</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Costs to attain term note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentsToAttainTermNote" scale="3" id="Tc_0OzgbkdqQECuEoibcZG-5w_59_3">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentsToAttainTermNote" scale="3" id="Tc_wCaAtqUs0UeBptlsvFQK-A_59_6">322</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Payment of finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_YqtBTDagaE2pD0Ew4yHUWQ_60_3">208</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_p99XDdG98EqlrQLh_6-VEg_60_6">5,830</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;"><span style="white-space:pre-wrap;">     Net cash provided by (used in) financing activities </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_XzMW8-3EbESgIClYo3QuZg_61_3">2,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_NcK0rB3SYUWUyWy9h9N4aQ_61_6">6,125</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Effect of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_4Au6qWbtT02yk-HB4psLWQ_63_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_IY1Uhs2MmU6NC99w1VrnxQ_65_3">21,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_3d_nDpONuEGYxpamiCm2cQ_65_6">48,732</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Cash, cash equivalents and restricted cash - beginning </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_2moamYbiyUiNGaA32Ytrrw_66_3">28,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_AX-qv76m80KxttRwg1ICBg_66_6">77,404</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Cash, cash equivalents and restricted cash - end </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gg9BU7QxpkC9IxAUZDU7fg_67_3">7,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_YEBNKL24Mky496RHhKvtjw_67_6">28,672</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In Thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_aa1d9163_4506_46ea_b318_f99a4f587062"></a><a id="Tc_CeaLBV73lU-0_r3t9WR-oQ_1_2"></a><a id="Tc_R8E5Rf4h-kyhgj4L1lcAhw_2_2"></a><a id="Tc_cdxeRCHhaUaks5DPMadb7w_3_2"></a><a id="Tc_YsjkeRywZEuMoKzvtvUztA_3_5"></a><a id="Tc_ZZq6WF3S60eVOPgNqTiEjw_4_0"></a><a id="Tc_EKD1SbGK6k2fxN0RZRHyQQ_5_0"></a><a id="Tc_n3d_HMx_7EiKd2aGU2dhug_5_2"></a><a id="Tc_DALqtojwH0OIrTT2o-7zKQ_5_5"></a><a id="Tc_ESVpuJnRS02R_DZsJIQMwQ_6_0"></a><a id="Tc_OKuQVM_qhkq-Qd6uzeB85g_6_2"></a><a id="Tc_pRPG7FcPc0alCtDVL3hIbw_6_5"></a><a id="Tc_9E7iNPmQ90yuc9klS9PCTg_6_6"></a><a id="Tc_wVPoFH5WUE2M2lFZcbeKZA_7_0"></a><a id="Tc_s58QuRbvgEyOgauTSzydPw_7_2"></a><a id="Tc_PrEoR-m00Emk28nqhDxFGQ_7_5"></a><a id="Tc_NsLne_L4TUOOVkTK14DDlw_7_6"></a><a id="Tc_ECF1j6CILk2Rl6ZhmoOunQ_8_0"></a><a id="Tc_ejnTLAL8REK5BN0rppfvHw_8_2"></a><a id="Tc_-8fCH4FTyE24HkclF62TUw_8_5"></a><a id="Tc_CGPrp93s70iowhuVRQXLDg_8_6"></a><a id="Tc_QgxlCwPEwEeRdkS2Amaf5A_9_0"></a><a id="Tc_pN5zvkNRkkaimRYNOefTdA_9_2"></a><a id="Tc_DW4DUkb5Ekm1FS12hwjMiA_9_5"></a><a id="Tc_pWXNojbdNkqG6U9LdihADw_9_6"></a><a id="Tc_P7VnBb3DAU-UdtmYX--iuw_10_0"></a><a id="Tc_uuXQ5ienRkWcV2ft3Fws2A_10_2"></a><a id="Tc_pxYxyzkYLE-oedeH7WeNEA_10_5"></a><a id="Tc_g4m57xhUNUKe2M2WcyxDSw_10_6"></a><a id="Tc_nWUZpfC--kCR4CzliCdClA_11_0"></a><a id="Tc_yV93KHnoDESQKmTLAELcLw_11_2"></a><a id="Tc_bzr48tjxyUChgKV9O2wvlA_11_5"></a><a id="Tc_5qlFFdqBS0GDbYboMuEbwg_11_6"></a><a id="Tc_sQ7Dfo5Vy0C7IlSWshDxSQ_12_0"></a><a id="Tc_G8pjdfukdUuGhsZ9LY-xYA_12_2"></a><a id="Tc_KM0auV2HC0mzQ4v4w-JkTw_12_3"></a><a id="Tc_oYhsfD4teEKSkZmV75NJkQ_12_5"></a><a id="Tc_KUE3cZvFQUWEYMzvabTZ2w_13_0"></a><a id="Tc_zWzHcKaaUEKN3OVZBAIbEg_13_2"></a><a id="Tc_A8bUufxDZ0OOE1AdcUilig_13_3"></a><a id="Tc_8uWmzMDrNEqVUy-4nQSAAQ_13_5"></a><a id="Tc_D7i7IS94iEWACf4vBYmJXA_14_0"></a><a id="Tc_SBqFK_HCZEaveO2Viej5sA_14_2"></a><a id="Tc_cjBqjy9eaU2IBoZQocW-Jg_14_3"></a><a id="Tc_nhkcW2sUf0a5-HDe_iifyg_14_5"></a><a id="Tc_xOPh-ZdomUSl8_-AbCa1jw_15_0"></a><a id="Tc_9k2uthWfqEe_wMGSPiB8hg_15_2"></a><a id="Tc_FVHZmewycUaKxYdt8sKQ5w_15_3"></a><a id="Tc_JZos5GXFP0a8xLPFN9mnig_15_5"></a><a id="Tc_BXF806CCokGWS1S-8O06nA_16_0"></a><a id="Tc_4sluQF7DHUqCpXx2d75YFg_16_2"></a><a id="Tc_faTOxxvNDE-fFbTi-Nbnpg_16_3"></a><a id="Tc_t5ZikeFa0Uijch0RTqz6dw_16_5"></a><a id="Tc_IUpIw-TTm0q-gNMsjDQ0nA_17_0"></a><a id="Tc_6wv5zM2bGEuTT7ZNmB_y_A_17_2"></a><a id="Tc_92JMBpK6GUSGLw6olTQlWg_17_3"></a><a id="Tc_fJqdC8B7XEiMc1jeoilhQA_17_5"></a><a id="Tc_M0MsDM3a2EqaT1yZnJ1OBg_18_0"></a><a id="Tc_Yalg8Sx82U-El-9nVPyOpA_18_2"></a><a id="Tc_pbzAFAOGs0Shyi34oaqStg_18_3"></a><a id="Tc_3aHL-2e_lEiNh61ncvTLNw_18_5"></a><a id="Tc_2G6vOUyauEKSxMAcEQwJEw_19_0"></a><a id="Tc_mLLi_mEjZEiHP0mlmadmLA_19_2"></a><a id="Tc_X2vEaApcGk6MGDh3Nx_08Q_19_3"></a><a id="Tc_km1kO4ZNREWvTcQhvx21OA_19_5"></a><a id="Tc_9iU2_0yfhEuZ5GXs6C87aQ_20_0"></a><a id="Tc_cqRqO4a6yECo_LFzjD1KYg_20_2"></a><a id="Tc_ZFZEREY8806vPXQKHWPCSQ_20_5"></a><a id="Tc_4kPXJ7qVE0qvSm1tpdAQWw_21_0"></a><a id="Tc_kXZxQjC8e0m-q4Eye5Xymg_22_0"></a><a id="Tc_m7ufqNlk8kO_ysRXuJ7ghg_22_2"></a><a id="Tc_CDdxlUGJ4EW5T-URaLz1fQ_22_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Schedule of non-cash activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets included in accounts payable in prior period, paid in current period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid" scale="3" id="Tc_9wo1Zml-AE-GJYQftAaElA_5_3">1,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid" scale="3" id="Tc_qQousekQ7kqC-dcurBHXdg_5_6">791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in finance lease ROU assets for new leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_3nhcFGX_ZEubDt6gwrpwzA_6_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in finance lease obligation for new leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" scale="3" id="Tc_TX3pD6fQm067Iu6E0T5xCA_7_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">RubrYc asset acquisition by issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_GrGr53KP9EqZAfZDN8c0KA_8_3">650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Costs to raise capital paid directly from gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds" scale="3" id="Tc_wWqbn65tRkud-iIcTDZYFQ_9_3">636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Subscription receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:NonCashTransactionOfSubscriptionReceivableForCapitalRaise" scale="3" id="Tc_mG_cxzx0L0-4jwlEjA9tNQ_10_3">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cost accrued to amend term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CostAccruedToAmendTermNotePayable" scale="3" id="Tc_2rmRpjVZb0-ELkZJbOrakg_11_3">125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unpaid fixed assets included in accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsIncludedInAccountsPayable" scale="3" id="Tc_587TDCpFukyVwDgsyf2NzQ_12_6">1,769</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Termination of finance ROU assets including issuance of warrant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" scale="3" id="Tc_ZZKD7U_hI0yMwbXQpOj4Hg_13_6">25,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Note payable to acquire Facility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesIssued1" scale="3" id="Tc_JImxhkh6Pkmfp-UdW5A8Eg_14_6">22,375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in operating lease ROU assets for new lease - net of lease incentive</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" scale="3" id="Tc_2HVW-58ujkuiKkkO6whuSA_15_6">5,570</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Settlement of revenue contract</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:NonCashSettlementOfRevenueContract" scale="3" id="Tc_-HdNQM9bQE2ya4yZKBr52w_16_6">580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of warrant for final finance lease obligation payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinanceLeasePayment" scale="3" id="Tc_-RxyF0a2b0GFvsKBSsblVg_17_6">217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Lease incentive for construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LeaseIncentiveForConstructionInProgress" sign="-" scale="3" id="Tc_2ja5kCcNkECAQ-waYRGeYg_18_6">82</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" scale="3" id="Tc_-8Gkn-jfokqdXIwzYKkCQQ_19_6">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized (gain) loss on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_FxgNiT3ltESEN-gioRGlWA_20_3">159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_A91mtingy0OsXABdUagu_w_20_6">150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid during the period for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_C9dAFBVJjUygTStTQdeiuQ_22_3">687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_09JNGZfRJEiIfOB7lP-MyQ_22_6">1,045</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk83294670"></a><a id="Notes_to_Consolidated"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:NatureOfOperations" id="Tb_lcpodruSqUqAlCKPgLsK7g" continuedAt="Tb_lcpodruSqUqAlCKPgLsK7g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1.&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">Nature of Business</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (also referred to as &quot;we&quot;, &quot;us&quot;, &quot;our&quot;, &quot;iBio&quot;, or the &quot;Company&quot;) is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, iBio made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. (&quot;RubrYc&quot;). This acquisition commenced our transition to an AI-enabled biotech company and led to the divestiture of our Contract Development and Manufacturing Organization (CDMO) business. This strategic decision allowed us focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key features of iBio&#8217;s technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with unprecedented precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. &#160;Another integral part of iBio&#8217;s technology stack is the machine learning (ML) based antibody-optimizing StableHu&#8482; technology. When coupled with our mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio also developed the EngageTx&#8482; platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of our antibody products. By incorporating EngageTx into iBio&#8217;s own development initiatives, the Company&#8217;s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to our potential partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">iBio&#8217;s scientific team, composed of experienced AI/ML scientists and drug hunters located side-by-side in our San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows us to quickly translate scientific discoveries into potential therapeutic applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Artificial Intelligence in Antibody Discovery and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company&#8217;s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pre-Clinical Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">iBio is currently in the process of building and advancing its preclinical pipeline. The focus of this pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging iBio&#8217;s technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:171.6pt;"><ix:continuation id="Tb_lcpodruSqUqAlCKPgLsK7g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">on the learnings of competitors, iBio&#39;s programs are primarily adopting a fast follower strategy. This approach allows iBio to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230630x10k030.jpg" alt="Graphic" style="display:inline-block;height:171.6pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Digital Infrastructure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">iBio is a firm believer in the transformative power of digital technologies, including robotics, automation, artificial intelligence (AI), machine learning (ML), and cloud computing. These technologies are integral to operationalizing our strategy, accelerating our learning curve, and executing at scale. As such, the Company has made substantial investments in these areas. &#160;iBio&#8217;s aspiration is to digitize our operations to the greatest extent possible, harnessing the potential of digital technology to maximize our impact on human health. As the Company continues to grow, we remain committed to further investing in our digital infrastructure to support our ambitious goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Strategic Alliances, Collaborations, and Joint Ventures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio has formed collaborations and strategic alliances to gain access to funding, capabilities, technical resources and intellectual property to further its development efforts, commercialize its technology and to generate revenues, including through the use of our patented epitope-steering AI-engine and our EngageTX platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_WGj48966IUa9HzcjzcRdCw" continuedAt="Tb_WGj48966IUa9HzcjzcRdCw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of iBio Inc. and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#8220;iBio CDMO&#8221;) for an affiliate of Eastern Capital Limited (&#8220;Eastern Capital&#8221;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. See Note 6 &#8211; Significant Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company&#39;s ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company completed a public equity offering and at-the-market offerings, reduced its work force by approximately <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_jlUMpefIxE2J1KvfkMobTA">60</ix:nonFraction>% (a reduction of approximately <ix:nonFraction unitRef="Unit_Standard_position_oflWAv0coEqkT6ZpEJ9RSQ" contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="Narr_Ahlvl83hvUqp2tRjCChjtA">69</ix:nonFraction> positions) in November 2022, and ceased operations of its CDMO Facility thereby reducing annual spend on expenses. Additionally, the Company has executed the Purchase and Sale Agreement for the sale of the CDMO Facility, which sale if consummated will allow us to pay all outstanding amounts under the Term Loan; however, the consummation of the sale is subject to closing conditions </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WGj48966IUa9HzcjzcRdCw_cont1" continuedAt="Tb_WGj48966IUa9HzcjzcRdCw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">for which there can be no assurance that they will be met or the closing will occur in a timely manner, if at all. If the closing is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely that the Company will have sufficient funds the repay the Term Loan on its maturity date, which Term Loan has an outstanding balance of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_26_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_dm18S2OvJ0Sy2-xaPQ94EA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_cRyZc8Uek0-lXe5GKE_w4g">12.7</ix:nonFraction> million as of September 26, 2023. Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#8211; Discontinued Operations for more information.) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s cash, cash equivalents and restricted cash of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-5" format="ixt:numdotdecimal" name="ibio:CashAndCashEquivalentsPlusDebtSecurities" scale="6" id="Narr_pKtqWeL1fEKpvunxq98YVA">7.6</ix:nonFraction> million as of June 30, 2023, is not anticipated to be sufficient to support operations through the second quarter of Fiscal 2024 unless the Company reduces its burn rate further, sells the CDMO Facility for amounts above its term note payable or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plan. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Annual Report. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 22, 2022, the Company&#39;s Board of Directors approved the implementation of a reverse stock split at a ratio of one-for-twenty five (<span style="-sec-ix-hidden:Hidden_C1BZAkhphkSP6NLYZ6XiZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span> : 25) shares of the Company&#39;s Common Stock. The reverse stock split was effective as of October 7, 2022. All share and per share amounts of our common stock presented have been retroactively adjusted to reflect the <span style="-sec-ix-hidden:Hidden_6s-44Ts3DkK4VQjk-RCW4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty five reverse stock split. See Note 17 &#8211; Stockholders&#8217; Equity for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WGj48966IUa9HzcjzcRdCw_cont2"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 1.45pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="Tb_u5Ne9qXJzE-0ms7CQcSbKw" continuedAt="Tb_u5Ne9qXJzE-0ms7CQcSbKw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;Discontinued Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_nNN_D-atW0O82J4OERPduQ">60</ix:nonFraction>%</span><span style="font-style:normal;"> of the current Company staffing levels (a reduction of approximately </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_position_oflWAv0coEqkT6ZpEJ9RSQ" contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="Narr_fqUY5FPOiUmZmD5yctYZNA">69</ix:nonFraction></span><span style="font-style:normal;"> positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, the Company continues to market for sale the </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw" contextRef="As_Of_11_3_2022_x45ryYnU3UWbXnPzJBxuug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_MyehNjMjqkqn2Q7dVpgnKQ">130,000</ix:nonFraction></span><span style="font-style:normal;"> square foot cGMP facility location in Bryan, Texas (the &#8220;Facility&#8221;). Additionally, on February 10, 2023, the Company entered into an Auction Sale Agreement (the &#8220;Auction Sale Agreement&#8221;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#8220;Auctioneers&#8221;) for the sale at public auction of equipment and other tangible personal property (the &#8220;Equipment&#8221;) located at the Facility. The Auctioneers guaranteed an amount of gross proceeds from the sale of the equipment of </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_2_10_2023_To_2_10_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_GuaranteedAuctionProceedsMember_atQz6mAuyUK6kUqxRjzLBA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="Narr_v1TiRUfNj0mBrtpScd2ikQ">2.1</ix:nonFraction></span><span style="font-style:normal;"> million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately </span><span style="-sec-ix-hidden:Hidden_0UtmYiIXKka_hRPj17MXuA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.9</span></span><span style="font-style:normal;"> million. In accordance with the Auction Sale Agreement, the Company received </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_ExcessAuctionProceedsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_2ZiYX-syC0ai3JUx-2X5gQ" decimals="INF" format="ixt:numdotdecimal" name="ibio:PercentageOfAuctionProceedsReceived" scale="-2" id="Narr_4yBtrIQTtUyFx7Mm9-uyCA">80</ix:nonFraction>%</span><span style="font-style:normal;"> of the excess proceeds, after Holland Industrial Group&#8217;s </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_90XItF3zBE20jmvLFm1lDQ" decimals="-5" format="ixt:numdotdecimal" name="ibio:AuctionFee" scale="6" id="Narr_KdCgdmrxCUalTuG5djabcg">0.2</ix:nonFraction></span><span style="font-style:normal;"> million fee. &#160;Total proceeds received in Fiscal 2023 were approximately </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_AI8GxgTdWkG2tUl-e2so6Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="Narr_qmOvQtnV60CVmWEU6cqsDA">2.6</ix:nonFraction></span><span style="font-style:normal;"> million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company incurred pre-tax charges of approximately </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw" decimals="-5" format="ixt:numdotdecimal" name="ibio:EmployeeReductionExpenses" scale="6" id="Narr_FsfbVUgsF0O7S9nT7A4Nbw">1.9</ix:nonFraction></span><span style="font-style:normal;"> million for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_D_DabM02qyekqEwyzN94-Wtg" contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw" decimals="INF" format="ixt:numdotdecimal" name="ibio:SeveranceTransitionalPeriodDays" scale="0" id="Narr_WZAyNZWCf02psn_aNOQxCg">60</ix:nonFraction></span><span style="font-style:normal;">-day transitional period during which impacted employees remained employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The Company recorded a charge in discontinued operations for approximately </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-5" format="ixt:numdotdecimal" name="ibio:EmployeeReductionExpenses" scale="6" id="Narr_nMbw8DKpWkKiM8y2KSxFgw">35.7</ix:nonFraction></span><span style="font-style:normal;"> million in Fiscal 2023, of which approximately </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="Narr_ITeFOF0ioUK_2tL4VMiJvQ">17.9</ix:nonFraction></span><span style="font-style:normal;"> million was the result of a fixed asset impairment charge (see Note 11 &#8211; Fixed Assets for more information), approximately </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-5" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" scale="6" id="Narr_ls-eBHrFVUm_69K74YYGqg">4.9</ix:nonFraction></span><span style="font-style:normal;"> million to write down inventory to its net realizable value, approximately </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-5" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" scale="6" id="Narr_r7lGjQdOtES042DBrOryew">7.5</ix:nonFraction></span><span style="font-style:normal;"> million of personnel costs including severance and the balance related to operational costs related to winding down the CDMO business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">As such, the results of iBio CDMO&#39;s operations are reported as discontinued operations for the year ended June 30, 2023. The Company has retrospectively recast its consolidated statement of operations for the year ended June 30, 2022 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#8220;held for sale&#8221; as of June 30, 2023. The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statements of cash flows. Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Consolidated Financial Statements refers to the Company&#39;s continuing operations.</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="Tb_gqgoYUn1JE6REFn2oZGm3Q" continuedAt="Tb_gqgoYUn1JE6REFn2oZGm3Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_447fed6f_69a7_4225_b7ac_b57acc366c87"></a><a id="Tc_HRgHpj6YWE6_KHD7gKmRtQ_1_2"></a><a id="Tc_-TAks9JXUEKBNrpyR9KvOg_2_2"></a><a id="Tc_mi1IGuLvk0u9bfOYdh5JuQ_2_5"></a><a id="Tc_gtpBfimL-EeXUELaDPmX-Q_3_0"></a><a id="Tc_3PvMDdgsHEmIuB8gRRJwEA_3_1"></a><a id="Tc_mVzyycG5A0ehNnSCKTEJ5A_3_2"></a><a id="Tc_KcxgZqgHMUK-HpP_Sa6GCA_3_5"></a><a id="Tc_S7Z3PA4iIkal9lCISxxhUQ_4_0"></a><a id="Tc_msooKhVGdECWjl2xaNgInw_5_0"></a><a id="Tc_fuM7lCbzBUKIKsazmHuBQg_6_0"></a><a id="Tc_7D2ynSwOn0uGr1FZUFDg-Q_7_0"></a><a id="Tc_PFGLgSBQhkeNRxBdx0j7KA_8_0"></a><a id="Tc_Pko_GzXhiU-oPfMBLwQlug_9_0"></a><a id="Tc_7X91tn2tjE6BYeSXYWA8cg_9_6"></a><a id="Tc_M4DBOZIeuUmNZ1p2Zc8y8A_10_0"></a><a id="Tc_63o3QtwXHEmLRb-7q6RFFA_10_6"></a><a id="Tc_lTqgp6cmDU-EyzcUa7AMLw_11_0"></a><a id="Tc_bkLXrxRREEur2NDdfqZO6g_11_6"></a><a id="Tc_GWvRUAhOmU6eEaWdqx5oow_12_0"></a><a id="Tc_8Q6rF3HcDE-YsDgON_uvrQ_14_0"></a><a id="Tc_JelfkyrYTUKjW6JDHcK8DA_15_0"></a><a id="Tc_rA3_kAO2wEKYTNcJZgX4vw_16_0"></a><a id="Tc_KohoC4tYU0qQb85SNzY0lA_16_3"></a><a id="Tc_yD5O9vNWQU2ku_91ZcjKPg_17_0"></a><a id="Tc_jz4QJpgjLUigFpoagUowBg_17_3"></a><a id="Tc_ChCgX56WKUSlYHVVZRHi-w_18_0"></a><a id="Tc_oYdfvqiSDUSxMOLNp2ZHDw_19_0"></a><a id="Tc_gVkTmWm8p0uFhdvYO3cVqg_19_1"></a><a id="Tc_7L-6lbUFekSyyt3GjMgDIQ_21_0"></a><a id="Tc_vQMqnvECV0a8jfNb8r4zIA_21_1"></a><a id="Tc_DmGWjQNVxkmkMi38DUxI0g_21_2"></a><a id="Tc_ldeHJbpYl0-IGCOveFPuWw_21_5"></a><a id="_54655c47_78e4_4c22_87e4_e9adf1f988b6"></a><a id="Tc_TdkIzZWZk0eYoePZLsYfqw_1_2"></a><a id="Tc_Z34cYO4DwUGGAjLj9TFzIw_1_5"></a><a id="Tc__OVYt8jIBEqyqFF6vEaUhQ_2_2"></a><a id="Tc_YFVoeK_Jbk2I7paB8iiAmQ_2_5"></a><a id="Tc_9FydmnZ-V0aWfXl-NtLbqA_3_0"></a><a id="Tc_Vnj5MMmRg02ya5oaOibGaA_4_0"></a><a id="Tc_wFZrafBHkEui46xe6H6BuA_4_2"></a><a id="Tc_VNXQqtwc1kGRnqw6TPLN-Q_4_3"></a><a id="Tc_tgOaVMoIDU6DhfxUZ9EPiw_4_5"></a><a id="Tc_B7Vn-9nJXkCGGAXHA2jyuw_5_0"></a><a id="Tc_fJPuS1PcDU2zBemjg6AFuA_5_6"></a><a id="Tc_pOHe4gSDx0K6DBkAjY_hhg_6_0"></a><a id="Tc_1yCKtP9-AkWT5r6HJ1PIlQ_6_6"></a><a id="Tc_vLG-PSgd-kqacwiFyRBJpA_7_0"></a><a id="Tc_eYdxbuJwTU-gObwVfDAN4g_7_2"></a><a id="Tc_AmTNhHlywUeOj1-e-6x1kg_7_5"></a><a id="Tc_eVv9WIA_XUGcegw0xtD-jw_9_0"></a><a id="Tc_d8e-ns3jX0mbDJTNtWhrWg_10_0"></a><a id="Tc_9ERAZOh1oUmqCMm9bT8NqQ_10_2"></a><a id="Tc_mkZvGNTHjEiZPEXB397sVg_10_3"></a><a id="Tc_xRx69e87oke_LmO7F4DCpQ_10_5"></a><a id="Tc_Uu4jNI23i0iwwGV_FGJjHA_11_0"></a><a id="Tc_WqjL3vCBv0i-fNqqAbghOA_11_3"></a><a id="Tc_q31VOhtTNE-zeWPNMmOvlg_12_0"></a><a id="Tc_ZBeLGcTNw0Cuw7_1D0IKgA_12_3"></a><a id="Tc_Js_xtFpExU2Y74cxuMP7Pw_13_0"></a><a id="Tc_WLCRgmJG7UW68_5V6xfL2g_13_2"></a><a id="Tc_hAL0fF5cY0OKHh0S1PMFRw_13_3"></a><a id="Tc_grmSjxUeQ0GHaIpOrxJnTg_13_5"></a><a id="Tc_VGMPpyvEu0SwlihZE7JQtQ_15_0"></a><a id="Tc__byw796rLEej5YEgxcI3IQ_16_0"></a><a id="Tc_qDrsWIATiEqGIJSXYlB77g_16_2"></a><a id="Tc_nt_KLyPmAUyB2hAaDTtxHQ_16_3"></a><a id="Tc_2JRE-feV50S0Xo0ADMB-ZA_16_5"></a><a id="Tc_041RwfIQR0GtMXLTNVfDXg_17_0"></a><a id="Tc_BBGQB-aMfk6z2DxXrqX0HA_18_0"></a><a id="Tc_PaKHZVteBE-AXXNjf7ozlQ_18_2"></a><a id="Tc_ETlDxkBPBEuJK9fgcB7aPQ_18_5"></a><a id="Tc_Y_3CFbOnZ0Cq_nzDbKy61Q_20_0"></a><a id="Tc_NkRowXjhbE2RS01JkB3B9g_21_0"></a><a id="Tc_o7gJfDPZLUi_TZr38oqMUg_21_2"></a><a id="Tc_gwVOQrWk10KdOPqBD1DsCA_21_3"></a><a id="Tc_FzZNkLhZs0u5xbq6QBy9tQ_21_5"></a><a id="Tc_4tHd4HCPCk2vkC-ZedEOWQ_22_0"></a><a id="Tc_2fcM7FGLy0uRgdc9BGAk0g_22_3"></a><a id="Tc_zBPioSeEP0Gzma0G3Gg0aA_23_0"></a><a id="Tc_4JBKHaA0vkyGqT9ACIllhw_23_2"></a><a id="Tc_8kRVh_PcQUGim2dYB-0WWA_23_3"></a><a id="Tc_Ncv9Kej0aECU78BCvkPLyg_23_5"></a><ix:continuation id="Tb_u5Ne9qXJzE-0ms7CQcSbKw_cont1" continuedAt="Tb_u5Ne9qXJzE-0ms7CQcSbKw_cont2"><ix:continuation id="Tb_gqgoYUn1JE6REFn2oZGm3Q_cont1" continuedAt="Tb_gqgoYUn1JE6REFn2oZGm3Q_cont2"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_fgVMPSNo2kmeAaHU_3V-Jg_3_3">391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_iGH4bVqTT0mUZ9dHsZ3CiA_3_6">499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_rO7SOyw_akqT6looj6V_Qw_4_3">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_PbmHhGQHCEaw8MChprl7sw_4_6">216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc_c-YSMKTz90GZBKkW0VrkDg_5_3">339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc_GV61WaJEGkimbSyfdIP6yQ_5_6">283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_3NfVQqZ9nUuh-ln6uZmM8A_7_3">6,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_L9-8B1vI3kaJHTnhNZpGGg_7_6">7,902</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_zL3i4gV7fk6XcySnYD6lOA_8_3">6,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_mzFk05HIi0286mhB-JAVLg_8_6">12,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed asset impairments</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:TangibleAssetImpairmentChargesDiscontinuedOperations" scale="3" id="Tc_upuKu-_5f0GoVT2YwHadkw_9_3">17,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:GainOnSaleOfFixedAssets" sign="-" scale="3" id="Tc_P3N7ADu0RUicgfyiAQmMBA_10_3">773</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory reserve</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" scale="3" id="Tc_PknFTwuPlEyTFpWT1UPDwA_11_3">4,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_1_D3pW9pbEyn8iq2OsJ-cQ_12_3">35,137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_hE03cln0F0yaTLrJ6yexFw_12_6">20,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc__zL1VVEZakWPhAbtmCKHaA_15_3">900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc_Jr6Pfj7pBEWOOSTjXhT80g_15_6">602</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupInterestExpenseRelatedParty" scale="3" id="Tc_esaJ7vRSQkKsqWzpAkXPOw_16_6">810</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupGainOnDebtForgiveness" scale="3" id="Tc_q7T1--4zEUSukRUAYCKRpA_17_6">607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" scale="3" id="Tc_sNvEtPtGGkCSAXe0r0ezVg_18_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" sign="-" scale="3" id="Tc_4LwEVXL6rkyWKQ1HyOyYVA_18_6">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_JKeLO7u9fE6B6n2QiTZqyw_19_3">901</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_1iHXK2o05U6_zRAdp5642g_19_6">799</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_9OtYCge7oEmiv7np529PyA_21_3">35,699</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_x9HQ9u3oy0uu-pPciyB3Yw_21_6">20,791</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2023 and 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="3" id="Tc_XZ_936ZEO0WQTwyTwhHnnQ_4_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupOperatingLeaseRightOfUseAssets" scale="3" id="Tc_S8IpdVH6AECegAgUGfrLgQ_5_3">1,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" scale="3" id="Tc_7LPc05h2y0qHbzHbDOxbNg_6_3">16,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_iLWMnRgAVUG3Wy0YL6GJyQ_7_3">18,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_jLoXDlJk5EiQHStdLz5AoQ_7_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="3" id="Tc_jE9gp4Q5yUq18N6n5DcAJg_10_6">35,289</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" scale="3" id="Tc_6yD9tUgGaUiQMnN5MP5kZQ_11_6">74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" scale="3" id="Tc_L3ZhiBcZj06Ell3PQSQ4bQ_12_6">1,951</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="Tc_rByvgkVPUUC5W4uHq_9rvg_13_6">37,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:middle;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" scale="3" id="Tc_4505sNR9RU2LNBT4rI1lpQ_16_6">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" scale="3" id="Tc_pAuucrshoECl_Dsw2Xh2bg_17_3">1,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" scale="3" id="Tc_bl-CRQHs30S2rKggvyeLQA_17_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_7pclosq9nk2fyyiTGXIIdg_18_3">1,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_1W9_LpCYN0Wwgwv-sKd_8g_18_6">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" scale="3" id="Tc_eidSyLWW5UulyriYAPoA-w_21_6">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupNoncurrentOperatingLeaseObligations" scale="3" id="Tc_tvpIxt2HtEuixEK10fEMHA_22_6">1,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="Tc_L9r5bBsszEKbIJNsAZp6jQ_23_6">1,971</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cdac17ea_bb15_4c2b_97b2_a5ad6eaabed8"></a><a id="Tc_DORbaQWCEUSZe30na_dtbQ_1_2"></a><a id="Tc_-zAN93xx9USQvw880Po_OA_2_2"></a><a id="Tc_h2E7EHFtUUqb6xHnqprMXA_2_5"></a><a id="Tc_qUuyLE0j2Ua2NvPQ_0666w_3_0"></a><a id="Tc_DYMKlRVou0iG5joevf9nog_3_1"></a><a id="Tc_tgWY-UxSSUC_mVj9hyfCVw_3_2"></a><a id="Tc_9po5qRvNyUiuuJYmrBKMnQ_3_5"></a><a id="Tc_JzvnKKBXP0yKpNcMhba7Og_4_0"></a><a id="Tc_om-9RK9qdUSRRhA8co_FXw_5_0"></a><a id="Tc_hB8Ls3016kO-RqWYY8pPaQ_6_0"></a><a id="Tc_u8QkraEJ9USCiBLX0hWnkQ_6_6"></a><a id="Tc_YaiBG22so06qRkQPtKVJVA_7_0"></a><a id="Tc_qqL2nEDxXk-zko8U1u-zRA_7_6"></a><a id="Tc_rDScmsP3CE20MnA8DhQgKQ_8_0"></a><a id="Tc_NZ8OQxtQ-UmPYxHHl-ICAw_8_6"></a><a id="Tc_wDTeCdNYeEe867Uil5slPA_9_0"></a><a id="Tc_FYuftiZcpEWJ5vHTUDCkvg_10_0"></a><a id="Tc_psDivkGcVE-GRxGeZZte3g_10_3"></a><a id="Tc_mGTaDRvV-ESSJU8zSP1tCA_11_0"></a><a id="Tc_dkXHlk5_GEqVJzOoeghWTA_12_0"></a><a id="Tc_X5sAurqNn0yVcsPW1BHXQw_12_3"></a><a id="Tc_n1t5PDxBFEykms9JzwrwVg_13_0"></a><a id="Tc_BgtiSw3Zik62GsEcIrUaBA_13_3"></a><a id="Tc_4dxPZ0YcnkSc7wfsWhPR6A_14_0"></a><a id="Tc_0iCPyatbyEelyPDmvTzbeg_14_3"></a><a id="Tc_CgqMtOxl_ESGAtI4WrMPrA_15_0"></a><a id="Tc_H9mbt2XjQkS78AYcJsJANw_15_3"></a><a id="Tc_Ut_GZxICqU-MPlab8_ezdQ_17_0"></a><a id="Tc_3yvv8UzJc0GyyJotGQGCYg_18_0"></a><ix:continuation id="Tb_u5Ne9qXJzE-0ms7CQcSbKw_cont2"><ix:continuation id="Tb_gqgoYUn1JE6REFn2oZGm3Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:67.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="Tc_upyMqjmFB0e_JLQLaaGFRw_3_3">273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="Tc_tYiWAeQRiki-zw3ii2vUjA_3_6">2,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" scale="3" id="Tc_PY-v-CC630St8YNXHsonBw_4_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" scale="3" id="Tc_YL2atnczcUiaXkrx-_S4wA_4_6">599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" id="Tc_W8SbKHhyVkC4F5IVMxIBWg_5_3">1,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" id="Tc_BBm8Q4krHkW0SiSpo6meOg_5_6">5,809</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed asset impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:TangibleAssetImpairmentChargesDiscontinuedOperations" scale="3" id="Tc_P9gp0Zj6YEyLVZSiTyphAg_6_3">17,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" scale="3" id="Tc_1ubaak21RkSvpKtNnu7-KA_7_3">4,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales proceeds of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_3g9Ak0ePk0GF1xndXxwXXg_8_3">2,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Increase in ROU operating assets and liabilities for new leases</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases" scale="3" id="Tc_3MBOwsbW90K48loF_Ekreg_10_6">1,952</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" scale="3" id="Tc_qPgNasYcEUKYjpW4OB5Jlg_11_3">1,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" scale="3" id="Tc_tZh6t2hJBUSGwjh6gfK79w_11_6">791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations" scale="3" id="Tc_-k68dCveTkyJ_BBuushkKg_12_6">1,542</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Termination of finance ROU assets including issuance of warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant" scale="3" id="Tc_MhQKN6ZUEE6g9DJKiu_4iA_13_6">25,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Note payable to acquire Facility</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromNotesPayableFromDiscontinuedOperations" scale="3" id="Tc_Ncg278cyvk-5fN-yRjoyoQ_14_6">22,375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Issuance of warrant for final lease obligation payment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:IssuanceOfWarrantForFinalLeaseObligationPayment" scale="3" id="Tc_jA7zC-9mx02L-otDdRUskQ_15_6">217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Cash paid during the period for interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidDiscontinuedOperations" scale="3" id="Tc_skZcFPTX0k-iO3e1on8qAw_18_3">603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidDiscontinuedOperations" scale="3" id="Tc_vbzKL3iLqkaJOTOivvTjIg_18_6">1,045</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_mpbawGQr1kygKPtrA2ChMQ" continuedAt="Tb_mpbawGQr1kygKPtrA2ChMQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:UseOfEstimates" id="Tb_nZSLxaXYVESwEPCdGIiNJg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_IKiElWNzdkG6HdjqHVoOdw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At June&#160;30, 2023 and 2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_zj03u6DALEiSEuaQJuW8Qg" continuedAt="Tb_zj03u6DALEiSEuaQJuW8Qg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification (&#8220;ASC&#8221;) 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mpbawGQr1kygKPtrA2ChMQ_cont1" continuedAt="Tb_mpbawGQr1kygKPtrA2ChMQ_cont2"><ix:continuation id="Tb_zj03u6DALEiSEuaQJuW8Qg_cont1" continuedAt="Tb_zj03u6DALEiSEuaQJuW8Qg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and / or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June&#160;30, 2023 and 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" id="Narr_Y55_crN1lUC6DMAX-LJG4g"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" id="Narr_tzn0y4a5e0qwrb4bQmKi-A">no</ix:nonFraction></ix:nonFraction> contract loss provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time and is summarized below (in thousands). &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="Narr_UyhxKLDMMEKTIC3PkloDIA">No</ix:nonFraction> revenue was recognized in the year ended June 30, 2023. &#160;Revenue was recognized from a license agreement and the settlement of a revenue contract in the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mpbawGQr1kygKPtrA2ChMQ_cont2" continuedAt="Tb_mpbawGQr1kygKPtrA2ChMQ_cont3"><ix:continuation id="Tb_zj03u6DALEiSEuaQJuW8Qg_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:ContractAssetsPolicyTextBlock" id="Tb_dSyzlYHkh06dXgqqHsXLFA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contract Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A contract asset is an entity&#39;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2023 and 2022, contract assets were $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr__E5uIz0JjUW1uy9D-2d6SQ"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_eDsvStIgdEyLYcR9WH-3Wg">0</ix:nonFraction></ix:nonFraction>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:ContractLiabilitiesPolicyTextBlock" id="Tb_ViD-DTlorEiCRT-dvqmDhQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2023 and 2022, contract liabilities were $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr__r9gdijMn0uJ7d2Y4waumA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr_0JHUTBihnkGmpqzLlivJjg">100,000</ix:nonFraction>, respectively. The Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_XC8CgiJii0O20dEqWufP8g">100</ix:nonFraction> in 2023 that was included in the contract liabilities balance as of June 30, 2022 and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_ZwboMjes40Syv6vxZY0yWA">178,000</ix:nonFraction> in 2022 that was included in the contract liabilities balance as of June 30, 2021 and was reported in discontinued operations. &#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_bYOK-W7bRkCfhdjB_kT_pA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company accounts for leases under the guidance of ASC 842, </span>Leases<span style="font-style:normal;">. The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. &#160;The determination of the Company&#8217;s incremental borrowing rate requires judgement. &#160;The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_QHz6bc_OfEmdBBiHVdGbGQ" continuedAt="Tb_QHz6bc_OfEmdBBiHVdGbGQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2023 and 2022 consisted of money market accounts. Restricted cash consists </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8aad1b31_3d83_45e2_a92e_09eee794e858"></a><a id="Tc_1oU26G92h0SaPqrctvbqKQ_1_2"></a><a id="Tc_V4cFLpnb30WCsN3CkGOX-w_1_5"></a><a id="Tc_tFRwYTqOnUC7tatuL-osZQ_2_2"></a><a id="Tc_S1RDD8yjYkWo7QsF9HWoyQ_2_5"></a><a id="Tc_nevGS6BKzUu6XoP6-cYjWw_3_0"></a><a id="Tc_GDim-CZA3kuzvVQ1xZV0yQ_3_1"></a><a id="Tc_lpL0LpzjaEuAhGVAFNU0qw_3_2"></a><a id="Tc_SzpJKU1vcEaJ3legs5WXsQ_3_5"></a><a id="Tc_iFjSt7pwKEe2qHq6cGZZcw_4_0"></a><a id="Tc_21A0Z1MvCEecj3S9dyjveg_5_0"></a><a id="Tc_B3xESZnDbEm5Hb2ip4nn1A_6_0"></a><a id="Tc_91l9ZoE25UuUuqgy3xroFw_6_1"></a><a id="Tc_XWxH6hLLVUKcrUGzy6r1dg_7_0"></a><a id="Tc_RuSb_gSr7Um5dYbmq2s7vw_7_1"></a><a id="Tc_pkb5U8gRq0uC8tHq0o7Ftw_7_2"></a><a id="Tc_pwEE_8Fznku7mJNXia_vYA_7_5"></a><a id="_0f5a0ff0_e32b_4679_b456_56274ef3a823"></a><a id="Tc_7s0_aZ1BsUeWVO3UycQhbQ_1_2"></a><a id="Tc_k_ynlmn3W0K_anpzuGl5ag_1_5"></a><a id="Tc_RGk8aeKcMkmAik0bJWxs0w_2_2"></a><a id="Tc_X5EFpNfQc0WYdIs1zCK-SQ_2_5"></a><a id="Tc_KXM1YLHWCUCgV6uvez2_BA_3_0"></a><a id="Tc_83V8_ZdaCUi_1UAAIhe4Cg_3_1"></a><a id="Tc_LwRP5CSqT06m1g7sT-6EoA_3_2"></a><a id="Tc_E4xW2NX5CUeLxqqoYp3FJA_3_3"></a><a id="Tc_VraDgPe-tUSzcuyuDhYpoQ_3_5"></a><a id="Tc_pCESQ0oTe0yyio0jM9K2-A_4_0"></a><a id="Tc_PwJXKtFXLE-WsQikxvgBbw_4_3"></a><a id="Tc_9VktfE_v3kqEKOzDE4zrLw_5_1"></a><a id="Tc_JtyHT_RACEyS-4VdaDPhhg_5_2"></a><a id="Tc_vEjUssiPREObvUzWFPwXHA_5_3"></a><a id="Tc_WOY3PY2Hrk6ibfGNKAwkLA_5_5"></a><ix:continuation id="Tb_mpbawGQr1kygKPtrA2ChMQ_cont3" continuedAt="Tb_mpbawGQr1kygKPtrA2ChMQ_cont4"><ix:continuation id="Tb_QHz6bc_OfEmdBBiHVdGbGQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_lYOxtlA7SECAFRsqcF-SfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="Narr_Hj0ATEir00iBAcci-xxikw">3.0</ix:nonFraction> million held within a Company account at Woodforest Bank for the Term Note payable (see Note 6 &#8211; Significant Transactions and Note 14 &#8211; Debt) collateral, a letter of credit obtained related to the San Diego operating lease (see Note 16 &#8211; Operating Lease Obligations) and a Company purchasing card. The Company&#8217;s bank requires an additional <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="ibio:PercentageOfCollateralRequired" scale="-2" id="Narr_58KcmmaqYk60KAEWm3a43Q">5</ix:nonFraction>% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. &#160;Restricted cash was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_BQtVvm4jGEWOxKIzdm0SCg">3,278,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_ao9JhOHCKE20zTHrwyVnng">5,996,000</ix:nonFraction> June 30, 2023 and 2022, respectively. </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_vX_Ner53X06KWC4x065TUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ZhW3xWpfd0a3q7uQ9Iw-yw_3_3">4,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_UEqL3_mj30icu2sNnXrN_A_3_6">22,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_lYOxtlA7SECAFRsqcF-SfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gsMQGR66OkeoFqyIJyoqeA_4_3">3,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_F9D1CtdJIUGZ_NarVuJabA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gA7wnm6jHE2K5Zbj3xpqtQ_4_6">5,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_pojHavUPcEas5qPQYCAHRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_XfThqERSLUqbRJL9aCF0zg_5_3">198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_9NVLwycAS06AXqdN0JVz6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_HQYeWl-4vUaVUQq9tRT0jw_5_6">198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_TZN5AIYJp0-6KjjZaFqg6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_DwV9J5K8CkWeMhQxxya3Sw_6_3">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_w4qDIzxgXUiJo3l8Fvo9Bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_CEBrvlpZSUKMIOIOAXuWdA_6_6">55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_nQ3dVtUMsUmmhsmQzIpZow_7_3">7,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_beOH5YTti06lCDwctq455w_7_6">28,672</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" id="Tb_waY9oBs4IEqQrWwHZIXf-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investments in Debt Securities</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 6 - Significant Transactions. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:InventoryWorkInProcessPolicy" id="Tb_JRsK7Vq8bkexOk60_0Putg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. Inventory held is related to the CDMO business ad has been classified as held for sale. &#160;See Note 3 &#8211; Discontinued Operations for more information on the inventory reserved reflected in the year ended June 30, 2023. &#160;The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. Inventory consists of the following (table in thousands): </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_3qR8Wh40OkWFF-NmPzUijQ" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" id="Tc_zF07IRwL_kmpgkygBZGnuA_3_6">3,896</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_fxMC8jZHTUu7znh5moFsqw_4_6">4</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_M-t6m1lOEESJyuqinOuWqw_5_6">3,900</ix:nonFraction> </p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_bJHjSL7HrkmO0XjzKnBcuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, &#8220;<i style="font-style:italic;">Research and Development</i>&#8221; (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the years ended June 30, 2023 and 2022, research and development expense was reported in both continuing and discontinuing operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:RightOfUseAssetsPolicyPolicyTextBlock" id="Tb_xsWq1VW610O44bGtds0gjw" continuedAt="Tb_xsWq1VW610O44bGtds0gjw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mpbawGQr1kygKPtrA2ChMQ_cont4" continuedAt="Tb_mpbawGQr1kygKPtrA2ChMQ_cont5"><ix:continuation id="Tb_xsWq1VW610O44bGtds0gjw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_jWsJfxfMq0qsfkNWOQIppg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from </span><span style="-sec-ix-hidden:Hidden_uabS_NI-Z06ict9nQUkf0w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-style:normal;"> to </span><span style="-sec-ix-hidden:Hidden_9YJQTd2bdk-gA4FmiAYIkg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine</span></span><span style="font-style:normal;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="Tb_N8Ln422Ec0C1v_ac32i6EA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over <ix:nonNumeric contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_vWjaGf1rRUSldHjzTxec7g">20 years</ix:nonNumeric>. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_VHzpBtLNF0eYuov7NOqoeA" continuedAt="Tb_VHzpBtLNF0eYuov7NOqoeA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mpbawGQr1kygKPtrA2ChMQ_cont5" continuedAt="Tb_mpbawGQr1kygKPtrA2ChMQ_cont6"><ix:continuation id="Tb_VHzpBtLNF0eYuov7NOqoeA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility is based on historical volatility of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_rjCoRLyVzE6lxmAAheDfIg">zero</ix:nonFraction>. In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 &#8211; Share-Based Compensation for additional information.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_uohe0puGPk2BKUcpHV-OgA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_KFovHO6hK0eVBoLEviTR4A"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_z_n6ihN25EGHcHqY9zYn2A">no</ix:nonFraction></ix:nonFraction> liability for uncertain tax positions as of June&#160;30, 2023 and 2022. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2023 and 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_v0OZVArE8E-wRXZ5Py6izg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June&#160;30, 2023 and 2022, amounts in excess of insured limits were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_Zin4pF5AgE2PpH8IDAVsGw">6,900,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_41REYp_9MEO3RM-ZOZd2ZQ">18,200,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the Fiscal year ended June 30, 2023, the Company reported <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="Narr_g-g_KjrMIU-QYoZls9rg8Q">no</ix:nonFraction> revenue from continuing operations and generated $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_ibio_FourCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y8MwivQ9ekC2NZNY1aglKQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="Narr_438hlKMVmEKeT_SelP7Rmw">391,000</ix:nonFraction> of its revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_bk92zj7mYE-AcFFVra0SUg" contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_ibio_FourCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y8MwivQ9ekC2NZNY1aglKQ" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_4uHJ4f5IAECB3fvSWWANUw">four</ix:nonFraction> customers. During the Fiscal year ended June 30, 2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract and generated $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_ibio_EightCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_6zllRl-74kWHjjUok5X3fA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="Narr_qad4THEPHk22Ug79Bn7QbQ">499,000</ix:nonFraction> of revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_bk92zj7mYE-AcFFVra0SUg" contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_ibio_EightCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_6zllRl-74kWHjjUok5X3fA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_66i37j98IEaSITlXtpw-LQ">eight</ix:nonFraction> customers.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_tvS7NL2YXEKjCO5C5kHzYQ" continuedAt="Tb_tvS7NL2YXEKjCO5C5kHzYQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</i>, <i style="font-style:italic;">Derivatives and Hedging (Topic 815)</i>, and <i style="font-style:italic;">Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mpbawGQr1kygKPtrA2ChMQ_cont6"><ix:continuation id="Tb_tvS7NL2YXEKjCO5C5kHzYQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk83294729"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_H_WwJv8g0ESfKHVbJdiTAg" continuedAt="Tb_H_WwJv8g0ESfKHVbJdiTAg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">5. &#160; Financial Instruments and Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Company&#8217;s consolidated balance sheets approximated their fair values as of June 30, 2023 and 2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, term note payable and finance lease obligations approximated fair value as of June 30, 2023 and 2022 as the interest rates related to the financial instruments approximated market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of plan investments that fall under each category, and the valuation methodologies used to measure these investments at fair value:<span style="display:inline-block;width:12.24pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>Level 1 &#8211; Inputs are based upon unadjusted quoted prices for identical instruments in active markets.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Level 2 &#8211; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Level 3 &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company initially marketed the CDMO business and during the second quarter of Fiscal year 2023, changed its strategy to selling the stand-alone CDMO assets. These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. As a result, the carrying value of the Facility and equipment was reduced to their estimated fair values of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_7qBiEha-vECXgWze-i-g6Q" decimals="0" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="0" id="Narr_l5NroDVMOkmGzEKewBdCNg">16,350,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_nbd9NMQisEiyfXHpBgaVUQ" decimals="0" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="0" id="Narr_87b6OfIQGU2s-B0Izpl8aw">2,100,000</ix:nonFraction>, respectively. In the second quarter of Fiscal year 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember__ZIfD-ddyUWPf60tnoVcmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="Narr_JJHbRiSHeku62M5_-O51tw">6,300,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_SFHPA8kiYE6ZzTtqaqm52A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="Narr_pRIyoudrikCSoeSfOmAHhA">11,300,000</ix:nonFraction> for the Facility and equipment, respectively. In the first quarter of Fiscal 2024, the Company entered into an agreement for the building for $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5qaPdrZ830G5d8zR_8zrkQ" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfBuildings" scale="6" id="Narr_bXPdOE8GA06il0NGg1-l6g">17.25</ix:nonFraction> million, and an additional impairment of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OBOy6kxRiU-oe0ymEhUYpw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="Narr_mlQhZF95Q0eQCmwifosEmw">0.3</ix:nonFraction> million was recorded in the fourth quarter of Fiscal 2023 to reflect the agreed upon sales price less estimated costs to sell. &#160;The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_dZg1WhqNY0uE1A0c9lHl3A" decimals="-5" format="ixt:numdotdecimal" name="ibio:FixedAssetsHeldForSale" scale="6" id="Narr_4JVmexfTMU6Nj5zgGShs4Q">16.1</ix:nonFraction> million. The machinery and equipment were sold during the third quarter of Fiscal year 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table shows the fair value of the Company&#39;s fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of June 30, 2023 (amounts in thousands):</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc__l8Ny1C6S0-rLO7c3wOS1A_1_3"></a><a id="Tc_FhZAFDQJt0-VZoUyVeGSqg_2_3"></a><a id="Tc_3UD_Aq2SLkKfD7m9-wctXw_4_3"></a><a id="Tc_h_u9SlJ-f0C0bn87wDygPg_4_6"></a><a id="Tc_RCEQcJrBJ0WRQcQbdN3TVQ_4_9"></a><a id="Tc_EbvmhF_Ckk2PShAiWXeokg_4_12"></a><a id="Tc_1EdqbW4-nUqX3nAnZ5vS-g_4_15"></a><a id="Tc_Xt7K6dcIPkuGj32kTS5x2w_5_0"></a><a id="Tc_HYHLCX61JEq5Ufy8XIeI4A_5_2"></a><a id="Tc_olBeHsMwakKVXDojwFmsXw_5_3"></a><a id="Tc_QZcJV-nB1Ua5-wRrBwgq_A_5_5"></a><a id="Tc_FLh8TVaRWUqq8J-1HDNgzg_5_6"></a><a id="Tc_ABjuS3vk30qgIw2jpx6twg_5_8"></a><a id="Tc_k5p_jY8fIEqsLrD8-Cfwxg_5_11"></a><a id="Tc_M_LNPQWSekSREbhVqyrMtA_5_14"></a><ix:continuation id="Tb_H_WwJv8g0ESfKHVbJdiTAg_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_J1zRVgOww02pfH0ycNgVeA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Hierarchy</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_LDEVyL3h-0GVW39rjQJBaQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="3" id="Tc_GjgWCUX5C02cF-qp21Hj1w_5_9">16,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_dZg1WhqNY0uE1A0c9lHl3A" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="3" id="Tc_Toxpqdoe2kuOLzXE-ftiGw_5_12">16,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_gsFictXunUazEpdpJkg4ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Tc_CnrncWy4ckSTkZReMkYl2Q_5_15">6,600</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the second quarter of Fiscal year 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). See Note 12 &#8211; Intangible Assets for additional information.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:SignificantTransactionsTextBlock" id="Tb_sfg-VZzMHkyHusuJb1lrRg" continuedAt="Tb_sfg-VZzMHkyHusuJb1lrRg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Significant Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Affiliates of Eastern Capital Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#8220;Sublease&#8221;) until the purchase of the Facility described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Purchase and Sale Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On November 1, 2021, the Purchaser entered into a purchase and sale agreement (the &#8220;PSA&#8221;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#8220;Ground Lease Agreement&#8221;) that it entered into with Texas A&amp;M (the &#8220;Landlord&#8217;&#8217;) related to the land at which the Facility is located together with all improvements pertaining thereto (the &#8220;Ground Lease Property&#8221;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Ground Lease Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" scale="0" id="Narr_IS7OCGGwUkqKvL5QYJsEhg">28,750,000</ix:nonFraction>, which was paid $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" scale="0" id="Narr_4AZ8O6k0RkS8-p6cc1bBVw">28,000,000</ix:nonFraction> in cash and by the issuance to Seller of warrants (the &#8220;Warrant&#8221;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w" decimals="0" format="ixt:numdotdecimal" name="ibio:FairMarketValueOfProperty" scale="0" id="Narr_w6viHrULIkGaGXY--ge1og">151,450</ix:nonFraction> for the prior year, is <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w" decimals="3" format="ixt:numdotdecimal" name="ibio:BaseRentPercentageOfFairMarketValueOfProperty" scale="-2" id="Narr_lF2-Y0WtB0qKEqbLzPWjeQ">6.5</ix:nonFraction>% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sfg-VZzMHkyHusuJb1lrRg_cont1" continuedAt="Tb_sfg-VZzMHkyHusuJb1lrRg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the June 30, 2023 and 2022 consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Equity Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#8220;Equity Purchase Agreement&#8221;) pursuant to which the Company acquired for $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w" decimals="0" format="ixt:numdotdecimal" name="ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired" scale="0" id="Narr_JGzZDJKwb021Oue7DLziZA">50,000</ix:nonFraction> cash, plus the Warrant, the <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_yQtckMjz-Eqm8XRVYD1YnA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:EquityAgreementWarrantsIssuedOrIssuable" scale="0" id="Narr_QRpIU2jeGEmTb-M8moy1ug">one</ix:nonFraction> (1) share of iBio CMO Preferred Tracking Stock and the <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_yQtckMjz-Eqm8XRVYD1YnA" decimals="4" format="ixt:numdotdecimal" name="ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" scale="-2" id="Narr_kaSgYTAvPE6YBt_whDpxPA">0.01</ix:nonFraction>% interest in iBio CDMO owned by Bryan Capital. iBio CDMO is now a wholly owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Wllg_X7FK0iPGlaGUB08bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_BlMaIIBPB0mHch2erRiuYg">22,375,000</ix:nonFraction> secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See Note 14 &#8211; Debt for further information of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_8uleh9q5Pk6eSedTZ8VzHw">51,583</ix:nonFraction> shares of the Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_74kfOX1Lo0-vPyn9E43e9g">33.25</ix:nonFraction> per share. The Warrant expires on October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the total shares that can be exercised under the Warrant, <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w" decimals="INF" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent" scale="0" id="Narr_Y7ZjQqa_fUuhSSTyZmksng">11,583</ix:nonFraction> of such shares were valued at $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w" decimals="0" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue" scale="0" id="Narr_xLNaFo0GN0StU17ZTQ5BVQ">217,255</ix:nonFraction> to reflect the final payment of rent due under the Sublease. &#160;The Warrant, as shown on the consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Ground Lease Property acquired. &#160;See Note 17 &#8211; Stockholders&#8217; Equity for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;) described in more detail below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The Company entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields<span style="color:#0000ff;">.&#160;</span>RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="color:#0000ff;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_gEwHZzbqxEeEtYmR5kIkBg_1_0"></a><a id="Tc_TWi5EAkCWk-7Ojez-GnjAA_1_1"></a><a id="Tc__bCrxulvukyotxZqLyf9pQ_1_2"></a><a id="Tc_f-W1GOxm10W_pVDoNnmC6w_2_0"></a><a id="Tc_o6u8XDyu30K0fQv3KyUF-g_3_0"></a><a id="Tc_LJ2HrjF52kCr6qphxAalgA_3_1"></a><a id="Tc_X6arJF6NZUOp9Y0rwZ8gVw_4_1"></a><a id="Tc_GFmlMqjzT0SQOeYnJkFfzw_4_2"></a><ix:continuation id="Tb_sfg-VZzMHkyHusuJb1lrRg_cont2" continuedAt="Tb_sfg-VZzMHkyHusuJb1lrRg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into an agreement with RubrYc (the &#8220;Collaboration, Option and License Agreement&#8221;) to collaborate for up to <ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_YH7c7zxS4Um37Nlh67R2QQ" format="ixt-sec:durwordsen" name="ibio:CollaborationAndLicenseAgreementAgreementTerm" id="Narr_7oDM2TpeMk6u3eA7705YgA">five years</ix:nonNumeric> to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) <span style="-sec-ix-hidden:Hidden_1lNt1UglOEOd6nh1BKY2Rg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby the Company purchased a total of <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_0ZWSZA9Kr0KCCrEbl4ckpA" decimals="INF" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementNumberOfSharesPurchased" scale="0" id="Narr_2IQivKgWykuzEXjfHKHq8Q">2,864,345</ix:nonFraction> shares of RubrYc&#8217;s Series A-2 preferred stock (&#8220;Series A-2 Preferred&#8221;) for $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_0ZWSZA9Kr0KCCrEbl4ckpA" decimals="INF" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementValueOfSharesPurchased" scale="0" id="Narr_-Ruj5Rs2QECQ9fky3CXpJA">7,500,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_23_2021_To_8_23_2021_s69drdBtfkiXxiX5xIaWhw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_jR5cV4OjWk-O7BEnb3Iorg">7,500,000</ix:nonFraction> as follows:<span style="font-size:12pt;"> </span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_p3xe_xFZZkWNjC4NdaEdxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_qGJJOjg520eitr0OnzDv_A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_Wzuas3FKU0KDQ_R6lMTxVA_1_3">1,760,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_aQUPv9G7qESYPE20QdAeDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_PZI00TXdWUa4u7QCM5e-BA_2_3">4,300,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_03q0Za05A0K0e2L2ZORfzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_Y6wvZ1C7CUixnx8jN8EZrg_3_3">1,440,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_23_2021_To_8_23_2021_s69drdBtfkiXxiX5xIaWhw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_pDspN8KyKEGvDWBbwyKCKg_4_3">7,500,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations and completed bankruptcy proceedings in June 2023. &#160;The Company recorded an impairment of the investment in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_qGJJOjg520eitr0OnzDv_A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_0gU71PNErEqiLnM_HwC-JA">1,760,000</ix:nonFraction> during the year ended June 30, 2022 which was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Lh5bPHn7wEyfg1z7EBU_sw" decimals="0" format="ixt:numdotdecimal" name="ibio:ImpairmentOfPrepaidExpensesCurrent" scale="0" id="Narr_4VQioUMhqkSMe4EcinhqKw">288,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Lh5bPHn7wEyfg1z7EBU_sw" decimals="0" format="ixt:numdotdecimal" name="ibio:ImpairmentOfPrepaidExpensesNonCurrent" scale="0" id="Narr_aYjtXWHoVk-EWtVJ5GV62A">864,000</ix:nonFraction>, respectively, during the year ended June 30, 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. The Company issued <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_dj-dsQcEtkq53NmB8lZZ7A" decimals="0" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementNumberOfSharesPurchased" scale="0" id="Narr_2iOp7EhI-0ioNQx3qN6G2g">102,354</ix:nonFraction> shares of the Common Stock to RubrYc with an approximate market value of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" scale="0" id="Narr_kLF31ToHF06cplPmmrxvsA">1,000,000</ix:nonFraction> (the &#8220;Closing Shares&#8221;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA" decimals="0" format="ixt:numdotdecimal" name="ibio:FairMarketValueOfProperty" scale="0" id="Narr_b_O7zikNJkiWxBkjY8iaCA">650,000</ix:nonFraction>. The Company also agreed to make potential additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="0" id="Narr_uwZKGKF840mz113-U2PktA">5,000,000</ix:nonFraction> upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#8217;s option. In addition, the Company had advanced RubrYc $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_dj-dsQcEtkq53NmB8lZZ7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForAdvanceToAffiliate" scale="0" id="Narr_F-_mcsViBUSMkZcKKjptqg">484,000</ix:nonFraction> to support their operation costs during the negotiation period and incurred transaction costs totaling $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_dj-dsQcEtkq53NmB8lZZ7A" decimals="0" format="ixt:numdotdecimal" name="ibio:AssetAcquisitionTransactionCosts" scale="0" id="Narr_KLJfnkn2qEORJkbqRANyAQ">208,000</ix:nonFraction>, which were also capitalized as part of the assets acquired. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_hPDjWIGprUqB64-EfpB-HA_1_0"></a><a id="Tc_E222p3oZdkePeVdh1j9sJg_1_1"></a><a id="Tc_LgiTNMUznkKzYTDs1YaY-g_1_2"></a><a id="Tc_tXSr4DVQCkeqxV72BKz9cQ_2_0"></a><a id="Tc_qx3jYXC8u0-60uebJsHR9g_2_1"></a><a id="Tc_Kf9WzzUcgkaqDo2NTvYfew_3_1"></a><a id="Tc_J2fi2NcIxEaQODYpC799CQ_3_2"></a><ix:continuation id="Tb_sfg-VZzMHkyHusuJb1lrRg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_bemSi36ZV0q8YMFpN_6fHw">1,342,000</ix:nonFraction> as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_ibio_RubrycTheraputicsInc.Member_a0DlE4N_I0GxjgfDV7eBFg" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_GLRHE-rEtEu_8L6IWXhbAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_UDQEaykRk0-p2VWL-WDKDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_WYIjBb_bFkKCcVGqmOpyCQ_1_3">1,228,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_JyKBqBRPyU6zhBnwdkIH9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_4qNarJVnWkmnSs0yOgQ5dw_2_3">114,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_AU4wRtUy4UqbqKuPdJT0MA_3_3">1,342,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, the Company assumed <ix:nonFraction unitRef="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_hTvAgRyir0mqjNy-vlCRyA">three</ix:nonFraction> equipment leases that were accounted for as finance leases totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="0" id="Narr_ZmcurC6AHkG_naamvqRzKg">814,000</ix:nonFraction>. See Note 9 &#8211; Finance Lease ROU Assets and Note 15 &#8211; Finance Lease Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Former CEO Departure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#8220;CEO) and former Chairman of the Board of Directors (the &#8220;Board&#8221;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and General Release</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with Mr. Isett&#8217;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#8220;Agreement&#8221;). Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. Following Mr. Isett&#8217;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for <span style="-sec-ix-hidden:Hidden_YMSx4gGHzEiJmUbTbVGKZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the <span style="-sec-ix-hidden:Hidden_SYAPHltUpUekE3X9uPDPUg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;), the Company will pay the full cost of this benefit for up to <span style="-sec-ix-hidden:Hidden_CQT6G5UgS0uV_qC3r8ildA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the <span style="-sec-ix-hidden:Hidden_0Ap6AYAnBkSKK9C3lFNv3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to <ix:nonFraction unitRef="Unit_Standard_item_hCBMRpViQ0aEEJdOwEy49g" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" scale="0" id="Narr_1NQ3J9pLC0CqwsPRfrXlEg">six</ix:nonFraction> (6) times the monthly amount paid by the Company for the COBRA subsidy. The Agreement includes a general release of claims by Mr. Isett. The Company accrued approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_YzbY9GLiGE2-ktZqZfwryg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="Narr_A6W0FHv5fEWoIL5c6P6aVA">2.13</ix:nonFraction> million to general and administrative expenses in the second quarter of Fiscal 2023. As of June 30, 2023, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" scale="6" id="Narr_Z_c53oFASUKh48qVJYg07g">1.1</ix:nonFraction> million is recorded in accrued expenses and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_UWTbx3EXRkCgwv1m35o82A" decimals="0" format="ixt:numdotdecimal" name="ibio:AccruedLiabilitiesNoncurrent" scale="0" id="Narr_U7AzavVZzUaVbkM6JA-HLg">527,000</ix:nonFraction> in accrued expenses &#8211; noncurrent.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_Hlk83294681"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_Bgs2Oc5i6UCZxWJxUVyttA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Promissory Note Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On June 19, 2023, the Company issued a promissory note (the &#8220;Note&#8221;) with Safi Biosolutions, Inc. (&#8220;Safi&#8221;) in the principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XheyQ-Fl9UOlWW6gNyl5VQ" decimals="0" format="ixt:numdotdecimal" name="ibio:LoansReceivableAmountInvested" scale="0" id="Narr_KgS8ssG-EEmssn-3szssjw">1,500,000</ix:nonFraction>, which was issued in exchange for the convertible promissory note (the &#8220;Convertible Note&#8221;) issued by the Company to Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableFixedRatesOfInterest" scale="-2" id="Narr_A8UUGnQMp02CdIH0kxRaIA">5</ix:nonFraction>% per annum and will increase to <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableRateOfInterestForFirstOneYearExtension" scale="-2" id="Narr_4hzY4vRXA0y9NXj5ZxKwCg">7</ix:nonFraction>% for the first one (1) year extension and <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableRateOfInterestForSecondOneYearExtension" scale="-2" id="Narr_TteSEThOBUCmBXe7BRcboQ">9</ix:nonFraction>% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableFixedRatesOfInterest" scale="-2" id="Narr_O_1fsg4PC0WlkBSRRMSYvw">5</ix:nonFraction>% per annum and had a maturity date of October 1, 2023, was voided. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the Fiscal years ended June 30, 2023 and 2022, interest income amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_OXGEMBaf90uzpnugexjTyQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Narr_mG3WN11nakqkch_9HWoFMw">75,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_1SxKBjeXXku5LCaQyLli3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Narr_8Ksve7nQT0mpBm5HmemMjA">75,000</ix:nonFraction>, respectively. As of June 30, 2023 and 2022, the Note balance and accrued interest, which have been classified as long term, totaled $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_0YcPqwpOjkuyZyE_8SFtfw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="0" id="Narr_eha2pniJgUSCJ29-YqLM4A">1,706,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_j1xUG58p10iMMcwJJ-ZzWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="0" id="Narr_Zccmmbmr8EudbWl2sfRC2w">1,631,000</ix:nonFraction>, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a3ad8a6b_ef32_4866_9cd7_9185b7f657e9"></a><a id="Tc_4YLbXXQFuku09b6WddrCmw_1_2"></a><a id="Tc_i9L8RUP6lU-q3LWGrR5G1A_1_5"></a><a id="Tc_Dkm2aKykbk-ac7XW_bOSsg_2_2"></a><a id="Tc_4FLC-SJg40u4ksPukx5zfQ_2_5"></a><a id="Tc_K2LiiIoSBECTuvt98qA3ow_3_0"></a><a id="Tc_9mFVQBajOk2guFQ9a4KAjg_3_1"></a><a id="Tc_ddVw84duMEuWzkRd8E1lDw_3_2"></a><a id="Tc_G8BPVyiD-0CbovqVSzvIKw_3_3"></a><a id="Tc_bz2aMaQVRUCo8EkExTMVdw_3_5"></a><a id="Tc_oFdfYw4iTk-Zh1Z7v_qy7Q_4_0"></a><a id="Tc_cEL2SKFDgkSdbTSPaRHxjw_4_1"></a><a id="Tc_CUpfv48Ye0O2mcA8nkI2pQ_4_3"></a><a id="Tc_pNDw1fIZUkWMxdCptME3kA_5_0"></a><a id="Tc_-WFm8tg1BEWwvJvdJwCqQg_5_1"></a><a id="Tc_q0tQ_Adhi0CJWZYl5_534g_5_2"></a><a id="Tc_Cm7v2qkASEWYc3aURKC6Pg_5_3"></a><a id="Tc_PpQyecVGSkOKt--IukamNg_5_5"></a><a id="_9113ecdb_df4f_4b82_ad53_e5e1edbc1e3a"></a><a id="Tc_xrQL3u5_wk28Wi8t1KwRww_1_2"></a><a id="Tc_BzJys7JwaUWrZO7YiUSEHw_1_5"></a><a id="Tc_K8jQChezbEuesqeR3zP_2A_2_0"></a><a id="Tc_qfkfhfKBe0WakvwBVyJMAw_2_1"></a><a id="Tc_pE9HKS2yaUCnTWprB6rl7g_2_2"></a><a id="Tc_AcrVSODyJE2iWci9y8NqBQ_2_5"></a><a id="Tc_4GQd2C5xBU-bMD9noDaa6A_3_0"></a><a id="Tc_q7pIymPRPkKOMtmPgVQAIw_3_1"></a><a id="Tc_MYaBa9yMdk-zfYtHCCgonA_3_2"></a><a id="Tc_-q2z66vwCUeF90KIin7wDg_3_3"></a><a id="Tc_82Bydf7oN0SCWowgIa3XRQ_3_5"></a><a id="Tc_b0VOp1F_qEi3dVRJA6k4iA_4_0"></a><a id="Tc_9KqfzrhM6k6otiwOznEtJA_4_3"></a><a id="Tc_YMqpwqNM2E-uwUABmDd2-w_5_1"></a><a id="Tc__wda9yVL5kuX9nQ68jFHIg_5_2"></a><a id="Tc_LLy2Sv2mXEWjXiV0HRx4fQ_5_3"></a><a id="Tc_atqFFBrau02oc1Fywx7UKw_5_5"></a><a id="_67f3d0e4_8046_4e65_a9d0_acc0a86b4f37"></a><a id="Tc_gp4NlhQiuUSl-lTVf4Mh8w_2_2"></a><a id="Tc_dFxPUyJPtE67W0EW8OOdaA_3_2"></a><a id="Tc_mToL8lH2sEGu2PBWXa5x3g_3_5"></a><a id="Tc_pZXbjdNPckKEjTje5DYaaw_4_0"></a><a id="Tc_6z-ohJi320is4p6lrY299g_4_2"></a><a id="Tc_DGihUvUp2Ea6_BEUktD7Zg_4_5"></a><a id="Tc_isvtCwnUZ0ix4MHrKzALTQ_4_6"></a><a id="Tc_yeVtjJqxykaZb4XVeWzAfQ_5_0"></a><a id="Tc_JqACxBEzykSCgxi-e3dRAA_5_6"></a><a id="Tc_kL_WFUCju06bu2-fHrjSMw_6_0"></a><a id="Tc_rtWN0ycwekCOGQ60gAx37A_6_2"></a><a id="Tc_uYiN7Sv1k0OboLtNsvzqyA_6_5"></a><a id="Tc_fdiFtA7pQkC4RNQtZFm7dg_6_6"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Tb_-Q3s_llX8kOOnsidhtESfg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Investments in Debt Securities</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_CpwuTpu6606fq--7yLgfQQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10.8pt -0.7pt 0pt 0pt;">The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_yUhusodndkGZ9Pg8BtBMJg_3_6">11,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_QNmha4DzSE-8JLmPyEo6YQ_4_6">184</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_z2uwi71Qi0OACeBW54szZQ_5_6">10,845</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.6pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="Tb_i_PUfljiB0-64M2_PwUnCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">The fair value of available-for-sale debt securities, by contractual maturity was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_dPhyG0Hc5ECzmxAsnYSZLg_3_6">8,054</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost" scale="3" id="Tc_EEJ2ymd1PEmW1edHwkxiQg_4_6">2,791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_oNeZBLcnvkWEcsFQ0bdDxg_5_6">10,845</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.6pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Amortization of premiums paid on the debt securities amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Narr_ujoqMV9AOkqyhFNm0nfVYg">67,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Narr_hsF2MGe2c0Ko8to7J-dONQ">312,000</ix:nonFraction> for the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" id="Tb_jO8E1GzVCEqp2DTts5NWqQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Realized losses on available-for-sale debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="Tc_Yh6IxtgaiE-Xnjx7lKtUGQ_4_3">6,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CostOfDebtSecurities" scale="3" id="Tc_m5rhVBYlAEmT6kXrDjxiZg_5_3">6,837</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" sign="-" scale="3" id="Tc_wuJmNn2aJUKUaHova2_AVw_6_3">98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk83294671"></a><a id="_15407510_d0aa_4613_a7dc_ccbe108b0180"></a><a id="Tc_UufLmkAYxkiPUp0eXbIQWQ_1_2"></a><a id="Tc_ZsWFGjMAk0KElYxKcn9TKQ_1_5"></a><a id="Tc_I64dij8uh0GgZWAnWNVx4A_2_2"></a><a id="Tc_qWifWW8VgEKTG9UkZCoi0g_2_5"></a><a id="Tc_5ow0g0EP0kyFNBl0yy4j0w_3_0"></a><a id="Tc_7HtZZzd9J0itoKSLBgnnaQ_3_2"></a><a id="Tc_cxuaWBJZ-ESG2HekL9nN4g_3_5"></a><a id="Tc_LDjmQNssakOJT3UFjD8Mkw_3_6"></a><a id="Tc_ipnqpN0Azk6vFiC6ZuBk5Q_4_0"></a><a id="Tc_rxGd_BYOZUCwThrjkH4WHw_4_6"></a><a id="Tc_f8JYOKMbhkaTOo3cPacfnA_5_0"></a><a id="Tc_o9plo5GkOUmP-n6Ksg3HIQ_5_2"></a><a id="Tc_vMJHU2jkKEKSzNKsDaapsg_5_5"></a><a id="Tc_mOdba4E7Tk6LvqXJslBLGA_5_6"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock" id="Tb_iYJnyZjGKUS_IyMpnc1beQ" continuedAt="Tb_iYJnyZjGKUS_IyMpnc1beQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;Finance Lease ROU Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. The lease for the mobile office trailer was terminated in December 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">See Note 15 &#8211; Finance Lease Obligations for more details of the terms of the leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" id="Tb_y69Vf-sPAUGM9DJewo2m-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cDhv992H80uLjlrOUmMXpA" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinanceLeaseRightOfUseAssetGross" scale="3" id="Tc_nhToeAi410iv955O7rIGdQ_3_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="Tc_s_ENqpaGjEyHFCE4A8KTtQ_4_3">204</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_7IXbArNb70222zuNEJvRdw_5_3">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Amortization expense of finance lease ROU assets was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="0" id="Narr_rsI2XGwBiEKwiCQmOaBjGA">204,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="0" id="Narr_wihzDv6RG0-cldw3C0aohA">0</ix:nonFraction> for the years ended June 30, 2023 and 2022, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_iYJnyZjGKUS_IyMpnc1beQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock" id="Tb_I-DqDDpSPEC6qjeRocTmvw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;&#160;Operating Lease ROU Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">San Diego, California</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2021, the Company entered into a lease for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw" contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_TGH9l60V1UCBOfLxXdr9QQ">11,383</ix:nonFraction> square feet of space in San Diego, California. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_wjdtfDalW0ygIE-XjcuXXw">3,603,000</ix:nonFraction>. The net carrying amount of this ROU operating lease asset was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_zGNI2BK3JEW4qvOK25bq4g">2,722,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_su_QVmWZ1064wm_NXC1gNw">3,068,000</ix:nonFraction> at June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bryan, Texas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_11_1_2021_9whzlfUgsUeBm5EBeEsgEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_-y9y6nYVTk2F6_ZB8PmltQ">1,967,000</ix:nonFraction>. The net amount of this ROU operating lease asset is included in assets held for sale. &#160; &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">See Note 16 - Operating Lease Obligations for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk83294649"></a><a id="_eb306f27_3d23_4d88_b747_498eb796baf0"></a><a id="Tc_rEIwOzO8yU2eNVpIbi-Pcw_1_2"></a><a id="Tc_ej2ry8jtakOj5BUbwg6Exw_1_5"></a><a id="Tc__n7jhzaJVkqAFaDHhnBfoQ_2_2"></a><a id="Tc_ekb3h7S1AkqG6vsHZD-UvQ_2_5"></a><a id="Tc_lMS-qrJfF02LkWROnrppgw_4_0"></a><a id="Tc_Y0x1U4pr_0uOtJMChR3IeA_4_2"></a><a id="Tc_2cm0wdfJaUWZ4yER5WyvlQ_4_5"></a><a id="Tc_LhvxWYH_B0WRxnevhVGi2g_5_0"></a><a id="Tc_ZH7RvFSwb0OzcYFYIRAQiQ_6_0"></a><a id="Tc_09tSlj64Pk2JQyt9i_O7Yw_7_0"></a><a id="Tc_zFvwVwKiy06ywT12kHOZ8g_9_0"></a><a id="Tc_zJpscE5x2U-z-bhCNCVrJA_10_0"></a><a id="Tc_rfj5vOOMdEqV5NoQ4M8n_g_10_2"></a><a id="Tc_Azf5nfT9P0-xFS0Izp3WUw_10_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_Pik_7BK64kGNS2DaNf3arA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;Fixed Assets</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_RAzUQZVXfEOOGBtEt1cyzw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_dZg1WhqNY0uE1A0c9lHl3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_iW_4S4IM8kqXDbJqaU1Ihw_4_3">695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_rnZo30pQDUukbPb7XP4wQA" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_cWz2KHg9vEKN3lyufXj06w_4_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_3cd_ntn9tk-FS9Dj6nY5OA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6r3M4NOfu0SZSrsOe4IIHg_5_3">3,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_0UI15QK8_EKkODArRfq0rg" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_pUAF-FNQPkKWgaNMn4tdGg_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_-LP9qePrKEKSRn6V__dvKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-IyN7wMFIEmOr00GPt_m7A_6_3">403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_6o-7lqfD3E6XYI9oPMTzMg" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_5BHBXWcQoUGYrNJ4NJCRdQ_6_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_eQjpKMv4a0WIG8KhXwtaAg" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_UoxNkCZBWUaUADBcZ0q-Kw_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_n8A-vIkPIk-D3alQ6Tlk4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_5yzWTE5fnUm72MHcsmMJDQ_7_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_zP6ZMW_U2kiusQwTk-Qo4g_8_3">4,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6aCF_sXdPUeXRZnofsaF_Q_8_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_KSQwdw1B_EWL-DNIRztPOw_9_3">400</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_iquQ_hHuj0Sx7nWN9whFVg_9_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_cyhD2OVrkEyNpbPCxIDsNg_10_3">4,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_JMpnD4YOV06Vk1-MOEHPDQ_10_6">1,373</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Depreciation expense was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Narr_lrOB_Ylyt0C9ptaiC_8dAA">400,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Narr_1SUy-zXYokyf9YibQiDS8w">0</ix:nonFraction> for the years ended June 30, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Fixed assets held for sale at June 30, 2023 and 2022 in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="ibio:FixedAssetsHeldForSale" scale="0" id="Narr_97PbTRkjvEWnarqIj7pJQQ">16,124,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="0" format="ixt:numdotdecimal" name="ibio:FixedAssetsHeldForSale" scale="0" id="Narr_ADHf-cLkhEaG2BBhSFCEuQ">35,289,000</ix:nonFraction>, respectively, are included in assets held for sale. &#160;The depreciation expense for the years ended June 30, 2023 and 2022 is classified as part of loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the Fiscal year ended June 30, 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company recorded an impairment charge of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="Narr_1s49lu2fxkqjdgdXqOr-Pg">17.9</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">See Note 5 - Financial Instruments and Fair Value Measurement for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7c7b2db9_e501_4acf_8fe7_9408881b0f11"></a><a id="_Hlk83294728"></a><a id="_Hlk83294699"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;&#160;Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has two categories of intangible assets&#160;&#8211; intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December&#160;2003 from Fraunhofer USA&#160;Inc., acting through its Center for Molecular Biotechnology (&quot;Fraunhofer&quot;), pursuant to a Technology Transfer Agreement, as amended (the &quot;TTA&quot;). The Company designates such technology further developed and acquired from Fraunhofer as <i style="font-style:italic;">iBioLaunch</i>&#8482; or <i style="font-style:italic;">LicKM</i>&#8482; or <i style="font-style:italic;">FastPharming</i> technology. The value on the Company&#8217;s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company&#8217;s patent portfolio.&#160;The intellectual property also includes certain trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) whereby in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_GMLt8Z0kCUWGHfk9AJSpeA" decimals="-5" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementTotalInvestment" scale="6" id="Narr_MRu21ZC7xEO4zCkcY4fy3Q">7.5</ix:nonFraction> million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (T reg) cells while enhancing T effector (T eff) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate, plus a PD-1 agonist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In January 2014, the Company entered into a license agreement with the University of Pittsburgh whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the &quot;Licensed Technology&quot;) which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#8211; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (&quot;IND&quot;) &#8211; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company&#8217;s financial obligations for the management of the patents under the license agreement ceased on August 14, 2023, and at such time, transitioned back to the University of Pittsburgh and the Medical University of South Carolina. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_14_2022_To_8_14_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_TbCIxSxD_ka6X8lcCqL-Eg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="Narr_dJyt4DdAMUaJlHg59aFcMQ">25,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the second quarter of Fiscal year 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that will no longer be utilized and therefore were fully impaired. The Company recorded an impairment charge in general and administrative expenses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="Narr_g4MdTR0O9kmE5DuzVj-tyg">565,000</ix:nonFraction> for the year ended June 30, 2023. <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_MeaCIqKJOEawOzUh7Pp-PA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="Narr_7w0uyBGUD0ymd0Y82kDiAw">No</ix:nonFraction> impairments were recorded in Fiscal year 2022.</p><a id="_112eaa57_6e2c_4bc5_b2f2_99a11be224ee"></a><a id="Tc_6X-12hJb-UWUEPtxL7cgfw_1_2"></a><a id="Tc_C3nMA2dFlEy9C_bu4ZCZKw_1_14"></a><a id="Tc_kev-X6RK-EebdocGPLHquQ_2_2"></a><a id="Tc_RNWp1T_NlEC9Rgf-bhvAwQ_2_5"></a><a id="Tc_FhNNdPn3m0iGaoVf1QtkDQ_2_8"></a><a id="Tc_62COCOJlnEWL1mGpXoggaA_2_11"></a><a id="Tc_8weKRA9xTE6u0k4U8nT5Ng_2_14"></a><a id="Tc_utin4Y9Ya0WwAo_JyK_PBw_3_0"></a><a id="Tc_Bn5364qvbkmW1ueQgWvneg_3_2"></a><a id="Tc_Lm-wJlN_9kmLzA1i18tdBw_3_5"></a><a id="Tc_EjUdXEPxc0yyHDZw2dXMkQ_3_6"></a><a id="Tc_S-RpE5LY0kighHG3H4kCtA_3_8"></a><a id="Tc_OgyIXzI4uUuKbijMpBckRQ_3_11"></a><a id="Tc_LMOxh1BbJ02bDli24oHygg_3_14"></a><a id="Tc_RL0n8xxvTk6wKHTOLKufUw_4_0"></a><a id="Tc_B3COspvyGkyp5DdlV2E3cQ_4_6"></a><a id="Tc_V64DeZX7kUODRWxTB9op2A_4_9"></a><a id="Tc_-j9Bv2dSRkKQ-TxX1vmvyA_4_15"></a><a id="Tc_yxkh8fivkE6DpCwXkVtJCg_5_6"></a><a id="Tc_YBxC8XMBmUKlsf-Z-dRWbQ_6_0"></a><a id="Tc_V9_ztxTo7kG8xjAFek8iPg_6_9"></a><a id="Tc_mtN0OOxed0SWkGzkSVroGw_7_0"></a><a id="Tc_e5OUW5CLEECym0jCRdZBRw_7_9"></a><a id="Tc_H1TewJQGB0yDYMDyQ_C7QA_7_15"></a><a id="Tc_UpNTaNL8Qk-c3OGwOYRuCA_8_9"></a><a id="Tc_pRi4znyHRUa9hMLHCEkpMA_9_0"></a><a id="Tc_qfKKEsGl50CAHd7ZMsib8g_9_5"></a><a id="Tc_8CX3Rs7q1EqXvrgEr2hqzQ_9_11"></a><a id="Tc_xOPbR6As6U-ab3C5PpnBqA_11_0"></a><a id="Tc_KbqYEopKpk-K9cUgg348WQ_11_6"></a><a id="Tc_WXcSqlnquE6oDHO3z3Z-Ug_11_12"></a><a id="Tc_yap0a_Jfw06iIOF7m4sFnA_13_0"></a><a id="Tc_2IlxZyYfoE2kXY3sSBMVLA_13_2"></a><a id="Tc_Z2s3Akzpj0WKQxJANWX4wQ_13_8"></a><a id="Tc_yELiDWCi8U24nfOiH4GOkg_13_14"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_NvWLbd6qjk2406-uSv9TQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impairments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_6Fl1dC8ctUaESD30gx10sA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_1tr3Sh6kAU6aLNGihlPDbg_3_3">3,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="Tc_4Q3EppoHYU-E-QU6UUtNiw_3_9">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw" decimals="-3" format="ixt:numdotdecimal" name="ibio:ImpairmentOfIntangibleAssetsGrossOfReversals" scale="3" id="Tc_m-lcyzV6GECIcXN4j-3Mwg_3_12">3,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_8lgND34HlkmhXTglE1MoHg_3_15">400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_OUSYNzx-3kmj7vrVQcR-fw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_VdhsbYkE10-X-_veBa_qRQ_4_3">2,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw" decimals="-3" format="ixt:numdotdecimal" name="ibio:ImpairmentOfIntangibleAssetsGrossOfReversals" scale="3" id="Tc_sLl8-49YdECH63HEOj92Dg_4_12">2,846</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_XN8zQP-Mn06lKZYkVqGjRw_5_3">5,946</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="Tc_lh7InptnPU-4jXwOCt5sZw_5_9">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:ImpairmentOfIntangibleAssetsGrossOfReversals" scale="3" id="Tc_ZHbDWmuirUe_b24T17RxHw_5_12">5,946</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_ql8J76eMNE2mZvDgpTdSug_5_15">400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_6Fl1dC8ctUaESD30gx10sA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_iA2A1X6bW0Guc2iQxF-FTQ_6_3">2,867</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_RjIeTcJxP0i9TZ-cWpQ-Xg_6_6">79</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReversalOfIntangibleAssetImpairment" scale="3" id="Tc_XpGc17M7r0mP6tIZ4-Ca8A_6_12">2,931</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_IWUCvtPkMU-p9Uio4a7ZcQ_6_15">15</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_OUSYNzx-3kmj7vrVQcR-fw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_0uO53UmEgk6HjwZipAEdmA_7_3">2,403</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_syV6yHmyC0e5a5tQWNG6gw_7_6">47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReversalOfIntangibleAssetImpairment" scale="3" id="Tc_5INtzCnyEEGSUpXHuhjrXQ_7_12">2,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_eb4XGpjuTUOR1s53jj05dw_8_3">5,270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_OmEd8axsAUSzH6GrXF5zRA_8_6">126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReversalOfIntangibleAssetImpairment" scale="3" id="Tc_yB6AbA-qREO_00gfJttTEA_8_12">5,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_UTa5x0RtuECjlVJZ3oka0Q_8_15">15</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_qW_-_-hZRkSzc7zlwVal0A_9_3">676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_tFC30wu8L0mxiOMzhk9u3g_9_6">126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="Tc_cv1KdiR-z0KZinTTkfLBMw_9_9">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_Hta0Wa6M7kGRthezSNw2aw_9_12">565</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_V0bW8Xv8J0O4nIQuaygUUw_9_15">385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_t0oZ7pDi4kK6CN06AhPQ4w_11_3">4,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="Tc_9Ozrj4vktUeQ4pTTnuw7BA_11_9">828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_u-IAXOxZz0mfF2So18IbDA_11_15">5,003</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_p9n28jljtkue-xwPoO2acA_13_3">4,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_vEQqufD90USP1VGzaUl2Uw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> 1,228</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_GpPrmvIBuUO2hLYJxnTIkw_13_15">5,388</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Amortization expense was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="Narr_ojA-5S03aEepHqGA3RsE-g">126,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="Narr_skeGLCbHtkeek6QQl_Yc5Q">401,000</ix:nonFraction> for the years ended June 30, 2023 and 2022, respectively. The weighted-average remaining life for intellectual property and patents on June&#160;30, 2023 was approximately <ix:nonNumeric contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_ebkIfIUrME63nGJOKcNuOg">19.3</ix:nonNumeric>&#160;years and <ix:nonNumeric contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DA4mNb1HCESUnEtjTHgS3w" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr__pDjnsdA40mso9Fw77L1ww">1.5</ix:nonNumeric>&#160;years, respectively. The estimated annual amortization expense for the next five&#160;years and thereafter is as follows (in thousands):</p><a id="_9e43c1cc_250c_4450_858c_4f1f3b321d93"></a><a id="Tc_ItH60eSew0qj4OL2JMgIsw_2_0"></a><a id="Tc_wjKOp9BpvU-GpRpFyUxJ_A_3_0"></a><a id="Tc_matjuLgXWkaHvHY_cgWzFw_3_2"></a><a id="Tc_gas1f_AP3Ey8gIjrQewHGQ_4_0"></a><a id="Tc_sWjba0J3MkaVh_gOlVHJ5g_5_0"></a><a id="Tc_CNTIAz0aP06Y_-82pYVn3g_6_0"></a><a id="Tc_PpG4r4-4UEa6O-DN1Te3nw_7_0"></a><a id="Tc_j3Bf3ChGgEW0oFEByWwcnA_8_0"></a><a id="Tc_rY2_UGLNEk6m7wIkBhfdOg_9_0"></a><a id="Tc_Pq6XL9VX4UqgmAMyknA1rg_9_2"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Tb_0SGjXcjVIUm_sr0wPDMzug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:44.49%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc__l9o546nIkuzkEc6SlI_Ag_3_3">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_rJHCPc9UcUKT3YINSeLsvA_4_3">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_nbeWnSn3AkOlHvc1mgFzsQ_5_3">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_9BNQ8j_jiUCWLgrOIZQfpQ_6_3">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_3AjU-D83Ek-EG9dumOaLKQ_7_3">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="Tc_9J6kLN4AJ0aZH-XSAWBaNw_8_3">285</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_zhYNMnI7_kWT5Jsmm3cA3g_9_3">385</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk83294731"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3e575f19_f5c0_4777_b40b_819ffd93d8ca"></a><a id="_Hlk83294651"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13.&#160;&#160;&#160;&#160;Accrued Expenses</p><a id="_4ece258e_84e7_4dfb_bfd1_91ba20fc0837"></a><a id="Tc_9CIu-wlJnEm5Hj2ibKaB9Q_1_2"></a><a id="Tc_ezL-P4SxgEC2r850lzurnw_1_5"></a><a id="Tc_rVujVaVdI0y6N80hyz2MVA_2_2"></a><a id="Tc_KXrrsqvD1kS-uVNmw1J5iQ_2_5"></a><a id="Tc_UepN4urDTECdPnMNqLNLZw_3_0"></a><a id="Tc_Pr6iIVpr3E2Glu_aPr8iTw_3_2"></a><a id="Tc_pXduAqp0gEaHHMetAnQ7uQ_3_5"></a><a id="Tc_Q2ivCabolEqyA3lUPJPDBg_4_0"></a><a id="Tc_6orGClRgTEqy7oUCsUiX5g_5_0"></a><a id="Tc_TRKWfSDXrUSBzILQc3-vng_6_0"></a><a id="Tc_xZHBGNyryEmMKC6RMCYc9g_7_0"></a><a id="Tc_scJ78OZlL0afi44l9Ym7Wg_8_0"></a><a id="Tc_gyY1uVPwLkyJ_GQx-MRNaQ_8_2"></a><a id="Tc_rDAydIU3TUGeigUYq8LKMQ_8_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_M_O-OefXtk-z-xl2sc2qIg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_pnd2pBHikkGxmkKK5MTWtQ_3_3">3,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_e8FLXgvSQ0qzzIWX2yUx4A_3_6">3,066</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Real estate taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedRealEstateTaxes" scale="3" id="Tc_bZq98Qh2q0eY7l0onYMyyA_4_3">268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedRealEstateTaxes" scale="3" id="Tc_Eaj1SHQpA0WPZNJEDJtFHQ_4_6">284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and fees related to term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="Tc_83552zqAgUqONC_MZq3Xrg_5_3">183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="Tc_mODzEXkSjUaB4pM-48ZkPg_5_6">59</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_DSiYk--K_0OhhY4D6anU7w_6_3">31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_Ee_EC0y_60-TGRUkVFd7pw_6_6">126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_ABvOnqOwCkGQiy25mITEdQ_7_3">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_er2rjZTY6E-RLNc-92l4Vg_7_6">229</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_0eZaEibzbESQapZhGkdZkw_8_3">4,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_WfVeFemN80yff7T4WMKaeg_8_6">3,764</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk83294696"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:DebtDisclosureTextBlock" id="Tb_Cz2K5CnNA0aoSF82--1aRA" continuedAt="Tb_Cz2K5CnNA0aoSF82--1aRA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_gu1NRcCf3UK-cY9abE950Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_BELP1O2TPU-yxUiz91QVeQ">22,375,000</ix:nonFraction> secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#8220;Term Note&#8221;) (for a complete description of the Transaction please see Note 6 &#8211; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_gu1NRcCf3UK-cY9abE950Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_jjhjTG8TfEapkrEqG3CUHw">3.25</ix:nonFraction>%, with higher interest rates upon an event of default, which interest was payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_2RUbpio7FEeipqf0K7mQCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="0" id="Narr_HCdp9C78ZkKD9UOwHzOq0w">5,500,000</ix:nonFraction> of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember__jVFiqLstUOWmy568nqUUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="0" id="Narr_1f9AQXd9ekagZfre3cDrIQ">5,100,000</ix:nonFraction> of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (the &#8220;Fraunhofer Settlement Funds&#8221;) (see Note 20 &#8211; Fraunhofer Settlement for more information), (iii) include principal payments of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_nz1JdBks80Cs0AMppzhnXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_k5IRfhVc10G_rae5EDqKpw">250,000</ix:nonFraction> per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_4NB7YEQHAUqVr8MzcB_kuw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" id="Narr_ItTR5NpPQU-P_cDrJdpcnA">22,375</ix:nonFraction> and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#8220;Liquidity Covenant&#8221;) in the Guaranty (as defined in the Credit Agreement) from </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Cz2K5CnNA0aoSF82--1aRA_cont1" continuedAt="Tb_Cz2K5CnNA0aoSF82--1aRA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_NCgEbLSz3ky2W-1HFoSejQ" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="0" id="Narr_YbtODMd_vEu3dxijHruBxg">10,000,000</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_4NB7YEQHAUqVr8MzcB_kuw" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="0" id="Narr_3cQw_P92cESg7N1jg3WbEQ">7,500,000</ix:nonFraction> with the ability to lower the liquidity covenant to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_N0d1OE5sOk6a6vFBAShgiw" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="0" id="Narr_r0ma_1o9FkiuqvPJ3OQVrQ">5,000,000</ix:nonFraction> upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company&#8217;s unrestricted cash decreased below the required $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_CQLMvmW4IEONf8twopcH1w" decimals="0" format="ixt:numdotdecimal" name="ibio:CreditAgreementThresholdLimitUnrestrictedCash" scale="0" id="Narr_NU6yYs6_0UOGlDoHCzYb5g">7,500,000</ix:nonFraction>, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#8220;Second Amendment&#8221;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than <span style="-sec-ix-hidden:Hidden_sMGyGM4rm0etbg7foCVLZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_2_20_2023_To_2_20_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_kHwI2oYS2kqmmWDijalKcw" decimals="2" format="ixt-sec:numwordsen" name="ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility" scale="-2" id="Narr_qfzeSwI9zkytwzmlOYYcqA">forty</ix:nonFraction> percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AMSxbpHjr0eHHzhd2SU4ZQ" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility" scale="-2" id="Narr_HVM23Tyog024RhG8CScEPA">40</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_utNLNmYSRU-7gHrqgVWwQg" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility" scale="-2" id="Narr_ntlxE0evj0qYGwVb2IdFTQ">20</ix:nonFraction>%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AMSxbpHjr0eHHzhd2SU4ZQ" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment" scale="-2" id="Narr_XxN7M3KQskCNFskj_P9bHw">40</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_utNLNmYSRU-7gHrqgVWwQg" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment" scale="-2" id="Narr_ScHzQ8bk5kqMnLzME9PoDA">20</ix:nonFraction>%, and (iii) allowed the Company to retain $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AMSxbpHjr0eHHzhd2SU4ZQ" decimals="0" format="ixt:numdotdecimal" name="ibio:AmountRetainedFromProceedsOfLegalSettlement" scale="0" id="Narr_8c8hHRz_QEaCrsy7Kg1fQg">2,000,000</ix:nonFraction> of the $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_3_24_2023_To_3_24_2023_l9rVfdViGkK2f-fdYObPPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_yqp6_dC3KEKhB91fYT6_ng">5,100,000</ix:nonFraction> that the Company received from the Fraunhofer Settlement Funds, with the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_bMRwgJhi-EeZTQrY-DJ9ig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" id="Narr_FKYw4DUag06ynct8YEMeTw">3,000,000</ix:nonFraction> being held in a Company account at Woodforest. &#160;In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_EbZx7U23KkqqedJKnH3P9Q" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_6CqJ4ZqUWE29p4jtdJytYg">75,000</ix:nonFraction> on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_bMRwgJhi-EeZTQrY-DJ9ig" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="0" id="Narr_Td8VLxihZU6bTlwxW5HbWA">7,500,000</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_GmkcutYho0qIygUE-r1Kyw" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="0" id="Narr_r5J0dmF4r0a5WdaelUbT7Q">1,000,000</ix:nonFraction>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KaGEDjN0e0GNLqwZeqxNuw" decimals="0" format="ixt:numdotdecimal" name="ibio:AmountToBeReleasedFromRestrictedCash" scale="0" id="Narr_4Uv3ZHdJgUW85pBWWCQ1zA">500,000</ix:nonFraction> of the $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_56vZG9jEekWgY4y74laSeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" id="Narr_pvi84bm3CEWTXV-1Qe6kAQ">3,000,000</ix:nonFraction> being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10,000,000 and for each additional $2,500,000 reduction of the outstanding principal amount, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_JHTUWvDAy0mSeOtQy7guzQ" decimals="0" format="ixt:numdotdecimal" name="ibio:AmountToBeReleasedFromRestrictedCash" scale="0" id="Narr___r4EMxRPkureLsuaq9GMw">750,000</ix:nonFraction> will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_CU79tDBZJ0-os-9D7HXbbQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ip0DW0E3P0e74PLZTNjanQ">5.25</ix:nonFraction>%, and the Term Loan shall further accrue interest, payable in-kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_i3ZFj12p9UazqqscbySntw" decimals="4" format="ixt:numdotdecimal" name="ibio:DebtInstrumentPaidInKindInterestRate" scale="-2" id="Narr_vJjO-yboFEWaTqHdfS3jOg">1.00</ix:nonFraction>%, if the Facility is sold on or before June 30, 2023, (b) <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_nNBE8O_Yc0GrXHryQ3ARjw" decimals="4" format="ixt:numdotdecimal" name="ibio:DebtInstrumentPaidInKindInterestRate" scale="-2" id="Narr_2wMEUMOimkegic27eNGtLA">2.00</ix:nonFraction>% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) <span style="-sec-ix-hidden:Hidden_HmO8mI3b8UikyAnwMIet_Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3:00</span></span>%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_0UIjDWk4GkapKTIJmMsJJw" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_M9568SGWGECucwNtdQGk1w">75,000</ix:nonFraction> if the Facility is sold on or before June 30, 2023, (y) $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_GcE4nP69ekilykVs1dNbZA" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_KL31n-Ey9kW_56DyRIJO4A">100,000</ix:nonFraction> if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_9TjCBbgA7UyTlQwWmTS87Q" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_HhZB1e40C0WD4_7HsKqABw">125,000</ix:nonFraction>, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#8220;Sixth Amendment&#8221;), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_P6kllRf93EingEnEr-uMKw_1_0"></a><a id="Tc_sbtRNh8T2keghysXen5fNA_1_2"></a><a id="Tc_S7VKCmN_S02SqdrbGI1VEw_1_5"></a><a id="Tc_HABv8s01Oka0XrYPp8MNcg_1_8"></a><a id="Tc_kJSe0oyh-k6ouvp_SO6eDA_2_0"></a><a id="Tc_i24pHG7ynE-BWVMTgytdBw_2_2"></a><a id="Tc_PdwiBY6GKkSASwwSE8vwsw_2_5"></a><a id="Tc_Lc7qKNWPY0Ox33omSWNJ6g_2_8"></a><a id="Tc_tlR7ZnTK0UKzvCraBY-dKA_3_0"></a><a id="Tc_bexY2kxJKEeopXGPkdfdUQ_4_0"></a><a id="Tc_8YEvg9doKEujJcXTYNShjA_6_0"></a><a id="Tc_wMsgC838cEmnRNEfoJOs2g_6_5"></a><a id="Tc_vQzOGZydXk-yrlKGAHq-rA_6_8"></a><a id="Tc_Ccci_rBAjkeYNGfsXQdYBg_7_0"></a><a id="Tc_lJe9O0OJnUyMqvqhaAlDJQ_8_0"></a><a id="Tc_jf2jxaRkYU-wADwvN79R4A_8_2"></a><ix:continuation id="Tb_Cz2K5CnNA0aoSF82--1aRA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Purchase Agreement for the sale of the Facility within <span style="-sec-ix-hidden:Hidden_v7l5jYByc026hKF0AEadYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> business day after entry into the Sixth Amendment, and (ii) if the Facility is not sell on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ni7O9yqrp0G3jZAhtH1cdg" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_tlyT6Ou_KkKZ4tYT4xJLgw">20,000</ix:nonFraction> upon the earlier of the date of the closing or the Maturity Date. &#160;In addition, if the closing and funding of the Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMO&#8217;s real estate, including the Facility, at the cost of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">At June 30,&#160;2023, the balance of the Term Loan was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_ip8TzvFk80eYolQL5zegdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_TE7io7zR60q53N9U-xj7Fg">12,937,000</ix:nonFraction> which consisted of the Term Note of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_ip8TzvFk80eYolQL5zegdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_hxzh4zMHP02VrPFIRvhjuw">13,057,000</ix:nonFraction>, net of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_ip8TzvFk80eYolQL5zegdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_TfjeoXl1p0e3dE88UyZVgQ">120,000</ix:nonFraction> of deferred finance costs. &#160;At June&#160;30,&#160;2022, the balance was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_X5uA0-qoeEeIkEVG5KZZjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_UEMPi_2vHEOQ5_BZrfGY3A">22,161,000</ix:nonFraction> which consisted of the Term Note of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_X5uA0-qoeEeIkEVG5KZZjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_g8qmzpxsgk6MrJjmC-L5ZA">22,375,000</ix:nonFraction>, net of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_X5uA0-qoeEeIkEVG5KZZjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_A9zD0B81UEuUDP6UdoA74Q">214,000</ix:nonFraction> of deferred finance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_10_12_2022_JPfG9ZEqqUa0LmbfHdCHIg" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingAmountBorrowed" scale="0" id="Narr_A4uL5uZamEqrbmnhL23TJw">500,000</ix:nonFraction> was borrowed over <ix:nonNumeric contextRef="Duration_10_12_2022_To_10_12_2022_L-VOkowDDUifCXu94CAHuw" format="ixt-sec:durwordsen" name="ibio:LesseeEquipmentLeaseTermOfContract" id="Narr_Mb_eshKFMk6Lsu344kzbnA">36 months</ix:nonNumeric> at an imputed interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_10_12_2022_To_10_12_2022_L-VOkowDDUifCXu94CAHuw" decimals="4" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingLeaseImputedInterestRate" scale="-2" id="Narr_6AjALkFwY0-xgHIBhj4YIg">10.62</ix:nonFraction>% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_10_12_2022_JPfG9ZEqqUa0LmbfHdCHIg" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentLeasingMonthlyInstallmentPayable" scale="0" id="Narr_WKOwS3ltBke3X926mlhkHA">16,230</ix:nonFraction> through October 2025. &#160;At June 30,&#160;2023, the balance owed under the financing was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingBalance" scale="0" id="Narr_3_95FgwX_EGM21IXhPP3MA">401,000</ix:nonFraction>. &#160;Interest incurred under the financing for the year ended June 30,&#160;2023 totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingInterestIncurred" scale="0" id="Narr_ZnDbnY0XwUeJHU04-IrgFA">31,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb__zwhHIKQpkydWwrYYk5Veg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="Tc_Aaq2aytfaEiGHPBiyvyZ6Q_2_3">160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="Tc_2eX1LOvRG0aLtq_Ju9XwCw_2_6">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="3" id="Tc_UmAvnBbrEU2MjurKxMKsfA_2_9">195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="3" id="Tc_uw8vsoEDpEqnRf4vzwQOug_3_3">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="3" id="Tc_6Q56690gQ0SSXYht0-adWg_3_6">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="3" id="Tc_pvj2wVJuTkmYr2p2DEaQkg_3_9">194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="3" id="Tc_O6tn6dZo60y0JRBLH5DFEw_4_3">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="3" id="Tc_TOMvBHbW5UyZzGTKeBL5LA_4_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="3" id="Tc_m6ptjJcV_k2geRlWOpeiOQ_4_9">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="Tc_sAbOGznrjE2zfncONmbtGw_6_3">401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="Tc_qAdHSxLM3UyL1SOeBXvfxg_6_6">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="Tc_q6k6i7V1QE6H3v3vhPEMVg_6_9">454</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="ibio:ContractualObligationCurrent" scale="3" id="Tc_X75-tQzsd0-K-PM-z4addQ_7_3">160</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="ibio:ContractualObligationNoncurrent" scale="3" id="Tc_KbHWRBgeT06WKZJ_1nTc-A_8_3">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note Payable &#8211; PPP Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-weight:normal;">On April 16, 2020, the Company received </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_XdqoL_rkxkCM1xpi2PlAeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="0" id="Narr_d9ZPhVLzMUib3WPHvWBYlA">600,000</ix:nonFraction></span><span style="font-weight:normal;"> related to its filing under the Paycheck Protection Program and Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). &#160;</span><span style="font-weight:normal;">The Company elected to treat the Small Business Administration (&#8220;SBA&#8221;) Loan as debt under ASC 470, </span><i style="font-style:italic;font-weight:normal;">Debt</i><span style="font-weight:normal;">. &#160;At June 30, 2021, the Company owed </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_rv5XUgdp7EGs6FYMQwZaCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="Narr_H8TzFsac_UCclKYFPYsdrw">600,000</ix:nonFraction></span><span style="font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, <i style="font-style:italic;">Liabilities - Extinguishments of Liabilities &#8211; Derecognition</i>, the Company derecognized the liability and accrued interest in the first quarter of Fiscal 2022. The forgiveness is included in loss from discontinued operations.</p></ix:continuation><a id="_Hlk83294674"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:LesseeFinanceLeasesTextBlock" id="Tb_GQpiKatddEiuW0xpZxq0pQ" continuedAt="Tb_GQpiKatddEiuW0xpZxq0pQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;&#160;Finance Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. &#160;See Note 16 &#8211; Operating Lease Obligations for additional information related to the ground lease.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fe3e2447_b777_4795_acfe_3f7e2a639427"></a><a id="Tc_mK6qZVlPOka3z9DDxQr5kg_1_2"></a><a id="Tc_F0PouGJCp0eYD3Yh3BeBcg_1_5"></a><a id="Tc_3JCqi_9Vt0CziySoeHuFHg_2_2"></a><a id="Tc_lj_RAnh4UkyiPI_6wPDa7w_2_5"></a><a id="Tc_6tGUXH993Uy9OFJ9PM8G_g_3_2"></a><a id="Tc_aMtDoQgukESYf204UQDCYA_3_5"></a><a id="Tc_LIwrVHHf30ekFjuRPLJBgA_4_0"></a><a id="Tc_mnCN1TRUQU2JwWcPQC1nmw_5_0"></a><a id="Tc_V7mdti4sV0S4vXPoflpY6A_5_2"></a><a id="Tc_qrrf9u7frkuE5WM17J6oUw_5_5"></a><a id="Tc_VXStSTQvaUKsGStjqdjUUQ_5_6"></a><a id="Tc_DbZ-3LL1KkavUjbK4adXDw_6_0"></a><a id="Tc_JAMTHT_QI02u16FoMN7UqQ_6_6"></a><a id="Tc_0DnTsf0CMUWBiaW03B55Mg_7_0"></a><a id="Tc_VvLFNtkaJ0SDJb3S498LQQ_7_2"></a><a id="Tc_FEnOKjIs2kiH3vbb4xU0FQ_7_5"></a><a id="Tc_Fc4uEdJOWEK78aw-f0AFCg_7_6"></a><a id="Tc__Esll7VbfUKRHKZ9lddNHg_9_0"></a><a id="Tc_UBhZ42PxDkeGauOBt5WjFQ_10_0"></a><a id="Tc_VZ3EWBUVwUSJycM9WOvBxQ_11_0"></a><a id="Tc_jB9mF-uJ3EyB6sRTENrbDQ_11_2"></a><a id="Tc_vdtMdgKHaUupwA6z5v9NyQ_11_5"></a><a id="Tc_zhdzmCC2y020SK7RobKaAw_11_6"></a><a id="_f1e0863d_74f6_447b_a9e9_d4e64c941c4b"></a><a id="_Hlk83294706"></a><a id="Tc_HsmBWw0uYUSolXSOZfHdVg_1_2"></a><a id="Tc_KI2SLBwoOUShRuJeMa5FYg_1_6"></a><a id="Tc_3p0UbF95HU-05viVel5aCA_2_2"></a><a id="Tc_89emh5nrYkmv7SlWrkO31Q_2_6"></a><a id="Tc_JF2fuaAEyk6PEw7LXHhJNw_3_0"></a><a id="Tc_RELf0YUU2UWUFXdhZm8vag_3_2"></a><a id="Tc_pa-_9u1amkGJF_I0rIyDSA_3_6"></a><a id="Tc_MUA7ptGv5EWRLC8Y1aX8WA_3_7"></a><a id="Tc__Odl8kU9iUejIvOJklx_oQ_4_0"></a><a id="Tc_nfDI6MngmUuhUfg0xGcWEQ_4_2"></a><a id="Tc_PQHkuVty1E6MvcRhigDeZQ_4_6"></a><a id="Tc_T_4Eg537bEKYepgI9uv-HA_4_7"></a><a id="Tc_eZdAOLwsPkeQ22bwADdquA_5_0"></a><a id="Tc_g8JF8oaLWUGFJzgyN-gzhQ_5_2"></a><a id="Tc_E18jUUx3GEC0n6Og64ImrA_5_6"></a><a id="Tc_e2g4vYn8cU-YlwEgiSN-qQ_5_7"></a><a id="Tc_D9jbBA0XzEKEZqf0OKrksQ_6_0"></a><a id="Tc_gr0ybAKBxk-ghgQ1nRMcjA_6_4"></a><a id="Tc_hgcDVyc8EUeTxReh0CxPKA_6_7"></a><a id="Tc_atbrqKKlWU6Ysy_OSfFsIg_6_8"></a><a id="Tc_mtBE47l0pEqmnQn9kmvqCg_7_0"></a><a id="Tc_sa6DgBd5M0iLRTVfLLHG1w_7_4"></a><a id="Tc_ncch8XeFXUSJICTkuJdGug_7_7"></a><a id="Tc_IgZ2CU1HlUixD9KY-KzODQ_7_8"></a><a id="_ce119801_89e4_4a10_9f52_91fafd64640c"></a><a id="Tc_AuIlBVXiLEqeNMfmMPuFNg_1_0"></a><a id="Tc_UcrqGwYzaUeHZCtE1NeLeg_1_2"></a><a id="Tc_TMimXij7jUO1pQj3YoUTzA_1_5"></a><a id="Tc_ws9vxlg3T0qg6zbCCAfNOQ_1_8"></a><a id="Tc_X-_JBdnisESMLylYhYUzJw_2_0"></a><a id="Tc_iCgIEPEFlUay9tFgKm-RhQ_2_2"></a><a id="Tc_3wRnHxgroUiwyG-R006ahw_2_5"></a><a id="Tc_BYB4_0fXYkOQfcJFfRGchw_2_8"></a><a id="Tc_5CFGojd3s0ys8BlF7lt5uw_3_0"></a><a id="Tc_piOXhGlr3ECgBff51HRFMA_4_0"></a><a id="Tc_e4L8RVBhmE-db30QtjPS4w_6_0"></a><a id="Tc_ei1xcbu3u0qV2vBXpeURCw_6_5"></a><a id="Tc_EzouZZVYgEq6peNI6jjFhA_6_8"></a><a id="Tc_e8ml0-A2RkeaxCFi03Vhrg_7_0"></a><a id="Tc_BT5GvrtvI0q1-RZi9cZ61Q_8_0"></a><a id="Tc_NdS6w-FxkUi3u2hsjMPjDQ_8_2"></a><ix:continuation id="Tb_GQpiKatddEiuW0xpZxq0pQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses related to College Station, including rent related to the increases in the Consumer Price Index (&#8220;CPI&#8221;) and real estate taxes, were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_SecondEasternAffiliateMember_DgnY7nozKk6LLsBoViwjXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" id="Narr_J53xOaGEik-ON6vvJ93Ftg">250,000</ix:nonFraction> for the year ended June 30, 2022. Interest expense related to College Station was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_SecondEasternAffiliateMember_DgnY7nozKk6LLsBoViwjXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_TDmuLBNQW0OD671mWcLlFA">810,000</ix:nonFraction> for the year ended June 30, 2022. Such expenses were classified as part of loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed <ix:nonFraction unitRef="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_raCrpv955kqcMjb0QKsvNA">three</ix:nonFraction> equipment leases that were accounted for as finance leases totaling $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="0" id="Narr_P1z0fdMpK0OBNCVpK9sTxQ">814,000</ix:nonFraction> as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the <ix:nonFraction unitRef="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_3vhdMTUKvkGItEprATNMCw">three</ix:nonFraction> leases is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_oxMyEE3vMkKthpi_lTkUeg" decimals="0" format="ixt:numdotdecimal" name="ibio:LeaseRentExpensePerMonth" scale="0" id="Narr_fZoOj-eelkewJAxlB4aAAQ">14,000</ix:nonFraction> per month and all <ix:nonFraction unitRef="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_VOl5CODHHEmJ7jZpPywkaA">three</ix:nonFraction> expire on August 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mobile Office Trailer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_4_1_2021_To_4_1_2021_94fR0DLTmEC12g7MPaQqxA" decimals="0" format="ixt:numdotdecimal" name="ibio:LessorFinanceLeaseMonthlyRent" scale="0" id="Narr_cei-9ZBDMESOQUo1SVi-BQ">3,819</ix:nonFraction> through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" id="Tb_71bkc_RkJkejpWD-YTB9Bw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_PTZhhyexwkyT64a6gHlVmg_5_3">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_YXRhZfMKvUqpkWNSjdpp9w_6_3">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_GVM8jrocb0aFNiIc2ifhNw_7_3">273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinancingCashFlowsFromFinanceLeaseObligation" scale="3" id="Tc_tH64YqBZ90KyqivK7eLgkQ_11_3">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_3NSp7K4E9USqgv1Dr54qkg_3_3">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_nktzHwoq1kqWwp0XUu7ZGw_4_3">272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_DSR1Ped8TUaHTZTHrmS_4g_5_3">351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_lDxJQBCgP0ClcFBm87jmdA_6_3"> 2.17</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_zSfh2svmTU2urAImHYxBMQ_7_3">9.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" id="Tb_KHnJOWajikWpmeUUHnZmLg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Future minimum payments under the capitalized lease obligations are due as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on June 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_3gI8m0U9N0SbuIwPaj9GFw_2_3">272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_PhEQb799l0S_x557a1dNRw_2_6">47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_3MI8jPsNg0KIm7OHF0QEQQ_2_9">319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_ze_tE6jE5E2noI5kXcVCWA_3_3">299</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_-6PYFwRGlUeliNRD8uictg_3_6">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_cIvClsV1T0SQuJctEuOKwQ_3_9">319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_qwqnRS1tZE2yVqOVCJHK-g_4_3">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_prTQZG1P5kuU57ofWWHtbw_4_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_V_lNE6liZkuGDYibxQW1tQ_4_9">53</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_87heAcYJ80242j1MsxI3Fg_6_3">623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_ft7DJKMhg0qmaggEbLiVsA_6_6">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_4H7ZB0aBm0C-wAxuCl_kww_6_9">691</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_ada1tUkfQUW8w0tqHURP4g_7_3">272</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_pNyytjELtUqhU94NQYj5TQ_8_3">351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fcab2eb6_5d5b_4fc3_8b05_ad07a045e3db"></a><a id="Tc_JTFtJdCrH06sAyUXuO3a6Q_1_1"></a><a id="Tc_E9QJto87fU-k42T4XCQoDQ_2_1"></a><a id="Tc_rLu-m7QmY0-8M1yoHYXnvw_2_4"></a><a id="Tc_pIqrt3qjlEG5eq8DJjPkvQ_3_0"></a><a id="Tc_YzbPSWAimUOAB0YfwB0_4w_3_1"></a><a id="Tc_xLiFLem0x0mI4nadZbBN7A_3_4"></a><a id="Tc_3erzboZMWE6V4n51SAkxIw_3_5"></a><a id="Tc_ttHdna7Bh06VigS4lQDnyw_4_0"></a><a id="Tc_brW3nnWBC0-rsMbgwCTyHA_4_1"></a><a id="Tc_EvZ89tVzxUK7_-7GT0SpPQ_4_4"></a><a id="Tc_Y0-Yow38ckO052WxUfqBvQ_4_5"></a><a id="Tc_hIQ-SJJslEifLyK0FlxjXQ_6_0"></a><a id="Tc_a6DMb2SQm0aiUy-8BDWHHg_7_0"></a><a id="Tc_gufUo6PrYEqN8f5ZVllAqw_8_0"></a><a id="Tc_IIY0LxRjdEiRatto606nJQ_8_1"></a><a id="Tc_thmfBitbZkWSuS1Ic1C5zQ_8_4"></a><a id="Tc_Aqk3Yps4k0uvUvA9f7J4FQ_8_5"></a><a id="Tc_82YzAbsinkiHCmsCrwjRww_9_0"></a><a id="Tc_XLW5hMl9d0KEO34YlN2k1w_9_1"></a><a id="Tc_0X7i_gKqD0WqIYGeb-ggSw_9_4"></a><a id="Tc_FoKTvBXekkK46-MGjDm8TA_9_5"></a><a id="Tc_J2yXGOnoREmgzWyfBzv5Cg_11_1"></a><a id="Tc_37XFcicvfkq-EwXKKPameQ_12_1"></a><a id="Tc_sYuX9m-LtkiT58qMYZfQ7g_13_0"></a><a id="Tc_oMDwGDgE8kWGs3NkCFghlg_13_1"></a><a id="Tc_VmnegTEnbEGkWGRKadZAlg_14_0"></a><a id="Tc__DCga2QE8EqO9PdgPFmn5A_14_1"></a><a id="Tc_hLPr_0yZEk6cKzxov86Kbw_15_0"></a><a id="Tc_3DzML5qQ4EOQAL2s-6ZRRg_15_1"></a><a id="Tc_QwpwuGOhTkKymY2Uv_Rqow_16_0"></a><a id="Tc_DT_SIUFGe0qFiHoZWiDIGA_16_3"></a><a id="Tc_RTY9fTV7bEixgYuT4IID7w_17_0"></a><a id="Tc_GHz8rqhti06qFAqXIgJq9A_17_3"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_coN_XAWJeU-j0IQCzleHtQ" continuedAt="Tb_coN_XAWJeU-j0IQCzleHtQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;&#160;Operating Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Texas Ground Lease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w" decimals="0" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseMonthlyRent" scale="0" id="Narr_VfcyPsQFJUyKkpWDj5ihkA">151,450</ix:nonFraction> for the prior year, is <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w" decimals="3" format="ixt:numdotdecimal" name="ibio:BaseRentPercentageOfFairMarketValueOfProperty" scale="-2" id="Narr_cl6QcbLEeUKeIeNFUzuo6A">6.5</ix:nonFraction>% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">San Diego</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2021, the Company entered into a lease for <ix:nonFraction unitRef="Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw" contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr__tdZYOBZzkGml1g4PfVc5A">11,383</ix:nonFraction> square feet of space in San Diego, California. &#160;Terms of the lease include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The length of term of the lease is </span><ix:nonNumeric contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_JCweKuXT_kKM-InkT7S3nw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">88 months</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the lease commencement date (as defined).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease commencement date is September 16, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The monthly rent for the first year of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_9_10_2021_To_9_10_2021_U6Pc1fTlZUCT-CsKaG5_qg" decimals="0" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseMonthlyRent" scale="0" id="Narr_-9ZEe1MYBUm5yZnH0UsrTw">51,223</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and increases approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_9_10_2021_To_9_10_2021_U6Pc1fTlZUCT-CsKaG5_qg" decimals="2" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" scale="-2" id="Narr_j07pyAFyvESKjEoWn73Nog">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease provides for a base rent abatement for months </span><span style="-sec-ix-hidden:Hidden_3yjQiksPYkaMOne7lIAO3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span style="-sec-ix-hidden:Hidden_coC25BjKxUC8oCpGfnMVKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the first year of the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The landlord is providing a tenant improvement allowance of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="0" id="Narr_P3tdZzrsd0Wy-nq99pexkQ">81,860</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to be used for improvements as specified in the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is responsible for other expenses such as electric, janitorial, etc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company opened an irrevocable letter of credit in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_tLpytXewLUGWxGC9zN2FKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GuaranteeObligationsMaximumExposure" scale="0" id="Narr_Q_M-2aeJNUSjSF5_3AFKVA">188,844</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in favor of the landlord. &#160;The letter of credit expires on October 8, 2022 and renews annually as required.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. &#160;Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease right-of-use asset in the accompanying balance sheet. &#160;Rent expense for the San Diego facility commenced in Fiscal 2022, when the Company began making improvements to the facility.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" id="Tb_eZgpv9NJc0O5aFd-xaad9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_Uhv7yueo8UuUx8v1C9wu_A_3_2">563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:TotalOperatingLeaseCosts" scale="3" id="Tc_TBD7zBMi6EG-vTvk1493vQ_4_2">563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_Nmd_zhwhAUSluSjuT6IDyQ_8_2">563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:OperatingCashFlowsFromOperatingLeaseObligation" scale="3" id="Tc_umt37kcuAkyP7t6qQ_-RXw_9_2">307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_5418wDlsVE6D-8T4CGXLwg_13_2">2,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligations - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_WoFhF36wHEWQvAgGZEdRWA_14_2">389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligations - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc__e6yh3uEI0iV-NsnRCUMKg_15_2">3,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_0kEgE3kH9UmjPhwyhJPPmg_16_2"><span style="font-size:9pt;"> 6.50</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate - operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_P79ry0SOGEG3Wl1-NNaIlw_17_2">7.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_647509d6_b05d_4750_ac9c_0bdb9437e37a"></a><a id="Tc_pt2KASNrckykmQtvgpxnmg_1_0"></a><a id="Tc_gTlSS6kgoUCoy2AI3Uw0zA_1_2"></a><a id="Tc_qR0ChbWU7UqBqve_V4rBkA_1_5"></a><a id="Tc_iKUBlwyShEeKgerv0x04KQ_1_8"></a><a id="Tc_xTVI7bnaSU-eldw_LCRuew_2_0"></a><a id="Tc_viWwjPR97Em-vr2WjuDYkw_2_2"></a><a id="Tc_siMRSwjRtEKfFW2Qk-lqmw_2_5"></a><a id="Tc_hTFLPi3SUEKok8d3IUAc_Q_2_8"></a><a id="Tc_A0v50ZqBXkOVtuKM6HvW8Q_3_0"></a><a id="Tc_KJLEAzyV8ECEuGWW93tkhQ_4_0"></a><a id="Tc__-hQof8YpkuNNl_B3Bqdxw_5_0"></a><a id="Tc_2mz-x70P90iV3v68EYVuGw_6_0"></a><a id="Tc_b6fVEVeQeUq6niKlSRY4IQ_7_0"></a><a id="Tc_5hc4oYYZrE-kTt-8WSQVVw_9_0"></a><a id="Tc_HmhL4mQug0eziUqj-0zw7Q_9_5"></a><a id="Tc_aBSUnrXBIkyNTmPCo-eYoA_9_8"></a><a id="Tc_1Ilk1sC2bkewnOo56hvFSw_10_0"></a><a id="Tc_cFlHzZhtgECA930DmfXaFQ_11_0"></a><a id="Tc_9YZ3WtS-90-aBRAA6rpGQw_11_2"></a><ix:continuation id="Tb_coN_XAWJeU-j0IQCzleHtQ_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_lTrNR_6R-EGrkL_P6IgT4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Future minimum payments under the operating lease obligation are due as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on June 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_WOlgde6q0U24vCIuYEIg8A_2_3">389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne" scale="3" id="Tc_3ZgocOLZiESG4bkajDDRjA_2_6">242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" scale="3" id="Tc_L-fx8a_7b0WU7thZQbAUbA_2_9">631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_5_piRl0Irka_39CwO3hfig_3_3">436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo" scale="3" id="Tc_lsjSyc0fqkeVxZ-hUHyk8g_3_6">212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" scale="3" id="Tc_-7-LHk2VWEyTHlAom7t_HA_3_9">648</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_bnDWKND140y8Tx11IEBegQ_4_3">490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree" scale="3" id="Tc_lRPePZXSSUG1zXdzsb253A_4_6">179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" scale="3" id="Tc_MZZXYys-aEuoBau7i09m0A_4_9">669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_3yLfgg9mAUqMBUjq0e4ASg_5_3">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour" scale="3" id="Tc_m8VIl7YbnEGUNKarBVvRbQ_5_6">142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" scale="3" id="Tc_x0m61xy1EEeO_8m0W5vi-A_5_9">688</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_JLGS1rq2_0qarazil8WnJw_6_3">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive" scale="3" id="Tc_rK8vVSN2fE-SRbm5NukYCg_6_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" scale="3" id="Tc_S41IThaLh0WTBC17hL-8qQ_6_9">710</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_LepEkuHf10mXi9Mjc-B8sQ_7_3">1,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" scale="3" id="Tc_ikcXezYRcUay3WSDBvz2ig_7_6">61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" scale="3" id="Tc_R3jzZ4T5Lka9YFqJXKaqAg_7_9">1,104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_IG9W7O0oz0uLIBU4skapew_9_3">3,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal" scale="3" id="Tc_L-f1GP4dKEK6hfvRWcObhg_9_6">936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" scale="3" id="Tc_cfARW3caUEGu3-Pqwy6zaA_9_9">4,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_EU2A7wWuBkucYE4eA-J-kQ_10_3">389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_xC2C7D2J00eiri1DRKjvlw_11_3">3,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_dKrVh06lfU-auK1pgrL-Aw" continuedAt="Tb_dKrVh06lfU-auK1pgrL-Aw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_THPbiQgb-UumAregDK_Q2Q">1</ix:nonFraction> million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock (&#8220;Series 2022 Preferred&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_-uulEswf2EOU3Yjcrnq5ZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_FNxMafJlhU-D6H3CN-fLdQ">0.001</ix:nonFraction></span><span style="font-style:normal;"> per share, out of the Company&#8217;s </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_pQdbo9JatkySdEtngX31eQ">1</ix:nonFraction></span><span style="font-style:normal;"> million authorized shares of preferred stock. Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (</span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_m5xJ-VdP5EGewGg_SkDIbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_N90-dCJ5pUyBGGIGYN_gFg">1</ix:nonFraction></span><span style="font-style:normal;">:1) shares of the Common Stock on a pre-split basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company issued <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_m5xJ-VdP5EGewGg_SkDIbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_u_ZHpZw-YEur-rgS3jeFJA">1,000</ix:nonFraction> shares of Series 2022 Preferred and received proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_m5xJ-VdP5EGewGg_SkDIbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="Narr_cNmRrRoPHU6M5p9-ZBedXg">270</ix:nonFraction>. &#160;Pursuant to the terms of the preferred stock, the Company&#8217;s Board converted the Preferred Stock to <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_kGxSOxgACUGRePau63QWAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_BTaL7X2Fy0KQBeZZGHNogA">40</ix:nonFraction> shares of Common Stock on July 19, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">iBio CMO Preferred Tracking Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_sAVoKqkVwEuYlSh556L0JQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Narr_Bcd2OUooN0KptfUS3PPWmA">one</ix:nonFraction> share of a newly created Preferred Tracking Stock, in exchange for <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_sAVoKqkVwEuYlSh556L0JQ" decimals="INF" format="ixt:numdotdecimal" name="ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" scale="0" id="Narr_znVcJJf_aUuBcbwkaCR5LQ">29,990,000</ix:nonFraction> units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_sAVoKqkVwEuYlSh556L0JQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_eNK0E2hVW0qsBYyYSxsGcQ">13</ix:nonFraction> million. After giving effect to the transaction, the Company owned <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_pjd-weRrSUC1EbGtOeMjCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_u8B8UX-Vb0ywfjLD5mlROA">99.99</ix:nonFraction>% and Bryan Capital owned <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_2_23_2017_srt_CounterpartyNameAxis_ibio_EasternAffiliateMember_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_UjXKotGel0yQY9BFBXctgA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_pAiUBofNcEy6Y7PII9eKJA">0.01</ix:nonFraction>% of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Board of Directors of the Company created the Preferred Tracking Stock out of the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_FwWIEJa9v0C2SMNLlbmbzg">1</ix:nonFraction> million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_xoNlaRhK6ku3VdMk_jLIIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_hwbnluXyQkC-ejEJo00cgg">2</ix:nonFraction>% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board of Directors, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_8uq-EWtWF0WoADmNPR7Tfg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Narr_7qev4LAbiUCHVDc8u2XK8Q">No</ix:nonFraction> dividends were declared through October 31, 2021. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_1C24-uZb10SvLErWVqmo3w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_9269YEhegkyVGjAingJLTg">No</ix:nonFraction> iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dKrVh06lfU-auK1pgrL-Aw_cont1" continuedAt="Tb_dKrVh06lfU-auK1pgrL-Aw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The number of authorized shares of the Company&#8217;s common stock is <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_1baBjGvk0EeBMwhUemt22g">275</ix:nonFraction> million. In addition, the Company has reserved <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_PlanNameAxis_ibio_OmnibusIncentivePlanMember_joWgB2aWOEyl8YJ2QrOPgA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_9_KHx4r1u0WHEye57vtPIQ">1,280,000</ix:nonFraction> shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#8217;s 2020 Omnibus Incentive Plan (the &#8220;2020 Plan&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company&#39;s certificate of incorporation, as amended, to implement a reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_NSsLunwOnk-e7VxuFTCjbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25). On September 22, 2022, the Company&#39;s Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into <span style="-sec-ix-hidden:Hidden_SIzvssG14kSIBSMx9LhFKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a <span style="-sec-ix-hidden:Hidden_E34AVy54BU-rs9CUNflyRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty five (1:25) reverse stock split of the shares of the Common Stock, either issued and outstanding, effective October 7, 2022. The Company&#8217;s common stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Issuances of Common Stock for the years ended June 30, 2023 and 2022 include the following:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cantor Fitzgerald Underwriting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&quot;Cantor Fitzgerald&quot;) to sell shares of Common Stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_PideCfI-jEiSzj_q8lGFBQ" decimals="0" format="ixt:numdotdecimal" name="ibio:AggregateCommonStockPurchased" scale="0" id="Narr_fY1_pDK7AE6xkjwww1dBNA">100,000,000</ix:nonFraction> through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022 and June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_KNMSVlZ63keio6WMZ-FPmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_UBD8jEkPaE-n-cgIsY1-rQ">5,782,871</ix:nonFraction> shares of Common Stock. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_KNMSVlZ63keio6WMZ-FPmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_g2TgymATj0aD9KUh_80-Qw">6.4</ix:nonFraction> million during the Fiscal year ended June 30, 2023 and holds a subscription receivable for $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j4x0PspL1UuXk5bJ7v3ZFw" decimals="0" format="ixt:numdotdecimal" name="ibio:SubscriptionReceivableCurrent" scale="0" id="Narr_scOHuLkw4E21e3LT4Tot0w">204,000</ix:nonFraction> at June 30, 2023 for proceeds received on July 6, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In Fiscal year ended June 30, 2022, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j-fx3hLA50uNFaaqQkekIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_F3JVKNKUM0-35m6K4ALpvA">175,973</ix:nonFraction> shares of Common Stock. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j-fx3hLA50uNFaaqQkekIA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_QvtobkQQZUuHAl2aEYoDDQ">1.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On September 19, 2022, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_Cv9PGmmvqkGnVfZIFMlTCA">102,354</ix:nonFraction> shares valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_dEqmtKqnPk2wqCpHRKBOvQ">1,000,000</ix:nonFraction> to RubrYc as part of the payment for purchasing the assets of RubrYc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Wainwright Underwriting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 6, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#8220;Offering&#8221;) (i) <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mX_BARMd50iV5vznznteBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_QevPjssoBEaKh0_B7A1BIQ">1,530,769</ix:nonFraction> shares of the Company&#8217;s Common Stock, (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ldHkHQ1HnEC1Bn3XAgpiXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_nLcnsbDCoE6K_L33Wxq8eQ">1,834,616</ix:nonFraction> shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#8220;Series A Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8w4IUbsDIki_jJ-9mVfRmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_YY0uzbu5IEq0kycrm0N8cQ">3,365,385</ix:nonFraction> shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#8220;Series B Warrants&#8221; and together with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8Im5yjRmNUarH6CaeVLVOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_nwq7-CQ5cUWWWbmTjFgSUA">3,365,385</ix:nonFraction> shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_RcSxNMoHXEuPH5gaHQojLg_1_0"></a><a id="Tc_LsmXaJOD5ke6SAlhCALKZA_1_3"></a><a id="Tc_IZAYgyfbsEO7fQYhogYdmA_2_0"></a><a id="Tc_DNmTTCQwCUGP1QZ8Yt7yig_2_3"></a><a id="Tc_EiJDrgga70y3F87osLz5dA_3_0"></a><a id="Tc_JRbHBg1xREOS-wsqdLGQWw_3_3"></a><a id="Tc_hiGOrKDVaE25xFJeWkoeYw_4_0"></a><ix:continuation id="Tb_dKrVh06lfU-auK1pgrL-Aw_cont2" continuedAt="Tb_dKrVh06lfU-auK1pgrL-Aw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg" decimals="3" format="ixt:numdotdecimal" name="ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" scale="-2" id="Narr_47G4wLodeEKK7pxMNejuKA">7.0</ix:nonFraction>% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a <span style="-sec-ix-hidden:Hidden_sSHbFN61YUW0p-uuiWxmGw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30-day</span></span> option to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg" decimals="0" format="ixt:numdotdecimal" name="ibio:NumberOfAdditionalSharesIssued" scale="0" id="Narr__glVWIJvikK-hRGJvp_H0g">504,807</ix:nonFraction> shares of Common Stock and/or Common Warrants to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg" decimals="0" format="ixt:numdotdecimal" name="ibio:CommonWarrantsToPurchaseAdditionalShares" scale="0" id="Narr_2Bn4LAusXUS0Stzr68_N1Q">1,009,614</ix:nonFraction> shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_7hZGnl4YaECwuy-_woxKIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_K7qSTBhYaky6YTqHPKVApQ">504,807</ix:nonFraction> Series A Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_br7oNpaVRECbzfYrlkkvkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_x4Wl0_Jx-0-tUW7_uVOEYg">504,807</ix:nonFraction> Series B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#8220;Representative&#8217;s Warrants&#8221;) to purchase a number of shares of Common Stock equal to <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg" decimals="3" format="ixt:numdotdecimal" name="ibio:PercentageOfAggregateNumberOfSharesOfCommonStock" scale="-2" id="Narr_xFdrraF4GUugjViS-BVlCw">6.0</ix:nonFraction>% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_tOoXZBADJEadNjNS6JvQtQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_8EaG3wK1skCT_IKZkJ-pyg">201,923</ix:nonFraction> shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_MxfSfJOzJkeMtljQsXxuRA">2,864,000</ix:nonFraction> after deducting underwriting discounts, commissions and other issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Vesting of Restricted Stock Units &#8220;RSUs&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bdlOYYhGck24BhiEx8F8Rw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_6tyEW5gL1EWvcr4JHwlOnA">217,553</ix:nonFraction> of Common Stock vested during the year ended June 30, 2023. RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nKpGtSGxbEyiWH4EXHdW8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_Q3__b_Aj20yw2_FDwsg3yQ">8,854</ix:nonFraction> of Common Stock vested during the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Exercise of Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_Mw9GYinnB0a2SlCSc1kLjg">No</ix:nonFraction> stock options were exercised in the year ended June 30, 2023. &#160;In the year ended June 30, 2022, options for <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_IrnxZ9Z-GUGjvFnHipnOXg">3,380</ix:nonFraction> shares of Common Stock were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bryan Capital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued to Bryan Capital a Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_KUhSpp2yXUmuN2SxNzFOPg">51,583</ix:nonFraction> shares of the Common Stock of the Company at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_z1o8omyLF0afPerPZawv7w">33.25</ix:nonFraction> per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of the Warrant using the Black-Scholes model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_o77NiAlVOUOqpWUlIgvjbA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_rZ1rHQ0ZHUSWW77arLucKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_r7V8IalV1kWwwwsbgEA0QA_1_2">0.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_8k_8F3ieCk6zFGf27VtTEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_Fd0gD6kCLkOVqmBQx-Z4Ng_2_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_M0zc34V5Q0m5WCVOKFey5g" decimals="1" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_CiCmbGtpw0K38h8xZhVAaA_3_2">136.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C3bH4V8Ib0S8XH9UELJ_gw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_bEWZN6GCnkefoEvUvo8YCQ_4_2">4.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Wainwright</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">As discussed above, the Company issued various warrants with the following terms:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pre-Funded Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_i1SOU2raCEu41QFjJywLPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ngJDZh78p0-yNx_qECykRw">0.001</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class A Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_Zw6WafGCsUCnHKMzdWedpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_C3wAfFMKNkaoUjZDMKtSbQ">1.04</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_Zw6WafGCsUCnHKMzdWedpg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_YzNJThSxhUOv3S5Bnnz_rQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class B Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_oMAsA2QZvk2xKNG3oHvjzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_P8g6ZmEtCUu9tWQ-t0FRMw">1.04</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_oMAsA2QZvk2xKNG3oHvjzQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_Iq8Vua5JIk2zh25RMoneOw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Representative Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_m9_bmICRfkK3AwOGcAYudw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_nJgwu2P0UEiISu3SPPiNiA">1.30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_m9_bmICRfkK3AwOGcAYudw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_nh_ki10qdkurLeLtZkWn9A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dKrVh06lfU-auK1pgrL-Aw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_X8mbSSFy70ubOrSPbND4oA" decimals="0" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_4yugBz_yw0CVTlaloMwyJA">341,300</ix:nonFraction> Class A Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_aSOPBLDfl0qZrWSm0hH1mg" decimals="0" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_vezw9h-h5UCNkxmmwNTUqg">1,781,216</ix:nonFraction> Class B Warrants were exercised. The total proceeds from Class A and B Warrants exercised during the year ended June 30, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_-HXRfzZt7EeeqOAod_TF_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_6XYjqe8UV0mLJyhcwPMFyg">2,207,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_O9UHa1q5u0uVaR1ViiQn-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_E0rfPNRudEOrYT0v4UqOqw">3,475,916</ix:nonFraction></span><span style="background:#ffffff;"> shares of common stock and existing Series B Warrants to purchase up to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_TBHg74MkiUewy0H-HarEhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_iSBckdZ5f0q94U635Qp9Bw">2,058,000</ix:nonFraction></span><span style="background:#ffffff;"> shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with </span><span style="-sec-ix-hidden:Hidden_CLcT6POV_06On0uZXB8YcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise</span></span><span style="background:#ffffff;"> prices of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_iwp_hRW6o0erhC__pkGDFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_HRgpm5XqCUKOsQDfIynULw">1.04</ix:nonFraction></span><span style="background:#ffffff;"> per share (the &#8220;Existing Warrants&#8221;), to lower the </span><span style="-sec-ix-hidden:Hidden_uJKhf1drZEWLizl1NaG14A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise</span></span><span style="background:#ffffff;"> price of the Existing Warrants to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_O9UHa1q5u0uVaR1ViiQn-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_u9o1lcb5DUyyzwoOUh91zg">0.50</ix:nonFraction></span><span style="background:#ffffff;"> per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk83294679"></a><a id="Tc_f4gjMA8qykC-UOLzk5pI4Q_1_2"></a><a id="Tc_YfIP9nsp80CDmafhyq2SlA_2_2"></a><a id="Tc_NS6hhNmmS0-T7vvO3JapWw_3_2"></a><a id="Tc_pUnIIBgMwk2-eH504dKTyg_3_5"></a><a id="Tc_v1nhBpCeiUuFiMGXLZZRug_4_0"></a><a id="Tc_A0-06YPY3k6y2fOMDYh8hA_6_0"></a><a id="Tc_SBsllIE0ME-PWORqj1nBZw_6_2"></a><a id="Tc_zEgdCfMQeEmRxAuh4W7fww_6_5"></a><a id="Tc_NMFaU7rEIE-geCRfc7WiKA_7_0"></a><a id="Tc__v4UHzPB7U688NW826o1YA_7_3"></a><a id="Tc_RU-41elZLUWOaDCyMED0Lg_8_0"></a><a id="Tc_IMJXkkWMK0C_du5D9gaYLw_8_2"></a><a id="Tc_DEX9iDUHc0ml2ynd-xOYTQ_8_5"></a><a id="Tc_U2q-SJ4HhEu9wWBnCSxNnQ_10_0"></a><a id="Tc_spmgjSyfqUChhbwEpuuyeg_10_2"></a><a id="Tc_LzJ8JTAHeEmXHUkBDkelOw_10_5"></a><a id="Tc_-izUtFDohUWR__I1jIcpqg_12_0"></a><a id="Tc_7K9Rop8Vak2HtN1_CkvPHg_12_2"></a><a id="Tc_Exjky0wJ3EuK0x99P7w_uA_12_5"></a><a id="Tc_KhLTW_4thUWEcszPy5a97g_14_0"></a><a id="Tc_VPomBlVMmEu_EzL9efV8cg_16_0"></a><a id="Tc_gQA28pWwDEuFciqbmEYbrg_18_0"></a><a id="Tc_I0emeTQwMk-itrUuWMKrQw_19_0"></a><a id="Tc_gnSOk6GPTUKK_STpZAgY1w_20_0"></a><a id="_Hlk83294698"></a><a id="_2f7e6719_1a22_4ddf_bd10_83cccf4e62a8"></a><a id="Tc_5o4y6Ntd_0qqz4aqjjBevQ_1_2"></a><a id="Tc_hNuauYyvkUKLord1QXvi9g_2_2"></a><a id="Tc_x-h5UyWPXEWdFx30Z9OWgw_2_4"></a><a id="Tc_Q4p_BrplWEavBZKk7rWzcA_3_2"></a><a id="Tc_v9KREJtDgE26prohs9ScVA_4_0"></a><a id="Tc_df_m_K60XkCeLocCxhawqw_5_0"></a><a id="Tc_v6vBzxEDMkelOT9nCg7VQg_6_0"></a><a id="Tc_08m-8xaScUi38LGDk5P-JQ_7_0"></a><a id="Tc_3giFsRtyk0y1KGoQGttBEA_7_2"></a><a id="Tc_zOoFgb6R6kayB0aXwETUWw_7_4"></a><a id="Tc_lrEP1lh2KkW8a3G54fMOZg_8_0"></a><a id="Tc_dzwbvYU-JkquGvcsidGZLg_10_0"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_nqqeo6vCvUOM4bmFG3_fpg" continuedAt="Tb_nqqeo6vCvUOM4bmFG3_fpg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18.&#160;&#160;&#160;&#160;Earnings (Loss) Per Common Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Group_XA6L3cVMN0-FlMbM-VRE0w" continuedAt="Group_XA6L3cVMN0-FlMbM-VRE0w_2" escape="true">The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</ix:nonNumeric></p><ix:continuation id="Group_XA6L3cVMN0-FlMbM-VRE0w_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_2k6503CmK0ehwbDFIHwwUA_6_3">29,311</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_SYlBDDQmz0Kfcbr75HlGpA_6_6">29,512</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_-WTs_vNgSUOVeWUZvlomAg_7_6">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_Ol7GrSPOPUSS3Tk181kokA_8_3">29,311</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_iMG3hPyNdkubjBNVgVZFAQ_8_6">29,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_KPGvlq04Pkie70BDsq52lw_10_3">35,699</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_lAI9XDLobUyUvJFrCYgIFg_10_6">20,791</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc__1pAefXP_UqSLTih6TRvmw_12_3">65,010</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_7Nrkm0ewlE2DYz81Qfkv0A_12_6">50,391</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_6_2foJVt4USGLUE-lUuDIw_16_3">12,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_8xBaKZRSbEqvfjh6j82-oA_16_6">8,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_VSCcaFQWPEqZ6HuNP22L4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_yiwgO4hC7EWd9Hs58c9FYA_18_3">2.39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_szGXjMD-xEyf9K1Eh278Xw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_UnQhKQZNJE-x-9YtxF5Wpw_18_6">3.39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KWCju4zEm0OFrF28ztSNUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_OFo_RNBjs0qLGa0fybUf4Q_19_3">2.92</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_g9LgYZJp_E2abMmTXdVUKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_W3TDFMCtGUaNZz85qi-Osg_19_6">2.39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NyTbTzFAwU-jeS3gdyqc7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_NoRDGRjlw0aUSa0y4joS_A_20_3">5.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_GSNMn7paDkWrRL314FWinw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_u0RdGmHXQUaR4RwDUVSs-A_20_6">5.78</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_qA9ie3Sxm0O7Vrx761hMeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In Fiscal Years 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June&#160;30, 2023 and 2022, shares issuable which could potentially dilute future earnings included were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_vveLDkXdfkmYnuPBTD5qQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_-3pZV8rGck6GYBT1XUHbng_4_2">292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_OAl5YM-9vUiYev8izSQcBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_AlTYNoBR6EO3EF0HFuUsow_4_4">622</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cUS-0Y50wkGSIGh6RCynOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Rb8jlkfTsk6KSRnzTJpw0g_5_2">248</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_17hKRS8vdUK0th6qBY6JZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_bK-TZlOacUKlmHbgTnwACA_5_4">51</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_2Unp8yCqvUWviC4g1sxLBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_MCgAcHu21EyIoh_OvjHBXw_6_2">5,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Ak8TEYVQm0SAkhapZ3V0_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_SI-0nDFA9U6zD0-Ux3HVsg_6_4">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series 2022 Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_bdhiK2hZHEubNq6Ukrfx9g_8_2">6,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_6PKLvXcBu0GgUMdGxmmNDQ_8_4">694</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">*  Less than 1,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nqqeo6vCvUOM4bmFG3_fpg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk83294726"></a><a id="_026393b5_0030_4f21_9ed1_f1b83a4949fd"></a><a id="Tc_DbpKAGPJsUijyYV2llcGpg_1_2"></a><a id="Tc_tILYhA65GUSTY8XHaEI1WA_2_2"></a><a id="Tc_lZmIEfG3aUGmD9nJ-vRALQ_3_2"></a><a id="Tc_kZzzTFRcnkadb6blbe3jAQ_3_5"></a><a id="Tc_K3IXJsFPSkC5rlsGH9hkQw_4_0"></a><a id="Tc_4oPDS9nabUmKrQuAdJNu0Q_4_2"></a><a id="Tc_Fw4KOYzQR0OwtNFNY0-j0A_4_5"></a><a id="Tc_jzXt4v61hUGimDdx6c95UQ_5_0"></a><a id="Tc_fjRFH-Qi4UuTVfU7fYzqyA_6_0"></a><a id="Tc_4_2V6ZqRuEiAmYycFlDPog_6_2"></a><a id="Tc_oUTYjhYZZ0ey5o-cMyYbnw_6_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb__QFdWjozr0WfEQRXaagocw" continuedAt="Tb__QFdWjozr0WfEQRXaagocw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.&#160;&#160;&#160;&#160;Share-Based Compensation</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_itnhX5NbfUeS0IY2E6BH2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-cLI1L4-PUeoHAyAedVjig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IULbm_8D1kOVv6AC3Iye8g_4_3">149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7JFoPwEFAEm9j_JAvuBOqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_stEvdIgAqUyN27JNR1-DSw_4_6">182</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_L1pakgn-HEqXSQrFTkRD1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HAUaHKc4zkChptg0xu0EcQ_5_3">2,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_F6t0DfzkFkyMeMWVv6D4Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_G3mIBZHKF0KgFhUXw1O5Xg_5_6">3,776</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_MNuJ4nqfvUC22u93Kp5mGw_6_3">2,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6j5Mm8bBy0qebva1pEtoGg_6_6">3,958</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember__JoTwj7JekqGkccr8jaLLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_bWlxFkn__EW703Oiy-vELw">1,528,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_lUPOZKyWjkGiiwoG4yyWyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_3UxZH0lpqEmMAg8JlVhMBg">419,000</ix:nonFraction> for the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;) </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9KRNjiJqDUK-i_ivBqGgvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_EyccetOkmE-sTtlw6uRPYg">1,280,000</ix:nonFraction> shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9KRNjiJqDUK-i_ivBqGgvw" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_IL43iiEgDUWOfV3eK4PygQ">500,000</ix:nonFraction>; provided, however, that such amount shall be $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HptY7B29EUeK8ToPssBmJg" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_U3pLdzsOZEONlTgmHQanIg">750,000</ix:nonFraction> for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_TkpAIuZ6B0q3R1zaoy1iDg" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_PrmfB5nahkmjOHKb4pw3qQ">1,500,000</ix:nonFraction> for any non-executive chair of our Board of Directors should one be appointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Vesting of service awards is determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally <span style="-sec-ix-hidden:Hidden_LToFWvo-BkiblBBqRkPxFg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or <ix:nonNumeric contextRef="Duration_12_9_2020_To_12_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_TS5Xb__b0USUWuxhMopskw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_gMZwOEgzfU-l_nuI82oxwg">five years</ix:nonNumeric>, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Issuances of stock options during the year ended June 30, 2023 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2023, the Company granted stock option agreements to various employees to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9bo96afqQUqvQatv96XUtg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_MbtPISlZwEehX0Ia8OJRhA">303,869</ix:nonFraction> shares of the Common Stock at exercise prices between $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_xtVTtCXFJ0G4QbVCIxGD0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_r69_6Vk8qEKwdeLVoy91PQ">6.75</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_2Y54sBBMcUylpJ4aaoVljQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_itEizcfnw0Kqga2UHTCpEg">9.50</ix:nonFraction> per share. The options vest <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9Cz54lZIsEqkhtb-zVdBsQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_GE0Yc3-LwEOQKolYw6FA2Q">25</ix:nonFraction>% after <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9Cz54lZIsEqkhtb-zVdBsQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_pE22ZMewBEWffeEBnULK0Q">one year</ix:nonNumeric> and then in equal quarterly installments over a <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_N5IDTAkcGkqXFW4wZwmQCA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_0LHzP_1VIk-HAQlFLqKWjA">36-month</ix:nonNumeric> period and expire on the tenth anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_aQMKS-a1cUKkGuXWIbzRCg">4,000</ix:nonFraction> shares of the Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_WKUi-G2J5US8stdTlX-eTQ">6.75</ix:nonFraction> per share. The option vests in equal monthly installments, over a period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_pGbeNi5lRk-czvmFtop12g">12 months</ix:nonNumeric>, starting after the second month and expire on the tenth anniversary of the grant date. &#160;During the third quarter of Fiscal year 2023, the Company terminated the consultant&#8217;s services. &#160;As a result, none of the <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_2f36iHzMBU-qLt5aWb74Uw">4,000</ix:nonFraction> shares pursuant to the stock option agreement were exercised and as such, all <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ENEaA-fTBkS1TjbeQgRAHA">4,000</ix:nonFraction> shares will be forfeited. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Issuances of stock options during the year ended June 30, 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">During the first quarter of Fiscal Year 2022, the Company granted stock option agreements to various employees to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_YvKXv6XQlUSg6GU05Ezz1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_NSM-VYqW6EyFLFJzgA1UUg">165,488</ix:nonFraction> shares of the Common Stock at exercise prices between $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_xCmsPvHt_0-4XRMWv2OvcQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_rIRFJrt_fkG2LuLlGaoq7Q">26.50</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ZsC7M5TDO06bqBrcL1vesg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_hT_BckjUxkO7ewV6FKPn7A">33.75</ix:nonFraction> per share. The options vest </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_60b39852_dff5_4389_8efb_4d2a5021df35"></a><a id="Tc_zZS8mlGs1EKpd8c4agXYsQ_1_7"></a><a id="Tc_qYrCFH5lIUe7YOP1K7QoSQ_2_4"></a><a id="Tc_hIvJLgXO4Em21NOhzRiyGA_2_7"></a><a id="Tc_vUP9GsXZDkOq0gDVocHcng_3_4"></a><a id="Tc_4dOE1xsY502UzJGSA5FQLQ_3_7"></a><a id="Tc_tnENMPUbLU6OiqxtOkVBow_3_9"></a><a id="Tc_hKp4jK-N-0KY1jzrJzsxtw_4_2"></a><a id="Tc_TlbJ38IfrU-ikDQ_HU37Rw_4_4"></a><a id="Tc_6dLmQelWyE-BoV4DHi7CbA_4_7"></a><a id="Tc_yhiv2tQJBUmnKdbqH4VBuQ_4_9"></a><a id="Tc_bTeooT9z-U2i5aH_JN0r8w_5_2"></a><a id="Tc_By-mlGsgMkaC8ovoLirlag_5_4"></a><a id="Tc_NJu6nQj2rUmT-8GE4hyjrQ_5_7"></a><a id="Tc_sL9JoHd560G8yLj0eqTkoQ_5_9"></a><a id="Tc_nMgfil_xy02z4ue0JQl-eA_6_0"></a><a id="Tc_XYTt-xg9jUOaNG2ijjrqIg_6_4"></a><a id="Tc_p6JVgtI3GEqX_1r2WM4JFQ_6_9"></a><a id="Tc_EvTXe9vgMkun-VLfDTZRzA_7_0"></a><a id="Tc_1oBPCg9lNEaTbpnayndUmQ_7_7"></a><a id="Tc_fdSJVWNQAEOMNEXomtNQGQ_7_10"></a><a id="Tc_cTVL_vB7qkiITnUtRDp_og_8_0"></a><a id="Tc_q0D_3FOXaE-dQNTRvvrZew_8_7"></a><a id="Tc_DVjZUEVsC0S9Mm_D_bEOlg_8_10"></a><a id="Tc_siwUArhHoUGNz0WK8RiPYg_9_0"></a><a id="Tc_yyo43wA0H0KnFCGnPItspg_9_7"></a><a id="Tc_5Sg0EG7wdUm8iUA8cKejJQ_9_10"></a><a id="Tc_4sgt4r4QXEa9D8H0SPgA3Q_10_0"></a><a id="Tc_UTzaFGJ9ekqU_TUOGJdD1A_10_4"></a><a id="Tc_QjocRxeDQUqEOCkZ-1T1zw_10_9"></a><a id="Tc_wxpXlmndnEmN3S-JotUK1w_10_10"></a><a id="Tc_ecTaZbnuF0GgJRzcwV3lzQ_11_0"></a><a id="Tc_hECbY03Orkau8B30aMh7YA_11_4"></a><a id="Tc_wo-fF-TRiEmE-T8QZTJSZA_11_9"></a><a id="Tc_xJqwaULYWU-HOQZNRkJ55w_11_10"></a><a id="Tc_fF2n80oWYkOf7OiSgxgDmA_13_0"></a><a id="Tc_qFMZ63AOUU6ST4ZLIgUD5Q_13_4"></a><a id="Tc_1O3TKg4me0ulAET_B9ISWg_13_9"></a><a id="Tc_TfwlFb8_0kGSItokuh84Gg_13_10"></a><a id="Tc_WrDsHzKBfEu_3kyV32NhTQ_15_0"></a><a id="Tc_JAqf8asrYEioWX6rts78MA_15_4"></a><a id="Tc_qeeT9BI4bEedIp9tHbowJg_15_9"></a><a id="Tc_b5tNiJ86lUK5JJJlo2kVIA_15_10"></a><a id="Tc_z-Eh2sDP9k6iMzD-8jefpQ_16_0"></a><a id="Tc_i9kUU6GnVUuF6YUJ0lKReg_16_7"></a><a id="Tc_FECH85wK6U-fgYIf25RmdQ_16_10"></a><a id="Tc_GJodHTrV_0ivgYSWIN6rOw_17_0"></a><a id="Tc_7O7TRZptkESeW0YY-v8ZqQ_17_2"></a><a id="Tc_OaQ1gu2F3k6pZUDz1xxkUA_17_5"></a><a id="Tc_Z6eU09mQq06k8yYXv0h2Iw_17_7"></a><a id="Tc_7W5kmNvuCESFRxmZjIfwNg_17_10"></a><a id="Tc_oT6R68rdxEeWwLPp_od26g_18_0"></a><a id="Tc__D_IGLl7CEWGvatrPrpcdA_18_7"></a><a id="Tc_X9KK37VThkO4JkcF_stLcg_18_10"></a><a id="Tc_JL5su-gKlE-yEVKU0P-vsQ_19_0"></a><a id="Tc_W2VCESd_zkSsqqM5p59KrQ_19_4"></a><a id="Tc_UGy2dVwf9kmcd1A2nZMURg_19_9"></a><a id="Tc_ySy__2-Dr06eLAouZqTMPQ_19_10"></a><a id="Tc_Nv3i8nJmt02Kn-ljoezJEg_20_0"></a><a id="Tc_wzhk_GIfRUOpd7gM1LpB0g_20_4"></a><a id="Tc_SLUTiqj1Uk2cJadJ-jBssQ_20_9"></a><a id="Tc_AOoziOLw8EWwLRFSMV2asw_20_10"></a><a id="Tc__pEIemUv6E-37LvYJydwtw_22_0"></a><a id="Tc_jXJpn-m4ykGrWbdh0Oe9Ug_22_4"></a><a id="Tc_9PaNsixcyUCisGy1twfmUw_22_9"></a><a id="Tc_TcZClA-u80ee6FFj7cAbWw_22_10"></a><ix:continuation id="Tb__QFdWjozr0WfEQRXaagocw_cont1" continuedAt="Tb__QFdWjozr0WfEQRXaagocw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_YvKXv6XQlUSg6GU05Ezz1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_oHadQMvhwkW26SUM01rFGg">25</ix:nonFraction>% after <ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CSnFR5tK_UmMcPFIliPY2w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Y4Ja4KXroUaKWtiaW6TCvw">one year</ix:nonNumeric> and then in equal quarterly installments over a <ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_sbtMBgPfE0GQWHaJX1zw5A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Qqcp4w3SE02PhQX4MsSC3Q">36-month</ix:nonNumeric> period and expire on the tenth anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2022, the Company granted a stock option agreement to a new member of its Board of Directors to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_BoardOfDirectorsOfficersAndEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_3f1m_cPO-0Ki-AKnAQsaNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_TDsFuEzmi0epQNndyN8JIw">4,000</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_BoardOfDirectorsOfficersAndEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_3f1m_cPO-0Ki-AKnAQsaNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_0jqHTIWxSEul8Af_MFOYAw">31.50</ix:nonFraction> per share. The option vests monthly over a period of <ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_BoardOfDirectorsOfficersAndEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_3f1m_cPO-0Ki-AKnAQsaNw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_VcQhTDouFU2pWrtk5Xkm1g">three years</ix:nonNumeric> and expires on the tenth anniversary of the grant date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2022, the Board of Directors approved an option grant award to Mr. Isett to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ibio_IsettMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_e88Xq6AsD0WbXCbo4ZpVbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_tFoiHSe6EUabRtmFWWQvpQ">80,000</ix:nonFraction> shares of Common Stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ibio_IsettMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_e88Xq6AsD0WbXCbo4ZpVbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_uqMrom1y5EKq8gxgf8FScw">29.25</ix:nonFraction>, which vests in equal monthly installments over a <ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ibio_IsettMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_e88Xq6AsD0WbXCbo4ZpVbQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_RnArTuqgrk2hz8jWb9EsuA">36-month</ix:nonNumeric> period following the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the second quarter of Fiscal year 2022, the Company granted a stock option agreement to a consultant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_29aKQDG9Jk-9VeYaA8v7cw">4,000</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_2RCQC4nuGEWC7C8SKMS_SA">21.25</ix:nonFraction> per share. The option vests over a period of <ix:nonNumeric contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_lZiIYcKuEEyAg8CasaPvlg">eight months</ix:nonNumeric> commencing in April 2022 and expires on the <span style="-sec-ix-hidden:Hidden_0OdVFTQWiE-Lr_bsSKBPmA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the second quarter of Fiscal year 2022, the Company granted stock option agreements to various directors to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_VWpflBnKMUSOgPXIJVhq_g">34,880</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_aIAbx8TctUaVdjmE-EzZTw">17.25</ix:nonFraction> per share. The options vest over a period of <ix:nonNumeric contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_UsD26BBA8EmaCR86BGGutw">one year</ix:nonNumeric> commencing in January 2022 and expire on the <span style="-sec-ix-hidden:Hidden_mpImJhbCfEK69FYXeZdXCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third quarter of Fiscal year 2022, the Company granted stock option agreements to <ix:nonFraction unitRef="Unit_Standard_item_hCBMRpViQ0aEEJdOwEy49g" contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfConsultantsToWhomStockOptionGranted" scale="0" id="Narr_0yeiJg-MC0msfZdEMHbXew">two</ix:nonFraction> consultants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_h26T-HqYTEqo72EGujYHjw">1,200</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_e5_ylYm-dUGlXaMJM_0v8g">13.00</ix:nonFraction> per share. The options vest over a period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_XVpnmz7SV0eO1fNU0Arm2w">12 months</ix:nonNumeric> and expire on the <span style="-sec-ix-hidden:Hidden_z9rBFPXNl0qc-K8BGo9Big;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span>th anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third quarter of Fiscal year 2022, the Company granted a stock option agreement to various employees to purchase <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_XbzQngOnPkuMI19LjLTR6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_WeOZp_LLNE6qydwXb5z2FQ">24,000</ix:nonFraction> shares of Common Stock at exercise prices between $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9AU5LSHRJ0uhtE7EOzns8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_yg8z7m7Q6EeyvLxmCdLy7Q">8.50</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_1_1_2022_To_3_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SHgrCz-qZEG92jvNuUFSAQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_ZfaYQvD3-0m30Pq22id5Kw">11.50</ix:nonFraction> per share. The options vest <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_XbzQngOnPkuMI19LjLTR6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_r3GoyThD8UawZCA2HyPs4A">25</ix:nonFraction>% after <ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_VGPTPTFClUWUEjRTn7IMzA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_L8zO6dbYwk24P3hWWFeIvg">one year</ix:nonNumeric> and then in equal quarterly installments over a <ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_XZG8-Y3yAUK2kmzzd5QisA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Y3eMqsQik0St6IJ5wk0ocw">36-month</ix:nonNumeric> period and expire on the tenth anniversary of the grant date.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_rRkhrEG7Aka7aIzZ5l9r7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes all stock option activity during the&#160;years ended June&#160;30, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term&#160;(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of July 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ERBN_qHQ9k-E8vS114Jxrg_6_2">341,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ZGkct8CFO06pkVqy4KuyKQ_6_5">32.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2020_To_6_30_2021_uOAx-6C-q0ysOGltI-sj8Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_emoGxMKWD0GVAnJvhg7trw_6_7"> 8.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_Owlvj_LMvUi8K33WnE0Nbg_6_10">1,995</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_MBynxYyLtEuqLLnOxOz0_A_7_2">313,568</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Lk19T9tvPkGpcSXIoS6QrA_7_5">27.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_xCJkdH1_B0So_SErY0O_4w_8_2">3,380</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_apf8MyrHo0-dtwfFVZ1xcw_8_5">22.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_IRqBvUzVLUCCRbMsWKtSyg_9_2">30,068</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_eh3pvqQdfUWVRODnUC23QA_9_5">35.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_tK6CLeS26Ui5VVUeWM38FQ_10_2">621,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_BKAw1xjnDUGXWEK0TAaBSg_10_5">30.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_2tYJRHBDf0WpXRfqPeVydg_10_7"> 8.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of June 30, 2022, vested and expected to vest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_LqoEhWxAXU2CKWeQEpdnYA_11_2">620,810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_XQ0BNJgfM02zECcSpMIWvg_11_5">30.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_EUoTJsRwqEayRIk58lPcwQ_11_7"> 8.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_Z3MQ0DrVIEO1k-Tsh2dp1w_13_2">197,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_RBg53GSKsE29tJf21hc5vA_13_5">29.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_d8KkA2Te506p9fAPCz5NEg_13_7"> 6.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_fr047q7i_Uey7NUvKUxxOg_15_2">621,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_gXLlHGaKOkq2ohUak0eSCQ_15_5">30.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_7zV6GHZMa0yMpuG8N6OcHA_15_7"> 8.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_Eq_55V0TaUyX_IbBG7cCcw_16_2">307,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_n7ygtLyvLUGN-XKQKRkYyQ_16_5">7.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_n9z6f4rEN0iBN59P4FKkpA_18_2">637,191</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_pY-07zuXEEeht_UjKqu5Yw_18_5">23.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_MVXNjjlcdEicShScFag5QQ_19_2">292,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_oYxn1411Qk-i1a3Ejt4L4w_19_5">19.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_zdj-aMKOQkKvh5TgvmtFwA_19_7"> 8.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of June 30, 2023, vested and expected to vest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_joScF8Lfo0yRScXqYUwWOQ_20_2">292,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_IeN3K9tdc02UyjjXrOY8xg_20_5">19.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_Q-AaMCCFd0OxOve6IJ36mQ_20_7"> 8.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_oOGrO2pUUkmUFJ1XP6liMw_22_2">96,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_wR78Ngy-N0OXW2uXEjfHGw_22_5">29.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_A33FIJ051kK1aHLIpQlVXQ_22_7"> 7.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_21d006b9_3ce6_4b79_92c1_fc1fbe2eba0b"></a><a id="Tc_dox9rz6_RUKiKlMIMb2qZA_1_2"></a><a id="Tc_97gAPBnRoEyGtzzmp0IwBw_2_4"></a><a id="Tc_z5R7WVaTSUyUZgwG_pLJwg_2_6"></a><a id="Tc_lUPVLjTmD0SVFBpnmiwcOA_3_4"></a><a id="Tc_wHKjtKl72kWnNfukWAbZBQ_3_6"></a><a id="Tc_qzOHyeflDkyK2X0pWlBfDw_4_2"></a><a id="Tc_zaldVeYuPUus1AJNY85LOQ_4_4"></a><a id="Tc_7cI4-XOgdUaAtL0t1mlMug_4_6"></a><a id="Tc_fcVu2zqeyEajuihxiS1Z-g_4_9"></a><a id="Tc_mmyJIAQ1OUOmCly2TPjEww_5_2"></a><a id="Tc_-BOHH6hwcEmilifPQLUjiA_5_4"></a><a id="Tc_QTyaBy5inEicS2MWMJJrHA_5_6"></a><a id="Tc_6dBpo_MeZ0C8VpA3aAYgiQ_5_9"></a><a id="Tc_EH2srZEetEe9Di1drBg4fQ_6_0"></a><a id="Tc_Ot9KMTp3yk2laJEidsru3Q_7_0"></a><a id="Tc_mEtOs9TJekW60g6Gq-8F0A_7_6"></a><a id="Tc_aUAat-a5lkScbOD-L2W4mw_8_0"></a><a id="Tc_NH-deDTiXkK7e0HwT-rhLg_8_6"></a><a id="Tc_iiTg1zo580uj-XXKWvBx5w_9_0"></a><a id="Tc_CrK_O1jdSkiymeAdB4IUjQ_9_6"></a><a id="Tc_LKQaad1J20i9YjyPkgr9LQ_10_0"></a><a id="Tc_rAUQCQJa0UCOO-VRcRKPqg_10_6"></a><a id="Tc_imxbRbwtG0u2H00YCS32ig_11_6"></a><a id="Tc_FxwPmXdTaEiP9uqRK5UbGg_1_3"></a><a id="Tc_dtzmykMCvE2ozHH-8bXGlw_1_6"></a><a id="Tc_OWekmNXKAUuEmQh8r59Mwg_2_0"></a><a id="Tc_3yUi6hr4_02UMrH4h1AoFw_2_3"></a><a id="Tc_JHWpIfU2B0SlA6xIHV_uPA_2_4"></a><a id="Tc_7REJoW2byUGM4cDJYGAjFA_2_6"></a><a id="Tc_2yj_iPgSXkCbgE3kT77mow_2_7"></a><a id="Tc_odSwgW6oGU6hYZdcXdz0DA_3_0"></a><a id="Tc_JHmaP27BoEe0LLg9Fwns_Q_3_4"></a><a id="Tc_dHAHIHm-uk-ANGd56-226g_3_7"></a><a id="Tc_XhqP9CpsJU-IG6LwnVP5ag_4_0"></a><a id="Tc_hSCk0kyxN0SNbNgaT6wLMA_4_3"></a><a id="Tc_IW-bz80JNkyYiUV1A4seAA_4_4"></a><a id="Tc_RCKeRTIn3EmCgZE0p_i7NA_4_6"></a><a id="Tc_l7c6-7V4GUCGQF0blzOZfA_4_7"></a><a id="Tc_4IFcmRhsk0Cpql79XdjmDQ_5_0"></a><ix:continuation id="Tb__QFdWjozr0WfEQRXaagocw_cont2" continuedAt="Tb__QFdWjozr0WfEQRXaagocw_cont3"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="Tb_NeD17pLQ-EiZLMylTbTETA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes information about options outstanding and exercisable at June&#160;30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:65.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise prices:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_DhwMK66Jc0W1ZHFYrQtkXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_9SDSxRulPkGC7_UtMgxPzg">7.00</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_DhwMK66Jc0W1ZHFYrQtkXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_68EUuno1PEy414CDiRDPxA">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_ygGJi-7VwkSgwUh8hFlAmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_2yMEQBgeUkWAvbPfrG7zTA_7_2">151,309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_DhwMK66Jc0W1ZHFYrQtkXA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_7Z0kjpB3ZE6EXV-6YbvF6w_7_4">9.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_ygGJi-7VwkSgwUh8hFlAmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_O_uUp0PYs0qj2oj2n2wo-A_7_7">7.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_ygGJi-7VwkSgwUh8hFlAmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_0lWFZw4CokaxAeFBxdfaww_7_9">6,250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_sM74qrP0cUKZ4Ya1U1gVYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_2no3n3htYUeSn2TygBg-Uw">17.35</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_sM74qrP0cUKZ4Ya1U1gVYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_nh2WBoCWMEmSi3er88Nf0g">26.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_FzOe7EM0YEaXLo9qcItmHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_LWvao9nAR0Of-nOkwTmZEg_8_2">29,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_sM74qrP0cUKZ4Ya1U1gVYg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_psVC_i4GRUqVtmJvtaG8Ig_8_4">7.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_FzOe7EM0YEaXLo9qcItmHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_V98zwPs-HkyvwwtodFyCvw_8_7">18.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_FzOe7EM0YEaXLo9qcItmHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_3WGDax6I6k-1nou6-3nZKg_8_9">29,652</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_QgG8WNbPyUmBAvmup53SMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_YvD7YObulU-KjzWbWupMnA">26.50</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_QgG8WNbPyUmBAvmup53SMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_DAzSbWulAkOsvyHCVXMxwg">39.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_E7yiwtNsC0mz-2dHsOptEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_mczotPT4m0yWRGaRnSLW5Q_9_2">95,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_QgG8WNbPyUmBAvmup53SMA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_v_OJNkg_gE6Pg-akRemMAA_9_4">7.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_E7yiwtNsC0mz-2dHsOptEA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_fHzDLj0IuEKKkHKinBnW-g_9_7">33.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_E7yiwtNsC0mz-2dHsOptEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_ltS_kvl5tU6B5JrX9qX7_g_9_9">47,483</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_JqlBsxB3WEy25nmRrsywXw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_4iOEgWOFTE2GL_am5Od3Fg">41.25</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_JqlBsxB3WEy25nmRrsywXw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_LoQhd_WTAES9kmmoWngahA">61.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_ac-7x3LW9E6Qyh9TSY9ZPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc__PZlPt7LvEe4JW2G8gIlIQ_10_2">16,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_JqlBsxB3WEy25nmRrsywXw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_6BQ6S6R_hESTLDJcza_opw_10_4">7.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_ac-7x3LW9E6Qyh9TSY9ZPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_ydlTTwrVM0mx1bYH9meIKw_10_7">48.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_ac-7x3LW9E6Qyh9TSY9ZPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_GN-0UGOr80irNQbbpkLF2g_10_9">12,665</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_icrmcFW9e0SOHltDlJrxWQ_11_2">292,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc__sWmaIhvZk6_3nexmVqtDw_11_4">8.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc__iJ8pT_ypUC-Ek_mqBMQqA_11_7">28.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_N8OAHYWaPkC05EouYIgiYw_11_9">96,050</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The total fair value of stock options that vested during 2023 and 2022 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr___zHDxZ8kEG63xx9Ow2zBg">4,828,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_-wJ3tnTfVEyOpF_1tjhoTA">3,334,000</ix:nonFraction>, respectively. The total cash received for stock options that were exercised during 2023 and 2022 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_xoixG9m8x0uQ_FMG38ELfg">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_2lLiMndb90SecinF0aDsCA">77,000</ix:nonFraction>, respectively. The total intrinsic value of stock options that were exercised during 2023 and 2022 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_-vv6rJoPpkCjnn6NgnJRnA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_tLDOsxCLfEqoxQx0TgZ33A">19,000</ix:nonFraction>, respectively. As of June&#160;30, 2023, there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="Narr_3oL2yPxn9ESd7Ae48w0yYA">2,193,000</ix:nonFraction> of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_HuS9UCfLQUGBLHEez3MTEQ">2.3</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The weighted-average grant date fair value of stock options granted during 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_6aCBFiynPkqL69bcMoznlA">6.30</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_OkDvYpFjukWQw-eDzuW-YA">23.25</ix:nonFraction> per share, respectively.&#160;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_5YE334tL50WGq4G_Xty22Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_6WXoqw_WeE6XFhmFBmLoIA">3.21</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_cg3Jl5dGk0mkNr6j46Q2UQ">3.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_3W0UA1FTH0Kz-S5cNDa20g">0.80</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_ogBG4m0WL0qcGR4M0RuECg">2.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_8yLSlghkmUyf85KkM_iRYA_3_3">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_xIIUaULyOU2CumJm_hz1ug_3_6">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_-QaoIcylsUy96Hokxs2hIw">115.52</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_fqBAU8ygpkKE3Zs16PtXfQ">116.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_q0NaTpdfyEW0-08dpF8vhQ">119.16</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_uDpawk64AUSONzNQvO8AHw">120.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_wnI6Pc6_xkuZSyDM1S5J-g_5_3">7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_2vAhQ23HCE-898FaxLyUgw_5_6">6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company&#8217;s closing stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_4lfSOh2Vw02OHfMWf5sbNw">0.61</ix:nonFraction> as of June 30, 2023 and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_vQ0k7ta3lUaj6rv38uy73g">6.50</ix:nonFraction> as of June 30, 2022, which would have been received by the option holders had all option holders exercised their options as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Restricted Stock Units (&#8220;RSUs&#8221;):</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Issuances of RSUs during the year ended June 30, 2023 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 29, 2022, the Company issued RSUs to acquire <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_lVI4OJZQYUW1Ag-bs75zPA">6,954</ix:nonFraction> shares of common stock to various employees at a market value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Tre0-mn9B0uOLa9qj0v9MQ">7.06</ix:nonFraction> per share. &#160;The RSUs vest over a <ix:nonNumeric contextRef="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_SrYuDQ71YEG30GVqJ1CZuw">four-year</ix:nonNumeric> period. &#160;The grant date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_31xlSd400kK7hhkzl-KclQ">49,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Company&#8217;s former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_11_10_2022_To_11_10_2022_srt_TitleOfIndividualAxis_ibio_Mr.IsettMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lgDtxmNOk0-1j1MhUErEmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_t42I-Z3OVUSDJGKacJVFwA">200,000</ix:nonFraction> shares of Common Stock.&#160; The RSUs vest over a <ix:nonNumeric contextRef="Duration_11_10_2022_To_11_10_2022_srt_TitleOfIndividualAxis_ibio_Mr.IsettMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lgDtxmNOk0-1j1MhUErEmg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_sj2ZzT8Rvkur5Q29D_4bKw">three-year</ix:nonNumeric> period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_11_10_2022_To_11_10_2022_srt_TitleOfIndividualAxis_ibio_Mr.IsettMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lgDtxmNOk0-1j1MhUErEmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_KPXY4kK_uEC7hIk270yCKA">296,000</ix:nonFraction>. The performance conditions were not met and the RSUs did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__QFdWjozr0WfEQRXaagocw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 11, 2022, the Board of the Company granted Mr. Robert Lutz, the Company&#8217;s Chief Financial and Business Officer at the time, RSUs to acquire <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Mr.RobertLutzMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SVjgzLilBkyuvpaaJZlWoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_yy32pY5GREey2OSdusqm1g">100,057</ix:nonFraction> shares of the Company&#8217;s Common Stock in exchange for Mr. Lutz&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Mr.RobertLutzMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SVjgzLilBkyuvpaaJZlWoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_Jpj_Gjx5pUGDbYZE-o8RLQ">175,100</ix:nonFraction>. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, the Board of the Company granted Dr. Martin Brenner, the Company&#8217;s Chief Scientific Officer, RSUs to acquire <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dpjHIDhP7ESwXkYz03k_Zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_r9A5R7thuUiUGj2AM_0EHw">95,348</ix:nonFraction> shares of the Company&#8217;s Common Stock in exchange for Mr. Brenner&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dpjHIDhP7ESwXkYz03k_Zg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_5sbwIn9-CE6Dwf0yuPBdUA">167,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_igEZn9PhVEiylIxh6caSLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_I0ePmME1tkaYReZCiPnQIA">130,000</ix:nonFraction> shares of the Company&#8217;s Common Stock, which RSUs shall vest pro rata over a <ix:nonNumeric contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_igEZn9PhVEiylIxh6caSLA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_-7IfnQTBz0mBXIa2IwOwSg">12-month</ix:nonNumeric> period, such vesting to terminate if Dr. Brenner is no longer the Company&#8217;s Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_igEZn9PhVEiylIxh6caSLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_vpTMGzq2Qkm0N2CQhgm0ig">91,000</ix:nonFraction>. Upon appointment of Dr. Brenner to permanent Chief Executive Officer on June 22, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_6_22_2023_To_6_22_2023_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kqjXeqU8mEmZuO4mrfyDSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Narr_rgAihvdnv0mE8vulmaWjgw">75,833</ix:nonFraction> of the RSUs terminated and did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Compensation Committee (the &#8220;Committee&#8221;) of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HfFb1iTZDEK4b5gZPeFNew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_Y6ZoC5RPI0Ct5BCXlXo1Dg">225,000</ix:nonFraction> RSUs under the Company&#8217;s 2020 Omnibus Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), which awards included a grant of <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_ibio_InterimChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HhEQxy6pnUCpQsZ0aKHI-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_io2Aawwf2E6VOlSLyd3o9Q">50,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_a-ruAN-Fp0aT8KVbiaSHbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_D7P1aspip0KhKy_QEu4Tww">37,500</ix:nonFraction> restricted stock units to each of Dr. Brenner, and Felipe Duran, the Company&#8217;s Interim, Chief Financial Officer, respectively, vesting quarterly over <ix:nonNumeric contextRef="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_4UJTvMaPYUmEsDKWssS5fA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_frCjRRVKW0WvSLfXGsjPKg">12 months</ix:nonNumeric> commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_4UJTvMaPYUmEsDKWssS5fA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_57qAAl_-Hku-iPsox16SnA">468,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 26, 2023, the Board of the Company granted Dr. Brenner RSUs to acquire <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_6_26_2023_To_6_26_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_A3-mdp0Omkera-zLt8EKJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_O40QO3kaDk-Kk3NUfxwKtw">75,833</ix:nonFraction> shares of the Company&#8217;s Common Stock, which RSUs shall vest pro rata over a <ix:nonNumeric contextRef="Duration_6_26_2023_To_6_26_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_A3-mdp0Omkera-zLt8EKJg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_qRJINavSGUmLlFiMliyNDw">seven-month</ix:nonNumeric> period. &#160;The grant-date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_6_26_2023_To_6_26_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_A3-mdp0Omkera-zLt8EKJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_VnkH85yV6kKPm0rWQ2pNAw">52,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Issuances of RSUs during the year ended June 30, 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company issued RSUs to acquire <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_TgbuJohtVUWolagz8o0jIg">4,229</ix:nonFraction> shares of Common Stock to various employees at a market value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ln6_Vp0mbEydaJEaNDBwjw">31.50</ix:nonFraction> per share. The RSUs vest over a <ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_MJBc0ST6fk2HaPs0peL-Ug">four-year</ix:nonNumeric> period. The grant-date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_8atN_vL9uUWCW-l1vWF6Fg">133,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">As of June 30, 2023, there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_G00b6C-z9kKKm4HpP4CcHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="Narr_HJWZsduzz0qAf9oRb--qSw">445,000</ix:nonFraction> of total unrecognized compensation cost related to non-vested RSUs that the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bdlOYYhGck24BhiEx8F8Rw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_-4zOSdODDkKTXCduGbOKCQ">0.8</ix:nonNumeric> years.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk83294720"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="ibio:GainLossRelatedToLitigationSettlementTextBlock" id="Tb_mN-m9je0RkyVqdbkrgQVCQ" continuedAt="Tb_mN-m9je0RkyVqdbkrgQVCQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">20.&#160;&#160;&#160;&#160;Fraunhofer Settlement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Fraunhofer Settlement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2021, iBio, Inc. (the &#8220;Company&#8221;) and Fraunhofer USA, Inc. (&#8220;FhUSA&#8221;) entered into a Confidential Settlement Agreement and Mutual Release (the &#8220;Settlement Agreement&#8221;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#8220;Lawsuit&#8221;). The Settlement Agreement, among other things, resolves the Company&#8217;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The terms of the Settlement Agreement provided for cash payments to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember__8CY_8OqkkmBwgmzP9GZVw" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_do_N_H7qQU-Ci-UZtZ8YTA">28,000,000</ix:nonFraction> as follows: (i) $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_gQzJcEQS6U-ffQ0wp3xFOA" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_p8VyunIOW0qLZRyIYrOYdA">16,000,000</ix:nonFraction> paid no later than May 14, 2021 (which was paid <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_49sQrs8MA0CP9gEl5c6S8w" decimals="INF" format="ixt:numdotdecimal" name="ibio:PercentageOfLegalFeesExpectedToBeReceived" scale="-2" id="Narr_nKhd0JxrokSEDFgmSbXENw">100</ix:nonFraction>% to cover legal fees and expenses); (ii) <span style="-sec-ix-hidden:Hidden_jYLIaZRQbkaIs4FnEH9rdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mN-m9je0RkyVqdbkrgQVCQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Ng3EGcHwDUSSHJ0vzePC6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SettlementAssetsCurrent" scale="0" id="Narr_nRqGWMozmEachjulhtuyAA">5,100,000</ix:nonFraction> paid by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, <span style="-sec-ix-hidden:Hidden_kXKwXnCsRkauOXx5_TATcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Fy-Gf6u-0EitjXayqqPTHw" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_Ou-FkWag9kevV7s8UIUdxQ">900,000</ix:nonFraction> paid by March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#8217;s aggregate net cash recovery as a result of the Settlement Agreement was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_z9FbEXk9g0ql9OZ20V-ejg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainContingencyUnrecordedAmount" scale="0" id="Narr_G-syk2Yjh0OEJj_qB1Ybjg">10,200,000</ix:nonFraction>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company held receivables related to the settlement in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_xiBf2oc6W0C50iTxTcBcmw" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr___YEvK4tIEq15q_EJCqXxQ">10,200,000</ix:nonFraction>. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. During the quarter ended March 31, 2022, the Company received the first payment of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_QFHntIxLBEO846_F3J6DgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_nJbbQfjSWkWYL9kZ7uz90w">5,100,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 17, 2023, the Company received a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_3_17_2023_To_3_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_GhYBtnMX2kWlAFeWO0dmuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_QLSKRYbmuU6t5XLcnVvTJw">5,100,000</ix:nonFraction> from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_3_24_2023_To_3_24_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_t8lePepQ2kKL5ThSHCVZjg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_34Z7pfFALkqtPqFmvg3H5g">3,000,000</ix:nonFraction> to a Company account at Woodforest on March 24, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company would recognize the $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_2umbQoBSEk60AzYnxpGopg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="Narr_FIFQAw9oNkiPgXV1veHJMQ">1.8</ix:nonFraction> million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_2umbQoBSEk60AzYnxpGopg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_myz6Xc-7FEupgUWZt-sTBw">900,000</ix:nonFraction> payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. The second $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_2_17_2023_To_2_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_KnJIktsPp0-EQ6aH9Z2wWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_siBzo90JbkeNiYXxcPAYug">900,000</ix:nonFraction> payment was received on February 17, 2023.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4cba65a7_d0cb_4d1b_8156_56e93e6e0990"></a><a id="Tc__9wET66390OjQtFD4p_vQw_1_2"></a><a id="Tc_707wf4pH6Ue7foocsD_spw_2_2"></a><a id="Tc_nX29dAEZhEKJ9DjR-O5bbg_3_2"></a><a id="Tc_FGlNTD2pmUyyFrkUKQe02A_3_5"></a><a id="Tc_-t70OnrLLUytgDlKR4Wa-Q_4_0"></a><a id="Tc_3G7iyuig8UOqmhIR-xHGVw_4_2"></a><a id="Tc_4pGYjVijmUCSQQ-1xSsV_A_4_5"></a><a id="Tc_lFThmQRKsUqyxC83vpqdCA_5_0"></a><a id="Tc_1T_G9vKkEku-KJruH7mdoQ_6_0"></a><a id="Tc_2MaCBFPyx0GTiURKK6Tltg_7_0"></a><a id="Tc_FwPX8SbffEuKZzqK0-7p3Q_8_0"></a><a id="Tc_jzQZvH69M0qD5RTKHANzkQ_9_0"></a><a id="Tc_A4F67nhGxkCTUwoh0Cb1wg_9_2"></a><a id="Tc_IU7mmlzSLEeIovGpLmSosw_9_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_ERjpWGp-EEWG5A7-N451yg" continuedAt="Tb_ERjpWGp-EEWG5A7-N451yg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21.&#160;&#160;&#160;&#160;Income Taxes</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_jdEyeQ_OD0CEjq3TDZnkiw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The components of the provision (benefit) for income taxes consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current &#8211; Federal and state</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_EnnC-TXEKEie5AHRQ1d--A_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_WIRHm_Y5oEm1ZFOFFdq1rg_4_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred &#8211; Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_qPDmY67ouUOaGkg2CxkOng_5_3">12,153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_72n_7A0kAUa77giOxG0ZiQ_5_6">9,051</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred &#8211; State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_uROYCmDzwEGjiYDgY_Iiuw_6_3">637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="Tc_1rMjxdIgYEq1pvafsSpmcg_6_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentAndDeferredFederalAndStateTaxes" sign="-" scale="3" id="Tc_NoXhlz5DH0yJrdAM8WyL_g_7_3">12,790</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentAndDeferredFederalAndStateTaxes" sign="-" scale="3" id="Tc_yKI-tQSZCU-mBKJEX-di-g_7_6">9,051</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncomeTaxExpenseBenefitValuationAllowance" scale="3" id="Tc_ZvKY9oG7UkqaCrpUkhQlKA_8_3">12,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncomeTaxExpenseBenefitValuationAllowance" scale="3" id="Tc_0IGO1BnbXky1R_GyjvKspg_8_6">9,051</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_xxeaT-PJZUOnvMCejDRS_g_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_YoEHXXDFW0q9pUW1MECTZg_9_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has deferred income taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_96c278d7_c70a_43ab_8077_b8e80caf8d3f"></a><a id="Tc_mYjWXnTJCUy0yyn2qfLJXQ_1_2"></a><a id="Tc_MxEF35gDYkm1dOX8RIGK9A_2_2"></a><a id="Tc_oIi3Yslwu02fEgXYKKD6nw_2_5"></a><a id="Tc_UbclPnhdpE6Ygpwp3cQLKg_3_0"></a><a id="Tc_OXpQjmrkjUe1PAPMYGTTXA_4_0"></a><a id="Tc_gzlCnWwweUSBxBRGoHq3Ng_4_2"></a><a id="Tc_3GZXxbWYq0GOrdpD-XQ_fA_4_5"></a><a id="Tc_0lSuYbWcoE2H3zD_Rg26iQ_5_0"></a><a id="Tc_FIsny0NScUeu77Qxs_dffg_6_0"></a><a id="Tc_QKgx8IuHokSq5ZdroZ_Smw_7_0"></a><a id="Tc_QhAQEnC-iUCxA96tfl6egg_8_0"></a><a id="Tc_xNGy-zP3LUWt5qMWH_syQQ_9_0"></a><a id="Tc_E4Ad5R2z8UGXPJ53gFqZog_10_0"></a><a id="Tc_w2iKezOO00-MpV3vqHlQ6w_11_0"></a><a id="Tc_tJzWQnSjv0G6irT-4CrkZw_12_0"></a><a id="Tc_iPAV68jINkC-8pFK-vMo3g_13_0"></a><a id="Tc_JRdbBeYBbkSVejJPMlLRIA_14_0"></a><a id="Tc_zgFx4vTpvE-ZkdRqe6D91A_15_0"></a><a id="Tc_EY_lz4gYZkmONdLqcmOW5g_15_2"></a><a id="Tc_AL8EKyKbk0uyPsJ9UAeVnQ_15_5"></a><a id="_7eb64b37_a547_4ccd_930e_b64c0bfc9ab6"></a><a id="Tc_kGCspHpuCkq3CcpXFR6igQ_1_2"></a><a id="Tc_60724bpKSEm0YZlPiGZsfQ_2_2"></a><a id="Tc_mEhKUT7f30-9CGU_OFKyiA_3_2"></a><a id="Tc_OHTVbQtmGUOKNJVvGHucFw_3_5"></a><a id="Tc_2FSYeqBBxki3k-GkGVv_Nw_4_0"></a><a id="Tc_oqpojahfmkOXTos8BJOruw_4_3"></a><a id="Tc_xi8WKl8JG0-lbuSKcPe2kw_4_6"></a><a id="Tc_ZV2OcOhink-hbCYDdTNp9Q_5_0"></a><a id="Tc_fonYyWC500qrX91KKJp_bQ_5_3"></a><a id="Tc_LVUBfjgzdkKZKoOtSWDMrQ_5_6"></a><a id="Tc_QyEvvrDoIECJPIurqMfrBg_6_0"></a><a id="Tc_CHKOfoOf-0aMmtUx8YYy_Q_6_3"></a><a id="Tc_80ON4jVdpE2xuNJbtonauA_6_6"></a><a id="Tc_xOzAA52Ls0GUKC5EwCX5rg_7_0"></a><a id="Tc_T6S1GUPtLESOC2OzWMWKwQ_7_3"></a><a id="Tc_ElK8u_gmqEetJ4MJ0j1sdA_7_6"></a><a id="Tc_ojYHkQqV9Ei6IPB3g-kfHA_8_0"></a><a id="Tc_Ujz-IPa7UkWfU0vw9Bn0tg_8_3"></a><a id="Tc_xP3Be0KfJ0WvbdN7v9owWg_8_6"></a><a id="Tc_Uiq39I5pLEy74lItOuVr3w_9_0"></a><a id="Tc_aBVzqTRJSkO5J9lhKB9Byg_9_3"></a><a id="Tc_XzGURNYLN0iSFXVc2IYOKQ_9_6"></a><ix:continuation id="Tb_ERjpWGp-EEWG5A7-N451yg_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_mgMR0w6ns0KlsPDu201qig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets (liabilities):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_VHC2Nn12e0eiHrwdRIA8tw_4_3">42,951</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Gb2IY2dS5E-kX8AIaq3wMg_4_6">35,829</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_zP_yD57RMEWkR5OMmU5ELQ_5_3">883</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_2GVd_Z6LJEWUBZS_pA-vyA_5_6">1,248</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredTaxAssetsResearchAndDevelopmentCosts" scale="3" id="Tc_EX1WVGR40UeWOGRtGICxAg_6_3">2,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:zerodash" name="ibio:DeferredTaxAssetsResearchAndDevelopmentCosts" scale="3" id="Tc_740EYdsyI0ap6LCcoRllDg_6_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_JBvlPeWcVk2kyduLh1BGuw_7_3">1,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_TxzZgFd0NkeRNEnMWcI64Q_7_6">1,764</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment in equity security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="3" id="Tc_f0yBL0_CB0md9LbyJBa7Ag_8_3">395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="3" id="Tc_DiXmmo2Dxk-ylvNoDK5pTg_8_6">370</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_sVxT9XMVI0u8Idfvj_UBww_9_3">121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_ozWgzCUY0kq9mn4J9oDUuA_9_6">2,520</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="Tc_t4h4YixPR0SmUT483oJQrw_10_3">42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="Tc_mVs_pJWsMUCOaKxD6SZAxQ_10_6">71</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating and finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" scale="3" id="Tc_UFHg9Rc-_0ajRgyCZFWsfA_11_3">1,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:zerodash" name="ibio:DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" scale="3" id="Tc_-Ow-nkDm-0m-A3SgfF2l4Q_11_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating and finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" scale="3" id="Tc_97-7CZLK-0Cuc8JljqvhhA_12_3">1,184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:zerodash" name="ibio:DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" scale="3" id="Tc_GespMebEI0Wah85xU7b8tQ_12_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_Xd7pqK_vDUiYN2P58bAWbA_13_3">529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_fsl43GLag0aW4-Gdr5HtWg_13_6">145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_8Hb69CpJIkSsgc-Mfv2PsQ_14_3">49,555</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_QNJPlva8w0S7FUcyp_OeAg_14_6">36,765</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_T-vYsgTcxUmB4RSfPd7VUg_15_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_duNYzzn1jU-75gFiwHKpwQ_15_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has a valuation allowance against the full amount of its net deferred tax assets due to the uncertainty of realization of the deferred tax assets due to the operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Federal net operating losses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2008_80RUzZ4LGECu9HWLvLycUA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="Narr_Dv71B3PKDEStiZsVUSDmLQ">5.5</ix:nonFraction> million were used by the Former Parent prior to June&#160;30, 2008 and are not available to the Company. The Former Parent allocated the use of the Federal net operating losses available for use on its consolidated Federal tax return on a pro rata basis based on all of the available net operating losses from all the entities included in its control group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">U.S. federal net operating losses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="Narr_rvPdv8vNgkylSb6MjvkOLg">202.1</ix:nonFraction> million are available to the Company as of June&#160;30, 2023, of which $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="Narr_lHui_t3lIUq39La0GJHzxA">63.9</ix:nonFraction> million will expire at various dates through 2039 and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="Narr_pP5pOYPCn0SLjE9P_JxQUg">138.2</ix:nonFraction> million with no expiration date. These carryforwards could be subject to certain limitations in the event there is a change in control of the Company pursuant to Internal Revenue Code Section&#160;382, though the Company has not performed a study to determine if the loss carryforwards are subject to these Section&#160;382 limitations. The Company has a research and development credit carryforward of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_AZyAVySM7UKPZ8RTjixNPg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_n3Iei2ce_kmowmQUMxIABA">1.76</ix:nonFraction> million at June&#160;30, 2023. In addition, the Company has net operating loss carry forwards from various states of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_Pbbi-qGAtUqsQ-vqbRd2lA">35.2</ix:nonFraction> million which expire from 2029 through 2042.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_7QsEHrip7EqvPSW2SF3nww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">A reconciliation of the statutory tax rate to the effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_cFnyDEDWNkqDBzyGfdhOHQ_4_2">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_HY0mInYwi0aWU9mFmpRLkA_4_5">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_eJ66kzGKDEiyEipphHhecA_5_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_teNfjUYUxk2XxJFK21VAoA_5_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiration and forfeiture of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="ibio:EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" sign="-" scale="-2" id="Tc_gdI2FNnX4UuR3sEYJGddtg_6_2">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:zerodash" name="ibio:EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" scale="-2" id="Tc_2aSgw-NpuEyd_t-8lrD4vA_6_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change related to iBio CDMO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:zerodash" name="ibio:EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" scale="-2" id="Tc_EMuQISJH4km3d00rDJd1pw_7_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="ibio:EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" sign="-" scale="-2" id="Tc_bnXPP9diG0Wkh-PdYzJN-w_7_5">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_2oHcKtF0qEuhslfZZdylTA_8_2">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_ZL5H2Cb5Ukm3sqyPJGq3gg_8_5">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_1z9Kff6iM0C2RaEuGThqsg_9_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_GFXoOW2p_kmStSm22uItsg_9_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has not been audited in connection with income taxes. iBio files U.S. Federal and state income tax returns subject to varying statutes of limitations. The 2019 through 2022 tax returns generally remain open to examination by U.S. Federal authorities and by state tax authorities.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_hZ1gSfx_x0m7A5ZD6fcTkg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">22.&#160;&#160;&#160;&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">CRO Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce IBIO-101 in addition to process development and GMP manufacturing of IBIO-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. The Company has incurred costs totaling approximately </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_olBr2CcxoUyuzZH0lS6s3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" id="Narr_-89H0JByMkaR1sc7pfKEYQ">1,209,000</ix:nonFraction></span><span style="font-style:normal;"> through June 30, 2023. The Company is committed to additional costs totaling approximately </span><span style="font-style:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_Nj1rBi5mf0-4KTZgTQfTXw" decimals="0" format="ixt:numdotdecimal" name="ibio:EstimatedAdditionalCostOnDevelopment" scale="0" id="Narr_-fHMdHGmr0CxMPDE6MFxpQ">171,000</ix:nonFraction></span><span style="font-style:normal;"> as of the date of the filing of this Annual Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inflation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"><span style="font-style:normal;">Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#8217;s operations.</span><i style="font-size:12pt;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_vxcma61mbUOCmvYCKO4YAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">23.&#160;&#160;&#160;&#160;Employee 401(K)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#8220;Plan&#8221;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_GmpUlCwSBEqzeFfhmLql_Q">100</ix:nonFraction>% matching contribution that is not in excess of <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_J0Ljzb9gCEiBSKnlSP-Law">5</ix:nonFraction>% of an eligible employee&#8217;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. Employer contributions made to the Plan totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_9-AmOlTVZEGzhThRl_JLPg">263,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_RBs9kUn5m0uBkCzByJX8eA">169,000</ix:nonFraction> for the years ended June 30, 2023 and 2022, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember__JoTwj7JekqGkccr8jaLLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_UHpiIyRC2Uq34hrbVgsGWQ">135,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_lUPOZKyWjkGiiwoG4yyWyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_1nXBjRxg4k6m9QM4XVH2Pw">150,000</ix:nonFraction> for the years ended June 30, 2023 and 2022, respectively,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_AVDvHfDGWEmGGfXSv8V5qg" continuedAt="Tb_AVDvHfDGWEmGGfXSv8V5qg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">24.&#160;&#160;&#160;&#160;Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Purchase and Sale Agreement with Majestic Realty Co.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 15, 2023, iBio CDMO entered into the Purchase and Sale Agreement with Majestic Realty Co., pursuant to which iBio CDMO agreed to sell to Majestic Realty for a purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_ushJsRuZQEyiUOY_3efaUg" decimals="0" format="ixt:numdotdecimal" name="ibio:GroundLeasesAgreedToSellPruchasePrice" scale="0" id="Narr_6Ic0TyLpSUe8mEuxX5hw5A">17,250,000</ix:nonFraction> its Facility located in Bryan, TX consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;M University System (together, the &#8220;Ground Lease&#8221;), related to <ix:nonFraction unitRef="Unit_Standard_acre_scgUJO-cMUuybvEVKZVJgQ" contextRef="As_Of_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_ushJsRuZQEyiUOY_3efaUg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="Narr_Ae7Auo5oLke-RuRuRjx_Nw">21.401</ix:nonFraction> acres in Brazos County, Texas land (the &#8220;Land&#8221;); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the &#8220;Improvements&#8221;); (iii) all iBio CDMO&#8217;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the &#8220;Personal Property&#8221;); (iii) all iBio CDMO&#8217;s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the &#8220;Contracts&#8221;); and (iv) all iBio CDMO&#8217;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the &#8220;Intangibles&#8221;; and together with the Ground Lease, Improvements and Personal Property, collectively, the &#8220;Property&#8221;). The closing of the sale of the Property is to occur, with time being of the essence, on December 1, 2023 or such other date as mutually agreed. &#160;Pursuant to the terms of the Purchase and Sale Agreement , Majestic Realty deposited with a title company (the &#8220;Escrow Agent&#8221;) $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_ushJsRuZQEyiUOY_3efaUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EarnestMoneyDeposits" scale="0" id="Narr_hXCinM0mYUSdeJ1znxERng">200,000</ix:nonFraction> as an earnest money deposit. Majestic Realty will also be afforded access to the Property to conduct a due diligence review of its condition. The closing is subject to certain closing conditions, including: (i) Majestic Realty&#8217;s delivery to iBio CDMO and the Escrow Agent of written notice of its approval of the condition of the Property on or before 5:00 p.m. Central time on October 16, 2023; (ii) Majestic </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_AVDvHfDGWEmGGfXSv8V5qg_cont1" continuedAt="Tb_AVDvHfDGWEmGGfXSv8V5qg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realty obtaining the approval of The Board of Regents of the Texas A&amp;M University System of Majestic Realty&#8217;s purchase from it of the fee interest in the Land on or before 5:00 p.m. Central time on November 13, 2023; and (iii) the delivery at closing by the title company of a title policy to Majestic Realty in the amount of the Purchase Price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Credit Agreement with Woodforest National Bank</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#8220;Sixth Amendment&#8221;), to amend the Credit Agreement to: (i) set the maturity date of the term loan to the&#160;<i style="font-style:italic;">earlier of</i>&#160;(a) December 31, 2023, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement, (ii) provided that iBio CDMO will, immediately upon receipt of the proceeds of the sale of the Property, apply the net proceeds to satisfy all outstanding obligations under the term loan, and to the extent such net proceeds are sufficient, to pay off the term loan, and (iii) change the annual filing requirement solely for the fiscal year ending June 30, 2023, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation; provided that (y) iBio CDMO shall deliver an executed copy of the Purchase and Sale Agreement for the sale of the Facility within one business day after entry into the Sixth Amendment, and (z) if the Facility is not sold on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_CreditAgreementWithWoodforestNationalBankMember_2dAEJVyuAUOVNF-AXyg-lA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" id="Narr_oIktmPACckS4zuEvtjuywg">20,000</ix:nonFraction> upon the earlier of the date of the closing or the maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Repriced Existing Warrants issued pursuant to Wainwright Underwriting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">On August 4, 2023, iBio, Inc. (the &#8220;Company&#8221;) agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A warrants to purchase up to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_r68Y0EmbuEeMR0WnlD99_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_IOGn_sg530G6Iu5eloQP7w">3,475,916</ix:nonFraction></span><span style="background:#ffffff;"> shares of common stock and existing Series B warrants to purchase up to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RSn4_RfPj0SPtSJMEmhzUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_nTfEmVyiYUqc_OwQ9E75RQ">2,058,000</ix:nonFraction></span><span style="background:#ffffff;"> shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with exercise prices of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_uUlIkQW2oEq35oK92beemA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_r30jz5RpW0OKuo9gGi5Dxw">1.04</ix:nonFraction></span><span style="background:#ffffff;"> per share (the &#8220;Existing Warrants&#8221;), to lower the exercise price of the Existing Warrants to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_6d6Raa3cZUiRPuWmRc-WaA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_mWnWKZDeqEeQM2vii6tMUw">0.50</ix:nonFraction></span><span style="background:#ffffff;"> per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Lincoln Park Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 4, 2023, iBio, Inc. (the &#8220;Company&#8221;) entered into a purchase agreement, dated as of August 4, 2023 (the &#8220;Purchase Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to&#160;<span style="background:#ffffff;">which, under the terms and subject to the satisfaction of specified conditions set forth therein,&#160;</span>the Company may sell to Lincoln Park up to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw" decimals="-5" format="ixt:numdotdecimal" name="ibio:MaximumAmountOfCommonStockAgreedToSell" scale="6" id="Narr_87ZBwHpmOE-2FXi-9Wg3cA">10.0</ix:nonFraction> million (subject to certain limitations) of the Company&#8217;s Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the &#8220;Registration Rights Agreement&#8221;), with Lincoln Park, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;), to register under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by the Company to Lincoln Park under the Purchase Agreement. The Company cannot sell any shares of Common Stock to Lincoln Park under the Purchase Agreement until such time that all of the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase Agreement, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the &#8220;Commencement Date&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company&#8217;s discretion, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw" decimals="-6" format="ixt:numdotdecimal" name="ibio:MaximumAmountOfCommonStockAgreedToSell" scale="6" id="Narr_koJRXg9rv0y0aWRvZDU8mQ">10</ix:nonFraction> million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company may, at its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_65MqqZL2kUWg5zU9Y4i3kQ" decimals="2" format="ixt:numdotdecimal" name="ibio:ClosingPricePerShareOfCommonStock" scale="0" id="Narr_3vOamBgHz0WMVLVHQu2HZw">0.15</ix:nonFraction>, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw" decimals="INF" format="ixt:numdotdecimal" name="ibio:MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" scale="0" id="Narr_nwQqxTEVbU-ZHgR4WaP7_g">100,000</ix:nonFraction> shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a &#8220;Regular Purchase&#8221;);&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the maximum number of shares the Company may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_odmv-ki5qUWWcb8GBFn57Q" decimals="INF" format="ixt:numdotdecimal" name="ibio:MaximumNumberOfCommonStockToBeSold" scale="0" id="Narr_ZRTrZT3MfEipD-WXuKfDTw">150,000</ix:nonFraction> shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_odmv-ki5qUWWcb8GBFn57Q" decimals="2" format="ixt:numdotdecimal" name="ibio:ClosingPricePerShareOfCommonStock" scale="0" id="Narr_QfSh401s9kqsN5K9WDBKag">1.00</ix:nonFraction>, and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_Dw9k-bulX0-p0mYFE2o_Ug" decimals="INF" format="ixt:numdotdecimal" name="ibio:MaximumNumberOfCommonStockToBeSold" scale="0" id="Narr_e-zkYpJ0bEqF5euudb5Ezw">200,000</ix:nonFraction> shares, if </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_AVDvHfDGWEmGGfXSv8V5qg_cont2" continuedAt="Tb_AVDvHfDGWEmGGfXSv8V5qg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the closing sale price of the Common Stock on the applicable purchase date is not below $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_Dw9k-bulX0-p0mYFE2o_Ug" decimals="INF" format="ixt:numdotdecimal" name="ibio:ClosingPricePerShareOfCommonStock" scale="0" id="Narr_3JupPqUc0km43idjH1a-pg">2.00</ix:nonFraction>;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that Lincoln Park&#8217;s maximum purchase commitment in any single Regular Purchase may not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw" decimals="0" format="ixt:numdotdecimal" name="ibio:MaximumCommitmentInSingleRegularSaleOfCommonStock" scale="0" id="Narr_4nHJm4am-U26ZXq9sbSKoQ">500,000</ix:nonFraction>. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, provided that the Company has directed Lincoln Park to purchase the maximum amount of shares that the Company is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw" decimals="2" format="ixt:numdotdecimal" name="ibio:MinimumClosingPriceOfCommonStockToSellAdditionalShares" scale="0" id="Narr_j12UFcaZU02RE5R-E2e3bw">0.20</ix:nonFraction>, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an &#8220;accelerated purchase,&#8221; and one or more &#8220;additional accelerated purchases&#8221; on the business day immediately following the purchase date for such Regular Purchase,&#160;<span style="background:#ffffff;">as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable,</span>&#160;calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company will control the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Actual sales of shares of Common Stock to Lincoln Park will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, market prices of the Common Stock from time to time during the term of the Purchase Agreement and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of Common Stock to Lincoln Park. The Company expects that any proceeds received by the Company from such sales to Lincoln Park will be used for working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As consideration for Lincoln Park&#8217;s commitment to purchase shares of Common Stock at the Company&#8217;s direction pursuant to the Purchase Agreement, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_bF8JjLvH802Tuo3wC7Kovg">211,473</ix:nonFraction> shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Initial Commitment Shares&#8221;) and agreed to issue <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w" decimals="INF" format="ixt:numdotdecimal" name="ibio:AdditionalSharesAgreedToIssue" scale="0" id="Narr_AWhREwwQeEyWw3SqoYqwFA">211,474</ix:nonFraction> additional shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Additional Commitment Shares&#8221; and, collectively with the Initial Commitment Shares, the &#8220;Commitment Shares&#8221;) at such time as the Company has received an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_VCQvHDTigUaXlfwWRtTIoA">5,000,000</ix:nonFraction> in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, if any, that the Company elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Under applicable rules of the NYSE American, the Company may not issue or sell to Lincoln Park under the Purchase Agreement more than&#160;</span><ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw" decimals="INF" format="ixt:numdotdecimal" name="ibio:MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" scale="0" id="Narr_JSW7tgVvgUS5CNwMjo5csA">4,474,945</ix:nonFraction> shares (inclusive of the Commitment Shares), subject to adjustment as described above, of Common Stock (which is equal to approximately <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w" decimals="4" format="ixt:numdotdecimal" name="ibio:PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" scale="-2" id="Narr_5FHfZLznLUy9-22SNyhgpg">19.99</ix:nonFraction>% of the shares of Common Stock outstanding immediately prior to the execution of the Purchase Agreement) (the &#8220;Exchange Cap&#8221;), unless stockholder approval is obtained to issue shares of Common Stock in excess of the Exchange Cap in accordance with the applicable rules of the NYSE American. In any event, the Company may not issue or sell any shares of Common Stock under the Purchase Agreement if such issuance or sale would breach any applicable rules or regulations of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Purchase Agreement also prohibits the Company from directing Lincoln Park to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock then beneficially owned by Lincoln Park (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in Lincoln Park beneficially owning more than <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w" decimals="4" format="ixt:numdotdecimal" name="ibio:MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" scale="-2" id="Narr_a_OrbV7adEan-yHh-TMupg">4.99</ix:nonFraction>% of the outstanding shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_AVDvHfDGWEmGGfXSv8V5qg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or Registration Rights Agreement, other than a prohibition (with certain limited exceptions) on entering into specified &#8220;Variable Rate Transactions&#8221; (as such term is defined in the Purchase Agreement) for a period specified in the Purchase Agreement. Such transactions include, among others, any sale of debt or equity securities that are convertible into or exercisable for shares of Common Stock at a conversion price or exercise price that is based upon and/or varies with the trading prices of the Common Stock after the initial issuance of such securities,&#160;<span style="background:#ffffff;">or effecting or entering into an agreement to effect an &#8220;equity line of credit&#8221; or other substantially similar continuous offering with a third party, in which we may offer, issue or sell Common Stock or any securities exercisable, exchangeable or convertible into Common Stock at a future determined price.</span>&#160;During any &#8220;suspension event&#8221; under the Purchase Agreement, the Company may not initiate any Regular Purchase, accelerated purchase or additional accelerated purchase of Common Stock by Lincoln Park, until such suspension event is cured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Lincoln Park has agreed not to engage in or effect, directly or indirectly, for its own principal account or for the principal account of any of its affiliates, any short sales of the Common Stock or hedging transaction that establishes a net short position in the Common Stock during the term of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time with one business days&#8217; notice, at no cost or penalty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Between August 16, 2023 and September 15, 2023, Lincoln Park purchased pursuant to the Purchase Agreement <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_8_16_2023_To_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_iUI1PTAMS0mokeLZNB2Fjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_tEkMKT3370-blvQv_-YPSQ">3,622,834</ix:nonFraction> shares of Common Stock. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_HvdB1ZWYLEujtiGbTKuLOg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_nW-p1GqVAUKgEcRyqB2Z7A">1.2</ix:nonFraction> million during the first quarter of Fiscal 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cantor Fitzgerald Underwriting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Between July 3 and September 26, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_3_2023_To_9_26_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_UNfYWTucIEGpRkg5uUnc2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr__7D4IuK5b0a6IzzsaeoUQQ">3,419,795</ix:nonFraction> shares of Common Stock. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA" contextRef="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_E1rZVhR8okSSqW6gfMvzJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_AFHzA9pSakWYtPpwY5TD-Q">1.7</ix:nonFraction> million during the first quarter of Fiscal 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"><span style="font-style:italic;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuances of stock options during Fiscal 2024 were as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In Fiscal 2024, the Company granted stock option agreements to certain officers and employees to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rm5qrexyo0mItmFx_ydLbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_nxE1Q-hVjUKpNafrJCq_yg">473,000</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ" contextRef="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rm5qrexyo0mItmFx_ydLbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_onppLtXfbkukwRnKKCfcTw">0.35</ix:nonFraction> per share. The options vest <ix:nonFraction unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A" contextRef="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_G3Cg20_u1k-sLeLr-GIKSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_FrVu9AV_yEWEFRafFbTu-g">25</ix:nonFraction>% after <ix:nonNumeric contextRef="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_G3Cg20_u1k-sLeLr-GIKSA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_3379tc0FGkyaH4X7Ud4PGw">one year</ix:nonNumeric> and then in equal quarterly installments over a <ix:nonNumeric contextRef="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Mz-O4KcM5kmuLTNfOTFLBA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_dMAY3ExAD0KJCZuMC2vHQQ">36-month</ix:nonNumeric> period and expire on the <span style="-sec-ix-hidden:Hidden_jBumV3Rkt02i3MRw82WE7Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span>th anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Vesting of RSUs during Fiscal 2024 were as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the first quarter of Fiscal 2024, RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_u3o7OY19vkGgjeV5Z4Mo1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_4aQpr-GvIUOA33hGqaVRVw">33,153</ix:nonFraction> shares of Common Stock were vested.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#404040;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ibio-20230630xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 9/27/2023 05:26:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Subsidiaries of Registrant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio Manufacturing LLC (&#8220;iBio Manufacturing&#8221;) is wholly-owned and incorporated in Delaware</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio CDMO LLC (&#8220;iBio CDMO&#8221;) is wholly-owned and incorporated in Delaware. Name was changed effective July 1, 2017.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ibio-20230630xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 9/27/2023 05:26:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the following Registration Statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Form S-1 (File No. 333-233504, File No. 333-224620 and File No. 333-273749),</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Form S-3 (File No. 333-171315, File No. 333-175420, File No. 333-200410, File No. 333-236735, and File No. 333-250973) and on</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Form S-8 (File No. 333-181729, File No. 333-229261, File No. 333-25027 and File No. 333-252028) </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt -12.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">of iBio, Inc. and Subsidiaries of our report, which includes an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern, dated September 27, 2023, on our audits of the consolidated financial statements of iBio, Inc. and Subsidiaries as of June 30, 2023 and 2022 and for the years then ended, included in this Annual Report on Form 10-K of iBio, Inc. for the year ended June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">/s/ CohnReznick LLP</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Holmdel, New Jersey</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">September 27, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ibio-20230630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 9/27/2023 05:26:16 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 302 OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I, Martin Brenner, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I have reviewed this Annual Report on Form 10-K of iBio, Inc. for the fiscal year ended June 30, 2023;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">d)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:35.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: September 27, 2023</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:35.99%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:35.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer and Chief Scientific Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ibio-20230630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 9/27/2023 05:26:16 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION 302 OF</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I, Felipe Duran, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I have reviewed this Annual Report on Form 10-K of iBio, Inc. for the fiscal year ended June 30, 2023;</p></td></tr><tr style="height:3.3pt;"><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">d)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.</p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:92.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b)</p></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:35.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: September 27, 2023</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:35.99%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Felipe Duran</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ibio-20230630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 9/27/2023 05:26:36 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">18 U.S.C. &#167;1350,</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Annual Report of iBio, Inc. (the Company) on Form 10-K for the fiscal year ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Martin Brenner, Chief Executive Officer and Chief Scientific Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:92.01%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.</p></td><td style="vertical-align:top;width:92.01%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr><tr><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:92.01%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.98%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:top;width:92.01%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">September 27, 2023</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer and Chief Scientific Officer&#160; &#160; &#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to iBio, Inc. and will be furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ibio-20230630xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 9/27/2023 05:26:37 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Annual Report of iBio, Inc. (the Company) on Form 10-K for the fiscal year ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Felipe Duran, &#160;Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.</p></td><td style="vertical-align:top;width:90.96%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr><tr><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.96%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.97%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:top;width:90.96%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">September 27, 2023</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Financial Officer &#160; &#160; &#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to iBio, Inc. and will be furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ibio-20230630x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &M Z@# 2(  A$! Q$!_\0
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M1U/_  DUK_<E_(?XT?\ "36O]R7\A_C7,44>Q@)P1T__  DUK_<E_(?XT?\
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MJ7^VX?[DGY"L*GTO9Q!Q1M?VW#_<D_(4O]M0?W9/RK$I1UH]G$.5&U_;,/\
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M/\*/^%V?&C_H@-S_ .%/:?X5] 8HQ1]8I?\ /F/WR_\ D@]I'^1?C_F?/_\
MPNSXT?\ 1 ;G_P *>T_PH_X79\:/^B W'_A3VG^%?0&*,4?6*7_/F/WR_P#D
M@]I'^1?C_F>7? ?XT7GQ@LO$JZGX:D\+:MH&J/I5W8O=K<XD5%8_.H XW8[]
M.M%<;^RM_P CC\<_^QXNO_1:45.+A&G6<8*RT_%)BJQ49M(^A****XS$***0
MD*"2< =Z (+Z]BT^W::4X X '4GT%<3J.I3:E-YDIP!]U!T6IM:U,ZE=D@_N
M4X0?U_&L^O0I4^17>YT1C97"@=:*!UKH+'4445* 5>M.IJ]:=5 %.7I3:<O2
MH 6BBB@ H'6B@=:!(=1110)A2KUI*5>M#&AU%%%2,<O2EI%Z4M NH4X=*;3A
MTH!A2CK24HZT$CJ***@ HIDTT=M#)--(D4,:EWDD8*J*!DDD\  <DU\(_M&?
MMNW^MW-UX=^'-T^GZ2A,<VO1_+/==B(<_P"K3_:^\W;:*[<+A*N+GRTUZOHC
M:E2E5=HGUE\1_CWX#^$VZ/Q'XAM[:]QD:=;YGNC_ -LTR1_P+%>#:]_P49\,
M6LKIHWA#5M24' EN[B*V!]]HWFO@R65YI9)9':260EG=V+,Q/4DGDGW-;ECX
M"\1:AKLFBQ:/=IJL=N]T]G<)Y$BQ+&9"Q#[>-@R/7C&<U]53R?#4E^]=WZV7
M]?,]6.#I17O:GV#:_P#!2.V,H%U\/YECSR8-54MCZ-&!7I/@K]NOX8^*I8X-
M1GO_  K</QG5(-T /_76,L!^(%?G1I'AS5O$&JV^F:9IEYJ&I7+;(;2V@9Y9
M&QG 4#). 3^%4)(W@E>.16CD1BK*PP5(."".Q!K:>482>D59^3_SN4\)1>BT
M/VFTK5;+6].@O].NX+^QG7=%<VLJR1R#U#*2#5JOR(^$_P ;/%OP8U@7OAO4
MFAMW8&XTV;+VMR/1X^F?]I<,/6OTG^ OQ_T'X\>&VO-/_P! UBU"C4-(E?=)
M;D\!E/\ '&>S?@<&OFL;EM3">^M8]_\ ,\VMAI4==T>H4^F4^O&9QL*4=:2@
M?> [G./?UI(%L/HHKP_7?C-\1+WXL^+_  =X'^'^C>(X?#,&GRW5UJ7B%M/E
MF:ZA:1$C3R'7C81DD=JENQ)[A17G'@7X[^&?%GP@L_B)JES%X/T9O-BO1KMS
M'"+&>*5X98GD)"DK(C*"#\W!'7%:NB_&GX>>(=+_ +3TWQUX=OM,$,UR]W;Z
MG"\:0PE?.D8AOE6/>FXG&W<,]:+H:.RIPZ5Y-\#?VAO#GQC^$J^-FU31M/BM
MO._M2.+4DDBT[9+(J^=(2-FY$63YL<,.V*Z[P-\5_!7Q,L[RZ\(^+M$\36]E
M_P ?4FE7T=P(.,C?M.5! )!/!I73!LZNBN)L_CA\.M0\1:=H%KX\\-W.N:E$
MDUEIT.JPO/<HZ[D**&RVY>0!R1R :Y[3_P!HCPW?_M#:I\*UU71OM]II4%W&
M5U%#<RWCRRK+:>3_ 'XXXUD('S8?) '-%T!ZU17%GXU_#T>-O^$./CGPZ/%G
MF>3_ &(=3A^U^9U\OR]V=_\ L_>]JN^._BCX.^%UG;77C'Q5H_A:WN7,<$FK
MWL=N)F'4(&(+8[XZ=Z5Q'4#K3J\"UW]K#2O#T7Q)U1K.VU;PYX4DTL6VH:5?
MQ/\ ;H[RV\WS%W.JOM8@!(RSN/N@MQ75?LX?'6U_:$^'%OXGMM.?3&#);W$+
M3(W[_P I&EVH&+HH9F51*%=@ VW#"E=,+GJ=*O6N.\<_&+P'\,;FSM_%_C/0
M?"]Q> M;PZOJ,5N\J@X+*K$';GC=T]ZU=5\<^&_#]I:7>J>(-*TZTO(GGMKB
M[O8XXIHTC\QW1RV&54^8D' '/2G<#=HKCO"WQ9\*?$G0M5O_  +XIT'Q8;&-
MP[6&HI+%%+L)192A)121U(Z9(S7F3_M5:7X;U[X1>'_%.J>$;35O&5E/=:A+
M8ZXDEM9XA#V[0,W^MCG?Y$8X!(.TL:5T%SZ '2EKBO%/QL^'O@7Q%;>'_$?C
MGP[H.NW.WRM-U+4X8)VW'"_(S C)X&<9[5K^*/'_ (8\$1F3Q%XBTK08Q;O=
MEM2O8[<>2A57DRY'R@N@)]64=Q3N@-ZBN>\$?$/PM\2]);5/"7B+2_$VG+(8
MFNM)NTN$5Q_ Q4G:WL<&LS3_ (V?#W5O&<GA"R\<^';SQ5&[1MHT&J0O=!U^
M\GEALEAW4<CN*3:$SM*4=:3K7%^&?C;\//&7B>X\.:!XZ\.ZUK]OO\W3+#5(
M9KA=OW_D5B3M[XSCO2 [>BN'\2?'/X<>#;E;?7O'OAO1K@W3V7E7VJPQ.)TV
M[XR"V0R[USGIN&>M;?BWQWX;\ Z"VN>)O$&F>']&4J#J&I7:009;[H#L0"3V
M R3VI7$;RTM>9>(?C9HFH?#S6-:\!>)_"'B#4H=-?4;/[9K4<=BT:R!&DEE0
MDI&&W*6[,,'%:OB+XU^!? MH6\6^-/#?AVY@\F.ZCO-4BC$4LD?F*GS$'E<L
M..5&[I1<#N*<O2L/4O&WAW1O"S>)K_7],LO#:PK<G6+B\C2T\IL;7\TG:5.1
M@YYSQ4'@3XD^$_B=I<FH^$/$NE>)[&*3RI+C2;Q+A8W_ +K;2=I]CBAL#I**
MXFT^-_P\O_&S^#K;QUX=N/%:.8FT6+5(6NPXZIY8;)8=UZCTJEX[^-7AKPY!
MJVDZ?XJ\+?\ ";1072V.C:MJ\=OON8H/.*38):-0I5F;'RJ<U((]#HKS^7XU
M^$_"OA6PO_&WB[POX=O_ +!:7-\AU:/R(WG0E?+9B&>-F238V/F"$]C731>-
M?#T_A-?%$>O:9)X9:W^UC65O(_L9A_YZ>=G9M]\XHN(VUIU<3X.^-OP]^(!M
MQX9\<>'M?:XG:UA33M2BF:254,AC55;)8(K/C'W03T%=M0,*5:2E6@!:***
M'#I2T@Z4M2 4X=*;3ATH)8M<Y\2/^2=^*?\ L$W?_HEZZ.N<^)'_ "3OQ3_V
M";O_ -$O5T_C7J7'='$?L?\ _)LOPX_[ \/]:]BKQW]C_P#Y-E^''_8'A_K7
ML5:XO_>*G^)_F.K_ !)>K"BBBN0R"BBB@ HHHH **** "BBB@ HHHH ****
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M:\ \\2BE92APRE3Z$8-)4H!5ZTZDC5G.%4L>?NC-+5 %.7I3:<O2H 6BBB@
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M2+2UGFC&R27[1MD1,EE57/ /.#\'M.M9K+]B%[BUBE/_  C-\',D08D+I,1
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M/+!VX(W$G'4"OT['%?#GQQ\'_&#P?^VI=_%#P+\)Q\1M(E\,P:0%N9XHX-Y
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MU+G[NV)F#'/;CGM7S+\'/AS8:A^T+X(;Q5O\5ZKHGPFT[[/?>(M/$5T&>_D
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MFR_#C_L#P_UKV*M<7_O%3_$_S'5_B2]6%%%%<AD%%%% !1110 4444 %%%%
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M"MGX;\)Z-:Z%H=IGR;.T4A02<LQ))+,3R68DGUKHE SGO24J]:-D-#L =J0
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MS#D#J.]?H;0"000<$=Q7=A,94P<N:&SW7<WI5I47>)^*7_ZJV/#GC#6?"/\
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M_P#??_UZ/[/L?]G_ +[_ /KT>T78.9&#3ZV_[/L?]G_OO_Z]+]@L?5?^^_\
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MYJ=KV=]=5\T?(7Q%^)VH>&_"=S\6]!T>2^\7^&$6'Q/X>@D$3S0 [6F*\D*
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MVHW+-*L#D8>.)P<#RSM4GG?(6'0$U]17'@I-9CEN-5E675GC9(+J%1_H!*D
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MDX]J?7@OQB_9-L_B_P#'+P%\1YO%>I:1+X6,?_$MMD#)/Y<IE78^08BQ.UR
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MPZ4M(.E+4@%.'2FTX=*"6+7.?$C_ ))WXI_[!-W_ .B7KHZYSXD?\D[\4_\
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M-1MH#;-Y;AVSMD*Y52!R21S@<U@>'_BUI.MV]E#'(;G5IBB/9PQE#D_>*[\
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M8_\ ^39?AQ_V!X?ZU[%6N+TQ-3_$_P QU?XDO5GA/PMUF?X)^*H?A3XCG?\
ML>9F;P=J]PV5N+<<_8'8_P#+:'.%!^_'C'(->[5SGC[X?Z'\3/#-SH/B"S%W
M8S$.I5BDD,BG*2QN.4=3R&'(KRRW\6^/?@4/L?B^ROOB!X.BX@\4Z3!YFHVL
M?87MLO,F!UEB!SC)4&M))8KWH_'U7?S7GW7?;LJ:]KJM_P _0]VKS'7?V<?
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M]-;=%<UE"<JB=ERK^K['DE>M_LFP2W'[1'@H1 DI=22/C^X(9"WZ5Y)7U_\
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MW7([V]UGPGO.E6YN<6<,C$DRF''S/G!W9_@3^[7H=*.M)I/<D=TKQ#]LH$?
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MV?J:3O+]Y'?K_F>&Z[+=VVE74EHN+J-<A67)&#\PQZCGBN5A^(["R82VH:[
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MY@.W;COG%4?"GCKPWXYAGF\-^(=*\0PP,$FDTJ^BN5C8] Q1C@_6OFCXD/\
M#*Z^&OAJ]\,6ELWP83QU]H\7#3+>1=.FC".#*5QM>T%U]G,AC'E'!)X#5O27
MW@;7?VD?AK-\+I='O-7MXKS_ (22Z\,&)K9='-LPCCNFA^0DW'DF)6^88<C
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M6W2*-+=4\L0J@"!,8VA>F,=NE5=&T#2_#L#P:5IEEI<,C^8\=C;) K-_>(0
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MN:A_X1&7_GY3_ODU5E\2WTAX=8QZ*O\ C4)UR_/_ "\M^0_PKI4:O<UM+N:
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M ,_#?D*/[8O?^?AOR%%JG<5I=R]_PB\O_/=/^^32CPO*/^6Z?]\FJ']L7O\
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MLD6E_"CPK<Z?:7IW6EM=W,SV[7+KW"@HS<\B/'%=9\<? GC#X-_"ZY\3Z/\
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M/_\ 9<\3W^D_'31= ^'T'BA/!%S'<MJ_A_Q+9<:%P3B.?T+A..,\ ACR/O\
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MR3_P4)^%7A#P'HO@C4/#GAW3]"NKC4);:9M/@6$2($# ,%P#@C@]>M>EA:.
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MP3=_^B7JZ?QKU+CNCB/V/_\ DV7X<?\ 8'A_K7L5>._L?_\ )LOPX_[ \/\
M6O8JUQ?^\5/\3_,=7^)+U84445R&0E+110 F*6BB@ I,5Y7\?_C_ *=\"M&T
MMWTRZ\0:]K%S]DTO1K+B2YDXSS@X RHX!)+  <UY[X2_:_U?4/BEX7\ >)_A
MEJOA+7-9=]QO;I3'&@1F5TPO[P'8P/3!KMIX.O4I^UC'37JNF^F^AM&C.4>9
M+0^EL4M?(=S^WCJMU:^);O1OA1JVJV/AN\DAU2]COD$$$2L5#EMF=QVD[<<
M9)Q7=>.OVP-%\/>"O!&J:!H6H>*-=\91"72="ML),PX#;S@XPQV\ Y(.. 2-
M)9=B8M1<-_-=KZZZ::ZE/#U4TK'T#QTH]Z^)O"_Q5U[XC?MM^ EUOPUJO@C4
M++0[RWN]&OI]R.WES.LJXPKJ01SC@@CM7T'^U3XNF\#_ +/?CG5K:X:UNDTY
MX(9HW*NCRD1J5(Y!&_.1Z4JF"G3JTZ3>L[?B[?,)47&48=6>K=:!S7PK\$?V
MBM2\(?LE?$--=O+I_%/A5FMK=KZ5FG)NQFV)+$DX=F_!172?L3_%N3PO\$/'
MD_CK4[TGPIJ+S7DVH2/+/'&\2,$^8DD[E8!?4XKHJY95I1G*]^5I>M^J^]?>
M:2PTHJ3[.WJ?8])TKY1L?VZ+JW33M>\0_##7O#_P^U*=8;;Q+*X=0&.%=T"\
M*<9X)X!QNKJ?VT/B==>%O@]!I?AVZ<>(/%UW#I6FO:2$2;9""[H5Y^[@ C^^
M*P^H5U5A2FK<S\FO/;MU,_83YE%K<^A>#1BOF;]B?QOK/_"/>+/AYXMNIKGQ
M1X,U*2WF>XF:5Y(')96#-RP#!P#_ '2M7/A)^UOJ/Q=\=)I^E_#G5_\ A%)[
MN:SB\11SQR+$T8)+3Q\>4#QC)SR,9.<*I@:L)SC'51Z[:/5;]UJ$J$DY)=#5
M^)7[)MCXT\:W?BO0?&GB;P-K%^H6^;1+PK%<X &2A/RD@#.#@XSC/-=K\$_@
M=X?^!7AJXTK1'NKN:\G-U?:C?R>9<74I&-SG '3H![]22:]$HK&>*K3IJE*7
MN_Y;$.K.4>5O03%+117*9"8I:** "BBB@#Y[_96_Y''XZ?\ 8\77_HM**/V5
MO^1Q^.G_ &/%U_Z+2BN[&_QWZ+\D;U_C^[\CE/\ @HE\4+CP;\)K+PU8S-#=
M>)KAH)F1L'[+& TH]?F)1?H6K\SJ^UO^"GBS#QCX#8Y^SFPNPOIO\V//Z8KX
MIK[[):<88*#76[?WV_0][!14:*:ZG8_"KX2^)?C-XJ7P_P"%[);N]\LSRR2O
MY<4$0(!>1NPR0.Y). *V?C+^SWXO^!DNG'Q%#:RV6HAOLNH:?/YT$K*,LN<
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M%E?I)?BG?\D3'6D_)_FO^ >S4HZTE*.M8HE;#J\N\?? ?3O'OQ:\$>-[B[>
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M56R"1SRWQ!\5_$J/Q]\'-*\9^&])T^UO/&-O+%JOAG5)KBW5EM;G=;3K)&C
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M<SE?2Q/=_M>?#:QLKK4Y[W5T\-VYD7_A)O[$NO[)F=,Y6.ZV;')*E5(^5FP
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MD%RZA&+?PYP'_ASD5R/C#X5Z]X[_ .&E]#M8IM//BJUL+72KVY!CAN2NG!"
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MT*YX]*1>E'LH=A\B.B_X2E/^?9O^^A2_\)0O_/LW_?0KG:<>E+V4.PE%&_\
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M:.M.I,!R]*3O2KTI.](74=7._$;_ ))WXI_[!5W_ .B7KHJYWXC?\D[\4_\
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M@> ]!T_Q)JSZYXA@LXUU'49 H,]QC,C *  NXD  = *=\1O^2=^*?^P5=_\
MHEZ4/C7J:QW1PO[(O_)L_P ./^P/#_6O7J\A_9%_Y-G^''_8'A_K7KU;8O\
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MVE=;^ NG:_8Z5HND:Q;ZVT9NEU5'8;45EV@*0""'.0:]+_:&_:=T+XJ?L_\
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MWCYQVZG6Z3^R!\-M&TGX>:;:V.I+:> M0EU30U;4'8QSR2K*YD./W@W*.#C
MXKI]2^"6AGXHZE\3]-C,7C^?1'T6"ZNY6DLUCV_('@&,C<%S@Y(S7BWPZ^.G
M[0F@?%#P]X3^*WPDM9=-UZ4PP>(/",OFPVC ;F,XWLH51R<E3CINZ5QUU^UW
M\>_$?Q4^)GA_X>_"K0?&.E>"=5>QN-MT\5TZ;W$9 ,HW,PC;A%//:L[Q2V)N
MCY^\7_L@?$CQ#>ZYIJ?LTZ18>)=2F=$\2:5XB>/1+?><&XBMFD(4@$X!; S]
MSC%?<+?L:>"?%O[/O@3X9^.K3^VG\,6$4,.J64A@GAGV_O7A?&0K,3\K @@*
M2,@8K?"K]KZ'XP_ 3Q+XW\/>#=3O/%_A\M9WO@N &2Z%[P$C4A02C9)W;<@(
MX(RM>??"7]K+XNVWQ]\'_#KXP>!='\/R>-+-[S2AI,Q-S985V"W$9D8C_5D'
M.TC(/."*A*$?F)61Z=\*/V'OA5\%_&VF>+_#-AJL7B2PAFA6_O-2><R^8K(S
MR*0 S;7(&,=!]:^._BS^R_\ $;6OB!XHNK[]FS0_$VN:C/(UMXB\.:Y+9:5,
MS9VW$UJTOW\G>5)0%NH/?]01EL #)/0>M?&WA#_@H#'XG_;*O/A-_9=@GA!K
MZ?1K#74,GG37T:="2=FUI%=  ,\J<\U4XQLD]!M([7X/?L9^']/_ &3/#_PB
M^)-A;>(3"TM]=F"0K]GNI)&?,$HP04#;=PX;G@@UT/P8_8L^&'P+\5MXGT"Q
MU*_\0B$V\.I:UJ#74EO&1@K&, +D$C."<$C/->F^,OBEX.^'=SIEOXI\4:3X
M=FU,N+)-3NE@^T%,;]I;@XW#/U%<JO[2WPXUOP!XK\4>'/'&@:O9>'[626ZG
MBNP8X'VGRA(."%=]J@]"3@&G:*^0[(T=&^ _A30?B?XO^(6GIJ%IXJ\4VBV6
MH7<=XVT(JHJF)<8C8>6I!&>1FN0L/V+?A+8_"K7/A[_PCTUUH.MWHU&_FN[M
MI;V:Y!RLOV@_,&7D#V9^NXY\#\%?MS>./B3\,_A3K>B3^ [?7]9\3OI'B/3+
MV]\@V\)D @6)'DW!W3>V06;(7"G)KTCPE^V;IVF_&[XT^&?B-KWAWPKX;\(:
ME!8Z/<W#&&>YWE]P?+$R, H/RJ,9YJ>:#%=,^D/"'ABV\%>%M+T"RN+RZLM-
MMUM8)=0N#<3F-1A0\AY8@8&3S@"M9>E8V@>-?#_BOPQ%XCT;6]/U30)8FF34
M[6Y1[<HOWF+YP ,'.<8QSBN7\#?M"?#/XE:]-HGA7QWH.OZO%N+65C>*\K =
M2HXW@>JYK6Z6A1Z%3CTKA/B'\=/AY\);RRM/&7C/1O#5U>#=!!J-T$D=<XW;
M>2%S_$<#WKQ;X*_MC6GBKQ1\9V\;Z[X;T/PAX2\00Z5I&KI)Y<4\4IGV%Y2S
M*Y81*01@'FI<DG829]2+2US?B[XC^%?A]I=GJ7B;Q#INA6%[,EM:W-_<"-)Y
M7!940_Q$@$@#M69\<?'EW\+?@YXU\86%M!=WVA:3/J$-O<[O+D>-<A6P0<?0
M@T-H9W(Z4=Z^&/A#^WC\2M0\4_#"/XE_#;3=$\)?$:7[/H>NZ1=LQ,A8*"T;
M.YQN900=I ;(SC%?5'C+]H#X:_#OQ/;>'?$_CG0M!URXV[+"^O527YONEA_
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MI6LQIQO>QW7@CX1^$_AYX(N?".BZ/!!X>N9;N6>QD4.DQN79YE8'JIWE<=E
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MHW3,2,%EB[@U[$O2D[U*DT[BY5L.KG?B-_R3OQ3_ -@J[_\ 1+UT5<[\1O\
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MZGKGB'7$LDOK'3]1NPUAITAD<9BC SQC(!. ><$@5Y3\%;[X(Z!\2_V@;?\
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MO6GS.]Q<BM8^>M.^#WQ)N4T;1=3'P\TS3[&:(WGB;1M(W:GJ$49!VK;R1>5
M\@&';<X&YMH'&-^?X>_$/P!XQ\4ZA\/KCPWJ.A^)[PZI<Z7XDDN(&T^^9%26
M6&2%6\R.0(K&-@"&!PV#7L[4HZ4<P<B/G32/V;/%EKX-U'[7XPL9O'T7C.;Q
MGI>NQV3"V6=XUC,,T&<^4R>9&55LA2I!)%:MW\.OBMX\\>_#_7?%6H^%=&TG
MPKJW]HOHVB-<7!O&-O-"9&FD5=I7S!MC"X^9B6) %>Z_Q"EI.;)<$C@/C!\-
M[_Q]I.AW6A:I#HOBKP[J2:OH][<PF:W$RH\;Q3(""T4D<CHVT@C((Y%<]H/P
M^\>>,/B+X:\3_$2X\/V5CX8:6XTO1/#<D\ZRW<D1A:YGFF53A8VD"1JO5R2Q
MP*]@]*4=:GF>Q3BGJ</\%_A_=_#/P(-"OKF"\N/[3U&]\VV#!-EQ>33HOS '
M(60 ^X..*Y;4_A[X]\$>/_$GB/X?7.@:CIOB>:.\U/0_$4DUN(+U(EA-Q!-$
MK\.B1[HV7JF01DBO8Z7!*\ FCF=VQ<JM8\?B^&'C77-<^'>N>*?$&CZAJF@:
MKJ&HW::?:/;P+%<6<L$<$&26?87!+R$%ADX' K.^#'P!U?X9ZIX"NK[4["\7
MP]X.G\.3K;!P99GNHIA(FX?<VQD<\Y(XKW =:?@^AQZXHYG:PN5;GA?BO]G_
M %GQ!XV\1:W!JEA##J7BGPYKT4<@?>D6G+&)4; QN8H=N..1G%26/P[^)?PM
MU;Q!:^ +GPOJ_A;5]1N-6M[/Q)+<V\VE7%PYDG5&A5A-"9"SA3M9=Y&2,5[B
M./:D/6ESMZ,.17/&_$WPI\<W4?@GQ3I_B?2KSXE>'(+FVN+B]LFM]-U6WN2I
MGMVCC)>$ QQ%'&X@Q_,#N-<OK_P0^)OQ(\4ZEX@\5:WX;L1/X1UCPU9Z+I8G
MDAM'O%CVS-,ZAI22GS?*NT*H4$DFOH[]:7L:%-H'!&/X*T67PQX1T#2)Y$FF
MTZPMK222/.UVCC5"1GG!*G&:\A\#?L^ZQX5@^$R7&IV$Q\':KK-_=^4'_?I>
M+="-8\CJOVA=V['W3CM7NN,=L4IZ"I4FA\J9X7XK_9UU'Q+JWC[5;?7H-)U;
M4O$&F>)/#]ZD)E^PW5G:10KY\9P'1RCJRJ>4D/(-5=>^&WQ>^)7B+P-=^*-1
M\(:'I7AG7[36)M/T1KFX;43$'!)DD1?* W96, Y)^9N!GWY>M.JN=D\B/FG5
M_@!X[A^#Q\ 64?@?Q#IE]/JTE]'X@AN,0/<WDL\%Q"R@Y:)9<%<*=PRKC%?0
M'@_0Y?#'A/1-'N+^;59].L8+.2_N/];<M'&J&5_]IBNX_6M:E7K4RDWN-12V
M%I?X124O\(J66 ZTZFCK3J3 <O2D[TJ]*3O2%U'5SOQ&_P"2=^*?^P5=_P#H
MEZZ*N=^(W_)._%/_ &"KO_T2]73^->HU\2.%_9%_Y-G^''_8'A_K7KU>0_LB
M_P#)L_PX_P"P/#_6O7JWQ?\ O%3_ !/\RJO\27JQ1WI*4=Z2N-F0X]*1>M*>
ME(O6A@.IQ^[3:<?NT@$'6G4T=:=0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!\]_LK?\CC\=/^QXNO\ T6E%'[*W_(X_'3_L>+K_ -%I
M17=C?X[]%^2-Z_Q_=^1]"4445PF 4444 <AXCTDVDYN(Q^YD/./X6_\ KUC5
MZ++$D\;1R*'1A@J>]<=K&A2:<YDC!DMCT;NOL?\ &NZE5NN5[F\9W5F9=*?N
MTE*?NUU&@+UI:1>M+28#QTI/XJ4=*3^*A[ +3ATIM.'2D M%%%(!5Z4@ZTJ]
M*0=:!,<>E(O2E/2D7I0 M./2FTX]*3W! M+2+2TF"'#I1WH'2CO0'46G#I3:
M<.E F*.])2CO24D'0<.E+2#I2TNHALL23Q/%*BR1NI5T=0RL",$$'J".,5X,
M/#?B_P#9BU>[U?P!83>*?AS=2F>_\&HV;G3F)R\MD3U7N8__ -8][IRUK3JN
M%XM7B]T^O]=RXRY=-T5/A;\;_!OQBTS[5X:UB*YF3B?3YOW=W;-W62(_,I'3
MT]#7=YS7@GQ!_9Z\%?$;41JMYI\ND^(5YCUS1)C9WBGU+I][_@0-8$/PZ^-/
MA!?+\,_%^'6K-?N6_B[25FD&.QFC.X_4U,L-1J:TY\OE+_-)_BD)TX2^&5O7
M_-'N_CSP!I'Q'T>+3-825K>*X2Y0P2;'5UZ8/H02#[&I[#P1H&E^*-0\1VND
MVD&O:A#';W6H)&!--&GW%9NX']!Z"O"?MO[2C+Y?]H_#A1_SW%O=D_\ ?.:K
M3_##XP^,1Y?BOXQ-IEDWW[3PAIBVK$'J/.?+#ZBHC@5"3DZD5?1VN[KY(SCA
MHQDYW2;W?>VQZO\ %?X^^#/@Y:K_ &[JBOJDW%KHUD//OKICT5(EYY]3@>]>
M.:=X&\6?M">([+Q3\4;,Z)X4LI1<:/X$+[BSC[D]\?XF](^@[@<Y[CX<? /P
M5\+KE[[1]*-QK4G^MUK4Y3=WLA[GS7R5_P" XKT+O71&5/#K]Q\7\SW^2Z>N
MK]#9.-/X-^_^0      #C I],I]<K,F*.]>._$[]JGP1\)?BOX3^'VNG4/[;
M\1^5Y$EM;;X(!)(8HC*V01N<$?*#CJ<5[$.]8.L> _#7B'Q!I6NZIH&FZCK6
MDDFPU"ZM4DGM2>3Y;D97GGZ\CFG&W4EWM[IT&,'!ZC@U\>?%#Q;X$M?VE/&^
ME_$'Q=XOTC_0=(70['P[J&HQ%W:"5IA'':Y#2':IP1DXSTS7V$.E>+>*/V>_
M^$Y\7_$>]U2]%E;:]%H\FC:AI\A6^TN]LHY0MTAP K*[J1@G<NY3P:(-)NYG
M--VL<OX:^-OB;X;?!KX?6?BFQGU;XA>(IKNWTZT\0WD6G2M:Q.[I<7\S#;$R
MV_E%\ L78 +N)KH?"W[35G#J?B#2?',&DZ%?Z1H\WB#[9H6KKJEC=V,) F9'
M"JZR1DKF-U!.X%2><0>-_@_XO\>Z%X!\0:W9^$]9^(/A?[1'=Z?J,9ET?5HI
ME"2CYHRT+MY<<JMM;8VY>5.:CT/X#W_BRV\86_BOP[X0\%:-K>BRZ)#H_A"T
MBDN(Q+_K+F6\\F,E^@6-0$P,MDXQ7NO5DKG3LCDOC?\ %WXFW'[//C+Q!=?#
M@Z'X<U#0YS!-:ZX'UG3XY$_=7$\ 0*H&Y2RQR%T!SS@U[CX$^(1\1>,O$GA5
MK(PMX=L=)E-V9=WV@W4#N?EQ\NWR^N3G=VKRGQUX$^.OCSX2:Q\.[B7P;:M=
M::^G2^+$NYS)?1[0HQ:>7B!Y  '8NRKEBH/%=1JW@;Q]X'^(E_XK\#6F@:_#
MKFE6-AJ>E:U?261AN+176*>*58W#(5D*LA /R@@TG9JW]= 7,G<=)^T66T*1
MK'PU/JOB:Y\4ZAX6TC0[>Z53>2VKN'G>5AB*((C2.Q!V@8&XD5O^%_''CFVU
MJ:T\<^"['1-,6SEO1K^BZM]NLH1& 7CG#I')&VW)4A65MIZ8KA;+]GOQ/H?@
M[PSJ>FZYIC?$O1M<U#Q')/-%(-,O)KXR?:[0@?.D120*K@%@8U8@Y(KM=$L?
MB+XSO;VV\:Z=X<\/^%;C3I[*;2]*O9;^[NWE787,[)&L2*I;"A6+%N2,4I6Z
M#3EU/,A^V)?OX:/CE?"^C'P %-S@^)H1KILAS]J^Q;=OW?G\GS/,V]MW%=_K
M?QHUK7?%\GAKX:>'++Q7=6=C;:AJ.JZGJ1L=/M8[A"]O&'6-WDED0;]JKA5(
M)/(%>::7^SOXST+PK9^"K/PE\+Y([1%LH?'MUIL<MZ+5<*LCV+6Y5[D( "3)
ML+?,>N*]#U/P!XU^'_Q"U;Q/\/[?1=<T[7K6TAU30M8NFT\QSVT7DQ7%O+'&
MZ@&+:KQ%0/D4J1TIOEOH2G/J9W[/7BW6O%OQ0^,LNNZ3>>'[ZUO]*MI-(N;D
M7"6SK8_,87'RM&_#A@!N!R0#D50\>?%G3/A!XN^,GBBW\.:AJNJ:1:>'1=QI
MJ;LMZMP[11K#"V4B= 3]W_6$C..M=;\%?A]XS\+>*_B#XB\:W^DWFH>)[NRN
MHHM'\SRK5(;;RO)&\ D+P YY;DX7.*POB1\"->\8:O\ $FZL[K3XX_$C>&S:
M">1@4_L^X\V?S,*<;E^[C.3UQ2TYM=M/T':2CIYC+_X]?$/P[XOTGPIJ_P +
MK=-?\2P33^'XK+7EF@S"5,Z7TIC'D&-'5R4$@;[JY.*BUG]I_5/"'@KQ1=Z]
MX*8^+/#6NZ=HE[H>E7XGCN?MC1>1-;3,J[@RS#"NJD,"#CK7I'BKP-?:[\8_
M WBN"6W73M#M=6@N(Y&(E9KI(1&4&,$#RVSDCJ.M>?>,_@-K_B+Q3XUU*VN]
M/2#6O$GAK6+=99&#+#I_D^>KX7ACY;;0,@Y&2*2Y7:Z_J_\ D#YULQMQ\>?B
M+I'C6S\$ZG\,;-/%FM6CW^C+9Z^);$0Q,%N/MDYB!B:+='G8CARX"UH:/^T5
M?&VLK+6_#":9XFC\9VW@W4[""^\Z&"2:+SDN8I=H,D9C*,%*J?F(.,5V>M>!
M;[4OC?X:\8QRVXTS3-#U+3)8F8^<9;B:V="HQC:!"V3GN.M>>^*?@%XCU2^\
M=ZOI>I:;:ZU=>+]-\6^'S=!W@\RUM8(?*N0HRJOY<JY3) 8'J,4>ZP?.MCT#
MQK\4SX2\>:-X;&F_:O[0T35-8^T^=L\O[)Y7[O;@YW^;USQMZ'->8Z!^T_XL
MU#P!X:^(^I?#F+2/AYJILEFN9-8#ZE;I<.D2W/V<1[3 ))%'WPY0[MHZ5MV'
MP[\>>.?&]UXL\;6VA:#)9^'KW0M(TG1[Z2]'F76PRW$TS1I@?NHU5%4X!8D]
M!5C6O@MK6I?LK:1\-(KFQ77+32M*L7G9V^SE[:6!Y"&VYP1$V..XZ4+ETN#Y
MG=HM:S\7_%VN>-/$.@?#KP;8^(XO#<JVNJZKK.K'3[;[64$AM8-L<C22*CH6
M8@*I8#).:I?\--PW_@S1[G2?"VH7GCC5-7G\/1>#YIDBG@U& ,URDTW*+%$B
MF0RC(*%2H)8"G7'@KXB?#3QMXNU#P#9^'_$GA[Q1?'5I=-US4);";3[YHTCE
M=)$CD$L3B-&*X#*V[!(/'G_C7P%+\%O"GA?Q7JWBRRL?'O\ PE5WK-SX@N[&
M4Z&;N]A,4UM<;<O;VK1+'$DQY5D0GJ122BR6Y([_ $_XW^,-$^)WA/P3XW\#
MV6BR^(%O9H=:TO5_M=@L=O;F9U):-'$@X!5@!M.X$X(''K^V)J%]H-QXTTSP
MOHMWX"A\R9/.\3P0ZW=6B$[KJ*S*[<%5++$T@=AC@$@5AZ1XDU[XS?M)> 8]
M0U;PIK&FZ)8ZM<7^F^#+R34+>SCGM?(62YNV"CS)"^U(E7( =B3VN:1^SAXP
M\)>%8_ ^D>#_ (87]M;+]DL?'6JV"27T-J.$>:S,!$URB8&[S-CE0S=2*JT5
MO_6Y/-)[;'?7O[06N>(_B(_A'X?>$K7Q*7T"P\10ZYJ&IFSL%MKDR;3(1&[[
MCL7:J@DY8G:%YRXOBIIWQ%USX63:UX;OM,\1VWC'4-"N+*+566+3;^WM)VE8
ME,+=1,J#:& &) < @BN^\'?#*\\+_%7Q%XA,UJ^E7WA_2='MDB01R![5K@N6
MC50B*1,F O'48  KC-+^ FO6?CC3M9ENM/:TM_B#J?BJ1%D;>;2YL7MT0#;_
M *P,V2.F.YJ/=Z?UH5[Q9T[XV^/O'.FW'B3P%\.K+7/!\<DBV=SJ>N?8KW5T
MC8JTMM#Y3*J,5;8977>,'@$&JGB/Q'-<?$KQ#=Z+X9O(?&<GP[@OUBU;5Y+:
M**)[F53;R0H'2.:,JS&5022 N<<TWPCX+^+_ ,(/#"^!_"EMX3\0^'[+?!H>
MMZS?SVUQ8VQ8F..YMTB83&(-M#(Z[PHS@Y-=9#\,/$#_ !)U#Q+?ZC8WOVOP
M/%X<DFBC:$R7BSRR/*(N0D9\P8&XD<CMFAV5[![S1PO[.?Q=U^P\#_!?0O%^
MDQ0Q>*-!VZ=KD>I-=-<7$-O'*D<^Y%*RRQ>;(/F;F)ADUZS\/_B2/B%K?C.*
MSL/+T;0-4.CP:EYN[[=/&BFY*KCY5CD;R\Y.65NF*\8^+_@N[^'W[''A;P]+
M=(/'7AV'1K3P_<6'SYUR-XX[;R@P&Y6<L&R/]67R*]P^%?P^MOA;\.]#\*VL
MAN/[/M]D]RWWKBX8EYYF]WE9W/\ O4I<K]Y#CS7L>(?$+XVZMXU\(_&FTNO
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M7K2GI2+UH8#J<?NTVG'[M(!!UIU-'6G4 %%%% !1110 4444 %%%% !1110
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MFOY4<Z#F,C^(4V:&.YADAFC26*12KQR*&5@>H(/!'L:V?LT7_/-?RH^S1?\
M/-?RI<Z$V<YI.B:=H%J;;3-/M--MRV\PV5ND*%O4J@ S[U>'6M7[-%_SS7\J
M/LT7_/-?RHYT%T9E':M/[-%_SS7\J7[/%_<7\J.=!<RQUIU:/V>+_GFOY4OD
M1_W%_*CG07,QX(I]GF1I)Y;ATWJ&VL.C#/0^XIQZUH^1&/X%_*CR(_[B_E2Y
MD%RA2CH:O>1'_<7\J7R8_P"X/RI<R"YGTIZ"K_DQ_P!P?E1Y*?W11S!<H+UI
MU7?)3^Z*/*3^Z*.8+E*E7K5SRD_NBCRD_NBCF%<J4O\ "*M>4G]T4OEK_=%'
M,.Y4'6G59\M?[HHV+Z"BX7(%Z4G>K&Q?04;%]!2N*Y#7._$;_DG?BG_L%7?_
M *)>NHV+Z"JVIZ9;:OIMW874?F6MU"\$J9(W(RE6&1[$U49*,DQIV:9Y-^R+
M_P FS_#C_L#P_P!:]>S7SY!^PS\++:%(88=?AB0;5CCUVY55'H 'P*?_ ,,/
M_##^YXB_\']U_P#%UZ-;ZK5J2J>T:NV_A[_]O'1/V4I.7,]?+_@GT"".>:3-
M?/\ _P ,/_##^[XB_P#!_=?_ !='_#$'PP_N^(O_  ?W7_Q=8^SPO_/Q_P#@
M/_VQ'+2_F?W?\$^@B1CK2 C/6OG[_AA_X8?W?$7_ (/[K_XNC_AA_P"&']WQ
M%_X/[K_XNCV>%_Y^/_P'_P"V#EI?S/[O^"?061ZBG%ACJ*^>_P#AA_X8?W/$
M7_@_NO\ XNC_ (8?^&']WQ%_X/[K_P"+I>SPO_/Q_P#@/_VP<M+^9_=_P3Z#
M!&>H_.G;AZBOGK_AA_X8?W/$7_@_NO\ XNC_ (8?^&']SQ%_X/[K_P"+H]GA
M?^?C_P# ?_M@Y:7\S^[_ ()]"[AZBC</45\]?\,/_##^YXB_\']U_P#%T?\
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15(U:KG#;3\$D35DI3;1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ibio-20230630x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &H Z@# 2(  A$! Q$!_\0
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MSZ7X_P"9V_5:/\I]C?\ #S7QK_T)WA__ +_S_P"-'_#S7QK_ -"=X?\ ^_\
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M_:@_Z)/X5_\ !X/_ (NO;/B+\4?#GPMTJ*]U^\:$SOY5K:6\33W-U(>D<42
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M. >*Z%'$>U56+>T$[I:ZN]^UD^EC2U3FYE?I^;N>-T4&BO=.\**** "BBB@
MK[N_X)??>^(G_;C_ .UZ^$:^[O\ @E]][XB?]N/_ +7KQ<Y_W&I\OS1Q8S^!
M+^NI]Y4445^8GS(4444 %%%% "$@#).!5"77+6%2[";RA_RU$#E/S Z>_2OG
MK]KGXVWFB:/+X#\#P:GKGCR^C666RT0 26=J3@R2S'Y8 V-H).3S@'%<'\/O
MCE\3? GPRM)O$WP[UJ"QL4:WN]8M=4765C().^XA4">+"D9= XP,D8KLAA*M
M1)Q2UV5TF_1-W?E9:]"7)(WOVY_@+;?%+PG9>+?#X$_BJR @@CA(/V^)C_JL
M_P!X'E3]1WKY<_8O_:1UWX4>.%\&7DL T/6;KR/*U(NBV5T3M#< E03\K#'H
M>U?:_P &;;7O%$VG:K<&RU?PY?2C6;;6-+U%;BVSM*B$)P0P/)8#![X(KYL_
MX*&?LM'0DG^+'@VW:$)()=;LX!PISQ=(!TP<;OS['/A8G#RI5/;05I+='W.4
MYG3Q&%>48UWA+X'_ "O_ (?;[MF=G_P4%\$:U?>#-#\5ZF;+=871M6BL48A8
MY.[.V"?F XQ7;_L1_%=_%7P2LM"25Y]6T25[218X_,=8<[HSC@="1DD=.]8?
MPZ^+FB?M=_LHWVB:E>10^)DMTT^[CD;YEN0/W,P'4AB >.^17C7["7B;4/!'
MC+XB^%+N&_M?$,$88VD"@E9(20V4)^88.> >*R7NXI58_#-?B=,W[7(JF J_
MQ</.Z_PO>WEJW]Q]]Z9XJFEU :1XATO^SIYP?L\C,)8+D>F>BOCJI_ FNATS
M1;#1EE6QM(K197WNL2[06]<5SW@S5#\0_ ]C?:G9&"2X4ED(*\@D!U[C.,BI
M]$UI[;Q+<^&[B1[B6"V6ZBG8<F,MMP?<&O6/S\Z>L?Q9J%SI>@W4]H56X"X1
MV&0I/?'?%:^:Y_QY>QV?AB[WMAI%\M .K,> !0!E?#75]=GBOM-\1W-O?ZA:
M2!H[VWA\H7$+#*L4R0K#H<<5VU<)X'NUOO$>I^5ME6TMX;::93G]Z!DIGH<=
MZ[N@ HHHH *0]*6D/2@#YG^"G_)W'QF_ZYVG\J*/@I_R=Q\9O^N=I_*BO0QW
M\5?X8_\ I*.BO\2]%^1],T445YYSA1110 4444 %%%% !17A_P"UA\4/$7PJ
M\'^'M0\-W<5I=7FN6UE,TL"RAHG)W !NAXZUZ!\4/BSX9^#WAIM<\4Z@+&SW
MB.-50R2S.>B(@Y9JZ?J]1QA**OS722WT-/9R:374["BO*_A+^TMX&^,UQ>VF
MA7UQ;ZE9IYLVGZG;-;3K'_?"MU7W!XKEI?VX/A/%XJ;1#K-V8UG^RMJRV,AL
M!)G&WSL8Z]\8]ZI8/$.3@J;NM]"O8U+M<KNCWVBO'OB7^U9X ^%'B)-#UR[O
MFU&6T6\@BL;)[@3HQPH0KP2<=*Z+X1?''PG\;M)N;[PQ>R2FUD\NYM+J$PW$
M#=@Z'IG'7D5,L-6C3]JX/E[VT)=.:CS-:'?T445S&84444 %%%% !1110 44
M5DZGXJTG1[22YO+^*&)&*')RQ8=@HY)]@*3:BKO8:3;LC6K"'COPXVJG3!KN
MG?V@#M^R_:D\S/IC/7VK$FDU3XA8ACAN]$\/'_6S3 Q7-V/[JKUC0]R<$]@*
MW#X(T!M(&EG1[)K # @,"E?KTZ^_6N2-6I5=Z:M'N[Z^BZ+S?W6U-G&,-)/7
MRZ&WG-+7(1:!K'A-2-#G&I:>/NZ;J$Q#1^T<N"<>S9^M5I_B#J>BQ/=>(/"]
MUI.FQD"2]CNHKE8Q_>8(=P7WQQ0\2H?Q8M?)M>MTMO6P>RYO@:?X/[G^ESN*
M*CM[B*[@CFA=98I%#(ZG(8'H14E=FY@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "$X%?"W[6G_!5+P;\"=5O/"_@RQC\<>++8F.X<3;+"T?NKN.
M9&'=5_%A4_\ P5,_:MO?@3\++;PGX:O&M/%7BA7C^T1G#VUJ.'=?0MG:#VYK
M\/))'FD9W8N['+,QR2?6@#Z:^-O_  47^,WQVTUM*UO5=-L-&,PG73]-TZ-$
M5A]WYWW.<9[M7E6D?'77[*1?MJ6^H1?Q!HQ&WX%?\*X&QTN\U,L+2TGNBHRP
MAB9\?7 JNZ-&[(ZE64X*D8(-=E'&8C#Z4IM+MT^[8VA6J4_AE8^I/!WCS3/&
MEL6M',5R@S):R_?7W'J/<5T=?(FBZQ=:#J<%]9R&*>%MP([^H/L:^J/#6N1>
M)-#M-1AX69,E?[K=Q^=?>Y5F7UV+A4^-?BNY[N%Q/MURRW1IT445[YZ!V?PK
M^$7B7XS>()M%\+6T%UJ$,!N'2XN%A4(#C.X_7I6C\7/@'XQ^!_\ 9W_"6V=I
M9_;]WD?9[Q)\[<9SMZ=17J_[ [V\7Q'\6/=Q23VJ^'+DS10G#NG\04]B1D"N
MG^#8^%OCKX_^%K+0/ ^KV%B+:\:]MO$\QO(Y\*NW8LC,!CG\Z\:MBZM*O-6O
M"*OMY-[WT^YG%.M*,Y*VB7]=?T/CP,"2 P)'4 ]*"R@X+ 'T)YK[%\1ZOX:^
M,OP#^(ES_P (1H'A:?PKJD4&FW.D6PBD2)I%7YVZL<,<]CZ5V/B.[T'X3?$3
MP%\+M*^$>B>(?#VI16CSZI>V)FN;MW(+2I)C'R'DYST/053S!KW?9OFUTNNB
M3W^:']8Z<NI\?^'/A'KGBGX<^(?&UE)8?V/H<B1W2RW(6=BV/N)W'S#N.^,X
MKB-Z\?,O/3D<U]N?%+P;H&G^&?VAC:Z)I]J;#6+%+7RK9%^SJ1%D)@?*.3T]
M37H%UJ?@VP_:!\-?"Y?AKX6DTO7='1]0O7L%%PSF(LNP@84 +]<G.:P69-)R
MY;[OM9*,6_7<CZR]7:_^5D_U/SD)"C+$*/4G%*.>G-?<WPO\!^!_A;\(+[Q9
M/<^%K'5KW7+JP74_%VGR7]O:Q12NBPJB'Y6(3.21G)Z\46GPN^#_ ,4_VA_"
M/]E7&D7<4NF3WVM:/I,$MO:37$>PHRQN 0C[R=HSG9[G.KS."E+W'RJ^MNW]
M=R_K*N]'9?H?# 96SM8-CK@YQ1N4G 92?0&ON+XF:C\)_&7P\\866KZUX#CU
M&QB=M%F\,Z-<65Q:3J"5@E<@AMVT+@XZGCIB7XGZ)X9\0?&+X9_"B/PQHFBZ
M'J\-GJ6IWUG:+%=W3".0B+S%QM5@@!QR23S3CF-]Z;6]_1).^NX+$=XO_ACX
M8#*20&4D=0#S2/(L:EF8* ,\G&:_0OQ:_P 'KV\\4^#_ !'J'@'3M#LHY+>V
MMM+T6XM]3TN53M1WGP03GKP 3CJ#SY@-4T3]GC]G?P!K.E> =$\:ZCXN$LFI
M:IK-J;B,@'B!,#*D@X _V2<$T0S'VB25-W;22VOHWN_0(XCFVB[L^=?B3\*M
M<^%4^B0ZY]EWZOIT>IVWV68R#R7)"[N!AN.GZUQ]?4?[?KQR^-? 3Q:>=)B;
MPM 5L&ZVP\QL1_\  >GX5\N5VX2K*O0C4ENS:E)S@I/J%%%%=9L%?=W_  2^
M^]\1/^W'_P!KU\(U]W?\$OOO?$3_ +<?_:]>+G/^XU/E^:.+&?P)?UU/O*BB
MBOS$^9"BBB@ KAOB[\5M&^$OAN+4]9FFBCN)UMHEMX_,D=SV4?0'D\"NYKS[
MXV_#&+XI>#_[/.!=6TRW5N3W9>H_$$C\: /GRVM[O1/B9XHM["WTJ>'Q>R:N
M+R=#-*5\M$C(E&"=NUL;20,]CUYG6O'/Q9^&7Q6M/"#>-_"V@V6H:5+J4>K:
MU8RWZR+&ZJ( @>)LC?G)+$#.,U]"^"_A[I5MX=72+ZYBGTJR3SY$NN)+)R3D
M1OD&+HV[].M>2_M0?!+5_CK::/<_#K3XX[[P^YN;+4[EO)MYP1B2$,?FD$@X
MW8QG!W5V89P=6U3JFDWLG;1ORO\ @3+;0[S]FSX._$+X:>+O%NI>)M4\++H.
MM!+B+2/"L%S%;B[S^\N1',2(BZ_>5"02 >O7V'QQXA\+:'H4Z^+=5TK2])N4
M:&5M7N8X(9%(P5)D(!XKP:S_ &B_&WB;0=/\*>"OA?XGM/':PI;7ESXKT]K/
M2]+95"O+)<9VS@8)58=V_CI6UX>_9/\ !NFN_B+XA1+\4?'=RN9M8\16XND5
MSSY=K:G,<,8/157/J3756A>3J8R6O96;=M-=;)>>K?9K42?\I\$?%;X%:Y\"
M/&UQ\2/@9JMIXX\ B<RM%H]Y'=R66#EHV1&)DC7C##)'?IFN:\;?M6Z1XH^)
MNB_%;0M-;P_XWL]D6OZ.^3!?H."X'#!L9#*>H[\5]]>!? 5I\+M+U..^TF'P
MLMQ/+<VM[:6WV:&*1NTBQ_*4.!VR/:H?^&:_AE^U)HTU[XZT>+4_$-HOV1]1
ML)A#-'T(99H\&0'L7W<?C7@5:$6W[)V7F?28;-G&2>(CS-*U^MNSZ->ORL>W
M_!GXK>'_ (P_#G2O$_AZ6/[!<1 /"N ;9P/FC8#IC^6#7'^,-2N]4\1KK5A<
MW6D:5SIC:I:LN]VW9!4,,;0PQD]^!WKY^M_@%J7['GC2RLO!>LZE??#KQ#F*
MYL]4N=SP7*\J-R[<AAD XR*]VTGXB^"O%^A'1]1TC4@8QY<ME"S2A"O0 1/E
M1GD9 _.M8.37O;GD8F-*-2]%WB]5W7D_-?CN:\^C_$CPWI]U??\ "166L6\*
MF9$O%,,P4#.UB@9&S_NCZU7\0>'M6\:^$]/U+4-4E@:_\LF2WS$FGQMU('5C
MVW<8SD8KSW7/BG9:?JVFZ='KDEIX=EN?LDUOJMSE8P!GYR1N!P.!D^]>DZM\
M8/"5AHS"S\5V][$L9 B6:!U9<<#&WI[5H<IW/@W0X/!>G6VAVZI]CC4FWD10
M"W<AO5N^>]=-7@OP(U'Q7XUU6;4KHR6?@^T9OL,<T9$ERY[@D ^6O;%>]4 %
M%%% !2'I2TAZ4 ?,_P %/^3N/C-_USM/Y44?!3_D[CXS?]<[3^5%>ACOXJ_P
MQ_\ 24=%?XEZ+\CZ9HHHKSSG"BBB@ HHHH ***\7^+_[5GA7X+^+[7PWJ^E:
M_J.HW%H+U1I%D+@"/<1S\X/&TYXK:E1J5Y<E-79<82F[15SF/VY= UO7OAOX
M?_L+1-0U^ZM->MKI[73;=II=B;B3A0<#W]ZX7XL:IXP^+MGX*^(MG\,->A_X
M0[6C+=>%]6A"W-Y"54^;&F/FP>,8)ZU[7X>_:?\ !_C3X:Z]XP\-+?ZXNBQ-
M)=:1!;%;Y& )"F(]S@X(R.#Z5WW@+Q<GCOP;I'B!+"\TM-1MUG%G?Q[)HL]F
M'K_3%>G"O5PM.,9T]8MK6_5:JWIU.E3E2BDX[/\ ,^5M(\/^*?VB_C=<>-H?
M!^J> =%L] N=+6XUF+R+F\FE1E'R]2%W=?;KSBN$A7QO8_ 6;X$'X0:Q)XC+
MM:C5TMQ_9S R9^U&;ID#OGL.>U?H'G%<C\5OB18_"7P#JOBO4+6XO;/3T$DD
M%KM\Q@2!QN('?UJZ>/E*481III6Y5=Z-7MKUW'&NVU%1[6/CW7M0U'X*?M-^
M#B?#5]XWN=%\&PVUS!I<8EN4"[E::-3UP>/7%>J_LP>'/$.N_%3X@_$S4_#%
MSX-TO7Q%!9:7?)Y<[A<9E=.Q./U[]:];\/>"/#/B?Q7I/Q3AM+F+7+S24@B>
M2<[5@<;PI0';NYZUZ!FHQ&.4H<BC[S23?SN]-MQ5*]X\J6MK,6BDS2UXQQA1
M16=JND-JA3_B87EHB]4M9 F[ZG&?R(H OO(L:EG8*HZDG %>;?$G]H3PA\+9
M[2+5Y[F<W(8H=/B$X7'4-@\&NM3P/HOF"2>S^W2#^.^E>X/_ (^2*R/B!X"\
M%ZUH)F\2Z+8W6G::&N565-BQX')XQV[&@#S<_MP?"I,"35+^$^CZ=+D?I75>
M$_VG/AMXV8QZ3XDBGN!_R[R0R12'V 91G\Z\:^'WC[3?'=X/#_@/X8>&]-U
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MC@B@NH&;#.0-Q=@" .OS9]*T-?5;Z&ZT#PO8PW%U*W^F7FT)!$_=I7 ^9O\
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M]'^,OV4M/^('QV&MZ_H^E:AX%304TR/3V=DEBE1B5**H&T ' (:O3=-_9_\
MA]I'@&\\%6?ABTM_#5X<W-BA<>>?5WSO8\=2:IYA1IQ@KMZ1TTLK.]_7I^I7
MUB$5'KM^?YGR7'I&G_%_XQ:%X-\>>)+[0_#.E>$[&ZTRPM[\V:74K1+N??D9
M(Y]_E^M4/A=\/I/'/AKX[^&M#\3:AK1TZZADTC5)+UY)&>(,R8?=SRNTD<'%
M?7OCC]G7X<_$>PTJS\1>%K348=+B6"S)9T>*,  ('5@Q7 '!)J;P[\'/#?PJ
MT773\/O#MAH^HWT/^K$CI%)(JD1[LEMH&>PK+^TH>SY873TLM+)IWO\ /J1]
M9CRVCOIZ;GS'\&_'>K_M4_$SP0MT+NTT;P5IZW.KIO:-;C4 =BJV#\P^7.#Z
MGTK[='%>1?LS_!FZ^#G@>YAUB2VN?$VK7DFH:I<6F3&TC,2%4D#Y0#Z#J:]>
MKS<?5A4K<M+X(Z+]?Q.:O.,IVAL@HHHKSCG*>J:K;:/:F>Y?:N=JJHRSL>BJ
M.Y/I67;Z/+KKB[UF(>7UATYOF2,>KCHS?H*UY=.MI[N*ZDA1[B($1R,,E<]<
M>E6: (+6RM[%-EO!% G]V) H_2IZ** "BBB@ HHHH ANK2"]A:&XACGB;[T<
MJAE/U!K%M?A_X:LKY;R#0M/CN5.5D%NN5/J../PKH**SE3A-IRBFT4I22LF%
M%%%:$A1110 4444 1SP1W,+PS1K+%(I5T<95@>"".X-<BCR> ;U8G+2>')W(
MC(5F-DY.0IQG]V<G'"J@7!/-=E45U:PWUM+;W$,<\$JE)(I5#*ZGJ"#P0?2K
MC*VCV*3L2*P=0RD,I&00>#2UQUO=S^!+E;2^E>?09&Q!?2LS-;'&=DK'/R\,
M0YVJ,JO7&>P5@R@@Y!Y!%$H\OH)JPM%%%0(**** "BBB@ HI#Q7YR>,_^"D?
MB+P]^W"G@V!+,_!^QUN'PUJ-^;3<PNW0J[^?G"[9<_+W6)C0!^CE%?+/[?'[
M0OB_]GOPI\/[_P (3V<%QK7BBWTF[-Y;"8&!XW9@H)&#E1S7TWJMR]II=W/'
M@21Q.ZY&1D D4 6Z*_+OX!_M+?M;_'SP_%XDT?Q1\-;/1EU!K*6'51';7)V%
M=Q$?/!#<'/-?:GQ&_;8^"GPE\1:UX?\ %GCVRTG7='2-KS3Y()VE7>H90@5#
MYA(8'"9(!R<4 >X45\V?$3]I_0?B3^R[XX\<?!SXAZ+;W6FVIVZQ?0N4L),@
M_OH6C+J2N=NY",\X(!KYT\=?M\:]\+KO]G'2]6^(>BWTVL017WC6^M-,9XI+
M.211',A,8*Y590=B@Y4G &!0!^CU%>)?%3]M+X,?!:XTVV\7>.;+3KO4(([J
M"UBBEN)C"XRDC)&C%%(Y!8#-=)=?M'_#6S^$[?$QO%]A+X%7;NUFVWS1*2P0
M*512P;<0"I&1GD"@#TFBOGG1O^"@7[/_ (@\8V?AFP^)6F3ZG>%%@8Q3);NS
M8VKYS((PW(X+#!X/->A?&7]H3X>_L_:+!JGC[Q/:>'[:X8I;I*&DFG8=0D:!
MG;'<@8'>@#T2BO-O@O\ M&?#G]H32[F^\ >*;3Q!';$"XBC#Q3P9Z;XG"NH/
M8XP:])H **** "L+QQXXT/X;^%=2\2>(]1@TK1M/B,UQ=7#;511_,GH!W-;,
M\R6T+RRN(XT4LS,<  <DFOPS_P""E'[:=S^T)\0)O!_AN]=? .@SF-1&V%O[
ME20TS>J@Y"CIW]* *W[;'_!1WQ7^T=J%[X;\+3W/AGX=HY1;:)REQJ(!^_.P
MY"GM&./7)Z>#_ +]F#XB?M*^(?[+\$:%+>Q1L!<ZE/\ NK.U![R2G@?[HRQ[
M"O8_V#/V#]4_:K\1MK&M-/I7P^TZ4+=WJ#;)=N.?(A)[_P!YOX1[XK]R?AY\
M./#?PI\)V'AKPII%MHNBV2;(K6V0*/=F/5F/=CR: /ASX!?\$>/AWX(BMM0^
M)&H3^.M84!GL86:VT]&], B23ZD@'^[7W'X'^&GA3X::4FF^%/#FE^';%  (
M-,M$@!]SM )/N<FNEHH 3 STI:** /&_VK?V;-%_:B^$FH>$M486MZ/](TW4
M-N6M;@#Y6_W3T(]*_GZ^-GP,\8? #QQ>>%_&.D3:;?0L?*E*DPW,>>)(GZ,I
M]OQK^FFN.^)WP?\ !GQF\/MHOC7PW8>(]./*Q7L08QG^\CC#(?=2#0!_,1TH
MK]5_VT/^":OPC^$_@!O%7A237M+N&O8X/L37JSVZJV<XWH7[=V-?&^D_!GPS
MI4JR/;S7[KR/M4F5_P"^0 /SKV,'E5?&Q]I"RCYG91PM2LN:.QY+\.OAS=^,
M+Y)YHVATJ-LR3$8W_P"ROK_2OH^"".U@CAB4)%&H55'0 4L4201+'$BQQJ,*
MB#  ]A3Z^\P& IX"'+'5O=GNT*$:$;+<****]0ZCTKX ^%-'\7>.EM=3\<#P
M%>Q1&;3-28!5-T/N*9"0$'OWY'U^F?B[XLT"/XA?!,Z_XG\/Z]X[TR]4:WKF
MD2*+;R!]PR/T!SD\XQ[5\-D9&",CT- 4*,!0%] .*\^MA/;554<MDU:RZJV^
M_P CGG1YY<S9]A_%OQSH-]\)OC39V6O:?/<ZEXP$]O!#=(SW,.%^= #EEXZC
MCBMSPDGA3XL>'/@QXE_X3S0/#K>!8DCU?3]6N1%<?NR#^[4]<D?3!_"OB# ]
M!^5;FG^ _$FLVD5W8^&]6O[:3F.XMM.EE1O]UE4@_@:PE@(QARJ=M=].JY7^
M!FZ"2MS6_P"&L?6?A[XI>$_BKJ7QM\+1>*+?P?<>+]1^U:5K-\QAAG1<#RW?
MC:"%Z=PWU%>4ZQ\,+'X/^+?A\MW\2]!\23IJ\,MQIVDW3S06$8E4F0N3L /?
MA3]1S7A=S;2VD\D%Q"\,T;%)(I4*LI'4$'D'V-1!0HP  /0#BMJ>#]FWR3M%
M]++M;<N-'E^%Z?\  L?<-MXW\)>)/C3\=?#$WBG2]-M_&-E%!INL3SJ;-I43
M[ID!Q_$._8]ZV_!7BKPE\*_$OP.\!W/C+1-4N?#K:C<ZIJEG=+]B@,L3[%\T
MG&26(P>>!TS7P'@8Q@8],<4!0!@* /3'%<\LLC)<O.[6\M^7EO\ =T(>&3TO
MI_P+'US^S%\4_#NC>*OBQH.K7VBV]WXGF=K"^\0 OIUPRR2?NIF!'RL&!Z\\
M]>A9^TKXXF\/?">V\$)<_#+RK^\6[FTKP-%,3:LIR)=^XH-W0@@'GC/)KY*Z
M\=1Z5<DT'4+;2(-3?3KF'2YW,<5X8&6"1QU57QM)&#P#VK5X&FJZK7[:>:5D
M5["//SW/<OV4?$>D^']/^+*ZIJ=IIS7OA.>WMA=3+&9I2'PB9/S-R.!S7?G2
M=#_:0^#GPRLM,^(VC>"-0\(6GV34M,UBZ-OL(V_Z3#@C<V%R#[]00:^02 >H
M!^M!4-C*AL=,C.*NI@^>HZL96E=/9/I;\ARHWESIV?\ P+'N'[8/Q'T+XE?%
MP77AZ[_M2PT[3H--.J8_X_7CW%I!ZC+8![X)'&*\0HHKKHTE0IQIQV1M"*A%
M170****V+"ON[_@E]][XB?\ ;C_[7KX1K[N_X)??>^(G_;C_ .UZ\7.?]QJ?
M+\T<6,_@2_KJ?>5%%%?F)\R%%%% !7#:WX\T32O$1T^[GAFUAGV6MI+(J  *
M"6RW"CGJ>>PS7<UYIXM^%EA<>,X_%-OM;4701RVLF2)PO0KUP<>V/I0!D:O\
M!H_'OB:+7]?U62$QG?!;Z.Y38W9C,>21[ 5O:;X6\1> ],-M::\NJZ- IVQW
M]O\ Z3$G?$D8^<_5<^]8OCSQQ=^$Y],M])TB&TO+B:.)V:3[F6 .53Y2?KFO
M6;BX2VA:1SA10!Y'\1_&.CQZ-/I/]HRRZ=?1?9[NX\QF>V#_ "J_/.,GD>F:
MJZ#J=A\'/""FW>ZN+6)]LL:%7A=L DI\V1QCD<'TJ]\9-+&O:7;VSLTLL\JI
MY<8WGD] !UP,G\ZZ'4?A[X8UW0HX2DCV<$*XAMYFB5@HP"RC')QSGF@#YA^)
MNFV;>*9O$-QX(U/7[36(O/MG$<K0,&'#.%!PZ\C!..AQ5+X=_#.X\2S"\D6U
M\+6&F*;NTL2HW2R+S@KG(SCEFY]!7M_Q;O8M:\)V-CI6N26-CYB1W<L4<A@B
MC _U>5 7VY/U->1V/@<ZAXDATOPU=W>I7DHVF23"11*>KL%]/<_G0![=X!\
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MHHKSSG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/BI<CK-Z23_!W?Q.^MNWH5"G5=G/HU_6[/.:***^B/1"BBB@ HHHH *^[O\
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M&JNK:[#?6FFV=I;+"TDR;% &$7/;TJ/6=0O-.\312EY9R7*);N=D:@C@Y_\
MK4 5?!FC^)_#\]W-=K:Q:>YW"U+YV^I4@9'TK:\'Z_/K6M:PK1)'!"45=G0G
MG)K2N+74;Y0+BXCBM&7YDM4/F _[S=OH,U<TC1[+1[8QV40C1SN9LY9SZDGK
M0!?HHHH **** "D/2EI#TH ^9_@I_P G<?&;_KG:?RHH^"G_ "=Q\9O^N=I_
M*BO0QW\5?X8_^DHZ*_Q+T7Y'TS1117GG.%%%% !1110 4444 %%%% !1110
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M;Q1BOUD_X88^"G_0G'_P8W7_ ,<H_P"&&/@I_P!"<?\ P8W7_P <H_U@PO\
M++[E_F']H4NS_KYGY-XHQ7ZR?\,,?!3_ *$X_P#@QNO_ (Y1_P ,,?!3_H3C
M_P"#&Z_^.4?ZP87^67W+_,/[0I=G_7S/R;Q1BOUD_P"&&/@I_P!"<?\ P8W7
M_P <H_X88^"G_0G'_P &-U_\<H_U@PO\LON7^8?VA2[/^OF?DWBC%?K)_P ,
M,?!3_H3C_P"#&Z_^.4?\,,?!3_H3C_X,;K_XY1_K!A?Y9?<O\P_M"EV?]?,_
M)O%&*_63_AACX*?]"<?_  8W7_QRC_AACX*?]"<?_!C=?_'*/]8,+_++[E_F
M']H4NS_KYGY-XHQ7ZR?\,,?!3_H3C_X,;K_XY1_PPQ\%/^A./_@QNO\ XY1_
MK!A?Y9?<O\P_M"EV?]?,_)O%&*_63_AACX*?]"<?_!C=?_'*/^&&/@I_T)Q_
M\&-U_P#'*/\ 6#"_RR^Y?YA_:%+L_P"OF?DWBC%?K)_PPQ\%/^A./_@QNO\
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M  PC\$/^A*7_ ,#[K_XY1R8+^>7_ ("O_D@M1[O[E_F>Q_\ "<^'/^@]I?\
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MY)+S)JR4Y7CMH>B4F:6OF[]J'5K[3OC'\ 8;2]N;6&Y\12)/%!,R+,N(_E<
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M'S_@EG\"O^%N_M*Z?JU];^=HOA9/[4GW+E6E!Q"O_?9!QZ U^[X&!0 M%%%
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MPKZ;HH_M#$_S?@O\@^L5._Y'S)_PQ3<?]%E^(O\ X-!_A1_PQ3<?]%E^(O\
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M_P"&-9_9P\+WDEKX=U&]^-FM6S)%91V4DLWAC3VXWR(%.R[N. JD9CBRYYD
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MX"FK:!+QNDDM\DF,\>8JL4;&X$-7S/IGB?4=,U:RU".[F\ZUF2:/YSA64@C
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MXX_X)M_%[0)OV1?!MIJ_B/3+.[T_S[0Q7=[%&X59"1\K,#C#5]/?\+3\&_\
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M:*RL#U'(=5QQQ@4 >)2?!OQAX_U6V\4_VI9Z9I]A.+C3HIKI84DD4[E<F3@
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M ?RX;C[?D*-Q]OR%?U'_ /"':#_T!-._\!(__B:/^$.T'_H":=_X"1__ !-
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M%P[B-8H\NVXG@87)%;-90JTZC:A)-K>SV]2Y0E%)R5KA1116I 4444 %%%%
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M9-_+D_Q,0V%49+-@#K79_&KXP:AX)\,67PI\$WU_X;\+6\!DU:QMYS&]]/*
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M/ACX#0:LVD(UUJ&I7#RRWTZC>L6XF.!?1$! ]SDGVZHQH*G+G;Y^EMOG_P
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M)*E95R<%AA:\A^,/P4\4_#"^LM8NKJ'Q-X6NV6:R\0Z9<F[LIU)X^<\J3Z.
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M"OA7X>\$Z*@%II=LL;2XP9I3S)(?=FR?I@=J .\HHHH **** "BBB@ HHHH
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MBN;/@:V[:GK(_P"XG-ZD_P![W_E2?\(/"",:OK0Q_P!1*7V]_;]3ZUI:'?\
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MIX'^Z,L>PK]4?@3_ ,$>?AIX"DMM1\?:G=^/]3CPQLROV33P?0HI+O\ \"8
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M?_$4?\*C\=?]"5XC_P#!1<?_ !%?JS_PUC\'_P#HH>A_^!/_ -:C_AK'X/\
M_10]#_\  G_ZU']L8O\ Z!W^/^0?7*O_ #[_ #/RF_X5'XZ_Z$KQ'_X*+C_X
MBC_A4?CK_H2O$?\ X*+C_P"(K]6?^&L?@_\ ]%#T/_P)_P#K4?\ #6/P?_Z*
M'H?_ ($__6H_MC%_] [_ !_R#ZY5_P"??YGY3?\ "H_'7_0E>(__  47'_Q%
M'_"H_'7_ $)7B/\ \%%Q_P#$5^K/_#6/P?\ ^BAZ'_X$_P#UJ/\ AK'X/_\
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M -:CV<?^@5_?+_(.5?\ /I_B<!_PVTW_ $1_XB_^"@_XT?\ #;3?]$?^(O\
MX*#_ (UW_P#PUG\'?^BB:%_X%?\ UJ/^&L_@[_T430O_  *_^M1[./\ T"O[
MY?Y!RK_GT_Q. _X;:;_HC_Q%_P#!0?\ &C_AMIO^B/\ Q%_\%!_QKO\ _AK/
MX._]%$T+_P "O_K4?\-9_!W_ **)H7_@5_\ 6H]G'_H%?WR_R#E7_/I_B<!_
MPVTW_1'_ (B_^"@_XT?\-LM_T1_XB_\ @H/^-=__ ,-9_!W_ **)H7_@5_\
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MNO1@ZAAR",BJ]O5_G?WLQ<YIV;9P7_#/WPR_Z)_X9_\ !3!_\31_PS]\,O\
MHG_AG_P4P?\ Q-:7Q1^*7ASX.^#[SQ-XIOQ8:7;8!8*7>1B<*B*.68G@"O"_
M"_[=_ACXE>(-,TOP=I.KWTTTC"Z2>Q8R0J/NG"%A@YZD\=ZS^MS4N3VCOZLZ
ME0Q4J#Q2B_9IV;Z7?3U/8O\ AG[X9?\ 1/\ PS_X*8/_ (FC_AG[X9?]$_\
M#/\ X*8/_B:[R%VDB1F4HQ4$J>Q]*?6GMZO\[^]G)SS[LX#_ (9^^&7_ $3_
M ,,_^"F#_P")H_X9^^&7_1/_  S_ ."F#_XFN_HH]O5_G?WL.>?=G ?\,_?#
M+_HG_AG_ ,%,'_Q-'_#/WPR_Z)_X9_\ !3!_\37?T4>WJ_SO[V'//NS@/^&?
MOAE_T3_PS_X*8/\ XFD/[/\ \,O^B?\ AG_P4P?_ !->@4AZ4>WJ_P [^]AS
MS[L^6?V>M#T[PW^U+\8-.TFQMM,T^&*U$5K:1".-![*.!15[X*?\G<?&;_KG
M:?RHKJQ[;JIO^6/_ *2C6O\ '\E^1],T445YQSA1110 4444 %%%% !1110
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M?$*NV6DLW.5(_P!UB1_P(4 ??%%%% !1110 4444 %%%% 'RY_P45_Y($O\
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M_6OW"\%>-]"^(OAFQ\0^&]4MM9T:^C$EO>6K[D<?T([@\CO0!N4444 %%%%
M!117.>//B-X8^&&@3:WXLU[3_#VE1?>N]1N%B3/H,_>/L,F@#Y__ ."BO_)
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M;)VO?H^;E:W(>(?,DE_5[=SX2VGT-2VMI->W,-O!$TL\SK%'&HY=F("@>Y)
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M1RA8<C/J*^P_C#X%\(_%G]IG5H/$&CS1Z9X0\-KK.I?9+ES+JJ[%,<.W^ (
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MCK;5)KKY(<</"4=+ZV^5UU/T:U/XM^"]&U\:'>^*=)MM9,T=N-/DNT$_F/\
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M\LY0KF/B;JO]B> ]9O2,B*#)^A(!_G5OQ#XWT#PI<6<&KZM:Z?/>2+#;Q32
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ML_48KE!&+ZPO([F%W'W989D) 8'!&2&'H:^-/'OPZ\<_L-_%?3O%WAR^;4=
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MG"BBB@ J!K*W:Z6Y,$9N%7:)B@W@>F>N*GHH KQV%M$9REO$AG.92J >8?\
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MBU'3;<SPW2#A6.WE&QU##&>AJ;6-+UCXA:9=:?=P+H>BW49CECF42W4R'J,
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MG\:W3V.ERF+1XV*W.HQ.?WW',<3+]2"X8%2N,&NHLK*#3K9+>VB2&%!A408
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MZUJS3^=8ZI8D(QCQ\QDCP-IZ >OO7T77:KI:F3/"K?PXWP*\=S:A:20KX?\
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M%>H=04444 %?H;_P3%_Y$3QM_P!A2'_T0*_/*OT-_P""8O\ R(GC;_L*0_\
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MYUD=;)'25:I&7.KKE;=EYW2_"^QVU>-_'M+K2-/FU630[?Q#HOE@W-O<6ZW
MA9<X?8><$$@D5[)7D_[1>B#Q-X4L-*FU9M%L[F]C6:Z"!A@'.TY( ST&>,XK
ML/FCY6\&>,=1NK*3PIX#\-GP]I=U</.\,.^&(NY^9MTK84>R]!T%?1/PJ\ R
M?"'7=+2[O8;^]UX%9WA'RH0I(13_ !*/7UK@_%7PJ^&WAC11//KVO&]09CGA
MO(MV[L0BJ1^!_.M/X ZC=>-/&-GJ5[<2RZ9I$;6UE]HXDGE8$&4@<8 !''<T
MDDE9%SG*I)RF[M]6?4-(RAU*L 0>"#WHZ#VJ&2^MX<[YXUQR07%,@YS3=/@\
M&Z@UM;QI!IMTY=4C4*J.3SP/>NJKE/$.L6^JA=/LLW-X6! 0?=YZGT'O740J
M4B16.6"@$^M #Z*** "BBB@ I#TI:0]* /F?X*?\G<?&;_KG:?RHH^"G_)W'
MQF_ZYVG\J*]#'?Q5_AC_ .DHZ*_Q+T7Y'TS1117GG.%%%% #7&5(KY,_9CL(
M;/QC\=?AIJ3M:W\FKS7T:GAGMKA2-Z^P#)_WT*^M:YB;X:>%Y_'$/C%M%M?^
M$GBA^SKJB@K-Y>"-I(/(Y/7-=E"LJ<)PE]I+[T[HVA-1C*+ZGPSH_P"R3XL\
M*I_PC5S\&M!\83QW)6'Q9<^(I[:"2WW=9($D!#!>.!^!ZGZS73-?\-7VD^"+
M'PM9VGPUCT*2*ZU:*^9Y+24*0(D1B7=?0G)Y[8P?6J0C/6MZ^85,1;VB_%[]
M][+RMIY&D\1*I\7Z_P"9^9TGQ*\2^ O@)XG\ Z+KG@C7?!L8N((-=CU4+>&%
MR28A:G#F0YQRN 2>3BOKCX'7WCG0_"/PGT6V\+V\WA>;0U?4]4FN@DUH^S,:
MB+J<Y'_UJ[2\_9T^&5_XF/B"X\"Z'-K#2>:UT]FI+/G.XCH3GG)%>BJH10J@
M  8 ':NC%8ZE6ARPANVW?NU:^CWZ]%Y%U:\9JT8^9Y=^T9\&6^-WP[DT>UO1
MINL6LR7NG7; E8KA#E=V.<'H<>M?,GQ(^&/QE^-MG8:'XO\ A'X<NM>LXC:1
M>,I]5S'$A(W2K$K\L< ]#SV[5]VT5RX?'5,,DHI.VJO?2^^S7W/0RIUY4U9+
M8^4-?_9<U/16^!^BZ-IT&M:+X6O&EU>>9HU0AN7?RW/S L3P >,5[%\<?@O:
M?%GX57_A*T>+2)/EFL98HPJ03(=R':.V1SBO3:*B6,K2E";>L=?G>XG6FVGU
M7_#GR;8>+?VHM,T*'PLG@#0Y=2AC%M'XH?44,!4# E,6<DXYZ?A5OXR_L_\
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M[O,D&TR'M@=<>YJ\EO%%C9&JD#&0H%24 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?+G_!17_D@2_P#83@_K7YA5^GO_  45_P"2
M!+_V$X/ZU^85?HV0_P"Y_-GT6 _@_,****^B/1"BBB@ HHHH **** "BBB@
MHHHH **** )9[N>Z$8FGEF$:[4$LA;:/09/ ]A45%% !1110 4444 %?H;_P
M3%_Y$3QM_P!A2'_T0*_/*OT-_P""8O\ R(GC;_L*0_\ H@5X6=_[E/Y?F<.-
M_@/Y'VG1117YH?-!1110 4R4*T;!P"A!!##((I](1F@#Y;_9A^#7@G0_B_\
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MK;_)%]86VIVDMK>6\5U;2J4DAG0.CJ>H(/!%)8:?:Z79PVEG;Q6EK"H2."!
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M_P#QNC_AW3\6?^>GA[_P8/\ _&Z**/[>QGE]W_!#Z_6\@_X=T_%G_GIX>_\
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0J\^>22VV\M#.<W4?,S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ibio-20230630x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &. Z@# 2(  A$! Q$!_\0
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MGJ=P?#OAEB<@:7:N0\J'N)I]S9]$%?35 !1110 4444 %%%% !1110 4444
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MK*P96&00<@BG5XM^Q[HVL>'O@'X=TW6O$FD>*YK4210:EH=X]W;- '(C197
M9MH^7)]*]IH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGEV7 X%?I528% '@'P@_99T[PS\-?A-IWB)Y#KO@AVOH182[(!<R*0ZD8.Y
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M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !J4//\ X]0!TM%-1UD4,I#*PR"#D$4Z@ HHHH **** "BBB@ HHHH ****
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M_P!J:4]3DG))Y8G\O*?@=X0UOQY\0H_$L\\HAL[C[1<WSYW2R?\ /-3[]QT
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MVQ@_B17V8.E?G/I/AL^&+UM<^),'B;X<^(]8G6^TGQMI\ADM+564;+>9%^Z
M.H;GZ<U] >'?VC/$OPSM[2/XGV4.L>&Y\"T\>^'!Y]E,IZ&=%_U9]2/RKX2O
M4]M5E/N?2TH>S@HGTS17S9XS_:>%MJC2:;XQ\ :;X;)5XKZXU-KFZF3 )Q#&
M"5/48(J]\'OVBM*^(OCV/2=/U/7=>$L<G^E1Z08;!,#.2Y.1TXXHA2YXRE?;
MU/+Q>9+"8FCAO9N7M'NG%)>MY)OY)GT+1116![(4444 %%%% !1110 4444
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MHH CN+>*[@DAFC66&12CQN,JRD8(([@U\/\ QX^#%_\ !GQ+!XE\-M-#HCW
MDMYHB=]A-G(0G^[G[I/^Z??[DJEK.C67B'2KK3=1MH[RQN8S%-#*,JZGJ* /
M(OA/\2-%_:*\ ZAH'B&TAFU 6_D:G8N/DF1N!*GH"?Q5OPKX?U:QU3]D3]I"
M-;6YDEM;"=)HY#Q]KL)#RC^IVAE/^TF:^_\ X5_ /P]\)-5U'4-*FO+FXNT\
MH&[D#>5'G=L7 &>0.3D\"ODG_@H]91Q^/_"=T% EFTR:-R!R0LH(_P#0C^=
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MPKUIGDQ_\\T_[Y% 'W=_PPE\*#T\?7G_ (%VG_Q-)_PP=\+#T\?7G_@3:?\
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MOX5_)^VW$&X/_"2W@Y^LM 'Z:#H*6D'04M !1110 4444 %)2T4 )BC%+10
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MN)M?N$;;)=2]Q O([=P"#N-?5OP[\&3>%[.:XO90^HW87S$BXBA51A(T4<
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M@[X)6CC0;)I=1E7;/J=X1)<2CTSC"CV4 5Z910 4444 %%%% !1110 4444
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9,C21.J.8W*D!P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?:9$& #N)P.O QU/K7= 8&*PI^UN_:;=#DHJNI2]JU;I][_2PM8'C7P%X?\
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M.G X%<Z57VMW\/\ PW_!.1*O[9MM<G_#?\$Z&BBBN@ZPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%_X=\*:?X6T75#H^KZ5'-<37EXT5W]ENKBVEX2-%D#%$=69@IR1D4 ?7E)D
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MWB"Y32/$EU)X5O=%U&XA$GA'2[347UFTMI755<3E/)FE0.&>,(JX5MKG S]
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M6DVGAN^ETI;/7[/47N-9N8,+.Z/ "EK$7W*A/FM\I+ #BMKQW^VT\R> M/\
M#PT[P?J'B/0%\1WMYXPL[J9--@9_*6 6\ #RS&19!RR*%B)R<@4 ?7%%?']G
M^V5XNU3P&ITCP]HVO>,(O%VG^&!-"UU;:3J,=VI:.Y@>5!)'MY#J0^PQN,ME
M37K7PU^(OCBW^+6H_#WQ^F@W>H-HJ:_I^I^'8IH(FB\_R989(I7<AD<H0X;#
M!N0I% 'LU%>#?$3XF_$RZ^.K_#CP'9>&K:&/PY%KL^MZ^L\HA9KB2$1"&)EW
MEMH(.Y=H#$YX%>?:9^TU\6+GX<V_Q.U#P[X6T[PAI^JIH^JZ2DUQ-?7+)>"R
MNKFWFX1$67<4C="653E@2* /KJBOGN'XH?%;XEZ_XKNOA[8^%;'POX<U.?1T
M'B,7#W.KW5N=MQL:(A;>,/F-7(D)*D[0,9Y'0_VF_B=X\T7X16^@^&O#NF^(
MO&Z:T;_^TY)WM])^PS%-V$.Z4X&"N5W,1@J* /K*BODF/X\_&^[\/^/;V+1?
M!4+_  ZGGM]8EE:Z9-:DCB6?;:@'-L/)=,F0R?.V , FMB/XZ?%7XF>,O$FG
M?#O2_"MEH^D:/IFL)?\ B+[1(\YNX&E6VV1,H4_)S)DA1_"Q/ !]/45\J>#/
MVD_B5K>C?#GQ_J_A_P .Z9X$\8ZA:::NCQ2S2ZI9_:#Y<=PT_$3 R<^6$&$8
M'=NR*W;'XJ_&#XCPZ_XI\":3X3B\(Z9>W5E8V&N&X^W:Q]FD:.:02QL$ME+H
MZIE7)VY; .* /HN29(@2[J@'=B!3Z_/+QG\5&^(=I)XR\3^&-.U,ZGX!T^YN
M=!N))A:K(=81<95@V5(!SGJOI7T3'\3OBK\1]=\43_#JP\*V'A?PW?RZ4I\1
MBX>XU:YA \X(8F MXP3L#$.25)VXH ^A**^3M$_:<^)WC;3?A=9Z)X7\/6/B
M/Q@^L1WJ:C/,UOI7V.5TW?(<RX"8*C&YL8*BO7?@G\1?$OB?5?&/ACQC;Z8/
M$?A>\B@EO-&$B6MY#-%YD4BQR%FC;[RLI9N5R#@T >J4444 %%%% !1110 4
M444 %%%% !2$@5!?W/V*QN+C:7\J-GVCJ<#.*^6/A#\#O"W[2?A1_B+\3K9_
M&.KZS=7)M;6\NI1;:3;I,\:0P1*X6-@$RSXW$GK0!]74M?&4WQ7\5?LWP?$7
MPAH&[QO!X?OM+_L*'6[MY)(HKQRAM7GY9MA7*LV2 <'.*],;XF_%3X=^*O#E
MK\0+3PK>Z+XEN1IUO<^'EN4DTR[<$Q+*)6(FC)&TNNPY_AQ0![^\BQXW,%R<
M#)QDTZOA/P+>ZY:Z7*WC&P\.>)H)/B=]GM%2.ZC:UG+KNE4F4@X&-J],YSFN
MHE_:<^,-OX"NOB*WAKPG)X7M=8ETI=&26X6_NT%P85G6;)CCYQ\A5L\\CB@#
M["=UB0L[!5'4DX I0<C(KY%^+'Q0\::+X?\ %GA3XJ>'O">OP7GA]]8M+;3/
MM4<.$E17MI]S[FQN!$B%<X^Z*Z'5?BM\3/#?Q$\(>%-''@R[TS4;=;V2RCLK
MS[3IFEQQ@M-))YVS/\*C'S'% 'TU17PY<?MY:[?_ -H>(M+N/"::':W4D<'A
M>YM=0?5KR!'*LXN$4PI(V"53:PZ989KV2\^,/CWXF>,I= ^&-EH>F6^G:?:W
M^I:IXKAGDVO<)OBMD@B9&W;?O,S8'8&@#WX,"3@@XZTM?//[)U_XAO\ 6/BM
M+XIL;;3==7Q&4N;:RG:: ,(E^:-F .T]0",CI4B?$[XL?$K7_$MQ\.]/\*VG
MAG0+V33D/B$7#W.K7$>/,$9B8+ @)VAF#DGG&* /H*BOD?PQ^T]\4_B#+X"T
M?1/#7AG3M=\1V]_+>OJ$L\D&FFWE*$@*09>GW<KD]Q6+\;/B1\0O%_P4\6:1
M>'P_I_B;PSXCL["_NK>.X-K=HTL;121+OWQYR-RL6[@&@#[/$J%F7>NY>",\
MBGU\*_&'5=3M-7\2+IWAO1Y?&EIXH\/":YL9I[=-2F>-C^\+L^Q%]AG YR:]
MGN?C!\0?A%XGTBV^)T'AW4=!UI)A!J/AF*>%[*>.,R&*2.5V\Q2H.)%*\CE1
M0!]!T5\NGXY?&"W\"I\5)] \+CP$<73^'U>?^UTL"V/.\_/E&0 [C'LQCC=F
MNA/Q<^(?Q5\7:W8?"^W\-V&B:#Y4=UJ7B>.>5KRX>,2>5%'"R^6H5@#(Q;GH
MIH ^@ P;H0?I2U\<_L^?%SQ)X,BLAXGT:UT_3O$'C#5--U)TG:8V%\7S"%D.
M 8GPP&0#G%>_?!KXFZA\51XEU7[';6_ANWU26QTBXCW>9=QQ?*\KY.,%PVW
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M6/V]9+?GSHRH*;?][( ^M '$:A\ =0\2> _["\2^/-6\0:C)JL&JRZG<6\2
M-$X8110J L<?&,<GODFNT^*GP\@^*7@74?#-Q>RV$-[Y>ZXA0.R[9%?@'C^'
M'XUY!HMM^T3XVT*+Q;%XG\(>%I+J(75EX0GT.2[01,-R1W%YYZL'((R43"D]
M#BE\7>.OBWJWQ \%>#]*O/#W@K6-0T2?4M36[LGU:))HW"[(V62([3USUH F
M\2?LA0ZQ=P7VG^-]7T'4[7Q!-XBMKRR@A+Q321A-A# AD&.01SG'%.U']E*]
M\:P:Y=>//'U[XI\07UA_9EI?1:=#9P:= 75W\JW4D%W*C<S,?;%8VN?'[X@_
M#6U\7^&?&]GH;>+++0YM:T36M(CE%AJ$:'#!X)&+1NAQE=Y!'(-4? 'QV\<Z
M9X]^'FB^(?%G@[QU;^,("[VGA^S:UOM,(B$GF.HGE#1#.TDA>?RH ]3\>_ N
MX\0ZAX=UWPUXJNO"/B[0[7[#!JL=K'=17%N0-T4\#D!U)&1@J0>AKAQ^Q[-J
MFLZIK?B/XAZKX@US4[JPNKFYELH(HU-JY9$BC7B-#G&,DCKDU[7K?Q#T;P[X
MNT+PYJ$TMOJ.MB7["6B;RI6C&63?T#8.0IY/:N6U_P#:.\"^&[;Q'/>ZG,$T
M*]33;@16DDC37;C*V\"J"9I.VU <&@#C?VD/A$WQD\>?#+2GT:XFT[3]0DU'
M4-60[(XH$ /V=B#\WF,%^4@C"U[?K6@6'B'0;W1K^W2?3;RW>UF@(P&C92I7
MVX->06?[8'@)]2GTS4X/$/AS6H+"?5)-+UO0[BUN%M8E#/* RX9<'C:3SQUJ
MGX;_ &BM+^('C?PY>Z3K]]HGA6YTZ[O/LFL^'I+==2BC56-S'<2$&.- >Z_-
M^% %>V_99UN>QT[PSK?Q.U36_AUI\T<L'AZ33X([B5(V#10SWB_-+&I XVJ3
M@;B:].\ _#"U\ Z_XOU2WO9+@^(K];]X'C55MR(P@1<=1@=Z\ZE_;6^'5I#!
M>W<7B2QT.[G6VL-=NO#]U'87\C.%58)BF&R3P3@$9()K1\1_M;>!_#WB'6]#
M2V\1:SJ6AD-JL6CZ'<70L8BH;SI65<!,=P2>#QQ0![517S]XL_::CL/B[\.=
M&T>VU#5/#'B.QGO)-0L])EGB==J&-UF'"JN27X^7C.*[SX9_'3P]\5]0O+;1
M+/7(XH4\V&^O](GMK6\BW%?,@E=0LBY!'7/?&* /1:*** "BBB@ HHHH ***
M* "BBB@ KD/BAX&O?'_AD6&E^)M2\(ZI!<1W=IJFF,"T<B'@21M\LL9R0T;<
M$>A -=?10!\]V'[)KW9O=4\3^-;K7_%FHZ]IVMWNK1:?%:Q.++ @MXX%)")M
M&"=S-DDYKJHOV?+*+X*>*?AR-9N3:Z\VHL]_Y*>9#]KFDE;"]#M,A SUQS7K
M5% 'Q_\ $S1/%?PV^)^L77ABW^('AZUU.TMA-J?A#2;77K75GCB6/>]O*NZT
MN5"A-_*.H4G)'&G\!OV5;C_A$_#>H>-'U&&[@U/6]2FT?598[J>>'4=R&.ZE
M7@R;""VSC<Q'05]68!I: / ]!_9M\5:+!H_A]OB]KTG@#29XY+;1H;2*"^>*
M-@T5O+?J=[Q+A0<*K,HPS')SZWXZ\!Z-\1O!NK^%]<MC<:3JELUK<(C%'VG^
M)6'*L#A@>Q -=#7AGC;]K?P=X<;Q)!:1ZYJ%OHGG6^H>(-/T2XNM*T^Y13F.
M:X12H*M@/C(3^(KS0!=\+_!CQ]IFJZ,NM?&/5];\/Z3*LL5A%I=O:7-V%!")
M=W*9,J@'D(L>X@9S6(W[,?B+2+;4O#WA3XJZQX4\ :A=2W#Z)9V$+W=HLKEY
MH;2])WP1LS-CY69-QVL,#&'X%_:1DM=$\.^*/&/BM&M+GP+I^M76@V&A.\DE
MS<3^4LT4R$EC)(RQ+ %SD@YYKM-3_:V\#:'I>@W.J6_B/3+[7)[JTL-'N= N
MA?S7,&SS(%@"%BYWC;C*L,D' )H CU;]E[3=3\<2^(QKU]&[ZQH^KBW=!+AM
M/@>%$+L=S;P^68\Y%=C\6/ GB7QSI5M:^&_&C^$)%\V.Z#Z5!J$%W$Z;2DD4
MN.G52& S]X,.*\O^(W[55G+\'O'VJ>%!>Z'XT\-002SZ+XETQ[6[MUEF14D:
M"3&^-@6PZDJ2#SD8KL/%O[3/A3PCXEN] ^QZ_P"(M2TV*.;5O^$<T:?4(]+1
MUW*;AHE(0E?FV#+[>=N* .=T_P#97N? *:'<?#;QS>^#]3L=%M=!O)+NQBU&
MVU.WM@1 \T+%,2IN8!T9>&VD$  =#X=^ EW8>*?!WB37/&^L>*=;T!M3D>YU
M"*)1<->+$K*J( (8XQ$-B+GJ<DGFKW@/]I'P'\2;CPTF@ZK+=Q>)(KZ;2;AK
M:2.*[%G*(IPK,!\P)#!3R5^8< UU7A3XA:+XVU3Q)8Z1-)=2>']0_LN^E\IE
MB%R(TD:-'/#E1(H;'0Y'4&@#S#5/V=O$NF:SXE?P'\3]0\#Z%XDNY-0U#2X]
M,@O&@N9?]?+9RR',#2$;B"LBAR64 DUH>)?V>K@7_AC6_!?C+4O"OBK0M+&A
M_P!K7T8U4:C8Y#>5>)*P,K!QO60.K!F?DAB*Y30_&?Q6_:%O]8U7P+K^B_#_
M , V&H7&FZ=J-]HYU2]UB2"1HII]AEC2&#S$=5^\[;23@$"CQYX_^,?@CX;Z
M=:ZLWABP\77OBW3?#UIKMG!)<65U:W,J)]I-JSJ\3C<08_,(RN0V"* .GM/V
M=;FYTK1QXA\<ZSXEURT\46WBBYU*\5%266 %4MX8%^2WAVX&U.<Y)+$DUVC?
M#.W;XQ0_$#[=+]ICT&30OL.P>64:X2?S-W7.4QCI@UY?)\1?BA\&?%OABU^(
M\WAWQ5X/\0ZE#HL>NZ#936%SIU[,=MN)X'DD5XI'Q'O5@59ER"#QY5JG[3OQ
M'\.>%/%7C^?Q;X'NM.T?Q-J&DQ>"9[%X=1O(8+][9(HIUN"3<.J@J/*(+$#&
M#F@#ZGA^&T$/Q:OO'8OI3<W>BP:*;/8-BK%/),)-W7),A&.G%<;-^S;83_ N
M_P#AF=<NA:7>HSZ@=0$*>:IDU!KTJ%Z8#-LSZ#/6M7]HSQ_JWPV^#>K>)-$:
M*#4[>:R2,W,7F*!+=PQ."N>NUV'L:\?UG]I^[\ ^,]#35/% \0:#>>,]<T6Z
MCL_#TJW,?D6I:VL(8T+/-()=J^8H_>;N@QF@#O\ 4?V>?$&E^)?$5YX$^)%]
MX*T7Q'=-?ZII*Z9!>A;IP!+/:22<P/( "V1(N[Y@H).9?AE^S#IWPRA^',5M
MK]_J*^"[;5+6![M%,EV+V42,TK#^)2.H^]R34B?M:> [;0?%.HZS_;/AFY\,
MVBZAJFD:WI4UM?16K-M6=8B"9(R<C<A8 @@X/%/O/VJ/"-GHFD7ITWQ-+?:U
M-*FD:'%H<[:EJ,<85FN(K;&\0[64^8^U>1G!(% &K!\#+.'0/B?I?]K7!3QU
M=W%W/)Y2YM#+:1VQ5!_$ (@W/<TOPP^!MI\,KG6YK?5;B_.J:;INFL)8E7RU
ML[=H5<8ZE@V2.QZ5RS?MJ_#"#1]=U"ZOM6L?["N+*SU6SNM&N8[JRN+IW2&)
MX2F_>2AR #P5/(85VWP^^-WA_P"(1UN&&#4]#U#18XIM0T[7K%[*YMXI59HY
M&1_X6"/SZJ0<$$4 8%K^SG8VOPK\ >"1K=TUOX1O=/O(;SR4WW)M9!(JLO10
MQ&#CI6-<_LV>(-*N]>LO!WQ.U/PCX1UVZFO;O1H=.@N9;>68YG-G</S ')+$
M%7"LQ*[<UZUX#\;Z7\2/"&E^)M%::32=3A^T6LEQ"T+21DD*^U@" P&1GJ"#
MWK?H ^:1^Q'I">$[705\4ZAY-OX>MO#RS-;QES'#>"Y$A]6)&T]N_6NFU3]G
MGQ!IOB3Q#>>!?B/?>"M(\17!O-4TI=,@O5%PRA9)[5Y#F!W"C=D.N1G:#G/N
M%% 'B?PS_9@T_P"&;^ #;^(=1U,>$(M3BA>]1&DNQ>2%V:5A_$N>H^]U-=UX
M3^&T'A3QUXR\31WTMQ-XE>U>2W= %@\F-D&TCDYW9YKLJ* "BBB@ HHHH **
M** "BBB@ HHJ&\NELK2:X<,R1(78(NYB ,\#N?:@"4C(P>E>$W'[.OB;PKK&
MK3_#+XE3^!=(U:X>\NM%NM'AU2UBG?EY;?>R-"6/)&67/.VNVA^/7@B3PIX;
M\12:TEMIGB&\2PT][B-D:2X9RGEE2,JP92#GI@YKG/BE\9;+3/$MKX;TKQ0=
M$U>SU&P2_/\ 8[7T<B7#E4M]P(".^#SDE1SB@#SOXO?LS2Z7\#-1T#0KC7/$
MGB;7-=LK_5]?+H=1N9%F7=/D *@C4?*JC:H'2N]T7X :]>^,-#UKQW\0[SQM
M;>'Y3<:3IQTR&QC2?&%GN#&29I%'0_*N>=N:\EUS]L/7+7PM\0=3-I>:/'X=
M\46]BMWJFARPPK9-)&KJ23\TOS,<#G!!Q7O/P\_:!\-?$;Q)-H%K:ZUHVKK;
M_;8+77M*FL&O+;./.A\P#>F2/<9&0* ,9/V;+!+&.V_MRZPGBK_A*=WDIS)D
M'R?]WCKUI\_[.-C/\(SX#_MNZ%L=1.H?;1"GF9-P9]NWIC)QGTKF_C!\8_$6
MA?M#>!O!&E3ZEIFDW-K-J.HW-MH!OEN$0@"/S2<1H.2SCD<>M>D2?&[PK%\,
M[?QXUW<?\(Y<,%CG^S/O),IB'R8S]X?UH POC!^SW9?%W59;ZYUFYTYI-'FT
M?9!$C@+)(KE^>XVXQTYKF_#G[-OBKPKX]UCQ'8_$LR)JS0)=6UWX?@F?[-$N
MU;9)2^Y$QG@#J2:Y<_M)^(])\?M;:G+"^A6WB35+&Y2VL3)-]DM[195VA3DL
M"220,D5[C<?&+PO;V'A"[6^>YB\5RQQ:3]GA:1IRZ;P< ?* O+$XQWH \WC_
M &:/$NCVUSX?\._%?6?#W@*>Y><Z+:V,)O+=7;>\-O>D[XHR2?X2PR<,*V_%
M7P#U0^,/^$I\!^-[OP5K-Q9Q6&H>=9)J5O?1QC$;O'(P(E4=) W.>0:H_&7X
M]M\(_BSX+TJ\\^?1M8M;O-CI^GO=WEU<(!Y:0J@+9Z]L>I%;WA_]I+P7XAL+
M&9)=1L;JYU5=$?3K_3Y8+NUO&&1'-$PRG'.X\$=#0!/\$_@L?@];^(O.\2ZE
MXJOM<U ZE=WVJ)&LIE90&QL &..!C@<5SFJ?L]^(-.\1Z]>>!OB/>^"])U^<
MW6I:6NF07BB=AAY;9Y"# [#KPZYY !KK_'/QT\(_#J]U:UUR\GMI-+THZU=%
M+9Y%2U#A"V0.3D]!S7"P_MI_#N22*)X?$MO->Q";2(9_#UVDFM*>GV)2F9OH
M ,#GIS0!:^%/[+EA\*]2\)WD'B/4-6?P_9WEFAO8TWW(N)-[/(P_B!]!S5WQ
M'^S=8^(K3QK ^MW4 \3ZI:ZI*5A0^0T!4A%SU!V\D^M7+3]ISP'-\/K_ ,7W
M5]>:796%U]@NK&_L)8K^&ZS@6YMMOF&0DC"J#G/%9NB?M:>"-4\0P^'[RU\1
M>'?$$UK/?1Z5KNAW%G.]O$F]Y5#+@KCT.<\8!H H_$?]E.R^(ESXDN&\5:IH
MT^LZEI^I^?IZ1K+;26B%4$;,#USDD@^G>K.C?L[:KJOBJQUKXC^.[GX@+I<4
ML6F:>VFPV%M"9%V/+(L9)EE*\;B0!DX44OA7]K_X?^,;_14T_P#MQ=*UF86M
MAKUUHUQ#IL]P<XA$[*%W\$>A(P#FNG^.OQ7F^$W@Z&\T[2_[<\0:E>1:9I.F
MF3RUGNI3A=[8.U  68@9P* //$_90UC^QT\'2_$_5I?A>DP8>&CI\ N3"'WB
MV:]^^8<]MN['&ZM_7/V?=7T_Q;J.N_#OQU<> CJT<::G8?V9#?VTS1J$26-)
M"/*E"@#=D@X&5-9<.@_M%Z%';:U)XL\&>*9V=6N_"XT62PB5"1N6"\\YVW*,
MX+I@XZ#-9EOXH^,WQ ^(7CNT\*>(_"FA6'AV\BM(=.U?1)KLRLT0<[YXYT(&
M3CA: ,OQY^S=<>#OV:/$7@#2)M8\<ZIKVJF=-0NBJW-O//,&:Y9TQ@1_,V1C
ML,5]!_#WP99?#OP1HOAO3U"VFF6J6R?[6T<L?<G)_&OG3Q9^TWXQ7X9W,/V?
M2/"'Q"TOQ-:^'=6-VC7EA#YN2+B++(6C9<,-Q!&<&M'P9^TGJ?A'QAXNT#QY
MXD\.>+M.T+3(=3;7O"5I(IB,DAC6VF@$DO[UCC:%;)##B@#Z<HKE?AS\1;#X
MEZ$VIV.GZQI025H9+36].EL;B-AZI(!D>XR#ZT4 =51110 4444 >4?M"_#;
M7?'.A^'M7\)26B^+_"6KQ:[I4-^Q2WNG1'CDMY& )19(I9$W ':2#VK!A^,G
MQ5\1O8Z7I'P4U30-4>9%O=0\3ZI9KIMI'N'F,CV\LDLYQG:%1<G!.!FO=:3
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MO\.?$/7C#X3UCP#X!DM]W]@:QJ<%["M^9&+O8^6[F.$J02"5!)X45]'T  4
M+1110 4444 %%%% !1110 4444 %%%% !1110 4444 (1FOE+PSIOQ-^$'PX
MUWX6:=\,I_%TA>^CT;Q%#J-K%IMS#</(ZO>"1Q+&Z^9AU5'WD9!^;CZNI,#/
M2@#XQTGX&>*-&\-:%%XA^'<GC#3[?X:Z9X>U#1+74(8))+J.Z+RI$Y=0'C4B
M12&7)4 ,#S6!;-\4?!'C?X+7&I^'=0\3:E:7/B233M$US4[=]9322EL(E>X!
M,3W2@]WY4[6?=DU]VX%4KK0M.OM3LM1N+"VGU"Q61;6ZDB5I8!( '",1E0VU
M<XZX'I0!\B_%OX9?$3X^1>.?%0\$3^%7?PU'X=T;1=2NK=M0ORU]%<2S3&.1
MHXD41A40N3RY.-P%=OX?A\>_ ;Q=X[L[#X=7WCS2/$^L2:]IVI:/?6L#133)
M&LEO>">1"@1D^65-XV$#:"N#](8&.E! /:@#XC\0^!O%/PJ_8^L-=UNQL?#_
M ,3/"GB>YU_2+.T?SH)+RXU&54LT*8+1W$=R8L<'$@)QCCZ<^!'PU;X4_"[1
MM!N)_MFK!7N]4O3RUU?3.9;F4GONE=S],#M78ZOX?TSQ EJNIZ?:Z@MK<QWD
M"W4*R"*=#E)%R.'4\AAR.U:% 'S3X)_X3[]F4ZKX1@^'^J_$+P,=0N[_ $'4
MO#=S:BZM8[B9YVM+F&XEB^Y)(X65&8%2N0"#3?B=#\5OB'\-M'UB_P#A]%;:
MKIGC/2M9M/#&GZI#+>_8+>='?SI7*PB8X8[48J 0-Q.:^ER >HS1B@#YPUNQ
M^)'[0GB;PGIVM> I?AWX(T76;77K^YU?4K:YO=0EM9!+;VT,5NSJB^:J,[NW
M1< <UYQX7_9<UWX=>(H_BOI/@K3-0\=6_BK69-3TJ=+=I=6TFYU*66&:*9N(
M[J)&22-MRDKNC8\C'VMC%&* /*OVG/!FL_$/X)ZSH>@V1O=5N9[%X[<R+'D1
MWD,C\L0!A48]>U>"S_"CXG^#?'&D>*='\%1>(&TWXA^(==>QDU""%I;"ZM3%
M')&S' D;<=JMCD88J#D?:%)B@#XS^-'PW^(W[1<'BKQ O@.X\)Q6WA:Y\/Z3
MI&JW=L=0U*6YN;:65Y?*D>..)%M@%4N2Q<GC SZQ\2O#_BGP/\;-(^)?AWPM
M+XVTUM#D\/:EI.GSPQ7UJGGK-'/;^<R)("05=-RG&PC.W%>Z8'I1C- 'QEJ/
MPN^)?Q(^(7B+Q3JW@)/#MGJ>O^$KNULI+^WFN/LEC=S/.]P48J)55P=JEN"H
M!8@XW?VM_ VI:[\4? MAX5U)-.UKQU#<>$]<C /F2:-C[1/<*1T>$(RJQ_Y^
M".I%?6&!5"70-,GUJWUB73[635K>%[>&^>%3-'$Y4NBOC(5BJD@==H]* )=)
MTNUT32[/3K&!+6RM(4@@@C&%CC10JJ!Z  #\*MT44 %%%% !1110 4444 %%
M%% !1110 4444 %(1D8I:* /D+7/V-]3\4^/_&-MJ5U'_P ($L<^I>&+6-AO
MM-4N1^]DYZ;"NY3V,C8JSH?P!\=6WPV\,W.OPPZM\0;_ ,76.N>([FWD14"0
MR!1M)/*K&@.!SEFKZTHH ^5/%OP2\7:OX4\>V":*)Y-4\<6FKVT33QXEM$:$
MM)R<#&QN#SQTKU3Q/X)UG4/VB?!/B:WL]^C:?I5];75UYBC8\FW8NW.3G'85
MZMBEH \E\8^ M7USX^>&=>AM<Z);:#?V-Q=[U_=R2E=HVYR<@'H*\27P/\3;
MSX8:?\%I/A_<V\5KJ8#>+VU"V;36LEN3,)0H?SO,(.WR_+Z_Q8K['I,#.>]
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>?O(KO4K:R_Y9QW$L;,K,.WS,0,9)-%>P]** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ibio-20230630x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %^ Z@# 2(  A$! Q$!_\0
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MC%KW#]NW_DYWQ3_UPL__ $0M>!*Q1@RDJP.00<$>]3W^HW>JW3W-[=3WMR^
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M>)X[.UMK?4?!6KAHI[:-<!/LCKC!Q_"IR.X(-;FM6ND^-/CQXS:XTF$:;=^
M(9TL)T!$2[-R+C_9XQ]*^Q/$7PA\$^+==M]:UKPII&J:K 08[RZLTDE&.GS$
M<X]ZT9? 7AN;5[G5)-!TY]2N;?[)/=M:H99(?^>;-C)7VZ5BLSBJ<8V;:5KW
M]/\ +?<E8E<J6M[?Y'P?X=^%4%Q^QEX<\<>'=/BM_%>@WIUDW5O&!+/Y;D/N
M/4_+7K/[*GVSXZ?$OQ#\:-:M#!%Y2:5HT$G/E*%'FLI^I(_&O:/B=\+;W4OA
M%J/@SX?_ -E>%#=Q_9T(A,<,$;']YM6,<,1G%=%\+?A_9?"[P#HOABP"^3I]
MNL1=1CS'ZLWXG)I5L>JE&;^U)NW=1>K7]>8IUU*$N[;^XZNBBBO . **** "
MBBB@ HHHH YSX?\ _(L6_P#OR?\ H;5T=<Y\/_\ D6+?_?D_]#:NCK2I\;*E
MNQDP)B<+]X@X_*OQ#^(D$]KX^\1Q7((G349PX;KG>:_;XC-?F[^WI^SM?^%?
M&%S\0-'M'FT#5&#7QB7/V6?NS =%;U]:^DR#$0I5I4Y?:6GJCTL!449N+ZGC
M?[.OP6\4?&[Q7+HVBW5SINCX4ZM?1R,L:19^Z0#AV/93GUKOOVQ]*USPZ?#/
MA^+PK>^'/ FAQM8Z3->%-U[(.9)3M8D9[ XXKYWTOQ!JNA[_ .S=3O=.\S&_
M['<O#N],[2,TNI^(M6UQ474=4OM15#E%N[J28*?;<3BOLI4*DL0JKDN5;*WX
M[[_H>PX2=12OHBC"CR2HD>2[, H'J3Q7[@> X9[?P5H,5R29TL80^?78*_,+
M]CG]GG4/C!\0++6+NU>/PII$ZSW-RZX2>13E8E/<YP3Z8K]6401HJJ % P .
MU?)\05X3G"C'>-[_ #/*S"HFU!=#Y&_;QT4>(]>^$^E-=3V(O=9:#[3:MMEB
MW!1N0]B.U<A:?!V/X-_MB?#/3X_$NM^)OM=I/,9M<N?.DCP&&U3V'>OM+7/!
M^A^)[FPN-7TBRU.>PE\ZTDNX%D:!_P"\A(^4^XI;WPAH>I:_9ZY=:197.L62
M%+:_E@5IX5/4(Y&5!]J\NEF#IT8T;:6DG\[V^XY88CE@H=+/\3X)\,_$#P[\
M/_AW^T'X8\0:E;Z5KUUJ-R8+"X.V6?<,+M7^*O:OA]9_%[0_V>?AM;_#NQ\/
MFY&G WL?B R)M! *;0OXYS7N7B'X/>!_%FNQ:UK/A+1M3U6+!6\NK*-Y..F2
M1SCWKKT18T5$4*JC 51@ 45\?"HERPU;N[ZJ]K?\$)UXR6B\W?TL?&_QYU#5
M/A?\;?A1\2_&MHLFE6]F;#5+BQ1I(;.X;.64=<<\=R,UZ]K?[8_PFT@:8L'B
MJ#69]0FC@AM](1KB4%C@,RCE0,\]_8U[!JVCV.O:?-8:E9P7]E,NV6WN8Q)&
MX]"I!!KD/"WP)^'O@G5?[3T+P9HNEZAG(N;>S02+_NG'R_ABLGB,/5A%5HN\
M596:2:W^6Y'M*<XKG3NNQ\I?M#Z]J_[-?QCUOQ-X;M))K'X@:4UND<0VA-0X
M57Q_>^;..N6'I6/\:O@O:_#[X!?"7PO?1A[O4?$$,FJR#AI99L>9S^)&:^FO
MB3\$=6^)OQD\':]J>HV?_"'^'-US'I8#F::[/1VXVX''Y"O3]?\ ".B>*UM%
MUK2;+55M)A<6XO(%E\J0='7<.&'J*[%F$:4:+6K7Q6\KJ*^2-EB%%0MOU_0^
M.M3^'VF?"G]K?2-/\ Z9%HDEWX1NG2VLAM62<*0AQW)(7\:\I\)VWP2G_9W\
M57/CB2W/Q1\RZ-PUZ[?VB+K>?+\L'G'3/XYK]&YO"&AW/B&WUZ72+*36[>(P
M0Z@T"F>.,]45\9 ]JP]3^#/@36O$B^(+_P (:+>:TK!_MTUC&TI8=&)(Y/N>
M:*>9I)*?-=):IZMJ^_D[A'$JRYK]/P.=_9>DUZ7X"^#F\2><=4-BF\W&?,*?
MP;L\YVXZU\__ +/GQ'T#]GGXF?$?P5\0+J+PYJ-[J[ZC::E? I%=Q-]W]YC'
M3D9XY/<&OM15"@   #@ 5S/C7X9>$_B/!%#XG\.Z;KJ1?ZLWULLC)_NL1D?@
M:X*>*AS5%5C[L^W36ZL81JQO)26DNQX/\7OVD? ?Q-^'GQ*\*>&=4;6;VST&
M6YDN;>%FM".A42]"1Q['/!.#7B?C+P;9^$_V)_ UWI&GFQTK5[JRN/%5U8)B
M:X@.<M(PY(SZ\?=K[@T3X5>#O#?AZZT+3/#&DV.CW:[+FRAM$6.<>CC'S?CF
MMBU\,Z19:"FB0:99Q:.D7D+IZP*(!'C&S9C&W';%=%/'4L.E&C%V4D]7OI_3
M1I&O&G903M>Y\)>)H/A=8?%[X.GX&-9_\)$]^HOET1W96L\+O\_WV[\YY]>U
M8-P_@WX<_M#Q:K9S>&/B=I>I^*MNQBPUG2[QGQE3_P M45CP>5)'8\U]X^$/
MA+X+\ 7<]UX;\+:3HEU/Q)/8VB1NP]-P&<>W2F1?!_P1!XL_X2>/PGHZ>(=Q
M?^TELHQ-N[MNQ][WZUTK,Z:]VTFK-:O5ZWU?ETL:+$Q6FK5K'PGXT?P;\/?V
M@[OQ#;3^%_B7I]_XHC%SIUR676-,O"__ "R/'F(K'_:4E0" 0#7UTUU\:6^*
MZ+#9^%A\.3<#]XSR?V@(-GI]W=N_2NR?X/\ @B3Q:OBAO">CGQ"K;QJ1LH_.
MW?WMV/O>_6NPKCQ&.C54;1NTK:_I;33N8U*ZDEI?2VI^6WQU\,:QJ?Q:^->M
MV-W?#2-'U2V;6=/L)VB:YM)"0QXX.TCN"!NSV->B?M.1Z;)IGP+M?#TVEVOP
MQ>US:/KGF2:8)L+L%UL^8_+Z]RV>]?<J?#_PS'=:S<KX?TT7&LKLU*46J;KQ
M<$8E./G&">N>M1-\-/";>%!X8/AO2SX=&<:4;1/LPR2<B/&!R2>/6NU9M&]-
MN+]W_P"1M]Z>WEH;_6U>.FW^5CXL^"GA'4H/C3K6J^%/%WP\.IPZ'<)>:'X%
M$\<<Y,;>1($*F,L)-F2&X],DUP7@:T^!\W[,GB2?QB]I_P +0#77G->,PU(7
MNYO*$8/.W.W/;[VZOT0\%_#;PK\.K:6#PQX>TW08ICF46%LL1D/;<0,G\:S]
M1^"?@'6/$$^N7W@W0[S5YU99;R>PC>23<,'<2.21QD\TO[4@YMOF2]VS5D]+
MZ/RU%]:5W>_3UT/@[56MF^"?[-=OXN::+X8232_VP8BPB,@<^6)=O.W&??&_
M'-?2'P]\-?LUZE\2GL/!T>@7/B.ZTF6![/3)':":U<;9054^6Q*G!!YQBO=_
M^$!\-?\ "*KX9_L#33X>5/+72C:H;8+G.!'C:.>>E5/!?PJ\'_#DSMX8\,Z7
MH3S\2O8VJ1LX]"P&2/;-85LPC5@TN:+UV=D[N^I$\0IIK5;_ (OJ?FNOA?2+
M+]F'5M3@TZVBU!OB/%8&Y5!O-O&6,<6?[JDD@>]>V_M2ZCK?[-OQ<U+QKX6M
M2]MX_P!%ETJ>./@1ZBH"QR@#JV""/4[J^N#\)?!1T9](/A/1CI;W?]H-9_88
M_*-S_P ]BN,;_P#:ZULZYX8TCQ-':)J^EV>II:7"75NMW LHBF7[LB[@<,,G
M!'-;RS6,ZBE*-X^]=/JG:WW-%O%)RNU=:W_#_(^)O$?PJB^#M_\ LI^&V1!?
M1Z])<WSX&7NI/):4D]\$[<^BBF?"[X ^%/B%X\_:6\+KHUC;&"X6PTJ58@/L
M.\2,!'_=!=$)QZ5]LZQX1T3Q#J&F7VIZ39:A>:7*9[&XN8%D>UD.,O&2,J>!
MR/2J\7A'3M!?7=1\/Z3IMAKFJ RSW(@$?VJ< [&F91N;!/7DX)K'^TY\C2NI
M/KY\_-?]"/K+Y?/_ (-SX8^!-YXA_:1\>_#SPEXHLY$TKX76[S:LLXR+F]CD
M,5N&'J BC!_N.>]?H**\B_9L^"-W\%_"NJKK>H0:SXKUO4)=2U;4K=6"S2,3
MM5=W. ,]>[-7KU<N85X5JUJ7PK;\V_F_PL98BHIS]W9!1117F',<W8?\E UC
M_L'6G_H<]=)7-V'_ "4#6/\ L'6G_H<]=)6D]UZ+\BI;A45T";:4#J5.*EI"
M,BLR3\,?$MO/:>)-7@N05N8[V=)0W7>)6!S^.:]!^!?PAUWXE7FI:MX=ATK6
M=1\-^5J'_"/7^2^HH&R41>C#(P02/O#UKUK]NW]G>^\!^.KWQSI5J\OAG6I?
M.N7C7(L[H_>#^BN>0>F21Z5\O:5K&H:#?1WNF7USIMY']RXM)FBD7Z,I!K]9
MI5OK>&4Z+M=?\.F?5QG[:FI09].?MP6LMY:?#?7M8LV\.^*;[3'BO/#"S!XM
M/C0C88U'W V>GT'\)KY>LXWFNX(X@3(\BJH'7)/%2ZKJ]_KM])>ZE>W.HWDG
MW[B[F:61OJS$DU]%?L4?L[7WQ4\?V7B74;1D\):+.L\DTBX6[G4Y2)/[P!P6
M/8#'4U"<<OPMZCTC?_AE^2$K8>E[SV/TZ\.0RV_A_38I\^>EM$LF>NX( ?UK
MY+_;ZT2Z\2>(_A/I5C>OIU[>:M)!!=QL5:)V4!6!!!&#CI7V(.*R-;\'Z'XE
MO-/N]6TBRU*YT^7SK.:Z@61[>3^\A(^4^XK\VPN(^KUU6:VO^*9\W2J>SGSG
MP;\)[.72OV</C3:Z8M^/BO:&6WUN2:X:6YDC4D!HR><;=_J2<'/(KC/B'9_
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MU9>6H_K2O>W]6MH?#WPO;PS:_L]_%^RO8IX?BHMK<GQ"-5P;J0YX*'O%]/\
M"L31?!6C>/\ Q?\ LX:+KME'?Z7-H,C2VL@^20*Y(4^WM7W=JOPO\(:[JT^J
M:CX8TF]U*>(P2W<]G&\LD9&"C,1DKCL:DM/ASX6L+O2KJV\.Z7!<Z5$8;"6.
MT16M8SU6,X^0>PJ/[3BG*44[N[WV;C;3R70GZRM6D[O_ "L?"MYH%WX#U?\
M:3T+P);R:=;6UI"T5G99'E(2-^P#IP3T[5YYH_@_3]<\%^$HK#Q?\)= O6GB
M:RO+9+J/6%GSG;*ZACDG@[ACTK].+'P?H>F:OJ&JVFD65MJ6H@"\NXH%66X
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MQ1)HNF37LNMV<,K!4FD!A\ER 0SQH1M&<,V.0#[-HKY9\8_%[XJ^.OA[XO\
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MW7/"OAS1=6T74;*QFUB:]N)=)CBG1F^U2E4\Q(\J%Y'RD_,<<T ?6E%?)OQ
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M3H[0RK+YGE/"WEL/,#<$'(&* -.3]FK4[22^TK0_B9XC\/>"+Z\DO9_#]C'
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MDA6W)D5FVK.+3S//\@GG?MSM^8KCF@#N?BE\++#XI^';;3[F]O=)OK"ZCO\
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M'@K]H:5?#NDZ1H&E>*/B9XJO3=W/V><V=M+!;QW#1EYY2R1(FX;4'+-QQUH
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M7%+/%)@_;F8Q_P#?.>?7M7L_Q!^/O@SX::U;Z-J][>3ZQ+";HZ?I6G7%_/%
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M!K'_ &#K3_T.>NDKF[#_ )*!K'_8.M/_ $.>NDK2>Z]%^14MPHHHK,D****
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MX53^1- '445R_P#PEEW;#-WH]]"O=A%O _[YS6AIGBK3]5.(9U+CJI."/J*
M-BBD#!AD'(I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YNP_
MY*!K'_8.M/\ T.>NDKF[#_DH&L?]@ZT_]#GKI*TGNO1?D5+<****S)"BBB@
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M]G^C\SUL/B%779H[ZBD!R,TM>(=84444 %%%% !1110 4444 %%%% !1110
M4444 <W8?\E UC_L'6G_ *'/725S=A_R4#6/^P=:?^ASUTE:3W7HOR*EN%%%
M%9DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 (S!%+,< <DFN.\
M%?&/P/\ $?5M4TOPOXJTK7M1TMBM[;6%RLLEL0VTAP/N\\<UV)&17QUXV^ '
MQ+TOQ'XJ\3>%--L[JZE\6KJ]MIL6J"R-]:FU\E@T@7"D,=VULYQZT ?8N[Z_
ME1GZ_E7P78_L5>/=06PE\0WEW=WUO/I49GM?$UU$!:@R&^0!77)(<+DC+ <8
MJ'4_V5_C%%:Z+8PI+JD5DD]KHUR?%MQ;?\(ZWVLO%=%5S]I_<X7:Q)'3IS0!
M]]9KP?XORZE?>/+:SCMGG7R52V0 G);J5&.><9]!5[]G/X<:K\'/A]KDOBF5
MKC7KO4;J^N[MKQ[CSDW$QD%B0@V_PC &:- ^+FLS?VUJ%ZBRV<4.Z&W$03RG
M9L(N[J<CDYKFK\K2A)VN>WE:K4YRQ%**ERZ:]WHK&5K-G8V^B3Z0MK/I]YI)
M^T27UZ D=W*0 R*3R2<_+C/2N3L[=;^]@MT C>XE2)F9<8R1U-9?B+Q%/):W
MNJ'S-2U&-RK-*'<JQ/(&>=H]JYVZ\>7-LUA#/8J)I5#3J6*LN3QM[@]^:\J=
M2+DG;0_0,+A:M*E*+E=O\';7\=3UGQKX=EM/&UU8QH88YVC:.:0;8U4@ L6/
M QCUIWB34] 2_@MM,T6TU.WL8A;_ &JYN)=LV.3M",!C/\1SGTKC?$/Q $MQ
M:Z=K.JW5X$ :..Y&^.//0L<<GW.:N6MA+JDD?V>QGO98B"%M87EV$].5&!^-
M6ZB;?LUN<L,'*,(/%3TBK:-I>K>G0^C_  1K=IK_ (;L[JSMQ:1!?+-N.D17
M@J*WJ^9M9N/$WA%;#3DO)M+*C[4\43,""Q[[>"1@<'(KZ!\(:E-K'AG3;VXQ
MY\T*LY QD^M>G2J\_NM:H^&QV!^KI5HR3A)NQL4454U75;30].N+^_N([2SM
MT,DL\K;511U)-=*3;LCQF[:L;K&L67A_2[K4M1NHK*QM8S+-<3-M1%'4DU^8
MO[6/[5U_\;-4DT+0FFLO!=K)\B?=>^8=))/]GT7\373?M1?M%:A\:-0?1=(>
M6S\'VTGRQ\JUZPZ22?[/HOXFOGK^PO;]*_1LERJ.&MB,0O?Z+M_P?R/DLPQS
MK7I4G[O5]_\ @'LW[)?[65[\&-1B\/>(9);OP7<R=\L^GL3]]/\ 8]5_$5^F
MVEZI::WIUM?V%S'=V5S&)89X6#(ZD9!!%?C'_87M7T7^RU^T=??!V]CT#7))
M;OP?</T.6:Q8_P :?['JOXBEG64QQ-\1AU[_ %7?_@_GZCR['.C:E5?N]'V_
MX!^C=%5M.U&UU>P@O;*>.ZM)T$D4T3;E=3T(-6:_.FK:,^MW"BBBD 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!SGP_\ ^18M_P#?D_\ 0VKHZYSX?_\
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M:YM90.C*4W8_-17IYM1C7P51/HKKY'GT;TZR:/T\T2]74--@F4Y#*#5^N8\
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M1K-@;>WG%];&&X8+#)YR[9">@4YP3]*SO'6/^$,UW.,?8INO^X:_/;P.VO\
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M&?\ V+FG_P#I.E 'I5%%% !1110 4444 %%%% !1110!S=A_R4#6/^P=:?\
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M/_0YZZ2M)[KT7Y%2W"BBBLR0HHHH **** "BBB@ HHHH **** "BBD) !)X
MH RO%7BG2_!>A7>L:Q>)8Z?;+NDFD!('8   DDG@  DU\1VW[='B_P +>,=5
MFU>PBUW0YVF^QV)C6Q>-5DVQF)BI>3MN5@".V.E>M_M>_$Z"X\$_\(SX;N]+
MUG5+N3==6]O*+F[M84!;SHXD<-E64?-_#R<<5\:W6E7>J>"O[?G@FO+"8!)+
MYIQ/)/<DC?'<2Q<6XR0ZLY!P"O(KQ\77FIJ--VMJ?.9ABJD:BC2E;EU;Z?/I
MM]S/T-_9\^+]]\8?#%]J-]I]K;-:W/D+<Z?(\EK<?*"=C. <J3M;W_*O4R<5
M\/?LU_&'4_">I:3HUMHMH]EK]Q"S6=JDL.#S$\EJ@W(R*4W2.6&2>@[_ $_\
M8[W5+/3M*^S7.J6.D/=;=3N]&A,EU%%M.W;M5F52V S*I(!)XZUWX>I[2FFW
M=GJX.M[:DFW=K<]#HKYTTCXA_$:TTEW33KRVT:$I''?:O82W]V8VD(\\B)8F
M=0H&%*!N06..2^'XL_$Y-"EU>^T:."U7,*PV^@W37!.'*S>69-P&0GRXZ,>>
ME=)W'T117S]8?%/XEZPZZ39Z=ICZA +9[O4Q83- %GZ!8?,#AEVONW$= >]5
M-6^*OQ;T>QM1+X>LII9]DCW<>FW(BA)#8A*!F8DE1\W;=TH ^C**R?#&N#Q!
MH\-T4,4^ D\9C=0DH WJ-P!(!)&<<XK6H **** "BBB@ HHHH **** ,_7HO
M/TBYC_O+BO/O["_V:].FC$T;(>AJE_9$?M713J<BL93AS,\^.A?[->A:%#Y&
MDVT?3:F*3^R(_:KL48BC5!T Q14J<ZL$(<K'T445SFH4444 5=1U2RTBW\^^
MNX+*#(7S+B58USV&20*BN]?TRP1'N=1M+=73S%:6=%!7^\,GIR.?>O)/COX#
MUOQ'XD\/ZM9V=QJ^FV<,\,ME:);R21R/C;(([@&-A@;2>H[5SNB? ^Y>[\-P
M:KH<E]IUIH5]'Y6I/#,;:XDE#1Q?)@< MMP,#/L*\R>)K*I*G&GM;77R\O/\
M/N\2KC<3&M*E"C=*UGK;6WEYO[ON]_N]:T^P$!NKZVMA.<0F695\P_[.3S^%
M-FU_3+>"">74;2.&X.V&1YT"R'T4YP?PKY3U2PA\%?V!%XMTC3=;N4\+)9_V
M9JE_%"]A(K-F0;SM8-D#*$L-O%:WACP)J4OASP1JMSX-'C+3&\/&R2PDD1#:
M3M*SB7;(0,,I W#D8KG6/J2DXJ&OSTVWT\^GS.2.;59S<%3U2VUNMM[+SZ7\
M['TK+X@TN""":74K2.&=MD4CSH%D/HISR?I1<>(-+M;..[GU*TAM9#M2>2X1
M48^@8G!-?*+Z-%\/X?"T/BS1-+U1XM$N+?\ L34K^*$VCF=V\Y2YV,"I )4E
MACI4^E_#G7M9\#> =4M],NM3TR'3;B$V5HEO(\+O,S+($N 4*LI W#YA@5*S
M"HVTJ>MKVUNMO+S_  U(6;UI-Q5+WDKVUNOAWT\^FNFMCZJ?6=/2YBMFOK9;
MB4 QQ&90[YZ8&<G.#T]*6^UBPTR2)+R]MK5Y3B-9Y50N?8$\_A7C?PG^$]WX
M:\:V=]J6F2O!::'%!:W%^\4TEO,979HU9>,JK8! Q@XJ#XH^ M3OO'.K:C)X
M.3QI9ZCI:V=DS31K_9\HW9)#D;0V0=R\\5U_6:JI>T<-;[:_Y7_ [WC,0J'M
M72L[VMKHN[LK^6B/97\2Z1&4#:I9*77>N;A!N7!.1SR, G/M33XIT41R2'5[
M )&P1V^TIA6/0$YX)]*^>M)^#FMKX?UK[7X?5M2/A.WTZS9S&6%P%D$B*<\'
MD GISUK0F^ L O[OR_"MM]F/A18(QM3:=0Z$XS_K,?Q_K62Q6(:35/\ /_(P
M6/QDDFJ/WW\_+R_%'OQU:R6]CLS>6XNY%WI;F5?,9?4+G)'O5NOG;PU\/?$6
MG?$;PEJ7_"-2!X;*TBU&]OG@FB4)#M9HSGS(Y%/RX&0>M?1-=N'K2K)N<;69
MZ6$Q$\0I.I#EL[=?U2"BBBNH[PHHHH **** "BBB@ HHHH *1F"*68A5 R2>
M@I:X;XW^%-6\<?"KQ+H>ASBWU2]LWB@)?8&)_A+=L],^]7"*E)1;LGU*BKM)
MF];>-_#MXLC0:]IDZQAF<QWL3!0OWB<-QCOZ5A^-?C%X8\$^#]4\1S:C!J-C
MIVT3II\\<L@9B %QNQGGH37R%<? GQ-K,U])HWP<_P"$(B_X1.XTF1([FV)O
M+HA0#A'[X.&/)SS70>*_V8-1M;#Q)8^'_!-O%97OA2P@6" 1*DNH1R*7)!;_
M %@&?G/YU[2P6&C)<U3\NZZIG9[&DFKR_+_,^FO#'Q>T?Q+<:[NBFTNPTDP[
MM2OWBCMIQ(F\,CAR,#H<XYKI8O%6BSV,]['J]C)9P -+<+=(8XP1D%FS@<>M
M?$'Q0^&\_@"YO]3U[1M+C\,?V]ITT6A:E=Q6EMJL:6VQHU8G8"K<A9, UA>&
M/AWJ?Q6\"^-[CP5X=AT[2$\56]XV@:3<6\T<\*1D,D3MF"0J2#M.4SQ5_P!G
MT91]HIVCIKI;IY_\ KZO!KF4M#[Z'B[0CIT-^-9T\V,Q(BNOM<?E2'T5LX/X
M&KNG:E9ZO9QW5C=0WEK(,I/;RB1&^C D&OB[P[^S/K&HZ?X=34/"VIMI-SXI
MCO[_ $?638B.&!8R#)Y-L%C0,<909Z5[=\!/AKJ_@;P3XST)[#^P8KC5KU]+
MB5EV1PN/W;(%)VC/../I7%7PU&G%N%2[^7^9C.E"*TE<]4'C+0/MDMI_;FF_
M:HFV20?;(]Z-UP5W9!]JC/CSPTL+3'Q#I0B4D%S?1;00,GG=V%?$EO\  #Q7
M&/"NG1?"-;#6M&N[EM2\5QW=NYU(.KX<?-O;<2"=W2NWT?\ 9CDFL?A#I^I>
M"+233]-LKM]9MY$B*+<NA"M(,_.Q..>:Z)8+#PWJ_EY^?6VGJ6Z--?:_+_,^
MK;3Q5HM]=K:VVKV-Q<M%YZPQ7*,YC_OA0<[??I4VE:YIVN1R2:;?VNH1QN8W
M>UF64*PZ@E2<'VKXU\(?LS:MX8TSP+=0>"?(U2WO-175GMIHHIVMG5Q$AEW=
M", ==OI7I_['WP^\0_#W2/$5EJOA<>&],>Y5K$7:6_V^10#N\YX#MD /"N<,
M1UK&MA:-.$IPJ7MZ:ZM=_F1.E",6XRN?1-%%%>4<ISGP_P#^18M_]^3_ -#:
MNCKG/A__ ,BQ;_[\G_H;5T=:5/C94MV%%%%9DA1110 4444 %0WEY!I]K+<W
M,R6]O$I=Y96"JH'4DGI4U?,_[6WB/5=1U'0_!FEB23[:/.DAC.#.V<(GTX)K
MDQ6(6&I.I:_EYGGX_%K!8>59J[6R[M['=ZC^U/\ #W3[\VPU.XN@#@SVUH[Q
MC\<<_AFO1/"WC#1O&NF+J&B:A#J-J3@O$>5/HP/(/L17YWZ/X-UC7/$8T*VL
M9/[3#E)(9!M\K'WBY/W0.Y->I_##7[#X9_%S1]-T'59]5M[G%EJDO MYI3GF
M(=2%/ )]Z^>PV;5I37MHKE;MVU_7S/C\%Q!B9U$\3!*#=M-&G\WK;KV/M:BB
MBOK#] "BBB@ J.:WCN%*R*&!]:DHH YNY\$6;3--:M)8S'DO;.8R?KCK48\/
MZU#Q%KUSM_Z:(CG\RM=113N!RW_"+:A<\76N7LBGJJ,(P?\ OD"K^F>$M/TM
MB\<(,IZR-RQ^I/)K:HI (JA1@# I:** "BBB@ HHK/\ $&JC0]"U'4F7>MG;
M27!7UVJ6Q^E)M)79,FHIR?0P/'7Q8\+?#E4&N:HEO<2#<EK&IDF8>H1<D#W.
M!6%X1_:*\#>,M0CL+756M+R1ML45]"T/F'T4G@GVSFOBCQ%_;_B=;GQ=J4,\
M]O>W;1O?,,IYN,[/; ( '3CBM;2/ EK9^%)?$?B>YFTZQGC9-+M( /M-]+CA
ME!^[$IY+'KVKY!YQB)U/<@N7?7MWO_7S/SQ\18NI6?LJ:4%KK?;NW?\ 3RU/
MT-HKRG]FCQI>>-/AA:R:A*T]Y8RO9/,YRT@7!5C[[2!GVKU:OJJ-55Z<:D=F
MC[S#5XXFC"M#:2N%%%%;'2%%%% !1110 4444 <W8?\ )0-8_P"P=:?^ASUT
ME<W8?\E UC_L'6G_ *'/725I/=>B_(J6X4445F2%%%% !1110 4444 %%%%
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M.Y!<PK(%/J,@XJQYD,#10;HXV88CCR 2 .P]A4M<=XE _P"%A>#^.?\ 3/\
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M>]=1^S1\+[_Q;XTL]<EMWCT737\TSL,++(/NJI[XZG%?66J?#SP;?ZBMU?\
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M=A_R4#6/^P=:?^ASUTE:3W7HOR*EN%%%%9DA1133(@D"%@'(+!<\X'4X_$4
M.HJO=ZC:V 4W-S#;ANGFR!,\@=_<@?C4^: %HJ.*>.=2T<BR*"5)0Y (X(H6
MXB:=H1(AF50S1[AN /0D=<<&@"2BBO)M4_:4\-6/C_4/"=II/B77+O36$6H7
MVD:+-<V5E,8_,6&6=1M5RN#CH-PR1F@#UFOCS_@H1\7?''PL@\"GP9K>H:.]
MW=7)NVT\P#Y(X&</+YL<F8D(W.%&=H.".M=7XO\ VYO"MD?"Q\+:=J/B>/5;
MO34O)K>U?98PW<C*N]ATF&Q_W1YRO.*R?B)^W!X&'A>_U+1_#&I^(;^U*-81
M:EHTL,6HVKSK;RW%K(RGS(U+X)&,Y'&#F@#A-<_;;\;3>,]9\&6NAZ?-#96W
MV*76;*\CCN&F^Q"8WT*.XW0Y.54(25YW<8JG\,/V\_&5YK>BZ!<>$4URSM;"
MWBO+EKQ$U*YE^Q+.UTJ%QN0D_=5"2,D'C%>S6W[2GPCO?$MXL'A?49M0LK6Y
MM[6_7PRVV]6V7-Q:VLI7]XT8#!HU/\# 9P:YP_M>?#'_ (2?0O$>G:/:-X9N
M-+NOLNNMHTJ7]UY+1(D5DOEYD0M+LQD?," #@T >=I_P4$\9'P]K%]'8?#[4
M9H-'M-9B&GZX[K:I-.J-!/OVYF1228U(9B, =CUGA;]NCQ!XM^-FC>%=.\)V
M-WH%T]E!)="Z\FYE^T0"4W,*2LK&)<\*4+, >01BO8(_&OPUB^%6M^-M:\$S
M>&=%@+MJ%CKWAK[+=NRD'F!DS(68C!&[)[YKD]*_:M^%>K>*[ -X1UVQ\4Q3
MC3ECU#PR8+VS7R3*=Q;YHXA&I8G. !0!B?&K]L#7OA[\3]6\-:?IF@_9-->S
MMFL]0OWCUC46N=P66R@"D/'&1\V<YYZ5Z1^Q]K/B3Q)\!]$UCQ7K!US6+^>Z
MF>[,A?*^>ZJHR!@#;@ < 5Q-S^V=\(=0GGUJ]\/ZZ;G3K07=G?7GAF02W-M)
M,L*R6C,-SJ[L -N,@YQ71>'_ -L+X9OH%W-:0:KI<.FVDUW<V$NDM;RVHCF6
M*1&CXVN'D7Y?0YH ]]HKY6TO_@H%X&THO:^,/,TK43J=U:B.PC:X2&VBF$:3
MS$X*AB1P 3UXP,U['\*OCSX8^,NJ>);+PV-0E70;K['<W5S9M%!))C/[MC]X
M?@/4<4 >C4444 %%%% !1110 4444 %5=3U"'2=.NKVX)$%M$TTA R=J@D_H
M*M5'/!'<PR0RHLD4BE'1AD,",$&FK7U$_(\/\'?&KXB>.+ Z]I_PWMAX5NX)
MIK"[DUI1<.$!V&2+9P'(P-I)&>E<;XI_:FU/QGX&O8_!FE*NJQZ!-J.IW!O3
M&=)D4E1'G8=SY!(!QTKU'PC^SCX7\">(X]8T>ZUU%MVDDM=)EUB=M/MV?[VR
M'.T ^AR!Z5F?#+]GJV\.^&O&MKKZ6K7WBV[GFO\ ^RRR(D3\+&C$ C ZG'6O
M?57 1DYJ&UK+7OK?5WLO34\QPQ32BY;WOM^&BZ_@<1X?_:)\<IX>TS3].\&P
M^)=8TS0X-6UR>?5Q"%B9<KY9*?/(R@L1P!TS6+9?M/ZU;^/?$WB:6QFNO!HT
M"SO++31>#>))6VQX7;@,S'#'. !GFO6_$O[+?@GQ.+ R-J^GO:V2:=))INIR
MVS7=LO BG*G]XOUYK5F_9Z\$3_VHCZ6QM-1TV'29K,2L(5@B^X$ ^ZP/.X'.
M:I8G+U=^SWWW[J_7[K6MMJ3['%.RYMO\O3[]S@H_VC/&.G#6=-USP%:V'B6Q
MTY=9@LH=7$L-U9Y^?$FP;9%&?E(P?6N;N/VAM1^(5GX&\2V]KJ/AOPY>^(#;
MVQM=0427D"1,7,\80C;D'" Y.,YKT2Q_90\$VFEZE92W&NZ@VHB**ZN[_599
MKB2",Y6WWMR(O51C/>M"Q_9F\#Z7J<-U96MW9P0Z@-3BT^&Y(M8YPFPE8\8
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M4Y]&=+12#GFEK$ZCSOQU_P E0^'W_7:[_P#1!KT,=*\\\=?\E0^'W_7:[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>17]-OP@^$GAWX)_#[1?"/AJQCL]-TVV2!650'F('S2.P^\S'+$GN37XS?\
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M=;>=9+[477<+2 @%5[%F/"C]:Y;P_P#M(:1J5ZD&I:=-I2.=HN!()47_ 'L
M$#WYK])A@,-"'+&E&WHC\C^N9WB5]952=O)V^Y?Y(^M_ ?[3>I:-<PV/CR*W
MN-/=@B^(;&,QB(D\&XAR=H_Z:(<#NH'-?24,R7$22Q.LD;J&5T.0P/((/<5\
M)*T=Q"""LL4BY!&"K*1^H(KV[]ECQC,D>I>";N5I$TY%N],9SDBU8X:+/I&^
M,?[+@=J^-SO**=&F\3AU9+==/5'WG#'$=7&U/J6,=Y='WMT?F?05%)D>M-DE
M2&-GD8(BC)9C@ >I-?#GZ8/KG?B!XZTKX;^$M0\0:S.(;*T3=@<O(YX2-%ZL
M[,0H4<DD5Q/B']I+PK:ZC+HOA;[3\0?$R?+_ &1X7071C;_IO.#Y, ]3(Z_0
MU!X4^&'B#Q?XFLO&/Q-FM9K^Q?SM'\,6#F2PTER/]:SD W%Q@X\P@*G.Q?XB
M :'P*\':II6EZKXH\30^1XL\4W O[ZW)R;.(#;;VN?\ IFG7_;9Z]/HHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** &2'%<1>R6EYKE[<3'P\SQXMXYI"9IPHY9''\.
M&/2NVEZUQ5C=RR?:6ANW;-Q)N^R:,R\[L<EOO$?WN]9R=CBQ.MD_Z_%#"ED3
ME6T8D=XF>$_F#5F)I@A53(\1_AWK<Q__ !5/9[Q^K7KCT>P0#]:B$.6!:$9]
M3:A&_-6K.YRI6>A8A"[-J@! <[ Q*@^W\2?RJY%#N/&3W]_\_2JT0)(SDXZ%
MLG]2,_K6G:IS6D6;PC<DBMAZ"OE#]K4^(M,\:Z=<FYN8=&: "T,$C(BR@G?G
M!^]T/TIGB_\ :1\:^&_BEJ$+2)%I=C=M =*:%=KQ@]2V-V2.<Y[BOH/7='T+
MX\_#,"*026E]$)K><?>@E'0^Q4\$?6O$KUH9G2J4*3:E'Y7M^AX&(JTLYH5<
M+AY-3AWTO;]/^ <Q^SC\7A\0_#O]FZE-NU_3U"R,QYN(^BR>Y['\#WKV95K\
M[+*[U[X+_$(,5-MJNES[9$/W95[CW5E_G7WMX$\9V'C[PQ9:UIS@PW"_,F<M
M$X^\C>X-5E>,=>#HU?CC_7_#FV19B\53>'K_ ,2&COU7^:ZG04445[I]2-85
MYC^T%\:-.^!OP\O=>NRLM\P,-A:9PUQ.1\H^@ZD]@#7HFKZK:Z'I=UJ%].EM
M9VT32S32'"HBC))/TK\D/VF?CK??'_XDR7=OYO\ 8=HQMM)M!G)4G'F$?WG.
M/PP*]G*\"\;6][X%O_D=F%H>WGKLMS:_9\\:_$?X@_M':-J%EK.HWNJ7=YY]
M^6G<P?9\YD#)G:(PO &/3'-?JC);#!P..U?/_P"R'^S_ &WP'^'<FMZZL</B
M34X1<7TTF!]EA W"+/; Y;W^E?-GQ9_;Z\:WGQ,F_P"$&O;>T\+V<WDP0O:I
M*;X X+N6&0&[!2..>]>CBJ<LUQ+AA4E&"M?9?UV-ZT/KE2U):(_06:WVY[>_
MI5-QY8)!*\8)! ./3/11[#FI=!U&?7/#.E:C=6QL[J[M8IY;<_\ +)F0$K^!
M--N%PV1U'3C_ .L<?ABODYWB[,\22L[%/=*J%85:)#U\A0@/UD?K^ JJR6Q;
M,K:;N[F[N7G;_"K$T0=MQB$C>K0F0_\ CS4Y#=(!L^U(/^F5C'C^=97,3-OX
M[$V^]1X8FEA82Q"Y0Q*K#D'=SC'K7=6-RMU:Q3+)'('0-OA;<C9'53W'O7*W
M%Q<^1*);BZ";3D3Z1O3IW"]:W?#<OGZ+9N)$E!C'SQVY@4_2,\K]#5IFU/1F
MQ1116AT!1110 4444 %%%% '.?#_ /Y%BW_WY/\ T-JZ.N<^'_\ R+%O_OR?
M^AM71UI4^-E2W84445F2%%%% !7*?%?7IO"WPR\5ZO;9^T6.EW-Q$5ZAUB8J
M?SQ75UY%^UOJDVC?LT_$>\@.)4T6< _[PVG]#0!_.!K.HS:OJ][?7#F2>YF>
M:1F.269B3_.J=6+:RN-0N?)MH9+B8@MLC4LQ &2<>P!-5Z "BBB@ K]C_P#@
MBQXOO=4^#'B_0;AB]KI>KA[?)X421JS ?\"R?QK\=Q87)LC>""0VH?RS-M.S
M=C.W/KCM7ZF_\$0]4E(^)NFD_N%^R7 '^T=RG]%% 'ZJ4444 %%%% !1110
M4FX#J0*Q_&6D:AK_ (3UC3=)U:30=3N[26"VU.&,.]K(RD+*%/!*D@X]J_/F
M[_8]_;4TJ:3^R_VD8;Z L=K7E[<JY'N&A<#Z T ?H]D'W^E>-?M$_M:_#C]F
M;P]/?>+=<@_M3RRUKH5HZR7UTV. L><J/]ML*/7M7QW+^P_^V'XN0VWB3]I+
M[)92<2"PU"\9L?[J)&#^==O\(?\ @D3\./"FLIKGQ"U[5?B=K&X2/'??Z/:2
M/ZN@9GDY[,^#W!H ^?O@/\/_ ![_ ,%)?VE8/B[X_P!/DTSX8Z#.ILK)\^3*
M(VW1VL.?OC=\TK]"<CO@?KE'&L2*B@*JC  ["JFCZ-8>'M,MM.TNRM].T^V0
M106MK$L<42#HJJH  'H*NT ? ?\ P5/_ &O[[X1>$;?X7>$2X\6>*K5OM5U%
MR]K9.3'M0#GS)2&4>B@]R,?DSX=\":WX&^.OAGPYXFTN73=7BUBP%Q87:@NN
M^6-@K#GJK#(/KS7[$_\ !0K]FOQSX\\0?#WXK?"?2;?4_'O@Z[#O:NT:O=0!
MP\8&\@,%8/E<@D2''2OBOXS? C]HSXI_'+3/C;<_ 6^TV]CO;*XO-(M;Z.7[
M3-;>7\P3=YB(X11T.#GDT ?K'^T!\0E^$WP"\:^+-VR72M&GF@(X_?;"L0_[
M[917Y\_\$9O@E]ON?&/Q>U6 R3M(='TR249.3B2YD&?4F-<^S"NM^/7Q2^/W
M[5_P(\1_#BV_9P\4>$=7N_L\DEW<WL:VLD4<H=D#3"+DE5P%+=Z]M_X)M^'O
M'WP^^!R^!O''PWE\!MH,I2VNY;M)6U,R,SR2%%)VD,>N2#D8Z&@#ZVKY,_X*
M!_L3P_M9> [:\T62*R\?:$CMIDTQVQW<;<M;2-V!(RK?PMG/#&OK.B@#\7?^
M"?/[8.L?LF?$>\^#WQ3CN=)\+W%\UN5U!2CZ'>EL$L#TA<XW=@2''!;/[/Q2
MI-&LD;!T8!E93D$'O7R#^WW^P=H_[47A2X\0Z!!#IWQ,TVW)L[M0%74449%M
M/ZYZ(YY4D _+T^</V+OVQ/C-\'T\+_";XC?"3Q9K6F+J4>CV>N/97$5Q8Q,P
M18W#1E95C/0[E(08R0!0!^J%%(#D4M !1110 4444 <W8?\ )0-8_P"P=:?^
MASUTE<W8?\E UC_L'6G_ *'/725I/=>B_(J6X4445F2>6_M.S20_ [Q3Y9(W
MVZQOC^XSJK?^.DU\RN )".@!Q7V9X_\ "L7C?P5K>@S':FH6DEONQG:64@'\
M#@U\3Z;+<-;M!?1F#4K1VM+V$]8YT.UQ^)^8>H8'O7Z%PS4BZ-2GU3O\FO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#QR@44#K0!]C_%WX')\,/^"?GPRUR>-1JGB76IM3G8#D1O$HB7\%4?C7T?\
M\$0XXA'\3I 1YY-HI'?;A\?KFN.^-EQ_PL3_ (),_#36$;S)=!U"*SD(Y(V[
MXSG_ +Y%<K_P1M\=3Z%^T9K'AS<?LNM:0[LN>-\+ K^CF@#]K:*** "BBB@
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MC4(BVDBJJC  "G  KQ<+@)83VD>:\'LCYO Y5++_ &T7.].6R_S_ "\SX/\
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M;_[\G_H;5T=<Y\/_ /D6+?\ WY/_ $-JZ.M*GQLJ6["BBBLR0HHHH *^&?\
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M(4444 %?"O\ P6'U:&S_ &68+1XP\MWK5N$;^[M#$_SK[JKP7]M;]G _M/\
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M_9;^&#7NDW<?AA;6XTO/V9[6^N8,@R&7;)LD'FKO8L%DW $\"NA\!_!KP?\
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M@UY^-GC?8_[1"R;WZZ7TW\WTU[LZL-'#^T_=2NTMON\O)'14445X!Z@4444
M%%%% !1110 4444 %%%% !1110 4444 %9/BS_D6-5_Z]I/_ $$UK5D^+/\
MD6-5_P"O:3_T$U$_A9G4^"7H?!GP%_Y*YX5_Z_%_E7,_\%(?^2Y:5_V!H_\
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MPM[]O7^M#Y1N_A[J\+$0WEM-"/XY"48#W&#^E;GA'P;;Z:$OY;A;ZXD7,<B
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MVOWG?A72J0]I3C8****\L[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*R?%G_(L:K_U[2?^@FM:LKQ6"WAK5 !DFVDX'^Z:B?PLSJ?!+T/@OX"_\E<\
M*_\ 7XO\JYG_ (*0_P#)<M*_[ T?_HQZZ?X"J3\7?"PP<B[4_H:YG_@I"#_P
MO#2C@X.C1\_]M'J>!?XS^?Y(^>X'^"?J_P D?5'[!W_)M^@_]=[C_P!&&OH:
MOGK]@]2O[-^@Y!&9K@C/_70U]"UZ>._WJK_B?YGUE?\ BR]0HHHKA, HHHH
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MC=]6%%%%(04444 %%%% !1110 4444 %%%% !1110 4444 <Y\/_ /D6+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&"YC,4RNY*$CC+DCI6Y5SUDRI;L****@D**** "BBB@ HHHH **** "BBB@
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M">00-O%??%<UXCN_$>D7$5UIUM;:K8>:&NK=V:.>&$*2QA"AO-D)P K%1[T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ibio-20230630x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %8 Z@# 2(  A$! Q$!_\0
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M^ /^A#\4_P#?RT_^.T?\/A? '_0A^*?^_EI_\=K\I:*/JE+L'MYGZM?\/A?
M'_0A^*?^_EI_\=H_X?"^ /\ H0_%/_?RT_\ CM?E+11]4I=@]O,_5K_A\+X
M_P"A#\4_]_+3_P".T?\ #X7P!_T(?BG_ +^6G_QVOREHH^J4NP>WF?JU_P /
MA? '_0A^*?\ OY:?_':/^'PO@#_H0_%/_?RT_P#CM?E+11]4I=@]O,_5K_A\
M+X _Z$/Q3_W\M/\ X[1_P^%\ ?\ 0A^*?^_EI_\ ':_*6BCZI2[![>9^K7_#
MX7P!_P!"'XI_[^6G_P =H_X?"^ /^A#\4_\ ?RT_^.U^4M%'U2EV#V\S]6O^
M'PO@#_H0_%/_ '\M/_CM'_#X7P!_T(?BG_OY:?\ QVOREHH^J4NP>WF?JU_P
M^%\ ?]"'XI_[^6G_ ,=H_P"'PO@#_H0_%/\ W\M/_CM?E+11]4I=@]O,_5K_
M (?"^ /^A#\4_P#?RT_^.T?\/A? '_0A^*?^_EI_\=K\I:*/JE+L'MYGZM?\
M/A? '_0A^*?^_EI_\=H_X?"^ /\ H0_%/_?RT_\ CM?E+11]4I=@]O,_5K_A
M\+X _P"A#\4_]_+3_P".T?\ #X7P!_T(?BG_ +^6G_QVOREHH^J4NP>WF?JU
M_P /A? '_0A^*?\ OY:?_':/^'PO@#_H0_%/_?RT_P#CM?E(S!1DD >YI/,3
M:#O7:>AR,4?5*78/;S/U<_X?"^ /^A#\4_\ ?RT_^.T?\/A? '_0A^*?^_EI
M_P#':_*3<, Y&#T.>M ()(!R0<'V-'U2EV#V\S]6_P#A\+X _P"A#\4_]_+3
M_P".T?\ #X7P!_T(?BG_ +^6G_QVORDW*0#N&&X!SU^GK2;U#!=R[CVSS1]4
MI=@]O,_5S_A\+X _Z$/Q3_W\M/\ X[1_P^%\ ?\ 0A^*?^_EI_\ ':_*3/..
M]%'U2EV#V\S]6_\ A\+X _Z$/Q3_ -_+3_X[1_P^%\ ?]"'XI_[^6G_QVORD
MS_A0"",@Y'M1]4I=@]O,_5O_ (?"^ /^A#\4_P#?RT_^.T?\/A? '_0A^*?^
M_EI_\=K\I:*/JE+L'MYGZM?\/A? '_0A^*?^_EI_\=H_X?"^ /\ H0_%/_?R
MT_\ CM?E+11]4I=@]O,_5K_A\+X _P"A#\4_]_+3_P".T?\ #X7P!_T(?BG_
M +^6G_QVOREHH^J4NP>WF?JU_P /A? '_0A^*?\ OY:?_':/^'PO@#_H0_%/
M_?RT_P#CM?E+30ZDX##/IFCZI2[![>9^KG_#X7P!_P!"'XI_[^6G_P =H_X?
M"^ /^A#\4_\ ?RT_^.U^4E('4MM#*6],\T?5*78/;S/U<_X?"^ /^A#\4_\
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M*Q?\FL0_]C%8?^U:_'6O5P?\+YG%B/C"BBBN\Y@HHHH **** "BBB@ HHHH
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M3S_$KQO8?$%+I/B!ITGA[7M1\(Z;K6G1"\34K4H[:?=(B@7(MO-,D8&4=44
M#YDKQG1_B]XS^,%U%X?\:ZS)XB\)W&HV(U/4+VRCE;186NHT:>*94'V488KP
M0I!QCICBO$_QA\;^,O$&F:YK'BC4;O5]+YL+Q91"]H=V_=%Y84(Q;YBP )/)
M)JSXQ^.7C[Q_H[:5X@\4WVHZ8\@FEM,1PQSR#H\HC5?-8=B^ZA4VOZV!S3/:
MF^*GQ$3]HT_#9-(A'AP:[_8@^'/V"/[ ;'SO+V>7MSGR?G^T9W9_>;Z7PW\-
M/#/QEAN/#UM?PII'PV\1WOVS5-RAY_";S2R--NXWM$\3*#R<72=L5XV/V@?B
M0/#'_"/#QIJHTK[-]B\OS%\W[/C'D^=M\WR\<;-^,<8QQ7%Z=K%]I$5['8W<
MUI'?6S6=TL+E1- Q5FC;'5244X_V11[-]-!<Z/JW2_C7:S_"[4/%UUXHUCX=
M-KOCF_,,7AK1;:[(MULK7RK=A(\>U8DV 8SD[B?6NM\%:U9Z1\#/"OB"[U^Z
MUS1]-\/:CJ&L> XM&@E;6[>;4;V'[9+(Y^1%<QB1DW-$-I''(^3O!7QJ\=?#
MG2I=,\,^*+[1M/EG-T]M;^6R-*5"E\.K<X4#([ 5G6GQ*\56&I:;?V^OWT%Y
MIL,]M9S)( 8(IFD::-1C&QVEE+*00=YXJ72OHBE4/9+'Q[IJ?L]OXT?25;XB
MV07P#%JNQ/)-I) THNRF.;I;=7M@_P#=8-]X9KYV  & , =!5Y-;OTT)M%6[
ME&DM<K>M9@_NS.J&,28_O!"5SZ&J5;QCRW,F[A1115DEK2M*OM=U&VT_3;.X
MU&_N7$<%K:1-++*YZ*J*"6/L!6QXJ^''BOP-?6EGXC\,ZOH5W>?\>T.HV4D+
M3\X^3</FY('&>37HW[.HU&[T;XE:9X5E>+XA7^BPPZ(+=_+NIX1<*U]!;-D'
MSG@ P%(9E$BKR<'KOAWHGBKP=\+]6M/'EMJ&E:9J&OZ+_P (UIVNI)'.^I)?
MQF:>WBD^=46W\Q9' "G<BDDXQC*;3-%&YXW=_!?X@V&IV6G7/@7Q+;ZA>EQ:
MVLNDSK).4&YPBE,L0.2!T'-26GAOQS\)/%FCZU<>&=4T?5=,OK6ZM5U33947
MS]Y: %6 W;FC;"_Q;6QT->P?&OXRV-OXQ\;^"_#>FZU9"_\ ')OM0O\ 5M;:
M[82P7<R 6T:H@@5C*^XY9B JYP*]#T^QD\3_ !=\?65U/++"/C1I<CM*Y?9%
M#_:$S8R> %C/'2H=25KR1?*KZ,\"LOCOK:ZSJ\-IX$\'!]9A-EJ&DQ:"YBNR
MLXG!>+S<F19$R"",<C%5)[OQY\4_#_\ PCV@^!PNC7=X?$']G>%]$D$4SH@M
MA+@;RT:891SA7>3NU?0?P]UCPA%\3?#WQU\NPW^.-4M]'@T$'(L-5N9O*U6;
M9VC2%_-C/]Z\7^[65X)^&.HW-Y\,?^)9J6K6'@71=<U'4=-TU)7EO#;:S<)!
M:A8^3YLXC4C^[O/8U/.ET'RM]3Q^P^+?CGPRC^#M4\+Z;J\MCID>CW&DZ_HS
MS3+;6TSW42RIN5LPEW()QM3@\"J&IGXD_M!16DVF>%+O5-'T1#96FG^%-$9+
M#3PY\QD2.%2%9R=S,Q+-P23@5[%\']?_ .%0WGB;XJ_$^]N]&\;>(=6FTZSA
MO=&:]FD D275F>!F0HKJZVP8GCS) !QQAZ9X5B^&_CGXO6GAR_N7\*:AX U'
M6M N8Y7036$Y@>W8@'[Z M$W<-&PI\R3=E_745FUJSP*W\%>(;K7+/18=!U.
M;6+Q0]MI\=G(UQ.IS@I&!N8?*W(&.#Z58\1_#OQ5X0UFUTG7/#>K:/JEWM^S
M6=[9212SY.!Y:D?/D\?+GGBOIV:/5]7^'<VD^$))F\?WWP^\,F"&T<B^N],5
M[HWT-L0=S.6-NSHGS,B-U&15+X,Z1XD\)^&?".F>/H;_ $X7OQ \/S>%--UC
M>EW&ZW.+Z>&.3YXX#&8T8X"L^S&2IP_:O<7(MCY7MM,O+W[5]GM9Y_LL33W'
MEQEO)C4@,[X^ZH) )/ )%5J^L[K5?#?Q!L_C9XOMI+30O&<'A[5K#6]&C7RH
MM1)NXA'J%LHX!.S$T?9L.O#D#Y-;[Q^M:QES=")1L)1116A 5]6? 3^R++X=
M>$]0U?0;+Q#96]EXXN+G3KL;5NTCLK1A&S@;E[[6'*DY%?*=;FG>.?$&DZ;'
MI]EK-W:V,<=W"EO$^$5+I%2Y4#'21456]0HK.<>961<7RL^N?@Y\.='\-P^%
M=?\ #ERFM>#=<^(6DS:1>7:(US $LKXRV=RN#MFB;8&'W7&QQD-QY3X6\8Z_
M\<OAE\08O'$]KJUIHFF0WVF^);ZUBBETZ^:ZABCA-RB M',LD@:-MWW-P VU
MXYX;\<^(?![P/HFM7NEF"]BU&(6TNT)<QJRQS =-ZJ[ ''1B*U/&GQA\;_$2
MQ@LO$OBG4M8L8)/-BM)Y0L*/C&_RT"KNQQN(S[UG[-WN7SJQ[3\%Q9_"?P9\
M5KJ;QS#9^5%HH37_  ;%%JKQ>9=3J8AYIC W ?-SP,=<UI:@?!/Q*^$.E66N
MZM))JOB'Q1K"Z/X_U>V2UFBGCM[(1Q7L<995MY2Q0D$^4P1QQO%?/G@?XH^+
M?AI)?/X6U^\T-KY$CNOLVPB94)*!@RL#@DD?6JOBCQ[XB\:@C7=8N=44W,M[
MMGV[?.E5%DDPH !98XP>/X!1[-N5PYU:Q]22?"Z/1?VBY=3\50:1HVG^ ?"N
MAWE]!KDRP6,FJ#3X4M+29U# B2X&YB =R1N><YJ32O#VC?#;XM_$7Q1I6NII
M7A+6O!-QK^E:YX=@CU%;(O>6R7$=N'**YBG\Z+DJ=I'3.*^5M2\>>(]9TE]+
MO];OKS3WD@E:WGF+*SP1&& G/)\N,E%R> >*TO"?Q?\ &O@6&VAT#Q-J&E0V
MRW"PQP,I6-9RAF #*1AS%&6'0E >M)TI-;@IJ^Q[[\>--T[^POBSKVG0VPTK
M7H/"6L:=<"U6VEEBE\Y&FDBVJ(99'BD=T4!<G(R"#5KX>R>&=,^$VF:AXF\.
MP^(=&C^&MV]U:)MCF8-XD$?FQ28^69%;*,>Z@'Y217@NE_'KXBZ-K^K:W:>,
M]6CU?5A&M_>/*LKW(C_U8?>K#"Y^4  #M6-??$CQ3J5M=6]UKU[/!<VTEE-$
MS@*\$EQ]I>,@#&UI_P!X0/XN:/9RM;^M@YU>Y]6^#O@YI?A_PYX*AB33O'>G
MW>K>(]<\*N\0\O7GBTJW>SMY8_O!Q,C*]N?^6D;+R&&?.O"/C'XA?'OPMXUT
MS6?'^BW:6NG75]<:'XBTPL;2&"/S&GMFC@V6;*1Y:_,GS$+M.17@T'B75K6Q
ML[.#4[N"ULKLW]K%%.RK;W)"@S1X/RN0B?,,'Y1Z5UGBSX^?$3QUH<VCZ]XO
MU'4M-N&5KF!_+3[45.5,S(JM,01G]X6YYZT>SEZASHX '< <8R,X/:EHHKI,
M0HHHH *!U]:** /H+QQ\1_$_P2\)?#K3O >H/X6T'5/#EIJ\VJV,4:R:Q?2;
MOM1EF927$4@\D19VJ$Y7+9.7XMO[_6?@CXVU;7M'M-$UJY\::4\T$&G+8A=V
MFW396+ V!^)"  "6R!R*X?P9\;/'?P]TIM+\/>)[W3M-,IG%GB.:&.4]9$25
M6".<#++@G S4N@_'?XB>&+S5[O3?&6K076L7"W6H3/*LSW<R@A9)#(K98 D
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M-N!_R [[_P!)WKH]&4?V18\#_41_^@BCZ[4[(/J\#\#_ /AD?XV_]$G\7?\
M@K>C_AD?XV_]$G\7?^"MZ_?W:/04;1Z"CZ[4[(/J\#\ O^&1_C;_ -$G\7?^
M"MZ/^&1_C;_T2?Q=_P""MZ_?W:/04F%]!1]=J=D'U>!^ ?\ PR/\;?\ HD_B
M[_P5O1_PR/\ &W_HD_B[_P %;U^_NU?04F%]!1]=J=D'U>!^ ?\ PR/\;?\
MHD_B[_P5O1_PR/\ &W_HD_B[_P %;U^_NT>@I-J^@H^NU.R#ZO _ /\ X9'^
M-O\ T2?Q=_X*WH_X9'^-O_1)_%W_ (*WK]_,*.PHVJ.PH^NU.R#ZO _ /_AD
M?XV_]$G\7?\ @K>C_AD?XV_]$G\7?^"MZ_?W:/04;1Z"CZ[4[(/J\#\ O^&1
M_C;_ -$G\7?^"MZ/^&1_C;_T2?Q=_P""MZ_?W:/04;1Z"CZ[4[(/J\#\ O\
MAD?XV_\ 1)_%W_@K>C_AD?XV_P#1)_%W_@K>OW]VCT%&T>@H^NU.R#ZO _ +
M_AD?XV_]$G\7?^"MZ/\ AD?XV_\ 1)_%W_@K>OW]VCT%&T>@H^NU.R#ZO _
M+_AD?XV_]$G\7?\ @K>C_AD?XV_]$G\7?^"MZ_?W:/04;1Z"CZ[4[(/J\#\
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MIH^IYE_S[7WK_,/[*J=OQ1^?'_#(_P ;?^B3^+O_  5O1_PR/\;?^B3^+O\
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MU0!B/;=FOCN(E#EIO[6OW'CYCRVCW.KHHHKX@\0**** "BBB@ HHHH ****
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MC?\ P[*\;?\ 0W:!_P!^Y_\ XFC_ (=E>-O^ANT#_OW/_P#$U[)_P\I^&_\
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MP/SD_P"'97C;_H;M _[]S_\ Q-'_  [*\;?]#=H'_?N?_P")K]&Z*/[<QO\
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M?^E%I7>5P>I_\EO\/_\ 8 U#_P!*+2@#O**** "BBB@ HHHH **** "BBB@
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M0!S_ .T'^S?X<_:$\/PVNJ%]/U>SW&QU:W4&2'/56!^^AP,J?3((-?$.N_\
M!.7XG:=?/%I]WH>JVV?EG%TT)(]U9>#^)K],[BXBM())IY%AAC4L\CD!5 ZD
MD]!7C^M_MA_![P_?R6=UXXL'GC.UOLJR7"@_[T:D?K7N8''8VC'V>'7,NUKV
M.VA7KP7+3U7WGPW_ ,.]?BY_S[:+_P"#(?\ Q-'_  [U^+G_ #[:+_X,A_\
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M444 %<'J?_);_#__ & -0_\ 2BTKO*X/4_\ DM_A_P#[ &H?^E%I0!WE%%%
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M%% !7!ZG_P EO\/_ /8 U#_THM*[RN#U/_DM_A__ + &H?\ I1:4 =Y1110
M4444 %%%% !1110 4444 %%%% !1110!P$7_ "7>Y_[%N+_TJDHHB_Y+O<_]
MBW%_Z5244 >-_P#!1G_DWN'_ +#EG_[4KO/V-_\ DV/X??\ 8//_ *->N#_X
M*,_\F]P_]ARS_P#:E=Y^QO\ \FQ_#[_L'G_T:]>[/_D50_QO\CN?^ZK_ !?H
M>ST445X1PA1110 4444 %%%% !1110 4444 %%%% !1110!Q_P 8_P#DD?C;
M_L!WW_I.]='HW_((L?\ KA'_ .@BN<^,?_)(_&W_ & [[_TG>NCT;_D$6/\
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M^E]S#Z]6_D_,_*K_ (93^+W_ $3_ %G_ +]+_C1_PRG\7O\ HG^L_P#?I?\
M&OU5_P"%T> /^ATT#_P90_\ Q5'_  NCP!_T.F@?^#*'_P"*H_MO&?\ /I?<
MP^O5OY/S/RJ_X93^+W_1/]9_[]+_ (T?\,I_%[_HG^L_]^E_QK]5?^%T> /^
MATT#_P &4/\ \51_PNCP!_T.F@?^#*'_ .*H_MO&?\^E]S#Z]6_D_,_*K_AE
M/XO?]$_UG_OTO^- _94^+P8,/ &M!@<@B(9!_P"^J_57_A='@#_H=- _\&4/
M_P 51_PNCP!_T.F@?^#*'_XJC^V\9_SZ7W,/KU;^3\S\JO\ AE+XN_\ 1/\
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M.P' ZY)QC[%HHKP,3BJN+J>TJN[_ "//J5959<TPHHHKD,@HHHH *X+XA_\
M(Z?#7_L-S?\ IONJ[VN"^(?_ ".GPU_[#<W_ *;[J@#O!TI:0=*6@ HHHH *
M*** "BBB@ HHHH **** "BBB@#@/&'_)5_ '_7/4O_1,==_7 >,/^2K^ /\
MKGJ7_HF.N_H **** "BBB@ HHHH **** "BBB@ HHHH *X/4_P#DM_A__L :
MA_Z46E=Y7!ZG_P EO\/_ /8 U#_THM* .\HHHH **** "BBB@ HHHH ****
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M^D[UT>C?\@BQ_P"N$?\ Z"*YSXQ_\DC\;?\ 8#OO_2=ZZ/1O^018_P#7"/\
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M5S^LA?%?PE\?>/8["Z\0?"X?'K^W-8%I&S)?:0J@-(!CYX\NN?=AZ< 'W_\
M#?\ ;Y^"GQ3\8VWAC1?%9CU6\D\JR34;*:T2\;H!$\BJKD]@#D]J[31OVFOA
MUX@^,]_\*M/U\7/C>Q222XL$MI=J!%4N/-V["1N&0#UR.H-><2?M-?LV^,?$
M?P\TFTU7P[XGU>YOXDT"VT^R6ZDL)BK!'VJI-OCIDXP2/3(Y_P :6\<'_!33
MX<F.-(M_@'468JH&6-PW)]30!]#^)/C!X4\)_$/PMX'U/5%@\3^)5G?3+!8V
M=I5A4-(20"%&,X+8!P<=*[.OR3\9?'WQ7X9_;,\8?$Y=5T>3Q!I/B>#P%8^
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MX;3NR,=#74L1!Z*#_#K\S7VB?0\A_M_5/^@G??\ @7)_\51_;^J?]!.^_P#
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M10 4444 %%%% !1110 4444 <!XP_P"2K^ /^N>I?^B8Z[^N \8?\E7\ ?\
M7/4O_1,==_0 4444 %%%% !1110 4444 %%%% !1110 5P>I_P#);_#_ /V
M-0_]*+2N\K@]3_Y+?X?_ .P!J'_I1:4 =Y1110 4444 %%%% !1110 4444
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M4/\ THM* .\HHHH **** "BBB@ HHHH **** "BBB@ HHHH X"+_ )+O<_\
M8MQ?^E4E%$7_ "7>Y_[%N+_TJDHH \;_ ."C/_)O</\ V'+/_P!J5WG[&_\
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MKG_@0/\ "O-J*/J]'^1?<@]G#^5?<>D_\-)_%/\ Z'[7/_ @?X4?\-)_%/\
MZ'[7/_ @?X5YM11]7H_R+[D'LX?RK[CTG_AI/XI_]#]KG_@0/\*EM/VG?BO9
M7"31^/=89T.0))5=?Q!7!KS&BCZO1_D7W(/9P_E7W'Z&_LG_ +<5WX]\0V?@
MWQZ($U6[/EV&K0KY:7$G:.1>BN>Q'!/& <9^TZ_"2SOI]+NX+VUD:*ZMI%GB
M=#@JZD,I'OD"OW,T"]EU'0]/NIEV33V\<KKZ,R D?F:^%SO!4\+.-2DK*5]/
M-'AXVC&E)2CU+]%%%?,GF!1110 5P7Q#_P"1T^&O_8;F_P#3?=5WM<%\0_\
MD=/AK_V&YO\ TWW5 '>#I2T@Z4M !1110 4444 %%%% !1110 4444 %%%%
M' >,/^2K^ /^N>I?^B8Z[^N \8?\E7\ ?]<]2_\ 1,==_0 4444 %%%% !11
M10 4444 %%%% !1110 5P>I_\EO\/_\ 8 U#_P!*+2N\K@]3_P"2W^'_ /L
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M7[K2Q)/$\<B+)&X*LC#(8'J".XKRK7/V5?A/XBOI+R]\#Z6;B0EF:%6A!/\
MNH0/TKZ[!9XJ-)4J\6[:)KMYGK4,<H04)J]C\B)/$6JRS2ROJ-R\DMQ'=NYE
M.6F0$)(?]I03@]LTESX@U2\:9I]0N)C-;FUD+R$[X2^_RSZKN^;'K7ZT?\,;
M_!S_ *$:R_[^R_\ Q='_  QO\'/^A&LO^_LO_P 77?\ V_A?Y'^'^9T?7Z7\
MK/RFMO'_ (FLK:]MX->U"*"]01W"+.<2J(Q& ?\ @ "<8^48Z5GG7]3+RO\
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MABJEBV2<>]<3UK]>/^&-_@Y_T(UE_P!_9?\ XNC_ (8W^#G_ $(UE_W]E_\
MBZ<<^PL%:,&ON_S!8^DMHL_(>C%?J1\1OV4_A3HC>%OL7@VS@^UZ[:VLV)93
MOB;?N4_-T.!77K^QQ\'"H/\ P@UET_YZR_\ Q=7_ *PX;^27X?YE?VA3[,_(
MC%&*_7C_ (8W^#G_ $(UE_W]E_\ BZ/^&-_@Y_T(UE_W]E_^+H_UAPW\DOP_
MS#^T*?9GY#XHQ7Z\?\,;_!S_ *$:R_[^R_\ Q='_  QO\'/^A&LO^_LO_P 7
M1_K#AOY)?A_F']H4^S/R'Q17Z\?\,;_!S_H1K+_O[+_\74UK^R#\'[.=9H_
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M*_-OX6_ME_%&\^$_Q\U"U\0:;\18?!^BV]_H_BR/3VM(&N)%_>Q,IP',8RP
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M3X2?M=Z3X>TWP%#\0O"%KH%AY=O'XM2UDDU,VL8 4>6PV%]H .1SZ]Z^U**
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MI"NB@,MLK!E4'U!4'=UXK8G^,7B2;4(+Y6T^WNTEDGEEM]/B0W3NA20S<?O
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M%% !7!ZG_P EO\/_ /8 U#_THM*[RN#U/_DM_A__ + &H?\ I1:4 =Y1110
M4444 %%%% !1110 4444 %%%% !1110!P$7_ "7>Y_[%N+_TJDHHB_Y+O<_]
MBW%_Z5244 >-_P#!1G_DWN'_ +#EG_[4KO/V-_\ DV/X??\ 8//_ *->N#_X
M*,_\F]P_]ARS_P#:E=Y^QO\ \FQ_#[_L'G_T:]>[/_D50_QO\CN?^ZK_ !?H
M>ST445X1PA1110 4444 %%%% !1110 4444 %%%% !1110!Q_P 8_P#DD?C;
M_L!WW_I.]='HW_((L?\ KA'_ .@BN<^,?_)(_&W_ & [[_TG>NCT;_D$6/\
MUPC_ /010!=HHHH **S/$;:JFER-HXM3>@@C[8S"/;W^Z"<XKC?!_P 2+A_
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M%Y?6LQ91+YVW*!ARNUD1E8<@CN*DM?BC96Z?9&\(:5-I,-U'?6=@TLH6WG5
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MK7AN_P#"UQ!;WEMK< AES*KLGRY)'RIG!QU%>UT <%_PI?0?^?K6O_!Q<_\
MQ='_  I?0?\ GZUK_P '%S_\77>T4 <%_P *7T'_ )^M:_\ !Q<__%T?\*7T
M'_GZUK_P<7/_ ,77>T4 <%_PI?0?^?K6O_!Q<_\ Q='_  I?0?\ GZUK_P '
M%S_\77>T4 <%_P *7T'_ )^M:_\ !Q<__%T?\*7T'_GZUK_P<7/_ ,77>T4
M<%_PI?0?^?K6O_!Q<_\ Q='_  I?0?\ GZUK_P '%S_\77>T4 <%_P *7T'_
M )^M:_\ !Q<__%T?\*7T'_GZUK_P<7/_ ,77>T4 <%_PI?0?^?K6O_!Q<_\
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M ,#[W_&OSHL])N[];MH8B1:6YNI=QV[8P0">>O+#@56,4@SE&&!D\'IZT_\
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MUK7_ (.+G_XNN]HH X+_ (4OH/\ S]:U_P"#BY_^+H_X4OH/_/UK7_@XN?\
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M_P _6M?^#BY_^+KO:* ."_X4OH/_ #]:U_X.+G_XNC_A2^@_\_6M?^#BY_\
MBZ[VB@#@O^%+Z#_S]:U_X.+G_P"+KBM1^$.A+\8]"MOM&L;7T._<M_:UQNR)
M[4#G?G')X^GI7N5<'J?_ "6_P_\ ]@#4/_2BTH 3_A2^@_\ /UK7_@XN?_BZ
M/^%+Z#_S]:U_X.+G_P"+KO:* ."_X4OH/_/UK7_@XN?_ (NC_A2^@_\ /UK7
M_@XN?_BZ[VB@#@O^%+Z#_P _6M?^#BY_^+H_X4OH/_/UK7_@XN?_ (NN]HH
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M_P#(PE_A_4\F_;1OO$?Q@\:>$_@CX*L;/6+EC'XI\2VM]<&"W;3[>9?)MI7
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M;V]FE>>YNG' ,DKDLV.P)P* +?QC_P"21^-O^P'??^D[UT>C?\@BQ_ZX1_\
MH(KG/C&?^+1^-O\ L!WW_I.]='HQ_P")18_]<(__ $$4 7:*3-&: /#?VX[.
M?4/V1_BK;6T,EQ<2Z%.J11*69CQP .M?/GA;]E#2/AI^R/XS\<B_UWQ'XUUW
MX9-9>9JTQE>T@:S$GV6%,950V!CVQZU]ZG!&#@BC QCC'I0!^56G>-+C]H_X
M)_L\_!;P?X3UU_$?AR\T:ZU;6[W3W@M]*2TCQ,RR,!G/;'!P.^*_0#PAHOQ=
MM?BSK]YXCU[P[=_#R43_ -F:?96LB7T1+J8O,<G:<+O!QW(KU0*J] !]*7-
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M.&(# ,,@C><<C_PRA\6_^A%U7_OV/\:/^&4/BW_T(NJ_]^Q_C4-8*3NZR_\
M EZ#3Q"T5-_<SII/B9X?O-<OI]*UJQ\+RG5[>ZN[P::TD>HVR01HZJI0D?O%
MD8H0H?S,\8P-&/XJ^"5U2QN[FXMKB"WUC49;.UAM&6.&.8W)BGG79]Z-Y(B-
MI.5ZKE!7$?\ #*'Q;_Z$75?^_8_QH_X90^+?_0BZK_W['^-)PP+5O;+_ ,"7
M:V_]>0U+$K7V;^YG5WGQ-\-7L^J0W&IV,0FT+['<WUG;R-/<S!I7C$;M'AR-
MR(VX+N4]<H#7SRN=JYX.!G%>GZC^S/\ $_2?LOVSP;J4'VJ=+:'>@^>1L[5'
M/4X-6_\ AE#XMG_F1=5_[]C_ !KJHU<'0ORU5KYHQJ0Q%6UX/[F>345ZS_PR
MA\6_^A%U7_OV/\:/^&4/BW_T(NJ_]^Q_C73]=PW_ #]C]Z,?J];^1_<SR:BO
M6?\ AE#XM_\ 0BZK_P!^Q_C1_P ,H?%O_H1=5_[]C_&CZ[AO^?L?O0?5ZW\C
M^YGDU%>L_P##*'Q;_P"A%U7_ +]C_&IK7]D?XN7=PD2^"-1C+'&Z4*BCZDGB
ME]=PO_/V/WH/J];^1_<SR?3]-N-9O[;3[2-IKN[E6WAC09+.Y"J!^)%?N%H-
MB^F:)86<K;Y+>WCB9O4JH!/Z5\F_LK?L1O\ #77+;Q=XVE@NM<MOGLM.@.^*
MU?IYC-T9QVQP.O6OL#(K\YXAS&EC*D*=%W4;Z^;_ .&/KLJPD\/"4ZBLY=!:
M*3-&:^2/=%HI,T9H 6N"^(?_ ".GPU_[#<W_ *;[JN\S7!_$(_\ %:?#;_L-
MS?\ IONJ .\'2EI >*,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "
MT4F:,T <#XP_Y*OX _ZYZE_Z)CKOZ\_\8'_BZ_@'_KGJ7_HF.N_S0 M%)FC-
M "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M<'J?_);_#__ & -0_\
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M"Y_\%T7_ ,51_P (%XO_ .B@7/\ X+HO_BJ** #_ (0+Q?\ ]% N?_!=%_\
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M_P"$"\7_ /10+G_P71?_ !5%% !_P@7B_P#Z*!<_^"Z+_P"*H_X0+Q?_ -%
MN?\ P71?_%444 9U[\(_$>H:SINJ3>/;LW>GB58&&GQ8 D4*V1GG@"M'_A O
M%_\ T4"Y_P#!=%_\5110 ?\ "!>+_P#HH%S_ ."Z+_XJC_A O%__ $4"Y_\
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M_@NB_P#BJ** #_A O%__ $4"Y_\ !=%_\51_P@7B_P#Z*!<_^"Z+_P"*HHH
M/^$"\7_]% N?_!=%_P#%4?\ "!>+_P#HH%S_ ."Z+_XJBB@"[X2^'U[H?B:[
>UW5/$$^N7TUFEDGF0)$L<:R,_1<Y)+?I1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ibio-20230630x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &O \L# 2(  A$! Q$!_\0
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MK"\(C?>JJQP!GC##O7R'_P %,O\ DH/A'_L&R?\ HVO0?V!O^2*WW_89F_\
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M0 4444 %%%% !1110 4444 ?G;_P4R_Y*#X1_P"P;)_Z-KT']@;_ )(K??\
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M[.GC'P'9^$_$GAK7=*U?X@Z9<ZM=ZPFJ));:=J_]IS+/=QJ4#O;[)$C,38;
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M'[KX>:E9Z3<:ZIOKVVO+:XL8,?:)$GMW9=T6Y2Z'# ,"-PY'FWQ?_:D\8/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC42++M97P<JK )@*,=9X$^&?C_7/B]9?$'XCSZ!:7.C:/<:/I6E>'))IH_\
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M#T:-QV=6!5AV(- '7T444 %%%% !1110 4444 8_C#_D4]:_Z\I__1;5\??
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MJK>>'K^SAU:66)432IUM[LJX.QV8@ >O(/2M*[U6WTCX?Z*\AB:6UU\W,L0
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M3X/?\%?OAIXKEBTWX@:1J7P]U8$))),AN;0-T/SJ-Z\_WD 'K7D/_"-?MO\
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M,<*);Q3)(/.+;@.>F['KUQ1XBS'I[W$:Y=!MQTX/&?PJ1]6TJ[EB1KB!I';
M!P=WL34UU96PMF<VI9<'=''\NX>A ZUSWUNSU.5<CC%G.^&Y%E>6W[$!U4@
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M8&>[NY1'%$#I%BHW,>!DD#\17O\ :6D%C:PVUM#';V\*"..&)0J(H& J@<
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M<DCW,B-^_*^4 A8#:I.22<U[?;7,5Y;QSP2)-#*H=)$8%64\@@CJ* ):***
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M4;?78([PWTD<=W9[S^X2,B18WVGARVUBO8 9ZU[9X7^%7A'P;.)]'\/V5C<
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M++3PYH5OXC\1^((_"%WKEVAN]/MI5U-H%MHVAC4O&)I(?.\[,@CW8" G;EB
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M\-N\4]DUQ(S65Y$)H"2YY"G[I]U(JG\0M-MM*\?ZS96D*V]K#=[(XESA5PO
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M448"J, #T% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M0\@U\F?&&]O-&^*?B":PN#;F3REEC*AXY1Y:\.ARK#ZBOK,]*^2/CC_R4O7/
MK%_Z*6DTI*S&FT[HXGQQ! ;3PO>QVEO9SW^F"XN%M4*1M)YTBY"Y..%%9'Q
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M!!I:* /$/%OPHU&RO9GTVW-]82$E47!9 ?X2.]1^"O@]=/?))>V2:;8JP:1
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MXSQCI5+X;_"?Q'8:7^S;'8^'[K1]2AM/$'V^Z^QM&;6XEAD2&2<XX)^3!;G
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MZO<:WK7@>[GENM*6R;4+59"6%LZNBLJ^BL'''3(]S0!]W>-O^0)X'_[ H_\
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M3+_DH/A'_L&R?^C:]!_8&_Y(K??]AF;_ -%Q5\/#_D=5/3]$?U+B/^38X/\
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M?<UAXDCFPEP/*?\ O#[I_P *XT:G9Y_X^[?_ +^K_C3QJ=GG_C[M_P#OZO\
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M6\<FQ8]Y=L*GR*JDY'"CT%?>'[/?[*G_  S39ZE'J]Q!?^++U(UNYK?F*"/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBZ1_WP__ ,53A^S?\+L_\B)H_P#WP_\ \57HJ]:<O6@#SH?LW_"[/_(B:/\
M]\/_ /%4X?LW?"W/_(B:/_WP_P#\57HPZTX=: /.?^&;?A;_ -")H_\ WP__
M ,54B?LW_"Y&#+X$T<$?[#__ !5>B4^@#EM,_9I^$FH1\^!=*65?O+M;\Q\U
M>A^"/A]X<^&^E3:;X8T>UT6QFG:YDAM4VAY2%4N?4D*HS["LNWG>VE62,X9:
MZVQO4OH!(O!Z,OH: +%%%% !1110 4444 %%%% !1110 4444 %(2 "2< 4M
M<3XU\3[2^G6K\])I%[?[(_K7-B*\</!SD=%"A+$34(D'B?Q<UVSVEDY6 95Y
M1U?V'M7,KVJ%*F7M7Q]6M.O/GFS[&E1A0AR01!JFF6NM:9>:?>PBXL[N%X)H
MB2 Z,,,N001D'L:\,_9?^&GAKPUXB^)FHZ;I@MKVQ\6:AI-M*;B60Q6BQV["
M$!G(V@DGIGGK7OHYS7DWC?P%K/@WX?>-6\%75VVK:]KPUFZ:--TT4<LD*W2P
M!>21%&=N/FY..<5K2EHX7W,:L?>4[;'J]]JUEI3VJWEW#:M=S+;6XF<*993D
MA%SU8X/ ]*DTG5['7K&.]TZ[AOK.0L$GMW#HQ4D'!'!P01^%?.?A?P-X@\1:
MIX4N-6FUJ]TO3]=OYK.299H'MX&TQE!)E_>,AF)",X!&X@9&#7KWP*\-2>#_
M (-^"]'G@GMKFUTJW2>"Y.9(Y=@+JWN&)&.U:2@HK?4SA-S>VAWJ]:)AF$]\
M<T+UIX&121;/G_XS6,[7&@W"Q.\ M9(#(JY D$[L5/OAE/XUZE\/+26ST;18
M)XS%-#ID*21L,%&+.V#Z'# _C6W/H9,K26]Q+;%SEA&>"?7!XS[U=T[3DL$;
M!+NQW,[')8^I->=A\OA0QE7&*5W-)6MMMUZ['?B,PE7P=+!N-E!WO???ITW+
MXZ4X=*:.E.'2O8/('T4452)%7K3J:O6G59+'(2K @D$<@CM71Z3K'VG$,QQ+
MV;^]_P#7KFUIP)4@@X(Y!%;4JLJ4KHPJTHU59G<45G:1J8O8MCG$RCGW]ZT:
M]R$E-<R/#G%P?*PHHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** *&G_\?VI?]=5_] 6K]4-/_P"/
M[4O^NJ_^@+5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#R+XR?LQ^$OCEK%CJ/B-KSSK.$P0BVE" *3DYX.>:O_
M  T^ 6A_"7P_)HWAZYN8K&2X:Y9;@B1M[  \\<845I>/OC7X8^&NI06.NW4E
MM//'YL>V,L&7.#TI_A?XQ:!XSTY[[1VFN[59#"7";<, "1S]11_9UG]:]EO]
MJV_S/H7F.;RP$<(ZL_JZVC=\N[>BVWN;'_")G_G];_OV/\:4>%G'_+ZW_?L?
MXTG_  F=M_S[S_D/\:4>,;<_\NT_Y#_&G[%_RGC\];NQ?^$7<?\ +ZW_ '['
M^-.'AJ0?\OI_[]C_ !I!XN@/_+K/^0_QI?\ A+(?^?6?\A_C1[)_RBYJO=BC
MPY*/^7X_]^Q_C2_\(]+_ ,_I_P"_0_QI!XIB/_+K/^0_QIP\3QG_ )=)_P A
M_C1[-]B>:KYB_P!@3?\ /\?^_0_QI1H<X_Y?C_WZ'^-)_P )(I_Y=)_R'^-.
M_P"$B'_/G/\ D/\ &CD?85ZGF T6X'_+]_Y"'^-1W7AV:\@:%[]@C==L8!/Z
MU*-?S_RYS_D/\:7^W2>EE/\ I_C1ROL3>1CCX>P#_E\D_P"^!2_\*^A_Y_)/
M^^!6Q_;3G_EQG_\ '?\ &E_MB0_\N,__ ([_ (T69-F8W_"OX?\ G\D_[X%+
M_P (#%_S^2?]\"MG^UI3_P N$_\ X[_C2C5)C_RX3_\ CO\ C2$8P\!Q _\
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M0/\ E]?_ +]C_&E'@['_ "^M_P!^Q_C6I_:4W_0/N/\ QW_&C^TIO^@?<?\
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M_P _X_[\C_&C['>_\_X_[\C_ !I/[2F_Z!]Q_P"._P"-']I3?] ^X_\ '?\
M&@!?L=[_ ,_X_P"_(_QH^QWO_/\ C_OR/\:3^TIO^@?<?^._XT?VE-_T#[C_
M ,=_QH 1["]D1E_M#;D8RL0R/UK!/PZ@))-Y*2>22HYK?_M*;_H'W'_CO^-'
M]I3?] ^X_P#'?\:RG2IU?CC<UIUJE*_)*Q@CX=P#_E[D_P"^12CX?0#_ )?)
M/^^!6[_:4W_0/N/_ !W_ !H_M*;_ *!]Q_X[_C67U6A_(ON-?K5?^=_>8@\
M0C_E\D_[X%+_ ,(%$/\ E\D_[X%;7]I3?] ^X_\ '?\ &C^TIO\ H'W'_CO^
M-/ZM1_D0OK-;^=_>8W_""QYS]MD_[X%._P"$'3_G]?\ [X%:_P#:4W_0/N/_
M !W_ !H_M*;_ *!]Q_X[_C3^KT?Y4+ZQ6_F9DCP2@_Y?'_[X%'_"%+_S^O\
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M?VE-_P! ^X_\=_QH 7['>_\ /^/^_(_QH^QWO_/^/^_(_P :3^TIO^@?<?\
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M[X2\=Z#K&M:TESIWAVQN;'3+."YDD15FV#A'4>6JJF "SGG&[ Y /H"BBB@
MKC/BI\5=%^$OAQM4U:0L[GR[:TBYDG?^ZH_F>@KLCQ7P#^U'XKG\8?&G4K0R
M%K+1@MC!'G@-@-(V/4L<?\!%5%79]-P]E4<VQGLJC]R*N_3M\V_N-#Q/^UGX
MV\8WDT6E7$&@6H/^IM5#S =MSGO]!7"ZOXG\7:O;RR3:_J=U.5)57NG"D]N
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M_P -970Q\7*:3E?KT2\CZH\ ?$@^([G[!?QK%>$%HW3[L@'48[&N]-?+_P
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MRXV;&< G%?+'B[Q+(OV[5[LM+(S;L9ZDG 7V%?5.0PXY%>(?$+X/75R]VME
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M*5KOPY?7/A^]!W(H8O&#[?Q#\Z]?^'7AJ^\'^#-,TC4M3?6+VUC*R7DF<O\
M,2.O. "!SZ5AF&,A7PZC3JN:OM)>\O\ MXQQ^+A6H*-.JY*^TE[R_P"WCI**
M**^9/FPHHHH *JZGIEMK.GW%C>1">UN$,<L9) 93U''-6J* .+M]3U7P4#;Z
MNL^JZ6OW-4C7=(BX7_7*!VQ(Q8#  '>G>&/B_P"$/&/BS5_#.D:[:7FO:3'#
M+>6"/^]B25 Z$J><%2/IWKL2,BO']8^#/@3P7XWU'QUI?AZVMO&VLR/]IU@,
MWG.I0*PZX *A1C':@#N-9\:Q6L_V>T E8-AY3]U?\:_-/Q'^WI\=? _Q)U[^
MW)- BM-,N9VN/"TT1@G6U0L0T<I/SDJJD'')D7WK[MDD6*-G=@B*,EB< "O%
M_B]JVC>+=+GM[7PW9ZWJC 6]M>75JDCQ[C@E"PS_ /KH P)?B/=_&N[N?$LC
MR)I&HV]O::=!<KM,:X$S2L.Q168G_?Q7IG[//PWT3XA:1K6L7FGS1V$CR6-F
MS3_.R$$/)P/E." /QKSW2O!(U'P]+H^GZC#8S>6-/M))!\LOS W4@QZGY1Z@
M8KY1TG3_ (^?L[>-6ATVX\8WFO6LQ:U\F/[9I&L@N<1A1Q&K;AGH0!ZU\OA,
M)A\PQ$LRJP3UM"_:/VOF[M>5CZC%8S$9?AXY;2FUI>?K*WN_)63\[GZO?#GX
M0>&OA;'<C0K1HYKC EN)GWR,!T7/8>U=K5/1[BZN])LIKZW%I>20(\\ ;<(W
M*@LN>^#D9]JN5]0?+A1110 4444 %%%% !1110 4444 >4?M47NKZ=^S]XUG
MT-I4OULOOP9WK&742D8]$+5^2N 1C V^G:OV]G@CNH9(9HUEBD4HZ.,JP(P0
M1W!KPN;]B;X43^(3JIT*5<R>:;);AA;DYSC;UQ[9K2,DC]+X5XFPF2X>I0Q,
M&[NZ:MKI:SU7;3U9<_8UO]8U']GCPM+K+223!98X))B2[6ZRL(B2>ORC ]@*
M]K/2H;*RM]-M(;6UA2WMH4$<<4:A510,  #H!6=XQE>#PCK<L;%)$L9V5E."
M"(VP12BN>27<^#Q==8W%U*T8\JG)NW:[/F[]H?P1=^ O%-G\5/![*IBF!U!(
M3E0_3><?PM]UO?!K%U3P[K5]JVE?%SX66C.+U7>_TV,9,,XXE0I_$K'.0.XS
MWIGP=NY[K]E/XD">9Y@GG;?,8MC,,9.,^_->L_L?#_BS%M_U_77_ *'7W-:K
M4P6'DY6DZ<N37:46KV:\NA]56JSP5"3E:3IRY-?M1:O9^G0\QE^/?A+Q<W]F
M_$WP1]BO/NM=QPG<I]>SC]:(/@'X8\4-_:OPP\<_9+H?,MN\Q#*?3(PP_$5]
M.^)_ GA_QE;F'6=)M=04C&Z6,;A]&'(KP_Q5^QSIIN#?>$=9NM#O%.Y(W8L@
M/LPPP_6N3#YCAMJ<Y47V^*'W/5')A\PPVU.<J3[?%#[F>E?!/1O&VA>&KFU\
M;WT5_>+<$6SHP9A%@?>8=><XKT2N8^&N@:OX8\%:9INNZG_:^J0(1+=G^++$
M@9/7 (&?:NGKY?$S]I6G+3?HK+Y(^:Q,_:5I2TWZ*R^2"BBBN8Y@HHHH ***
M* /+?BQ^T;X4^#.L:=IOB&#63-J!C2VDL=,EN(Y))&94C#("-Y*GY>M>A>']
M:A\2:'8:K;1SPP7L"3QQW41BE56&0&0\J>>0>E>/?M4?ZGX4=?\ DH6B_P#H
M<E>E7_Q+\+Z5XH@\.7>N6<&M3%52S>3YRS?<7V+=@>30!T]%>,^!OVFM$\?^
M*-!T73;*;S-8FU002O(H @LI%B:4CK\[M@+UP"37LU !1110 4444 0W=I#?
MVTEO<1K+#(-K(PX(KA+CX,Z5+<EX[FXAB)SY8P<>P->@TAKDKX2AB;>V@G8Z
MZ&+KX:_L9M7.?MTT/P!IJP^;'9Q$Y)D;YW/J?6K&F>)M'\1AHK:[ANCWB."2
M/H:^9/C#XBU'51=WBR.-\Y0[3_JXQG 'IT%<C\,M6U&UUIG@GE"1IOW[B=C
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MBCX%ZI\'-5OM7@\=:SI^JZU:Q:G-&(4ACDM-BRW>S.!"&W2,HZ+T%?2WCKX
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MT4\!^$X? O@[2-!MW,D=A;K%O/\ &W5F_$DG\:_0#\J-^BBB@ HHHH ****
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M5&,>2FG>V[;\_P#(Z?3=(LM'@\FQM(+.+^Y!&$'Z5;HHK[(^-"BBB@ HHHH
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MB@# N_ 7AV_\.7>@7&C64VC7<DDL]B\(,3O)(9'8C^\78MGKDYK*T?X,^"-
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ME7M4J5$O:I4K-F1,G:I4[5$G:I4[5FR&2I4J=:B2I4ZUFR&2KTJ2HMP12S$
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MT9Y&5E.006."#0!/\6?^2A:W_P!=$_\ 125P?QF_Y+#XT_Z_S_Z+2N\^+/\
MR4+6_P#KHG_HI*X/XS?\EA\:?]?Y_P#1:5^;<*_[_F'^/_VZ9^D\4_[AE_\
M@_\ ;8'WK\&?^23^$/\ L%V__HL5V=?-&L_M;?#3]FOX,^#I/&>OQV]_)I%N
M\.EVP\VZE'EC!"#D#W-?-'B'_@MEX1MKYX](\ :M>6RGB:XN(XRWX5^DGYL?
MI=17P!\-/^"Q_P *O%=]!:>)='U;PD9&V_:956>%3ZDKR![U]R^#_&>A^/\
MP_::YX=U2UUC2;I=\-W:2!T<?4=_:@#:HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH RM5\+Z5K4F^\LHII/[Y&#^8JSIND6>CP^59
MVT=O&>H08S]:N45DJ5-2YU%7[VU-75J./(Y.W:^@5YU\9-;GL-,M+&!S&+IF
M,C+P2JXX_$G]*]%KD_B+X1?Q5I*"W(%Y;,7B!Z,".5_'C\JXLRA5J82I&C\5
MO^'_  .W+ITJ>+IRK?"G_P -^)\P:IXXL]+OVM3&\Q0XD9.BGT]Z]J^#'BP>
M5=P2SYTX6_VM'8\( 0#] <C\J\3U_P"#NO3Z],8+25?.?<5=#E2>OUKUBU^'
MUWX)^&UR\P(N'$4+)W2(/DY^IQ7Y;D[S"CBJE:<&HP3>UOE\S]0S=9?6PM.C
M":<IM+>_;7Y'2:C\:DCNF6RL/-@4X#RMM+>^*ZOP?XYL_%T;JBF"[C&7A<\X
M]1ZBOD?QEXIO=/U/[):OY*HJLS8R6)Y_*O2/@1K%UK&O:9/C$H>2.4J.&4*<
MG^7XUZN7\1UJV/6'F[W=K6\[:>AY>8<.4:. >(@K65[W\KZ^ITWQCU:63Q(]
MO(Y6VM(58+VR1N9O\^E>+6_Q%BFU!8WMBELS;1)NY'N17TS\3/AZ_BA1>684
MW0C\J2)C@2+]?7DUX5IG[.>N2ZPBO"Z6JOG]X,<>A-<6>X+,WC;X>#DI/>U]
M.GW;';D6-RU8*V(DDXK;;7K]^Y[E\+W'B+P;=Z;J"?:;9':#:_(9"H./PS_*
MN4\7>$/*8Z9J67N A72]3<X\T#E8I#_>'3GJ.1WKU3PEX;B\+:-'9(WF/DO)
M)C[SGJ?IV_"KFL:?8ZK9R6E^D<L$HP4D_F/0^XK]0P,)4<+"E7UTU_KR/S3%
M5E+%RKX?373^O,\$A^%=T]NKRWZ1RF,$QA,@2=QGT]ZYEO!T-SI[I/*QN7&4
ME7@1L.F!7L]]HVI^%22JRZOI(Z2+S<0C_:'\8'J.:\_G8W!DN55?*DD8@I]U
M3GI[?C716P]-14J:/1P>98BK-PJS].AYC)%):7$EO<)Y<\>-RYSUYR/8TS'0
M9)([^M=OJ?ABPU.5Y739/(03*A^8X&*RY?!.+B(+>,;<D&19!\^ >0"/7I7C
MRH/H?:TLR@XVJ+4]H_9].?!$_P#U^R?R6O3JX+X-6D%CX9N8;>,11BZ<[0<\
MX7FN]KV*:Y8)'YOCIJKBJDUU;"DI:0UH<)\F?$+]NF]T+QWXXTGPA\--:\;Z
M%X&)C\0ZQ8NJI;S!2SH@/WB@!W?0UE3_ /!0:[U&V^%UOX;^&VJ>(M<\?Z'/
MJ]CIUK<(&A,<CH5<GL C,3Z4>-OV//B;I_CCXE3?#+XA:?X<\)_$666ZUJRU
M"R::>WN)(RDKP,.!OR>O3/M6S\%_V,]7^%_C/X+ZU=>(+*]C\!^&+W0;B**)
M@;EYI'8.F>@&['/I0!XM\:_VWO%OCGP'\$?$_@7P]K&F37OCU=(UG3$G17DN
M(&"MIS$]1+NR#VVG->T_LE_%ZT,?QEO?%/BJ]CM['Q]>Z7'_ ,)%<QJELRHK
M>1$<_=&3@?[-86F?L(ZY8^&?"NEGQ-8,^C_%)_'[N(7Q) 6W?9QZ/[]*[CX<
M_L7Z!86'Q)TWQ_:Z;XRTKQ1XVN_%UI:R1L%M3*@15/3+J"PR./FH X#XK_M
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M2N!RAD!!7ZUW'[*O[3VI_M-6VL:M'X)N_#OANRD>TAU&ZG5_M5PDI21$4=E
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MWPE\:ZE/J.HZ?=61DO;;SR#/%"_3:V,<]J]2\'_LF-X'^+^N^)=,U2!=!N?
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M 4444 ?&7[;?_(\:#_UXO_Z'6[^RY_R3RZ_["4O_ * E87[;?_(\:#_UXO\
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MA^)S>1R*^+F"9RKJ H(//(  !KI?!'[,7QP^,5W]BL/#.N7$%S(LDL^H[HH
MR@JKNS\9 )&?2F(^CO\ @CI\6/$6B?M W7@6*XEG\-:WIMQ<3VC$E()H0&68
M#L2,H?7</05^T]?#'[#7[%=I^RGI]WK6HWL>J^.=3A$-Q=0C]U:0Y#&&//7)
M +-WP!TK['L?$V2$N5Q_MK_A0!T%%,BE29 Z,&4]Q3Z "BBB@ HHHH ****
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MI(CT92M=N'KNA>RW.+$4%7M=VL?,WQ6&WXA:T/22,?\ D)*^E=-_X_\ 4O\
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M_P"QH?\ GK/_ -_#1_8T/_/6?_OX: -"BL_^QH?^>L__ '\-']C0_P#/6?\
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M :%%9_\ 8T/_ #UG_P"_AH_L:'_GK/\ ]_#0!H45G_V-#_SUG_[^&C^QH?\
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MJ_5>SL8[(.(RQ+MN8N<DG&/Z58H **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ibio-20230630x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &L \L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BH+R]M]/MWN+J>.V@09:69PBJ/<G@
M5YEX@_:F^$GA>X:#4?B#H,<RG!CANQ,P_"/=6L*52J[4XM^BN5&,I?"KGJE%
M>(1_MK_!.23;_P )]8I_M203JOYF/%=KX3^.?P]\=,J:#XTT/5)6X$,%]&9#
M_P  )!_2M)X6O35YTVEZ,MTJD=7%_<=U12 @TM<QD%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8OB3QIH'@^V-Q
MKNMZ?HT.,[[^Z2$'_OHC->97_P"V3\%M-E:.7XA:3(Z]1;&2<?FBD5O"A5JZ
MTX-^B;+C3G+X4V>ST5XO8?ME?!;495CC^(6E1.QP!=>9 /S=0*]-\-^-O#_C
M&W$^A:YIVLPXSOL+I)@/KM)Q1.A6I*]2#7JF@E3G'XDT;=%%%8$!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$X
MKB_%OQJ\!>!"R^(/&&BZ3(O!BN;Z-9!_P'.?TJXPE-V@KL:3EHD=K17B$W[:
M_P $X7V_\)_8.>F8H)W7\PF*V-!_:K^$7B6X6"P^(6A-*QP$GNA Q/TDVUT/
M"8B*NZ<ON9HZ51;Q?W'J]%5K#4K35+5+FRN8;NW<96:"0.C?0@D59KDV,@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HI"<5Q_BWXQ>!_ >X>(?%NC:.Z]8[N]C1_^^<Y_2KC"4W:*NQI.6B1V-%>
M(S_MK?!.!]I\?V$AZ9AAGD'YJA%:FB?M8_!_Q%.L-E\0]#,K<!+BX\@G_OX%
MKH>$Q*5W3E]S-/8U%]E_<>M454TW5K+6+5;FPNX+VV;[LUM*LB'Z,I(JW7*U
M;1F04444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHK,\2^)-,\(:#?:UK%Y%I^F6,33W%S,V%C0#DG_#N>*:3;LAI7T18U75
MK+0M.N=0U&ZAL;&V0R37%PX2.-1U+,> *^=K[]H/QG\9+N:P^#&BPIHJ,8YO
M''B&-H[($'G[-%]Z8^_3V[UB:7H>L?M<ZE;^)_&$5QI7PJAE\W1?"K$QR:K@
M_+=7>.=AZK'Z?F?H:SLX-/M(+6U@CMK6!!'%!"@1(U'154< #T%>BU3PFDES
M3_!?YO\ !>9O:-+1J\OP7^?Y'B-M^RAI/B.=+_XE^)M<^)>IYW&/4;IK>P0^
MB6T9  ^IKTGP_P#"?P3X4A6+1_"&AZ:BC \C3X@?S*D_K75T5S5,36J:2D[=
MME]RT(E5G+=G(^)/$/@[PYJFE:/K":=!=ZH_EVD$EDK!SD#GY2%&2!D]S7 Z
MIX ^"WQ1\9:OX5O/!VE7&N::F^>2*P^RL.F=DL>TDKN&?KWKG?VK@;#Q1\/]
M3'!BN74M])(F_P :?X;/]E_MB>((0<+>6TC#WS"C_P#LM>_0P26%6(A.2DX2
MEH^L9)?D>_2P,'A574G=PE+?K&27Y&E_PHSQO\+"+KX3^/KU+6,Y_P"$7\6R
MM>V$@_NI*?WD7^>:ZSX;_M-6VK>(X?!OC[1IO 'CEN(K*]?=:7_^U:S_ '7S
M_=//UKTVN7^(WPS\.?%;PW+HGB73DO[-COB?[LMO)VDB<<HP]1^.:\=8F-;3
M$J_]Y?%_P?GKYGA^T4]*B^?7_@GI=%?-7PV^(_B'X(>,=.^&WQ(U%M6T?4#Y
M?AGQA.-OVC'2TN3T$H& &/WN.N17TK7/6HNBUK=/9]&OZ^XSG!P?D%%%%<YF
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y9\=OC?#\)M+LK
M+3K)M>\9:S)]ET;1(3\]Q*>-[?W8UR"S?A6E.G*K-0@M65&+F^5&U\5OC1X5
M^#6C1W_B._,<L[>7:6%LAENKN3^Y%$.6/OT'<UXZ9OC5\<_WT]Y_PISPC+S'
M;VZB?6[A.Q9C\L&1V'(]ZVOA1\#)-"UI_&_CJ]3Q5\1[P9DU"09@T]3T@M4/
M"*O3<.3_ #]>KM=2EA_=I)2E_,]5\D_S?W(V<HT](:OO_DCQWP[^R5\,]&N1
M>ZCH;^+=6)R^I>)KE[^9V]<.=H_ 5SFI^/;7PEK\QL?"NFZ/IF@71M]9TB/3
MX/-:U<@17D3! =H[@=,C-?0M>6_&CP1<W<<'BW0[=)]<TN-DFM6&5U"S(_>P
M,._!)'XUTX/$*K6Y<4^:^BN]%_E?:_1V?0[L%5A.KRXC6^BN_P"K7VOT=GT.
MVD\.>&O$UA%-+H^DZG9W$8D1Y+**174C((RO<5YUXC_9+^&6N7'VVQT%O"NJ
M@[DU+PU</83(WK\AVG\161\$/&UMH%]9^&OM#3>&]75KKP[<RG+1G/[VS<_W
MT.<?_7KTS1OBMX2U[6+K2K77+9=3MI6ADM+DF"3<#@[0^-P]Q4U:.*P=24:3
ME9:W5]O/\G?JFB*V&KX:I*,+M+6^NWGV[/SNCS-7^-/P,S+:W@^,?A&+E[6[
M @UN!.^QQ\LV!V/)KV#X3_&KPM\9=(DO/#UZQN+<[+S3;I#%=V;]TEC/*GWZ
M'UK8((Z@BO(OBQ\#&\0ZQ%XT\$WR^%/B-9#,.J0C$5ZH_P"6-T@X=6Z;B"1[
MUSJI2Q'NU4HR_F6WS2_-?<SDYHU-)Z/O_FCZ HKRKX$_&Z/XJZ=?:=JUD=!\
M;:(_V?6=$E/S1/VDC_O1-U!]\>A/JM<E2G*E)PFM48RBX.S"BBBLB0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ;XH?M+:?X5U\^$?"
M.E7'COQVXXTC33^[MO\ :N9ONQ*/3K]*YWXJ_%+Q#\2O&EU\,/AE>BQN+91_
MPD/BE1N33(S_ ,LHO[T[#\OU';?#3X5^&_@_X<;3="M/(5OWMY?3G?<7;]6D
MFD/+$\GT':O0C3IT(J==7;VC^K\NRW?D="C&"O/5]O\ ,\VE^#OQ ^**->_%
M7Q_<:9IK#<WAGPC*;.UC7^[+<GYW]^WO65;)^S'\(9#'&/"2WL9^:1U_M*Y)
M]V(<YKY;_:0_:%UKXN>*[^QMKV:U\)VDS0VMC"Y5)PIQYLF/O$XR > ,5XJH
M"C &!Z#BG+$5IKEYK+LM%^'ZG[!EO TJU&-3'UG%O7EC96]6[Z]]/F?IOX<_
M:.^"FLW"65CKVBVCL=J)=:?]E0^P9XPOZUWNL?#3P3XPLQ_:7A?0=6MIEW*\
MEA"X93T(8#D>X-?D9U&.U?07[*W[1VH?##Q+9^']7NY+CPA?2B)HI6+?8G8X
M$D>>BY^\O0CGK7-[T7S1;N99OP(L/0E7RZI*3CKRRM=^C26OE;7N?5-[^R9X
M>T6Y?4/AYKFM_#35NJMHMVSVC'T>W<E2/88IMK\=?'WP3FBM?B[HT6K^'<A%
M\:^'(F:)/0W5OUC]V''M7N@((R"".Q'0TR>".Z@DAFC2:&12CQR*&5U/4$'@
MCVK=8N4_=KKG7GO\GO\ ?=>1^1JJWI4U_/[S6T#Q!IOBG2+75=(OH-2TZZ02
M0W5LX>.13W!%:%?*FO>#M:_9AUBZ\9_#VWEOO \K^=KO@U"6$2_Q7-I_=(')
M0<8%?1_@OQGI'Q!\,:?K^A7B7VEWT8EAF0]NX([$'@CL16=:BH)5*;O!]>WD
M_/\ /H3.%ES1U1N4445R&04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5X[\5OVD=)\":ROA?0-.NO&OCJ9<PZ#I0W&//1IY/NQ+]>?:N>
M^+_Q:U_Q=XPD^%WPSG2+7?+#ZUX@8;X='@/IZS$=!VKJ?A5\(/#WPAT5[/1H
M&EO;D^9?ZK='?=7TG=Y'/)R?X>@KOC2IT(J==7;VC^K[+RW?D="C&"YI_=_F
M>>GX3_$WXM_Z3\2_'$_A_3).?^$6\&R&! O]V:Z^\Y]<<5I3_L[>!OASX9OK
M[PE\/]$U+7((_-C;5XC=RS$<G+R$G)&<=.:]GHH^NU;JSM'LM%\[;_/4%7DI
M)].W0^>_A=XVL++Q'##=P6TGAWQ$Y;3Y9K:,&QNAQ):/\O ST_#WKV#7/AIX
M1\2PM#JWA71=1C;@K<Z?$WZ[<UXY\8? EMX6U6YO65HO">O2*+UHQSIUY_RS
MNE]!GK^/K78> OBK<IX6U.SUNSNK_P 2>'U"W5MI\?F2W<7\$\8S\P88)KUL
M71]M".*PO7?\OO6S^3ZGLXN@J\(XG#==U^'X;/Y/J8VH?LD^%=-N7U#P'J>L
M_#75^JS>'[QQ;D_[=NY*L/;BHH?C1\2/@:R1?%+2(O%7A93L_P"$Q\.0G?".
MS75MU7W9>/K7?^$_C-X0\92BWLM7CMK_ *-87X^SSJ?3:^,_@37:21K-&R.H
M='!5E89# ]01W%>=.M6IOV>,A?\ Q;_)[_FO(\JI[6D^3$1?SW^_^D7_  OX
MJTCQKH=KK&AZA;ZIIETN^&YMG#(P_H?8\BM:OEGQ1\/M:_9[UN[\=?#&!IM
MD;SM>\&1D^5.G\4]L/X) ,G:.#^E?0?P^\?Z+\3O"5AXBT&[6[TZ\3<I'WD;
M^)&'9@>"*YJU%1BJM)W@_O3[/^M3"<$ES1U1T=%%%<AD%%%% !1110 4444
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M[D@Z_2O0P[]M%X=]=8^O_!6GK8Z*?OITW\O7_@GTW12"EKSSG"BBB@ HHHH
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MM_A[?)[>K*_B4[/>/Y'T=1117GG.%%%% !1110 4444 %%%% !1110 4444
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MT;_T2KPK_P"%+_\ 84?4Y_S1_P# H_YA[%]U]Z/H6BOGK_A/OVC?^B5>%?\
MPI?_ +"C_A/OVC?^B5>%?_"E_P#L*/J<_P":/_@4?\P]B^Z^]'T+17SU_P )
M]^T;_P!$J\*_^%+_ /84?\)]^T;_ -$J\*_^%+_]A1]3G_-'_P "C_F'L7W7
MWH^A:*^>O^$^_:-_Z)5X5_\ "E_^PH_X3[]HW_HE7A7_ ,*7_P"PH^IS_FC_
M .!1_P P]B^Z^]'T+17SU_PGW[1O_1*O"O\ X4O_ -A3)O'?[14L+I)\*O"I
MC92&SXE(X[_P4?4Y_P T?_ H_P"8>Q?=?>CZ&2195W(P8=,@YIU?%'[&_BGQ
MY9_%7Q3X3ATFVD\#6T[RW*V^IF]M](N&^8Q0W!'[S+9S'VY.>#G[7J,5AGA:
MGLV[]?O%5I^RERW,/QSK:^&_!NMZJV MG9RSDG_90G^E>-?LG:*VD? ;PU<2
MC_2]5$NJW#'JSS2%LG\,5W/[2$KP_ ?QX\?WQH]SC_OV:I?!>-(?A#X*2/[B
MZ-:X_P"_8JEIA'YR7X)_YCVI>K.RHHKSCXI_&2V^&FM>&].>S:];4[E1=2#?
MML[;<%:9BJD#YF4 -@'GGBN$P+?Q"^%WAOXQVT^F^)+ 7EI:_)!+&^R6&5AE
MG1P<@@8X(QSWKY:\7_\ !//6(;MW\+>*K*[M"?EAU>)HI5'H70,K?7 KW70?
MVCIM>O?[,MO#MO=ZM/.8[**VU>,0.@:8?O960>5)B%F\O#$Y&.]=SX4^(EQX
MLU.2W@\,ZC!902&VN-2:>W>&&Y"!VB(5]S ;@-X&TD\>M4I-;'T66\09CE*Y
M,+4M'L]5]SV^5CYC^'__  3W>.\CN/&OB2*6W4Y-AHRL"_LTK@8'^ZN?>OK7
MPQX+T/P9X>BT+1=+MM/TF-2HM8TRK9ZEL\L3W)R36U4=S<Q6<$D\\B0PQJ6>
M1SA5 [DT.39EF6=X_-FOK=2Z6R6B7R7YO4\*\?\ P^D^']Y!K.@74EM8VY:2
M*.!@;G3N[F%2?WMOW>$]!RN*L3V?C_4774UM]=4W*+()/#_B*W-LX*C#1P3Q
M_(",';D]:Z+QY<6/C6#1-0T.1=8?3]06.>*T!=Q!*#')\N,XPV<].*Z7X7VU
M_8>!M-L-2@E@N[$/9D2C!9(W*HP]BH4@U[[Q;6&C5DE*6VN_7LU?_@][MV\6
MUAXU9)2EMKOU[/7_ (/>[>KX5-XWAZP_M!;Q;WR\2C4#&9]V3]_R_DS_ +M:
MM%%>!*7-)RM:YX,GS2<NYXS^S&?^$;^(_P 7_" .VWM-934[:/LJ7";FQ_P(
M5]$U\[?##]W^UU\3$3[CZ+I[MC^]DC^5?1-=F,UJ*7=1?X(UK?%?NE^045Y%
M\1_%GQCTGQ/);^#? FA:]H@B4K>7^M?9I2YSN&S:>!QS7+_\)]^T;_T2KPK_
M .%+_P#85,<+*45)2CK_ 'E_F)4FU>Z^]'T+17SU_P )]^T;_P!$J\*_^%+_
M /84?\)]^T;_ -$J\*_^%+_]A5_4Y_S1_P# H_YC]B^Z^]'T+17SU_PGW[1O
M_1*O"O\ X4O_ -A1_P )]^T;_P!$J\*_^%+_ /84?4Y_S1_\"C_F'L7W7WH^
MA:*^>O\ A/OVC?\ HE7A7_PI?_L*/^$^_:-_Z)5X5_\ "E_^PH^IS_FC_P"!
M1_S#V+[K[T?0M%?/7_"??M&_]$J\*_\ A2__ &%'_"??M&_]$J\*_P#A2_\
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M--)GJO[._AQ_"7P,\":5("LMOH]MO4]0S(&8?FQKT2HX(4MX4BC4)&BA54=
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MBO..<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A/C;\,+7XO\
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MKDBUL8XQV:9BQ_(8J+^S%]*/[,7TKXVMC<75?NOE7E_F?0T<%A*2]Y<S\_\
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M+=6P.5+N?GE3(.2<=J^ZZ0@&LL10H8VBL/BX<\$T[7:U79K\M4^J9Z."Q]?
M3]I1=G9KY/>W8_/C]G#2[7XS?%.76M2O[74!%*VIW:+*N9IBV4C"9S@''&.
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MBC@5Z/116DYRJ2YIN[/+E)S?-)ZA1114$A1110 4444 %%%% !1110 4444
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MG]62_0\O_8YTKXB>%?$/BC1==T;5M,\$A1+I<&L:I%J$UE,& >#S4;."#G!
MQ@=R<X_[9MG-KGQG^#VA_P#"27OABSU.>YM[B]LKIH&128QU! R<[03TW5]
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MT4Y\VC3?+W:V*]O3T4G?1]#T/XYZ%_PE7P@\2V4>IWFFB2Q>07=A($E 5=V
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MR*7'DJ!P75<9#$  G/3M2>%?@?H?A#Q?XR\1VEU?R7OBG;]LCFD0QQX7;^[
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M7L<$S*P#P+D87:W_ '\YX)KVZF68:+A%2>KW_FTOIHDM=%J]SMEAJ:<5??\
M'0^G/A=^UM\-OB[XC70=$U>:'6)%+P6>HVKVSW"@9)CW##<#. <XYQ5'QO\
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M/JT;;]^FFA]/? +XW7WQ;_X39M3L+33(_#^L2Z=&T$C$21IGYWW=#QVXKO\
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MZKXC\':3J^I( !=7%N#(0.@8C&[\<UW]%;>WJ\W/SN_>[*]I.][NYX9^T+\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%59]3M+5)WFNH8EMP&E9Y%41@]"V3Q^- %JBH$OK>2X6!9XVF:/S1&'!8I
MG&['7'OTJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%9Q\1Z4+J2V_M.S^T1P"Y>+[0F]8CTD(SD+_ +72F0^*-&N/[/\ *U6QE_M
M$V>RY0_:0!DF/GY\?[.: -2BJ>G:Q8ZN)S8WMO>""0PRFWE63RW'56P3AAZ'
MFKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !12$@#)X%9O_  DND9M!_:EEF[D,-O\ Z0G[YQD%4Y^8C!X&3Q0!
MIT53L-8L=5:X6RO;>[:WD,4P@E5S$XZJV"<'V/-7* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJGK.IQZ
M+I%[J$W^IM())W^8+\JJ6/)X' [U\T^ _P!N>T\5>-?".@:O\.?$OA6/Q1;V
MMUINH7US8S1/%<EQ;2%8IF<*[(RYV_*2-P .: /J*OE_]H;X::YXV_:#^&^I
M6'PWFU;2-*FM;R_\76=W:K>0&&X,D-K$)I5,46_YYGC4O(F(QD9Q](/X@TR/
M54TQ]1M%U)UWK9M.HF(]0F=V/PK0H ^3;;X5>,]7_:YT/XE+X-N]*BNH(!J=
MWK-UIUW;VEHME,AM[<(IN(KD3NN2CM&R,Y)Y"UV5M=?$7X?_ !T\"Z'K7Q _
MX2S0_$B:GYEG+HEM:& P0K)&5DC^8XW8.>M?0%>+_%#_ ).0^"G^YKG_ *21
MT >T4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 444V218D9W8(BC)9C@ >YH 4C-?&/Q.^ 'B?2#\:9]"^'B?$!O$V
MJ:3>Z7;ZWJ23Q/,B2>;<2I-*H=(6(VP,0APJ@!1D?9D,T=Q&LD3K)&PRKH<@
MCV-.H ^&O@K^S-XV\%_&SP7JI\.WUAI&EQ6S_P!OZKJ%M+>0V4>E/:MILBQR
M,2QN6$VU,Q $$-E0*]DMKWXB> /COX'T'6OB!_PE>A^(DU(R6<NBVUH8/)A\
MR/;)'\QP3@YZU]!5XG\3O^3EO@Q_N:U_Z2+0![91110 4444 %%%% !1110
M4444 %%%% !117(^+_BUX-\!:OIVE^(?$FGZ/J&HG%K;W4P5I.<9]AGC)P,U
M482F[15V7"$JCY8*[\CKJ*0$$9!R*,U) M%)2T %%%% !1110 4444 ?)/\
MP4*\+0^)?"GA$-XXTCP=<1W]PD3:REP\;J]I*LLD8A!(ECC+NI;Y<CD\BM7_
M ()YZ;X<L?@EJ4OA75[74M#NM<N)+:VL[6:U2R01Q(D;13 .KLB+*W8M*2,C
MFN/_ &\O'GP>UY;7P?XEO/%NK^+])5[_ /L/P% TM^;5XV69)V*F..%XV(8L
M00.:]+_8=TJZB^#MQKUQX>NO#D?B;4I-:LX+_4TO[B6TECC%NSNBJJ 1JB+&
M!\JHN2230!]#5\^_MF?!WQ'\8O!/ART\.VYU%M,UJ*_N]-6X@A:[A5'7:IG1
MXB0S*V'4@[?7%<K\4/CMXT\)?&2X\*WGCOP?X*#117.E6FH>';R_COXY'9%1
M[E9H]DF5Y54P PP6YKZ<\/MJC:+9'6TM(]6\H?:EL'=X/,[["X#;?3(S0!^?
M.K?L7_%?5YK]9M*T*+49=,9IM9L[J.%+L'38;;^S!&%W)$)(W;G]V V0,\5<
ML/V.?B0?$.B7J^&]*TJ&?4#=VPCOX2?"<8U(7)CA"KAM\8VXAP,G!XYK]"J*
M /DC]F/]G+QY\/-"\86MU/%\.[R^MK"R@O-&:VO7N)K=YS+?%70IF82H/G4O
M\O/05Z=\ M<\5OXO^)/AKQ/XHG\6C0-0MH;2^NK.WMI=DENLC*P@1%/)ZXS7
MM->*?!?_ )+7\;O^PK8?^D2T >UT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!F>)=$@\2>']1TJY$C6]Y \$@BF:)B
MK @@.I#+]00:^%=9_8V\?'PUX#T?3]"TT#3;6[L(YWOTSH3-J2W$=W&2"S'R
M5*G8=^6P>]??M% 'R-^S=^SAX]\ 7'C0WEQ%X&GO;2.QAU32GM[N6^G6YGE:
M^9&0IN9947]X"W!SP!7J/P.U3Q7;_$#XA^%O$OBVY\7Q:,;%[2[O+*VMI4$R
M2EU(@1%(R@QD9KV<]*\;^%W_ "7_ .,'^YI/_HN>@#V6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HJ&ZNX+&!Y[F:.WA09:25@JJ/<G@56T[7],UAG6
MPU&TO60986\ZR%1[X)Q4\R3M?4T5.;BYI.RZE^BBBJ,PHHHH **** "BBB@
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MR47 OTUR]VV-Q(6_=&W9GVM@X(*<!<_2OU*I,5SK$SC=1T3W7?U[F#FV[O\
M0^$_V^?B;\:O#G[-^MWJ>&1HMNL\"W5YI5[YCI"7 ;=L<L$/ )'KSQFNO_X)
M<^,O%/C?]F"WO_%$E[,ZZG/%92WA8[[<*F"A8DE-Q8>F00*^NYH8[B)XI462
M-P59'&01Z$4EO;Q6D*0PQI%$@VJB*%51Z #I6\LPQ$L-]3O:G>]K+?O?>_3?
M;0P<(N?M&M22BBBO.- HHHH **** /GW]H;X _!;XH>)-'A\:VJZ1XQUTOIV
MF:OI5Q+9:A,1&S-&)8^' 0-\LF5QGBN]^!'PJOO@OX M_"=SXLU#Q=96#^7I
MMQJ<,<<]M:*BK';DQ@!PFTX8@'G':OG;_@IKJ>@Z?\//"8UG1K6_F.IR2V=[
MJ>LW6F6=G)';R/EI+<JS2,%*(F0"S#FNX_8&UG1M8^#VK#0K)K?3K;7+B!+E
M-9N-5@O/W<3"6*><EMN&"E02H='P30!X[^T]K_BSQ#^TQ:6WAN?QO90:+!:1
M7"6FD:@(%$DK9EMY8I%MSN&,O/\ +^[P"?F6OO<5^>W[5_PZBTO]J_PY<Z=X
M4L=3E\3K;?NK[4R8;VYCD/\ K8GO(O+50$QLC<-N8X)&#^A(H 6BBB@ KQ3X
M+_\ ):_C=_V%;#_TB6O:Z\4^"_\ R6OXW?\ 85L/_2): /:Z*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBO%_BO^UCX(^#WC?3O"^M_;Y;^Z5)))+2
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M"_LLM\=?&GAG71XD&DKI"F/RWLO/DBS*DGFVS[U\J;Y-NY@XVL>* /0OAO\
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MZ;::3\8/C7:V-K!9VR:K8;8;>-8T7-FO15 % 'NE%%% !1110 4444 %%%%
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M[5O"7B;P5X[TS2$O;F\T?5?%-W#>)!9G8([0W D9Y'!WGD8 .,G%<3_P4/\
M$7@[Q]J/AKX<GQMX=TSQ?;3&\71_%4%S_94HEBDBC,\\2E(9%+%XRYQN4<<B
MO1/^">4=DWP8UNZLM6LM86Z\0W4LDVC6T\.F)+LB5ULS-\\D9*[C)@!G9\#%
M 'SQ\<O!GA7X4_M=76IZYK,&L7>MM;:EB_\ "^FWDUI^]8+&CSRI)*?E(!C1
MF4*H.3M!_2H5\1_$JX^%$GQRFN?$>L?%_P#X2#1]0CN$865V^G6!>0*C12&
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MCCMHH84A2-$B0!515 50.@ Z#%2T45\H;!1110 4444 %%%% !1110 4444
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M-!H+/80G_A+8/[1$+O(PB&=D!+;H]@XWG(% 'Z,9S7BOP7_Y+7\;O^PK8?\
MI$M>4_LL?&SXD^,O#_C6Y9I?B+?645E/':WCQ::+:^E>875B)1$ HB5(SM8,
MPW8)YKN_V9-4UK6?B7\9KOQ#HB>'=5?5K'S-/CO5O!&!9K@^:JJ#D>W% 'T-
M1110 4444 %%%>&_M>?'K6OV?/AE%X@T+1H=5O9[M+4/=AS!;A@3O<*02.,#
MD<D<UZ&7X&OF>*IX/#*\YNRN[:^K,:U6-"FZD]D>M^)_$</AK33<.C7%Q(PB
MMK6+F2>4_=11ZG\@,D\"N!T/P[<>*M6O/M\JW(9@-6NHSE)&'*V41_YY)GYR
M/O'CN0O!_ [XA:Y\>?"ND>)[VT&FZ_J$+QA85/D:;;!BKS1[N2\I!"D]@>P8
MGZ&TK2[;1=/@LK2(16\*[44<_4D]R3DDGJ2379C*,\JG/!R_B)M2MW3V3[)_
M>]=DKZT9*457[ZQ]._KV^\LQHL2*B*%51@ #  IU%%>&,**** "BBB@ HHHH
M **** "BBB@ HHHH *^/OVI_BMX*\:ZSXG^$GC32M5@CLHM/U&UU72_#=QKA
MW.[E@8XXF$1'EXR3DACCI7V#7R-\>_VF-0_9M^.,,$O@KPK<:;XDMXPNLS>)
MK72[R<Q+)A)1.0,*S#:QX^9AU- 'T[X'UG2_$'A'2=0T6UELM)GMU:UMIK-[
M1HHQP%,+JK1XQ]T@8KY__:T_:EU#X(^)O!>@:1 (I-2OH'U'4+JSFEB2U,JH
M8XRJ$&5BW )X )ZX!^@O!FN7?B7PKI>JWVG#2;J\@69[-;J.Z$6>0!+&2CC&
M#N7@YK1O=.M=2C6.[MH;J-'614G0. ZG*L >X(!![4 ?*G[.7[37C7X@2^+V
MU&QA\8O:V46IVNG:!#%;W%J7N)XOL;F24(SJL*MERIY.1TKLOV>O$-_XG^,?
MQ<OM2\.:CX6NF_LM3I^IR0/,H$<V&S#(Z8/^]GBO;](\,Z/X>>]DTO2K'37O
M93/=-9VR1&>0]7<J!N;W.37EOPM&/C_\8/\ <TG_ -%ST >RT444 %%%% !2
M'I2UG>(;\:9HE[='_EE$S#ZXXI2:BFV7"#G)06[,WP>/M+ZMJ)4C[5=L$)[H
M@V#]0U='69X:T]M*T&QM7&)$B7?_ +YY;]2:TZSI)J"ON;8F:G6DX[;+T6B_
M ****U.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RW]I?Q/XC
M\%?!_5=?\+W^GZ;J6FW%G=2S:I=PVD!M4NHC<QM-,-B%X?,0$]V&,'%>1_LF
M>-?B/X@\9*?&/BV#7;#6_#$7B V376GRK;74EW)&4L3:DEK5$55+.6^<H 2=
M^/0/VRCIA^ >KQZC9ZA?S27VG1Z;!I<\4$YU WL(M"))5:-5$WEEBZLNT-D'
MI7E'[,O@V+PG^T_XODUKP?'X&\6:CX=6^&F:'K:ZEHLMO)>?O9808HVMI?.4
M;XP-C%BXY)H X]KS1?B%_P % 8=:T?7(S96%W!:S03W;QRW=S%;,I^S8M2?*
MC.Y6B,J@N)#P&.[[T7H/I7YX?&S2+[XG_M5_V%9Z]K7@_5=7>&2RDNI[B":S
M>*"2)46&*_6,PLT?GAS%O+;005)QZU^T+#\1%_:0\$R:$/%,NG1QZ.=.DTKS
MO[.WC4G.K_;0G[OFQV;?-Z](_FH ^M<\UXQ\4/\ DY#X*?[FN?\ I)'7ED%_
MXJUW]L;0/$5A!XMOO#FHVT"C2]1T[4-/LM+L_L4S-=>9YPMY)#.5C:"6+S 7
M4C&W-;E^?B,?VGOA+_PFZ^%ULO+US[%_8#71ES]F3_6>< /NX^[WH ^GZ***
M "BBB@ J"^OH--LI[NZE6"V@C:665SA44#))/H *FZ5YAXT\1?\ "2Z@MA:0
MB]TZVN1"L /&I7JG(AS_ ,\8B-\K=,KMYPP/5AZ/MI:Z16[_ *ZOI_E=B=VU
M&.[*VE6<_COQ.\]["T:3K'<7,,@Y@LU;=;6K#L\C S2#T 4]J]8Z5D>%]!_X
M1_3/*DF-U>S.9[NZ88,TS?>;'8<  =E51VK8HQ%;VT[K1+;T_K_@ENT4H1V7
MXOJ_G^04445RDA1110 4444 %%%% !1110 4444 %%%% !1110!^>O[<WPZ\
M+^"_B]9>++338]"U+6M-NKB[U2ZN-7-OJMU$8%CLHTL)$,=Q*JCYR<$1CY'(
MX]N_:D\8Z/H?[(@MM<N)?"EYK&FV=I::=/?B.9)V$9\AY),EU09$N<DHKU)^
MT3^U)K?PWGO?#^@Z-:V?B2.[@$-WK,\#V,MLXYDWB=%A?=\H6X:$'DJ6X!UO
MVC]:\07_ .S6QEL+N#Q!?6$%Q=2:!.3;VTB!)94^TK+&R1OM:,2JV0&S0!;_
M &*K&2P^ FE1S:S9Z].;JY:2\T[4EOK4MYA!$3JH"J,?<&<'/)S7NS*'4JP!
M!X(/>OF#]A3PYXAM/!VM>(-3UV[O-*UFXW6>D76H37_]GNDDN]5FEFE)7:T:
M@AAD1Y(!->Y?%'QY<?#GPI-K%KX=U+Q-.LB1BRTTQ(P!/,CR2NB1QJ,EG9@
M!0!TT>GVL4ZS);Q),L?DK(L8#!/[H..GMTKQOXG?\G+?!C_<UK_TD%9'PY_;
M0\*?$OQCX=T73M%UJVM-;@A\G5;N.)(([N2T:\6U==Y?=Y"EMX4H> &.15/Q
M)\2?"7CK]I_X16_AOQ1HOB"XM(]9^T0Z7J$5R\/^B@?.$8E>01S0!]'T444
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M3Q!H/VE[/2T5U;)BB8*\SXV R9559B1V(!]69R#7C?PN_P"2_P#Q@_W-)_\
M1<]>0_LO^&/BYI-UX[::#4=(OY;>,&7QEY]Q:3ZG]IG,DT*>9N,1B,(S&57A
M<#@UZ#^SU%XFA^,?Q<7Q;<Z3=ZQ_Q*]\FBV\L%OM\N; "R.[9ZYYH ^@J**H
MW^KP:<ZI*EPQ89'DV\D@_-0:B4XP7-)V1$YQIKFF[(O45D?\)19_\\K[_P
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MDHCBB0=V8T :]%<Q\._B;X5^+7AF+Q#X.UZR\1:-*[1K=V$N]0Z]5/=6''!
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M7-RL=RM]';7#R#R@&-L65656"\$G- 'WKFHKBZ@@,:32QQF9O+19& WM@G:
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MH:%\HT3>HKZGHH I:-IBZ-I5I8K<7-V+>)8A/>3&6:3 QN=SRS'N3UJ[110
M4444 %<%\1O@CX3^)S+=:K8M;ZU#L-IKE@_DW]FR-N5H9ARA!_ ]""*[VB@"
MO86,6GVRPQ <<L^T NW=C@ 9/4G%)J44\^G74=K((KEXF6*0]%8@X/X&K-%
M'Q];?LP>./&VM7&E>/M=N/M8M(5N?%FD10M;ZW K[EAN+>3F*ZA8YCN(P#MY
MX.0?KFPL8=.MD@A7:JCDXY8]V)[D]SWJQ10!X_\ M#_&RQ^%NEV6DO?RZ-JW
MB!)K73]8:#S+6QF"$K)<'GRTS@;R-H)&<5\U?#/X&^,OC'XGU>U\77WB[1(4
MMK7[??ZK9P,UW+')GR1+L$<Y1LR0WD(5T5BK9X%?<^L:)I_B#3[BQU.R@O[.
MXC:&:"XC#I(C##*0>H(IGAWP]I_A30['1])MEL]-LHE@M[="2L:#@*,DG H
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M[=;33K&!+>W@0DB.-1A1SST% %R"WBM8_+AC2),D[44*,DY/ J2BB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH **** $Q1@>E+10 E(4#8R <<TZB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^V@N8+>6XBCN)\^5$[@/)@9.T=3@<\5/0 4444 %%%% !1110 4444 %%%%
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M<NH1G69+[[4-(TRWOKMEA@#KM6>1$"Y/)SGIBL >.?B#KFI>(K"+QG8^#O\
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M8$$<@ '%?#GP+J/@GQC\8;BTM-0CBU2\AO;*ZNIGG:YE-L=Q1G8G"MA0O 4
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M;RY$E$@F+"1G!8GG#$X%>J>+/@#X3\7>#+'PS<)J<%EI\K7%E+#JUT)X)B&
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M[+Y<R_=; //7H>*^9O%7[.?Q-^(NI2#Q3XA&IZ?;:FUU:P?;VBCVDOM*JJ<
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MX>MO'GAW6K/;;Z9HUY)JD=@XDE<WAB$2NLC.0B!0"4"\L <U[-10 G2EHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ibio-20230630x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '^ \L# 2(  A$! Q$!_\0
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MA7/LI- 'K]%<;\3_ (Q^"?@OHL.K>./$VG>&=/GE\F&;4)@GFOC.U%ZL<<X
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MLQ &,Y/2I]<^//P]\,_#_3O'&K^,-(TSPIJ,2366J7ER(HKE7&4\O=@L2.0
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M(?(CF6-%(("J\CD =,UY?XGTZUM/^"3'@Z:"U@@FN+3P\TTD42JTA&I6^"Q
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M,2>26)[UYX?V,_ L'[/WB;X36<VJ6VF^)&,VKZV]P)]3OKAG5WN)9I%(>0E
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M?'0;<VG@^XU6UUO2K1C#J<GVA(X;H1LV8]H9D>')&Y<@X(KFOV0O#/Q*T_\
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M8'?</6N@\0_L_P"J?&#_ ()_>'/AN\7]C^(_^$3TD0P:A&5$-[;10R+%,I'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY)>P6EK8W]W;KH7V2 Q26=[9R+L>W)&Z.52-SA22<FOT<'2@!:*** "BBB@
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M7_&CQA\5W_9MTZ203:U-XIU^[NM2TT-9Q>)4TVT_=7D@ 4N)68*Q8<LAZ=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ0!C [#M6G10!3GT>PN6E::RMY6EC$3EXE)= <A3D<CVZ5:1%10J@*H&  ,
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MZTHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N6^*1Q\./$^"1_Q+I__ $ UU-<I\576/X;^)BS!1_9T
MXRQQ_ :ZL+_'I^J_,[,%_O5+_$OS1TUKS;Q'K\@_E4M063J]I"RL&4HI!!R#
MQ65XT\:Z)\//#5]K_B'48=+TFR3?-<3$X&3A54#EF8D*JJ"S$@ $G%<SW.66
M[+FOZ_IOA;1;W5]7OK?3-+LHFGN;RZD$<4,:C+,S'@ #O7BUKH^I_M/S0ZCX
M@M+K1OA,CB6Q\/W2-%<^(R#E;B]0X,=KT*6QPTG#2X7$=3Z+X+UGXXZS9^*_
MB%I\NC^%+.5;K0_!%W@-N4YCO-27.&FZ,EORL7!;=)]SU'4OB#X9T8E+O7;"
M&0?\LOM"M)_WR"2?RJX4YU':$6_0NG2J57:G%M^2N<'\6?$?AS0;LZ???#S6
M_$EP;'$5WI7AMK^*-3N58_,484C'W>P(]:X']DW7=&M/ /PXT*3X<>(-'UV#
M1;>"75[SPTT$"2+;C>3<8QAL$ Y^;(]:R_VIOB_?7<>DZ3H%W>V>DW,<DMQ<
M+#+;&X(( 0,P4LHSDXX)(S69^R'X[US_ (35_#<EU/>:--:23"&5RXMV3;AE
MS]T'.".G2OK8Y'B_[->,=2UDWRZ[+?Y^1]U'AS'?V1+,)5;63?([_"KI_/R_
M4^PJ***^./@ HHHH **** "BBB@#Y\_;C^$>H_'?]GW7O"OA^\L$\0P3VNI6
MMK?RJD-P\,H<0R9( #@$ GC.,\<U\XZ9:?&K]J/XQ?!\>,OA3H_PIT#P%K,6
MKW.IKJ$4LMS)$/EM[95.X1N0!M&5Q@EOE -;_@HWK_PI^%FN>(KGQ)X&\3^(
M/$GC.RTZ*>>.ZDM]+FMK>X4[5E1LI*GE@[=O.5[-7CGPH7]GU/CU\*E^$/PO
M\?WOB!O$EJ9[GQ#-<0PV, ;+7 "LP<IU*MA< Y- 'Z^"O!OVX=-\,>)_V8_'
MWA_Q/XKM?"%E>6"L=2N=SB%EF1HRT: NR&154[5)P3Q7O5?GG_P5U7X:KX"T
MZ3Q7X3UZ]\8?8Y5\/:_IL>VTA;S8_,AN) WI\P5E(^;CJ: /%Y_AS\39/$UG
M>_%_Q'X \+> _$/BG0;Z\U3191<S7<UI"D%K%:Q1;C")%C!9F5 N220!M/ZY
MCI7XQ>$IOV;(/$/P_;X<?!GQKXE\;OK&G+Y&OO=)9+EE\R4;)#N*M@@,-AZG
M@8K]G1TH 6BBB@ HHHH ^:/^"D?_ "9+\4O^O.V_]*X*]_\ !W_(IZ+_ ->4
M'_HM:\ _X*1_\F2_%+_KSMO_ $K@KW_P=_R*>B_]>4'_ *+6@#8HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYM_X*& ']E?Q," 1]ILN
M"/\ IYCKZ2KYM_X*%_\ )K'B;_KXLO\ TICKU,J2>88=/^>'_I2,,1_!GZ/\
MC\AO*3^XO_?(I?+0_P "G\*=17^@WU/#?\^X_<C\?]I/^9F_\.(D_P"%B^$_
MD7_D,6?\(_Y[I7[T#I7X,_#C_DHOA/\ ["]G_P"CTK]YATK^5?%JE"EF]!4X
MI+V:V5OM2/ON'I.6'G=_:_1"T445^'GU(4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<^/)?*>8-IR
MG][VJ2O+_CW\5/$OP@\/6.NZ'\/M4^(-@L[+JEMH<J_;;6#82)HX6_UWS  J
M"" <]J /@#]E3_AIZ3X;79^$UA\.])\"_P!M:C]AT;Q-(9+_ $[_ $J3?!(5
M ;*MN \SYL8[8K]*?AH/$H\ >'_^$Q&GCQ5]BB_M,:5G[+]HV_/Y6>=F>E?D
ME<6G[#7VV[DU&\^*FE:W<3-)<:;<).MSYK')# (03D]VK] _V0OBE+XOT&P\
M.>&OAMXK\,_#30-+2UTWQ#XO98;F^9"JHB0<LR[-S&4G&0!CF@#Z0KP#]I6P
M^-(US0;_ .'.C>&_'7A;R);?6O!NOF*#[3(>8IUF=2,*<93CIWS\OO\ 10!^
M<F@_L/?%CX7?#CX/>(]!CT77?B#X(\1:CKDGAHWA@LA;WH0/:03'A=GE@]AE
MWQG W6G_ &%/B5=_L\WUW*VD1_%NX^(0^(JZ9]I)LUE4D"T\[&,[3G=TSQG'
MS5^B-% 'YW:O^Q#\4/C%X!^.OB7Q7#H_A;XC^.]1TW4-,T>"\^TV]HMAS'')
M,!C,@)7(SC )ZD#V#]F'X,?$P_'SQO\ &7XJ:3I?AG6M6TBTT"QT73+T7@CA
MBV&25I!Q\S1J0.O)ST&?K&B@#SN__9U^%6IWUQ>WGPT\(7=Y<2M--<3Z';/)
M(['+,S%,DDDDD]<UXC_P33M(+'X":W;VT,<$$7C#6D2*)0JJHN<  #H  !CV
MKZQ/2OE/_@F[_P D,\0?]CEKG_I4: /JVBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_/\ _;N^*/C+
MP]X[OK>?PS<7/A/2=/6\@DCU2*-9UVDR2^41DL""O/\ =]Z^]-7U:TT+3+G4
M+Z=;:TMHS)+*_15'\_IWK\4?^"K?QD\<Z[\<[?PUJ,USHOA^WTF"YM-*1BA*
M3;F)EQ]YN,$= 5([9KVLKQ/U"H\6ULFEMN^UT_GY>JO]%DV+_LRJ\:ULFEM?
MF>UKI[=>RZZJ_P!>_LY?';QCX/T'7_[;L(]!\-0+#]FDN)_[4GEO93B*SM+:
M(JSS2C)" X^7. ,FO>/"'P5\6_$S5--\:?%;6[NVU.SD:?1/#&G&*.WT<,,"
M24@,);O:2#(#MCR5C/5V^)/^"-OBB_\ '7B_Q59>(HIM>_X1JPCFT:_O9'E_
MLPSR,LR1@G"M* /G^]MC*@[<BOU@J<?F#Q>(E6A&U^ZC?;JTE_7GJ9YGFCQV
M+EB*<>5/751O>UKMJ*_+\=3D!\*O#DK![ZUGU>0?QZG>2W.?^ NQ7]*W],\/
MZ7HJ[=/TZTL%]+:!8Q^@%:%%>=.O5J*TYMKU/*J8FO57+4FVO-LY7XB?#W0?
MB'H36>NV0NXX=TL,BL4DB;'56'(]^Q[USGP&^'6@>#O!>FZCIED(]0U.SAFN
MKJ1B\CDJ#C)Z+DG@<5U^O^']2U>XW6OB*\TJ Q[&@MX('5CSELNC'//KVJCX
M4\$WWA:.PME\2W]YIUG$(4LYX+<*5"X4%EC#<<=^U=\<1-8-X?VVC:?+[UNN
MFUM[>1ZD,5-8"6%^L6BVGR^];K=;6U=O(ZRBBBO)/""BBB@ HHHH **** /F
M?_@HAXWU'P#^S)JVH:6NFQW4VHV%I]NU:RCN[>P$EPJFY,<BLI*=02#@D'J!
M7QO\._C!\9-"^.GA#1_&?[0+:_;P_$:+PQ?>&K2VABNKRW*B2WO5"J"UK,&0
M,<_*'_BK['_X**ZWK?A_]E?Q'=:#']JNC=6<4MB=-6_6\A:=1)"T3*PVL#RQ
M!QCC!P1XE\+/VD_@)\2_CKX-UE?@1XITGXC7DEMIEMKE]H:B.U;:(D9W$FW"
M+A1)LW!0,8 X /T%KQ+]M;QM<?#K]EOXA^(;31K+7KFRT\&.RU&U6YMR6E1!
M))$P*NL>[S,$8^3FO;J\H_:I^*5O\%_V>_''C&ZT2+Q'#IU@0=*N%W0W)D98
ME608/[O,@W?[(- 'YW>"/VH?'_P^U>WM+/XX67Q)OH/&FAVD5DJ(R:W97MFA
MGAMHE_U20O(5R N&4=#\I_6<=*_)_P #^!OB!^R9XY\#_%'QG\%OAC%H.OZQ
M:Z?_ ,4ZLAU#2I+HX1H5>1E# $\(&Z$97.:_6 <B@!&=4&6(4=.32E@.M?GY
M_P %'-$^(\7BOX?:]=>+K>U^'B>--&LM.\.:?&R33SOEI9[F3C.THRH@R,-G
M@]:W[>GP\^(7CW]H#2]0L/AYXD\8_#[P[X6FGN1I&O\ ]CH]P97=R)>=[*BK
M^["Y;MTH _0MG55W$@#U)I0<U^7]A-X6_:;\:?LR?#+2[_Q'9_"'4/"^IZQ+
MILVJ2+=S743SQ[)IU.7,4D38/3&<#!KW+]A/XP:_8?L8ZEJ^KVVM^/+SPEJ>
MH:7;6]BGVG4+V"&5?+1 3\[ /@9/1?:@#N/^"D?_ "9+\4O^O.V_]*X*]_\
M!W_(IZ+_ ->4'_HM:_/C]MC]KG4_B)^R]X]\.3_!#XG>%HKZVA1M7US1E@L[
M?%S$V9'#G:#MVCCJ17Z"^"FW^#]#;!7-C <'J/W:T ;5%%% !1110 4444 %
M%%% !1110 5Y3^T?^T1H/[-7P_G\4:]:7MY$,I!%:V\C(\G&$>4*R0[LX#28
M!/&<D5ZM7/>-OA_X<^(^G6NG^)](M=;L+:ZCO8[6\7?%YR9V,5Z-C)X;(]J
M$^'WCS2OB9X2L/$FB?:SI=\&:W>\M);61U#$!O+E56VG&5)&&!!'!%=%65X6
M\,:7X*\.:;H.B6BV&D:= EM:6J,S+%$HPJ@L2< <<FM6@ HHHH \'T/]L3P9
MKW[0%]\)K>UU==<M8E_>/IERH,OF2JX93'\D:JB.)V/EL)DVL2:]XKB;/X+>
M"-/\>2>-;?PY9Q>*Y)I9WU=0WVAVDB2)\MGE2D2#:?E&W( ))KMJ "OFW_@H
M7_R:QXF_Z^++_P!*8Z^DJ^;?^"A?_)K'B;_KXLO_ $ICKU<I_P"1CAO\</\
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MRG_P3=_Y(9X@_P"QRUS_ -*C0!]6T444 %%%% !1110 4444 %%%% !1110
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MFN;N7_67$S<O(_N3^0  X KX\_9%U+5(_BNMK;M+)8S64WVM22RHHP4;V^?
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MYB/X,_1_D?D31117^B!^.'0_#C_DHOA/_L+V?_H]*_>8=*_!GX<?\E%\)_\
M87L__1Z5^\PZ5_)WB[_R.,/_ ->E_P"E2/T#AW_=I_XOT0M%%%?A9]6%%%%
M!1110 4444 %%%% !1110 4444 %(2 ,DX'O2UY_^T#(T7P,\?R(S1NFA7K*
MZ$AE(A;!!'0^]73CSS4>[*BN9I'H%%?&_P"QK^V2OCJ.R\#>.;Q4\2JHBT_5
M)B -1 '$;GM,!W_C_P![K]D5T8K"U,)4=*JM?S\T75I2I2Y9!1117(9!1110
M 4444 %%%% !1110 4444 %-9@HYIU>3?M&? (?M!^%=.T4^-/$G@D65Z+S[
M9X9N_L\TOR,GENW=/FSCU H ^$/B?=6/B[PSXDT73OV"=9M=4OX)[>VU1=.$
M)BE8,%G#I"&&&(;@CIUK[]_9I\-Z_P"#_P!G_P"'NA^*;:&S\0Z?H=K;7MO;
MJJK'(L8!7"?+D< XXSG%?D]XDOO".DZYK3:1XW_:1\5>"-$NVL]1\::5J :P
MB96VNRY&&4>I9<]AR,_KE\"X-*MO@WX+CT+Q!=^*M&&DVQL];OY/,N+V(Q@K
M+(W=F!R<]Z .ZKXZ_;V_:D\/_L\W/AVTT?3]#E^+VMPO:Z1K.K1HJ:+:NVQ[
MF64@L$R6P@X8JQ((!!^Q:YSQ%\./"?B^]2\UWPQHVM7<:"))]1T^&XD5 20H
M9U) R2<>YH _+^TT[P'\&;S]DWQ#IGCJR\6>"-'\3ZQ_PD?BU"5M!JUS% [,
MY(&Q1A0N?X4R>]<7>))/\"]7^(<22-\/S^T FN?:E0F%K 90W'3[FXA<^IQU
MK]<F^&?A!_#<OAX^%M%.@ROYLFE_V=#]E=^/F,6W:3P.<9XJ^GA+0X_#O_"/
MKHVGKH7E>1_98M4%KY?]SRL;=OMC% 'Y#?'&Y3XG6O[77CWPD_\ ;G@5M?\
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MQ7+AE88(/R]P:]?\(^&+'P3X4T7P[IBNFFZ190V%JLC[V$44:QH"QZG:HYH
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M:X']JSXBZ)\*?V>O''B?Q'H">*=&L[ QW&C2@;+P2NL0C<D$!2T@R<' R<4
M?GOX7^.?C7X<:NDFMZ]\/_'-S8>-=#L9;>PTBRC%]:7]FDNRQ,<08F)Y =_7
M<@YQE3^KXZ5^57P+^ _C+P9\3?#?B_2OV-M-T1FO8)TO[WQ8]T-.C=UW3)!+
M*<,BDL 02".,&OU5% 'PA^W[X[^-/ACQCX'?2M0@\)_#0>+='L%N=.O'74=7
MFF)9UDV_<@3:ZE#]\D$Y'3/_ &F?$/COXK_M-?$'P1H?Q"\0> M&^'W@-_$U
MLGA^X\AKR_P'7SVZO'AE&W_9XQDU])?M5_L_W_[0WAKP?I=AJ]MI#Z'XHL=?
MDDN8FD$J0;\QC:1@G<.3QQ7G/[1O['_C3Q]\5M5\>_#7QQ8>$=2\2>')/"OB
M"#4[$W,<]HQ_UD1'*R!<#G^Z,$<T >#Z9\9?B%^U???LV> F\<ZSX'B\4^%[
MW6]?U;PW(+:\NY[<RPIAP/E4O 6*C@[SZ#'N?[&G[2=Y=?LAWWC3XGZU+>OX
M2O[[3=1UDPM++/'!( DC*@+,VUU!(&3C)YR:J>*?V%M;\+Z?\(=2^$?C.V\.
M>,OAWI<VC0WNLV7VBWO[>96$K2(OW6WO(XQD?/[ U[+^RW^SW;?LW_!C3?!)
MU$Z]>"6:\U'49(M@NKF9]TC!.<+T4 ]E&: /D3]MO]O+X,?%G]ESQ]X2\,^)
M;J]UW4K:&.VMY-(NX5=EN8G(+O&%'RJ>IK] /!3B3P?H;J<JUC 0?;RUKY[_
M ."C]A;0_L4?%%X[>)'%G;X98P"/]+@]J^AO!W_(IZ+_ ->4'_HM: -BBBB@
M HHHH **** "BBB@ I#TI:0]* /Q7^*__)5/&O\ V';_ /\ 2AZY6NJ^*_\
MR53QK_V';_\ ]*'KE:_6<%_NU+_"OR1^XY?_ +G1_P ,?R05^G'_  3P_P"3
M=8?^PO??^C!7YCU^G'_!/#_DW6'_ +"]]_Z,%>%Q#_ A_B_1GS7%/^ZT_P#%
M^C/;_BU_R2OQE_V!;W_T0]?F[I'_ "";#_KWB_\ 0!7Z1?%K_DE?C+_L"WO_
M *(>OS=TC_D$V'_7O%_Z *]G@+^)B/2/ZGY#C=HENF3_ /'O+_N-_(T^F3_\
M>\O^XW\C7Z_+9GF'Z$? '_DAWP__ .P!8_\ HA*\K_X*%_\ )K'B;_KXLO\
MTICKU3X _P#)#OA__P!@"Q_]$)7E?_!0O_DUCQ-_U\67_I3'7\P95_R,</\
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MG);D9&!]365^TS\'+KXZ?"RX\.:=?VEAJ<5]9ZG:-J5M]HLI9K:=9DBN8O\
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M444 %%%% !1110 4444 %131H<2-&)'CRR< L#C''H>U2TUV"(2Q 4#))]*
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ML=PFR10UQN 9>Q&<$=CFOK<CZ_G7RI_P3>.?@9X@SS_Q66N?^E1H ^K:***
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MDD0W,08]^5/&.>U>K4F >U80QE3VWMZS<WYMW^]-/\3:*=-6I/E]#YL_9U\
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M_P#(+^%?_7:^_E%7Y0T %?<G_!'K_D[(_P#8#N__ &6OANON3_@CU_R=D?\
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M+I?IMVUV.OT;X%^$M-OH]1O[.;Q-K"<C4O$,[7\RGU3S,K'_ , 517H 4*
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M_P#$?S'Q'_R-\1_B/Q7^*_\ R53QK_V';_\ ]*'KE:ZKXK_\E4\:_P#8=O\
M_P!*'KE:^\P7^[4O\*_)'Z;E_P#N='_#'\D%?IQ_P3P_Y-UA_P"PO??^C!7Y
MCU^G'_!/#_DW6'_L+WW_ *,%>%Q#_ A_B_1GS7%/^ZT_\7Z,]O\ BU_R2OQE
M_P!@6]_]$/7YNZ1_R";#_KWB_P#0!7Z1?%K_ ))7XR_[ M[_ .B'K\W=(_Y!
M-A_U[Q?^@"O9X"_B8CTC^I^0XW:);ID__'O+_N-_(T^F3_\ 'O+_ +C?R-?K
M\MF>8?H1\ ?^2'?#_P#[ %C_ .B$KRO_ (*%_P#)K'B;_KXLO_2F.O5/@#_R
M0[X?_P#8 L?_ $0E>5_\%"_^36/$W_7Q9?\ I3'7\P95_P C'#_XX?\ I2/=
MQ'\&?H_R/R)HHHK_ $0/QPZ'X<?\E%\)_P#87L__ $>E?O,.E?@S\./^2B^$
M_P#L+V?_ */2OWF'2OY.\7?^1QA_^O2_]*D?H'#O^[3_ ,7Z(6BBBOPL^K"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *^/_P#@HY\'=>^-GASX3Z#HMAJ]S!_PFUH^HWFBQEIK"U,<
MB/<;A]S9NSN/ .*^P** /AW_ (=7: 3G_A<OQ1Z_]!E?_B*^O?AMX)B^&_@'
M0/"T&H7NK0Z191627VHR>9<3A%QOD;NQ[FNEHH **** "BBB@ HHHH YWQG\
M//"_Q$M+>U\4^'-*\1VUO)YL,.JV<=RD;D8+*'! ..,U\W_\$T[2"Q^ >MV]
MM#';P1>,-:1(HE"JJBYP  .@  'X5]8L<"OE/_@F]Q\#/$ ((/\ PF6N=?\
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MLGWK^B/^(QK_ * /_*G_ -H?&_ZM_P#3W_R7_@GR3\.6 ^(GA0Y'_(7L^_\
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M%K_Q<_:X^(?QHF\(Z[X1\+S>&['P]91>(;,VEQ<S*8WF(C/.U#&1GH=P[Y
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M6VOH-8UJ:[1_*M 4PK8 P7)[]O2@#[]HI!T%+0 4444 %%%% !1110 4444
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MW9."3]E_LZ?LXV7@KPWX5U_QOX1\'#XKZ=9&SN==T#3TC+#[BL'V@ES&%#,
M.2P& <5[I:6-O8JZVT$4"NYD81(%#,>K''4GUH F'04M%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >>?'WX(:!^T1\*]:\"^(VGBT_4
M51EN;5@LUO*C!XY4)!&58#@\$9'>N)_9U_94@^!WB;Q-XMUCQAJWQ \:^((H
M+6ZUS5T2-UMH5"QQ(BY ' R<\[1^/O-% !1110 4444 %%%% !1110 4444
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MW1W(P:^4?B+IUY^V#^T%XT^'WQ+UW4OA7XWT^TAE^'=G:7_F:3>HLDDOVK.
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MHZ$MGZ@^%W[(?P]\!P^.S8:1>0>'_'@CGU+P??S!].M6*?.D<*_*I8D[L$]
M%.T 5ZMX"^'?AGX7>&[?P_X2T.Q\/:- 2R66GPB*,,?O,0.K'N3DGUH Z*BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?M+^._%_QH^-MY^S=X2\2VGP[^U^&AKEUXDF$K7MP?-&VWLPCIC[N7;).W>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=\-M2^)$7@9=-GMH#H?BS3==N/M+,-\%N[%U7 /S'<, X'O7SKXS_8)U:_\
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M\-_LL?!#XY:EX=^,MW\-/L&N:K##JK6NH1R6I:4@,K7-J&$;N#SEE.[J<YH
M]@\1?"_P5\4]1\)>)M=\/6FJZEH4RZEH]W=1XEM)&7(8?F#M.1N53C*@UVU
M  P.E&: .:^)7Q&T#X2>!M8\7^*+TZ?H.DP^?=7(C:0HNX*,*H)))8  #O7Q
M?^W?-I'B&X^#GQFO-)C^*/P/TIKC^V]-M',T*PW2*L5^%4@/LY'/0X'&XD?3
M/[6?P[;XL_L]>,O"@\0V/A6+4;:-9]6U+_CW@A65'DWG(V@JK+N[9S7S%;^!
MO%'["'CFWM/#.E7_ ,1OV</&-VEK/H,49OKG0;B<A08TY\V"0MR.AS@_-@N
M9GP.U>#]F'XZ> ]'^'GBI?&?[/GQ8EE71K'[5Y\NAWP3?MCR=WEG@$'!&3N
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M@<D@'SGP!>R? 3PS\5]<UW0KZ#3)O&\L]E;64*%YK:<6EO%)$FX#9N[=<*<
M\"KOQKM=:\*_&/X>?$2Q\-ZKXJTC2K#5=)O[/1(1/=P&Y^SO%*L18%UW6Y0X
M^[O!/&2 #TS0/B=X8\2?#RU\<VFL6R^%;BS^WC4[E_)BCAQEFD+XV;<$,&P5
M((."*@^%'Q6\._&GP7;^*_"MS)>Z'<SW$$%S)$8_-\F9XF8 \[2R$@GJ,&O.
M?V;?"FH>%_A/H/@#Q?X5N$N)+&XU:]^T113V$3W%[+-]C9MQ#2H)!D!2O&03
M6U^R_P"%M5\'_#.]T_6;"73;Q_$FNW:P3 !C#-JES+$_'9HW1A[$4 >FOKVF
MQB4O?VRB)5>0F91L#?=)YX![9J6;5+.WF2*6ZACE=2ZH\B@LHZD GD<CFOA7
MX8?L@62_\*>;Q#\-H97.E>(CXG^W6ZN)KB25&M%N@2?,QF0QALA/X=N!7BVK
M^#KGPQ\&==TWQYX.N]>\<I%X6M[+Q UQ#--X>C5+./[#,3)YL$@82-Y:J?.$
MZGYN=H!^B_\ POCPS_PM-/ '^F_VV]R]FL@M\VYF2T6[=/,SU6)T)XZNHKN6
MUFP3RMU[;CSE+1YE7YP.I'/.*^&OB3^SQ\1_B1I/A.[T:._\->(=<U;Q1K>J
M3RC;]F6XA\NULYV#!HUDAB@@9T^91G&#7F/QNTS35\"_%&YUCX6RPZE/H.B0
MZ#;QO;E_!H2)(VLW'F![?]\'E7RU/VA95 W<@ 'Z@45' ,0H",$*./PJ2@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^5/VY
M/VJ-4^!^C^&O#7A<P:9K_B^]_LN#Q9JHQI6BG(5Y9I,$>8H;(0C@ L<@8(!]
M4/*D:,S,%51EB3@ >]?!WQ*_;>\4^+O 'B;Q5IGP8O/$W[/K-=:/J'B*+4TC
MO;FVRT$]S#;X)$0.X GTR2N#CR7PG\6?"7[(7[7]OH6J?'?6?%_A>[T.4^-9
MM<DDOK8ZDW^K$(C#[7)() SL7(+'H.O^%'P$\6^,_!WB[P5\#/CAX9U7X!:]
M=3Q7"SVCW.IZ-'<#=/;0\!<LKG[Q'7.%))( G@_]F#XT?$7X(Z9\([7QKX8U
M[]GS61:WNG^)[F!SK46E;UN([=(L;0XPH!.=O(!Q@#]%]-L(M*T^VLX-WDV\
M2PIN;)VJ !D]^!6/\/O ^F?#3P-H'A/1D=-*T6QAT^U$C;F\N- JECW)QD^Y
MKH: $) &3TKY>\3?\%&O@]X8^**>#);_ %&[C6_72[GQ%9V9DTFUNV.!"\X/
M4'J5! YR>#C4_:+\2ZA\4-9\3_ '0==N_ ?BW6?"W]L:5XA5E\NZ43-'-;+@
M;EP%7<RG<%D)'W>?A+PYIWQ"^,.@Z#^R3:>&_"/PEUCP:5U/6(=9=V7Q#/#(
M&C>%54LX<8DD8,=PY!"C;0![#\6K?P7\:/VQ?B3X'^/7B[4?">DZ5IMG)X)M
MAJITZR:)HBT]TKY"/,'Z;L\*PP=O%O\ 9(_9E\#_ +4GPH_MOXIZ2?'=SX?U
MR\T;0_%TD\UO<:UI4#A87F=&4S)]Y07R=J[<\5ZCX#^!OQ6^+/B8V7[2GA#X
M7^+O#NEQE].U&QM)'NVD)X10<!4XRP(&?EP#R1]9:1I%CH&F6VG:99V^GZ?:
MQB*"UM8ECBB0<!550  /04 ,T+0M.\,:-9:3I-E!INF64*V]M:6T82*&-1A5
M51P !5YF"C)JMJ>IVFBZ=<W^H74-E8VL;33W-PX2.)%&69F/   ))-?$_P 2
M?CKX7_;=M+KP9\$/BEJ?AGXD^&IQKNCN(I;6TU8PDJ5)9?WL63].A*LH- %S
MQWKWCW]JW]IGQQ\*?#'CS4/AEX+\ VUJ=6O=$PNI:G=W"%E5')!2)0"..I'.
M=PV^>WNG_%'P+\1V_9C^)GQ'UG6_!_Q'LID\+^/+4B/5+9XOFDM9B<[E9048
M$DX=<, Q"\1X*UOXA?%KXT7GCCX?3V'P^_:7T*V72_&W@#7\Q66OPQ[5%S%[
M8"9&>,(0V""_TU\*?@-\5?B3\;M$^+GQWET/3[[PQ!-;^&_"OAYFE@M))5VR
MW$TA)W.1P ">QXQR ?0OPF^%'AKX)_#_ $CP;X2L!IVAZ9%LAC+;G=B<O([?
MQ.S$L3ZGM784=*Y+XI?%7PM\%_!=_P"*_&.KP:+HED!YEQ-DEF/W411R[D\!
M5!)H ZJ6588V=C@*"Q^@KX!^'.B?%+]O?3/$'Q)@^,&N?"_PRFI7&G^&=!\-
M?+Y:0-M\Z[8,#(S'DIGZ8&!6C\0OBAKO[2NGZ=\:/V:_&&I7WB+P \EKJG@+
M48G@AU&!_G=&@;'[UE7Y3D[@N%*LO/EW[-=Y\2$O/$/C/]F"XT/4_#&MWC7'
MB'X8>+9S!/X<U-O]9Y9RO[LD':P(RH"E24X .W\!:'XH_:GOO$/[.GQZUS48
M_$7P]U&UU.[N]%<0P>*=,;_5B< #N8VR,'YAQN!-??NC:-8^'M(LM+TVUCLM
M/LH$MK:VA&U(HT4*J*.P  'X5X%^R[^SWXH\!^)O%_Q+^)NKV>M_%#QAY*7O
M]F*5L]/M8AB*UASR0,#+'KM'7!)^BJ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHK!\1VWB2>6 Z%J&F6<04^:M_923ECG@J5E3 Z]<UI
M3@IRY7)+S=_T3$W97M<V?M$1G\GS$\W&[9N&['KCTJ6OR5TKX4_'E/VIHYS8
MZXGBI=9\Z76W27['Y7FY,ADSL,!3^#/3Y<9K]3O#EMXB@>X_MR_TV\0X\D6%
MG) 5ZYW;I7SVZ8[]:^SXCX<HY"J+IXN%;VD>;W>GW7379MJ]GH>9@\9+%<W-
M3<;.VI=UC7M-T"*WEU.^MK".XN([2%KF4())I&VQQKGJS,0 .I-<I8?'3X<Z
MIXK;PS:>.?#MSXB6=K8Z5%J<+7/G*<-'Y>[=N!!!&,\5PG[7*%_"W@'"[L>/
MO#IX&?\ E_CKXFU/7HUT36=/3Q;X8U>_M/BE<WL/P\M]) U^]=-<,BK%=J[.
MA)&_<(A\@*E@I)KX@]0_275_BEX.T#0+_7-2\4:18Z/874EE=7UQ>QI#!<(V
MUXG<G <,""O7/&*N^#O&_A[X@Z)'K'AG6K#7]+D8HMYIMRD\18=1N4D9'<=:
M^%?#-WHWA;XL:7XI\;P(O@'3_B!XXADOKR+=96&JRWD7V.>?(*IF-;E$D;A6
M?J"PKT?P/XKU'4OCI\4?&?P3\,V/B_PM=V.E6-TRZB--T_4-51[DSW$,WENL
MC)"UO&[*N&. 3E* /J^YU_3;/6++2I[^VAU.\226VLWE42S)'M\QD7.6"[ER
M1TW#UK,T#XC>%/%.NZGHNC>(]*U75],.V^L;*\CEFMCG&)$4DKSQSWXKY_\
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M+%(./)\OHO6@#](**C@):%"3DE1R?I4E !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M01$#R>] 'JE%%% !1110 4444 %%%% !1110 4444 %%%>"_&[]JV#X6^/\
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M:C"JJC@  8 %6Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKC_ !WXXO\ PEI^ISV?A?5=
M9:ULY+E)+7RO*=E0L$YD#=N<*>O&:N,7-V1<(.I+ECN=%::'IUA>3W=M86MO
M=3_ZV>*%5>3_ 'F R?QJ]7YW_L__ +9_Q-\6?&72M-U<KXBTS6)6C;2K*TCC
M> ;&8-"W'W<<[V.1G)!K[]T'6)]9MI)9]*O=(97VB*^\O<PQ]X;'88_'M7=C
M<'6PDU&L[NW<]/,,!B,#-1KM-M=[^774AU;PAH^N:]H>M7UA%<ZIHDDTNG7+
MYW6S2QF*0K@X^9&*G.>#6)JGP;\$:WJ/B:^U#PUI]]/XFM8;+6?M$6]+^*($
M1"5#\K%0Q ;&X<<\#'C'[7^LZK;>./@]I%D?%EU8:IJ.I)>Z9X-OS9WMVL=B
M\B /YD?"L Q&X< ]>E>,^%/B?XUO?!&IVVC^)/$>@>&?%/Q"T_P?I\WB2]2[
MU_P^A1UOQ(S;O*=Y(@D2REF4RAOXE%><>2?6'@S]F3X7^ ;F_N-&\'6"7%]:
M-87$UZTEX[6S##P!IV<K&PX*#"GN*SC^R)\(6\.W.AMX+M&TVYN;>[E1KB<N
M9(%98,2&3>%C#ML0,%7)P!7SQ\5?B%-^S1=^.[?PSXC^(@OX_#&HR6MGXN@G
MU&PN[N%8F^VVEW.QPT2R$M&,H^1PNWG0\(W>KZ=#XP\+>+O'?C/X:QV^EZ9X
MBO;C7]9@U%VTT32K/+!>J0;:28H(Y(P"(R 8L[N #WP_LG_"EO#D>AMX3C?3
MXKQ[Z+=>W)FBF>/RG9)O-\Q0R?*RA@K#J#3/$/[)'PC\47UK>7W@RU$]KI\.
MEP-:7$]L(K2+/EPJL4B@(N3@8]Z^;K+4_'3Z?X8GUS4/B1;?!_4]<U2>QFL/
MM$OB 6GDP#3A<M&IN5A>7[4ZY&\ P"0X.*SX_&WBOQS\!_#'B*^\=^+V^(FJ
M6%YHGA'PIHDBVEY=:E;WMQ"+^["?+(H2. S&0"&,+)U+B@#Z_P#B;\)H?&GA
M30K#2[I='U+PYJ%GJFC7;JTRV\UN<!6&X%D>(R1-SG;(3G-:Z?"WPG'X<\0Z
M!_85HVC>(9[JYU6R="T=W)<DFX9P2?ODDG],5YS\:=>\16NC_"WP:^I-9ZUX
MLURTTW5=1TYVA*PQ6\EU=^2PY0R?9S&".0LA(Y KY*\<^/\ Q'!:_$R]CN_B
M;#XDE\=:IH'A[Q):Z^MOX>L)_M9CLXYUDE*)"C;5;?'AON@Y84 ?:]I^S-\,
MK'Q-IOB"'PC9C5M.^SM;S-)*RB2",1PRLA<H\J( JRN"X 'S<"H1^RU\*A?:
MK=_\(7IYEU,2+<*3(8P'E6:01INVQ;Y$5F\L+N(&<UYG<_M-^,]$;5=?NO#^
MD7?@+PWXCM_"6KW@O)$U&:Y,D-O-=PP["GE+/, (RV]E4L,< \3\3OVA/BGX
MG_9WUCQO8:)INA>'-:L3>:'=Z=K#)J=J4O(5A2=64*?/0MDQ$^7G#9SF@#Z=
M\6? [P+XYFUB;7/#=I?W&K-:/=SN765WMM_V=U=6#(\?F/M9"I&X\\USR_L[
M:!IVK>!+?1H+;1O"?A:^N-:71X(V9KO4G1DCN)968LQ02S,2V69V4D_+SX]X
MR_;"\8_#74-8\)^)?#>BCQG'JVGV%G/IL]W<V'DW=M/<>9(J0F<F);:12J(=
MQ*D;1G%W3?CUX@\467PT\;S6=WH<Z>,F\%ZQI@$\=GJ,%R"D=U"DR(^!(+>1
M"R!E!E4]\@'NOA3X.>'O#?PIB^'US;_VYX>^S2VL\&I@2BX25V=U8'MER .P
MQZ55\.?L_?#_ ,)Z7;V&E^'(;:"#5(M:5C/-)*UY$-L<KRLY=RJ@* S$  #&
M!78^)(]6G\/:C'H4]I:ZR]NZV<]]$TD$<Q!",Z*064'!(!!/3(KR+]D75?$.
MI_#K7X_%'B"X\3ZQ8>+-;T^34[E!&9A#>R1KA 2(UPO"#A1@#I0!ZQ;^$='M
M/%5[XEAL(DUR\M(;&XO1G?)!$SO&AYQA6ED(X_B-9&M?"/PAXAD\0OJ.@VUV
M_B'[)_:A?=_I7V8YM]V#_ 1D8Q[YKYF\+?M5_%_QI;^#WT[P;X0M_P#A,])U
M'5=*-SJUS_HL=BZ+*;@+#SYHD38$^[D[CQ3;[]M?QIKOPXUSQ[X4\&Z-)H/A
MK1-+U'5[;5=2DCN9)[RWCN&CM]D94K$DJ$L^-Y) QB@#UOXW_LW6OQ'B:YT-
M-#L=2N-2CU/44UG3I+N"_D2W\B-F:.6.6)T3&UXG7(!5@P8T[X2?LF^"_AM\
M++KP=>Z?:ZXNIP^5J\[0F".['GRSK&L08B.)'F?:BG@'DD\UX'\8/VC=2^&'
MQ(;XA7-[K=[X5A\5ZAHD.B6$C&*YBL=(E5LK]U5-XTQ>0\*( Q.%KL?%O[4_
MQ+T+P_XPUBQ\+^%=0M/!%I8-KI75IL7-Q=11SXLV$9#1Q131G>^/,.[:!QD
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MT#-#;MVDDR1D<C ]365\5OVA?&?QV^+VL_!KX&Z[9^&Y/#J&7Q=XZO461=-
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MKK_ WP9<>"_%OA2XT=;K0?%5W>7NK6D\C.)Y;IR\S DY7+<C;C:0",8KO:*
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M))PHYJSX,\"Z/X!LM0M-%MVMX+[4;K59U>1GW7%Q*TLK9)X!=B<#@=!7044
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ibio-20230630x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %< FX# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**\/\
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MRZ\5^+9Y_(O+R([9H;2W@&]UC;Y6E9E4L"%#;2:K^*/CQ\3OAU\-?%M_XO\
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M_BEX9UK4M1M;:TEL?$&J:0B6N[:T=K=R0HQW$_,50$]LGB@#T>BBB@ HHHH
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M)]J]5HH ^6O@7X3M9OVFO$>O7>F ZA9?#[PS:6EY- =T2O\ :S,B,1P3LCW
M<\#->6#P3:ZWJ^DZ'?:/]IT2']H&_N%L9+8F 1BSEF!V8V[/-.[^Z2?>OOBB
M@#Y#_:BTN0?$[QE/:VDC/>?!3Q-!-)#"3YK)+;F%"0.2/,DVCK\S8ZFN:\/>
M.?"'PH_:<L?$7CC3Y=.M?^%9Z#96OBBYLG>UTZ0R71DADE"D0M* ,,<#]T5)
M!(!^X:H6FLZ;JEU=V=M?6MU<VK;+B"*97>(GLZ@Y7\: /A#XAW%M\1;?XQ^/
M/!6FW2>!=8O/"=I%>K:211ZUJ,&K1FXO(8RH+(L311&7&'*<$A,UZ]J_AWQ%
MXA^)W[4FG>&WDLM=U/PKI5II5V<QJ+EK.]6,J_0$.R\@\9%?3X4*,#@4M 'P
MEXM^)_PP\5_LF)\(?#F@3CQZ^DQ:1IO@&/3I(M2TW5E4*DKC8/*\F8>:UR2%
MPA8,<C/L?[-?AA]+^-'Q[U*_@$FLSZSI-I/J)BVFY$6C6>2I(Y7S'E.!QEC7
MT1Y:[BV!N/&>].H ^>OBW;3/^U-\,YDAD>)/"OB16D5"54G['@$XP"<' [XK
MQM/ ]IX?_P""5=O9:?H_V:['AJWU0Q1VQ$QO?-28S$8W>;O ;/4$#TK[IHH
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M(\"N"0!GC% &Y\7?B5J?@+Q-\+M/T^&VEA\4>*!HMXUPK%DA-E=3[H\$8;=
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M7/!TEY;VVM:9H=G/!=:/'/*L*313O(PN5C>1-X*(6&67&-M<A\=OV?M:TWX
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M*>$+ZTFCU:]L%B#1:A;SE]DJR2'!54VHO#,&'/E5W\=_%7CK]FKXJ^)?%O\
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M=@T[0KS1?L'DY\SSYX)?,WYXV^1C&.=W48KO* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M\7^.W[6O@+X ZA::/K,U_K/BF]B\ZU\-Z#9O>7\T9) ?8O"J2I +$ X.,XH
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M[R0[]/CDVA5D;:%W%G55 Y8GY0:Y2_\ V(I+S2UB3Q>L&H'_ (2ZXDNUT_\
MUEWK8*"8CS,_N(V* 9^8=UIUW^Q"(_#FKP:9XJ2SUIM>T77-*O9M-$L-N=+L
MH;6V@FB+CSH\1,Q&5P7R.5R0#T/3/VHO"7BSQ5\.=+\)SQ^)[/QE-J42:A:2
MA5LOL4(DE\U& 8-ED3:0""P)KV2OG/X2_LE3^ /BC8^/M8\5_P#"0:ZW]K7F
MHE+ 6T4]]?-:AI8D#GRT2*U2,+\Q.2Q;.:^C* "BBB@ HHHH **** "BBB@
MHHHH XOQWXYUWPI>VL&D^ ]:\6QRQEWGTR>TC2(YQM;SIHSGOP"/>N5^%7QZ
MU/XKV^B:C9_#;Q)IF@:JAEBU>^GL?*1,'#,B7#/R1C 4GD5VOQ)^)_A3X0^%
M;CQ)XRURS\/Z+ 0CW=[)M4L>BJ.K,>R@$GTKQ;]@WXP^"_B1\!O#>E>&_$-E
MJFJ:+9)#J%E$^)[9BS8WH0& /8XP?6@#Z2HHHH **** "BBB@ HHHH ****
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M.X#R.)4A4,&D(,AR!G+8&3WQS4PT^U6]-X+>(79C$1G$8\PH#D+NQG&><=*
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\@_:Z\!>)/B?\
MLV_$#POX1E,7B'4M-:*U E\OS<,K/%N[;T5DYX^;GBO7Z\*_;DOKW3?V2_B?
M=:=K_P#PC-Y%I#M'J/F-&5^=<QJR\AI!F,$=W% 'Y]?"OX7^-/%WQ1TK0?#O
MP,UKX96MKXUTCQ#%JE\SPVVC6]M:QPW:(Y \YIFC9NISN'<FOUY'2OR0^!=Y
M^R_?>,/ $MDGQ=7Q*^H6+6XOI9'MQ=&1-OF%1M*;\9(XQFOUO% "T444 %%%
M% !7F_QN\'?$#QEH>GV_P]\>0^ M1ANO,N;R;2TOQ/%M(\O:Q 7YB#GVQ7I%
M(W3\10!\F_\ !,NWNK7]G*^AO;H7MVGBK65EN FP2.+DAFV]LD$X[9KZSKY6
M_P""<'_)!-7_ .QOUS_TK:OJF@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N5^)WBV]\"^"]0UVRL[&\^PIYTXU'4%L8(
MX1S)(TK*P4*!GI74.ZQJ69@JCJ2<5\@?MJ>.;?XZ? KQQ\.OA\TFN:C=QQP7
M.LPSQV^E6CI-&YAENY&6-G?84\M"S9(W!1DT <!X(_X*QZ#X\\;7'AFST#2=
M/G0D0W^J^(1:V=R0"3LE>  =.-VW/;-?1]OXT\=_'&")/"%O+X&\)RH/-\4Z
MC;[KRZ&,G[!;.!A3VGF &#E8W'-?A'\'/@-XM\=?&&Q\,PQ+HMU9WL9O[Z^F
M2&*P17!:1W8@< $@#)8X SFOZ28'62%'1Q(C*"'!SN&.#0!RGP\^%7AWX8V5
MQ%HMHYO+MA)?:I>2M<7M])_?GG;+.?0$X'10!Q6WJ_A;1M?DCDU/2;'49(P5
M1KNV24J#U + XK4HH Q++P1X=TV\CN[30=,M;J,Y2>&SB1U.,9#!<CBMNBB@
M HHHH Y[Q+X@U?1[B&/3O#EQK4;H6:2&Y@B"'/0B1U)_"L3P3\1M4\:1:==Q
M^$[VRTN]7>MY/=6Y"+S@E%<MU&.G>M+QC\//#WB^:&\UI+HM;1E%>'4;BU55
MSDY$<B@_4UY?^R[\//#K?##P;XBA^US:HEKN,IU6YDCW$L#F,R%.AZ8KKC@Z
M4Z+Q+KR7*TG'EC:[NUK>]O==]+ZZ'ES5?ZS%*?NN[MITM_=OU?7YHZWQC9?%
MZ;Q%=/X7U?P?:Z(=OD1:II]U+<#Y1NW,DJJ?FSC Z5P_C_6OCUX"\">(_$TN
MK^ +N+1M-N=1>W72[U3*(8FD*@^=QG;C/O7T+7G?[1G_ ";[\3O^Q8U/_P!)
M9*Y#U#L/"VK2:]X:TG4I46.2\M(;AD7HI=%8@?G6I7D&H_'#P9\%OAIX*F\6
M:W;:6U_9V,%M!)(HDEW^1$75202B&5"[=%7)/ KU'0]<T_Q+H]GJNE7D&HZ;
M>1+/;W=M('CFC895E8<$$=Q0!>HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O%?VSO#EOXN_9?^(>CW
M6HZ/H\-YIWE'4-?E:*SMSYB8DD=>1@X(//S;>HKVJO/OCY<Q6WPB\2O+X+;X
MBJ+8$^%T0.VH?O%^0*00<?>Z'[M 'PO\(_VA_BN?%G@[0;OX]?!#6M/-]:6<
MMO92L;VZBWJI2,!57S&7@8 &2*_2@5^8$W@[6OB5\1?AJG@W]DMOA3J.D^)[
M+4[CQ)>01Q0Q6L;YF1U" ,"IXSD@@;><5^GXZ4 <S\1?B;X6^$OAJ7Q!XOUR
MR\/Z1&ZQ&ZO90BEV^ZB]V8\X R>*PM$_:%^''B+X<7_CW3_&6D7'A&PW"[U4
M7*B&W9<95R?NMR/E//(]:\]_;5\4_"GX>?#K2O&?Q1T=/$']@ZDEWH.F%F+W
M.HX/EJJ9VMP"3O!4 $GW^%OB#X#N=#_9>U;Q?XANM$BN_&_Q-TG6O$>@Z'.D
MMGH]FS2;+>382N>06]\#J#0!^EGA/]H/X=>./ FI^,]%\8:5>^&=+W_;M26X
M"Q6NT9/F$XV<$'G'44> OV@_AU\3?"^K>(O#7C#2M4T;2-QU"[CN %M %W$R
M[L%!M!.3Q@5^7W[2HB74?VQ1X6$:^"_[3\)?;1IP M=VY?-QL^7[V=V._6M/
M]IX6J^+/VK_^$ 6V7P^?!7A[[8-("B#=]HM_[GRY\K?GVW9[T ?IG\*OCQX
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M_O"MU\5[\^+?"/B:'P7J4D45M!I_C+49;C3@H*EAF51+O)!89&,<>E '[;Y
M&:\T\9?';2-#UJ3PWX>LKKQKXQ !_L310KM!GHUQ*2([=.G,C#/8'I7.67@W
MX@?%6TA3Q+?S?#[PF$")H&C7?FZI<Q@8 N;T$B+( RL.6Y_UM>H^#/ GA_X>
M:)'I'AO2+71]/0EO)M8]N]CU=SU=SW9B2>YH \U3X0>)OBBXNOBEK*_V6QW+
MX-\/S/%8 =ENI_EDNCZK\D9QRK=:],G\#>'+KP[#H$V@:7+H4 41:9)91M;1
MA3E0L17:,'I@<5N44 <8WP7^'SJ%;P-X:91T4Z/;X_\ 0*["*)((DCB18XT
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M;9:WN?F=;"U*N?QQ$YM/FCHM;)+:_9WU^>^Y^JE>=_M&?\F^_$[_ +%C4_\
MTEDKT2O._P!HS_DWWXG?]BQJ?_I+)7PQ^IG,^)_V?_!_[07PF\%Z5XRM)[VP
MLK&&>*&&;R_WC6GEAR0,Y3?O7L&520<8KU[2-,AT72K/3[<L8+6%(4+XW$*
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M?FR$QD\=!7Z/ 8% '#?%+X'^!?C7:Z?;>./#5EXD@L'>2VCO0Q$3, &(P1U
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M_F<[O]6I7;TQWZUP/CKP?\>/'?@GQ!X:N;KX?VUMK.GW&G2S1F^+1K+&T98
MKR0&S7T'17B'69GAC26T'PYI6FO()7L[2*W+J,!BB!<_I6G110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[XU:GXSO;W0_A7IT7B&[MF:*]\170;^R;!A]Y=R\W,H_YY1=^&9*_*+XD?\
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MI39-M$K@R^;( 1&"FX<D$Y %?F!X+\6>=XSTZ.PU?4--NGNX4LKPS+%Y4A8
M,6Q\O)')X'>M*&3X_-XU,1E\)3A15Y\JD]-N5<NCEKS-;V1\#G>;SPV*IPH1
M<DM96;\U96Z]?N/VXAWK"GG,K2A1O9!@$XY('850U7Q/I&AQ>9J&IVEE'_>G
MF5!^IKP]M:T75W%GIVK>+_B=?Q@12+I4_DV@8#'SS1B.(<]07)]JOZ3\'-?U
M9UFEM=!\#V[$-MT^W&I:C]#<S#:A^BO]:V^H8R*O74:2_OM\W_@"3E\]O,^I
M^LUYZ4H+[[_EI_Y,=9KO[07@K0K26Y?4VNH8^LMK \D?_?8&W]:\.^/OQ?\
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M_P#;VZ[JQ=KQW]HK7_#7@O1[37?$?B+7])52;>VL]#N_*>Z<_,1MQR0!U)
MKJ+CXM:;>3O:^';2\\57:G:1I<>Z%#_M3,1&O_?6?:O"/VJ/@W\1/C!X>TO5
MX["Q%SI3R&/1+.=I9F20+N8N0JLP*+\JCH3R>E?D>)S*OA*,ZV7KFJ):65UY
M^6W0_3LCR3#8K,:-'.I^RHR>MVHRVTT>J3=ES-62ZF7^R_\ $3P"=)LHI?%W
MB'2]0T6)I'T[5-0Q:S*68?(N,/\ >'RYSG'%?0__  GFN^)1M\+>')G@;@:I
MK6;2WQV94(,C_@H!]:^4OV+O@)XCA\=6?CC5[$Z?H]G#*+7SP-]S(X*95>H"
M_,<GOC%?=6*Y\!CLRS?#QKYA-\VU[:M=VWWUZ7>]SU^+<#D>19K4P^5152.[
M3E>,9.]XI1M>VC^*RO9K0X,?#6\U]O,\6:_=ZNIY.GV1-G9CV*J=[C_>?!]*
MZ_1]"T[P_9+9Z98V^GVJ](;:(1K]<"KU%>K"C"F[Q6O?=_>]3X2OC:^(CR3E
M[O9:1_\  59?@87B'QSX?\*7$,&L:O::=-*I>-+B4(64'&1GWK@_@3X\\/3>
M _#&C)K%FVJFVV?8_-'F[@6)&WKG%>JR6\4Q!DC1R.FY0:1+2&-@RQ1JP[A0
M#64J=5UE44E975K=[=;^78Z:>)PT<)+#RA+FDT[\RM=*26G+M[VNO0EHHHKK
M/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O _V\Y)8OV/\ XJ-%IMOJS?V,X-M=$[ N]=TG
M!'S(,NO/WD%>^5YO^T9X8OO&7P4\5Z-IGAFP\97UW;*D6AZG.8+>[/F(=KN"
M"H !.<CE10!\>_!2^^+,EWX(\[]K7P3KVE-+9F32TC@>XNXB4W0!BH8NRY7/
M7)]:_0FORDLOA9K_ ,'/B3\.;_Q9^S/X#\*Z=J'B:QL(M;@UN:;[).\H,;<3
M, V5^7<,%@!WK]6Q0!6U2P35=-N[*1F2.XB>%F7J RD$C\Z\$@_8H\%_\,OV
M?P0NKW4[G0K)S/::GYBI>6\_GM,DJL!@,K,1TZ<5]"T4 ?-&B_L'>"H_AM\0
MO#'B35]9\7:AX[EAGUKQ#J,JB]D>''V<H5&%\LC(&#WSQQ3O!W["?@[2/"WQ
M TSQ/K6M^.M1\<6D-AJNLZQ,OVG[/"H$"1[1A=A"L#SDJ,]*^E:* /!OV>_V
M2-%^ WB75/$K^)-:\8^);VQ@TE=3UR16>WL8<>7 @4# X7)/)VCWS[NW3\:=
M2-T_$4 ?*_\ P3A_Y()J_P#V-^N?^E;5]4U\K?\ !.#_ )()J_\ V-^N?^E;
M5]4T %%%% !1110 4444 %%->18URS!1ZFH;W4+73;*6[NKB.VM84,DDTKA4
M10,DDG@"@"Q7#_$;XO:#\-Q:VUVT^I:Y>G;8:%ID?GWUXP[1Q#G [N<*O4D"
MN,F^)_B;XQ2R6/POA2QT#)CG\<ZG"6MB,X/V&$X-RW7$AQ$,?>;[M=I\.OA#
MH7PW^U7=J+C4]?O@/[0U_5)//OKPCD!Y,?*@[1H%1>RB@#\+OC%^PA\<]#^*
M-_:_\*^UK5/[4NWN;>ZLD^UQL)&+X>5,J'&[#9/4'M@U^RW[%/P9UKX _LT^
M#?!7B&X$^M64,LUTBOO2!YIGE,2GH0F_''&0<5%\0?VU?A3\-O&4OAG5M>9M
M1MW\NZ-K \L=LW<.RC&1W SCO7L.G^*]'U30[76;74K6;2[J)9X;M91Y;HPR
M&!Z8KHJX>OAX1JUJ;C&6L6TTFNZ;T:]#EIXJA5E*,)IM;ZFM17G'B']H?X>^
M&G:.Z\3V4LR]8K5_.;/IA<UQDO[5^GZM+Y/AGP]J6M2DX!6)B#]!&KM^E8TH
MSKJ]"$I_X8N7Y)F,LPPL7;G3?EK^5SW6Y=H[>1ESN"DC"[CG'IW^E?$'BW]O
M9/#'BN#2$U:2ZB61H[N=O#SPO"PXPL;3Y8@CGI[9KV67QU\6O$L;FR\,W&DP
M#YB\D$<&T>[SR _^0C7Y'>,K"^TWQ;K-KJ9#7\5Y*L[;PX9MYR0PX8'J"."*
M_1N#^#*7%.(JT<=4=)0C=<LX\[N_Y4VU%?:YDGJDK7;7R^<X^LU#V'-!:ZZJ
M^VVOWW5^Q^P_@'X]IXP\)1WFC0W?BB[9W!N6T]M,MH@.GF/*Q &,]"2?2L>]
M\<VWBF[>VU#6;[Q=<*?F\/>"(I&MU_V9KD8S[Y:,>U<C^QK\&='US]GSPA>>
M*EN-<N#'+(FG7MX\MI;J979%\@$)NVE20P8Y/X5],FZT3PIIRQ>99:38PC"Q
M@I#&@]AP!7Q6,P.7X"O4H5:CK<DFM'RPT=KW]Z4T_.Q[>#PV(QM&FZKO=+17
M:^[=_-R]#YT^.'@GQ;XV^"&O^&DT_P -?#3P[=1+&(;J?S)G82*Z*QB CC+,
MJ@G<_4U^<O@GX"^(/$WCS^P+R2RT6*VE3[;J%[<)]GA3KN!!._(!P%SFOT\_
M:.^+&A7WPA\3P:%?3:IJ4=N'BDTQIML+!Q^\:6+ 4*"6Y.#C!K\]O#NO:S8^
M)XKZWU/5;J\N9XEG7^T)PUX P 1RK9.<X]1GBO7RWQ3CPG0J9?0M%5%>*C3Y
ME"6BO=U8MZ+9WLTM;71^HY1X68KB7#O%N/+[-VM*?(VK7LE[.5EKO>VZMU/U
M[T:&&#2;..!85A6% @@7;'C ^Z.P]*MLX49) 'J:X"V\/>.[^UBBN/$&G:'"
MB@+%I]HUQ*H Q@RRL,GWVU./A)8WK%M9UG6]=+?>2YOVBC/_  "'8/SKXOVM
M67PP?JVE_F_P/ ^J8:E_%KKTBG)_BHQ?R9NZUXY\/^'1_P 3+6;*R.,A9IU4
MGZ#->3_''XV/'\)O$MSX,CU2YU%+4[-1M[&40VZE@'D\QE"\*6((SSBO5M%\
M ^&_#I#:;H=A9R#_ ):QVZ^8?JY&3^=6O$MW/9Z1,]OI,FMNV$:RC:,%U/#9
MWD+C'49K"O"O4I2BY*-T]DVUZ/3\CNP-? 8;%TJBI.IRR3]Z48Q=G>S5GH_.
M5NY^3W@+QAXFT'QSINI:#J-X-;END56$C2-.S,!M<$_.#GD&OT]MOA-IMY*M
MSXCN[SQ5= AL:G)FW4_[,"XC_,$^]>5^"OAC;>"_'NL>([+X1R0O*T3:>([B
MV)M2$Q(5!EPI+<C'Z5]%0LSQ(S(8V*@E"02I].*^>R'+)86G-8A\UWHFG;KK
MKU9^A\><40S2O0G@(JG:-G)2@Y.Z3Y;P;:4=5O9MOL-M[:&S@2&")(88QM2.
M-0JJ/0 <"L+Q/JWB'3KB!=&T&/5XF4F1WO%@*'/ P1S7145]?*/-&R=O3_@G
MY!2J*$^><5+R=[?@T_Q/,?A7;^,/"^BZ-H.I^'+>&UMU9);V/4$? )9LA,9/
M4"O3J**SHTO8P4$VTN]OT2-\9BOKM:5=P47*[=KZMN[>K?\ D%%%%;G"%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\>_M2_M#V.C_ !IF^#/BGQ=;?#GPCKO@
M\ZH/%D5T;>]MKL7>Q4C<D*,K&WOUYK["KYO^)7[(NG?%K]J?3/B)XJL=&U_P
ME:>%6T7^Q]0B,DGVK[0TJS 8VX"L1G.>3Q0!\T>!?AG^S[KGQ'\(RZS^U%J_
MQ'EL=5M[K3M U/7UEAGO%<>3\N3D[\<#!/3/-?I,.*\CTG]D?X-:#JMGJ6G_
M  V\.6=_9S)<6]Q%9*'BD1@RLI[$$ CZ5Z[0 4444 %%%% !7G'QL^/GA'X
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M,<MH*T(RE_X##\$I_F<++X[UG5X98M,\$:Q*'!4RWQCLDP?]]M_Y+7Y4>/\
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M;W:C?E3?=*YZ5;/,=B,+]5JR33LG+ECSM)W47.W,XIV:3=M%V1[A@4M>'?\
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M ()K?_XBN]HH X+_ (4%\,_^B>>%O_!-;_\ Q%'_  H+X9_]$\\+?^":W_\
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M^B>>%O\ P36__P 11_PH+X9_]$\\+?\ @FM__B*[P$$9'(I: ."_X4%\,_\
MHGGA;_P36_\ \11_PH+X9_\ 1//"W_@FM_\ XBN]HH X(_ +X9D'_BWGA7_P
M36__ ,17EWPX_8S\*>$/B[\4/%.I^'_#&JZ-XHGL9=,TMM)C(TY88#'( &7:
M-[?-\OXU]'44 <%_PH+X9_\ 1//"W_@FM_\ XBC_ (4%\,_^B>>%O_!-;_\
MQ%=[10!P7_"@OAG_ -$\\+?^":W_ /B*/^%!?#/_ *)YX6_\$UO_ /$5WM%
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M'WC'XC>"_#E^FMZ]XILH18WL_AN&W(@O(Y_M$*HURDI,LD6&94+@'E@1G82
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M$MC\;EL;6[$GC>US,ME+>S21K<BV5&E",QC^T?9]NX_?V$L>I)ZJ_P#@_P"
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M;#!E>25Y7;&20-SMC))QC))YKMZ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /+_VC/V@=!_9I^'$GC/Q':7U[IR7<-GY6GH'E+R$A>"0,<>M>9_#S]OS
MP-XT^(.C>#=7T+Q-X&UC6CLTP>)M.-M'=OV1'R1N/09ZG ZFN-_X*T.(_P!D
MN5F(55\0::23V'F-7F?[;'Q5\'_'W4?@-X+^'&O6'BWQHOC"QOE;29A.UG B
MD2.[KG8,[6.3_P LR>U 'Z)R7]M#*(I+B))3T1G 8_A3TN(I"X616*<. <[?
MK7XS?M:^,=)\7:O\;O%WAQKZTU?0/$*V*:UK?BIX;Z&>.54,6GV,8'[K 8@L
M>%!/4&O1?CC\5_%'[,7C/Q=?6UU?WEO\9O -I-HYBD>18M;*10RE!GY21-))
MQW=: /U/?4K2.-9'N851_NLS@ _0U85@ZAE(*D9!'>OR4^.OP=U+P%XC\ >$
M/[>TKQE<>'_!,8OO!NO>()]+D%TS-)<7L,Q=5=R[G&68@)C:0*^Y?V!?'UE\
M1?V7?"6I:?!K-O;P^?9A==N_M=QF.5@<3;1YB=E..@QVH ^AZ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\9^#_P#A,--FM?[6
MU'2C)!+#YEA*$/SKC<<@Y(ZCI715B^*-=O="L)I[/1[G5I$ADD"6[(.5&0OS
M$'GIQFKC7EAG[6+LUY7_  +A1>(DJ2Z]W;\78^5?V6?V&];^!WBW7M7U?Q<9
M(KJW^QV\>C,T;2+O#>9+N7&>. ,\D\^OUU-:M_9KVR,TC>48PTAY)VXR37S#
M^S7^TQXV^*7BC7=/UKPZ+FWMX?M$;:?'Y9MVW@>4Y=@#P3CH?E/%?3UU.ZZ;
M+,%,4@B+[3C*G;G'X5UXOB;$<5U/[0Q$N:3T^'EVTZ'I9EPW6X7KO 5TE)6>
MDN;=7]?P/AS3?V4/B1IT.EZ<EJJR+:^&P+Y-;"V-O-81PB4S6N#]H :+('\7
MR\C&:](^'OPH^(WP7OI-7TK0-+\3W&IV$MA<VDNH+ ]HR:E?7,#B1E(:)TO!
MO4?,&3@-GCQK0OC_ /$F:RTWQ#<>(-3EM;&T\)SWDJRV8M5CNHX&O#);E1-*
M7#L1Y70D8Z&O2/AW\0O$OQ0OY-,\0?$:[\'V^FZ3<ZC!=6JV\<E[)_:E_ 9'
M:1"ICMX[:%2B@9+Y8\BN$\H]#\)?LYZOX<^#DO@S4]>M_$=DOATZ?!H]Q91B
MTAO-A(E1VRVT2'Y0P^4 =Q7*6?[/OC2RU+2],^S6,NE7[>%KO4-3^U 26,FE
M+'YL2IC+^885"D<#S')QCG9\/_&KQ=X]_9SDO;%)M"\;CPQ_:KZQ=Z3*; X0
MGS(B<*S,H#JF[C<,Y -<=8_&7QC>:QHM^_B22*6S/A&U31/*CVZHFI*GVN9_
MEW%AO<J4("^0V0<F@#V7P!X2U+X3:SXBM[#P_"^E>(_%YN88].VQQV-FVGPJ
M9F4  ?O;<J0/^>@/>KOBOX>71^,6@^.-'TNRDFL]%U2TO'RL4US+)]E-LC/C
M)4>3(,GA<^]4_@1XF\1W]S\0+'QAK-MJ>H:=XJDT^U>WA$$21&SMIEAC4DD[
M?,?DDD\GCH%UO7?%6F_M)^%]+?5K?_A$M3T/4IH],B@Q)Y\#6G[V20GG_7,%
M50,<DDY& #C?#WP@\8I\3[*XO;"SMM!B\5S^,WU%;L-+YDVG-;&SV 9)621O
MG^Z41>YP.0\8_LE:SXH\2>(=6GMX+B?4;OQ%/O?495W+/!&NG @-@".1"P'\
M!^8<FNB\8_M)^.-.\:ZQI&C>'-$FL;?5=0TBVGO=0E21I+33DOWD=5C("LK-
M& "3NP3Q7,W'[:.N:MIL-[9:+IME9:U#J%IIL+WI;48KN&U5HB\.W&V2:1%7
M!^Z5/\0% 'GGAKX<>+/$?Q2L?"IL);O48SJEMXJ\227,P>YM9[FVXD1P%R(1
M)''C(8#*\$UN>)_@?XL^&-KJ.L:X8]<\.WVOC49K!KF0)!;'4;J06!V#"V[K
M<17!<C_61E7)4KCH/!7[3_BO0'U_PIJ$$>JZQI>NG1+?5=:E^SI=M+J3VB3C
M8F#;PB,J[CGS&10.<UZG:_'?Q)J?[._B'QS8^&H=3U_3)=5MEL=+NEF@9[2:
M:(2AVV;T)A#$#YL' !- &K^R3IVHZ7^S]X6AU2QGTVZ8WDXM+AW=XHI+R:2)
M=S_,0(V3&[G&*]?KQGQ9\;-9\,_!_P />)+K0X])U_6+JUL8],U&0N5DESRH
M@$C.=JLP1><=<8./+O#'[87BSQAIEIJ=GX8TNVT]?[+M;MIKV0RBYOI[BV4Q
MIY>"B20JQW$$JY&,B@#ZWI*^3?A-^T;X@UCX<ZG<:[]MOM>DT/3YX[W3+5KB
MTAGETI;@R-MCQ"NYLG>2-P;!P*X31_&7Q:?PAX&U6]\0^)M%\.>(3H-K?ZGK
M)L//:XNKB'S'M/+4[(S$TF?,7C*8YS0!]W45\A>)?B1X^T/P3\2K;0O&::K:
M>$_$.G0Q>(+NVCEN)[:9;=IK4% L9D1I=IDV\*X&-PS7T?\ $S7(]-^'WB:\
MC\2VOA<V5J[3:U.BRKIX #&1E) R%.0#W(Z]* .NHKYBTWQUXU'[./C+5;7Q
M!Y6J75U(/"][K\UO;W<=F[01QR7!P$5]TCLH900'C##.16AX9^,NNZ!\%=6O
MUAGU[Q/IGBB+PU(NKWL3123S7<$(99X8PK1J+A3D)G*LI&10!]&T5\I_\-8>
M,=,>WM=5\-:+'<ZC=76E6,\.H2&".YMM6BTV6:<F,%(2TPD!&2 N",D5R_C#
M]J?QA>6=IKEA;,3X8UD6&KZ5X<87G]J.VJM:QQ1%E!)>*UG8#@CS!Z4 ?:E%
M?,7A7]JS6_$7B7PU -.T"72=2UFQT.62UU)WF,MQ8?;?/A4Q@/"H*QY)!)5S
M@ 5].*<@'UH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTC$4%I:1"**)1V51P!5^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)_\ AFCP<OQ,T_QG'#+#<Z?,+FUT^%(DMH9A&Z!EPF\#$CMLW;=S%L9KU<#
&Q2T4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ibio-20230630x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &X VX# 2(  A$! Q$!_\0
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M':0IN&YCY@V@?D:\+^'O[(OQ/EU7P[X=UK]F3X3:=;64D<6J>*KVX:9+R%<
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M"E8X(\+M'MMS^%=Y^WU='X:?M(_L_?$^[0KHFGZDVG7EQCY8O,;()/;K7?\
MQ#^ OBOXI?MK>!/'DUA;W/PWT/1I42]^UQGS)I1G CSN(.>N,<T ?(O[6/[2
M.I?'']C7X2^$M 26]\1>(H3)J=M$<,%M%P^[\1DYKL/%_P"T7XK'[!OP2T#P
M=J;Z-K_C*:+P]-JL;$/;(IVOM8<J2"!D<UT_[-G_  3R\2_#?]HOX@>(/$5O
M"WA 6U[;^&R;M9=WVG()\L',> >X%3>$_P!@?QMXH_9-N_AUXB>+PKXKT#Q!
M/JWA?45N4G107W)N,9)4' ]QZ4 =*O\ P2'^$A\%1VXU/Q#!XU$8D/BI-08R
M_:>ID\O[N-W;@_[6>:\6_P""CW@?3/A]H_[/OAKQSK6N^-M)T^>2#4M0.#J%
MW&%&[;C'S>G)/J37JL7C+]O)O#:>"U\ >%;?4UC%K_PFQOXB-HX\W9YI&['.
M=G_ <U:_:A_9Y^/OB[3_ ((ZQHT6D>/?''@Z5KK4KN26.QMIIL#!VLZD@]R"
M,^@H YW_ ();7.E>-_"'Q7\*IJLVI>!6OVAT[PQKMP)KZUM74J3(G15;VXS[
MUU/_  3B>Z^&_P 1OC7\&VE>32O#&L&YTY'/^JBD)^4>U;G[)G[/?Q-\+_&;
MQY\:OC"N@^'=8UJU$ T?0G!@BC7YFDD8$CH/[S'N37._\$^+A_B1^T!^T!\4
M+="VBZKJHL;.<CB78Q)*^HH ^]:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!#R*_./XL^,M8_8Z_;I\7?%#7/ _B'Q+X+\6Z/%;VU[H-L)O+G14
M&QLD '*$8)!P00#7Z.TA&: /R7\/?"GQQ<?L(?'_ ,3ZEX4U/3;SQQK4>J:;
MHSVSM=F'SHOF,8&[UQQT&>E>F?M*> M5G^ G[)UGIWAZ^FFTS6=):XM[:R=F
MM4"P[RZA<H..<XZ<U^CF.*,4 ?FU'XTUO]A7]JCXL^)/%?PZ\0^+/#7CR=;_
M $O7O#UH+ET.6;[.Q) 7E\$$@_*#@@BO(_%7PX\6:?\ L=?M&?$SQ)X9E\$V
MWCS6[2_T[P]<(8Y;> 7.X.R$ KGS, $ D+G&"*_8$C->=_'_ ."&C_M$?"W5
MO NNWM[I^F:D8S+<:<R+,NQPXP75AU'<4 ?FU\2OCIK_ .T7^S)X0_9^\-_!
M;Q/9^-;B*P@DDNM/V:=:1Q!<7$4G9&'.X@ *QY/?VO3?AQK_ (5_X*$_#V.6
MRO[W3]+^':Z=-JJV\AMVE16!!DQMR2,XSGFON?PAX9M_!OA;2-"M))9K73;6
M.TBDF(+LJ*%!;  S@=A6N>.: /Q<'PS\47/[&FEZ7-X4UE[EOBP9Y+-M-F\S
MR#& 7*;<[.V[&*^O/VD/!-]JO[>?[-FHP:%=7>FV5K<"YNXK1WA@VK*4#N!M
M7!((R1R:Q=3_ ."K%QHVN^*#/\%?$-[X2\-ZJ^F:GXBTR]\^*W(<J&<>4%4D
M<A6<=1S7VOHGQ0\+:]X8T[Q!!K=E#IE]9PW\,MS<)%^YE ,;,&(QG(Z]Z /S
MZ^)W@G79/VI_VL;RWT#4GL]1^'LD-K<164ACN93! -D;!<.V0>!D\&O-/B7\
M0/%VB?L3_!GX,V'AGQ;"NK6D=QXJN-+T>>2>VL!<-B!1M \Q\%BI(X50>&K]
M9M8\4Z+X?2!]4U:QTY+@[8FN[I(A(?1=Q&?PJS>:I9:?9B[NKN&WMN/WTLH1
M.>GS$XYH _+[]I/PRW[07[/?PSU[X8?#_P <Z-X7^&6K?8KOPZUG]@U<VHCA
M/VFU7Y\LNW[X!(8DXX)J+]G;X>>"/C7^T%X,O--M_P!H/6AX:G354UWQM>PF
MRL)XV#^2X="2KE IV,&/]W&2/T^MO$^CWFJ3:9!JME/J,"[Y;2.Y1IHU]60'
M('/4BLV_\;6<_AG7=2\.2VOB>\TVVFD6RL;R-C),B%EA+ D(S$ <],T ?G1\
M'?B9KW[!'Q+^+'@SQ=\+/%/BN;Q-K<NJZ%J_AVQ^T+JBN2(XF<]N<\;BI9P5
M]?4O^"3FA:[HWPW^)+Z]X:O/"EU=^+9[E=.N[1[<1JT,?RH& RJG*Y''%?0?
M[.WQSUCXE_!FU\:?$+P[#\.+Q[F:&2TO;P",*K[4?<^-N[T;G(/8BJG[1WQW
M\5?"C3O ]YX'\$?\+"AU[5XK*YDMKP(MO"V,2*1D'=DX;[HV\GD4 >$_ME^
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MK>)]9DT>/0TU0!XF5IE#>9Y1W9,73:/O>U>B_LT_MGV/[0&J>+O#>I^#=9\
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MU?JK9?M*_!Z;X,IXQA\7:#%X+6P# &XC'EQA,>08<[@X'R^7C.>,5O\ PO\
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M+^T!%O=2VZ-+#GKL<C*Y]C6C10!GZ7X?TO0Y+J33M.M+![N3S;AK6!(S,_\
M><J!N//4\T7WA[2]4O[.^O--M+N]LV+6UQ/ CR0$]2C$94\=L5H44 9^I^'M
M+UJ>TGU#3;.^FM'\VWDN;=)&A?\ O(6!*GW%-U[PWI/BK3WL-:TNRU>Q<@M:
MW]ND\3'W5P0:TJ* ,O2_"VC:'H_]DZ;I-CI^EX(^PVMLD4&#U&Q0%Y^E1_\
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M -^7_P#B: -.BLS_ (2*P_YZO_WY?_XFC_A(K#_GJ_\ WY?_ .)H TZ*S/\
MA(K#_GJ__?E__B:/^$BL/^>K_P#?E_\ XF@#3HK,_P"$BL/^>K_]^7_^)H_X
M2*P_YZO_ -^7_P#B: -.BLS_ (2*P_YZO_WY?_XFC_A(K#_GJ_\ WY?_ .)H
M TZ*S/\ A(K#_GJ__?E__B:/^$BL/^>K_P#?E_\ XF@#3HK,_P"$BL/^>K_]
M^7_^)H_X2*P_YZO_ -^7_P#B: -.BLS_ (2*P_YZO_WY?_XFC_A(K#_GJ_\
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MY#=L.WD2?S6K]9\W_(<M?^N$G\UH OXHQ2T4 )BC%+10 F*,4M% "8HQ2T4
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M266,9P')Y(Z"L#E/4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPG_V#(/_ $ 4 3ZS\7/!?AW4Y].U/Q3I5C?P$"6WGND5T) (!&>."#^-4O\
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M<UU;WK\N[]3YM_:Z\;>)/"DL::+K%YI-NVB7<TCV]PUN@=9(@':4*Q0@%OF
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M)Z)\5-'\'7NO3HG_  F=Y-L_LE;4>8+F"0G:3.1Y9/S$9ZXS7Z9#I0 M%%%
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M$!+L*YW"8DY Q7TO7->&?B/X:\9ZSK.E:'J]MJE]H[1I?I;-N$#2*612W3)
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M]G-Q/.A+F0V3[C?0U3T3_D%V_P!#_,U<D^XWT-4]$_Y!=O\ 0_S-8EF%X_\
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M@_\ KW#_ -)1]4?\$^O^1]\5_P#8-C_]&U]0?&W_ )!FA?\ 84B_]!>OE_\
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MO//L0HHHH ^3/B]^P[>?$_XC:SXGB\91:<FH2*XM6TXR&/"A<;O,&>GI6Q\
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M3S-PQY(S$.H/>L1GU11110 4444 %%%% !1110 4444 %%%% !1110 4444
M%)BEHH 3%?/O[2G[0WBOX/>+/ FE:%X/;4-+UK6K+3M0U^^8+:VZSR,HBC4,
M&>4A2<XVJ ,YSQ]!UYU\:O@Y;_&;3O#-I<:G-I8T37K374>&)9#*T!)$9R>
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MV84^!>IZUK&H>++[QGKNI6MIIPO[VVCM_(L[5"D$*I'P2 3ECRQYK*^+Y/\
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MA?\ !.3_ )&CQI_UYVW_ *&U;U?@9Y67?[S'Y_D?=U%%%>>?8A1110 4444
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\\?%_\
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M^1K^63VC]!?A7_R2_P )?]@BT_\ 1*U^?O[0'_)<?'/_ &$O_:,5?H%\*_\
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MJC-/X,?7]#A:^PO^"<G_ "-'C3_KSMO_ $-J^/:^PO\ @G)_R-'C3_KSMO\
MT-JWJ_ SRLN_WF/S_(^[J***\\^Q"BBB@ HHHH **** "BBB@ HHHH ****
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M8M4445B,;)]QOH:IZ)_R"[?Z'^9JY)]QOH:IZ)_R"[?Z'^9H O4444 %%%%
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MZ^7_ /@GU_R/OBO_ +!L?_HVOJ#XV_\ (,T+_L*1?^@O7\]<5?\ )25?6/\
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M;:>S<--(W(>7]%Z*&(KHIQE?W/BZ=E_>?Z+J_1DMI?$[(D^)'Q#O8]6M="M
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MS0!V7P[^*O@_XM:1-JG@WQ)IOB73X93!)<:;<+*J2#JK8Z'D'GUKR+XOD?\
M#77P(Y_Y<]=_]%05Y?\ LN>!=5\>ZK\7M6TFU\2?"_0->MM&L-/NEL!I]['<
M6UJJ7$D44J$#YALW%2&YKM=4_8DU36/$^C>(+OX\?$B?5M(29+*Z>:R+P"4
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MI15N>-E?_#;I<ZJ,?9I)GS43S3)C^XE_W&_D:]R_X=U6/_18OB'_ .!-G_\
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M?\9X/BWZM]4IRA[/FOS6UYN7:S?8TPN'E0OS/<^.?CZ1_P +R\=\_P#,5?\
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M>I.(,5\[3FH.[/V3&8:6(IJ$7L?#F:^P_P#@G(1_PE'C3G_ESMO_ $-JU/\
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M(OFJA7)2%!QSGENWJ<&O;-(O? GPB@30=(W:AJJ\G3].C-Y>R/C[SJF=I/\
M>?:/<"K5E\'Y9DDBUGQ)?75B\A8Z;I2C3;5@?X6$1\QOQDP?2NUT'PUI7A>Q
M%GI&G6NFVH.?*M8EC4GU.!R?<\UZ=6IA8O63GY1]U?-M7?IRKR9A&AS-2FKO
M^ME^NYQ5I=^/_%^IW$4UHG@G0RI\J9C'=:C)T[ M%%WZ[S[#%=-X6\!:/X1:
M:>SADGU"X_X^-1O)#-=3_P"_(W./]D84=@*Z*BN.KC)SCR02A%](]?5N[?S;
M\CJ4;;A1117 6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% #9/N-]#5/1/^07;_0_S-76&X$>M16=L+.VCA#%@@QDT 34444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M(!BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN"_TZYC*HS(/,MGQ\LL3=4=3@@C'2O)?V4/C/;2_ 'P[)XZ\4Z?;ZI:7%YI
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M^-=%^'/A+5?$WB*^33=$TN!KF[NI 2(T'4X ))Z  #)) KR?]APY_9+^%_\
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M7,[2L%C1G5MJ(,X&2:R]F][Z=R^8^H:*^2O"'QT^,&G:E\<-(\3Z7I>J^(/
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M!+=8KN,"/(^]@D_-W&*^ZQTISAR+4(RYA:***R+"BBB@ HHHH **** "N?\
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ME;7-S=K"X=;>WC@=AAF49D<C@<"O?]1^'VA:KXVTKQ;<V9DUW3+:6TM;GS6
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MW8<B/F;Q#\3/CO\ $_2I?#GA;X477PWO+Q3!<^*/%&J6LL6GH1AG@A@=VFD
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MOAOPQ]LDU'^Q].@L?M4OWI?+0+N/IG'2L9M.*-(W3.EHHHK T"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BDR/6@\4 +1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T44F: %HHHH *
M*** "BBD)Q0 M%%% !1110 4444 %%%% !1110 444F>: %HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **2C- "T4A('>EH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC>06DK9+0JVPX!*@DX-5))T_DB4_>/K"BBBN,W"BBB@ HHHH **** "BBB@
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M":WX-%T^UU.ZU&&QMH=0NE5+B[CA599E7A0[@98#MD\5=HH;;W%8Y'Q?\(/
MOQ!OK>]\3^#=!\17EOCRKC5--AN)$'H&=20/:MS3?#>DZ-<RW%AI=E8W$R)%
M)+;6Z1NZ(,(I*@$A1P >@Z5I447>P61Q&O\ P.^'?BK7QKFM>!/#>K:R"&_M
M"]TF":<D="79"2?K74W^A:;JVE/IE]I]K>::ZA&L[B%9(64$$ H1@@$#C':K
MU%%VPLBAJV@Z;K^DS:7J>GVNHZ;,GERV=U"LL+K_ '61@01[8K'\%?##P?\
M#>&>+PIX6T;PU'.=TRZ3816PD/8ML49_&NGHHN[6"R,VS\-:1IVF3Z;:Z596
MVG3F0S6D-NB0R;R3)N0#!W9.<CG)S3+?PIHEI-I\T&CV$,NG0FWLI([5%:UB
M.,I&0/D4[1PN!P/2M6BB[&4KS1=/U"^LKVZL;:YO+(LUK<30J\D!888HQ&5R
M.#C&17SKXS^%?Q5L_$6I"#3? _Q?\,W-T]UIUOXZ!AO=)+')B218)%DB!^[D
M!@."37TO151DXDM7/&O@7\'-?\(^(/$7C/QK?:7=>+M=C@M3::%"T>GZ;9P
MB&V@W?,P!9F+$#);H *]8U'1-.UB2TDO["UO9+.87%LUS"LA@E (#H2#M;!(
MR.>35VBDY.3NQI6T*]UI]K>R6[W%M#.]O)YL+2QAC$^"NY2>APQ&1V)]:AO]
M#TW5;FRN+W3[6\N+&4S6LMQ"KO;R%2I>,D95L$C(P<$BKU%2,QO%7@S0/'6E
M/IGB/1-/U[3G.6M-2M4N(B?7:X(S[UB^!O@QX"^&4LDOA+P9H/AN:48DFTO3
MHK=W'H6502/;-=G13N[6%9;G+^)?A;X,\9WZ7WB#PCH6NWJ((UN=2TR&XD"
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MOO#O@7XA>+O#D+,K>(M$\./+8N!U:-F96D4>JJ1Z9KUSX8?%CPM\8_#$>O\
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MJR_5A7TFVE._A\Z:U[=*[6WV<WB2?OP2NWS Q!^?N#CK6;@X[E)WV/._AO\
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MQ:!:_:+@>:X7S"N1\BYR37A/PN\!^,?VE_!]I\1?%7Q+\6^%;;7D^V:/X?\
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MJ?AGQ)/-:B"\VA6N+:>-'QO"KN1EZC(-?0V:\^^(WQ9_X0#QGX T#^S/MO\
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M2V6+RQ')N YY/ R.:YO]G']EZ+X$:]XJU.;56UE[^;R-*\PDG3].#%DMEST
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M!+2WDB^R2^-K9KDWIA(VF1+,IL6<KW\S:#R*^F:*E5&BN5'@/BW]EM;/X>>
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M+E(XXMS$DL[,69B>PP*=X;_9IT.T_9WA^$GB"Z?7=)$,T4EVB?9Y"7F>970
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &>2GF^;L7S,;=^
M.<>F:?110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ibio-20230630x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &" RL# 2(  A$! Q$!_\0
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M+J^(7_0]^)O_  <7'_Q= '].F?K^5&?K^5?S%_\ "ZOB%_T/?B;_ ,'%Q_\
M%T?\+J^(7_0]^)O_  <7'_Q= '].F?K^5&?K^5?S%_\ "ZOB%_T/?B;_ ,'%
MQ_\ %T?\+J^(7_0]^)O_  <7'_Q= '].F?K^5&?K^5?S%_\ "ZOB%_T/?B;_
M ,'%Q_\ %T?\+J^(7_0]^)O_  <7'_Q= '].F?K^5&?K^5?S%_\ "ZOB%_T/
M?B;_ ,'%Q_\ %T?\+J^(7_0]^)O_  <7'_Q= '].F?K^5&?K^5?S%_\ "ZOB
M%_T/?B;_ ,'%Q_\ %T?\+J^(7_0]^)O_  <7'_Q= '].F?K^5&?K^5?S%_\
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M#I7X(_\ !+#_ )/%\+?]<+G_ -%U^]PZ4 4M3^ZGUK/K0U/[J?6L^@ HHHH
M**** !F"@DG ')-<CX?^+W@?Q9KKZ+HOB[1M5U=-V^QL[Q9)EV_>RHY&*ZX]
M#7R=\29+O0M7^-4_A^[;0-4>_P!%MXM1L(T2:$2"-7*G'4@F@#ZQHKY:UZXM
MM+\6>*M"\5?%37O!\'AVPBDT0/JX@DO 8]S73NXS<MYGR^7R!TQ6%H7CJ;QI
MXWM[+XA_$S5? \9\,6E^EC;7ZZ6LTQ+!IRY'WMH#>7GOT- 'V"S!5+$@*!DD
MG  KF?"_Q0\(>-]2O=/\/^)M+UF^LCBYM[*Y61XN<<@=L]QQ7F'PQ\7>*_&/
MPWM(]=TJ'6O#-TEQ;W7B6\U(64LMF"RK,8MF3N3DL",]:P?@WXD\%_$OXJV>
MJ>$[_0[+0?#=C+I&D6=I<Q&]OUW#S)FC!W")<87<,GD]Z /I2LSQ)XHT?P=I
M$VJ:[JEGH^FPX\R[OIEBC7/09/<^G6OG3Q]\0M;TWX^Q:):>)]0A\ 2WMN-:
MU"-,KIEZ1^ZLEF_@CEX+<':<#(S74?&>?1])^-'P\U?QIY*^#(+>ZCM[F^ -
ME;:FQ7RWF)^524R$9N <\Y- 'H^B_&#P/XBT&^UK3/%VCWNDV W7=W%=KLMQ
MZR=U_$5;\)_$KPEX\\[_ (1OQ-I.NF$9E73[Q)3&/5@#D#W->,?''Q/\-==\
M$^.IM"N]#U#Q#!IMO]OO=-"2!+?[0A"RS)\GJ=I.<>U97CWQ+X"\1>,O 4G@
MR?2]:\1V4CS:G+X=5)V32Q WGI.T/!5CM"JQR3T% 'OGACXE^$_&NHWVGZ!X
MDTS6;ZQ.VZM[*Y61X3G'('OQGI725\N^!-1\/W?[1OAF_P#">MZ-KOAZ[T&>
MWLM)T>W2"30XE96/G["2V]N,2;6!!P.M?45 !1110 4444 %:MA_Q[BLJM6P
M_P"/<4 6:PW^^WUK<K#?[[?6@!M%%% '/^,/B%X8^'MM;W'B?Q!IWA^"X8I%
M+J5PL*R,!D@$]36EH>NZ=XFTFVU32;Z#4M.N5WPW=JX>.1?56'45YG^U7:PW
M/P(\2F6&.8J;4KYB!MO^E0],CBO-O'NI^*='\0?&37=(\0:M#%X9BTZVTS2[
M5LVEA'-#&;JZ\A1^]9$9I #D KG% 'U'17QE\2_'LO@'0_$B?#OXHZMXMM'\
M'WVJ7]W-J*ZFVE3QM#]FNDD _=M)NE'D]]N0!BNR\/\ BK^P_'O@F'P#X_U#
MXGW.N6EW-K&E7^K)<Q>6EN7CNRP7%F?/V1;< $2$;<K0![SXT^(WA;X<VEO<
M^*?$&G:!!<.8X7U"<1^8P&2%!Y.!R?3O6[:7<%_:PW5K-'<VTR"2*:)PR.I&
M0RD<$$'.17S_ /%KXF:-X"_L;7?%.A:'I_Q3U>WGT/0]*U#5XYK986</)++*
MP5$A& TC8R0H09) JWJ5K8?"W]E#3;70_&3E]*L8(]*UK2"LPOKP29CBBC4D
M2)+*3'Y8/W3C(QF@#WJN*USXV?#_ ,,^(O[!U;QGH>G:SN5397-ZB2(3]T-S
MA2>P8BN2_9X\3^(/&'P]UJ\\07TJ>/C>W$>JZ//\L>B7>W]W:QKS^Z4;&5\G
M?N+9YKB/@CXL^%?AKX%?V1XNO=!TW5[:*6/Q9I^O&,7DM\6;[0TT;_/*7))4
M@-N!7;0![5K_ ,8? OA76AI&M>,=#TG5"B2?9+V_CBDVN,HV">A['O5SQ=\1
M_"O@'3K6_P#$GB+3=$LKI@EO/>W*HDQQGY#_ !<<Y' '->&^'/%GPP\/?$WX
MDQ>(;_PYI>C3:;H36=IKGE1;K7[$P 6*;YMH&!MQGMUKF/!-WX<LOA;;:7-K
M=AX"U6^&MR^"-;\46"R)9Z*UV-L2BX*KDQ[&$;$-Y>TXP"* /KBVN8;VVBN+
M>5)[>5!)'+$P9'4C(8$<$$'.14E?&7Q$\::]X+_X)S:+JOA:^N_"NK6EGI]C
M:WMI(Q<(+Q8/.0N,[)4&\ C[L@%>-?M)_$GXE?#;XL3^"%^)6I>']'T+0+:Y
MTC5=7\0+ITFJ7+Y:2XD?R'^U%7.WRAMP * /TRHZU^>_B[XN^)M5\=:+H?Q=
M^,=[\&]+A\(6FJ6FH^'"(H-:OWSYL@E:,[@H"D18&<]*UK_Q'XX\6_$'XA_\
M(_\ %#Q-K-AX;^'=KJ^CK:%;==2NY89 +B2((/F. VT8^;'I0!]O^)O$^D^#
M-!O=;UW4;?2=(LHS+<WMV^R*)/5CVJOX>\;^'_%EU>6VBZS9:I<6:0R7,5I,
M)&A65-\18#H&7YAZBOSE\6_M&:M\5/ .J)H?BVY\0:9IGPD,^OICS(8=6,L:
M_O@RX\[[W!K#<>(/!!^/&N:/\4+OPEJ#_P#"-1>??78MH;@36J2&)95C/DN
M#&CXPJD@]<T ?JC17DG[)OCA_B-^SWX-UZ2ZU>^FN+9TDN==9'NY621E+,Z
M*XX^5P!N&#7K= !4UI_Q\Q_6H:FM/^/F/ZT ;%5-2_X]_P 15NJFI?\ 'O\
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M1_#M)_V7/"7B^S\)VWA34[2[U#7'2VM1]HOHYIUM([B?!(AWLORL=I!&[(%
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MMU]HW!]^Y^$!^4T ?3WB'7]&\%V+ZKJ<D=C!/<06SW BRTDLCB*)6VC)RS
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MIZ@$@G'M7S%\4_B7X7N/%3?#*\O-,\,2:C+#>^+M6M[6<Q3R97%O;L4.^1L
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MG.,9%<_\(GU!_%V@/%XO$/BIQ,WB**QL]6GO]NUO,^UK-*88]IY4A1T&T$4
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MF ] :G_L^;T'YT?V?-Z#\Z ( [+T8CZ&D9BQR22?4U8_L^;T'YT?V?-Z#\Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH@UG*S.DET(V#FW94(\Q6 888'&3TK-^)7Q(NO%WPN2+PCX<2"U1+2\T]&E
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MGVOT/2****\P[0HHHH **** +6F_\?:?C6Y6'IO_ !]I^-;E !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %9'B7PMI_BVR@M-2C:6&"ZAO$".4(DB<2(<CL&4<=ZUZ* /,[G]GSPM]
MDMH=.EU;0'M)KB2UN-'U*6VEMXYV#30(RGB%F 81]%(!7;@54\1_LS>#/$D$
MUK)_;%EI]W91:??V=CJ]Q#%J$4:[8_M&&S(RKQO)W,  Q8#%>KT4 >=?\*"\
M&&V\00-I\S)KBXO#]KD#9%Q)<*Z,"#&RRRLZLN"#C'05"WP"\/RZ1]FGU#7[
MG4ENUOHM<FU>9M0AF5#&&CES\@V$H4 VD$Y!R:Z/QU\2_#?PWLH;C7]3CM'N
M&V6UJBM+<W3_ -R*% 7D;V4&N,'B;XH>/^= T&S\!:0_W=0\3J;F_93_ !+9
MQ,%3_MI)GU6@#</P0\+7.G"SU"*]UA387&G2RZE?RSRS13R+)(6=FSN+HI##
M&W VXQ61>_!?PC8Z)<6NKZWK$]U+<174>KZGKLK7MO)$"(FAE9AY>T,WW1\V
MYMV[)IJ_ (:W\_B_QOXK\5.P_>6_]HG3K0^PAM!'Q[,S?6I-(_9Z^$5O=SP6
M_@SPY?7D&/.6[MTNYDSTW&3<PS[T 2^$?"7@'PYH&O:'8ZXNH1Z]+)-J,MYK
M/VFXN9)(Q&[%V<D$JH&!@#' %.E_9_\ "-WK5CJ:#48XH%L_,L(-1E6SO&M0
M/LTDT0.V1H]JX)Z[5W9VC&A-\ OAE/&4?X=^%2I&.-%MA_)*QG_9A^'D$C3:
M3I%SX:N>T_A_4KG3V7\(I%7\P: -^P^#WAC3K*QM(+680V6EW&CP@W#DBVF9
M6D4G/))1?FZBL<_LZ>#_ .T()E34H[%/L[3:2FHRBQNI($5(I9H<[7=1&G)X
M;8NX' JJ?AY\1/"/S^%OB VNVZ]-,\9VJW /L+J$)(OU824^S^.G_"/7<-A\
M1=!N/ MS(PCCU*647&DSL> %NU "$]EE5#]: .K'PST$>#K'PP+>7^R;*2*2
M&,S-N#1R"1"6SD_, ?>N.L/V=M'.C>++.^N[J*7Q-K$NJ:A+H\SV1E5AL6%M
MI.Y-@PP/#%F/!KUF*9)XDDC=9(W4,KJ<A@>A![BGT >;Z9\ ?">D:SI-]:IJ
M$<.EW+WMMIYOY6M%N&R!+Y1."P#$ ^A[X%>D444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M4-7_ ./=?][^E9%:^K_\>Z_[W]*R* "BBB@ HHHH *\3_:^^%GB#XN_!NZT;
MPWB?48;N&\^PO($6\2,Y,63QD]1GC(%=3\</C?H7P'\(IKFMQ7-VT\XM;2QL
MP#+<RD$[03P  "23P *YWX!?M1^&OCX-1MK.SNM"U>P599M/U"1&+1$X$B.I
MPPSP>A'%=E&G7II8J$?=B][:7.>I*G-NA)ZM;=3YN_9+^%FI_#/QAJT'Q/\
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M5AT/\(YZXK@]>^,6A?!WXA^$_AK9^';HQZF(E2X@8!8S)(R [3\TIW*6=LY
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MJ](.[#,.@;/7L<5\Z_LA?LJZG=ZC\0(?B#:1V6G/;_V+=Z2MP'D9\[_,++P
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M73P51N*]Q[/]&:U%%%=)XH4444 %%%% !1110 5X1\7O%C^(M<?1(7/]EV#
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M:/)XA-J0;=GM_L=J&'1FR2[X]  *ZWXO^)[7Q-XAM;"T<W%MIC,9W_Y9F8C
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M1R1Y&KH^?QV4O%5UB*4^67^74].CTWP9\+=1^VWFK3Z[K$>?L]IE))$/LB
M'_::N.\6>+M1\<WJ37X%M90MN@L$;*J?[SG^)OT%8L%K#9H5AA6$'J$7&?\
M&F65X+V'S!#+#\Q7;,NUN.^/2HE5<ERQ5D=F'RZ-*I[:K)SGW?3T12USQ+9^
M'VMENO,S</L38N>?>KE_\UA,P[)N!^G(J66"*?;YD:2;3E=Z@X/J*DCL9=7O
M+73+==T]Y((P!V7.6;Z 5BDV[(]2<E"+E+9'TUX=N&N=!TZ5_O/;QD_7:*T
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MMW=3-<7=_%J7EZPNL6RQZIYY/E131^3YVT CAWPI4;:_0:B@#QG]E?X6:_\
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M&/-@8]#QPRGLPX/UXKHZZ91<79GO4ZD:L5.#NF%%%%2:!1110 4444 %%%%
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M'8^/OKR16-^T5\3=)^''ARS^$_A*58+O[,HO$B;]Y% >B\=7D.2>^#[BNW^
MG[/=GX9\$BZUR!D\0:B%E,B';+9KU1$;LW<_D>E?65J\)4I8V3Y;NT$K7LN_
M]:?<>)3I24UATKV5Y-]WV.>\(65W:>)_[-T*WU+2+&PN-U_%J4Z,LZL,!E4
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M\.?%GX3Q7OB">6[O;R L[[C''I]PA^]&@.-R,,Y8GIZ&J/P&_:*\$:CX#O\
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MFG>$=!L-&TFU2STZQA6"""/HB@<?4]R>Y)-:5 !1110 4444 %%%% !1110
M4444 %%%% !1110 45C>+_$D?A+P[>ZK)"TZVZ;A&AP6/89[?6O%]3^+/BW5
M49(Y[/2(V_Y](C)*!_OOQGW"UA4K1IZ2/3P>75\:FZ2T75G5_&/P1=WUQ!K^
MEV[W<T2>5=6\0R[Q]0RCN5]/2O&;=K8:C*\1NI;N4!#;".1FR.PCQP:]Q^"G
MB'5M<L-3CU"ZEU""VF5(;N;&YB1\RD@#...?>N=\4>(_B+;>+;B"SANUA6;%
MK#;V*R6\B<<M(1]<\C%<=6$)I55?7R/I,%B\1A)2P4N5\G5NWZ:F[\,O#LO@
MK0=3U_68C:W$R;S"WWHHE&0#[GKBO/\ 4_B)XEU^]-ZFKW.E0EMT%K:; J+V
MW94[CZYXKW^]TT:YH4EE?J%^TP;)E0]"1S@_6O#KCX0^*K2_^P6T-O<VN=L>
MHM,%54]73KN [#@U=:$XQC&GL<V78G"UJU6MC;<SVOM;R/2_A1XPO?%VB7']
MHA'O+.;R7GC7:LO&0V.Q]17GGQFGDG\>PQ29\JWLP8@>@+-\Q'\J]>\&^%+;
MP;H4.G6Q,A7+RS-]Z5SU8UQ_QE\&W.KVMMK.G0M<7ED"LL*#YI(3UQZD=<5I
M5A-T;/<X\#B,/3S+VD5:#;MY7/(*@O5S;.P)5T^=&'56'((I8;R"=-R3(0."
M,X(/H1U!J[H6BW'C/5(]+TX&8,P^T3IRD,?<D],^@KR4G)V1^AU:D*4'.;T1
M]'>$]0DU7PUIEW-_K9K='8^IQR:TY(DF0I(H=3U5AD&H[&TCL+."VB&V*%!&
MH]@,5/7T*VU/QV33DVMB*WM8;5-L,20KUVQJ%'Z5+113(W"BBB@ HHHH ***
M* *&K_\ 'NO^]_2LBM?5_P#CW7_>_I610 4444 %%%% !1110!6U2Z^PZ9=W
M/_/&%Y/R4FO$O!,1C\)Z8S<O-#Y[GU9R7)_-J]G\00-=:#J4*_>DMI$'U*D5
MXWX,E$WA+1V'_/I&OXA<'^5<V,_W;_MY?D[?J?.9G?VL/1_FC9K/UN]:QL69
M#B1CL4^F>]:%9'B:(OIP<<^6X8_2O-P483Q-.,]KHY,+&,J\(SVN<MGKR23W
M/>BBBOTL^^+>E3207\/EOMW, 1G@CWKM:\_SMP02".A'7-=QIYD:RA,V3(5!
M;/6ODL\I).%7Y'S6;T]8U/D6*S-1F-CXA\+7RG#0ZK%&3_LR9C8?DU:=9&N1
MFXO_  [;+]^;5[4#\'#'] :\/ 7^M0]?PZ_@?-NZLUO=?F>XXQQ12DY)/J:2
MO9/N0HHHH **** "BBB@"UIO_'VGXUN5AZ;_ ,?:?C6Y0 4444 %9/\ PBFD
M?;C>?V?!]H)W;]O&?7'3/OBM:BHE3A.W,KV+C4G"_*[7/E?XUZ9_PK+Q6\&I
M6PE^&'BW-IJ C4[K&Z;A90>PS5/X??&G4_@MX/\ &_A3Q 'UF[\(0+-IUVC;
MA<V\AQ"&/MD?A7U7J&FVFK6S6][:PWD!()BGC#J2.0<'BOAOX\J$\<?&M5 5
M1I-D !T'SBLZ-"G0CR4HV7E]Y=6M4KRYZLKO^D/TRS\10SVN@V4_VWXG^/\
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MO;S.=T*<JGM6O>V/@K]G+]B/XC>!?C9H^N>(A8:?HNA2O(EU:W8E:\RI50J
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M..*]$HHK##X:&&BXQZ_UTL;XC$SQ,DY=/7];A11176<@4444 %%%% !1110
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M=6Z+T'K7HE%%=\I7LDK);+HOZ_X<^BH4(8>')#_@OU"BBBI.@**** "BBB@
MHHHH M:;_P ?:?C6Y6'IO_'VGXUN4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5%/;17*J)HDE"L& =0<$=",]ZEHH BFMH;@QF6))#&V]"Z@[6]1GH?>I:**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *&K_\ 'NO^]_2LBM?5_P#CW7_>_I610 4444 %%%%
M!1110 449 [T9'J* "BC(]11D>HH **,CU%&1ZB@ HHR/449'J* "BC(]11D
M>HH **,CUHH **** "BBB@ HHHH M:;_ ,?:?C6Y6'IO_'VGXUN4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M444 6M-_X^T_&MRL/3?^/M/QK<H **** "BBB@ HHHH **** "BBB@ HHHH
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M^&K'P[X_U'0-0TK2[O1+F_73X9_MME<3&62,QN<(P)X<'C'0UZ%_PM+XD_\
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MM4 %%%% !1110 4444 6M-_X^T_&MRL/3?\ C[3\:W* "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ibio-20230630x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (F L@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKS/Q9^
MTS\)_ ?B.XT#Q'\1O#.A:U;E1-8:AJ<4,T>X C<K$$9!!Y]: /3**SM \1:5
MXKTFWU31=2M-7TRX&Z&\L9UFAD'JKJ2#^=:- !17+?$3XH>%/A+H2ZSXPUZR
M\/:6TJP"ZOI-B%V^ZN?4UT&G:A;:OI]K?6<R7-I=1+-#-&<K(C %6!]""#0!
M9HHHH **:[K&A9B%4#))[5R/@#XO^#/BG-J\7A+Q)8:_)I$_V:_6QEWFWER1
MM?T.5;\J .PHI"0!D]*\;\7?MD?!+P+X@DT/7/B;X<L=5B;9+;&\#F)NZN4R
M$/LQ% 'LM%97AGQ5HWC/1K?5] U6RUK2[@;H;W3[A9X9![.I(-:M !1110 4
M444 %%%% !1110 45Y?\2_VG_A1\'M233O&7C[0]!U%AG[%<W0,X'J8URRCW
M(%=/\/OBGX0^*^C_ -J>#O$NE^); '#3Z9=),$/HP!RI]B : .IHHK$\:>-=
M$^'?AB_\1>(]1ATG1;",RW-Y/G9$GJ< F@#;HKREOVI_A2EMX4N#XVTT0^*B
M5T5_WF+TAMIV?+Z\<XKU4D $DX [T +17'>%OC#X'\;R:TF@>+-'UAM%9DU(
M6=XDGV,C.1+@_)C!Z^E<K>?M9_!ZR\):MXG/Q$T&YT'2I$AO;ZRNA<I"[G"H
M?+W'<>P S0!ZW17F,W[3/POM[SPE:/XSTX7'BR,2Z(@+DWRDX!3"^O'.*BB_
M:C^%4T'BV9?&VFF/PF"=:8EQ]BP<?-E>>>,+F@#U.BN:^'?Q(\-?%CPG9^)O
M"6KP:YH=X"8;RWR%;!P00P!!'H0#72T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "'I7XK_ +5FJ_";2/\ @H;\2)OC'I&J:UX6-E$L=OI+LDPN#;1^6<JZ<=>I
MQ[&OVH/2OSN\&^ )]6_X*N^/]0U;PW)>:#)I \N[O=/,EJSBWAQM=U*$YST-
M '(_\$YOB"W[/?[-_P 7OB-XAM-5T_X90:@+K0+2]YFF'SC;'G +-F%"PX+#
MV-7(OV[OVJ[_ ,)2_%JT^#&CM\)$+3!&+FZ-LI.9=WF[R!@_.(MO!XP*^N_V
MTO@;??'K]FSQ3X*\/F&'5988YK"$D)&\D3!TC] &V[?09KX2TO\ ;7^(V@_L
M]CX#O\$/$C?$>#3CX>B?[*Y@*8,8E,83<6"GH#M.,[L&@"]_P44_:!U?]H']
ME/P%XM\'Z/;GX?ZK=J^ISW4H^UV-^C@);[=PR"=^6"G(VGC->K:[^V[XZ_9^
M_9U^&.D:UX,TV[^+7B2&.UT;1H;D"U%HJ1K#/*P<\L&7Y=PY/.W!KR3XV?LU
M>*O@Y_P37\+^#;O3KK4?$\OB"'4[VQL(FN&MFD/W/D!SM55R1QDFMW]O/]F[
MQ!XL\'?!7XC6?A*\\<:/X=T6UM-?\-VC21W30>7&Q(V?..C*2HRN0<8!H ZO
M1_V]?C-\%O&WANT^//A3PI_PBNOW*VJZMX2OTF>QD;M(J32 X[@XR <$XK<_
M:'_;L^*_@/\ :FC^$GPY\$Z)XQFO["&73TF:1)6ED5B'9PX3RUQD].,_,*^8
M_A+\/?@=\9/B;X?\/^#?V7_'DMK)(#J6JZEKUQ;)IV#]_))1E'?<RD] ,U]$
M0>"=0TW_ (*P:1>P:/?#0+7PV+>._:WD:!=MO(H!E(VYZ#K0!<^"/[:GQL\5
M^-_B'\)/'7@;1;/XI:5I5Q>Z5#9L8[>>54W+%)F5E*L""'5QZ'V\P_X)+:W\
M1V^*WQ-M9= TY?#%SJ<LOB"]$H\VTO@92D40W\J6+@G#< <UZ7X>\,ZO'_P5
M8\4ZNVE7RZ2_AUD6_-LX@9OL^,"3&TG/&,U9_P""6OAO5O#NN_'=M5TJ]TQ;
MGQ+YD!O;9X1*OF3\KN W#D<CUH Z[_@J5\:_$'PH^ MEI7AF\DTW5/%6HII!
MO825>&)E)?:P^Z2!C(Y&>*K?!7_@EO\ !/0OAAIUOXM\-GQ;XDO;5)K[5;N[
MF1A*ZY(B". H!. >2<9)KT']OG]FJ^_::^!\VD:#-%%XHTFY74]+$K!5DE0$
M&,MVW D ]CBOESP'_P %._''P;\*VO@OXH_!?Q)/XSTF%;-9[53"MWL&U6=6
M0X) &60L#U% 'T7\)?V=_!/_  3T\&_$?QA;^)M<OO##1M?G3+R8&*UC09"H
MHX>0GC>0#C ]2?G_ ,.?MU_M4>/] U/XG^%O@SH]]\++5I&2%W87<D2YRRMY
MH9RO<I&1P0,UZ!X3OOCE^VK^SG\5=+\>^#+7P+8ZY;,/#*S[X;C./ECDC8;B
MF0/WC!<DG QT\-^#_P"V9\1?@?\ !-O@9J/P1\2ZAX_TJWGTVP-O;MY$BL6(
M>10I) W$Y3(88Y% 'KW@+_@H/X[\6?L6>.OC#<:'H$.OZ'J(M+:SCCF^S,A*
M<N#)N)^;L17G&J_\%%?VE]*^'&@?%J]^%7AZR^&,\J6\]P6D:2Y8MM+I^]W1
MJ3PI*$9[FN#^%'@CQ/#_ ,$Q/BUIEWX>U6'6;G6Q(EB]C*LS_-'DK'MR1UZ"
MO</COX5U>\_X)0:!H]MH]]/JR6-@#816KM.I$X)S&!N&.O2@#U+]HS_@H##\
M,/ ?@"3P7X8D\5>._'=K%<Z1H;L<1*ZKS)MY;#,%"C&?4"N7^'7[0O[7^A?$
M#P_I_P 2O@?8ZAX?UJ4(;CPVZB6Q4\EI&\^1%VCDA]N>QS7COQE^$OQ$\":!
M^SK\=?"'AFZ\43^#M%M8M5T%(7,\:J V[RP-V/O D D<'&*]D^&__!2#Q-\9
M_B+X>\.>#O@1XHFM;B79JUWJ#B%;)>[!]NS"]<N5SC &: -']IW]N#QCX:^,
ML/P?^#?AS2==\:)")]0O]?N5AL[)2,[3ET!('));C(P#FL_X$?MU>._^%LR_
M"KXT>&]$T?Q3=6CW.DZKX?NA/979520AVR..<8!#9SP0.M?/'[;/[/,'P_\
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M#XL_8G_X)]?#_P"(OPIL/B7\6+*7Q[XJ\5JU^[:A=R^7"K,0.$8%G.,EB3V
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M3/CK_P!'7>)/_"?M?_BJ^N** /D<?LE_'4?\W7>)?_!!:_\ Q5)_PR7\=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML?#?]F2+X:>#;.?3IH;CX@V5G)#:ZGJ=W=WME;R.V6$4$DF(E; !\L*<?3%
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MNJ7'#WMV_,DNT?*@)Z*H  IOQ'(UCXE_#[1@V/+NIM3E'^S%&=O_ (\17IE
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M%#E-L>-HP>1QP:Z+(K-3Q-I4OB"30DU"V;6([=;I[$2#SEB)*ARO7:2",^U
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M^![RXMKS4M%BU+4D :>ZE=U^U.#G?*@8+(<Y/S XZ=!7HZ(L2*B*%11@*HP
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M%I%BB50Y/4D <D^].L-.M=+MQ;V=M#:0 DB.",(H)Z\  4 ?!_B*(7/A6_\
M%/B.WDO=(L_BA)<>+(3&9!':Q$I"TB ',4?R'I@#FNQ^-?QQ\$ZR==UCX4R1
MZIXHL=*@AU+QQX;5+B'2[!YU#J9%)5I0A9@-K%1R<8KZ>T'X<:3X:\4^(M<L
M3/'+KS))>VA8&W:55V^8%QD,1P><'TK>L=(L=,MVM[.SM[6!B2T4$2HI)ZY
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M(=9"6&J>&]'&F6VH(;>-FS&% =XW9HS(!AMO%?5= !1110!\Z_MW?\D1MO\
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M+J5R+.S1P<S3$$A% '7 )_"OS_UG0HM9L=>L?AC9>,;;P!<QZ/#>K*NH09U
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M[!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?^">U_\ DFM'QO\ M ZCH/QUA\ 6A\*Z?%]E@NFGU_4I8)[G>Q!2WC2-@S
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;69)H=%TZ*5#N5TM(U93Z@A>*V* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&]F-M:
M3RJ,LB%@/7 KX2_9P^/'Q%UWXM^ -0UWQ3>Z]I'Q"3Q$\OA^2WA6'2OL$I$
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M\;6/BZ;3(I/$=C;26=OJ!+;XX7(+H!G&#@=J .AHHHH 0U^?/[4OQ:\<Z/\
M&+QUJ.D^-=8T"+P1#H[Z;HMG<!+2]-Q<;)3/%C]Z&'RC/3M7Z#UYWXS_ &>O
MAS\0O&VE>+O$7A'3M6\1Z9M^RW]PAWJ%.5# $!P#R P.#TH X7]L#5?'*?L\
M^(=4\"^)+7PM>V5E)=7]YY+2W*1+'N,<!# 1R$X&X]!D@9KTCX):C=:O\'?
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MPY^&WC#5O%/AGPCIVCZ_JI8W=[;H=S[CEL DA,GD[0,GK7HE !1110 4444
M?.W[7GQOL_A?I6E:5<Z)\1KZ346,T=_\/+823VY0]'8Y7!_NL"#7R0WQQ^'<
M$6F?V?\ #7]H?1[NSCN(Y;ZPL/+N+P3MNF,SG))8]UVX[8K]/\9HQ]?SH ^
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M$W_]G7V5CZ_G1CZ_G0!\:_\ #S#1O^B+?%S_ ,)O_P"SH_X>8:-_T1;XN?\
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M0 4444 %%%% 'C/[6?QIU#X'?![4-9T&WBOO%=Y+%IVB64J[UFO)6"Q@KD9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9&017S1JO[2/B3X&?%CX^:-X3']G:QXLUU].77YGV0Z>AE.YLXX8@\'MR>:
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M(]M;^-;"0/83*N01(%V $\<8R.HS7W[^U/\ \FZ?$3_L"W/_ *!0!\3^%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPMX:T^_N)/#]IJMTL;3RRL?WR _PCYF'IN6OU)_X9@^#O_1*?!/_ (3UI_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8X=9LM;^TBVME?,=G#;")1&@ZEMQ+&@#ZCHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\&UC]L7PKHGQ.'@*
M?PMXYD\0,Y$:P^&YWBEB#A6G1Q]Z($\N.*]YKQG7OA7KNH_M3^'_ ![$+?\
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M<3?$WQ;X.\9ZCHNKOI5K:W4%YI&G268(E!)5E>63.,=0:]DH **** "BBB@
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MHH \6\%?\G1_$?\ [!6F_P#H)KVFO%O!7_)T?Q'_ .P5IO\ Z":]IH ****
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M ).C^(__ &"M-_\ 037M->+>"O\ DZ/XC_\ 8*TW_P!!->TT %%%% !1110
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MRZ0K+<#;;1M_RRA[?BW4_A3=>)UO5;?14.8 !<7A']P'Y4_X$?T%=$ %  &
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M':AK^I_M0:/J^J:'XS'B:RUBWT:74?$/AWP[:>;:"-%>9KE1]H <%B%BW9#
M*XSM'Z$GH:_/^7P)\.M7_;7O]3OM5U7P_P",K/QG!(D=WX6>\745^S6SQ)!J
M*Q;8$WJZG<V0K.O3:0 ?H!2T@I: "D;[II:1ONF@#QG]D_\ Y)GJO_8TZ_\
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M^\DZK]%Z?\'\K!11170=0445#>7D&GVTMQ<S1V]O$I9Y96"JH'4DG@4TFW9
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M;S 7 #E#VR% /TJE<_L_?#>\;Q(T_@C1)&\1HB:LS6:9O A#+O/<A@&R,'<
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MM".W%BFU9_[XXZ_I71^'_A=X1\*>)=4\0Z/X<TW3-;U0 7E_:VZI+.!TW$4
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M!QP* /2+&Z6^LX+E056:-9 #U (S_6BI418T5$4*JC  Z 44 .HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ibio-20230630x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'X W\# 2(  A$! Q$!_\0
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M#J7[+OQ$^&.C:?8Z?>:?KLS2ZM]LC<RQ6P=%_=[6 5OG/4'ITJO^UQ^WA<_
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M=?)F651N4' 9>#CI56Y^)7A*SU.[TV?Q1HL&HVB[[BTDU&%985]70ME1[D4
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MBBB@ HHHH **** "BBJ\E_;17<5J]Q$ES*"T<+. [@=2%ZG% %BBBB@".?\
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M?"&/X4>"++Q;)\0K)YH+34KM[>2"56VE68?+A2#DGKCM6!<_L5_'OP#9^+/
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M5RBQ@L3)@@OMRQXYQ7Q)\/O#>M?M,?\ !,2#X?\ @NUBO_%VCS1Z5<Z=-<)
M8W@FR=S.0!E<-SZU]C?#B3XE6OC"7PEX@\(:5;_#NST.UCMM96]$EQ<W/EA9
MHGBS]T'<,X QCDYX .#U#]O#PY/X*^$VK>']!N]?U;XBW2VMCHT-RD<UK@XF
M:1BI'[LY!XYVGTJY^SS\:/&5_P#'+XG_  H^(%U;:AJWA^2&_P!*U"WM5M_M
M%A,,H&5>"R\9(]:\D_9@_8+UOX/_ +4WBCQ;K,@G\$:29_\ A#[=KD2>5]H<
MO(1&#^[*@D<@9+$UU'P4U&+XD_\ !0#XP^*=&*W&A:%I5GX?DO(V#1RW2\R*
M".I4K@_44 ?9%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !12=*6@ HHKF/$GCZP\.SK;
ME)+NX*[RD6-J+ZLW0?2DVEN-)O87Q_X!TSXA:&^GZ@FV1<M!<H/WD#]F7^HZ
M&OF;0?#'C+X'?$&+6=1L[BW\(VDOE:AJ%EB5)XFZ,4SD(#@DD<5]9:-JB:SI
MD%Y&C1+*NX(Y&1^56I(DFC>.1%='!5E89!!Z@BNNEB9TX.FM8LX:^$C5DJBT
MG'9_Y]T,M+J&^M8;FWE2:"9!)'(ARKJ1D$'T(J:N4CM6\!NJVL1?PZQP;>)<
MFQ)/5 .L>>JC[O4<<#JE8, 000?2N4[%>VHM%%% PHHHH **** "BBB@ HHH
MH **** &30QW$31RHLD;##(XR"/<&FVUM#9PK%!$D,2]$C4*H_ 5+10 5\P?
MM\_M3^(OV4/AIH_B7PYI>FZK<7>HBSDAU-9"@0HS9&QE.<@5]/,=H)P3CTK\
MK/\ @K-^T5X(^(/@&U\#:5?W:>*M'UD27FFWMA-;/&H1ER"Z@,#D$%<Y!R*U
MIQN[VV+BKL[[]B3_ (*3>.OVG?CE9>"]<\-Z!I>G2VL\[SV"S>;E$+  M(1U
M'/%?HK7\_G_!.3XO>%?@C^T59^)_&&I'2]'BLKB%IEA>5M[H54!$!)R3V%?O
M3X+\76/COPQI^O:8ETFGWT8F@-Y;/;R,AZ,8W 8 ]1D#CFG-72E8&M$S;HHH
MK$@**** "BBB@ HHHH **** "BBB@ HHHH **** "D(# @C(/8TM% %>RTZU
MTV(QVEM#;1LQ8K#&$!)ZG '6K%%% !7CW[7'Q#UWX5?L]>,O%/AJZ2RUK3;0
MS6T[Q+*%;(ZJP(/XU[#7P_\ \%*/VDM%\$?"CQ/\/=9T#Q!:WNNV1CT_5A;1
MMI\QSDCS!)N!'<%<UK2CS3145=GQW\ O^"F'QY^(/QG\'^'-7\2V4FF:CJ,5
MO<)'I5NK,A/(!"9'U%?M&IR*_F8^ ?C+3_A]\9/"GB35/-.GZ9?QW,P@7=(5
M4Y(49&3^(K^BGX*?%^T^-W@N#Q1IN@:WH>E7)_T7^W($@DN$_P">BHKL=OH3
MC-5*\H*0WJKG?T445@0%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "&OR^_;Y_P""@/Q6_9[^/>I>#_"\VCG1%M(9%BOM.69LN@+
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M.TNKJVMBLSQ/Y9=C\JMW'N1755S.N>"XM3N&N()!#*QW$$94GUJ97Z%1MU.
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M@!_T23PM_P" (H _&S_AYE^TM_T4VY_\%=C_ /&*/^'F7[2W_13;G_P5V/\
M\8K]D_\ AA?X ?\ 1)/"W_@"*/\ AA?X ?\ 1)/"W_@"* /QL_X>9?M+?]%-
MN?\ P5V/_P 8H_X>9?M+?]%-N?\ P5V/_P 8K]D_^&%_@!_T23PM_P" (H_X
M87^ '_1)/"W_ ( B@#\;/^'F7[2W_13;G_P5V/\ \8H_X>9?M+?]%-N?_!78
M_P#QBOV3_P"&%_@!_P!$D\+?^ (H_P"&%_@!_P!$D\+?^ (H _&S_AYE^TM_
MT4VY_P#!78__ !BC_AYE^TM_T4VY_P#!78__ !BOV3_X87^ '_1)/"W_ ( B
MC_AA?X ?]$D\+?\ @"* /QL_X>9?M+?]%-N?_!78_P#QBC_AYE^TM_T4VY_\
M%=C_ /&*_9/_ (87^ '_ $23PM_X BC_ (87^ '_ $23PM_X B@#\;/^'F7[
M2W_13;G_ ,%=C_\ &*/^'F7[2W_13;G_ ,%=C_\ &*_9/_AA?X ?]$D\+?\
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M^R?_  PO\ /^B2>%O_ $4?\ #"_P _Z))X6_\ 10!^-G_#S+]I;_ **;<_\
M@KL?_C%'_#S+]I;_ **;<_\ @KL?_C%?LG_PPO\  #_HDGA;_P  11_PPO\
M #_HDGA;_P  10!^-G_#S+]I;_HIMS_X*['_ .,4?\/,OVEO^BFW/_@KL?\
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M **;<_\ @KL?_C%'_#S+]I;_ **;<_\ @KL?_C%?LG_PPO\  #_HDGA;_P
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M&S_AYE^TM_T4VY_\%=C_ /&*/^'F7[2W_13;G_P5V/\ \8K]D_\ AA?X ?\
M1)/"W_@"*/\ AA?X ?\ 1)/"W_@"* /QL_X>9?M+?]%-N?\ P5V/_P 8H_X>
M9?M+?]%-N?\ P5V/_P 8K]D_^&%_@!_T23PM_P" (H_X87^ '_1)/"W_ ( B
M@#\;/^'F7[2W_13;G_P5V/\ \8H_X>9?M+?]%-N?_!78_P#QBOV3_P"&%_@!
M_P!$D\+?^ (H_P"&%_@!_P!$D\+?^ (H _&S_AYE^TM_T4VY_P#!78__ !BC
M_AYE^TM_T4VY_P#!78__ !BOV3_X87^ '_1)/"W_ ( BC_AA?X ?]$D\+?\
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MT,B*<,V0<?3KSQ<T?_@H-XI?6? UMKWP(U[PYI_C>]CMM"U&\U: QSHXRK.
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M;58K8F"V D#G"*1U.>_>L7XC_L1_#;XS:/X53QSI<VKZQX>TF/3+6]MK^YM
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MPQ1CK\J* !^ J_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 44F:,T +129I: "BBB@ HI*6@ HHHH **8LT;R,BNK.OWE!Y'UHDFCB*AW
M5"QPNXXR?04 /HICS1QD!G52>Q(%/H **** "BBF^8N_9N&_&=N><4 .HIH=
M68J&!9>H!Y%!D4.$W#<1D+GG% #J*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/A[K7Q$MHM"CT'1[G6S-IT$$*10M#Y8&Y%7@#.>PH ]AHHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,C6VFZC#<2!?[Q5&)Q[T =71110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7(_%SQ)K'@_X8>*=;\/Z?_:VMZ?IT]S9V6TMYTJH2
MJX')R1T%==7 _'S1]0\0?!7QOINE/?)J5UI%S%;G34+W&\QD+Y:@@EL] "*
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M-$L8[.V0#)49=SZLW4FJ510_AV<N^Z7_ ,D__)5UYM8D*K?^#J^^Z7I_,_\
MR5?WM4>!^(OV+[?QDT.HZCXEN+;6I3NNY$C\]9/^!,0Q;_:Z>B@<5U=I\)M/
M^"NDR1Z7I$6O^$+@*VL:9<6R33;U_P"7E<C]YCJR'/3*],5[?17)A,-A\)B9
MXI0O.I\3=VW_ )/K=''@\!A,%BJF,A3O.I\3;;<NOR=]=+&#INF^&_$-M_:U
MG8Z;?1:A:K";M($;SX.R%L9*_P"R>!Z59A\*Z+;R64D6D6$4EC$8;5TM4!MX
MSU2,@?*I]!@5QVK:'?\ PYU*XUWPY;O>:-.YEU/0XAR"?O3VX[/W9.C=N:[;
M0=>L/$VE6^I:;<I=6<Z[DD0_F".Q'0@\@UZ=:@HQ56F[P?WI]GY_GT/8JTE%
M>T@[Q?X>3\_S*\?@W0(8+6"/0]-2&UF-S;QK:1A893UD08^5CG[PYHE\':!/
M!=PR:)ILD-Y,+BYC:TC*S2CH[C'S,,=3S6Q17(<QES>%M%N)KR672+"26]B$
M%R[VR%IXQT1SCYE'H<BEC\+Z-#/;3QZ38I-;0FV@D6V0-%$>L:G&57_9'%:=
M% &/!X/T&VBL8H=$TZ*.QD,UJB6D8%NYZM& /E)]1@TC^#= DMYX&T/36@GG
M%U+&;2,K),#D2,-N"^?XCS6S10!E3^$]$NGOWFT>PE?4$$=XSVJ,;E!T63(^
M<#T.:<OAC1TN8[E=)L5N(X/LJ3"V3>L/_/,'&0G^STK3HH R+?PCH5HM@L&B
MZ?"NGDM9B.UC46Q/4QX'R9_V<4W_ (0SP^;9K?\ L/3?(:X^UF+[''M,^<^;
MC;C?GG=U]ZV:* ,FX\(Z'=_VAY^C:?-_:./MGF6L;?:<=/,R/GQ_M9I__",:
M/]J:Y_LJQ^TM;_9#-]F3>8?^>><9V?[/3VK3HH R;?PEH=HVGM#HVGPG3E*V
M9CM8U^S ]1'@?(#_ +.*O6.GVNF6X@L[:&T@!)$<$8102<G@<58HH I7.BZ?
M>2F6>QMII#U>2%6)_$BO+M;TVTL/VC/!?V:U@M\Z-J&3%$JY^:+T%>O5Y5XF
M_P"3C/!7_8&U#_T**@#U6BLS5/$VD:)<VMOJ.J65A<73;((KJX2-I6]$#$%C
M]*76O$FD^'(8I=6U.STR*5Q'&]Y<)"KM_=!8C)]J -*BLF_\7:'I6I6&GWNL
MZ?9W]_\ \>EK<74:2W'_ %S0G+_@#4TWB#2[;68-(EU*TBU6XB::&Q>=!/)&
M#AG6/.XJ#U(&* -"BFO(L2EG8*H[DX%.ZT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM&^+?@ZS\3:";EM,NL^6UU:RVS-CJ0DBJV/0XP>HKJZ "BBB@ HHHH ****
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M 4444 %%%% !1110 5P'Q_T33_$?P3\<:9JNJIH>FW6D7,5QJ4@)6V0QG,C
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M*95M_+P8E>1%)+AN20,"@#Z(KRW]H?7]:T;X=:S%I7A:Z\00SV,ZW$UO>6\
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M>C_L[_ "Q_9[\+ZMI-IJUSKD^J:I/JMU?742QO)+*V2,+Q@# _"@#U:BBB@
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M^V32<4US-):WZMV/1QF%Q5J?M4TN5-7:2^]NQWE%<']M^(^HX,6E^'-$0_\
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MM=U+5(H'MHIM9UR[OQ%&Y!8*LTC!<X'(':OFSPST&BBB@!  .U+110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\8O%MOX#^%GBOQ%=Z
M9_;-MIFFSW4FGX'^D*J$E.0>O2NQKS[]H*ZU*R^!_CJXTB\73]3CT:Z:WNG0
ML(G$;8; !S^1^E 'PAX$_8Q\=>(H-"\7Z7\,OA3;:1>>5J]EH=YXIURXLH-X
M$BG[,,P$C(. -N>@K])],6X33K5;M84NQ$@F6VSY0? W!,\[<YQGMBORY^$M
M_P#LFV?@/P[%J7C'XGZ/K"VL7VNQ-QK<2I<$ R + GE ;\XV\8K]/_#QM#H.
MFFQDDELOLT7D23%B[1[!M+%OFR1C.>?6@#0HHHH *\P_:$\?>&O!OPXUNWU[
M7]-T:>_L9X[6.^NDB:=MAX0,?F/TKT^N+^,D$<OPP\3EXT<KIT^"R@X^0^M
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M0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\D\4_ [_A*/V@?#7Q!NI[*?3M)T>[TU].N+;S&D>9D8.">
M!L/;/->MT4 8O_"%>'_^@'IO_@''_P#$UL(BQHJJ JJ,  8 %.HH *\I/[05
MK<_$?4?".F>#/%FM'3+N*RO]:L;2 Z?:R.@?#N\ROA58$[4.,UZJ>E?&7C?X
M':IJWQ6NY]"^$]QX?\87'B6WU)/B'9ZOOM&LEV>:T@:7S [(K1F 1E3D'/<
M'MGAG]J#PSXI\;VV@0:5KMK9WUY<:;IWB&[M%33=0NH,^;#%)O+9&U@"R*&*
ML%)Q78_%\Y^%WBG'_0.G_P#0#7SEX(^%_CIM7^'W@B_\(W6F:5X,\37NMS>)
MI+F!K2\MVDFD@6$*YD,C&8*P91MVDY.17H_Q>^"&GKX'\5:B?%/C4N;2XF\@
M>)[SR 2I.T1[]NW_ &<8QQ0!Z?\ "S_DF/A'_L#V?_HA*ZBN7^%O/PR\(_\
M8(L__1"5U% !1110 R:9+>)Y9&"1H"S,W0 =Z\*T&%_CU\1'UVX4MX+T&8QV
M,3#Y+RX'5R.ZC_ =S6C\8_$-_P"-/$-I\,_#<QCO+U?.U>]CY%G:9YR?[S=
M*]4\->';'PEH5EI&FPBWLK2,1QH/0=SZDGDGU-:4_=_?/_MWUZR^6R\[O1Q5
MXA[TO:]%MZ]7_P!N[+^]=Z.*OI=*6BBLRPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
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MQ!%!H=Y#;P/'I6EAG5X@Y+9MB"<^@%=K_P *H\<?]%G\3?\ @KTG_P"1:UO
M'BKX<ZWXL\40^$=>T;5-?:=9-8@T^_6>5)%&P%T#';C&W@8S[UW]=1W'@_B7
MX??%33]<\-6^E_%7Q)>Z?=W;QZE.=*THFVA$;%7'^C#&7"CH>O2NB_X51XX_
MZ+-XF_\ !7I/_P BUZM10!Y!JGPN^(%OIEW+:?&+Q-/=)"[11'2M*.]P"5'_
M !ZCJ<51\'_#?XEZIX6TF[UKXM>)=/U>:VCDN[5=*TH"*4CYE ^S'H?<U[;1
M0!Y5_P *H\<?]%G\3?\ @KTG_P"1:Y[1OAY\4KOQ7K]G??%;Q+;:/:B Z?=C
M2M*S<%E8RY/V8YVD+V'7O7NU% 'E7_"J/''_ $6?Q-_X*])_^1:YSQ;\/OBI
MIEYH":-\5/$FH0W5^D-^[:5I1^SVYSND'^C#D?C]*]XHH \J_P"%4>./^BS>
M)O\ P5Z3_P#(M07OPL\>PV<\D'QC\32S+&S(G]EZ3\S8X'_'KZUZY10!X9X&
M^'7Q0UCPIIUYK_Q7\2Z7K$L9-S:+I6E 1MN( _X]CV /4]:WO^%4>./^BS^)
MO_!7I/\ \BUZK10!X-I_P_\ BK-X[U73[CXJ>)(O#\-K#):WXTK2LRRDG>I/
MV;MQV'U-=)_PJCQQ_P!%G\3?^"O2?_D6O5:* /GGXF>&_B%X)L-%GM/C#XAF
M:]U:VL)!-I.ED!)&(8C%L.1CBNQ_X51XX/\ S6;Q-_X*])_^1:L_%CXE_"KP
MU=:?I7Q!\7>'M#NHY4U"UM=7U2.UD+1GY9%#,"0#^%=]HFMZ=XDTFUU32;ZW
MU+3;J,2V]W:2B2*5#T96'!'N* /-9OA5XZ2)V3XR^)F<*2!_9>D\G_P%K#\"
M_#OXH:SX5L;SQ!\5_$NEZO('\^T72=* CP[!>/LS=5 /7O7NE% 'E7_"J/''
M_19_$W_@KTG_ .1:YV#X>_%-_'EQIS_%7Q(GAY+!9H[_ /LK2MS7!?!CS]FZ
M!>>GXU[O10!Y5_PJCQQ_T6?Q-_X*])_^1:YOQ[\/OBKHNB1S^'OBIXDU6_-U
M#&T#Z5I1 B9P)&_X]EZ+D]?P->\T4 >5?\*H\<?]%F\3?^"O2?\ Y%H_X51X
MX_Z+-XF_\%>D_P#R+7JM% '@W@#X??%76O#XN?$7Q4\2:5J7GRH;=-*TH#RP
MY"-_Q[-U7!Z_E72?\*H\<?\ 19_$W_@KTG_Y%KU6B@#P>?X??%1/'UMIJ?%3
MQ(_AU[!II-0_LK2MRW ? CS]FZ;>>GXUT?\ PJCQQ_T6?Q-_X*])_P#D6O5:
M* /"O'?P[^*.C^&+J[\/_%?Q+J>JH\0BM6TG2B&!D4.?^/9>BECU[5O1_"GQ
MRR*6^,OB96(&1_9>D\?^2M>KT4 >5?\ "J/&X_YK-XF_\%>D_P#R)7'?##PY
M\0O'&DZI=7?QA\0PO::K=V""'2=+ *12%5)S;'DCK7NFO^)-*\+6*WFL:C:Z
M9:O*D"S7<HC5I';:B GJQ)P!WK)0^%?A=8!7N;/0K74M0)7[3<;1/=3,3M4L
M>68YPH_"@#DO^%4>./\ HL_B;_P5Z3_\BUS=[\/_ (J1>/--TZ#XJ>))/#TM
MG++<Z@=*TK=',& 1,_9NX)['IUKWCK2T >5?\*H\<?\ 19_$W_@KTG_Y%K!\
M<_#KXH:/X3U*\T#XK^)-4UB&/=;6C:5I1$C;@,$?9AVSW%>YT4 >1V7PL\>S
M6<$D_P 8_$T4S1JSI_9>D_*V.1_QZ^M3_P#"J/''_19O$W_@KTG_ .1:]5HH
M \'\(?#[XJ:I/KBZU\5?$FGQVVHRP6++I6E#S[8'Y)#_ *,>3^'T%='_ ,*H
M\<?]%G\3?^"O2?\ Y%KU6B@#R+2?#'Q"\*_$?P\L_C;6/%OANY@NO[02_L+&
M)('41^20T,,; G+\<CBO7:** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR5&[)SP*;KW[>7@/2?#?A?5++1?%.OW?B&YGL+71M,TO??QWD7^LMI8BX*R
M\8Y'O7SMX@^#'B.Y\?Z;\1=>^%OQ%U/2-8\/6FF7&D>&-;_L_5-,NK<;?WJ1
M7$8EB?J#N.WKBNO^$'[//BOPSXO^$NKGP#/X9M(-:U+4]0M'U9]2EM$DCVQ/
M<32R,3*W\00D T >_P#QW^-FM>"_V8M<^(.B>'M8LM:33?M$&G7EFAN;)SQN
MGB+X 3J0"?H:A^!_[2=M\0#X4\.:MH^MZ9XLU#P]'K,PU&UBB5EX5FPCG&XG
M<HQT/;I74_M(>$-4\?? ;QQX=T6W^UZMJ.ERP6T&X+YCD<+D\#..]?+_ (:_
MX6-X#\;?#WXAM\'O%6IVL7A0>&K[1K-[7[?:7$97;(RM*%,3X^\&X'44 >P>
M(_VXO!'ARQ@G;1?$VHS7&O7'ARWL].L$FGFO(ADA5$G*MT!_/%<^?^"@WAT0
MZQ"/AK\1GUG0F+:[I*:*AFTJ(<^;,WF["I'(",S>U>5?"WX*?$UO$7P^U?Q!
MX(NM'FA^(FHZY?VYGAE%I:RQ81V96PPSQ\N><UZU8?"SQ5%XM_:3NGT2X6#Q
M+;(FD2$IB[(MF3"?-_>..<4 =%XC_;2\*VE]IVG^%/#7BGXBZE<Z;'K$UIX7
ML%E:RM'&4>8R.@4D9PH))QTJEXA_;P^'^D^%/"&MZ;I?B7Q.?%,LUKI^FZ-I
MOFW@N8OOV\D3,"D@.01R!CK7C?P2\,_$K]EG4DUBX^%FN^-+'Q!X?L()(-!D
MMVN]/O8$*F*9))% C/!WJ3CTJU\*OV=OB!X9\9?"C6]:\/\ D3-XBU;7M6@M
MI4DCTM;E?W<;,#@L.A*Y&: /HKXO?$@6W[.&M>,;B7Q'X$']G+<NT5G$VJ6&
M6 QY+MLWCI@G'-</KG[;'A[P?JESX8M/"?CCQMK6CZ5:ZE?R:1I<4FVVDB#^
M?(QD50<9)7KG. :[K]K3PAK'CS]G7QQH.@6$NJ:Q?6/E6UI"5#RMO4X&X@=
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A /49H
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(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ibio-20230630x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'N Z@# 2(  A$! Q$!_\0
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/>EI#WH
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M*0STHH]**@M"4PT^F&@HYCXG?\DV\6?]@B[_ /1#UY]_P3*_Y)YXP_["L?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !2'O2TA[T (>E![T'I0>]
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M2" <@')KS"YM+C]H&/\ :S?P-HEY;_V_8:&^GQW5N]HVLB*-S(ZA@"!<+&R
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MD@,#MP,5/(^X_;I:M.Q]EE5.<@'/7(ZT, >H!'O7S3XRF^*7P8M_"_C?7?B
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M,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%^!OQ7^!?A32]6\(KKJ^$[ZW62W;2K])S++<$<36X&'WY QM.1CDUZ#+\?\
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MKP/\'/$]W\18/'OQ*\0Z=X@UW3[.:PTC3-&LWM].TZ.; GD D9GDED50I9B
M%X YKH/#7[0/PY\8I/-HWBO3K\P:;-JLXB8^9#:PMME>12-R;6(RK8/M61#^
MU?\ "6YUS3])A\<:;+=7_E+ Z%S"7E4-&C3;=BNP9<*S \CBB[",::=VSD]'
M^"OQ7^&>DS^$OAU\0-$T_P $B20Z:-<TN6YO]&B=BQAA99 DJH6.SS!P, Y
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M3<7!M8%C\Z4]7?:!N8]R>:NUB]ST()I),2F&GTPTC4YCXG?\DV\6?]@B[_\
M1#UY]_P3*_Y)YXP_["L?_HD5Z#\3O^2;>+/^P1=_^B'KS[_@F5_R3SQA_P!A
M6/\ ]$BO._YF5'TD?9O_ )(K,?\ KY2_,^S****^I/P8**** "BBB@ HHHH
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MMGR;YH%\Y,@@X?&>02.M:M%%<C;>[-TDM@HHHI#"BBB@ HHHH ***1F"@DG
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M#:0TM(:DM#33:<:;04A#3#3S3#29:$J&Y69[>1;:1(KAD(BDD7<JOCY21QD
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M_LW0KZ[4GU6!ROZXKDY?@YJ\/Q!^#&KKJ4>H6?@G2+_3;^YNG(N+MYK6&%)
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M** "BBB@ HHHH **** "BBB@#Q/]JG_D > ?^QVT?_T<:]K%>*?M4_\ ( \
M_P#8[:/_ .CC7M8KBI?[Q4_[=_4^FQO_ "*,%ZU?SB+1117:?,A7">)O@9X$
M\7ZA+?:IX;M)KR5Q))/$7@>1P<AF,97<P(!!.3Q7=9%&1ZUI"I.D[PDT_+0B
M4(S5I*Y^2G[:WAK3O"7[0FM:;I<+V]G'9V;+&\SRD%HLGYG))_.MS_@GW_R<
MKIG_ &#+W_T%*]<_;9^$_@KQ)\5X]5G\9G0]<GLHDO+)K"2Y3:H(C<%/NDKQ
M@^@-3_L0?"GP7X:^)]WJEMXQ.NZ]%8R1VMFMC);((V*B1\O]XX &!TR37W4L
M;3EEO*VW+EML][6W.A9[E:7U%5X^UMR\MU>_:Q]VT445\"9!2,P4$G@"EI",
MT 4Y]9LK?/F3JF/6LVY\=:'9@F6_C7Z FME[2"3[\,;?50:B.DV).39VY/\
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MLL1C7 _X%G\*\1F_9V\1Z;\1[/X?:?:I_P *7U2YM?$VIE>$BN+5462P"_\
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M7^R_C9BB( 7*(2&<C!#8R<<?8JNDH(5@P'!P<T,Z1#E@H'KQ6$\!&;?O:/\
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M_*O2?-M?[\7Z4>;:_P!^+]*/8/N/^TO[GX_\ \TV-_=/Y4TJ?0_E7IOFVO\
M?B_2CS;7^_%^E+ZN^Y7]I_W/Q_X!YCL;CY3^5,V-_=/Y5ZCYMI_?B_2CS;3^
M_%^E'U=]Q_VI_<_'_@'EVQO[I_*F[&X^4_E7J?FVG]^+]*3S+3^]%^E'U=]Q
M_P!J_P!S\?\ @'E6QN/E/Y4;&_NG\J]5\VT_O1?I1YMI_>B_2E]6?<K^UO\
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M;%:/A36_$_C<Z)X0\-:Q'X:L-%\-Z9=7^H_9Q//+)/"?+CC5B%"A8R68YY(
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M_4[S5K76+_5[C:9[J:"1'0$#A4 C"A1T%=9>>"K>]\>:9XI:>1;JQL+BP2$
M;&65XW+'OD&(?F:T6'K2UDWTZ]+N_P [65_N.&IF^6TKQHTX._.VW36LO9P4
M6KK2/M%*2CHK.TE;0\=B^*?C&PT^Z\(K>6E_XL_X2K_A&K;69X=D7E&U6Z^T
M21@\NL9(V@X+ 5J7=UX_^'WQ#\!Z5?>)[?Q)H6NW\MO<RSV2P7$;+;2R!1M)
M!0E<YZC;CG-=/K'P,TG6H_$1EO;N&[U75XM<@O(&"2V-U'#'$CQ'Z1\@]0S
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MC>\\ ^")=0TVWBNM5N+FVT^RCG.(O/GF6)&<]E!?)]ABL_P]\%--\.:1\/\
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M-!M1 % ] *\6\(?#CXD^!-,N--L-=\.SK<7,EW<ZQ=VTS75Q+(V6D= =I;&
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MW"LT<MQ*(\ ]B#R"#P1V((KH5.7)&=.][V_R^_\ 1F3FN9QEL?$G[9OA?1/
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M_K33TIQ_K33TJQB'O2'K2GO2'K30T(>OX4VG'K^%-JBC%\:?\B=KW_8/N/\
MT6U<]^PU_P BCXE_Z_H__10KH?&G_(G:]_V#[C_T6U<]^PU_R*/B7_K^C_\
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M / /_8[:/_Z.->UBO%/VJ?\ D > ?^QVT?\ ]'&O:Q7%2_WBI_V[^I]-C?\
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MGFF&J0T-8@8R>IQ25\B?M<>./&7B?X@6?A/X;ZDEIJ/@"Q'CG5P9-HNY4/\
MHFG'GDRJ)F*^FVO7/&G[1.FZ1^S'>_&70K4:QIBZ-'K%O:F39O5F0&,GL5+,
M#[J12YD)21ZZ:C:5 Y0NH<#<5R,@>N/2OGVX_:$\>>&U\.^)?%G@"WT3P#KF
MHVFGK,NH"34;#[4XCMY;B'&T*S.@8 DKN&:YZ;4_&\O[<_B'3IM$TZ70V\%0
MPS ZDP/]G_;IQYX3&/-)RI7L,<T<R'S(^G(;^VNDB>&YAF28%HFCD#"0#J5Q
MUQ[5(U?"FD>/&T=_V4=5\!^#)Y/[4T/Q#'IWAB&])2-Y!%S),Y^XF'=F/0=*
M]_T7XS>,?#7Q \/^%OB7X5L-$7Q+*UKHVLZ->FZM)+M4+_99=RAD=E!*G&&P
M134T-21[6>M(:\$;XY>/?'^NZ^OPN\%Z=KGA[0[V739=8UK4?LB7UU$<31VP
M"G(5OEWG R#5C_AJO21\(Y/%4FAZ@OB*/6/^$8;PG@?;/[9W;1:>G/W]W39S
M5\R*YD>W331P1EY76-!U9R !VZFHX[J&:>:%)HWFAP)(U8%DR,C<.V?>OC;]
MJGX@_%6T^"=_9>,_ UCI6GZM?Z;#'J.A:I]I-A+]N@<)<# (#!67<N1N('>O
M1[_XJ^#/A)\0OVB?$][HKZ?-H4ND'4KZ&=I)-5DFMLV\:1DX1MSK& .N<FCG
M5PYU<^A>XI#VKYLO_P!IGQIX"L;7Q+X\\):)IO@Z22-;R32M;2ZOM+21@JR3
MQ 8906&[83MY]*Z2?XW^+=9^,>O^%/"WA73]6TKPW=65KJDMQJ:P7DBW$22F
M>"(C#1(KC))^8A@.E4IHI21[8>@J(W,.V-_-CVR,%1MPPQ]!ZFJ'BJ?5[30+
MZ70+2VU#5TC)M;:[F\F*1L]&?!VC&3T[5\$^%_&WBG0?V3/@-K.JZ.UY'9>-
M].;38=.NS-=:F#+>@HX.-K%R% )(QSVIRER@Y6/T(/6F-WKQCP[\7_&^C_$G
MPQX5^(7A+3]#7Q4+B/2+O2M0^U*ES#%YK6T^0,,8PQ##(.TUEVOQQ\?_ !&U
M#6+OX9^"-.UGPIIEW-8+JVL:E]D.IS0L4E%LN#\@<%0[8!(-4IHOF1[Q(ZQH
MS.P55&2S'  I,Y&1R*^1_B=\=O$?Q<_9)^,^JZ7X7.A76CRZCH=]::A=F*XM
MHHK=6EE&!S(K/@*#SC.:^BOA1=Z]>_#O0Y?$=C:Z?JAM(@8;.X,Z&,1KL;>0
M.2.2.QH4TW9#4DW9'5)*DI;8ZOM)5MIS@CJ#[U'<74-G&'GFC@0D(&D8*"Q.
M ,GN:^4_A)XV^(9\7_&/1/!7A6TU5+/QWJ<]QJVN7YM[52ZP[((@ S,P"DG@
M!=P]:T_'?QCTCQY\-[BT\9>#9(?$/AWQAHVE:KX=FNROV:YGN$$%S'*G^LC*
MOO4]&P0<4*:#G5CZ</6F^E>#R_'?QWXM^*'Q \%^"O!-G?7'A/44M;C5M6O_
M +/:.KPI(@&%),C%F^4# "@D\U-;_M0VP^$</B:Z\/7:^*)-<D\*KX6A</-)
MK"2&-K='Z%?E+[^FWFK4XL?.CV^6:.!-\CK&F<;G( YX%+_C7Q[^TOX^^)]K
M\+H;#QEX*LM+L=5UK28XM2T+4_M(LY1?PN([@8! 8*RAER,X'>OL:X_X^IO^
MNC?S--2N[#C*[L0G^M-/2G'^M-/2M300]Z0]:4]Z0]::&A#U_"FTX]?PIM44
M8OC3_D3M>_[!]Q_Z+:N>_8:_Y%'Q+_U_1_\ HH5T/C3_ )$[7O\ L'W'_HMJ
MY[]AK_D4?$O_ %_1_P#HH5WR_P"177]8_F=TO^1;6]8_F?3-%%%?&GR(445G
M7WB'2],NHK:[U"UMKB7[D4LRJS?0$TTF]$.U]C1HJI=ZO8V#(+F\@MRZEE$L
M@7('4C)Z"N4^(?Q+A\(_#;6?%>D6O_"2_8(?,6UL95)E.X C.<#&<GV%7"G*
M;48K?0:BY-)';45Y-X4_:!L/$GQ.L?!,NFS6&I7&@0ZVS32IB-I,9MR <[QG
MGZ5Z3'X@TR746L$U"V>]7K;B93(/^ YS5U*-2D[372_R'*$HNS1?-?''A/X)
M^*]9_9H^-'A2;2I]/UC6=?OKJPANEV>>FZ-T(SV;80#7UO?>(M+TPRB[U&UM
MC%CS!+,JE<],Y/&:LB_MC:?:A<1&V*[O.WC9CUSTQ71A\34PR?*MW%_.+NC2
MG4E26BZK\#Y)^&FG>-?B?\:/AEK&J^#-0\*Z;X'T::SNY]0 47$[Q"/$8[C@
M'\ZY"/X)^)Q^Q7XJT ^%;O\ X2>Z\127<=GY'^D2)]I3:X[XV _AFOM_2];T
M_6HVDT^]M[U%.&:"4. ??%<-\6OC3IWPFU/PA9WUL]RWB'5$TU&215\C</\
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MEH[??K]Q7_+K3O\ YGHU%%%<)@%%%% 'B7[:?_)L/CK_ *X0?^E,53?L;_\
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MLB:#XGT.]\7?%KPZFI?$7Q-?3ZKJFZ[E46@=L0VB^6X!6*((OU)KF?$_[/\
MXM\,_!#XZ_"/PQHKWOA34$6^\' 3#$:W$B/<6/S'($<B,RY[/7L-]^TII5O\
M/OBYXIBTV6:+X=WM]97%L)DW7AMHHI"\9SPK"4 9]#7J>FZO;:E;VKK)&DUQ
M!'<?9RX+J&4-R.O>HM%[$I1>QYG^TYX'UCQ_\(?[%T*S-[J(UG1KH0A@/W<%
M_!+*<GT1&/X4V3P3K)_:JU_Q=]C/_"/W/@>'2(KO<,-="^FE,>.OW'4Y]Z]6
MNKJ"SC\RXFC@CSC=*X49^IIRNLB!T8,K<AE.01]:NR;+MK<^+?#_ ,*?BO\
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M_-N].* /5:*\Z\-:QXDN?'U[:W@)L$,F]<?*BC[FT]^WYUZ+0 4444 %%%%
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M59FN+_1M%U-K>SN)&.7;8!\FXYW;2,Y-=9XD^"'@SQ-\.[+P1<:-';>'M/\
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MX]?PIM448OC3_D3M>_[!]Q_Z+:N>_8:_Y%'Q+_U_1_\ HH5T/C3_ )$[7O\
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M3N>90UK&N>H $9'ZL:MW!QKENB-\@\M6/OB0X_' _2JT4P4:FQ;$:Q2NG/\
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M8!6X\N$.V?5OZ[:()%74+UF.(525AZ<%1^F#3&5-1 .D"3_EI(EX['ZH^?\
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MY4+@XW 1 AQ\I#C!K336]0_9R^,?Q+NM8\-ZOK7A'QIJL>NV6MZ-:-=M!/\
M9TADM9T7YE \L,AZ88UY?XLT[QK\4?\ AI[7'\":KHEOXA\ V6G:#;74.+F^
M\L7(&Y1TD);.SJ%*YHYF#;/8M6_:0A\)^-]/^&7A_P (ZYXK\2KX=L-5M(HI
M%P]O(&0M-*QPNSRUW,?O%QCFF:O\?;_Q5\'?B9-I_A/5+#QIX9BGT_4] >:-
M+BS=[9I$G63.UDV$2!@>0#CFK'P[\)ZG8_M+>(M:NM-FAL)/ .@Z?%>21X1I
MHYIVEB!_O+E"1]*H#PEK ^(7[3-S_9EQ]FUK1=.BTZ3R_ENY%TJ>-EC_ +Q#
ME5/N15>\T4KM&9\+_P!H6Y\)_LT_#C5O%&@:O<>)-6LK+3M(TR.1;B]UZ8VR
M/YT>#P&&YB6QM R:UG_:DO\ PYXK\)^'/&?PYUOPMJGB;5(--TUWDCGMI"^=
MS&5#@%,#*'D@Y&<&N1;P7XI\(?#G]G#QO9^';O6;_P !Z*MIJ_AZ)/\ 2_)N
M;".&5XE/66)D!V]2"PJ/XE_$35_C;XO^$UOX7\"^(!H&D>--.U35-9U.P:V%
MN$$JA45OF.-Q+MT  '>G=H=VC1M/CAX2^!OAOQ_X@:V\1ZC:/\2)M!O4N9_M
M4B7<@3+6Z]1#R L8YR:[CPQ\?M0N?'FA>&/%O@35O!,OB)9O[%N;Z6.5+F2)
M#(\+["?+EV MM/H?2O(=0^''B*YM]3C?0KQUD^/D&N!3$3NL T1^T_\ 7,;3
M\WM7L?QP\/ZCK7Q"^!]W8V4UU!IGC![N]EB7(MX3I]TF]SV7<RC/J15)O<I7
M.W^(WQ"T7X6>#-2\4>(+@VVE6"!I"BEW=F8*D:*.6=F(4 =2:\2\8_M=:M\-
M/"-SXJ\9?"?Q+H'AX1;[>Z9XI6+DCRXYE4YA+9P"W /!KN?VF? 6M>/OAA%'
MX=@CO==T75]/U^TT^=MJ7KVDXE,!/;>NX#/?%>,_M(_&/6?C-\!?&'A+PA\-
M?%5QX@U2P,5Y;ZEIS0I8KO5GRQXD<8PH7.3S52DT.3:/:_B%\<8_"OB/3/"V
M@^'M0\8^+[^S&HC2=/*I]FMB<":>1B%C4MD#/)(.*J>'?C5KNMV_B+3[OX=:
MWI?BW2+5+M-&F>,I>QNVP-#< ^6<'.03D8KD=?DUCX)?'/5_'=QX?U+Q#X1\
M5:%IMA=SZ3 ;BYTJYLPX4-&/F,3K(3D=&%>A_#?XJ7WQ,U/53!X2U?1?#5M"
MOV;5-8B^SO>3$G<J0GYMH&/F/4\52;;U*3=]3YL^#GCJY\6_LZ? ^Y\<VGB6
MVF?Q7IMG8:I;ZDH;4IY9KC;)*0<M"NW:R-R<#%?2?@WXT:/XJ\.>+]6O8Y-!
M;PI?WECK-M>L-UH;<%RY(XV/'MD4]PU>!>#_ (?>)+3]F;]F[2)M$O(M3T?Q
MCI5WJ-HT1$EK"ES<L[R#LH#*2?<5M?'WX$^)?%7Q>LX/#I,/@KXAI;V'CGR\
M@QQV3>:D@]#-$#;D]QBIBY)7%&Z1M^%_B59>-/BGX8\56F@>(U\2ZEX"GUBQ
MT&2\5+>6U^V*J(\9.T3ON5@QZ*V#7&?L_?M#:SX:^!\&N^-?#VK+I0\4W&G3
M:Y<W4<HB2?49H@S<Y$<#;(V/N".!7KK^&[V+]KOP_K$.G21:#;^!KBP^THF(
M(I?[0B9(L] =BD@>@KG/@5\*3K_[-&K>!O%NFS6<.L7^NV]Q;W";7$4]_.T<
M@!]F5U/L#5)2N-)W/2O%OQ+L_"WCWP;X1%I-?ZOXEEN=B0$8MK>"/?+<29_@
M!*+[EQ78?X5\N?L7:;XC\;'5/B-XSGBO]1M+5?!>C7<1W)-9V3E9[I3ZSS+D
MGOY=?4?^%:P;:N:Q?,KC?2F^E.]*;Z5H6)2#M2T@[4#0T_UIIZ4X_P!::>E6
M,0]Z0]:4]Z0]::&A#U_"FTX]?PIM448OC3_D3M>_[!]Q_P"BVKGOV&O^11\2
M_P#7]'_Z*%=#XT_Y$[7O^P?<?^BVKGOV&O\ D4?$O_7]'_Z*%=\O^177]8_F
M=TO^1;6]8_F?3-%%%?&GR(4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %><?$J[UV'7--33;9Y+<KU1<B1BW*
M-[<"O1Z* /+X[_Q+_P + NE%D3 H<K&5_=_<^5L^IX'XUE:;J'BEO#FM%K.1
MI 8@C-&0T8W'(4>B]1Z5[+10!XUJ=_XJ_P"$;T8K9R"1GEWNB9>3)& P[;AG
M/K6I+?>)#X^M$-B5M\1[HU7]WC9RQ/J"2/PKU&B@#Y,_:*NM<N/@#\3/[3MF
MCA%K#RR;1&WVN+Y5]NIK3^!5UK%M^RM\,_[+B=@;:3S)(ERZGS7 'T.37<_M
MCV5QJ'[-/CF"U@DN)C;1,(XE+,0MQ$S' ] "?PJ?]D.RN-._9M\!6]U!);SK
M8DM'*I5@#(Y&0?4$'\:]RZ_LFW_3S_VT\VS^O7_N?J6;R^\3_P#"2Z&GV I$
M8H-\2)^[;NVX]MO./2F:?J'BAM9U[=8&0+#/LC=/D5L\;?7/ZUZU17AGI'C$
M6H>*%\&S.+:7S?MB_P"D%/WH4+UQ[$ 9JQJM[XI#^'E6P*Y@3>B)Q(V[E7].
M #CWKU^B@#S;1+O7Y/B1<)<6K+8[Y,@K\B+C <'U.!^=>DT44 %%%% !1110
M 4444 %%%% !1110 GI2#M2^E(.U  >U)Z4I[4GI0 4AZ&EI#T- !_C2'O2_
MXTA[TT- >](>E*>](>E,:&UQ_P 3+G5+;1[<Z7&[,9LR21C+Q@#@CZGBNPI#
M0!Y3J5]XG%YX?5+ H#!&'C5/E<[N0_IC ./>I[:^\2_\)=JW^@EXU2<QQLO[
MM3M^4@]R<#ZUZ;10%CR"SU#Q./">H-]EE+B>/;,R?O%49SM'L0OTR:?J=_XG
M73-""63JQ1@VU"3(2_W7],@ GZUZWZ?6D-.P['E^HWFOOXLOTFM2MEY$I8!?
MW:KY)&\'U[5\X?L&37T/P'\:MI\7FSG6HP0!DA?L\62!ZBOM/5T:72KY$!9V
M@D55'<E" *^5?^"<ND7VD?"[Q2M[9SV;/K>%$\90G;!&K8SZ$$5[F&LLOQ"O
MUA^;/,K)_7*/I+]#UB_O_$P\,Z81:R"1I9=\JH3(^<8W#WR?KBM*:^\1?\)I
M8+]BV0%8MT:K^[(V\DGU!+8],5Z.>]![UXECU+'E6G7OB5EU\R63.PA8*KIP
MA+\A/7@DX]J@EU'Q+_PB4+^1*)#=,3/M_>D;1@_S&:]:/>FDT^4=CS*]O?$:
MZOHBK8E$\F'=&J?*QSDAO3'Z5Z5WI331VJTK%)6 ]!3#3ST%,-4BT-/]::>A
MIQ_K33T-,8A[TA[TI[TA[U0##WI#_2E/>D/]*"D(:8:>:9Z52&A"3G.3GUIN
M3SR<TII*90F2O0D?0XII)]3U]:4TTTT TGKS3&)]3QTIY[TQJHI"$\YSSZT,
MS'DL2<=S0>M(:8QI8^IZ8ZTRG&FU10G<4%V.W+,<=.>E'<4A[4T,;DK@@D'U
M!IK$DY)).>II3T%(?ZTP$).3R?SIC=Z>>M,;O310A/&.WI5+5[!=7TJ]L7FF
MA2Z@>W:6!]LB!U*DJ>S '@]C5QJ:>]4-&%X)\':7\/?"&C>&=$M_LNDZ3:I:
M6T1.2$4=2>Y)R2>Y)-;7^%+WI/\ "A#&^E-]*=Z4WTJAB4@[4M(.U T-/]::
M>E./]::>E6,0]Z0]:4]Z0]::&A#U_"FTX]?PIM448OC3_D3M>_[!]Q_Z+:N>
M_8:_Y%'Q+_U_1_\ HH5T/C3_ )$[7O\ L'W'_HMJY[]AK_D4?$O_ %_1_P#H
MH5WR_P"177]8_F=TO^1;6]8_F?3-%%%?&GR(4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !17 Z]\8]'TFYDMK:.74;F*1HY4B&T(0<')/'4$5S5
MQ\<EGT.XBG@?3;Z43)'<Q8>.+Y"8VR>I+87'K6#K4T[7/3AEN+G'G5-V_KYG
MH7BSQSIGA&!3=2&6Y<X2VBYD;WQV'N:\_M/CE=)>RFZTL/:-)F,1/^\2/..0
M>I[\5YM/=SW\\EY>RO/=RX:664\D@=/H,5D6_B;3KF]6UCN0TC'@_P )/H#7
MGSQ4V[QT1]EALAP\*=JWO2?X>A]4>$_$]OXNT6+4K9&BC=F7RY,;EPQ'([9Q
MG\:V:\%^$.LW&G^,(K)&5;;44831MQAT4LK#W(R/<#VKW@NJ]2!VYKT*-3VD
M+GQN8X3ZEB'36VZ]!U%%%;GF!1110 4444 %%%(>* /E3XF?M!>-M$_;P^&?
MPNTK2GE\+7NCW-_J31LI:97W*LI_NK"T8^N]O:OJL5\9?",K\4?^"D7Q=\4Q
M@S:=X(\/6?A:"7JHN)6$LH'N"L@-?9U 'A/[<NO:CX:_91^(>HZ5>3:??1V<
M2)<0-M=0]Q$C8/;*LP_&K'[$^O:CXG_96^'.I:K>2W]_-IQ$EQ.VYWVRNJY/
M?A0/PK(_X* _\F?_ !&_Z]K;_P!*X:G_ &"O^30OAG_V#W_]'R5W67U2_P#>
M_0YK_O[>7ZGOU%%%<)TA1110 4444 %%%% !1110 4444 %%%% !1110 GI2
M#M2^E(.U  >U)Z4I[4GI0 4AZ&EI#T- !_C2'O2_XTA[TT- >](>E*>](>E,
M:&TAI:0TQC?2BCTHH!">GUI#2^GUI#312*&MSR6NBZA-$VR6.WE=&'9@A(/Y
MBOCO_@EQXVU[QK\(?&$NO:M=:M-#KY\N2[DWLN^WC=P#Z%B3CWK[!\1_\B]J
MO_7I-_Z+:OB/_@DA_P D;\;?]A]/_22*NVFE]7J/T.6;_?0^9]TGO0>]![T'
MO7&=0T]Z:>E./>FGI5(H:::.U.--':J0P/04PT\]!3#312&G^M-/0TX_UIIZ
M&F,0]Z0]Z4]Z0]ZH!A[TA_I2GO2'^E!2$-,]*>:9Z52&AII*4TE,H::::<::
M:: :>],:GGO3&JBD(>M(:4]:0TQC#3:<:;5%"=Q2'M2]Q2'M30QAZ"D/]:4]
M!2'^M,!#UIC=Z>>M,;O310UJ:>].:FGO5#0WO2?X4O>D_P *:*&^E-]*=Z4W
MTI@)2#M2T@[4#0T_UIIZ4X_UIIZ58Q#WI#UI3WI#UIH:$/7\*;3CU_"FU11B
M^-/^1.U[_L'W'_HMJY[]AK_D4?$O_7]'_P"BA70^-/\ D3M>_P"P?<?^BVKG
MOV&O^11\2_\ 7]'_ .BA7?+_ )%=?UC^9W2_Y%M;UC^9],T445\:?(A1110
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M%% !1110 GI2#M2^E(.U  >U)Z4I[4GI0 4AZ&EI#T- !_C2'O2_XTA[TT-
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MCV']8B<)WI/\*[S_ (1RP_YX#\Z3_A&]/_YX#\S1]9AV']8CV."]*;Z5W_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI:#97=U.1@R2O K.V/<DFN^KR[]EO_DVWX6_]BQIW_I.E>HT %%%% !1110
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MD<8P[+G:6X'S8SQUKH?^$)T'[:;S^RK;[2=0_M7S=GS?:_)\GSO][R_DSZ4
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M (:6^%W_ $/&C?\ @1_]:C_AI;X7?]#QHW_@1_\ 6KK/^%>^%O\ H6](_P#
M"+_XFC_A7OA;_H6](_\  "+_ .)H Y/_ (:6^%W_ $/&C?\ @1_]:C_AI;X7
M?]#QHW_@1_\ 6KK/^%>^%O\ H6](_P# "+_XFC_A7OA;_H6](_\  "+_ .)H
M Y/_ (:6^%W_ $/&C?\ @1_]:C_AI;X7?]#QHW_@1_\ 6KK/^%>^%O\ H6](
M_P# "+_XFC_A7OA;_H6](_\  "+_ .)H Y/_ (:6^%W_ $/&C?\ @1_]:C_A
MI;X7?]#QHW_@1_\ 6KK/^%>^%O\ H6](_P# "+_XFC_A7OA;_H6](_\  "+_
M .)H Y/_ (:6^%W_ $/&C?\ @1_]:C_AI;X7?]#QHW_@1_\ 6KK/^%>^%O\
MH6](_P# "+_XFC_A7OA;_H6](_\  "+_ .)H Y/_ (:6^%W_ $/&C?\ @1_]
M:C_AI;X7?]#QHW_@1_\ 6KK/^%>^%O\ H6](_P# "+_XFC_A7OA;_H6](_\
M "+_ .)H Y/_ (:6^%W_ $/&C?\ @1_]:LKQ7^T?\,KKPOK$,7C;1WDDLYE5
M1<<DF-@!TKT'_A7OA;_H6](_\ (O_B:/^%>^%O\ H6](_P# "+_XF@#C_P!E
MU2G[-WPN# J1X9TX$$8(_P!'2O4*C@MXK6".&&-(88U"I'&H55 Z  =!4E !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ibio-20230630x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'U Z@# 2(  A$! Q$!_\0
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MH ***JW&JV5I>VUG-=P0W=SN\B"255DEVC+;5)RV!UQTIVOL!:HHHI %%%%
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M_$MKXCT.+0?$WAS43IVH6UM(7B+8."N<D<JP(R>F0>:\Q_X*$>);_P />'_
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MPH_:9^,%S\4]'\%?%/X&:AX5&M)(]EKNB7JZA91;%W,+AEXCXP,[LY(^4YR
M#ZEHKY,^/'[?FB_!']IOP9\*;C1EOK35/LPU?6C<E!I9N'*0@IM(;^%FR1A6
M%=9^U[^TYK_[.EOX$@\,^#(_&^M>+-9&C6NGO?\ V0F5E!0!BK EF('.![T
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MFN727'EC1[-1B.5AM(8LP(VG'5<?>% 'N5%)2T %%%% !1110 4444 %%%%
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M^A2L_P#OY+_\71_PS/\ #/\ Z%*S_P"_DO\ \71RT/YG_P" K_Y(+0[O[O\
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MD5YC_P ,S_#/_H4K/_OY+_\ %T?\,S_#/_H4K/\ [^2__%T<M#^9_P#@*_\
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M64$?0AZJ:C\.M>^&B'5?A_J-]?VMN-\_A+5[U[FWNHP.5MI9"SP2]=OS&,G
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M2 ?KNLSQ-XBTCPGH=WJVO:C9Z3I%LH:XO+^98H(@2%!9F( !) Y[D4 ?%?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG;W=G-L\B 6Z!$,>%#9('.2:]2H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S\*_P#)?O'_
M /V!M&_]#O:],KS/PK_R7[Q__P!@;1O_ $.]KTRNBO\ $O2/Y(TGO\E^0444
M5SF84444 %%%% &!XQ\/:AXFTZ*SL/$-[X<_>AIKG3HXFF>/!RBM(K!,G!W
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MPG2?LI/;\^OY'DPE&:YX]0HHHK T"BBB@ HHHH **** "BBB@ HHHH ****
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M?_"GO"__ #PU'_P<7G_QVC_A3WA?_GAJ/_@XO/\ X[0!VF:,UQ?_  I[PO\
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MA86R&2:YN9!''&HZEF/ %>3^(_VB_P"S/#]WX@TKP3XAU?P];*&.J2)%91S
ML%7R4G=9)-Q8 83G(QFNFC1JU&G277?;7U[F-2I""M,\5_;,^">C> _@;XEU
MK2M2UXRW-W8K-;7>JRW$$@6543<LA);:O"Y/&!Z5X=_P3I!'[0TG'_,$N_\
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M8PM;VIUZZ"1M;M 5P(P?D901R#VYZ]Z[]ONFN%^%%Q/=1>*I;BU>RF;7KG=
M\BN5^6,#E21R.?;- '=T444 %%%<Y\1?$,WA3P-K>JVP4W5M:NT ?[OFD83/
MMN(J924(N3Z&U&E*O5C1AO)I+U>A!X'\=1>,[CQ%"D)A;2-3ET\\Y$@4 AQ]
M<D?A755X9^SLT^EZOKFG7\B/?W5O!?RE/NO*6D68K[!BOYBN^OO%DR?%#3=&
MB;_0_LTBSC_ILPWQC\%1O^^A1@(5,73;ZI-OT1T<2?5\FQGLE\,G",?-R2_"
M]WZ([6BBD/%4<(M><^./@KI_CG7=3U6XOKBWN+W3+?2\1C*QI%<F?=C.&))Q
MR. ..IJDO[3/PZM/%/BCP]K7BG2?#.IZ!?+8S0ZUJ$%LTQ:".821JS@E,2@9
M('*M5S_AI+X3?]%.\'_^#VV_^+H K)\%9--\16>MZ1KS65_#=:E(_P!HLDGC
MDAO;A9Y(PN1M9610'!SC.0>W.?%WX:>%XM5\/:SK_C?4M!>QO5FTE[FY\U([
MUI4;=E\\$*(PF0-KL/XJZS_AI+X3?]%.\'_^#VV_^+K!\3_&;X0>*IM'^U?%
M?PM'::?>I?/:1Z[:[+ET!\M9/GR55RLF!_$BYZ4 <_XR\&>&_$Q\;>);/XCQ
M:/:S7D*W<UO&DL=I-'!);L#N;+,R38 &%!52%)R3;T3]F*Q@N_[6L/%,S)/J
MEOK$$T%LN&VRR2Y)W;9&82E!(P.$Q@9PPXO1%^#OAS1+_3]/^.?AZ+[3J?\
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M/G;_ (*+:_KOAG]DSQ=>>'[N[L+HR6L4UQ9$K(EN]PBR_,.5!4X)]":^#/\
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MHH *2EKSOXX>#-?\<>%+2P\/7IL;N.]2=W6Y: E0K@?, <@.R,1CD*<$-@T
M>AD_*:X3X3O=O%XJ:^BAANCKUSO2WD,B#Y8\88JI/&.W6N?\%_#KQGI?A'7-
M/F\2OH>JW4T30ZC;,-08.JJ)IPMPI \Y@6V8(7/'-:OP1TZ_TG2?$=IJFL2:
M]?Q:Y<B74)K>.!ICB,C*1@*, @<#G&>M 'H]%%% !7GOQUGV?#V>WX_TN[M;
M?'J#,A/Z UZ%7E/QZN]T/AC3QUEU!KD^NV*)S_Z$RUS8EVHR^[[]#V\EASYC
M1\GS?^ ^]^AROP\G,'Q/T8@X^T6]W WN-J./_0:U;R[(^(<][G!CUV*+/^R$
M6(_^A&N=\)R?9_B#X4DSC-Y)%_WU!)_A6A?W&ZXU*[[C6'ES_NW('_LM>UPW
M'F55=[+[[?Y'S7B?+V=7!R71.7SBY?YGOE'6BEKSCJ.)TGX.^%]*U_Q/K#:;
M#?W?B"^74+HWT,<VR001PX0E<A=L2G&3R3ZU>MO"7@^\N;JWAT/2))K5PDR"
MQBRA*AAGY?0UU%>1R^*G\*>(=<U)(C<?:YY81#G >2,@)SV^4/\ E7E8['1P
M/)*?PMZ^2MT^=CTL%@Y8SGC#XDM/6_\ E<[W_A /#/\ T+ND_P#@#%_\31_P
M@'AG_H7=)_\  &+_ .)K;MYEN((Y5^ZZAA]",U)7J)IJZ/.:L[,P/^$ \,_]
M"[I/_@#%_P#$T?\ " >&?^A=TG_P!B_^)K?HIB,#_A /#/\ T+ND_P#@#%_\
M31_P@'AG_H7=)_\  &+_ .)K?HH \ZF^&>B>!['XA:QI$)M9?$%MY]U;H%6%
M7BM?)4HJ@;<JHSZGFNH\"_\ (D^'_P#L'V__ **6I/&G_(GZ[_UX3_\ HMJC
M\"_\B3X?_P"P?;_^BEH W:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S\*_\ )?O'_P#V!M&_
M]#O:],KS/PK_ ,E^\?\ _8&T;_T.]KTRNBO\2](_DC2>_P E^04445SF8444
M4 %%%% &+XLUG4=!TH7>FZ'<>()5D426=K-''+Y?.YD\PA6(_NY&>QKQSXC_
M !(76_["U;0?#?BEO%VA7GVJWTR?0;E#<1NICG@:0KY:AHV.&W8#(IZ5[[65
MXGM=5O=!O8-#O8--U66/9;W=Q#YR0L>-Y3(W$#) )QG&>*:/3P6(I49Q<X7=
M][M*ST:EH[JV]DG:^I\;?MD:SX]_: _9I\=V7AWP:;+3-,OXH;N&[O%>_N#!
M/&TJI%'F/"GKER3M8 9%?+G_  3?\-^)/A;\<=1\5ZSX4UZW\/P:-/:7=S:Z
M>\IC:22)D+1IERO[MSD*<8]Z^^?VE/#F@_#3]E35K";6(])TK3!#+)>Z@69K
MB0SAF+;02TDLC$\#EF[#I\^?\$_?&'AGQ?\ %[4_[)\1VMQ>VVE2'[ T4L<T
MJ-)&"ZAT *J0,\Y&X<=Z]:ARK#R<MNQ\7G&8XA9S3PV"PO[AI>_KIJ]7>^O7
M?K9'T5>_&SP7\3?B9X/CTKQ5I@T70TEUR[NY[D6X>1XG@MX5$A4DXDE=N. J
MY^\*]/\ #WQ:\,^+O$)TC0+UM<>-&::\TZ)IK.#&/E:X \O<<\*&)X/ KFO!
M?PQ_L'5=0\.:KH.FZWX2A:2[T34+F**5[19)"SV3HP+81F8HXXV$*<%>?4K6
MTAL;>."WAC@@C&U(XE"JH] !P*RQ,L/I&FFTEIJO6[TWUVTL>K157XI-:O73
M_@DM%%%>:=@4444 %%%% !117/V_Q"\+W?B%M!@\2:3-KBNT;:;'?1-<AE&6
M'EAMV0 21CC%4HN6R&DWL>;?M;Z]K^D_"%[#PK>SZ=XEUW4[+1].N;:0QR)+
M+,.C#I\JMSZ9KQ+P-^T1XF^(WQE\ 7\=U=V?A8V!\.:G;!RL<FM/9RSOE>Y1
MH@H/;/O7U]K_ (3T?Q3-I4NJV,5Z^E7B:A9&0G]S<*&59!@]0&;KZUR>J^ _
MAMX%TN.]U'3])T.PAUQ=:2>XD\F-=2D;8LVXD?.Q?:!TYQBO4P^(HPI>RE"\
MG?7UT_RL=5.I!0Y7&[_S/F70?C%XMTKP#\']:@UB^UG4CX1\1:E=6LUP9/MT
M\$8,1F'5]K XS[BO4?A3X%DETKP)XYN?C)K]_JFK>1<W,=QJ$3Z?J;2)N:UB
MMR-J8)P-GS#:>_3U+PE\#/ /@7Q'?:]H'A>PTW5KU72:YB4D[7;<ZJI)"!CR
M0H -9^@_LW?#+PSXIC\1:7X-TRTU>*5IX9D1BD,AZO'&241N>JJ#6M7%T))J
M"<=^BUNV[/71*_\ P-K5*M!W4=/DO,\Z\*>.Y_A;XE_:"O=:UO5]=T;PP]I?
MP1ZC<><T8>U:9XX\ !5+D  # &/2MG]DWQ]J_BCPUK6D>*_[4C\;:?=B]U2'
M49$=(UNP9H!;E20(1&0H4\C!SUKU7_A7_APW/B.X;2+627Q$J)JQD7<+Q5C\
MM0X/! 3Y?I5;X>_"SPG\*=.N;'PIHEMHMM<R":982S-(V, LS$DX P 3@#@5
MSU,11G3DN7WGRZ^B2?Z^NFUC.52$HM6UT_ ZNBJ&N:[IWAK2KG4]5O;?3M/M
MEWS75U((XXUSC+,> ,D5>5@ZAE(((R".]>;9VN<PM%%<7\5KZ:S\/V4*3/:V
ME[J5K97ETC;3#!)(%8[NV20F>V_-1)\JN-*[L=/9:WI^HW$\%I?6UU/!CS8X
M9E=H\_W@#D=.]7:\^\;>&-%T/1X-3L;S3?".IV!"V>I7!6*'<?\ EC,21OC?
M&""<]QR :Q] ^*OC1]<TF#Q%\/X=&T6^G%HNL6VO0WBM*RDQLD:*"8F(QN)#
M#(RO4U,9/:0VNQZS12#D4M:$A1110 4444 %%%% !1110 4444 >4?'S]F3P
M)^T=I5I:^+M/E-W9;OL>IV,ODW5N&QN"M@@J<#*L".,XS7YZ_MM_L<?#?]FK
MX<Z-J>@^(]7F\27M^MO'I^ISQ2?:8=I,DBJJ*5V?+ST^8#J17Z?>.U\6-H@_
MX0V31H]7$JD_VXDS0&/!W#]T0P;.,'D=>*^2?B#^Q!X_^*VNZMXH\6^+/"VM
M^*]0B>RMY+S2[B6ST2V*@(+*'S0N\$N=TH;G#<&DP/RBHZ5^MOQH_P"">_AC
MQ#\"=&\.^#/#^B67C?2;>""+6II);<S8QYSRL@8R%CDC>#C/&.E?-O@C_@E+
M\2=8U0)XGU_0O#NF@G=-:.][,?3:FU%YXZM2L![U_P $G_%E[JOP5\2Z'<NS
MVFCZT?LI;HB31+(R#V#[FQ_MFOH'XP_M!1^!/$.G>"_"VCOXU^)&JH9+30+:
M81+;Q#K<W<I!$,(]2,MT4&O'OAS_ ,$^[[X/V9'@?XS^*_#5W=HJZFUO;6SP
M7;#.&6%U(1@"0#EB/6O>/@W\ _#/P5MM0ETLWFJZ]JL@FU7Q#K$WVC4-0D]9
M)3V'9% 4=A3 X_\ MW]H#PE:-KNNZ5X+\3Z="/-N]#\.&ZAOHXQRWD22DI,Z
MC)",$W8P""17MNC:M;:]I%EJ=DYEL[R!+B%RI7<CJ&4X/(X(XJYUIL<:0QJB
M*$11A548 'H!3 =1110 4444 >7?#[_DM?Q6_P![2O\ TD->HUY=\/O^2U_%
M;_>TK_TD->HUTXCXUZ1_])1I4W^2_)!1117,9A1110 4444 %%%% "-]TUY[
M\';5+)?&4$<TT\<?B*Y DGF:9SF.(\LQ)/7\!QVKT)ONG/I7F/P)DTR2#QQ_
M9$<,5@/$UT(TMXO+0'RH=V%P,?-G/'7-)]"XJZ?]=4>GT444R KQ+XT7!G\>
MZ1;GE+;3)9L>ADE5?Y(:]MKP/XH3"X^*%]C_ )=]-M8C]2\K_P"%<.,?[NW=
M_P#!/J>'(WQKG_+%_C:/ZF)ITGD>)_#,V<;-6MAGV8E#_P"A5>FD,WAV\G_B
M=II_Q\UFKG/$%V=.TM[X<&SDBNLCL(Y%8_H#7211^;X3P.KV1/XE"?ZU]%PS
MI[7UA_[<?#^*BN\);^2JOQI_YL^A8G\V)''1@#3ZHZ'.+G1;"8=)+>-Q^*@U
M>KS9+EDT==.7/",NZ*]_>Q:=93W4YVPPH9'(] ,FO);>,W%LS7"8>=WF8-R5
M+DG\\-7H'Q E\OPE?*#AI=D(]]SA<?D37$GJ<=*^/SB?/7C3>R5_O?\ P#ZW
M*H<M&4^K?Y+_ ()W'@?4OM_AZWC;B>T MI5/]Y0!GZ$8/XUT%><>$KQM/\3Q
M1AB(;Y&1U)X\Q!N4_7;N'Y5Z/7LY97]MATGO'1_+_@6/(S"C[&NVMI:_?_P;
MA1117JGFA1110!C>-/\ D3]=_P"O"?\ ]%M4?@7_ )$GP_\ ]@^W_P#12U)X
MT_Y$_7?^O"?_ -%M4?@7_D2?#_\ V#[?_P!%+0!NT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !112$XH 6BO'OB3^U?\-_A
ME?MIE[K1U;7 =HTC18C>71;^Z53A3[,17%)^T%\8?&V#X+^"5Y9VK<I>^*[Y
M;-6'8^7][]:[88.O./.U9=VTE^-C=49M7M9>>GYGTM17S8+/]J;7R7:_^'WA
MI3SY:QSW+#\>13CX _:;?D_%#PC%_LIH9(_45?U2*WJQ^]_HF/V2ZS7]?(^D
M,BEKXG^%?@/]IC3/C-XAU"36;&+1I;\_;I]51A87Q554O;VP.]<A1AE* D<D
MU]K)NVC=C=CG'2L\3AUAY)*:E==":E-4W923]#S7PK_R7[Q__P!@;1O_ $.]
MKTRO,_"O_)?O'_\ V!M&_P#0[VO3*SK_ !+TC^2)GO\ )?D%%%%<YF%%%% !
M1110 5A>,_%:>"]$;59M.O\ 4;6*1!<#3H/.DAC)PTI0?,RKU8*"V,D XK=K
MF_$WC)/#7B#POILUJTD6N7DED+K>%6"18))5!'?=Y94>]:4X\TMK_P# U9$W
M9;V/DK]K3QMI'[0WP5^)WA'2_%OAR"2SNM-N=(,EU@WB!8IG7C+;M_F)PORE
M?FQR:^;/V!?@EX_\%_%C6=?T+4/"QUNWT2>"VT_4+J5A<>8R98%$^7844G.<
MYQCG(^Z?VT[_ ,(>!_@#XE\1:]ITI6)X-CZ9!$+J29IE5 &88 )/S$GIFODW
M]AK]I'X:S?%+4GU ZOX<NX],D,$^IO$]JR[T\S<T8RK 8()^7&><XKV85*7L
M92IQVZ/7HO3<^6KK.)9G1H8>G&5*6[^U=M[*_32VC/M[X+6WC'P[I.D^'=5\
M-1:;I]C;-]HU&ZUA+FYNIV)9G6.-, ,[.QRPQD "O5Z\&TKXR>!]3^,NNZ]_
MPF&C0:3INC0::DTFH1JMQ,\K3.4&[Y@J^6,@=6([&O2_!GQ$A\>7MRVF:5J*
MZ)'&&BUF[@\B&Z8GI$KX=E YW[0I[$UY-:HZLW-JU^U_U;/NZN65\'!<R=DD
MVVK6NM%TN[=-SKJ***P. **** "BBB@!#T-?">ASKHGQ9^,5Q#JSZ=XA74->
MN;#3U\,&2>;%FQ26/4=N8^0<*#R5Q_%7W;28KMPV)^KJ2M?F5OZNG_74VIU/
M9WTW/B)M9^*/@[PY?QZ5XG\3>(+[5?A]I^NR/?H)Y;2Z>Y1+@VRE0%<0LY$?
M4E0>36#?^,;_ %67QKI6A>*?%GBS0;2/PW-:CQ+;LTZ22:FHF*H\88@J/O%>
MQ .%S7U'\>?B)X8T"VT_PAXB\*ZSXQ7Q-%<*FE:/9BY>5(0K/D;U(QN4@CD8
MSQBG?#72/AE\+08='EM-!U?6?(-Q:ZKJ6_47<INCAD\V1GW*K8"9XR<5ZT<4
ME3]I*EJ]59*SLU\^C6W<ZU52CS..O_#?Y'A/A/6?B+8>)O#FOQ^)/$.J3ZKX
MJ\0:0^BW[%K%;>);DVPV;1M^>-,.3T8 '%8?P1\=_%G4]4OI8?$%UJWB"/0;
MZXU/0M2%W(R7P0^0JQR6R16[K+A?+60AESUZU])7?[1?AW3/'$?A?4+2]L+V
M?7/["MY9VB$<TGV<3>:/WF1'R$R1G<RC'-=_:>,-!OK^^L;?6M/GO; %KNWC
MNT:2W ZF10<KCWQ64\5*,7S45JM/2[\O.WR1$JK2UAN? ^C_ !!^*,O@7Q-<
MV/C35;JYCTFV;4(F:\EN[2]>[A7='YELB0N 9%:%&8;>1D#-=;\:M;^(O@[X
MF77AZR\7:SI-I8V5E%X;NKN>[E.H2G_6RR+#;R"Z?S,JR.5VKC [U]DZ-XS\
M/^(KF:VTK7-.U.XA199(K.\CE=$/1B%)(!SP:?H7B[0O%#W*Z/K.GZLUJWES
MK8W23&)O[K[2=IXZ&AX^T^;V*M_G:W3R^YV#V^M^3^M/(^(OVE]?U_4A\3-(
M\5:]XEL=76&TBT'P[I-I(^EZA:F.,S2-B,A_WGFY9F4IM7'I7W98#%C;YZ^6
MO7Z"I\4M>?7Q*K4X04;<O^27;R\]S"=3GBHVM;_@?Y!6-XGN=%_L&]37);;^
MRI(WCN%N6&QEQAE([GV'-;%>+#P%K.A?$+7]:N[W[-H4THN+0QQQSQP$C,CL
MKKE&+9)(Z\<]AY=63@KI7,X)2>KL8_PY^&MKJNJZ?JGCR&^\0&ZBD;P_9>(]
ML\6EP[B1"(F7F<QA&,LFZ0C*Y&T@];8>#H[I/%.E>'EATS3K.]MY].C12+>"
M]CQ))M4<*A;8"%X!+=ZUO!WBC1_C'X?U14D^V0:=J)LS>6X>$/+&J2"6(YW+
M_K!SGJ#U%=IINF6VD64=K:QB*%,D <Y).22>Y)))-2H<R78;EJ<QX<^(%SJ&
MOKH.K>'M0T;5# T^\[9[1U4@';,A.,YX#A2<' X-=E7BVI7>J?"&Y\4>)=:\
M1*^G23-=F&YM2T;IT54* NK #'&1W(YS7J_AO7(O$WA[3-7@CDA@O[6*ZCCF
M7:ZJZA@&'8X-.E/FO%[H)QM9K9FE1116YF%%>(_$8_'\>,;_ /X0D>"?^$9_
M=_9?[7\_[3]P;]^WC[^[&.V*YK/[5/I\./SN:[HX7FBG[2*OYFZI75^9?>?2
M=%?-F?VJ?3X<?G<TC']JC:<CX;XQSDW-5]3_ .GD?O'['^\OO/I2BOG[]CW_
M (6U_P (1-_PLK9]CW?\2O[7N_M#R\G/F_[']S=\^.O&*^@:YJ]+V-1T^9.W
M5;&4X\DG&]PHHHK @**** "BBB@ HHHH **** "BBB@ HHHH \N^'W_):_BM
M_O:5_P"DAKU&O+OA]_R6KXK?[VE?^DAKFO'1_:'_ .$NU3_A$QX&_P"$<\T?
M8?[3^T?:=FT9W[>,[MW3MBN^=+VM2W,E[L=W;[*-W'FE:]M%^2/=J*^;,_M4
M^GPX_.YHS^U3Z?#C\[FG]3_Z>1^\?L?[R^\^DZ*^8]2/[4W]G77F#X=^7Y3[
MO*-UOQM.=OOZ5U'[(O\ PM3_ (5I%_PLW9YF$_L[[3G^T?)Q_P O/;/3&?FZ
M[N:4\)R4W4]I%VZ)ZBE2Y8\W,CW2BBBN P"O//C3\0-6^'GA_3[W2+"*\DGO
M1#,\X+)%'Y;OT#+EF**BC/+.!R< ^AT4 >2>#/BSXC\0>$-;U7_A&)=;OK.6
M)8M.TO%O(2ZJ9+=C<.J^9"25<Y )' !XJ7]G_5[W7(/'5YJ.DW.A7;^)I]^G
MWDL<DL.(+< ,T;,AR.1@G@BO5&^Z?I7EWP,DNI+[XD_;8X(KH>*IPZV[LZ#_
M $:VQ@L 3QC/'7-0]T;TU>,_3]4>IT4459@%?.WC:87/Q+\42+TC>V@_%8 Q
M_P#0Z^B#TKYGU"X^V^*/$]SD,)-6G56'=4VQC_T"O.QK]V*\_P!#[/AF/[VM
M/^[;[Y)_H4=919=(O4<!E:!P0>_RFM_PM<C5O"NF3$;?.M$! [';M/\ *N<\
M02&/1KLCKY9'Y\5K?#I_^*6@C!_U$TT6/3$AQ^AKZ;A_W:,GW?Y)?YGY]XCV
MJ8FDG]F*_P#)G*__ *0CW/X>W9O?!&BR'J+5(S]5&T_RKHJXWX43;O"KP=K>
M\N(A[#S"P_\ 0J[*N;&1Y,347F_S,,JJ>UP%"3WY8_?97..^(USF'3+(=9KC
MS6_W8QN_]"*US%:WCB7S?%$$><B"S+8]"[_X)637YOC9^TQ51]G;[DOUN?I6
M#CR8:"^?WO\ RL,,SVES:7<<;2M;3I-Y:?>8#A@/?!->D:)XDT[Q#'(UA<K.
M8MHE0 AHR1D!@>A]J\ZK9\!R"'Q'>Q# \^U23'J5<@_^A"MLNQ$Z->--?#-Z
M_<[6_!&./H0JT7-_%%:?>KW_ !._HHHK[8^0"BBB@#&\:?\ (GZ[_P!>$_\
MZ+:H_ O_ ")/A_\ [!]O_P"BEJ3QI_R)^N_]>$__ *+:H_ O_(D^'_\ L'V_
M_HI: -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHI.E &=XB\1:;X2T.]UC6+V'3M,LHC-<74[;4C0=23_ $[G@5\P0ZA\0?VQ
M;B5],O+[X=?!_>42[B&S4];4'!*G_EG$>>?_ $+H)O'D<O[5?QUE\ QR/_PK
M7P5*D_B%HV(74;[K':Y'\*X.?HW?;7U+:6D-A:PVUM$D%O"@CCBC4*J*!@*
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MORL.>)G)-=&%%%%>4<@5YAX_U*=M:FTI])FO'N4!MKV])33K=< ')'WI-V>
M,XQR!7I]<3XX\41Z=>C39-3^P230AH;>WC\RYNF)8%4'. ,#)QWZBN7$J+I/
MFV-:5U-6(?A+X?TOP7I5WH%FICOXYOMMYOE$AF>;.)01C"G85 P,!,=LGH?&
MNH76E>$=9O;'B[M[26:,XS@JI/3\*X#X*> AX<UOQ+K=S<S#4]4\E)+"?.^V
MC3>4WD_>9B['()48P"<&NJ\4:R^LS:AX;TUUCG%N#?WLF/+LHI <'G[SD!B!
MTXR>*<'^Z027OLP/$'@[X?ZUH4MCKDD=R-0MQYTT]RYG=' ))8'*!@<<8X)
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M5H_2<9A:&&IQDW>4HJUK\M^KNUKII9=;W:M9[M%)D>HHR/45)X0M%)D'O2T
M%%%% !1110 4444 %%%% !1110 4444 %<MXAUSPV=573+OR-0UE(O-2QA02
MW*H3@-@<HI(ZG ./:NG+#FN*\%V,%GXZ\?/%"HEN+ZVFEFV_,Y^R1*%)ZD *
M,#H,^]2^PT4? WA?7K+XA>(==U)V73+ZSMH+.VFG\R2 (TA*8' ^^#G)R3[5
M7^(^FQZ3XATK4GD\K1]6N[>PUF,]'5=Y@8GL-Y5&]5;VKTVJ6KZ-8Z_I\ECJ
M-K'>6DA4O#*,J2"&'Y$ _A4.G[MD4I6=RVBJB@* H P .U<S\28Q<^#[V!3^
M^F:*.$#J9#(NS'XXKISTKSOP]I L_%=S'X@UO4+Z_CN&GLH;V=!;,CL=C1(J
MKEESLP22,9[YJI=B5W/1!2T458@HHHH **** "BBB@ HHHH *YKQ'-:ZQ:3V
MIN2EN$D29D3+9& 54D<]QQ69XBU^^G:[2RD$)MY/+*,< C/WB1SZ\5R]K]K$
M8%Q-]JF!R'5-I/?IGKFM52<UY'/*NH;;F[;ZQ8S:-<I<;?[0EC-M<)9,56,!
MCM!/7<%*YQWI^@:@BQV%E--"T5K*WSJ0JE=QP2/X2"!]>?6N8CNA<WTP07"+
MA2K/%B,G^(C^\2>Y]>*=>23!-L-M%<>85W-(^W !Z=#DXZ9XK*-)\JD_0J5?
MWN5>OR/1;*VAU#6;R4D1@!D,4<F1.IP-[#VQ@8Z'-6KF!]/TN"$MYL4;*LC;
M<NPSP0,]<XR?J:Y/0M6F^UQ++=RP?*$#*H9<#/!!'3)Y(QT%=U+;1WUJ([E4
MF4@$X'!(Y!'ISR*4J;A=-&D*D:BNF3TM5K*PCT]/+A,@B  ".Y8+CTSS5FF4
M%%%% !1110!Y=\/O^2U_%;_>TK_TD->HUY=\/O\ DM?Q6_WM*_\ 20UZC73B
M/C7I'_TE&E3?Y+\D%%%%<QF%%%% !1110 5R?Q)^&>C?%308])UHW:V\4ZW,
M3V=R\#I(N=K94\XR>#D=^H!'644 >?Z9\$_#5KX=U31-4M_^$DTR_,2R6VKH
MDR"*$ 01;=H!5 !@G))Y))KC/V8K#0=)U#XHV/AF&QMM#@\4.MO!IH40)_HL
M&X*%X^]NSCOFO<F^Z?I7B_[/VH#4O&/Q?F$$]L#XG&([F(Q2#_0X!RIZ=,CU
M!!K*?Q1]?T9WX97I5_\ "O\ TN![31116IP'%?&>Y-M\+O$14X:2V,"^Y=@@
M'_CU>,E0A*C@#@5Z7\>M0QH^BZ2#_P ?^H*TB^L<*F4_^/*GYUYIUZ]:\7%.
M]5KLD?IV0TW3R^+?VI2?RT7YIF%XH?/V&/N92WY*?\:Q+F=K-8KM#A[66.<'
MTVL,_IFM7Q&^_4K5/[D;O^9 ']:S98EGB>-QE'4JP]B,5]I@(\N#IKNG_P"E
M,_(,^J*IG&);V3BODH1O^-SV33;X:7XCT:_R!%'<B)V_Z9RC9_,H:]1\:7S:
M?X7U&5#B5HO*3_><[1^IKP'PW?3:YX0EB=LWML'MF8=W0 HWXC::].\0>,+?
MQ+I^F6ELDKR.8+J=PG[M1LW[=WKDKQ[UQ\258T\&JU[-IQ7J]5^OW'C\'TYQ
MQU7!R5U%J;]%I)^EE'[S/BB6")(E^ZBA1] ,4^BBORA::(_:=PHHHI@+;3_9
M-6TNXSM\N[C!/LV4/_H5>KUX]J*LUC,4_P!8J[U^J_,/Y5ZU8W:7]E;W,?W)
MHUD7Z$9_K7T.33M*I3]'^:?Y(\'-H:4Y^J_)_JR>BBBOISYTQO&G_(GZ[_UX
M3_\ HMJC\"_\B3X?_P"P?;_^BEJ3QI_R)^N_]>$__HMJC\"_\B3X?_[!]O\
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MAU*:E9\R6G];(^D,T9KYO_X5;^T=_P!%GT7_ ,)R/_"C_A5O[1W_ $6?1?\
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MH_ O_(D^'_\ L'V__HI: -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!G*I*?Q,****YS,**** /+OA]_R6OXK?[VE?^DAKU&O+OA]_R6OXK?[^E?\
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MLBD9Z'*8SU&>*\$_X90\?_\ 1R/Q#_[]6/\ \9H_X90\?_\ 1R/Q#_[]6/\
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M^,G_ #T\#_\ ?%Y_C1M^,G_/3P/_ -\7G^-'L?[R^\.3S1Z?17F&WXR?\]/
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M@J<%9(^KC%0BHQV04Z&&2YE2&&-I9I&"1QJ,EF)P /<D@4VO?/V(_AD/B/\
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MC*E:?+2@FE:[OW5]--?PN=$:TIRM!:*W7OV/"-+T;4-;N#!IUA=:A.!N,5I
M\K >I"@G%1C3;QKUK-;2X:\4E3;"%C*".H*8SG\*^U+_ ,>:G^S%^R7\-=4^
M'MG:07_B@_:-6UZ6V$Q$A3<$;/&2<J,\ 1G R<U)\:O'-S%\+_@I\>+O3(=(
M^(*Z@BW*V\9B-_;@2;LJ>2K(F1GH)2.F*S6/G*2M#W6W%:ZW5]U;1.PO;MO2
M.C;2UZGQ*EC<R7?V5+>9[K<4\A8V,FX=1MQG/MBI;;2+^\O_ +#!8W4]]DC[
M+' [2Y'4; ,_I7Z1WG@3PSX"^(OB?]I..2"?PW-X<35+"$$9:^F7:QQZNHC
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MPV^![:)JGC;6K675YKZYNIFVRZDBW!4V/RNV]OER$+'AQZXHHY96J-Q>CO\
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MG[R\9R/^>M?H+17?#,JM.G[.*5K)?<V[_.[N;K$RC'E7D?!^I_#SXA2_L\?
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M2=6U;7M-\5+=7I:,RW%M9A_W;W)&<$+U)YZ9YS7W-BEJEFE2RO%-W;OKUO\
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MV]^GKY/_ (!Z:S%6]Z)^*.Y?[R_F*-R_WE_,5^U7_"D/AY_T(WAW_P %</\
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M+_>7\Q1N7^\OYBOVJ_X4A\//^A&\._\ @KA_^)H_X4A\//\ H1O#O_@KA_\
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M ")7IE%'M8_R+\?\PYE_*OQ_S/,_^$A^*_\ T)GAG_PHY?\ Y$H_X2'XK_\
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MM_V [[_T0]:TOXD?5%P^)%OX;6\=I\._"\$2[(HM+M411V A0 5TE<_\/O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/C#_ ,DE\;?]@.^_]$/7
M7UR'QA_Y)+XV_P"P'??^B'K6E_$CZHN'Q(O_  ^_Y$/PY_V#;;_T4M=!7/\
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M%73O_2N\KTNO--._Y.-U_P#[%73O_2N\KHH[3]/U1I#9^AZ71117.9A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<A\8?^22^-O^P'??\ HAZZ^N0^,/\
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M>:?#G_DJGQ8_["EC_P"FVWKHI?!4]/\ VY&D=I>GZH]+I#2TAKG,SS3X#_\
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M8NZ.#_:E\.ZCXH\?_##3X[5[K39-2W/'##'*[LA$C#:3DJ$4D@_+QSVS](*
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M?A>YD@6"Y+Q-ME_<L F1D'/<'U7/OBL?5;B?5-5MXIF;3K"!@Y+Y$D[E<!%
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M@7\77T35+/X9>*(XK'6K& 0V]P9 !<D$$*P).V0ATPFYG/);&1GZ$KR;XV?
MB/XI3:7JVFZH=!\2:26DLK]8]P5N2 0""/FV_-S@;L#FI_"'QFTQ?"R6VL"X
MM?%.F.NG:AHC-YUX+E4'0#&]'7#K)PI5@3CD#JK)55[:/S\FV_P%S17N[/IY
MI)?C>^GW'J5?-G[0'AO4O$GQ\^%D'V,W.EI,]QB."*4DQLID+ G.U=T9.[Y1
MDD9/%=Y>>/\ Q1J9/V6"PT2$C@3YNIQ[D*50'VRU<#J?A?6-5^(^D:W=ZS?7
M5G9Z;=PM,;UH95N)9(2NQ(PH5-D;9QWQUK.A-4Y-OL_OMI^(-V:=KV:TZ/7K
MY'TH.E+7CNF^)/$/AEU>&[EU^R'W[*^9?/Q_TSEP,GV?.?[PK!^)OQ*UKXHZ
M6WA[X5M=W.I12(=7O8E$2Z>IX,+.S*1<!BK;%R0JG=@$9FE3=1VV2W?8&[62
MW>BZ?G_2.E\:_'V'1/$VG:+X=T:Z\77C2DWD.G<M%!AQYBM]TGS$*8)'S KD
M' /JMI<?:K6&;RY(?,17\N5=KKD9P1V([UYI\%_@1IOPEM)+F2[EUKQ%<AOM
M>JW'WG+,"VT=5!VID9.2H/6O4:JJZ=E&FMNO<IJS>O?\]/72W1>@5YIIW_)Q
MNO\ _8JZ=_Z5WE>EUYIIW_)QNO\ _8JZ=_Z5WE%':?I^J-(;/T/2Z***YS,*
M*** "BBB@ HHKR[]H;XKW/P<\&Z7KL"VQADUNQLKM[E&=8[>67;*X"\[@N2.
MOT-:4Z<JLU3ANRHQ<VHH]1HKY\\"_M8:3XF\6Z]%,PG\-GQ!9:#H^HVMNZ@R
M3VWF W&\@J#(K(#CJ5'?-5M>_:L">/\ PU;Z#HNJ:]X?OVU>U:.PT\S75Y/:
M/&F^WPX!BW&0%CP=OY]?U&OS<O+TO^%_O-?85+VL?1E%?/VO_M;Z#J7AZZ'A
M6VU.XU23P_=:U'<RZ>6@L%A\U'-TNY64I)$5*#DD@#K63\0OVM1X7^'&IOI>
MGW^L>*-.\/VVHWE_:Z8[Z;97$\"R1+.=V4#;@<9. 1DT1P.(DTN75@J%1NUC
MZ7HKQ6[_ &I_#&AZDMAJ-IJTL=H;2WU;6K2Q9].TZYG1&2.67/RGYUS@$+N&
M2*K:W^UYX4T+Q!?Z7+HGB:X%GJ[Z"][;:89;=KX#*0(P/S,_\( ^N*A8/$/:
M#%[&H^A[G17BD/[5WAB[TG39;71/$=YK5]?W6G#P];Z<7U"*6VQ]HWQ[L!4W
M+DY_B &37>_"WXFZ3\7/"$/B/18[N&QEGFMPE[#Y4H:*0QME<G'*GKS6<\/5
MIQYIQLOZ_P F3*G.*NT==1117.9A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7(?&'_DDOC;_ + =]_Z(>NOKD/C#_P DE\;?]@.^
M_P#1#UK2_B1]47#XD7_A]_R(?AS_ +!MM_Z*6N@KG_A]_P B'X<_[!MM_P"B
MEKH*F?QOU%+=C)76.-F=@JCJ2< ?C7-Z)HL]O;P'.^V$DTJ1ARK!7&5'H.<\
M9/8YSFM37=-N=5MXX(+I+5-X:1FA$I8 @A<'CJ.?\FM(#  K)J[N*YFP:G"F
MCI<SRKL"9=F(P/7)KX^^+G[65V+I])\(WS_9;>X=6U,VP"E 3B-2>.!QN] #
MG)KW_P#:"\&P:S\+]<-JEU;W%K!)>1KIUR]L975&^5PA&]2"<HP(-?G)JU];
M70-K-J2:=9,C+<W36K7"1@@85U4@JI&X%AG'%<.,<805:;E:'O-1NV_)I)R:
MZV6_6ZT-J2<I<B2N]->GWZ'HGP_^/'B7PA>I)H>L?:M.N)Y[BYA#!TEFD8O)
M*6YRY8Y)/7-?7'P?^/\ H/Q"TNVT^^?[/XGE!B.GS2*)KUU3+/&%.",#)Q@)
M[<5\-^*]"LX)-2U"'2HM(U(:I%)^ZU4LS6;!8X;@0+A5$A38489')[5[E^QS
M;3M\1;S4)+65Q';BU"Q*KF/>VXNQZA?D X]>AKY[*<YPV94?[0490;<8-<RD
MN9\MK)-K[2]ZR;6ZT1W8K"5,//V#:>C=[6T5^Z\MM3[(EBFDTY[66V6S,B\[
M1YR2DC!4\9Y'>N?6TBBG:;2[:[BOK>3$D"B1H=^X[RH; /#L.N "N!Q7:27A
M-O%) HE,C  ,2O!/)Z=AD_A5FOKG%-W/+N,MQ(($\T@R8^;'3-24458CS#QQ
M_P ES^&/_7MK'_HJ"N]O?$NDZ;<&"[U.SMIP 3'-.B, >G!-<%XX_P"2Y_#'
M_KVUC_T5!4'C_P#9<^&7Q0\33^(/$WAB+5-7FC2)[E[B5"508485@.!7=:FU
M3]JVER]%?[3\T;^Z^7F?3]6=Q9^/?#FH:X-&MM=T^XU4P_:!9Q7*-*8\D;@H
M.2,@]*XZ'_DY:]_[%&W_ /2V:N=\.?L7?"7PIXOL_$.F^&O(NK,*;>!KF1H8
MY <B7:3DOT')QQTKHH?^3EKW_L4;?_TMFJK45S>Q;:Y>JMV\V.T%?D?0]/HH
MHKSSG"JNIZC!I&G75]=/Y5M;1--(Y_A51DG\A5JN$^,%P6\.V6F@_+J=_#;2
M>\8)E<?BL9'XT <%:P'6-:G\4:C;1KK5]"(E<H/,MK7):.W#=<#.YO5F/M5'
MQ;X\T3P1 LFK7JPNXS' @WRO]%';WZ5T0^=QGN>:^*/&NM77B#Q9JM]>.S3/
M<.H#?P*K$*H]  * /<9/VF]$6Z")I&H/!GF4L@/_ 'SG^M>F^%?%NF^,-+34
M=*N!/#G# C#QM_=9>QKXFKTW]GS7I]+^($-BKG[-J,;Q2)VW*I9&^HP1^- '
MT5H>@P^ I4O/"EG#831N\DUG&=L=\'8NZR$YRY+$JYR03_=)%>T^&O$]AXKT
MU;RPD+*&*2Q.-LD,@ZHZ_P +#T_$<5Y?5_X>YC^(MV(N$DTH-<A>[";$1;WQ
MY@!]![4VV]6&QZO1112 *\T^'1Q\4_BP3T_M2Q_]-MO7I=>9_#U!)\4?BTC#
M*MJ=B"/;^S;>NBE\%3T_]N1I':7I^J.S_P"$ST#./[:T_/\ U]1_XTOAOQ?H
MGC&UEN-#U6SU6"*5H9'M)ED".I(93@\$$=#7CY_8:^"9))\$09)S_P ?<_\
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M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYK9=1G6"XEEE65Q+&&VNN]%8 CC%>L45I]:KWOSO[RO:S_F84445RF04444
M%%%(6"C).!0 R>:.VADEE=8HD4LSN<!0!DDGL!7FGP.1]>MO$7CB6-D/BK4#
M=68<8(L8D$-KQ_M(AE_[:UF^)=6?XYZA/X3T"9_^$.@D,7B#6X3A+D _-86[
MC[Q;I*XX5<KG<WR^N6UM%9V\4$$:0PQ*$2.,85% P !V ':NIKV4'%_%+\%_
MP?T\S5^Y&W5DM%%%<ID%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P".T?\ "P_'O_1*M1_\'%C_ /':],Q1BCVL/^?:_P#)O\PYU_*OQ_S/,_\
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MC_\ ':/^%A^/?^B5:C_X.+'_ ..UZ9BC%'M8?\^U_P"3?YASK^5?C_F>9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ibio-20230630x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &J Z@# 2(  A$! Q$!_\0
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M\51JR482N]SS\7D68X"E*OB:+C!-1N[6NTFK:ZW33NKJVIV-%%%=1X04444
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M;MT7:[N[:=6NMSTX\9X^$8J-."E9*4K.\^6#IQYO>M[L9.W*HW>KN>1?M2^
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M'=7^%6G:E%;S@7'B67Q5<I;30AL[A;H^5;';&/;O7J6I_#WXE_"#XJ>(];\
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MI;6-I_PD4M]/(FX%A(\CF,#C@Y!]J^O?!FFSZ/X2T:QND$=S;6<44B @@,J
M$9'7FMJBM\/@Z>&=X=K=.[?1+N>9G/$F,SN"IXE*RDY+6;:O&,;7G*3M:*W=
M[WU"BBBNX^5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKG?#/Q$\,>,]3UG3M"U_3]7OM&F%O
MJ-O97"RO:2'/R2 'Y3\IX/H:=@.BHKS2^_:7^%&F:]<Z+>_$;PQ9:K;3M;36
MESJD4<D<H."C!F&"#QBND\9?$[PG\/=$MM8\2^(M-T32KF18H+R]N5CBE9E+
M*%8G!) )&.PI\LNPKHZ>BN+\!_&CP+\4+R[M?"7BS2/$=S:1K+<1:;=K,T2L
M2%+ = 2#CZ&NTI--:,$[[!1112&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 44UW6-&=V"(HR68X 'J:X7P;\=_A[\0_$5WH7AKQCH^M:O:AC+
M9V=TKOA3ABH_B /!*Y II-ZH5T=Y17"?$+XZ_#_X4W,%MXM\7Z3H-W.NZ*UN
M[D"9U_O",9;'OC%;O@SQYX<^(FBQZOX8US3]?TQSM%UIUPLT>>X)4G!]CS3Y
M7:]@NKV-ZBJ%SKVG6FKVFES7L$>HW:N\%JS@22*HRQ5>I [FK]2,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HK(\6>+='\"^'[S7-?U&#2M)L
MT\R>[N6VH@Z?B2> !R3TKE_AU\=_!'Q5GO[?PYK)N+RQ19;BSN[2>SN(XV^[
M)Y4R(Q0]F P?6GRMJ]A76QW]%<IX!^*7A;XH0:C-X8U9-5CTZY:SN]L4D9BF
M')4AU4_B.*YOQQ^TM\.?AYXA?0=7\0[];B023:=IEE<7\\"'HTB6\;F,?[V*
M?+)NU@NMST^BN8^'WQ-\*_%31/[7\)ZY9ZY8!C&\EJ^6C<=4=#AD8?W6 /M5
MJS\<:%J/B[4/#%MJ,<^O:?!'<W=F@8M#')G86., G!XSG'.*5F%T;M%%%(84
M444 %%%% !1110 4444 %%%% !1110 444V0E48CJ!0 ZBO$/A?\=KWQ3H^J
MV.N6Z:9XAB6^GTV7 \G4;:&:2/S(_P#;0H Z=1PW1N/0OAWXDOM?^%WAS7+U
M3=ZC>:5!=S+ @7S)&B#-M&0!DG@9Q7-2Q%.M9PZJY[>.R?%Y>YQQ"2Y9*.^]
M[V:>S6C]'H]4[=;17B?@;X\7+^!5U+Q#HVK/J]SJ]SIUA80P0F>]99I L<:J
M^T;$0AF8J!M)R1S6Q?\ [0ND:)I6H3ZOH>MZ9JEA-;0S:/);I)=$3OLB>/8Y
M61&;(RK'!!!Q4K%T7%2;MI<WJ</YC3JRHQI\S4N71IW=[:=6KM*]K7T>NAZI
M17E%Y\?XK/4+S3O^$-\2W&IV%K'>ZA:V\$#FTA?=@LWF[2V$/R*23V!P:GT;
MX[Z7XENM/CMM+UJQTS6$D&EZY<VJ);W3K&7P@+;P=H8KO4!MIQVRUBJ+=N;7
M^OUT]3)Y'F$8>T=+W;7O=/2U^CZKWEWBFU=)L]0HKQ?PS\=H4T_1M(MK#Q%X
MUUZ;2TU,S0V4$+20EV7>_P ZQH05QMSSD8SS707'QSTB72M#GTG3-5US4M96
M1K72+.!1<J(SME,N]E6,(PVDLW7@9R*4<52DKW_K]=^A57(LPI3Y'3OJU?;:
M[N[V<59-WDEHGV=O2**\7OOCFVO7UC8Z3::EH>H6FO:?I^J6FJ6J(ZK.QR@Y
M8'*C[RG'(P:] \<_$"Q\"V]D)K6\U/4;^;[/9:9IT8DN+E\$D*"0   268@
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MP^)5UOPSK6C7_A[3EU.]M)UB<M$SE5\IU<K)G!.0>Q!P1BN..+HN*DW:ZO\
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M110 4444 %%%% !1110 4444 %%%% !15&_OA"\$<<B&1I45EW#(4D9XJ]0
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MC].U6+J14@?+!25..<$\5!HV?[,M\YSM_B.30!=HHHH **** "BBB@ HHHH
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M*ZCP0HHHH **** "BBB@ HHKRCXS>*M4OM1TOP!X7N3:Z_KH9I[Y!DV%FO\
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MS^G:MJL_5\8M,[?^/B/&<_WNU:% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2$@#).!2U6U&PBU2SDMIMWER8SM.#USUH AUC2;+5;;
M%Y;17 C!9?-7(!Q2Z& -*M@NW&SC;T_"H]6OVTRV54M+J[#@K_HZ!BO'4Y(J
M71<G2[?.<[?XA@T 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA8LD*KE< GD\@G)Y.>>:_&K6_P!K*UN?$%Y/IOP_TZVTEYV:"UFU.Y:18]W
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M)^MN@4445U'@A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Q_B35O'%IJKQZ%X:T74M/"J5N+W6Y+60G'(,:V
MT@&#WW<^U9?]O_%#_H2_#7_A33?_ "%7HE>:^'_CSH'BS69K'1XIM0CM=3N=
M+OKR*XMO*LWA4L9),R[MC8(4J">Y '-6I+M^8K>9-_;_ ,4/^A+\-?\ A33?
M_(5']O\ Q0_Z$OPU_P"%--_\A5T<GQ$\*PV]]<2>)=(2"Q94NY6OX0MNS?=$
MAW80GL#C-6=8\8Z#X>M;6ZU76M.TVVNF"P37EW'$DK'H$9B Q/M1S+LOQ_S"
MWF?(/Q?^+/[4.A_M(>'=(\#^!M.U719]*274---TT^G*?.D'FO>-%$8),#&T
M;L@ [37V7I,M[/I=I)J-O%:7[1*9X()3+'&^/F57*J6 /? SZ"K*E7 8$,#R
M".13JJ<U-)**5A)6ZA1116104444 1K;Q*P81H&'0A1FI*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,4M%% !1110 4444
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M?#XR9+C6IU6\EXX$<$9;:,]Y&!_V:UO TWB%]%\CQ-:PPZI;.86N;:0-%>*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,$T9F,0=3*!N* \@>N
M*?7*^+OAGH/C2Z@OKV":VU:W0I!JNGW#VMW$.N%EC(.,_P )R/:K@HM^^[+[
MR972]U&)\3[U_#'B'PEXGEFD32;.[>TU##X2.*=/+65ATPLFPDGH"371>/\
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MB5AT9^/F(]379_:T>9/E;UOJ[OXE*VVVFGJ;?6U>]G]_FG^A\7WGPUT[X/\
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M_P!MZ=@'[?:X/0^<O^-')+L'-'N7:*I_VQ8$ B]MB#C'[U>?UH.L6 !)OK;
MZGSEX_6ERR[!S+N7**I_VQ8%<_;;?'3/FK_C4L%];73$0W$4Q R1&X;^5'*U
MT'=$]%%%2,A%TINS;X.\)OSVQG%35D6\WG>(KC]TZ;(0FYTP&^;.0>XYK7H
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M%4YK%4C=XVE5PO&)6Q^6:LPOYD2-ZC-)KJ@3[CZ***0PHHHH **** "BBB@
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MPD#],_9AZY^]^5:58>F2W<NLR&]AB@E\@82*4N,;NO08[UN4 %%%% !1110
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M+8ZU9'_EC>P+(%/JN1E3[C!KSA?V7O#^F''ASQ-XR\(P=K71]?F$"_2.7S%
M]@*WMAYZW<7]Z^_?\'ZE_NY>7XGL>1ZBC(]17CG_  SSJ7;XO?$/_P &-O\
M_&*/^&>=3_Z*]\0__!C;_P#QBE[*E_S\_!ARP_F_,]A=4E0HX5E/!!Y!J&*P
MM('#QV\*,.C*B@C]*\D_X9YU/_HKWQ#_ /!C;_\ QBC_ (9YU/\ Z*]\0_\
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M /QB@?L\ZD3\WQ=^(A'<#4K<?^T*/94O^?GX,.6'\WYGL3R+$C.[!449+-P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^&?C7_P I,OA#_P!@A_\
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MV_D1G/,C'<[>IJ:J;Z(2[L****D84444 %%%% !1110 4444 %%%% !1110
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MDEI$2))UDB*+CKD[^*VHK.WB=WCAC1I/OLJ %OJ>]-33[6.!H5MH5A;EHQ&
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MXD?^$7?_ /QNC_AIG3/^A%^)'_A%W_\ \;KV'%&!0!X]_P -,Z9_T(OQ(_\
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ibio-20230630x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &K Z@# 2(  A$! Q$!_\0
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M)$>C.H^ 0^(DGPZT?XW?%#XG:M+91:.UZWA6PABAL3 (SM>4A=SR-C<3D#)
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M:UY?]H:=:7WEG*?:8%DV_3<#BIK[4[33-/FOKNYAMK*%#+)<3.%C1 ,EBQX
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M3^>;G-6D]-?7_,F,=EV/;Z***XS<**** "BBB@ HHHH **** "BBB@ HHHH
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MQ#U30=.U[5!ILNGV^GV4T<*BUFE+HTD3/N+1+U)')P* /;LT9KRP?"OQP?\
MFL7B'_P5Z9_\CT?\*J\<?]%B\0_^"O3/_D>@#U/-&:\L_P"%5>./^BQ>(?\
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MT9KRS_A57CC_ *+%XA_\%>F?_(]'_"JO''_18O$/_@KTS_Y'H ]3S1FO+/\
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MAHT)P&(0G SWKN* "BBB@#$\<';X-UT@D'[!<<@X_P"635@_ O\ Y(OX&_[
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M?_A'O_\ %T?\-X:;_P!$9^,?_A'O_P#%T ?3]%?,'_#>&F_]$9^,7_A(/_\
M%U5_92^.FM_&;XT?%DW<7B+2M$L7M!8:)XDM/LL]GN3YOW1R5R>>M 'JVC?\
MG(>(/^Q?M_\ T<:]3KRS1O\ DY#Q!_V+]O\ ^CC7J= !1110 4444 %%%% !
M1110 4444 %%%% !1110 5X9\7_ GA^W^,7PO\51Z3;)XBN-?^S2ZD%/G-$+
M"YPA.<8X';M7N=>&?%^/Q/\ \+B^%[S7&CGPK_;^(84@F%^)OL%SDL^[R]G7
M@+GIS0![D.@I:0=!2T %%%% !1110 5Y3^T=XBM[#X;ZKI8F07U^B1)#GYBC
MRHC$?]]#\Z]6KY9^,.E+XQ^.IDFN'%MX?M8 +<'Y9'<L_/T(4_A7!C9N%%J.
M\M/O/K.&,+3Q&8QJ57:-)<[\^5JR^;:1Z?\ LU2+%\.Y=/!Q_9VHW-J%_NJ'
MROZ&O5NE>)_L]WZVNO\ C'1W.)6N(M0C7U1TVD_]]+7J/C;Q OA;PMJ.I%=[
M0Q'8G]YSPH_,BM\OC*M3ITX;O3\;'G<4SC@\=B,15=H_&WY./,_S+FB:Y:Z_
M;2SVC;XXYI(&/^TC8-:%>2_ %9M-M=;TJ>4RR13I<DGUE7+?AD&O6J]?'8>.
M%Q$Z47=+;T:NCXK)L=/,L!3Q516D[W79IM/\4%%%%<![045XO^TU\?)?@!I?
M@[4C'IPL-7\06NE7UUJ<IBBM8),[Y=P( *@=6XK2_P"&KO@N.OQ7\&?^#VV_
M^+H ]6IKN(T+'H!FO*_^&KO@O_T5?P9_X/;;_P"+J*Z_:L^#+V[JOQ7\&9(Q
M_P AVV_^+J9.R;&M6>I6]X)X7<KM*]14EO,)X5D'>O'O^&I?@W&LJK\5_!GS
M)@8UVWZ_]]U/9?M5?!F"+8WQ6\&=3C&NVW_Q=8PG)M*1M.,;-H\/LOB/XEO?
MVH+FV;7]030+G4KC2[61-1X658,^3+89_=Q@G<+@#)Q7>?LZ^*X?"^K>*]#\
M4:]=WNKZ:L4UWK-WXC?4=.E61SL\LR$"%^@,>!^-=./C_P#L]#69=7'CWX=C
M594\N2^&I67GNO3:9-VXCVS4-E\=?V<]-T^>PM/&_P .+6QG?S9;:'4+)(Y'
MSG<R@X)SW-=!@<_\.=3N_#W[16IZ+KFL:CKMYJPN+S3Y;/Q!+=65M N/W4MH
M<+"P[$9SZU])5XIIG[07[/FBZA=7^G^/_AY8WUUS<7-MJ=G'+-_OL&!;\:U?
M^&KO@O\ ]%7\&?\ @]MO_BZ /5J*\I_X:N^"_P#T5?P9_P"#VV_^+H_X:N^"
M_P#T5?P9_P"#VV_^+H ]6HKRG_AJ[X+_ /15_!G_ (/;;_XNJ^H_M:?!VWT^
MYEM_BGX,FGCB9TC_ +=M_F8 D#A^YH ]=/2O+/V>O^1?\2_]C%?_ /HRF?LQ
M_&&]^.WP>TKQC?VMI9SWLDR^78LS1;4D*J06)/( -/\ V>O^1?\ $O\ V,5_
M_P"C* /5**** "BBOG?]H**;5/BGX8TUM2U.SLFTB\N&BT_4)K4-(LL(4MY;
M#. QZ^M<]>K[&'/:^WXGL93EZS/%+#N?*K2=[7^%-[77;N?0^:*^1_\ A"K?
M_H,^)?\ PH;S_P".59\)Z=+X=^*_@,6NKZW)'=WT\,\-YJ]Q<1R(+:5@"CN1
MU /3M7"L=*Z3ANTM^[MV/J)<+T>2<H8AMQC*5G"U^6+E:_.^W8^L**0=!7%^
M+/B=;^%/B%X(\*2V,UQ/XHENHHKE'4) 8+=IB6!Y.0N!CN:]8_/SM:*X&/XO
M:<OQ3USP7=0&R.DZ1;ZO+J5Q,B0%)99(PO/0@QDY/'(KI-*\:>']=U:]TO3=
M=TW4-3LO^/JRM;R.6:WYQ^\16)7\10!M45QOB'XL^%]"T3Q%?IKNE7DF@Q/)
M?6T>H0AX& X23YOW9)X&['6H? 'Q=T#QU\+-'\=&^LM-TJ^L8;R9YKV)H[0N
MBN8Y)<A0R[L'..>PH [BBN.U;XEZ=+X/O]8\*W>D^*[F.TEN;.UM]6@CCNB@
MY F)*J,D L>!GFGQ?$W0M.\/V%_XDU?1_#=S-#";BWN]5@V032(&$7F;@&[X
M(^]C(H ZZBJ&HZ_IFD:2^J7VHVEEIJ()&O+B=8X50]&+DA0/?-,T#Q-I'BO3
M5U#1=5LM8L&)"W5A<)/$Q'7#H2* -*BO*_B5^T1X8\">'K^^TZ_TWQ/?V-U!
M;7.EZ?J41GA,DJQY< L5P6[BO4Q0 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!!>V5OJ-K+;74$5S;RKM>&9 Z,/0@\&OD[0_#?@:/]M'Q=8>,
M='T2UO8=(LSX2MKVTACA>V*DW+P*5 :3S<ACRP  '%?7%?'?[9OQ.\/ZQ>7_
M (3D^%6C_$Q?#*6E_K=[KKB*WTE+B58XUC(4N\S!@VU"H QD]J .@^$UGX7T
MS]L+QQ;?#FVT]-";0[=_$?\ 9448M8M4\UPBAD&T2&+!=5] 2,U]25X/\ ?$
M_ASPIXNU_P"%&G> ;/X=RZ5&FIZ?;Z=L-MJ=E*2%N4*J"'W JZMD@]S7O% !
M17)^+/BCX<\$ZQI^F:M?&"\OBOEHL;/M5G"*SD#Y5+D*">YQ3?#7Q4\->+O$
MFI:%IE^9]1L"WF(8F17VML<QL1APK J2N<'B@"I\9O%3>$OA_JURNB:OKIFM
MYH/(T:V$\J9B?YV4LN%&.3GN*3X$G=\%? IP1G1+/@]1^Y6G_$#QQX<M?#7B
M&RGU_2X;M+*X1X);V)75O+;@J6R#3/@4<_!;P*1R/[%M/_1*T =U1110 444
M4 %%%% 'A/Q]N?M/C_P58'[L,5Y>'ZA50?\ H5>?>.T)\)Z@Z_?A59EQV*.&
M'\JZ_P"+%U_:'QJ6$CC3M%4 _P"U+*2?T2N:\5P_:/#&K1CJUK)C_ODU\UB/
M>G4?];6/VS*8^QP^"B^B3^^3E^31]):CJFWP?<:CG_ER,^?^ 9KP.TSIOA;P
M_<KPUK+;7&?JXS_Z$:]2N]2$WP%6[#?ZS0D.?<P@?SKS36(3%X*= .8K5"/^
M @'^E?JF16E0O_-)?E_P3^0N-TZ>/E36].$K>O-_]J?1ZG< 1T/-+572Y?M&
MFVDN<AX4;/U45:KY%JS:/TZ$N:*DNH5F>)_#]MXK\.ZEHUXSK:W]O);2M$<,
M%=2IP?7!K3HI%G(?"7X=6_PE^&_A[P?:7DVH6NC6JVD5S.H5W12<%@.,XP/P
MKKL?7\Z6O//BSK=[HYT5K&5HY!<>:P7^)5&2#[8KAQN+C@J$J\U=*WXNQV83
M#2QE:-&+LW?\KGH6/K^=&/K^=0V-W'?6<%Q$P:.5 ZD="",U/7:FI)-;'(TX
MNS$Q]?SHQ]?SI:*8A,?7\Z,?7\Z6B@!,?7\Z,?7\Z6B@!,?7\Z,?7\Z6B@!,
M?7\Z\^\(?!K3O!GQ1\8^-;.^N9+GQ,L'VFUEP4C:(8!0]>1V->A44 >6:-_R
M<AX@_P"Q?M__ $<:]3KRS1O^3D/$'_8OV_\ Z.->IT %%%% !1110 4444 %
M%%% !1110 4444 %%%51JEF3<@7<!-K_ *\>8O[KC/S<_+QSS0!:KQ;XP^*M
M$F^*7PLT&/6-/?7(O$)FDTQ;I#=)&;"YPYBSN"\CG&.17LL$\=S"DT,B2Q.
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MGF*5]1BOET^9<W>[^_4_=)P]A-4OY%&/_@*4?T.JM[XR_LMZ=(#]_388<_\
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M_2Q]9E"C"A.IRIMNR?5::V];EFH+ZV^V6<T.<;U*YJ>BO):4DTSU4VG=';>
M]8_MCPW;%QMGM_\ 1Y5_VEX_48KHJX+X82^7/K=J>JSK*![,*[VOMLLJNMA*
M<I/7;[G;]#X_,*:I8J<8[;_?K^H4445Z9YP4444 %%%% "'I7EG[/7_(O^)?
M^QBO_P#T97J9Z5Y9^SU_R+_B7_L8K_\ ]&4 >J4444 %%%<UXI\?Z7X1O+:U
MO5NY)[A&D1+6V>8[5(!)VCCJ*UI4JE:7)35WY'-B<31PE-UL1-1BNKT6NB.E
MHK@O^%SZ%_SZ:Q_X+9?\*MZ/\5M%UK5K73HHM0AN+IBL7VFRDB5B%+$;B,=
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MJKM 4=!P*Z#XK29L=*@[2WJ9_#G^E8%?#9E+FQT_)17YO]3[++X\N#AYMO\
M)?H%%%%<!W&+?)?Z1J7]KV=]) D91I+=!Q)@]_;%>VVTZW5O%,A!610P(]"*
M\GNH1<VTL1&0ZE:[?X=7YO\ PG9;CF2 &!_JIQ_*O5R62I8B=);25_FGK]]S
MR\WC[2A"K;6+M\FM/R.FHHHK[,^3"BBB@ HHHH 0]*\L_9Z_Y%_Q+_V,5_\
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MYP*7X._%;Q!XK^*5]IE_JD%_:SPWLTVG1QH&TAX+KR8XF*_-ET^;Y^I!(XH
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MM(.E+6IPA1110 444AZ4 ?-OCF47GQK\2R*=RVUC:6Q]F.]R/U%153FG%_\
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M<]/R%?F6<U.7"."^VU'Y/?\ "Y^X93#FQ2G_ "IO[MOQL5J***^3/J HHHH
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M_D7_ !+_ -C%?_\ HRO4STKRS]GK_D7_ !+_ -C%?_\ HR@#U2BBB@ HHHH
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MRLTPRQ6'3MJM/E+_ "?YG5>'W7QQ8I>ZG )#!%'9(K'D&+AC[9-=:JA%"@8
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M,71EYV^]-'/BH\^%JQ\K_<T>E4445^@'PX4444 (>E>6?L]?\B_XE_[&*_\
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MCY0D:\L6XYQD$BL#X;?&O4?&GCJ72+S2[:UTZ\AN[G3)H)&:7R[>X\A_.!&
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MV:M\U_P+&Q\/[H6NIZGI[' <BZC^AX;]0/SKNZ\J^V'1M6LM3&?+B;RYL?\
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M3PU-J&L7EU9->OJMY!?SI<2LR":$8C90,;<4?V5A_/[P_M+$>7W'S9>?M>^
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MJE-4DDHK6R[_ (EZBBBNXXPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]$MX_%\&R\^W0Q"-Y60NJ%N.5(.X#WXKVRF11)!&D<:+'&@"JBC  '0 4^@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\/\ _@(O_P C4 ?8>:,U\>?\*>_:X_Z+'X?_ / 1?_D:C_A3W[7'_18_#_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^S=X.M-2\'W.FP7&D6_A73+K2=.L;)U6!8;B/8^X$$EL<@YZDDYH ^4OA_\
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M^&/#,LRW$VE:?#:22K]UF50&(]LYQ76T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)C-+10 F,4
MM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F!Z4M% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ibio-20230630x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '# Z@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM.M;ZW+&"YB6:,LI4[6 (R#R#@]* +-%%% !114<EQ%$Z(\BJS\*I(!/T]:
M)***ADNX8I$C>5$=^%5F )^@H FHI 0>E+0 44BL'4,""",@CO2T %%%075[
M;V0B-Q/' )9!$AD<+N<]%&>I/I0!/12;ANVY&<9Q3(YXYBX1U<HVU@I!VGT/
MI0!)113)IH[:%Y976.)%+,[D *!U))Z"@!]%5[#4+75+5+FSN(KJW?[LL#AT
M;Z$'!JQ0 45 U[;HLK-/&!$0KDN/E)['TZBIZ "BBHY)XX2@=U0NVU0Q W'T
M'K0!)1110 4444 %%%% !1110 4444 %%5(-6LKF_GL8KN"2\@ :6W253(@/
M0LH.1^-6Z "BBB@ HHHH **** "BBB@ HHHH **0G R>E-AFCN(EDB=9(V&0
MR'(/XT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.
MXN(K2!YIY$AAC4L\DC!54#J23T% $E%8.@>/?#7BNXE@T7Q#I6KSQ?ZR.PO8
MIV3ZA&)%;U !139)$AC:21E1%!9F8X  ZDFLVS\4Z+J#Z>MKJ]C<MJ,+7%DL
M-RCFYB7&YX\'YU&Y<D9 R/6@#4HHHH **** "BBB@ HHHH **** "BBN8;XD
M^'E=E^VNQ5BI*VTI&0<'D+ZBN>KB*.'M[::C?NTOS-Z5"K7O[*#E;LFSIZ*Y
M?_A97AW(!O9%R0N6MI0,DX')6NHHHXBCB+^QFI6[-/\ (*M"K0M[6#C?NF@H
MI.E&:Z# 6BBDS0 M%%("#WH 6BDS1F@!:*** "BBB@"O?W1L;26=8)KHH,^3
M  7;V ) _6N/\$:\VJ^-/&MF]E):?99[23]]C<WF6RGH"<8V^OK7<5Y[X)/_
M !=?XCC&/GT[_P!)JWIQ4HS;Z+]4OU.'$5)0J48Q>DI-/TY)/\TCT' ]!1@>
M@I:*P.X3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"N7\+^,#X@\2^)M-*!$TN
MXCBC/=U*?,?^^PPKJ:VJTIT9<DUK9/[U=?@SDPN*I8RG[6B[QO)?.+<7^*8F
M!Z"C ]!2T5B=8F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T
M4 07@'V2;@?<;^597@;_ )$O0?\ KP@_]%BM:\_X])O]QOY5D^!O^1+T'_KP
M@_\ 18H W**** $/2OS+%O\ !#5M3^*]_P#M->(;O3OBSI^LWICBU#5+BUGL
M;$,38G2HT8*Z&/:RE0Q+?>&#S^EFH_:?[/N?L>S[7Y;>3YGW=^#MS[9Q7P+^
MS#KOP L_@AJT7Q@NO"Z?$QKB['CF/QN83JDEYYKAP1+\Y3;M""+C&,?-F@#I
M[?XS_%CP?^QW\'M%E\Q?C1X\N8O#^GW>KIF2T5VD9;RX4YRZ6JH[ Y.]LD'D
M5V^C_P#!.CX2W&FM-XX@UCXC>*;@;KSQ+KNL77VJ60\ED"2 1#)X"]!CDUX3
MX'\ ^/-9_97\"^/O".G:EK-SX \;7GB'PCHFIL_VN_\ #OF/&EME_FWM"S%,
M\[54#.17T=:_M7_ OXY?#/4[2]^(EAX9AO+9[?4-/U'51H^J6)Z.C!F5XW4@
MC<N>G!- '3_ ?X$:S\#=6UNP@^(.L>)_ LZ1MI.AZ]_I-SI<F3YBK=L=SQ$;
M0J$<>OKY1_P4$_:"UWP9\/\ 6? /P[S/X[U#0KW5K^YC?;_8VCPQL9[IV'W7
M?!CC[EF)'(&>$_9D\)6'BS]I&^\6?";5O%6J?"_PSI%S9?VIXAUV]N;+6]6E
M^4+")2=T429S( ?F(QG@GE_B?\!_V@_AK\*/CYXLUW5_AMK<WBO2KVZU[4V2
M^:_6S6W8+:VQ("(D:;@BD8R<L30!]Q_ -MWP+^'3<G/AO33R<G_CUC[U7\'?
M&:S\4_%CQS\/I]-N-*UOPREK=*9W5DO[2X0E+B+'\(971@>C#WK#_9'7Q8O[
M/7@C_A+Y-&EO#I5H;,Z(LHC%G]GC\@2>9SYNW[V/ESTKRO\ ;<N/$'P4UGPM
M\>?!FE-J^L:/#/X:U33HN#>6=YQ;;N.?*O/)8#_IHU 'M/PW_:!\*_%+XB?$
M/P9HMP9=6\$WD-G?@E=KL\>XLF#DA7#QG/1D/M7AGQE^+GPZ^+^IZ?8>(_!>
MIZ_HOAGXH:5X:TW5(+[R(I-88'?*H5@6C@9MC _>)..E>5>/OA-XJ_8C\ ?#
MSXF>#[%_$'C7^S[CP]XO1,%]3O=18RPW+G^+RK]U4$\E7"\5V_Q3^$T?P/\
M@#^SGX1:87-_:?$GP]+J-XQRUU?2SR27,I)Y):5W//;% #_$'Q'\<6G_  41
MMH[?X9ZK>1Q>#)M/B2/5[1%FLSJ:9U$ O@(.GEG]Y[5G?!WXX:QX/^,G[0/A
M/PAX$U;XA^+9?'-QJ$EG;7$=G:6=J;6W17FNIOD4NR.%10S'8QP ,UZGJ1'_
M  \8TH9&?^%77)QW_P"0HE)^R':PK\2/VDKD1J)Y/B%-&T@')5;.W*@GV+-^
M9H ]&^!'QXMOC39Z_:W.A7_A'Q;X;O1I^N>'=39'FLI60.A#H2LD;J=RNO!
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MH0L M5S(&8G!#*-N3NP :^<?A+;17?PA_80CF59476IY,-SAEL[ME/X,!^5
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M]YI]AJ5Q%=6NI0I_K#;7,1V2,@Y9.& YQUQYY<>-=&_9W_;3\>ZQ\0KF'0M
M^(6EZ6-"\2WYV6<<MHCQS63S'Y8V.X2 -@'US4/Q'^(?AW]HS]I/X.>'_AQJ
M%MXHD\&:S)XCUWQ!I+B>TTZV%O)$MN9URI>=W V*2<)D\"@#>\ ?M>:E\=M0
MU73?"?PRUF;0M-O;[2-=\17M[!!:Z?)%YBCRP3NN&*JK%4 V^8H)S7#_ +.'
M[1>C_!S]CWX(Z2+"^\6^.=>TM8](\*:1A[Z\_>OND.XXCB49+2N0HP>M=A^Q
M!;1P_LW>*V10K3>)O$CN1W/VR9<_DH_*OF?]B$W'[)OP^\*?$OQ3I":_\/\
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M,.RE&(#*<#F@#1\7?L/?"36[&V?P[X8M/AWXAL6673O$?@Z%-.O[.13PP=
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M0>/?#7B+X@^$]5DT#PS86VF>'X);I%>&UU"\N8!?W4RGAC9)*D8#?*)%F#<
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M_$CPWJ,WB.VLM+U^QN_LUYI%O'/%-8.8T?R9EE&2PW\2(2DBE74X; ].KF?
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MD^!O^1+T'_KP@_\ 18K6O/\ CTF_W&_E63X&_P"1+T'_ *\(/_18H W****
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M->6EOX+M-<AU;Q%:REO-OXK?]Y!;* ,%&E"E\D<(,9KI=3^/'PWT:\TBTO\
MQ]X:L[G5XUET^*?5H$:[1ONM$"WSJ>Q'![5;\4_&+P)X&UNQT?Q%XRT'0M6O
ML?9K'4=2A@FFR<#:C,"<GB@#KP,"JU[I=GJ,EL]U:P7+VTHF@::-7,4@! =2
M1\K8)&1SR:BO-?TS3]0T^PNM1M+:^U%G6SMIIE62Y*+N<1J3ER%Y.,X'-&JZ
M]IFA?9/[2U"UT_[9<):6WVJ98_.F?.R--Q&YS@X4<G% $NHZ79ZO;K!?6D%Y
M"KK(([B)9%#J05;!!&00"#V(JGXD\):'XRT_[!K^C:?KECN#_9=2M4N(L^NU
MP1FL_P 0?$WPAX3AU6;6O%.C:3%I7E_;WO;^*$6GF M'YNYALW $KG&<<9JU
MX/\ ''A[X@Z+'K'AC7-.\0Z5(2J7NEW27$)(ZC>A(R/2@"WHGAW2O#6EQZ;I
M&F6>EZ=&"$M+*W2&% >N$4 #\JGT_3+/2;&*RLK6"SLXEVQV\$:I&@] H  '
M-<EXO^.'P[^'^LP:1XF\<^'?#^J3X\NRU/5(+>9L]"$=@<&NRMKJ&\MHKB"5
M)H)5#I+&P974C(((X(/K0!%IVF6>D6,5E8VL%G9Q#;';V\:QQH.N H  ZGI2
M6.DV.EZ>EA9V=O:62 JMM!$J1@$DD!0 .23V[UR,?QS^'4OB\>%$\=^''\3%
M_+&CKJL!NB^<;?*W;MWMC-=1I7B+2M=T][_3=2M-0LD>2-KFUG62-61BKJ64
MD94@@CL0<T 9&C?"WP9X=FOIM)\):%I<M\C17<EEID$+7"-]Y9"JC<#W!R#6
MTNAZ<LMA(+"U$E@ACM&$*YMU*A2(SCY 0 ,#' Q7)>'/CO\ #?Q?XCDT#0O'
MOAO6-<C)#:=8ZK!-< CJ-BL3QWXKIM4\5:+H=Y%::CJ]C874L,MS'!<W*1N\
M48!DD"D@E4!!8]!D9H MWNF6>HO;-=6L%RUM*)X&FC5S%( 0'7(^5@">1SS5
MJN2\#_%SP1\37NT\(^+]#\3O9MMN%TC4(KHPG_:",<?C7/?!B]\9W=]X['B[
MQ-X;\100:_/#I:>'P0]A:@ K;W/I,N1D=>>O(P =V?#&CMI<^F'2K(Z=.S/+
M:&V3RI&9MS%DQ@DMR21R>:T@H4  8 X %<!-^T%\,;?Q1_PC<OQ"\+Q^(-_E
M_P!F-K%N+C?_ '?+WYW>W6J7C^]\9P?%GX<P:'XE\-Z7X9N9+L:OI.J _P!H
M:D%C#(+3U*<LW3 ()R.* .HTOX9^$-$UV;6].\*Z)8:S-N\W4;73H8[B3=][
M=(JACGOD\UI0^&M(MH=/BBTNRBBT]BUFB6Z!;8D$$Q@#Y#@D?+CJ:\&^''[6
M&A^+?V@_B?X.NO%OA8Z!HD.F/HL\%]$)+II+>22[&_S")/+*<[1\H!S7T%IF
MJ66MZ=;:AIUW!?6-S&LL%S;2"2.5&&596!(((Z$4 %WI=G?SVLUS:07$UK)Y
ML$DL:LT3X(W(2/E."1D=C1>:59:A+:RW5I!<R6LGG0/-$KF)\$;D)'RG!(R.
M>34.B^(=+\26LESI.I6FIV\<SV[RV<ZRHLB'#H2I(#*>".H/6L#Q/\7_  -X
M+^T_V]XQT'1C:W$5K.+_ %&&$Q32+NCC8,PPS+R >2.>E &IXI\$>'?'%I':
M^(]!TO7[6)MZ0:I9QW**WJ%=2 :O:-HFG>'=.AT_2K"VTRPA&V*ULX5BBC'H
MJ* !^ KR[X5^,->T'PKXTUGXF^-_"%_86&N7:P:CI$PAMM/LU*A(+EW("S(2
M0P/(R 236#^T1^T3;^'/V6?&?Q+^&FO:+X@FTRV22TOK:5+VU+F:-&!V-@X#
MGC- 'O MXA<-.(T$S*$,FT;BH)(&>N 2>/<T"WB6=YQ&@F=0C2!1N*@D@$]<
M#<>/<^M8^J^,]$\,6.GSZ]K-AHXO72"!KZY2 33,.(TW$;F/91S6Y0!G:]X=
MTKQ3ILFG:SIMGJ^GRXWVE_ D\3_5&!!_*H?#7A'0O!FG_8= T;3]#L=V_P"S
M:;:QV\6?7:@ S6O10!4L-)L=+M7MK.SM[2W=WD:*")40LQ)8D  9)))/<FHX
M="TVWT@:5%86L6F",P_8DA40[#U78!MP<GC&*OT4 5M-TVTT>Q@LK"UALK.!
M0D5O;QK''&OHJJ  /859HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JLFHVDM]+9+<PM>1(LDEN) 9%1B0K%>H!P<'V-6:^,O$_B_QGH/[=
MOC72O ?A6W\1:_JO@S1S]IU.[-KIVGQ1W-UNEN)%5G.2ZA4126.>@!- 'V6=
ML8+'"@#)/3%5-(UG3_$6FPW^EWMMJ5A-DQW-I*LL3X)!PRD@\@CCTKQ#P3\:
M?%<'Q)B^&'Q<\+Z7H^MZS97%UHNIZ'=O=:9J\<0'GPCS$5XY45@Q1@05)(/'
M/C'PY_::D^'7P;^ .F?#OX36>/'YU:&R\-Z9?F..SGAD9@?,=?\ 5EB[R.W*
MJ&(#<"@#[B  HQBO!? ?QG^(.D_%_2_AY\4_#6A:;?:_I]SJ.AZKX9OY;FUG
M-N4\^WD$L:.LBK(K!@"K#/0C%8.F?'OXL?&*YU35_A'X*\.7?@6PNIK.WUCQ
M5JLUK)K3PN4E:U2*)]L>]6422'#$'B@#Z$O_ !7HNE6M[<WNKV-I;6+K%=33
MW*(D#MC:KDG"D[EP#C.1ZUJ @C(.0>XK\Z(/'VGZU\(?VJO%7C/X<)>QIXRT
MT7W@_7IL!)UAT^!E:2+.0KY=77A@%/1J^@-?_:#^(5_\>/&'PC^'G@32KZ\\
M/VFGW8US5]0>WT^V@FB+$3*B,Y?< J(@.0&)*A: /IBBOGKPI^U7_8W@CXG7
MGQ0T>+POX@^&\J1ZY;:9.;NWN$EB66VEM68*S"8.%56 (;@UBW7QL^/VA>&)
M_'>K_"71%\)Q0->2^'K36Y'\06]N%+;V0Q"%G"\M$K[N" 2>* /I^BN!^ GQ
M*G^,7P8\&^-KFQCTVXU[3(;][2*0R+$77.T,0"0/I7?4 %%%% !1110 E>,V
MOC[Q5?QO,FH6,*&655C^PEMH61E'.\9X%>S&OG_0V T_J/\ 73]_^FSU]#E5
M.$X5)2BG9K=)]^Y\)Q+7K4JM"%.;BFIMV;5[.%MFN[-B^\?>*]/MC<-J%C*J
M,F4^PE=P+@$9\SCK7M-?/GB%@='GY'WH^_\ TT6OH.C-:<(0IN,4KN6R2_E[
M>HN&J]:K5KPJ3<DE!J[;M=SONWV1A:UXTTKP_K^AZ-?3M%?:RTZ6:["58PQ&
M63<W1<(">:N2^(]*@T^"_DU*T2RG(6*Y:=!'(3T"MG!S[5Y-^T/\--2^(5]X
M=-MI,^L:7;6FL0:A;VEW';7#I<6#PHD;N0 [,V 3P#R>*\OT?X2^)-/@\,ZE
MXJ^%UGXVTRVTW4-.B\-Q0Z= UD\ET7BNI+8N+42SP[%F:)CL93M&UV ^>/O#
MZYR",]J\KU_]I#PMH>M:M8Q66OZW!HTAAU;4M%T>>\M-/D #.DLB*0612"RI
MN*?Q 5/\#=#\2^!_!?A[PEKUA)(=/TF-FU-;Q9HDD,KXLU)/F-Y,?EKYC##
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M+B_9PT_X,WDVHWGA_3V,MG?B80WMK,)VGCFBD0#8\;-\I Z#!SDT <W_ ,%
MR)/V?[:!<--/XHT&.-.[M_:4!P!W. ?RK"TKPKH?QS_;4^)EKX_M(-<M? -C
MI47AOP_J2"6UC%U$TL]]Y+?*[EP(PY!VA<=<5U'AS]C^:3Q?X>UKQ_\ $[Q5
M\3+?PW<K>Z1I6M>1%:P7*_ZN>18D4S2)U5G/!YKJ?C%^S1I/Q1\4Z9XQTO7]
M9\">/=-@-I;^)/#\J)-);DY,$\;JR31YY"N.#T(H T[?]G+X=:5\3M'\>:1X
M=M?#_B>PAFMQ/HO^A)=QR+ADN(X\+,!P1O!P0#V%?&7P(TWQ[\1/$GQ%^(EQ
M\'O"/Q,US4?$NHZ8^I>)]>1)M.@MYC%'8QV[V\@A1%7/!RV\$]J^K/AU^S$?
M#GCVR\;^,O'WB3XD^*=.BDATZ?6'BM[6P60;9&BMH%5 [+\I9LG%4_&7[*;7
M'CK6?%_P^^(/B'X7ZQKK"368=&2"XLK^4# G:WG1E6; P77!/?GF@#Q[X,_
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M'&*X+P3\']-\#?$CX@^,K2\NI[[QG<6=Q>03;?*A-M;B!!'@9P5&3DGF@#Y
M\'_!_6?C%\&OBI9^'TTV[U71OC;J^O1Z1K0/V#53;W08VMQC/R/G.2"-RKGB
MJOQG\4>$?$/[&'[0\&D_#V/X8>.+(6D?BOPX(HT*7)DA,,@>/Y)(W3E9% W<
MDC/7Z,N/V3;6U\*ZUIGA[QWXH\*ZE?\ BV\\8QZKI=PB20W5P27B:,KLEAP2
M-C@]CG(J@G[%^B7WPF^(/A+7?%6N^(-:\>O%)KWBF\:+[;.8BGE*BA?+1$5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!>$'_HL4 ;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOFE#F?JK?GJ<!'&(EVC)[DDY)/<GWIU=[_PHWQ#S_P 3;3/_  'E_P#BJ0?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:-K^F^(8;B73;R&\CM[F6SE:%@P2:)RDB'T96!!'J* .8_X3_7/^A!UW_O\
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M:\<V\45H!LN897/[QV#8W/\ ,FWC[W"@= !3&MXFE24QJ9$R%<J,KGK@]LT
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M)YKMJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI,XH 6BD!S10 M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%)D#O2T %%%% !1110 4444
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M!7WI&^.04>N[^'FH:QJO@W2KKQ!#';ZU)%_I<42%$60,0=H/...* .CHHHH
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M2)4>Q8QVQE7AG!#OMSE0<\;J]-_;PU673/V3?B)# V+G5+*/1XE'5FNYX[;
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M,\8'TE\+_"7C3PLFHCQ?XWC\8F<H;8QZ4EC]G SN'RNV[.1Z8Q[T =W1110
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MPIK>%M';KIEK_P!^A1[PK4>[^Y?YG'3?'+0^(+73];O-4;B/3%TN:.>0_P#
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MQ)\-_%GPI:^(_"FK0:SH]R65+B ]&4X9&!Y5@>"I (/6@#/UWX)?#WQ1K/\
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M@<L3R2>352'PIHMO;V4$6D6$4%E(TUK$EJ@6"1MVYT &%8[VR1@G<?4UJT4
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M'3+RUTW4KC29[>QN;V_$:JFG"[D,4 F!;=DL#G:&VC!/!!H ]>J$_P#'X/\
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M:VN(UEBD0Y5U8 J1[$$&O(KO]L;X+6%W/;7'Q(T"&XA=HY(VO%!5@<$'Z$4
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MU\^_#[2]0\"_LV?"S]HC3[>6;5=%O]3UCQ!! N9+W0]1OY9+I<#EC$#%.O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2KUI*5>M #J***
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** &'K10>M5M4U*VT;3;O4+R406EK"\\TK=$15+,3] #0
M!9HKA/AU\6+7X@7=Q:'2K[1KM+.WU**"_50T]I/O\J9=I.,E&!4\J1R*[N@
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M]LB]3_WR: )J*A^V1>I_[Y-'VR+U/_?)H FHJ'[9%ZG_ +Y-'VR+U/\ WR:
M)J*A^V1>I_[Y-'VR+U/_ 'R: )J*A^V1>I_[Y-'VR+U/_?)H FHJ'[9%ZG_O
MDT?;(O4_]\F@":BH?MD7J?\ ODT?;(O4_P#?)H FHJ'[9%ZG_ODT?;(O4_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIV!1@4 -HIV!1@4 -I5ZTN!1C% "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ibio-20230630x10k019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &9 Z@# 2(  A$! Q$!_\0
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M:>+M/D6.ZU/4K>1D615E9E)4C(8 ]B.AK&^+[1^]_P"1Z?+P]_/6_P# 8?\
MR1_2I_PMCP3_ -#AH'_@T@_^*H_X6QX)_P"APT#_ ,&D'_Q5?S2?\+"\3?\
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M#2#_ .*H_P"%L>"?^APT#_P:0?\ Q5?S2?\ "PO$W_0;OO\ OZ:/^%A>)O\
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M[_R#EX>_GK?^ P_^2/Z4/^%L>"?^APT#_P &D'_Q5'_"V/!/_0X:!_X-(/\
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MV$\DQ6TD'BV)3$B2$F,* %V_[(SDBOB6#]C7]HBVBABB^%WC2*.&7SXT2PF
M23CYP!T;@<CGBK,O[)'[2<SL\GPX\=.[+M+-:3DD;M^.O][YOKSUH ]1L_AE
MX8^+7_!1SXJ:)XJMWU6U76_$%[::&EW]E;6+N)Y7@LA+_!YC#&1S@$#K73^$
MO@/HOBWXSZ;#XN_9[/P^U"/PGJFL:7X)_M>X1/%-];LHA@"RMYL/!8E0V7V9
M'!Y^>F_8O_:$>]-XWPK\8M=&3S3.=/EW[\YW;NN<\YJY=?LC?M)7VK1ZI<_#
MCQU<:E'@I>2VD[3+CIAS\PQVYH ^M=4_9X^&OA[0;'Q7XJ^!T/AK48_AKKWB
MB_\ !\VIWBJM[;7UI' 2YDWHI21CLSE5D(.2 :QV_9O^'5SJ7B#QAX7^%B^+
MM=D\$>'/$NE?#*+4+CR"]^'%W,FUO.ECAVKA W5\GC&/F*Z_9'_:3OFD:Y^'
M'CJ=I$>-S+:3L65B"P.3R"0"1W(I+3]D3]I&POH+RV^&WCFWO((Q%%<16<ZR
M1H!@*K#D#'8<4 ?3/P4_9L\">(O$_P 6M0\2_":30/%&BRZ9%:?#IVOM:%A#
M<1[I;GRK>1)Y58X ^8B+=\V:X[]J?X5?"+X1?!/Q-?\ @_P1-)JE_P"-;C0+
M:]U][F.ZT:*.TMIY(5B\S:Q60NJNX8[&YR>:\7L_V1?VDM.U234K3X;^.;;4
M9-V^[ALYTE;/7+CDY[\U6F_8S_:&N8#!+\+?&<D)D:;RWT^8KO/5L'C)[GK0
M![3\ O@9HFH?L^>#O$F@_!-OCQXA\0ZI?6>O*NJSVW]@I$RK#$OE,!&TBL9/
M-D! P!WKTS]GS]ESX0:W\"/#&N:UX+U'Q-<ZW-J@U^XT^TOKVYT;R971+>*6
M"18K=XU"ONG5O,SP,$"OE'3/V0?VC]&AN8;#X:^.+&*Y79.EM9SQK*OHP7&X
M>QHLOV0/VCM-L;JRM/AIXWM;.Z&+BWALITCF'HZCAOQH ^WET/3M=^"]IHLF
MG:GXHT.Z^'7@2U;3M//E7>H6Q\172^7'D@+(Z=,D8)ZCK7RG^VK\)=%^$_[0
M_A2'PYX<L_"VB:K9VFH6VFVYNHYT4SLO^D07#,\$ORX*@E3MW _-7&#]C[]H
MT1"+_A6?C;RPB1A/L4^ J-N1<>@/('8\BF:E^QS^T5K-\U[?_##QK?7C8S<7
M-C-)(<=,LV3Q0!]Q_M7?!7PEX@\;?&#Q!XV^%*^#+'2M6TR]TWQW/JDV-?DF
MN88YK=D9MC*T328$8!CV<G.:S/"7[.?A?X"?&S1];NO L6G7-Y\:[73/"37=
MU,/,T9H9666 "0^8B.87#MG+  DC(KXUU']D7]I+5[5+:^^&_CF\MTD,JPW%
MI/(@<]6 ;(R?7K2W'[(W[25W)8O/\-_',SV("VK26D[& #H$S]T<#IB@#L_A
M3X!\(?&S]M/QY9ZWH$<ME%)K6HZ=X2M+YX!J]["7:&R69FW+YC DG.>"!BO1
M_!OP&T;Q7\857Q5^SX? NKV_@W4-;TGP$=6N$C\3WT,BK'&%D;S8L*7)C#9?
M9D<'!^>(_P!BS]H.*Z6Z3X5>,4N5?S!,NG2APV<[L]<Y[U=N/V1_VD[O5TU6
M?X<>.IM30@K>R6D[3*1T(<_,,?6@#ZRUS]GWX8^%-#'BKQ/\#X- U&V^&>H^
M)[SP?/JEXJQZA%J,,<>Y_,WJNQ_N9RJMM/S#-?,G[2_PJ\#Z)^T-X#T_2K5/
M!7A/Q9I&A:M>0QSO+%I@O$4SE&D);8F68;B>A[<5D77[(_[2=Z9#<?#?QU.9
M$:-S+:3MN5FW,IR>03R1W/-4[K]B[]H2^=&N/A5XQG9$$:F73I6*J!@*,] /
M2@#Z:^)/[-_A6W^)>C^$M3^!4OP[^'47C&QT6'XD_P!MS,;^RD<C<_F,8Y#.
M &$B "+=@UUFN_LU^ H]/T34/%_P'@^%<*_%/2_#8>?5KIX]0TEVD5V8O)@!
ML*#*N W!4C!KY"OOV0?VC]3LK6SO/AKXXNK2U&(()[.=XXAZ(IX7\*?J/[(_
M[2>KQ"*^^''CJ\C&WY+BTGD'RC"\$GH"<>E 'TMX<_9+\(>!?$7@32_''PPU
M.]U?4O&'B/=H]IYTMW<:1;P+]EF\A90TD"2'<=A#N.A;(![;P7^QU\,=+U[X
ME/JG@FR\2:Y9>+8-*_X1W1HM2U2#2].DM(IU=8X9$FC>0NW[R8E8F4J>A-?&
MTW[)G[2UQJ5MJ,OP[\>27]LH6"Z>UN#+$!T"N3E0/8TVS_9)_:4TZ]NKNU^'
M/CNVN[H$3SPVDZ/*#U#L#EL]\T >K_LC:=X5\"_\%*[31O#6GW.H>'X-2U*S
MTU=8\R&ZLP+:4_, 1ETVO'\W!!)QG%>D>!?V;_AIXS\$>%9C\+HW\&>*/#=]
MX@USXFV^KSK'X7O1YS"T16?8$@,<<>R0%GWYR<&OE.T_8N_:$L+E+BV^%7C&
MWN$R5EBTZ56&>#@CGO5B+]C[]HV#2YM-C^&?C>/3IF#RVBV4PB=AT+)T)]R*
M /H^U_9[\(:;^S=X8\=6OP_CL/BI);Z3)?Z7#JTOF:;IS7I5==6VW>8KS!47
M!.Q,[PH%=S\3?@9HM[XR\9^(-#^#=Q\?O$>K>/-4TK6(I]8N8WT.WA\L0)N1
M\JTJL7$TF54*!Z5\<_\ #(?[2'VE[G_A6OCC[0\0@:7['/O:/CY">I7@<=.*
MDM?V2_VE;*6\DM_AUX[@DO1BY>*UN%,X]'(/S?CF@#[&^$5Y8^%?V:[%KWPZ
MVI*?A?XVE.FZGJ-S)';1PZPB-:J%< *P*!V4 DQ*01DUX7\9_A-\(O!W[/DG
MQ@TC3+1Q\0M-T^Q\+: EU,W]C7\8(U:4Y;+!&B"IN+#,_(QBO)4_8Z_:+BMU
M@3X8^-4A6-H1&MC,%",<LN.F">2.AKI_'?[/7[3/Q#\/^#]#U+X2>(X-(\*:
M<=-TRSL]&DBC16<O)(PYW2R,<L_? ]* />/V8_ __"<_L<> ;1O@ZWQ=MF^(
M%[;W-O\ ;IK==-@EAMU>?]TR\X& [?(F,GJ*H>'OV</@1J+^-]7:2VG\/?!S
MQ-JA\0*E](TOB#265VT] P;&_P"T(;8LFW<O/4BOG73OV1_VD]'A\JQ^''CJ
MRCPPV6]I/&,,,-PI'4  ^N*Z'2_V>OVF=%^%6M_#ZR^$GB.VT+6M0@U#4)(]
M%D%Q<M"I$43R=XE+%PN/O<T =;_P3ZLAXJO_ (]PVO@L>+!=^"YY(?"EM<R0
MK='[9 ZVZNK;\<8P#N8# .37MR_!;PQX:LO%]K;^%[CP'=^)/!WAV]\1>"(-
M3G:.PN)M<CA:)QOW!9(?F$<A)3<>F:^.]/\ V-OVB-)D:2R^%_C2T=@ S06$
MR$@$$9(QW /X5-+^R%^TA/=75U+\-?'$ES=$&>9[.<O*0007/5L$ \^@H ^K
M=>_9X^!?CSQ@=(B\&0_#_3?#_P 7AX)NKRTU2X?^T;-K>>3;(TK$(SRPHBLN
M-HDQR>:];^%_@JXT+2/ACI]Q\*KKX*+<_%BX5=*LM2N2US&FB7JK<*[.77(7
M82IVOL)'!-?GE-^QQ^T5<),DOPP\:R+-+Y\BO8S$/)S\YSU;D\GGFKEQ^RC^
MTS>3I-/\/?'L\J,'622VN&92%V@@D\$*2/IQ0!]":M\&_A/=> )?#O\ PKV&
M/Q+-\&9/B$_BQ=1N3<B_C=L 1%S'L;:2W'.>,8KI_&_[+GP_TOX<_$QM+^$,
M#^$O#W@+^V/#GQ/76)Y3K%XT,3,YC63RR=S284+A/+Y&&%?)/_#'?[1><_\
M"L?&V?(^S9^PS?ZK_GG_ +O^STKW#Q%:_M=>(OAI?>#/^%+7&EV^H62:;J&J
MZ5X2%M?WMLI!\J211C:Q4%MJJ6QSF@#-_9@B\+^)_P!D#Q1X4\2:?9V.F:K\
M1/#^GW^OO<2)):0SEP9P-VP&)%<#(Q^]8L#@8T/VM?@!X3\'?![Q1K<OPL/P
M@U;0?%,>B^'G.IRW/_"36)$F^4K*S;F5423S4PIW[><5X6O[%W[0B6DEJOPK
M\8K;2.'>$:=*$9AG!*]"1D\^]3ZE^Q[^T;K*6R7_ ,,_&UZMLGEP+<V4T@B3
M^ZN[.T>PH ^JO ]WK\'_  31\)1Z3I7C[4+)[+Q-]NG\(W\5O96\?GODWZ.I
M:2/!<X7'RB09YKU6Q\/_ !-\3_%W28O 'CO6/ ?P#'A^S/A2_P##6CP:CH@M
M_(47 U!7=8T<-YQ<S9;/:O@2#]D3]I&UT\V$/PV\<Q61#*;9+.=8R#U&T<<]
M^*6V_9'_ &D[/29M+@^''CJ'3)SF6RCM)UAD/^T@^4_B* /H?QY\1]"^&/["
M_A3PI::]XGU.TU[5O%&GZ9?Z%>1V5E?I'>(JR7D!5B\;!PP1",!F&>:]6_X*
M>>-+JR^'$4_AVYU'5KG2?&ML]]J%Y,C'PS>Q6$3P0VR!-R1SK()=S,064CJ1
MCX6D_8N_:$EMH;9_A7XQ>WA+&*)M.E*H3U*CH,X&<5/<?L>_M&W:7"3_  R\
M;3)<LKS+)93,)2HPI;/4CMGI0!T?_!0_4KK6?CGHU_?7$EW>W7@_0IY[B8Y>
M21K)&9B>Y)))^M?4'C[PA\/+.WF\6>,_!"_$+4(I?!.AV@U?5;M?(BN]-#3<
MK("PSN(4\!B#TX/QK=_L7?M"7\BR7/PK\8W$BHJ!I=/E8A0, 9/8#@"K$O['
MW[1LZ;)/AGXWD3*-M>RG(R@PA_X".!Z#I0!V/ASX+^#='_X*":O\/KCPGJ_B
MWP5IFO:C;KH>FEYKEH(DD:/(#*\BIA6958,RH0,D\_7^@_L\>!8- ^(OP_\
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MF58CY6_B''![BO=K;]DG]I2S=FM_ASXZ@9H/LQ,=K.I,7_//@_=Y/R]*R_\
MAB#X^?\ 1(_%O_@KD_PH ]9_X)+_ /)Y_AS_ +!NH_\ I.U?N^.E?C=_P32_
M9C^*_P ,/VKM!UWQ9\/O$'A_1HK"^CDOM0L7BA1F@(4%CQDG@5^R(H 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO"OVRO\ DD-M_P!AW3/_ $I6O=:\*_;*_P"20VW_ &'=,_\ 2E:X<=_NM3T9
M]5PK_P CS!_]?(_F>Z+T_$T4+T_$T5W'RHM%%% !1110 4444 %%%% !1110
M 4444 %%%% !7A/@K_D[[XD_]@'3/YM7NU>$^"O^3OOB3_V =,_FU<.)^.E_
MB_\ ;9'U62?[OF'_ %Y_]RTCW:BBBNX^5"BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AXI:YKXE#5&
M^'_B(:*&;5383"V"?>+[#C'OZ>] 'PW^T3\0O^%A_$W4)X)-^FZ>38VF#P50
M_.X_WGR?H!7K7[%WP\WRZGXRNHN%S8V)8=^#*X_\=7_OJOF?1-!OO$&MVFCV
M%N\VH7,H@CAVG<&)QR.V.ISTP:_2GP+X2M? OA'2M"LP/)LH%BW ??;JSGW+
M$G\: -ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVG9:Z[=?1GF_[0OQS\,^./ NH>'/#>HRZJ)Y8UN[JV0)I[1JX+0RW;LJ*CX
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MIU/8:***Z#R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM_\ &C_A3OQ@_P"BW2_^$_;_ .-+ZQ5_Y\R^^/\ \D:?V/@?^AE2_P# :_\
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M1_V,DO\ Z3P5\*?MS_\ )VWQ,_["*?\ I/%7W7_P23_Y(-XH_P"QDE_])X*
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MZ'UJS%I%Q#&J+$^U1@9.3^=#YNPI8BZT9QE_87=J(H]J/)*/+0(223U)']W
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MEE4CD>BH5'_U\UZ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI3%?6\_^KGC?/]U@>V?Y<UY/'<Z9'I&D1W=N96^PPLQ\LMZ]\?W X_$>N:?
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M(Z3IR:AX1MK*.ROK:VB6XL7W)-#!$(H #D@A4 4>PH ZRBBB@ HHHH ****
M"BBO)OVC?VB_#_[.G@S^UM5S>:E<DQZ?ID;8DN9 .>?X5&1ENW'4D"LZE2-*
M+G-V2.O"86OCJ\<-AXN4Y.R2/6,T9K\;OB-^W'\6OB#J4LR^))?#]D2?+LM'
M_<J@[?/]XGWS^%<-_P -%_$__H?O$7_@QD_QKP)9W13M&+9^NT?"[,9P4JM>
M$7VU=OF?N5FC-?AK_P -%_$__H?O$7_@QD_QH_X:+^)__0_>(O\ P8R?XU/]
MN4_Y&;_\0LQO_03'[F?N5FC-?AK_ ,-%_$__ *'[Q%_X,9/\:/\ AHOXG_\
M0_>(O_!C)_C1_;E/^1A_Q"S&_P#03'[F?N5FC-?AK_PT7\3_ /H?O$7_ (,9
M/\:/^&B_B?\ ]#]XB_\ !C)_C1_;E/\ D8?\0LQO_03'[F?N5FC-?AK_ ,-%
M_$__ *'[Q%_X,9/\:/\ AHOXG_\ 0_>(O_!C)_C1_;E/^1A_Q"S&_P#03'[F
M?N5FC-?AK_PT7\3_ /H?O$7_ (,9/\:/^&B_B?\ ]#]XB_\ !C)_C1_;E/\
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M_)WWQ)_[ .F?S:N'$_'2_P 7_MLCZK)/]WS#_KS_ .Y:1[M1117<?*A1110
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M_P"$3T;X>7_ABYM+=M3TZ+QAJ-KJ+!99-'54+6\8_P"?B7S<(/6%Z /JRBO
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MXO@\ 7.G>%8/&=OH?B2/5+[29Y8XQ) MK<)E=Y"LRO(A53P2 #7D>O\ P/\
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M(E@;5/AA;_$.UO\ PAIFB6]FK6VW3+B&)Q/ PD("12NX<RQY)(.>BU[Q\/\
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MM %6QDMT:  = $(VX'TJ>+1[""WMX([*WCAMT,<,:Q*%C4C!51C &.,"KE%
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MVF_]!"U_[_+_ (UY'_PQQ\*?^A<?_P #I_\ XNC_ (8X^%/_ $+C_P#@=/\
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M$+7_ +_+_C7D?_#''PI_Z%Q__ Z?_P"+H_X8X^%/_0N/_P"!T_\ \71SXO\
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M?5^'_P#H)K?^"H?_ "X]<_M[3?\ H(6O_?Y?\:/[>TW_ *"%K_W^7_&O(_\
MACCX4_\ 0N/_ .!T_P#\71_PQQ\*?^A<?_P.G_\ BZ.?%_R1_P# G_\ (A]7
MX?\ ^@FM_P""H?\ RX]<_M[3?^@A:_\ ?Y?\:/[>TW_H(6O_ '^7_&O(_P#A
MCCX4_P#0N/\ ^!T__P 71_PQQ\*?^A<?_P #I_\ XNCGQ?\ )'_P)_\ R(?5
M^'_^@FM_X*A_\N/7/[>TW_H(6O\ W^7_ !H_M[3?^@A:_P#?Y?\ &O(_^&./
MA3_T+C_^!T__ ,71_P ,<?"G_H7'_P# Z?\ ^+HY\7_)'_P)_P#R(?5^'_\
MH)K?^"H?_+CUS^WM-_Z"%K_W^7_&C^WM-_Z"%K_W^7_&O(_^&./A3_T+C_\
M@=/_ /%T?\,<?"G_ *%Q_P#P.G_^+HY\7_)'_P "?_R(?5^'_P#H)K?^"H?_
M "X]<_M[3?\ H(6O_?Y?\:/[>TW_ *"%K_W^7_&O(_\ ACCX4_\ 0N/_ .!T
M_P#\71_PQQ\*?^A<?_P.G_\ BZ.?%_R1_P# G_\ (A]7X?\ ^@FM_P""H?\
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M?_P.G_\ BZ.?%_R1_P# G_\ (A]7X?\ ^@FM_P""H?\ RX]<_M[3?^@A:_\
M?Y?\:/[>TW_H(6O_ '^7_&O(_P#ACCX4_P#0N/\ ^!T__P 71_PQQ\*?^A<?
M_P #I_\ XNCGQ?\ )'_P)_\ R(?5^'_^@FM_X*A_\N/7/[>TW_H(6O\ W^7_
M !H_M[3?^@A:_P#?Y?\ &O(_^&./A3_T+C_^!T__ ,71_P ,<?"G_H7'_P#
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M '^7_&O(_P#ACCX4_P#0N/\ ^!T__P 71_PQQ\*?^A<?_P #I_\ XNCGQ?\
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M4_\ 0N/_ .!T_P#\71_PQQ\*?^A<?_P.G_\ BZ.?%_R1_P# G_\ (A]7X?\
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M71SXO^2/_@3_ /D0^K\/_P#036_\%0_^7'KG]O:;_P!!"U_[_+_C1_;VF_\
M00M?^_R_XUY'_P ,<?"G_H7'_P# Z?\ ^+H_X8X^%/\ T+C_ /@=/_\ %T<^
M+_DC_P"!/_Y$/J_#_P#T$UO_  5#_P"7'KG]O:;_ -!"U_[_ "_XT?V]IO\
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MUY'_ ,,<?"G_ *%Q_P#P.G_^+H_X8X^%/_0N/_X'3_\ Q='/B_Y(_P#@3_\
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M7'KG]O:;_P!!"U_[_+_C1_;VF_\ 00M?^_R_XUY'_P ,<?"G_H7'_P# Z?\
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M^%/_ $+C_P#@=/\ _%T<^+_DC_X$_P#Y$/J_#_\ T$UO_!4/_EQZY_;VF_\
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M[U^:*S<I<MU_@8$>_:JED.&@[2JM?<-X&@MY/\/\C]<_^%U> _\ H;M&_P#
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M:WK3B5#^ZN9'CA; .>6C<8[8KB'B,3%7CV,.S+@T1R##3^&JW]PE@*,MI/\
M#_(_:K_A=7@/_H;M&_\  Q/\:/\ A=7@/_H;M&_\#$_QK\5FA9$5FC(5NA*X
M!^E*;=UQF$C.,90\YZ5?^KM#_GX_P*_L^EW?X?Y'[4?\+J\!_P#0W:-_X&)_
MC1_PNKP'_P!#=HW_ (&)_C7XJM"4QNCV[NF5QFE>!HW"M$58] 5P:/\ 5VC_
M ,_'^ ?V?2[O\/\ (_:G_A=7@/\ Z&[1O_ Q/\:/^%U> _\ H;M&_P# Q/\
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M66(R/#X>E*JYMI:]"9X*C3BYR;LO0_1C_A;W@K_H:-+_ / I?\:/^%O>"O\
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M;W@K_H:-+_\  I?\:/\ A;W@K_H:-+_\"E_QI_\ PJ?P;_T*^D_^ B?X4?\
M"I_!O_0KZ3_X")_A1_L7][\ _P!C_O?@,_X6]X*_Z&C2_P#P*7_&C_A;W@K_
M *&C2_\ P*7_ !I__"I_!O\ T*^D_P#@(G^%'_"I_!O_ $*^D_\ @(G^%'^Q
M?WOP#_8_[WX#/^%O>"O^AHTO_P "E_QH_P"%O>"O^AHTO_P*7_&G_P#"I_!O
M_0KZ3_X")_A1_P *G\&_]"OI/_@(G^%'^Q?WOP#_ &/^]^ S_A;W@K_H:-+_
M / I?\:/^%O>"O\ H:-+_P# I?\ &G_\*G\&_P#0KZ3_ . B?X4?\*G\&_\
M0KZ3_P" B?X4?[%_>_ /]C_O?@,_X6]X*_Z&C2__  *7_&C_ (6]X*_Z&C2_
M_ I?\:?_ ,*G\&_]"OI/_@(G^%'_  J?P;_T*^D_^ B?X4?[%_>_ /\ 8_[W
MX#/^%O>"O^AHTO\ \"E_QH_X6]X*_P"AHTO_ ,"E_P :?_PJ?P;_ -"OI/\
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MG\&_]"OI/_@(G^%'^Q?WOP#_ &/^]^ S_A;W@K_H:-+_ / I?\:/^%O>"O\
MH:-+_P# I?\ &G_\*G\&_P#0KZ3_ . B?X4?\*G\&_\ 0KZ3_P" B?X4?[%_
M>_ /]C_O?@,_X6]X*_Z&C2__  *7_&C_ (6]X*_Z&C2__ I?\:?_ ,*G\&_]
M"OI/_@(G^%'_  J?P;_T*^D_^ B?X4?[%_>_ /\ 8_[WX#/^%O>"O^AHTO\
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MKS!YF:#:74F2(1[54+C''O66?^"<OQ./6YT0_6Y/^%'_  [E^)Y_Y>=$_P#
MD_X5-\ FW[=?/7OOWW^0OW%[\YLZ9\6M"T7]G==&L]:TN+49O#6F6TUJJ1EW
MF_M23SU((ZB%R?8$'K6]KGC;0]1U7Q*WP_\ %OA'PYJ3>)[JYU6ZUF*-DO;)
MHT\DQ%E(:,88%5Y)KB/^'<OQ._Y^=$_\"3_A1_P[E^)W'^DZ)Q_T\G_XFB^
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MGV.I'Q+\+/\ #'1+"/6]%DO8M-\+1&UU"3,&^#4+EYDE R=JJREN. PKR_\
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M+?LW:]INFV7CB&+5-)T/QQ>6\ T+5=;13;Q8E)N%!8%5D9<8)%=J/^"<OQ.
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M6_Y.5\=?]@;3OYO7KE>1^%O^3E?'7_8&T[^;UWX3X*W^'_VZ)Z&%^"M_A_\
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M>=J>B*VBWA)YW08$9/UB,9KE.8^C:*** "BBB@ HHHH **** "BBB@ HHHH
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MS6WF+W\I]Q'X5'#87UR<16DH]6E^0#\Z+P:O=?@'MU_*OP.6_M;5_P#GO/\
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M.8_?0=;9S_?7MZBO9JNO2E0ERI^Z]4UU7];]GH:XFE*G/WGS)ZI]U_6_9B
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MG]G3X?Z])9-=: FRVLX=/,,,\D<<]O",113*K 2JHX ?/''3BNCO/AIX:O\
M2]>TZ?287LM=G6XU&'D+<2*D:*3@\86&,<?W173T4 )TI:** "BBB@ HHHH
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M?\#Y'N8O-ZV.P\:.)C&4HVM.UIV6EFU;F7^)-JVC1)11172>&%%%% !1110
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M;N>UB\XQ>/H1H8MJ?+M)I.:5K<O-NX^3;M;2P4445TGBA1110 4444 %%%%
M!1110 4444 %%%% !112 YH 6BBB@ HHHH *YS5_^0V?^O9?_0S71USFK_\
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M/_@._P#A7Y/DD=<BDR?4T?ZOX7^:7WK_ "#^SZ7=GZP_\-T_!W_H9C_X#O\
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MM"LUM+"VCM;=22$C&!GU]S5VBI44G=(UE5J3BHRDVEYA1115&04444 %%%%
M!1110 4444 %%9VLZW!HL,;2*\LLS^7%#$N7D;&< ?05RD=RVO7>J2ZCJ,^B
MR6K!8;;S AC7:"'/][))_*@#NV(4$DX ZDU\PZTROK-^R,&4W$A##H1O/->I
MZEXDUW6/#EKIB6#KJ&HP_NYT<#<@QO8C^'((_.O*M3TRYT>]DM+N(PSQXW(?
MTH JCK7O_P +KB.;P3IR(ZL\09'4'E3N)P?S%> 5W7P?U>2R\4"RW'R+N-@5
M[;E&0?YB@#W&BBB@ KF?%7PW\,>-%O!KFC6VH_;+>*UG,P.9(HY?.C4D'.%D
M^<8Z&NFKYZ^..HP'XM:5I_C#6]6\/^!CHS7%G/IKO$D^HB8B19)$!.4B\LHI
MX)9SSB@#TCP=\/OA\FE6LOA[1],DL;6>\BC>%-X$KDPW().=Q)C*-G/W<=JN
M>"_A)X0^'=Y/=^'M#M]-N9XQ"TJ%F81@Y$:EB=J9YVC KY"^&UT$\*>#M/\
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MHQ/H>*]XHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M['4$?E7GOP7\#WW@2+QE;7-O%:6=[XEO=0L(82-BV\HC(P!PN6$AQ[^]>CT
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MN/\ H>$_\ __ *]??%%']LX[^?\ !?Y!]<K_ ,Q\#_\ #L6X_P"AX3_P#_\
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M-A;M;K @D0*[MN)+8[<8'OBNGAABMXQ'$B1(.BH !3\T +129HS0 M%)FC-
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M&/\ D>3?\(E\6/\ H==)_P#!:?\ &C_A$OBQ_P!#KI/_ (+3_C7K-%'UV?\
M)'_P&/\ D'UR?\L?_ 8_Y'DW_")?%C_H==)_\%I_QH_X1+XL?]#KI/\ X+3_
M (UZS11]=G_)'_P&/^0?7)_RQ_\  8_Y'DW_  B7Q8_Z'72?_!:?\:/^$2^+
M'_0ZZ3_X+3_C7K-%'UV?\D?_  &/^0?7)_RQ_P# 8_Y'DW_")?%C_H==)_\
M!:?\:/\ A$OBQ_T.ND_^"T_XUZS11]=G_)'_ ,!C_D'UR?\ +'_P&/\ D>3?
M\(E\6/\ H==)_P#!:?\ &C_A$OBQ_P!#KI/_ (+3_C7K-%'UV?\ )'_P&/\
MD'UR?\L?_ 8_Y'DW_")?%C_H==)_\%I_QH_X1+XL?]#KI/\ X+3_ (UZS11]
M=G_)'_P&/^0?7)_RQ_\  8_Y'DW_  B7Q8_Z'72?_!:?\:/^$2^+'_0ZZ3_X
M+3_C7K-%'UV?\D?_  &/^0?7)_RQ_P# 8_Y'DW_")?%C_H==)_\ !:?\:/\
MA$OBQ_T.ND_^"T_XUZS11]=G_)'_ ,!C_D'UR?\ +'_P&/\ D>3?\(E\6/\
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MQ8_Z'72?_!:?\:/^$2^+'_0ZZ3_X+3_C7K-%'UV?\D?_  &/^0?7)_RQ_P#
M8_Y'DW_")?%C_H==)_\ !:?\:/\ A$OBQ_T.ND_^"T_XUZS11]=G_)'_ ,!C
M_D'UR?\ +'_P&/\ D>3?\(E\6/\ H==)_P#!:?\ &C_A$OBQ_P!#KI/_ (+3
M_C7K-%'UV?\ )'_P&/\ D'UR?\L?_ 8_Y'DW_")?%C_H==)_\%I_QH_X1+XL
M?]#KI/\ X+3_ (UZS11]=G_)'_P&/^0?7)_RQ_\  8_Y'DW_  B7Q8_Z'72?
M_!:?\:/^$2^+'_0ZZ3_X+3_C7K-%'UV?\D?_  &/^0?7)_RQ_P# 8_Y'DW_"
M)?%C_H==)_\ !:?\:/\ A$OBQ_T.ND_^"T_XUZS11]=G_)'_ ,!C_D'UR?\
M+'_P&/\ D>3?\(E\6/\ H==)_P#!:?\ &C_A$OBQ_P!#KI/_ (+3_C7K-%'U
MV?\ )'_P&/\ D'UR?\L?_ 8_Y'DW_")?%C_H==)_\%I_QH_X1+XL?]#KI/\
MX+3_ (UZS11]=G_)'_P&/^0?7)_RQ_\  8_Y'DW_  B7Q8_Z'72?_!:?\:/^
M$2^+'_0ZZ3_X+3_C7K-%'UV?\D?_  &/^0?7)_RQ_P# 8_Y'DW_")?%C_H==
M)_\ !:?\:/\ A$OBQ_T.ND_^"T_XUZS11]=G_)'_ ,!C_D'UR?\ +'_P&/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ibio-20230630x10k020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '9 Z@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&BBBN,Q"LR?Q/H]KKMOHLVJV4.L7$9EAT^2X19Y4&<LL9.X@8/(':M.OEO\
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MG<$)[8Q^A[U];UY&*H?5JTJ5[V_X<Y*L/9S<0HHHKE,@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXD>.K
M#X:^!]9\2ZDX6TTZW:9AG!<@<*/<G 'UKQ;]FSP-?IIVH?$7Q2GF>,O%["[E
M+\FTM#S#;KGH N"?PJ']IEC\1_B=\.OA<K%K"\NFUG5T'>UM^0K>S-_*O<%5
M44*JA% PJJ,!1V KT)/V&'45O/5^B>B^;U^2.A^Y32ZR_(6BBBO/.<*0$$ @
MY!Y!'0UX1^UO<ZU!X1TJ/3Y)TL)[HQW2VY(+DCY%..2">WKBN$_9^UOQ#I<F
MH>%9M6DT9]2BS8^8OVB:VF'.X0\E01GEMHSBM:=.565HK\]%W=NAK3IRJRM%
M?GHN^A]%_$CPYHOB;PK<VNN7,5A:C]Y'?2R",V\@^[(K'H0:\C\$^.I]#U*?
M5+CPXGBR\:$6MQX@\*W\=RUS&A^5Y+;(8-@#)QFLV#P=?^)M3>6V\*ZOXPOH
MG*'6O'=R;>S5@<$QVPZCTXKTR+X&>'M:TJV?Q#I&F#7E7]Y?Z#&UC@YXV;"#
MP,=?2OHU[#!TO8UI\R?1=/DI)VVWMT]T^@7L,)2]E6ES)]%T^2DG]]NGNE[1
M/CGX*UNX%K_;2:9?9P;/5HVM)0?3#@#]:[F*:.>-9(I$EC895XV#*1[$5Y#K
M7P*U1[<PZ=XL?4K4#C3_ !59QZC%] Y <?@:[;X9^$/^$*\+16#V6GV%RTC2
M31:69#;ECW42$D<=NE>7BJ6$4.?#S;?;^DOU]3S<32PBAST)MOM_27Z^IU=?
M/2M_PS?\?;:Y@ @\!>/)Q#<1#B.RU'^%P.@#]_QKZ%KSSX^^ E^(_P *->TE
M!B]2'[592#K'/'\Z$?B*Y\+449\D_AEH_P#/Y/4XJ4DI6>ST9[*.:6O.?V>O
MB ?B9\'_  WKDK9O)+80W8/59H_D?/OD9_&O1JYZD'2FX2W6AG*+BW%]"OJ%
MA;ZK8SV=W$)K:=#')&W1E(P1^5>=WO[-OPUU'P=8>%;GPE9R^'[&=KBVL2\F
MR.1NK [L\_6O0=4U2TT33KF_O[A+6SMHS+-/*<*B@9))]*Y'PK\</ 7C>]N;
M30?%>F:K/;6PO)A:S;EBA/\ &S= /J:TINM%.5.]EVN5'G2O&X>"O@?X#^'=
MA?V?ASPO8:3!?QF*Y\A#OE0C&UG)+8]LU+IWP:\$Z5X&E\&V_ARR'AB4LSZ9
M(IDB)8Y)^8DYSWSQ67X>_:.^&7BOQ'_8.D>-]'OM7+%%MH[D9=O12>&/T)KH
M?'7Q.\*?#*P2]\4Z_8Z';2'"->2A2Y]%7JWX"M)?6>?EES<SUZW?9E/VM[.]
MV<[\.OV<OAQ\*-4DU+PMX4LM+U"0%3= M+(H/4*SDE1],5WFM:-9>(=)N],U
M&W6ZL;J,Q30N2 Z$8(..:Q/ OQ0\)_$W3Y+WPMK]CKEM$<2-:2ABA_VEZK^(
MK!E_:,^&4'BD^')/&^C)K(D\HVQNAP_3;N^[GVS2DL15FW)2<EOO=":J2EK=
MM&/H?[)7PC\-ZO9ZIIO@>PM+^SD66"=))28W'0C+XKH_B5\#O WQ>BA3Q;X<
MM-7>$8BG<%)4'H'4AL>V<5?\6_%;P?X#O;.T\1>(].T6XO$:2W2]G$?F*O4C
M/&!7/67[3/PLU#0K[6+?QUHKZ;9,$N)S<[=A/08/)SVP#FM%+&3:JIR;Z/7\
M&5>M*TM?74O?#/X#^ _A!YS>$O#=II,TPVR7"[I)F'H7<EL>V<5L:3\-/#.A
M>,-4\56&D0VWB#4T5+R^5FWS*.@()Q^0KR_XU?M#6UA\ =8\=?#G6]-U=[9T
M2.Y5?/C5BV"&7((/L<5K^ OVF? 7B"+0](O?&>BGQ5=VT32V:3A?WK*"5'\(
M.?X<YJI4L5.+JRN[W3WOI9Z^0W"JTYN_9_\ !.XU3X9^&-9\9Z;XLO='AN/$
M.G1F.TOV9M\2GJ  <?F*C\(_"OPIX#UC5]4T#18-+OM6D\V]D@9@)GSG<5)P
M#] *\[U?XD>*]-_:6M_#;:QX<A\'#2FO)K*68"_! R7V_>P/RQ6[)^U)\)8G
MLT;X@:'NNW,<06Z!R0<<X^[SW.*ETL3RI1NTTMKO3LQ.-2R2UNCK_#/PY\->
M#=5UC4M$T>VTZ^U>;S[Z>%2&G?U//\L5G+\&?!::AXDOAH%N+OQ&GEZK+N?-
MVOHWS<?ABM#QE\2O"WP^T./6/$6O6.D:9)@1W%S, LF1D;,<MQZ9K%\,?'SX
M=^,]1L+#0_&&DZG?7R-);VUO<!I)%7K\O48]ZR2Q#3J+FMWUZ>?D2O:-<RN#
M? 3P ^C>']);PS:G3M F^T:9!ODVVTG]Y?FR?QS7::KI5IKFF76GWT"W-E<Q
MM#-"V<.A&"#BO.=3_:@^%&C[Q>>/=%A9)S;,GVC++(.H*@$C'KTK@?VDOVH8
MOA=+X''A[6M%FCU>[22\:X_? 6)QF92K  =?FY^E;1H8JO.,&G=WM>_JRU3J
MSDEJ>K'X(^!V^'W_  @Y\.VQ\*=?[,W/Y?7/7=NZ^]6M?^$?A#Q18:%9:IH<
M%Y:Z'*DVG1.S@6SKC:5P>V!US6I<^(X+CP?<:YI<\-Y ;)[JWF4[HY $+*?<
M'%?)WPH^._[17Q;M;;6=%\,^$KCP\;TV\T[2-%(%5\.0K2YR!GM54:6(K*4U
M.W*^KMJ_UT'"-2:<N:UN[/J+PC\+O"W@35=7U+0=&ATZ_P!7E\Z^N$9F>=_5
MBQ/Z4FK_  L\*Z[XRT_Q9?:-!/XBT^,Q6VH;F62-#G*\$ CD]0:\6^,O[27B
MNT^(,'PV^%WAZW\1>,O*$M[<7;'[-9 C/.".1W)( ]S57P5\1_VAO#/CO1]&
M\>>!],US2-3D\LZIX?? M.Y9R6P /0@9[$U:PV(<?:N:3:ZRLVO\K#]E4MS-
MZV[ZV.XU+]COX.:M@W/@33V;SFG+H\JNSL<G+!\D'TZ5U?B7X%^ O%W@ZS\+
M:IX6T^XT&RQ]ELUC\L0<8RA7!4_0\]Z\2^+GQW^+-G\?+CX>?#O1_#^IO'I\
M=Z!JFY&P0-WS^8H[],4WXP_'GXM?#/PW\.;,:-X?/C7Q#,]M=V<FY[=9>-H1
MA( !SU)-;*AC*CI_O=7JO>U6E[^1?)6ER^]OMJ?0/P[^%_A;X4:&=(\*:-;Z
M-8%S(T<&27;^\S$DL?J:S?'?P,\"?$[58-2\4^&;/6[V"!K:.6ZW';&>2  0
M._7&17DWP<_:DU:[U?Q?X>^*^FZ;X1UCPS&D]U=VLQ:U\MCC).6P<XY!(Y[5
M[9JGQ.\*:+X/A\57VOV%KX<F5'CU.28"%PWW2&[YKDJ4\31JW;?,^J=[W\UO
M<RE&K"=^O<Q?A[\ ?A_\*[>^A\+^&;32Q?(8[B1"SR2(?X2[$G;R> <5$/V=
MOAR/"]MX='A6T_L6VO/[0BL]\FU+C.?,'S9SGWQ7 6O[0VMW_P >/%_A*VCT
MZ;0-,\/_ -K6=PL;^;(YC#C<V[!7GL :\\?]K[QHO[.^B^.19:-_;%YK_P#9
MDD7D2>2(MY7(&_.[ ZY_"NI8;&SDI<SN^7J^J=OP^XU5.LW>^]NO?8^H=:^&
M7ACQ#XDT37]1T>&ZUC101I]V[,&M\C!VX.._<&N9\:_LS_#+XB>)4U_Q#X/L
M-1U8$,UPVY#*1TWA2 __  (&O1M/G:ZL;>9P \D:N0.F2 :L5YD:U6F[QFU;
M3<Y5.4=F<KX!^%WA7X76-W9^%=%M]$M;J8W$T5MNVM(1C=@DXX Z5U5%%92E
M*;YI.[);;=V%%%%2(**** "BBB@ HHHH CEMXI]GF1K)L;>NY0=K>H]#SUJ2
MBB@ HHHH Y+XK_$2P^%'P\USQ5J/S6^FV[2B+.#+)T2,>[,0/QKR7]FWX=ZA
MH6@W_C/Q2!/XZ\72#4=2F8<P1MS%;+Z*BXX]?H*H?M$D?$WXV_#?X9'][I4+
MOXFUF+.5>*$[84;V+YX]Q7N?^>*]"3]AAU!;SU?HME]^OW'0_<II=9?ET"OS
M]_X*!03)\8-'E<'R9-%B$1['$LF[]2*_0*O!/VO/@7<_%_P3;7VBP^=XDT0O
M);PC@W4+8\R$?[7 9?<$=ZX8NS/I^%,?2R_-:=6N[1=XM]K[/[[7\C\W:*?/
M!);3R0S1O#-&Q22.12K(PX((/((]#3*Z3^GMPKV+]D*VN;G]HKP?]E#'RI9I
M9B.T0@?>3[<C\Z\BL[.?4+N"UM8)+FZG<1Q00H7>1CT55'))]!7VI\%O@+XL
M^ 6CP^-+B*%M9N(BM[9A3)]BMR0?+E R65L NT?S1D#AP&%73I^UE[--)ON?
M+<1X^CA,!4HSDN>I%QBGU;5ON7^2W:/L0=!17%Z5\6=#U+2([UA=1S JD]G#
M;O<RP$C(8^4&S&PY60?*W8YX%/X@_$N71OAS=^(/#5LVJ70F6VACFMY$PY;!
M+(P5CM'.._K6$Z%6G\<6C^8IT*M/XXM'H!&:^?/!C?\ #-_[0G_"-)^Y^'_Q
M D>XTV/.(]/U11^\A7L%D&"!ZE?2O2/@OXWU?Q[X,&H:Y8#3]1BN'MW58VC6
M0  APK<CKCTXK#_:@\#2^./@YK(L 5US2 NL:9,GWX[B#YQM/;*AA^-;X2:4
M_93^&>C_ $?R>OWA2=I<DMGI_7H>]45R'PA\=P_$WX8^&?%$)&-4L8KAP/X9
M",./P8,*Z^N2<7"3C+=&+3B[,*R?%7A72?&WA^^T/7+&+4M*O8S%<6LV=LBG
ML<<_E6M7SK^U-^TC<?!37O!6FZ;J&E0S:C?H=3BOT+O%8DX:488;1D$;CGIT
MK;#T:E>HH4OB_P BZ<)3DE'<]<U3X2^#]:L/#EE>^'[.XM?#LL<VE1.IVVCQ
MC"%>>P['/O5CQ-\-O#7C'7-"UC6=)AO]2T.8W&G7$C,&MI#C++@@?PCKGI3-
M#^*/A/Q+K[:)I>OV-]JRVB7YLX)=TGV=PI27']TAE(/N*H-\;O ::1K6JMXJ
MTP:=HMP+34;GSODM9BVT(Y['/%-+$7TO?Y]?\_Q'^\OU_P"'_P RUJ7PF\):
MOXNE\47FB03Z]+9-ISWS,^]K=@08\ XP<GMGFJEK\$/ MGX!/@F/PS8GPL2S
M?V9(IDC#$Y+#<20<\Y!R.U4=-_:-^&6L>(5T.S\<:+<:HR>8($NEP1MW<-]W
M..<9S5[P1\<? 7Q)U:ZTOPQXKTS6M0M@6DM[6;<P ."1_> ]1D5;6*BM5))6
M?73M_P  ;55+6^AD_#[]F;X9?"W6#JOAKPC9:?J7(6Z8O+)'GKL+D[?PQ71^
M'OA7X4\*R>()-*T6"R?7Y6GU,HS'[4YSEFR3C[QZ8ZUD>*?VA/AOX)\0C0M<
M\9Z1INK$@&UFN!N0GIOQD)_P(BM;Q5\6?!O@B'3IM>\2Z;I<.HJS6<MS<*J3
M@+N)1NA&.:)/%3:<N9\WKK;\P?M9;WU+G@;P!X?^&OA^/0_#.F1:1I4;M(EK
M"6*AF.6/S$GFH=+^&GAG1?&&K^*;+2((-?U:-8;Z]!8M.BXP&!.,<#H.U:/A
M3Q7I/CCP_9ZYH5]'J6DWBE[>ZASLD4$C(R >H-:4\\=K"\TTBQ1(I9W<@*H'
M4DGI7/*=12ES-W>__!(;E=WW/([C]D3X07?B5M=E\":8VH-)YK8#B(OG.3$&
MV=?;%=IX[^%7A+XF>'X]$\2Z%::KID1!B@D3;Y1 P"A7!3CC@CBL#2OVE?A=
MK?B)="L?'6BW.JL_EK ER/G;^ZK'Y2?8&M_Q_P#%?PA\++.&Z\6>(K#0H9CM
MB^UR[6D/?:HR3CV%=,GBW.*ES<W3>_R_X!HW5NKWOTW.<\'?LR_#'P!JVFZI
MH'A"QTW4M.W?9KN)G,B[A@DDM\QQZYJ/Q9^R_P#"[QQXI_X2+6_!NGWVKE@S
MSL&42D="ZJ0K'W(I/&?QJTN^^"?BCQGX%UO3M9.GV,LT-Q"PFC615R ZY!'T
M.*\=\._M)^--2UGX#6T\M@8O&,,KZKMM,%BKX'E_-\G'UKIIT\94O54VFKK5
MN^B;:_KJ:1C6E>5]?7YGMA_9P^&I\&7'A,^$+#_A'Y[DW;66&*B8]74YRI[?
M*16U\-OA'X1^$.E3:=X1T.WT6UF?S)1#N9I&[%F8DG'N>*YS]IKXAZQ\+/@O
MK_B;06@35+)$:)KF+S$Y< Y7(SP:GT7XV>'M)\%^#;SQ=X@T[2]7UZRAEBAE
M<(T\K(I(C3D]37/;$U*7-S-IO:[>J5[V,_WDH7O=-G3:_P##;PUXH\3:+XAU
M328;S6=&8O87;LP:W)ZD8..PZ@US_P 1_P!GCX=_%K4(;[Q7X6L]5OH1M6Y)
M:.0K_=+(06'L<UX1XJ_:"^(WAK1?C)J)UCPO>+X=FC72X;+$TMN&;&)D!!Z?
MWN<].*T]!_:%\;:M\5?#/AWS]+6TU+P?_;,AFM]@%UY;-DOGY4R!QCI75'"X
MJ"YX3M9=&]-$_P!354JL?>3V\_F?27A3PAHO@;0[?1] TRVTG3+<8CMK5 J+
MZGW)]3S6Q7@'P3^/A3X5V.N?%#Q=X7AO;W4);2WO-/N5%O+CHFX?+N'/X8S7
MH_@GXW^ _B-J]WI?AKQ5IFLZA:Y,MO:S;F !P2/[P'J,BN&MAZT)2<DW;=ZM
M?>83IS3=U?S.XHKSSQ#^T)\-_"?B8>'M7\9Z1I^LY"FUFN &0GH&/13[$BND
M\'>//#WQ!TV34/#>L6FM64<K0//9R;T#CJN?45C*E4C'FE%I=[$N$DKM:&_1
M1161 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !2&EI#T- 'S3X+_XJ?]KKXEZM(3(NA:79Z3 3_"9/WCXKW2O"?@(2WQF^
M.C/_ *W^VK4?\!\CBO=J[\;I54>T8_\ I*-ZWQ6\E^04445P&!S_ (]\,GQ?
MX3U'2TE>&>6(F%TD9,2#E<E2#C.,X(XK\>=.^*WQ8T[X]:-I#W-S:>(-,UN.
M)= TZ,P1&59,$&)>7!'\3EL@YS7[22R+#$\CD*B LQ)P !7Q#XR^-7B?_A9=
MQK=JZ:;-#(8[9#9QJYA!P S%=S CW[\5K[6:A[-2?+O;H:^TJ*'(F^7MTN?<
M +, 7&U\#(SG![C\**S_  ]J$NK:!IM]/%Y$US;1S/%_=9E!(_6M"LC(****
M "D*AP5(R#P12T4 >+?L@LVBW7Q.\*DXAT?Q'*\*?W4F&\8KZ,KYQ_9ZROQ_
M^-:I_JOMEH3_ +WE<U]'5WX[6NY=TG]Z3-Z_QW]/R.(^-O\ R2/Q=_V#)_\
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MCK:J#9 G)$7'R<^E7+,X2YKI]>W\KCT*>*3OI_5K'F/[;_\ R;1XM_ZYQ_\
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M[I67316+KU(.F[.[=CTZBBBOESS HHHH **** "BBB@ HHHH **** "BBB@
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MV/@;3EFN ;BZER(+5#@N1U)/91W->*ZA\:_%-[<%XKJ*RCSQ%;PKC'IELDT
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M_P &3+J&M3 YCGN_^64'OCJ?_K5M?&GXN:E_:\/PY^'JIJ?C_4QMD9/FCTF
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M0UU.G+11G@*O^VW0#\?2N)5):SFM+^[YGI8Z6&P=&$*$FYM>^FK>]_*O+O\
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M5]%NK18I;+<Z3*X)90VTA@. <]Q7KE:J2DKHWC)25XL****HH**** "BBB@
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M8;ZQ5JSJU^7EO[EK_#W=^K\N@M%%%>@>F%%%% !1110 4444 %%%% !1110
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M@A5'E/JQ R?QK1HHJ8QC!6BK$1A&"M%604445184444 %%%% !1110 4444
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MYD9&TE<ALY %;?[//CO0OB-\</C#K/AW4%U+36@T6(3K&\8W+'=9&'4'N.U
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MHKXL,RZUI%U<P&TO(7C>-86Q$)!&BOA5#C&!UKGOV*;+3_ UMJFB:A;MX?\
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M<5\P?M>?#/QKXA\3>%/%'A'PY)XN^PV6HZ7<:9;W<-O(GVJ$QK,#*RJ54GD
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M?AQX;EU[[1_;3Z?";S[4FR7S=@W[Q@8.<Y&* .JHHHH **** "BBB@ HHHH
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M,QS"VY>2N[@XKZ?MK>.TMXH(EVQ1J$5?0 8 H EHHHH **** "BBB@ HHHH
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M^)HW^)?^>6E?]_)?_B: -VBL+?XE_P">6E?]_)?_ (FC?XE_YY:5_P!_)?\
MXF@#=HK"W^)?^>6E?]_)?_B:-_B7_GEI7_?R7_XF@#=HK"W^)?\ GEI7_?R7
M_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?XE_YY:5_W\E_^
M)H W:*PM_B7_ )Y:5_W\E_\ B:-_B7_GEI7_ '\E_P#B: -VBL+?XE_YY:5_
MW\E_^)HW^)?^>6E?]_)?_B: -VBL+?XE_P">6E?]_)?_ (FC?XE_YY:5_P!_
M)?\ XF@#=HK"W^)?^>6E?]_)?_B:-_B7_GEI7_?R7_XF@#=HK"W^)?\ GEI7
M_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?XE_YY:5_W
M\E_^)H W:*PM_B7_ )Y:5_W\E_\ B:-_B7_GEI7_ '\E_P#B: -VBL+?XE_Y
MY:5_W\E_^)HW^)?^>6E?]_)?_B: -VBL+?XE_P">6E?]_)?_ (FC?XE_YY:5
M_P!_)?\ XF@#=HK"W^)?^>6E?]_)?_B:-_B7_GEI7_?R7_XF@#=HK"W^)?\
MGEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?XE_YY
M:5_W\E_^)H W:*PM_B7_ )Y:5_W\E_\ B:-_B7_GEI7_ '\E_P#B: -VBL+?
MXE_YY:5_W\E_^)HW^)?^>6E?]_)?_B: -VBL+?XE_P">6E?]_)?_ (FC?XE_
MYY:5_P!_)?\ XF@#=HK"W^)?^>6E?]_)?_B:-_B7_GEI7_?R7_XF@#=HK"W^
M)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?X
ME_YY:5_W\E_^)H W:*PM_B7_ )Y:5_W\E_\ B:-_B7_GEI7_ '\E_P#B: -V
MBL+?XE_YY:5_W\E_^)HW^)?^>6E?]_)?_B: -VBL+?XE_P">6E?]_)?_ (FC
M?XE_YY:5_P!_)?\ XF@#=HK"W^)?^>6E?]_)?_B:-_B7_GEI7_?R7_XF@#=H
MK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_X
MFC?XE_YY:5_W\E_^)H W:*PM_B7_ )Y:5_W\E_\ B:-_B7_GEI7_ '\E_P#B
M: -VBL+?XE_YY:5_W\E_^)HW^)?^>6E?]_)?_B: -VBL+?XE_P">6E?]_)?_
M (FC?XE_YY:5_P!_)?\ XF@#=HK"W^)?^>6E?]_)?_B:-_B7_GEI7_?R7_XF
M@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?
MR7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_ )Y:5_W\E_\ B:-_B7_GEI7_ '\E
M_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?^>6E?]_)?_B: -VBL+?XE_P">6E?]
M_)?_ (FC?XE_YY:5_P!_)?\ XF@#=HK"W^)?^>6E?]_)?_B:-_B7_GEI7_?R
M7_XF@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GE
MI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_ )Y:5_W\E_\ B:-_B7_GEI7_
M '\E_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?^>6E?]_)?_B: -VBL+?XE_P">
M6E?]_)?_ (FC?XE_YY:5_P!_)?\ XF@#=HK"W^)?^>6E?]_)?_B:-_B7_GEI
M7_?R7_XF@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B
M7_GEI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_ )Y:5_W\E_\ B:-_B7_G
MEI7_ '\E_P#B: -VBL+?XE_YY:5_W\E_^)HH W:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***\F^*G[37@KX57RZ3<7,^N>)Y>(= T6(
MW-XY/0%5X3_@1%:TZ4ZTN6FKLJ,93=HJYZS29%?-#>+_ -H7XFX?2=$T+X5Z
M2_*2ZVQOM0*^OE+\JGV--/[._CK6<OXD^.OC*>1_O1:.D5A%] %SQ75]6A#^
M+5BGV5W^2:_$U]DE\4DOQ_(^F<T9'K7S*/V4Y(3OMOB[\28)_P#GI_;(;]"M
M.'PA^,7A7]YX7^-MWJ@7I:>+-,CN4;V,B?,/K1["A+X:R^::_1AR0>T_P9],
MT5\T#]HKXC_"O;_PM3X>F?2%(5_$GA"0W5N@_O20GYT'^<5[AX ^)GA?XHZ*
MNJ^%M:M=9LCPS6[_ #1G^ZZGYE/L0*RJX:I27.U>/=:K[T3*G**OT[G3T445
MRF04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:9:QL\EY!=H\*8&?F8' _&O-_P!EW]H";X[^'-6NM1&EVFIV5])"+/3Y23Y
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M<7MM-+J:D^:VZ3&WZ  8':NV\16OA/Q1^UC!;?%^>(Z&N@V[:3'JLQCM)&*
MG<V0.3GOR>M9/+:+=XR;2YKZ:^[;;7S(^K0W3=E?UT/MG1O'GAKQ'??8]*\0
M:7J5WY0G\BTO(Y7\L]'VJ2<>];U?"_[+^F^"]*_:_P#&=MX!DAE\-IIN(3;O
MOB5MPWK&QZJ#TYK[HKR\9AXX:HH1;LTGKH]3FK4U3E9=@HHHKA, HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /,OVB?BE_PJ3X6ZIJ]NOFZO,!9
MZ; !EI;J3Y8P!WP3D^PK$^ OPP'PK^'EGI]RQN-=O2;_ %>[DY>>[D^9RQ]L
M[1]#ZUR7Q8/_  L7]J;P'X4?$NE^&K27Q%>1]5:7[D (^N3^->Y=>O)KT*O[
MFA"DMY>\_P DOU^9T2]RFH]]7^@4445YYSGPO^T9J4^H_%W6_/5D%OY<$:M_
M<"@@_0Y-?3G[.GAT^'OA1I(=-DUYNNWR,'YC\OZ 5\F_\%(?C?J_PX\8^&-'
MT'2--MKR>T-[)K=W8I<3, ^T1)O!7 ZG(/4=*]B_88_:CG_:$\#7EAX@>V7Q
MAHA5;D6\8B6Y@/"2J@X&#\K <=.F: /IR@ GH,T5Q?Q@TB\U;P#J)TZ:6'4+
M0+>0&)BI+QG=MXZ@XQBM:4%4J1@W:[M<UI052I&#=KNUSIM)US3]=BFET^\B
MO(X96@D:(Y"2+]Y3[BKU>+?"?Q#%%X\N4B.S3O%5C'K%JO9;A1MG0>^>:Z#Q
MQ\4IX=3E\.>$HX-0U]%WW5U.?]$TR/N\S=,C^[7=4P,U7]E#:U[OHNM_1W7J
M=M3!35;V4.U[OHNM_1Z'I-?/WQL@E^#GQ-\._%S3%9+&21-)\20I]V6V<X24
MCU0D<UZ_X$\56GB_P_%=VE\-3\H_9Y;Q(&ACFD4?,R ]5)Z$<4GQ&\)6_CSP
M+KN@72!XK^TDAP>S%3M/X'%949/#5^6HM-FO+J<J3HU'&:\F>@VUQ'>6\4\+
MB6&50Z.IR&4C((_"I:\8_9&\7W'BOX):1%?L6U/1WDTFZW')WPMM!/X8KV>N
M>M3=&I*F^CL93CR2<>Q7U"QCU.PN+24L(IXVB<J<'##!Q^=?,LO_  3P^&OE
M+%;ZEXGM(G<M<I%J8 N03G:XV8P.V!7TW?W7V*RN+C;O\J-GVYQG SBODWPS
M^VUXS\9W$C:#\%-8UC3X[MK1[ZRO#)&I#;221%V'.*[L&L7:3PSLE:^J7IN;
MT?:V;INWS/;/$O[.?@7Q/\+[;P!/I/V;P_:!?LRVLA26!QTD5^3NSR2<Y[UB
M_!K]E'P;\%M;N=:TV;5-7UF:+R!?:O=>=)''_=3  %9OQK_:KL_A=K.G>&-&
M\.WOC#QO?QK(FBV)P8@1QYC $@^P';M7.>"OVMO% \<:3X8^(/PJUKPA<:M)
MY5G=0[KF-F]" HX]2"<=Q6L:6.E0=F^65W:ZN^[M>[*4:[@[;/S/8?A;\&]!
M^$1UXZ')>R?VU>M?W/VR828D.<[,*,#GIS2>,_@SH/CKQUX7\6:C)>KJGAUV
M>S6WF"Q$GKO4J=WYBO,OC1^U1K/PT^*-OX(T+X?7GC/49K-;Q197>R0@YR @
MC;ICKFJ'C[]KK7_ '@_P?J5]\,[]-<\0S20#0IKSRYX67[H_U>6+>F!41P^,
MG*-5;SVU5VK>O82IUI-26[\T>LI\$_#J_%:\^(+->2:W=V/]GRPO*#;&+&/N
M;<YY]:\JU7]@/X8ZIXAGU!7UNRT^XF\^;1;6_*63MG/W<9 ]@?IBNG^!G[3=
MO\7[_7=&U#PQJ7A/Q/HR"6YTB]^>0IZKP#GV(K,^&/[46I>//C/=^ =4\!7W
MA6:*WDNHYM0N?WKQJ?E8Q;!C<.>IJHK'T7/E;3BE?5;=/7Y#7MX-V=K+OT.U
M\8_L^^$O&<?A&&>*ZT^V\+3K/IUOI\HBC4J,!6!4Y'Y5W/B+0;;Q/H-_I-V9
M%M;V!X)3$VUPK#!P>QK2HKS'5G*UWML<KE)VN]CY=_X=W_#-%MX8M0\2Q62D
M&XM!J?[NZ(Z&0;>O;C%>I:]^SIX/UV\\%S"&ZTZ/PDX?3+:QE$<0QV<%26'X
MBO4**Z)XW$U&G*;=OU-'6J2WD><>"_@-X;\!S^+Y=-EU!F\42O+??:)PX4LI
M4^7\HV\'WK#B_91\!#X3'X>7%M>7VAB=[F*6YG!N896.=R2 #!'T^N:]CHK/
MZS6O?G=]']VWW"]K/>Y\V>'_ -@GX>:%JFEZFVI>)-0U'3KE+B"XN]1#D;#E
M8\;<;!Z#'UKM=0_9@\(:E=>/;B6?50_C1%CU+;<J H!R/*^7Y?QS7KU%:2QN
M)F[RF_Z=_P QNM4;NY'E?B?]G'PKXM^'7AWP7>S:DND:%)#+:M#<!9B8_N[V
MVG/OP*^>_P!JOX;:GJ_Q MKN]^$6H>+-(AMUBM=<\(:D]OJ. ,;)UVLIQZ[>
MG0]J^V*3%7A\;4H34GKOU:WWVL53KR@[[GR+^Q1\#M;\%>)O%'B[4_#$_@O3
M]1C2VT_1KRX,URB*22\C'G)SWQGT%?4/C/PCIWCSPMJ?A_5HVDT[4(6@F5&V
MMM/<'L1U%;/2EK/$8J>(K>V>CT_#8FI5E4GSO<\@U7]E?P'K'PY\.>"KBUN_
M[&T&=+BU99P)F=3D[VV_,&_BX&:W?&WP/\.^/?$GA/6]0>]BNO#,OFV*6LP2
M/.,8<%3D<>HKT*BH^LUKWYGU_'?[R?:3WO\ TSRC1?V9?!.D6'C*QDM[K4[+
MQ9.;C48+Z8.N\_\ // !7'4<Y%>:1_\ !._X:&&2&XU+Q/=0*P-M')J?RVHS
MDB,;,<]\BOJ*BM88[$P;<:C5RU7J1VD5]/L8]-L+>TA+&*"-8DW')P!@9_*N
M+\3?!K0?%?Q,\.>.;V2]76M!B>*T2&8+"0V<[UVDD_,>XKO**Y8U)0;E%V;_
M %,E)Q=T?+GBGX6:K\6OVO=,UK5/#4UCX3\*6BF+4;B$*NH7&25"G/S!22?^
M BIOVR/A3JGQ4UOX8V-KH=YK&D1ZJZZHUH.(8&V LS @J, \CTKZ<Q1C-=L<
M=4A4A-+X%9?Y_C<W5>2E&2Z*QX1\,OV-/ ?PR\81>)H9=7UW5+8%;-M:O/M"
MV@QCY!@<@< G..U3?%+]D'P5\3_%4OB5KG6/#>N7"[+J[T&\-N;D=/W@P03C
MN,9[YKW*BL_KN(Y_:<[OM\B/;5.;FYM3BOA-\(?#OP6\*KH'AN&>.T\PS227
M4QEEED/5F8]_H /:NUHHKEG.523G-W;,FW)W84445 @HHHH **** ,?Q!X0T
M3Q6VGMK&E6FIMI]PMW:FZB#^3, 0'7/0C-:X&*6BFVVK,=V%%%%(1Y3^TO\
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M,EM<38?!X!(&=H/J<"N%^-'[1>FZ;\&_&7B+X?>(-*UC5M"$2R-$1<QQ,[@
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M;7,;F.>$8QA9%YQ['(]JY?X6?L??#/X1ZZFM:/I,]YJT7^IO-3N6N'A]T!P
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MCVY0;?WD,41 /7_EBK?4UWX2NJ*FI/1K;=-]#3#8CV;GSN]UUUN^E_\ ,@\
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M2_#S7Y/BP?&'AR=;'P4\EREYIR>/%\1-;QF,"&WE"2R)OWY<,#D 8)-?H)0
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MT76IIM:DBDFCM+K3+NT:1$QO*F:) V,C.#WH ](HHHH **** "BBB@ HHHH
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MMI7P,@UAX=<U;Q/J>J&);C4M::)I?*B39#$HC15"JO'3)ZFJ/P? 7XV?&/
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M1V4C8'(W4 ?4OAGQYX:\;+<MX=\1:3KPMR%F.EWT5SY1/0-L8X/UKS?X0_\
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MXQ[W$/\ \57D-EH/Q.E^-(U&:2YM_#YE+%7N5: 08X38#][IV]\T >[T444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZFLG-@_V@QP1HMN[$,84+R@\!G3'6N@_:A_:UN_A/\0/!W@SPK#87FIW>J6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?%O[<?[/'COXQ^-M(U#P]X'T_P ;6%MHMQ9P#4-;6P_LV\=U
M*7,:D'<R@<=/J*^TJ\*_:&N_C?9>(?"J_"VY\.QZ/>S_ &74VU?3WN9;4G[L
MP FCW(.A RW.>: .E_9^U+XAW7@B"R^(OA*U\+:GIT,-I$;;65U'[8J1A6E9
M@B["2,XYZ]:^%?VOM T72OVII&\0ZQ>^&]#U]H(IY[32K'6IKDE=A5%$HN;8
M8[F-E!^9>:^]?@[%X]M++5+7X@^)?#7B+5HI5\O_ (1VQ>T$"$=)$>1SD]1T
MKXK_ &F=)T.]_:HGUV:]\1>'K?0C:G5/$OP\\/O]IL@_W5O[]IP A_NI$Q"]
M: /T,T6&"WTBRBMF=K=($6-I<[BH4 9SSG&.M7:R;C7M*\/^&O[5U#5H+;2;
M>W$LFI7TZQQB,*/WCNV  1SD^M1Z%XTT#Q/X<3Q!I&MZ?JFAO&95U*SNDEMR
M@ZL)%)7 [\T ;)Z5XU\(?^2V?&/_ *^]/_\ 1!KO?!/Q2\&_$M+QO"7BO1?$
MZV;!+@Z/J$5UY+'H'V,=I^M<%\(?^2V?&/\ Z^]/_P#1!H ]FHHHH **** "
MBBD) !)X% %?4+^+3;22XF.$0=!U8]@/<U3T2PE3S;Z[ ^VW."P_YYK_  H/
MI_.JUKGQ#J(NVYTZV8B =I7Z%_H.@_.MZ@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2/B[I7PUGT^VO8;B>YOB1$L*C:H&!EB3TR1TR: .JU?5O[/6.*&/[1>S';#
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M>.UO[FQ:WD^RW!\P+"0W2/C!]: /K^LKQ+XITOP?I4FHZQ>)96:$ R/DY)Z
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M<5\RM^WC\-U +>./"8#*&!,][R#T/_'KT..*^1_V\_VX/%&OV7A2T^"_Q"M
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M:C\0>$-:MM>T>21XEN[7=L+*<,.0#D$>E=370= 4444 %%%% !1110 4444
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M **** "BBB@ HHHH XWXM_"K1OC-X'O?"^N/=0V=PR2I<64@CG@E1@R2(Q!
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M,NG1!BMPQ?>)-S.3D<C %?(/QA%XG[7MX\B7P\>CQ)I3^'Y52?*Z.(V^U;&
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M<=^M?<_[!*7D?[/ED)%NDTDZE?'1UNPX<6'VA_L^ _S;-F-N>V* /HNBBB@
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M ,="/:O@+]D;X0W^M^)M2TBX\/\ B+PC%%X.NM(\5ZA%;3:;-=:D^H-(NV?
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M%% !1110 4444 %%%% !2$ @@\@TM% #0H4  8 Z4GE+MV[1M],<4^B@!I
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M^LV$^OVD"W-QI<=RC7,,3'"NT8.X*3QDC%:=Y/\ 9;2:;8\GEH6V1J69L#.
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MEJ[>'8+!8H_-D&SY%D67>2?O X/W: /TWZUQ]W\8O FG^-H?!USXQT*W\5S
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A9[J,2(64Y4X/&01FM$#'2EHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ibio-20230630x10k021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '9 Z8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5JEKQK]DOP5<^$?@IH$^H>)=;\5:GK%M%J=W?ZY=FXD\R1 2J9^Z@[ 5[+0
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ME54NV7!4#!&>U?.GQL^+WCSXQ_ [0K^^U:SN-?L?BR-.TJZN8$C@A"$B+>%
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M58=C0!U%(#F@@,"",@\$56T_3;;2XFBM8_*C9BQ7<2,GZGB@"U1110 4444
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MMGU&3^->"^&M.U7X7?%7]F_POJ/CKQG>ZEJ>G3W5^C7XEM;Z9E+,9PY+$#.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY[2QMK6:X.Z:2&%4:0^K$#G\:NT %%%% !1110 4444 %%%% !1110 4444
M%>1_M7?!N\^/GP#\6>"=.NTLM1U&!3:R2G$9E1PZJW^R2N#]:]<HH _.O4?
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M"<7Q\\9_M%? Z\\3>.-0AU'54U26V22&V2!5C55(&U !W/-:.%E>Y7+H<O\
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MWC /<*LT CB)QO#9V_6BZ"S.EHIJ.LBAE(92,@CO3J8@HHHH **** "BBB@
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MG6:-2DM@T%TRI*O._LR^M:0O;<H&\^/:>^X5E^()[26TV,(YI3]SH2OO2?=
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M **UX,_\'EO_ /%U^.?_  ZA_:1_Z$^P_P#!W:?_ !RC_AU!^TC_ -"?I_\
MX.[3_P".4 ?L9_PUU\$O^BM>#/\ P>6__P 71_PUU\$O^BM>#/\ P>6__P 7
M7XY_\.H/VD?^A/T__P '=I_\<H_X=0?M(_\ 0GZ?_P"#NT_^.4 ?L9_PUU\$
MO^BM>#/_  >6_P#\71_PUU\$O^BM>#/_  >6_P#\77XY_P##J#]I'_H3]/\
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M1_Z$_3__  =VG_QRC_AU!^TC_P!"?I__ (.[3_XY0!^QG_#77P2_Z*UX,_\
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M+_HK7@S_ ,'EO_\ %T?\-=?!+_HK7@S_ ,'EO_\ %U^.?_#J#]I'_H3]/_\
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M  UU\$O^BM>#/_!Y;_\ Q=?CG_PZ@_:1_P"A/T__ ,'=I_\ '*/^'4'[2/\
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M(/ _,^V:]BK:E)RC=G/BJ<:51QC]W:_0****U.0**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!*6BB@ HHHH 0@$8(R*:L,:.SK&JNWWF Y/UI]%
M !1110 4444 %%%% !5/3M)L])25;.W2 2R&63:/O,>I-7**!W=K!1110(:S
M!%+'H.:^6K?_ (*.?"L^+KG1=0L/%>BVEOJ3:3)K]_HQ&EBX5MNTSH[ <^H'
MOBOJ289B?Z&ORRMM8\477PI^*GP4T_X5>,=7\3>*/%-Y):ZA)I31Z9;PR2C$
M[3L1]T#/ _&@#]/KKQ)I-E]F^T:G9V_VI=T'FW")YHQG*Y/S<>E<S8^ ? -W
M\1)?'-IINE3^,/LHMWU>%PT_D<X4D'[O7M7YV_&#X56_A/XC>*++XM?#CQ9\
M2))_"]II_A#4M$M)KR"WFCA"NH\MOW3[QG<>U8.I^#?'GPB^%GP4UCPA9OI7
MBOQGHLG@O5-.O T-P-\C&.;8<'<@)ZB@#]8K2\M[^$36T\=Q$20)(G#*<=>1
M7GGQM^.5C\#M(L=0OO"WBOQ3'=RF(0^%=*-_+%@9W.H8;5]ZE^'GPL;X4?!7
M2_!?A6>"PO-.TX6]O=SQ>8GVC&6E=>-V7))YKR#XM:I\:/A[^SGJ^GZC?P>.
M?B%K5TNEV%[X<TA[:&T68A/,D7<V @))8D"@#T[]GG]HWP[^TKX6O]?\-:9K
MFFV5G=M92+KEFMM(9%^\% =LX/!YX->JUY_\!OA-9?!+X4>'O"%E\YL+<"XG
MSDSSMS+(3W)8GGZ5Z!0 4444 %%%% !1110 4444 %%%% !1110 4444 %<#
M>_'WX:Z;XM?PO>>//#EIXB23R6TN?4X8[@/V786!S[5WIK\M/B%=_!6/QW^U
M/!\3GT(:X]_G1$NPAU$S>2-GV;^/._'W?QH _4L,& (((/((KDY_A1X0NOB%
M#XZET"RD\7PVYM8]8*'SUB/5 <]*_/71_B'XXO6^&'@?QY\7-4^"VEVO@Q-4
M&HQR1P3:A<C.%DEE!!VJ!E.IK-\$?M1?$CX9_"GP?\7]6\8:QX_\+KJFI:'J
ML+8=)_F;[)<!0!@D@#KT- 'ZD%@H))  [FN(\*?'#X?^.O$^H>'/#WC/1-:U
MZPS]ITZROHY9HL'!RH.>#UQTKROX5V?C]_V3-8U3Q5JU[JGC/6M+O-25)VR;
M7S8V:*!  ,!00!7QI^S_ #^"KCQI^RU#X).G'QO$U]_PD@L OVI4VGS/M./F
M^_\ WJ /U7HI!TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C_'GQ
MA\#?"Z2T3QAXNT7PP]WDVXU:^CM_-QUV[R,XS70:%X@TSQ1I4&IZ/J-KJNG7
M"[HKNRF6:*0>JLI(-?&/[:%UX'L_VJ/@9+\17T6/PF+;4Q=G7_+^R?<&W?O^
M7KT]Z\#TCXEWOPT^&WQ3N_A%K,WA?X3ZIX]M--T_Q%!$S0:7:RC_ $J>WW#
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MX/'!RZ8/3/2G^'_#W@?P!X_UEK6ZM+7Q=XLF^WW$-S=AKJZ$:!!L1CN\M N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWQ4\:6/Q,^(7A;Q9;:%X;\%7AM[+P\VFQ3IJ:Q*K3&>5OG4D'"[",8[U#+\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5+"Z>^T_1KK5IYM,L;AN6EAM68HC9)[8'8"@#Y=_L'2I?V*=9\32V=L?%?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\D^)O[4?P_^%FM
M#0K_ %"\UGQ*5W?V#X=L)=2OE'JT4*L4'NV* /6Z*\'\,_MI?#G6M9MM*UC^
MWO =_=.([:/QEHL^EI.QZ*DLB^63[;LU[9J>K6ND:5<ZE<R[+.WB:>2107P@
M&20!DGCTH N45X5^SY^TU_POSQEXVT^V\-WVA:3H;0"SGU2)X+B\212?-,3
M%%./ESR1527]J^SO?VG]/^%&D:8+ZR^RW$FHZX7(CAN(UW>0F!AF Y;GCB@#
MZ HKY4G_ &OO%:QW/C.'P18R?"6VUG^QI-4.I,-2;$GEFY6#9L\H.<8W;L<U
M9\7_ +5_B^#4_&6K>$_!-AK?@'P9<K;:OJ-UJ30W<[8!E-K$$*L$# G<PSVH
M ^D/$-IJ5[I,\.D:A#I=^P_=W4]M]H1/K'N7/YBO,OV88;NW\ ZE%?7,=[>+
MK5\);B*'R5D;S.H3)V_3)KO3<_\ ">^#+6\T;5[K28]2MX[FWO[1(VE16 8$
M"167.#W!K@OV8;26P\ ZE;SWDVHS1:U>J]U<*BR2GS/O,$ 7/T % 'K]%%%
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M]GKXQ?#?XZ?"K36OO#NI:=:6NHFZUFRT:[V$RC,S7$AD(\Z3/RG@>QK] J*
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MAKX7QB)K/5=.^TS:K*D;.^YB?W2$(P!'M[D 'VK%X!\-0:CI6H1^'],2^TF
MVNGW*VD8DM(B,&.)L91<=A@5G0?![P);>,6\60^#=!B\3L2S:RFFPB[)/4^;
MMW9/KG-?%=M^UU\7?C9XL^"&C> ]0T;P<_COPU=7]_)J&G_;$M;B&21'DC!(
M+#]W\JDXYYKVW]A/XY>,/C5\/_%<?CJ>SOO$/AGQ'=:%+?V, @2Z6(*0Y0<*
M?F(X]!0!] :3X1T/0M5U/4]-T>PL-1U1Q)?7=M;)'+=,. TC 9<C)Y.:UZ**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#G/X5[)10!\[^%_V&OA[X2T;P+IEE<ZR;?P=K4^O:=YMTK,UQ*<L)#M^9<]
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M6+O4;_PZ;GPU)837DT:R6TE\7-NRG!!.SYL$'M7G/[,'VW_A =1_M+[/]O\
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M>PP $ASND/(P@- #?@!I6J_#/]I2+PIJ6J_#S7(]0T2:\AN?!WABUTVXB*,
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MP_ UYE^S#IL.C^ =1L;=IF@@UJ]1#<3/-(0)/XG<EF/N230!Z_1110 4444
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M5\9^%O$ TG3)].2+1K5X)-C\CC8%/)/)K[.HHH **** "BBB@ HHHH ****
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M)'CY1DJI]:^F/ .D0VN@6-XXDFU"XMT::ZN&+RN2.A8\X]NE4?&JC_A,/!?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAZ[QV88C K"*2]E?X4DM=^WZGHE<AJOQ'MEOY=+T&UE\1ZO&=LD%F1Y5N?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=^6+8#=CRMG&S&*FE\(6/Q'^"WQ8^,VL27)^(6F:S/)IFJ"ZD633DMV01Q1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.@59&=0/^ UT/PR^(WA#XEZ&-4\(ZC97MLW^L2W*K)&>0!(@Y4\<9KLJURG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHP=2H[)&%:O3P]-U:LK16[.PHKR[X0_'O2_BOX>_M!-.O--G6X-L\'E/,@;
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M7]LV[M?$&DLO@S4;;1K:VUQ_$$%PT)NK.;3XT=HTQ)M<8<'(SN#+CO6Y%^V
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MI@,Z[@W^STS6?>6]I8_MO^$QI"11"7P?.MZ(  #$L@\G=CL.V?PH ^EJ***
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MDJ "BBB@ HHHH YOQ_\ $?PQ\+/#SZYXLUNTT'2D=8OM-X^T,[?=11U9CV4
MDUREC\;/A5XH\)3_ !'M_$NC7NB:$LL4VM%O^/'<4$B-D;HR2$RI )XJG^T-
MJOP\\&Z3H7C3QY:-?SZ!?>;HEK"KRW$]](I1(X(%/[V5@2%!!QUXQFOFSQ-\
M%?$_BKX<>-?$7BK6-#^&&O\ Q.\2Z7)%I>JC?#:11,OD6\@7 DN9/+!8< GC
M/>@#ZK^&'[0GPZ^,]Y?6O@GQ;I_B.XL462XCLF8F)6)"DY ZD'\J]#KYJ^"_
MB_QMX._:"UOX4>+M8TKQ=$NA0Z[9:WIVEII\L"&4Q&WFC0E3R-RGJ1G-?2M
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MIDUM=2V]S9$+M!BGC99%.!@X//>H?B%^TE\,/A3<64'BSQQHVBSWD0G@BGN
M7>,]),+DA/\ :.![UR7B+]L'P+X?^,?A?P,VKZ=)%K>E2:JNJB[!C51@QJH
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MX.^%/@UHUSIOA73FLXKJ=KJZGN+B2YN+J8\&26:1F=VP ,D]!7:T44 %%%%
M!1110!YQ\8OV?/ _QYCTA/&FES:D-)E:>R,%]/:M"[  L#$ZG. .>U8.C?LA
M_"W1?"&N^&$\/W%[HFM&-[RVU'5+J[):/E'1I9&:-E/(9"#FO9:* ///A1\!
M/!?P7;4YO#&F317VILK7NHW]Y->W=QM&$#S3,SE5' 7.!Z5Z'110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %)FEKC/B!X3UW6M&U4^'?$5WI>KS0&
M.T$CJ+:*0C 8@(6QWZ]:VI0C4FHRDHWZO;\#6G!3DHRE;S9V08, 000?2H-0
MU"VTFPN;V]GCM;.VC:::>9@J1HH)9F)Z  $DUY3\#_A1XM\"^"K'2/%/B^YU
M*[L92(7L)1Y3PYRJN'CW9'(//3%=W\1[";5/A_XDLK?1X?$4USIUQ"ND7$WD
MQWNZ-AY+/_"'SMSVS6N*HTZ%65.E44TGNKV?GJ:8BE"C4<*<U)+JNOWGEW@?
MX\?!*^U;7=4T*2QTK4O[-FUFZO9-$EL)K^RB&Z2YC=XD:XC7J2A;J#W%2_#?
MXK?!/XB:O=^'_#D.FQZCKT#7LUA>:#)8-JL0P6DQ-"@N  P)QNP#D\5\Z6.A
M>,]7T?5]!\,Z%\0KS0$\&ZS9W&E_$#24:72)WLRD%OI]XRB29F?;&54NI0 E
MNE=U9R^+/C"_P<TOP_X+\1>%K_P9MO[S7O%^D26=M!(E@]N($1F$DV^20;@F
M!M4Y;I7(<Q[!\3_&OP<^%VM1GQ?;:+::K=V1E=O['^TS+9QX0R3&.)C' F0N
M]\(.F>M6+GXN_"6/XA:7X:DU#29?$F;>VLV2R,D<3R)YEO"+@(8T=D.Y(]X)
M!! Y&?&?CKK?CZ".R\$ZUX<U34I]<TZ6'Q'XY\#>$Y[DK8%V T^W&YV65P6R
M[L50,6"EB,5_B/I.I:[XB\!Z#X3\ ^*]"ET#7='OM.MWLA_8=_9(L.^XOI,
MQRP1*ZA';S%DBCP&R, 'MGAWXV?"/7=6U'2=,U;2?-TFSNS(S6AAM_LT+8NO
M)E9!')&C#$GELP!ZUBZ5\7?@3J6CZOXRM6T1(M,^R17=W+HK0W8#D"T"HT(E
MD#D+Y6P'=@;>E>'_ ! T#QG\0_&U[=>&?A]K]A>6GACQ!H]WX?\ $-HBZ):F
M6(K#]AD 5))+AU0L5)!5B&*8KC8_A=XMG\/:U)I6C_$+4O#_ )GA@WNK>(+
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/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ibio-20230630x10k022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &M Z@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4ZY^3X@^
M&(I&C?Q'I*NI*LK7\0((X((W5OGI7XA^-O\ D?=>&!C^TKCM_P!-6KPLTS)Y
M<H-1YN:_6VQ^J\!\%4^,JF(A4KNE[)1>D;WYK^:['[<"ZA(!$J$'D$,*/M,/
M_/5/^^A7GE@!]AMN!_J8_P#T$59 &.E>I[;R/@Y9>HNW-^!W7VF'_GJG_?0I
M?M$7_/5/^^A7#@#'04N!5>U?8AX%?S';_:(O^>J?]]"C[1%_ST3_ +Z%<4!Q
M3@!CI1[3R%]27\QV?VB+_GHG_?0H^T1?\]$_[Z%<:!S3P!GI1[3R)^IK^8Z_
MSXO^>B?]]"CSX_\ GHO_ 'T*Y+ ':G#K3]H+ZHNYUGG1_P!]?SH\Z/\ OK^=
M<JHYIZBCVA/U5=SI_.C_ +Z_G1YT?]]?SKFJ4=*?.+ZLNYTGFI_?7\Z/-3^^
MOYUSP'%+3YR?JZ[G0^8G]Y?SH\Q/[R_G6!BGXHYR?8+N;GF)_>'YT;U_O#\Z
MQ!UIP'-/F%[%=S9WK_>'YT;U_O#\ZR5'-.HYB?9>9J;U_O#\Z-Z_WA^=9JTY
M11S"]GYFCN'J/SHW#U%4*<.E.Y/(7=P]11FJ@Z4HZT[BY2UFC-0#K3QUHN38
MDS13:5>M,0ZBBB@04444 (2%!). .YJ+[9!_SVC_ .^Q7+?%XD?"WQ:0<'^R
M[GD?]<VK\+9]6O1-(!=3X#'_ ):&O&Q^8O!2C%0O?SM^C/TOA/@Z/$U"K6EB
M/9\C2MR\U[J_\T;'[]_;(/\ GM'_ -]BC[9!_P ]H_\ OL5^ ']KWO\ S]S_
M /?PT?VO>_\ /W/_ -_#7E_V[+_GU_Y-_P  ^Z_XA13_ .@Y_P#@M?\ RP_?
M_P"V0?\ /:/_ +[%'VR#_GM'_P!]BOP _M>]_P"?N?\ [^&C^U[W_G[G_P"_
MAH_MV7_/K_R;_@!_Q"BG_P!!S_\ !:_^6'[_ /VR#_GM'_WV*/MD'_/:/_OL
M5^ ']KWO_/W/_P!_#1_:][_S]S_]_#1_;LO^?7_DW_ #_B%%/_H.?_@M?_+#
M]_\ [9!_SVC_ .^Q1]L@_P">T?\ WV*_ #^U[W_G[G_[^&C^U[W_ )^Y_P#O
MX:/[=E_SZ_\ )O\ @!_Q"BG_ -!S_P#!:_\ EA^__P!L@_Y[1_\ ?8H^V0?\
M]H_^^Q7X ?VO>_\ /W/_ -_#1_:][_S]S_\ ?PT?V[+_ )]?^3?\ /\ B%%/
M_H.?_@M?_+#]_P#[9!_SVC_[[%'VR#_GM'_WV*_ '^UKW_G[F_[^G_&C^UKW
M_G[F_P"_AH_MV7_/K_R;_@!_Q"BG_P!!S_\ !:_^6'[_ 'VR#_GM'_WV*/MD
M'_/:/_OL5^ /]K7O_/W-_P!_3_C0=6O1_P O<_\ W\-']NR_Y]?^3?\  #_B
M%%/_ *#G_P""U_\ +#]_OMD'_/:/_OL4?;(/^>T?_?8K\ ?[7O?^?N?_ +^&
MD_M>]_Y^Y_\ OX:/[=E_SZ_\F_X ?\0HI_\ 0<__  6O_EA^_P#]L@_Y[1_]
M]BC[9!_SVC_[[%?@!_:][_S]S_\ ?PT?VO>_\_<__?PT?V[+_GU_Y-_P _XA
M13_Z#G_X+7_RP_?_ .V0?\]H_P#OL4?;(/\ GM'_ -]BOP!_M>]_Y^Y_^_AI
M/[7O?^?N?_OX:/[=E_SZ_P#)O^ '_$**?_0<_P#P6O\ Y8?O_P#;(/\ GM'_
M -]BC[9!_P ]H_\ OL5^ ']KWO\ S]S_ /?PTO\ :]Z?^7N?_OX:/[=E_P ^
MO_)O^ '_ !"BG_T'/_P6O_EA^_WVR#_GM'_WV*/MD'_/:/\ [[%?@#_:][_S
M]S?]_#2?VO>_\_<__?PT?V[+_GU_Y-_P _XA13_Z#G_X+7_RP_?_ .V0?\]H
M_P#OL4?;(/\ GM'_ -]BOP _M>]_Y^Y_^_AH_M>]_P"?N?\ [^&C^W9?\^O_
M ";_ ( ?\0HI_P#0<_\ P6O_ )8?O_\ ;(/^>T?_ 'V*/MD'_/:/_OL5^ ']
MKWO_ #]S_P#?PT?VO>_\_<__ '\-']NR_P"?7_DW_ #_ (A13_Z#G_X+7_RP
M_?\ ^V0?\]H_^^Q1]L@_Y[1_]]BOP _M>]_Y^Y_^_AH_M>]_Y^Y_^_AH_MV7
M_/K_ ,F_X ?\0HI_]!S_ /!:_P#EA^__ -L@_P">T?\ WV*/MD'_ #VC_P"^
MQ7X ?VO>_P#/W/\ ]_#1_:][_P _<_\ W\-']NR_Y]?^3?\  #_B%%/_ *#G
M_P""U_\ +#]__MD'_/:/_OL4?;(/^>T?_?8K\ /[7O?^?N?_ +^&C^U[W_G[
MG_[^&C^W9?\ /K_R;_@!_P 0HI_]!S_\%K_Y8?O_ /;(/^>T?_?8H^V0?\]H
M_P#OL5^ ']KWO_/W/_W\-6+#5;QKV &ZG(,BY'F'UH_MV7_/K_R;_@!_Q"BG
M_P!!S_\ !?\ ]T/W\!!&1R*6N<^''/P_\-=_^);;?^BUKHZ^KB^:*9^ 5J?L
M:LJ=[V;7W!1115&(4444 %(2%&2<#U-+7&_&,X^%?BHC@_V=/_Z :B<N2+EV
M.G#4?K%>%&]N9I7]78ZS[9!_SVC_ .^Q1]L@_P">T?\ WV*_ V\U^_ANI$6X
M8*IP!4/_  D>H_\ /RU?)+/IM7]E_P"3?_:G]"2\),/"3B\P>G_3I?\ RT_?
MC[9!_P ]H_\ OL4?;(/^>T?_ 'V*_ ?_ (2/4?\ GY:C_A(]1_Y^6I_V]/\
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M!_\ A(]1_P"?EJ/^$CU'_GY:C^WI_P#/I?\ @7_VH?\ $)L/_P!#"7_@I?\
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M,&UWPGKMU9V6H:YHEE)IMU?7I>5M5MG^]'< GGZCFH/B/^U*GC3X9W?@;2/
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M (MZ?K?Q4U+QG;06^[0KF96CO+&$$<-/NWD^P.!CCKBOF_\ 8R^(^IV_Q_\
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M?_!H_P#A7U'11]2PW_/M?<'^L^=_]!E3_P "9\N?\.W_ (,_\^.L_P#@T?\
MPI/^';WP8_Y\-8_\&C_X5]1TM'U+#?\ /M?<'^L^=_\ 094_\"9\M_\ #M[X
M,?\ /AK'_@T?_"C_ (=O?!C_ )\-8_\ !H_^%?4E%'U+#?\ /M?<'^M&=_\
M094_\"9\M_\ #M[X,?\ /AK'_@T?_"C_ (=O?!C_ )\-8_\ !H_^%?4E%'U+
M#?\ /M?<'^M&=_\ 094_\"9\M_\ #M[X,?\ /AK'_@T?_"C_ (=O?!C_ )\-
M8_\ !H_^%?4E%'U+#?\ /M?<'^M&=_\ 094_\"9\M_\ #M[X,?\ /AK'_@T?
M_"C_ (=O?!C_ )\-8_\ !H_^%?4E%'U+#?\ /M?<'^M&=_\ 094_\"9\M_\
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M9XK_ *^3_P#2F>BGI7XA^-O^1]U[_L)7'_HYJ_;P]*_$/QM_R/NO?]A*X_\
M1S5\CQ-\-+U?Z']"^!_\?,/\,/SD?KK8?\>-M_UQC_\ 015E>E5K#_CQMO\
MKC'_ .@BK*]*^E6Q^(3^)CQTK\9OC'\M[^V,HX7^V[#@=/\ D(BOV9'05^-/
MQ24RQ?MFNHW*-<L,L.W_ !,ZZ*9Y6,V7S_(_5C]GCCX"?#C_ +%S3_\ T0E>
MB#I7FG[-;!_V>OAH0<@^'+#G_MBM>ECI4/<Z8_"A1UIZ@LP !)] ,TP=:^>O
M^"@&J7VC?LE^/+S3KRXL+R.& QW%K*T4B?OXQPRD$4)7=A3ERQ;/HHQG&2A
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MEF_:<^)O@3]E/QYX6T_Q3>Z[=:+XN3PQ8>*TDW7)M',F0DI/WOW> Q)QOX/
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M#K_XY?LJ^,?CSXA^,OB>#QG<1W<SQPZCLL($4D?99(_1@<;<@=.*+";/TQ^
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M-\=?^2*>/O\ L 7W_HAZPK_PI^C_ "/4RK_D88?_ !Q_]*12_9Q_Y()\/?\
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ML_/_ %+X<:O>_!*T^%5K^R?XSTCPK;W<=^?L'BW3EN9IT8-YDDC!MQ) SQT
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M]JF/?R?_ (Y5G%&* *W_  ELP^]X?U4?18C_ "DH_P"$R5?]9HVL1_6S+?\
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M_-A1116AQA1110 5QWQB_P"26>*O^P=/_P"@&NQKCOC%_P DL\5?]@Z?_P!
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M)4MXW,2GJ-^,CIFNS\%>.M ^(_AJT\0>&=6MM:T>[&8KNU?<K8."#W!!X*D
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M#W_L!6?_ **6BEAOX$/1?D:YU_R,\5_U\G_Z4ST4]*_$/QM_R/NO?]A*X_\
M1S5^WAZ5^(?C;_D?=>_["5Q_Z.:OD>)OAI>K_0_H7P/_ (^8?X8?G(_76P_X
M\;;_ *XQ_P#H(JRO2JUA_P >-M_UQC_]!%65Z5]*MC\0G\3'CI2T@Z4M68L<
M.E/'2F#I3QTIDL4=:>.M,'6GCK00QU*O6DI5ZU1#'+UIZTQ>M/6@ACJ5>E)2
MKTIHACQTI:0=*6J('TZFTZ@@4=:>.M,'6GCK5(@>O6EI%ZTM,ACEIRTU:<M!
M+'4X=*;3ATJB&.'2E'6D'2E'6@ACQUIXZTP=:>.M,ACJ5>M)2KUJB&.HHHH$
M%%%% '(?%_\ Y)9XN_[!5S_Z+:N;_9>_Y(%X(_[!L?\ *ND^+_\ R2SQ=_V"
MKG_T6U<W^R]_R0+P1_V#8_Y5P/\ WQ?X7^:/KH?\DW4_Z_Q_](D>IT445WGR
M)SWC[P=;?$#P?J?AZ\E>&UOXQ%*\8!.W<"1SZXQ^->63?LJ:7)!;VJ^(-06R
MM(?LMG 8T;[/!^]VQACRP7SCC/. *]THKGJ8>E5?-.-V>S@\XQ^7TW1PU5QC
M>]K+>UKZIZV5CYZG_8YT0SZC/!KMW'<7+EDEEMHIC&&5U<$-D.#O8C(RIQBO
M<O#6B1^&O#^GZ5%*TT=E D"R. "P48R<5ITE%+#TJ+;IQM<>/SG'YG",,95<
MU':Z7:W1?U\PI:2O+KW]H'2K4LT/A[Q%?V[W3VMK<VMFC1W902&1HR9!D*(G
M.&P2 "H.:Z#Q3U&JFK:>FJZ7=V4APEQ$\1/IN!&?UKSFZ_:-\(6D<TLCWJ0K
M<VEK%-) $2<W$?FQNC,P&P("68XQM-=KX8\<Z!XSDU&/1-6M-3DTZ<VUVMM*
M',,@&=IQ]: /D7Q]H]WIR26L\12XLYBDZ@<\# /T[CV-<-D>H_.ON+QO\--+
M\;J)9C)9WZKL6[@QNV^C \,/U'8UYPG[.=TEP"-1TX+G_6BS._'KC=C/XT >
M._#;PO=:QJ\%HD?[V]94 .<K&#EG(],9_3UK[4B011J@& H %<SX*^'FF^"8
MG:#?<WTHVR7<V-Y']T <*OL/QS744 8GB3P^FK_9;E8H);JT+-&L\08,".5S
MU7.!T.,@9!Q7QSXZ^,7CK1_CU)H]M,MGX2T7RGU!]1B A:W*AI)9)6&026(0
M*>6  !R:^U=9U*WT?2KR^N[J*QMK>)I9+F<@1Q*!DLQ/85^9_C?Q*?&GPVUM
M=>^*UEXDUFTUA;VRT\BX_?Q;61MA:-1GYE95Z !N1FO+QJM9IGUW#V#6)J3E
M."E'2.J;MS/XE9-77FU:]^@[X9?'?Q##%XVTZ/QA=:3K>OLDFGZE?7($$$HD
M)='9@WDET(56 PI49P.:^JO@Q\5/$O@3X?:7;?$2:Z\3ZS>ZV-/@DT=X]2EM
MH9 /+>Y>$D!=V[!Y.,5^8=KJ<%AJ+0VT7F12/M9RQ+,?;VK[+_9A\$1_!OXG
M>#M>\3>*=+TD>);#;IVDV4KRSW@G \OS@J[8T!Q@L>6P!T-<6%JR4DO^&U/O
M<]RO"1H3DDDWK91]YN,;636J5E=Z-==-3] :Q=7\3Q6%S]BM(6U#4\!OLT1
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M-VT$>82%QQ73> /"FM^#O$MB/$/CF.X>?2TLK;PTI@2-6CD<[HAL1WVH44L
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ME?#OPEIGAO1(#;Z7IT(@@C9BS8'<L>22<DGU-;F,?_KH ^)OBIX/U#PU\2/
M7CC7=:\:^&O"X\)PZ2VL>$K47$VFW PS+/$8)G5'&!N5.",$UA7O@.+Q?\,/
MC%XBT:#X@^)X=:MK#3TU3Q=$D;ZLD<Z9:&T2VBD"J"1O=<L!TP*^]B,T8XH
M^>/BAX'34OB5^S\ZZ*US:Z1<W+EUMBR6F+554L<83G(&<<UY9\>_"FN7WQ0^
M)\UGHVHW-M<R^%WBD@M)'28QW">85(&&V@<XZ <U]M48H ^5/!GQ!TW]G#Q[
M\1;/Q_I&M64FO:U+JVG^(+#1KJ_@U&!P/+A+V\;E9(P-FQ@. ,5[Y\+/$%MX
MJ\'0:M:>%K_PA;W<LDJ:?J=FEK<$%C^]>)2=I?[V&PW/(!KKR,TM 'Q%\//
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M8FGB)QA)1=[>SI1O;;50NM>UGYH\W_9]^'>M_"_X7Z3H&OZW+K>H0)EF<Y6
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M_1_D>IE7_(PP_P#CC_Z4BE^SC_R03X>_]@*S_P#12T4?LX_\D$^'O_8"L_\
MT4M%+#?P(>B_(USK_D9XK_KY/_TIGHIZ5^(?C;_D?=>_["5Q_P"CFK]O#TK\
M0_&W_(^Z]_V$KC_T<U?(\3?#2]7^A_0O@?\ Q\P_PP_.1^NMA_QXVW_7&/\
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MB?P7\$6GQ#M=?N?$'B-/#%GHU@=0EN&M#.\J!PF%0,N6RP ]217Z2?LN>+]
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M?^2?^&O^P9;?^BEKHZYSX<_\D_\ #7_8,MO_ $4M='7T=/X(^A^"XW_>:O\
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MJLT#>4@M8)7!V$$^8V",X&:^J/C3\+_^%N^"O^$?_M'^R_\ 3+:[^T>3YO\
MJI ^W;D=<8SGBNF\2:%_PD'A;5M&$WV?[=9RVGG;=VS>A3=C/.,YQ0!\K_"C
MXB>./$'A+P!\-_AP^D:1>V?AJVU+5]?UNU>[CM8WRL4<5NCQ^8[8))+@ >M:
M,WQ ^+NJWOQ4^'GB67PQ;7^D>&?MMEKEC8S/#>JZN&9H&E!0[01M#G!YR1Q7
M4)^S)KO@Z'PKJO@+QE#H?BS1]*31KNXO]-^TV.JVZG*B:$2*RLI)*LKY'3FK
M?@?]G+Q#I/BKQMXH\4^/#XEUOQ5HXTJ81::+6VLP P'DQAV(0!NC$DD9+<T
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MH **** "BBB@ HHHH *X;XZ_\D4\??\ 8 OO_1#UW-<-\=?^2*>/O^P!??\
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MKW>IVNG[1/,J.WW8QEG;Z*.3^55%-NR,Y-1U9<'2EK/6^O9Q_HVE3D=GNG6
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M%>"];NM4FFN[/QGX:BO);VP(_<F&66=#-#MX"(O!XQFJFI:;X*\(^&_V</\
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MKC_T<U?(\3?#2]7^A_0O@?\ Q\P_PP_.1^NMA_QXVW_7&/\ ]!%65Z56L/\
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M6W_HI:Z.OIJ?P1]#^?,;_O-7_$_S84445H<84444 %<=\8O^26>*O^P=/_Z
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M_P"2?^&O^P9;?^BEKHZYSX<_\D_\-?\ 8,MO_12UT=?34_@CZ'\]XW_>:O\
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M Q:Z2^X9\+M>U3Q'I6I7>JL6=KS$($+Q(B>6AVJ' ; 8L,GN#6MXEB5?(D"
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M $,>D?\ @?%_\51[2'=!]3Q/_/N7W,Z&BN>_X6%X7_Z&/2/_  /B_P#BJ/\
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M"/\ QH_LE?\ 0/\ ^2_\ /[:S_\ Z"JW_@<_\S-_X9+^$/\ T(6D_P#?#_\
MQ5'_  R7\(?^A"TG_OA__BJTO^&D_A9_T4#P]_X,(_\ &C_AI/X6?]% \/?^
M#"/_ !H_LE?] _\ Y+_P _MK/_\ H*K?^!S_ ,S-_P"&2_A#_P!"%I/_ 'P_
M_P 51_PR7\(?^A"TG_OA_P#XJM+_ (:3^%G_ $4#P]_X,(_\:/\ AI/X6?\
M10/#W_@PC_QH_LE?] __ )+_ , /[:S_ /Z"JW_@<_\ ,S?^&2_A#_T(6D_]
M\/\ _%4?\,E_"'_H0M)_[X?_ .*K2_X:3^%G_10/#W_@PC_QH_X:3^%G_10/
M#W_@PC_QH_LE?] __DO_   _MK/_ /H*K?\ @<_\S-_X9+^$/_0A:3_WP_\
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M_@PC_P :/^&D_A9_T4#P]_X,(_\ &C^R5_T#_P#DO_ #^VL__P"@JM_X'/\
MS,S_ (9*^$/_ $(>E?\ ?+__ !5*/V3/A$I!'@/2LC_9?_XJM+_AI/X6?]%
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MDOX0_P#0A:3_ -\/_P#%4?\ #)?PA_Z$+2?^^'_^*K?_ .%\?#[_ *&_2?\
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MK?\ ^%\?#[_H;])_\"11_P +X^'W_0WZ3_X$BC^R/^H;_P D_P" ']K\1?\
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MHBFE!Q(6'[I /F*D]!R!D@C)&[UKH1TKRWX_:9<W>@Z==QEVM+2<^<BG@;@
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M_ $U]#@ # & . /:O#/V<_@OJWA.XU/QMXUE^U^.==.^<$@_9(SSY8]^F<=
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M9[+X/\7MIEW!:7,TCZ>XV*K+Q&QZ=LX]J]"\+7L=O=3:<C9@(\ZVSV4GYD_
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M6H?\_P#=?]_F_P :IT5]!=GH<\NY<_MK4/\ G_NO^_S?XTJZUJ&?^/\ NO\
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M;K_A5?@O_H4="_\ !9!_\31_PJOP7_T*.A?^"R#_ .)H_P!8Z?\ S[?W_P#
M#^T8_P I^(OG1_\ /1/^^A1YT?\ ST3_ +Z%?MU_PJOP7_T*.A?^"R#_ .)H
M_P"%5^"_^A1T+_P60?\ Q-'^L=/_ )]O[_\ @!_:,?Y3\1?.C_YZ)_WT*M:7
M*AU.T D0GS4X##U%?MA_PJOP7_T*.A?^"R#_ .)K@/CQ\.O"FF?"?Q'<VGAG
M1K6YCMBR30Z?"CJ<]00N16U'/X5:L::IO5I;]_D;4,<JM6,.7=I'IW@O_D3]
M#_Z\8/\ T 5M5B^"_P#D3]#_ .O&#_T 5M5\+5_B2]6>#5^.7JPHHHK(S"BB
MB@ J"^_X\Y_]QOY5/4%]_P ><_\ N-_*FMT-;GXM_&3_ )*+K'_79_\ T)JX
MJNU^,G_)1=8_Z[/_ .A-7%5^SGW-?^++U"BBB@P$QFK$&G7-U"\L-I/-"A >
M2.%F53V!(& ?K5<]#CKVK[Z^%=[XNN?!/PGD^%VLZ+IWA"T4+XG@FG@C<3[_
M )S,LGS-D=-O.<5Q8K$O#14DM^[LMK[V>_0PJU/9I,^#(M.N;BY-M%:3RW/>
M!(6:3_OD#/Z5UOP_^%.L?$7_ (2'[ T5L^B6#WURERD@9E7JB@*?F]CBOL:>
M[UJ^U+XL6WPJU'3+3XDR^(B\SRS0I<RV6!CR7D^7&>M<UX*\<?$/PUXU^*47
MBWQ+ICZ^GA@SO)I,MN4\Y5PA8QJ 90.#GFN%X^<X-P235M&]>G2VVNY@Z\FG
M9*_KZ>1\L^/?AK-X#&E'^T[#68[ZR2]+Z9O=;;=T20D?*U<LME._E!;>5O..
M(P(F/F'_ &>/F/TS7VW<>-=-F^(G@_PMKUZC>'_&/@^'3;^4.I$<[9,<A[!@
MW]*M>'?&VCO\:=:\(>%+_3[:]\,^'SHWA*ZOV00F[7_6N&/R[V/0T+'U(Q]Z
M%W:]^EMNW?\ #4%7DEJO,^-_"/@+5?&'BW2_#T%N]G>:A<BU22[AD5$<_P![
MY<C'TS6_XP^#-WX)\-7VK7NM:4\]EJLFDR:;&SBXW)G,@# ?(<<>Q%?9<WB#
MQ]X;T+X2KXXUZRD\6+XH:"[DMKB"218&0_+*T?RYQC]*P=5\7Z/K,5I>^-[^
M"_TV+XBRI.URR%1"JLL6X#^ ';[>M9?VA5E)-)<OD[WU>VG6Q/UB3=TM/(^%
MY["YM(X7GM9H$D&Z)I8F0./521@_A3GTR[AA>5[*XCA0@-(T#A5)Z DC _&O
MN;XH7GBJV^'WQ#/Q6UC0]1T.\N(6\(0VTT$DGF>8-K0"/YE0)C.[WK<\5_$W
M4-<^)?COP7>:I;3^$HO _G16)\HQ&<0J=^[J6R?7L/2M%F,VKJ"?H].FVFKU
M^]%?6&]E^/IY>9\+> ? .M_$OQ/;:!X?M5NM2N%9@KR"-%11EF=SP% [FNPU
MD>./V<I?$G@Z\MK+3[C7+2..YN8ML[26QY'DS X"MSG ]J[+]B33H9_B[<Z@
M'-QJ&G:;--9Z0+B.#^TW(VF M)\N,<D'V]*[7]MSX6K%*/'Z:^U]+<SQV<FA
M0I"Z:.@C&(6>)B!@Y XY]?76IBE];6&G;E:_'H7*K^^]F]OU/GNU^$VL7GPJ
MN/'T;PMI4&I+IAMPKF<R%=P8 +C;VSGK7(&RG7S%-O*/*.9 8F^0^K<<?C7U
M7\*OB;?^'?V4[2.;6FM[&U\:6D$D.Y<K9Y61UQC.W<-Q/MUKM_BIH3>"="^.
MOBC4K[3?[(\:-9KH4EO>QRO=_O QPJDD8&<Y]*GZ[.%1PFNME]Z7;L[B]LXR
M<6NNGX'Q ^EW<<,DSV5PD*8$DC0.%7/3<2,#/O3;JRN+.14N;>:W=E!59XV0
ME3TP& )%?HO<_&36(/CCXA\-_P!JVDOAFR\%"]@LI4A>$W20JZN21\S;CT)/
M0<<5R'@OX@Z?XWT#X)>)/'VHZ??:ZUSJUO%J&I+&%2<8%MYH  "@CC(QG'>L
MUF-2RE*GIY/75-KIY:DK$2M=Q_'ROV\CX8GTRZM9HX9K.>&9QF..2!D9@?[H
M(R?PIL]G/9F/SK>6W+#<GF1LF1TR,@9'N*^_([OQ3IUIX8@^,FK:3?\ BM_&
M%I-X?\F>"2XBM\_O6W1\+$1G /MGM7RA^T;XUU+QI\;?$<^LW\FHVUEJ$MG;
MJI&V*U24XCCQQC&?Q-=>'Q<L1/EY5;NG=?+17-*=9U)6L8'PJ^%&K?%CQAIG
MA_3F2P;4/-\J^O(I/L^40NPW*IR< ]*Y?^Q[M[BZC@MIKHVS%97MX6<+@XR2
M <#CO7Z6^#=1\82?%;0M1\/Z]H4?P-;25CL[:*YMT4-Y'W%0_.)0^23TVY'M
M7)? S5X_^%1>%4\$6]W=7=I?7$NO1Z5K=GI[+/YA.Z[$Z,9(RO3;V[=,>?\
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M),\FJ7*%)IP!%&W6.+L/J>I^M;M)TI:ZY/F=SYA*QSGQ&_Y$+Q#_ -@^?_T
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M'H*,#T%'^L5?^1?C_F']H3_E1^.1_99^+IZ_#K73QC_4+_\ %4?\,L_%T?\
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M&1P&(W#\S79@O]YI?XE^9V8/_>:?^)?F>G^"O^1/T/\ Z\8/_18K:K%\%_\
M(GZ'_P!>,'_H K:KGJ_'+U9SU?CEZL****S,PHHHH *@OO\ CSG_ -QOY5/4
M%]_QYS_[C?RIK=#6YY=^S-_R31O^PE=_^C37K%>3_LS?\DT;_L)7?_HTUZQ7
M?F'^]U?5G=C_ />JGJPHHHKSS@"N?U/7I[BZDL-)V-.AQ/=2#,<'MC^)_;MW
MI_B74IHS#IUD^R]NL_O!_P LHQ]Y_KV'O3+&QATZUCMX%VQIT]2>Y/J3ZUK&
M.EV2WT1#I^D0Z>[R@O/=R?ZVZF.Z1_Q[#V&!5ZBBM+W$%%%%( HHHH ****
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MIE%TUM&/]'9P1LV,A.#M#GG!Q61"W[/FK75SIL:76H7%Z\9:!8KJ1C*\9RW
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M!( V>=Q Z <9]:]-OM+M-3C$=W:PW48.X)/&K@'UP0:\6KET:S<OA_KJ?J6
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MEK?:/='<MAJ"2HQ<'G8ZX(&0,A3GIU!K&\<>!HO!S:9(NHR:@]P\B[)X44H
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M&026>EVS[98N^T$?+",_W,L>[5]$0Q+!"D2YVHH4;B2<#U)ZTRT<R6D+-U*
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MG_\ 1K5]9PK\5;Y?J?4\,?%5^7ZGWA:_\>L'_7-?_0157Q!X?L?%.C7.EZE
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M1OV7OVG)?CNWB30?$/AJ7P7X^\+S"#5]$DD\Q%SP)(VZE<]CGJ""0:\@\7?
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M^[T.Q[37@F<>JQ*7_P#0@M5]5\5Z+H.H:=8:EJ]C87VHOY=G;W-PL<EPW'"
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MXJNM0C5KF-K^YL<OY<8'F2HPP6 Z%E_D:V])U)GLKVY-G<:>DEP&LX67$A<
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M&C62VL1.Z1R=TDK8^\['EC6_115)):(HYKQ1FWUK0;H\1F66T8^GF)E?_'D
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MT@'WAP!M/0X/-<F78JI*NKZOSU1S)RC2E0G*3ARMV3L].B>Z7>QY?H_PNE\
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MT_PI>'4;"[2\MKN?5[AY(W4Y5?O8*CT(KZ=7I3UZ5#2):1\H_'S]GOQ3\?\
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M\8/_ $6*VJQ?!?\ R)^A_P#7C!_Z *VJ]:K\<O5GX15^.7JPHHHK,S"BBB@
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M?U&>E<KK7P \6:Y*/$&F^($\*^)8)OM5O'%^]CEDYSYS#A<Y/"AASR#6_P#
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M?_SXVW_?E?\ "C^Q=/\ ^?&V_P"_*_X4<^"_DE_X$O\ Y .?!_R2_P# E_\
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ME?\ "CGP7\DO_ E_\@'/@_Y)?^!+_P"1/.?^&G_AA_T-<'_@/-_\11_PT_\
M##_H:X/_  'F_P#B*]&_L73_ /GQMO\ ORO^%']BZ?\ \^-M_P!^5_PHY\%_
M)+_P)?\ R <^#_DE_P"!+_Y$\Y_X:?\ AA_T-<'_ (#S?_$4?\-/_##_ *&N
M#_P'F_\ B*]&_L73_P#GQMO^_*_X4?V+I_\ SXVW_?E?\*.?!?R2_P# E_\
M(!SX/^27_@2_^1/.?^&G_AA_T-<'_@/-_P#$4?\ #3_PP_Z&N#_P'F_^(KT;
M^Q=/_P"?&V_[\K_A1_8NG_\ /C;?]^5_PHY\%_)+_P "7_R <^#_ ))?^!+_
M .1/.?\ AI_X8?\ 0UP?^ \W_P 11_PT_P###_H:X/\ P'F_^(KT;^Q=/_Y\
M;;_ORO\ A1_8NG_\^-M_WY7_  HY\%_)+_P)?_(!SX/^27_@2_\ D3SG_AI_
MX8?]#7!_X#S?_$4?\-/_  P_Z&N#_P !YO\ XBO1O[%T_P#Y\;;_ +\K_A1_
M8NG_ //C;?\ ?E?\*.?!?R2_\"7_ ,@'/@_Y)?\ @2_^1/.?^&G_ (8?]#7!
M_P" \W_Q%'_#3_PP_P"AK@_[\3?_ !%>C?V+I_\ SXVW_?E?\*/[%T__ )\;
M;_ORO^%'/@OY)?\ @2_^0#GP?\DO_ E_\B>:2_M*?"J;_6>);1_]ZUE/_LE,
M3]HWX2QG*>(;)3[6<H_]IUZ=_8NG_P#/C;?]^5_PH_L73_\ GQMO^_*_X4^?
M!?R3_P# E_\ (!S8+^27_@2_^1/.!^T[\+U&!XJMP/06\W_Q%+_PT_\ ##_H
M:X/_  'F_P#B*]&_L73_ /GQMO\ ORO^%']BZ?\ \^-M_P!^5_PI<^"_DE_X
M$O\ Y .;!_R2_P# E_\ (GG/_#3_ ,,/^AK@_P# >;_XBC_AI_X8?]#7!_X#
MS?\ Q%>C?V+I_P#SXVW_ 'Y7_"C^Q=/_ .?&V_[\K_A1SX+^27_@2_\ D Y\
M'_)+_P "7_R)YS_PT_\ ##_H:X/_  'F_P#B*/\ AI_X8?\ 0UP?^ \W_P 1
M7HW]BZ?_ ,^-M_WY7_"C^Q=/_P"?&V_[\K_A1SX+^27_ ($O_D Y\'_)+_P)
M?_(GG/\ PT_\,/\ H:X/_ >;_P"(I)/VGOABR,!XK@R0?^7>;_XBO1_[%T__
M )\;;_ORO^%']BZ?_P ^-M_WY7_"CGP7\DO_  )?_(!SX/\ DE_X$O\ Y$\N
M_95<2?!C2F4Y5KF[(/J#</17K4$$5M&(X8TB0=%10 /P%%<^)K?6*TZMK<S;
0^\Y\15]O6G5M;F;?WG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ibio-20230630x10k023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N Z@# 2(  A$! Q$!_\0
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M3&D93&2'DSD#8",9S^%>AV?[0/@.^^%C?$-->A7PLBDO=.I#HX.#$4QN\S)
MVXR<C&<U,L)B().4'9[: Z-2*3<7J>BT5X=\._VQ/A]\1O%-EX?MSJ^C:C?C
M-@-;T]K5+WVB<D@D]NF>W-3?%+]KOX??"CQ*WA[4)]1U;6HE#SV6BV;73VZD
M9!D(("\<XSG%/ZGB.?V?(^;>UN@>QJ<W+RNY[5G%&1ZU\L?&OX^Z?XX^$_A;
MQ5X#^(-UX9LKC7X+*:X@TYI96<YS!(G5>Q/8_0UX]=?'_P 2^+?B?\6"OQ%\
M1>&K'2K.Z73+:#2_-MHEB0J\DB]4<,I*]VW>P%=E++*M6+DW:U[W3TLTNWF;
M0PTY*^WWGZ$T5X)I'[0WAOX4_ CP5KOC7Q3/K5YJ5DAAG2T;[7J#]25A'/ Q
MDG'N<FH])_:I\'?%SPGXNLO#6L:CX;\0V&F37/EZEI[)<P*$/[Y8R2'VG!QG
M-<OU*OJU%\J=KV=M[&7L9[VT[GOV12U^?US^U-KG@W0O@NC^--9U^.YF:]UF
M^72MK7UIYK((P&!9F&TC PQ&*^O/AW\>/"WQ+?Q''ILEW:7&@.$OX-1MS!)$
M"I8-@GE<#K6F(P%;#QYVKK7OT=BJF'G35^G](]%HKBOA3\6M#^,GAR77?#RW
MATM+E[9)[NW,0E*=60$\K[UX7\0OBE\2?B]\8M5^&WPLU&U\,V6AQJVL>(KB
M(2NKL 0D8(/J!P,DYY %8T\+4J3E!^[R[WZ>I$:4I2<7I;>_0^J,YHSBOGCX
M9^'OCS\//'5O9^*?$FE^._!$D3R7.ISQBWNK0@9 50,L3Z<CKR*X/2O&GQB_
M:H\0ZY=^!/$UO\// FF73V5O>?9A-<7LB'EN1T[X!  (ZFME@KMM5(\J^U=V
MUZ;7OY6+5"]_>5NY]B4E?.WA&?XW^!/"WCB#QWJ6E:Q::;ISSZ3XBM J7$L@
M4G#1;<8&.=P'./O=OGKX:?M/_%/2Y? &LZQX\T7Q?8^(KY;.X\-K!$M_;J6V
M[SL4%?4'W'!K2GEM2JI.G.+MYO72^FGYV*CAI3ORM.Q^AV<4M?"GQ_\ CG\0
MH_B[XSTBP\?V?PZT[PQ9)=6-G<P(7U9L X!8'<221@<<=.M?5?P$\;:M\1?A
M!X8\1:Y:_9-5O[023H$V!CDC>%[!@ <>]8U\%4H4HUI-6=OQ5U^'8B="5."F
MWN=_THZU\G>*/B7\4/CU\5M?\%_##5[;P=X>\.N(-2\030":66;^X@(./3 P
M>#DUVOPBT/XY^!_&[:7XTU[2?&?@QK=I?[:91;W4+CHNT#)S[Y&._:B>#=.%
MYSBI6ORWUM]UK^5[@Z+BKN2OV/?:3-?/NM?MR_#'1=?N].,VL7MK9S?9[G6+
M+3));&%\X(:4>A[@&L;XG?%G6!^T'\+['P[XAD/AC6K"XN9(K9E,-R N4;.,
M_K1' UV[3CRZ-Z^2N"H3;U5CZ;!S2UX!^QKXZ\0>/OAYK=]XBU6?5[N'6[JW
MCFN-N5C5OE48 X%>._'_ ../Q(\._'/Q-HV@>/\ 3O"VDZ1I2:A';:I;PM'<
M-@YC4LI8LWIFKAE]2I7EATU>/K;\O,<</*4W33V/N#.*6OD;QC\8?%7B/X2_
M"'Q)<^)KGP!J6LZE%'=0VFGM,MYDD;<9RJMC//'-=[XX_;4^'?P^\2:OX>U(
MZS<ZQI;B.>WL]-:0MP"64YQ@ \DD5+P%?107,]=%?2SL+V$]DK[_ ('OE)G%
M>5S?M-_#Z#X41?$.36"GAV8^7&3$WGM+T\H1]2_M^N*\#\3?M?P?$GXI?#/3
MO VK:SHT%QJGE:IIU]9_9VFB8?*2"""I]C2HX"O5;]UI*]VUM8(4*D[Z;'VA
MG-+7RM\+_CS!X"\.?$CQ'XR\:ZEXKTO3-?-FJC3&1[/+$"-1GYE^G''O7;>
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MQ/-HUIZGQ7^T1XEN/BG\ _!.JZ;X(U?PRC^*[=UTRXLMLGE@N?.V1CA6SG)
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M4VI;+?KTN/ZO.^O]=3[+HKY#TK]JOXD7=QI&N3^'/#H\&:AXC?0H3'--]MF
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILDBQ(SNP5%&2S'
M ]: '45QB?&CP%(FB,/&6A[=;E:#3"=0B'VUU.&6+GYR#QQWJO+\>/AQ#I5_
MJ;^._#J:=87@T^ZNCJ</EP7!Z1,V[ ?VH [NBN=TKXB^%M<\2WGA[3O$6EWV
MO6<2SW&FV]Y')<11MRK,@.0#D<X[BNBH **** "BBB@ HHHH **** "BBB@
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M=/B!X77Q/XF\0Z3;:7IEU GB36)M1>*20S!RC2$E0=J\#TKZ"KQ;P3_R=/\
M$G_L!Z1_.>@#VFBBL3QK%J4WA'68]'+KJSV<JVAC8*PEVG9@G@'..34R?+%R
MM>Q$Y<D7*U[&UG-+7B7[-FE_$S3;;7/^%BR7KR-)']C^V7,4V%V_-C83CGUK
MVVN?"UWB:,:K@XWZ/1KU.7!XEXNA&NX.%^DE9KU04445U':%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM<*[(PZJR@Y5AW!&:^&_^"?7C[PIXF\-^,;GX6_"F>WT9;XIJ%K?ZMYMP6"
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M>8_L\_M!>&?VE/AZOB[PM(_V(7<]G+!*0989(W*X8#IN78X_V7%>G4 %%%%
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M+I5I+<74B^>_[V>4GC..@]AT'_UZ\XTWX>:YJ?Q1C\8OJK0Z4<M%:.S&39C
M7'0 ]?7FN\N?^*AU$VJ\Z=;,#.1TE?J(_H.I_ 5N=*\BO@Z68R@ZE^6G)25F
MU>2ZZ=%^+/G<;@Z6=583KWY:<E*-FU>4>NG1;6Z_)"T445[)[@4444 %,E#M
M&PC94D(^5F7< ?ID9_.GT4 >7^+?#WQ!O/&6E7.E:Q%'I<>/-"?ND'/.Z,D[
M\CW_ "KTBSCNHXV%U/%.Y/!BB,8 ^A8U/2T ?+GC'PAXWLOBSXM\0:)+K\-I
M=ZAIMJVGVT*-9WEL8I%G=@4+-MR!N##;FO(;#Q3X^\(6^@>%H]:\0^'M5\^S
MT[3M*MX8C9B.8S>9]J)4NDA.TC)!QRH(S7Z 5S[>&/"VH^*_[8;2M(N?$EF@
M3[<;>)[R!2.!OQO4'G'- 'RA\,O"-S:^-/ ^FZ=\-9M'U&VBGMO$6L3Z-=V5
M[$[*1+<#4UD6*Y#GE5Q(>0?E(X[WP1X'UOP9^S1XNT.PTB_&HQWE\;*TO(C<
MSS*9058B7<9-PR<MG->]:WXQT#PU=6EMJ^MZ;I5Q=MLMH;V[CA>9O1 Q!8_2
MK$7B/29M8DTF/4[-]5C02O8K<(9U0]&*9W >^* /B_0_$WQDM[B\LM1;QQ_8
MGGP?VCJ-AI7ESV=OG#1V]NUN?G Q\T#2KMYPIXJI>^(/BAX#N[KX@ZC)XD^V
MVNDPR);:E$L4&HP)<,HAE&P+'<,C(=N58XZ=17W!;ZQ87=E)>07MM-:1[M\\
M<RM&NW[V6!P,8Y]*@O\ 2M'\4V5L;VSLM7M Z7,'GQ)/&&'*2+D$9'4,* /B
M^'QO\8I-?UFRT36O$VN^,+)[<QZ>UA&='CCE@:2599/* #J2H4%P<C@$$U[/
M^RKJOQ!U*RUO_A-+C4[F!3"8#JUC+;RI,4_?*K21QEE#=,)M'\+,*]P@M+"S
MO)VAAMX+JY(DF:-55Y2. S8Y;'3)JWP* %HI,YI: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **IOK%C'=?9FO+=;C./*,JA\^F,YJY0 45\H
M_M6_M*>*O@_\6/!NA:3);V6B7%LM_?2O:Q7$UUFY6$01H\J$_>!/E;G&X'&
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M]1U6#7;5[>1;6U=$@9H5"HQ.-V[@'(/! KVCPYJMS#>3>%_$#+<WR1%X+IT
M74+?IN(Z;QD*Z^I!Z,*YTN65XJSZ/^OZ^9I5PL)Q=:C)<^[237K?1)Z[I:+=
M>7RS^T-\2/C]\*O@]J?A_P +6%K>>)V2-M%U+3YIM3OI[8N \:(;<+)-$I7+
MMU0[\$YQZ3^S7XU^.GBCX)>%M2\7^'-%E\136Y^UMJ=W/IUR6#L!YL MB$?
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MVC*%)O@OK/A7]FWQ)X4M(;6>^E:XO+31]*WFVM@T@D%K 9,,RY!Y;&2[8"C
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MW)/8_9/A?Q)8^*-)%[8HRVHD:)"X4 [3C*[21M/:N/M_VAO 5QH6MZK_ &Y
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M ?/?Q7_:STWP%\?_  '\+[$:?<WFL7D<>KW%U=+&;&*6.0P*B;@6DD:,]B
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M%XJ^&-[HVE^)='\)^%M2NK:ZN)I]:UV5;.01, IA>.%F._/ =5(Z8- #=/\
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MM9SW&7LD@B\U)%^7]XDB\JW%=_\  #XU?\+J\,7M]<Z;'HNJV-T8+G3X[H7
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M2M*VS3]7("K>\?ZMP.%F ZCH^,KW4=J#FMX34T=\*BJ+3?MV%HHHJS0****
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MB%#.0"3C.:YB3]KOX/Q:'J.L-X[TW^S]/O1I]Q*%D)68@L %";F7:K-O4%<
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MDA1A0<=@.GI6+H'@K1/#-]?36=NBW%]>RZB?-(=DED5%D,>>5#;02!QDGUH
MX?XB>,O%WA#5?#7ASPU_9=]/-I=Y>7.HZ^TC,1;+"/NQ;=S.9.3P!UP>A\M@
M_:6\57%YK,UO;0S0>(8;2Q\)P@;U@U5K2&:6"5@.4VW DW''RV\OL*^I9;6W
MGD662&*2159 [*"0IQN&?0X&1[5!9Z;IT,06UM;6.-)"P$,:@*X&TG@<'''K
MCB@#QKX#>/\ 6/%FNH-0U&741<>%=,O9E.!&EX))X9V1?X0[)G'^S71_#OQ]
MXQ\2^,/%^G:]X3?0],TZX6.SO#=12;QY2-C"G+9+$[AP.AY%=EHO@K2M U_5
M=8LX6CO-1CABF^;Y%2+>45%Z*,R.3CJ6)K=Q0!\E3?&?X@:3X%@.H7]AY>I2
MWYT^^MBQO(A!J&S$I;Y&#1DKA5&W Y;)(L^)/VG_ !A!8"6P_P"$7EDU.#4S
M:Z9:22S:GIQMHY"&FBSB0CR\LH"[2=HW9S7T_+H6FS0I$]A:O&F[:AA4A=QR
MV!CC)Y/O7&>'/@=X9\,^,)/$D O;G4,RF$7ETTJ0&3.\KGDD@D98MM!(7 XH
M \\\%^)K'1/B%X>TBQ\=^*?&R^(-.EG%XUW8WEC*50N9]J$2V^, #:HCRZKR
M:OV_C'7++]EW4]<&LW,^LVD-^L>I3E&F_=7,J(S':%)"J!G':O7-%\&Z!X<N
MKJYTG0]-TNYNSFXFLK2.%YCG.7*@%N?6M#^S;0V;6GV6'[*V=T'EC8<G)RN,
M<DDT ?.\7[17B>[UB;0 _A;2]8.IS6XN-0ED:TMK=(WDC+.DF)I)50XVLF,.
M"N4P?3_!_P 39O&7PQ_MZVM[5M;%E).=/MKCS59E:1%=#P3'(8RR,0,J1732
M^!?#<]C<V4GA_2I+.YF^T3V[641CEE_OLNW#-P.3S6C:Z5964[36]G!!,T:1
M-)%$JL47.U20.@R<#H,T > ?#[5!J'AS1/$J_%VYOO$NJVDDDNE75U UI+<&
M(L]NEJ%#1>4P(PI#C8=Q/-:?[-OCS6]?AGA\5:]!J&H26.G/"%(C5W>&1WV*
M3DDA<GKTSP*]>L_!?A_3]8N-6M="TVVU6Y!$]]#9QI/*#U#.%W-^)JTF@:9%
M/!,FG6BS0',4BP*&C.TK\IQQ\I(X[$B@"_1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% ',ZE\,O!^L^);;Q%J'A/0[[Q!;,C0:M<Z;#)=Q%
M#E"LK*74J2<8/':O/?CD!_PM'X&_]C3/_P"FN\KV?->,?'/_ )*C\#?^QIG_
M /37>4 >SCH*6D'04M $2VL*/N6)%;U"@&I:**!MM[A4"65NDGF+!$KYSN"
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MO3O _P 2/&_B+XDZ!%+K>F76AZOX3&HVEK%8M%_I((#22L3N(+?PKM 'KUH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2<!CCGBK7AWX"ZA#XAT[7?$'B*WU74K*2+9]ETW[/%Y<<)B08,CD-@Y+9Z]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#R_$?8CS:)Z>:N:O#U.BO_5SZ9HKQ+XL_M9^$OA3XKA\,G3]9\3:^T0GEL-
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MMO#?$2^9-$C#&6*J$)/KUK[-P/2CBM%F=6-K):?_ &O_ ,C^+*^LR73^M/\
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MH>G06-G'Y=O"NU%Z\4/V/L]$^:_E:WW _9\FE^;\+%RBBBL#$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *3-<O\ %.TUJ^^&OBFW\.%UU^73+E-/,<_DL+@QL(R)/X3NQ@]J
M_/OX9:7\:[KXC>'+KP]J?QB>VLIK&'5;?QIKEK+;O,93]K80JQWVPB!PW!#E
M<9S0!^EM(>AI V,!B,FC((.* /&/V>/^1J^,/_8WS_\ HF*O::\6_9X_Y&KX
MP_\ 8WS_ /HF*O:: "BBB@ HHHH **** "BBB@ HHHH ***\W^-GQ#?X?:7I
ML\33>;<3E-L,BJ2HP6/S(PZ?3KWKBQN+I8##SQ-=VC'<X<=C*.7X>>*Q$K0B
MKMMI?G9'I%%<YI6N7^N:;:3Z?:A(98D<7=\2 V0#E4 #-UZG;FK?]BWEP/\
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M'!Z=:L5';JJ6\2JP=0H 8  $8Z\<?E4E>Q&_*N;<]B"DHI2W"BBBJ+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I",TM% $8@C#*1&H*Y"G XSUQ7C'[0O_ ".GP3_[
M'./_ -(KJO:LUXK^T+_R.GP3_P"QSC_](KJ@#VH=!2T@Z"EH **** "BBB@
MHHHH **** "BBB@ HHHH **** $)P,GI61"AUNZ\^3FRA;$2=I&'\9]@>GYU
M-K$KR^591,5EN#@L.JH/O'\N/QJ_#$D$21QJ%1 %51V%;+W(WZLU7NQOU8^B
MBBL3(**** "BBB@!LDBQ(SNP1%&2S'  IL%Q%=1++#(DL;<JZ,&!^A%<YXU\
M#IXQT>]LFU"[M#<)MRDI*#ZIT(]JH_#WX;+X%T6"R.IW5VZ.9#M<QQ9/8)DC
M% &_XH\5:7X,T>35-8NA96,;*C3,K, 6(4< $]2*AE\:Z+#XDM-!:_3^U;JV
M>\A@ )WQ(<,VX#;P3ZUS/QY^'UU\4?AGJ7ANTCMY7O'B#QW3%8W02*6!(!Z@
M&OF_XA?LUZWX2M?$^H:=;65IX7C%VUMI>G+-(/(DEB?R3#%&66-MC;M@.,YP
M>: /I[QW\8/"WPZ%BNKWTSW5^6^RV6FV<U]<S!1EF6*!'<J!U;&!ZU7LOCKX
M#U&/PR;?Q-922>)93#I4&2)KEQG<HC(W*5((;<!@\'%?+GP<^&/C2 ZQXY\)
M>$['2K34+F]LHO#\-_+IIBM9"A2>SGDM\K\RGAHE!&<5ZUX8^"/C!-"\ 2^(
MKNRU/Q%H^N_VA=WDLWG31VI)(A$_E(92,C)VJ": /<V\0V*:K-I[RO'<0Q+,
MYDB98PI.!^\(VDY[ YJ>^U2TTVWEGNKB."**)IG9V VHHR6^@'>OF[]H_P#9
M^\3_ !,\27VI:;:VVHV3VUO'%;2:@L#>8CDEBDL,L3CG[KJ0>Q!P:X^/]E7Q
MS=W<,.I:;X;N+V802-XDBNI%DLH4A:-[&.$H28V)'1@O4D=!0!]=Z+XATWQ%
MI%MJFFWL-YI]R@>&XB;*.IZ$&K7VVW$7F>?'Y>[;NWC&?3/K7P5)\#O$.F6^
ML>'[72!!I.D>'3>7VE:=#-]G.K!#%$(9 BB3<AWD("0>O-3W'[(_CKQ)IFFZ
MI;:'IF@:5);11MX-LM1C6,3?9@GVUFFM9$64MR0(]XZAMU 'WK16#X#T.Z\-
M>#-$TJ]N&NKNSM(H)9GE,I9E4 G>0"WU(&?2MZ@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#R_\ :0\2Z+HOPF\0:=J^K+HSZY8W6FVE
MPZS%1,\$A&3"C,H 5CG';UKY1_X)]7WA@^/KNPTG2?A;#J%OI.V74/!VGZG!
M?S@.H)E:ZA1"I/)PQ.:][_;4O[RR^&NG?8-4FTJX?4!B2#QJ?"S,JQNS#[2$
M?< %)V8YQGM7CG[#GC*?Q!\3M4MY?%LNNA=.+"W?XM-XJV_.OS?9C$FS_?S[
M=Z /2_VI_ASKWC3XB?#Z]\.>#M0U'5M-OK>>/Q!#>1I;6T:RDS12@RJ\0VG?
MOC1B^ AXKC?V9?@C\4O"UMXPB,MS\.KVYBLHI=0OHXM36_OH_,^U7:1&4@B7
M='\[%6.W[M?9F*", T >!?LH:?JFEW?Q5M=:U9==U2+Q9.)]02T6U$S>3%SY
M2DA?P->_5XM^SQ_R-7QA_P"QOG_]$Q5[30 4444 %%%% !1110 4444 %%%%
M $%[>PZ?:R7$[^7%&,L>OX =SVQWKYR_:C\0>)-(TC0;^'2UOH9[B3_0Y+3[
M0MO@*8]W^VQR"/3*CN3ZU=ZW<>*?$,MII")<1:=)L>XE!,$4PZLW]]EZ!!WR
M21A<R:[X6FM[>">WM)M>U4SQ2/=SS(K(J2*Y"!L! <$ *![^M>)BJ/\ :-*=
M-_!MZ^?GV73KVMT8##X7$XB,LQ@IT-N1NREI\4GT2WCWMS).Z:=X5\5ZKJ?A
MC29%T*[>]>UB:<SH+.)9"@W !OFX.>BD5K*OB6Y;E]+L%/8))<,/QR@K;A9G
MA1G0Q.R@E"02I],CBGUZT8-))LUG7@I/V=-+\?ST_ ^?OVC=6^)/A;3-$;PS
M-+JYGN29UMM+5Q&R,C0]R1E^!SSTKU/PUI&L:CX>TNZU36]3AU":UBDN(5CA
MCV2% 67'E\8)(Q6CXQE2/3+;>ZIF^M,;F _Y;QUN*00"#D'O6$:-JLI.3:=M
M+['K5\Q]IE]&C&C",HN5Y**O+;?3IM\C"/A>8]==U8_]M8Q_)*\?_:'^ MU\
M1K#0_)\0S1?9;GRC_: ,^3,R("N,8QU/K7OU8/BVUU&\M;6/3[:"X9+F*=_.
MN#$ (Y%? ^5LYP1VQ3KT(5:;A)73]3/*LTQ6!QE/$4)J,D][1MJK/=6VN7/#
M6E-H7AW2]->02M9VL5N9%& Q1 N0.V<5I4R(NT:&10CD LH.0#W&>]/KJ225
MD>'.4IS<I;L****9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445'.<0N1R=IH ?FO-?VB]3
MMM)^$>M7%YK>L^';8>4KZEH?FK/"#(H^9XHWDCC)P'D1=RH6(((R/@;X+>+/
M@_K7Q'TZU\:Q^(=)U)H6N9;J'5O$00:K_:,J+;>7YC1[/*6)_P"[\QYQP/U#
MH _-[X;_ !3^*FH>,?A3#J'B#Q=)J,O]D0V-K*LWV36+5M0NTU.XFS&!(JVR
M0,KR[7";'QN<Y]\^*4OQ-?XN_"-?%=IX2A\-CQE_H<FCW5U)>'_1+KR_,62-
M4'R_>P3STR*^I<5XK^T+_P CI\$_^QSC_P#2*ZH ]J'04M(.@I: "BBB@ HH
MHH **** "BBB@ HHHH **** "D)P*6J&M7#0V12+_73$11_4\9JHQYFDBHKF
M=B+2A]KNKF^;D,?*B_W%/)_$_P JU*BM;=+2WCA3[D:A1^%2TYRYI76PY.[T
M"BBBH("BBB@ HHHH KWM_;:;;M<7=Q%:P+]Z69PBCZD\4W3]4LM6A,UC=P7D
M0.WS+>59%SZ9!-<9\5_A=_PLGPQ?Z9'J=Q92W07!=WDA7!_YYY -9OP;^#!^
M%N@_8)M7GOI!<-.#;L\$1SC@Q[B#0!Z9+,D$9>1UC0=68X K \1_$'P_X4T2
M?5M1U.&.QA"L\D1\T@,P53A<G&3C-8/QV^'UU\4?AMJ/ARU%L[W;Q;TNV(C9
M%D#,#@'J >*^>]<_8QU&&.Z;PY8^'M'FGU*]F+VP,)-K)Y9BB^5.BE2=GW0>
M1UH ^J-?\;:%X7T?4-4U35;:SL=/C\VZE>0'RE]P,G/MC)K@K;]J#P#-9WDT
M]WJFG3VPB86&H:+>6]W.LIQ$T,#Q!Y0YX&P'\*^5_#7P1UWQOXZO]%L/#]OI
M-WIMI>>?XFNK"ZA>^N3="6'[6)(E#YQCY'E^4 @@<5Z_J_@KX^WFI:_K^EOI
M>DWU[;):1:3<^(Y;ZVBD+CS+F O; 0$*"%3:W)R>E 'KC?M"^ 8]+\/:A+KZ
M06^O7W]F6/G02QNUR.&B=&4-&P(P=X&*[.^\0V6FZE;65PTD<D\;R+(8F\I5
M09;=)C:OXD9KY7F_9)\2>-=/2"_O1X(MM/TN2WL+73K^/4Y;B\D?S)+BXFEM
MU.68+R@5L$X(&*ZKXP_ WQE\4O#OAG[:FFW6I6>DRVNHP?VA) D\[!1E)!&W
M4KGYD(YP5(H ^AO[6LML!^V08N!F(^:O[P=<KSS^%4/#GC/0_%VD_P!IZ/JE
MMJ%AO9/M$4@VAE8J0<],$$5\@:1^R/X[BM8(+_3O"EW+<K#';WYE\N?P^B3;
MR85C@5)'<9W&,1 D\C%5+?\ 9\US1/%.F>&8-.AM;,6UY=Z^NF6TIMKR.-WD
MLV\S8B>:[-M:,;CA1SB@#[8_MBQ\F:;[9;^5"<2R>:NV,_[1SQ^-6D=9%#*0
MRD9!!R"*^!]"_9-\;^*_"&A:G#HFD>%H[6&(7/A^WNA&=:8.[&6Y\VVD1)%W
M# >.3OSTK[!^"?@B]^'/PQT+P]J$HEN[.$J^+@SJF6)VARB;@,X^ZH] !0!W
M-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8_M"ZSJ.D?#
MVY&D^$M<\5ZC=;K: >'[>UFN;)V1@+@+<.J':>V><XZ&O OV,/\ A;>I>/-4
MO_BCX3UGPO)%9FWLHX-(L+#2Y(PR_O)/*D>5[AL9(SL7G%>S?M2?$#Q)\.?
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MV>?^1J^,/_8WS_\ HF*O::\6_9X_Y&KXP_\ 8WS_ /HF*O:: "BBB@ HHHH
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M3Y?(WI03DN=.WD=Q'(LL:R(P9& 8,.A%94C?V[=>4G-A"W[QQTE8?PCV'?\
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M=4L&TNW:9EU6!8@Y"%AC:[9Z<]*P/@A\%M0\"1ZU#KT.E2VUW!%:-!9YDCO
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MI%0!BH-N3C(.,G-=)_PI2'_H:=<_%+(_^VU8KZRM'R_>_P#(SG43FVJ-E?\
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M(.,=$/MFO-/BSK>K6/QQ<+J&LV^MQW.D_P#"/VEM+<"UFM3*_P!O+(G[IP%
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M2/\ \(VS_P#CE'_"J/C/_P!%TC_\(VS_ /CE3.E4EM5=_D_T,_9U$G^]>O\
MA_\ D3IO!O@[Q)%X5TF.37KFQ=+9%-M)%\T6!C:>>U;'_"'Z\>OB><GUVD?^
MS5Y'X\\&_&KP;X,UO7(_C9#=2:?:2W*P-X.M '**3@D29YQ3_ W@GXU>+_!7
MA_79/C;#:R:II]O>M O@ZT(C,D:N5!,F2!NQ6ZC9)7.B7O2<NXOQX\%^()XM
M(C^T7^O1!W8I%'(0AQ@$A2?4UT_PU\%>))/ VFI_;UYI)5646TT;ED&XX'+
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M_@#\8M6^+]MXODUCPV?"USHFN2Z4MA)<K/+L6*-U:0IE0Y$G*J2!TR:BT?\
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M%3RV:PM3\):E8WEY?3:'XIT^WO%TNRMF\2ZB+N66]6X#2>5F21U& Q/(4]0
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M[P! S79_ ^V\5Z=X8DLO$.MVOBS3871M#\1HY^U:A8L@:-KI-H43+G:74XD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ1DTV3Q7X<L-<DTZ3S;62ZCRT1.,@$8)5L#<ARK8&0<5V%% #4144*H"J!@
M=J=2=** %HHI"<4 +129'K2T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ibio-20230630x10k024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '? Z@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7P\^.4%KXNF^%?BK4)-6^)/A_P /1:SK5]967E64ZDA6:+D<DL/EP*X75/\
M@HS\)-(\%^"_%$Z^(FT[Q=->6^EI!I32SO);.J.K1JQ(+,RA0,YSVKA/CWX
M^+_PS_:EUGXJ_#KP#'\2-+\3^%?^$>N+*/4([2:QG5LK(V\C<GRKT_VAQP3Q
MWPT_8\^(7P^N/V3K2^T:+4%\'W^K:CXBGM[B(QV#W+"2->6!<J<#* \KZ8-
M'I3?\%4?@R-'GO%L/&3WEG,\>HZ4N@O]JTU$(!EN1NV1IEL??)R",9%>C_$W
M]M[X7?"_POX1UFXOM1\02>++=;S1=*T"Q:ZOKR$J&\P19&T#.#N(YR.2#7CF
MD_LZ>-[?4?VQ)I/#.T>.H@GA]C-#_I_^C3*0/F^7YW7[^.37%Z-\!OC)\#KO
MX'_$_P .>!(?&FL^'O!J^%]<\)/?Q6]U;?,[>;#*24)_>$'!/3N&) ![_-_P
M4(^$$/PB'Q$&H:I)HT>J)HUW9II[?;K&Z8,0DT!.5X4\C(/;)S7MWPT\>V_Q
M/\$:5XGM-+U71K748S+%9ZU:_9KM%#%07CR=N<9'/0@U^=?B#]D;XQ>-O"_B
MGQKJ_A&VL/%7C3QWI.LS^%+&\B==.L;82!GD<L$9SO&=I)/)ZL0/TZ P* %H
MHHH **** "BBB@ HHHH **** "BBB@!#TXZU\'_&KXP?M,^&OVKM"^&?AG6O
M T.F^*_M-WHK7UC*[06\*;G6=@,[SAL;01TK[QKY6^+GPK\5^(/VZ?@QXQL-
M$N;GPOH^F:E!J&J1E?+MGDB8(&R<\D@< ]: -KQY^WO\)OA?XKO/#&MZMJ%]
MJ6DA$UB[T?2I[NSTYR.1-*BD+SV&<=^:T_BK^W#\)/A _AU=7UVXU#^W;(:G
M:-HME)>C[&>EPY0?+'[]>#QP:^&?%7[*GQ'^''CSXE:0_@7XD>.--\4:M<:A
M87O@WQ@-,TV[BG9B8KV(JV"NX@ENHSVYKM/VAOV<O%_@[PW\--)^&OPI\7KX
MDT+0S#IGBW0_$L4L^GW+RF1K&[RBK-;J7;YR%!!P.,@@'L\'[;'V_P#;HTWX
M86EY-+X/O=$B,2_V/()'OY?WB-YA&X1&-D^8@*#D'D''NGQZ_:7\!?LW:-87
M_C74Y;9]1F\BQL;.W:XNKIQU$<:\D#(R3@#(YR17B?@;X7_$E?VT/"GC;Q5I
M,DT$7PX@TS5=9MRGV8ZEO+2QJ <]23P,<\4?M??#?QYI?QP^%?QG\%^$/^%B
MQ^$_M-M?>&XY52XV3  30[N"R\] 2"%.,9P =)HW_!1?X*:]H'B?6+36=4:T
M\-VL5UJ@DTB=)+=9)5B"E2H)8.X! Z=>E>1_$3_@I-I4OQ:^%-EX/GU6#PCK
M5S.NJ2:AX<F#W47"PR6Y8;F4MG.T9QUKR/QQ\&/C1\8;W]H'Q/>_!^^\*7'B
M[2=-BTS2EG@EDF,5W 3O96 \S8C,P(&,8ZCGZ3^*_P (/%^L?%K]F'4=,\/W
M4^E^%X)4U:6(H$L<VT2 ,-WJI'&>E %GX*_M;V?ACX&>*O'7Q=^(&EZE9Z?X
MFO-)@O+#2Y;8G81LMTAVAI'Y.-H/'4G!-2ZG^WKX+^(OPE^)=Y\.=5N[+QGX
M<T"YU6*QUK2W@E540E90D@VNF<=^_2OG*P_95^*^E_!_1-<M?!0U7Q!X1^)=
M_P")U\(ZG+&HU6S<IM9#N*Y^7@'MNXS@'WKQ#XT^*_[0GPJ^+6EWOP(O_ T=
MYX9GM-/GU&_A?4+^Z*,! (P!\GS<,2 #]> #;T#]N3PIX'^#?PSU'X@ZE=ZG
MXU\3Z-%J!TO0=,>YNI05^>7R8AA$SGDXZ''0U[E\'_C1X0^._@^/Q+X,U5=4
MTQI&@DS&T4L$J_>CEC8!D89'!%?G#XJ_94^)OA'5?AGXU/A+QOK%M'X+M-!U
M'3_ ^OC2]6TVYBW<$C.^)MW('&<Y[9^OOV%/@O-\*?A[K6HW_A?7?!^L>(M0
M-Y=Z;X@UY=6N#MR%E>147:[ACN!R<@9/:@#Z8HHHH **** "BBB@ HHHH **
M** "BBB@#RK]I_XVO^SQ\$_$7CJ+23K<^FQH(K,N41G=PBEV .U 6!)] :\Y
M^ '[3/C77? >N^+/C)X:T/P3X9L;:&^M/$^DZF+G3KR"09^4!G8%>A.<9XP#
M7HW[3OBN[\'?!GQ!J%M\/I_B;#Y7E7?AZW(W3P,=LAVE6+@*2=H!)QQ7YZ_"
M+X>^*OB!\+/VAO"GPS\.^+=.^%.H:/YWA_1?%4!AEBU(E6>"WW$Y7 8=?[N>
M<4 ?I)?_ !L\%V=UX<L1XBL3J/B6U:[T2W+'-_&$#[DXY&"#SCK7SW\!/^"B
M7@/QAX=9/B3XL\,^$?%<FLW6GP:9%+(H,,;A8W?<6V%N>6(!QQ7AWPDUGQ'\
M?/C-\"!9> ?%'AZU^&WAVXM->O-=T]K6)9_LXB5(RWWR63IP>>G!KQ_P;<Z?
MH/[/WQ&^&VK_ +/?BC5_B#XGUB]71]7'AYFCN"\F(G\]@'C\H_-QQS]: /U"
M^(?[3/PM^%&N:5H_B[QSH^A:EJ:+):6]U/S(C'"N2 0JGLS$ ^M0_$W]J;X3
M?!S4;&P\8^/-'T.]O8Q+!;S3%W:,]'(0-M4]F. ?6OSH^.O@'Q!\--9^&R6/
MA3Q9J/Q5T_PSIVF7!?P['K.@:R%?)M'+9V/'G&\#L.G!I/B]X+\:_#S]HCQ[
MXB\8Q>-]%MO%]C;/97'A+PK:Z]#*ODHLMDQF!\HJP( !&1R: /TQ\6?'7X?>
M!O 5MXUUSQ?I.G^%;E5:WU5[D-#.&^[Y97)<GT4$\&N<\*_M<_!WQO#J$NA?
M$+1=433M/?5+S[/,2;>V4X:1QC*@=P>?:O@[Q%\!M1^$GPM^ GBF;P=XM\>>
M /#FK7.I:MX7U?3(AJ-G'/MV%K2-F0JI5CC/\?(4$XJ>"#8_'#]ISXVP^!O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQYX#TSX@Z&^G:C
M'AA\T%R@'F0/V93_ #'0BNDI*J,G%W6Y,HJ:<9*Z9\:0S>)_V>?'++MW1M]^
M+)$%]#G[R^A_53P>*^KO!'C33?'_ (<MM9TJ0R6TV5(8?,C@X9#[@\5'XY\
MZ+\1-%;3-:MC/!G<CQL4DC/JKCD9'%<EX1\'S?!:YGM+*X:X\"R_/%;R9:73
M)"?F^;^*)NI)Y4\\@G';7KPQ$%*2M/KV:_S/-H4*F%J.$7>F]NZ?^7]=V>GT
M4U'61 RD,K#((.013JX#U HHHH **** "BBB@ HZT44 ><ZU^SK\-?$2>*EU
M+P;I=ZOBF6"?6A+$3]ODA.8FDYY*GD5N3_"[PG<^,=&\5RZ#9OXBT>U:RT_4
M2G[VV@8$-&A[ @D?C7544 ?,'[0?[$^A_$[1O#^F>%+#0_#UG'XS@\5Z[;W%
MLSQZFP#"8,!G+N&QSP>:]/\ A_\ LQ?"KX5VVMP>%/ NCZ)'K436^H?9H/FN
M(FSF,L22$.?N@@>U>H44 >8Z]^S+\+/%'P\TOP+JO@;2+WPGI9+6.F20_):D
MDDF,@[D)+-D@\Y-9=I^R[\%/!'AG7[*#P+X=T70]6MHK754\H0PW$4; H)22
M <-@Y)R3U)KV*OG7_@H5C_ACCXG9P?\ B6@\_P#75*J*YI)#2N['>Q^&?A1K
M?B/PC>11^'+W6O#<+6>@O'<QO+9QL@0QP@-G!10,<\"K2?L]?#=/AU=> QX,
MT@^#[J5YY=&:W#0-(S;B^#T;(!R.0>E?A1_P3UE:3]L?X9!V+#^TP<'_ '&K
M^AE?NCZ4Y)))H;2Z'D_@3]D_X0_#'4([_P +?#[1=$ODMI;3[5;0$2M%)PZL
MY)+9!QSDXXK4T?\ 9W^&V@0>%(=.\&Z79Q>%)I;C1%BB(%A)*=TC1\\%CR:]
M%HJ"3R;7OV3O@]XH\>CQIJWPZT"_\3>:L[7\UH"9)!T=U^Z[<#YF!/%=D/AE
MX57QZWC8:%9CQ6UC_9K:L$_?FVW;O*S_ '<\XKIZ* .<\"?#KPU\,=&ETGPK
MHUKH>FRW,EV]M:)M1IG.7?'J<"NCHHH **** "BBB@ HHHH **** $90P((R
M#U!KY^UG]@+]G[7_ !%J>N7WPQTF74=19GN762:-"Y;<76-7"HQ/.5 /7U-?
M05% 'D7Q2_9*^$?QHM=&@\9>";#61H\"VUC*7DBEAA4 "/S(V5B@ ^ZQ(I/%
MW[)'P@\<_#_2/!.L> ]+F\,:0Q>PL8%> 6S'J4>-E8$]SGYN^:]>HH \NT+]
MF+X7>&;KPS<:5X.L;"7PU:SV6DF!I%%K#.")E W88ODY9LGGK2#]F'X7I\.M
M-\"#PE:CPEIMZ-1M-,\Z;9%<!RX<-OW'YB3@G'M7J5(WW30!^67[6G@BQ\3?
M'3Q-->?$3X%:A.[_ &</XTM7M]6T@;1A"(%V7!4-\IE#'IQQS]U?LB?#S0/A
MC^SGX,\.^&]>@\4Z3;VC,NLVW^JNW>1FD=/]G<6 ]A7XA_\ !0,G_AL+XD_]
MA ?^BTK]IOV$#_QB)\,/^P5_[4>MIQBEIY%M)'$_#+]DC4_!GQ"^+WA[6;71
M]?\ @GX]G;4QIKW,L=W;73\RH450#&Q)Y#@C"\<&O0OB!^RMX,UGP_K<WAW0
M+'3?%LOA27PGIVI2R2[8+0QE(XB,D;5S][!;&>:]NHK$@^5_V>O^"??PP^%F
MA^#M5UWP7HFH?$31[6-;C5K=I7A>X4DB58V(0L./F*9R,UJ:;^S[XN\4?MD2
M_%OQA/I<7AW0-,?3?"^FV4[RS!I,B2>;**%8AFX!/\//%?2E% !1110 4444
M %%%% !1110 4444 %%%% !1110 5\Y_%S]@SX7_ !C\>W7B_4EUS1]7OX1;
MZG_8.J/9QZE&!@+.JCYN !D8) &>@KZ,HH ^=)?V"/A+/\&+'X9R:=J#:%I]
MZ^H:?=_;F%]93L>7BF !'I@@C'7-4M+_ &,_@Q\'_AIXVM-4N;]+#Q!;>5KO
MB77=:?[8\(Q@-<Y78H.#@<' SFOIBOG[]O89_9)^)7&?^)5)VJHKFDD-*[L>
M/^#_ -G']EK4=(N_!NG?$=?$NI:]?6DSSS>*X[K4;A[=@8(5;KM! ^4#G ]!
M7T/8_LR>#-.UWXC:M$-1^U>/8$M]8W7>5V+'Y8\H8^0[?K7X:_L!$G]K_P"&
M/4_\3>+^=?T1@YJI)630W;H?!7[3_P"QQK<>A?#S1? 'PXT[QYX;\*VSVT!;
M7Y=)U^V)8M\EWN$;1G/*E"01QZCM_P#@GS^RQXB_9]L/&^M>*-+M/#M_XGO(
MI8=!M+]K[[##&&P))V)\QV+9)R>_K@?7]%9DA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 45%<2&*,N.B\FL/5_&EEIEO))O1EC7
M?)*[A8T'<EC2;2&DWL;MQ<16D+S32+%$@RSN< "H-.U:SU>)I+.YCN44X)C.
M<&O/-0UM/&FE)*MW!>V$H\R)K=]T38Z'(/S#\:\_T3XIZKX;UF2TL;>"YL%E
M"O"P(>1CP<-V]NM8RJJ#5]CJI8:=6ZCNCZ.HKA[7QKJTJ#SK&V@8\Y$A; ],
M>M.D\4ZC(/EDBB_W8\_S-:\R.;E9VU%>?77BF]$?E7-VB*_1E383[9S2V&MS
M:=,LJR-*IZQLW##_ !I<R'RL] HJ&SNH[ZVCGB.4<9%359 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% ",2!D=:HW&M6EI%OFE"G. @Y8_A5XC(
M/./>O-+W1M3TN=O.\V>/))N"-Q<YZDBID[%Q29T-QXW65Y(K-$+H<-O<$K]5
M!X_&O,/$WB>X\'ZM!J<TT^I7)EWI&\NT/UR..%5?3OQ5[1/!^AZ#KNKZW8:=
M%:ZKJ[*U]<HS$SE>F<G _ "IO$/A&R\2212W#S1RQ*55XF'3.>AX_&N>?-*.
MFYUTO91J+FOR]?ZOW-_PU\8EU^VS_8MRL\;;9_+<-&O<;6.,\=N*WSXS69#_
M * P5AC;(XR1[CFN0TG2+;1+);6U4K&#DECDL>Y)]:N5I%R2]YZF-3D<FX*R
M-#2M:?18I(+6 ?92Y:."24D0@_PKQPN>0.V>.*TH?'21G_3+*6%/^>D1\Q1]
M0.?TKG:*=V9V1Z%8:C:ZI;B:TGCN(C_$C9_/TJS7BVI37&@ZG'>:;.UI,XRV
MW[K$=F7H17=^"_B%:^)V:RN MGJT8R\!/RR#^\A[CVZBFIJ]F#@TKHZZBBBM
M#,**** "BBB@ HHHH **** "OB__ (*-? KXI_$/X;:MJ7PY\4ZI<69M?+U?
MP865X+Z%>=\(QN$@QDJ#\V..>&^T*0C(P:N$G!W0T[.Y_.;^R%\*/B=\0OCG
MI-G\-_.TKQ%82^;)J[)A-,0'#2N2,#&2,8R2< 9K^@SX;>$;[P/X-T[2-3\1
M:CXKU*%,W.KZHP,UQ(>6;  "KGHHZ#'4Y-/\*?#?POX&U'6[_P /Z#8Z1>:W
M<_;-1GM(0C74V,;W(ZG],DGJ23TE5*2MRQV&WI9!11161(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7+?$SX?VGQ-\&ZCX?N[[4-,6Z3"7VE7
M;VUS;O\ PNCH000><=#T((KJ:*:;3N@V/YZ?VM/V5OB;\)OC:=&U_P"W^++G
M6I\:7K6UY7U,$X7DY)D&0"I)(XZC!K]7OV!_V4/$GP*\#V.I^._$>JZGXDEM
MPD&BR7\C66DQ'GRUBW;#)ZG''('<GZKO]%T_5+BSGO+&VNY[.7SK:2>%7:"3
M!&]"1\K8)&1S@FKG2MI5+IVZ[EN7;J+1116! 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5\C?MZ_LAZS\??!5YJO@C7=0TKQ7;P%7TU+
MV1;/5(ASY4D>[8'_ +K8]CZCZYHJXR<'=#3:=T?ST?LI_LF?$SXN?&QM T>.
M_P#"EQHMQMU;5V5H6TT X/(P1)U  Y/TYK]ZOA;\.-/^%/@K3_#FGW5]?QVR
M_O+S4KE[BXN)#]Z1W<DDD]N@Z"NAL](L-.N;NXM;*WMI[MQ)<2PQ*C3.!@,Y
M RQP ,GM5RG*=URQV&WI9!11169(4444 %%%% !1110 4444 %%%% !1110
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M %&:=.HF^5L<Z,K<\5H=+11170<H4444 %%%% !1110 4444 %%%% !1110
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M_ NT_P#D>C_ARO\ !O\ Z&KQM_X%VG_R/0!YY_P_%L/^B0W/_@_7_P"1Z/\
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M'H_X?BV'_1(;G_P?K_\ (]>A_P##E?X-_P#0U>-O_ NT_P#D>C_ARO\ !O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=YHV ;>IY]L_I<!@4 +1110 4444 %%%% !1110 4444 %%%% !1110!X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%)GF@!:*3-&: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3QK,D1D42N"50L-Q ZD"@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X[5TU,>-].MH==O+>RN8
MI)7MDB@*C9MP 3&6P<G//Y5E4J>S2=KZI??ZF%:K[))V;NTM+==.K1V-%%%:
MFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1ZUZROW1]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M #1N4445T'6%%%% !112$@=^/6@!:*Y;7OBCX0\,%EU3Q+I=G(O6*2Z3S/\
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M/^_:LJ?AMKT:BCZCAW\<>;_$W+\VT']FX5_Q(\_^)N7X2;1@:#X!\->%@O\
M9&@:;II7HUK:(C?F!FM[%+179"G"FN6"LO([Z=.%*/+3BDO+0****LT"BBB@
M HHHH *IZQ_R"KS_ *XO_P"@FKE4]8_Y!5Y_UQ?_ -!- 'S3_P $YO\ DWB;
M_L8=4_\ 2@U]15\N_P#!.;_DWB;_ +&'5/\ TH-?45 !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !28I:* $ Q2T44 %)2T4 )CFEHHH
M3%&*6B@!"H(((R#U!JCHVAZ?X=L19:9:0V-HKLXA@7:@9F+,0!TR23^-7Z*
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M8=4_]*#7U%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>2E%179*WY!1116IL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&NVHO3P+*V8W%P3Z"*,,WZ5C'XC^)_$'R^&? M]Y3<"^\0RKI\7U$?S2D?\
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M/U?YA11176<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLDS)+IT+!I)!B1R"OWF'!/4]ZL6G@?PY86^F06V@:7;P:8VZQBBLHE6T/K$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRO+8*GAUS6VTT^2>B^:J+J>=:)XPM;R\%[X)\!^(?'>IM]WQ'KX^Q6Y]UEN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS]5K_P"!*TOQ/*;GQ+;1S7AUK4/%WA@W%BMC_I$*&"!AG]_'(D;J)3GEB2O
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M_P#1M>B_^%U:_P#Q-?5RMN4$ C(SR,&EKP#QSXD_9[^&7QN\+?%WXH?$W6/
MFD^#6U]K67_A%;?4K>ZBO0BD2%)XN8Y>X+#:Q)!_O#ZZ\%^.M*\=Z=)<Z=)(
MDT#^3=V5RGEW%I*.L<J'E6_0CD$@@UT-<1XT^'+:MJ4?B#P]>C0?%ENFQ+Y4
MW17,?7R;E!CS(_\ QY>JD&@#MZ*XOP3\1EUZ^ET+6K,Z%XLM5W3Z9(^Y94Z>
M=;OQYL1]1RN<, >O:4 %%%)0 M%)FC- "T4F<TM !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSXUZ+
M82ZEX'U-["V?4HO$>GQ)>- IF1#+RH?&0#GH#WKU)?NCZ5Y)\;O#.G3Z_P"
M]<DBD.IV_B&P@CD%Q($"&4Y!C#;">3R5)]Z];7[H^E "T444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***P]/\ '7AO5_$-[H-CK^EWFN62[KK3+>]CDN8!ZO&&
MW+U'4=Q0!P/QNT6277? >IC5;^.*+Q%81'3D=!:RDRGYV4IN+#/&& X'%>LK
M]T?2O)OC;9ZJVN^!+F/4XH](7Q%8++IYM SR2>:<,)=WR@<<;3TZ\UZROW1]
M* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M61HO)8?Z0XC4^7&K,,R/A 3R:],MKB&[MXI[>5)H)%#QR1L&5U(R""."".]
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MMWQ4_P"@+X/_ /!O=_\ R+7H5% 'DDGC;XFQ>,+?PZ= \)FYFL9;\3?VO=;
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M=+\16<.LV9%A!IR+(45TCW"!9BOEF0)SY>\MCM0!=^W?%3_H"^#_ /P;W?\
M\BT?;OBI_P! 7P?_ .#>[_\ D6O0J* /*M5\4_%;2[_2;8>&/#%T+^=H#-#J
MEV4M\1L^]_\ 1> =NWZL*T_MWQ4_Z W@_P#\&]W_ /(M>A44 >>_;OBI_P!
M7P?_ .#>[_\ D6C[=\5/^@+X/_\ !O=__(M>A5@^-_'6@?#?PW=Z_P")M5MM
M&T>U ,MW=-M5<G  [DDX  R2>E ' :!XY^)GB#4]=L8= \)Q2:1=BTE9]7NB
M)&,:R9'^B],.!SZ5M_;OBI_T!?!__@WN_P#Y%K.\8?&7X8?!>^$VMZW;Z/>:
M^#J+(D,T\LR*BJ9V2-6*(%"@N0%'<UZ/I&KV6OZ7::EIMU#?:?=Q+/;W-NX>
M.6-AE65AP00<YH XG[=\5/\ H"^#_P#P;W?_ ,BUG^(/$OQ5T'1+[41X:\+7
MYMHFE%K:ZK=M++@9VJ/LO4UZE10!YS!J?Q4G@CD_L/PBF]0VUM6NP1D=#_HM
M2?;OBI_T!?!__@WN_P#Y%KT*B@#SW[=\5/\ H"^#_P#P;W?_ ,BU%HWC?Q;:
M^/-.\/>)=(T:!-0M9KB*XTJ_FF*F/;D,LD*<'=U!KT2::.WB>65UCB0%F=S@
M*!U)/:N0\+>(O!OQ+@M?&>AWMKK%O9FXM(-5A9O+7#;9@I. 1E/O<CC@XH [
M*BN?\#^/?#_Q)T%=:\,ZI#K&E-+) MW;YV,\;%' ) SA@1D<'M704 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\@_&3QEH/PK^/7Q
M*O\ QO)]FL/$G@*VL=%:6%G6]DAENO/M(L [I6,T)$8Y;.0#BO>_V=M"U3PO
M\!OAYI&M1R0ZM8^'[&WNHI?OQR+ @9&]P1@_2O0)(DE*[U5MIW+N&<'U%/H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ibio-20230630x10k025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &C Z@# 2(  A$! Q$!_\0
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MVK_X(C_\O/?**\#_ .&'_A1_T#-4_P#!S=?_ !='_##_ ,*/^@9JG_@YNO\
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MVK_X(C_\O/?**\#_ .&'_A1_T#-4_P#!S=?_ !='_##_ ,*/^@9JG_@YNO\
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MVK_X(C_\O/?**\#_ .&'_A1_T#-4_P#!S=?_ !='_##_ ,*/^@9JG_@YNO\
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MVK_X(C_\O/?**\#_ .&'_A1_T#-4_P#!S=?_ !='_##_ ,*/^@9JG_@YNO\
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MVK_X(C_\O/?**\#_ .&'_A1_T#-4_P#!S=?_ !='_##_ ,*/^@9JG_@YNO\
MXNCVF+_Y]Q_\"?\ \B'U3A__ *#:O_@B/_R\]\HKP/\ X8?^%'_0,U3_ ,'-
MU_\ %T?\,/\ PH_Z!FJ?^#FZ_P#BZ/:8O_GW'_P)_P#R(?5.'_\ H-J_^"(_
M_+SWRBO _P#AA_X4?] S5/\ P<W7_P 71_PP_P#"C_H&:I_X.;K_ .+H]IB_
M^?<?_ G_ /(A]4X?_P"@VK_X(C_\O/?**^-?VA_V9O GPK\!VVO^';34+74X
M]5LXEDDU.>4!6E (VLQ%?8=E_P ></\ N+_*JHUJDYRIU(I-6>COO?R78PS/
M+,)A<+1QF"KRJ0J.<?>@H-./+VG.Z?-W1/1117:?-!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S7Q,_Y)WX
MG_[!ES_Z*:N-_94_Y-W\!_\ 8-3_ -":NR^)G_)._$__ &#+G_T4U<;^RI_R
M;OX#_P"P:G_H35P/_?%_A?YH^LI_\D[5_P"O\/\ TBH>KT445WGR84F1ZTQJ
MB;V!/T%.PKEC</44F]?[P_.J; ^A_*H6Z52C<5S1\U/[Z_G09HQ_&OYUDOUJ
M%NE5R"YC3N-8L+2ZM;:>]MX;BZ8I;Q22JK3,!N(4$_,0 3@=A1#J]C<:A+8Q
M7D$E["BRR6R2 R(C$A6*YR 2#@^QKD/%?A73O&&E/8:E"7CW"2*:,[);>0<K
M+$XY1U/(85YNMMJ>I:R-*O[R+3?B-HT37&DZ^D6V/5+7(!\Q1]Y2<+-%_"2'
M7&1CKIX:-2-^;7^M?3OU6^IA*K*+V_K^MCZ#HKE/AWXZC\;Z3,9K<Z=K5C)]
MEU/37;+6TX&< _Q(PPR/T92#UR!U=<4X2IR<9;HZ(R4E=!16=K?B+2O#-F+O
M5]3L]*M2P03WMPD*;CT&YB!GVK.O?B+X4TW0H=;O/$VC6FC3-LCU&?4(4MW;
M)&!(6VDY!X![5!1T5%85[X\\-:;IMGJ-WXATJUL+S_CVNIKZ)(I_]QRV&_ F
MMJ&:.YA26)UDB=0R.A!5@>001U% #Z*** "BBB@ HHJ);F)HC*)4,0SEPPP,
M=>: ):*K)J-I)+)&ES"TD:"5T$@)5#G#$9X!P>?:LO7/'?AOPSIL&H:QX@TK
M2;"X($-U?7L4,4A/0*[, <^QH W:*@LKVWU*TBNK2>*ZMIE#QS0N'1U/0AAP
M1[BIB<#)X% ".ZQJ68A5 R23@"JIUFP%LMP;ZW$#8Q+YJ[3GI@YKA?$WB%/$
M,EQ%YOE>'[4D3RYQ]I8=5S_<'?U/%4=*L6U66+4+R$1PIS9V97 B7L[#^\>W
MH/>@#T_[5#_SU3_OH4OGQ?\ /1/^^A7)(*L1CI0!TWG1_P!]?SI1(I_B'YU@
M)5B.@#8W#U'YT9'K6>G05.E %JBFITIU !1110 4444 %%%% $5Q.MK \KAB
MJC)"*6/Y#DU(K!E!'0C/-4M<7?I-R-N[*],9SSZ;6_D:MPC$*=OE'\J 'T44
M4 %%%% !112'I0 M%0O43'K3L*Y;I,U08GGFHG)YJE&XKFIFC(K%8G/6HFZ5
M7L_,7,;<=W#*TJI-&[1'#A6!*GT/I2P3QW,2RPR)+&W*NC!@?H17E'B_PK>6
M.HOXH\+QHNO(H%W9$[8M4B'_ "S?L) /N/U['@US_ASQ3;^";2/Q1X?223P/
M>R$ZKI6TA]*FSAY43^$!N)(^@^\.]=:PO/'F@[O]>W^7?U,'7Y96DOZ[_P"?
M8][HJ&TNH;ZVBN+>19H)5#I(ARK*1D$&IJ\\Z@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***R_$6OP>'=/-Q*IEE8^7# GWI7/11_4]ADT 79[VWMI
M8XYIXHI),[$=P"V.N!WQ35U*T>9XENH6E0 N@D!*YZ9':O++NYO&O@S-'<^(
M;Q<F0C,=I%GL.RCL/XCUK;TG2X=+MS'$"SL=TDS\O(W=F/<T =Z+F(])4_[Z
M%+Y\9_Y:+^8KE$%68QTH Z+S4/\ &OYTN]?[P_.L..K"4 :NX>HHS5)*L)0!
M-12#I2T >$_MF?\ )'8_^PQ8?^CA7M]C_P ><'^XO\J\0_;,_P"2.Q_]ABP_
M]'"O;['_ (\X/]Q?Y5P4_P#>JGI'_P!N/K,9_P B'!_]?*WY4B>BBBN\^3"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#FOB9_P D[\3_ /8,N?\ T4U<;^RI_P F[^ _^P:G_H35V7Q,_P"2
M=^)_^P9<_P#HIJXW]E3_ )-W\!_]@U/_ $)JX'_OB_PO\T?64_\ DG:O_7^'
M_I%0]7HHHKO/DR-J^6/^"@J03_"O187\8VGAR5=72X72K[5Y-*AUY8XW9[(W
M4;*8F*@LK$@;E4'K7U.U>1_M/^-=+^'?PCU7Q%K?@,_$/1M.(N;W2]ELXCB7
M):<K/\I"8SQD\\4^@NI\02?&_P =Z+XX7Q/X"\2>3I6I>#O"MOI]AXLMY;Z6
M%+N^-OOF?S5\R53YC&7'S@KTQD^F3?M;?$#2?B;+IMUKOA.Y&F^+;;P?+X):
MQ>/6]11Q&KZE&1)\BL7:14"% BD%LU]2^!+C2/'/P_TGQ9K/@NV\+O=V<4[V
M6JQ6TDEK#&Q>'?(F4VJ )%P?ER.A!KF/#_QN^!GC;4=;\6:1XJ\&:IJ'A^W)
MU#6XWA,]I;YP6:8J&\O/&02I)QWJK"/F32/VP?B_I%C9>(=37PYXGTW7-.\3
MS:9HVG:9)!<0R:6S>66D$C&0/M^8*HP!QS7??LP?M%^+/B5\8KCPIJ_CCP;X
M]TH>$XM?^V^%+$P?9;F29%-O(?,?)56/'!Z;@#72_$'X^_">;P/H4_ANWL?%
M6D:SJ-QH"7/AJ=+.?39);:6:5E=562%F6,_=VDE@>:M?LC?!GP;X9\(:9\1=
M ;7;O4?%>C6TGG>(;Y+J>UM6_>+;J4C1<;N2V"S$9)JE>Y+V/?WZURGCWPD_
MBG2XGLIQ8Z[I\GVO3+[&?(G X#>J,,JZ]U8^U=6_6HFZ5UPDX24D8R2DK,\H
M3Q%<S06OQ%T>PD@UG30UAXAT13EY8HS^^BQ_%)$29(F_B4XZ/7NNE:I:ZWIE
MKJ%C.ES9W42S0S(<JZ,,JP^H-?.OQ ^)GA+X._%.RN=1\1:?IHUV)(=5TZ:7
M$BXR(+S;Z#!C8]U(/\-4_AM^TU\,/!&NZMX>/CO16\,R9O\ 3+A;GY+4LW[Z
MV)QP QWI[,P_A%>A6P=6O352G!OJM'MV^3V\CEIXB%.;C.2\]>O?Y]?,]5_:
M3T:TUOX%>.(;NPAU +I%R\<4T EPXC;!"D'GTQS7CUE'X(\!?%+2[SXBV>FZ
M7H;^&;*'PS>:G;HFF6DOSM>1J6'EQ3OF(Y."R@@$X(KU _M;_!L_\U'\/_\
M@6*9+^UC\&)T*2?$3PZZ'JK70(/X8KR_J6*_Y]2^Y_Y'9]8H_P Z^]'@?Q<L
M]*UR7P9>_!;PWH&IV2W.L70L]0T222PO&%N/.:",E%+,,['!",P//)-?2W[.
M^DZ3HGP8\*VFAZC+JNF+;&2*YFM_LS$N[.R^3_RR"LS((_X H7M7&>-/VU_A
M'X/\.7.HVOBFS\17,.T1:7I$JR7,S$@ *K$ =>22 !7E@_X*;>#EX'@GQ+^#
MVG_QVMZ>68VJKQI/[K?F9SQF'@[2FC[,HKXS_P"'G'@[_H2O$O\ WW:__':D
MG_X*<^!6D)LO"?B6\M\#$VVVCR<<C:TN>#D?A6G]D8^]O9,CZ_AM^='V117Q
MG_P\X\'_ /0E>)?^^[7_ ..UT>B?\%!_!^N>#O$^N1^'-<MY-#CAD:SN# #.
M)9!&NUU<J,,1G/:LZN6XRA!U*E-I+J=&&KT\96CAZ$N:<G9+NSZ@U*X-II]S
M.!DQQL_Y#-?#WAN+QQ<?#Z7X<P?VLMK\04N==M];\L_\2NVDDD>]AWG[C;3'
MY0/.96]*U8_^"FVA39$?@35),==NHVYQ^M/_ .'EVC?]$_U?_P #[>O.Y6?8
MKA;.7MAW]Z_S+'P]MO&OB>_OKWPWK.G^'Q_P@FEPWB:IHLEZTKQBX0JK":+:
M05;.=W456^#M[X+\':IHM_\ %1+"R2?PKIL/A[4=?A"V4:+&WVJ&-I!LCE+;
M"RG#,N,9 - _X*7:,/\ FG^K?^!]O6[X+_X*&^!_%.OP:9XCT6X\(Z?,&_XF
M>IW,,ENC 9 ;;R,XP#ZT<K,ZO#6;T8.I/#NR]/T9[]\'I/!L_@Y9O =DECX<
MFN99(5@M)+:&1BWSO$C@?(3DAE&T\D58\<ZU(S1Z)92&.XN%W3RKUAAZ$_4]
M!^)[5P]U^V/\%[:UED3XCZ!*R*2(TN@2WL!BO-YOVH_AD;2XNO\ A86@/JVH
M."[?:<B'/ !XZ(/US4GC_4,7_P ^9?\ @+_R/48+:+5KU+6) NDZ>0I0?=EE
M'1?<+U/J:Z=*\>TS]I;X.Z=:0VL/Q&\/[4&,FZ.6/<GCJ3S7K=A>0:A:0W5K
M,EQ;3HLL4T9RKH1D,#W!!H,*N'K4+>U@XW[IK\RZE6(^U5TJQ'VH,"PE6(ZK
MI5B.@"PG05.E0)T%3I0!83I3J:G2G4 %%%% !1110 4444 4-= .DW.<$;>^
M/7WJW!_J4_W1_*JFN,%TFY). %ZDX[_4?SJY#S"G^Z/Y4 /HHHH **** "D/
M2EI#TH B>HF[U*]1-WJT00MWJ)^]2MWJ)^]:(1"W4U&W2I&ZFHVZ5HB&0M7F
MOBB ?#WQ(_B2&/=X>U1U@UNVQE(G/RI=;?0YVOZ@@UZ4U4]1L[?4;&YM;N-9
MK6:-HY8W^ZR$8(/X5T4I\DM=GN93CS+3<Y7P#J+?#OQ.GA*=V;P_J.Z;0YV;
M<(6ZO:Y]!G<GL<=J]<KY4L_&OA.[T75O!.I^-M%AO-&E632-6DU&(?*#F%MV
M[[Z'Y&'7%>I> /VC?!7B#PO:W&J^+=!T[5$S#=02ZE"N)5.&*Y;E3U!'K6V+
MPE1OVD8M]]-^S^?7S]3.A7@O<;7]=/D>LT5Q'_"\?AW_ -#WX;_\&L'_ ,51
M_P +P^'?_0]>&_\ P:P?_%5YOU>M_(_N9U^UI_S+[SMZ*\.^(?[9_P *?AQ>
M6MK=>(?[8FN$,@&A1_;@BYQ\[1DA?H3FN1_X>*_"+_GKK_\ X)Y?\:Z89?BY
MKFC2DUZ,REBJ$79S7WGT_17S);_\%$O@[))B:^UFS3!/F7&D2A<]AQGD]!4?
M_#Q7X1?\]=?_ /!/+_C5?V;C-O8R^YB^MX?_ )^+[SZ?HKY@_P"'BOPB_P">
MFO\ _@GD_P :T?&/[>'PX\):1X?U)(]7U:VUJV-W ;2U5#&@8KA_-=<-D$8Y
MZ5A5P>(H)2JTW%>:.[!0EF-54,)[\^RU9]'45\EC_@I#\/R,CPYXI(]1;V__
M ,>H_P"'D/@#_H6_%/\ X#V__P >KFY6?0_ZN9O_ - TON/K2BODO_AY#X _
MZ%OQ3_X#V_\ \>KTCX9_M@?#7XD:5<W9UN'PQ+;R^4]IXAN(;64\9#*-Y#+S
MU!I69S5\DS+"P]I6H22[V/;**X3_ (7S\-O^A_\ #/\ X-X/_BJ/^%\_#;_H
M?_#/_@W@_P#BJ1YOU:O_ "/[F=Q-,EO$\DC!(T4LS,<  =2:\KU37?[1N9=>
MN59H$'E:?;]R"< X_O.<?05G>.?CQX"U,V^D6WCGPZ;>;]Y=2KJL./+!X0'=
MU8]?8>]<W%\7? >HZSYDGC3P['9V/RPJVJ0@/)CE_O= .!^- ?5J_P#(_N9W
M^A:<]I')/<D/?7!WS..@/91[ <"MA.E<EHWQ/\&Z[J$5CIOBS0]0O9>([:UU
M&*21_HH;)_"NM3I08SA.F[337J6$JQ'VJNE6(^U!!.E6$JNE6$H L)5A*KI5
MA* )1TI:0=*6@#PG]LS_ )(['_V&+#_T<*]OL?\ CS@_W%_E7B'[9G_)'8_^
MPQ8?^CA7M]C_ ,><'^XO\JX*?^]5/2/_ +<?68S_ )$.#_Z^5ORI$]%%%=Y\
MF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2;;B#/:6%L.G7N/I7H= !1110!S7Q,_Y)WXG_P"P9<_^BFKC?V5/^3=_ ?\
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M 'DOB/Q_\<_BQ^T]H'PQ\(_%!O!&G7GP^L]>OKLZ7;W+K,=H=XPR@AW=D!Y
M"EL#.*\X\*_'OQQ\4--_9L?Q?=Z=J_B&V^)%]X?NM5FTRWDDF$(A"2KN0^6X
M\S[R;2=H/6OT L?V>?"VF_'4_%BV:^B\1_V$OAY;995%FMJ'5QB/;D-E0,[L
M8[5Y_P"'OV#OAUX9/A(VE]X@;_A&?$]QXLLO-O(SNNYMF]9,1#,8\M< 8/7Y
MCF@#X7^&%O\ &?X7>$_VE_'/A'XBW.H:EX/\://JFFG3( FL>5(#=7#DJQ3,
M>3L3  4X.<5]8_!+]I37_P!JC]IWSO ^M26WPC\+>'[>XU1(X8V74-3NDWI
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MXFMK8GJL4G[ZV8?[I8@?[E=])J4+2V7Y/1_=H<M1-2NNOYK47XM_#?6/B/\
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MD$^E=I_PHG6_^C=?A=_X-#_\CUR8C!4)3YW4W7>'I_-W1M2Q%51Y5';RE_\
M(GT!\2/CCX2^&7@^_P#$.HZI!=P6JC%M8S)+-*Q.%55!ZDGZ#J:^'_B7^T7X
M]_;!B'@KP+X7N]-BC+75U;VVH O<P@8"RG"*HR<XW')P.:[KXD> [WX;^#M0
M\0:G^SA\/)+"T4&8Z=>M-*BDXW;5@!P,Y)!X%:/[*W[6WPU1+G0;KPOHOPR?
MRS-]KM946TN,=F=@&#>@8G/8UWX3#0PM"6*H4O:RB]'=-+Y1D[_UL<M>M*O4
M5&I/DB^EG=_-I'BFE?LY^./V;_#%S\6/$%O9Z?J&ALC:;I:.)G:=V"*\Q3Y0
MB[LE026Q@X%?5G[$_P"T%XA^.7A371XH-O-JNE7$:?:K:'RA*C@D90< @J>G
M6NB_:-^*WA6']GGQ+KMO#I7CC29(EMA;1W EMY7D8*H=D.0 2#P0>.,5\5?L
MT_!W6OCE;Z_<>&AH_A:*PDB24?:-242E@Q'^KN!TP>N>M%2H\SPU2MC%RR3L
MG;;;2U[]?Q/J<!@Z%'"24--=]^Q^HNX>_P"5-DD$:,QSA1D\5\4_\,2?$#_H
M;='_ / O5_\ Y*K.\1?L=>.]#T:ZO9O%FDF.)"=JW>KY/L,W)%>#]4PO_01^
M'_!-?94O^?GX'O5Y>S/8ZIJFQS)=RO(AVGD9V)^@'YUJ:;I[V-E;VXC?]V@7
M[IZ]_P!<U\BS_LI>+XI+.V/B;2B97V@"?4\# R<CS_;M6@O[)'C,_P#,TZ3_
M .!&J?\ Q^CZIA?^@C_R5_YA[*E_S\_ ^N4AD SY;X_W34J5\M>$_P!EGQ=H
MGB33-1N/$NES06MPDSQI<:F690<D#=/C/UXKZF!R2?6N+$4J=)I4Y\WRL8U(
MQC\,KDZ582JZ5.IP"?09KE,B60R"&0PA#-M.P2$A=V.,X[9KY^'[(=I/X=EU
M>75+@?%*2_.M_P!NIJ-V+-=0#[D(M]^S8J!8_N9VBM_2OVH-&U"UCU5O"?BF
MR\*&]?3W\2W=G$EG',LAC.Y1*9?+W#'FA"HSR>N)(?VI]#DT./4U\,^(%CO-
M0DTS2H9EM89-4GC9UE\K?,%6--C$R2%%QTS0!<NO@MK6H^ /B)H\EYIT.I>*
M=3_M!)(S(8HLI$"K'&3@QMC Z$53\3?L_P"JZY>:[.^H6QMK_P 26^M>7%O\
MWR(X51XQD8\PE3CG'(R:M6W[4_AZ]M[*&QT/6M0\03ZBVF2>'[<VINK>98_,
M.7,_E."GS+L=B_0#/%2ZS^U=X5T+6-0MY-,U:XTC2YUM-3UR(VHM[*8@$HT;
M3"9]FY=YCC8+GO0!XOH.J>-/&EQ\//AU##!)IWA_5[9KD'0KZTOXK6!CAKDR
M(+> A0/FCDD\P_= S79>%/V1=5T'5M/TV73_  U=Z#8:FU^FLW.H:A-=S1^:
MTJI]B+"!)0S8\T,1QD)FO0Y/VH]$CU;4H5\-^)9M$TK4DTO4/$*VT7V&VE8+
MM.3+OD3YURR*=N><5S</[0>NM\0==TK5+:^\/:;IGB6#3;>3^S[>X%Y$8MQB
M+"?*9Z[\<#'&: .MTKX&:KI_@3P3HGVVQ^TZ'XA&L7$B[]DB?:7E*KQG=AP.
M>,U[;7B/A+]JSP]XF_LJ[N/#WB+P_H&K13OI^MZO;11V]P859I% 61G4X5B"
MR@-C@U-H_P"T]I^HZUX:M+OP7XLTBP\37*VVC:M?6<(MKO(W*YVREXE(Y'F*
MI((P* /:**** "BBN&^(_P ;O!/PDELX_%FNQ:.]X&: 20R/O Z_<4_K43J0
MIQYINR\SJPV$Q&-JJAA:;G-[**;;^2U.YHKQ+_AM'X,_]#O;_P#@)<?_ !NC
M_AM'X,_]#O;_ /@)<?\ QNN7Z]A?^?L?O7^9[O\ JOGW_0!6_P#!<_\ (]>U
MP[=)N23M^7J3COZY'\Q5N#_4IW^4?RKPO5?VSO@[)ITZQ>-H3(5X"6ESG]%'
M\Q5B+]M'X-"-0?&]OG SFTN/_B*/KV%_Y^Q^]?YB_P!5\^_Z *W_ (+G_P#(
MGN%%>)?\-H_!G_H=[?\ \!+C_P"-UYMKO[<OAW1/BGI_V/Q%I_B'P-?HL$B6
MEI+%=Z?+G_6,74>8A]!T]*SGF.$II-U$_1I_J=N%X-S_ !<I0C@ZD6DW[T)1
MO;HFU:_9-J^RULG];45!97D.H6D-U;R"6"9%DC<=&4C(/Y5/7H[GQK3B[,*C
MN%+P2*!DE2!^55]7^W_V7=_V6;<:CY3?9S=AC#YF/EW[>=N<9QS7SY^S'\??
M%OCSPKK.M_%&^\%Z%#%K$VCV(TR66W\V6)MKY-Q(<Y/W0O/K0(^;=$_87^)7
MAF]\'ZSH\<6G2S^)Y+_Q/I/VR)D=%F=K:\4[MI<*P!53DCM78_!']F;X@>$?
MC7X?U:]\'V_AVYTJ^O;C7/'<>N"YD\3PRDF.(P@[QC()W@!<8%>_Z=^U?X;U
M[QU=:!I7AKQ=JNF6EV]C<^*[/2#)H\$Z#+JTP;< O=]NT'O7F&O?\%#?!6K:
M)XIA\)17@URTT^ZNM(N=6@C^QZBT'#[0DQD ]!(J%ATS3T%J?5[=#43]Z\4_
M9?\ C;KOQIT_Q9-KEO8P/I6H16L'V&-D#(T"2$MN8Y.6/IQ7M;]ZVB0R%NIJ
M-NE2-U-1MTK1$,A:HF[U*U1-WJT2R!JC>I&J-JT1)!*B2HR2#=&P*L#W!X(_
M*O)]'TJ74/ACXC\,[B;[19YH(#GY@8V\V _D!7K+=ZX73?\ B5?%O6[?&(M3
ML(+T#U="8V_0"NRA)J,K=+/[G_P3FJ*[7W?>>L^!=>7Q1X/T?55.?M5LDA.?
MXL<_KFMVO,O@-*;3P_J^B,3G2=4N+=<GI&6W)^AKTVO(KP5.K**VN=]*7-!-
MA2=:6BL#43%+110 AX%?&,G[<>NQ_M-?\(4='L1X6_M+^RMQ5Q=;\[?-W9Q]
M[^''3O7V<:_,+XY^*O"WC;]IF\TW0/!$,6L2:HME_:K:Q=6IEN0VWS2L7"<]
MQSWKW<JH4Z\ZD:D+KE^[SW1W86$:CDI*^GW'Z>@_7\JXWXG7;'2K2P3<6O+A
M0P _@7YF_D*^9/\ AF#XN?\ 05M/_"YUO_XFN4\0?L_?$Z'6ULYM4MGEAA$G
M_(Y:O(!N/8L,@\=!6/U.A_S^7X?YD>QA_/\ U]Y]%^6]UXAC78VRUA+GY3]Y
MN!^@_6MQ(W_N-_WR:^1=.^ GQ(NS<2QZE;?ZPQDGQ;J@)V\=0.1]:T%_9[^)
MQZ:G;?\ A8ZM_A2^IT/^?R_#_,7L8?S_ -?>?64<;_W&_P"^34R@@X((/H17
MR6O[/'Q//_,3M?\ PLM6_P *^@/A!X7UCP?X*MM-UR9)]021V9TOY[T8+9'[
MV;YS].@[5SU\/3I1YH5%)_UYLB=.,5=2N=Y'4Z=*@CJ=.E<)@6$JQ'VJNE6(
M^U $Z582JZ582@"PE6$JNE6$H E'2EI!TI: /"?VS/\ DCL?_88L/_1PKV^Q
M_P"/.#_<7^5>(?MF?\D=C_[#%A_Z.%>WV/\ QYP?[B_RK@I_[U4](_\ MQ]9
MC/\ D0X/_KY6_*D3UPGQVU^;PO\ !SQEJ=NVRXM]+G,;_P!UBNT'\S7=URGQ
M5\+/XV^&WB;0HO\ 7:AI\T$?^^4.W]<5TUE)TI*.]F>+EDJ4,=0G7^!3C?TN
MK_@?B=(Y>1F8Y).2:;4][:R65W-;S(R2Q.4=6&""#@BH*_$S_3]--)H*Z3X;
MSZ;;>/\ P])K%I%?Z4+^$7=O-]QXBX#@_@37-TJG:<@X([BG&7+)2[&5>E[:
ME*DW;F35UOKV/O[PO^R/X4N?&_Q<M=0TNW@LYY!9>&DE)"PRRP-.IC.>2H9?
M7A37C?BGX#I+\./A'X3T'08I/B#XE>YO+JZDRDBPACL#D_=15))X_@KJOB3^
MV3INMV7P@DTB6X:\T2Y@O]<#0E,RJBQLJG^/Y3+R/455\>?M=Z))^U#H/C?2
M(9]2\+Z;8#3VA,1AD,;AO-**<8(9^.F=OO7UU:67N+C%I:I7\I-2;_[=U1_/
M.6T>,(5(UJT92?)*:BV[<]&$J48O;2JW&I9M7:OYGGWCG]DO4?#/A;5]:T3Q
M=X?\8KH;!=8M=(G+367."2I^\H.<G@\'C@XT]5_8OU;3_%OAWPM%XOT*\\1:
MTPDCL(O,#06OE,[3R9' &T@+U)Z>VU<_$GX1?"7PAXW'P_U;6O$6N>+(#9"+
M4+4PQ:? Q)8,2!O89(!&>W3G-#QW\8/!7C']I'0O%"^(=<T?0+6PMX3JFDP;
M+J"9(BN0K?PANO!R,C!S7%*E@H[VNW'12T6KOKZ6]#Z:AF'$]9M1<U34:C4I
M4;2DU"'*G"UTN=R2M9S2LKVN^3O/V7=3NOB;IG@[PWXFT+Q/+>6[74E[9SE8
M[*-"0YN 1F,C'3DG(]:9X^_9HN?#'@ZZ\4:!XKT;QIHUA<+;:C+I3.'LW8@*
M65ARA) W U[=J'[6_@GP]\9O#FO6$EWKP&CRZ3KOB2#3DL[BZ+LK),L1X+(4
M'4<[B!T%<U\</VA]/U?X?W>BZ1\5O$GC*?49E2:VNM%MK.U6VR"4<^6'+@@8
M*G\J=2A@(PJ-2NU>UGY*UKO77?XO4SPN:\65<5A(3I.,)*/-S0>OO24W+EI^
MZ^5)QYG2W3<7=I4+[]@W6K2^N=)3QQX:G\1_83J%IHJ22"XN8@,DX(^7G@$Y
MS["N&\!?LS77B7P99^*?$7BK1_!&D:C.UOISZL7+W;J=K%54<*",;C_*O5V_
M:1\$']KFT\>_;[L^&H]'%F9OLC^8)/(*8V=<;N]6_A7^U-H2_"O0_#%]XXUC
MX=ZAH;R1_:]/TJ.^BU"W9BR@JR,4<#CT[\YP-%1RZ51ZV2YDM=[6L]6N[ZK8
MY)9GQC1PD7*+E*2I2D_9V<.95.>*483;LXPO[DFN9Z).\?(](_9'\8WWQ0U;
MP?>3Z?ID>DVHO[W6KB;_ $*.U(RLP;J0PS@<=#G&#7>>-O@;H'P__93U?5X-
M0\/^+KR7Q!"+/Q%I7SL("@5HBQY7#*V5]P>]/TG]IKPWK/Q%\<Z=XNU;7]9\
M$^)=,71TUBYMX4OK9$+,CE(E"E=SOV)^[D=165X\\=?"GP[^SGJ7P]\$ZYJV
MMZC/K,6HR75_9-"DV%P2@Z*  HP>2<FHC#!PIU)4VMI;O7R2773J=-3$\28G
M%X2EBXR24Z#:A3?(U9.I*4]XM2T<';3H[W7S+1117S1^VA7OO[#7B*?0?VDO
M#4<3E8M12XLI@/XE:)F _P"^D4_A7@5?2?[ /@N?Q-^T#8:FL9-IH5K->RR8
MX#,IB1<^I+D_137HY>I/%TE#?F7YGQ_&,Z-/AW'RK_#[*:^;BTOG>UO,_4H<
MBB@<45^Q'^;@M?%?[;WA/XA^%?CC\(?C7X0\'7'Q)TGP<+JWU#PU: O<1B92
M/M$2 $EL$_,JDJ40D8R1]J5\+_\ !07X@^,M2^(O@GX3>'/%]WX"TO6-&U;7
M=0U73G,=W=FT@>2.UB<$%=QC.0""=PZXP0#-^#,WQ'_:@_;-\._&&]^&^K?"
MWP9X4T:XTW=KJ&*\U5Y5<!"I52RJS[NA5=G7+ #[Y[<U^=/[*GQQ\<:=\3?V
M:_"ESXDDUKP[XN\ 3R7VEW+&6>"YA>>07CNQ+$OL" DXVAA@X!K[8^._Q6;X
M)_"K7?&:^'=3\5-ID:.-*TE-T\VYU3C@X4;LL<' !.* /B;]H2X_9CB_:.^(
M_CGQAX6UV_\ $7P]M-/OM4:VD TS4[Y]JVUNT9/S38,> <*P5R<A&SZ3^P/X
MW\!>//B!\8=9TOP=XD\$?$74[VUU'7],\37)N)!%*C- 86*J5C.6;81QO7!V
M[0/G#XW:[\*/%'Q[L_B%KWP"^,.HZK<V^G:K>Z;86H&F7LWD1R1_:(]I+,@8
M(P# $J<CDY^EOV$]8\,>-/B/\8/&.E^!O'_A77=?N[6]U"X\<1[0X(D"PVQQ
MG8A#$@YP&0#A10!]1_$S_DG?B?\ [!ES_P"BFKC?V5/^3=_ ?_8-3_T)J[+X
MF?\ )._$_P#V#+G_ -%-7&_LJ?\ )N_@/_L&I_Z$U<#_ -\7^%_FCZRG_P D
M[5_Z_P /_2*AZO1117>?)D;5$U2M4352)9"_0U^''_!2O66\._MW:CJBC+64
M>F7 '^Y$K?TK]QWZ&OPL_P""HFG7.K_ML:[8V4+W-W<6NG10PQC+.[0J ![D
MFF]@1^V/A+Q58>.?"NC^(]+F6XT[5K2*^MY$.04D0,/YX_"M)NE?D%^P9_P4
M"?\ 9U#_  J^+$-[;>&K2YDBM;]XF:?1I=Q\R&6+&XQ[LG ^9#G@@\?JSX-^
M)?A+XBZ5%J7A?Q-I'B"QD 99M/O8Y1^(!RI]B :TC),AJQOOUJ)NE.:://\
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MG"Q1L6W@@%6(!4C-??GP;^"/A?X%^')M'\,03K#/+Y\]Q=R^;-,^, LV!T'
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M/[S$UC1=/BTRX=+&V5@O!$*@CGVQ_.K46A:<T2$V%J25'_+!?\*?K8+:5<@
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MZ"'B7_P-A_\ C5'_  [A^%W_ $$/$O\ X&P__&J/]7\;V7WA_P 1@X8[U/\
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M5]0*<DGUJO'4Z5QU\34Q+3J.]C&I4E4UD6$JPE5TJPE<ID3I5B/M5=*L1]J
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M5[?8_P#'G!_N+_*N"G_O53TC_P"W'UF,_P"1#@_^OE;\J1/1117>?)A1110
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M^T6VK^%/$&F^/?&ML\ME<1M97&N:@BS,C@[EWR,"X! ]<9KL?B_^UIX;\1?
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MX8J.01SC)]2H **** "BBB@ HHHH **** "BBB@#FOB9_P D[\3_ /8,N?\
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M&3_"O;*HZUKVF>&[!K[5]2L])LE(#7-_<)!$I/0%W( _.CZCAOY$'^M6=_\
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MY>'_ .^13AX<0?\ +=O^^16S10!E#04'_+9ORJ1=&5?^6I_*M&B@"B-+"_\
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MV(339Y;V QQ;L84E-X7U4''%>O\ PL\%WFE_$/\ :#U"XT:>U_MG68FM;B2
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M7@U]#FNX=-$3Q(#++*GR%V<L&\P[O2OT!7X]Z-#<::)(+RUT[4;B&WM-3-Q
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M!DC[C\;NAYKL' 8$$ @@@@C(->47&AV7A/49?".IQ>=X)\0,R6(8\65R?F,
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MG3(+^99EL;=_F6WA? 8PKGY Q8@'&<5^?OB[X=_%;Q7\-M#?4;3Q1XL5=/\
M%<6GF]TF\2ZM8);.-((7^T%IF#.&\LR'>02.U?I#X0MY;3PCH4$T;131:=;(
M\;C#*PB0$$=B",5<=R'L:3U$U2O435NC,\NAT>U\.>(;_P &W]N)O"GB<32V
M$;#Y(;A@6N+7V#C,J>X<#M7:?"+Q#>)#>^$=:F>;6=#"*ES+]Z]LVSY,_N<
MH_\ M(3_ !"N ^,7P*_X6E=1W\?C#Q'H=Y:P@VEKI]X([59UR4E*8SNR>2#G
M%>/#X+S7'@NV\9VGQ!\?-JUA_H^K6QU8&X@C1P+N&-@N<KMWJ#D, O'->TJ-
M'$TO>J6;MT>_1_-:/SU//<ZE&?NQNO7I_P  ^Y<T9KYWL/V5XM3L;>\M/C'\
M1[BUN(UEBE37 5=&&58?)T((--U+]E.6RT^YN%^+OQ(+11,X!UL8R 3_ '*\
MOZOAKV]M_P"2L[?:UK7]G^*/H._U"UTNTENKRXBM+6(;I)IW"(@]2QP!7/\
M_"TO!O\ T-FA_P#@R@_^+KX-USX-^(OB/^R*/&;>-?%&O:K,?-FT?4]83[!(
MD=P5.5E(!(5<@%NM?+Q^%>MY/_$CLO\ P/L/_CU>WA\DP]7G4\0DXNVW;U9Y
MM7,:L.5QI735]_\ @'[)_P#"T?!I_P"9LT/_ ,&4'_Q=2W7Q'\*6,QAN/$VC
MP2@ E)=0A5@",@X+=Q7XS_\ "JM</']A67/_ $_V'_QZI+GX)>*= F-EJ.B6
M+7: .Q&IV$G# ,O/G>A%=/\ 8&%YDOK*_#_,R_M2M:_L7_7R/V/_ .%I>#?^
MALT/_P &4'_Q=2R?$;PK%I%YJK>)=(&F68!N;P7T1BA!Z;V#87/O7XS_ /"J
M];_Z 5E_X'V'_P >KVGX%_!F2;X=_%"Z\3JVB^'(K&UFG?3)[6XGD,4PEV*B
M2, 2%(#,,#/>N/&Y-A\-0E5A74FNFG^9Z668J>.QE+#5*;C&32;6K7HK'Z%?
M\-(?"O\ Z*)X9_\ !I#_ /%4?\-(?"O_ **)X9_\&D/_ ,57Y=ZWH_A?Q'I,
M^H^$]/OM!EL7075GK>KPSQR1.=JR),ZQ[7#8!3D$'(Z5S T*X8@"72LGC_D+
M6G_QROF>1'[E#@K .ZJXB4)+=-1NON;7W,_6O_AI#X5_]%$\,_\ @TA_^*K7
M\+_&+P-XUU,:;H'B_1-9U J7%K8WT<LA4=2%!R<5^16L^"-6\/7IL]2BTZRN
M@BR&&75K/=M894\2G@@@CV->A?LV_".\^(WQ;TK3D\0?\(^D:2S27VA:U;I>
MH AXBVLS$GO@=,TG%=SEQ?".6X?#3Q$,9>ROLG^3/UAEE6&-I'.U%!))["O*
M=2UMKZ>YU^=',6/*L8<'.S. 0/5S^F*\F\5?LNM87=IID?Q>^)=S)< O.LNN
M!E6(=<C;U)P!6):_LP?;]2FA7XI?$,VEGM4,=8!/F^B_+QM'\ZC0_/?J^$_Z
M"/\ R5GOVA:9+8VS/."]Y.WFSO@_>_NCV X%:R5X''^RL0P/_"VOB3QS_P A
MH?\ Q->ZZ9:?8+"VMO/FN?)C6/SKAMTDF!C<Q[L>I/K0<M>G1IV]E4YODU^9
M?C[5.E01]JG2D<A93K4\=0)UJ>.@"PE<U\3?AMIOQ9\'77AO5;B[M;.X9':6
MR<)*I5LC!(('(]*Z5*L1]JB<(U(N$E=,Z,/B*N$K0Q%"7+.+3371K9G@L?['
M>GA %^)GQ&  P -?( '_ 'S3O^&.[#_HIOQ'_P#"@/\ \37O\?W:?7']0PW\
MGYGTO^MF=?\ 00_NC_D?/O\ PQW8?]%-^(__ (4!_P#B:/\ ACNP_P"BF_$?
M_P * _\ Q-?05%'U##?R?F'^M>=?]!#^Z/\ D?/O_#'=A_T4WXC_ /A0'_XF
MC_ACNP_Z*;\1_P#PH#_\37T%11]0PW\GYA_K7G7_ $$/[H_Y'S[_ ,,=V'_1
M3?B/_P"% ?\ XFC_ (8[L/\ HIOQ'_\ "@/_ ,37T%11]0PW\GYA_K7G7_00
M_NC_ )'SM??LBV-G:2S#XE_$=R@SM/B%AG_QP_RJ5/V/;!T5O^%F?$<9&<?\
M) ?_ (BO==<(&DW)) &WOCU]R*N0_P"IC_W1_*CZAAOY/S#_ %KSK_H(?W1_
MR/GF]_9#LK6SGF7XF?$8M'&S@'7VQD#/]VIOV5+Z]O\ X0V[:AJ%WJ=Q'?74
M/VF]F:65E63 RS<G@5[OJ_\ R"KS_KB__H)KP+]DTA?A I)  U.]))[?O36$
M:%.ABH*FK74OS1Z=7,\7FF18B6,GSN-2E;1:7C4OLEO9'LI(4$D@ <DGM7@/
MB;Q-K7[1?B:[\#^![N2P\(VC^5K_ (GA_P"6GK;6Y[D]"PH\3>)M9_:+\37?
M@?P/=R6'A&S?RM?\3P_\M/6VMSW)Z%A7T+X)\$Z/\//#5EH.A626.FVB;4C0
M<D]V8]V/4FKE)XQN$':FMWW\EY=W\D84J5/ANG'$XF*EBY*\(/54T]IS7\_6
M$'M\4NB#P3X)T?X>>&K+0="LDL=-M$VI&@Y)[LQ[L>I-;AZ4M(>E>C&*BE&*
MLD?%U:M2O4E5JR<I2=VWJVWNVR)ZB;O4KU$W>M4<Y"W>HG[U*W>HG[UHA$+=
M34;=*D;J:C;I6B(9"U8GBOPW:^+=!O-*O,K%.ORR+]Z)P<I(ONK8(^E;;5!*
MN]'7)7((RIP1[BM8MQ::(DD]&>4Q2:OXCT19T3R_'_A"X(8 8^TX'(]TF3D?
M[6*]J\(>*+3QEX<L=8LB?)N8PVQOO1MT9#Z$'(KY0^('[/9\+7L?B6+XB^.A
M;2W*Q:K,FJ@2Q0,<*RL%^ZC$<'. :=IW[/"Z!XXL]$_X6?X]LM&UB-I;.XM=
M7";KH?,ZOA<$LN&!QSS7KUL/AZ\%)5+=5H_FOU7D<%.M5IRLX?BOD_T/L7-&
M:^?O^&27_P"BO?$G_P '8_\ B*/^&27_ .BO?$G_ ,'@_P#B*\KV&%_Y_?\
MDK.[VE;_ )]_BCZ!S67K7BS1/#C1KJVKV&F-*,H+RZ2$L/;<1FOD3XY?!K5?
MAA:^%I=-^*OC^Y;5=:M]-F^U:T2%CD/)7"CYOK7A_P"V'^SMK?A/QWI;P:GJ
MGC*QGL<)=^(]6MI)XV#'*+YKH0O?@$5Z&'RRA6E!.O92O;3MZLY*N,JTU*U*
M[5NO<_1C_A:7@W_H;-#_ /!E!_\ %U-;?$;PI>NR6_B;1YW52Y6/4(6(4=3P
MW0>M?C-_PJO6_P#H!67_ ('V'_QZI+?X(^*===H=/T2Q$T:F=\ZG8)\B\MSY
MW/':O5ED&%BK_65^'^9Q+-*S=O8O^OD?L?\ \+2\&_\ 0V:'_P"#*#_XNC_A
M:7@W_H;-#_\ !E!_\77XV?\ "J];_P"@%9?^!]A_\>H_X57K8ZZ'98_Z_P"P
M_P#CU5_J_A?^@E?A_F+^U:W_ #Y?]?(_8WQ)\7/!/@\6AUOQ;HNE"[3S;?[7
M?QQ^:G]Y<GD>XK%_X:0^%?\ T43PS_X-(?\ XJO@GQU\/O#W@#X9_#34/'-C
MJ>JZK-H_V2#1]*U&*WBB17+>8]RJR;OO !%&/4UY!XE\*6MI?13Z-/$='O85
MN;1=5U"UBND1NJR LN2#D;@ #UKX^I2C"<H)W2;5^Y^UY-PQA<RP5+%5ZLJ?
M.NRY;]4M;Z>:5];'ZJ_\-(?"O_HHGAG_ ,&D/_Q5'_#2'PK_ .BB>&?_  :0
M_P#Q5?E%H_@?5_$%R]OIL.G7LZ1-,T<6K6>0BC+-S*. .35#^PY_^>VE?^#:
MT_\ CE9\B[GN?ZE98W;ZYKZ+_,_9OPMXRT+QOIO]H>']8L=;L=Y3[183K,@8
M=1E2>?:MC/U_*O@#]D?]FJZ\=^!-2U>7X@>(_#"2WS+':^$M=B$3!5 +2!-P
M#Y]3G&*]RD_8],,;._QF^)R(H+,QUX8 '?[E0TDS\_QV7X+"8F=!8FZB[?"_
MT/:/'&N2V%C'8V1(U"])CC8#F-/XY/P'3W(K@WLEO+F#1X(V%C:!9+G@_,>J
MH?K]X_A7B%Q^SH7M+C59/BK\2'&2EKNUH>8Z$X0$[?XCSCWK1L/V47C@5I/B
MM\1(YY/FE\K60 6/4_=I:'!]7PG_ $$?^2L^A44J.5('N*G2O'/!/[/9\'>)
M;+5_^%C^.M9^S$G[#JFJB6VER,8==O([U[&E(XZT*<)6I3YEWLU^9/'5A.HJ
MO'5A.HH.<L1]JG2H(^U3I0!92ITJ!*G2@":BBB@#PG]LS_DCL?\ V&+#_P!'
M"O;['_CS@_W%_E7B'[9G_)'8_P#L,6'_ *.%>WV/_'G!_N+_ "K@I_[U4](_
M^W'UF,_Y$.#_ .OE;\J1/1117>?)A1110 4444 %%%% !1110 4444 %%%%
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M')\?O%3(X*LIL+7D'KVI;WQ6)]&\*?$NVC:&33SMU.W'5;9SY=W&1ZQNN_\
M[9U]!1R++&KHP=& (93D$=B*G%8O$4Y*6FN_NQW6_3Y_,JC0I25M?O>SVZ_(
M^(_BY^QEXZTOX)7?AWPQX]UGQ;8VS1R0^%9[>WA@F E#L Q/4'+ $\D5\N']
MCKXO9_Y)G??]]VG_ ,<K]@:3:/05KA^(,7ATU:+N[[6_*QG5RNA5:=VK>?\
MG<_'_P#X8Y^+QX_X5G>_]]VG_P <I%_8I^,>E#[-+\.I[EU^8R6\]K(ASS@$
MR#IG'X5^P.T>@HV@]A73_K-B[WY8_<_\S'^QJ%K7?X?Y'X__ /#'7Q>_Z)G?
M?]]VG_QRO4_A#\!?C-\*O!?Q!U6Q\'3Z=J5Q:VL%O9.EO<->*)PTJ&$,P==F
MX$'&<X%?I;M'H*, =JYL5GV)Q=&5&<59]K_YG=@,#1P&)IXJ/O.+O9[/R9^4
M'BKX;?%3Q-:PV<'P<O?#E@DOGM:Z)H<L2S2X(#NTCNQP"<*"%&>!7-']GWXH
MN"H^''B?)XYTUO\ &OV$Q1BOGN=GZ[2X\QE"/)3H02_[>?XMW9^2GBW]G#XH
MZ=KLD7_" :[= PP$2V5IYT9_<H"-RG&0001VQ7HO[*/P9\>>&/CGH.MZWX-U
MG1=)T])YKB\U&U\B-%\I@.2>221P*_2;%<;\2=0)L[;2(VQ)?/\ O"#RL*\N
M?QX'XTN=VL<E?C3&5\%+!2IQLX\M];[6[G&7>L22PWNMR(6N+U@+>(]0G2)?
MQSN/UK3TBP_LVQB@+;Y!EI'_ +SGEC^=9:@:AKT<8 ^SV"AL#IYK#"C\!D_E
M6^G:H/STL)U-3I4"=34Z4 6(^U3I4$?:ITH LIUJ>.H$ZU/'0!82K$?:JZ58
MC[4 3Q_=I],C^[3Z "BBB@ HHHH **** *.N-MTFY.[;A>N<8Y]=R_S%6X3F
M%/\ ='\JJ:VQ32KDAMI"]<X[^N1_,5;AYA3_ '1_*@"MJ_\ R"KS_KB__H)K
MX7^")\6_&'PK+\._#PN-!\-V^HW3:]XAQM9T:4G[/ ?[Q'4U]X3PK<P21/DH
MZE6P<<$8K,\+>$])\%Z/%I>BV45A8QEF$48ZLQRS$]223U->?B,++$5(RYK1
M2:?=WMI^&I]AD^>T\IP5>DJ2G5E*$H-ZQBXJ2YK=6N;W4]+ZO:SA\$^"=&^'
MGAJRT'0;)+'3;1-J1H.2>[,>['J36[117=&*BE&*LD?*5:M2O4E5JR<I2=VW
MJVWNVPI#TI:0]*HR(GJ)N]2O43=ZM$$+=ZB?O4K=ZB?O6B$0MU-1MTJ1NIJ-
MNE:(AD+5!*I9' 8H2" PZCWJ=JB;O5HEGA>L? /QKK"WD,_QO\3M976]7MFL
M+4IL;JGTP<5P>G_!;QSKEIJVB2_%[Q -3\.S@V=D]M 8VVKFWD5OO ,.,\XZ
M<U]4M7 >-O\ BE?%VB>*4RMK*PTK4L=/+<YBD/\ NOQG_:%>U0QM9^[IY>['
M?[NNQY]3#4U[VOGJ_P#,X_P+\(O'WCGPO9:Q;_'SQ7#YZXE@:QM2T,@.'0\=
M0016]_PSI\1O^B_^*O\ P M?\*ZCP/=?\(?\3=2T1CMT[7D;4K,?PK<+Q.@^
MO#_C7K=<.(QE:G/W>6SU7NQ_RZ;'12P].<=;W7]Z7^9\R^(_V1?%OBZ.S36?
MC=XDU%+.X6[MQ-86W[J5?NN,8Y%?//[3O[(WQ8U7QK87MM/JOQ6A-F(_[0NU
MM8I;<AC^[VEEX[YK](*0@'J,U5#.,50FIJSMTY4M_1)BJY?1JQ<=5?S?ZW/Q
M_P#^&.OB]_T3.^_[[M/_ (Y2-^Q3\8]3'EQ?#J>W9/WA:>>U0$#JH/F')/85
M^P.T>@HVCT%>D^)L6U;EC]S_ ,SC634$[W?X?Y'X_P#_  QU\7O^B97W_?=I
M_P#'*!^QU\7@?^297W_?=I_\<K]@-H]!1M'H*K_6?&?RQ^Y_YB_L;#_S/\/\
MC\YO$WPX^+G@GP'X#\,S?#:/QEI%OI(\[2[BQ-['9W6]LD/#(KHVTJ" VTUY
M)KOP:^+7B+59]0N_AMXACFEP!%:Z.8H8E PJ(@.%4 8 K]=,48KY:I6E4FZC
MW;N?JN4\4ULGP\*%&C%\JM=\WY7M=]6EJ?DIX4_9O^*.HZI*G_" :[;!;.X.
M^\M?)0GRR H+'!8G@#O6,/V?OBBJ@?\ "N/$^0,?\@UJ_83%&*CG9[$>/L=&
MI*I[*&MN_2_GYGS#^P1\/O$G@'X=:]'XDT2\T*>\U,S0V]]'Y<K((U7<5ZCD
M'K7MWQ%U1A9P:1"Q6:_)$A!Y6%?OG\>!^)KL#@ GI[UY#J>MK?7VJ:Y)\T"Y
MBMQZQKP,?[S<_C4-WU/@,?C)YABJF*J))S=]-B((-0UJ*!1BUT\!F'8RD?*/
M^ CG\:Z!.@K(T"S:SL%\WFXE)EE;U=N3_A6NG04C@+$=6$JO'5A* )XZL)U%
M5XZL)U% %B/M4Z5!'VJ=* +*5.E0)4Z4 34444 >$_MF?\D=C_[#%A_Z.%>W
MV/\ QYP?[B_RKQ#]LS_DCL?_ &&+#_T<*]OL?^/.#_<7^5<%/_>JGI'_ -N/
MK,9_R(<'_P!?*WY4B>BBBN\^3"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KX5_;YT'5_!?QU^#7QHN_!UYX_P# /A$W,&KZ58P^
M?)9M+]RY$9X."5()X#1*"1D&ON>8.T+B-@LA4[2>@..*_,7XH^!OVOO#7QL\
M"ZCKWQN\%:?)%;WGDZM+>6]AI]LI4@B>UD5#<%L@*1')M)&2O6@#J_@KXC/[
M57[=V@?%KP)X%U3PEX'\,:)<6.IZWJEFMH^K32)(J1[5R'*[U[D@)SCY17Z(
MG...M?'/[-^I?'&X^*^F1>-OC[\,_'?ASR9S-H7AHV_VR9O+.QDV1*<*V&//
M0&OL8\ T ?FM^T=H_P"TI=_M(_$SPSX2TSQ/-I7CRVT[2M%U^SN'72=(L%VF
MZD<@8CESO7=E6 =\!BRX]3_8"^%WC/X/?$OXS^%KE/%"?#G3;VTM]$D\4MND
MNK@1G[1<0GIY;_*WR\89 ?F!KRW]HRR_:6G_ &C_ (F^%_".F^*I=+\=V^G:
M5HFNV4SKI&D6*[3=2N0,1S [UW95@'? 8LF/4_V OAKXV^$GQ*^,WA2\/BIO
MAUI=[:6VB3>*V+27-P(S]HG@/3RWRK?+QAD!^8&@#ZQ^)G_)._$__8,N?_13
M5QO[*G_)N_@/_L&I_P"A-79?$S_DG?B?_L&7/_HIJXW]E3_DW?P'_P!@U/\
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MQ/H&H:3/Q%=PM%N_NL?NM^!P?PK6:HWK6+<6FB&DU9GDC:G>ZS\-]/UM5/\
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MS_D0X/\ Z^5ORI$]%%%=Y\F%%%% !1110 4444 %%%% !1110 4444 %%%%
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M_L&7/_HIJXW]E3_DW?P'_P!@U/\ T)JX'_OB_P +_-'UE/\ Y)VK_P!?X?\
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MS_DG?B?_ +!ES_Z*:N-_94_Y-W\!_P#8-3_T)JX'_OB_PO\ -'UE/_DG:O\
MU_A_Z14/5Z0]*6D/2N\^3&-4+]*F:H7Z5:)(GJ-N]2/4;=ZM"9"_6HB2.Y_.
MI7ZU":T1#(W8^I_.HF)]:D>HFJT00N>*B)Q4K]*B-:HDA8UD^*9O(\-ZM(>
MEI*WY(:UFKE/BE>?8/AUXFGS@KI\^#[E"!_.MZ:YIQ7F9S=HMG(20$?"CX?V
MN/FDGT6/!]Y(C7TF!7@FKV?V9/AKI0'(U6P0K[0Q%S_Z!7O8Z5EC7?E\[O\
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M#X7ZL*K:CIEIJ]J]M?6L-Y;/]Z&XC$B-]5((-6:*XT[:HZ=SXT_:5\':_P"
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M^V?\+?BUXH^-7PO^(GP7C\-_V[X5M[R.6]U6^1"RS84PLC'#(5,G3!!8X(H
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MQ]JL)T% %B.K"57CJPE $\=6$ZBJ\=6$ZB@"Q'VJ=*@C[5.E %E*G2H$J=*
M)J*** /"?VS/^2.Q_P#88L/_ $<*]OL?^/.#_<7^5>(?MF?\D=C_ .PQ8?\
MHX5[?8_\><'^XO\ *N"G_O53TC_[<?68S_D0X/\ Z^5ORI$]%%%=Y\F%%%%
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MU,D;#J* )8_NT^FH"!S3J "BBB@ HHHH **** *.MY_LJYQG.WL#Z^U6X?\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:^)G_ "3OQ/\
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MO;['_CS@_P!Q?Y5\N_$WP_\ 'CXM>'[?0=4\'^&=.LOMMO=27%KJS,X$;AN
M>*^I+6,Q6\2-]Y5 /Y5&'DZE>I4Y6E:.Z:[]SIS>E#!Y5A,(ZL)S4ZK?).,[
M)JG:[BW:]G]Q+1117I'Q04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ibio-20230630x10k026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &@ Z@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH *\O\1?M%^$O#7B#4-&N5U6:]L7$<XM--EF525##YE!'0UZ>>E>1
M_"#_ )*G\6O^PA:?^B*]#"TZ4HU*E5-J*3LG;JEV?<[\-"E*-2=5-J*3LG;J
MEV?<9_PU)X-_Y]M?_P#!+/\ _$T?\-2>#?\ GVU__P $L_\ \37K^*,4_:X/
M_GT__ O_ +4?M<)_SZ?_ (%_]J>0?\-2>#?^?;7_ /P2S_\ Q-'_  U)X-_Y
M]M?_ /!+/_\ $UZ_BC%'M<'_ ,^G_P"!?_:A[7"?\^G_ .!?_:GD'_#4G@W_
M )]M?_\ !+/_ /$T?\-2>#?^?;7_ /P2S_\ Q->OXHQ1[7!_\^G_ .!?_:A[
M7"?\^G_X%_\ :GD'_#4G@W_GVU__ ,$L_P#\31_PU)X-_P"?;7__  2S_P#Q
M->OXHQ1[7!_\^G_X%_\ :A[7"?\ /I_^!?\ VIY!_P -2>#?^?;7_P#P2S__
M !-'_#4G@W_GVU__ ,$L_P#\37K^*,4>UP?_ #Z?_@7_ -J'M<)_SZ?_ (%_
M]J>0?\-2>#?^?;7_ /P2S_\ Q-'_  U)X-_Y]M?_ /!+/_\ $UZ_BC%'M<'_
M ,^G_P"!?_:A[7"?\^G_ .!?_:GD'_#4G@W_ )]M?_\ !+/_ /$T?\-2>#?^
M?;7_ /P2S_\ Q->OXHQ1[7!_\^G_ .!?_:A[7"?\^G_X%_\ :GD'_#4G@W_G
MVU__ ,$L_P#\31_PU)X-_P"?;7__  2S_P#Q->OXHQ1[7!_\^G_X%_\ :A[7
M"?\ /I_^!?\ VIY!_P -2>#?^?;7_P#P2S__ !-'_#4G@W_GVU__ ,$L_P#\
M37K^*,4>UP?_ #Z?_@7_ -J'M<)_SZ?_ (%_]J>0?\-2>#?^?;7_ /P2S_\
MQ-'_  U)X-_Y]M?_ /!+/_\ $UZ_BC%'M<'_ ,^G_P"!?_:A[7"?\^G_ .!?
M_:GD'_#4G@W_ )]M?_\ !+/_ /$T?\-2>#?^?;7_ /P2S_\ Q->OXHQ1[7!_
M\^G_ .!?_:A[7"?\^G_X%_\ :GD'_#4G@W_GVU__ ,$L_P#\31_PU)X-_P"?
M;7__  2S_P#Q->OXHQ1[7!_\^G_X%_\ :A[7"?\ /I_^!?\ VIY!_P -2>#?
M^?;7_P#P2S__ !-'_#4G@W_GVU__ ,$L_P#\37K^*,4>UP?_ #Z?_@7_ -J'
MM<)_SZ?_ (%_]J>0?\-2>#?^?;7_ /P2S_\ Q-'_  U)X-_Y]M?_ /!+/_\
M$UZ_BC%'M<'_ ,^G_P"!?_:A[7"?\^G_ .!?_:GD'_#4G@W_ )]M?_\ !+/_
M /$T?\-2>#?^?;7_ /P2S_\ Q->OXHQ1[7!_\^G_ .!?_:A[7"?\^G_X%_\
M:GD'_#4G@W_GVU__ ,$L_P#\31_PU)X-_P"?;7__  2S_P#Q->OXHQ1[7!_\
M^G_X%_\ :A[7"?\ /I_^!?\ VIY!_P -2>#?^?;7_P#P2S__ !-'_#4G@W_G
MVU__ ,$L_P#\37K^*,4>UP?_ #Z?_@7_ -J'M<)_SZ?_ (%_]J>0?\-2>#?^
M?;7_ /P2S_\ Q-'_  U)X-_Y]M?_ /!+/_\ $UZ_BC%'M<'_ ,^G_P"!?_:A
M[7"?\^G_ .!?_:GD'_#4G@W_ )]M?_\ !+/_ /$T?\-2>#?^?;7_ /P2S_\
MQ->OXHQ1[7!_\^G_ .!?_:A[7"?\^G_X%_\ :GD'_#4G@W_GVU__ ,$L_P#\
M31_PU)X-_P"?;7__  2S_P#Q->OXHQ1[7!_\^G_X%_\ :A[7"?\ /I_^!?\
MVIY!_P -2>#?^?;7_P#P2S__ !-'_#4G@W_GVU__ ,$L_P#\37K^*,4>UP?_
M #Z?_@7_ -J'M<)_SZ?_ (%_]J>0?\-2>#?^?;7_ /P2S_\ Q-'_  U)X-_Y
M]M?_ /!+/_\ $UZ_BC%'M<'_ ,^G_P"!?_:A[7"?\^G_ .!?_:GD'_#4G@W_
M )]M?_\ !+/_ /$T?\-2>#?^?;7_ /P2S_\ Q->OXHQ1[7!_\^G_ .!?_:A[
M7"?\^G_X%_\ :GD'_#4G@W_GVU__ ,$L_P#\31_PU)X-_P"?;7__  2S_P#Q
M->OXHQ1[7!_\^G_X%_\ :A[7"?\ /I_^!?\ VIY!_P -2>#?^?;7_P#P2S__
M !-'_#4G@W_GVU__ ,$L_P#\37K^*,4>UP?_ #Z?_@7_ -J'M<)_SZ?_ (%_
M]J>0?\-2>#?^?;7_ /P2S_\ Q-'_  U)X-_Y]M?_ /!+/_\ $UZ_BC%'M<'_
M ,^G_P"!?_:A[7"?\^G_ .!?_:GD'_#4G@W_ )]M?_\ !+/_ /$T?\-2>#?^
M?;7_ /P2S_\ Q->OXHQ1[7!_\^G_ .!?_:A[7"?\^G_X%_\ :GD'_#4G@W_G
MVU__ ,$L_P#\31_PU)X-_P"?;7__  2S_P#Q->OXHQ1[7!_\^G_X%_\ :A[7
M"?\ /I_^!?\ VIY!_P -2>#?^?;7_P#P2S__ !-'_#4G@W_GVU__ ,$L_P#\
M37K^*,4>UP?_ #Z?_@7_ -J'M<)_SZ?_ (%_]J>0?\-2>#?^?;7_ /P2S_\
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MM<)_SZ?_ (%_]J>0?\-2>#?^?;7_ /P2S_\ Q-'_  U)X-_Y]M?_ /!+/_\
M$UZ_BC%'M<'_ ,^G_P"!?_:A[7"?\^G_ .!?_:GD'_#4G@W_ )]M?_\ !+/_
M /$T?\-2>#?^?;7_ /P2S_\ Q->OXHQ1[7!_\^G_ .!?_:A[7"?\^G_X%_\
M:GD'_#4G@W_GVU__ ,$L_P#\31_PU)X-_P"?;7__  2S_P#Q->OXHQ1[7!_\
M^G_X%_\ :A[7"?\ /I_^!?\ VIY!_P -2>#?^?;7_P#P2S__ !-'_#4G@W_G
MVU__ ,$L_P#\37K^*,4>UP?_ #Z?_@7_ -J'M<)_SZ?_ (%_]J>0?\-2>#?^
M?;7_ /P2S_\ Q-'_  U)X-_Y]M?_ /!+/_\ $UZ_BC%'M<'_ ,^G_P"!?_:A
M[7"?\^G_ .!?_:GD'_#4G@W_ )]M?_\ !+/_ /$T?\-2>#?^?;7_ /P2S_\
MQ->OXHQ1[7!_\^G_ .!?_:A[7"?\^G_X%_\ :GD'_#4G@W_GVU__ ,$L_P#\
M31_PU)X-_P"?;7__  2S_P#Q->OXHQ1[7!_\^G_X%_\ :A[7"?\ /I_^!?\
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MF&[4?PFO%O#'[7GPJ\9Z/#JFE>)))K.;5K;1(VETZXA9KJX&8 %= 2CCD/\
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MN3;.Q2K$?2JZ58CZ4CA+"5.G6H$J=.M %A:L1]15=:L1]10!83K4E1IUJ2@
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M %%%% !1110 4444 %9GA[']EQ8QC)Z8]3Z5IUF^'FW:5$=P;D\@@]S[G^=
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M?6O[#_[95W^U_I/BJ]NO"EOX7.B2P1JEO?-<^=Y@<Y.Y%QC;[]:P?V'OV?\
MX8>*OV4/ASJVM?#GPIJ^J75C(\][?:-;S32D3R %G9"2< #GTKZ9\'?#7PC\
M.8KJ+PIX7T;PS'=,K3II%C':B4C[I8(!G&3C/K6D4][DNQO/435*]1-6Z,R)
MZA-3/4)K1$GGTH'A7XIKD8T[Q1!L8'[HO(5)'_?<>X?\!%=#\%[PZ'>Z]X,E
M;Y=,F^UV )ZVDQ+ #_<?>OT*UG?%#19]7\)W$MEQJ>GNFH6;#J)8CN _$ C\
M:RKKQ%;VVK>"_']HVRPN-EG>$' %M<8QN_W)-OY&NZ4?;4K=7I\UM]ZT.5/V
M<[_U9[_CJ>\T5Q/Q8^(LWPU\.6VH6NC2:_>W=];Z?;V,=S';[Y)7"+F1_E4
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M?^#7_P *_P#2HGKM%%%><>>-:H7[U,U0OWJD21-7YK?\%K/^2;?#K_L,3?\
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M$?\ L8A_Z3R5^@[5^>__  6>_P"3??"7_8PC_P!)Y*;V$>L_\$S/^3*_ /\
MV^?^E4M?3[5^=/\ P2%_:,T?5OAS<_"+4KR.U\0:5<37NEPRN ;NVD;>ZIGJ
MZ.6)7KM8$=#C]%F.:TB[HAD+U$U2O435LB"%Z@E!*.  201ANA^OM4[U$W>M
M$2?.<WPB\8M(Y'PX^#6"2039S9Z_]<ZXW2OA#XJ;5?$_A5_ _P +6N&4WWG3
MP3AHX;K> () F[;&RN!GE3@#C%?7+UP?C/\ XD?CSP?KH^6&YDET&[;_ &9Q
MYD!/TFB _P"VGO7MT<=4=XV7X[K7O\CS:F&@K/\ R_R/*_AQ\,_&7B'PO#Y'
MPX^#<\NGR2:9<O?Z?*+@S0,8G:3;$1EMN[CJ&![UT4_P4\<JO/PR^" ^EC/_
M /&J],^'ET=!^+'B;1R2MMK=I#KENO;SDQ;W/X_+;M_P(UZI<)O0UQU\?5A5
MT2L]>O7Y]-CIHX6$HJ[>FG3_ "/DFZ^#GC1<Y^&WP77_ ';.<?\ M.O ?#G[
M3$7PX^(-S9^(/A?X>\.3).;>Y?2+0VUY;\X+#?G<._&W(Z&OT6OX/O9Z>M?*
M'QS\8:'\0C/I-GI]K?:=EK*36/LD<]S=2'C[/9%@3N!/,@X7^?L9;B'BI.G4
MIW3ZIM6_/[CU:658C$-/!3M*.NJ37Y:'9>&_BIX,\;:D;30O%&FZE=YXMXIL
M2-_NJP!;\,U\H_M1>/H-1^,\^AIX5T.YGL/)LC?7]L\D\S,%;DJZ_*-X ')Z
M\U8O_P!AOXBV-_:3Z/<Z?/&VV6.6:[^S7%JW7#C!PRGNA/(XKZSLOV=?#&LZ
MSX>\3>*-.BUGQCIUM;I/J*NZ1W,T:@"1X\X8@C()'UKJG+"8*:J4Y\Z:>G5,
MZ\!CL14<HXNERM=5L_Z]6>56W[$VJ2?\Q7PB#Z-HEW_\E5JV_P"PMJT@&-5\
M&G_N!7G_ ,F5]565N<C/)KH+.+8N:^;J9IB5M+\$;5,346S/B[7OV)]2T'1[
MN_FU3P:T<$9?:-!O,L>P'^F=2<"N.N/V0=2@6SMCJ?A@RW+[,C2+K<O!9B3]
MIYQCTK[2^)UX9!I6EJ>)YOM$H]8X^>?^!%*XNW_TOQ#-(>4M(A$/]]_F;_QT
M+^=<_P#:N+_G_!'/]:J]SYT7]C;42/\ D*>$Q_W!;O\ ^2J]P^"?PRF^%?AB
MYTN>XTZX>:Z-QNTRUDMXP"H&"KR.2>.N1]*[=.E6(ZPK8[$8B')4E=?(SG7J
M5%RR9.E6(^M5TJQ'UK@,"PE6(^E5TJQ'TH L)4Z=:@2ITZT 6%JQ'U%5UJQ'
MU% %A.M25&G6I* "BBB@#D_BO_R3;Q+_ ->$W_H)JM\%_P#DE/A7_L'Q?RJS
M\5_^2;>)?^O";_T$U6^"_P#R2GPK_P!@^+^5>C_S!?\ ;_Z'H?\ ,%_V]^AV
MM%%(3@$UYQYYQ?Q:^+GAWX,>$;CQ!XBNO)MT^6&"/F6XD[(B]R?R'>OSE^*_
M[>/Q(\?7T\>AWY\':/DB*#3L&X*]B\Q&<_[N!6-^V9\7[KXI_&/4[=9V.C:)
M(UC9PAOEW+_K'QZD\?A7@]?H>6952I4U5K1O)ZZ]#Z##86,(J4U=LZVX^+_C
MRZE:27QMXCD=N2QU:XY_\?J/_A:_CC_H=/$7_@WN/_BZY:BOH/94_P"5?<>A
MRQ['4_\ "U_''_0Z>(O_  ;W'_Q='_"U_''_ $.GB+_P;W'_ ,763J'A?6-)
MTJPU.]TR[M-.U $VEW-$5CN .NQN^*S,4*%-[)!RQ?0ZG_A:_CC_ *'3Q%_X
M-[C_ .+H_P"%K^./^AT\1?\ @WN/_BZY;%&*?LH?RK[A\L>QU/\ PM?QQ_T.
MGB+_ ,&]Q_\ %T?\+7\<?]#IXB_\&]Q_\77+8HQ1[*'\J^X.6/8ZG_A:_CC_
M *'3Q%_X-[C_ .+H_P"%K^./^AT\1?\ @WN/_BZY:C&:/90_E7W!RQ['4_\
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M%T]SA3_P5D_9];_F)^(A_P!P5O\ XNMW0?\ @I/\$_$I L;[Q V>GF:,Z_\
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MT?PUX:U'6;NXATV6]U#48-&TN'46G64QF%X+F=(56,CYVBSGL5'- '2?$?\
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ML'QI>>(+'0Y)?#-A::EJH=0L%].88RO<EA5PCSR45U[Z%1CSR45U-ZBO'O\
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MUOD4[QG!!&<"O;QKH9G3Y<-4DW37VM>;T^[<O*\#52J3J63Z)(_3ZLWQ)/\
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M6%:GA8PO2FV_0SG&DE[LKL[A*L1]:KI5B/K7 8%A*L1]*KI5B/I0!82ITZU
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M:*_D_'_@'X5T5^ZG]CV/_/G;_P#?I?\ "C^Q['_GSM_^_2_X4?ZQK_GU^/\
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M110 4444 %9V@,6TR,DDG)Y))[GU)_G6C6;H *Z9&""#D]0?4^H% &E1110
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M_;^+9;$>45UZ.6RU*/'&UY /F^KH3[U^SCUS/B[X>>%?'T0B\3^&='\11@8
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M?Y\SL98JC4]V5:+G%=G^ED?6_A']E/X9_#][B[\/^&+:VU1XW2*^N7>XDA+
MC*&0G;C/48-? OPY_M+]F+X_SZKJ3Z9J\>G2W$,L=IKEHC2J^0"=[C:><D-@
MUZ3X)_X*->)9[F2R\8:+I]QIMTK1?;=*5X9K?<,!MK,P<#.<<&H?V2_V:O%D
M7QS.O^)?#[-X<MTFN%O[R-7@OO,!,;1YSOR&#9QQWYK>%'$X*%9YA*Z:ZN]]
M]$[W_P"'/H\JQ.%G2J*E9+JK6/6_^'AFD_\ 0I+_ .%+IW_QRHKO_@H+I%U:
MS0GPFH$B%<_\)+IW<8_YZ5]0_P#"O_#'_0N:3_X Q?\ Q-(?A_X8_P"A<TG_
M , 8O_B:^<^L8'_GQ_Y,SK]I0_D_$^&9?VQM+;2(K?\ X1T[HBI#?V[9?PGT
MW9K8'[;FD@Y_X1@_^%#8?_%5[7?^!]$B.MV7]B::&BFE5?\ 0HL@'YA_#5K2
M?"^@W.G6LIT/2R6C4G_08NN.?X:7M\#_ ,^/_)F+GH?R?B>'#]N#2!_S+!_\
M*&P_^*KZ+\)Z\GBGPYINKQQ>1'>P+.L?FI+M![;T)5OJ.*JKX/T#_H!:5_X
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M5TJQ'TH L)4Z=:@2ITZT 6%JQ'U%5UJQ'U% %A.M25&G6I* "BBB@#D_BO\
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MT :6Q?[J_P#?(HV+_=7_ +Y%>$2_M33:-I,]QXB^'VKZ%>2:3_;.FVK:C:7
MOX=Z(0)$;$3 R)D. ,'K74>&/C7=77B;2] \6^"M5\$7^KHSZ9/=75O>VEXR
MKN:-9H&.R0+SL<#(!P3B@#T_8O\ =7_OD4;%_NK_ -\BN2^)WQ ;X;>'[;5_
M['GUFV>^M[.<6UQ'$UNLLBQB4[S\P#,,JO-=>.: &[%_NK_WR*4*%Z #Z#%+
M10 4444 >7>,?!VK>#?$$OCCP/$&OR,ZKHJ\1:C&.K*.TH['O_/T_P  >/\
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M&,M@8&:?]@MO^?>+_O@4@U*T;&+J$YZ8D'M[^X_,4?VE:?\ /U#_ -_!_C0
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M ,7O'7AS1?!&EZ#HFFWFB?VOJ=UKT<UQ-9,DYBF@5(G0.=RL V0!P3GI7/\
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M9+[^WN:M44 5?[+LO^?2#_OTO^%']EV7_/I!_P!^E_PJU10!5&EV0_Y=(/\
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M#T]!4'_#2/PY_P"AC7_P$F_^(H_X:1^'/_0QK_X"3?\ Q%']GXS_ )\R_P#
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M &YB#WZ>]?,_Q#T+XO?!?X]^)O'4/PQU;XBQ^-_"-OI5PWATJWV.^6(J_F
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M#X3?'?X3^&;/4O#&H^,/#+V.DS :7J$MS$5GLWRT<98]7B^:,CT5#_%7>_\
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M]A"T_P#1!KUSM7D?P@_Y*G\6O^PA:?\ H@UZ.&_@5_\ "O\ TN)Z&'_@U_\
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M58CZT 65J=*@6ITH L)VJPE5T[582@"=.@JRE5DZ"K*4 3QU)4<=24 %%%%
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MA%<WETUM\19X;*6X>XCMI=)$@0LQ89Q,%+#/WMH-0?\ #LQO^BDM_P""-?\
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MDM-*W )Y)+'UK<T+Q%I7BC38M0T;4[/5K"4L([JQN$GB<J<-AU)!P00>>"*
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M&4+9O=+;AAW.]ACBMRBKA)1DFU?R_P"&*BU&2;5_(\C_ .$_^*__ $2VV_\
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MM_Q77C)CCI_::\_^.UYEX.^,>L_#W5;NQUB;5=2T:U<I?6&K$2:GI/.!*&4
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M1/A!\6/!MM\,?#4-WXOT*WN(K*.-XIM3A5U*C&""V1TKYLT#X8^*I[SQ:8_
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M]CWXR6/PF\'_ !Q^%KWFJF7S9S'H+,FI:<\4KQDA <RH0F<IGJ05QU]$L/\
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MR/X0?\E3^+7_ &$+3_T0:]<SD9KR/X0?\E3^+7_80M/_ $0:]'#?P*_^%?\
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M0UXYV'B%T<VVD2>DL1_,5OK7-3DCP[:2=X6C)_!L5TJ\F@"S'VJ=*@C[5.E
M%A*L1]:KI5B/K0!96ITJ!:G2@"PG:K"573M5A* )TZ"K*563H*LI0!/'4E1Q
MU)0 4444 %%%% !1110 5F>'5VZ5$-H7D\ 8[GV'\JTZS/#Q!TJ(C&,GICU/
MI0!IT444 %%%% !1110 QNE1-UJ5NE1-UJD)D35^?'_!9W_DW[PC_P!C$/\
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MUBS_ *BQ5P"7(^]*1D9[=3[?)^S<-I/_  GGBUSCI]KBY_\ '*\U\&?%[4_
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MI?-7M]R.'%8>5)JM!*26Z:N_D[7/L.V\ ^&+/4?[0M_#FDP7^<_:H[&)9?\
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ME:I<VD4MU8DY,$K("Z?@216MBEKRLQS+^T>5NFHM=5U/D<+A%A7+EDW%[)]
MHHHKQ3T#@/B9:^3J&C:@  "[V<A]G&5_\>0?G7(V)^S:[?0]%N$2Y7ZCY&_D
MM>F^.]+?5O"M]%$,W$:":+CG>AW+^HKRV[N4:72=4CXB9@C'_8E&/T;;0!T"
M=*L1U73I5B.@"=*L1]:KI5B/K0!82K$?2JZ58CZ4 6$J=.M0)4Z=: +"U8CZ
MBJZU8CZB@"PG6I*C3K4E !1110!R?Q7_ .2;>)?^O";_ -!-5O@O_P DI\*_
M]@^+^56?BO\ \DV\2_\ 7A-_Z":K?!?_ ))3X5_[!\7\J]'_ )@O^W_T/0_Y
M@O\ M[]#M:***\X\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $/2O(_A!_R5/XM?]A"T_\ 1!KUP]*\C^$'
M_)4_BU_V$+3_ -$&O1PW\"O_ (5_Z7$]##_P:_\ A7_I43UVBBBO.//&M4+]
MZG(S3#$#W-4F(K-41JZ;=3W-,-FI_B-4FA6,]ZA-:AL$/\34TZ;&?XFJU-$V
M9D/435M'28C_ !/^E-.C0G^-_P Q5*I$GE9A/4)KH3H<!_CD_,?X4T^'[<_Q
MR?F/\*M58BY&<!XW\1+X4\+:EJA&YX(CY2#J\AX11[EB!7$7?AN>P\'>&? J
M.3J>MS"*]D7K@DRW<GY;A^5>M^)/AM8^)FTL7%S<+!97D=X85V[9F3E5;(Z
MX/'I4]MX!M+?QG'XB:XFFN(;-K2&&3!2/<P9W'&=QP!]*ZX8FG"&F^_SZ?YG
M/*C*4O+;_,Z2W@CM8(X8D$<4:A$11@*H& !^%2445Y!WA2$9&#TI:* ,+3_
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M1U$:Y'Z5\I^*?!_BOX5^/+2]AOI&OKF;R=,\2&/]W>EFXLM051CGHLN/3/\
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M_GZ__ ?_ +8]>S]?RHS]?RKR'_AE[PE_T$?$G_@ZG_QH_P"&7O"7_01\2?\
M@ZG_ ,:/98/_ )^O_P !_P#M@]EA/^?K_P# ?_MCU[/U_*C/U_*O(?\ AE[P
ME_T$?$G_ (.I_P#&C_AE[PE_T$?$G_@ZG_QH]E@_^?K_ / ?_M@]EA/^?K_\
M!_\ MCU[/U_*C/U_*O(?^&7O"7_01\2?^#J?_&C_ (9>\)?]!'Q)_P"#J?\
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M?$G_ (.I_P#&C_AE[PE_T$?$G_@ZG_QH]E@_^?K_ / ?_M@]EA/^?K_\!_\
MMCU[/U_*C/U_*O(?^&7O"7_01\2?^#J?_&C_ (9>\)?]!'Q)_P"#J?\ QH]E
M@_\ GZ__  '_ .V#V6$_Y^O_ ,!_^V/7L_7\J,_7\J\A_P"&7O"7_01\2?\
M@ZG_ ,:/^&7O"7_01\2?^#J?_&CV6#_Y^O\ \!_^V#V6$_Y^O_P'_P"V/7L_
M7\J,_7\J\A_X9>\)?]!'Q)_X.I_\:/\ AE[PE_T$?$G_ (.I_P#&CV6#_P"?
MK_\  ?\ [8/983_GZ_\ P'_[8]>S]?RHS]?RKR'_ (9>\)?]!'Q)_P"#J?\
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MG_@ZG_QH_P"&7O"7_01\2?\ @ZG_ ,:/98/_ )^O_P !_P#M@]EA/^?K_P#
M?_MCU[/U_*C/U_*O(?\ AE[PE_T$?$G_ (.I_P#&C_AE[PE_T$?$G_@ZG_QH
M]E@_^?K_ / ?_M@]EA/^?K_\!_\ MCU[/U_*C/U_*O(?^&7O"7_01\2?^#J?
M_&C_ (9>\)?]!'Q)_P"#J?\ QH]E@_\ GZ__  '_ .V#V6$_Y^O_ ,!_^V.S
M^*W/PV\2]?\ CPF[?[)JM\%_^24^%?\ L'Q?RKDI?V6?"$T;))?>(I$8897U
MF8@CT()KU'P]H5KX8T2RTJR#BTM(A#$)&W-M'3)[U56=".']E2DY.]]5;I;N
MRJLZ$</[*E)R=[ZJW2W=FC1117F'FA1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ibio-20230630x10k027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &R Z@# 2(  A$! Q$!_\0
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M4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\
MAYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\
M%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\
MGOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH
M_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"
M8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_
M (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC
M_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC
M\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^
M>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC
M_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )
MB]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^
M(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZM
MHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^
M4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\
MAYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\
M%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\
MGOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH
M_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"
M8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_
M (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC
M_AYC\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC
M\%?^>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^
M>_BC_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC
M_P )B]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )
MB]_^(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^
M(KZMHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZM
MHH ^4O\ AYC\%?\ GOXH_P#"8O?_ (BC_AYC\%?^>_BC_P )B]_^(KZMHH ^
M4O\ AYC\%?\ GOXH_P#"8O?_ (BFR?\ !37X)0QM(]SXG1$!9F;PS>@ #J2=
ME?5]<5\;N/@QX^_[%_4/_2:2@#1^'/Q T;XJ>!M$\6^'II+C1=8MEN[266)H
MF:-NA*MR/H:Z2O"/V$_^30/A+_V+]O\ R->[T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ&OQ6_
M::_Y/-^-_P#V$;'_ -(XZ_:D]#7XK?M-?\GF_&__ +"-C_Z1QU[F2_[]#Y_D
MSNP7\=?/\CB:***_3#Z4**** /T?_P""9O\ R2'Q-_V'F_\ 2>&OL&OC[_@F
M;_R2'Q-_V'F_])X:^P:_+,U_WVIZ_H?+8K^-(****\HY0HHHH **** "BBB@
M HHHH 2O*++Q;\2M3UVWMAX<LK.VME,UVTID43*"X"12,-N6..HRH7)X<5ZQ
M2'H: .,^%WQ NOB!INKO?Z))H&I:5J4NF75F]REP!(B1ON61."")%]#UKM*\
MP^"?_(4^)G_8W77_ *3VU>GT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 (V<'&,]LUY+I%_\6=2UJ+[5;:386EI;^;-')&4CO)3&P5%<
M,[(N_D\94!>6R:];IK?=/TH XKX3^.=2\=:)JDNL:=:Z9J>FZK=:5/%97+7$
M+-"^W>CLB'!ZX*C%=O7EWP&_X]O'?_8WZK_Z-%>HT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7*VOC.2X^)^I^%#:JL-IH]KJ
M8NMYW,TTUQ&4VXX \@'.>=WM755YEIG_ "<CXB_[%33/_2R^H ]-HHHH ***
M* "BBB@ HHHH **** "BBF2RI!$\DCK'&@+,S'  '4DT /KBOBY\34^$WA(:
MZ^@:SXD4W<%I]CT*U^T3CS'"[RN1\JYR3]/6LKP3XJ\>^+-=\5PZCX<LO#V@
M6M\(M$U8W1G?4+7;S+Y/!0YZ9('/0XR>S3PS;2,'O99]1DZYN9"5_!!A1^5:
M\JA+W]1[/4EG\2:7;<2ZA;1O_<,J[OR!S7(>'/CKX1\6>,O$WA;2[N[NM8\.
MM"M_$MA/M0R+N7:VS#<>E=W;65O9KMMX(X%](T"C]*<EO%%+)*D:K))C>X4
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MJ_\ HT5ZC7EWP&_X]O'?_8WZK_Z-%>HT %%%% !1110 4444 %%%% !1110
M4444 %%-9@@))  [FL+0?&ECK]@;I$GM )9(O)N4VR91BI.T$\9!P>_6LI58
M0DH2=F_T_P"'-HT:DXN<5=*WXWM^3-^BL+5O&.GZ/)8).YC-[<K:PF53&K2-
MT4$CD\=*W:(583;C%W:W%.E.FE*:LGL%%%%:F04444 %>9:9_P G(^(O^Q4T
MS_TLOJ]+>18U+,P51W)P*\TTSG]I'Q%_V*FF?^EE]0!Z;1110 4444 %%%%
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M#\5:5XX\1:-?W^FO_:$,'A"XU&T+>: (#M7;(I W;@>"O!'2OE_I7T]^RO\
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ME'*%?#_[?W_)>OV7_P#L:?\ VXLZ^X*^'_V_O^2]?LO_ /8T_P#MQ9T 7_\
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M3Z]-FN9I8B*?V=&O/JOE^?7L=*D\-)JWO:IWUMT>_7\NFNI272+?(:53<O\
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M65'6$C9<(9?G4-G&#CJ..,GP*E@OX"]7\M7IN]%LM6%'X/O_ #/T?_X)F_\
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MJ@; 3*XV$@N54*"[NQR6KU!ONGZ4 >7_  &_X]O'?_8WZK_Z-%>HUY=\!O\
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MKNEV_B"+4+&+S87;520&R!TV<]: /Q(/6@<&OW1_X=$_L_GG['XB_P#!N?\
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M\$B?@ >MIXB/_<7/_P 10!^%M>P_L=?\G6_"+_L:=._]*$K]</\ AT1^S_\
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MO[T*,X+5W-MX^\6Z)XK\.:/XBAT8R7?A.ZU:_CM2\8BO[=[<2*LCL5\D_:"
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MX:UF&VGE:X6_N(X/,EA8_*8HYKF./:?F8*[9' (![_12#D4M !1110 4444
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M1U7X7^'O$Y^(&DZ99Z_I]K976GVVEWCR0WS7C2QP0;G4,K++"X=L$!!OX (
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M=^P5]+?"_P .:EX0^'/AG0]8O(]0U33M.@M+FYA7:DDB1A25X''& <#.,X%
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M!%KRWXH?#3X/);Z]X??P?;Z;=V,%O>/=V%K$KD>=$?+0LPQG<H).%PS<_*<
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M\*/^$2T3_H#V'_@+'_A0!5_X6#X8_P"AATO_ ,#(_P#XJC_A8/AC_H8=+_\
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MT0Y)TBPSD_\ +K'_ (4O_"):)_T![#_P%C_PH J_\+!\,?\ 0PZ7_P"!D?\
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M *3PU]@U^=9K_OM3U_0^=Q7\:04445Y1RA1110 4444 %%%% !1110 4444
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M)M9Y;A>5&4BFMY(L]_O=#S[Q5:33;6:[@NGMXWN( PBE906CW !L'MD#%6:
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M$.D>&%\4ZA'=:6Y%RT\MQ]FLF3S?W.V*W(E<%B'<;1A3GT"S_9HTR6.X.O\
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M .$UUO\ Z$?6?^_]I_\ 'J/^$UUO_H1]9_[_ -I_\>KL,4TR(KA"P#'H.YH
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M_P!I_P#'J/\ A-=;_P"A'UG_ +_VG_QZNO9E098@"@D 9. /6@#D/^$UUO\
MZ$?6?^_]I_\ 'J/^$UUO_H1]9_[_ -I_\>KKC(@4-D;3WIV* ./_ .$UUO\
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M[_A7LGB5Y][_ &W^WTB50N!L\O9WSG.?:O/Z=",8TTH1:79CII**459'Z/\
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MM]/U=K5+&&2V<7,TEPRK#&(<;]YW#Y<9 !)P : &_P#"+^+O^AR3_P %4?\
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MP6$7E1&=]SD9)Y. .I/   Z  #%;M.]MAB4M%%2(3&:6BB@ HHI&.U2?0=Z
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MR^,__(;^%_\ V-T/_I%>5Z/9W<.H6D-U;R+-;S(LD<B'(92,@CZ@BO./C/\
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M +"6F_\ I=!74_;(/^>R?]]5R7Q2N8I/":*LBL3J>F\ _P#3]!0!V0HH%%
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MA3]IBYOM7AL?$_A.7PL%\17'AB\N)KV.6.VNTM([F%BP&#%,KN%;CD+D M@
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M(!P/X1[Y] K-+F?,S1M07*OF%%%%:F04444 %%%% !1110 5X#^U%XCM]/\
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M &$;'_TCCK]J3T-?BM^TU_R>;\;_ /L(V/\ Z1QU[F2_[]#Y_DSNP7\=?/\
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M_P"C!7J% !12;AG&>?2EH ***S=7\2Z3H$UC%J>I6MA+?3"VM4N9E0SRGHB
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M_P!B_J'_ *325VU<3\;_ /DB_C[_ +%_4/\ TFDH \^_83_Y- ^$O_8OV_\
M(UZ#)_R6:#_L 2?^E*5Y]^PG_P F@?"7_L7[?^1KJ_$GB%/#WQ@LI'L;^^\S
M0I5"V%H\Y7%RG+!0<4 >F45QG_"S(?\ H7_$?_@GG_\ B:/^%F0_]"_XC_\
M!//_ /$T =G17&?\+,A_Z%_Q'_X)Y_\ XFC_ (69#_T+_B/_ ,$\_P#\30!V
M=>5^./@MJ/CGQYI&K7?BV<>'=/U.SUA-#:QB=H[JV^X8;C(:-'.-ZX8L-P#
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M[1)!"9,0L@E=>K*1MRAVBO2/^%F0_P#0O^(__!//_P#$T?\ "S(?^A?\1_\
M@GG_ /B: .B\.Z';>&- TW1[+?\ 8]/MHK2'S6W/LC0(N3W.%&36C7&?\+,A
M_P"A?\1_^">?_P")H_X69#_T+_B/_P $\_\ \30!V=%<9_PLR'_H7_$?_@GG
M_P#B:/\ A9D/_0O^(_\ P3S_ /Q- '9UQGQC_P"29>(?^O;_ -F6C_A9D/\
MT+_B/_P3S_\ Q-<C\6?B+#<_#G7H_P"PO$$>ZW/S/I,P ^8=RM 'L"]/Q-+7
M&#XF0C(_X1_Q%U/_ #")_P#XFC_A9D/_ $+_ (C_ /!//_\ $T 5_B1\-[WQ
MAJF@:WHFNGP[XBT5IUM[Q[4743PS(%EBDB++N!*1L"&!#1CJ,@\_I_P2UKPY
MX2M-!\/>.[W2HK*&%X)GLXY7>]%Q)/<3S<CS%G,I#1#;CJK UU'_  LR'_H7
M_$?_ ()Y_P#XFC_A9D/_ $+_ (C_ /!//_\ $T >7ZY^RWJ^M>'X]//CU@]W
MKDOB'71/I"2VVKW)5%CCDA\P;8(Q%'B/<=Q0;RW(/NFA6=Y8:/9VVHWJZC?1
M1*DUVD/DK,X'+!,G;GTR<5S?_"S(?^A?\1_^">?_ .)H_P"%F0_]"_XC_P#!
M//\ _$T =G7(?%3_ )%%?^PEIO\ Z705'_PLR'_H7_$?_@GG_P#B:YOQ_P"/
M(M5T*VM%T;6[8RZIIRB6YTR6*-?]-@^\Q& /K0!ZL**!10 'H:_%;]IK_D\W
MXW_]A&Q_](XZ_:D]#7XK?M-?\GF_&_\ ["-C_P"D<=>YDO\ OT/G^3.[!?QU
M\_R.(;[C?2ON&^_Y2)^#?^O&R_\ 3>]?$"A2RACA21D^V>:]>N/$?AIOCO9:
MDGQ \2R>'XH47_A*&B(U*(B J%5<9P&PG^Z37W>+I.IM_+);7WM_5NI[E6/-
M]S_0]-^&7PR\6^"O#'[0%_K_ (<U+1[*Z\,WBP7%[;-&DI\]FPI(Y^7GZ5\I
MGJ:^GO'OC_P1J/@K6[6Q^-OC[7+R6SD2'3=0A<6]RY7B.0D?=)X-?,)ZTL'S
MOGG-:MKHULK=0HW=Y2Z_UU/T?_X)F_\ )(?$W_8>;_TGAK[!KX^_X)F_\DA\
M3?\ 8>;_ -)X:^P:_/LU_P!]J>OZ'S^*_C2"BBBO*.4**** "BBB@ HHHH *
M*** "D/0TM(>AH \:^'T^L6VE?%V7P_;P7>MIXFOFLX+E]L;R_9[?:&/IGZ?
M4=:[KPC?^,;GPSILNOZ7IUMK3P@W<,%T=BOW PI]N,G'3)ZUS?P1_P"0A\2O
M^QNN_P#T1;5ZA33 X#6-1^(J^/-$M].TC2&\+R12'4+J2Y8RQ.,[0HP#_=Z*
M<Y.2N.>F9->9& DL(FP<':[@']*V:*=_(9P'P[\-^.].\/&W\8>)[74M3^T2
M-Y]A:A1Y9QM&2 /4_=X! R<9+O&GP:T;X@S:/)KEWJ5TVEWBWL 2Y\M2XQPP
M4 8X'3!ZX(R<][11S/<1!:V-O8QE+>".!#R5C4*#^534M%2 5D^*_%6E>"?#
M]YK6M7D=AIMHH:6>3.!E@J@ <DEB  .22 .36M7$_&31SK_P]U*P.@7'B6.5
MHC)86=T+:YVK(K>;!(2 )8RHD3D'<@P0: ,J_P#VCOAUIEMI=Q<^)[6*'4K4
MWL#L&QY(<QL[<?( X93NQ@J0>AKNI/$&G)H#ZV+N.72UMC=_:HCO1H@N[>",
MY&WGBOG;P79?$SPGK>EZ[K?A#4O%%[<>'9--?R;BSCF#+?S20?:<R*GF- \9
M<IE=^^O0_@Q\-O$_@#P;H^FW^K6D=M!9S;]%M+;,=O-++)*$CG+ [(Q((U&T
M<(.E &UKGQU\"^'='T#5+_Q%:P:?KL"W5A<9)66 A3YQP/EC =,NV%&X9(S6
M]K'CSP_H&H-9:CJUK:7*6$VJ.DL@'EVL1423-_=0%AR?Z5\^>,OAWXME_9W\
M,^ &\)7]]=R^%XM,FN]'U""*:UO%C11#.7(#6SD'?@L"%((.15?3/ ?Q/T/X
MN>(->&C3:U?7H=+X7-U;IHM_I\5H1:6D"L#)%()V8G(V_-(6R&7 ![KHOQF\
M':]X/U3Q1::Y;_V)I>[[=<RYC^S;5#G>K %<JRL,CD,",Y%;USXLTFSU31]-
MFOHH[_5Q(;*V8X>8(F]R!UPJX)/;(]17R9KOPC\9:W%K%\WA_P 4Q^&-5\4Q
M:W=:2M_:G6Y9([7;&Q=F,9MTN$A*Q,20(P<%>*WM!\!?%J+XO>&?$>M)>SZZ
MMKIEE=:C!<VYTJ.P$2MJ,+Q_?\]YPS!D&"1%SM0B@#ZLHI!TI: "BBB@ I&^
MZ?I2TC?=/TH \7^'-EJ^I>#?BE:^'[^+3-<E\2ZPEE>31^8D,Q<;&9>X!QGV
MKTGPOINOV'AO2[?6=6@U#5XK:-+NZBMMB2S!1O91G@$YQ7'_  '_ -1X\_[&
M_5/_ $8*]0J7%/<I2:V/-]:\!^(+_P",?AOQ-#KUU#I%AIMU;7&GQJ@MYI7*
M^6[*6W$@;^G^S[Y[EK&[D4J]\0#P=D8!_/-7Z*GV:\_O9?M)>7W+_(XKX;_#
MJZ\ >%(=&N/%.L>(I$EEE:_U.423/O<L%)(/"@A1SV]Z/&?PFT/Q[>^';K6$
MDNY="U)-4LS(0=LRJR@].GS9X[@>E=K11[./8/:S[E>"PM[8YCA1&_O <_GU
MJQ115I*.B,VW+5L*P_&GC+2_ 'AJ[US6)GAL+8HK&.-I'=W=8XT1%!+,SNJA
M0,DL!6Y7'?%S1+CQ'X"U+3;?0;7Q.MQL6;2KJY^SB>+>"^R3^"0 ;D.1AE'S
M+U#$8%[^T=X,L(K%Y9-5)NK)M0,<6CW4CP0K*T3-,JQDQ8=&4AP/NFNT;QEI
M<GA%?$MG,^JZ1);+=PS:9$UT9XV *M&L8)?(/8&O"/!WA7XK>!M4T?6;C1$\
M5:B= ?2Y/M6LQ)+!MOII;=)I2O[QE@>)'D4'+(QP<UUW@OX9>,/AC\-TM]+U
MF/4=:MM.N#%HRI'%IWVZ:227<KE?,$:O)@#/W5'&>* -:']HWP;<:2U]$^JR
M$:K)HHLUTBY-TUW'$9I(Q#Y>\[4!)(&!C!.:EF_:'\$6NOW6E7.I2VCVHE$M
MW<6DL=JLL4'GRP^<5V>:D679,[@ >.#CS_X@_ [4++P!X;\.Z/X;B\7W%C;7
M;?VO)J[Z?>6^IS+\U]O4C(=WE9\$L,C:K#@9&L?LK:SXDOO$+7FJ,B-H+16J
M-<LUI>ZY/;>5<:D\('[K@; !U\V5L9(R >GP_M(^#+C3/M,<FIM=FY2U32O[
M*N!?R,\33(5M]GF%6B5G# 8P#SP:FLOVB_ NI:SHVGV>JR71U5;4PW4-K*UL
MC7()MXY)=NV.23!VHQ!)&,9(KSGQ+H7Q:U&[UWQ1I7A:RTKQ%K$-AHR1C48)
M)M.M8?/>XNHW/R-*QN&2-<XPH9_[M<M9_LX^)(?&VA7]GX>?3([6YT6>RNFU
MI7@TRVM% FAN+<'%U.Q,Y68ACF=3N3RQ0!]=T4@Z4M !1110 4444 %>9?&?
M_D-_"_\ [&Z'_P!(KRO3:\R^,_\ R&_A?_V-T/\ Z17E $R? [15^,%]\1/M
M5X-6N[%;)X4<+&  JE@0-W*HHQG'&>IKJ->\#:1XFT2^TG4X9KRPOH6M[B)[
MF3#HPP1PU;PZ"EK3VD^[,E2IJ]HK4YKPI\.O#W@O0[72-*TV.&QMMWEI(3*<
ML[.Q+,222S,>?6K5UX*T2]UW3=8FTRV;4M-#BUN/+4-%O&&P<=Q6W12E.4OB
M=RHPC!6BK(*JZ?IMMI4#16L0AC9VD*@DY9CECSZGFK51SEE@D*()'"DJA.-Q
MQP,U!9P2?'_X>2:3?:FGB[2FL;&[2QGG%P"JS/G8GONVMC'7:<=*ZGPMXPT3
MQOI*ZGH&J6FKV#,4%Q9RB1-PZJ2.A'<5\M:)X7\8Z-;6ALO!.NV_A;0O$&EW
MUCHMT('O;156Z%U;P.'_ 'MK$9(C&2<C>X7*J*].^'_A/QA=^+O%GBRSLX/
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M5\EXW8M@$AA%G: 30!]3ZIXLTC1M%@U:[OX8].N'@CAN V4D:9U2$*1UWLZ
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M58S*!@1G*C<*[;Q;K_C'1(M"M_$VI:#K4D_B/1H[=]%>XLWB,MPRMYD8D.]
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M>'_"LL5Y:W%PU\FHW1AA,;1*J,?L_#/YI*_]<VK7%U\72/\ D&^#/_!G=?\
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MSP]8:GJNG%?LUU<1;G0*P=0?[P##< V0&Y&#7#_\)MX\_P">_A__ +\ST?\
M";>//^>_A_\ [\ST =5%\#? ,/BI_$@\)Z6VMO=-?&\> ,WVACDR@'(#YYW
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M6T+EX8U QM",Q9<8*DY!KC?^$V\>?\]_#_\ WYGH_P"$V\>?\]_#_P#WYGH
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M_P!%7\+?^#*/_&C_ (;<^ __ $5?PM_X,H_\:\#_ .&G?V7/^B3M_P"$ ?\
MXS1_PT[^RY_T2=O_  @#_P#&: /?/^&W/@/_ -%7\+?^#*/_ !H_X;<^ _\
MT5?PM_X,H_\ &O _^&G?V7/^B3M_X0!_^,T?\-._LN?]$G;_ ,( _P#QF@#W
MS_AMSX#_ /15_"W_ (,H_P#&C_AMSX#_ /15_"W_ (,H_P#&O _^&G?V7/\
MHD[?^$ ?_C-'_#3O[+G_ $2=O_" /_QF@#WS_AMSX#_]%7\+?^#*/_&C_AMS
MX#_]%7\+?^#*/_&O _\ AIW]ES_HD[?^$ ?_ (S1_P -._LN?]$G;_P@#_\
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M0 EKXD_9TC:!;GX\Z'=6L9+FW^VQ(K$KM"</_JEX98^BOEL\XK8UOXH_L_\
MB'4[N>\^.'A[:UM!';SC4HS-'*D<4;.?FP?E@&/^NTOKSD?\-._LN?\ 1)V_
M\( __&:/^&G?V7/^B3M_X0!_^,T 7_ _Q!_9W^'FO:9?:7\:O#<T-M- 66XO
MX@Z06\5Q';P1D'A%%P5P>R^]>V#]MSX#C_FJ_A;_ ,&4?^->"?\ #3O[+G_1
M)V_\( __ !FC_AIW]ES_ *).W_A '_XS0![Y_P -N? ?_HJ_A;_P91_XT?\
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MP/\ X:=_9<_Z).W_ (0!_P#C-'_#3O[+G_1)V_\ " /_ ,9H ]\_X;<^ _\
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ML;=H!-PO7&?+=E]!6]_PT[^RY_T2=O\ P@#_ /&:/^&G?V7/^B3M_P"$ ?\
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M!Y ((((XKK*P?!_@G3?!%G=PV!N9YKVX-U>7M].9[BZE*A=\CGKA550
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MO;^\WYTVB@">S=OMEO\ ,?\ 6+W]Q7KP^M>06?\ Q^6__71?YBO7Q0 44M%
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M;7BC>\C#J".S#KGKGFO;QT% !12T4 )12T4 )12T4 )12T4 )12T4 )12T4
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MY-^T(=6\3:-IO@'0K+[==^)9&&H*;@VRII<.UKL&;!V-(&2%3C/[PXZ5VO\
MPF%U_P!"KK__ ("K_P#%T?\ "877_0JZ_P#^ J?_ != 'S_'8>)_$EI\,?"&
MM6VFCQ3X7UZ\TZ\?5[0ZC9RPKIDKVTY'RB3?"R#=Q\ZMWXK.USP1IGPO\?:!
MH>H>(_#UE;VWA5PEYXBT);N"6634YIGC@C+@0A=^ H)PFT=J^D?^$PNO^A5U
M_P#\!4_^+H_X2^Y/7PKKQ^MJG_Q= '%_V1IY^,'CU[M%L]-O?!FG)>7L \C<
MOFWJNWF+R"(^ASE1C'05XCI6J^"?%/B'2O%=A;Z;IG@BSU+3K&XT2*W"XT^
M7(@OK^,# !N9(<!P2J!2_7 ^HO\ A,+D_P#,JZ__ . J?_%T'Q=<$$'PIKV"
M,$?9$Y'O\] 'S%X@\'SZQI4VI>$K#2M1@UW6]8T#PYH^L6#2V?V.[,3RWL '
M$*QM%<R!L8*$!<9&>JU2'3?"7Q:T<:7JZZ]XHM9]$\-R:#JVD+)<2VD*8>]@
MG;YT 6228R+\NY"IYKW/_A,+D #_ (177\ 8'^BIQ_X_1_PE]SNW?\(IKVX#
M;N^RIG'IG?T]J .D_4>M%<W_ ,)A=?\ 0JZ__P" J_\ Q='_  F%U_T*NO\
M_@*O_P 70!TE%<W_ ,)A=?\ 0JZ__P" J_\ Q='_  F%U_T*NO\ _@*O_P 7
M0!TE<Q\4/^2=^(/^O;_V=:?_ ,)A=?\ 0JZ__P" J_\ Q=<U\2_%MS)\/]>0
M^&-=C!MOO/;* /G7K\] 'IMQ_P ?$O\ OM_.HZY^?QC=&>7_ (I77_OM_P N
MJ>O^_4?_  F%U_T*NO\ _@*O_P 70!MZGI=GK6GW%AJ%M%>V5PNR:WG7<DBY
M!P1W&0/RI$TJSCU6XU-;:(:C<0I;RW6W]X\:,S*A/H"[''JQK%_X3"Z_Z%77
M_P#P%7_XNC_A,+K_ *%77_\ P%7_ .+H U+;P_IMG:ZI;06,,5OJDLLU]$BX
M6Y>5=LC..Y91@^HJ[;P1VMO%!"BQPQ(L<:*,!54 *![  #\*Y[_A,+K_ *%7
M7_\ P%7_ .+H_P"$PNO^A5U__P !5_\ BZ .DK'\5?\ 'A8_]A;3?_2Z"J?_
M  F%U_T*NO\ _@*O_P 76=K?B:XO4TR!_#VLVBOJ^F@SW%NJQI_IL'+$,>*
M/IH44"B@!:*** "BBB@ I#TI:0]* /B7P?\ \GZ_M&_]@SP[_P"DYKW6O"O!
M_P#R?K^T;_V#/#O_ *3FO=: "BN=M_B'X<N/%&N>'1J]M'K.BP175]:2N$:&
M&1-Z2G/5,=6' Q@TGP_^(.A_%#PQ%XA\-WG]H:/-//!#=*I"S&*1HV9<]5+*
M<'N.: .CHHHH FL_^/RW_P"NB_S%>OBO(+/_ (_+?_KHO\Q7KXH 6BBB@ HH
MHH *0]*6D/2@#S3]G;_DFK_]AW6__3I=5Z97F?[.W_)-7_[#NM_^G2ZKTR@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \O^/O\
MR!O"'_8WZ)_Z6QUZ>.@KS#X^_P#(&\(?]C?HG_I;'7IXZ"@!:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G?B-_R3[Q-_V"
M[K_T2]9WP7_Y)!X'_P"P%8?^D\=:/Q&_Y)]XF_[!=U_Z)>L[X+_\D@\#_P#8
M"L/_ $GCH [.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN)^-_P#R1?Q]_P!B_J'_ *325VU<3\;_ /DB_C[_ +%_4/\ TFDH \^_83_Y
M- ^$O_8OV_\ (UL?$,9^*]C_ -@*7_TIBK'_ &$_^30/A+_V+]O_ "-;'Q"_
MY*O8_P#8"E_]*8J (,#T%&!Z"BB@ P/04*H9@,#DXHI5.&!]"#0!Y/X'^/$/
MB[QY<^')M'6Q7.IFWNDOHYR5L;CR96FC7YH0Q.5W<$9YS33^TCX57X(67Q,/
MFC2[MXH$M"!YXN'F$1A(_O*<L?\ 94GI7,Z=^SIK-EKU_?Q7F@:=)YNN3V^H
M6%K(M]=F_68)'=O@!HHC,&VC<28TQC%6[_\ 9@M;D:A;QZKMTJ;P\UA;Z8T?
M[F'5&LA9-J'U,*(-OKN;J: .V\,_$F]\3?$CQ)X=@T#;INBW<EA+J/VR/S1*
MJ(ZLUO\ ?6.0.?+?G=M/2LB3XW2ZA?MIF@>'I-:U6YU2^L=-A%RL44\%F42Y
MO))&XCB69S$.I9@, YK,O_AUX]A\6IXJ2\T.[U;2-+O;>PFLXWM[G4GE@"P6
M]T6^3RH9?W@;))(& N6SHP?![4?">D^!IO">H6D6N^&--DTR3^TD8V^HPS;'
MN!(5^9&,R"4. >2000: -ZV^(\NAZ)?WWCG21X1-I/';K)]H6Z@NS(/D\AD&
MYV)XV;0V>U1)\9?#MW?:#]BNX+C2M1CU%Y]0=_*6R-G$DDBRJP!4X?D-C&,G
MK7/>,_A;XL^(VCV,VO:AHPU72]7BU73K"T^T1VB!89(GCDG4K*682LP=0-A"
M\$9KE]<_9RNY?"6HM*;=KV>+5;BXLM'\V5Y9+BW@CA5'N'S*R_9UW%RH<';@
M"@#TG3OCMX"U07AB\1VL?V2S;49A<*\)6V5E4S8<#*$NH##@DC&:D7XW>!SH
M5SJ\FOV]M8VUU%93-<H\3Q32@F)&1E# OCY>/F[5XQJ/@;QC^T/XCNY_$4::
M5:6F@BT@N&TNYLT:\^W6UTJLLI61TS;?,J8" _*Q)KMM%^ UZNH1ZIJ!TJTO
MO[:TO46BM);JZ!ALVE<(TUPQ9F+2DKP N.^: .V?XR>#8_#T.LMK,?V.:[>P
MC40R&=KA1EX?)V[]ZCDKMR!STKI/#WB#3/%>C6NK:1>0ZAIURI:*XA.5;!((
M]B"""#R""#7DGC+X!7NN>+KGQ/:WEI<W_P#;-SJ,-G=SW%O$T4]E;6TBM+"0
MZR VH8,,@AB".>/0/A=X(/P^\'PZ2YM6N&N)[NX-DL@B,LLA=MOF,SGKC<QR
MQ!)QG% '68'H*,#T%%% !@>@KE_B@!_PKOQ!P/\ CV_]G6NHKF/BA_R3OQ!_
MU[?^SK0!U5P!]HEX'WV_G3,#T%27'_'Q+_OM_.HZ # ]!1@>@KAO'VNZ^?%'
MA?PKX;N[/3+_ %A;RYEU*]MS<+!!;K'D+&&7<S/,@Y(  8\G%0^%O%6M>./A
M3;:PEYI_AW6QYT5Y<S0M<6L,EO/)%.P7<I*'RF8$G@'GI0!W^!Z"C ]!7S[<
M_'?7O"_P<TK6];FLIO$7B>^DCT'98RQQI99RMY<1!G8(D(,[@'HZ+P37O6FW
M]MJNG6M[9W,=Y:7,230W,1!25&4%74CL0<_C0!8P/05C>*0/L-CQ_P Q;3?_
M $N@K9K'\5?\>%C_ -A;3?\ TN@H ]]%% HH 6BBB@ HHHH *0]*6D/2@#XE
M\'_\GZ_M&_\ 8,\._P#I.:]MU(73:;=BQ:);XPN+=I@2@EVG86QSMW8S[9KQ
M+P?_ ,GZ_M&_]@SP[_Z3FO=: /SH^+GP9^)OQ\^)5UHOB'Q+\.-/\8^';>#[
M>UG]KL9;NRG7<L$C])H6Q@@9*],BON#X*Z/K'A[X9:+IFNC04U"T1X=GAE"E
M@D8<B-8P>>%QG/?-?(_[07PUN_C7^U)XOT;0?ASX8\6:AHFBV%S=ZCJVJ7-M
M(OF1_NX<)(JY.#C QC!)KWK]B/5+36/V;/#-Q9:/::!$)[V)M,L99)8[=UN9
M%9=TA+$Y&3R1SQQ0!R/[7,/Q3LO%V@W_ (/\3V/AWPQ?:7-HMY=WVHQVD=A<
M32J3=%7.9&$0(0+R&Y^O<?LK^"?%_P /_#/BS1_%.IWNJ64'B&Y30Y=3O5O+
MG["JJH+R#^\X9@IY7)%>%?\ !0[X=^)_$NJ:3KEAX:O_ !?HD6BRZ?;PZ<IE
M.F:B;N*3[2T8ZAH5:/.#BO:/V1M!U^P\.^.=<UG2;[P[9^)_%%WK>EZ+J3EK
MBTMY57[X).TNX9MO;\: /?K/_C\M_P#KHO\ ,5Z^*\@L_P#C\M_^NB_S%>OB
M@!:*** "BBB@ I#TI:0]* /-/V=O^2:O_P!AW6__ $Z75>F5YG^SM_R35_\
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MW'/- '6?$;_DGWB;_L%W7_HEZSO@O_R2#P/_ -@*P_\ 2>.M'XC?\D^\3?\
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MP#I'@"RN+31TN8[>>5IG2XNY9_G8EF(WL<99F)QU))KHCTI:0]* /-/V=O\
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M5JW_ '^MO_CE %,_!S1;GX6R>!;ZYO[[3I5)DO))@MT9?-\T3!U "NLF&7
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M<H @^&?PQ3X=QZC))K%YK5]J#HTT]S'%$BA 0JQQQ*JJ.23U))Y/0"Q\5/\
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MYM#E$\L/V6^B(DPCE0_!/# 9'UJN72Y#JI24;.[.KDE2( NZH"<#<<4^O/\
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MK.<\^_83_P"30/A+_P!B_;_R->[UX1^PG_R:!\)?^Q?M_P"1KW>@!,48I:*
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MXS@ 9]J -RS_ ./RW_ZZ+_,5Z^*\@L_^/RW_ .NB_P Q7KXH 6BBB@ HHHH
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M/IEQ\/\ P=XHT?2+[51XHNQ8VNG[H[>:&81322)-YK*J,GD2*P)SN&*X34=
M\!:C\'O#7PVE^(.EMX?M)81JY2Y6-[Z!"TC0IM;]TK2[. >$!45DQ_#[X:P:
MI#:?\)KHE_X0C\0KXD&D:I=?:6%PUK<0W WNQR'>6.7GHP?^\* .^\-_M.6G
MC/5M-LM$\-7]R+FT@NKB2>YMH/LPDN)[<J0\@+E7MI<[-P(Q@G(KI+OXRI /
M%T$7AW4[K4] U6#25L8 CO>23I$\3H0V%0K,I)<C: Q.,5Y1KFF>#$^*MKXD
MTC7/AX=*%C8:?'9ZG&C26:VTL\G^C%>$R)N ,8* UN:_KNGP0_$>[\)_$GPY
MI6N>*+BWFM+RZD$BV.RUAMV;:#\S8B9E[ D9SB@#0?\ :DMA;WWE>$M8N+S1
M8[B?Q#;1&)CI44,IC=RV_$N2KLHC+$JC'MBK>G_M0:)=ZO=1S:7>VVBB/4I+
M+5V:-H[O[ ";G"!BZ#"L5+ !MIQVSY+:>$[/3=!GTW3?B)X.TQ=5T>30-5*S
M/,6MVEED%RC,=SW!-Q<%B_#%U.>,'I+;PI\/=*\2^,O$ND^,/#%CKVIZ='I6
ME2N$EAM(%1=YFC+ 2/*Z_O&&"45!U!R >V?"GXB'XH>%(==72Y-*MY\&%);F
M&<NA56R3$[ 'G!4G((/%=E7@GP9UKPGX"7Q'?ZCXR\+?;=>ODO9+/1)EBL;8
M+"D*B-3C)81[F; R3TXR?2/^%R^!_P#H:](_\#$_QH [.BN,_P"%R^!_^AKT
MC_P,3_&M?P[XWT#Q;)/'HVL66IR0!6E6UG60H#G!.#QG!_*@#<HHKFO&'Q T
MCP.;5=3>97N5D:%8H6?<4VY7@=3N&!WY]* .4^/O_(&\(?\ 8WZ)_P"EL=>G
MCH*^=_C/\9O#&I>'/",TUZ-/8^*],N$BN@5=[>&]3?.!_<V_-GTKT$?M%?#?
M _XJ_3/^_P!0!Z17'?&/7K[PM\)/&NLZ9+Y&HZ?HE[=VTNT-LE2!V0X/!P0.
M#63_ ,-%_#?_ *&_3/\ O]6?J7Q[^$WBO0[W3[OQ7H^H:7?0R6MQ$9]R2QL"
MCH<=CR#0!XGIO[07C[P_X<GMIH;S4M<L/%-LLFGZI!$+^71S8-=SL?))C9RL
M%R8]O/RJK '-=)KGQO\ %GQ#\1>,--\"7-LFD2:/#)X<U%'16OYH;N-+\Q._
MR9*3I%&6^7S%)/%=-X8\5_ ?P:]M)I&I:):36\[7,<QN'DD$C1>46+N2S'R_
MD&2<#@8J*\\0_ "]T.RT=[OP_'IUC;O:VD$$AB%O&TB2D1E""G[R-&R,$%00
M: ,H?%6[/A'P*_AZ]O-9UBZ%_J6K7,]BD-]):Z<)//MY4 PLAN/(MB1W+$8K
MHOAQ#XFU#PUX7\<ZE\26O#J,$6H7NF):PFPDCDCWF"W Q("N["L68G;RO.!6
M\*^.O@;X(UV*YT?Q'I5E=)IHT^"W%T6$=N)FE<J#DDM)+N=R26.W)JMI.L_L
M_P"AZ[#J]CJ&C074$[7,""ZD,$$K9W/'"6\M&.X\JHZG'6@#D+C]JOQ-XM\'
M2WECX?FT&'4["/4M+U$)(QAC^TVZA)]\:IN>.;(*%@#D9SC/73?M,ZM80:/X
M@N_#EH/!NKZA>6=O/%?[KZ-+>&ZE,CP;<9<6K *&)&X;L<T66K?L^Z>]V8+W
M1 MRAC:-[F1T1#(LI2-2Q$:EU5MJ #('I7%Z;I_P=T;X@Q>+]2^(FDW=OI][
M=:I#!+&L6V69)%=I'W;2 LK@[44MP6+8Y -W2_VL?$=SH,U[-X%=KFYM+"[T
MZ-)9(XV^TW<%N(99)(U =?M"OE=RD*V#QSH:[^TQXAT/6E\)R>&+:3Q>E]<V
M\_D33362PQ06\_F!HXFD)8742[=G!#$\#FWHNO? #0(Y4L=0T5$D\CA[J20(
ML,HEB1-S'8BR*K!%PN0..*M>(?&7P+\42S3:CJ^D27$UU]L>XANY(9C+Y2PE
MA(C!AF-%0@'! &: (?B+\6M>U?X%^$_$VBVNJ>']3UO5=-M9K."*-[R-9;D1
MRQH)!M).#@D=#FL+PW<?$S7]?T+PWX@\5W_A6Y;2]5U)9%@MFN)8DO8([4W
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M&1L ==I!.5VG).:\WM]3_9RTFTU&S6[\/10ZPOV6=);EV,B[S+Y:%F)0;P7
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M .30/A+_ -B_;_R->[UX1^PG_P F@?"7_L7[?^1KW>@ HHHH **** "BBB@
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MV4-GH=GX)&GZ6M\0\C,YV+,\TK2C<@)5G^91V5^<$ 5[G1B@"$65N1_J(_\
MO@4R:T@CB=UMD=E4D*$&2?2K5% '@;^-KV\U/2/$D7@8S:^--U"V5275%C!2
M79RG\30H"3@C!QG->XVUM!/;Q2-;1HSJ&*E!P2.G2K6*\3\:^,?&^A>-M9:R
MM=0N8+=XEL+"'3S):2VK0KYMQ)*.0Z2E_D7DA% 4[L@ ]F^PV_\ SPB_[X%<
M#\6/LMQ:67AN[T(:GHWB 2V.H/&"ICA8*K8*J<':[-R1Q&W.<5PL/Q<^*/\
MH\ESX*6VM;B3RQ*(IY&A"A/G= N<2E\*!RO\70UE?\+@^,FK:)?SP^!(]*N(
ME95$J2RN&;( "@ -Y9'S<X;C% 'NGA&:35M%$U_I46G7*3SP&  ,-L<K(K X
M&=RJ&_&MG[#;_P#/"+_O@5\W:I\8?BZTJ6L/@XP![=+I[J.TF<1 S+^[ (Y8
MQL1[$'KBMWPU\5/BAJ6K:?!=^"Q;60DA^VR2)*'C#31Q/$/EPS(KF4N/E(&!
MT- 'NGV&W_YX1?\ ? KE/"&BVMKXH\:2#1DLFN=1AE:X)W"[_P!$@02 $87
M0)@?W,]37DOC+X@?%B[LM?MO"VF127 OI;.WN6@9VMY/M-PB97H4$4$+,2<_
MZ4".!ST7PD\<>.=>\93Q>)K"33[2^^V7=OI\T'ER6=LJV?V<,>[%I;A3[H?[
MIH ]C^PV_P#SPB_[X%'V&W_YX1?]\"IZ* /*OC%.VG7FBSIX736(]-D.IVTZ
MLR^3<K^Y4,JJ204GD_'''<>DVMM#-;12/:)"SH&,;(,J2.A^E7** (/L-O\
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M]_T7+XA?^!B4 >J_@:/P->5?\, WW_1<OB%_X&)1_P , WW_ $7+XA?^!B4
M>J_@:/P->5?\, WW_1<OB%_X&)1_PP#??]%R^(7_ (&)0!ZW9_\ 'Y;\'_6+
M_,5Z^#7R,O[ =^C!A\<_B$"#GB\2KW_##>K?]%W^(_\ X'I_A0!]5YHS7RI_
MPPWJW_1=_B/_ .!Z?X4?\,-ZM_T7?XC_ /@>G^% 'U7FC-?*G_##>K?]%W^(
M_P#X'I_A1_PPWJW_ $7?XC_^!Z?X4 ?5>:,U\J?\,-ZM_P!%W^(__@>G^%'_
M  PWJW_1=_B/_P"!Z?X4 ?5>:,U\J?\ ##>K?]%W^(__ ('I_A1_PPWJW_1=
M_B/_ .!Z?X4 ?5>:,U\J?\,-ZM_T7?XC_P#@>G^%'_##>K?]%W^(_P#X'I_A
M0!]5YHS7RI_PPWJW_1=_B/\ ^!Z?X4?\,-ZM_P!%W^(__@>G^% 'U7P:.*^5
M/^&&]6_Z+O\ $?\ \#T_PH_X8;U;_HN_Q'_\#T_PH ^J^*.*^5/^&&]6_P"B
M[_$?_P #T_PH_P"&&]6_Z+O\1_\ P/3_  H ^J^*BEM8)IH99(D>6$DQNR@L
MA(P<'MD'%?+/_##>K?\ 1=_B/_X'I_A1_P ,-ZM_T7?XC_\ @>G^% 'U-=6L
M%["T-Q$D\3$$QR*&4X.1D'W J7(KY4_X8;U;_HN_Q'_\#T_PH_X8;U;_ *+O
M\1__  /3_"@#ZKS1FOE3_AAO5O\ HN_Q'_\  ]/\*/\ AAO5O^B[_$?_ ,#T
M_P * /JO-&:^5/\ AAO5O^B[_$?_ ,#T_P */^&&]6_Z+O\ $?\ \#T_PH ^
MJ\T9KY4_X8;U;_HN_P 1_P#P/3_"C_AAO5O^B[_$?_P/3_"@#ZKS1FOE3_AA
MO5O^B[_$?_P/3_"C_AAO5O\ HN_Q'_\  ]/\* /JO-&:^5/^&&]6_P"B[_$?
M_P #T_PH_P"&&]6_Z+O\1_\ P/3_  H ^J\T9KY4_P"&&]6_Z+O\1_\ P/3_
M  H_X8;U;_HN_P 1_P#P/3_"@#ZKS1FOE3_AAO5O^B[_ !'_ / ]/\*/^&&]
M6_Z+O\1__ ]/\* /JO-'%?*G_##>K?\ 1=_B/_X'I_A1_P ,-ZM_T7?XC_\
M@>G^% 'U7Q1Q7RI_PPWJW_1=_B/_ .!Z?X4?\,-ZM_T7?XC_ /@>G^% 'U7Q
M1Q7RI_PPWJW_ $7?XC_^!Z?X4?\ ##>K?]%W^(__ ('I_A0!]5*JJ6( !8Y.
M.YHVKOW8&[&,]\5\J_\ ##>K?]%W^(__ ('I_A1_PPWJW_1=_B/_ .!Z?X4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ibio-20230630x10k028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &B Z@# 2(  A$! Q$!_\0
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MQCXH\<ZC)'KO@=(XVL["TW<RPE?NJB\[@!R.X!R ?HSTI:^3O^"B_P 6-?\
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M?(<$C*XZUK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/B>2:UO&6V>,.'D(S'E3G.%Q^-?H+KR:HGAJ^31EMVU@6KBT6Z<K$9MOR;B
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MU)O8>P..E7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &@Y[GX Z%X@UWPOK^H7_B#2KEG_ .$7T.YOH$VAE$I"@F*.0$.F\\@]3C-
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M'?PZT[X:Z/=6.GW%[>O=W3WMU>:A,)9[B9@H+L0 ,X51P!TR<DDD ZJBBB@
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M /L6--_])DKTZO,?V8?^3<?A?_V+&F_^DR5Z=0 4444 %%%% !1110 4444
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M^RE?0ZE\,;RY?0AX:UF77=4;6=+;46OY8+_[4_GB29E7<=V"-HV[2F"17LM
M!7&_%_Q;IW@GX<:]JFJ-<I:):R1DVEI+<R;G4JOR1*S8R1DXP.IP*[*N,^,/
MC#3/ WPWU[5M7FG@LDM7C+VUK-<N&=2J_)$K-U(YQ@=3@4 8G[,/_)N/PO\
M^Q8TW_TF2O3J\Q_9A_Y-Q^%__8L:=_Z3)7IU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45D:WI-_J$D;VFMW.EH@(9((87#GU
M)D1B/PKF_ EMKFKZ79ZE>^)KN?\ ?2!X/LMLB.$E90#B/<,A1T-:*%X\U_S_
M ,BK:7N=W63XL_Y%?5O^O67_ -!-:U9/BS_D5]6_Z]9?_0369)\U#I10.E%
M'HGP3_Y&*]_Z]?\ V<5[/7C'P3_Y&*]_Z]?_ &<5[/0!!>7UMI\0DNKB*VC)
MVAYG" GTR:ICQ/HY.!JMB3_U\I_C5Z>VBND"31)*H.=KJ&&?QK T/2K(ZKKP
M-G;X6[7'[I>/W$?M0!T8.12T=** "BBB@ HHHH **** "BBB@ HHHH ****
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M[V41QJ[J50%CW+$ >YH POV8?^3<?A?_ -BQIO\ Z3)7IU>8_LP_\FX_"_\
M[%C3O_29*].H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** &O]PUS'PS_ .1-M/\ KM<?^CY*Z=_N&N8^&?\ R)MI_P!=KC_T?)6B
M^!^J_4K[+.IK)\6?\BOJW_7K+_Z":UJR?%G_ "*^K?\ 7K+_ .@FLR3YJ'2B
M@=** /1/@G_R,5[_ ->O_LXKV>O&/@G_ ,C%>_\ 7K_[.*]GH *Q="_Y"WB#
M_K\3_P!$15M5BZ%_R%O$'_7XG_HB*@#:HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR3]J[6T\._L_P#C+4)=/LM4
MAAL\RVFHQ/+!(A=0P=5921@D\$5ZW5#7K:_O-'O(=+NX+#47B9;>YN;?SXXW
MQPS1[EW#/;</K0!\'>']5_9,O/B-XLTW4HO =MX;LH+)]*O!-,IN'<2^>"YD
MP^W;'P ,;N<YK[P\/_V?_8&F_P!D&(Z5]EB^R&$Y0P[!Y>WVVXQ7QYXH\5?%
M7X:W\K?&KXCZEX/\,2W AA\3^!]'L?[*PQ 19S-'+<VSDD#)#)D_?K[%T+RO
M[$T_R;V348?L\>R\F8,\Z[1B1B  2PY)  YZ4 ?,'Q'_ &6?'7Q$^(7B7Q!=
M:UX82W)@D\.1_99P=/:*X@N&61%(5_/>!!+)R^U5"X YH> ?V(M4\*>,=%O=
M2\365YH4;+J.I16T,T%TUZ(KR,I!*'^2 _;7/]\;!@\DCZ\I&. 3C/M0!\R_
MLQZ7X0T7XX_%VQ\%:I_:VEV]MI,4LIU>74VCG7[4'C:661V!7 RN>/05]-U\
M^? W7+/7OVB?C#-9:5?:0D5KI,#Q:AI[6;R.IN\R*K %E/9^AKZ#H **** "
MBBB@ HHHH **** "BBB@ HHHH *Y7PY_R.?BCZVW_H#5U5<KX<_Y'/Q1];;_
M - :M8?#+T_5%+9G54445D2%<O9_\E'U3_L'6_\ Z,DKJ*Y>S_Y*/JG_ &#K
M?_T9)6L-I>GZHJ.S.HHHHK(D**** "BBB@ HHHH **** /"OB_\ \C@?^O=/
MYM7$UVWQ?_Y' _\ 7NG\VKB: %'45]/Z1_R";+_K@G_H(KY@'45]/Z1_R";+
M_K@G_H(H MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q9^T_X
MZ7PI^T!X?G\8^)-0\-:%97^@S: /MLUIIUQ&US,-4DE9"$DE1/)&V0_*C;E&
M2Q'VG7YQ:9^UWJ6C+X+UV3XC:5XSUCQ>EZFL>$O$=Q;6FE^&[@9>UE++%YD,
M<0!C=6+O*2-OS8H ^O/V5=2U35?A-'->W>I:CI0U*^30K_6=_P!MNM*%PXLY
M93( [$QXPS@,RA&/)S7L->>? ;5_[?\ AO8:BWCFV^(EQ<RS23ZY91I%;/(7
M.Z.%%SMCC/R*"6;"_,Q))KT.@ KCOB[XJT3P;\.=>U+Q!J=GI&FK:R1M=7T@
MCC#.I5 2>,DD 5V-<E\5]?T7PU\/->OM?U*PTK3EM)$:YU*>.&$.RD("SD+D
ML0 .Y- '/?LP_P#)N/PO_P"Q8TW_ -)DKTZO,?V8?^3<?A?_ -BQIW_I,E>G
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<#\>?'&H_
M#;X0>*O$VDK ^HZ99/<0+<H7C+ C&X @D<^M=]7D'[7/_)MOQ _[!<G\Q71A
MHJ5>$9;-K\S2FDYQ3[GQ(W_!1OXJY(^Q^&\?]>,O_P =JCHW_!07XG:%IT=E
M;6GAXPHSL"]E(3EF+'I)ZL:^9SU-%?I_]G82UO9(^F^KT?Y4?IG^QC^T[XO^
M/FO>)K/Q+#I<46G6T$L)T^W>,EG=@=VYVSP!7TOXL_Y%?5O^O67_ -!-?!G_
M  3$_P"1M\=_]>-K_P"C'K[S\6?\BOJW_7K+_P"@FO@,VI0HXN4*:LM/R1X&
M+C&%9QBK(^:ATHH'2BO'.0]$^"?_ ",5[_UZ_P#LXKV"]XM)O]QOY5X_\$_^
M1BO?^O7_ -G%>P7W_'G/_N-_*@#Y@%W/C_7S?]_&_P :07,RDD32 L<DASS]
M>:C'2B@#M_A-<2R>,[=7ED=?*DX9R1TKW2O!_A'_ ,CK;_\ 7*3^5>\4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50UV
MUO[W1[R#2[Z/3=1DB98+N:W\]87(X8Q[EW8],C-7Z\\_:!\>ZM\,?@]XG\3:
M':1WFIZ?:F6(3(SQQ<@&5U7YF1 2Y Y(4T >(:=^S9\5= \9#Q3JNO>#OBYK
MT4K26M_XPM+NU>S!Z+;1122V\&.FY(MQ[L:^JM/:Z>PMFO8XHKTQ*9XX'+QK
M)@;@K$ D9S@D#(["OD;P9^T3X[T#QWJ=A:ZM8?M ^"[#3K>_U'6_"5I%#?:<
MTK, B11.T5R-J^9Y:L)0IZ-QGZWTK4H=9TRSO[;S/L]U"D\?G1-$^UE##<C
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MUD2 +RWR3@#S5YY ]?4C\Q0-6L2 1>6Y!&0?-7I@'U]"/SH MT54.JV0ZW<
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M-_!FXBM_$%XTLB1*;;:"[  DN,#GO7K-YJUBUG-B\MSE#C]ZOH/?_:'YCUH
M^9ATHH%% '9_"/\ Y'6W_P"N4G\J]XKP3X4S1V_C*W>5UC3RY!N<@#)& /SK
MV_\ M>QQG[;;XZY\U?3/KZ4 7**J'5K(9S>6XP<']ZOO[^Q_(THU2S)P+N#.
M<?ZU>O'O[C\Q0!:HJI_:UEC/VRWQC.?-7TSZ^A%!U:R7.;RW&.N95XZ^_P#L
MM^1]* (/$GB"Q\*>']1UK4YUM=.T^WDNKB=SA8XT4LS'Z &O%_A[^U;8^,_
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M1]8U2X_9SN]&TQ+O3-"L=*M;FW\0ZDS/YC12^4PNHOEB BC"2GS#NP1Q]H^
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M_P#D-ZE_U]S?^C&JE5W6_P#D-ZE_U]S?^C&JE7[,MD?8K8]W_8>_Y.8\)?\
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M^D?\@FR_ZX)_Z"* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]> ?!6+7X?VB_C /$=WIEW=FTT@P-I=O) BP9N_+5P[N2X'5@0#V KW[(]:
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MOO:?P1]$>['X4>J?LM6YNOV@O \(ED@,FH*OFPD!TRIY!(/-?JX/A_,JJ?\
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M!SD?@":/;_Q57B%L$'YKN,YQL_Z9_P"Q_P"/MZC#?^%>S>3Y?_"6^(\XQO\
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MZ'_V'8O_ $3+7J97_OM+U.G#?QH^I^;%%%%?JA]4?IM_P3>_Y(#??]AZY_\
M1<->@_M>_$7Q!\+/@AJOB'PS?+I^K07%M''.T*2@*\JJPVN".03VKS[_ ()O
M?\D!OO\ L/7/_HN&MS]O_P#Y-IUS_K[L_P#T>M?F]6,9YMRR5TYK\SYR23Q=
MGW/BD_MU?&LY'_"71?\ @KM?_C=5=,_;9^,>C:?;V-GXJBBMK=!'&ATRV.%'
M3DIDUX:>M%?=_4L+M[*/W(]WV-+^5?<?I]^PI\:_&/QH\/>++KQ?JJ:I/87D
M$5NRVT<.Q6C)(PBC/([UZ'^US_R;;\0/^P7)_,5X'_P3"_Y%/QY_V$+;_P!%
M-7OG[7/_ ";;\0/^P7)_,5\'BH1IYIRP5DI1V^1X-6*CBK15E=?H?C\>IHH/
M4T5^DGTA]K_\$Q/^1M\=_P#7C:_^C'K[S\6?\BOJW_7K+_Z":^#/^"8G_(V^
M._\ KQM?_1CU]Y^+/^17U;_KUE_]!-?FF=_[]/Y?DCYK&_QW\OR/FH=**!TH
MKPCA/1/@G_R,5[_UZ_\ LXKV"^_X\Y_]QOY5X_\ !/\ Y&*]_P"O7_V<5[!?
M?\><_P#N-_*@#Y;'2B@=** .S^$?_(ZV_P#URD_E7O%>#_"/_D=;?_KE)_*O
M>* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I"< G&?84M(<X.,9]Z / O@KKM[X@_:+^+\U]H6H:!)#::1
M D&HO"SRHIN\2KY3N C=0"0WJ!7OU?/_ ,$E\0K^T7\8/^$DETJ6[-KI)@.D
MQRH@M\W?EAQ(Q)DQU(X]!7T!0 4444 %<C\6_'4GPS^&_B'Q1%9KJ$FE6<ET
M+9Y/+$A49V[L''UQ775Y1^U5_P F\>/O^P3/_P"@UOAXJ=:$9;-K\S2FDYI/
MN?*W_#T#4_\ HGMK_P"#9O\ XU6=H/\ P4FU'0K26!? 5M*)+B:XW'5&&/,<
MOC_5=LXKXPHK]*_LC!6M[/\ %_YGT?U2A_+^9^I_[+/[6MW^T7X@US3KCPU#
MH2Z=:I<"2.\,YDW/MQ@HN*^D:_/#_@F/_P CWXT_[!L/_HVOT/KX7-:%/#XJ
M5.DK+3\CP\5"-.JXQ6@4445Y!R!5?4/^/&X_ZYM_(U8JOJ'_ !XW'_7-OY&F
MMQK<_#36_P#D-ZE_U]S?^C&JE5W6_P#D-ZE_U]S?^C&JE7[,MD?8K8]W_8>_
MY.8\)?\ ;Q_Z(>OUEF_U+?2OR:_8>_Y.8\)?]O'_ *(>OUEF_P!2WTK\_P"(
M/]ZC_A7YL\',/XJ]#\1OB5_R4;Q7_P!A>[_]'-7.5T?Q*_Y*-XK_ .PO=_\
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MC=9%_O*01^E?)/\ P4K_ .2+Z'_V'8O_ $3+74_\$_23^S9I!))/VZ]ZG/\
MRV-<M_P4K_Y(OH?_ &'8O_1,M>%@Z7L,RC2O?EE8X*4/9XE1[,_-BBBBOTP^
MF/TV_P"";W_) ;[_ +#US_Z+AK<_;_\ ^3:=<_Z^[/\ ]'K6'_P3>_Y(#??]
MAZY_]%PUN?M__P#)M.N?]?=G_P"CUK\YG_R-_P#M]?F?.O\ WOYGY6GK10>M
M%?HQ]$?H+_P3"_Y%/QY_V$+;_P!%-7OG[7/_ ";;\0/^P7)_,5X'_P $PO\
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M\G%^ ?\ L))_(U^PA^Y^%?#<0_QX>GZL\/,/XB]#\;_VG/\ DX'Q[_V%'_\
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M^(K_ ,P 8OM9AD"X]/W8Q7J/)L9:_)^*_P SJ^IUK;'WM7Q3_P %._\ D2?
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M@]:*_1CZ(_07_@F%_P BGX\_["%M_P"BFKWS]KG_ )-M^('_ &"Y/YBO _\
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MMO(]16,HN+LT:)I["T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF\>/O^P3/_Z#7?Z!XQT'Q5YW]BZWINL>3CS?L%W'/LSTW;2<9P>M<!^U4?\
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M^B,-Q;,^FJ)$/496S!'X&O?**YW4G*7.Y-OOU,W)M\S>I\7M_P $M_ .,_\
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MZXU.:WA6)[V[V>=.0,%WV*J[CU. !Z 5=HHK$T"BBB@ HHHH **** "BBB@
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M\$>)?",EZVO_ !!U?QNLP41)J=C96XMR,Y*_9H8\Y_VL].*[>BBN4V"BBB@
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M!6R02/EWLH4.X+8Z5Z50 56U/4[31M/N;^_N8K.RMHVFFN)W"1QHHRS,QX
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ME037G?P:\)>$?B)XK^S1>#TL=-TS3U&L:;X@FCO3>WC[&ANXU+N)%*^81=#
MD#XYP0H!WWP9\"S:SH?A'6[GQ+<ZKX=TJ-GT/3I;%('B&UHD>656/G!4+!"
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M0PL5O"D2 ]SM4 #)YX% %WI2T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=_$7X2Z;XJ
MO9]?A754UQ;,VQBTO7+C2UOD4EHXI7B/W0S-@XR-S>I%>B44 >:?!KX5GP5I
M<>I:Y;6ESXPGC>"?4MYN;E;7S6>&V>Z=1).(U*KO<9;;GTKTNBB@!KHLB%6&
M5(P0>]>$>*?V?+C39=*MO!%UJEC ;X3.]WXCNOL6GP^8'DCCL3NCF5P77RVP
MHW=0*]YHH RO#'A71_!>BP:1H.F6NCZ7 6,5G91"*)-S%CA1P,DD_C6K110
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M;2C/*NJ73ZE/<73LTDTD@7YCG&,(J*%P,*@&.*Z.BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2^)'CQO >DV<
MT&FOJVH7]Y#I]G:"984DFE;:H>1@0B^IP3V )(%:OB[Q78>"?#]WK.I?:39V
MRAG%G:R7,IR< +'&K,QR>@!KYQ^+?@VR\2Z1+XY_X6*CZ+J]RQA;[+<ZC;7%
MH8 L-HEO'(%#"=3()%42!L $$4 ;-A;ZO?ZYXABTJRO8]5N#O\2^ O$6I&:"
M\AE^47-C<DE4X!4!<(=NUU1L-7KGP^^%>B?#A;I]--]<W5RD<4EUJE[)=SB*
M,$10AW)(1 3A1ZDG).:P/@UX!O=-T[3/$WB'4-9O_$EUI4-N\&L3([6",%=X
M1M12QW@9:3<_R@$\'/J% !1110 4444 %>:_%'XTZ/X-\&>)M1T[4-*U*^T7
MRX[R&2Z!CL3(P4/<[,LB*"6;C.T&M+XO^,)/!OA1KA8Y(X+J064NHH1MT_S
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MG2O-OBE%X+\;^&XCKNN6<FA:3JD$U[;JZ7$-Q(K%4MIHQNW;G9<1XR6"X!KE
MOCK\0;#6EU_P!!K\/A2\ALH+N[UG4[V*SL]CN2MHSF19L3)'*C20C,8.0P;
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M[/\ 9H^%^F6>B:+XR%M<1WDNGF+3[H7LZK<V$ZQ2JTUH6,44V54.(_E+(67
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M::=;RRWEMX>C=5TZWO) 1)<QQ@95V5GX!V98L%#$FO3** "BBB@ J*XM8;M
MD\23(&#A9%# ,#D'GN" :EHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:/A#_P!$K\%?^$]:?_&Z .-_X;R_9]_Z*SX:_P# H_X4?\-Y?L^_]%9\-?\
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MO_16?#7_ (%'_"C_ (;R_9]_Z*SX:_\  H_X5T/_  HKX%_]$^^'W_@FL?\
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M]$K\%?\ A/6G_P ;H_X9H^$/_1*_!7_A/6G_ ,;H XW_ (;R_9]_Z*SX:_\
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MD;*SJX**?WB''(P<@XW;OX$>)-!\.?#.[\)ZYIL'B_P5I*:1_P 3*WD>PU&
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M_P"'IGP(_P"@CXB_\)ZZ_P#B:^M/L4'_ #QC_P"^!_A1]B@_YXQ_]\#_  H
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MIGP(_P"@CXB_\)ZZ_P#B:/\ AZ9\"/\ H(^(O_">NO\ XFOK3[%!_P \8_\
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M-?6GV*#_ )XQ_P#? _PH^Q0?\\8_^^!_A0!\E_\ #TSX$?\ 01\1?^$]=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ibio-20230630x10k030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230630x10k030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %8 Z@# 2(  A$! Q$!_\0
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M^*?^_EK_ /'*/^'PO@#_ *$/Q3_W\M?_ (Y7Y2T4?5*78/;S/U:_X?"^ /\
MH0_%/_?RU_\ CE'_  ^%\ ?]"'XI_P"_EK_\<K\I:*/JE+L'MYGZM?\ #X7P
M!_T(?BG_ +^6O_QRC_A\+X _Z$/Q3_W\M?\ XY7Y2T4?5*78/;S/U:_X?"^
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MTW>I.-PSZ9H^J4NP>WF?JY_P^%\ ?]"'XI_[^6O_ ,<H_P"'PO@#_H0_%/\
MW\M?_CE?E)GFD#J3@,,^F>:/JE+L'MYGZN?\/A? '_0A^*?^_EK_ /'*/^'P
MO@#_ *$/Q3_W\M?_ (Y7Y29'K1FCZI2[![>9^K?_  ^%\ ?]"'XI_P"_EK_\
M<H_X?"^ /^A#\4_]_+7_ ..5^4>]=VW<-WIGFER"<9YH^J4NP>WF?JW_ ,/A
M? '_ $(?BG_OY:__ !RC_A\+X _Z$/Q3_P!_+7_XY7Y2 @D $$GICO1N !.1
M@=3GI1]4I=@]O,_5O_A\+X _Z$/Q3_W\M?\ XY1_P^%\ ?\ 0A^*?^_EK_\
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MEI,CU%'U2EV#V\S]6_\ A\+X _Z$/Q3_ -_+7_XY1_P^%\ ?]"'XI_[^6O\
M\<K\I"0.IQ2*ZL2 P)'4 T?5*78/;S/U<_X?"^ /^A#\4_\ ?RU_^.4?\/A?
M '_0A^*?^_EK_P#'*_*0L%ZD#ZT @]"#]*/JE+L'MYGZM_\ #X7P!_T(?BG_
M +^6O_QRC_A\+X _Z$/Q3_W\M?\ XY7Y29H+ #)( ]:/JE+L'MYGZM_\/A?
M'_0A^*?^_EK_ /'*/^'PO@#_ *$/Q3_W\M?_ (Y7Y2!@0"""#TP:,C.,\T?5
M*78/;S/U;_X?"^ /^A#\4_\ ?RU_^.4?\/A? '_0A^*?^_EK_P#'*_*3(]:,
MC .1ST]_I1]4I=@]O,_5O_A\+X _Z$/Q3_W\M?\ XY1_P^%\ ?\ 0A^*?^_E
MK_\ '*_*6BCZI2[![>9^K7_#X7P!_P!"'XI_[^6O_P <H_X?"^ /^A#\4_\
M?RU_^.5^4M%'U2EV#V\S]6O^'PO@#_H0_%/_ '\M?_CE'_#X7P!_T(?BG_OY
M:_\ QROREHH^J4NP>WF?JU_P^%\ ?]"'XI_[^6O_ ,<H_P"'PO@#_H0_%/\
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MB_'#1O!>M?$6U@U75O\ A(9+"POKF-8)-<B6V:46\S*%\T"8(F_K\^W-?/\
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MD\U9_:(\??\ "N6L+]-7/Q!N[CQ#-?Z;JMSHT%O:V$$4DD<^G[AEW8Y"LC
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M_P!$G\7?^"MZ/^&1_C;_ -$G\7?^"MZ_0K_AZ#)_T3P?^#7_ .U4?\/09/\
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M&O\ ]JH_X>@R?]$\'_@U_P#M5'U/,O\ GVOO7^8?V75[?BC\]?\ AD?XV_\
M1)_%W_@K>C_AD?XV_P#1)_%W_@K>OT*_X>@R?]$\'_@U_P#M5'_#T&3_ *)X
M/_!K_P#:J/J>9?\ /M?>O\P_LNKV_%'YZ_\ #(_QM_Z)/XN_\%;T?\,C_&W_
M *)/XN_\%;U^A7_#T&3_ *)X/_!K_P#:J/\ AZ#)_P!$\'_@U_\ M5'U/,O^
M?:^]?YA_9=7M^*/SU_X9'^-O_1)_%W_@K>C_ (9'^-O_ $2?Q=_X*WK]"O\
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MQQVKY;^)'["OQ0UWQ6FH>%_&/A;3+2[\*VOAC4%U33GNG*1IM=XP1@$]CUH
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M4=_:*Q<7)_$%%%%;&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;X?_ .^)_P#XFC_AV7XX_P"AM\/_ /?$_P#\37M/_#R;X:_] KQ#_P" J?\
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M_P"AM\/_ /?$_P#\37Z.44?VYC?YE]R#Z]6[_@?G'_P[+\<?]#;X?_[XG_\
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MNOZ5Z#7GVO?\EF\+_P#7A=?TH ]!HHHH **** "BBB@ HHHH **** "BBB@
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M>N^K@?&W_)2_AY_U\7W_ *2/7?4 %%%% !1110 4444 %%%% !1110 4444
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MR5<6V^< ^FY%(_6O;P..QM&/L\.N9=K7L=M"O6@N6GJCX3_X=[?&#_GRT?\
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M\%_^AWMO_ :?_P"(KP'@\4]73E]S//\ 8U?Y7]Q[C17AW_#;'P7_ .AWMO\
MP%G_ /B*/^&V/@O_ -#O;?\ @+/_ /$4OJ6*_P"?4ON8>QJ_RO[CW&BO#O\
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MKW_)9O"__7A=?TKT&O/M>_Y+-X7_ .O"Z_I0!Z#1110 4444 %%%% !1110
M4444 %%%% !1110!P$W_ "7"'_L!?^UVHHF_Y+A#_P!@+_VNU% 'C7_!1G_D
MWV+_ +#=G_[/7>_L;_\ )LGP_P#^O _^C7K@O^"C/_)OL7_8;L__ &>N]_8W
M_P"39/A__P!>!_\ 1KU[L_\ D50_QO\ ([G_ +JO\7Z'L]%%%>$<(4444 %%
M%% !1110 4444 %%%% !1110 4444 <O\3_^2>^(/^O.3^5:'@[_ )%/1?\
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MF\]O+\C.<;.F<]Z[>B@ I*6B@ HHHH 2@*!TI:* $Q1@$TM% !1110 4444
M%%%% !7"_&C_ )$=/^POI7_IPMZ[JN%^-'_(CI_V%]*_].%O0!YI^U7^RA8_
MM!:=;ZEIUS%I/B^PC,<%W*I,5Q%G/E2XYP#DAAR,GJ#7P1KO['WQAT"_>U?P
M/?WNTD"?3V2>)O<,&_F!7Z]CI6!JWQ \+Z#<M;:GXCTC3K@=8KJ^BB<?@S U
M[N"S;$X:'LH+F7GT^X[J.*JTERK5'Y(_\,M?%W_HGFN_]^!_\51_PRU\7?\
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M ,3 (Q@DE4V!2OM3EB6K-+_@^G?^ODW4[+^O(^=O*7_GFO\ WR*/*3_GFO\
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M!^H-?M\.E''O7T6"SJKA::I2CS);=&>C1QLZ4>5JZ/PP_P"$;U?_ *!&H?\
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M='YTGQ%?>C^/_ %_:%]X?C_P#\-[S2?$&HS"6ZL-5N90JQAY;69CM4849*]
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M2-$\M?[OR@9 ]37)2Z9=^"O$C^(-0T_P_K6FZOJXVW4<9:\M_,.V(J[ A@,
M8&/:@#V>BBB@ HHHH **** "BBB@ HHHH *X7XT?\B.G_87TK_TX6]=U7"_&
MG_D1T_["VE?^G"WH \'_ &SOVN;OX.O'X/\ "+1?\)7<PB>YO9%#K81-G9A3
MP9&P2,\ <D'(K\]->^)7BSQ/?/>ZOXHUC4+ESDRSW\I_(!@!] !79?M4W5W=
M_M&?$)[PL95U:2-=W:-558_PVA:YWX/6=OJ'C^S@NH8KB!K6])CF4,I(LYBI
MP?0@$>X%?I^ PM+"8534;NUV^KTN?34*4*5)-+6USG?^$EUC_H,:C_X&R_\
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MCS);,]2CCG3CRR5['XA?:3G/G'.[=G?W]>O7WI&N2V<S$Y&#E\Y'IUK]L/\
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M'?\ (IZ+_P!>4/\ Z+6L_P")_P#R3WQ!_P!><G\JT/!W_(IZ+_UY0_\ HM:
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M /KNC-?GAXE^+/CK7/BQXKN]5N;SPW=S_"6757T6SOI3!9W)0L&3./G&1\V
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M1?&#6O$=YK=S-''%)J=C'IK,KNS16RMNV!F.6W=R?7M7!X/I7ZV?\,2?!?\
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M^C7KW9_\BJ'^-_D=S_W5?XOT/9Z***\(X0HHHH **** "BBB@ HHHH ****
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M5C+J=Q9S>:SP6T4[0R.2JD$AT.$'+#I7;['+_P#GW'_P'_@&W)0_E7W':_\
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M .39/A__ ->!_P#1KU[L_P#D50_QO\CN?^ZK_%^A[/1117A'"%%%% !1110
M4444 %%%% !1110 4444 %%%% '+_$__ ))[X@_Z\Y/Y5H>#O^13T7_KRA_]
M%K6?\3_^2>^(/^O.3^5:'@[_ )%/1?\ KRA_]%K0!L4444 <-\;?A1IOQO\
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M#MM)\&AECNP,?OIL@#/''UK[/HH **** "BBB@ HHHH **** "BBB@ HHHH
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MA1T'_O[-_C7J/P?_ ."C&A^*]7M]+\::,/#4D[!$U"WE,ML&/3>"-R#WY%?
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M77?44 <#_P *:TO_ *#?BC_P?W7_ ,71_P *:TO_ *#?BC_P?W7_ ,77?44
M<#_PIK2_^@WXH_\ !_=?_%T?\*:TO_H-^*/_  ?W7_Q==]10!P/_  IK2_\
MH-^*/_!_=?\ Q='_  IK2_\ H-^*/_!_=?\ Q==]10!P/_"FM+_Z#?BC_P '
M]U_\71_PIK2_^@WXH_\ !_=?_%UWU% ' _\ "FM+_P"@WXH_\']U_P#%T?\
M"FM+_P"@WXH_\']U_P#%UWU% ' _\*:TO_H-^*/_  ?W7_Q=<9\7/A)IEGX-
M21=8\2N?[5TQ<2:[=,.;Z '@OUYX/8X->XUPOQH_Y$=/^POI7_IPMZ (9/@_
MI,2/(^N^)D1069F\070 '<GYZ\KUSXB_!'PY?R65_P#%;4DN8SM=(/$=Y.%/
MH3&S#]:\&_;Y_:(U/4?%US\-]#O9+31]/5/[5>!BK74[ -Y3$?P(I7([L>>E
M?&?"CT ]*^XR[AQ8BBJV(DUS:I+MYW/F\7FSHU'3I1O;=L_33_A<GP%_Z*OK
M/_@ZU&C_ (7)\!?^BKZS_P"#K4:_-34-/NM)N?L][;RVD^U'\J=2C;74,IP>
MQ4@CU!I(K&YFL;B]CA=[2W=(Y9A]U&?.P'W.UL?0UZO^K&#M?VDOO7^1P_VU
MB-N5?C_F?I9_PN3X"_\ 15]9_P#!UJ-'_"Y/@+_T5?6?_!UJ-?FI86%QJ:W3
M6B>>MK"UQ,5=?DC7&YCD]LC@<U5\U#_RT4\X^\*/]5\)MSR_#_(/[:K_ ,J_
M'_,_37_A<GP%_P"BKZS_ .#K4:/^%R? 7_HJ^L_^#K4:_,HRH,YD48Z_,.*7
M</4?G3_U6PG\\OP_R%_;5?\ E7X_YGZ:?\+D^ O_ $5?6?\ P=:C1_PN3X"_
M]%7UG_P=:C7YEB13G#J<=<'I3[=&NI4CA!E>1@JJG)8GH!1_JMA/YY?A_D/^
MVJ_\J_'_ #/TQ_X7)\!?^BKZS_X.M1H_X7)\!?\ HJ^L_P#@ZU&OSTU7X8>+
M=#N+6'4?#U_8O=2^1"9XPJO)_<W9VAO8D&N7=A&SJS*"A(;+#@U$>&<%-7C4
MD_FO\AO.,1'XH)??_F?IG_PN3X"_]%7UG_P=:C1_PN3X"_\ 15]9_P#!UJ-?
MF49% !+J >A+=:7S%Y^<<#/6K_U6PG\\OP_R)_MJO_*OQ_S/T/\ &_Q5^"5_
M'HHLOB=K%T8M4MI9MVL7YV1J^6?GT'IS72_\+D^ O_15]9_\'6HU^97FJ0#O
M7!Z'<*=DT?ZK83^>7X?Y#_MJO_*OQ_S/TS_X7)\!?^BKZS_X.M1H_P"%R? 7
M_HJ^L_\ @ZU&OS,S1FC_ %6PG\\OP_R#^VJ_\J_'_,_3/_A<GP%_Z*OK/_@Z
MU&C_ (7)\!?^BKZS_P"#K4:_,S-&:/\ 5;"?SR_#_(/[:K_RK\?\S],_^%R?
M 7_HJ^L_^#K4:EMOBU\"+R=8H_BQJP=C@>9KM^B_FV *_,?-&:7^JV$_GE^'
M^0?VU7_E7X_YG[&Z/\-?#?B'3X;_ $SQ1X@U"RF&8[BU\27,D;#V828J[_PI
MK2_^@WXH_P#!_=?_ !=?F9^S#^T!J_P2\=V(6ZDD\-7LRPW]@S9CPQQYBCLP
MSU'45^MEM<1W=O%/$V^*10ZL.X(R#7QF:99/+:JBW>+V9]#@L9'&0;2LUNCA
MO^%-:7_T&_%'_@_NO_BZ/^%-:7_T&_%'_@_NO_BZ[ZBO%/1.!_X4UI?_ $&_
M%'_@_NO_ (NC_A36E_\ 0;\4?^#^Z_\ BZ[ZB@#@?^%-:7_T&_%'_@_NO_BZ
MXCX@?";3;?Q+X&C&L>)&$NJLI+Z[<DC]P_0E^#QVKW6N ^(__(U^ /\ L+M_
MZ(DH 7_A36E_]!OQ1_X/[K_XNC_A36E_]!OQ1_X/[K_XNN^HH X'_A36E_\
M0;\4?^#^Z_\ BZ/^%-:7_P!!OQ1_X/[K_P"+KOJ* .!_X4UI?_0;\4?^#^Z_
M^+H_X4UI?_0;\4?^#^Z_^+KOJ* .!_X4UI?_ $&_%'_@_NO_ (NC_A36E_\
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M  ?W7_Q==]10!P/_  IK2_\ H-^*/_!_=?\ Q='_  IK2_\ H-^*/_!_=?\
MQ==]10!P/_"FM+_Z#?BC_P ']U_\71_PIK2_^@WXH_\ !_=?_%UWU% ' _\
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MM'.\;JCZI;;692 WR=CWKZUIH158D* 3U('6G4 %%%% !1110 4444 %%%%
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M-'_#-7Q6_P"B=^(__ $_XUT_6L/_ ,_(_>C'V%7^1_<SS:BO2?\ AFKXK?\
M1._$?_@"?\:/^&:OBM_T3OQ'_P" )_QH^M8?_GY'[T'L*O\ (_N9YM17I/\
MPS5\5O\ HG?B/_P!/^-36O[,/Q9O)TBC^'FO*S' ,MMY:CZLQ %'UO#K_EY'
M[T'L*O\ (_N9YQIUG-J&H6UK;J7GGE2*-5&26+ "OVX\'64NF^$]&M)R3/!9
MQ1OGKN" &OD/]E?]AR\\%:[:>+O'_D'4;4^99:/"XE6%^SRL."P[*,@>M?:E
M?G'$.84L94A2HNZC?7S?8^MRG"U*$93J*S?0****^0/?"BBB@ K@/B/_ ,C7
MX _["[?^B)*[^N ^(_\ R-?@#_L+M_Z(DH [^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#@?&W_)2_AY_P!?%]_Z2/7?5P/C;_DI?P\_Z^+[_P!)'KOJ
M "BBB@ HHHH **** "BBB@ HHHH **** "O/M>_Y+-X7_P"O"Z_I7H->?:]_
MR6;PO_UX77]* /0:*** "BBB@ HHHH **** "BBB@ HHHH **** . F_Y+A#
M_P!@+_VNU%$W_)<(?^P%_P"UVHH T?B?\/[?XE>&1I%R+ QB=)Q_:.G1WT0*
MY_Y9N0,\\'M7.:'\,/%OAG2;;2](\9V.F:;;+L@M+3PY!'%$N<X51)@#)-%%
M7SRY>2^G;H3RJ_-;4O?\(=X__P"BA0_^""'_ ..4?\(=X_\ ^BA0_P#@@A_^
M.445!0?\(=X__P"BA0_^""'_ ..4?\(=X_\ ^BA0_P#@@A_^.444 '_"'>/_
M /HH4/\ X((?_CE'_"'>/_\ HH4/_@@A_P#CE%% !_PAWC__ **%#_X((?\
MXY1_PAWC_P#Z*%#_ .""'_XY110 ?\(=X_\ ^BA0_P#@@A_^.4?\(=X__P"B
MA0_^""'_ ..444 '_"'>/_\ HH4/_@@A_P#CE'_"'>/_ /HH4/\ X((?_CE%
M% !_PAWC_P#Z*%#_ .""'_XY1_PAWC__ **%#_X((?\ XY110 ?\(=X__P"B
MA0_^""'_ ..4?\(=X_\ ^BA0_P#@@A_^.444 4]9^''C?7=*NM/NOB%']GN8
MS$^S080<'KCYZEL/ /CK3;&WM(?B%&(8(UB3=H,).U0 ,_O/:BB@"?\ X0[Q
M_P#]%"A_\$$/_P <H_X0[Q__ -%"A_\ !!#_ /'*** #_A#O'_\ T4*'_P $
M$/\ \<H_X0[Q_P#]%"A_\$$/_P <HHH /^$.\?\ _10H?_!!#_\ '*/^$.\?
M_P#10H?_  00_P#QRBB@ _X0[Q__ -%"A_\ !!#_ /'*/^$.\?\ _10H?_!!
M#_\ '*** #_A#O'_ /T4*'_P00__ !RC_A#O'_\ T4*'_P $$/\ \<HHH /^
M$.\?_P#10H?_  00_P#QRC_A#O'_ /T4*'_P00__ !RBB@ _X0[Q_P#]%"A_
M\$$/_P <H_X0[Q__ -%"A_\ !!#_ /'*** #_A#O'_\ T4*'_P $$/\ \<H_
MX0[Q_P#]%"A_\$$/_P <HHH /^$.\?\ _10H?_!!#_\ '*/^$.\?_P#10H?_
M  00_P#QRBB@ _X0[Q__ -%"A_\ !!#_ /'*/^$.\?\ _10H?_!!#_\ '***
M #_A#O'_ /T4*'_P00__ !RLWQ#\+O&GB;318WOQ"7R!<07/[O0H =\4J2IU
M<\;D7/MFBB@#2_X0[Q]_T4*'_P $$/\ \<H_X0[Q]_T4*'_P00__ !RBB@ _
MX0[Q_P#]%"A_\$$/_P <H_X0[Q__ -%"A_\ !!#_ /'*** #_A#O'_\ T4*'
M_P $$/\ \<H_X0[Q_P#]%"A_\$$/_P <HHH /^$.\?\ _10H?_!!#_\ '*/^
M$.\?_P#10H?_  00_P#QRBB@ _X0[Q__ -%"A_\ !!#_ /'*/^$.\?\ _10H
M?_!!#_\ '*** #_A#O'_ /T4*'_P00__ !RC_A#O'_\ T4*'_P $$/\ \<HH
MH /^$.\?_P#10H?_  00_P#QRC_A#O'_ /T4*'_P00__ !RBB@#.UKX7^-=?
M6S6Z^(2XM+J.[CV:% /G0Y7/SGC-:/\ PAWC_P#Z*%#_ .""'_XY110 ?\(=
MX_\ ^BA0_P#@@A_^.4?\(=X__P"BA0_^""'_ ..444 '_"'>/_\ HH4/_@@A
M_P#CE'_"'>/_ /HH4/\ X((?_CE%% !_PAWC_P#Z*%#_ .""'_XY1_PAWC__
M **%#_X((?\ XY110 ?\(=X__P"BA0_^""'_ ..4?\(=X_\ ^BA0_P#@@A_^
M.444 '_"'>/_ /HH4/\ X((?_CE'_"'>/_\ HH4/_@@A_P#CE%% !_PAWC__
M **%#_X((?\ XY1_PAWC_P#Z*%#_ .""'_XY110 ?\(=X_\ ^BA0_P#@@A_^
M.5F:O\+/&>M7NEW5S\0E\W3;@W,&S0H0-^TKS\_(PQ]*** -/_A#O'__ $4*
M'_P00_\ QRC_ (0[Q_\ ]%"A_P#!!#_\<HHH /\ A#O'_P#T4*'_ ,$$/_QR
MC_A#O'__ $4*'_P00_\ QRBB@ _X0[Q__P!%"A_\$$/_ ,<H_P"$.\?_ /10
MH?\ P00__'*** #_ (0[Q_\ ]%"A_P#!!#_\<H_X0[Q__P!%"A_\$$/_ ,<H
MHH /^$.\?_\ 10H?_!!#_P#'*/\ A#O'_P#T4*'_ ,$$/_QRBB@ _P"$.\?_
M /10H?\ P00__'*/^$.\?_\ 10H?_!!#_P#'*** #_A#O'__ $4*'_P00_\
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'Y-%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>37
<FILENAME>ibio-20230630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/27/2023 5:26:56 PM-->
<!--Modified on: 9/27/2023 5:26:56 PM-->
<xsd:schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://www.ibioinc.com/20230630" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ibio="http://www.ibioinc.com/20230630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
        <link:definition>00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss CALC2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails">
        <link:definition>40403 - Disclosure - Summary of Significant Accounting Policies (Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" id="DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details">
        <link:definition>40702 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities2) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" id="DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails">
        <link:definition>40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails" id="DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails">
        <link:definition>40804 - Disclosure - Investments in Debt Securities (Realized Losses on Available-For-Sale Debt Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" id="DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails">
        <link:definition>41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" id="DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails">
        <link:definition>41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" id="DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails">
        <link:definition>41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" id="DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
        <link:definition>41301 - Disclosure - Accrued Expenses (Summary of Accrued Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" id="DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2">
        <link:definition>41304 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Finance Lease Obligation) (Details) (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2">
        <link:definition>41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3">
        <link:definition>41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" id="DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails">
        <link:definition>41503 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails">
        <link:definition>41603 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>42101 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>42102 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>42104 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>10101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10401 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" id="DisclosureFinancialInstrumentsAndFairValueMeasurement">
        <link:definition>10501 - Disclosure - Financial Instruments and Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactions" id="DisclosureSignificantTransactions">
        <link:definition>10601 - Disclosure - Significant Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable" id="DisclosurePromissoryNoteReceivable">
        <link:definition>10701 - Disclosure - Promissory Note Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" id="DisclosureInvestmentsInDebtSecurities">
        <link:definition>10801 - Disclosure - Investments in Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" id="DisclosureFinanceLeaseRouAssets">
        <link:definition>10901 - Disclosure - Finance Lease ROU Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" id="DisclosureOperatingLeaseRouAssets">
        <link:definition>11001 - Disclosure - Operating Lease ROU Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssets" id="DisclosureFixedAssets">
        <link:definition>11101 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>11201 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>11301 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>11401 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations" id="DisclosureFinanceLeaseObligations">
        <link:definition>11501 - Disclosure - Finance Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations" id="DisclosureOperatingLeaseObligations">
        <link:definition>11601 - Disclosure - Operating Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11701 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" id="DisclosureEarningsLossPerCommonShare">
        <link:definition>11801 - Disclosure - Earnings (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>11901 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" id="DisclosureFraunhoferSettlement">
        <link:definition>12001 - Disclosure - Fraunhofer Settlement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>12101 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>12201 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" id="DisclosureEmployee401KPlan">
        <link:definition>12301 - Disclosure - Employee 401(K) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>12401 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20402 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30403 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" id="DisclosureFinancialInstrumentsAndFairValueMeasurementTables">
        <link:definition>30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" id="DisclosureSignificantTransactionsTables">
        <link:definition>30603 - Disclosure - Significant Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables" id="DisclosureInvestmentsInDebtSecuritiesTables">
        <link:definition>30803 - Disclosure - Investments in Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" id="DisclosureFinanceLeaseRouAssetsTables">
        <link:definition>30903 - Disclosure - Finance Lease ROU Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" id="DisclosureFixedAssetsTables">
        <link:definition>31103 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>31203 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>31303 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" id="DisclosureFinanceLeaseObligationTables">
        <link:definition>31503 - Disclosure - Finance Lease Obligation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" id="DisclosureOperatingLeaseObligationsTables">
        <link:definition>31603 - Disclosure - Operating Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>31703 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" id="DisclosureEarningsLossPerCommonShareTables">
        <link:definition>31803 - Disclosure - Earnings (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>31903 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>32103 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" id="DisclosureBasisOfPresentationNarrativeDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" id="DisclosureDiscontinuedOperationsNarrativeDetails">
        <link:definition>40301 - Disclosure - Discontinued Operations (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" id="DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails">
        <link:definition>40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails">
        <link:definition>40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails">
        <link:definition>40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" id="DisclosureSignificantTransactionsNarrativeDetails">
        <link:definition>40601 - Disclosure - Significant Transactions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" id="DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails">
        <link:definition>40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" id="DisclosurePromissoryNoteReceivableNarrativeDetails">
        <link:definition>40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" id="DisclosureInvestmentsInDebtSecuritiesNarrativeDetails">
        <link:definition>40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" id="DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails">
        <link:definition>40802 - Disclosure - Investments in Debt Securities (Components of Investments in Debt Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" id="DisclosureFinanceLeaseRouAssetsNarrativeDetails">
        <link:definition>40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" id="DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails">
        <link:definition>40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" id="DisclosureOperatingLeaseRouAssetsNarrativeDetails">
        <link:definition>41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" id="DisclosureFixedAssetsNarrativeDetails">
        <link:definition>41101 - Disclosure - Fixed Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" id="DisclosureIntangibleAssetsNarrativeDetails">
        <link:definition>41201 - Disclosure - Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" id="DisclosureDebtCreditAgreementDetails">
        <link:definition>41401 - Disclosure - Debt (The Credit Agreement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" id="DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails">
        <link:definition>41403 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" id="DisclosureDebtNotePayablePppLoanDetails">
        <link:definition>41404 - Disclosure - Debt (Note Payable - PPP Loan) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" id="DisclosureFinanceLeaseObligationNarrativeDetails">
        <link:definition>41501 - Disclosure - Finance Lease Obligation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" id="DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails">
        <link:definition>41502 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" id="DisclosureOperatingLeaseObligationNarrativeDetails">
        <link:definition>41601 - Disclosure - Operating Lease Obligation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" id="DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails">
        <link:definition>41602 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>41701 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" id="DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails">
        <link:definition>41702 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" id="DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails">
        <link:definition>41703 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" id="DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails">
        <link:definition>41801 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>41802 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>41901 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" id="DisclosureShareBasedCompensationNarrativeDetails">
        <link:definition>41902 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" id="DisclosureShareBasedCompensationStockOptionActivityDetails">
        <link:definition>41903 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" id="DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails">
        <link:definition>41904 - Disclosure - Share-Based Compensation (Options Outstanding and Exercisable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" id="DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails">
        <link:definition>41905 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" id="DisclosureShareBasedCompensationRsusDetails">
        <link:definition>41906 - Disclosure - Share-Based Compensation (RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" id="DisclosureFraunhoferSettlementNarrativeDetails">
        <link:definition>42001 - Disclosure - Fraunhofer Settlement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>42103 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>42201 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" id="DisclosureEmployee401KPlanNarrativeDetails">
        <link:definition>42301 - Disclosure - Employee 401(K) Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" id="DisclosureSubsequentEventsNarrativeDetails">
        <link:definition>42401 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" id="DisclosureDiscontinuedOperations">
        <link:definition>10301 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" id="DisclosureDiscontinuedOperationsTables">
        <link:definition>30303 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>31403 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" id="DisclosureDebtEquipmentFinancingDetails">
        <link:definition>41402 - Disclosure - Debt (Equipment Financing) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:element id="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" name="CapitalExpenditureIncurredForIntangibleAssetsPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="UnpaidFixedAssetsIncludedInAccountsPayable" id="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ContractAssetsPolicyTextBlock" id="ibio_ContractAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BasisOfPresentationTable" id="ibio_BasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseAgreementAxis" id="ibio_PurchaseAgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseAgreementDomain" id="ibio_PurchaseAgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_EasternAffiliateMember" name="EasternAffiliateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="BasisOfPresentationLineItems" id="ibio_BasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SummaryOfSignificantAccountingPoliciesLineItems" id="ibio_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityTable" id="ibio_StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredTrackingStockMember" id="ibio_PreferredTrackingStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityLineItems" id="ibio_StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_AggregateCommonStockPurchased" name="AggregateCommonStockPurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="EarningsLossPerCommonShareTable" id="ibio_EarningsLossPerCommonShareTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EarningsLossPerCommonShareLineItems" id="ibio_EarningsLossPerCommonShareLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxesTable" id="ibio_IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxesLineItems" id="ibio_IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PrincipalMember" name="PrincipalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_InterestMember" name="InterestMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SecondEasternAffiliateMember" name="SecondEasternAffiliateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ContractLiabilitiesPolicyTextBlock" name="ContractLiabilitiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_BoardOfDirectorsOfficersAndEmployeesMember" name="BoardOfDirectorsOfficersAndEmployeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CurrentAndDeferredFederalAndStateTaxes" name="CurrentAndDeferredFederalAndStateTaxes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_IncomeTaxExpenseBenefitValuationAllowance" name="IncomeTaxExpenseBenefitValuationAllowance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioCdmoMember" name="IbioCdmoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" name="ProceedsFromIssuanceOfPreferredAndCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_RightOfUseAssetsPolicyPolicyTextBlock" name="RightOfUseAssetsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" name="FinanceLeaseRightOfUseAssetDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" name="FinanceLeaseRightOfUseAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" name="SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" name="FinanceLeaseRightOfUseAssetDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FacilityMember" name="FacilityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" name="FinanceLeaseRightOfUseAssetDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetGross" name="FinanceLeaseRightOfUseAssetGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" name="ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SeriesWarrantsMember" name="SeriesWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseObligationOtherInformationAbstract" name="FinanceLeaseObligationOtherInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinancingCashFlowsFromFinanceLeaseObligation" name="FinancingCashFlowsFromFinanceLeaseObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_StockIssuedDuringPeriodValueCapitalRaise" name="StockIssuedDuringPeriodValueCapitalRaise" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_StockIssuedDuringPeriodSharesCapitalRaise" name="StockIssuedDuringPeriodSharesCapitalRaise" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioTwoMember" name="ScenarioTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" name="IbioInc.2020OmnibusEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioOneMember" name="ScenarioOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_PppLoanCaresActMember" name="PppLoanCaresActMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" name="ConvertiblePromissoryNoteReceivableAndAccruedInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" name="AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LoansReceivableAmountInvested" name="LoansReceivableAmountInvested" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LoansReceivableFixedRatesOfInterest" name="LoansReceivableFixedRatesOfInterest" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SalesAgreementMember" name="SalesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ConsultantsMember" name="ConsultantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CantorFitzgeraldMember" name="CantorFitzgeraldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FourCustomersMember" name="FourCustomersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashAndCashEquivalentsPlusDebtSecurities" name="CashAndCashEquivalentsPlusDebtSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_OmnibusIncentivePlanMember" name="OmnibusIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_VariousEmployeesMember" name="VariousEmployeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SubscriptionReceivableCurrent" name="SubscriptionReceivableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise" name="NonCashTransactionOfSubscriptionReceivableForCapitalRaise" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" name="ForgivenessOfNotePayableAndAccruedInterestSbaLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborationOptionAndLicenseAgreementMember" name="CollaborationOptionAndLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_RubrycTheraputicsInc.Member" name="RubrycTheraputicsInc.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" name="CollaborationAndLicenseAgreementRoyaltyPaymentTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ImmuneOncologyAntibodiesRtx003Member" name="ImmuneOncologyAntibodiesRtx003Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_Series2PreferredStockMember" name="Series2PreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementNumberOfSharesPurchased" name="StockPurchaseAgreementNumberOfSharesPurchased" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementValueOfSharesPurchased" name="StockPurchaseAgreementValueOfSharesPurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_CollaborationAndLicenseAgreementAgreementTerm" name="CollaborationAndLicenseAgreementAgreementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_GainLossRelatedToLitigationSettlementTextBlock" name="GainLossRelatedToLitigationSettlementTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" name="AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" name="IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" name="CashPaymentsReceivablesRelatedToLitigationSettlement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScenarioPlanExpectedLegalFeesMember" name="ScenarioPlanExpectedLegalFeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioPlanExpectedPaymentOneMember" name="ScenarioPlanExpectedPaymentOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioPlanExpectedPaymentTwoMember" name="ScenarioPlanExpectedPaymentTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PercentageOfLegalFeesExpectedToBeReceived" name="PercentageOfLegalFeesExpectedToBeReceived" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" name="LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" name="NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SettlementOfRevenueContract" name="SettlementOfRevenueContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LeaseIncentiveForConstructionInProgress" name="LeaseIncentiveForConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_NonCashSettlementOfRevenueContract" name="NonCashSettlementOfRevenueContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_SignificantTransactionsAbstract" name="SignificantTransactionsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SignificantTransactionsTextBlock" name="SignificantTransactionsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NoBiosimilarProductHasBeenApprovedMember" name="NoBiosimilarProductHasBeenApprovedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" name="OperatingLeaseRightOfUseAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" name="ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_LessorFinanceLeaseMonthlyRent" name="LessorFinanceLeaseMonthlyRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseMonthlyRent" name="LesseeOperatingLeaseMonthlyRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_BaseRentAbatementInFirstYearPeriod" name="BaseRentAbatementInFirstYearPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingLeaseObligationOtherInformationAbstract" name="OperatingLeaseObligationOtherInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingCashFlowsFromOperatingLeaseObligation" name="OperatingCashFlowsFromOperatingLeaseObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_TotalOperatingLeaseCosts" name="TotalOperatingLeaseCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" name="CollegeStationInvestorsLlcAndBryanCapitalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioCmoPreferredTrackingStockMember" name="IbioCmoPreferredTrackingStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SecuredTermLoanMember" name="SecuredTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" name="PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" name="PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_BaseRentPercentageOfFairMarketValueOfProperty" name="BaseRentPercentageOfFairMarketValueOfProperty" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FairMarketValueOfProperty" name="FairMarketValueOfProperty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" name="EquityAgreementConsiderationTransferredEquityInterestsAcquired" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_EquityAgreementWarrantsIssuedOrIssuable" name="EquityAgreementWarrantsIssuedOrIssuable" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" name="EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_CreditAgreementThresholdLimitUnrestrictedCash" name="CreditAgreementThresholdLimitUnrestrictedCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" name="WarrantsIssuedForFinalPaymentOfSubleaseRent" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" name="WarrantsIssuedForFinalPaymentOfSubleaseRentValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_StockPurchaseAgreementTotalInvestment" name="StockPurchaseAgreementTotalInvestment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_OperatingLeaseCostsAbstract" name="OperatingLeaseCostsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" name="LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" name="LesseeOperatingLeaseImputedInterestToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" name="LesseeOperatingLeaseImputedInterestToBePaidYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" name="LesseeOperatingLeaseImputedInterestToBePaidYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" name="LesseeOperatingLeaseImputedInterestToBePaidYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" name="LesseeOperatingLeaseImputedInterestToBePaidYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" name="LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" name="LesseeOperatingLeaseImputedInterestToBePaidTotal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_PaymentsToAttainTermNote" name="PaymentsToAttainTermNote" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" name="TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" name="NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_WarrantsIssuedForFinanceLeasePayment" name="WarrantsIssuedForFinanceLeasePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LetterOfCreditTermLoanMember" name="LetterOfCreditTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LetterOfCreditSanDiegoLeaseMember" name="LetterOfCreditSanDiegoLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" name="NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_DeferredFinancingCostsAmortizationExpense" name="DeferredFinancingCostsAmortizationExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_IncreaseDecreaseInSettlementAssets" name="IncreaseDecreaseInSettlementAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="PercentageOfCollateralRequired" id="ibio_PercentageOfCollateralRequired" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CompanyPurchasingCardMember" id="ibio_CompanyPurchasingCardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ImpairmentOfPrepaidExpensesCurrent" id="ibio_ImpairmentOfPrepaidExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ImpairmentOfPrepaidExpensesNonCurrent" id="ibio_ImpairmentOfPrepaidExpensesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedRealEstateTaxes" id="ibio_AccruedRealEstateTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Series2022ConvertiblePreferredStockMember" id="ibio_Series2022ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionIntangibleAssetsMember" id="ibio_AssetAcquisitionIntangibleAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionPrepaidExpensesMember" id="ibio_AssetAcquisitionPrepaidExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WoodforestMember" id="ibio_WoodforestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AmendedCreditAgreementMember" id="ibio_AmendedCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DateOfAmendmentMember" id="ibio_DateOfAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" id="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OccurrenceOfSpecificMilestoneMember" id="ibio_OccurrenceOfSpecificMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtCovenantLiquidityAmount" id="ibio_DebtCovenantLiquidityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CurrentLiabilitiesRelatedToAssetsHeldForSale" id="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NoncurrentLiabilitiesRelatedToAssetsHeldForSale" id="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="UnconsolidatedGainLossAttributableToStockholders" id="ibio_UnconsolidatedGainLossAttributableToStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockIssuedInRubrycTransactionValue" id="ibio_CommonStockIssuedInRubrycTransactionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInInventoryReserve" id="ibio_IncreaseDecreaseInInventoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" id="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EmployeeReductionExpenses" id="ibio_EmployeeReductionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DiscontinuedOperationsResearchAndDevelopmentExpenses" id="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupInterestExpenseRelatedParty" id="ibio_DisposalGroupInterestExpenseRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupGainOnDebtForgiveness" id="ibio_DisposalGroupGainOnDebtForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DiscontinuedOperationsMiscellaneousExpensesIncome" id="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupOperatingLeaseRightOfUseAssets" id="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" id="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" id="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupNoncurrentOperatingLeaseObligations" id="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" id="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" id="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="UnpaidFixedAssetsAttributableToDiscontinuedOperations" id="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedLiabilitiesNoncurrent" id="ibio_AccruedLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInAccruedLiabilitiesNoncurrent" id="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaymentsForFractionalSharesAfterReverseStockSplit" id="ibio_PaymentsForFractionalSharesAfterReverseStockSplit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromEquipmentFinancingLoan" id="ibio_ProceedsFromEquipmentFinancingLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaymentOfEquipmentFinancingLoan" id="ibio_PaymentOfEquipmentFinancingLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CostToRaiseCapitalPaidDirectlyFromGrossProceeds" id="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquipmentFinancingPayableCurrent" id="ibio_EquipmentFinancingPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquipmentFinancingPayableNoncurrent" id="ibio_EquipmentFinancingPayableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FractionalShareIssuedAfterReverseStockSplitValue" id="ibio_FractionalShareIssuedAfterReverseStockSplitValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FractionalShareIssuedAfterReverseStockSplitShares" id="ibio_FractionalShareIssuedAfterReverseStockSplitShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" id="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" id="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" id="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" id="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" id="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AssetAcquisitionTransactionCosts" id="ibio_AssetAcquisitionTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetAcquisitionFixedAssetsMember" id="ibio_AssetAcquisitionFixedAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetPurchaseAgreementMember" id="ibio_AssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeparationAgreementAndGeneralReleaseMember" id="ibio_SeparationAgreementAndGeneralReleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" id="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" id="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" id="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" id="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" id="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FixedAssetsHeldForSale" id="ibio_FixedAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquipmentFinancingAmountBorrowed" id="ibio_EquipmentFinancingAmountBorrowed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LesseeEquipmentLeaseTermOfContract" id="ibio_LesseeEquipmentLeaseTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EquipmentLeasingMonthlyInstallmentPayable" id="ibio_EquipmentLeasingMonthlyInstallmentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquipmentFinancingLeaseImputedInterestRate" id="ibio_EquipmentFinancingLeaseImputedInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContractualObligationCurrent" id="ibio_ContractualObligationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContractualObligationNoncurrent" id="ibio_ContractualObligationNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LeaseRentExpensePerMonth" id="ibio_LeaseRentExpensePerMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquipmentFinancingInterestIncurred" id="ibio_EquipmentFinancingInterestIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="H.c.WainwrightCo.LlcMember" id="ibio_H.c.WainwrightCo.LlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsMember" id="ibio_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" id="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfDaysOptionToPurchaseAdditionalShares" id="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfAdditionalSharesIssued" id="ibio_NumberOfAdditionalSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonWarrantsToPurchaseAdditionalShares" id="ibio_CommonWarrantsToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfAggregateNumberOfSharesOfCommonStock" id="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RepresentativeWarrantsMember" id="ibio_RepresentativeWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquipmentFinancingBalance" id="ibio_EquipmentFinancingBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Mr.IsettMember" id="ibio_Mr.IsettMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Mr.RobertLutzMember" id="ibio_Mr.RobertLutzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Dr.MartinBrennerMember" id="ibio_Dr.MartinBrennerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfEquipmentLeases" id="ibio_NumberOfEquipmentLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EstimatedAdditionalCostOnDevelopment" id="ibio_EstimatedAdditionalCostOnDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CroAgreementMember" id="ibio_CroAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetLossAvailableToStockholdersFromContinuingOperations" id="ibio_NetLossAvailableToStockholdersFromContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" id="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TangibleAssetImpairmentChargesDiscontinuedOperations" id="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ImpairmentOfIntangibleAssetsGrossOfReversals" id="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReversalOfIntangibleAssetImpairment" id="ibio_ReversalOfIntangibleAssetImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AuctionSaleAgreementMember" id="ibio_AuctionSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GuaranteedAuctionProceedsMember" id="ibio_GuaranteedAuctionProceedsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExcessAuctionProceedsMember" id="ibio_ExcessAuctionProceedsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HollandIndustrialGroupMember" id="ibio_HollandIndustrialGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfAuctionProceedsReceived" id="ibio_PercentageOfAuctionProceedsReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" id="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" id="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AssetAcquisitionValue" id="ibio_AssetAcquisitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetAcquisitionInShares" id="ibio_AssetAcquisitionInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CostAccruedToAmendTermNotePayable" id="ibio_CostAccruedToAmendTermNotePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" id="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AuctionFee" id="ibio_AuctionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SeveranceTransitionalPeriodDays" id="ibio_SeveranceTransitionalPeriodDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GainOnSaleOfFixedAssets" id="ibio_GainOnSaleOfFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases" id="ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant" id="ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromNotesPayableFromDiscontinuedOperations" id="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IssuanceOfWarrantForFinalLeaseObligationPayment" id="ibio_IssuanceOfWarrantForFinalLeaseObligationPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" id="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" id="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsResearchAndDevelopmentCosts" id="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" id="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IsettMember" id="ibio_IsettMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" id="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoansReceivableRateOfInterestForFirstOneYearExtension" id="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LoansReceivableRateOfInterestForSecondOneYearExtension" id="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfConsultantsToWhomStockOptionGranted" id="ibio_NumberOfConsultantsToWhomStockOptionGranted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InterimChiefExecutiveOfficerMember" id="ibio_InterimChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseAndSaleAgreementWithMajesticRealtyCoMember" id="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CreditAgreementWithWoodforestNationalBankMember" id="ibio_CreditAgreementWithWoodforestNationalBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsNotSoldOnOrBeforeDecember12023Member" id="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GroundLeasesAgreedToSellPruchasePrice" id="ibio_GroundLeasesAgreedToSellPruchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfOutstandingPrincipalAmountReducedTo10000000Member" id="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" id="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsSoldOnOrBeforeJune302023Member" id="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" id="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" id="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsNotSellOnOrBeforeDecember12023Member" id="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodForPaymentFromIssuanceOfAtMarketFacility" id="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfPaymentFromProceedsOfSalesOfEquipment" id="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AmountRetainedFromProceedsOfLegalSettlement" id="ibio_AmountRetainedFromProceedsOfLegalSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AmountToBeReleasedFromRestrictedCash" id="ibio_AmountToBeReleasedFromRestrictedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtInstrumentPaidInKindInterestRate" id="ibio_DebtInstrumentPaidInKindInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DebtInstrumentAmountOfFeesToBePaidUnderAgreement" id="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" id="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockPurchaseAgreementWithLincolnParkMember" id="ibio_StockPurchaseAgreementWithLincolnParkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" id="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" id="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumAmountOfCommonStockAgreedToSell" id="ibio_MaximumAmountOfCommonStockAgreedToSell" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ClosingPricePerShareOfCommonStock" id="ibio_ClosingPricePerShareOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" id="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MaximumNumberOfCommonStockToBeSold" id="ibio_MaximumNumberOfCommonStockToBeSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MaximumCommitmentInSingleRegularSaleOfCommonStock" id="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdditionalSharesAgreedToIssue" id="ibio_AdditionalSharesAgreedToIssue" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" id="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" id="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" id="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MinimumClosingPriceOfCommonStockToSellAdditionalShares" id="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfPaymentFromProceedsOfAtMarketFacility" id="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EightCustomersMember" id="ibio_EightCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CostOfDebtSecurities" id="ibio_CostOfDebtSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>38
<FILENAME>ibio-20230630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/27/2023 5:26:56 PM-->
<!--Modified on: 9/27/2023 5:26:56 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" roleURI="http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638314324095466521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638314324095466521" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638314324095466521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638314324095466521" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638314324095466521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638314324095466521" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638314324095476894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638314324095476894" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638314324095476894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit_638314324095476894" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638314324095476894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638314324095476894" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638314324095476894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638314324095476894" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638314324095476894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638314324095476894" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638314324095476894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638314324095476894" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638314324095476894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638314324095476894" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638314324095476894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638314324095476894" xlink:to="us-gaap_AccountsReceivableNetCurrent_638314324095476894" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638314324095486928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638314324095476894" xlink:to="us-gaap_RestrictedCashCurrent_638314324095486928" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638314324095486928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638314324095476894" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638314324095486928" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638314324095486928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638314324095476894" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638314324095486928" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638314324095486928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638314324095476894" xlink:to="us-gaap_DebtSecuritiesCurrent_638314324095486928" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638314324095486928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638314324095476894" xlink:to="us-gaap_SettlementAssetsCurrent_638314324095486928" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638314324095486928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638314324095476894" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638314324095486928" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638314324095486928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638314324095476894" xlink:to="ibio_SubscriptionReceivableCurrent_638314324095486928" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638314324095496977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638314324095496977" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324095496977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638314324095496977" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324095496977" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent_638314324095496977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638314324095496977" xlink:to="ibio_AccruedLiabilitiesNoncurrent_638314324095496977" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638314324095496977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638314324095496977" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638314324095496977" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638314324095496977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638314324095496977" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638314324095496977" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_638314324095506818" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638314324095496977" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_638314324095506818" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638314324095506818" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638314324095496977" xlink:to="us-gaap_LiabilitiesCurrent_638314324095506818" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638314324095506818" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638314324095506818" xlink:to="us-gaap_AccountsPayableCurrent_638314324095506818" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638314324095506818" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638314324095506818" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638314324095506818" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638314324095506818" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638314324095506818" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638314324095506818" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638314324095516910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638314324095506818" xlink:to="us-gaap_NotesPayableCurrent_638314324095516910" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638314324095516910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638314324095506818" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638314324095516910" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent_638314324095516910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638314324095506818" xlink:to="ibio_EquipmentFinancingPayableCurrent_638314324095516910" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638314324095536511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638314324095506818" xlink:to="us-gaap_DeferredRevenueCurrent_638314324095536511" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638314324095536511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638314324095506818" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638314324095536511" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638314324095536511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638314324095536511" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638314324095536511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638314324095536511" xlink:to="us-gaap_PreferredStockValue_638314324095536511" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638314324095536511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638314324095536511" xlink:to="us-gaap_CommonStockValue_638314324095536511" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638314324095546936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638314324095536511" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638314324095546936" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638314324095546936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638314324095536511" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638314324095546936" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638314324095556854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638314324095536511" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638314324095556854" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638314324095556854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638314324095556854" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638314324095566834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638314324095566834" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638314324095566834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638314324095566834" xlink:to="us-gaap_DividendsPreferredStockStock_638314324095566834" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638314324095566834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638314324095566834" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638314324095566834" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638314324095566834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations_638314324095566834" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638314324095566834" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638314324095566834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations_638314324095566834" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638314324095566834" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638314324095566834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638314324095566834" xlink:to="us-gaap_NonoperatingIncomeExpense_638314324095566834" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638314324095566834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638314324095566834" xlink:to="us-gaap_InterestExpense_638314324095566834" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638314324095576490" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638314324095566834" xlink:to="us-gaap_InvestmentIncomeInterest_638314324095576490" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating_638314324095576490" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638314324095566834" xlink:to="us-gaap_RoyaltyIncomeNonoperating_638314324095576490" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324095576490" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638314324095566834" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324095576490" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638314324095576490" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638314324095566834" xlink:to="us-gaap_OperatingIncomeLoss_638314324095576490" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638314324095576490" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638314324095576490" xlink:to="us-gaap_OperatingExpenses_638314324095576490" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638314324095576490" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638314324095576490" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638314324095576490" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638314324095586824" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638314324095576490" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638314324095586824" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638314324095586824" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638314324095576490" xlink:to="us-gaap_Revenues_638314324095586824" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xlink:type="extended" xlink:title="00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss CALC2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638314324095586824" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638314324095586824" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638314324095586824" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638314324095586824" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638314324095596848" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss_638314324095596848" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638314324095596848" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_ProfitLoss_638314324095596848" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_638314324095596848" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_638314324095596848" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_638314324095596848" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_ImpairmentOfInvestments_638314324095596848" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638314324095596848" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638314324095596848" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638314324095596848" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638314324095596848" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638314324095606869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638314324095606869" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638314324095606869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_ShareBasedCompensation_638314324095606869" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638314324095606869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638314324095606869" order="8" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638314324095606869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638314324095606869" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638314324095606869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638314324095606869" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638314324095606869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638314324095606869" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract_638314324095616933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="ibio_SettlementOfRevenueContract_638314324095616933" order="12" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638314324095616933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638314324095616933" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638314324095616933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638314324095616933" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_638314324095616933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_638314324095616933" order="15" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638314324095616933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_Depreciation_638314324095616933" order="16" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638314324095616933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638314324095616933" order="17" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638314324095626908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638314324095626908" order="18" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInSettlementAssets" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_638314324095626908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="ibio_IncreaseDecreaseInSettlementAssets_638314324095626908" order="19" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638314324095626908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638314324095626908" order="20" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638314324095626908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638314324095626908" order="21" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_638314324095626908" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_638314324095626908" order="22" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638314324095636945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638314324095636945" order="23" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638314324095636945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638314324095636945" order="24" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638314324095636945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638314324095636945" order="25" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638314324095636945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638314324095636945" order="26" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324095636945" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324095636945" order="27" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638314324095646927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638314324095646927" order="28" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638314324095646927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324095596848" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638314324095646927" order="29" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638314324095646927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638314324095646927" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638314324095657111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638314324095657111" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638314324095657111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638314324095657111" order="3" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638314324095657111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638314324095657111" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638314324095657111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638314324095657111" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638314324095657111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638314324095657111" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638314324095666910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638314324095666910" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638314324095666910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324095646927" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638314324095666910" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638314324095676965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638314324095676965" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentsToAttainTermNote" xlink:label="ibio_PaymentsToAttainTermNote_638314324095676965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="ibio_PaymentsToAttainTermNote_638314324095676965" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ProceedsFromEquipmentFinancingLoan" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_638314324095676965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="ibio_ProceedsFromEquipmentFinancingLoan_638314324095676965" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_638314324095676965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_638314324095676965" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638314324095686894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="us-gaap_RepaymentsOfNotesPayable_638314324095686894" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638314324095686894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638314324095686894" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentsForFractionalSharesAfterReverseStockSplit" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_638314324095686894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_638314324095686894" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638314324095686894" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638314324095686894" order="8" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders_638314324095696916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324095666910" xlink:to="us-gaap_PaymentsToMinorityShareholders_638314324095696916" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638314324095696916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638314324095696916" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638314324095706937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638314324095706937" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638314324095706937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638314324095706937" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Summary of Significant Accounting Policies (Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_638314324095706937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_638314324095706937" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638314324095706937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess_638314324095706937" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" xlink:type="extended" xlink:title="40702 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities2) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638314324095717050" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638314324095717050" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638314324095717050" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesCurrent_638314324095717050" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost" xlink:label="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost_638314324095717050" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost_638314324095717050" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638314324095717050" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638314324095717050" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Investments in Debt Securities (Realized Losses on Available-For-Sale Debt Securities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CostOfDebtSecurities" xlink:label="ibio_CostOfDebtSecurities_638314324095726866" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_2" xlink:to="ibio_CostOfDebtSecurities_638314324095726866" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638314324095726866" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_2" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638314324095726866" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638314324095726866" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638314324095726866" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638314324095726866" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638314324095726866" order="2" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638314324095736856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638314324095736856" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638314324095736856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638314324095736856" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638314324095736856" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638314324095736856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638314324095736856" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638314324095736856" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638314324095736856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638314324095736856" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637045036842059670" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638314324095736856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_637045036842059670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638314324095736856" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638314324095746821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_637045036842059670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638314324095746821" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638314324095746821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_637045036842059670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638314324095746821" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638314324095746821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_637045036842059670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638314324095746821" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638314324095746821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_637045036842059670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638314324095746821" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638314324095746821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_637045036842059670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638314324095746821" order="6" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Accrued Expenses (Summary of Accrued Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638314324095746821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638314324095746821" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedRealEstateTaxes" xlink:label="ibio_AccruedRealEstateTaxes_638314324095756861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ibio_AccruedRealEstateTaxes_638314324095756861" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638314324095756861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638314324095756861" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638314324095756861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638314324095756861" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638314324095756861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638314324095756861" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" xlink:type="extended" xlink:title="41304 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Finance Lease Obligation) (Details) (Calc2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324095756861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324095756861" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638314324095756861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638314324095756861" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" xlink:type="extended" xlink:title="41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638314324095767075" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638314324095767075" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638314324095767075" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638314324095767075" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" xlink:type="extended" xlink:title="41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 3)">
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638314324095767075" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638314324095767075" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638314324095776871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638314324095776871" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638314324095776871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638314324095776871" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638314324095776871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638314324095776871" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638314324095776871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638314324095776871" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638314324095776871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638314324095776871" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638314324095786831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638314324095786831" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638314324095786831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638314324095786831" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638314324095786831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638314324095786831" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638314324095786831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638314324095786831" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638314324095786831" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638314324095786831" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638314324095796846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638314324095796846" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638314324095796846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638314324095796846" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638314324095796846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638314324095796846" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638314324095806871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638314324095806871" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638314324095806871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638314324095806871" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638314324095806871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638314324095806871" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41603 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638314324095806871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638314324095806871" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638314324095806871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638314324095806871" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638314324095806871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638314324095806871" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638314324095816856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638314324095816856" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638314324095816856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638314324095816856" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638314324095816856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638314324095816856" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638314324095816856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638314324095816856" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638314324095816856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638314324095816856" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638314324095816856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638314324095816856" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638314324095816856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638314324095816856" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638314324095816856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638314324095816856" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638314324095826851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638314324095826851" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638314324095826851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638314324095826851" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638314324095826851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638314324095826851" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638314324095826851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638314324095826851" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638314324095836822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638314324095836822" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638314324095836822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638314324095836822" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638314324095836822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638314324095836822" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="42101 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637045036843136768" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CurrentAndDeferredFederalAndStateTaxes" xlink:label="ibio_CurrentAndDeferredFederalAndStateTaxes_638314324095846838" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637045036843136768" xlink:to="ibio_CurrentAndDeferredFederalAndStateTaxes_638314324095846838" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638314324095846838" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_CurrentAndDeferredFederalAndStateTaxes_638314324095846838" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638314324095846838" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638314324095846838" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_CurrentAndDeferredFederalAndStateTaxes_638314324095846838" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638314324095846838" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638314324095846838" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_CurrentAndDeferredFederalAndStateTaxes_638314324095846838" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638314324095846838" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxExpenseBenefitValuationAllowance" xlink:label="ibio_IncomeTaxExpenseBenefitValuationAllowance_638314324095846838" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637045036843136768" xlink:to="ibio_IncomeTaxExpenseBenefitValuationAllowance_638314324095846838" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="42102 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638314324095846838" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638314324095846838" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxAssetsResearchAndDevelopmentCosts" xlink:label="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts_638314324095856867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts_638314324095856867" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638314324095856867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638314324095856867" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638314324095856867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638314324095856867" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638314324095856867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638314324095856867" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments_638314324095856867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments_638314324095856867" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638314324095856867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638314324095856867" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" xlink:label="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets_638314324095856867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets_638314324095856867" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638314324095867019" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638314324095867019" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" xlink:label="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities_638314324095867019" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities_638314324095867019" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638314324095867019" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638314324095867019" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638314324095867019" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637045036843146741" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638314324095867019" order="12" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="42104 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638314324095876949" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638314324095876949" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions_638314324095876949" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions_638314324095876949" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo_638314324095876949" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo_638314324095876949" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638314324095876949" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638314324095876949" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638314324095876949" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638314324095876949" order="5" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>39
<FILENAME>ibio-20230630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/27/2023 5:26:56 PM-->
<!--Modified on: 9/27/2023 5:26:56 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSignificantTransactionsTables" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureBasisOfPresentationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDiscontinuedOperationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSignificantTransactionsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosurePromissoryNoteReceivableNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebtCreditAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebtNotePayablePppLoanDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFraunhoferSettlementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureEmployee401KPlanNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ibio-20230630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" xlink:title="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_1" xlink:title="us-gaap_ReceivableTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" xlink:to="us-gaap_ReceivableTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1 To us-gaap_ReceivableTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:title="us-gaap_GuaranteeObligationsByNatureAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_1" xlink:title="us-gaap_GuaranteeObligationsNatureDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GuaranteeObligationsByNatureAxis_1 To us-gaap_GuaranteeObligationsNatureDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_1" xlink:title="srt_LitigationCaseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_1" xlink:title="srt_LitigationCaseTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_LitigationCaseAxis_1" xlink:to="srt_LitigationCaseTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_LitigationCaseAxis_1 To srt_LitigationCaseTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_1" xlink:title="us-gaap_LitigationStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_1" xlink:title="us-gaap_LitigationStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LitigationStatusAxis_1" xlink:to="us-gaap_LitigationStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LitigationStatusAxis_1 To us-gaap_LitigationStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherComprehensiveIncomeLocationAxis_1 To us-gaap_OtherComprehensiveIncomeLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="us-gaap_ReclassificationTypeAxis_1" xlink:title="us-gaap_ReclassificationTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="us-gaap_ReclassificationTypeDomain_1" xlink:title="us-gaap_ReclassificationTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ReclassificationTypeAxis_1" xlink:to="us-gaap_ReclassificationTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ReclassificationTypeAxis_1 To us-gaap_ReclassificationTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" xlink:title="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" xlink:title="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TimingOfTransferOfGoodOrServiceAxis_1 To us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchaseAgreementAxis" xlink:label="ibio_PurchaseAgreementAxis_1" xlink:title="ibio_PurchaseAgreementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchaseAgreementDomain" xlink:label="ibio_PurchaseAgreementDomain_1" xlink:title="ibio_PurchaseAgreementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ibio_PurchaseAgreementAxis_1" xlink:to="ibio_PurchaseAgreementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ibio_PurchaseAgreementAxis_1 To ibio_PurchaseAgreementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1 To us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="us-gaap_UnusualOrInfrequentItemAxis_1" xlink:title="us-gaap_UnusualOrInfrequentItemAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_1" xlink:title="us-gaap_UnusualOrInfrequentItemDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_UnusualOrInfrequentItemAxis_1" xlink:to="us-gaap_UnusualOrInfrequentItemDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_UnusualOrInfrequentItemAxis_1 To us-gaap_UnusualOrInfrequentItemDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:title="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_1" xlink:title="us-gaap_AdjustmentsForErrorCorrectionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1 To us-gaap_AdjustmentsForErrorCorrectionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_1" xlink:title="us-gaap_StatementOperatingActivitiesSegmentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_1" xlink:title="us-gaap_SegmentOperatingActivitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_1" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementOperatingActivitiesSegmentAxis_1 To us-gaap_SegmentOperatingActivitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1 To us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionValue" xlink:label="ibio_AssetAcquisitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AssetAcquisitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionInShares" xlink:label="ibio_AssetAcquisitionInShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AssetAcquisitionInShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitValue" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitShares" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Significant Transactions (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_RubrycTheraputicsInc.Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationTable" xlink:label="ibio_BasisOfPresentationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_BasisOfPresentationTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationLineItems" xlink:label="ibio_BasisOfPresentationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="ibio_BasisOfPresentationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="ibio_CashAndCashEquivalentsPlusDebtSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Discontinued Operations (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AuctionSaleAgreementMember" xlink:label="ibio_AuctionSaleAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="ibio_AuctionSaleAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GuaranteedAuctionProceedsMember" xlink:label="ibio_GuaranteedAuctionProceedsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_GuaranteedAuctionProceedsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExcessAuctionProceedsMember" xlink:label="ibio_ExcessAuctionProceedsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ExcessAuctionProceedsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_HollandIndustrialGroupMember" xlink:label="ibio_HollandIndustrialGroupMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_HollandIndustrialGroupMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfAuctionProceedsReceived" xlink:label="ibio_PercentageOfAuctionProceedsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_PercentageOfAuctionProceedsReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AuctionFee" xlink:label="ibio_AuctionFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_AuctionFee" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_EmployeeReductionExpenses" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceTransitionalPeriodDays" xlink:label="ibio_SeveranceTransitionalPeriodDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_SeveranceTransitionalPeriodDays" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FourCustomersMember" xlink:label="ibio_FourCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ibio_FourCustomersMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EightCustomersMember" xlink:label="ibio_EightCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ibio_EightCustomersMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_NumberOfMajorCustomers" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_LetterOfCreditTermLoanMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_CompanyPurchasingCardMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_LandSubjectToGroundLeases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="ibio_PercentageOfCollateralRequired" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfBuildings" xlink:label="us-gaap_ProceedsFromSaleOfBuildings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfBuildings" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ibio_FixedAssetsHeldForSale" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Significant Transactions (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_Series2PreferredStockMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_StockPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="ibio_IbioCmoPreferredTrackingStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FairMarketValueOfProperty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AssetAcquisitionTransactionCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_NumberOfEquipmentLeases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AccruedLiabilitiesNoncurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_Series2PreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionFixedAssetsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_NotesReceivableMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableAmountInvested" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableFixedRatesOfInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ibio_FacilityMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Intangible Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="ibio_StockPurchaseAgreementTotalInvestment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDeferredChargesAbstract" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfDeferredChargesAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AmortizationOfDeferredChargesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:to="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ReversalOfIntangibleAssetImpairment" xlink:label="ibio_ReversalOfIntangibleAssetImpairment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:to="ibio_ReversalOfIntangibleAssetImpairment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Debt (The Credit Agreement) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_AmendedCreditAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_DateOfAmendmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtInstrumentPaidInKindInterestRate" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_DebtInstrumentPaidInKindInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_DebtCovenantLiquidityAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmountRetainedFromProceedsOfLegalSettlement" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_AmountRetainedFromProceedsOfLegalSettlement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmountToBeReleasedFromRestrictedCash" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_AmountToBeReleasedFromRestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_PrincipalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_InterestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ContractualObligationCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ContractualObligationNoncurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" xlink:type="extended" xlink:title="41404 - Disclosure - Debt (Note Payable - PPP Loan) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PppLoanCaresActMember" xlink:label="ibio_PppLoanCaresActMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_PppLoanCaresActMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Finance Lease Obligation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecondEasternAffiliateMember" xlink:label="ibio_SecondEasternAffiliateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_SecondEasternAffiliateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_NumberOfEquipmentLeases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_LeaseRentExpensePerMonth" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_LessorFinanceLeaseMonthlyRent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_PrincipalMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_InterestMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Operating Lease Obligation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TenantImprovements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibio_ExchangeAgreementMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OmnibusIncentivePlanMember" xlink:label="ibio_OmnibusIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_OmnibusIncentivePlanMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_PreferredTrackingStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_Series2022ConvertiblePreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_PreFundedWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_RepresentativeWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesBWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_H.c.WainwrightCo.LlcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_EasternAffiliateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="ibio_IbioCdmoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CantorFitzgeraldMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AggregateCommonStockPurchased" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SubscriptionReceivableCurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_H.c.WainwrightCo.LlcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_PreFundedWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesBWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_NumberOfAdditionalSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_EarningsLossPerCommonShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="ibio_EarningsLossPerCommonShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="41902 - Disclosure - Share-Based Compensation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ScenarioOneMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ScenarioTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ConsultantsMember" xlink:label="ibio_ConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_ConsultantsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_VariousEmployeesMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BoardOfDirectorsOfficersAndEmployeesMember" xlink:label="ibio_BoardOfDirectorsOfficersAndEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_BoardOfDirectorsOfficersAndEmployeesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IsettMember" xlink:label="ibio_IsettMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_IsettMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfConsultantsToWhomStockOptionGranted" xlink:label="ibio_NumberOfConsultantsToWhomStockOptionGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibio_NumberOfConsultantsToWhomStockOptionGranted" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="41904 - Disclosure - Share-Based Compensation (Options Outstanding and Exercisable) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceOneMember" xlink:label="ibio_ExercisePriceOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="ibio_ExercisePriceOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceTwoMember" xlink:label="ibio_ExercisePriceTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="ibio_ExercisePriceTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceThreeMember" xlink:label="ibio_ExercisePriceThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="ibio_ExercisePriceThreeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceFourMember" xlink:label="ibio_ExercisePriceFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="ibio_ExercisePriceFourMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" xlink:type="extended" xlink:title="41906 - Disclosure - Share-Based Compensation (RSUs) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Dr.MartinBrennerMember" xlink:label="ibio_Dr.MartinBrennerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_Dr.MartinBrennerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Mr.IsettMember" xlink:label="ibio_Mr.IsettMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_Mr.IsettMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Mr.RobertLutzMember" xlink:label="ibio_Mr.RobertLutzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_Mr.RobertLutzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_VariousEmployeesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_InterimChiefExecutiveOfficerMember" xlink:label="ibio_InterimChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_InterimChiefExecutiveOfficerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Fraunhofer Settlement (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SettlementAssetsCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainContingencyUnrecordedAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="42103 - Disclosure - Income Taxes (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxesTable" xlink:label="ibio_IncomeTaxesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxesLineItems" xlink:label="ibio_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_IncomeTaxesLineItems" xlink:to="ibio_IncomeTaxesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="42201 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_CroAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EstimatedAdditionalCostOnDevelopment" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EstimatedAdditionalCostOnDevelopment" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" xlink:type="extended" xlink:title="42301 - Disclosure - Employee 401(K) Plan (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="42401 - Disclosure - Subsequent Events (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CreditAgreementWithWoodforestNationalBankMember" xlink:label="ibio_CreditAgreementWithWoodforestNationalBankMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_CreditAgreementWithWoodforestNationalBankMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementWithLincolnParkMember" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_StockPurchaseAgreementWithLincolnParkMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CantorFitzgeraldMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesBWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_VariousEmployeesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="10" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GroundLeasesAgreedToSellPruchasePrice" xlink:label="ibio_GroundLeasesAgreedToSellPruchasePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_GroundLeasesAgreedToSellPruchasePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarnestMoneyDeposits" xlink:label="us-gaap_EarnestMoneyDeposits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EarnestMoneyDeposits" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumAmountOfCommonStockAgreedToSell" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_MaximumAmountOfCommonStockAgreedToSell" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ClosingPricePerShareOfCommonStock" xlink:label="ibio_ClosingPricePerShareOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_ClosingPricePerShareOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockToBeSold" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_MaximumNumberOfCommonStockToBeSold" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AdditionalSharesAgreedToIssue" xlink:label="ibio_AdditionalSharesAgreedToIssue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_AdditionalSharesAgreedToIssue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" xlink:label="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" xlink:label="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" xlink:label="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>40
<FILENAME>ibio-20230630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/27/2023 5:26:56 PM-->
<!--Modified on: 9/27/2023 5:26:56 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="us-gaap_DebtSecuritiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Fair value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Fair value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Investments in debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - trade</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SubscriptionReceivableCurrent" xlink:to="ibio_SubscriptionReceivableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Subscription Receivable Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Subscription receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementAssetsCurrent" xlink:to="us-gaap_SettlementAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement receivable - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Current assets held for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Amount of convertible Promissory Note Receivable and Accrued Interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Convertible Promissory Note Receivable and Accrued Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Promissory note receivable and accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance lease right-of-use assets, net of accumulated amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance lease ROU assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net fixed assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net of accumulated depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Total net intangible assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses - noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Noncurrent assets held for sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligations - current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligation - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligation - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingPayableCurrent" xlink:to="ibio_EquipmentFinancingPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">The amount of current portion of equipment financing payable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">Equipment Financing Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">Equipment financing payable - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Term note payable - net of deferred financing costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current liabilities related to assets held for sale.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current Liabilities Related To Assets Held For Sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current liabilities related to assets held for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum lease obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligation - non current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligations - net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligation - net of current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingPayableNoncurrent" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">The amount of noncurrent portion of equipment financing payable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">Equipment Financing Payable, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">Equipment financing payable - net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AccruedLiabilitiesNoncurrent" xlink:to="ibio_AccruedLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued expenses - noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent liabilities related to assets held for sale.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent Liabilities Related To Assets Held For Sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent liabilities related to assets held for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Equity:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of June 30, 2023 and 2022</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Value of common stock issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2023 and 2022; 20,310,077 and 8,727,158 shares issued and outstanding as of June 30, 2023 and June 30, 2022, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split, shares received per share tendered</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Gain (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Loss on sale of debt securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Loss on sale of debt securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Realized loss on sale of debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyIncomeNonoperating" xlink:to="us-gaap_RoyaltyIncomeNonoperating_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xml:lang="en-US">Royalty income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Consolidated Gain (Loss) From Continuing Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Consolidated net loss from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc. from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Dividends, Preferred Stock, Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Preferred stock dividends - iBio CDMO Tracking Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Preferred stock dividends - iBio CMO Preferred Tracking Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Amount of net loss available to stockholders from continuing operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Net Loss Available To Stockholders from Continuing Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">The unconsolidated net gain (loss) attributable to stockholders.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">Unconsolidated Gain (Loss) Attributable To Stockholders</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive income (loss) - unrealized gain (loss) on debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive income - foreign currency adjustment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Per share amount basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Per share amount diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average common shares outstanding - basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average common shares outstanding - diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements of Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Equity impact of the value of capital raise during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Stock Issued During Period, Value, Capital Raise</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Capital raise</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Number of new shares raised during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Capital Raise</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Capital raise (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Cost to raise capital</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionValue" xlink:label="ibio_AssetAcquisitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionValue" xlink:to="ibio_AssetAcquisitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionValue_lbl" xml:lang="en-US">Equity impact of the value of asset acquisition during the period. (Value)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionValue_lbl" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionInShares" xlink:label="ibio_AssetAcquisitionInShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionInShares" xlink:to="ibio_AssetAcquisitionInShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionInShares_lbl" xml:lang="en-US">Number of new shares from asset acquisition during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionInShares_lbl" xml:lang="en-US">Asset Acquisition (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Options, Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitValue" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FractionalShareIssuedAfterReverseStockSplitValue" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue_lbl" xml:lang="en-US">Value of fractional shares after reverse stock split issued during period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue_lbl" xml:lang="en-US">Fractional Share Issued After Reverse Stock Split, Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue_lbl" xml:lang="en-US">Payment for fractional shares after reverse stock split</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitShares" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FractionalShareIssuedAfterReverseStockSplitShares" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares_lbl" xml:lang="en-US">Number of fractional shares after reverse stock split issued during period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares_lbl" xml:lang="en-US">Fractional Share Issued After Reverse Stock Split, Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares_lbl" xml:lang="en-US">Payment for fractional shares after reverse stock split (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Vesting of RSU's (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrant issued for Transaction</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" xlink:to="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_lbl" xml:lang="en-US">Adjustments to additional paid in capital acquisition of remaining portion of affiliate.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_lbl" xml:lang="en-US">Adjustments to additional paid in capital acquisition of remaining portion of affiliate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_lbl" xml:lang="en-US">Acquisition of remaining portion of iBio CDMO</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" xlink:to="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_lbl" xml:lang="en-US">The reclassification adjustment for the period on gains (losses) on avaliable for sale debt securities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_lbl" xml:lang="en-US">Reclassficiation Adjustment, Gain (Loss) On Available For Sale Debt Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_lbl" xml:lang="en-US">Reclassification adjustment for loss on available-for-sale debt securities realized in net income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain (loss) on available-for-sale debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of definite lived intangible assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of ROU assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of finance lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Amount of accrued interest receivable on convertible promissory note receivable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Accrued Interest Receivable on Convertible Promissory Note Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Accrued interest receivable on promissory note receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premiums on debt securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premiums on debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DeferredFinancingCostsAmortizationExpense" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Amortization of loan and debt issuance costs.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Deferred Financing Costs, Amortization Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInInventoryReserve" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">The increase (decrease) in inventory valuation reserve during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">Increase (Decrease) In Inventory Reserve</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">Inventory reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentCharges" xlink:to="us-gaap_TangibleAssetImpairmentCharges_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of fixed assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Fixed assets impairments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:to="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_lbl" xml:lang="en-US">Gain (Loss) on Sale of Leased Assets, Net, Operating Leases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_lbl" xml:lang="en-US">Gain on disposition of finance lease ROU assets</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SettlementOfRevenueContract" xlink:to="ibio_SettlementOfRevenueContract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Other than Temporary Impairment Losses, Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Impairment of investment in equity security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable - trade</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInSettlementAssets" xlink:label="ibio_IncreaseDecreaseInSettlementAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInSettlementAssets" xlink:to="ibio_IncreaseDecreaseInSettlementAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_lbl" xml:lang="en-US">Increase (decrease) in cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_lbl" xml:lang="en-US">Increase (Decrease) In Settlement Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_lbl" xml:lang="en-US">Settlement receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" xml:lang="en-US">Increase (Decrease) in Finished Goods and Work in Process Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses - noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Security Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued expenses - noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchases of debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Redemption of debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Sale of debt securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Proceeds from sale of debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xml:lang="en-US">Purchase of equity security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Sales proceeds for fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payment for RubrYc asset acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Preferred And Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">Proceeds from sales of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentsForFractionalSharesAfterReverseStockSplit" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PaymentsForFractionalSharesAfterReverseStockSplit" xlink:to="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_lbl" xml:lang="en-US">The amount of cash outflow for fractional shares after reverse stock split.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_lbl" xml:lang="en-US">Payments for Fractional Shares after Reverse Stock Split</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_lbl" xml:lang="en-US">Payments for fractional shares after reverse stock split</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToMinorityShareholders" xlink:to="us-gaap_PaymentsToMinorityShareholders_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xml:lang="en-US">Acquisition of noncontrolling interest</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ProceedsFromEquipmentFinancingLoan" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromEquipmentFinancingLoan" xlink:to="ibio_ProceedsFromEquipmentFinancingLoan_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_lbl" xml:lang="en-US">The amount of cash inflow from equipment financing loan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_lbl" xml:lang="en-US">Proceeds from Equipment Financing Loan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_lbl" xml:lang="en-US">Proceeds from equipment financing loan</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PaymentOfEquipmentFinancingLoan" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">The amount of cash outflow for equipment financing loan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">Payment of Equipment Financing Loan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">Payment of equipment financing loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment of term note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentsToAttainTermNote" xlink:label="ibio_PaymentsToAttainTermNote" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PaymentsToAttainTermNote" xlink:to="ibio_PaymentsToAttainTermNote_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PaymentsToAttainTermNote_lbl" xml:lang="en-US">The cash outflow for cost incurred with attain term note.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PaymentsToAttainTermNote_lbl" xml:lang="en-US">Payments To Attain Term Note</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_PaymentsToAttainTermNote_lbl" xml:lang="en-US">Costs to attain term note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Amount released from restricted cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash - end</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Schedule of non-cash activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:to="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">The amount paid for capital expenditures incurred for intangible assets during the previous year.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">Capital Expenditure Incurred For Intangible Assets Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">Fixed assets included in accounts payable in prior period, paid in current period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Increase in finance lease ROU assets for new leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:to="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">The increase (decrease) in finance lease obligations for new leases incurred during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">Increase (Decrease) In Finance Lease Obligations For New Leases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">Increase in finance lease obligation for new leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonStockIssuedInRubrycTransactionValue" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">The value of common stock issued in the RubrYc transaction.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">Common Stock Issued In RubrYc Transaction, Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">RubrYc asset acquisition by issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" xlink:to="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_lbl" xml:lang="en-US">The amount of cost incurred to raise capital directly from gross proceeds.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_lbl" xml:lang="en-US">Cost to Raise Capital paid Directly from Gross Proceeds</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_lbl" xml:lang="en-US">Costs to raise capital paid directly from gross proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise" xlink:label="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise" xlink:to="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise_lbl" xml:lang="en-US">Non-Cash Transaction of Subscription Receivable For Capital Raise</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise_lbl" xml:lang="en-US">Non-Cash Transaction Of Subscription Receivable For Capital Raise</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise_lbl" xml:lang="en-US">Subscription receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CostAccruedToAmendTermNotePayable" xlink:label="ibio_CostAccruedToAmendTermNotePayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CostAccruedToAmendTermNotePayable" xlink:to="ibio_CostAccruedToAmendTermNotePayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CostAccruedToAmendTermNotePayable_lbl" xml:lang="en-US">The amount of cost accrued to amend the term note payable during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CostAccruedToAmendTermNotePayable_lbl" xml:lang="en-US">Cost accrued to amend term note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:to="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">The amount of unpaid fixed assets included in accounts payable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">Unpaid Fixed Assets Included In Accounts Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" xlink:to="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_lbl" xml:lang="en-US">Amount of termination of finance lease right of use asset, including issuance of warrant.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_lbl" xml:lang="en-US">Termination Of Finance Lease Right Of Use Asset, Including Issuance Of Warrant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_lbl" xml:lang="en-US">Termination of finance ROU assets including issuance of warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Notes Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Note payable to acquire Facility</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:to="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">Non Cash Transaction Increase In Right Of Use Assets And Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">Increase in operating lease ROU assets for new lease - net of lease incentive</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NonCashSettlementOfRevenueContract" xlink:label="ibio_NonCashSettlementOfRevenueContract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NonCashSettlementOfRevenueContract" xlink:to="ibio_NonCashSettlementOfRevenueContract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Non cash Settlement of revenue contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Non cash Settlement of revenue contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WarrantsIssuedForFinanceLeasePayment" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinanceLeasePayment" xlink:to="ibio_WarrantsIssuedForFinanceLeasePayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment_lbl" xml:lang="en-US">The fair value of warrants issued in noncash financing activities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment_lbl" xml:lang="en-US">Warrants Issued for Finance Lease Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment_lbl" xml:lang="en-US">Issuance of warrant for final finance lease obligation payment</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LeaseIncentiveForConstructionInProgress" xlink:label="ibio_LeaseIncentiveForConstructionInProgress" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LeaseIncentiveForConstructionInProgress" xlink:to="ibio_LeaseIncentiveForConstructionInProgress_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_lbl" xml:lang="en-US">Lease incentive for construction in progress</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_lbl" xml:lang="en-US">Lease incentive for construction in progress</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" xlink:to="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_lbl" xml:lang="en-US">The amount of non controlling interest that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_lbl" xml:lang="en-US">Noncash or Part Noncash Acquisition, Non Controlling Interest Assumed</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_lbl" xml:lang="en-US">Acquisition of noncontrolling interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Unrealized (gain) loss on available-for-sale debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Business [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Business</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BasisOfPresentationAbstract" xlink:to="ibio_BasisOfPresentationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Represents the information pertaining to Basis of Presentation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Basis of Presentation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Financial Instruments and Fair Value Measurement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Financial Instruments and Fair Value Measurement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="ibio_SignificantTransactionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SignificantTransactionsTextBlock" xlink:label="ibio_SignificantTransactionsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SignificantTransactionsTextBlock" xlink:to="ibio_SignificantTransactionsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Convertible Promissory Note Receivable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Promissory Note Receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments in Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" xml:lang="en-US">Finance Lease ROU [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for lessee's right to use underlying asset under finance lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Finance Lease ROU Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Operating Lease ROU Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:to="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for lessee's right to use underlying asset under operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Operating Lease Right Of Use Asset Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Operating Lease ROU Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Fixed Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US">Finance Lease Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US">Finance Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="us-gaap_GainLossRelatedToLitigationSettlementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract_lbl" xml:lang="en-US">Fraunhofer Settlement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:to="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Entire disclosure on gain (Loss) related to litigation settlement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Gain Loss Related To Litigation Settlement [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Fraunhofer Settlement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee 401(K) Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee 401(K) Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractAssetsPolicyTextBlock" xlink:label="ibio_ContractAssetsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractAssetsPolicyTextBlock" xlink:to="ibio_ContractAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for contract assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractLiabilitiesPolicyTextBlock" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractLiabilitiesPolicyTextBlock" xlink:to="ibio_ContractLiabilitiesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for contract liabilities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Liabilities [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Premium on Purchased Options [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xml:lang="en-US">Investments in Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessPolicy" xlink:label="us-gaap_InventoryWorkInProcessPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessPolicy" xlink:to="us-gaap_InventoryWorkInProcessPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessPolicy_lbl" xml:lang="en-US">Inventory Work in Process, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessPolicy_lbl" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:to="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">The disclosure of accounting policy for right-of-use assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Right Of Use Assets Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of of total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets measured at fair value on a non-recurring basis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RubrycTheraputicsInc.Member" xlink:to="ibio_RubrycTheraputicsInc.Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RubrycTheraputicsInc.Member_lbl" xml:lang="en-US">RubrYc Therapeutics, Inc. [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RubrycTheraputicsInc.Member_lbl" xml:lang="en-US">RubrYc Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetPurchaseAgreementMember" xlink:to="ibio_AssetPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Asset Acquisition [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Summary of Purchase Price Allocation of Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of investments in debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of available-for-sale debt securities, by contractual maturity</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" xlink:to="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of realized gains (losses) on available for sale debt securities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_lbl" xml:lang="en-US">Avaliable For Sale Debt Securities Realized Gains (Losses) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_lbl" xml:lang="en-US">Schedule of realized losses on available-for-sale debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:to="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Summary of the gross carrying value and accumulated amortization of finance lease ROU</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of gross carrying value and accumulated depreciation of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Category the gross carrying value and accumulated amortization of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated annual amortization expenses for next five years and thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Finance Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Payments Under the Finance Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" xlink:label="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" xlink:to="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of undiscounted cash flows of capitalized lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to capitalized lease liability recognized in statement of financial position.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_lbl" xml:lang="en-US">Capitalized Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Payments under the Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair value of Warrant using the Black-Scholes model assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings (loss) Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Outstanding and Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Options Granted using the Black-Scholes Option Pricing Model</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationTable" xlink:label="ibio_BasisOfPresentationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BasisOfPresentationTable" xlink:to="ibio_BasisOfPresentationTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BasisOfPresentationTable_lbl" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SecuredTermLoanMember" xlink:to="ibio_SecuredTermLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SecuredTermLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to secured term loan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SecuredTermLoanMember_lbl" xml:lang="en-US">Secured Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationLineItems" xlink:label="ibio_BasisOfPresentationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="ibio_BasisOfPresentationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BasisOfPresentationLineItems_lbl" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Percentage of workforce reduction</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xml:lang="en-US">Number of positions reduced</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Debt balance</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:to="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents plus debt securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents plus debt securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AuctionSaleAgreementMember" xlink:label="ibio_AuctionSaleAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AuctionSaleAgreementMember" xlink:to="ibio_AuctionSaleAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AuctionSaleAgreementMember_lbl" xml:lang="en-US">Information pertaining to the Auction Sale Agreement with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AuctionSaleAgreementMember_lbl" xml:lang="en-US">Auction Sale Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GuaranteedAuctionProceedsMember" xlink:label="ibio_GuaranteedAuctionProceedsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GuaranteedAuctionProceedsMember" xlink:to="ibio_GuaranteedAuctionProceedsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GuaranteedAuctionProceedsMember_lbl" xml:lang="en-US">Information pertaining to guaranteed procedds from auction of company assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GuaranteedAuctionProceedsMember_lbl" xml:lang="en-US">Guaranteed Auction Proceeds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExcessAuctionProceedsMember" xlink:label="ibio_ExcessAuctionProceedsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExcessAuctionProceedsMember" xlink:to="ibio_ExcessAuctionProceedsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExcessAuctionProceedsMember_lbl" xml:lang="en-US">Information pertaining to proceeds from auction of company assets after counterparty fees.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExcessAuctionProceedsMember_lbl" xml:lang="en-US">Excess Auction Proceeds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_HollandIndustrialGroupMember" xlink:label="ibio_HollandIndustrialGroupMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_HollandIndustrialGroupMember" xlink:to="ibio_HollandIndustrialGroupMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_HollandIndustrialGroupMember_lbl" xml:lang="en-US">Information pertaining to Holland Industrial Group.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_HollandIndustrialGroupMember_lbl" xml:lang="en-US">Holland Industrial Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of facility to be sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfAuctionProceedsReceived" xlink:label="ibio_PercentageOfAuctionProceedsReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfAuctionProceedsReceived" xlink:to="ibio_PercentageOfAuctionProceedsReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfAuctionProceedsReceived_lbl" xml:lang="en-US">The percentage of proceeds received in an auction sale of company assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfAuctionProceedsReceived_lbl" xml:lang="en-US">Percentage Of Auction Proceeds Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfAuctionProceedsReceived_lbl" xml:lang="en-US">Percentage of excess proceeds received</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AuctionFee" xlink:label="ibio_AuctionFee" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AuctionFee" xlink:to="ibio_AuctionFee_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AuctionFee_lbl" xml:lang="en-US">The amount of auction costs incurred in a discontinuing operation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AuctionFee_lbl" xml:lang="en-US">Auction fee</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EmployeeReductionExpenses" xlink:to="ibio_EmployeeReductionExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Expected amount of expenses to be incurred due to employee reductions.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Employee Reduction Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Expected employee reduction charges</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceTransitionalPeriodDays" xlink:label="ibio_SeveranceTransitionalPeriodDays" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceTransitionalPeriodDays" xlink:to="ibio_SeveranceTransitionalPeriodDays_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceTransitionalPeriodDays_lbl" xml:lang="en-US">Number of days during transitional period of severance obligations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceTransitionalPeriodDays_lbl" xml:lang="en-US">Severance Transitional Period Days</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">The amount inventory written down in a discontinued operation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory Write down</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">Inventory reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">The amount of personnel cost including severance incurred in a discontinuing operation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Personnel Costs Including Severance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">Personnel costs including severance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Results of operations for discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenue reported in discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Gross profit</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Discontinued Operations, Research And Development Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" xlink:to="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_lbl" xml:lang="en-US">The charge against earnings resulting from the aggregate write down of tangible assets of discontinued operations from their carrying value to their fair value.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_lbl" xml:lang="en-US">Tangible Asset Impairment Charges, Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_lbl" xml:lang="en-US">Fixed assets impairments</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GainOnSaleOfFixedAssets" xlink:label="ibio_GainOnSaleOfFixedAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GainOnSaleOfFixedAssets" xlink:to="ibio_GainOnSaleOfFixedAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GainOnSaleOfFixedAssets_lbl" xml:lang="en-US">Gain or loss on the sale of fixed assets resulting from discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GainOnSaleOfFixedAssets_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Interest expense - term note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupInterestExpenseRelatedParty" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupInterestExpenseRelatedParty" xlink:to="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense to related party from discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Disposal Group, Interest Expense, Related Party</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupGainOnDebtForgiveness" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupGainOnDebtForgiveness" xlink:to="ibio_DisposalGroupGainOnDebtForgiveness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Gain (loss) on forgiveness of debt to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Disposal Group, Gain On Debt Forgiveness</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:to="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Miscellaneous expenses (income) attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Discontinued Operations, Miscellaneous Expenses (Income)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" xml:lang="en-US">Total other expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Current operating lease ROU assets attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Operating Lease Right Of Use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Other assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount classified as non current  assets attributable to disposal group held for sale or disposed of, expected to be disposed of more than one year.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Non Current Assets, Finance Lease Right of Use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Noncurrent operating lease ROU assets attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Disposal Group, Operating Lease Right Of Use Assets, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" xlink:to="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Current finance lease obligations attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Current Liabilities, Finance Lease Obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Finance lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:to="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Current operating lease obligations attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Current Liabilities, Operating Lease Obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Operating lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" xlink:to="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Noncurrent finance lease obligations attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Noncurrent Liabilities, Finance Lease Obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Finance lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:to="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Noncurrent operating lease obligations attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Noncurrent Operating Lease Obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Operating lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization of finance lease ROU assets attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Amortization Of Finance Lease Right Of Use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization of finance lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Capital Expenditure, Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Investing noncash transactions:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases" xlink:label="ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases" xlink:to="ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases_lbl" xml:lang="en-US">Increase in ROU operating assets and liabilities for new leases from discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases_lbl" xml:lang="en-US">Increase in ROU operating assets and liabilities for new leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:to="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Fixed asset charges incurred but not yet paid attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Fixed assets included in accounts payable in prior period, paid in current period</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:to="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable, attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid Fixed Assets Attributable To Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant" xlink:label="ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant" xlink:to="ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant_lbl" xml:lang="en-US">Termination of finance ROU assets including issuance of warrant from discontinued operaions.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant_lbl" xml:lang="en-US">Termination of finance ROU assets including issuance of warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ProceedsFromNotesPayableFromDiscontinuedOperations" xlink:label="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations" xlink:to="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations_lbl" xml:lang="en-US">The cash inflow from a borrowing supported by a written promise to pay an obligation from discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations_lbl" xml:lang="en-US">Proceeds from Notes Payable from Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations_lbl" xml:lang="en-US">Note payable to acquire Facility</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IssuanceOfWarrantForFinalLeaseObligationPayment" xlink:label="ibio_IssuanceOfWarrantForFinalLeaseObligationPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IssuanceOfWarrantForFinalLeaseObligationPayment" xlink:to="ibio_IssuanceOfWarrantForFinalLeaseObligationPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IssuanceOfWarrantForFinalLeaseObligationPayment_lbl" xml:lang="en-US">Proceeds from issuance of warrant for final lease obligation payment from discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IssuanceOfWarrantForFinalLeaseObligationPayment_lbl" xml:lang="en-US">Issuance of warrant for final lease obligation payment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidDiscontinuedOperations" xlink:label="us-gaap_InterestPaidDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidDiscontinuedOperations" xlink:to="us-gaap_InterestPaidDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidDiscontinuedOperations_lbl" xml:lang="en-US">Interest Paid, Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidDiscontinuedOperations_lbl" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FourCustomersMember" xlink:label="ibio_FourCustomersMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FourCustomersMember" xlink:to="ibio_FourCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FourCustomersMember_lbl" xml:lang="en-US">Four Customers [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FourCustomersMember_lbl" xml:lang="en-US">Four Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EightCustomersMember" xlink:label="ibio_EightCustomersMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EightCustomersMember" xlink:to="ibio_EightCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EightCustomersMember_lbl" xml:lang="en-US">Eight Customers [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EightCustomersMember_lbl" xml:lang="en-US">Eight Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for Doubtful Accounts</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Reserve for loss on contract</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized included in contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Fixed assets, useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Amount of liability for uncertain tax positions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Amount in excess of insured limit</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfMajorCustomers" xlink:to="ibio_NumberOfMajorCustomers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Represents the information pertaining to number of major customers.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Number of Major Customers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Number of major customers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LetterOfCreditTermLoanMember" xlink:to="ibio_LetterOfCreditTermLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LetterOfCreditTermLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to letter of credit term loan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LetterOfCreditTermLoanMember_lbl" xml:lang="en-US">Letter Of Credit - Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LetterOfCreditSanDiegoLeaseMember" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" xml:lang="en-US">Represents the information pertaining to letter of credit for sandiego lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" xml:lang="en-US">Letter Of Credit - San Diego Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CompanyPurchasingCardMember" xlink:to="ibio_CompanyPurchasingCardMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CompanyPurchasingCardMember_lbl" xml:lang="en-US">Information related to the Company purchasing card.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CompanyPurchasingCardMember_lbl" xml:lang="en-US">Company Purchasing Card [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WoodforestMember" xlink:to="ibio_WoodforestMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest Bank</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xml:lang="en-US">Area of facility</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xml:lang="en-US">Area of ground lease</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfCollateralRequired" xlink:to="ibio_PercentageOfCollateralRequired_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">The percentage of collateral required to be held by the reporting entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">Percentage Of Collateral Required</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">Additional percentage of collateral held required by bank</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted Cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Collateral held</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property Plant And Equipment Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Total Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Estimated fair values</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfBuildings" xlink:label="us-gaap_ProceedsFromSaleOfBuildings" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfBuildings" xlink:to="us-gaap_ProceedsFromSaleOfBuildings_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfBuildings_lbl" xml:lang="en-US">Proceeds from Sale of Buildings</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FixedAssetsHeldForSale" xlink:to="ibio_FixedAssetsHeldForSale_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Amount of fixed assets held-for-sale.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Fixed Assets Held-for-sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Fixed assets held for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Series2PreferredStockMember" xlink:to="ibio_Series2PreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Series2PreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Series2PreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeparationAgreementAndGeneralReleaseMember" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" xml:lang="en-US">Represents the member information pertaining to Separation Agreement and General Release.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" xml:lang="en-US">Separation Agreement and General Release [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementMember" xlink:to="ibio_StockPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationOptionAndLicenseAgreementMember" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration, Option and License Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration, Option and License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" xml:lang="en-US">Immune-Oncology Antibodies (RTX-003) [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" xml:lang="en-US">Immune-Oncology Antibodies (RTX-003) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" xml:lang="en-US">No Biosimilar Product has been Approved [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" xml:lang="en-US">No Biosimilar Product has been Approved [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" xml:lang="en-US">Represents the information pertaining to College Station Investors LLC And Bryan Capital.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" xml:lang="en-US">College Station Investors LLC And Bryan Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioCmoPreferredTrackingStockMember" xlink:to="ibio_IbioCmoPreferredTrackingStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_lbl" xml:lang="en-US">Represents the information pertaining to IBio CMO Preferred Tracking Stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_lbl" xml:lang="en-US">IBio CMO Preferred Tracking Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Purchase Price For Property, Termination of Sublease And Equity Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Total purchase price</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Purchase Price For Property, Termination of Sublease And Equity Interest, Cash Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Cash payment</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FairMarketValueOfProperty" xlink:to="ibio_FairMarketValueOfProperty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair market value of the property.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair Market Value of Property</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair market value of property</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Amount of base rent payable on percentage of fair Market Value of the Property.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Base Rent, Percentage of Fair Market Value of Property</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Percentage of base rent</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Consideration transferred for equity interest acquired under the equity agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Equity Agreement, Consideration Transferred Equity Interests Acquired</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Cash consideration for equity interest acquired</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Warrants issued or issuable under the equity agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Equity Agreement, Warrants Issued or Issuable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Warrants issuable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Equity agreement, percentage of equity interest issued or issuable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Equity Agreement, Percentage of Equity Interest Issued or Issuable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Percentage of equity interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Secured term loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Threshold limit of unrestricted cash to be maintained.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Credit Agreement, Threshold Limit, Unrestricted Cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Unrestricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Deferred finance costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Cost incurred to attain debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares to be issued upon exercise of warrants</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants, exercise price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Number of warrants issued for the final payment of rent due under sublease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Warrants Issued for Final Payment of Sublease Rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Shares issued under the Warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Value of warrants issued for the final payment of rent due under sublease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Warrants Issued for Final Payment of Sublease Rent, Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Fair value of the warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Payments for Advance to Affiliate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Amount advanced</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionTransactionCosts" xlink:to="ibio_AssetAcquisitionTransactionCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">This element represents acquisition-related costs incurred to effect an asset acquisition.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">Transaction costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and license agreement, royalty payment term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and License Agreement, Royalty payment term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and license agreement, royalty payment term</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares purchased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares purchased</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferential dividend rate percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xml:lang="en-US">Liability for the assumed acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment of current prepaid expenses.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment Of Prepaid Expenses, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment of current prepaid expense</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment of non-current prepaid expenses.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment Of Prepaid Expenses, Non Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment of non-current prepaid expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfEquipmentLeases" xlink:to="ibio_NumberOfEquipmentLeases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Represents the number of equipment leases.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Number of Equipment Leases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Number of equipment leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Severance Benefits, Period of Bi-Monthly Installments of Current Base Salary</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Period of bi-monthly installments of current base salary</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Severance Benefits, Period of Bi-Monthly Installments of target Bonus</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Period of bi-monthly installments of target bonus</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Severance Benefits, Maximum Period for Coverage of Health Insurance If Employer Elects Consolidated Omnibus Budget Reconciliation Act</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Maximum period for coverage of health insurance</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">Severance Benefits, Consolidated Omnibus Budget Reconciliation Act Subsidy Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">COBRA subsidy period</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Severance Benefits, Number of Times on Which Lum Sum Cash Payment to be Made if Health Coverage Not Made Under Consolidated Omnibus Budget Reconciliation Act</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Number of times on which lump sum cash payment tis o be made</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionIntangibleAssetsMember" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Intangible Assets [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionFixedAssetsMember" xlink:to="ibio_AssetAcquisitionFixedAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Fixed Assets [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Fixed Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionPrepaidExpensesMember" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" xml:lang="en-US">Asset Acquisition Prepaid Expenses [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" xml:lang="en-US">Asset Acquisition Prepaid Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Purchase price allocated</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableMember" xlink:to="us-gaap_NotesReceivableMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableMember_lbl" xml:lang="en-US">Convertible Promissory Note Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableAmountInvested" xlink:to="ibio_LoansReceivableAmountInvested_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Represents the face amount of notes receivable invested.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Loans Receivable, Amount Invested</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Amount invested</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableFixedRatesOfInterest" xlink:to="ibio_LoansReceivableFixedRatesOfInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Percentage of fixed rate of interest on notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Loans Receivable, Fixed Rates of Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" xlink:to="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_lbl" xml:lang="en-US">Percentage of rate of interest on notes receivable for first one year extension.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_lbl" xml:lang="en-US">Loans Receivable, Rate of Interest for First One Year Extension</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_lbl" xml:lang="en-US">Interest rate for first one year extension</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" xlink:to="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_lbl" xml:lang="en-US">Percentage of rate of interest on notes receivable for second one year extension.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_lbl" xml:lang="en-US">Loans Receivable, Rate of Interest for Second One Year Extension</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_lbl" xml:lang="en-US">Interest rate for second one year extension</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" xml:lang="en-US">Note balance and accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Adjusted cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after Two Years, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost" xlink:label="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost" xlink:to="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost_lbl" xml:lang="en-US">Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost_lbl" xml:lang="en-US">Available For Sale Securities Debt Maturities With In Two Year Amortized Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CostOfDebtSecurities" xlink:label="ibio_CostOfDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CostOfDebtSecurities" xlink:to="ibio_CostOfDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CostOfDebtSecurities_lbl" xml:lang="en-US">The cost of debt securities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CostOfDebtSecurities_lbl" xml:lang="en-US">Cost of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" xml:lang="en-US">Disclosure of information about activity in the balance of lessee's right to use underlying asset under finance lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FacilityMember" xlink:to="ibio_FacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FacilityMember_lbl" xml:lang="en-US">This member stands for facility.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FacilityMember_lbl" xml:lang="en-US">Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetGross" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">ROU, gross</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Area of lab and office</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment and software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Gross fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents and Licenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementTotalInvestment" xlink:to="ibio_StockPurchaseAgreementTotalInvestment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">The amount of investment under the stock purchase agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">Stock Purchase Agreement, Total Investment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">Investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Weighted average remaining life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, gross carrying value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total definite lived intangible assets, net of accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">License - indefinite lived</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDeferredChargesAbstract" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredChargesAbstract" xlink:to="us-gaap_AmortizationOfDeferredChargesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract_lbl" xml:lang="en-US">Amortization of Deferred Charges [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract_lbl" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward_lbl" xml:lang="en-US">Additions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Additions to definite lived intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets Acquired</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xml:lang="en-US">Additions to licenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Asset Impairment [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_lbl" xml:lang="en-US">Impairments</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" xlink:to="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_lbl" xml:lang="en-US">Gross amount of intangible asset impairment before reversals.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_lbl" xml:lang="en-US">Impairment Of Intangible Assets Gross Of Reversals</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_lbl" xml:lang="en-US">Impairment of intangible assets - gross carrying value</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ReversalOfIntangibleAssetImpairment" xlink:label="ibio_ReversalOfIntangibleAssetImpairment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ReversalOfIntangibleAssetImpairment" xlink:to="ibio_ReversalOfIntangibleAssetImpairment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ReversalOfIntangibleAssetImpairment_lbl" xml:lang="en-US">Reversal of intangible asset impairment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ReversalOfIntangibleAssetImpairment_lbl" xml:lang="en-US">Reversal Of Intangible Asset Impairment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ReversalOfIntangibleAssetImpairment_lbl" xml:lang="en-US">Intangible asset impairment - accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Personnel related costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedRealEstateTaxes" xlink:label="ibio_AccruedRealEstateTaxes" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AccruedRealEstateTaxes" xlink:to="ibio_AccruedRealEstateTaxes_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AccruedRealEstateTaxes_lbl" xml:lang="en-US">Accrued real estate taxes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AccruedRealEstateTaxes_lbl" xml:lang="en-US">Accrued Real Estate Taxes</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AccruedRealEstateTaxes_lbl" xml:lang="en-US">Real estate taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest and fees related to term note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AmendedCreditAgreementMember" xlink:to="ibio_AmendedCreditAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AmendedCreditAgreementMember_lbl" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AmendedCreditAgreementMember_lbl" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" xml:lang="en-US">I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" xml:lang="en-US">iBio, Inc. v. Fraunhofer USA, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DateOfAmendmentMember" xlink:to="ibio_DateOfAmendmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DateOfAmendmentMember_lbl" xml:lang="en-US">Date Of Amendment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DateOfAmendmentMember_lbl" xml:lang="en-US">Date Of Amendment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" xml:lang="en-US">Within Two Business Days Of Frunhofer Legal Settlement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" xml:lang="en-US">Within Two Business Days Of Frunhofer Legal Settlement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OccurrenceOfSpecificMilestoneMember" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_lbl" xml:lang="en-US">Occurrence Of Specific Milestone [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_lbl" xml:lang="en-US">Occurrence Of Specific Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" xlink:to="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_lbl" xml:lang="en-US">If Outstanding Principal Amount Reduced to 10,000,000 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_lbl" xml:lang="en-US">If Outstanding Principal Amount Reduced to 10,000,000 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" xlink:to="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_lbl" xml:lang="en-US">If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_lbl" xml:lang="en-US">If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" xlink:to="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_lbl" xml:lang="en-US">If The Facility Is Sold On Or Before June 30, 2023 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_lbl" xml:lang="en-US">If The Facility Is Sold On Or Before June 30, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" xlink:to="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_lbl" xml:lang="en-US">If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_lbl" xml:lang="en-US">If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" xlink:to="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_lbl" xml:lang="en-US">If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_lbl" xml:lang="en-US">If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" xlink:to="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_lbl" xml:lang="en-US">If The Facility Is Not Sell On Or Before December 1, 2023 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_lbl" xml:lang="en-US">If The Facility Is Not Sell On Or Before December 1, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtInstrumentPaidInKindInterestRate" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtInstrumentPaidInKindInterestRate" xlink:to="ibio_DebtInstrumentPaidInKindInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate_lbl" xml:lang="en-US">Represents the payable in-kind interest rate.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate_lbl" xml:lang="en-US">Debt Instrument, Paid-in Kind Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate_lbl" xml:lang="en-US">Payable in-kind rate (in percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Principal payment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt amortization payment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Amendment fee</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Fee amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtCovenantLiquidityAmount" xlink:to="ibio_DebtCovenantLiquidityAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Amount of required liquidity per debt covenant.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Debt Covenant, Liquidity Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Liquidity covenant, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" xlink:to="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_lbl" xml:lang="en-US">Represents the period for the payment to counterparty of equity interests from the issuances.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_lbl" xml:lang="en-US">Period for Payment from Issuance of At-the Market Facility</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_lbl" xml:lang="en-US">Period for payment of equity interests at-the-market facility</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" xlink:to="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_lbl" xml:lang="en-US">Represents the percentage of payment of equity interests from proceeds of sales of equipment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_lbl" xml:lang="en-US">Percentage of Payment from Proceeds of At the Market Facility</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_lbl" xml:lang="en-US">Percentage of payment of equity Interests from proceeds of at-the-market facility</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" xlink:to="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_lbl" xml:lang="en-US">Represents the percentage of payment of equity interests from proceeds of sales of equipment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_lbl" xml:lang="en-US">Percentage of Payment from Proceeds of Sales of Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_lbl" xml:lang="en-US">Percentage of payment from proceeds of sales of equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmountRetainedFromProceedsOfLegalSettlement" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AmountRetainedFromProceedsOfLegalSettlement" xlink:to="ibio_AmountRetainedFromProceedsOfLegalSettlement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement_lbl" xml:lang="en-US">Represents the amount retained from proceeds of legal settlement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement_lbl" xml:lang="en-US">Amount Retained from Proceeds of Legal Settlement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement_lbl" xml:lang="en-US">Amount retained</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLegalSettlements" xlink:to="us-gaap_ProceedsFromLegalSettlements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Settlement payment received</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmountToBeReleasedFromRestrictedCash" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AmountToBeReleasedFromRestrictedCash" xlink:to="ibio_AmountToBeReleasedFromRestrictedCash_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash_lbl" xml:lang="en-US">Represents the amount to be released from restricted cash.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash_lbl" xml:lang="en-US">Amount to Be Released from Restricted Cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash_lbl" xml:lang="en-US">Amount to be released from restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:to="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_lbl" xml:lang="en-US">Represents the amount of fees to be paid under Purchase Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_lbl" xml:lang="en-US">Debt Instrument, Amount of Fees to be Paid under Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_lbl" xml:lang="en-US">Amount of fees to be paid</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" xlink:to="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_lbl" xml:lang="en-US">Represents the threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_lbl" xml:lang="en-US">Threshold Period for Delivery of Executed Copy of Agreement for Sale of Facility from Amendment Date</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_lbl" xml:lang="en-US">Threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingAmountBorrowed" xlink:label="ibio_EquipmentFinancingAmountBorrowed" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingAmountBorrowed" xlink:to="ibio_EquipmentFinancingAmountBorrowed_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">The amount borrowed under equipment financing as at the end of the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">Equipment Financing, Amount Borrowed</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">Amount borrowed</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeEquipmentLeaseTermOfContract" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeEquipmentLeaseTermOfContract" xlink:to="ibio_LesseeEquipmentLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Term of lessee equipment financing lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Equipment Lease, Term of Contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:to="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Percentage of imputed interest rate on equipment financing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Equipment Financing Lease, Imputed Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Imputed interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:to="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">The amount of monthly installment payable under equipment leasing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">Equipment Leasing Monthly Installment Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">Monthly installment payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingBalance" xlink:label="ibio_EquipmentFinancingBalance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingBalance" xlink:to="ibio_EquipmentFinancingBalance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">The amount of equipment financing balance under equipment leasing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">Equipment Financing Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">Balance owed under financing</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingInterestIncurred" xlink:label="ibio_EquipmentFinancingInterestIncurred" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingInterestIncurred" xlink:to="ibio_EquipmentFinancingInterestIncurred_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingInterestIncurred_lbl" xml:lang="en-US">The amount of interest incurred under equipment financing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingInterestIncurred_lbl" xml:lang="en-US">Equipment Financing, Interest Incurred</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingInterestIncurred_lbl" xml:lang="en-US">Interest incurred</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PrincipalMember" xlink:to="ibio_PrincipalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PrincipalMember_lbl" xml:lang="en-US">Information pertaining to principal portion of the obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PrincipalMember_lbl" xml:lang="en-US">Principal [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_InterestMember" xlink:to="ibio_InterestMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_InterestMember_lbl" xml:lang="en-US">Information pertaining to interest portion of the obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_InterestMember_lbl" xml:lang="en-US">Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Total minimum equipment financing payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractualObligationCurrent" xlink:to="ibio_ContractualObligationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">The amount of current portion of contractual obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">Contractual Obligation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractualObligationNoncurrent" xlink:to="ibio_ContractualObligationNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">The amount of noncurrent portion of contractual obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">Contractual Obligation, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum equipment financing obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PppLoanCaresActMember" xlink:label="ibio_PppLoanCaresActMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PppLoanCaresActMember" xlink:to="ibio_PppLoanCaresActMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PppLoanCaresActMember_lbl" xml:lang="en-US">PP Loans Cares Act.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PppLoanCaresActMember_lbl" xml:lang="en-US">PPP Loan Cares Act [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, PPP loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecondEasternAffiliateMember" xlink:label="ibio_SecondEasternAffiliateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SecondEasternAffiliateMember" xlink:to="ibio_SecondEasternAffiliateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SecondEasternAffiliateMember_lbl" xml:lang="en-US">Represent information pertaining to Second Eastern Affiliate.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SecondEasternAffiliateMember_lbl" xml:lang="en-US">Second Eastern Affiliate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LeaseRentExpensePerMonth" xlink:to="ibio_LeaseRentExpensePerMonth_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">The amount of lease rent expense per month during the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">Lease Rent Expense Per Month</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">Monthly rent</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LessorFinanceLeaseMonthlyRent" xlink:to="ibio_LessorFinanceLeaseMonthlyRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">The amount of rent receivable monthly by the lessor under the finance lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">Lessor, Finance Lease Monthly Rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">Mobile office trailer monthly rent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:to="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Finance Lease Obligation, Other Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Other Information</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Lease Liabilities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement lease liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:to="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">The amount of cash outflow for finance lease obligations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">Financing Cash Flows From Finance Lease Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">Financing cash flows from finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term - finance lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate - finance lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Term of lease</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseMonthlyRent" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">The amount of rent payable monthly by the lessee under the operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">Lessee, Operating Lease Monthly Rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">Operating lease monthly rent payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease, Annual percentage increase in base rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease, Annual percentage increase in base rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Annual percentage increase in base rent</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BaseRentAbatementInFirstYearPeriod" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base rent abatement period in the first year.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base Rent Abatement In the First Year, Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base rent abatement period in the first year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant Improvements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xml:lang="en-US">Irrevocable letter of credit</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OperatingLeaseCostsAbstract" xlink:label="ibio_OperatingLeaseCostsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseCostsAbstract" xlink:to="ibio_OperatingLeaseCostsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">n/a</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Operating Lease Costs [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Operating lease cost:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TotalOperatingLeaseCosts" xlink:label="ibio_TotalOperatingLeaseCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TotalOperatingLeaseCosts" xlink:to="ibio_TotalOperatingLeaseCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total operating lease costs.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total Operating Lease Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:to="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Operating Lease Obligation Other Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Other information:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Operating Lease Liabilities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement lease liability:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:to="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating cash flows from operating lease obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating Cash Flows From Operating Lease Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating cash flows from operating lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term - operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate - operating lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Principal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Imputed Interest</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Imputed Interest, Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Lessee Operating Lease Liability Principal And Imputed Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Lessee Operating Lease Liability Principal And Imputed Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Principal and imputed interest, Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockholdersEquityTable" xlink:to="ibio_StockholdersEquityTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockholdersEquityTable_lbl" xml:lang="en-US">Stockholders' Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExchangeAgreementMember" xlink:to="ibio_ExchangeAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OmnibusIncentivePlanMember" xlink:label="ibio_OmnibusIncentivePlanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OmnibusIncentivePlanMember" xlink:to="ibio_OmnibusIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OmnibusIncentivePlanMember_lbl" xml:lang="en-US">Omnibus Incentive Plan [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OmnibusIncentivePlanMember_lbl" xml:lang="en-US">Omnibus Incentive (the 2020) Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PreferredTrackingStockMember" xlink:to="ibio_PreferredTrackingStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PreferredTrackingStockMember_lbl" xml:lang="en-US">iBio CMO Preferred Tracking Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Series2022ConvertiblePreferredStockMember" xlink:to="ibio_Series2022ConvertiblePreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PreFundedWarrantsMember" xlink:to="ibio_PreFundedWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PreFundedWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to Pre Funded Warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeriesWarrantsMember" xlink:to="ibio_SeriesWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeriesWarrantsMember_lbl" xml:lang="en-US">Represents information pertaining to series A warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeriesWarrantsMember_lbl" xml:lang="en-US">Series A warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeriesBWarrantsMember" xlink:to="ibio_SeriesBWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeriesBWarrantsMember_lbl" xml:lang="en-US">Represents information pertaining to series B warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RepresentativeWarrantsMember" xlink:to="ibio_RepresentativeWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to representative warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Representative Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_H.c.WainwrightCo.LlcMember" xlink:to="ibio_H.c.WainwrightCo.LlcMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_H.c.WainwrightCo.LlcMember_lbl" xml:lang="en-US">Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_H.c.WainwrightCo.LlcMember_lbl" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EasternAffiliateMember" xlink:to="ibio_EasternAffiliateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EasternAffiliateMember_lbl" xml:lang="en-US">Information pertaining to Eastern affiliate.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EasternAffiliateMember_lbl" xml:lang="en-US">Eastern Affiliate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" xml:lang="en-US">After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" xml:lang="en-US">After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioCdmoMember" xlink:to="ibio_IbioCdmoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioCdmoMember_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioCdmoMember_lbl" xml:lang="en-US">Bioprocessing (iBio CDMO) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Weighted average risk-free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockholdersEquityLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders' Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of LLC interest units exchanged for each share of preferred tracking stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Proceeds from sale of shares, net of issuance cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Shares issued upon conversion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares reserved for future issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant under the plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Shares vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term of the warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Fair value of the Warrant assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SalesAgreementMember" xlink:to="ibio_SalesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to Sales Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CantorFitzgeraldMember" xlink:to="ibio_CantorFitzgeraldMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CantorFitzgeraldMember_lbl" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CantorFitzgeraldMember_lbl" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AggregateCommonStockPurchased" xlink:to="ibio_AggregateCommonStockPurchased_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">Aggregate Common Stock Purchased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">Aggregate offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of preferred stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of underwriting discount paid on gross proceeds of offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of Underwriting Discount Paid on Gross Proceeds of Offering</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of underwriting discount</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of days option to purchase additional shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of Days Option to Purchase Additional Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of days granted to purchase additional shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfAdditionalSharesIssued" xlink:to="ibio_NumberOfAdditionalSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Number of additional shares issued.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Number of Additional Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Additional shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of common warrants to purchase additional shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Common Warrants to Purchase Additional Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Warrants to purchase additional shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of aggregate number of shares of common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of Aggregate Number of Shares of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of number of shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Net proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Basic and diluted numerator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Basic and diluted denominator:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EarningsLossPerCommonShareTable" xlink:to="ibio_EarningsLossPerCommonShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EarningsLossPerCommonShareTable_lbl" xml:lang="en-US">Earnings Loss Per Common Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="ibio_EarningsLossPerCommonShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EarningsLossPerCommonShareLineItems_lbl" xml:lang="en-US">Earnings Loss Per Common Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_lbl" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioOneMember" xlink:to="ibio_ScenarioOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioOneMember_lbl" xml:lang="en-US">This member stands for scenario one in which the value of maximum award in calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioOneMember_lbl" xml:lang="en-US">Scenario One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioTwoMember" xlink:to="ibio_ScenarioTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioTwoMember_lbl" xml:lang="en-US">This represents Preferred tracking stock exchanged for units.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioTwoMember_lbl" xml:lang="en-US">Scenario Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ConsultantsMember" xlink:label="ibio_ConsultantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ConsultantsMember" xlink:to="ibio_ConsultantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_VariousEmployeesMember" xlink:to="ibio_VariousEmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_VariousEmployeesMember_lbl" xml:lang="en-US">Various Employees [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_VariousEmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BoardOfDirectorsOfficersAndEmployeesMember" xlink:label="ibio_BoardOfDirectorsOfficersAndEmployeesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BoardOfDirectorsOfficersAndEmployeesMember" xlink:to="ibio_BoardOfDirectorsOfficersAndEmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BoardOfDirectorsOfficersAndEmployeesMember_lbl" xml:lang="en-US">Board Of Directors Officers And Employees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BoardOfDirectorsOfficersAndEmployeesMember_lbl" xml:lang="en-US">Board Of Directors and Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IsettMember" xlink:label="ibio_IsettMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IsettMember" xlink:to="ibio_IsettMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IsettMember_lbl" xml:lang="en-US">Isett [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IsettMember_lbl" xml:lang="en-US">Isett [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">2020 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Maximum value of all awards awarded under the Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options granted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock Options, Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price per share, granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share based payment plan term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based award, Number of awards issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Market value per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Grant date fair value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share based payment award, Grant-date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Stock options vesting percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Award vested in period, fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share based payment award, stock options, intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Compensation cost, not recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Compensation cost recognition period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value of stock options granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Market price</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfConsultantsToWhomStockOptionGranted" xlink:label="ibio_NumberOfConsultantsToWhomStockOptionGranted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfConsultantsToWhomStockOptionGranted" xlink:to="ibio_NumberOfConsultantsToWhomStockOptionGranted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfConsultantsToWhomStockOptionGranted_lbl" xml:lang="en-US">Represents the number of consultants to whom the stock options granted.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfConsultantsToWhomStockOptionGranted_lbl" xml:lang="en-US">Number of Consultants to Whom the Stock Option Granted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfConsultantsToWhomStockOptionGranted_lbl" xml:lang="en-US">Number of consultants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Stock Options, Outstanding at end of the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Stock Options, Outstanding at beginning of the period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Stock Options, Forfeited/expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Stock Options, Vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Stock Options, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average Exercise Price, Outstanding at end of the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average Exercise Price, Outstanding at beginning of the period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average Exercise Price, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average Exercise Price, Forfeited/expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average Exercise Price, Vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average Exercise Price, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average Remaining Contractual Term (in years), Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average Remaining Contractual Term (in years), Vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average Remaining Contractual Term (in years), Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value ,Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceOneMember" xlink:label="ibio_ExercisePriceOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExercisePriceOneMember" xlink:to="ibio_ExercisePriceOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One[Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExercisePriceOneMember_lbl" xml:lang="en-US">$7.00 - $11.50 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceTwoMember" xlink:label="ibio_ExercisePriceTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExercisePriceTwoMember" xlink:to="ibio_ExercisePriceTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two[Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExercisePriceTwoMember_lbl" xml:lang="en-US">$17.35 - $26.03 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceThreeMember" xlink:label="ibio_ExercisePriceThreeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExercisePriceThreeMember" xlink:to="ibio_ExercisePriceThreeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExercisePriceThreeMember_lbl" xml:lang="en-US">$26.50 - $39.75 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceFourMember" xlink:label="ibio_ExercisePriceFourMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExercisePriceFourMember" xlink:to="ibio_ExercisePriceFourMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExercisePriceFourMember_lbl" xml:lang="en-US">$41.25 - $61.88 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Exercise price - Lower range</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise price - Upper range</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-Average Remaining Life In Years</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk free interest rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Mr.IsettMember" xlink:label="ibio_Mr.IsettMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Mr.IsettMember" xlink:to="ibio_Mr.IsettMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Mr.IsettMember_lbl" xml:lang="en-US">Represents information relating to Mr. Isett, Former CEO.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Mr.IsettMember_lbl" xml:lang="en-US">Mr. Isett [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_Mr.IsettMember_lbl" xml:lang="en-US">Mr. Isett, former CEO</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Mr.RobertLutzMember" xlink:label="ibio_Mr.RobertLutzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Mr.RobertLutzMember" xlink:to="ibio_Mr.RobertLutzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Mr.RobertLutzMember_lbl" xml:lang="en-US">Represents information relating to Mr. Robert Lutz, the Company's Chief Financial and Business Officer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Mr.RobertLutzMember_lbl" xml:lang="en-US">Mr. Robert Lutz [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_Mr.RobertLutzMember_lbl" xml:lang="en-US">Mr. Robert Lutz</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Dr.MartinBrennerMember" xlink:label="ibio_Dr.MartinBrennerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Dr.MartinBrennerMember" xlink:to="ibio_Dr.MartinBrennerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Dr.MartinBrennerMember_lbl" xml:lang="en-US">Represents information relating to Dr. Martin Brenner, the Company's Chief Scientific Officer and Interim Chief Executive Officer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Dr.MartinBrennerMember_lbl" xml:lang="en-US">Dr. Martin Brenner [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_Dr.MartinBrennerMember_lbl" xml:lang="en-US">Dr. Martin Brenner</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_InterimChiefExecutiveOfficerMember" xlink:label="ibio_InterimChiefExecutiveOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_InterimChiefExecutiveOfficerMember" xlink:to="ibio_InterimChiefExecutiveOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_InterimChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Person with designation of interim chief executive officer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_InterimChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Interim Chief Executive Officer [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_InterimChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Interim Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares terminated</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedLegalFeesMember" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" xml:lang="en-US">Scenario Plan, Expected Legal Fees [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" xml:lang="en-US">Scenario Plan Expected Legal Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedPaymentOneMember" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment One [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment Two [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndMaintenanceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndMaintenanceMember_lbl" xml:lang="en-US">License and Maintenance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash payments receivables related to litigation settlement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash Payments Receivables Related to Litigation Settlement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash payments receivables related to litigation settlement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage of legal fees expected to be received.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage Of Legal Fees Expected to be Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage of legal fees expected to be received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyUnrecordedAmount" xlink:to="us-gaap_GainContingencyUnrecordedAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Gain Contingency, Unrecorded Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Estimated net cash recovery</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Litigation settlement, amount awarded from other party</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Settlement income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current - Federal and state</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred - Federal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred - State</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CurrentAndDeferredFederalAndStateTaxes" xlink:label="ibio_CurrentAndDeferredFederalAndStateTaxes" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CurrentAndDeferredFederalAndStateTaxes" xlink:to="ibio_CurrentAndDeferredFederalAndStateTaxes_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CurrentAndDeferredFederalAndStateTaxes_lbl" xml:lang="en-US">The sum of the current and deferred federal income tax expense or benefit and the deferred income tax expense or benefit pertaining to pretax Income or Loss from continuing operations; income tax expense or benefit may include interest and penalties on tax uncertainties based on the entity's accounting policy.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CurrentAndDeferredFederalAndStateTaxes_lbl" xml:lang="en-US">Current And Deferred Federal And State Taxes</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_CurrentAndDeferredFederalAndStateTaxes_lbl" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxExpenseBenefitValuationAllowance" xlink:label="ibio_IncomeTaxExpenseBenefitValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncomeTaxExpenseBenefitValuationAllowance" xlink:to="ibio_IncomeTaxExpenseBenefitValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncomeTaxExpenseBenefitValuationAllowance_lbl" xml:lang="en-US">Increase (decrease) in the valuation allowance of the income tax expense (benefit) reported during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncomeTaxExpenseBenefitValuationAllowance_lbl" xml:lang="en-US">Income Tax Expense Benefit Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_IncomeTaxExpenseBenefitValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxAssetsResearchAndDevelopmentCosts" xlink:label="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts" xlink:to="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Amount of deferred tax assets from research and development costs.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Deferred Tax Assets Research and Development Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments_lbl" xml:lang="en-US">Investment in equity security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" xlink:label="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" xlink:to="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities_lbl" xml:lang="en-US">Amount of deferred tax assets from operating and finance lease liabilities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities_lbl" xml:lang="en-US">Deferred Tax Asset Operating and Finance Lease Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities_lbl" xml:lang="en-US">Operating and finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" xlink:label="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" xlink:to="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from operating and finance lease ROU assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities, Operating And Finance Lease Right Of Use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating and finance lease ROU assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxesTable" xlink:label="ibio_IncomeTaxesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncomeTaxesTable" xlink:to="ibio_IncomeTaxesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research and Development Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxesLineItems" xlink:label="ibio_IncomeTaxesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncomeTaxesLineItems" xlink:to="ibio_IncomeTaxesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncomeTaxesLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Operating loss carryforwards, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory federal income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" xlink:to="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes from the expiration and forfeiture of stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Expiration Forfeiture of Stock Options</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions_lbl" xml:lang="en-US">Expiration and forfeiture of stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" xlink:to="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes from iBio CDMO.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change Related to iBio CDMO</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo_lbl" xml:lang="en-US">Change related to iBio CDMO</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CroAgreementMember" xlink:to="ibio_CroAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CroAgreementMember_lbl" xml:lang="en-US">Represents the information pertaining to CRO Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CroAgreementMember_lbl" xml:lang="en-US">CRO Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Costs incurred</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EstimatedAdditionalCostOnDevelopment" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EstimatedAdditionalCostOnDevelopment" xlink:to="ibio_EstimatedAdditionalCostOnDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment_lbl" xml:lang="en-US">The amount of estimated additional cost on development as at end of the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment_lbl" xml:lang="en-US">Estimated Additional Cost on Development</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment_lbl" xml:lang="en-US">Additional costs committed</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Employer matching contribution, percent of match</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Employer matching contribution, percent of employees gross pay</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Employer contributions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" xlink:to="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_lbl" xml:lang="en-US">Represents the information pertaining to purchase and Sale Agreement with Majestic Realty Co.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_lbl" xml:lang="en-US">Purchase and Sale Agreement with Majestic Realty Co</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CreditAgreementWithWoodforestNationalBankMember" xlink:label="ibio_CreditAgreementWithWoodforestNationalBankMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CreditAgreementWithWoodforestNationalBankMember" xlink:to="ibio_CreditAgreementWithWoodforestNationalBankMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CreditAgreementWithWoodforestNationalBankMember_lbl" xml:lang="en-US">Represents the information pertaining to Credit Agreement with Woodforest National Bank.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CreditAgreementWithWoodforestNationalBankMember_lbl" xml:lang="en-US">Credit Agreement with Woodforest National Bank</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementWithLincolnParkMember" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementWithLincolnParkMember" xlink:to="ibio_StockPurchaseAgreementWithLincolnParkMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember_lbl" xml:lang="en-US">Represents the information pertaining to Stock Purchase Agreement with Lincoln Park.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember_lbl" xml:lang="en-US">Lincoln Park Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member" xlink:to="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_lbl" xml:lang="en-US">Represents the information pertaining to the event if the Facility is not sold on or before December 1, 2023.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_lbl" xml:lang="en-US">If the Facility is not sold on or before December 1, 2023,</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_lbl" xml:lang="en-US">Represents the information pertaining to the event if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_lbl" xml:lang="en-US">If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_lbl" xml:lang="en-US">Represents the information pertaining to the event if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_lbl" xml:lang="en-US">If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GroundLeasesAgreedToSellPruchasePrice" xlink:label="ibio_GroundLeasesAgreedToSellPruchasePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GroundLeasesAgreedToSellPruchasePrice" xlink:to="ibio_GroundLeasesAgreedToSellPruchasePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GroundLeasesAgreedToSellPruchasePrice_lbl" xml:lang="en-US">Amount of purchase price of land agreed to sell.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GroundLeasesAgreedToSellPruchasePrice_lbl" xml:lang="en-US">Ground Leases Agreed to Sell, Pruchase Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_GroundLeasesAgreedToSellPruchasePrice_lbl" xml:lang="en-US">Purchase price of land agreed to sell</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarnestMoneyDeposits" xlink:label="us-gaap_EarnestMoneyDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarnestMoneyDeposits" xlink:to="us-gaap_EarnestMoneyDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarnestMoneyDeposits_lbl" xml:lang="en-US">Earnest Money Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarnestMoneyDeposits_lbl" xml:lang="en-US">Earnest money deposit</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumAmountOfCommonStockAgreedToSell" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumAmountOfCommonStockAgreedToSell" xlink:to="ibio_MaximumAmountOfCommonStockAgreedToSell_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell_lbl" xml:lang="en-US">Maximum amount of common stock agreed to sell</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell_lbl" xml:lang="en-US">Maximum Amount of Common Stock Agreed to Sell</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell_lbl" xml:lang="en-US">Maximum amount of common stock agreed to sell</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ClosingPricePerShareOfCommonStock" xlink:label="ibio_ClosingPricePerShareOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ClosingPricePerShareOfCommonStock" xlink:to="ibio_ClosingPricePerShareOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ClosingPricePerShareOfCommonStock_lbl" xml:lang="en-US">Closing price per share of common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ClosingPricePerShareOfCommonStock_lbl" xml:lang="en-US">Closing Price Per Share of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ClosingPricePerShareOfCommonStock_lbl" xml:lang="en-US">Closing price per share of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" xlink:to="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_lbl" xml:lang="en-US">Minimum Price per share of common stock to sell additional shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_lbl" xml:lang="en-US">Minimum Closing Price of Common Stock to Sell Additional Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_lbl" xml:lang="en-US">Minimum Price per share of common stock to sell additional shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" xlink:to="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_lbl" xml:lang="en-US">Maximum number of common stock directed to sell through written notice.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_lbl" xml:lang="en-US">Maximum Number of Common Stock Directed to Sell Through Written Notice</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_lbl" xml:lang="en-US">Maximum number of common stock directed to sell through written notice</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockToBeSold" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumNumberOfCommonStockToBeSold" xlink:to="ibio_MaximumNumberOfCommonStockToBeSold_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold_lbl" xml:lang="en-US">Maximum number of common stock to be sold.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold_lbl" xml:lang="en-US">Maximum Number of Common Stock to be Sold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold_lbl" xml:lang="en-US">Maximum number of common stock to be sold</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" xlink:to="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_lbl" xml:lang="en-US">Maximum commitment in single regular sale of common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_lbl" xml:lang="en-US">Maximum Commitment in Single Regular Sale of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_lbl" xml:lang="en-US">Maximum commitment in single regular sale of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AdditionalSharesAgreedToIssue" xlink:label="ibio_AdditionalSharesAgreedToIssue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AdditionalSharesAgreedToIssue" xlink:to="ibio_AdditionalSharesAgreedToIssue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AdditionalSharesAgreedToIssue_lbl" xml:lang="en-US">Number of additional shares agreed to issue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AdditionalSharesAgreedToIssue_lbl" xml:lang="en-US">Additional Shares Agreed to Issue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AdditionalSharesAgreedToIssue_lbl" xml:lang="en-US">Additional commitment shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" xlink:label="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" xlink:to="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican_lbl" xml:lang="en-US">Maximum number of common stock to be sold as per applicable rules of the NYSE American.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican_lbl" xml:lang="en-US">Maximum Number of Common Stock to be Sold as per Applicable Rules of the NYSE American</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican_lbl" xml:lang="en-US">Maximum number of common stock to be sold as per applicable rules of the nyse american</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" xlink:label="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" xlink:to="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican_lbl" xml:lang="en-US">Percentage of common stock to be sold on outstanding common stock as per applicable rules of the NYSE American.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican_lbl" xml:lang="en-US">Percentage of Common Stock to be Sold on Outstanding common Stock as per Applicable Rules of the NYSE American</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican_lbl" xml:lang="en-US">Percentage of common stock to be sold on outstanding common stock as per applicable rules of the nyse american</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" xlink:label="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" xlink:to="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement_lbl" xml:lang="en-US">Maximum beneficial ownership considered to sale shares under agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement_lbl" xml:lang="en-US">Maximum Beneficial Ownership Considered to Sale Shares Under Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement_lbl" xml:lang="en-US">Maximum beneficial ownership considered to sale shares under agreement</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>41
<FILENAME>ibio-20230630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/27/2023 5:26:56 PM-->
<!--Modified on: 9/27/2023 5:26:56 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureNatureOfBusiness" roleURI="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureBasisOfPresentation" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDiscontinuedOperations" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurement" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSignificantTransactions" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosurePromissoryNoteReceivable" roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtSecurities" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseRouAssets" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseRouAssets" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFixedAssets" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebt" roleURI="http://www.ibioinc.com/role/DisclosureDebt" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligations" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligations" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureStockholdersEquity" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureEarningsLossPerCommonShare" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensation" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFraunhoferSettlement" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxes" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxes" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureEmployee401KPlan" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSubsequentEvents" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDiscontinuedOperationsTables" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementTables" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSignificantTransactionsTables" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtSecuritiesTables" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseRouAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFixedAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIntangibleAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.ibioinc.com/role/DisclosureAccruedExpensesTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebtTables" roleURI="http://www.ibioinc.com/role/DisclosureDebtTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligationTables" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligationsTables" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureEarningsLossPerCommonShareTables" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureBasisOfPresentationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDiscontinuedOperationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSignificantTransactionsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosurePromissoryNoteReceivableNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFixedAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" roleURI="http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebtCreditAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebtEquipmentFinancingDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureDebtNotePayablePppLoanDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureShareBasedCompensationRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureFraunhoferSettlementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureEmployee401KPlanNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230630.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" />
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638314324098007157" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638314324098007157" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638314324098007157" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638314324098007157" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638314324098007157" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638314324098007157" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638314324098007157" order="7" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638314324098007157" order="8" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638314324098007157" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638314324098007157" order="9" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638314324098017072" order="10" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638314324098017072" order="11" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638314324098017072" order="12" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638314324098017072" order="13" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638314324098017072" order="14" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638314324098017072" order="15" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638314324098017072" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638314324098017072" order="17" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638314324098017072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638314324098017072" order="18" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638314324098027070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638314324098027070" order="19" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638314324098027070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638314324098027070" order="20" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638314324098027070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638314324098027070" order="21" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638314324098027070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638314324098027070" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638314324098027070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638314324098027070" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638314324098027070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638314324098027070" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638314324098027070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638314324098027070" order="25" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638314324098027070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638314324098027070" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638314324098037067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638314324098037067" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638314324098037067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638314324098037067" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638314324098037067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638314324098037067" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638314324098037067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638314324098037067" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638314324098037067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638314324098037067" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638314324098037067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638314324098037067" order="32" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638314324098046985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638314324098046985" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638314324098046985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638314324098046985" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638314324098046985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638314324098046985" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638314324098046985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="us-gaap_AssetsAbstract_638314324098046985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638314324098046985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_AssetsCurrentAbstract_638314324098046985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638314324098057154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="us-gaap_RestrictedCashCurrent_638314324098057154" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="us-gaap_DebtSecuritiesCurrent_638314324098057154" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="us-gaap_AccountsReceivableNetCurrent_638314324098057154" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="ibio_SubscriptionReceivableCurrent_638314324098057154" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="us-gaap_SettlementAssetsCurrent_638314324098057154" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638314324098057154" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638314324098057154" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638314324098046985" xlink:to="us-gaap_AssetsCurrent_638314324098057154" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638314324098057154" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_RestrictedCashNoncurrent_638314324098057154" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638314324098067054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638314324098067054" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638314324098067054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638314324098067054" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638314324098067054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638314324098067054" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638314324098067054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638314324098067054" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638314324098067054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638314324098067054" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638314324098067054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_SecurityDeposit_638314324098067054" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638314324098067054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638314324098067054" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638314324098067054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638314324098067054" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638314324098077009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638314324098046985" xlink:to="us-gaap_Assets_638314324098077009" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638314324098077009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="us-gaap_AccountsPayableCurrent_638314324098077009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638314324098077009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638314324098077009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638314324098077009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638314324098077009" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638314324098077009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638314324098077009" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent_638314324098087075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="ibio_EquipmentFinancingPayableCurrent_638314324098087075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638314324098087075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="us-gaap_NotesPayableCurrent_638314324098087075" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638314324098087075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="us-gaap_DeferredRevenueCurrent_638314324098087075" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638314324098087075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638314324098087075" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638314324098087075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638314324098077009" xlink:to="us-gaap_LiabilitiesCurrent_638314324098087075" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324098096757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324098096757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638314324098096757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638314324098096757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_638314324098096757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_638314324098096757" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent_638314324098096757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="ibio_AccruedLiabilitiesNoncurrent_638314324098096757" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638314324098096757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638314324098096757" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638314324098147016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="us-gaap_Liabilities_638314324098147016" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638314324098147016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638314324098147016" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638314324098147016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638314324098147016" xlink:to="us-gaap_StockholdersEquityAbstract_638314324098147016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638314324098147016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638314324098147016" xlink:to="us-gaap_PreferredStockValue_638314324098147016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638314324098147016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638314324098147016" xlink:to="us-gaap_CommonStockValue_638314324098147016" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638314324098157073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638314324098147016" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638314324098157073" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638314324098157073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638314324098147016" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638314324098157073" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638314324098157073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638314324098147016" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638314324098157073" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638314324098157073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638314324098147016" xlink:to="us-gaap_StockholdersEquity_638314324098157073" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638314324098157073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638314324098077009" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638314324098157073" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638314324098166975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638314324098166975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638314324098166975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638314324098166975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638314324098166975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638314324098166975" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638314324098166975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638314324098166975" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638314324098166975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638314324098166975" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638314324098166975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638314324098166975" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638314324098166975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638314324098166975" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638314324098177016" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638314324098177016" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_636900514088604338" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_Revenues_638314324098177016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_OperatingExpensesAbstract_638314324098177016" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638314324098177016" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638314324098177016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638314324098177016" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638314324098177016" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638314324098177016" xlink:to="us-gaap_OperatingExpenses_638314324098177016" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_OperatingIncomeLoss_638314324098177016" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638314324098177016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638314324098177016" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638314324098177016" xlink:to="us-gaap_InterestExpense_638314324098187006" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638314324098177016" xlink:to="us-gaap_InvestmentIncomeInterest_638314324098187006" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638314324098177016" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324098187006" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638314324098177016" xlink:to="us-gaap_RoyaltyIncomeNonoperating_638314324098187006" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638314324098177016" xlink:to="us-gaap_NonoperatingIncomeExpense_638314324098187006" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638314324098187006" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638314324098187006" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638314324098187006" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_DividendsPreferredStockStock_638314324098187006" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638314324098187006" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638314324098187006" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638314324098197824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638314324098197824" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_638314324098197824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_638314324098197824" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638314324098197824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638314324098197824" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638314324098197824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638314324098197824" xlink:to="us-gaap_ProfitLoss_638314324098197824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638314324098197824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638314324098197824" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638314324098197824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638314324098197824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638314324098197824" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638314324098197824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638314324098197824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638314324098197824" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638314324098206996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638314324098206996" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638314324098206996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638314324098206996" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638314324098206996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638314324098206996" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638314324098206996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638314324098206996" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638314324098206996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_EarningsPerShareBasic_638314324098206996" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638314324098206996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_EarningsPerShareDiluted_638314324098206996" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638314324098217343" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638314324098217343" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638314324098217343" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638314324098217343" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_637045036841541064" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324098217343" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_637045036841541064" xlink:to="us-gaap_StatementTable_638314324098217343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638314324098217343" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098217343" xlink:to="us-gaap_StatementEquityComponentsAxis_638314324098217343" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638314324098217343" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638314324098217343" xlink:to="us-gaap_PreferredStockMember_638314324098217343" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638314324098217343" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638314324098217343" xlink:to="us-gaap_CommonStockMember_638314324098217343" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638314324098217343" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638314324098217343" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638314324098217343" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638314324098217343" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638314324098227024" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638314324098217343" xlink:to="us-gaap_RetainedEarningsMember_638314324098227024" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638314324098217343" xlink:to="us-gaap_NoncontrollingInterestMember_638314324098227024" order="6" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638314324098217343" xlink:to="us-gaap_EquityComponentDomain_638314324098227024" order="7" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098217343" xlink:to="us-gaap_StatementLineItems_638314324098227024" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638314324098227024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_SharesOutstanding_638314324098227024" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324098227024" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_638314324098227024" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_638314324098227024" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638314324098237165" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638314324098237165" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionValue" xlink:label="ibio_AssetAcquisitionValue_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="ibio_AssetAcquisitionValue_638314324098237165" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionInShares" xlink:label="ibio_AssetAcquisitionInShares_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="ibio_AssetAcquisitionInShares_638314324098237165" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638314324098237165" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638314324098237165" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitValue" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitValue_638314324098237165" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitShares" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitShares_638314324098237165" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638314324098237165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638314324098237165" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638314324098247021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638314324098247021" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638314324098247021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638314324098247021" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638314324098247021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638314324098247021" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638314324098247021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638314324098247021" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_638314324098247021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_638314324098247021" order="18" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_638314324098247021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_638314324098247021" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_638314324098247021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_638314324098247021" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638314324098257116" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_ProfitLoss_638314324098257116" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638314324098257116" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638314324098257116" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638314324098257116" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098227024" xlink:to="us-gaap_SharesOutstanding_638314324098257116" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_ProfitLoss_638314324098267016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_ShareBasedCompensation_638314324098267016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638314324098267016" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638314324098267016" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638314324098267016" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_Depreciation_638314324098267016" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638314324098267016" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638314324098267016" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638314324098267016" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324098267016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324098267016" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638314324098277042" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_638314324098277042" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638314324098277042" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638314324098277042" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_638314324098277042" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638314324098277042" order="15" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="ibio_SettlementOfRevenueContract_638314324098277042" order="16" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_ImpairmentOfInvestments_638314324098277042" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638314324098286987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638314324098286987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInSettlementAssets" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_638314324098286987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="ibio_IncreaseDecreaseInSettlementAssets_638314324098286987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638314324098286987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638314324098286987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638314324098286987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638314324098286987" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638314324098286987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638314324098286987" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_638314324098286987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_638314324098286987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638314324098286987" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638314324098286987" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638314324098296996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638314324098296996" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638314324098296996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638314324098296996" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638314324098296996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638314324098296996" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638314324098296996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638314324098277042" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638314324098296996" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324098296996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638314324098267016" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638314324098296996" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638314324098307081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638314324098307081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638314324098307081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638314324098307081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638314324098307081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638314324098307081" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638314324098307081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638314324098307081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638314324098307081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638314324098307081" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638314324098307081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638314324098307081" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638314324098317080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638314324098317080" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638314324098317080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638314324098317080" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324098317080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638314324098296996" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638314324098317080" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638314324098317080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638314324098317080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentsForFractionalSharesAfterReverseStockSplit" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_638314324098327092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_638314324098327092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders_638314324098327092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="us-gaap_PaymentsToMinorityShareholders_638314324098327092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ProceedsFromEquipmentFinancingLoan" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_638314324098327092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="ibio_ProceedsFromEquipmentFinancingLoan_638314324098327092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_638314324098327092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_638314324098327092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638314324098327092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="us-gaap_RepaymentsOfNotesPayable_638314324098327092" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638314324098337102" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638314324098337102" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PaymentsToAttainTermNote" xlink:label="ibio_PaymentsToAttainTermNote_638314324098337102" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="ibio_PaymentsToAttainTermNote_638314324098337102" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638314324098337102" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638314324098337102" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324098337102" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638314324098317080" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638314324098337102" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638314324098347094" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638314324098347094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638314324098347094" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638314324098347094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638314324098347094" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638314324098347094" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383143240983470941" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383143240983470941" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_638314324098356833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_638314324098356833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638314324098356833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638314324098356833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_638314324098356833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_638314324098356833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_638314324098356833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_638314324098356833" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_638314324098367097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_638314324098367097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise" xlink:label="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise_638314324098367097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise_638314324098367097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CostAccruedToAmendTermNotePayable" xlink:label="ibio_CostAccruedToAmendTermNotePayable_638314324098367097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_CostAccruedToAmendTermNotePayable_638314324098367097" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_638314324098367097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_638314324098367097" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_638314324098377036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_638314324098377036" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1_638314324098377036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="us-gaap_NotesIssued1_638314324098377036" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_638314324098377036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_638314324098377036" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NonCashSettlementOfRevenueContract" xlink:label="ibio_NonCashSettlementOfRevenueContract_638314324098377036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_NonCashSettlementOfRevenueContract_638314324098377036" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WarrantsIssuedForFinanceLeasePayment" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment_638314324098387101" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_WarrantsIssuedForFinanceLeasePayment_638314324098387101" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LeaseIncentiveForConstructionInProgress" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_638314324098387101" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_LeaseIncentiveForConstructionInProgress_638314324098387101" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_638314324098387101" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_638314324098387101" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_638314324098397321" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638314324098356833" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_638314324098397321" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638314324098397321" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638314324098397321" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638314324098397321" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638314324098397321" xlink:to="us-gaap_InterestPaidNet_638314324098397321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638314324098407011" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638314324098407011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638314324098407011" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638314324098407011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" xlink:type="extended" xlink:title="10301 - Disclosure - Discontinued Operations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638314324098417017" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638314324098417017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10401 - Disclosure - Summary of Significant Accounting Policies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638314324098417017" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638314324098417017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" xlink:type="extended" xlink:title="10501 - Disclosure - Financial Instruments and Fair Value Measurement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638314324098417017" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638314324098417017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactions" xlink:type="extended" xlink:title="10601 - Disclosure - Significant Transactions">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SignificantTransactionsTextBlock" xlink:label="ibio_SignificantTransactionsTextBlock_638314324098417017" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="ibio_SignificantTransactionsTextBlock_638314324098417017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable" xlink:type="extended" xlink:title="10701 - Disclosure - Promissory Note Receivable">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638314324098427015" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638314324098427015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" xlink:type="extended" xlink:title="10801 - Disclosure - Investments in Debt Securities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638314324098427015" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638314324098427015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" xlink:type="extended" xlink:title="10901 - Disclosure - Finance Lease ROU Assets">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_638314324098427015" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_638314324098427015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" xlink:type="extended" xlink:title="11001 - Disclosure - Operating Lease ROU Assets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_638314324098427015" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_638314324098427015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssets" xlink:type="extended" xlink:title="11101 - Disclosure - Fixed Assets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638314324098437042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638314324098437042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebt" xlink:type="extended" xlink:title="11401 - Disclosure - Debt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638314324098437042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638314324098437042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations" xlink:type="extended" xlink:title="11501 - Disclosure - Finance Lease Obligations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_638314324098437042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_638314324098437042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations" xlink:type="extended" xlink:title="11601 - Disclosure - Operating Lease Obligations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638314324098437042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638314324098437042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11701 - Disclosure - Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638314324098447106" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638314324098447106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" xlink:type="extended" xlink:title="11801 - Disclosure - Earnings (Loss) Per Common Share">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638314324098447106" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638314324098447106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="11901 - Disclosure - Share-Based Compensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638314324098447106" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638314324098447106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" xlink:type="extended" xlink:title="12001 - Disclosure - Fraunhofer Settlement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_638314324098447106" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="ibio_GainLossRelatedToLitigationSettlementTextBlock_638314324098447106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="12101 - Disclosure - Income Taxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638314324098457008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638314324098457008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="12201 - Disclosure - Commitments and Contingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638314324098457008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638314324098457008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" xlink:type="extended" xlink:title="12301 - Disclosure - Employee 401(K) Plan">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638314324098457008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638314324098457008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="12401 - Disclosure - Subsequent Events">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638314324098457008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638314324098457008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20402 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638314324098467021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638314324098467021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638314324098467021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractAssetsPolicyTextBlock" xlink:label="ibio_ContractAssetsPolicyTextBlock_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_ContractAssetsPolicyTextBlock_638314324098467021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractLiabilitiesPolicyTextBlock" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_ContractLiabilitiesPolicyTextBlock_638314324098467021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638314324098467021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638314324098467021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_638314324098467021" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessPolicy" xlink:label="us-gaap_InventoryWorkInProcessPolicy_638314324098467021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryWorkInProcessPolicy_638314324098467021" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638314324098477038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638314324098477038" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_638314324098477038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_RightOfUseAssetsPolicyPolicyTextBlock_638314324098477038" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638314324098477038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638314324098477038" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638314324098477038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638314324098477038" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638314324098477038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638314324098477038" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638314324098477038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638314324098477038" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638314324098477038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638314324098477038" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638314324098477038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638314324098477038" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Discontinued Operations (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638314324098487191" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638314324098487191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638314324098487191" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638314324098487191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638314324098487191" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638314324098487191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" xlink:type="extended" xlink:title="30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638314324098497032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638314324098497032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Significant Transactions (Tables)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324098497032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638314324098497032" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638314324098497032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098497032" xlink:to="us-gaap_TypeOfArrangementAxis_638314324098497032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324098497032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638314324098497032" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324098497032" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638314324098497032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324098497032" xlink:to="ibio_RubrycTheraputicsInc.Member_638314324098497032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638314324098497032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098497032" xlink:to="us-gaap_AssetAcquisitionAxis_638314324098497032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638314324098497032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638314324098497032" xlink:to="us-gaap_AssetAcquisitionDomain_638314324098497032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember_638314324098497032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638314324098497032" xlink:to="ibio_AssetPurchaseAgreementMember_638314324098497032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324098507004" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098497032" xlink:to="us-gaap_StatementLineItems_638314324098507004" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_638314324098507004" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098507004" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_638314324098507004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Investments in Debt Securities (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638314324098507004" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638314324098507004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_638314324098507004" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_638314324098507004" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_638314324098507004" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_638314324098507004" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" xlink:type="extended" xlink:title="30903 - Disclosure - Finance Lease ROU Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_638314324098516676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_638314324098516676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" xlink:type="extended" xlink:title="31103 - Disclosure - Fixed Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638314324098516676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638314324098516676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Intangible Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638314324098516676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638314324098516676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638314324098516676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638314324098516676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Accrued Expenses (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638314324098527043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638314324098527043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="31403 - Disclosure - Debt (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638314324098527043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_2" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638314324098527043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" xlink:type="extended" xlink:title="31503 - Disclosure - Finance Lease Obligation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_638314324098527043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_638314324098527043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638314324098527043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638314324098527043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" xlink:label="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_638314324098527043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_638314324098527043" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" xlink:type="extended" xlink:title="31603 - Disclosure - Operating Lease Obligations (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_638314324098537048" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_638314324098537048" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638314324098537048" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638314324098537048" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="31703 - Disclosure - Stockholders' Equity (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638314324098537048" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638314324098537048" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" xlink:type="extended" xlink:title="31803 - Disclosure - Earnings (Loss) Per Common Share (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638314324098537048" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638314324098537048" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638314324098537048" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638314324098537048" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="31903 - Disclosure - Share-Based Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638314324098547071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638314324098547071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638314324098547071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638314324098547071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_638314324098547071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_638314324098547071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638314324098547071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638314324098547071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="32103 - Disclosure - Income Taxes (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638314324098556685" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638314324098556685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638314324098556685" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638314324098556685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638314324098556685" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638314324098556685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract_637045036841780422" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationTable" xlink:label="ibio_BasisOfPresentationTable_638314324098556685" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="ibio_BasisOfPresentationTable_638314324098556685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638314324098556685" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationTable_638314324098556685" xlink:to="us-gaap_DebtInstrumentAxis_638314324098556685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638314324098556685" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638314324098556685" xlink:to="us-gaap_DebtInstrumentNameDomain_638314324098556685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638314324098567042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638314324098556685" xlink:to="ibio_SecuredTermLoanMember_638314324098567042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BasisOfPresentationLineItems" xlink:label="ibio_BasisOfPresentationLineItems_638314324098567042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationTable_638314324098556685" xlink:to="ibio_BasisOfPresentationLineItems_638314324098567042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638314324098567042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638314324098567042" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638314324098567042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638314324098567042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638314324098567042" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638314324098567042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638314324098567042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638314324098567042" xlink:to="us-gaap_LongTermDebt_638314324098567042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_638314324098567042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638314324098567042" xlink:to="ibio_CashAndCashEquivalentsPlusDebtSecurities_638314324098567042" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638314324098567042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638314324098567042" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638314324098567042" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Discontinued Operations (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638314324098567042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638314324098567042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638314324098567042" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638314324098577010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638314324098577010" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638314324098577010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AuctionSaleAgreementMember" xlink:label="ibio_AuctionSaleAgreementMember_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638314324098577010" xlink:to="ibio_AuctionSaleAgreementMember_638314324098577010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638314324098567042" xlink:to="srt_StatementScenarioAxis_638314324098577010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638314324098577010" xlink:to="srt_ScenarioUnspecifiedDomain_638314324098577010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GuaranteedAuctionProceedsMember" xlink:label="ibio_GuaranteedAuctionProceedsMember_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324098577010" xlink:to="ibio_GuaranteedAuctionProceedsMember_638314324098577010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExcessAuctionProceedsMember" xlink:label="ibio_ExcessAuctionProceedsMember_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324098577010" xlink:to="ibio_ExcessAuctionProceedsMember_638314324098577010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638314324098567042" xlink:to="srt_CounterpartyNameAxis_638314324098577010" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324098577010" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098577010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_HollandIndustrialGroupMember" xlink:label="ibio_HollandIndustrialGroupMember_638314324098577010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098577010" xlink:to="ibio_HollandIndustrialGroupMember_638314324098577010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638314324098567042" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638314324098586695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638314324098586695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="us-gaap_AreaOfLand_638314324098586695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638314324098586695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638314324098586695" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfAuctionProceedsReceived" xlink:label="ibio_PercentageOfAuctionProceedsReceived_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="ibio_PercentageOfAuctionProceedsReceived_638314324098586695" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AuctionFee" xlink:label="ibio_AuctionFee_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="ibio_AuctionFee_638314324098586695" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses_638314324098586695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="ibio_EmployeeReductionExpenses_638314324098586695" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceTransitionalPeriodDays" xlink:label="ibio_SeveranceTransitionalPeriodDays_638314324098597012" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="ibio_SeveranceTransitionalPeriodDays_638314324098597012" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638314324098597012" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638314324098597012" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638314324098597012" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638314324098597012" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_638314324098597012" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638314324098586695" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_638314324098597012" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638314324098607045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_638314324098607045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_638314324098607045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638314324098607045" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_638314324098607045" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_638314324098607045" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GainOnSaleOfFixedAssets" xlink:label="ibio_GainOnSaleOfFixedAssets_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="ibio_GainOnSaleOfFixedAssets_638314324098607045" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638314324098607045" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638314324098607045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638314324098607045" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638314324098617026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638314324098617026" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupInterestExpenseRelatedParty" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_638314324098617026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="ibio_DisposalGroupInterestExpenseRelatedParty_638314324098617026" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupGainOnDebtForgiveness" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_638314324098617026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="ibio_DisposalGroupGainOnDebtForgiveness_638314324098617026" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_638314324098617026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_638314324098617026" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_638314324098617026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_638314324098617026" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638314324098617026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638314324098607045" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638314324098617026" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638314324098617026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638314324098617026" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098627042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638314324098617026" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098627042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_638314324098627042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098627042" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_638314324098627042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_638314324098627042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098627042" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_638314324098627042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_638314324098627042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098627042" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_638314324098627042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638314324098627042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098627042" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638314324098627042" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098627042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638314324098617026" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098627042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_638314324098627042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098627042" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_638314324098627042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_638314324098627042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098627042" xlink:to="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_638314324098627042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_638314324098637038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098627042" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_638314324098637038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638314324098637038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098627042" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638314324098637038" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098637038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638314324098617026" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098637038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_638314324098637038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098637038" xlink:to="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_638314324098637038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_638314324098637038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098637038" xlink:to="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_638314324098637038" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_638314324098637038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638314324098637038" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_638314324098637038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098637038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638314324098617026" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098637038" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_638314324098647056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098637038" xlink:to="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_638314324098647056" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_638314324098647056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098637038" xlink:to="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_638314324098647056" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_638314324098647056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638314324098637038" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_638314324098647056" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638314324098617026" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_638314324098647056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_638314324098647056" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_638314324098647056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" xlink:to="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_638314324098647056" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_638314324098657140" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_638314324098657140" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_638314324098657140" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" xlink:to="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_638314324098657140" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638314324098657140" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638314324098657140" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638314324098657140" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638314324098657140" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638314324098657140" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638314324098657140" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases" xlink:label="ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases_638314324098667051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638314324098657140" xlink:to="ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases_638314324098667051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_638314324098667051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638314324098657140" xlink:to="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_638314324098667051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_638314324098667051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638314324098657140" xlink:to="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_638314324098667051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant" xlink:label="ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant_638314324098667051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638314324098657140" xlink:to="ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant_638314324098667051" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ProceedsFromNotesPayableFromDiscontinuedOperations" xlink:label="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations_638314324098667051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638314324098657140" xlink:to="ibio_ProceedsFromNotesPayableFromDiscontinuedOperations_638314324098667051" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IssuanceOfWarrantForFinalLeaseObligationPayment" xlink:label="ibio_IssuanceOfWarrantForFinalLeaseObligationPayment_638314324098676683" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638314324098657140" xlink:to="ibio_IssuanceOfWarrantForFinalLeaseObligationPayment_638314324098676683" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638314324098676683" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638314324098647056" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638314324098676683" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidDiscontinuedOperations" xlink:label="us-gaap_InterestPaidDiscontinuedOperations_638314324098676683" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638314324098676683" xlink:to="us-gaap_InterestPaidDiscontinuedOperations_638314324098676683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_189" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_189" xlink:to="us-gaap_StatementTable_638314324098687057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098687057" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324098687057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324098687057" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324098687057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324098687057" xlink:to="us-gaap_IntellectualPropertyMember_638314324098687057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098687057" xlink:to="srt_RangeAxis_638314324098687057" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638314324098687057" xlink:to="srt_RangeMember_638314324098687057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638314324098687057" xlink:to="srt_MinimumMember_638314324098687057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638314324098687057" xlink:to="srt_MaximumMember_638314324098687057" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098687057" xlink:to="srt_MajorCustomersAxis_638314324098687057" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638314324098687057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638314324098687057" xlink:to="srt_NameOfMajorCustomerDomain_638314324098687057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FourCustomersMember" xlink:label="ibio_FourCustomersMember_638314324098697070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638314324098687057" xlink:to="ibio_FourCustomersMember_638314324098697070" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EightCustomersMember" xlink:label="ibio_EightCustomersMember_638314324098697070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638314324098687057" xlink:to="ibio_EightCustomersMember_638314324098697070" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638314324098697070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098687057" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638314324098697070" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638314324098697070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638314324098697070" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638314324098697070" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_638314324098697070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638314324098697070" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_638314324098697070" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638314324098697070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098687057" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638314324098697070" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638314324098697070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638314324098697070" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638314324098697070" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638314324098707197" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638314324098697070" xlink:to="us-gaap_CustomerConcentrationRiskMember_638314324098707197" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098687057" xlink:to="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_638314324098707197" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_638314324098707197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638314324098707197" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638314324098707197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638314324098707197" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_DeferredRevenueCurrent_638314324098707197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638314324098707197" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638314324098707197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638314324098707197" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638314324098707197" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638314324098717071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638314324098717071" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638314324098717071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638314324098717071" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638314324098717071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_UnrecognizedTaxBenefits_638314324098717071" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_638314324098717071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_CashUninsuredAmount_638314324098717071" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers_638314324098717071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="ibio_NumberOfMajorCustomers_638314324098717071" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638314324098717071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_AccountsReceivableNetCurrent_638314324098717071" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating_638314324098717071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_RoyaltyIncomeNonoperating_638314324098717071" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638314324098727332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_Revenues_638314324098727332" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638314324098727332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638314324098707197" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638314324098727332" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324098727332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638314324098727332" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638314324098727332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098727332" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638314324098727332" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638314324098727332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638314324098727332" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638314324098727332" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638314324098727332" xlink:to="ibio_LetterOfCreditTermLoanMember_638314324098737054" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638314324098727332" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember_638314324098737054" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638314324098727332" xlink:to="ibio_CompanyPurchasingCardMember_638314324098737054" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098727332" xlink:to="srt_CounterpartyNameAxis_638314324098737054" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324098737054" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098737054" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098737054" xlink:to="ibio_WoodforestMember_638314324098737054" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098727332" xlink:to="us-gaap_StatementLineItems_638314324098737054" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098737054" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638314324098737054" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases_638314324098737054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638314324098737054" xlink:to="us-gaap_LandSubjectToGroundLeases_638314324098737054" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired_638314324098747042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638314324098737054" xlink:to="ibio_PercentageOfCollateralRequired_638314324098747042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638314324098747042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638314324098737054" xlink:to="us-gaap_RestrictedCash_638314324098747042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638314324098747042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638314324098737054" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638314324098747042" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638314324098747042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638314324098737054" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638314324098747042" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638314324098747042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638314324098737054" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638314324098747042" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Summary of Significant Accounting Policies (Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract_638314324098747042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryNetAbstract_638314324098747042" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_638314324098747042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638314324098747042" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_638314324098747042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638314324098757066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638314324098747042" xlink:to="us-gaap_InventoryWorkInProcess_638314324098757066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638314324098757066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638314324098747042" xlink:to="us-gaap_InventoryNet_638314324098757066" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098757066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098757066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638314324098757066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098757066" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638314324098757066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638314324098757066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638314324098757066" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638314324098757066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_638314324098757066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638314324098757066" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_638314324098757066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638314324098757066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098757066" xlink:to="us-gaap_SubsequentEventTypeAxis_638314324098757066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638314324098837088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638314324098757066" xlink:to="us-gaap_SubsequentEventTypeDomain_638314324098837088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638314324098837088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638314324098837088" xlink:to="us-gaap_SubsequentEventMember_638314324098837088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324098837088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098757066" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324098837088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324098847065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324098837088" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324098847065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638314324098847065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324098847065" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638314324098847065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638314324098847065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324098847065" xlink:to="us-gaap_MachineryAndEquipmentMember_638314324098847065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098847065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098757066" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098847065" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638314324098847065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098847065" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638314324098847065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638314324098847065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098847065" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638314324098847065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfBuildings" xlink:label="us-gaap_ProceedsFromSaleOfBuildings_638314324098847065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098847065" xlink:to="us-gaap_ProceedsFromSaleOfBuildings_638314324098847065" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale_638314324098847065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098847065" xlink:to="ibio_FixedAssetsHeldForSale_638314324098847065" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098857365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098857365" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638314324098857365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638314324098857365" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638314324098857365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638314324098857365" xlink:to="us-gaap_FairValueInputsLevel3Member_638314324098857365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098857365" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324098857365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324098857365" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324098857365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324098857365" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638314324098857365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324098857365" xlink:to="us-gaap_MachineryAndEquipmentMember_638314324098857365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098857365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638314324098857365" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098857365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638314324098867060" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098857365" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638314324098867060" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638314324098867060" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638314324098857365" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638314324098867060" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Significant Transactions (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324098867060" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638314324098867060" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638314324098867060" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098867060" xlink:to="us-gaap_StatementClassOfStockAxis_638314324098867060" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638314324098867060" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638314324098867060" xlink:to="us-gaap_ClassOfStockDomain_638314324098867060" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638314324098879996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638314324098867060" xlink:to="ibio_Series2PreferredStockMember_638314324098879996" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638314324098879996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098867060" xlink:to="us-gaap_TypeOfArrangementAxis_638314324098879996" order="2" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324098879996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638314324098879996" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324098879996" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_638314324098879996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324098879996" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember_638314324098879996" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember_638314324098879996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324098879996" xlink:to="ibio_StockPurchaseAgreementMember_638314324098879996" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_638314324098879996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324098879996" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember_638314324098879996" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638314324098879996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098867060" xlink:to="srt_ProductOrServiceAxis_638314324098879996" order="3" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638314324098879996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638314324098879996" xlink:to="srt_ProductsAndServicesDomain_638314324098879996" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638314324098879996" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_638314324098887057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098867060" xlink:to="srt_StatementScenarioAxis_638314324098887057" order="4" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638314324098887057" xlink:to="srt_ScenarioUnspecifiedDomain_638314324098887057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324098887057" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember_638314324098887057" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098867060" xlink:to="srt_CounterpartyNameAxis_638314324098887057" order="5" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324098887057" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098887057" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098887057" xlink:to="ibio_RubrycTheraputicsInc.Member_638314324098887057" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098887057" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638314324098887057" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638314324098887057" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098867060" xlink:to="dei_LegalEntityAxis_638314324098887057" order="6" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638314324098897107" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638314324098887057" xlink:to="dei_EntityDomain_638314324098897107" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_638314324098897107" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638314324098897107" xlink:to="ibio_IbioCmoPreferredTrackingStockMember_638314324098897107" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638314324098897107" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098867060" xlink:to="us-gaap_DebtInstrumentAxis_638314324098897107" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638314324098897107" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638314324098897107" xlink:to="us-gaap_DebtInstrumentNameDomain_638314324098897107" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638314324098897107" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638314324098897107" xlink:to="ibio_SecuredTermLoanMember_638314324098897107" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324098897107" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098867060" xlink:to="us-gaap_StatementLineItems_638314324098897107" order="8" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_638314324098906741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_638314324098906741" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_638314324098906741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_638314324098906741" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty_638314324098906741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_FairMarketValueOfProperty_638314324098906741" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638314324098906741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638314324098906741" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_638314324098906741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_638314324098906741" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_638314324098906741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable_638314324098906741" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_638314324098906741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_638314324098906741" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638314324098917141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_DebtInstrumentFaceAmount_638314324098917141" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638314324098917141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638314324098917141" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638314324098917141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638314324098917141" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638314324098917141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_DeferredFinanceCostsNet_638314324098917141" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638314324098917141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_InterestExpenseDebt_638314324098917141" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638314324098927085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638314324098927085" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638314324098927085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638314324098927085" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_638314324098927085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_638314324098927085" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_638314324098937096" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_638314324098937096" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_638314324098937096" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_638314324098937096" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts_638314324098937096" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_AssetAcquisitionTransactionCosts_638314324098937096" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638314324098937096" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_FinanceLeaseLiability_638314324098937096" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_638314324098937096" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_638314324098937096" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_638314324098937096" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm_638314324098937096" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_638314324098947092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased_638314324098947092" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_638314324098947092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased_638314324098947092" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638314324098947092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638314324098947092" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_638314324098947092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_638314324098947092" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_638314324098957089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_ImpairmentOfInvestments_638314324098957089" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638314324098957089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638314324098957089" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_638314324098957089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent_638314324098957089" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_638314324098957089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent_638314324098957089" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638314324098957089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638314324098957089" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638314324098967064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_CommonStockValue_638314324098967064" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases_638314324098967064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_NumberOfEquipmentLeases_638314324098967064" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_638314324098967064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_638314324098967064" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_638314324098967064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_638314324098967064" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_638314324098977079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_638314324098977079" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_638314324098977079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_638314324098977079" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_638314324098977079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_638314324098977079" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638314324098977079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638314324098977079" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent_638314324098987381" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324098897107" xlink:to="ibio_AccruedLiabilitiesNoncurrent_638314324098987381" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324098987381" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638314324098987381" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098987381" xlink:to="us-gaap_AssetAcquisitionAxis_638314324098997081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638314324098997081" xlink:to="us-gaap_AssetAcquisitionDomain_638314324098997081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638314324098997081" xlink:to="ibio_Series2PreferredStockMember_638314324098997081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638314324098997081" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember_638314324098997081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638314324098997081" xlink:to="ibio_AssetAcquisitionFixedAssetsMember_638314324098997081" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638314324098997081" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember_638314324098997081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098987381" xlink:to="srt_CounterpartyNameAxis_638314324098997081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324098997081" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098997081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638314324098997081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324098997081" xlink:to="ibio_RubrycTheraputicsInc.Member_638314324098997081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099006745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324098987381" xlink:to="us-gaap_StatementLineItems_638314324099006745" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638314324099006745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099006745" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638314324099006745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638314324099006745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638314324099006745" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638314324099006745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638314324099006745" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638314324099006745" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_638314324099006745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638314324099006745" xlink:to="us-gaap_ReceivableTypeDomain_638314324099006745" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember_638314324099006745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638314324099006745" xlink:to="us-gaap_NotesReceivableMember_638314324099006745" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_638314324099006745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638314324099006745" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_638314324099006745" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested_638314324099006745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638314324099006745" xlink:to="ibio_LoansReceivableAmountInvested_638314324099006745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_638314324099017049" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638314324099006745" xlink:to="ibio_LoansReceivableFixedRatesOfInterest_638314324099017049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_638314324099017049" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638314324099006745" xlink:to="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_638314324099017049" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_638314324099017049" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638314324099006745" xlink:to="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_638314324099017049" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638314324099017049" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638314324099006745" xlink:to="us-gaap_InvestmentIncomeInterest_638314324099017049" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_638314324099017049" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638314324099006745" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_638314324099017049" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638314324099017049" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638314324099017049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Investments in Debt Securities (Components of Investments in Debt Securities) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638314324099026749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638314324099026749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638314324099026749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638314324099026749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638314324099026749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesCurrent_638314324099026749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099026749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099026749" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638314324099026749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099026749" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638314324099026749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost" xlink:label="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost_638314324099026749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099026749" xlink:to="ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost_638314324099026749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638314324099026749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099026749" xlink:to="us-gaap_DebtSecuritiesCurrent_638314324099026749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Investments in Debt Securities (Realized Losses on Available-For-Sale Debt Securities) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099037042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099037042" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638314324099037042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099037042" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638314324099037042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CostOfDebtSecurities" xlink:label="ibio_CostOfDebtSecurities_638314324099037042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099037042" xlink:to="ibio_CostOfDebtSecurities_638314324099037042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324099037042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638314324099037042" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638314324099037042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638314324099037042" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638314324099037042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638314324099047084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638314324099047084" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324099047084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638314324099047084" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324099047084" order="1" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099047084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324099047084" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099047084" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember_638314324099047084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099047084" xlink:to="ibio_FacilityMember_638314324099047084" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638314324099047084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638314324099047084" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638314324099047084" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_638314324099047084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638314324099047084" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_638314324099047084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638314324099047084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638314324099047084" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638314324099047084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638314324099047084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638314324099047084" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638314324099047084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638314324099056682" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty_638314324099056682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638314324099056682" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638314324099056682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Fixed Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638314324099056682" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638314324099056682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale_638314324099056682" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" xlink:to="ibio_FixedAssetsHeldForSale_638314324099056682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638314324099056682" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638314324099056682" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637045036841999830" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099056682" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036841999830" xlink:to="us-gaap_StatementTable_638314324099056682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324099056682" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099056682" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324099056682" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638314324099056682" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099066674" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099066674" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638314324099066674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099066674" xlink:to="us-gaap_MachineryAndEquipmentMember_638314324099066674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099066674" xlink:to="us-gaap_OfficeEquipmentMember_638314324099066674" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638314324099066674" xlink:to="us-gaap_ConstructionInProgressMember_638314324099066674" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099056682" xlink:to="us-gaap_StatementLineItems_638314324099066674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099066674" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638314324099066674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099066674" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638314324099066674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638314324099066674" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099066674" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638314324099066674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Intangible Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842069641" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842069641" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099076670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099076670" xlink:to="srt_CounterpartyNameAxis_638314324099076670" order="1" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099076670" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099076670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099076670" xlink:to="ibio_RubrycTheraputicsInc.Member_638314324099076670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099076670" xlink:to="srt_ProductOrServiceAxis_638314324099076670" order="2" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638314324099076670" xlink:to="srt_ProductsAndServicesDomain_638314324099076670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638314324099076670" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_638314324099076670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099076670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324099076670" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324099076670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324099076670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638314324099076670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324099076670" xlink:to="us-gaap_PatentsMember_638314324099076670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638314324099086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324099076670" xlink:to="us-gaap_IntellectualPropertyMember_638314324099086664" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099076670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099086664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_638314324099086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099086664" xlink:to="ibio_StockPurchaseAgreementTotalInvestment_638314324099086664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638314324099086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099086664" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638314324099086664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638314324099086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099086664" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638314324099086664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638314324099086664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099086664" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638314324099086664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842049705" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842049705" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099096670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099096670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324099096670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638314324099096670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324099096670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324099096670" xlink:to="us-gaap_IntellectualPropertyMember_638314324099096670" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638314324099096670" xlink:to="us-gaap_PatentsMember_638314324099096670" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638314324099096670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638314324099096670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638314324099096670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638314324099096670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638314324099096670" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638314324099096670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638314324099106691" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638314324099106691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDeferredChargesAbstract" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract_638314324099106691" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" xlink:to="us-gaap_AmortizationOfDeferredChargesAbstract_638314324099106691" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638314324099106691" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AmortizationOfDeferredChargesAbstract_638314324099106691" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638314324099106691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward_638314324099106691" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRollForward_638314324099106691" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_638314324099106691" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward_638314324099106691" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_638314324099106691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_638314324099106691" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward_638314324099106691" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired_638314324099106691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638314324099116676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638314324099096670" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638314324099116676" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_638314324099116676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638314324099116676" xlink:to="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_638314324099116676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ReversalOfIntangibleAssetImpairment" xlink:label="ibio_ReversalOfIntangibleAssetImpairment_638314324099116676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638314324099116676" xlink:to="ibio_ReversalOfIntangibleAssetImpairment_638314324099116676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638314324099116676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638314324099116676" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638314324099116676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638314324099116676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638314324099116676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638314324099116676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638314324099116676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638314324099116676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638314324099116676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638314324099126675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638314324099126675" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638314324099126675" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638314324099126675" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Accrued Expenses (Summary of Accrued Expenses) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_637600807447853642" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637600807447853642" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638314324099126675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AccruedRealEstateTaxes" xlink:label="ibio_AccruedRealEstateTaxes_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637600807447853642" xlink:to="ibio_AccruedRealEstateTaxes_638314324099126675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637600807447853642" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638314324099126675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637600807447853642" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638314324099126675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638314324099126675" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637600807447853642" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638314324099126675" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638314324099136722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637600807447853642" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638314324099136722" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Debt (The Credit Agreement) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638314324099136722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638314324099136722" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099136722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638314324099136722" xlink:to="srt_CounterpartyNameAxis_638314324099136722" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099136722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099136722" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099136722" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638314324099136722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099136722" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638314324099136722" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638314324099136722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099136722" xlink:to="ibio_WoodforestMember_638314324099136722" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638314324099136722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638314324099136722" xlink:to="us-gaap_DebtInstrumentAxis_638314324099136722" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638314324099136722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638314324099136722" xlink:to="us-gaap_DebtInstrumentNameDomain_638314324099136722" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638314324099136722" xlink:to="ibio_SecuredTermLoanMember_638314324099146711" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638314324099136722" xlink:to="ibio_AmendedCreditAgreementMember_638314324099146711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638314324099136722" xlink:to="srt_LitigationCaseAxis_638314324099146711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638314324099146711" xlink:to="srt_LitigationCaseTypeDomain_638314324099146711" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638314324099146711" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638314324099146711" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638314324099136722" xlink:to="srt_StatementScenarioAxis_638314324099146711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638314324099146711" xlink:to="srt_ScenarioUnspecifiedDomain_638314324099146711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_DateOfAmendmentMember_638314324099146711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_638314324099146711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_638314324099146711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember_638314324099146711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_638314324099157114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_638314324099157114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_638314324099157114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_638314324099157114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_638314324099157114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_638314324099157114" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_638314324099157114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_638314324099157114" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_638314324099157114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_638314324099157114" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_638314324099157114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099146711" xlink:to="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_638314324099157114" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638314324099157114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638314324099136722" xlink:to="us-gaap_DebtInstrumentLineItems_638314324099157114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638314324099157114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_DebtInstrumentFaceAmount_638314324099157114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638314324099167144" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_DeferredFinanceCostsNet_638314324099167144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638314324099167144" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_InterestExpenseDebt_638314324099167144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638314324099167144" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638314324099167144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtInstrumentPaidInKindInterestRate" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate_638314324099167144" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_DebtInstrumentPaidInKindInterestRate_638314324099167144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638314324099167144" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638314324099167144" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_638314324099167144" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_638314324099167144" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638314324099167144" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638314324099167144" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638314324099177068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_DebtInstrumentFeeAmount_638314324099177068" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount_638314324099177068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_DebtCovenantLiquidityAmount_638314324099177068" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638314324099177068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_LongTermDebt_638314324099177068" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638314324099177068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_RestrictedCashNoncurrent_638314324099177068" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638314324099177068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638314324099177068" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_638314324099177068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_638314324099177068" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_638314324099186898" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_638314324099186898" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_638314324099186898" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_638314324099186898" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmountRetainedFromProceedsOfLegalSettlement" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement_638314324099186898" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_AmountRetainedFromProceedsOfLegalSettlement_638314324099186898" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements_638314324099186898" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_ProceedsFromLegalSettlements_638314324099186898" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638314324099186898" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638314324099186898" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AmountToBeReleasedFromRestrictedCash" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash_638314324099197059" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_AmountToBeReleasedFromRestrictedCash_638314324099197059" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_638314324099197059" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_638314324099197059" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_638314324099197059" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638314324099157114" xlink:to="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_638314324099197059" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Debt (Equipment Financing) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingAmountBorrowed" xlink:label="ibio_EquipmentFinancingAmountBorrowed_638314324099207418" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingAmountBorrowed_638314324099207418" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeEquipmentLeaseTermOfContract" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_638314324099207418" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_LesseeEquipmentLeaseTermOfContract_638314324099207418" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_638314324099207418" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingLeaseImputedInterestRate_638314324099207418" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_638314324099207418" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentLeasingMonthlyInstallmentPayable_638314324099207418" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingBalance" xlink:label="ibio_EquipmentFinancingBalance_638314324099207418" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingBalance_638314324099207418" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EquipmentFinancingInterestIncurred" xlink:label="ibio_EquipmentFinancingInterestIncurred_638314324099207418" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingInterestIncurred_638314324099207418" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_3" xlink:to="us-gaap_StatementTable_638314324099217111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099217111" xlink:to="us-gaap_LeaseContractualTermAxis_638314324099217111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638314324099217111" xlink:to="us-gaap_LeaseContractualTermDomain_638314324099217111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638314324099217111" xlink:to="ibio_PrincipalMember_638314324099217111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638314324099217111" xlink:to="ibio_InterestMember_638314324099217111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099217111" xlink:to="us-gaap_StatementLineItems_638314324099217111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099217111" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_638314324099217111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099217111" xlink:to="us-gaap_ContractualObligationDueInSecondYear_638314324099217111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099217111" xlink:to="us-gaap_ContractualObligationDueInThirdYear_638314324099217111" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_638314324099217111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099217111" xlink:to="us-gaap_ContractualObligation_638314324099217111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099217111" xlink:to="ibio_ContractualObligationCurrent_638314324099227150" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099217111" xlink:to="ibio_ContractualObligationNoncurrent_638314324099227150" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" xlink:type="extended" xlink:title="41404 - Disclosure - Debt (Note Payable - PPP Loan) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_StatementTable_638314324099227150" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099227150" xlink:to="us-gaap_DebtInstrumentAxis_638314324099227150" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638314324099227150" xlink:to="us-gaap_DebtInstrumentNameDomain_638314324099227150" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PppLoanCaresActMember" xlink:label="ibio_PppLoanCaresActMember_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638314324099227150" xlink:to="ibio_PppLoanCaresActMember_638314324099227150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099227150" xlink:to="us-gaap_StatementLineItems_638314324099227150" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099227150" xlink:to="us-gaap_LongTermNotesPayable_638314324099227150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638314324099227150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099227150" xlink:to="us-gaap_NotesPayableCurrent_638314324099227150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Finance Lease Obligation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638314324099237108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638314324099237108" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099237108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638314324099237108" xlink:to="srt_CounterpartyNameAxis_638314324099237108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099237108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099237108" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099237108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638314324099237108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099237108" xlink:to="ibio_RubrycTheraputicsInc.Member_638314324099237108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SecondEasternAffiliateMember" xlink:label="ibio_SecondEasternAffiliateMember_638314324099237108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099237108" xlink:to="ibio_SecondEasternAffiliateMember_638314324099237108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638314324099237108" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases_638314324099237108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" xlink:to="ibio_NumberOfEquipmentLeases_638314324099237108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638314324099237108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" xlink:to="us-gaap_AccountsPayableCurrent_638314324099237108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_638314324099247067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_638314324099247067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638314324099247067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" xlink:to="us-gaap_InterestExpenseDebt_638314324099247067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638314324099247067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" xlink:to="us-gaap_FinanceLeaseLiability_638314324099247067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth_638314324099247067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" xlink:to="ibio_LeaseRentExpensePerMonth_638314324099247067" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_638314324099247067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638314324099237108" xlink:to="ibio_LessorFinanceLeaseMonthlyRent_638314324099247067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638314324099247067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract_638314324099247067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638314324099247067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638314324099247067" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638314324099247067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638314324099247067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638314324099247067" xlink:to="us-gaap_FinanceLeaseInterestExpense_638314324099247067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638314324099247067" xlink:to="us-gaap_LeaseCost_638314324099257051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_FinanceLeaseObligationOtherInformationAbstract_638314324099257051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseObligationOtherInformationAbstract_638314324099257051" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638314324099257051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638314324099257051" xlink:to="ibio_FinancingCashFlowsFromFinanceLeaseObligation_638314324099257051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638314324099257051" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638314324099257051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638314324099257051" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638314324099257051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638314324099257051" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324099257051" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638314324099257051" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638314324099257051" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638314324099257051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638314324099257051" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638314324099257051" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_StatementTable_638314324099267114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099267114" xlink:to="us-gaap_LeaseContractualTermAxis_638314324099267114" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638314324099267114" xlink:to="us-gaap_LeaseContractualTermDomain_638314324099267114" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638314324099267114" xlink:to="ibio_PrincipalMember_638314324099267114" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638314324099267114" xlink:to="ibio_InterestMember_638314324099267114" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099267114" xlink:to="us-gaap_StatementLineItems_638314324099267114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099267114" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638314324099267114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099267114" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638314324099267114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638314324099267114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099267114" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638314324099267114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638314324099276786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099267114" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638314324099276786" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638314324099276786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099267114" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638314324099276786" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324099276786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099267114" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638314324099276786" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Operating Lease Obligation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099276786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_StatementTable_638314324099276786" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099276786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099276786" xlink:to="srt_CounterpartyNameAxis_638314324099276786" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099276786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099276786" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099276786" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638314324099276786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099276786" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638314324099276786" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638314324099276786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099276786" xlink:to="srt_RangeAxis_638314324099276786" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638314324099276786" xlink:to="srt_RangeMember_638314324099287076" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638314324099287076" xlink:to="srt_MinimumMember_638314324099287076" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638314324099287076" xlink:to="srt_MaximumMember_638314324099287076" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099276786" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_638314324099287076" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_638314324099287076" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_638314324099287076" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsNatureDomain_638314324099287076" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember_638314324099287076" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099276786" xlink:to="us-gaap_StatementLineItems_638314324099287076" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099287076" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638314324099287076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099287076" xlink:to="us-gaap_AreaOfRealEstateProperty_638314324099287076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099287076" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638314324099287076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_638314324099287076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099287076" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent_638314324099287076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_638314324099296721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099287076" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_638314324099296721" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_638314324099296721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099287076" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod_638314324099296721" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements_638314324099296721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099287076" xlink:to="us-gaap_TenantImprovements_638314324099296721" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_638314324099296721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099287076" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_638314324099296721" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OperatingLeaseCostsAbstract" xlink:label="ibio_OperatingLeaseCostsAbstract_638314324099296721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_OperatingLeaseCostsAbstract_638314324099296721" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638314324099296721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseCostsAbstract_638314324099296721" xlink:to="us-gaap_OperatingLeaseCost_638314324099296721" order="1" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_TotalOperatingLeaseCosts" xlink:label="ibio_TotalOperatingLeaseCosts_638314324099307249" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseCostsAbstract_638314324099296721" xlink:to="ibio_TotalOperatingLeaseCosts_638314324099307249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_638314324099307249" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_OperatingLeaseObligationOtherInformationAbstract_638314324099307249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638314324099307249" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseObligationOtherInformationAbstract_638314324099307249" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638314324099307249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638314324099307249" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638314324099307249" xlink:to="us-gaap_OperatingLeasePayments_638314324099307249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_638314324099307249" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638314324099307249" xlink:to="ibio_OperatingCashFlowsFromOperatingLeaseObligation_638314324099307249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638314324099307249" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638314324099307249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638314324099307249" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638314324099307249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41603 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638314324099316779" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638314324099316779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638314324099316779" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638314324099316779" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638314324099316779" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638314324099316779" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638314324099316779" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638314324099316779" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638314324099316779" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638314324099316779" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638314324099327051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638314324099327051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638314324099327051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638314324099327051" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638314324099327051" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638314324099327051" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638314324099316779" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638314324099327051" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638314324099327051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638314324099327051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638314324099327051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638314324099337054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638314324099337054" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638314324099337054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638314324099337054" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638314324099337054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638314324099337054" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638314324099337054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638314324099337054" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_638314324099337054" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638314324099327051" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_638314324099337054" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_355" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable_638314324099346774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_355" xlink:to="ibio_StockholdersEquityTable_638314324099346774" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638314324099346774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638314324099346774" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099346774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638314324099346774" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099346774" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember_638314324099346774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099346774" xlink:to="ibio_ExchangeAgreementMember_638314324099346774" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638314324099346774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="us-gaap_PlanNameAxis_638314324099346774" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638314324099346774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638314324099346774" xlink:to="us-gaap_PlanNameDomain_638314324099346774" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_OmnibusIncentivePlanMember" xlink:label="ibio_OmnibusIncentivePlanMember_638314324099346774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638314324099346774" xlink:to="ibio_OmnibusIncentivePlanMember_638314324099346774" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638314324099346774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="us-gaap_AwardTypeAxis_638314324099346774" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099357051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638314324099346774" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099357051" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638314324099357051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099357051" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638314324099357051" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638314324099357051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="us-gaap_StatementClassOfStockAxis_638314324099357051" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638314324099357051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638314324099357051" xlink:to="us-gaap_ClassOfStockDomain_638314324099357051" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember_638314324099357051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638314324099357051" xlink:to="ibio_PreferredTrackingStockMember_638314324099357051" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_638314324099357051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638314324099357051" xlink:to="ibio_Series2022ConvertiblePreferredStockMember_638314324099357051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638314324099357051" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638314324099357051" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638314324099367084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638314324099357051" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638314324099367084" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember_638314324099367084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099367084" xlink:to="ibio_PreFundedWarrantsMember_638314324099367084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember_638314324099367084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099367084" xlink:to="ibio_SeriesWarrantsMember_638314324099367084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember_638314324099367084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099367084" xlink:to="ibio_SeriesBWarrantsMember_638314324099367084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember_638314324099367084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099367084" xlink:to="ibio_RepresentativeWarrantsMember_638314324099367084" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099367084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="srt_CounterpartyNameAxis_638314324099367084" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099367084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099367084" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099367084" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638314324099367084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099367084" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638314324099367084" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember_638314324099377076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099367084" xlink:to="ibio_H.c.WainwrightCo.LlcMember_638314324099377076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember_638314324099377076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099367084" xlink:to="ibio_EasternAffiliateMember_638314324099377076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638314324099377076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="srt_StatementScenarioAxis_638314324099377076" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638314324099377076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638314324099377076" xlink:to="srt_ScenarioUnspecifiedDomain_638314324099377076" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_638314324099377076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099377076" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_638314324099377076" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638314324099377076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="srt_OwnershipAxis_638314324099377076" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638314324099377076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638314324099377076" xlink:to="srt_OwnershipDomain_638314324099377076" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember_638314324099377076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638314324099377076" xlink:to="ibio_IbioCdmoMember_638314324099377076" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638314324099387064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="us-gaap_MeasurementInputTypeAxis_638314324099387064" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638314324099387064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638314324099387064" xlink:to="us-gaap_MeasurementInputTypeDomain_638314324099387064" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638314324099387064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638314324099387064" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638314324099387064" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638314324099387064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638314324099387064" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638314324099387064" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638314324099387064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638314324099387064" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638314324099387064" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638314324099387064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638314324099387064" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638314324099387064" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems_638314324099387064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638314324099346774" xlink:to="ibio_StockholdersEquityLineItems_638314324099387064" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638314324099397135" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_PreferredStockSharesAuthorized_638314324099397135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638314324099397135" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638314324099397135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_638314324099397135" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_638314324099397135" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638314324099397135" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638314324099397135" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638314324099397135" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638314324099397135" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638314324099397135" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638314324099397135" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638314324099406731" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638314324099406731" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638314324099406731" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638314324099406731" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_638314324099406731" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_638314324099406731" order="9" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638314324099416727" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_PreferredStockSharesOutstanding_638314324099416727" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638314324099416727" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638314324099416727" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324099416727" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324099416727" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638314324099416727" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638314324099416727" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638314324099416727" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_CommonStockSharesAuthorized_638314324099416727" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638314324099426718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638314324099426718" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638314324099426718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638314324099426718" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638314324099426718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638314324099426718" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638314324099426718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638314324099426718" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638314324099426718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638314324099426718" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638314324099436700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638314324099436700" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_638314324099436700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_638314324099436700" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638314324099436700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_ProceedsFromWarrantExercises_638314324099436700" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638314324099436700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638314324099436700" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638314324099446709" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638314324099446709" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638314324099506711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638314324099387064" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638314324099506711" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099516701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_638314324099516701" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638314324099516701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099516701" xlink:to="us-gaap_TypeOfArrangementAxis_638314324099516701" order="1" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099516701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638314324099516701" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099516701" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember_638314324099516701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099516701" xlink:to="ibio_SalesAgreementMember_638314324099516701" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638314324099516701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099516701" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638314324099516701" order="2" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099516701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638314324099516701" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099516701" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099516701" xlink:to="us-gaap_OverAllotmentOptionMember_638314324099526699" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099516701" xlink:to="srt_CounterpartyNameAxis_638314324099526699" order="3" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099526699" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099526699" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099526699" xlink:to="ibio_CantorFitzgeraldMember_638314324099526699" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099526699" xlink:to="ibio_RubrycTheraputicsInc.Member_638314324099526699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099516701" xlink:to="us-gaap_StatementLineItems_638314324099526699" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099526699" xlink:to="ibio_AggregateCommonStockPurchased_638314324099526699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099526699" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324099526699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099526699" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638314324099526699" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638314324099526699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099526699" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638314324099526699" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638314324099536696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099526699" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638314324099536696" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638314324099536696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099526699" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638314324099536696" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638314324099536696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099526699" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638314324099536696" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638314324099536696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099526699" xlink:to="ibio_SubscriptionReceivableCurrent_638314324099536696" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099536696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_StatementTable_638314324099536696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099536696" xlink:to="srt_CounterpartyNameAxis_638314324099546696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099546696" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099546696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099546696" xlink:to="ibio_H.c.WainwrightCo.LlcMember_638314324099546696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099536696" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638314324099546696" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638314324099546696" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099546696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638314324099546696" xlink:to="us-gaap_OverAllotmentOptionMember_638314324099546696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099536696" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638314324099546696" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638314324099546696" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638314324099546696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099546696" xlink:to="ibio_PreFundedWarrantsMember_638314324099546696" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099546696" xlink:to="ibio_SeriesWarrantsMember_638314324099546696" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember_638314324099546696" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099546696" xlink:to="ibio_SeriesBWarrantsMember_638314324099546696" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638314324099556695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099536696" xlink:to="us-gaap_AwardTypeAxis_638314324099556695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099556695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638314324099556695" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099556695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638314324099556695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099556695" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638314324099556695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099556695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099536696" xlink:to="us-gaap_StatementLineItems_638314324099556695" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324099556695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324099556695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638314324099556695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638314324099556695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_638314324099556695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_638314324099556695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_638314324099556695" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_638314324099556695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued_638314324099566701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="ibio_NumberOfAdditionalSharesIssued_638314324099566701" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_638314324099566701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares_638314324099566701" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_638314324099566701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_638314324099566701" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638314324099566701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638314324099566701" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638314324099566701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099556695" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638314324099566701" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638314324099566701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_638314324099566701" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638314324099566701" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638314324099576737" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638314324099566701" xlink:to="us-gaap_DividendsPreferredStockStock_638314324099576737" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638314324099566701" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638314324099576737" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638314324099566701" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638314324099576737" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638314324099566701" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_638314324099576737" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638314324099576737" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638314324099576737" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638314324099576737" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638314324099576737" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638314324099576737" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638314324099586738" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638314324099586738" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638314324099586738" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638314324099586738" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638314324099586738" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" xlink:to="us-gaap_EarningsPerShareBasic_638314324099586738" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638314324099586738" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638314324099576737" xlink:to="us-gaap_EarningsPerShareDiluted_638314324099586738" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637045036842717904" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable_638314324099586738" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637045036842717904" xlink:to="ibio_EarningsLossPerCommonShareTable_638314324099586738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638314324099596812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareTable_638314324099586738" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638314324099596812" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638314324099596812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638314324099596812" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638314324099596812" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638314324099596812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638314324099596812" xlink:to="us-gaap_EmployeeStockOptionMember_638314324099596812" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638314324099596812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638314324099596812" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638314324099596812" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638314324099596812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638314324099596812" xlink:to="us-gaap_WarrantMember_638314324099596812" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems_638314324099596812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareTable_638314324099586738" xlink:to="ibio_EarningsLossPerCommonShareLineItems_638314324099596812" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638314324099596812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareLineItems_638314324099596812" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638314324099596812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638314324099596812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareLineItems_638314324099596812" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638314324099596812" order="2" use="optional" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842727870" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638314324099606715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842727870" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638314324099606715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638314324099606715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638314324099606715" xlink:to="us-gaap_IncomeStatementLocationAxis_638314324099606715" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638314324099606715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638314324099606715" xlink:to="us-gaap_IncomeStatementLocationDomain_638314324099606715" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638314324099606715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638314324099606715" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638314324099606715" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638314324099606715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638314324099606715" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638314324099606715" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_638314324099606715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638314324099606715" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_638314324099606715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_638314324099606715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_638314324099606715" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_638314324099606715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638314324099606715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638314324099606715" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638314324099606715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638314324099616722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638314324099606715" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638314324099616722" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638314324099616722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638314324099616722" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638314324099616722" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="41902 - Disclosure - Share-Based Compensation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_495" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_495" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638314324099616722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" xlink:to="srt_StatementScenarioAxis_638314324099616722" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638314324099616722" xlink:to="srt_ScenarioUnspecifiedDomain_638314324099626706" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099626706" xlink:to="ibio_ScenarioOneMember_638314324099626706" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099626706" xlink:to="ibio_ScenarioTwoMember_638314324099626706" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" xlink:to="srt_TitleOfIndividualAxis_638314324099626706" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638314324099626706" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099626706" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ConsultantsMember" xlink:label="ibio_ConsultantsMember_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099626706" xlink:to="ibio_ConsultantsMember_638314324099626706" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099626706" xlink:to="ibio_VariousEmployeesMember_638314324099626706" order="2" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099626706" xlink:to="srt_DirectorMember_638314324099626706" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_BoardOfDirectorsOfficersAndEmployeesMember" xlink:label="ibio_BoardOfDirectorsOfficersAndEmployeesMember_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099626706" xlink:to="ibio_BoardOfDirectorsOfficersAndEmployeesMember_638314324099626706" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099626706" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" xlink:to="srt_CounterpartyNameAxis_638314324099626706" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099626706" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099636700" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IsettMember" xlink:label="ibio_IsettMember_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099636700" xlink:to="ibio_IsettMember_638314324099636700" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" xlink:to="srt_RangeAxis_638314324099636700" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638314324099636700" xlink:to="srt_RangeMember_638314324099636700" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638314324099636700" xlink:to="srt_MinimumMember_638314324099636700" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638314324099636700" xlink:to="srt_MaximumMember_638314324099636700" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" xlink:to="us-gaap_PlanNameAxis_638314324099636700" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638314324099636700" xlink:to="us-gaap_PlanNameDomain_638314324099636700" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638314324099636700" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638314324099636700" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638314324099636700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" xlink:to="us-gaap_VestingAxis_638314324099636700" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638314324099646699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638314324099636700" xlink:to="us-gaap_VestingDomain_638314324099646699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638314324099646699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638314324099646699" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638314324099646699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638314324099646699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638314324099646699" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638314324099646699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638314324099646699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" xlink:to="us-gaap_AwardTypeAxis_638314324099646699" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099646699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638314324099646699" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099646699" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638314324099646699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099646699" xlink:to="us-gaap_EmployeeStockOptionMember_638314324099646699" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638314324099646699" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099646699" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638314324099646699" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099616722" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638314324099656703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638314324099656703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638314324099656703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638314324099656703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638314324099656703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638314324099656703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_638314324099656703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_638314324099656703" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638314324099656703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638314324099656703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638314324099666726" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638314324099666726" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638314324099666726" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638314324099666726" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638314324099666726" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638314324099666726" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638314324099666726" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638314324099666726" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638314324099666726" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638314324099666726" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638314324099666726" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638314324099666726" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638314324099676712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638314324099676712" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638314324099676712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638314324099676712" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638314324099676712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638314324099676712" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638314324099676712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638314324099676712" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638314324099676712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638314324099676712" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638314324099686701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638314324099686701" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638314324099686701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="us-gaap_SharePrice_638314324099686701" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_NumberOfConsultantsToWhomStockOptionGranted" xlink:label="ibio_NumberOfConsultantsToWhomStockOptionGranted_638314324099686701" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099656703" xlink:to="ibio_NumberOfConsultantsToWhomStockOptionGranted_638314324099686701" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41903 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638314324099696703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638314324099696703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638314324099696703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638314324099696703" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638314324099696703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6383143240996967031" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6383143240996967031" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638314324099696703" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638314324099696703" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638314324099696703" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638314324099696703" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638314324099696703" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638314324099707083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638314324099707083" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638314324099707083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638314324099707083" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638314324099707083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638314324099707083" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638314324099707083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638314324099707083" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638314324099707083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638314324099707083" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638314324099716756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638314324099716756" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638314324099716756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638314324099716756" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638314324099716756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638314324099716756" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638314324099716756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638314324099716756" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638314324099716756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638314324099716756" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638314324099716756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638314324099716756" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="41904 - Disclosure - Share-Based Compensation (Options Outstanding and Exercisable) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638314324099727200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638314324099727200" xlink:to="us-gaap_MeasurementInputTypeAxis_638314324099727200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638314324099727200" xlink:to="us-gaap_MeasurementInputTypeDomain_638314324099727200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceOneMember" xlink:label="ibio_ExercisePriceOneMember_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638314324099727200" xlink:to="ibio_ExercisePriceOneMember_638314324099727200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceTwoMember" xlink:label="ibio_ExercisePriceTwoMember_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638314324099727200" xlink:to="ibio_ExercisePriceTwoMember_638314324099727200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceThreeMember" xlink:label="ibio_ExercisePriceThreeMember_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638314324099727200" xlink:to="ibio_ExercisePriceThreeMember_638314324099727200" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ExercisePriceFourMember" xlink:label="ibio_ExercisePriceFourMember_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638314324099727200" xlink:to="ibio_ExercisePriceFourMember_638314324099727200" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638314324099727200" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638314324099727200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638314324099727200" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638314324099727200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638314324099727200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638314324099727200" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638314324099727200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638314324099737358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638314324099727200" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638314324099737358" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638314324099737358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638314324099727200" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638314324099737358" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638314324099737358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638314324099727200" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638314324099737358" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638314324099737358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638314324099727200" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638314324099737358" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" xlink:type="extended" xlink:title="41905 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638314324099737358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638314324099737358" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638314324099746745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638314324099746745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638314324099746745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638314324099746745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638314324099746745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638314324099746745" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638314324099746745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638314324099746745" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638314324099746745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638314324099746745" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" xlink:type="extended" xlink:title="41906 - Disclosure - Share-Based Compensation (RSUs) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099746745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099746745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099746745" xlink:to="us-gaap_AwardTypeAxis_638314324099756728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638314324099756728" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099756728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099756728" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638314324099756728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099746745" xlink:to="srt_TitleOfIndividualAxis_638314324099756728" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638314324099756728" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099756728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099756728" xlink:to="ibio_VariousEmployeesMember_638314324099756728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Mr.IsettMember" xlink:label="ibio_Mr.IsettMember_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099756728" xlink:to="ibio_Mr.IsettMember_638314324099756728" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Mr.RobertLutzMember" xlink:label="ibio_Mr.RobertLutzMember_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099756728" xlink:to="ibio_Mr.RobertLutzMember_638314324099756728" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_Dr.MartinBrennerMember" xlink:label="ibio_Dr.MartinBrennerMember_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099756728" xlink:to="ibio_Dr.MartinBrennerMember_638314324099756728" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_InterimChiefExecutiveOfficerMember" xlink:label="ibio_InterimChiefExecutiveOfficerMember_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099756728" xlink:to="ibio_InterimChiefExecutiveOfficerMember_638314324099756728" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_638314324099756728" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099756728" xlink:to="srt_ChiefFinancialOfficerMember_638314324099756728" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099746745" xlink:to="us-gaap_PlanNameAxis_638314324099766711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638314324099766711" xlink:to="us-gaap_PlanNameDomain_638314324099766711" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638314324099766711" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638314324099766711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099746745" xlink:to="us-gaap_GranteeStatusAxis_638314324099766711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638314324099766711" xlink:to="us-gaap_GranteeStatusDomain_638314324099766711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638314324099766711" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638314324099766711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638314324099746745" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099766711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099766711" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638314324099766711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638314324099766711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099766711" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638314324099766711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638314324099776716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099766711" xlink:to="us-gaap_SharePrice_638314324099776716" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638314324099776716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099766711" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638314324099776716" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638314324099776716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099766711" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638314324099776716" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638314324099776716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638314324099766711" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638314324099776716" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Fraunhofer Settlement (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="us-gaap_StatementTable_638314324099786714" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099786714" xlink:to="srt_LitigationCaseAxis_638314324099786714" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638314324099786714" xlink:to="srt_LitigationCaseTypeDomain_638314324099786714" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638314324099786714" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638314324099786714" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099786714" xlink:to="us-gaap_LitigationStatusAxis_638314324099786714" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis_638314324099786714" xlink:to="us-gaap_LitigationStatusDomain_638314324099786714" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain_638314324099786714" xlink:to="us-gaap_SettledLitigationMember_638314324099786714" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099786714" xlink:to="srt_StatementScenarioAxis_638314324099786714" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638314324099786714" xlink:to="srt_ScenarioUnspecifiedDomain_638314324099786714" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099786714" xlink:to="us-gaap_ScenarioPlanMember_638314324099786714" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638314324099786714" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember_638314324099786714" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_638314324099786714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638314324099786714" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember_638314324099786714" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638314324099786714" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember_638314324099796702" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099786714" xlink:to="srt_ProductOrServiceAxis_638314324099796702" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638314324099796702" xlink:to="srt_ProductsAndServicesDomain_638314324099796702" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638314324099796702" xlink:to="us-gaap_ServiceMember_638314324099796702" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ServiceMember_638314324099796702" xlink:to="us-gaap_LicenseAndMaintenanceMember_638314324099796702" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099786714" xlink:to="us-gaap_StatementLineItems_638314324099796702" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099796702" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_638314324099796702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099796702" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived_638314324099796702" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638314324099796702" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099796702" xlink:to="us-gaap_SettlementAssetsCurrent_638314324099796702" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount_638314324099806708" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099796702" xlink:to="us-gaap_GainContingencyUnrecordedAmount_638314324099806708" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638314324099806708" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099796702" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638314324099806708" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements_638314324099806708" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099796702" xlink:to="us-gaap_ProceedsFromLegalSettlements_638314324099806708" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="42101 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638314324099816723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638314324099816723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638314324099816723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638314324099816723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638314324099816723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638314324099816723" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CurrentAndDeferredFederalAndStateTaxes" xlink:label="ibio_CurrentAndDeferredFederalAndStateTaxes_638314324099816723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ibio_CurrentAndDeferredFederalAndStateTaxes_638314324099816723" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxExpenseBenefitValuationAllowance" xlink:label="ibio_IncomeTaxExpenseBenefitValuationAllowance_638314324099816723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ibio_IncomeTaxExpenseBenefitValuationAllowance_638314324099816723" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638314324099816723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638314324099816723" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="42102 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638314324099826712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638314324099826712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxAssetsResearchAndDevelopmentCosts" xlink:label="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="ibio_DeferredTaxAssetsResearchAndDevelopmentCosts_638314324099826712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638314324099826712" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="us-gaap_DeferredTaxAssetsEquityMethodInvestments_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxAssetsEquityMethodInvestments_638314324099826712" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638314324099826712" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638314324099826712" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638314324099826712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638314324099826712" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities" xlink:label="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities_638314324099836715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities_638314324099836715" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets" xlink:label="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets_638314324099836715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets_638314324099836715" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638314324099836715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638314324099836715" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638314324099836715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638314324099836715" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638314324099836715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638314324099826712" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638314324099836715" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="42103 - Disclosure - Income Taxes (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637045036843156725" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxesTable" xlink:label="ibio_IncomeTaxesTable_638314324099836715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637045036843156725" xlink:to="ibio_IncomeTaxesTable_638314324099836715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638314324099836715" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_IncomeTaxesTable_638314324099836715" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638314324099836715" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638314324099846712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638314324099836715" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638314324099846712" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638314324099846712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638314324099846712" xlink:to="us-gaap_ResearchMember_638314324099846712" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IncomeTaxesLineItems" xlink:label="ibio_IncomeTaxesLineItems_638314324099846712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_IncomeTaxesTable_638314324099836715" xlink:to="ibio_IncomeTaxesLineItems_638314324099846712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638314324099846712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_IncomeTaxesLineItems_638314324099846712" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638314324099846712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638314324099846712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_IncomeTaxesLineItems_638314324099846712" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638314324099846712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_638314324099846712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_IncomeTaxesLineItems_638314324099846712" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_638314324099846712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638314324099846712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_IncomeTaxesLineItems_638314324099846712" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638314324099846712" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638314324099846712" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_IncomeTaxesLineItems_638314324099846712" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638314324099846712" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="42104 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638314324099856716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638314324099856716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638314324099856716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638314324099856716" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions_638314324099856716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions_638314324099856716" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo" xlink:label="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo_638314324099856716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo_638314324099856716" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638314324099856716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638314324099856716" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638314324099856716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638314324099856716" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="42201 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099856716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_StatementTable_638314324099856716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638314324099856716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099856716" xlink:to="us-gaap_TypeOfArrangementAxis_638314324099856716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099866713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638314324099856716" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099866713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember_638314324099866713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099866713" xlink:to="ibio_CroAgreementMember_638314324099866713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099866713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099856716" xlink:to="us-gaap_StatementLineItems_638314324099866713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_638314324099866713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099866713" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_638314324099866713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_EstimatedAdditionalCostOnDevelopment" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment_638314324099866713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099866713" xlink:to="ibio_EstimatedAdditionalCostOnDevelopment_638314324099866713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" xlink:type="extended" xlink:title="42301 - Disclosure - Employee 401(K) Plan (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638314324099866713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_StatementTable_638314324099866713" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_638314324099866713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099866713" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_638314324099866713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_638314324099866713" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_638314324099866713" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_638314324099866713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638314324099876716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638314324099866713" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638314324099876716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638314324099876716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638314324099866713" xlink:to="us-gaap_StatementLineItems_638314324099876716" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638314324099876716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099876716" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638314324099876716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638314324099876716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099876716" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638314324099876716" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_638314324099876716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638314324099876716" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_638314324099876716" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="42401 - Disclosure - Subsequent Events (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638314324099876716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638314324099876716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638314324099876716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="us-gaap_SubsequentEventTypeAxis_638314324099876716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638314324099876716" xlink:to="us-gaap_SubsequentEventTypeDomain_638314324099886756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638314324099886756" xlink:to="us-gaap_SubsequentEventMember_638314324099886756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="us-gaap_TypeOfArrangementAxis_638314324099886756" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638314324099886756" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099886756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099886756" xlink:to="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_638314324099886756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CreditAgreementWithWoodforestNationalBankMember" xlink:label="ibio_CreditAgreementWithWoodforestNationalBankMember_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099886756" xlink:to="ibio_CreditAgreementWithWoodforestNationalBankMember_638314324099886756" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099886756" xlink:to="ibio_SalesAgreementMember_638314324099886756" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_StockPurchaseAgreementWithLincolnParkMember" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638314324099886756" xlink:to="ibio_StockPurchaseAgreementWithLincolnParkMember_638314324099886756" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="srt_StatementScenarioAxis_638314324099886756" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638314324099886756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638314324099886756" xlink:to="srt_ScenarioUnspecifiedDomain_638314324099886756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099886756" xlink:to="ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_638314324099896754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099886756" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_638314324099896754" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638314324099886756" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_638314324099896754" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="srt_CounterpartyNameAxis_638314324099896754" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638314324099896754" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099896754" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099896754" xlink:to="ibio_CantorFitzgeraldMember_638314324099896754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638314324099896754" xlink:to="ibio_WoodforestMember_638314324099896754" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638314324099896754" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638314324099896754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638314324099896754" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638314324099896754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember_638314324099906763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099896754" xlink:to="ibio_SeriesWarrantsMember_638314324099906763" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember_638314324099906763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638314324099896754" xlink:to="ibio_SeriesBWarrantsMember_638314324099906763" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638314324099906763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="srt_RangeAxis_638314324099906763" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638314324099906763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638314324099906763" xlink:to="srt_RangeMember_638314324099906763" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638314324099906763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638314324099906763" xlink:to="srt_MinimumMember_638314324099906763" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638314324099906763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638314324099906763" xlink:to="srt_MaximumMember_638314324099906763" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638314324099906763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="us-gaap_AwardTypeAxis_638314324099906763" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099916750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638314324099906763" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099916750" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638314324099916750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099916750" xlink:to="us-gaap_EmployeeStockOptionMember_638314324099916750" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638314324099916750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638314324099916750" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638314324099916750" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638314324099916750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="srt_TitleOfIndividualAxis_638314324099916750" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099916750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638314324099916750" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099916750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember_638314324099916750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638314324099916750" xlink:to="ibio_VariousEmployeesMember_638314324099916750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638314324099926735" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="us-gaap_PlanNameAxis_638314324099926735" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638314324099926735" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638314324099926735" xlink:to="us-gaap_PlanNameDomain_638314324099926735" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638314324099926735" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638314324099926735" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638314324099926735" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638314324099926735" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="us-gaap_VestingAxis_638314324099926735" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638314324099926735" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638314324099926735" xlink:to="us-gaap_VestingDomain_638314324099926735" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638314324099926735" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638314324099926735" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638314324099926735" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638314324099936718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638314324099926735" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638314324099936718" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638314324099936718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638314324099876716" xlink:to="us-gaap_SubsequentEventLineItems_638314324099936718" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_GroundLeasesAgreedToSellPruchasePrice" xlink:label="ibio_GroundLeasesAgreedToSellPruchasePrice_638314324099936718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_GroundLeasesAgreedToSellPruchasePrice_638314324099936718" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases_638314324099936718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_LandSubjectToGroundLeases_638314324099936718" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarnestMoneyDeposits" xlink:label="us-gaap_EarnestMoneyDeposits_638314324099936718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_EarnestMoneyDeposits_638314324099936718" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638314324099946723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_DebtInstrumentFeeAmount_638314324099946723" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638314324099946723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638314324099946723" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638314324099946723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638314324099946723" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumAmountOfCommonStockAgreedToSell" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell_638314324099946723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_MaximumAmountOfCommonStockAgreedToSell_638314324099946723" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_ClosingPricePerShareOfCommonStock" xlink:label="ibio_ClosingPricePerShareOfCommonStock_638314324099946723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_ClosingPricePerShareOfCommonStock_638314324099946723" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_638314324099956730" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_638314324099956730" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_638314324099956730" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_638314324099956730" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockToBeSold" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold_638314324099956730" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_MaximumNumberOfCommonStockToBeSold_638314324099956730" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_638314324099956730" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_638314324099956730" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324099956730" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638314324099956730" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_AdditionalSharesAgreedToIssue" xlink:label="ibio_AdditionalSharesAgreedToIssue_638314324099966719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_AdditionalSharesAgreedToIssue_638314324099966719" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638314324099966719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638314324099966719" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican" xlink:label="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican_638314324099966719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican_638314324099966719" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican" xlink:label="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican_638314324099966719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican_638314324099966719" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230630.xsd#ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement" xlink:label="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement_638314324099966719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement_638314324099966719" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638314324099966719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638314324099966719" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638314324099966719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638314324099966719" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638314324099966719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638314324099966719" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638314324099999228" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638314324099999228" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638314324099999228" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638314324099999228" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638314324099999228" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638314324099999228" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638314324100006749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638314324100006749" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638314324100006749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638314324100006749" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638314324100006749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638314324099936718" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638314324100006749" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241704208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">iBio,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2797813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 HSC Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bryan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77807-1107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">355-0650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001420720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,586,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,435,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">CohnReznick LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Holmdel, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238352384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,301,000<span></span>
</td>
<td class="nump">$ 22,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">3,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Investments in debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,845,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SubscriptionReceivableCurrent', window );">Subscription receivable</a></td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">664,000<span></span>
</td>
<td class="nump">1,549,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Current assets held for sale</a></td>
<td class="nump">18,065,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">26,259,000<span></span>
</td>
<td class="nump">45,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="nump">5,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest', window );">Promissory note receivable and accrued interest</a></td>
<td class="nump">1,706,000<span></span>
</td>
<td class="nump">1,631,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net of accumulated amortization</a></td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,722,000<span></span>
</td>
<td class="nump">3,068,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="nump">4,219,000<span></span>
</td>
<td class="nump">1,373,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">5,388,000<span></span>
</td>
<td class="nump">4,851,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">41,207,000<span></span>
</td>
<td class="nump">99,406,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,849,000<span></span>
</td>
<td class="nump">4,264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,034,000<span></span>
</td>
<td class="nump">3,764,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations - current portion</a></td>
<td class="nump">272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation - current portion</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingPayableCurrent', window );">Equipment financing payable - current portion</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Term note payable - net of deferred financing costs</a></td>
<td class="nump">12,937,000<span></span>
</td>
<td class="nump">22,161,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale', window );">Current liabilities related to assets held for sale</a></td>
<td class="nump">1,941,000<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">21,582,000<span></span>
</td>
<td class="nump">30,436,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations - net of current portion</a></td>
<td class="nump">351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation - net of current portion</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,514,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingPayableNoncurrent', window );">Equipment financing payable - net of current portion</a></td>
<td class="nump">241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="nump">527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale', window );">Noncurrent liabilities related to assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,971,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">25,826,000<span></span>
</td>
<td class="nump">35,921,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of June 30, 2023 and 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2023 and 2022; 20,310,077 and 8,727,158 shares issued and outstanding as of June 30, 2023 and June 30, 2022, respectively</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">304,301,000<span></span>
</td>
<td class="nump">287,619,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(288,940,000)<span></span>
</td>
<td class="num">(223,930,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">15,381,000<span></span>
</td>
<td class="nump">63,485,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 41,207,000<span></span>
</td>
<td class="nump">$ 99,406,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible Promissory Note Receivable and Accrued Interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current liabilities related to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of equipment financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent portion of equipment financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent liabilities related to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981239726272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">20,310,077<span></span>
</td>
<td class="nump">8,727,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">20,310,077<span></span>
</td>
<td class="nump">8,727,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238042144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,884,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,327,000<span></span>
</td>
<td class="nump">9,827,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">19,016,000<span></span>
</td>
<td class="nump">21,754,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">29,343,000<span></span>
</td>
<td class="nump">31,581,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(29,343,000)<span></span>
</td>
<td class="num">(29,697,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(83,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="nump">177,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Loss on sale of debt securities</a></td>
<td class="num">(98,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Consolidated net loss from continuing operations</a></td>
<td class="num">(29,311,000)<span></span>
</td>
<td class="num">(29,513,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to iBio, Inc. from continuing operations</a></td>
<td class="num">(29,311,000)<span></span>
</td>
<td class="num">(29,512,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends - iBio CDMO Tracking Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NetLossAvailableToStockholdersFromContinuingOperations', window );">Net loss available to iBio, Inc. stockholders from continuing operations</a></td>
<td class="num">(29,311,000)<span></span>
</td>
<td class="num">(29,600,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(35,699,000)<span></span>
</td>
<td class="num">(20,791,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnconsolidatedGainLossAttributableToStockholders', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">(65,010,000)<span></span>
</td>
<td class="num">(50,391,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">(65,010,000)<span></span>
</td>
<td class="num">(50,304,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss) - unrealized gain (loss) on debt securities</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income - foreign currency adjustment</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (64,797,000)<span></span>
</td>
<td class="num">$ (50,454,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</a></td>
<td class="num">$ (2.39)<span></span>
</td>
<td class="num">$ (3.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</a></td>
<td class="num">(2.39)<span></span>
</td>
<td class="num">(3.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</a></td>
<td class="num">(2.92)<span></span>
</td>
<td class="num">(2.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</a></td>
<td class="num">(2.92)<span></span>
</td>
<td class="num">(2.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - total</a></td>
<td class="num">(5.31)<span></span>
</td>
<td class="num">(5.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - total</a></td>
<td class="num">$ (5.31)<span></span>
</td>
<td class="num">$ (5.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">8,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">8,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NetLossAvailableToStockholdersFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net loss available to stockholders from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NetLossAvailableToStockholdersFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnconsolidatedGainLossAttributableToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unconsolidated net gain (loss) attributable to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnconsolidatedGainLossAttributableToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241913248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 282,266<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (173,627)<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">$ 108,568<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issued for Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate', window );">Acquisition of remaining portion of iBio CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,303)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(50,304)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">287,619<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">(223,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,485<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">8,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodValueCapitalRaise', window );">Capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">12,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise', window );">Capital raise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Cost to raise capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AssetAcquisitionValue', window );">Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AssetAcquisitionInShares', window );">Asset Acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FractionalShareIssuedAfterReverseStockSplitValue', window );">Payment for fractional shares after reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FractionalShareIssuedAfterReverseStockSplitShares', window );">Payment for fractional shares after reverse stock split (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities', window );">Reclassification adjustment for loss on available-for-sale debt securities realized in net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,010)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 304,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (288,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,381<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital acquisition of remaining portion of affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AssetAcquisitionInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares from asset acquisition during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AssetAcquisitionInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AssetAcquisitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of asset acquisition during the period. (Value)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AssetAcquisitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FractionalShareIssuedAfterReverseStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fractional shares after reverse stock split issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FractionalShareIssuedAfterReverseStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FractionalShareIssuedAfterReverseStockSplitValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of fractional shares after reverse stock split issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FractionalShareIssuedAfterReverseStockSplitValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reclassification adjustment for the period on gains (losses) on avaliable for sale debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares raised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodSharesCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodValueCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of capital raise during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodValueCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238780640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (65,010,000)<span></span>
</td>
<td class="num">$ (50,304,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,391,000<span></span>
</td>
<td class="nump">4,377,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">224,000<span></span>
</td>
<td class="nump">599,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">356,000<span></span>
</td>
<td class="nump">516,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">674,000<span></span>
</td>
<td class="nump">2,275,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Gain on sale of fixed assets</a></td>
<td class="num">(773,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable', window );">Accrued interest receivable on promissory note receivable</a></td>
<td class="num">(75,000)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premiums on debt securities</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">312,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Loss on sale of debt securities</a></td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DeferredFinancingCostsAmortizationExpense', window );">Amortization of deferred financing costs</a></td>
<td class="nump">242,000<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInInventoryReserve', window );">Inventory reserve</a></td>
<td class="nump">4,915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases', window );">Gain on disposition of finance lease ROU assets</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan', window );">Forgiveness of note payable and accrued interest - SBA loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(607,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SettlementOfRevenueContract', window );">Settlement of revenue contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment of investment in equity security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable - trade</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="num">(886,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInSettlementAssets', window );">Settlement receivable</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories', window );">Inventory</a></td>
<td class="num">(1,015,000)<span></span>
</td>
<td class="num">(3,873,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">885,000<span></span>
</td>
<td class="nump">307,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses - noncurrent</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="num">(74,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="num">(21,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(625,000)<span></span>
</td>
<td class="nump">1,239,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">145,000<span></span>
</td>
<td class="nump">1,443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="nump">527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease obligations</a></td>
<td class="num">(101,000)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,436,000)<span></span>
</td>
<td class="num">(37,480,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,355,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Redemption of debt securities</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">13,618,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of debt securities</a></td>
<td class="nump">6,739,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of equity security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,760,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(5,738,000)<span></span>
</td>
<td class="num">(7,330,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales proceeds for fixed assets</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payment for RubrYc asset acquisition</a></td>
<td class="num">(692,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">7,009,000<span></span>
</td>
<td class="num">(5,127,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromIssuanceOfPreferredAndCommonStock', window );">Proceeds from sales of common stock</a></td>
<td class="nump">11,487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PaymentsForFractionalSharesAfterReverseStockSplit', window );">Payments for fractional shares after reverse stock split</a></td>
<td class="num">(39,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Acquisition of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromEquipmentFinancingLoan', window );">Proceeds from equipment financing loan</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PaymentOfEquipmentFinancingLoan', window );">Payment of equipment financing loan</a></td>
<td class="num">(99,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of term note payable</a></td>
<td class="num">(9,318,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PaymentsToAttainTermNote', window );">Costs to attain term note</a></td>
<td class="num">(22,000)<span></span>
</td>
<td class="num">(322,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligation</a></td>
<td class="num">(208,000)<span></span>
</td>
<td class="num">(5,830,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">2,301,000<span></span>
</td>
<td class="num">(6,125,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(21,093,000)<span></span>
</td>
<td class="num">(48,732,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning</a></td>
<td class="nump">28,672,000<span></span>
</td>
<td class="nump">77,404,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end</a></td>
<td class="nump">7,579,000<span></span>
</td>
<td class="nump">28,672,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Schedule of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid', window );">Fixed assets included in accounts payable in prior period, paid in current period</a></td>
<td class="nump">1,769,000<span></span>
</td>
<td class="nump">791,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Increase in finance lease ROU assets for new leases</a></td>
<td class="nump">814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases', window );">Increase in finance lease obligation for new leases</a></td>
<td class="nump">814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">RubrYc asset acquisition by issuance of common stock</a></td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds', window );">Costs to raise capital paid directly from gross proceeds</a></td>
<td class="nump">636,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise', window );">Subscription receivable</a></td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CostAccruedToAmendTermNotePayable', window );">Cost accrued to amend term note payable</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnpaidFixedAssetsIncludedInAccountsPayable', window );">Unpaid fixed assets included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,769,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant', window );">Termination of finance ROU assets including issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,386,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Note payable to acquire Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities', window );">Increase in operating lease ROU assets for new lease - net of lease incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,570,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NonCashSettlementOfRevenueContract', window );">Settlement of revenue contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinanceLeasePayment', window );">Issuance of warrant for final finance lease obligation payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LeaseIncentiveForConstructionInProgress', window );">Lease incentive for construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed', window );">Acquisition of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized (gain) loss on available-for-sale debt securities</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 687,000<span></span>
</td>
<td class="nump">$ 1,045,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest receivable on convertible promissory note receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid for capital expenditures incurred for intangible assets during the previous year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CostAccruedToAmendTermNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost accrued to amend the term note payable during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CostAccruedToAmendTermNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost incurred to raise capital directly from gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DeferredFinancingCostsAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DeferredFinancingCostsAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of note payable and accrued interest - SBA loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in finance lease obligations for new leases incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInInventoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in inventory valuation reserve during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInInventoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInSettlementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInSettlementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LeaseIncentiveForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease incentive for construction in progress</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LeaseIncentiveForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NonCashSettlementOfRevenueContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash Settlement of revenue contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NonCashSettlementOfRevenueContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Transaction of Subscription Receivable For Capital Raise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non controlling interest that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PaymentOfEquipmentFinancingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for equipment financing loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PaymentOfEquipmentFinancingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PaymentsForFractionalSharesAfterReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for fractional shares after reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PaymentsForFractionalSharesAfterReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PaymentsToAttainTermNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred with attain term note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PaymentsToAttainTermNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromEquipmentFinancingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from equipment financing loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromEquipmentFinancingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromIssuanceOfPreferredAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromIssuanceOfPreferredAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SettlementOfRevenueContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of revenue contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SettlementOfRevenueContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of termination of finance lease right of use asset, including issuance of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnpaidFixedAssetsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unpaid fixed assets included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnpaidFixedAssetsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinanceLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinanceLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481222/840-30-40-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482161/360-10-40-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-8A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243732656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1.&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">Nature of Business</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, iBio made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc"). This acquisition commenced our transition to an AI-enabled biotech company and led to the divestiture of our Contract Development and Manufacturing Organization (CDMO) business. This strategic decision allowed us focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key features of iBio&#8217;s technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with unprecedented precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. &#160;Another integral part of iBio&#8217;s technology stack is the machine learning (ML) based antibody-optimizing StableHu&#8482; technology. When coupled with our mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio also developed the EngageTx&#8482; platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of our antibody products. By incorporating EngageTx into iBio&#8217;s own development initiatives, the Company&#8217;s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to our potential partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">iBio&#8217;s scientific team, composed of experienced AI/ML scientists and drug hunters located side-by-side in our San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows us to quickly translate scientific discoveries into potential therapeutic applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Artificial Intelligence in Antibody Discovery and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company&#8217;s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pre-Clinical Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">iBio is currently in the process of building and advancing its preclinical pipeline. The focus of this pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging iBio&#8217;s technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">on the learnings of competitors, iBio's programs are primarily adopting a fast follower strategy. This approach allows iBio to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><img alt="Graphic" src="ibio-20230630x10k030.jpg" style="display:inline-block;height:171.6pt;width:468pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Digital Infrastructure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">iBio is a firm believer in the transformative power of digital technologies, including robotics, automation, artificial intelligence (AI), machine learning (ML), and cloud computing. These technologies are integral to operationalizing our strategy, accelerating our learning curve, and executing at scale. As such, the Company has made substantial investments in these areas. &#160;iBio&#8217;s aspiration is to digitize our operations to the greatest extent possible, harnessing the potential of digital technology to maximize our impact on human health. As the Company continues to grow, we remain committed to further investing in our digital infrastructure to support our ambitious goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Strategic Alliances, Collaborations, and Joint Ventures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio has formed collaborations and strategic alliances to gain access to funding, capabilities, technical resources and intellectual property to further its development efforts, commercialize its technology and to generate revenues, including through the use of our patented epitope-steering AI-engine and our EngageTX platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238343968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of iBio Inc. and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#8220;iBio CDMO&#8221;) for an affiliate of Eastern Capital Limited (&#8220;Eastern Capital&#8221;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. See Note 6 &#8211; Significant Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company completed a public equity offering and at-the-market offerings, reduced its work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of its CDMO Facility thereby reducing annual spend on expenses. Additionally, the Company has executed the Purchase and Sale Agreement for the sale of the CDMO Facility, which sale if consummated will allow us to pay all outstanding amounts under the Term Loan; however, the consummation of the sale is subject to closing conditions </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">for which there can be no assurance that they will be met or the closing will occur in a timely manner, if at all. If the closing is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely that the Company will have sufficient funds the repay the Term Loan on its maturity date, which Term Loan has an outstanding balance of $12.7 million as of September 26, 2023. Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#8211; Discontinued Operations for more information.) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s cash, cash equivalents and restricted cash of approximately $7.6 million as of June 30, 2023, is not anticipated to be sufficient to support operations through the second quarter of Fiscal 2024 unless the Company reduces its burn rate further, sells the CDMO Facility for amounts above its term note payable or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plan. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Annual Report. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 22, 2022, the Company's Board of Directors approved the implementation of a reverse stock split at a ratio of one-for-twenty five (<span style="-sec-ix-hidden:Hidden_C1BZAkhphkSP6NLYZ6XiZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span> : 25) shares of the Company's Common Stock. The reverse stock split was effective as of October 7, 2022. All share and per share amounts of our common stock presented have been retroactively adjusted to reflect the <span style="-sec-ix-hidden:Hidden_6s-44Ts3DkK4VQjk-RCW4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty five reverse stock split. See Note 17 &#8211; Stockholders&#8217; Equity for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Basis of Presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243671584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;Discontinued Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately </span><span style="font-style:normal;">60%</span><span style="font-style:normal;"> of the current Company staffing levels (a reduction of approximately </span><span style="font-style:normal;">69</span><span style="font-style:normal;"> positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, the Company continues to market for sale the </span><span style="font-style:normal;">130,000</span><span style="font-style:normal;"> square foot cGMP facility location in Bryan, Texas (the &#8220;Facility&#8221;). Additionally, on February 10, 2023, the Company entered into an Auction Sale Agreement (the &#8220;Auction Sale Agreement&#8221;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#8220;Auctioneers&#8221;) for the sale at public auction of equipment and other tangible personal property (the &#8220;Equipment&#8221;) located at the Facility. The Auctioneers guaranteed an amount of gross proceeds from the sale of the equipment of </span><span style="font-style:normal;">$2.1</span><span style="font-style:normal;"> million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately </span><span style="-sec-ix-hidden:Hidden_0UtmYiIXKka_hRPj17MXuA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.9</span></span><span style="font-style:normal;"> million. In accordance with the Auction Sale Agreement, the Company received </span><span style="font-style:normal;">80%</span><span style="font-style:normal;"> of the excess proceeds, after Holland Industrial Group&#8217;s </span><span style="font-style:normal;">$0.2</span><span style="font-style:normal;"> million fee. &#160;Total proceeds received in Fiscal 2023 were approximately </span><span style="font-style:normal;">$2.6</span><span style="font-style:normal;"> million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company incurred pre-tax charges of approximately </span><span style="font-style:normal;">$1.9</span><span style="font-style:normal;"> million for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a </span><span style="font-style:normal;">60</span><span style="font-style:normal;">-day transitional period during which impacted employees remained employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The Company recorded a charge in discontinued operations for approximately </span><span style="font-style:normal;">$35.7</span><span style="font-style:normal;"> million in Fiscal 2023, of which approximately </span><span style="font-style:normal;">$17.9</span><span style="font-style:normal;"> million was the result of a fixed asset impairment charge (see Note 11 &#8211; Fixed Assets for more information), approximately </span><span style="font-style:normal;">$4.9</span><span style="font-style:normal;"> million to write down inventory to its net realizable value, approximately </span><span style="font-style:normal;">$7.5</span><span style="font-style:normal;"> million of personnel costs including severance and the balance related to operational costs related to winding down the CDMO business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">As such, the results of iBio CDMO's operations are reported as discontinued operations for the year ended June 30, 2023. The Company has retrospectively recast its consolidated statement of operations for the year ended June 30, 2022 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#8220;held for sale&#8221; as of June 30, 2023. The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statements of cash flows. Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Consolidated Financial Statements refers to the Company's continuing operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">499</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">216</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">283</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,902</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,373</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed asset impairments</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (773)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory reserve</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,275</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (900)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (602)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (810)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (799)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,791)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2023 and 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,289</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,951</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,314</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:middle;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">30</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,971</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:67.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,275</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 599</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,809</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed asset impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales proceeds of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Increase in ROU operating assets and liabilities for new leases</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,952</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Termination of finance ROU assets including issuance of warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,386</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Note payable to acquire Facility</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,375</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Issuance of warrant for final lease obligation payment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 217</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Cash paid during the period for interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,045</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238626704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At June&#160;30, 2023 and 2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification (&#8220;ASC&#8221;) 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and / or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June&#160;30, 2023 and 2022, the Company had no contract loss provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time and is summarized below (in thousands). &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">No revenue was recognized in the year ended June 30, 2023. &#160;Revenue was recognized from a license agreement and the settlement of a revenue contract in the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contract Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2023 and 2022, contract assets were $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2023 and 2022, contract liabilities were $0 and $100,000, respectively. The Company recognized revenue of $100 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and $178,000 in 2022 that was included in the contract liabilities balance as of June 30, 2021 and was reported in discontinued operations. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company accounts for leases under the guidance of ASC 842, </span>Leases<span style="font-style:normal;">. The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. &#160;The determination of the Company&#8217;s incremental borrowing rate requires judgement. &#160;The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2023 and 2022 consisted of money market accounts. Restricted cash consists </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of approximately $3.0 million held within a Company account at Woodforest Bank for the Term Note payable (see Note 6 &#8211; Significant Transactions and Note 14 &#8211; Debt) collateral, a letter of credit obtained related to the San Diego operating lease (see Note 16 &#8211; Operating Lease Obligations) and a Company purchasing card. The Company&#8217;s bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. &#160;Restricted cash was $3,278,000 and $5,996,000 June 30, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investments in Debt Securities</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 6 - Significant Transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. Inventory held is related to the CDMO business ad has been classified as held for sale. &#160;See Note 3 &#8211; Discontinued Operations for more information on the inventory reserved reflected in the year ended June 30, 2023. &#160;The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. Inventory consists of the following (table in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,896 </p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4 </p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,900 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, &#8220;<i style="font-style:italic;">Research and Development</i>&#8221; (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the years ended June 30, 2023 and 2022, research and development expense was reported in both continuing and discontinuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from </span><span style="-sec-ix-hidden:Hidden_uabS_NI-Z06ict9nQUkf0w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-style:normal;"> to </span><span style="-sec-ix-hidden:Hidden_9YJQTd2bdk-gA4FmiAYIkg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine</span></span><span style="font-style:normal;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility is based on historical volatility of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 &#8211; Share-Based Compensation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June&#160;30, 2023 and 2022. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June&#160;30, 2023 and 2022, amounts in excess of insured limits were approximately $6,900,000 and $18,200,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the Fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers. During the Fiscal year ended June 30, 2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract and generated $499,000 of revenue reported in discontinued operations from eight customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</i>, <i style="font-style:italic;">Derivatives and Hedging (Topic 815)</i>, and <i style="font-style:italic;">Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243581376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">5. &#160; Financial Instruments and Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Company&#8217;s consolidated balance sheets approximated their fair values as of June 30, 2023 and 2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, term note payable and finance lease obligations approximated fair value as of June 30, 2023 and 2022 as the interest rates related to the financial instruments approximated market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of plan investments that fall under each category, and the valuation methodologies used to measure these investments at fair value:<span style="display:inline-block;width:12.24pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>Level 1 &#8211; Inputs are based upon unadjusted quoted prices for identical instruments in active markets.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Level 2 &#8211; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Level 3 &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company initially marketed the CDMO business and during the second quarter of Fiscal year 2023, changed its strategy to selling the stand-alone CDMO assets. These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. As a result, the carrying value of the Facility and equipment was reduced to their estimated fair values of $16,350,000 and $2,100,000, respectively. In the second quarter of Fiscal year 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6,300,000 and $11,300,000 for the Facility and equipment, respectively. In the first quarter of Fiscal 2024, the Company entered into an agreement for the building for $17.25 million, and an additional impairment of $0.3 million was recorded in the fourth quarter of Fiscal 2023 to reflect the agreed upon sales price less estimated costs to sell. &#160;The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $16.1 million. The machinery and equipment were sold during the third quarter of Fiscal year 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of June 30, 2023 (amounts in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Hierarchy</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the second quarter of Fiscal year 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). See Note 12 &#8211; Intangible Assets for additional information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243627760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsAbstract', window );"><strong>Significant Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsTextBlock', window );">Significant Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Significant Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Affiliates of Eastern Capital Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#8220;Sublease&#8221;) until the purchase of the Facility described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Purchase and Sale Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On November 1, 2021, the Purchaser entered into a purchase and sale agreement (the &#8220;PSA&#8221;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#8220;Ground Lease Agreement&#8221;) that it entered into with Texas A&amp;M (the &#8220;Landlord&#8217;&#8217;) related to the land at which the Facility is located together with all improvements pertaining thereto (the &#8220;Ground Lease Property&#8221;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Ground Lease Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the &#8220;Warrant&#8221;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the June 30, 2023 and 2022 consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Equity Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#8220;Equity Purchase Agreement&#8221;) pursuant to which the Company acquired for $50,000 cash, plus the Warrant, the one (1) share of iBio CMO Preferred Tracking Stock and the 0.01% interest in iBio CDMO owned by Bryan Capital. iBio CDMO is now a wholly owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See Note 14 &#8211; Debt for further information of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share. The Warrant expires on October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the total shares that can be exercised under the Warrant, 11,583 of such shares were valued at $217,255 to reflect the final payment of rent due under the Sublease. &#160;The Warrant, as shown on the consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Ground Lease Property acquired. &#160;See Note 17 &#8211; Stockholders&#8217; Equity for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;) described in more detail below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The Company entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields<span style="color:#0000ff;">.&#160;</span>RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="color:#0000ff;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into an agreement with RubrYc (the &#8220;Collaboration, Option and License Agreement&#8221;) to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) <span style="-sec-ix-hidden:Hidden_1lNt1UglOEOd6nh1BKY2Rg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc&#8217;s Series A-2 preferred stock (&#8220;Series A-2 Preferred&#8221;) for $7,500,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,500,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations and completed bankruptcy proceedings in June 2023. &#160;The Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022 which was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. The Company issued 102,354 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the &#8220;Closing Shares&#8221;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#8217;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,228,000</p></td></tr><tr><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,000</p></td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,342,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. See Note 9 &#8211; Finance Lease ROU Assets and Note 15 &#8211; Finance Lease Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Former CEO Departure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#8220;CEO) and former Chairman of the Board of Directors (the &#8220;Board&#8221;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and General Release</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with Mr. Isett&#8217;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#8220;Agreement&#8221;). Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. Following Mr. Isett&#8217;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for <span style="-sec-ix-hidden:Hidden_YMSx4gGHzEiJmUbTbVGKZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the <span style="-sec-ix-hidden:Hidden_SYAPHltUpUekE3X9uPDPUg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;), the Company will pay the full cost of this benefit for up to <span style="-sec-ix-hidden:Hidden_CQT6G5UgS0uV_qC3r8ildA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the <span style="-sec-ix-hidden:Hidden_0Ap6AYAnBkSKK9C3lFNv3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. The Agreement includes a general release of claims by Mr. Isett. The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of Fiscal 2023. As of June 30, 2023, approximately $1.1 million is recorded in accrued expenses and $527,000 in accrued expenses &#8211; noncurrent.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240345136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Note Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Convertible Promissory Note Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Promissory Note Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Promissory Note Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On June 19, 2023, the Company issued a promissory note (the &#8220;Note&#8221;) with Safi Biosolutions, Inc. (&#8220;Safi&#8221;) in the principal amount of $1,500,000, which was issued in exchange for the convertible promissory note (the &#8220;Convertible Note&#8221;) issued by the Company to Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of 5% per annum and will increase to 7% for the first one (1) year extension and 9% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of 5% per annum and had a maturity date of October 1, 2023, was voided. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the Fiscal years ended June 30, 2023 and 2022, interest income amounted to $75,000 and $75,000, respectively. As of June 30, 2023 and 2022, the Note balance and accrued interest, which have been classified as long term, totaled $1,706,000 and $1,631,000, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243628576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10.8pt -0.7pt 0pt 0pt;">The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,029</p></td></tr><tr><td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (184)</p></td></tr><tr><td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.6pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">The fair value of available-for-sale debt securities, by contractual maturity was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,054</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,791</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.6pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Amortization of premiums paid on the debt securities amounted to $67,000 and $312,000 for the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Realized losses on available-for-sale debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241531584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock', window );">Finance Lease ROU Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;Finance Lease ROU Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. The lease for the mobile office trailer was terminated in December 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">See Note 15 &#8211; Finance Lease Obligations for more details of the terms of the leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (204)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Amortization expense of finance lease ROU assets was approximately $204,000 and $0 for the years ended June 30, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243588576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease ROU Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock', window );">Operating Lease ROU Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;&#160;Operating Lease ROU Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">San Diego, California</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. The net carrying amount of this ROU operating lease asset was $2,722,000 and $3,068,000 at June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bryan, Texas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. The net amount of this ROU operating lease asset is included in assets held for sale. &#160; &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">See Note 16 - Operating Lease Obligations for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243584720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,373</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Depreciation expense was approximately $400,000 and $0 for the years ended June 30, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Fixed assets held for sale at June 30, 2023 and 2022 in the amount of $16,124,000 and $35,289,000, respectively, are included in assets held for sale. &#160;The depreciation expense for the years ended June 30, 2023 and 2022 is classified as part of loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the Fiscal year ended June 30, 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company recorded an impairment charge of approximately $17.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">See Note 5 - Financial Instruments and Fair Value Measurement for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243545120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#8220;Term Note&#8221;) (for a complete description of the Transaction please see Note 6 &#8211; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest was payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (the &#8220;Fraunhofer Settlement Funds&#8221;) (see Note 20 &#8211; Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#8220;Liquidity Covenant&#8221;) in the Guaranty (as defined in the Credit Agreement) from </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$10,000,000 to $7,500,000 with the ability to lower the liquidity covenant to $5,000,000 upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company&#8217;s unrestricted cash decreased below the required $7,500,000, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#8220;Second Amendment&#8221;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than <span style="-sec-ix-hidden:Hidden_sMGyGM4rm0etbg7foCVLZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed the Company to retain $2,000,000 of the $5,100,000 that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 being held in a Company account at Woodforest. &#160;In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3,000,000 being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10,000,000 and for each additional $2,500,000 reduction of the outstanding principal amount, an additional $750,000 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in-kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) <span style="-sec-ix-hidden:Hidden_HmO8mI3b8UikyAnwMIet_Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3:00</span></span>%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#8220;Sixth Amendment&#8221;), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Purchase Agreement for the sale of the Facility within <span style="-sec-ix-hidden:Hidden_v7l5jYByc026hKF0AEadYQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> business day after entry into the Sixth Amendment, and (ii) if the Facility is not sell on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the Maturity Date. &#160;In addition, if the closing and funding of the Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMO&#8217;s real estate, including the Facility, at the cost of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">At June 30,&#160;2023, the balance of the Term Loan was $12,937,000 which consisted of the Term Note of $13,057,000, net of approximately $120,000 of deferred finance costs. &#160;At June&#160;30,&#160;2022, the balance was $22,161,000 which consisted of the Term Note of $22,375,000, net of approximately $214,000 of deferred finance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $16,230 through October 2025. &#160;At June 30,&#160;2023, the balance owed under the financing was $401,000. &#160;Interest incurred under the financing for the year ended June 30,&#160;2023 totaled approximately $31,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 454</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (160)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note Payable &#8211; PPP Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-weight:normal;">On April 16, 2020, the Company received </span><span style="font-weight:normal;">$600,000</span><span style="font-weight:normal;"> related to its filing under the Paycheck Protection Program and Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). &#160;</span><span style="font-weight:normal;">The Company elected to treat the Small Business Administration (&#8220;SBA&#8221;) Loan as debt under ASC 470, </span><i style="font-style:italic;font-weight:normal;">Debt</i><span style="font-weight:normal;">. &#160;At June 30, 2021, the Company owed </span><span style="font-weight:normal;">$600,000</span><span style="font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, <i style="font-style:italic;">Liabilities - Extinguishments of Liabilities &#8211; Derecognition</i>, the Company derecognized the liability and accrued interest in the first quarter of Fiscal 2022. The forgiveness is included in loss from discontinued operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241669328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Finance Lease Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;&#160;Finance Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. &#160;See Note 16 &#8211; Operating Lease Obligations for additional information related to the ground lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses related to College Station, including rent related to the increases in the Consumer Price Index (&#8220;CPI&#8221;) and real estate taxes, were approximately $250,000 for the year ended June 30, 2022. Interest expense related to College Station was approximately $810,000 for the year ended June 30, 2022. Such expenses were classified as part of loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $814,000 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mobile Office Trailer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $3,819 through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Future minimum payments under the capitalized lease obligations are due as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on June 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 691</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (272)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238336368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Lease Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;&#160;Operating Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Texas Ground Lease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">San Diego</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On September 10, 2021, the Company entered into a lease for 11,383 square feet of space in San Diego, California. &#160;Terms of the lease include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The length of term of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">88 months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the lease commencement date (as defined).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease commencement date is September 16, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The monthly rent for the first year of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$51,223</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and increases approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease provides for a base rent abatement for months </span><span style="-sec-ix-hidden:Hidden_3yjQiksPYkaMOne7lIAO3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span style="-sec-ix-hidden:Hidden_coC25BjKxUC8oCpGfnMVKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the first year of the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The landlord is providing a tenant improvement allowance of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$81,860</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to be used for improvements as specified in the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is responsible for other expenses such as electric, janitorial, etc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company opened an irrevocable letter of credit in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$188,844</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in favor of the landlord. &#160;The letter of credit expires on October 8, 2022 and renews annually as required.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. &#160;Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease right-of-use asset in the accompanying balance sheet. &#160;Rent expense for the San Diego facility commenced in Fiscal 2022, when the Company began making improvements to the facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligations - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligations - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9pt;"> 6.50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate - operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Future minimum payments under the operating lease obligation are due as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on June 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 631</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 669</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 688</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 710</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,104</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,450</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (389)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243563488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock (&#8220;Series 2022 Preferred&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value </span><span style="font-style:normal;">$0.001</span><span style="font-style:normal;"> per share, out of the Company&#8217;s </span><span style="font-style:normal;">1</span><span style="font-style:normal;"> million authorized shares of preferred stock. Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (</span><span style="font-style:normal;">1</span><span style="font-style:normal;">:1) shares of the Common Stock on a pre-split basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#8217;s Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">iBio CMO Preferred Tracking Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued one share of a newly created Preferred Tracking Stock, in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $13 million. After giving effect to the transaction, the Company owned 99.99% and Bryan Capital owned 0.01% of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Board of Directors of the Company created the Preferred Tracking Stock out of the Company&#8217;s 1 million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of 2% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board of Directors, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. No dividends were declared through October 31, 2021. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. No iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The number of authorized shares of the Company&#8217;s common stock is 275 million. In addition, the Company has reserved 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#8217;s 2020 Omnibus Incentive Plan (the &#8220;2020 Plan&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_NSsLunwOnk-e7VxuFTCjbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25). On September 22, 2022, the Company's Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into <span style="-sec-ix-hidden:Hidden_SIzvssG14kSIBSMx9LhFKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a <span style="-sec-ix-hidden:Hidden_E34AVy54BU-rs9CUNflyRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty five (1:25) reverse stock split of the shares of the Common Stock, either issued and outstanding, effective October 7, 2022. The Company&#8217;s common stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Issuances of Common Stock for the years ended June 30, 2023 and 2022 include the following:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cantor Fitzgerald Underwriting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. ("Cantor Fitzgerald") to sell shares of Common Stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022 and June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 5,782,871 shares of Common Stock. The Company received net proceeds of approximately $6.4 million during the Fiscal year ended June 30, 2023 and holds a subscription receivable for $204,000 at June 30, 2023 for proceeds received on July 6, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In Fiscal year ended June 30, 2022, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 175,973 shares of Common Stock. The Company received net proceeds of approximately $1.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On September 19, 2022, the Company issued 102,354 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Wainwright Underwriting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 6, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#8220;Offering&#8221;) (i) 1,530,769 shares of the Company&#8217;s Common Stock, (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 1,834,616 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#8220;Series A Warrants&#8221;) to purchase up to 3,365,385 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#8220;Series B Warrants&#8221; and together with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to 3,365,385 shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a <span style="-sec-ix-hidden:Hidden_sSHbFN61YUW0p-uuiWxmGw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30-day</span></span> option to purchase up to an additional 504,807 shares of Common Stock and/or Common Warrants to purchase up to an additional 1,009,614 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 504,807 Series A Warrants and 504,807 Series B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#8220;Representative&#8217;s Warrants&#8221;) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 201,923 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Vesting of Restricted Stock Units &#8220;RSUs&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">RSUs for 217,553 of Common Stock vested during the year ended June 30, 2023. RSUs for 8,854 of Common Stock vested during the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Exercise of Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No stock options were exercised in the year ended June 30, 2023. &#160;In the year ended June 30, 2022, options for 3,380 shares of Common Stock were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bryan Capital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock of the Company at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of the Warrant using the Black-Scholes model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Wainwright</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">As discussed above, the Company issued various warrants with the following terms:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pre-Funded Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.001</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class A Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.04</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class B Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.04</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Representative Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, 341,300 Class A Warrants and 1,781,216 Class B Warrants were exercised. The total proceeds from Class A and B Warrants exercised during the year ended June 30, 2023 was $2,207,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to </span><span style="background:#ffffff;">3,475,916</span><span style="background:#ffffff;"> shares of common stock and existing Series B Warrants to purchase up to </span><span style="background:#ffffff;">2,058,000</span><span style="background:#ffffff;"> shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with </span><span style="-sec-ix-hidden:Hidden_CLcT6POV_06On0uZXB8YcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise</span></span><span style="background:#ffffff;"> prices of </span><span style="background:#ffffff;">$1.04</span><span style="background:#ffffff;"> per share (the &#8220;Existing Warrants&#8221;), to lower the </span><span style="-sec-ix-hidden:Hidden_uJKhf1drZEWLizl1NaG14A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise</span></span><span style="background:#ffffff;"> price of the Existing Warrants to </span><span style="background:#ffffff;">$0.50</span><span style="background:#ffffff;"> per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240370768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18.&#160;&#160;&#160;&#160;Earnings (Loss) Per Common Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,512)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,791)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,010)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,391)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_VSCcaFQWPEqZ6HuNP22L4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_szGXjMD-xEyf9K1Eh278Xw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KWCju4zEm0OFrF28ztSNUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.92)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_g9LgYZJp_E2abMmTXdVUKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NyTbTzFAwU-jeS3gdyqc7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_GSNMn7paDkWrRL314FWinw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.78)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In Fiscal Years 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June&#160;30, 2023 and 2022, shares issuable which could potentially dilute future earnings included were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 622</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series 2022 Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 694</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">*  Less than 1,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240370768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.&#160;&#160;&#160;&#160;Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,776</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,958</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $1,528,000 and $419,000 for the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;) </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $1,500,000 for any non-executive chair of our Board of Directors should one be appointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Vesting of service awards is determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally <span style="-sec-ix-hidden:Hidden_LToFWvo-BkiblBBqRkPxFg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Issuances of stock options during the year ended June 30, 2023 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Common Stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase 4,000 shares of the Common Stock at an exercise price of $6.75 per share. The option vests in equal monthly installments, over a period of 12 months, starting after the second month and expire on the tenth anniversary of the grant date. &#160;During the third quarter of Fiscal year 2023, the Company terminated the consultant&#8217;s services. &#160;As a result, none of the 4,000 shares pursuant to the stock option agreement were exercised and as such, all 4,000 shares will be forfeited. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Issuances of stock options during the year ended June 30, 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">During the first quarter of Fiscal Year 2022, the Company granted stock option agreements to various employees to purchase 165,488 shares of the Common Stock at exercise prices between $26.50 and $33.75 per share. The options vest </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2022, the Company granted a stock option agreement to a new member of its Board of Directors to purchase 4,000 shares of Common Stock at an exercise price of $31.50 per share. The option vests monthly over a period of three years and expires on the tenth anniversary of the grant date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2022, the Board of Directors approved an option grant award to Mr. Isett to purchase 80,000 shares of Common Stock with an exercise price of $29.25, which vests in equal monthly installments over a 36-month period following the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the second quarter of Fiscal year 2022, the Company granted a stock option agreement to a consultant to purchase 4,000 shares of Common Stock at an exercise price of $21.25 per share. The option vests over a period of eight months commencing in April 2022 and expires on the <span style="-sec-ix-hidden:Hidden_0OdVFTQWiE-Lr_bsSKBPmA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the second quarter of Fiscal year 2022, the Company granted stock option agreements to various directors to purchase an aggregate of 34,880 shares of Common Stock at an exercise price of $17.25 per share. The options vest over a period of one year commencing in January 2022 and expire on the <span style="-sec-ix-hidden:Hidden_mpImJhbCfEK69FYXeZdXCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third quarter of Fiscal year 2022, the Company granted stock option agreements to two consultants to purchase an aggregate of 1,200 shares of Common Stock at an exercise price of $13.00 per share. The options vest over a period of 12 months and expire on the <span style="-sec-ix-hidden:Hidden_z9rBFPXNl0qc-K8BGo9Big;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span>th anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third quarter of Fiscal year 2022, the Company granted a stock option agreement to various employees to purchase 24,000 shares of Common Stock at exercise prices between $8.50 and $11.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes all stock option activity during the&#160;years ended June&#160;30, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term&#160;(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of July 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 341,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,995</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 313,568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (30,068)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of June 30, 2022, vested and expected to vest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 620,810</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (637,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of June 30, 2023, vested and expected to vest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes information about options outstanding and exercisable at June&#160;30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:65.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise prices:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$7.00 - $11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,250</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$17.35 - $26.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,652</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$26.50 - $39.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,483</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$41.25 - $61.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,665</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,050</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The total fair value of stock options that vested during 2023 and 2022 was approximately $4,828,000 and $3,334,000, respectively. The total cash received for stock options that were exercised during 2023 and 2022 was approximately $0 and $77,000, respectively. The total intrinsic value of stock options that were exercised during 2023 and 2022 was approximately $0 and $19,000, respectively. As of June&#160;30, 2023, there was approximately $2,193,000 of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of 2.3&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The weighted-average grant date fair value of stock options granted during 2023 and 2022 was $6.30 and $23.25 per share, respectively.&#160;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.21% - 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.80 - 2.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">115.52 - 116.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">119.16 - 120.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company&#8217;s closing stock price of $0.61 as of June 30, 2023 and $6.50 as of June 30, 2022, which would have been received by the option holders had all option holders exercised their options as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">Restricted Stock Units (&#8220;RSUs&#8221;):</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Issuances of RSUs during the year ended June 30, 2023 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 29, 2022, the Company issued RSUs to acquire 6,954 shares of common stock to various employees at a market value of $7.06 per share. &#160;The RSUs vest over a four-year period. &#160;The grant date fair value of the RSUs totaled approximately $49,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Company&#8217;s former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 200,000 shares of Common Stock.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000. The performance conditions were not met and the RSUs did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 11, 2022, the Board of the Company granted Mr. Robert Lutz, the Company&#8217;s Chief Financial and Business Officer at the time, RSUs to acquire 100,057 shares of the Company&#8217;s Common Stock in exchange for Mr. Lutz&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $175,100. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, the Board of the Company granted Dr. Martin Brenner, the Company&#8217;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#8217;s Common Stock in exchange for Mr. Brenner&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $167,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire 130,000 shares of the Company&#8217;s Common Stock, which RSUs shall vest pro rata over a 12-month period, such vesting to terminate if Dr. Brenner is no longer the Company&#8217;s Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $91,000. Upon appointment of Dr. Brenner to permanent Chief Executive Officer on June 22, 2023, 75,833 of the RSUs terminated and did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Compensation Committee (the &#8220;Committee&#8221;) of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of 225,000 RSUs under the Company&#8217;s 2020 Omnibus Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), which awards included a grant of 50,000 and 37,500 restricted stock units to each of Dr. Brenner, and Felipe Duran, the Company&#8217;s Interim, Chief Financial Officer, respectively, vesting quarterly over 12 months commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $468,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 26, 2023, the Board of the Company granted Dr. Brenner RSUs to acquire 75,833 shares of the Company&#8217;s Common Stock, which RSUs shall vest pro rata over a seven-month period. &#160;The grant-date fair value of the RSUs totaled approximately $52,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Issuances of RSUs during the year ended June 30, 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company issued RSUs to acquire 4,229 shares of Common Stock to various employees at a market value of $31.50 per share. The RSUs vest over a four-year period. The grant-date fair value of the RSUs totaled approximately $133,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">As of June 30, 2023, there was approximately $445,000 of total unrecognized compensation cost related to non-vested RSUs that the Company expects to recognize over a weighted-average period of 0.8 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243684832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fraunhofer Settlement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlementAbstract', window );"><strong>Fraunhofer Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_GainLossRelatedToLitigationSettlementTextBlock', window );">Fraunhofer Settlement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">20.&#160;&#160;&#160;&#160;Fraunhofer Settlement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Fraunhofer Settlement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2021, iBio, Inc. (the &#8220;Company&#8221;) and Fraunhofer USA, Inc. (&#8220;FhUSA&#8221;) entered into a Confidential Settlement Agreement and Mutual Release (the &#8220;Settlement Agreement&#8221;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#8220;Lawsuit&#8221;). The Settlement Agreement, among other things, resolves the Company&#8217;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The terms of the Settlement Agreement provided for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 paid no later than May 14, 2021 (which was paid 100% to cover legal fees and expenses); (ii) <span style="-sec-ix-hidden:Hidden_jYLIaZRQbkaIs4FnEH9rdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of $5,100,000 paid by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, <span style="-sec-ix-hidden:Hidden_kXKwXnCsRkauOXx5_TATcQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $900,000 paid by March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#8217;s aggregate net cash recovery as a result of the Settlement Agreement was approximately $10,200,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,000 to a Company account at Woodforest on March 24, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. The second $900,000 payment was received on February 17, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_GainLossRelatedToLitigationSettlementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure on gain (Loss) related to litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_GainLossRelatedToLitigationSettlementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981337927728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21.&#160;&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The components of the provision (benefit) for income taxes consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current &#8211; Federal and state</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred &#8211; Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,051)</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred &#8211; State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,051)</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,051</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has deferred income taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets (liabilities):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,829</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,248</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,764</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment in equity security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,520)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating and finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating and finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,765)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has a valuation allowance against the full amount of its net deferred tax assets due to the uncertainty of realization of the deferred tax assets due to the operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Federal net operating losses of approximately $5.5 million were used by the Former Parent prior to June&#160;30, 2008 and are not available to the Company. The Former Parent allocated the use of the Federal net operating losses available for use on its consolidated Federal tax return on a pro rata basis based on all of the available net operating losses from all the entities included in its control group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">U.S. federal net operating losses of approximately $202.1 million are available to the Company as of June&#160;30, 2023, of which $63.9 million will expire at various dates through 2039 and $138.2 million with no expiration date. These carryforwards could be subject to certain limitations in the event there is a change in control of the Company pursuant to Internal Revenue Code Section&#160;382, though the Company has not performed a study to determine if the loss carryforwards are subject to these Section&#160;382 limitations. The Company has a research and development credit carryforward of approximately $1.76 million at June&#160;30, 2023. In addition, the Company has net operating loss carry forwards from various states of approximately $35.2 million which expire from 2029 through 2042.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">A reconciliation of the statutory tax rate to the effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiration and forfeiture of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change related to iBio CDMO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has not been audited in connection with income taxes. iBio files U.S. Federal and state income tax returns subject to varying statutes of limitations. The 2019 through 2022 tax returns generally remain open to examination by U.S. Federal authorities and by state tax authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243628576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">22.&#160;&#160;&#160;&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">CRO Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce IBIO-101 in addition to process development and GMP manufacturing of IBIO-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. The Company has incurred costs totaling approximately </span><span style="font-style:normal;">$1,209,000</span><span style="font-style:normal;"> through June 30, 2023. The Company is committed to additional costs totaling approximately </span><span style="font-style:normal;">$171,000</span><span style="font-style:normal;"> as of the date of the filing of this Annual Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inflation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"><span style="font-style:normal;">Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#8217;s operations.</span><i style="font-size:12pt;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243535536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(K) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee 401(K) Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee 401(K) Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">23.&#160;&#160;&#160;&#160;Employee 401(K)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#8220;Plan&#8221;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#8217;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. Employer contributions made to the Plan totaled approximately $263,000 and $169,000 for the years ended June 30, 2023 and 2022, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $135,000 and $150,000 for the years ended June 30, 2023 and 2022, respectively,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243630240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">24.&#160;&#160;&#160;&#160;Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Purchase and Sale Agreement with Majestic Realty Co.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 15, 2023, iBio CDMO entered into the Purchase and Sale Agreement with Majestic Realty Co., pursuant to which iBio CDMO agreed to sell to Majestic Realty for a purchase price of $17,250,000 its Facility located in Bryan, TX consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;M University System (together, the &#8220;Ground Lease&#8221;), related to 21.401 acres in Brazos County, Texas land (the &#8220;Land&#8221;); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the &#8220;Improvements&#8221;); (iii) all iBio CDMO&#8217;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the &#8220;Personal Property&#8221;); (iii) all iBio CDMO&#8217;s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the &#8220;Contracts&#8221;); and (iv) all iBio CDMO&#8217;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the &#8220;Intangibles&#8221;; and together with the Ground Lease, Improvements and Personal Property, collectively, the &#8220;Property&#8221;). The closing of the sale of the Property is to occur, with time being of the essence, on December 1, 2023 or such other date as mutually agreed. &#160;Pursuant to the terms of the Purchase and Sale Agreement , Majestic Realty deposited with a title company (the &#8220;Escrow Agent&#8221;) $200,000 as an earnest money deposit. Majestic Realty will also be afforded access to the Property to conduct a due diligence review of its condition. The closing is subject to certain closing conditions, including: (i) Majestic Realty&#8217;s delivery to iBio CDMO and the Escrow Agent of written notice of its approval of the condition of the Property on or before 5:00 p.m. Central time on October 16, 2023; (ii) Majestic </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realty obtaining the approval of The Board of Regents of the Texas A&amp;M University System of Majestic Realty&#8217;s purchase from it of the fee interest in the Land on or before 5:00 p.m. Central time on November 13, 2023; and (iii) the delivery at closing by the title company of a title policy to Majestic Realty in the amount of the Purchase Price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Credit Agreement with Woodforest National Bank</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#8220;Sixth Amendment&#8221;), to amend the Credit Agreement to: (i) set the maturity date of the term loan to the&#160;<i style="font-style:italic;">earlier of</i>&#160;(a) December 31, 2023, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement, (ii) provided that iBio CDMO will, immediately upon receipt of the proceeds of the sale of the Property, apply the net proceeds to satisfy all outstanding obligations under the term loan, and to the extent such net proceeds are sufficient, to pay off the term loan, and (iii) change the annual filing requirement solely for the fiscal year ending June 30, 2023, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation; provided that (y) iBio CDMO shall deliver an executed copy of the Purchase and Sale Agreement for the sale of the Facility within one business day after entry into the Sixth Amendment, and (z) if the Facility is not sold on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Repriced Existing Warrants issued pursuant to Wainwright Underwriting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">On August 4, 2023, iBio, Inc. (the &#8220;Company&#8221;) agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A warrants to purchase up to </span><span style="background:#ffffff;">3,475,916</span><span style="background:#ffffff;"> shares of common stock and existing Series B warrants to purchase up to </span><span style="background:#ffffff;">2,058,000</span><span style="background:#ffffff;"> shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with exercise prices of </span><span style="background:#ffffff;">$1.04</span><span style="background:#ffffff;"> per share (the &#8220;Existing Warrants&#8221;), to lower the exercise price of the Existing Warrants to </span><span style="background:#ffffff;">$0.50</span><span style="background:#ffffff;"> per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Lincoln Park Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 4, 2023, iBio, Inc. (the &#8220;Company&#8221;) entered into a purchase agreement, dated as of August 4, 2023 (the &#8220;Purchase Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to&#160;<span style="background:#ffffff;">which, under the terms and subject to the satisfaction of specified conditions set forth therein,&#160;</span>the Company may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of the Company&#8217;s Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the &#8220;Registration Rights Agreement&#8221;), with Lincoln Park, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;), to register under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by the Company to Lincoln Park under the Purchase Agreement. The Company cannot sell any shares of Common Stock to Lincoln Park under the Purchase Agreement until such time that all of the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase Agreement, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the &#8220;Commencement Date&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company&#8217;s discretion, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10 million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company may, at its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.15, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to 100,000 shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a &#8220;Regular Purchase&#8221;);&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the maximum number of shares the Company may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 150,000 shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00, and (ii) 200,000 shares, if </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the closing sale price of the Common Stock on the applicable purchase date is not below $2.00;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that Lincoln Park&#8217;s maximum purchase commitment in any single Regular Purchase may not exceed $500,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, provided that the Company has directed Lincoln Park to purchase the maximum amount of shares that the Company is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.20, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an &#8220;accelerated purchase,&#8221; and one or more &#8220;additional accelerated purchases&#8221; on the business day immediately following the purchase date for such Regular Purchase,&#160;<span style="background:#ffffff;">as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable,</span>&#160;calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company will control the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Actual sales of shares of Common Stock to Lincoln Park will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, market prices of the Common Stock from time to time during the term of the Purchase Agreement and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of Common Stock to Lincoln Park. The Company expects that any proceeds received by the Company from such sales to Lincoln Park will be used for working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As consideration for Lincoln Park&#8217;s commitment to purchase shares of Common Stock at the Company&#8217;s direction pursuant to the Purchase Agreement, the Company issued 211,473 shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Initial Commitment Shares&#8221;) and agreed to issue 211,474 additional shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Additional Commitment Shares&#8221; and, collectively with the Initial Commitment Shares, the &#8220;Commitment Shares&#8221;) at such time as the Company has received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, if any, that the Company elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Under applicable rules of the NYSE American, the Company may not issue or sell to Lincoln Park under the Purchase Agreement more than&#160;</span>4,474,945 shares (inclusive of the Commitment Shares), subject to adjustment as described above, of Common Stock (which is equal to approximately 19.99% of the shares of Common Stock outstanding immediately prior to the execution of the Purchase Agreement) (the &#8220;Exchange Cap&#8221;), unless stockholder approval is obtained to issue shares of Common Stock in excess of the Exchange Cap in accordance with the applicable rules of the NYSE American. In any event, the Company may not issue or sell any shares of Common Stock under the Purchase Agreement if such issuance or sale would breach any applicable rules or regulations of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Purchase Agreement also prohibits the Company from directing Lincoln Park to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock then beneficially owned by Lincoln Park (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in Lincoln Park beneficially owning more than 4.99% of the outstanding shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or Registration Rights Agreement, other than a prohibition (with certain limited exceptions) on entering into specified &#8220;Variable Rate Transactions&#8221; (as such term is defined in the Purchase Agreement) for a period specified in the Purchase Agreement. Such transactions include, among others, any sale of debt or equity securities that are convertible into or exercisable for shares of Common Stock at a conversion price or exercise price that is based upon and/or varies with the trading prices of the Common Stock after the initial issuance of such securities,&#160;<span style="background:#ffffff;">or effecting or entering into an agreement to effect an &#8220;equity line of credit&#8221; or other substantially similar continuous offering with a third party, in which we may offer, issue or sell Common Stock or any securities exercisable, exchangeable or convertible into Common Stock at a future determined price.</span>&#160;During any &#8220;suspension event&#8221; under the Purchase Agreement, the Company may not initiate any Regular Purchase, accelerated purchase or additional accelerated purchase of Common Stock by Lincoln Park, until such suspension event is cured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Lincoln Park has agreed not to engage in or effect, directly or indirectly, for its own principal account or for the principal account of any of its affiliates, any short sales of the Common Stock or hedging transaction that establishes a net short position in the Common Stock during the term of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time with one business days&#8217; notice, at no cost or penalty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Between August 16, 2023 and September 15, 2023, Lincoln Park purchased pursuant to the Purchase Agreement 3,622,834 shares of Common Stock. The Company received net proceeds of approximately $1.2 million during the first quarter of Fiscal 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cantor Fitzgerald Underwriting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Between July 3 and September 26, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 3,419,795 shares of Common Stock. The Company received net proceeds of approximately $1.7 million during the first quarter of Fiscal 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"><span style="font-style:italic;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuances of stock options during Fiscal 2024 were as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In Fiscal 2024, the Company granted stock option agreements to certain officers and employees to purchase an aggregate of 473,000 shares of Common Stock at an exercise price of $0.35 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the <span style="-sec-ix-hidden:Hidden_jBumV3Rkt02i3MRw82WE7Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span>th anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Vesting of RSUs during Fiscal 2024 were as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the first quarter of Fiscal 2024, RSUs for 33,153 shares of Common Stock were vested.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981233827360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At June&#160;30, 2023 and 2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification (&#8220;ASC&#8221;) 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and / or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June&#160;30, 2023 and 2022, the Company had no contract loss provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time and is summarized below (in thousands). &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">No revenue was recognized in the year ended June 30, 2023. &#160;Revenue was recognized from a license agreement and the settlement of a revenue contract in the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractAssetsPolicyTextBlock', window );">Contract Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contract Assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2023 and 2022, contract assets were $0.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractLiabilitiesPolicyTextBlock', window );">Contract Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2023 and 2022, contract liabilities were $0 and $100,000, respectively. The Company recognized revenue of $100 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and $178,000 in 2022 that was included in the contract liabilities balance as of June 30, 2021 and was reported in discontinued operations. &#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company accounts for leases under the guidance of ASC 842, </span>Leases<span style="font-style:normal;">. The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. &#160;The determination of the Company&#8217;s incremental borrowing rate requires judgement. &#160;The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash, Cash Equivalents and Restricted Cash</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2023 and 2022 consisted of money market accounts. Restricted cash consists </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of approximately $3.0 million held within a Company account at Woodforest Bank for the Term Note payable (see Note 6 &#8211; Significant Transactions and Note 14 &#8211; Debt) collateral, a letter of credit obtained related to the San Diego operating lease (see Note 16 &#8211; Operating Lease Obligations) and a Company purchasing card. The Company&#8217;s bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. &#160;Restricted cash was $3,278,000 and $5,996,000 June 30, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy', window );">Investments in Debt Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investments in Debt Securities</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 6 - Significant Transactions. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessPolicy', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. Inventory held is related to the CDMO business ad has been classified as held for sale. &#160;See Note 3 &#8211; Discontinued Operations for more information on the inventory reserved reflected in the year ended June 30, 2023. &#160;The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. Inventory consists of the following (table in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,896 </p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4 </p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,900 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, &#8220;<i style="font-style:italic;">Research and Development</i>&#8221; (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the years ended June 30, 2023 and 2022, research and development expense was reported in both continuing and discontinuing operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_RightOfUseAssetsPolicyPolicyTextBlock', window );">Right-of-Use Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from </span><span style="-sec-ix-hidden:Hidden_uabS_NI-Z06ict9nQUkf0w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-style:normal;"> to </span><span style="-sec-ix-hidden:Hidden_9YJQTd2bdk-gA4FmiAYIkg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-nine</span></span><span style="font-style:normal;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility is based on historical volatility of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 &#8211; Share-Based Compensation for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June&#160;30, 2023 and 2022. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June&#160;30, 2023 and 2022, amounts in excess of insured limits were approximately $6,900,000 and $18,200,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the Fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers. During the Fiscal year ended June 30, 2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract and generated $499,000 of revenue reported in discontinued operations from eight customers.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</i>, <i style="font-style:italic;">Derivatives and Hedging (Topic 815)</i>, and <i style="font-style:italic;">Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_RightOfUseAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_RightOfUseAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory in the course of production (work in process). If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243584720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">499</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">216</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">283</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,902</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,373</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed asset impairments</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (773)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory reserve</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,275</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (900)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (602)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (810)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (799)</p></td></tr><tr><td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,791)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2023 and 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,289</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,951</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,314</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:middle;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">30</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,971</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:67.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,275</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 599</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,809</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed asset impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales proceeds of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Increase in ROU operating assets and liabilities for new leases</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,952</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Termination of finance ROU assets including issuance of warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,386</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Note payable to acquire Facility</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,375</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Issuance of warrant for final lease obligation payment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 217</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Cash paid during the period for interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,045</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245139968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of of total cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,896 </p></td></tr><tr><td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4 </p></td></tr><tr><td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,900 </p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981239027680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fixed assets measured at fair value on a non-recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Hierarchy</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,600</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243783120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Purchase Price Allocation of Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,500,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member] | Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Purchase Price Allocation of Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,228,000</p></td></tr><tr><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,000</p></td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,342,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245543568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of components of investments in debt securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10.8pt -0.7pt 0pt 0pt;">The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,029</p></td></tr><tr><td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (184)</p></td></tr><tr><td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,845</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of fair value of available-for-sale debt securities, by contractual maturity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">The fair value of available-for-sale debt securities, by contractual maturity was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,054</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,791</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.6pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock', window );">Schedule of realized losses on available-for-sale debt securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;">Realized losses on available-for-sale debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains (losses) on available for sale debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981239900208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock', window );">Summary of the gross carrying value and accumulated amortization of finance lease ROU</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (204)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243630240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of gross carrying value and accumulated depreciation of fixed assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,373</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238786048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Category the gross carrying value and accumulated amortization of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Impairments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,846)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,946)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15)</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15)</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (565)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_vEQqufD90USP1VGzaUl2Uw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> 1,228</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,388</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated annual amortization expenses for next five years and thereafter</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:44.49%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 285</p></td></tr><tr><td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243588576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,066</p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Real estate taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 284</p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest and fees related to term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 126</p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229</p></td></tr><tr><td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,764</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240370768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments Under the Finance Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 454</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (160)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241703776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock', window );">Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments Under the Finance Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 454</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (160)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock', window );">Capitalized Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Future minimum payments under the capitalized lease obligations are due as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on June 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 691</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (272)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of capitalized lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to capitalized lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245437360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock', window );">Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligations - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligations - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9pt;"> 6.50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate - operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments under the Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Future minimum payments under the operating lease obligation are due as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on June 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 631</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 669</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 688</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 710</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,104</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,450</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (389)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243581376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair value of Warrant using the Black-Scholes model assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240412800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings (loss) Per Share, Basic and Diluted</a></td>
<td class="text">The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,512)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,311)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,791)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,010)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,391)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_VSCcaFQWPEqZ6HuNP22L4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_szGXjMD-xEyf9K1Eh278Xw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KWCju4zEm0OFrF28ztSNUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.92)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_g9LgYZJp_E2abMmTXdVUKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.39)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NyTbTzFAwU-jeS3gdyqc7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_GSNMn7paDkWrRL314FWinw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.78)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">In Fiscal Years 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June&#160;30, 2023 and 2022, shares issuable which could potentially dilute future earnings included were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 622</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series 2022 Preferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 694</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">*  Less than 1,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241894224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,776</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,958</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes all stock option activity during the&#160;years ended June&#160;30, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term&#160;(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of July 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 341,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,995</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 313,568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (30,068)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of June 30, 2022, vested and expected to vest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 620,810</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 197,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 307,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (637,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of June 30, 2023, vested and expected to vest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of Stock Options Outstanding and Exercisable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes information about options outstanding and exercisable at June&#160;30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:65.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise prices:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$7.00 - $11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,250</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$17.35 - $26.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,652</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$26.50 - $39.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,483</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$41.25 - $61.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,665</p></td></tr><tr><td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,050</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options Granted using the Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.21% - 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.80 - 2.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">115.52 - 116.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">119.16 - 120.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243538560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The components of the provision (benefit) for income taxes consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current &#8211; Federal and state</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred &#8211; Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,051)</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred &#8211; State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,790)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,051)</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,051</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets (liabilities):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,829</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,248</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,764</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment in equity security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,520)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating and finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating and finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,765)</p></td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">A reconciliation of the statutory tax rate to the effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiration and forfeiture of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change related to iBio CDMO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238825328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>position</div>
</th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Number of positions reduced | position</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashAndCashEquivalentsPlusDebtSecurities', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, shares received per share tendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember', window );">Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="nump">$ 12,937,000<span></span>
</td>
<td class="nump">$ 22,161,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashAndCashEquivalentsPlusDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents plus debt securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashAndCashEquivalentsPlusDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981242142768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>position </div>
<div>D</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Number of positions reduced | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of facility to be sold | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales proceeds for fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EmployeeReductionExpenses', window );">Expected employee reduction charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceTransitionalPeriodDays', window );">Severance Transitional Period Days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown', window );">Inventory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance', window );">Personnel costs including severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_HollandIndustrialGroupMember', window );">Holland Industrial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales proceeds for fixed assets</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_GuaranteedAuctionProceedsMember', window );">Guaranteed Auction Proceeds [Member] | Holland Industrial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales proceeds for fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_AuctionSaleAgreementMember', window );">Auction Sale Agreement [Member] | Holland Industrial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AuctionFee', window );">Auction fee</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_AuctionSaleAgreementMember', window );">Auction Sale Agreement [Member] | Excess Auction Proceeds [Member] | Holland Industrial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfAuctionProceedsReceived', window );">Percentage of excess proceeds received</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AuctionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of auction costs incurred in a discontinuing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AuctionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount inventory written down in a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of personnel cost including severance incurred in a discontinuing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EmployeeReductionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected amount of expenses to be incurred due to employee reductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EmployeeReductionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfAuctionProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of proceeds received in an auction sale of company assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfAuctionProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceTransitionalPeriodDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days during transitional period of severance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceTransitionalPeriodDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_HollandIndustrialGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_HollandIndustrialGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_GuaranteedAuctionProceedsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_GuaranteedAuctionProceedsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_AuctionSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_AuctionSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ExcessAuctionProceedsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ExcessAuctionProceedsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240675472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Reconciliation and Classifications) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Results of operations for discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">6,344<span></span>
</td>
<td class="nump">7,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,751<span></span>
</td>
<td class="nump">12,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TangibleAssetImpairmentChargesDiscontinuedOperations', window );">Fixed assets impairments</a></td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_GainOnSaleOfFixedAssets', window );">Gain on sale of fixed assets</a></td>
<td class="num">(773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown', window );">Inventory reserve</a></td>
<td class="nump">4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">35,137<span></span>
</td>
<td class="nump">20,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense - term note payable</a></td>
<td class="num">(900)<span></span>
</td>
<td class="num">(602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupInterestExpenseRelatedParty', window );">Interest expense - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupGainOnDebtForgiveness', window );">Forgiveness of note payable and accrued interest - SBA loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsMiscellaneousExpensesIncome', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Total other expenses</a></td>
<td class="num">(901)<span></span>
</td>
<td class="num">(799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(35,699)<span></span>
</td>
<td class="num">(20,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property and equipment, net</a></td>
<td class="nump">16,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="nump">18,065<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets', window );">Finance lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations', window );">Finance lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations', window );">Operating lease obligation</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations', window );">Finance lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupNoncurrentOperatingLeaseObligations', window );">Operating lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Net Cash Provided by (Used in) Discontinued Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation expense</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">2,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Purchase of fixed assets</a></td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">5,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TangibleAssetImpairmentChargesDiscontinuedOperations', window );">Fixed assets impairments</a></td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown', window );">Inventory reserve</a></td>
<td class="nump">4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales proceeds for fixed assets</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Investing noncash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases', window );">Increase in ROU operating assets and liabilities for new leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod', window );">Fixed assets included in accounts payable in prior period, paid in current period</a></td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations', window );">Unpaid fixed assets included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant', window );">Termination of finance ROU assets including issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromNotesPayableFromDiscontinuedOperations', window );">Note payable to acquire Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IssuanceOfWarrantForFinalLeaseObligationPayment', window );">Issuance of warrant for final lease obligation payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidDiscontinuedOperations', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">$ 1,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsMiscellaneousExpensesIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous expenses (income) attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsMiscellaneousExpensesIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of finance lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current finance lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current operating lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed asset charges incurred but not yet paid attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupGainOnDebtForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on forgiveness of debt to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupGainOnDebtForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount inventory written down in a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupInterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense to related party from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupInterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as non current  assets attributable to disposal group held for sale or disposed of, expected to be disposed of more than one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent finance lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupNoncurrentOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent operating lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupNoncurrentOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current operating lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent operating lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_GainOnSaleOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain or loss on the sale of fixed assets resulting from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_GainOnSaleOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in ROU operating assets and liabilities for new leases from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IssuanceOfWarrantForFinalLeaseObligationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of warrant for final lease obligation payment from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IssuanceOfWarrantForFinalLeaseObligationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromNotesPayableFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromNotesPayableFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TangibleAssetImpairmentChargesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets of discontinued operations from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TangibleAssetImpairmentChargesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination of finance ROU assets including issuance of warrant from discontinued operaions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid fixed assets included in accounts payable, attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period for interest owed on debt associated with discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981242152464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Reserve for loss on contract</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized included in contract liabilities</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Amount of liability for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount in excess of insured limit</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">18,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,884,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue reported in discontinued operations</a></td>
<td class="nump">$ 391,000<span></span>
</td>
<td class="nump">$ 499,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ibio_FourCustomersMember', window );">Four Customers [Member] | Revenue [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfMajorCustomers', window );">Number of major customers | customer</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue reported in discontinued operations</a></td>
<td class="nump">$ 391,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ibio_EightCustomersMember', window );">Eight Customers [Member] | Revenue [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfMajorCustomers', window );">Number of major customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue reported in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of major customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ibio_FourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ibio_FourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ibio_EightCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ibio_EightCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240498704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfCollateralRequired', window );">Additional percentage of collateral held required by bank</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 3,278,000<span></span>
</td>
<td class="nump">$ 5,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">4,301,000<span></span>
</td>
<td class="nump">22,676,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">7,579,000<span></span>
</td>
<td class="nump">28,672,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember', window );">Letter Of Credit - Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">3,025,000<span></span>
</td>
<td class="nump">5,743,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember', window );">Letter Of Credit - San Diego Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">198,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember', window );">Company Purchasing Card [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfCollateralRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of collateral required to be held by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfCollateralRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243809360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Inventory) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">$ 3,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory total</a></td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240468192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FixedAssetsHeldForSale', window );">Fixed assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,124,000<span></span>
</td>
<td class="nump">16,124,000<span></span>
</td>
<td class="nump">$ 35,289,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,064,000<span></span>
</td>
<td class="nump">16,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FixedAssetsHeldForSale', window );">Fixed assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfBuildings', window );">Proceeds from Sale of Buildings</a></td>
<td class="nump">$ 17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,350,000<span></span>
</td>
<td class="nump">16,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FixedAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed assets held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FixedAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of buildings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981242142224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Total Fair Value</a></td>
<td class="nump">$ 16,064<span></span>
</td>
<td class="nump">16,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Total Fair Value</a></td>
<td class="nump">$ 16,064<span></span>
</td>
<td class="nump">$ 16,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981237327104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 19, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 16, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>lease </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 23, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment of investment in equity security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,760,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,016,000<span></span>
</td>
<td class="nump">21,754,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember', window );">Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,057,000<span></span>
</td>
<td class="nump">22,375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Cost incurred to attain debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FairMarketValueOfProperty', window );">Fair market value of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Amount advanced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AssetAcquisitionTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased', window );">Stock purchase agreement, number of shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Liability for the assumed acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfPrepaidExpensesCurrent', window );">Impairment of current prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfPrepaidExpensesNonCurrent', window );">Impairment of non-current prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 864,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued | shares</a></td>
<td class="nump">102,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfEquipmentLeases', window );">Number of equipment leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FairMarketValueOfProperty', window );">Fair market value of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty', window );">Percentage of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired', window );">Cash consideration for equity interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent', window );">Shares issued under the Warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue', window );">Fair value of the warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementWarrantsIssuedOrIssuable', window );">Warrants issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember', window );">Separation Agreement and General Release [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary', window );">Period of bi-monthly installments of current base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus', window );">Period of bi-monthly installments of target bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct', window );">Maximum period for coverage of health insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod', window );">COBRA subsidy period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct', window );">Number of times on which lump sum cash payment tis o be made | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborationAndLicenseAgreementAgreementTerm', window );">Collaboration and license agreement, agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm', window );">Collaboration and license agreement, royalty payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased', window );">Stock purchase agreement, number of shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,864,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementValueOfSharesPurchased', window );">Stock purchase agreement, value of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent payable on percentage of fair Market Value of the Property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentPercentageOfFairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborationAndLicenseAgreementAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement, agreement term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborationAndLicenseAgreementAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement, royalty payment term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration transferred for equity interest acquired under the equity agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity agreement, percentage of equity interest issued or issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementWarrantsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued or issuable under the equity agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementWarrantsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value of the property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ImpairmentOfPrepaidExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of current prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ImpairmentOfPrepaidExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ImpairmentOfPrepaidExpensesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of non-current prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ImpairmentOfPrepaidExpensesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfEquipmentLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equipment leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfEquipmentLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, number of shares purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementValueOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, value of shares purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementValueOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued for the final payment of rent due under sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of warrants issued for the final payment of rent due under sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-8A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981233974976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Transactions (Summary of Asset Acquisition) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Aug. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 1,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember', window );">Asset Acquisition Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember', window );">Asset Acquisition Intangible Assets [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">1,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember', window );">Asset Acquisition Fixed Assets [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember', window );">Asset Acquisition Prepaid Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,440,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981233708960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Note Receivable (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 19, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="nump">$ 177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Promissory Note Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableAmountInvested', window );">Amount invested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableFixedRatesOfInterest', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableRateOfInterestForFirstOneYearExtension', window );">Interest rate for first one year extension</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableRateOfInterestForSecondOneYearExtension', window );">Interest rate for second one year extension</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Note balance and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,706,000<span></span>
</td>
<td class="nump">$ 1,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableAmountInvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the face amount of notes receivable invested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableAmountInvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableFixedRatesOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fixed rate of interest on notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableFixedRatesOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableRateOfInterestForFirstOneYearExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of rate of interest on notes receivable for first one year extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableRateOfInterestForFirstOneYearExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableRateOfInterestForSecondOneYearExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of rate of interest on notes receivable for second one year extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableRateOfInterestForSecondOneYearExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245164224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premiums on debt securities</a></td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="nump">$ 312,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240315168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt Securities (Components of Investments in Debt Securities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted cost</a></td>
<td class="nump">$ 11,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Fair value</a></td>
<td class="nump">$ 10,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240322752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">2023</a></td>
<td class="nump">$ 8,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost', window );">2024</a></td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Fair value</a></td>
<td class="nump">$ 10,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240321168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities (Realized Losses on Available-For-Sale Debt Securities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of debt securities</a></td>
<td class="nump">$ 6,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CostOfDebtSecurities', window );">Cost of Debt Securities</a></td>
<td class="nump">6,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Realized loss on sale of debt securities</a></td>
<td class="num">$ (98)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CostOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cost of debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CostOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245150896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981239076016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems', window );"><strong>Finance Lease, Right Of Use Asset, Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">$ (204,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net of accumulated amortization</a></td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember', window );">Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems', window );"><strong>Finance Lease, Right Of Use Asset, Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetGross', window );">ROU, gross</a></td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241567312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease ROU Assets (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lab and office | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset | $</a></td>
<td class="nump">$ 2,722,000<span></span>
</td>
<td class="nump">$ 3,068,000<span></span>
</td>
<td class="nump">$ 1,967,000<span></span>
</td>
<td class="nump">$ 3,603,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238907520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FixedAssetsHeldForSale', window );">Fixed assets held for sale</a></td>
<td class="nump">16,124,000<span></span>
</td>
<td class="nump">$ 35,289,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FixedAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed assets held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FixedAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241863344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Carrying Value and Accumulated Depreciation) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">$ 4,619,000<span></span>
</td>
<td class="nump">$ 1,373,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(400,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net fixed assets</a></td>
<td class="nump">4,219,000<span></span>
</td>
<td class="nump">1,373,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">695,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">3,521,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">403,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,373,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240666096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">565,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member] | Immune-Oncology Antibodies (RTX-003) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementTotalInvestment', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementTotalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment under the stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementTotalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981237979456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Carrying Value and Accumulated Amortization) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 5,946,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(5,270,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total definite lived intangible assets, net of accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="nump">676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">License - indefinite lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003,000<span></span>
</td>
<td class="nump">4,175,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,388,000<span></span>
</td>
<td class="nump">4,851,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredChargesAbstract', window );"><strong>Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126,000)<span></span>
</td>
<td class="num">(401,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Additions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions to definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Additions to licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract', window );"><strong>Impairments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfIntangibleAssetsGrossOfReversals', window );">Impairment of intangible assets - gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,946,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ReversalOfIntangibleAssetImpairment', window );">Intangible asset impairment - accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(565,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(2,867,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredChargesAbstract', window );"><strong>Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Additions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions to definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract', window );"><strong>Impairments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfIntangibleAssetsGrossOfReversals', window );">Impairment of intangible assets - gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ReversalOfIntangibleAssetImpairment', window );">Intangible asset impairment - accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,931,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,846,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,403,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredChargesAbstract', window );"><strong>Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract', window );"><strong>Impairments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfIntangibleAssetsGrossOfReversals', window );">Impairment of intangible assets - gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,846,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ReversalOfIntangibleAssetImpairment', window );">Intangible asset impairment - accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="num">$ (25,000)<span></span>
</td>
<td class="num">$ (565,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ImpairmentOfIntangibleAssetsGrossOfReversals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of intangible asset impairment before reversals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ImpairmentOfIntangibleAssetsGrossOfReversals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ReversalOfIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal of intangible asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ReversalOfIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981233618960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Estimated Annual Amortization Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245202880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Summary of Accrued Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Personnel related costs</a></td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="nump">$ 3,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedRealEstateTaxes', window );">Real estate taxes</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest and fees related to term note payable</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 4,034<span></span>
</td>
<td class="nump">$ 3,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedRealEstateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued real estate taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedRealEstateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981232385280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (The Credit Agreement) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 18, 2023</div></th>
<th class="th"><div>Mar. 24, 2023</div></th>
<th class="th"><div>Feb. 20, 2023</div></th>
<th class="th"><div>Oct. 11, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="nump">$ 5,996,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Amount released from restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,093,000<span></span>
</td>
<td class="nump">48,732,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility', window );">Period for payment of equity interests at-the-market facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember', window );">Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,057,000<span></span>
</td>
<td class="nump">22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,937,000<span></span>
</td>
<td class="nump">$ 22,161,000<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility', window );">Percentage of payment of equity Interests from proceeds of at-the-market facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment', window );">Percentage of payment from proceeds of sales of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AmountRetainedFromProceedsOfLegalSettlement', window );">Amount retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate', window );">Threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment</a></td>
<td class="text">1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | If The Facility Is Sold On Or Before June 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentPaidInKindInterestRate', window );">Payable in-kind rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentPaidInKindInterestRate', window );">Payable in-kind rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentPaidInKindInterestRate', window );">Payable in-kind rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | If The Facility Is Not Sell On Or Before December 1, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility', window );">Percentage of payment of equity Interests from proceeds of at-the-market facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment', window );">Percentage of payment from proceeds of sales of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Amendment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtCovenantLiquidityAmount', window );">Liquidity covenant, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Date Of Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Within Two Business Days Of Frunhofer Legal Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Occurrence Of Specific Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtCovenantLiquidityAmount', window );">Liquidity covenant, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If Outstanding Principal Amount Reduced to 10,000,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AmountToBeReleasedFromRestrictedCash', window );">Amount to be released from restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AmountToBeReleasedFromRestrictedCash', window );">Amount to be released from restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If The Facility Is Sold On Or Before June 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AmountRetainedFromProceedsOfLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount retained from proceeds of legal settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AmountRetainedFromProceedsOfLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AmountToBeReleasedFromRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount to be released from restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AmountToBeReleasedFromRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold limit of unrestricted cash to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CreditAgreementThresholdLimitUnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtCovenantLiquidityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required liquidity per debt covenant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtCovenantLiquidityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fees to be paid under Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtInstrumentPaidInKindInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payable in-kind interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtInstrumentPaidInKindInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of payment of equity interests from proceeds of sales of equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of payment of equity interests from proceeds of sales of equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period for the payment to counterparty of equity interests from the issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsSoldOnOrBeforeJune302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsSoldOnOrBeforeJune302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_WoodforestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_WoodforestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_DateOfAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_DateOfAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_OccurrenceOfSpecificMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_OccurrenceOfSpecificMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfOutstandingPrincipalAmountReducedTo10000000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfOutstandingPrincipalAmountReducedTo10000000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245099664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Equipment Financing) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingAmountBorrowed', window );">Amount borrowed</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeEquipmentLeaseTermOfContract', window );">Term of agreement</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingLeaseImputedInterestRate', window );">Imputed interest rate</a></td>
<td class="nump">10.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentLeasingMonthlyInstallmentPayable', window );">Monthly installment payable</a></td>
<td class="nump">$ 16,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingBalance', window );">Balance owed under financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingInterestIncurred', window );">Interest incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingAmountBorrowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount borrowed under equipment financing as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingAmountBorrowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equipment financing balance under equipment leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingInterestIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest incurred under equipment financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingInterestIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingLeaseImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of imputed interest rate on equipment financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingLeaseImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentLeasingMonthlyInstallmentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of monthly installment payable under equipment leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentLeasingMonthlyInstallmentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeEquipmentLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee equipment financing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeEquipmentLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981240621488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Equipment Financing) (Future Minimum Payments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember', window );">Principal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractualObligationCurrent', window );">Less: current portion</a></td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractualObligationNoncurrent', window );">Long-term portion of minimum equipment financing obligation</a></td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember', window );">Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractualObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractualObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractualObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent portion of contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractualObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245572096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Note Payable - PPP Loan) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">$ 12,937,000<span></span>
</td>
<td class="nump">$ 22,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_PppLoanCaresActMember', window );">PPP Loan Cares Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_PppLoanCaresActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_PppLoanCaresActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238848016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 16, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,264,000<span></span>
</td>
<td class="nump">$ 1,849,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LessorFinanceLeaseMonthlyRent', window );">Mobile office trailer monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfEquipmentLeases', window );">Number of equipment leases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LeaseRentExpensePerMonth', window );">Monthly rent</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_SecondEasternAffiliateMember', window );">Second Eastern Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LeaseRentExpensePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease rent expense per month during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LeaseRentExpensePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LessorFinanceLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent receivable monthly by the lessor under the finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LessorFinanceLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfEquipmentLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equipment leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfEquipmentLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_SecondEasternAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_SecondEasternAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238215376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation (Finance Lease Cost and Other Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinancingCashFlowsFromFinanceLeaseObligation', window );">Financing cash flows from finance lease obligations</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease ROU assets</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation - current portion</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation - non current portion</a></td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance lease</a></td>
<td class="text">2 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - finance lease obligation</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinancingCashFlowsFromFinanceLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for finance lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinancingCashFlowsFromFinanceLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238632096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligations</a></td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember', window );">Principal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligations</a></td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember', window );">Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981233677936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease Obligation (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lab and office | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">88 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseMonthlyRent', window );">Operating lease monthly rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent', window );">Annual percentage increase in base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Irrevocable letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentAbatementInFirstYearPeriod', window );">Base rent abatement period in the first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentAbatementInFirstYearPeriod', window );">Base rent abatement period in the first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty', window );">Percentage of base rent</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseMonthlyRent', window );">Operating lease monthly rent payable</a></td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentAbatementInFirstYearPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rent abatement period in the first year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentAbatementInFirstYearPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent payable on percentage of fair Market Value of the Property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentPercentageOfFairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Annual percentage increase in base rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent payable monthly by the lessee under the operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241567312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingLeaseCostsAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TotalOperatingLeaseCosts', window );">Total lease cost</a></td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating lease</a></td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingCashFlowsFromOperatingLeaseObligation', window );">Operating cash flows from operating lease obligation</a></td>
<td class="nump">$ 307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - operating leases</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating lease obligations</a></td>
<td class="nump">7.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingCashFlowsFromOperatingLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating cash flows from operating lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingCashFlowsFromOperatingLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TotalOperatingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TotalOperatingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981241828992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Obligation, Principal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">3,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(389)<span></span>
</td>
<td class="num">$ (91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligation</a></td>
<td class="nump">3,125<span></span>
</td>
<td class="nump">$ 3,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract', window );"><strong>Operating Lease Obligation, Imputed Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne', window );">2023</a></td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo', window );">2024</a></td>
<td class="nump">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree', window );">2025</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour', window );">2026</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive', window );">2027</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal', window );">Imputed Interest, Total</a></td>
<td class="nump">936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract', window );"><strong>Operating Lease Obligation, Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne', window );">2023</a></td>
<td class="nump">631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo', window );">2024</a></td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree', window );">2025</a></td>
<td class="nump">669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour', window );">2026</a></td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive', window );">2027</a></td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest', window );">Principal and imputed interest, Total</a></td>
<td class="nump">$ 4,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Principal And Imputed Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981231484544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>May 09, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 23, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 19, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Weighted average risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of the Warrant assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of the Warrant assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of the Warrant assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of the Warrant assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember', window );">Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,475,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember', window );">Series A warrants | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember', window );">Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember', window );">Series B warrants | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember', window );">Representative Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember', window );">iBio CMO Preferred Tracking Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember', window );">Series 2022 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,553<span></span>
</td>
<td class="nump">8,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibio_OmnibusIncentivePlanMember', window );">Omnibus Incentive (the 2020) Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock', window );">Number of LLC interest units exchanged for each share of preferred tracking stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Eastern Affiliate [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibio_IbioCdmoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibio_IbioCdmoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_EasternAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_EasternAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245496096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 25, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SubscriptionReceivableCurrent', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of preferred stock</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">102,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember', window );">Sales Agreement | Cantor Fitzgerald [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AggregateCommonStockPurchased', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,782,871<span></span>
</td>
<td class="nump">175,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SubscriptionReceivableCurrent', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AggregateCommonStockPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AggregateCommonStockPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981233893168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,553<span></span>
</td>
<td class="nump">8,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember', window );">Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,475,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember', window );">Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,058,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">201,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering', window );">Percentage of underwriting discount</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfDaysOptionToPurchaseAdditionalShares', window );">Number of days granted to purchase additional shares</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfAdditionalSharesIssued', window );">Additional shares issued</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonWarrantsToPurchaseAdditionalShares', window );">Warrants to purchase additional shares</a></td>
<td class="nump">1,009,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfAggregateNumberOfSharesOfCommonStock', window );">Percentage of number of shares</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds | $</a></td>
<td class="nump">$ 2,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,530,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">1,834,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">3,365,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">3,365,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonWarrantsToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common warrants to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonWarrantsToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfDaysOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfDaysOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfAggregateNumberOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate number of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfAggregateNumberOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underwriting discount paid on gross proceeds of offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981232337632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Basic and diluted numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to iBio, Inc.</a></td>
<td class="num">$ (29,311)<span></span>
</td>
<td class="num">$ (29,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends - iBio CMO Preferred Tracking Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">(29,311)<span></span>
</td>
<td class="num">(29,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(35,699)<span></span>
</td>
<td class="num">(20,791)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnconsolidatedGainLossAttributableToStockholders', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">$ (65,010)<span></span>
</td>
<td class="num">$ (50,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic and diluted denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">8,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">8,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</a></td>
<td class="num">$ (2.39)<span></span>
</td>
<td class="num">$ (3.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</a></td>
<td class="num">(2.39)<span></span>
</td>
<td class="num">(3.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</a></td>
<td class="num">(2.92)<span></span>
</td>
<td class="num">(2.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</a></td>
<td class="num">(2.92)<span></span>
</td>
<td class="num">(2.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Per share amount basic</a></td>
<td class="num">(5.31)<span></span>
</td>
<td class="num">(5.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Per share amount diluted</a></td>
<td class="num">$ (5.31)<span></span>
</td>
<td class="num">$ (5.78)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnconsolidatedGainLossAttributableToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unconsolidated net gain (loss) attributable to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnconsolidatedGainLossAttributableToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981237202192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,411<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,871<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EarningsLossPerCommonShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EarningsLossPerCommonShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981239033344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Share Based Compensation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 2,863,000<span></span>
</td>
<td class="nump">$ 3,958,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">1,528,000<span></span>
</td>
<td class="nump">419,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">149,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 2,714,000<span></span>
</td>
<td class="nump">$ 3,776,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981237470032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 29, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 23, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 09, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,863<span></span>
</td>
<td class="nump">313,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="nump">$ 27.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Award vested in period, fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,828,000<span></span>
</td>
<td class="nump">$ 3,334,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share based payment award, stock options, intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost, not recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="nump">$ 23.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost, not recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember', window );">2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember', window );">2020 Omnibus Equity Incentive Plan [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share based payment award, Grant-date fair value | $</a></td>
<td class="nump">$ 468,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_IsettMember', window );">Isett [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_ConsultantsMember', window );">Consultants [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based payment plan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfConsultantsToWhomStockOptionGranted', window );">Number of consultants | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based award, Number of awards issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,954<span></span>
</td>
<td class="nump">4,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Market value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="nump">$ 31.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share based payment award, Grant-date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based award, Number of awards issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | Minimum [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | Maximum [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based payment plan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_BoardOfDirectorsOfficersAndEmployeesMember', window );">Board Of Directors and Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_ScenarioOneMember', window );">Scenario One [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_ScenarioTwoMember', window );">Scenario Two [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfConsultantsToWhomStockOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consultants to whom the stock options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfConsultantsToWhomStockOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_IsettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_IsettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_BoardOfDirectorsOfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_BoardOfDirectorsOfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981232346384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding at beginning of the period</a></td>
<td class="nump">621,806<span></span>
</td>
<td class="nump">341,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">307,863<span></span>
</td>
<td class="nump">313,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock Options, Forfeited/expired</a></td>
<td class="num">(637,191)<span></span>
</td>
<td class="num">(30,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding at end of the period</a></td>
<td class="nump">292,478<span></span>
</td>
<td class="nump">621,806<span></span>
</td>
<td class="nump">341,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock Options, Vested and expected to vest</a></td>
<td class="nump">292,431<span></span>
</td>
<td class="nump">620,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable</a></td>
<td class="nump">96,050<span></span>
</td>
<td class="nump">197,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Outstanding at beginning of the period</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="nump">$ 32.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="nump">7.06<span></span>
</td>
<td class="nump">27.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Forfeited/expired</a></td>
<td class="nump">23.96<span></span>
</td>
<td class="nump">35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Outstanding at end of the period</a></td>
<td class="nump">19.18<span></span>
</td>
<td class="nump">30.00<span></span>
</td>
<td class="nump">$ 32.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">19.18<span></span>
</td>
<td class="nump">30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercisable</a></td>
<td class="nump">$ 29.17<span></span>
</td>
<td class="nump">$ 29.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Term (in years), Outstanding</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Term (in years), Vested and expected to vest</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value ,Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981233736768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Options Outstanding and Exercisable) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding | shares</a></td>
<td class="nump">292,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Life In Years</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 28.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">96,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceOneMember', window );">$7.00 - $11.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price - Lower range</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price - Upper range</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding | shares</a></td>
<td class="nump">151,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Life In Years</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 7.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceTwoMember', window );">$17.35 - $26.03 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price - Lower range</a></td>
<td class="nump">$ 17.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price - Upper range</a></td>
<td class="nump">$ 26.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding | shares</a></td>
<td class="nump">29,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Life In Years</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">29,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceThreeMember', window );">$26.50 - $39.75 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price - Lower range</a></td>
<td class="nump">$ 26.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price - Upper range</a></td>
<td class="nump">$ 39.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding | shares</a></td>
<td class="nump">95,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Life In Years</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 33.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">47,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceFourMember', window );">$41.25 - $61.88 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price - Lower range</a></td>
<td class="nump">$ 41.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price - Upper range</a></td>
<td class="nump">$ 61.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding | shares</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Life In Years</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 48.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">12,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243985328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Fair Value of Options Granted) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">3.21%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">3.61%<span></span>
</td>
<td class="nump">2.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, Minimum</a></td>
<td class="nump">115.52%<span></span>
</td>
<td class="nump">119.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, Maximum</a></td>
<td class="nump">116.93%<span></span>
</td>
<td class="nump">120.34%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981236952528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation (RSUs) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 26, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 20, 2023</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Aug. 29, 2022</div></th>
<th class="th"><div>Aug. 23, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,954<span></span>
</td>
<td class="nump">4,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Market value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="nump">$ 31.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Mr. Isett, former CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Mr. Robert Lutz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Dr. Martin Brenner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued</a></td>
<td class="nump">75,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">95,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Interim Chief Executive Officer | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Chief Financial Officer [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_Mr.IsettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_Mr.IsettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_Mr.RobertLutzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_Mr.RobertLutzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_Dr.MartinBrennerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_Dr.MartinBrennerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_InterimChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_InterimChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981232427296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fraunhofer Settlement (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Feb. 09, 2022</div></th>
<th class="th"><div>May 04, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfLegalFeesExpectedToBeReceived', window );">Percentage of legal fees expected to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Estimated net cash recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Settlement income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Legal Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment One [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment Two [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments receivables related to litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaymentsReceivablesRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfLegalFeesExpectedToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of legal fees expected to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfLegalFeesExpectedToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedLegalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedLegalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981344582672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components of Income Tax Expense (Benefit)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current - Federal and state</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred - Federal</a></td>
<td class="num">(12,153)<span></span>
</td>
<td class="num">(9,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred - State</a></td>
<td class="num">(637)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CurrentAndDeferredFederalAndStateTaxes', window );">Total</a></td>
<td class="num">(12,790)<span></span>
</td>
<td class="num">(9,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncomeTaxExpenseBenefitValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">12,790<span></span>
</td>
<td class="nump">9,051<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CurrentAndDeferredFederalAndStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the current and deferred federal income tax expense or benefit and the deferred income tax expense or benefit pertaining to pretax Income or Loss from continuing operations; income tax expense or benefit may include interest and penalties on tax uncertainties based on the entity's accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CurrentAndDeferredFederalAndStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncomeTaxExpenseBenefitValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in the valuation allowance of the income tax expense (benefit) reported during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncomeTaxExpenseBenefitValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981233910864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 42,951<span></span>
</td>
<td class="nump">$ 35,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DeferredTaxAssetsResearchAndDevelopmentCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">2,775<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Investment in equity security</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities', window );">Operating and finance lease liabilities</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets', window );">Operating and finance lease ROU assets</a></td>
<td class="num">(1,184)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(49,555)<span></span>
</td>
<td class="num">(36,765)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets from operating and finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DeferredTaxAssetsResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DeferredTaxAssetsResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating and finance lease ROU assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238005120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2008</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Operating loss carryforwards, net</a></td>
<td class="nump">$ 202,100<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">138,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">63,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="nump">35,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 1,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981245156736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions', window );">Expiration and forfeiture of stock options</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo', window );">Change related to iBio CDMO</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="num">(18.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes from iBio CDMO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes from the expiration and forfeiture of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981243701424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - CRO Agreement [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Costs incurred</a></td>
<td class="nump">$ 1,209,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EstimatedAdditionalCostOnDevelopment', window );">Additional costs committed</a></td>
<td class="nump">$ 171,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EstimatedAdditionalCostOnDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated additional cost on development as at end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EstimatedAdditionalCostOnDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_CroAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_CroAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981238749024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(K) Plan (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees gross pay</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">$ 263,000<span></span>
</td>
<td class="nump">$ 169,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139981226145744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 09, 2020</div></th>
<th class="th">
<div>Sep. 15, 2023 </div>
<div>USD ($) </div>
<div>a </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 03, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,863<span></span>
</td>
<td class="nump">313,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="nump">$ 27.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,553<span></span>
</td>
<td class="nump">8,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share based payment award, Grant-date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share based payment award, Grant-date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Stock Options [Member] | Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="nump">$ 26.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Stock Options [Member] | Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">$ 33.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember', window );">Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares to be issued upon exercise of warrants</a></td>
<td class="nump">3,475,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember', window );">Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares to be issued upon exercise of warrants</a></td>
<td class="nump">2,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember', window );">Sales Agreement | Cantor Fitzgerald [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,782,871<span></span>
</td>
<td class="nump">175,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Stock Options [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Stock Options [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Stock Options [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Stock Options [Member] | Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based payment plan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A warrants | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares to be issued upon exercise of warrants</a></td>
<td class="nump">3,475,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series B warrants | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares to be issued upon exercise of warrants</a></td>
<td class="nump">2,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase and Sale Agreement with Majestic Realty Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_GroundLeasesAgreedToSellPruchasePrice', window );">Purchase price of land agreed to sell | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of ground lease | a</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarnestMoneyDeposits', window );">Earnest money deposit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Credit Agreement with Woodforest National Bank | If the Facility is not sold on or before December 1, 2023,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fee amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sales Agreement | Cantor Fitzgerald [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,419,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lincoln Park Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumAmountOfCommonStockAgreedToSell', window );">Maximum amount of common stock agreed to sell | $</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares', window );">Minimum Price per share of common stock to sell additional shares | $ / shares</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice', window );">Maximum number of common stock directed to sell through written notice</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock', window );">Maximum commitment in single regular sale of common stock | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">211,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AdditionalSharesAgreedToIssue', window );">Additional commitment shares</a></td>
<td class="nump">211,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican', window );">Maximum number of common stock to be sold as per applicable rules of the nyse american</a></td>
<td class="nump">4,474,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican', window );">Percentage of common stock to be sold on outstanding common stock as per applicable rules of the nyse american</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement', window );">Maximum beneficial ownership considered to sale shares under agreement</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lincoln Park Stock Purchase Agreement | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ClosingPricePerShareOfCommonStock', window );">Closing price per share of common stock | $ / shares</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lincoln Park Stock Purchase Agreement | If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ClosingPricePerShareOfCommonStock', window );">Closing price per share of common stock | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumNumberOfCommonStockToBeSold', window );">Maximum number of common stock to be sold</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lincoln Park Stock Purchase Agreement | If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ClosingPricePerShareOfCommonStock', window );">Closing price per share of common stock | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumNumberOfCommonStockToBeSold', window );">Maximum number of common stock to be sold</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AdditionalSharesAgreedToIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares agreed to issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AdditionalSharesAgreedToIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ClosingPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing price per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ClosingPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_GroundLeasesAgreedToSellPruchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase price of land agreed to sell.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_GroundLeasesAgreedToSellPruchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumAmountOfCommonStockAgreedToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common stock agreed to sell</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumAmountOfCommonStockAgreedToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum beneficial ownership considered to sale shares under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum commitment in single regular sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common stock directed to sell through written notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumNumberOfCommonStockToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common stock to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumNumberOfCommonStockToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common stock to be sold as per applicable rules of the NYSE American.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Price per share of common stock to sell additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock to be sold on outstanding common stock as per applicable rules of the NYSE American.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarnestMoneyDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A deposit made by a purchaser of real estate to evidence good faith. It is customary for a buyer to give the seller earnest money at the time a sales contract is signed. The earnest money generally is credited to the down payment at closing, which is applied at closing as a component of payment against the purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarnestMoneyDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_CreditAgreementWithWoodforestNationalBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_CreditAgreementWithWoodforestNationalBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementWithLincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementWithLincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>ibio-20230630x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ibio="http://www.ibioinc.com/20230630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ibio-20230630.xsd" xlink:type="simple"/>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_rZ1rHQ0ZHUSWW77arLucKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_M0zc34V5Q0m5WCVOKFey5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C3bH4V8Ib0S8XH9UELJ_gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_8k_8F3ieCk6zFGf27VtTEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_AZyAVySM7UKPZ8RTjixNPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OBOy6kxRiU-oe0ymEhUYpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_SFHPA8kiYE6ZzTtqaqm52A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember__ZIfD-ddyUWPf60tnoVcmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_gsFictXunUazEpdpJkg4ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3j_LUG_w402t7idvNDSjIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_16_2023_To_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_iUI1PTAMS0mokeLZNB2Fjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-16</startDate>
            <endDate>2023-09-15</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mX_BARMd50iV5vznznteBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_I49KgjiFbkiWuxK9AUMMTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_43N1IQqzkEqJ13LA3fBcnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-10-07</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mHPAoRsEt0Gat8eBQF4yqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_84atjSQ3lkqV3dHvpF-GGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qeC92PWuXk6kis_CsVZ_CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sN_Hnjg5ykm1YYIBPdZ-vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_GVb0po6fo0GQxDi2ozIWyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rCT3Y6oqDkaJvtijpVT8fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_TEPezL3XWkKqi_B0FPpBFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kAxEI4glK0KksnZbo4Dl-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_K3rvxXz_kEOX2nxI7ySCQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TzGVANYEDkKQtb1ZjhZ9Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QblOI1ljmUWLbXeZ7kzXTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_D0mHT9ezdE2X0uInsc1A0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3umrq38u0aybR_OiS3qMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_FzOe7EM0YEaXLo9qcItmHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_E7yiwtNsC0mz-2dHsOptEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_ygGJi-7VwkSgwUh8hFlAmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_ac-7x3LW9E6Qyh9TSY9ZPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_sM74qrP0cUKZ4Ya1U1gVYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_QgG8WNbPyUmBAvmup53SMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_DhwMK66Jc0W1ZHFYrQtkXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_JqlBsxB3WEy25nmRrsywXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibio:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_xtVTtCXFJ0G4QbVCIxGD0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_2Y54sBBMcUylpJ4aaoVljQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9AU5LSHRJ0uhtE7EOzns8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SHgrCz-qZEG92jvNuUFSAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_xCmsPvHt_0-4XRMWv2OvcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ZsC7M5TDO06bqBrcL1vesg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_6_30_2021_uOAx-6C-q0ysOGltI-sj8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rm5qrexyo0mItmFx_ydLbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9bo96afqQUqvQatv96XUtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PlanNameAxis_ibio_OmnibusIncentivePlanMember_joWgB2aWOEyl8YJ2QrOPgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UksXtGeVpEqIW93JXYx-jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_u3o7OY19vkGgjeV5Z4Mo1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nKpGtSGxbEyiWH4EXHdW8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HfFb1iTZDEK4b5gZPeFNew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_a-ruAN-Fp0aT8KVbiaSHbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_ibio_InterimChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HhEQxy6pnUCpQsZ0aKHI-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Mr.RobertLutzMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SVjgzLilBkyuvpaaJZlWoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Mr.RobertLutzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-11</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dpjHIDhP7ESwXkYz03k_Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Dr.MartinBrennerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-11</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2023_To_6_22_2023_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kqjXeqU8mEmZuO4mrfyDSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_XbzQngOnPkuMI19LjLTR6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_YvKXv6XQlUSg6GU05Ezz1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Mz-O4KcM5kmuLTNfOTFLBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_G3Cg20_u1k-sLeLr-GIKSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_26_2023_To_6_26_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_A3-mdp0Omkera-zLt8EKJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Dr.MartinBrennerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-26</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_4UJTvMaPYUmEsDKWssS5fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_igEZn9PhVEiylIxh6caSLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Dr.MartinBrennerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="Duration_11_10_2022_To_11_10_2022_srt_TitleOfIndividualAxis_ibio_Mr.IsettMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lgDtxmNOk0-1j1MhUErEmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Mr.IsettMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_N5IDTAkcGkqXFW4wZwmQCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9Cz54lZIsEqkhtb-zVdBsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_XZG8-Y3yAUK2kmzzd5QisA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_VGPTPTFClUWUEjRTn7IMzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_sbtMBgPfE0GQWHaJX1zw5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CSnFR5tK_UmMcPFIliPY2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ibio_IsettMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_e88Xq6AsD0WbXCbo4ZpVbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:IsettMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_BoardOfDirectorsOfficersAndEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_3f1m_cPO-0Ki-AKnAQsaNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:BoardOfDirectorsOfficersAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_9_2020_To_12_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_uJ16IRXhB067Ywy6LTJl-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-09</startDate>
            <endDate>2020-12-09</endDate>
        </period>
    </context>
    <context id="Duration_12_9_2020_To_12_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_TS5Xb__b0USUWuxhMopskw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-09</startDate>
            <endDate>2020-12-09</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Ng3EGcHwDUSSHJ0vzePC6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_PoQNhovghEC-LFK4CiyRQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_3_2023_To_9_26_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_UNfYWTucIEGpRkg5uUnc2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-03</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_E1rZVhR8okSSqW6gfMvzJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_KNMSVlZ63keio6WMZ-FPmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_m5xJ-VdP5EGewGg_SkDIbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j-fx3hLA50uNFaaqQkekIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_pojHavUPcEas5qPQYCAHRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_TZN5AIYJp0-6KjjZaFqg6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_56vZG9jEekWgY4y74laSeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_F9D1CtdJIUGZ_NarVuJabA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_9NVLwycAS06AXqdN0JVz6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_w4qDIzxgXUiJo3l8Fvo9Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_lYOxtlA7SECAFRsqcF-SfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_WTIXjTIUo0WsYIlTKeDT7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_yedw2vciQ0GGT6sdYzn5Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_-LP9qePrKEKSRn6V__dvKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_3cd_ntn9tk-FS9Dj6nY5OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_eQjpKMv4a0WIG8KhXwtaAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_6o-7lqfD3E6XYI9oPMTzMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_0UI15QK8_EKkODArRfq0rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_n8A-vIkPIk-D3alQ6Tlk4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_rnZo30pQDUukbPb7XP4wQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Eqhm6X_g3kW4sI5yXUWYdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sF1HRLA4G0Wy2T1ygJ69aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_-HXRfzZt7EeeqOAod_TF_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_AI8GxgTdWkG2tUl-e2so6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <context id="Duration_2_10_2023_To_2_10_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_GuaranteedAuctionProceedsMember_atQz6mAuyUK6kUqxRjzLBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:GuaranteedAuctionProceedsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-10</startDate>
            <endDate>2023-02-10</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5qaPdrZ830G5d8zR_8zrkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_t8lePepQ2kKL5ThSHCVZjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_l9rVfdViGkK2f-fdYObPPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2023_To_3_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_GhYBtnMX2kWlAFeWO0dmuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2023_To_2_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_KnJIktsPp0-EQ6aH9Z2wWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_QFHntIxLBEO846_F3J6DgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_HvdB1ZWYLEujtiGbTKuLOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_1C24-uZb10SvLErWVqmo3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_-uulEswf2EOU3Yjcrnq5ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_8uq-EWtWF0WoADmNPR7Tfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_xoNlaRhK6ku3VdMk_jLIIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-23</startDate>
            <endDate>2017-02-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_olBr2CcxoUyuzZH0lS6s3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_9whzlfUgsUeBm5EBeEsgEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_rv5XUgdp7EGs6FYMQwZaCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:PppLoanCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_0YcPqwpOjkuyZyE_8SFtfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_j1xUG58p10iMMcwJJ-ZzWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_pjd-weRrSUC1EbGtOeMjCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2017_srt_CounterpartyNameAxis_ibio_EasternAffiliateMember_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_UjXKotGel0yQY9BFBXctgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:EasternAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_XdqoL_rkxkCM1xpi2PlAeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:PppLoanCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-16</instant>
        </period>
    </context>
    <context id="As_Of_9_26_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_dm18S2OvJ0Sy2-xaPQ94EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_2umbQoBSEk60AzYnxpGopg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_OXGEMBaf90uzpnugexjTyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_1SxKBjeXXku5LCaQyLli3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_SecondEasternAffiliateMember_DgnY7nozKk6LLsBoViwjXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:SecondEasternAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_14_2022_To_8_14_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_TbCIxSxD_ka6X8lcCqL-Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-14</startDate>
            <endDate>2022-08-14</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_MeaCIqKJOEawOzUh7Pp-PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_tLpytXewLUGWxGC9zN2FKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_YzbY9GLiGE2-ktZqZfwryg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_z9FbEXk9g0ql9OZ20V-ejg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DA4mNb1HCESUnEtjTHgS3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_OUSYNzx-3kmj7vrVQcR-fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_6Fl1dC8ctUaESD30gx10sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bdlOYYhGck24BhiEx8F8Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_G00b6C-z9kKKm4HpP4CcHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2008_80RUzZ4LGECu9HWLvLycUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2008-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lw4nMpzng0qzbfkprZhULg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember__jVFiqLstUOWmy568nqUUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_2RUbpio7FEeipqf0K7mQCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:DateOfAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_nz1JdBks80Cs0AMppzhnXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_CU79tDBZJ0-os-9D7HXbbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_CreditAgreementWithWoodforestNationalBankMember_2dAEJVyuAUOVNF-AXyg-lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsNotSoldOnOrBeforeDecember12023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CreditAgreementWithWoodforestNationalBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_ip8TzvFk80eYolQL5zegdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_X5uA0-qoeEeIkEVG5KZZjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Wllg_X7FK0iPGlaGUB08bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_gu1NRcCf3UK-cY9abE950Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_kGxSOxgACUGRePau63QWAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_r68Y0EmbuEeMR0WnlD99_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RSn4_RfPj0SPtSJMEmhzUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8w4IUbsDIki_jJ-9mVfRmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8Im5yjRmNUarH6CaeVLVOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ldHkHQ1HnEC1Bn3XAgpiXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_7hZGnl4YaECwuy-_woxKIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_br7oNpaVRECbzfYrlkkvkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_O9UHa1q5u0uVaR1ViiQn-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_TBHg74MkiUewy0H-HarEhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_iwp_hRW6o0erhC__pkGDFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_IJ_L-uKjmUGPDD1rWyktvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_Zw6WafGCsUCnHKMzdWedpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_oMAsA2QZvk2xKNG3oHvjzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_m9_bmICRfkK3AwOGcAYudw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_i1SOU2raCEu41QFjJywLPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_6d6Raa3cZUiRPuWmRc-WaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_uUlIkQW2oEq35oK92beemA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_ibio_RubrycTheraputicsInc.Member_a0DlE4N_I0GxjgfDV7eBFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_UDQEaykRk0-p2VWL-WDKDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_JyKBqBRPyU6zhBnwdkIH9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionFixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_qGJJOjg520eitr0OnzDv_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_03q0Za05A0K0e2L2ZORfzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionPrepaidExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_aQUPv9G7qESYPE20QdAeDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_s69drdBtfkiXxiX5xIaWhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="As_Of_11_3_2022_x45ryYnU3UWbXnPzJBxuug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_2Unp8yCqvUWviC4g1sxLBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cUS-0Y50wkGSIGh6RCynOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_vveLDkXdfkmYnuPBTD5qQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Ak8TEYVQm0SAkhapZ3V0_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_17hKRS8vdUK0th6qBY6JZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_OAl5YM-9vUiYev8izSQcBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember__JoTwj7JekqGkccr8jaLLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-cLI1L4-PUeoHAyAedVjig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_L1pakgn-HEqXSQrFTkRD1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_lUPOZKyWjkGiiwoG4yyWyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7JFoPwEFAEm9j_JAvuBOqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_F6t0DfzkFkyMeMWVv6D4Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_18_2023_To_9_18_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_WyyCJT9CnEeJevuU_YtSMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j4x0PspL1UuXk5bJ7v3ZFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_GMLt8Z0kCUWGHfk9AJSpeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-23</instant>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_0ZWSZA9Kr0KCCrEbl4ckpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_X8mbSSFy70ubOrSPbND4oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_aSOPBLDfl0qZrWSm0hH1mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_TkpAIuZ6B0q3R1zaoy1iDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HptY7B29EUeK8ToPssBmJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9KRNjiJqDUK-i_ivBqGgvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QsKwNCPfTEOZYuRBlUxk8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_20_2023_To_2_20_2023_KDi-T4qNR0iJnz_Le3NQ_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2023-02-20</startDate>
            <endDate>2023-02-20</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_utNLNmYSRU-7gHrqgVWwQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="Duration_2_20_2023_To_2_20_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_kHwI2oYS2kqmmWDijalKcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-20</startDate>
            <endDate>2023-02-20</endDate>
        </period>
    </context>
    <context id="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_49sQrs8MA0CP9gEl5c6S8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_ExcessAuctionProceedsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_2ZiYX-syC0ai3JUx-2X5gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ExcessAuctionProceedsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ibio:AuctionSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_ibio_FourCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y8MwivQ9ekC2NZNY1aglKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ibio:FourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_ibio_EightCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_6zllRl-74kWHjjUok5X3fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ibio:EightCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_sAVoKqkVwEuYlSh556L0JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-23</startDate>
            <endDate>2017-02-23</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_tOoXZBADJEadNjNS6JvQtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XheyQ-Fl9UOlWW6gNyl5VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-19</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_1_2021_94fR0DLTmEC12g7MPaQqxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_U6Pc1fTlZUCT-CsKaG5_qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_oxMyEE3vMkKthpi_lTkUeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Lh5bPHn7wEyfg1z7EBU_sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_ushJsRuZQEyiUOY_3efaUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:PurchaseAndSaleAgreementWithMajesticRealtyCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-15</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cDhv992H80uLjlrOUmMXpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_Nj1rBi5mf0-4KTZgTQfTXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_yQtckMjz-Eqm8XRVYD1YnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibio:IbioCmoPreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_10_12_2022_To_10_12_2022_L-VOkowDDUifCXu94CAHuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="As_Of_10_12_2022_JPfG9ZEqqUa0LmbfHdCHIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-10-12</instant>
        </period>
    </context>
    <context id="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_nbd9NMQisEiyfXHpBgaVUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_7qBiEha-vECXgWze-i-g6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_LDEVyL3h-0GVW39rjQJBaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_dZg1WhqNY0uE1A0c9lHl3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_i3ZFj12p9UazqqscbySntw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldOnOrBeforeJune302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_vDIIL2z8l0Kc9hg2BTNjnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_nNBE8O_Yc0GrXHryQ3ARjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ni7O9yqrp0G3jZAhtH1cdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsNotSellOnOrBeforeDecember12023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_0UIjDWk4GkapKTIJmMsJJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldOnOrBeforeJune302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_9TjCBbgA7UyTlQwWmTS87Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_GcE4nP69ekilykVs1dNbZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_EbZx7U23KkqqedJKnH3P9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_GmkcutYho0qIygUE-r1Kyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_bMRwgJhi-EeZTQrY-DJ9ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_N0d1OE5sOk6a6vFBAShgiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:OccurrenceOfSpecificMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-11</instant>
        </period>
    </context>
    <context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_4NB7YEQHAUqVr8MzcB_kuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-11</instant>
        </period>
    </context>
    <context id="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_NCgEbLSz3ky2W-1HFoSejQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_CQLMvmW4IEONf8twopcH1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:PrincipalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_0pwc1NvoEE2aEZVFYLQxng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:NoBiosimilarProductHasBeenApprovedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_YH7c7zxS4Um37Nlh67R2QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_65MqqZL2kUWg5zU9Y4i3kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_Dw9k-bulX0-p0mYFE2o_Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_odmv-ki5qUWWcb8GBFn57Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Fy-Gf6u-0EitjXayqqPTHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DwOwJATaWkOBScq2_qtADg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_xiBf2oc6W0C50iTxTcBcmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember__8CY_8OqkkmBwgmzP9GZVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_gQzJcEQS6U-ffQ0wp3xFOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedLegalFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_-VsXEX2vkE-Ouo9lo2p2sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_m-QTr2a_uU6kouKEDBmRAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="As_Of_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_90XItF3zBE20jmvLFm1lDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ibio:AuctionSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_dj-dsQcEtkq53NmB8lZZ7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-16</startDate>
            <endDate>2022-09-16</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KaGEDjN0e0GNLqwZeqxNuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfOutstandingPrincipalAmountReducedTo10000000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_JHTUWvDAy0mSeOtQy7guzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AMSxbpHjr0eHHzhd2SU4ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_PideCfI-jEiSzj_q8lGFBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-25</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lIakFT-JPkmRV8rez2kjQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_UWTbx3EXRkCgwv1m35o82A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_Dv8esl-yyEqZRtO2EUMxYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_26_2023_3j1VawjkGU6vNhxNJ-WHFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_acre_scgUJO-cMUuybvEVKZVJgQ">
        <measure>utr:acre</measure>
    </unit>
    <unit id="Unit_Standard_position_oflWAv0coEqkT6ZpEJ9RSQ">
        <measure>ibio:position</measure>
    </unit>
    <unit id="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_item_hCBMRpViQ0aEEJdOwEy49g">
        <measure>ibio:item</measure>
    </unit>
    <unit id="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ">
        <measure>ibio:lease</measure>
    </unit>
    <unit id="Unit_Standard_customer_bk92zj7mYE-AcFFVra0SUg">
        <measure>ibio:customer</measure>
    </unit>
    <unit id="Unit_Standard_D_DabM02qyekqEwyzN94-Wtg">
        <measure>ibio:D</measure>
    </unit>
    <unit id="Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw">
        <measure>utr:sqft</measure>
    </unit>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Hidden_9TX3NNNRy0W_FzlFVjryTg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">12245000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Hidden_LvpfSz29Z0-veCoAJrAqsQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8721000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_qJvxE-6pbUyNvTldIukVBQ_2_1">0001420720</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_2glO0_FEdkWLG5WBZlQMYA_3_1">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_L4fGRKc_UEWjh3u5KVPTwA_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_k0WmJqdSH028QAoInQdBTw_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Hidden_FffZNwmc2E6Z5H9UGIqZPg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">12245000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Hidden_fxymUTMtv0yzaYqtx0x1Eg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8721000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityFilerCategory
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Hidden_W7kAKHbkB0qlIFztIdEZZg">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Hidden_z5fi3FYiC0Sje7OERl8DoA">true</dei:EntitySmallBusiness>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      id="Hidden_uFvV_eO1B0iDE-lKD_tAZQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      id="Hidden_xc77VMaqY0C4oB8D5qP6Yg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Hidden_PSGT3Zxau0menl4RCH0N3Q"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.39</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Hidden_-eod8074fkioAk0b2mm6UA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-3.39</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Hidden_LuCOlpKQOUuSt-yj6PnmyA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.92</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Hidden_o1v8rmdOQ068c6OAx2PQXg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.39</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Hidden_8u14s749302L6GMFbCXKCQ"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-5.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Hidden_do79_3DIF0SwBQdVF3GLSA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-5.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA"
      decimals="2"
      id="Hidden_C1BZAkhphkSP6NLYZ6XiZg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA"
      decimals="2"
      id="Hidden_6s-44Ts3DkK4VQjk-RCW4A"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_AI8GxgTdWkG2tUl-e2so6Q"
      decimals="-5"
      id="Hidden_0UtmYiIXKka_hRPj17MXuA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_WTIXjTIUo0WsYIlTKeDT7A"
      id="Hidden_uabS_NI-Z06ict9nQUkf0w">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_yedw2vciQ0GGT6sdYzn5Tg"
      id="Hidden_9YJQTd2bdk-gA4FmiAYIkg">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_0pwc1NvoEE2aEZVFYLQxng"
      id="Hidden_1lNt1UglOEOd6nh1BKY2Rg">P10Y</ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm>
    <ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA"
      id="Hidden_YMSx4gGHzEiJmUbTbVGKZg">P24M</ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary>
    <ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA"
      id="Hidden_SYAPHltUpUekE3X9uPDPUg">P24M</ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus>
    <ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA"
      id="Hidden_CQT6G5UgS0uV_qC3r8ildA">P18M</ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod>
    <ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA"
      id="Hidden_0Ap6AYAnBkSKK9C3lFNv3w">P18M</ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Hidden_vEQqufD90USP1VGzaUl2Uw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <ibio:PeriodForPaymentFromIssuanceOfAtMarketFacility
      contextRef="Duration_2_20_2023_To_2_20_2023_KDi-T4qNR0iJnz_Le3NQ_g"
      id="Hidden_sMGyGM4rm0etbg7foCVLZw">P5D</ibio:PeriodForPaymentFromIssuanceOfAtMarketFacility>
    <ibio:DebtInstrumentPaidInKindInterestRate
      contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_vDIIL2z8l0Kc9hg2BTNjnQ"
      decimals="4"
      id="Hidden_HmO8mI3b8UikyAnwMIet_Q"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0300</ibio:DebtInstrumentPaidInKindInterestRate>
    <ibio:ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate
      contextRef="Duration_9_18_2023_To_9_18_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_WyyCJT9CnEeJevuU_YtSMQ"
      id="Hidden_v7l5jYByc026hKF0AEadYQ">P1D</ibio:ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate>
    <ibio:BaseRentAbatementInFirstYearPeriod
      contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_-VsXEX2vkE-Ouo9lo2p2sg"
      id="Hidden_3yjQiksPYkaMOne7lIAO3w">P2M</ibio:BaseRentAbatementInFirstYearPeriod>
    <ibio:BaseRentAbatementInFirstYearPeriod
      contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_m-QTr2a_uU6kouKEDBmRAg"
      id="Hidden_coC25BjKxUC8oCpGfnMVKg">P5M</ibio:BaseRentAbatementInFirstYearPeriod>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA"
      decimals="2"
      id="Hidden_NSsLunwOnk-e7VxuFTCjbw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA"
      decimals="2"
      id="Hidden_SIzvssG14kSIBSMx9LhFKg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_ODMv7ebgLUCuKM3VOvVeMA"
      decimals="2"
      id="Hidden_E34AVy54BU-rs9CUNflyRg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <ibio:NumberOfDaysOptionToPurchaseAdditionalShares
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_tOoXZBADJEadNjNS6JvQtQ"
      decimals="0"
      id="Hidden_sSHbFN61YUW0p-uuiWxmGw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">30</ibio:NumberOfDaysOptionToPurchaseAdditionalShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_IJ_L-uKjmUGPDD1rWyktvg"
      decimals="2"
      id="Hidden_CLcT6POV_06On0uZXB8YcQ"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_TBHg74MkiUewy0H-HarEhw"
      decimals="2"
      id="Hidden_uJKhf1drZEWLizl1NaG14A"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Hidden_VSCcaFQWPEqZ6HuNP22L4g"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.39</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Hidden_szGXjMD-xEyf9K1Eh278Xw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-3.39</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Hidden_KWCju4zEm0OFrF28ztSNUw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.92</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Hidden_g9LgYZJp_E2abMmTXdVUKg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.39</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Hidden_NyTbTzFAwU-jeS3gdyqc7A"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-5.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Hidden_GSNMn7paDkWrRL314FWinw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-5.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_12_9_2020_To_12_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_uJ16IRXhB067Ywy6LTJl-A"
      id="Hidden_LToFWvo-BkiblBBqRkPxFg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA"
      id="Hidden_0OdVFTQWiE-Lr_bsSKBPmA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ"
      id="Hidden_mpImJhbCfEK69FYXeZdXCQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw"
      id="Hidden_z9rBFPXNl0qc-K8BGo9Big">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_PoQNhovghEC-LFK4CiyRQQ"
      decimals="0"
      id="Hidden_jYLIaZRQbkaIs4FnEH9rdg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5100000</us-gaap:SettlementAssetsCurrent>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DwOwJATaWkOBScq2_qtADg"
      decimals="0"
      id="Hidden_kXKwXnCsRkauOXx5_TATcQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_UksXtGeVpEqIW93JXYx-jA"
      id="Hidden_jBumV3Rkt02i3MRw82WE7Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:AmendmentFlag
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_bpulpr2GX0edOpmjesUgFg">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_pW0EZhbHFkqvJOLQrUdUCA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_rc47N1-AYEmyIO_PVcTsuA_1_1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_kcAg6BFwmkm80vbYc92u-g">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_DWKCj03ISkii02eAoDG7Bg_1_1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_r_rEuqJ_4E2S-YFqsM5oqw">001-35023</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_92V9bpFdwUWJPhjCtBmLXA">iBio,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_qt4TZS3q8EStkl0BzJ6IuA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_ybYlvHh2RkCJPpkWZEARzA_1_1">26-2797813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_CZy8GWqa10KmTE3VzUTC0Q">8800 HSC Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_oAAwg509lkec6UOdU8B7WQ">Bryan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_3JkCyJ0yS0uqt1zv2E1U3A">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_cV_Ol7zKtEGfMr1VaHXGBQ_4_1">77807-1107</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_fQE2xkEYrki2w5gBucwp7g">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_kk7upLdpcEe4WFXn5ObKvg">355-0650</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_nacG919HZEOBctgWDgNSoQ_2_0">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_9fTlfcsHPUKxllLJMnme9A_2_2">IBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_JbtEXcJlS0KbXjeyKMydLg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_XkQ2OFCdW028NxqBDHVRiQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_PMfN4ef8R0qRica_5jUOHg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_yfS1EzCa5UqsykuwnN1X_A">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_FoAaIFaXLEeYVoQBjM4Xqg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_lEHQF680B0GxhIV7CQu1bQ_3_1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_AG2FJFWPoEeR2Gq_dq27hw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_12_31_2022_Dv8esl-yyEqZRtO2EUMxYg"
      decimals="0"
      id="Narr_6YnJz-wE9kaaiymYMXmGXQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5435812</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_9_26_2023_3j1VawjkGU6vNhxNJ-WHFQ"
      decimals="INF"
      id="Narr_aWJf8B4Qjkazrwlayk9GAg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">27586499</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_eePoY7LmDkyLwP19J6qcWw">596</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_sSeky8nxPEWmCESbcsnqhA">CohnReznick LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_cP_wYxJbQEqciPdu6tGZzQ">Holmdel, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_HW2Zh_CdcUmINkqJKOmJRg_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4301000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_sJX8uAX3JEixJ61u-Ri9Qw_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22676000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_srA1-T9CrE-vBRCnG6k-eg_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3025000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_Ygqv6edVi0SlYWBp8IY87Q_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10845000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_T5Ged7M890ODX5dT_DMc4w_9_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1000000</us-gaap:AccountsReceivableNetCurrent>
    <ibio:SubscriptionReceivableCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_6gbIy2_ny0-DGBKWzLyz-A_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">204000</ibio:SubscriptionReceivableCurrent>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_V9VAhJ7FVkKvQOYIo_C-7Q_11_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5100000</us-gaap:SettlementAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_g6qmK0TpmUidZSKO-MpZkQ_12_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">664000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_YlPHmmIUJky75NOJ4JEewA_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1549000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_lD7vbYcQCUqZEeasH56FSg_13_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">18065000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_FlJxWmtvkU6AWrFKxN4kpg_13_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3900000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_6uvMeshRB0WT6ZEPiI_9pQ_14_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">26259000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_z509ppTA70Kr1dD9soC1qQ_14_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">45070000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_5tLyWGbcaki8ghwGcq7ccg_16_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">253000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_gBfvjw3EOUOLcl3EAv582w_16_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5996000</us-gaap:RestrictedCashNoncurrent>
    <ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_-_69FtYLwkaDXUIBohy9yQ_17_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1706000</ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest>
    <ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_EJLc5zI_JEyqR4qyWJ7OsA_17_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1631000</ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_-Az0_iQZl0uTLmFnkqBb8A_18_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">610000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_BVckeON6jEyn0id7-upU-w_19_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2722000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_mUPRRtcZc0GVgvQYWyMnCA_19_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3068000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_HLS0mrBVBkeraNawF4tJ7A_20_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4219000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_AC8PkjhVm0e5pXQ8wtBukg_20_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1373000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_q_2X03U4MUCnbzJNp5Aadg_21_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5388000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_UfvrpHA94kyeaNKIKxjo3w_21_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4851000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_XK8KoXofQkyLxny1PKVnpA_22_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">50000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_ZTiNPhTTEEORMBMg1omVhA_22_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">29000</us-gaap:SecurityDeposit>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_BT-OzuWgZkqED8kV3QW1wA_23_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">74000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc__XdKiv0rw02gsD4-iDdO2A_24_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">37314000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_OL_2GZsdd0iD2skNIFnOIg_25_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">41207000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_6RlWUz45zkKcYkZj5rY-0Q_25_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">99406000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_TOnn5eE4SEmYuIMK3gtqqQ_29_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1849000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_w7qPYUf9aEWQGtobYCeQGw_29_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4264000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_c4qZCLvCgESd83r22tTdOQ_30_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_X2e-3qhm7EildyOdLFLCRA_30_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3764000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_uI8pMK9O6keSM3faoSLlBQ_31_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">272000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_oZNXhTPRmkyrHGghya41ug_32_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">389000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_YpM1i3sMoUGX23Whi5FaqQ_32_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">91000</us-gaap:OperatingLeaseLiabilityCurrent>
    <ibio:EquipmentFinancingPayableCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_tp5rbaqqVkaL-ZMAGoDKSQ_33_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">160000</ibio:EquipmentFinancingPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_2h8204qxoky1ELYw43OLng_34_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">12937000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_8KDS6eTsF0-WyySn-931JA_34_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22161000</us-gaap:NotesPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_e0TymSofhUyU3KE-K5xgMQ_35_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">100000</us-gaap:DeferredRevenueCurrent>
    <ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_yR2oTW2Q3UaOUjMhScF9Yg_36_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1941000</ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale>
    <ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_Ta9SJK7oYE2zE6b2C2ApXg_36_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">56000</ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_5m80TbrjAUOa2OUBAbOysA_37_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">21582000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_P0M07FSGKkqGiC_ZR0RbRw_37_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">30436000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_sS29Zc1eXEKaojZG1b7d1Q_39_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">351000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_wm-SKk8IYk6fXiY4vww7KA_40_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3125000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_laRiXyTtfUCyK6A477Mtkg_40_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3514000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <ibio:EquipmentFinancingPayableNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_u_I2cS1K5kKNv5ZtLSszlQ_41_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">241000</ibio:EquipmentFinancingPayableNoncurrent>
    <ibio:AccruedLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_-qj73e8Xj0-65s2pVn5a1g_42_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">527000</ibio:AccruedLiabilitiesNoncurrent>
    <ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_fueHJfE3ZUip91ZMnT6YTw_43_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1971000</ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_892naxQSc0yrp8HLeWD1Vw_45_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">25826000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_PhUDp_uYYU68N6WLgTDb3A_45_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">35921000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Narr_iYCCUz6sRESmGczh4J0oJw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr_yQ5XqH9_GEKr283m3eZNVg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Narr_UF4dBSyzYkSZ9DV0LCTQbQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr_Y_OhJf7rNUugpGOHrR99OA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr_LveuaG8c6Um0fu5ZnuTwLA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr_evGtdH66L0el-K33ESGCfQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Narr_esGAZvKj3kqLxFaN0KP3NQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Narr_7Hft50asqU6mr6wCM4gubQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Narr_tQ5hEIJhZE6D4CpVG8Fhjg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr_w6JFMAg4Skq00zQI5ttXhQ"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Narr_FwwdYLrkUkOJOBpMnk1xZg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr_MhCFtV4NeU2CDdvkwh5MIA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr_wV3lXrwc30SHLN3HF_UeUA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">20310077</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr__mR1_MNgo0OiB70vQoikQg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">20310077</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Narr_b_nAG08jLUaefKKLFSKJVQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8727158</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Narr_ZH6lE-kOT0WaMCXRUEEsQQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8727158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_JX5RR4fUok6x0ZWUZqa65A_49_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_bfqwe_fLjka8le-tWyEgrw_49_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_7U_X3BDZjEmpMMap69Ohcw_50_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">304301000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_yWh42IoTpUW4A8c0hxajFA_50_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">287619000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_5tOAW5PS1EWgHEfmscviEg_51_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-213000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_SdN2mH7T3kuqTY8juCisJw_52_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-288940000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_i9-fam8yHEe4jBEmrX5UxA_52_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-223930000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_NIOM7FvMN0u3RVxTNy9OPw_53_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">15381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_hIdxJRB780yXmwUA3zQ89A_53_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">63485000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_YNZoDq9xa06yLfrISCsVxA_54_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">41207000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_ep5Dcn7vZEu8X7sYa4EvGw_54_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">99406000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-8tnqA4_sEqkKGZD7W_uBA_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1884000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_sQgrv1udg0qc473TEU2HKg_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10327000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_ZNNSBUsT7UivVpO1dy0c9w_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">9827000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Pj2FIcCP2UWchyCgxKOBwQ_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">19016000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_JBb-z07ySUe5_FxmHblvkA_9_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">21754000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_SQFN_lJGk0GsxPfVdzIN8A_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">29343000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_RXwQSx3aI0Ol36EuSb04mg_10_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">31581000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_I5pWbEpI1UyzFOJ-fpxX6w_12_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29343000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_L_7CuUndckuSe-9yBv8QKg_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29697000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_W45Rhy12JEGQRc_mQ3mppw_15_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">83000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_wWPU-crKiEqy2_Oze8WHug_16_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">213000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_AQisFl6X0EKRcn-hHMrjLw_16_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">177000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_keIdyHRQnU2EDNqCZCY-cA_17_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-98000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_HZll7FXWZUWS8KxZ0HFPSQ_18_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_mAG25rPEtEO6D25pIIOcRg_19_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">32000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_SPgr5hZg0067GidogaDR6g_19_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">184000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_3fjV_NkHGE-8CHLuakwY-Q_21_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29311000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_pHBLBO-1CEqz4ENIhgjtkg_21_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29513000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_c3oDDd5l1EW3TxG7CKE-Rw_22_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-1000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_ZEUoBa8mb0K5deJD62AgnQ_23_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29311000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-lk1CYUkC0eHBOXyIdVtEw_23_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29512000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_Z3kOHG_JyEO__65LpZSVGQ_25_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">88000</us-gaap:DividendsPreferredStockStock>
    <ibio:NetLossAvailableToStockholdersFromContinuingOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_nmfl2wvydEKhwKsV1DDDUg_26_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29311000</ibio:NetLossAvailableToStockholdersFromContinuingOperations>
    <ibio:NetLossAvailableToStockholdersFromContinuingOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-S47DGD7w0a3fjH0wBFuiw_26_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29600000</ibio:NetLossAvailableToStockholdersFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_CHICDavBtkK1ZSLVWtcsUw_28_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-35699000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_qf6TuYoDL0W_xmx7vR3y9w_28_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-20791000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_83bdq1glhUi9c5hSBvAF5w_30_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-65010000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_4EtRScCXr0KE1H6HM_RNxQ_30_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-50391000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_lIdP0S2rdUSzw4owNJ5Hig_33_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-65010000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_HHOsyP_i-UmpLFLf1DcdBg_33_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-50304000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_gGYP91Oyp02z7Apn2TjUZw_34_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">180000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_ih3sYLJBxk2dyt5Dsq9BUA_34_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-150000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_gM6QsDl1ZE-n1vl5viT2mA_35_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_EbuakRM4rEWd7d22pIncPA_37_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-64797000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_Uuj8Tee2q0qHd5O2hjvQcQ_37_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-50454000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_x4amxarUG02YFrMnjeVv2A_39_3"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.39</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_4ry-cnPeiU6WgptUFoWV2w_39_6"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-3.39</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_7VmJDIdKQ0-s1HQ4kM7GAA_40_3"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.92</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_4wVWNWtHTkW8xP_YXzFSkQ_40_6"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.39</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_XqAq4vMxT0uFSr6_BhP64w_41_3"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-5.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc__1EelJXkOkii6MZBOwhjqQ_41_6"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-5.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_iP1gSwzv1EuxU-G3a5ZX2A_43_3"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">12245000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_32e8-Ncp8E2tatYBLql6ZQ_43_6"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8721000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3umrq38u0aybR_OiS3qMw"
      decimals="-3"
      id="Tc_URuqxq2tDUmd2OwxBRf-tg_6_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8715000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3umrq38u0aybR_OiS3qMw"
      decimals="-3"
      id="Tc_3iNAbjFTSkyibvpF_u95Vw_6_11"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kAxEI4glK0KksnZbo4Dl-w"
      decimals="-3"
      id="Tc_sYUw9evQJUuttBnm6Qyw0A_6_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">282266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_K3rvxXz_kEOX2nxI7ySCQQ"
      decimals="-3"
      id="Tc_D8ywOOY2O06LWQEg0YMj7g_6_17"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rCT3Y6oqDkaJvtijpVT8fA"
      decimals="-3"
      id="Tc_uPZJupSFPkWazlj48bXd3w_6_20"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-173627000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_TEPezL3XWkKqi_B0FPpBFQ"
      decimals="-3"
      id="Tc_Lsq47X-pCkSB9G2fji4kBg_6_23"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag"
      decimals="-3"
      id="Tc_3mhJIU4qPU-C62UjRmqJWQ_6_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">108568000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_I49KgjiFbkiWuxK9AUMMTA"
      decimals="-3"
      id="Tc_rmW3kXdeykKVG2E7Txaylw_8_3"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3j_LUG_w402t7idvNDSjIQ"
      decimals="-3"
      id="Tc_FDK0H6MP-kaSpwYhKKDM1Q_9_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">9000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg"
      decimals="-3"
      id="Tc_8LUBPPWrPkaUycvg2uitXg_10_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_JHNI8YMJU0W8sH7psis6eg_10_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg"
      decimals="-3"
      id="Tc_HNvkVPxJnUq3FCnjF_JrRw_11_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">68000</ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate>
    <ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lIakFT-JPkmRV8rez2kjQg"
      decimals="-3"
      id="Tc_DflYA79yK0SxvDavNNP8EA_11_23"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-18000</ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate>
    <ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_3nL9T0G5LU2OItogkHZ8Qg_11_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">50000</ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3j_LUG_w402t7idvNDSjIQ"
      decimals="-3"
      id="Tc_WBeU_LZmE0CgHMWO5qtthg_12_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg"
      decimals="-3"
      id="Tc_wmpDIuXVHkCF47tErMvF2A_12_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-pFg43vmIEKJTAXrJyY2kw_12_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Imm8u1tfQUCwaVxmWOE1Sg"
      decimals="-3"
      id="Tc_gobArSPwrkC8Z-c-AeEnhA_13_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4377000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_QXSZSznV90iqzTnuaj2Erw_13_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4377000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lw4nMpzng0qzbfkprZhULg"
      decimals="-3"
      id="Tc_96zNJsFLPECGrtb1mAsASA_14_17"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-150000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_lonk3hX_ikyvPyqIb1n3Ug_14_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-150000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sF1HRLA4G0Wy2T1ygJ69aA"
      decimals="-3"
      id="Tc_P6BrWMDb6EOUSNI-mIeRzA_15_20"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-50303000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lIakFT-JPkmRV8rez2kjQg"
      decimals="-3"
      id="Tc_mXzPEA4BT0yTozbLAV1p4Q_15_23"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-1000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_361iXLBTo0KyWic1JW_YPg_15_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-50304000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_QblOI1ljmUWLbXeZ7kzXTA"
      decimals="-3"
      id="Tc_eET4-0vMOUq5KGgptk-ekg_16_3"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_D0mHT9ezdE2X0uInsc1A0A"
      decimals="-3"
      id="Tc_M1zmXS1w4kSUnikzIHtQlA_16_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8727000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_D0mHT9ezdE2X0uInsc1A0A"
      decimals="-3"
      id="Tc_bYUgREt8jEu9b6QtePZo0Q_16_11"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sN_Hnjg5ykm1YYIBPdZ-vw"
      decimals="-3"
      id="Tc_kleoSPe-sE-qa68sjaSYSg_16_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">287619000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_GVb0po6fo0GQxDi2ozIWyw"
      decimals="-3"
      id="Tc_3B0WKD_yMkWbdv867W6r-A_16_17"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qeC92PWuXk6kis_CsVZ_CQ"
      decimals="-3"
      id="Tc_CGzqBdWkn0WpFnDWLwwcxQ_16_20"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-223930000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_EAraov8BxkyCPjzjIJNvEw_16_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">63485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ibio:StockIssuedDuringPeriodSharesCapitalRaise
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A"
      decimals="-3"
      id="Tc_I1OzDUlcEkOXPknNoIhSkg_18_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">11271000</ibio:StockIssuedDuringPeriodSharesCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A"
      decimals="-3"
      id="Tc_aK9dKZFpikarLMhKNjsRHw_18_11"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">11000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg"
      decimals="-3"
      id="Tc_2ulH7Al0x0ePm1YVGJLdTQ_18_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">12316000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_knPvVWmTSUikNYCev-epVw_18_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">12327000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg"
      decimals="-3"
      id="Tc_xvGFzAx8CUO2hXxNifXEGg_19_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">636000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_IpzHFXvgHUOzZo7tD_R5iQ_19_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">636000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <ibio:AssetAcquisitionInShares
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A"
      decimals="-3"
      id="Tc_zIkPSnJgJ0Kb6bR3fzp89Q_20_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">102000</ibio:AssetAcquisitionInShares>
    <ibio:AssetAcquisitionValue
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg"
      decimals="-3"
      id="Tc_2s6gygN070miGpaOB4IFcA_20_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">650000</ibio:AssetAcquisitionValue>
    <ibio:AssetAcquisitionValue
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_XMAqjWAMQU2wSx_KpKWDHw_20_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">650000</ibio:AssetAcquisitionValue>
    <ibio:FractionalShareIssuedAfterReverseStockSplitShares
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A"
      decimals="-3"
      id="Tc_ZVyJ7KdBPEmOFaf-nMxMfA_21_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">-8000</ibio:FractionalShareIssuedAfterReverseStockSplitShares>
    <ibio:FractionalShareIssuedAfterReverseStockSplitValue
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg"
      decimals="-3"
      id="Tc__H2Q5dDQnEuBwCPKSY48tw_21_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-39000</ibio:FractionalShareIssuedAfterReverseStockSplitValue>
    <ibio:FractionalShareIssuedAfterReverseStockSplitValue
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Pua2SPrdyEKBiBXldNl9GQ_21_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-39000</ibio:FractionalShareIssuedAfterReverseStockSplitValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dFg1xRz8IUuUt787sC_g8A"
      decimals="-3"
      id="Tc_LiVh_ZGE2EqRdGaGYO5U4A_22_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">218000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_43N1IQqzkEqJ13LA3fBcnQ"
      decimals="-3"
      id="Tc_e9dzIf-yy02dfzgBncVtHQ_23_3"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">-1000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sUXH0HJOdkuQXF3TmlcHSg"
      decimals="-3"
      id="Tc_P4j24UJ4Lkirv2irAWUe0A_24_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4391000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_17_tK_5FXk-PctEQB0pQ-A_24_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4391000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QsKwNCPfTEOZYuRBlUxk8g"
      decimals="-3"
      id="Tc_Tw3wn72QdEqKVHgAWUlUgw_25_17"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_TE6T74ul10y2ZfL3lz6VpQ_25_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QsKwNCPfTEOZYuRBlUxk8g"
      decimals="-3"
      id="Tc_cUxxLS-_nUuQIURedLw1OA_26_17"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">21000</ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities>
    <ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_wDxWavqmNUWTtJ1061m-Qg_26_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">21000</ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QsKwNCPfTEOZYuRBlUxk8g"
      decimals="-3"
      id="Tc_SwfWarEG7060mwrG0pN8Tg_27_17"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">159000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_hjt_5aa8Ake_YS88SCDt5g_27_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">159000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Eqhm6X_g3kW4sI5yXUWYdg"
      decimals="-3"
      id="Tc_oXUHrhGikUuFLjyNB7lY-A_28_20"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-65010000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_XMHC3h2Ngkyvirh62R3djw_28_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-65010000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TzGVANYEDkKQtb1ZjhZ9Kw"
      decimals="-3"
      id="Tc_KnKICKl1oUeLkddbVVqZkw_29_8"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">20310000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TzGVANYEDkKQtb1ZjhZ9Kw"
      decimals="-3"
      id="Tc_XdRo1N_PLE-kriTUKqVwsA_29_11"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_84atjSQ3lkqV3dHvpF-GGg"
      decimals="-3"
      id="Tc_KheEPVcxw0yrxPRf16-5HQ_29_14"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">304301000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mHPAoRsEt0Gat8eBQF4yqw"
      decimals="-3"
      id="Tc_jOlNeafLt0uepFgX4UrZQw_29_20"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-288940000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_-GWDCQ0-rkS-RDPIVVQgHg_29_26"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">15381000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_N2BpWPx5bkafNfEMJE-8xA_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-65010000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_POj6qCyKRkijQpGIBOs4EQ_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-50304000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Hosp_ec_cUGAgicTGc7wow_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4391000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_lSzvWp3Hd0aOJPGmW3u_9g_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4377000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_IBX6xFMcTUau_7CsMkgUBA_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">126000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_FsPD37-6N0-AcXgr__H7IQ_9_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">401000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_GxCoJ0riaESeCgctDc2DTA_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">224000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_tDcZ6mae00O4XBMEsOyrQg_10_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">599000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_rackOmLG60WgG1ATwmdsAw_11_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">356000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_3qwvQ9Fl8k6uTElYJT2c0A_11_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">516000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_neaecdELN0iDLASGZ0huvA_12_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">674000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-YDSJt2JLkWMuCmj2FWw1g_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2275000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_AJRNiun_0EWhXTiWBhXQUA_13_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">773000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_kCPEjlVYgU214FQyT_G0EQ_14_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">75000</ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable>
    <ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_UVD_IHiQL0-7jb6Ghg1Ovg_14_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">75000</ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_LTx9sBBTF0mlLh7F5h9GlQ_15_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">67000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_utqcEgdPPEK7EIjT5oMO8Q_15_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">312000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_AVRYMj7Sj0SJ1ne7wSxR5A_16_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-98000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <ibio:DeferredFinancingCostsAmortizationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_VpWV5WtzEE2eBep-8fFpEA_17_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">242000</ibio:DeferredFinancingCostsAmortizationExpense>
    <ibio:DeferredFinancingCostsAmortizationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_GijSoqHrR024x-BAEFlBUg_17_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">107000</ibio:DeferredFinancingCostsAmortizationExpense>
    <ibio:IncreaseDecreaseInInventoryReserve
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_pEc4uyLA-EqADDcyfoFsJw_18_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4915000</ibio:IncreaseDecreaseInInventoryReserve>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_J34rDr7HFk2h_wRDKBKu-w_19_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">17900000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_lM1swXuclE2r2G244c8UNA_20_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">565000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_gcqCuQpu9kGzLiGLAgxkEw_21_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5000</us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases>
    <ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_q19xFE7BGUqG66gmsuzzXQ_22_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">607000</ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan>
    <ibio:SettlementOfRevenueContract
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_Gq0d78DFukCtoPyHDx1fsA_23_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">84000</ibio:SettlementOfRevenueContract>
    <us-gaap:ImpairmentOfInvestments
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_3ikuTPSz_EipNY-9xKioaA_24_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1760000</us-gaap:ImpairmentOfInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Aj7_Ly1V_k2LVnNcpXftJQ_26_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-1000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_IiUmdQQREkKYR2SGut1SYg_26_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">886000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <ibio:IncreaseDecreaseInSettlementAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_kyCzLh6FO0iMbxDKKuXbiA_27_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-5100000</ibio:IncreaseDecreaseInSettlementAssets>
    <ibio:IncreaseDecreaseInSettlementAssets
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_3HEV9yUiuEukaEBQ1ZJZcQ_27_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-5100000</ibio:IncreaseDecreaseInSettlementAssets>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_8TqCvyHvYkecSWpUS0eL3w_28_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1015000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_rcvCCcZscEmyX9R8IWuBDQ_28_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3873000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_ZslbRkb6SkifMBELPr4Mog_29_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-885000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_b-mDmGGUyUaAPQUluS8Qig_29_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-307000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Ff8sPKIaLkKVumRcuhGlfg_30_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-74000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_ePrmt4y9tUOM-YM_i73fgg_30_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">74000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_cLW2_IDktkmlO96RJs6rgA_31_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-21000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_Emv8QOedjkKYGddn_xqP7w_31_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-5000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_zRAnXCqkGkCF7Xo3Nia2_w_32_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-625000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_dm5IsFeKhkiZIy-27R4PlA_32_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1239000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_NejoUzz-T0y7j2zev4_wig_33_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">145000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_XzT6vWdPUkW81t2G7hUjyw_33_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1443000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_ZrbzcizqXEe6d5oR-zNB8A_34_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">527000</ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_FIhKycmALkivfiphZmRlSg_35_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-101000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_BkAHpriEkUqTnuIF-Y_n7A_35_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-15000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_WkptxgXSV0iixGE7eg20cA_36_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_Z_ZUeuoOxkeFnDiR9e3ssg_36_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_OhcC-uUpS0OWxBeFE5A3iQ_37_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-30436000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_6UiNMb8FdE-uNyS6dN1OHw_37_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-37480000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_6vaHx6wdtkC0zF2mFlHhTA_40_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5355000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Mol-9pWUSEKzoUWQ4k07nA_41_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4100000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_VfQJm0XknEWwK3KJwk-L9A_41_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">13618000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_mz6XEKqJf06M7Q3-zWm3gg_42_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6739000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_1wiqSPZ5n0q_1jOmd0bqiQ_43_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1760000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_QyGb1twtP06uHQd1DD-dPA_44_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_2n4S68PXA0CihwCeokhYng_45_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5738000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_8eg2PJKj00mOasATuQzgfQ_45_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7330000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_1hk6LoVd9UqDbYQ1UdafTQ_46_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_iX44H8vSXEac2sEms0L-FQ_47_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">692000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_RvEZvc0Wh02fEoSqUNunUg_49_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7009000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_PB8VReMorE6M0dMJZF3WRA_49_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-5127000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ibio:ProceedsFromIssuanceOfPreferredAndCommonStock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_1AzKaY8iY0agzcRKabuXug_52_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">11487000</ibio:ProceedsFromIssuanceOfPreferredAndCommonStock>
    <ibio:PaymentsForFractionalSharesAfterReverseStockSplit
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_zyvCzqYUfUKtwbqWjaG2LQ_53_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">39000</ibio:PaymentsForFractionalSharesAfterReverseStockSplit>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_wfJ9jsxMcUyNbGcC7UxjZw_54_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">50000</us-gaap:PaymentsToMinorityShareholders>
    <ibio:ProceedsFromEquipmentFinancingLoan
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_WjbEs6SAPEC-IK4-00daKw_55_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">500000</ibio:ProceedsFromEquipmentFinancingLoan>
    <ibio:PaymentOfEquipmentFinancingLoan
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_rAR-cnNhlUSfKgzLUxEagw_56_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">99000</ibio:PaymentOfEquipmentFinancingLoan>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_ecPVD2r6xUuUoOEoE94ifg_57_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">9318000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_VYyHv-2MTEqF3d8gXnoniw_58_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">77000</us-gaap:ProceedsFromStockOptionsExercised>
    <ibio:PaymentsToAttainTermNote
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_0OzgbkdqQECuEoibcZG-5w_59_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22000</ibio:PaymentsToAttainTermNote>
    <ibio:PaymentsToAttainTermNote
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_wCaAtqUs0UeBptlsvFQK-A_59_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">322000</ibio:PaymentsToAttainTermNote>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_YqtBTDagaE2pD0Ew4yHUWQ_60_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">208000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_p99XDdG98EqlrQLh_6-VEg_60_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5830000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_XzMW8-3EbESgIClYo3QuZg_61_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2301000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_NcK0rB3SYUWUyWy9h9N4aQ_61_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-6125000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_4Au6qWbtT02yk-HB4psLWQ_63_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">33000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_IY1Uhs2MmU6NC99w1VrnxQ_65_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-21093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_3d_nDpONuEGYxpamiCm2cQ_65_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-48732000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_2moamYbiyUiNGaA32Ytrrw_66_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">28672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag"
      decimals="-3"
      id="Tc_AX-qv76m80KxttRwg1ICBg_66_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">77404000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_gg9BU7QxpkC9IxAUZDU7fg_67_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7579000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_YEBNKL24Mky496RHhKvtjw_67_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">28672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_9wo1Zml-AE-GJYQftAaElA_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1769000</ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid>
    <ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_qQousekQ7kqC-dcurBHXdg_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">791000</ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_3nhcFGX_ZEubDt6gwrpwzA_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">814000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_TX3pD6fQm067Iu6E0T5xCA_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">814000</ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_GrGr53KP9EqZAfZDN8c0KA_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_wWqbn65tRkud-iIcTDZYFQ_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">636000</ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds>
    <ibio:NonCashTransactionOfSubscriptionReceivableForCapitalRaise
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_mG_cxzx0L0-4jwlEjA9tNQ_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">204000</ibio:NonCashTransactionOfSubscriptionReceivableForCapitalRaise>
    <ibio:CostAccruedToAmendTermNotePayable
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_2rmRpjVZb0-ELkZJbOrakg_11_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">125000</ibio:CostAccruedToAmendTermNotePayable>
    <ibio:UnpaidFixedAssetsIncludedInAccountsPayable
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_587TDCpFukyVwDgsyf2NzQ_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1769000</ibio:UnpaidFixedAssetsIncludedInAccountsPayable>
    <ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_ZZKD7U_hI0yMwbXQpOj4Hg_13_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">25386000</ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant>
    <us-gaap:NotesIssued1
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_JImxhkh6Pkmfp-UdW5A8Eg_14_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22375000</us-gaap:NotesIssued1>
    <ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_2HVW-58ujkuiKkkO6whuSA_15_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5570000</ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities>
    <ibio:NonCashSettlementOfRevenueContract
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-HdNQM9bQE2ya4yZKBr52w_16_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">580000</ibio:NonCashSettlementOfRevenueContract>
    <ibio:WarrantsIssuedForFinanceLeasePayment
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-RxyF0a2b0GFvsKBSsblVg_17_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">217000</ibio:WarrantsIssuedForFinanceLeasePayment>
    <ibio:LeaseIncentiveForConstructionInProgress
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_2ja5kCcNkECAQ-waYRGeYg_18_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-82000</ibio:LeaseIncentiveForConstructionInProgress>
    <ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-8Gkn-jfokqdXIwzYKkCQQ_19_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">18000</ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_FxgNiT3ltESEN-gioRGlWA_20_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">159000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_A91mtingy0OsXABdUagu_w_20_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">150000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_C9dAFBVJjUygTStTQdeiuQ_22_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">687000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_09JNGZfRJEiIfOB7lP-MyQ_22_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1045000</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_lcpodruSqUqAlCKPgLsK7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1.&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Nature of Business&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2022, iBio made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc"). This acquisition commenced our transition to an AI-enabled biotech company and led to the divestiture of our Contract Development and Manufacturing Organization (CDMO) business. This strategic decision allowed us focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;One of the key features of iBio&#x2019;s technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with unprecedented precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. &#160;Another integral part of iBio&#x2019;s technology stack is the machine learning (ML) based antibody-optimizing StableHu&#x2122; technology. When coupled with our mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;iBio also developed the EngageTx&#x2122; platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of our antibody products. By incorporating EngageTx into iBio&#x2019;s own development initiatives, the Company&#x2019;s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to our potential partners.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;iBio&#x2019;s scientific team, composed of experienced AI/ML scientists and drug hunters located side-by-side in our San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows us to quickly translate scientific discoveries into potential therapeutic applications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Artificial Intelligence in Antibody Discovery and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company&#x2019;s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pre-Clinical Pipeline&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;iBio is currently in the process of building and advancing its preclinical pipeline. The focus of this pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging iBio&#x2019;s technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;on the learnings of competitors, iBio's programs are primarily adopting a fast follower strategy. This approach allows iBio to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;img alt="Graphic" src="ibio-20230630x10k030.jpg" style="display:inline-block;height:171.6pt;width:468pt;"/&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Digital Infrastructure&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;iBio is a firm believer in the transformative power of digital technologies, including robotics, automation, artificial intelligence (AI), machine learning (ML), and cloud computing. These technologies are integral to operationalizing our strategy, accelerating our learning curve, and executing at scale. As such, the Company has made substantial investments in these areas. &#160;iBio&#x2019;s aspiration is to digitize our operations to the greatest extent possible, harnessing the potential of digital technology to maximize our impact on human health. As the Company continues to grow, we remain committed to further investing in our digital infrastructure to support our ambitious goals.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strategic Alliances, Collaborations, and Joint Ventures&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;iBio has formed collaborations and strategic alliances to gain access to funding, capabilities, technical resources and intellectual property to further its development efforts, commercialize its technology and to generate revenues, including through the use of our patented epitope-steering AI-engine and our EngageTX platform.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_WGj48966IUa9HzcjzcRdCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2.&#160;&#160;&#160;&#160;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the accounts of iBio Inc. and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#x201c;iBio CDMO&#x201d;) for an affiliate of Eastern Capital Limited (&#x201c;Eastern Capital&#x201d;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. See Note 6 &#x2013; Significant Transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Going Concern&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company completed a public equity offering and at-the-market offerings, reduced its work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of its CDMO Facility thereby reducing annual spend on expenses. Additionally, the Company has executed the Purchase and Sale Agreement for the sale of the CDMO Facility, which sale if consummated will allow us to pay all outstanding amounts under the Term Loan; however, the consummation of the sale is subject to closing conditions &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;for which there can be no assurance that they will be met or the closing will occur in a timely manner, if at all. If the closing is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely that the Company will have sufficient funds the repay the Term Loan on its maturity date, which Term Loan has an outstanding balance of $12.7 million as of September 26, 2023. Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#x2013; Discontinued Operations for more information.) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s cash, cash equivalents and restricted cash of approximately $7.6 million as of June 30, 2023, is not anticipated to be sufficient to support operations through the second quarter of Fiscal 2024 unless the Company reduces its burn rate further, sells the CDMO Facility for amounts above its term note payable or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plan. It is the Company&#x2019;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Annual Report. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 22, 2022, the Company's Board of Directors approved the implementation of a reverse stock split at a ratio of one-for-twenty five (&lt;span style="-sec-ix-hidden:Hidden_C1BZAkhphkSP6NLYZ6XiZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt; : 25) shares of the Company's Common Stock. The reverse stock split was effective as of October 7, 2022. All share and per share amounts of our common stock presented have been retroactively adjusted to reflect the &lt;span style="-sec-ix-hidden:Hidden_6s-44Ts3DkK4VQjk-RCW4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-twenty five reverse stock split. See Note 17 &#x2013; Stockholders&#x2019; Equity for more information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw"
      decimals="INF"
      id="Narr_jlUMpefIxE2J1KvfkMobTA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw"
      decimals="INF"
      id="Narr_Ahlvl83hvUqp2tRjCChjtA"
      unitRef="Unit_Standard_position_oflWAv0coEqkT6ZpEJ9RSQ">69</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_26_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_dm18S2OvJ0Sy2-xaPQ94EA"
      decimals="-5"
      id="Narr_cRyZc8Uek0-lXe5GKE_w4g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">12700000</us-gaap:LongTermDebt>
    <ibio:CashAndCashEquivalentsPlusDebtSecurities
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-5"
      id="Narr_pKtqWeL1fEKpvunxq98YVA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7600000</ibio:CashAndCashEquivalentsPlusDebtSecurities>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_u5Ne9qXJzE-0ms7CQcSbKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;&#160;&#160;&#160;Discontinued Operations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;On November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;60%&lt;/span&gt;&lt;span style="font-style:normal;"&gt; of the current Company staffing levels (a reduction of approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;69&lt;/span&gt;&lt;span style="font-style:normal;"&gt; positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, the Company continues to market for sale the &lt;/span&gt;&lt;span style="font-style:normal;"&gt;130,000&lt;/span&gt;&lt;span style="font-style:normal;"&gt; square foot cGMP facility location in Bryan, Texas (the &#x201c;Facility&#x201d;). Additionally, on February 10, 2023, the Company entered into an Auction Sale Agreement (the &#x201c;Auction Sale Agreement&#x201d;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#x201c;Auctioneers&#x201d;) for the sale at public auction of equipment and other tangible personal property (the &#x201c;Equipment&#x201d;) located at the Facility. The Auctioneers guaranteed an amount of gross proceeds from the sale of the equipment of &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$2.1&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_0UtmYiIXKka_hRPj17MXuA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million. In accordance with the Auction Sale Agreement, the Company received &lt;/span&gt;&lt;span style="font-style:normal;"&gt;80%&lt;/span&gt;&lt;span style="font-style:normal;"&gt; of the excess proceeds, after Holland Industrial Group&#x2019;s &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$0.2&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million fee. &#160;Total proceeds received in Fiscal 2023 were approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$2.6&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;The Company incurred pre-tax charges of approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$1.9&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a &lt;/span&gt;&lt;span style="font-style:normal;"&gt;60&lt;/span&gt;&lt;span style="font-style:normal;"&gt;-day transitional period during which impacted employees remained employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The Company recorded a charge in discontinued operations for approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$35.7&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million in Fiscal 2023, of which approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$17.9&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million was the result of a fixed asset impairment charge (see Note 11 &#x2013; Fixed Assets for more information), approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$4.9&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million to write down inventory to its net realizable value, approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$7.5&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million of personnel costs including severance and the balance related to operational costs related to winding down the CDMO business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;As such, the results of iBio CDMO's operations are reported as discontinued operations for the year ended June 30, 2023. The Company has retrospectively recast its consolidated statement of operations for the year ended June 30, 2022 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#x201c;held for sale&#x201d; as of June 30, 2023. The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statements of cash flows. Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Consolidated Financial Statements refers to the Company's continuing operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed asset impairments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Gain on sale of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (773)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory reserve&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expenses):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (900)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (602)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (810)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Forgiveness of note payable and accrued interest - SBA loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,699)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2023 and 2022 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,951&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total long-term liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,971&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Purchase of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fixed asset impairments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Inventory reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales proceeds of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investing non-cash transactions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Increase in ROU operating assets and liabilities for new leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,952&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed assets included in accounts payable in prior period, paid in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Unpaid fixed assets included in accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Termination of finance ROU assets including issuance of warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Note payable to acquire Facility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Issuance of warrant for final lease obligation payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Supplemental cash flow information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Cash paid during the period for interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 603&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,045&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw"
      decimals="INF"
      id="Narr_nNN_D-atW0O82J4OERPduQ"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw"
      decimals="INF"
      id="Narr_fqUY5FPOiUmZmD5yctYZNA"
      unitRef="Unit_Standard_position_oflWAv0coEqkT6ZpEJ9RSQ">69</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:AreaOfLand
      contextRef="As_Of_11_3_2022_x45ryYnU3UWbXnPzJBxuug"
      decimals="INF"
      id="Narr_MyehNjMjqkqn2Q7dVpgnKQ"
      unitRef="Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw">130000</us-gaap:AreaOfLand>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_2_10_2023_To_2_10_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_GuaranteedAuctionProceedsMember_atQz6mAuyUK6kUqxRjzLBA"
      decimals="-5"
      id="Narr_v1TiRUfNj0mBrtpScd2ikQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <ibio:PercentageOfAuctionProceedsReceived
      contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_ExcessAuctionProceedsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_2ZiYX-syC0ai3JUx-2X5gQ"
      decimals="INF"
      id="Narr_4yBtrIQTtUyFx7Mm9-uyCA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.80</ibio:PercentageOfAuctionProceedsReceived>
    <ibio:AuctionFee
      contextRef="As_Of_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_90XItF3zBE20jmvLFm1lDQ"
      decimals="-5"
      id="Narr_KdCgdmrxCUalTuG5djabcg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">200000</ibio:AuctionFee>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_AI8GxgTdWkG2tUl-e2so6Q"
      decimals="-5"
      id="Narr_qmOvQtnV60CVmWEU6cqsDA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <ibio:EmployeeReductionExpenses
      contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw"
      decimals="-5"
      id="Narr_FsfbVUgsF0O7S9nT7A4Nbw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1900000</ibio:EmployeeReductionExpenses>
    <ibio:SeveranceTransitionalPeriodDays
      contextRef="Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw"
      decimals="INF"
      id="Narr_WZAyNZWCf02psn_aNOQxCg"
      unitRef="Unit_Standard_D_DabM02qyekqEwyzN94-Wtg">60</ibio:SeveranceTransitionalPeriodDays>
    <ibio:EmployeeReductionExpenses
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-5"
      id="Narr_nMbw8DKpWkKiM8y2KSxFgw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">35700000</ibio:EmployeeReductionExpenses>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-5"
      id="Narr_ITeFOF0ioUK_2tL4VMiJvQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">17900000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-5"
      id="Narr_ls-eBHrFVUm_69K74YYGqg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4900000</ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-5"
      id="Narr_r7lGjQdOtES042DBrOryew"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7500000</ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_gqgoYUn1JE6REFn2oZGm3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed asset impairments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Gain on sale of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (773)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory reserve&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expenses):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (900)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (602)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (810)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Forgiveness of note payable and accrued interest - SBA loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,699)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2023 and 2022 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,951&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total long-term liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,971&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Purchase of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fixed asset impairments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Inventory reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales proceeds of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investing non-cash transactions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Increase in ROU operating assets and liabilities for new leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,952&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed assets included in accounts payable in prior period, paid in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Unpaid fixed assets included in accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Termination of finance ROU assets including issuance of warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Note payable to acquire Facility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Issuance of warrant for final lease obligation payment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Supplemental cash flow information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Cash paid during the period for interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 603&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,045&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_fgVMPSNo2kmeAaHU_3V-Jg_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">391000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_iGH4bVqTT0mUZ9dHsZ3CiA_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">499000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_rO7SOyw_akqT6looj6V_Qw_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">52000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_PbmHhGQHCEaw8MChprl7sw_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">216000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_c-YSMKTz90GZBKkW0VrkDg_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">339000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_GV61WaJEGkimbSyfdIP6yQ_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">283000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_3NfVQqZ9nUuh-ln6uZmM8A_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6344000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_L9-8B1vI3kaJHTnhNZpGGg_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7902000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_zL3i4gV7fk6XcySnYD6lOA_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6751000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_mzFk05HIi0286mhB-JAVLg_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">12373000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <ibio:TangibleAssetImpairmentChargesDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_upuKu-_5f0GoVT2YwHadkw_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">17900000</ibio:TangibleAssetImpairmentChargesDiscontinuedOperations>
    <ibio:GainOnSaleOfFixedAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_P3N7ADu0RUicgfyiAQmMBA_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-773000</ibio:GainOnSaleOfFixedAssets>
    <ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_PknFTwuPlEyTFpWT1UPDwA_11_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4915000</ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_1_D3pW9pbEyn8iq2OsJ-cQ_12_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">35137000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_hE03cln0F0yaTLrJ6yexFw_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20275000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc__zL1VVEZakWPhAbtmCKHaA_15_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_Jr6Pfj7pBEWOOSTjXhT80g_15_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">602000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <ibio:DisposalGroupInterestExpenseRelatedParty
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_esaJ7vRSQkKsqWzpAkXPOw_16_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">810000</ibio:DisposalGroupInterestExpenseRelatedParty>
    <ibio:DisposalGroupGainOnDebtForgiveness
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_q7T1--4zEUSukRUAYCKRpA_17_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">607000</ibio:DisposalGroupGainOnDebtForgiveness>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_sNvEtPtGGkCSAXe0r0ezVg_18_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_4LwEVXL6rkyWKQ1HyOyYVA_18_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-6000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_JKeLO7u9fE6B6n2QiTZqyw_19_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">901000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_1iHXK2o05U6_zRAdp5642g_19_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">799000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_9OtYCge7oEmiv7np529PyA_21_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-35699000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_x9HQ9u3oy0uu-pPciyB3Yw_21_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-20791000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_XZ_936ZEO0WQTwyTwhHnnQ_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <ibio:DisposalGroupOperatingLeaseRightOfUseAssets
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_S8IpdVH6AECegAgUGfrLgQ_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1941000</ibio:DisposalGroupOperatingLeaseRightOfUseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_7LPc05h2y0qHbzHbDOxbNg_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">16124000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_iLWMnRgAVUG3Wy0YL6GJyQ_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">18065000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_jLoXDlJk5EiQHStdLz5AoQ_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3900000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_jE9gp4Q5yUq18N6n5DcAJg_10_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">35289000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <ibio:DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_6yD9tUgGaUiQMnN5MP5kZQ_11_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">74000</ibio:DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets>
    <ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_L3ZhiBcZj06Ell3PQSQ4bQ_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1951000</ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_rByvgkVPUUC5W4uHq_9rvg_13_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">37314000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <ibio:DisposalGroupCurrentLiabilitiesFinanceLeaseObligations
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_4505sNR9RU2LNBT4rI1lpQ_16_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">46000</ibio:DisposalGroupCurrentLiabilitiesFinanceLeaseObligations>
    <ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_pAuucrshoECl_Dsw2Xh2bg_17_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1941000</ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations>
    <ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_bl-CRQHs30S2rKggvyeLQA_17_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10000</ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_7pclosq9nk2fyyiTGXIIdg_18_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1941000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_1W9_LpCYN0Wwgwv-sKd_8g_18_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">56000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <ibio:DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_eidSyLWW5UulyriYAPoA-w_21_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">30000</ibio:DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations>
    <ibio:DisposalGroupNoncurrentOperatingLeaseObligations
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_tvpIxt2HtEuixEK10fEMHA_22_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1941000</ibio:DisposalGroupNoncurrentOperatingLeaseObligations>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_L9r5bBsszEKbIJNsAZp6jQ_23_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1971000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_upyMqjmFB0e_JLQLaaGFRw_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">273000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_tYiWAeQRiki-zw3ii2vUjA_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2275000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_PY-v-CC630St8YNXHsonBw_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets>
    <ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_YL2atnczcUiaXkrx-_S4wA_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">599000</ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_W8SbKHhyVkC4F5IVMxIBWg_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1542000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_BBm8Q4krHkW0SiSpo6meOg_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5809000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <ibio:TangibleAssetImpairmentChargesDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_P9gp0Zj6YEyLVZSiTyphAg_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">17900000</ibio:TangibleAssetImpairmentChargesDiscontinuedOperations>
    <ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_1ubaak21RkSvpKtNnu7-KA_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4915000</ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_3g9Ak0ePk0GF1xndXxwXXg_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <ibio:IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_3MBOwsbW90K48loF_Ekreg_10_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1952000</ibio:IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases>
    <ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_qPgNasYcEUKYjpW4OB5Jlg_11_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1542000</ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod>
    <ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_tZh6t2hJBUSGwjh6gfK79w_11_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">791000</ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod>
    <ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-k68dCveTkyJ_BBuushkKg_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1542000</ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations>
    <ibio:TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_MhQKN6ZUEE6g9DJKiu_4iA_13_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">25386000</ibio:TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant>
    <ibio:ProceedsFromNotesPayableFromDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_Ncg278cyvk-5fN-yRjoyoQ_14_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22375000</ibio:ProceedsFromNotesPayableFromDiscontinuedOperations>
    <ibio:IssuanceOfWarrantForFinalLeaseObligationPayment
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_jA7zC-9mx02L-otDdRUskQ_15_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">217000</ibio:IssuanceOfWarrantForFinalLeaseObligationPayment>
    <us-gaap:InterestPaidDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_skZcFPTX0k-iO3e1on8qAw_18_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">603000</us-gaap:InterestPaidDiscontinuedOperations>
    <us-gaap:InterestPaidDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_vbzKL3iLqkaJOTOivvTjIg_18_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1045000</us-gaap:InterestPaidDiscontinuedOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_mpbawGQr1kygKPtrA2ChMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Accounts Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management&#x2019;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At June&#160;30, 2023 and 2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its revenue recognition under Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and / or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June&#160;30, 2023 and 2022, the Company had no contract loss provisions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company generates (or may generate in the future) contract revenue under the following types of contracts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Fixed-Fee&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Revenue can be recognized either 1) over time or 2) at a point in time and is summarized below (in thousands). &#160;All revenue was recognized at a point in time for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;No revenue was recognized in the year ended June 30, 2023. &#160;Revenue was recognized from a license agreement and the settlement of a revenue contract in the year ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Time and Materials&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#x2019;s billing rate plus other project specific costs incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;A contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2023 and 2022, contract assets were $0.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;A contract liability is an entity&#x2019;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#x2019;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2023 and 2022, contract liabilities were $0 and $100,000, respectively. The Company recognized revenue of $100 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and $178,000 in 2022 that was included in the contract liabilities balance as of June 30, 2021 and was reported in discontinued operations. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;The Company accounts for leases under the guidance of ASC 842, &lt;/span&gt;Leases&lt;span style="font-style:normal;"&gt;. The standard established a right-of-use (&#x201c;ROU&#x201d;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#x2019;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#x2019;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. &#160;The determination of the Company&#x2019;s incremental borrowing rate requires judgement. &#160;The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2023 and 2022 consisted of money market accounts. Restricted cash consists &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;of approximately $3.0 million held within a Company account at Woodforest Bank for the Term Note payable (see Note 6 &#x2013; Significant Transactions and Note 14 &#x2013; Debt) collateral, a letter of credit obtained related to the San Diego operating lease (see Note 16 &#x2013; Operating Lease Obligations) and a Company purchasing card. The Company&#x2019;s bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. &#160;Restricted cash was $3,278,000 and $5,996,000 June 30, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Investments in Debt Securities&lt;/i&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 6 - Significant Transactions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Inventory&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. Inventory held is related to the CDMO business ad has been classified as held for sale. &#160;See Note 3 &#x2013; Discontinued Operations for more information on the inventory reserved reflected in the year ended June 30, 2023. &#160;The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. Inventory consists of the following (table in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,896 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,900 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 730-10, &#x201c;&lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;&#x201d; (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the years ended June 30, 2023 and 2022, research and development expense was reported in both continuing and discontinuing operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_uabS_NI-Z06ict9nQUkf0w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:normal;"&gt; to &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_9YJQTd2bdk-gA4FmiAYIkg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thirty-nine&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:normal;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;See Note 11 &#x2013; Fixed Assets for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The impact that share-based payment awards will have on the Company&#x2019;s results of operations is a function of the number of shares awarded, the trading price of the Company&#x2019;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#x2019;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected volatility is based on historical volatility of the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#x2019;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 &#x2013; Share-Based Compensation for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June&#160;30, 2023 and 2022. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June&#160;30, 2023 and 2022, amounts in excess of insured limits were approximately $6,900,000 and $18,200,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;During the Fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers. During the Fiscal year ended June 30, 2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract and generated $499,000 of revenue reported in discontinued operations from eight customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326)&lt;/i&gt;, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging (Topic 815)&lt;/i&gt;, and &lt;i style="font-style:italic;"&gt;Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_nZSLxaXYVESwEPCdGIiNJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_IKiElWNzdkG6HdjqHVoOdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Accounts Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management&#x2019;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At June&#160;30, 2023 and 2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_zj03u6DALEiSEuaQJuW8Qg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its revenue recognition under Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and / or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June&#160;30, 2023 and 2022, the Company had no contract loss provisions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company generates (or may generate in the future) contract revenue under the following types of contracts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Fixed-Fee&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Revenue can be recognized either 1) over time or 2) at a point in time and is summarized below (in thousands). &#160;All revenue was recognized at a point in time for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;No revenue was recognized in the year ended June 30, 2023. &#160;Revenue was recognized from a license agreement and the settlement of a revenue contract in the year ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Time and Materials&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#x2019;s billing rate plus other project specific costs incurred.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_Y55_crN1lUC6DMAX-LJG4g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_tzn0y4a5e0qwrb4bQmKi-A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_UyhxKLDMMEKTIC3PkloDIA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:Revenues>
    <ibio:ContractAssetsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_dSyzlYHkh06dXgqqHsXLFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;A contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2023 and 2022, contract assets were $0.&lt;/p&gt;</ibio:ContractAssetsPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr__E5uIz0JjUW1uy9D-2d6SQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_eDsvStIgdEyLYcR9WH-3Wg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <ibio:ContractLiabilitiesPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_ViD-DTlorEiCRT-dvqmDhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;A contract liability is an entity&#x2019;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#x2019;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2023 and 2022, contract liabilities were $0 and $100,000, respectively. The Company recognized revenue of $100 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and $178,000 in 2022 that was included in the contract liabilities balance as of June 30, 2021 and was reported in discontinued operations. &#160;&lt;/p&gt;</ibio:ContractLiabilitiesPolicyTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr__r9gdijMn0uJ7d2Y4waumA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr_0JHUTBihnkGmpqzLlivJjg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">100000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_XC8CgiJii0O20dEqWufP8g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">100</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_ZwboMjes40Syv6vxZY0yWA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">178000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_bYOK-W7bRkCfhdjB_kT_pA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;The Company accounts for leases under the guidance of ASC 842, &lt;/span&gt;Leases&lt;span style="font-style:normal;"&gt;. The standard established a right-of-use (&#x201c;ROU&#x201d;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#x2019;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#x2019;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. &#160;The determination of the Company&#x2019;s incremental borrowing rate requires judgement. &#160;The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_QHz6bc_OfEmdBBiHVdGbGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2023 and 2022 consisted of money market accounts. Restricted cash consists &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;of approximately $3.0 million held within a Company account at Woodforest Bank for the Term Note payable (see Note 6 &#x2013; Significant Transactions and Note 14 &#x2013; Debt) collateral, a letter of credit obtained related to the San Diego operating lease (see Note 16 &#x2013; Operating Lease Obligations) and a Company purchasing card. The Company&#x2019;s bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. &#160;Restricted cash was $3,278,000 and $5,996,000 June 30, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_lYOxtlA7SECAFRsqcF-SfA"
      decimals="-5"
      id="Narr_Hj0ATEir00iBAcci-xxikw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3000000.0</us-gaap:RestrictedCash>
    <ibio:PercentageOfCollateralRequired
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Narr_58KcmmaqYk60KAEWm3a43Q"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.05</ibio:PercentageOfCollateralRequired>
    <us-gaap:RestrictedCash
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_BQtVvm4jGEWOxKIzdm0SCg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3278000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr_ao9JhOHCKE20zTHrwyVnng"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5996000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_vX_Ner53X06KWC4x065TUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_ZhW3xWpfd0a3q7uQ9Iw-yw_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4301000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_UEqL3_mj30icu2sNnXrN_A_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22676000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_lYOxtlA7SECAFRsqcF-SfA"
      decimals="-3"
      id="Tc_gsMQGR66OkeoFqyIJyoqeA_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3025000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_F9D1CtdJIUGZ_NarVuJabA"
      decimals="-3"
      id="Tc_gA7wnm6jHE2K5Zbj3xpqtQ_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5743000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_pojHavUPcEas5qPQYCAHRg"
      decimals="-3"
      id="Tc_XfThqERSLUqbRJL9aCF0zg_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">198000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_9NVLwycAS06AXqdN0JVz6Q"
      decimals="-3"
      id="Tc_HQYeWl-4vUaVUQq9tRT0jw_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">198000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_TZN5AIYJp0-6KjjZaFqg6A"
      decimals="-3"
      id="Tc_DwV9J5K8CkWeMhQxxya3Sw_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_w4qDIzxgXUiJo3l8Fvo9Bg"
      decimals="-3"
      id="Tc_CEBrvlpZSUKMIOIOAXuWdA_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_nQ3dVtUMsUmmhsmQzIpZow_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7579000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_beOH5YTti06lCDwctq455w_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">28672000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_waY9oBs4IEqQrWwHZIXf-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Investments in Debt Securities&lt;/i&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 6 - Significant Transactions. &lt;/p&gt;</us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy>
    <us-gaap:InventoryWorkInProcessPolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_JRsK7Vq8bkexOk60_0Putg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Inventory&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. Inventory held is related to the CDMO business ad has been classified as held for sale. &#160;See Note 3 &#x2013; Discontinued Operations for more information on the inventory reserved reflected in the year ended June 30, 2023. &#160;The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. Inventory consists of the following (table in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,896 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,900 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryWorkInProcessPolicy>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_3qR8Wh40OkWFF-NmPzUijQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,896 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,900 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_zF07IRwL_kmpgkygBZGnuA_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3896000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_fxMC8jZHTUu7znh5moFsqw_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_M-t6m1lOEESJyuqinOuWqw_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3900000</us-gaap:InventoryNet>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_bJHjSL7HrkmO0XjzKnBcuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 730-10, &#x201c;&lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;&#x201d; (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the years ended June 30, 2023 and 2022, research and development expense was reported in both continuing and discontinuing operations.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ibio:RightOfUseAssetsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_xsWq1VW610O44bGtds0gjw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information.&lt;/p&gt;</ibio:RightOfUseAssetsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_jWsJfxfMq0qsfkNWOQIppg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_uabS_NI-Z06ict9nQUkf0w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:normal;"&gt; to &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_9YJQTd2bdk-gA4FmiAYIkg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thirty-nine&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:normal;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;See Note 11 &#x2013; Fixed Assets for additional information.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_N8Ln422Ec0C1v_ac32i6EA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ"
      id="Narr_vWjaGf1rRUSldHjzTxec7g">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_VHzpBtLNF0eYuov7NOqoeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The impact that share-based payment awards will have on the Company&#x2019;s results of operations is a function of the number of shares awarded, the trading price of the Company&#x2019;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#x2019;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected volatility is based on historical volatility of the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#x2019;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 &#x2013; Share-Based Compensation for additional information.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Narr_rjCoRLyVzE6lxmAAheDfIg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_uohe0puGPk2BKUcpHV-OgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June&#160;30, 2023 and 2022. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2023 and 2022.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr_KFovHO6hK0eVBoLEviTR4A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_z_n6ihN25EGHcHqY9zYn2A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_v0OZVArE8E-wRXZ5Py6izg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June&#160;30, 2023 and 2022, amounts in excess of insured limits were approximately $6,900,000 and $18,200,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;During the Fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers. During the Fiscal year ended June 30, 2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract and generated $499,000 of revenue reported in discontinued operations from eight customers.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_Zin4pF5AgE2PpH8IDAVsGw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6900000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr_41REYp_9MEO3RM-ZOZd2ZQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">18200000</us-gaap:CashUninsuredAmount>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_g-g_KjrMIU-QYoZls9rg8Q"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:Revenues>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_ibio_FourCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y8MwivQ9ekC2NZNY1aglKQ"
      decimals="0"
      id="Narr_438hlKMVmEKeT_SelP7Rmw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">391000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_ibio_FourCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y8MwivQ9ekC2NZNY1aglKQ"
      decimals="INF"
      id="Narr_4uHJ4f5IAECB3fvSWWANUw"
      unitRef="Unit_Standard_customer_bk92zj7mYE-AcFFVra0SUg">4</ibio:NumberOfMajorCustomers>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_ibio_EightCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_6zllRl-74kWHjjUok5X3fA"
      decimals="0"
      id="Narr_qad4THEPHk22Ug79Bn7QbQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">499000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_ibio_EightCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_6zllRl-74kWHjjUok5X3fA"
      decimals="INF"
      id="Narr_66i37j98IEaSITlXtpw-LQ"
      unitRef="Unit_Standard_customer_bk92zj7mYE-AcFFVra0SUg">8</ibio:NumberOfMajorCustomers>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_tvS7NL2YXEKjCO5C5kHzYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326)&lt;/i&gt;, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging (Topic 815)&lt;/i&gt;, and &lt;i style="font-style:italic;"&gt;Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_H_WwJv8g0ESfKHVbJdiTAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;5. &#160; Financial Instruments and Fair Value Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Company&#x2019;s consolidated balance sheets approximated their fair values as of June 30, 2023 and 2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, term note payable and finance lease obligations approximated fair value as of June 30, 2023 and 2022 as the interest rates related to the financial instruments approximated market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of plan investments that fall under each category, and the valuation methodologies used to measure these investments at fair value:&lt;span style="display:inline-block;width:12.24pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2013; Inputs are based upon unadjusted quoted prices for identical instruments in active markets.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&#x2022;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;Level 2 &#x2013; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&#x2022;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;Level 3 &#x2013; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of impairment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company initially marketed the CDMO business and during the second quarter of Fiscal year 2023, changed its strategy to selling the stand-alone CDMO assets. These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. As a result, the carrying value of the Facility and equipment was reduced to their estimated fair values of $16,350,000 and $2,100,000, respectively. In the second quarter of Fiscal year 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6,300,000 and $11,300,000 for the Facility and equipment, respectively. In the first quarter of Fiscal 2024, the Company entered into an agreement for the building for $17.25 million, and an additional impairment of $0.3 million was recorded in the fourth quarter of Fiscal 2023 to reflect the agreed upon sales price less estimated costs to sell. &#160;The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $16.1 million. The machinery and equipment were sold during the third quarter of Fiscal year 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of June 30, 2023 (amounts in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Hierarchy&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Other Observable Inputs (Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Unobservable Inputs (Level 3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Impairments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building in Bryan, Texas&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the second quarter of Fiscal year 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_7qBiEha-vECXgWze-i-g6Q"
      decimals="0"
      id="Narr_l5NroDVMOkmGzEKewBdCNg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">16350000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_nbd9NMQisEiyfXHpBgaVUQ"
      decimals="0"
      id="Narr_87b6OfIQGU2s-B0Izpl8aw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2100000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember__ZIfD-ddyUWPf60tnoVcmw"
      decimals="0"
      id="Narr_JJHbRiSHeku62M5_-O51tw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6300000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_SFHPA8kiYE6ZzTtqaqm52A"
      decimals="0"
      id="Narr_pRIyoudrikCSoeSfOmAHhA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">11300000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:ProceedsFromSaleOfBuildings
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5qaPdrZ830G5d8zR_8zrkQ"
      decimals="-4"
      id="Narr_bXPdOE8GA06il0NGg1-l6g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">17250000</us-gaap:ProceedsFromSaleOfBuildings>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OBOy6kxRiU-oe0ymEhUYpw"
      decimals="-5"
      id="Narr_mlQhZF95Q0eQCmwifosEmw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">300000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:FixedAssetsHeldForSale
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_dZg1WhqNY0uE1A0c9lHl3A"
      decimals="-5"
      id="Narr_4JVmexfTMU6Nj5zgGShs4Q"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">16100000</ibio:FixedAssetsHeldForSale>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_J1zRVgOww02pfH0ycNgVeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:71.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Hierarchy&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Other Observable Inputs (Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Unobservable Inputs (Level 3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Impairments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building in Bryan, Texas&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_LDEVyL3h-0GVW39rjQJBaQ"
      decimals="-3"
      id="Tc_GjgWCUX5C02cF-qp21Hj1w_5_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">16064000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_dZg1WhqNY0uE1A0c9lHl3A"
      decimals="-3"
      id="Tc_Toxpqdoe2kuOLzXE-ftiGw_5_12"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">16064000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_gsFictXunUazEpdpJkg4ug"
      decimals="-3"
      id="Tc_CnrncWy4ckSTkZReMkYl2Q_5_15"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6600000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:SignificantTransactionsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_sfg-VZzMHkyHusuJb1lrRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Significant Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Affiliates of Eastern Capital Limited&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (&#x201c;iBio CDMO&#x201d;, and collectively with the Company, the &#x201c;Purchaser&#x201d;) entered into a series of agreements (the &#x201c;Transaction&#x201d;) with College Station Investors LLC (&#x201c;College Station&#x201d;), and Bryan Capital Investors LLC (&#x201c;Bryan Capital&#x201d; and, collectively with College Station, &#x201c;Seller&#x201d;), each affiliates of Eastern Capital Limited (&#x201c;Eastern,&#x201d; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#x2019;s ground lease;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;otherwise terminated all agreements between the Company and the affiliates of Eastern.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;amp;M University System (&#x201c;Texas A&amp;amp;M&#x201d;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#x201c;Sublease&#x201d;) until the purchase of the Facility described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Purchase and Sale Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;On November 1, 2021, the Purchaser entered into a purchase and sale agreement (the &#x201c;PSA&#x201d;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#x201c;Ground Lease Agreement&#x201d;) that it entered into with Texas A&amp;amp;M (the &#x201c;Landlord&#x2019;&#x2019;) related to the land at which the Facility is located together with all improvements pertaining thereto (the &#x201c;Ground Lease Property&#x201d;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Ground Lease Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the &#x201c;Warrant&#x201d;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the June 30, 2023 and 2022 consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Equity Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#x201c;Equity Purchase Agreement&#x201d;) pursuant to which the Company acquired for $50,000 cash, plus the Warrant, the one (1) share of iBio CMO Preferred Tracking Stock and the 0.01% interest in iBio CDMO owned by Bryan Capital. iBio CDMO is now a wholly owned subsidiary of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Credit Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;See Note 14 &#x2013; Debt for further information of the Term Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Warrant&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share. The Warrant expires on October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the total shares that can be exercised under the Warrant, 11,583 of such shares were valued at $217,255 to reflect the final payment of rent due under the Sublease. &#160;The Warrant, as shown on the consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Ground Lease Property acquired. &#160;See Note 17 &#x2013; Stockholders&#x2019; Equity for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;RubrYc&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#x201c;RubrYc&#x201d;) described in more detail below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The Company entered into a collaboration and licensing agreement (the &#x201c;RTX-003 License Agreement&#x201d;) with RubrYc to further develop RubrYc&#x2019;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields&lt;span style="color:#0000ff;"&gt;.&#160;&lt;/span&gt;RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="color:#0000ff;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration, Option and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company entered into an agreement with RubrYc (the &#x201c;Collaboration, Option and License Agreement&#x201d;) to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#x2019;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) &lt;span style="-sec-ix-hidden:Hidden_1lNt1UglOEOd6nh1BKY2Rg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt; (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#x201c;Stock Purchase Agreement&#x201d;) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc&#x2019;s Series A-2 preferred stock (&#x201c;Series A-2 Preferred&#x201d;) for $7,500,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,760,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,300,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations and completed bankruptcy proceedings in June 2023. &#160;The Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022 which was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. The Company issued 102,354 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the &#x201c;Closing Shares&#x201d;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#x2019;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,228,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,342,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. See Note 9 &#x2013; Finance Lease ROU Assets and Note 15 &#x2013; Finance Lease Obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Former CEO Departure&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#x201c;CEO) and former Chairman of the Board of Directors (the &#x201c;Board&#x201d;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Separation Agreement and General Release&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In connection with Mr. Isett&#x2019;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#x201c;Agreement&#x201d;). Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. Following Mr. Isett&#x2019;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for &lt;span style="-sec-ix-hidden:Hidden_YMSx4gGHzEiJmUbTbVGKZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twenty-four&lt;/span&gt;&lt;/span&gt; (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the &lt;span style="-sec-ix-hidden:Hidden_SYAPHltUpUekE3X9uPDPUg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twenty-four&lt;/span&gt;&lt;/span&gt; (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#x201c;COBRA&#x201d;), the Company will pay the full cost of this benefit for up to &lt;span style="-sec-ix-hidden:Hidden_CQT6G5UgS0uV_qC3r8ildA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eighteen&lt;/span&gt;&lt;/span&gt; (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the &lt;span style="-sec-ix-hidden:Hidden_0Ap6AYAnBkSKK9C3lFNv3w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eighteen&lt;/span&gt;&lt;/span&gt; (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. The Agreement includes a general release of claims by Mr. Isett. The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of Fiscal 2023. As of June 30, 2023, approximately $1.1 million is recorded in accrued expenses and $527,000 in accrued expenses &#x2013; noncurrent.&lt;/p&gt;</ibio:SignificantTransactionsTextBlock>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w"
      decimals="0"
      id="Narr_IS7OCGGwUkqKvL5QYJsEhg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">28750000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w"
      decimals="0"
      id="Narr_4AZ8O6k0RkS8-p6cc1bBVw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">28000000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment>
    <ibio:FairMarketValueOfProperty
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w"
      decimals="0"
      id="Narr_w6viHrULIkGaGXY--ge1og"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">151450</ibio:FairMarketValueOfProperty>
    <ibio:BaseRentPercentageOfFairMarketValueOfProperty
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w"
      decimals="3"
      id="Narr_lF2-Y0WtB0qKEqbLzPWjeQ"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.065</ibio:BaseRentPercentageOfFairMarketValueOfProperty>
    <ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w"
      decimals="0"
      id="Narr_JGzZDJKwb021Oue7DLziZA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">50000</ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired>
    <ibio:EquityAgreementWarrantsIssuedOrIssuable
      contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_yQtckMjz-Eqm8XRVYD1YnA"
      decimals="INF"
      id="Narr_QRpIU2jeGEmTb-M8moy1ug"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1</ibio:EquityAgreementWarrantsIssuedOrIssuable>
    <ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable
      contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_yQtckMjz-Eqm8XRVYD1YnA"
      decimals="4"
      id="Narr_kaSgYTAvPE6YBt_whDpxPA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0001</ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Wllg_X7FK0iPGlaGUB08bg"
      decimals="INF"
      id="Narr_BlMaIIBPB0mHch2erRiuYg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w"
      decimals="INF"
      id="Narr_8uleh9q5Pk6eSedTZ8VzHw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">51583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w"
      decimals="2"
      id="Narr_74kfOX1Lo0-vPyn9E43e9g"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">33.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w"
      decimals="INF"
      id="Narr_Y7ZjQqa_fUuhSSTyZmksng"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">11583</ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent>
    <ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w"
      decimals="0"
      id="Narr_xLNaFo0GN0StU17ZTQ5BVQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">217255</ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue>
    <ibio:CollaborationAndLicenseAgreementAgreementTerm
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_YH7c7zxS4Um37Nlh67R2QQ"
      id="Narr_7oDM2TpeMk6u3eA7705YgA">P5Y</ibio:CollaborationAndLicenseAgreementAgreementTerm>
    <ibio:StockPurchaseAgreementNumberOfSharesPurchased
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_0ZWSZA9Kr0KCCrEbl4ckpA"
      decimals="INF"
      id="Narr_2IQivKgWykuzEXjfHKHq8Q"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">2864345</ibio:StockPurchaseAgreementNumberOfSharesPurchased>
    <ibio:StockPurchaseAgreementValueOfSharesPurchased
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_0ZWSZA9Kr0KCCrEbl4ckpA"
      decimals="INF"
      id="Narr_-Ruj5Rs2QECQ9fky3CXpJA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7500000</ibio:StockPurchaseAgreementValueOfSharesPurchased>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_s69drdBtfkiXxiX5xIaWhw"
      decimals="0"
      id="Narr_jR5cV4OjWk-O7BEnb3Iorg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_p3xe_xFZZkWNjC4NdaEdxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,760,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,300,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_qGJJOjg520eitr0OnzDv_A"
      decimals="0"
      id="Tc_Wzuas3FKU0KDQ_R6lMTxVA_1_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1760000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_aQUPv9G7qESYPE20QdAeDQ"
      decimals="0"
      id="Tc_PZI00TXdWUa4u7QCM5e-BA_2_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4300000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_03q0Za05A0K0e2L2ZORfzw"
      decimals="0"
      id="Tc_Y6wvZ1C7CUixnx8jN8EZrg_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1440000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_s69drdBtfkiXxiX5xIaWhw"
      decimals="0"
      id="Tc_pDspN8KyKEGvDWBbwyKCKg_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_qGJJOjg520eitr0OnzDv_A"
      decimals="0"
      id="Narr_0gU71PNErEqiLnM_HwC-JA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1760000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <ibio:ImpairmentOfPrepaidExpensesCurrent
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Lh5bPHn7wEyfg1z7EBU_sw"
      decimals="0"
      id="Narr_4VQioUMhqkSMe4EcinhqKw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">288000</ibio:ImpairmentOfPrepaidExpensesCurrent>
    <ibio:ImpairmentOfPrepaidExpensesNonCurrent
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Lh5bPHn7wEyfg1z7EBU_sw"
      decimals="0"
      id="Narr_aYjtXWHoVk-EWtVJ5GV62A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">864000</ibio:ImpairmentOfPrepaidExpensesNonCurrent>
    <ibio:StockPurchaseAgreementNumberOfSharesPurchased
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_dj-dsQcEtkq53NmB8lZZ7A"
      decimals="0"
      id="Narr_2iOp7EhI-0ioNQx3qN6G2g"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">102354</ibio:StockPurchaseAgreementNumberOfSharesPurchased>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA"
      decimals="0"
      id="Narr_kLF31ToHF06cplPmmrxvsA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1000000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest>
    <ibio:FairMarketValueOfProperty
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA"
      decimals="0"
      id="Narr_b_O7zikNJkiWxBkjY8iaCA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">650000</ibio:FairMarketValueOfProperty>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA"
      decimals="0"
      id="Narr_uwZKGKF840mz113-U2PktA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_dj-dsQcEtkq53NmB8lZZ7A"
      decimals="0"
      id="Narr_F-_mcsViBUSMkZcKKjptqg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">484000</us-gaap:PaymentsForAdvanceToAffiliate>
    <ibio:AssetAcquisitionTransactionCosts
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_dj-dsQcEtkq53NmB8lZZ7A"
      decimals="0"
      id="Narr_KLJfnkn2qEORJkbqRANyAQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">208000</ibio:AssetAcquisitionTransactionCosts>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg"
      decimals="0"
      id="Narr_bemSi36ZV0q8YMFpN_6fHw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1342000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_ibio_RubrycTheraputicsInc.Member_a0DlE4N_I0GxjgfDV7eBFg"
      id="Tb_GLRHE-rEtEu_8L6IWXhbAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,228,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,342,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_UDQEaykRk0-p2VWL-WDKDQ"
      decimals="0"
      id="Tc_WYIjBb_bFkKCcVGqmOpyCQ_1_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1228000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_JyKBqBRPyU6zhBnwdkIH9w"
      decimals="0"
      id="Tc_4qNarJVnWkmnSs0yOgQ5dw_2_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">114000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg"
      decimals="0"
      id="Tc_AU4wRtUy4UqbqKuPdJT0MA_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1342000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA"
      decimals="INF"
      id="Narr_hTvAgRyir0mqjNy-vlCRyA"
      unitRef="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ">3</ibio:NumberOfEquipmentLeases>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA"
      decimals="0"
      id="Narr_ZmcurC6AHkG_naamvqRzKg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">814000</us-gaap:FinanceLeaseLiability>
    <ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_rAwJKIJOaESss1i2YVKDCA"
      decimals="INF"
      id="Narr_1NQ3J9pLC0CqwsPRfrXlEg"
      unitRef="Unit_Standard_item_hCBMRpViQ0aEEJdOwEy49g">6</ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_YzbY9GLiGE2-ktZqZfwryg"
      decimals="-4"
      id="Narr_A6W0FHv5fEWoIL5c6P6aVA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2130000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-5"
      id="Narr_Z_c53oFASUKh48qVJYg07g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <ibio:AccruedLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_UWTbx3EXRkCgwv1m35o82A"
      decimals="0"
      id="Narr_U7AzavVZzUaVbkM6JA-HLg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">527000</ibio:AccruedLiabilitiesNoncurrent>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_Bgs2Oc5i6UCZxWJxUVyttA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Promissory Note Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;On June 19, 2023, the Company issued a promissory note (the &#x201c;Note&#x201d;) with Safi Biosolutions, Inc. (&#x201c;Safi&#x201d;) in the principal amount of $1,500,000, which was issued in exchange for the convertible promissory note (the &#x201c;Convertible Note&#x201d;) issued by the Company to Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of 5% per annum and will increase to 7% for the first one (1) year extension and 9% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of 5% per annum and had a maturity date of October 1, 2023, was voided. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;For the Fiscal years ended June 30, 2023 and 2022, interest income amounted to $75,000 and $75,000, respectively. As of June 30, 2023 and 2022, the Note balance and accrued interest, which have been classified as long term, totaled $1,706,000 and $1,631,000, respectively.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <ibio:LoansReceivableAmountInvested
      contextRef="As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XheyQ-Fl9UOlWW6gNyl5VQ"
      decimals="0"
      id="Narr_KgS8ssG-EEmssn-3szssjw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1500000</ibio:LoansReceivableAmountInvested>
    <ibio:LoansReceivableFixedRatesOfInterest
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ"
      decimals="2"
      id="Narr_A8UUGnQMp02CdIH0kxRaIA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.05</ibio:LoansReceivableFixedRatesOfInterest>
    <ibio:LoansReceivableRateOfInterestForFirstOneYearExtension
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ"
      decimals="2"
      id="Narr_4hzY4vRXA0y9NXj5ZxKwCg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.07</ibio:LoansReceivableRateOfInterestForFirstOneYearExtension>
    <ibio:LoansReceivableRateOfInterestForSecondOneYearExtension
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ"
      decimals="2"
      id="Narr_TteSEThOBUCmBXe7BRcboQ"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.09</ibio:LoansReceivableRateOfInterestForSecondOneYearExtension>
    <ibio:LoansReceivableFixedRatesOfInterest
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_a3bJT-4B40-0hZ0XHXDeHQ"
      decimals="2"
      id="Narr_O_1fsg4PC0WlkBSRRMSYvw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.05</ibio:LoansReceivableFixedRatesOfInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_OXGEMBaf90uzpnugexjTyQ"
      decimals="0"
      id="Narr_mG3WN11nakqkch_9HWoFMw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">75000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_1SxKBjeXXku5LCaQyLli3Q"
      decimals="0"
      id="Narr_8Ksve7nQT0mpBm5HmemMjA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">75000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="As_Of_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_0YcPqwpOjkuyZyE_8SFtfw"
      decimals="0"
      id="Narr_eha2pniJgUSCJ29-YqLM4A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1706000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="As_Of_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_j1xUG58p10iMMcwJJ-ZzWQ"
      decimals="0"
      id="Narr_Zccmmbmr8EudbWl2sfRC2w"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1631000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_-Q3s_llX8kOOnsidhtESfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Investments in Debt Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10.8pt -0.7pt 0pt 0pt;"&gt;The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Adjusted cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Gross unrealized losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.6pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;The fair value of available-for-sale debt securities, by contractual maturity was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.6pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;Amortization of premiums paid on the debt securities amounted to $67,000 and $312,000 for the years ended June 30, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;Realized losses on available-for-sale debt securities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Proceeds from sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Cost of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Realized loss on sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (98)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_CpwuTpu6606fq--7yLgfQQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10.8pt -0.7pt 0pt 0pt;"&gt;The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Adjusted cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Gross unrealized losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_yUhusodndkGZ9Pg8BtBMJg_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">11029000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_QNmha4DzSE-8JLmPyEo6YQ_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_z2uwi71Qi0OACeBW54szZQ_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10845000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_i_PUfljiB0-64M2_PwUnCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;The fair value of available-for-sale debt securities, by contractual maturity was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 59.6pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_dPhyG0Hc5ECzmxAsnYSZLg_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">8054000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <ibio:AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_EEJ2ymd1PEmW1edHwkxiQg_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2791000</ibio:AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_oNeZBLcnvkWEcsFQ0bdDxg_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10845000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_ujoqMV9AOkqyhFNm0nfVYg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">67000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_hsF2MGe2c0Ko8to7J-dONQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">312000</us-gaap:AmortizationOfDebtDiscountPremium>
    <ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_jO8E1GzVCEqp2DTts5NWqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;Realized losses on available-for-sale debt securities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Proceeds from sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Cost of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Realized loss on sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (98)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Yh6IxtgaiE-Xnjx7lKtUGQ_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6739000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <ibio:CostOfDebtSecurities
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_m5rhVBYlAEmT6kXrDjxiZg_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6837000</ibio:CostOfDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_wuJmNn2aJUKUaHova2_AVw_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-98000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_iYJnyZjGKUS_IyMpnc1beQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9.&#160;&#160;&#160;&#160;Finance Lease ROU Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. The lease for the mobile office trailer was terminated in December 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;See Note 15 &#x2013; Finance Lease Obligations for more details of the terms of the leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ROU - Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (204)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net finance lease ROU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;Amortization expense of finance lease ROU assets was approximately $204,000 and $0 for the years ended June 30, 2023 and 2022, respectively.&lt;/p&gt;</ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock>
    <ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_y69Vf-sPAUGM9DJewo2m-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ROU - Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (204)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net finance lease ROU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock>
    <ibio:FinanceLeaseRightOfUseAssetGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cDhv992H80uLjlrOUmMXpA"
      decimals="-3"
      id="Tc_nhToeAi410iv955O7rIGdQ_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">814000</ibio:FinanceLeaseRightOfUseAssetGross>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_s_ENqpaGjEyHFCE4A8KTtQ_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">204000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_7IXbArNb70222zuNEJvRdw_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">610000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_rsI2XGwBiEKwiCQmOaBjGA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">204000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr_wihzDv6RG0-cldw3C0aohA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_I-DqDDpSPEC6qjeRocTmvw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10.&#160;&#160;&#160;&#160;Operating Lease ROU Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;San Diego, California&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. The net carrying amount of this ROU operating lease asset was $2,722,000 and $3,068,000 at June 30, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Bryan, Texas&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. The net amount of this ROU operating lease asset is included in assets held for sale. &#160; &#160; &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;See Note 16 - Operating Lease Obligations for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A"
      decimals="INF"
      id="Narr_TGH9l60V1UCBOfLxXdr9QQ"
      unitRef="Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw">11383</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A"
      decimals="0"
      id="Narr_wjdtfDalW0ygIE-XjcuXXw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3603000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_zGNI2BK3JEW4qvOK25bq4g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2722000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr_su_QVmWZ1064wm_NXC1gNw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3068000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_11_1_2021_9whzlfUgsUeBm5EBeEsgEg"
      decimals="0"
      id="Narr_-y9y6nYVTk2F6_ZB8PmltQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1967000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_Pik_7BK64kGNS2DaNf3arA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11.&#160;&#160;&#160;&#160;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Building and improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;Depreciation expense was approximately $400,000 and $0 for the years ended June 30, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Fixed assets held for sale at June 30, 2023 and 2022 in the amount of $16,124,000 and $35,289,000, respectively, are included in assets held for sale. &#160;The depreciation expense for the years ended June 30, 2023 and 2022 is classified as part of loss from discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;During the Fiscal year ended June 30, 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company recorded an impairment charge of approximately $17.9 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;See Note 5 - Financial Instruments and Fair Value Measurement for more information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_RAzUQZVXfEOOGBtEt1cyzw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Building and improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_dZg1WhqNY0uE1A0c9lHl3A"
      decimals="-3"
      id="Tc_iW_4S4IM8kqXDbJqaU1Ihw_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">695000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_rnZo30pQDUukbPb7XP4wQA"
      decimals="-3"
      id="Tc_cWz2KHg9vEKN3lyufXj06w_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_3cd_ntn9tk-FS9Dj6nY5OA"
      decimals="-3"
      id="Tc_6r3M4NOfu0SZSrsOe4IIHg_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3521000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_0UI15QK8_EKkODArRfq0rg"
      decimals="-3"
      id="Tc_pUAF-FNQPkKWgaNMn4tdGg_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_-LP9qePrKEKSRn6V__dvKA"
      decimals="-3"
      id="Tc_-IyN7wMFIEmOr00GPt_m7A_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_6o-7lqfD3E6XYI9oPMTzMg"
      decimals="-3"
      id="Tc_5BHBXWcQoUGYrNJ4NJCRdQ_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_eQjpKMv4a0WIG8KhXwtaAg"
      decimals="-3"
      id="Tc_UoxNkCZBWUaUADBcZ0q-Kw_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_n8A-vIkPIk-D3alQ6Tlk4g"
      decimals="-3"
      id="Tc_5yzWTE5fnUm72MHcsmMJDQ_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1373000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_zP6ZMW_U2kiusQwTk-Qo4g_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4619000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_6aCF_sXdPUeXRZnofsaF_Q_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1373000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_KSQwdw1B_EWL-DNIRztPOw_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_iquQ_hHuj0Sx7nWN9whFVg_9_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_cyhD2OVrkEyNpbPCxIDsNg_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4219000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_JMpnD4YOV06Vk1-MOEHPDQ_10_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1373000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_lrOB_Ylyt0C9ptaiC_8dAA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr_1SUy-zXYokyf9YibQiDS8w"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <ibio:FixedAssetsHeldForSale
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_97PbTRkjvEWnarqIj7pJQQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">16124000</ibio:FixedAssetsHeldForSale>
    <ibio:FixedAssetsHeldForSale
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="0"
      id="Narr_ADHf-cLkhEaG2BBhSFCEuQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">35289000</ibio:FixedAssetsHeldForSale>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-5"
      id="Narr_1s49lu2fxkqjdgdXqOr-Pg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">17900000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:StockPurchaseAgreementTotalInvestment
      contextRef="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_GMLt8Z0kCUWGHfk9AJSpeA"
      decimals="-5"
      id="Narr_MRu21ZC7xEO4zCkcY4fy3Q"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7500000</ibio:StockPurchaseAgreementTotalInvestment>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_8_14_2022_To_8_14_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_TbCIxSxD_ka6X8lcCqL-Eg"
      decimals="0"
      id="Narr_dJyt4DdAMUaJlHg59aFcMQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">25000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw"
      decimals="0"
      id="Narr_g4MdTR0O9kmE5DuzVj-tyg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">565000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_MeaCIqKJOEawOzUh7Pp-PA"
      decimals="0"
      id="Narr_7w0uyBGUD0ymd0Y82kDiAw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_NvWLbd6qjk2406-uSv9TQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,846)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,946)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,867)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total definite lived intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (565)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License - indefinite lived&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net intangible&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_vEQqufD90USP1VGzaUl2Uw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; 1,228&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,388&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_6Fl1dC8ctUaESD30gx10sA"
      decimals="-3"
      id="Tc_1tr3Sh6kAU6aLNGihlPDbg_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw"
      decimals="-3"
      id="Tc_4Q3EppoHYU-E-QU6UUtNiw_3_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <ibio:ImpairmentOfIntangibleAssetsGrossOfReversals
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw"
      decimals="-3"
      id="Tc_m-lcyzV6GECIcXN4j-3Mwg_3_12"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3100000</ibio:ImpairmentOfIntangibleAssetsGrossOfReversals>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ"
      decimals="-3"
      id="Tc_8lgND34HlkmhXTglE1MoHg_3_15"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_OUSYNzx-3kmj7vrVQcR-fw"
      decimals="-3"
      id="Tc_VdhsbYkE10-X-_veBa_qRQ_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2846000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <ibio:ImpairmentOfIntangibleAssetsGrossOfReversals
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw"
      decimals="-3"
      id="Tc_sLl8-49YdECH63HEOj92Dg_4_12"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2846000</ibio:ImpairmentOfIntangibleAssetsGrossOfReversals>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_XN8zQP-Mn06lKZYkVqGjRw_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5946000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_lh7InptnPU-4jXwOCt5sZw_5_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <ibio:ImpairmentOfIntangibleAssetsGrossOfReversals
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_ZHbDWmuirUe_b24T17RxHw_5_12"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5946000</ibio:ImpairmentOfIntangibleAssetsGrossOfReversals>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_ql8J76eMNE2mZvDgpTdSug_5_15"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_6Fl1dC8ctUaESD30gx10sA"
      decimals="-3"
      id="Tc_iA2A1X6bW0Guc2iQxF-FTQ_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2867000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw"
      decimals="-3"
      id="Tc_RjIeTcJxP0i9TZ-cWpQ-Xg_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">79000</us-gaap:AmortizationOfIntangibleAssets>
    <ibio:ReversalOfIntangibleAssetImpairment
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Lgqz1GYQ3UyiUs35zwXdLw"
      decimals="-3"
      id="Tc_XpGc17M7r0mP6tIZ4-Ca8A_6_12"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2931000</ibio:ReversalOfIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ"
      decimals="-3"
      id="Tc_IWUCvtPkMU-p9Uio4a7ZcQ_6_15"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">15000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_OUSYNzx-3kmj7vrVQcR-fw"
      decimals="-3"
      id="Tc_0uO53UmEgk6HjwZipAEdmA_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2403000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw"
      decimals="-3"
      id="Tc_syV6yHmyC0e5a5tQWNG6gw_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">47000</us-gaap:AmortizationOfIntangibleAssets>
    <ibio:ReversalOfIntangibleAssetImpairment
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_faT3UFU2H0uF2uis9luXrw"
      decimals="-3"
      id="Tc_5INtzCnyEEGSUpXHuhjrXQ_7_12"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2450000</ibio:ReversalOfIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_eb4XGpjuTUOR1s53jj05dw_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5270000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_OmEd8axsAUSzH6GrXF5zRA_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">126000</us-gaap:AmortizationOfIntangibleAssets>
    <ibio:ReversalOfIntangibleAssetImpairment
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_yB6AbA-qREO_00gfJttTEA_8_12"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5381000</ibio:ReversalOfIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_UTa5x0RtuECjlVJZ3oka0Q_8_15"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">15000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_qW_-_-hZRkSzc7zlwVal0A_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">676000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_tFC30wu8L0mxiOMzhk9u3g_9_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">126000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_cv1KdiR-z0KZinTTkfLBMw_9_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Hta0Wa6M7kGRthezSNw2aw_9_12"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">565000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_V0bW8Xv8J0O4nIQuaygUUw_9_15"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">385000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_t0oZ7pDi4kK6CN06AhPQ4w_11_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4175000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_9Ozrj4vktUeQ4pTTnuw7BA_11_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">828000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_u-IAXOxZz0mfF2So18IbDA_11_15"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5003000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_p9n28jljtkue-xwPoO2acA_13_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4851000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_GpPrmvIBuUO2hLYJxnTIkw_13_15"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5388000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_ojA-5S03aEepHqGA3RsE-g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">126000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_skeGLCbHtkeek6QQl_Yc5Q"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">401000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ToW-0qDW2kebG6pJdD7-FQ"
      id="Narr_ebkIfIUrME63nGJOKcNuOg">P19Y3M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DA4mNb1HCESUnEtjTHgS3w"
      id="Narr__pDjnsdA40mso9Fw77L1ww">P1Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_0SGjXcjVIUm_sr0wPDMzug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:44.49%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 285&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc__l9o546nIkuzkEc6SlI_Ag_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_rJHCPc9UcUKT3YINSeLsvA_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_nbeWnSn3AkOlHvc1mgFzsQ_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_9BNQ8j_jiUCWLgrOIZQfpQ_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_3AjU-D83Ek-EG9dumOaLKQ_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_9J6kLN4AJ0aZH-XSAWBaNw_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">285000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_zhYNMnI7_kWT5Jsmm3cA3g_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">385000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_M_O-OefXtk-z-xl2sc2qIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;Accrued expenses consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,066&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Real estate taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 284&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest and fees related to term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_pnd2pBHikkGxmkKK5MTWtQ_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3352000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_e8FLXgvSQ0qzzIWX2yUx4A_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3066000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ibio:AccruedRealEstateTaxes
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_bZq98Qh2q0eY7l0onYMyyA_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">268000</ibio:AccruedRealEstateTaxes>
    <ibio:AccruedRealEstateTaxes
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_Eaj1SHQpA0WPZNJEDJtFHQ_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">284000</ibio:AccruedRealEstateTaxes>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_83552zqAgUqONC_MZq3Xrg_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">183000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_mODzEXkSjUaB4pM-48ZkPg_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">59000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_DSiYk--K_0OhhY4D6anU7w_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">31000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_Ee_EC0y_60-TGRUkVFd7pw_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">126000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_ABvOnqOwCkGQiy25mITEdQ_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">200000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_er2rjZTY6E-RLNc-92l4Vg_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">229000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_0eZaEibzbESQapZhGkdZkw_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_WfVeFemN80yff7T4WMKaeg_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3764000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_Cz2K5CnNA0aoSF82--1aRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14.&#160;&#160;&#160;Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Credit Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#x201c;Term Loan&#x201d;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#x201c;Term Note&#x201d;) (for a complete description of the Transaction please see Note 6 &#x2013; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest was payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (the &#x201c;Fraunhofer Settlement Funds&#x201d;) (see Note 20 &#x2013; Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#x201c;Liquidity Covenant&#x201d;) in the Guaranty (as defined in the Credit Agreement) from &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;$10,000,000 to $7,500,000 with the ability to lower the liquidity covenant to $5,000,000 upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#x201c;going concern&#x201d; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2023, the Company&#x2019;s unrestricted cash decreased below the required $7,500,000, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#x201c;Second Amendment&#x201d;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#x201c;Third Amendment&#x201d;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than &lt;span style="-sec-ix-hidden:Hidden_sMGyGM4rm0etbg7foCVLZw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#x201c;Fourth Amendment&#x201d;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed the Company to retain $2,000,000 of the $5,100,000 that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 being held in a Company account at Woodforest. &#160;In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#x201c;Fifth Amendment&#x201d;), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3,000,000 being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10,000,000 and for each additional $2,500,000 reduction of the outstanding principal amount, an additional $750,000 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in-kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) &lt;span style="-sec-ix-hidden:Hidden_HmO8mI3b8UikyAnwMIet_Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3:00&lt;/span&gt;&lt;/span&gt;%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#x201c;Sixth Amendment&#x201d;), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Purchase Agreement for the sale of the Facility within &lt;span style="-sec-ix-hidden:Hidden_v7l5jYByc026hKF0AEadYQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; business day after entry into the Sixth Amendment, and (ii) if the Facility is not sell on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the Maturity Date. &#160;In addition, if the closing and funding of the Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMO&#x2019;s real estate, including the Facility, at the cost of iBio CDMO.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;At June 30,&#160;2023, the balance of the Term Loan was $12,937,000 which consisted of the Term Note of $13,057,000, net of approximately $120,000 of deferred finance costs. &#160;At June&#160;30,&#160;2022, the balance was $22,161,000 which consisted of the Term Note of $22,375,000, net of approximately $214,000 of deferred finance costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Equipment Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $16,230 through October 2025. &#160;At June 30,&#160;2023, the balance owed under the financing was $401,000. &#160;Interest incurred under the financing for the year ended June 30,&#160;2023 totaled approximately $31,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Future minimum payments under the finance lease obligation are due as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on March 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum equipment financing payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (160)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum equipment financing obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Note Payable &#x2013; PPP Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;On April 16, 2020, the Company received &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$600,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; related to its filing under the Paycheck Protection Program and Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;). &#160;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;The Company elected to treat the Small Business Administration (&#x201c;SBA&#x201d;) Loan as debt under ASC 470, &lt;/span&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Debt&lt;/i&gt;&lt;span style="font-weight:normal;"&gt;. &#160;At June 30, 2021, the Company owed &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$600,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;"&gt;On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, &lt;i style="font-style:italic;"&gt;Liabilities - Extinguishments of Liabilities &#x2013; Derecognition&lt;/i&gt;, the Company derecognized the liability and accrued interest in the first quarter of Fiscal 2022. The forgiveness is included in loss from discontinued operations.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_gu1NRcCf3UK-cY9abE950Q"
      decimals="0"
      id="Narr_BELP1O2TPU-yxUiz91QVeQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_gu1NRcCf3UK-cY9abE950Q"
      decimals="4"
      id="Narr_jjhjTG8TfEapkrEqG3CUHw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_2RUbpio7FEeipqf0K7mQCg"
      decimals="0"
      id="Narr_HCdp9C78ZkKD9UOwHzOq0w"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5500000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember__jVFiqLstUOWmy568nqUUQ"
      decimals="0"
      id="Narr_1f9AQXd9ekagZfre3cDrIQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5100000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_nz1JdBks80Cs0AMppzhnXw"
      decimals="0"
      id="Narr_k5IRfhVc10G_rae5EDqKpw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">250000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_4NB7YEQHAUqVr8MzcB_kuw"
      decimals="0"
      id="Narr_ItTR5NpPQU-P_cDrJdpcnA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22375</us-gaap:DebtInstrumentFeeAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_NCgEbLSz3ky2W-1HFoSejQ"
      decimals="0"
      id="Narr_YbtODMd_vEu3dxijHruBxg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10000000</ibio:DebtCovenantLiquidityAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_4NB7YEQHAUqVr8MzcB_kuw"
      decimals="0"
      id="Narr_3cQw_P92cESg7N1jg3WbEQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7500000</ibio:DebtCovenantLiquidityAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_N0d1OE5sOk6a6vFBAShgiw"
      decimals="0"
      id="Narr_r0ma_1o9FkiuqvPJ3OQVrQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5000000</ibio:DebtCovenantLiquidityAmount>
    <ibio:CreditAgreementThresholdLimitUnrestrictedCash
      contextRef="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_CQLMvmW4IEONf8twopcH1w"
      decimals="0"
      id="Narr_NU6yYs6_0UOGlDoHCzYb5g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7500000</ibio:CreditAgreementThresholdLimitUnrestrictedCash>
    <ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility
      contextRef="Duration_2_20_2023_To_2_20_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_kHwI2oYS2kqmmWDijalKcw"
      decimals="2"
      id="Narr_qfzeSwI9zkytwzmlOYYcqA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.40</ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility>
    <ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility
      contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AMSxbpHjr0eHHzhd2SU4ZQ"
      decimals="2"
      id="Narr_HVM23Tyog024RhG8CScEPA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.40</ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility>
    <ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility
      contextRef="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_utNLNmYSRU-7gHrqgVWwQg"
      decimals="2"
      id="Narr_ntlxE0evj0qYGwVb2IdFTQ"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.20</ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility>
    <ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment
      contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AMSxbpHjr0eHHzhd2SU4ZQ"
      decimals="2"
      id="Narr_XxN7M3KQskCNFskj_P9bHw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.40</ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment>
    <ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment
      contextRef="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_utNLNmYSRU-7gHrqgVWwQg"
      decimals="2"
      id="Narr_ScHzQ8bk5kqMnLzME9PoDA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.20</ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment>
    <ibio:AmountRetainedFromProceedsOfLegalSettlement
      contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AMSxbpHjr0eHHzhd2SU4ZQ"
      decimals="0"
      id="Narr_8c8hHRz_QEaCrsy7Kg1fQg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2000000</ibio:AmountRetainedFromProceedsOfLegalSettlement>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_3_24_2023_To_3_24_2023_l9rVfdViGkK2f-fdYObPPA"
      decimals="0"
      id="Narr_yqp6_dC3KEKhB91fYT6_ng"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5100000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_bMRwgJhi-EeZTQrY-DJ9ig"
      decimals="0"
      id="Narr_FKYw4DUag06ynct8YEMeTw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_EbZx7U23KkqqedJKnH3P9Q"
      decimals="0"
      id="Narr_6CqJ4ZqUWE29p4jtdJytYg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">75000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_bMRwgJhi-EeZTQrY-DJ9ig"
      decimals="0"
      id="Narr_Td8VLxihZU6bTlwxW5HbWA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">7500000</ibio:DebtCovenantLiquidityAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_GmkcutYho0qIygUE-r1Kyw"
      decimals="0"
      id="Narr_r5J0dmF4r0a5WdaelUbT7Q"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1000000</ibio:DebtCovenantLiquidityAmount>
    <ibio:AmountToBeReleasedFromRestrictedCash
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KaGEDjN0e0GNLqwZeqxNuw"
      decimals="0"
      id="Narr_4Uv3ZHdJgUW85pBWWCQ1zA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">500000</ibio:AmountToBeReleasedFromRestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_56vZG9jEekWgY4y74laSeQ"
      decimals="0"
      id="Narr_pvi84bm3CEWTXV-1Qe6kAQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <ibio:AmountToBeReleasedFromRestrictedCash
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_JHTUWvDAy0mSeOtQy7guzQ"
      decimals="0"
      id="Narr___r4EMxRPkureLsuaq9GMw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">750000</ibio:AmountToBeReleasedFromRestrictedCash>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_CU79tDBZJ0-os-9D7HXbbQ"
      decimals="4"
      id="Narr_ip0DW0E3P0e74PLZTNjanQ"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ibio:DebtInstrumentPaidInKindInterestRate
      contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_i3ZFj12p9UazqqscbySntw"
      decimals="4"
      id="Narr_vJjO-yboFEWaTqHdfS3jOg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0100</ibio:DebtInstrumentPaidInKindInterestRate>
    <ibio:DebtInstrumentPaidInKindInterestRate
      contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_nNBE8O_Yc0GrXHryQ3ARjw"
      decimals="4"
      id="Narr_2wMEUMOimkegic27eNGtLA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0200</ibio:DebtInstrumentPaidInKindInterestRate>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_0UIjDWk4GkapKTIJmMsJJw"
      decimals="0"
      id="Narr_M9568SGWGECucwNtdQGk1w"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">75000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_GcE4nP69ekilykVs1dNbZA"
      decimals="0"
      id="Narr_KL31n-Ey9kW_56DyRIJO4A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">100000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_9TjCBbgA7UyTlQwWmTS87Q"
      decimals="0"
      id="Narr_HhZB1e40C0WD4_7HsKqABw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">125000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ni7O9yqrp0G3jZAhtH1cdg"
      decimals="0"
      id="Narr_tlyT6Ou_KkKZ4tYT4xJLgw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <us-gaap:LongTermDebt
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_ip8TzvFk80eYolQL5zegdA"
      decimals="0"
      id="Narr_TE7io7zR60q53N9U-xj7Fg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">12937000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_ip8TzvFk80eYolQL5zegdA"
      decimals="0"
      id="Narr_hxzh4zMHP02VrPFIRvhjuw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">13057000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_ip8TzvFk80eYolQL5zegdA"
      decimals="0"
      id="Narr_TfjeoXl1p0e3dE88UyZVgQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">120000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_X5uA0-qoeEeIkEVG5KZZjA"
      decimals="0"
      id="Narr_UEMPi_2vHEOQ5_BZrfGY3A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22161000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_X5uA0-qoeEeIkEVG5KZZjA"
      decimals="0"
      id="Narr_g8qmzpxsgk6MrJjmC-L5ZA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_X5uA0-qoeEeIkEVG5KZZjA"
      decimals="0"
      id="Narr_A9zD0B81UEuUDP6UdoA74Q"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">214000</us-gaap:DeferredFinanceCostsNet>
    <ibio:EquipmentFinancingAmountBorrowed
      contextRef="As_Of_10_12_2022_JPfG9ZEqqUa0LmbfHdCHIg"
      decimals="0"
      id="Narr_A4uL5uZamEqrbmnhL23TJw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">500000</ibio:EquipmentFinancingAmountBorrowed>
    <ibio:LesseeEquipmentLeaseTermOfContract
      contextRef="Duration_10_12_2022_To_10_12_2022_L-VOkowDDUifCXu94CAHuw"
      id="Narr_Mb_eshKFMk6Lsu344kzbnA">P36M</ibio:LesseeEquipmentLeaseTermOfContract>
    <ibio:EquipmentFinancingLeaseImputedInterestRate
      contextRef="Duration_10_12_2022_To_10_12_2022_L-VOkowDDUifCXu94CAHuw"
      decimals="4"
      id="Narr_6AjALkFwY0-xgHIBhj4YIg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.1062</ibio:EquipmentFinancingLeaseImputedInterestRate>
    <ibio:EquipmentLeasingMonthlyInstallmentPayable
      contextRef="As_Of_10_12_2022_JPfG9ZEqqUa0LmbfHdCHIg"
      decimals="0"
      id="Narr_WKOwS3ltBke3X926mlhkHA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">16230</ibio:EquipmentLeasingMonthlyInstallmentPayable>
    <ibio:EquipmentFinancingBalance
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_3_95FgwX_EGM21IXhPP3MA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">401000</ibio:EquipmentFinancingBalance>
    <ibio:EquipmentFinancingInterestIncurred
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_ZnDbnY0XwUeJHU04-IrgFA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">31000</ibio:EquipmentFinancingInterestIncurred>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb__zwhHIKQpkydWwrYYk5Veg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on March 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum equipment financing payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (160)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum equipment financing obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_Aaq2aytfaEiGHPBiyvyZ6Q_2_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">160000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"
      decimals="-3"
      id="Tc_2eX1LOvRG0aLtq_Ju9XwCw_2_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">35000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_UmAvnBbrEU2MjurKxMKsfA_2_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">195000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_uw8vsoEDpEqnRf4vzwQOug_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">177000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"
      decimals="-3"
      id="Tc_6Q56690gQ0SSXYht0-adWg_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">17000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_pvj2wVJuTkmYr2p2DEaQkg_3_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">194000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_O6tn6dZo60y0JRBLH5DFEw_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">64000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"
      decimals="-3"
      id="Tc_TOMvBHbW5UyZzGTKeBL5LA_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_m6ptjJcV_k2geRlWOpeiOQ_4_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">65000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligation
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_sAbOGznrjE2zfncONmbtGw_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">401000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"
      decimals="-3"
      id="Tc_qAdHSxLM3UyL1SOeBXvfxg_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">53000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_q6k6i7V1QE6H3v3vhPEMVg_6_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">454000</us-gaap:ContractualObligation>
    <ibio:ContractualObligationCurrent
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_X75-tQzsd0-K-PM-z4addQ_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">160000</ibio:ContractualObligationCurrent>
    <ibio:ContractualObligationNoncurrent
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_KbHWRBgeT06WKZJ_1nTc-A_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">241000</ibio:ContractualObligationNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_XdqoL_rkxkCM1xpi2PlAeQ"
      decimals="0"
      id="Narr_d9ZPhVLzMUib3WPHvWBYlA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">600000</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_rv5XUgdp7EGs6FYMQwZaCw"
      decimals="0"
      id="Narr_H8TzFsac_UCclKYFPYsdrw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">600000</us-gaap:NotesPayableCurrent>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_GQpiKatddEiuW0xpZxq0pQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15.&#160;&#160;&#160;&#160;Finance Lease Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Sublease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. &#160;See Note 16 &#x2013; Operating Lease Obligations for additional information related to the ground lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;General and administrative expenses related to College Station, including rent related to the increases in the Consumer Price Index (&#x201c;CPI&#x201d;) and real estate taxes, were approximately $250,000 for the year ended June 30, 2022. Interest expense related to College Station was approximately $810,000 for the year ended June 30, 2022. Such expenses were classified as part of loss from discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $814,000 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Mobile Office Trailer&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $3,819 through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate - finance lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Future minimum payments under the capitalized lease obligations are due as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal year ending on June 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 691&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (272)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_SecondEasternAffiliateMember_DgnY7nozKk6LLsBoViwjXA"
      decimals="0"
      id="Narr_J53xOaGEik-ON6vvJ93Ftg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">250000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_SecondEasternAffiliateMember_DgnY7nozKk6LLsBoViwjXA"
      decimals="0"
      id="Narr_TDmuLBNQW0OD671mWcLlFA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">810000</us-gaap:InterestExpenseDebt>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA"
      decimals="INF"
      id="Narr_raCrpv955kqcMjb0QKsvNA"
      unitRef="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ">3</ibio:NumberOfEquipmentLeases>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA"
      decimals="0"
      id="Narr_P1z0fdMpK0OBNCVpK9sTxQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">814000</us-gaap:FinanceLeaseLiability>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA"
      decimals="INF"
      id="Narr_3vhdMTUKvkGItEprATNMCw"
      unitRef="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ">3</ibio:NumberOfEquipmentLeases>
    <ibio:LeaseRentExpensePerMonth
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_oxMyEE3vMkKthpi_lTkUeg"
      decimals="0"
      id="Narr_fZoOj-eelkewJAxlB4aAAQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">14000</ibio:LeaseRentExpensePerMonth>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_Ppx5t2FvYkODMlNEPiMkoA"
      decimals="INF"
      id="Narr_VOl5CODHHEmJ7jZpPywkaA"
      unitRef="Unit_Standard_lease_V3aX-Vmz40CfCHa0tZcFLQ">3</ibio:NumberOfEquipmentLeases>
    <ibio:LessorFinanceLeaseMonthlyRent
      contextRef="Duration_4_1_2021_To_4_1_2021_94fR0DLTmEC12g7MPaQqxA"
      decimals="0"
      id="Narr_cei-9ZBDMESOQUo1SVi-BQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3819</ibio:LessorFinanceLeaseMonthlyRent>
    <ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_71bkc_RkJkejpWD-YTB9Bw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate - finance lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_PTZhhyexwkyT64a6gHlVmg_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">224000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_YXRhZfMKvUqpkWNSjdpp9w_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">49000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_GVM8jrocb0aFNiIc2ifhNw_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">273000</us-gaap:LeaseCost>
    <ibio:FinancingCashFlowsFromFinanceLeaseObligation
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_tH64YqBZ90KyqivK7eLgkQ_11_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">208000</ibio:FinancingCashFlowsFromFinanceLeaseObligation>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_3NSp7K4E9USqgv1Dr54qkg_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">610000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_nktzHwoq1kqWwp0XUu7ZGw_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">272000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_DSR1Ped8TUaHTZTHrmS_4g_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">351000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      id="Tc_lDxJQBCgP0ClcFBm87jmdA_6_3">P2Y2M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="4"
      id="Tc_zSfh2svmTU2urAImHYxBMQ_7_3"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0950</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_KHnJOWajikWpmeUUHnZmLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Future minimum payments under the capitalized lease obligations are due as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal year ending on June 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 691&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (272)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_3gI8m0U9N0SbuIwPaj9GFw_2_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">272000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"
      decimals="-3"
      id="Tc_PhEQb799l0S_x557a1dNRw_2_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">47000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_3MI8jPsNg0KIm7OHF0QEQQ_2_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">319000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_ze_tE6jE5E2noI5kXcVCWA_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">299000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"
      decimals="-3"
      id="Tc_-6PYFwRGlUeliNRD8uictg_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_cIvClsV1T0SQuJctEuOKwQ_3_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">319000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_qwqnRS1tZE2yVqOVCJHK-g_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">52000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"
      decimals="-3"
      id="Tc_prTQZG1P5kuU57ofWWHtbw_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_V_lNE6liZkuGDYibxQW1tQ_4_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">53000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_87heAcYJ80242j1MsxI3Fg_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">623000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_UaO7syGWlUSa1gfDHePWVg"
      decimals="-3"
      id="Tc_ft7DJKMhg0qmaggEbLiVsA_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">68000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_4H7ZB0aBm0C-wAxuCl_kww_6_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">691000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_ada1tUkfQUW8w0tqHURP4g_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">272000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_DVGmqAb3aUq2jnyjWV9nyA"
      decimals="-3"
      id="Tc_pNyytjELtUqhU94NQYj5TQ_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">351000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_coN_XAWJeU-j0IQCzleHtQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16.&#160;&#160;&#160;&#160;Operating Lease Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Texas Ground Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;San Diego&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 10, 2021, the Company entered into a lease for 11,383 square feet of space in San Diego, California. &#160;Terms of the lease include the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The length of term of the lease is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;88 months&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; from the lease commencement date (as defined).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The lease commencement date is September 16, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The monthly rent for the first year of the lease is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$51,223&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and increases approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The lease provides for a base rent abatement for months &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_3yjQiksPYkaMOne7lIAO3w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; through &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_coC25BjKxUC8oCpGfnMVKg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in the first year of the lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The landlord is providing a tenant improvement allowance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$81,860&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to be used for improvements as specified in the lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company is responsible for other expenses such as electric, janitorial, etc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company opened an irrevocable letter of credit in the amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$188,844&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in favor of the landlord. &#160;The letter of credit expires on October 8, 2022 and renews annually as required.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. &#160;Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease right-of-use asset in the accompanying balance sheet. &#160;Rent expense for the San Diego facility commenced in Fiscal 2022, when the Company began making improvements to the facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease obligations - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;"&gt; 6.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate - operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum payments under the operating lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal year ending on June 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Imputed Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 631&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 142&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 688&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 710&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 936&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (389)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ibio:LesseeOperatingLeaseMonthlyRent
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w"
      decimals="0"
      id="Narr_VfcyPsQFJUyKkpWDj5ihkA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">151450</ibio:LesseeOperatingLeaseMonthlyRent>
    <ibio:BaseRentPercentageOfFairMarketValueOfProperty
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Yw-DJpiKfke9cg3T2iH34w"
      decimals="3"
      id="Narr_cl6QcbLEeUKeIeNFUzuo6A"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.065</ibio:BaseRentPercentageOfFairMarketValueOfProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A"
      decimals="0"
      id="Narr__tdZYOBZzkGml1g4PfVc5A"
      unitRef="Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw">11383</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A"
      id="Narr_JCweKuXT_kKM-InkT7S3nw">P88M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibio:LesseeOperatingLeaseMonthlyRent
      contextRef="Duration_9_10_2021_To_9_10_2021_U6Pc1fTlZUCT-CsKaG5_qg"
      decimals="0"
      id="Narr_-9ZEe1MYBUm5yZnH0UsrTw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">51223</ibio:LesseeOperatingLeaseMonthlyRent>
    <ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent
      contextRef="Duration_9_10_2021_To_9_10_2021_U6Pc1fTlZUCT-CsKaG5_qg"
      decimals="2"
      id="Narr_j07pyAFyvESKjEoWn73Nog"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.03</ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent>
    <us-gaap:TenantImprovements
      contextRef="As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A"
      decimals="0"
      id="Narr_P3tdZzrsd0Wy-nq99pexkQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">81860</us-gaap:TenantImprovements>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_tLpytXewLUGWxGC9zN2FKw"
      decimals="0"
      id="Narr_Q_M-2aeJNUSjSF5_3AFKVA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">188844</us-gaap:GuaranteeObligationsMaximumExposure>
    <ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_eZgpv9NJc0O5aFd-xaad9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease obligations - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;"&gt; 6.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate - operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Uhv7yueo8UuUx8v1C9wu_A_3_2"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">563000</us-gaap:OperatingLeaseCost>
    <ibio:TotalOperatingLeaseCosts
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_TBD7zBMi6EG-vTvk1493vQ_4_2"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">563000</ibio:TotalOperatingLeaseCosts>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Nmd_zhwhAUSluSjuT6IDyQ_8_2"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">563000</us-gaap:OperatingLeasePayments>
    <ibio:OperatingCashFlowsFromOperatingLeaseObligation
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_umt37kcuAkyP7t6qQ_-RXw_9_2"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">307000</ibio:OperatingCashFlowsFromOperatingLeaseObligation>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_5418wDlsVE6D-8T4CGXLwg_13_2"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2722000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_WoFhF36wHEWQvAgGZEdRWA_14_2"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">389000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc__e6yh3uEI0iV-NsnRCUMKg_15_2"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3125000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      id="Tc_0kEgE3kH9UmjPhwyhJPPmg_16_2">P6Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="4"
      id="Tc_P79ry0SOGEG3Wl1-NNaIlw_17_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0725</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_lTrNR_6R-EGrkL_P6IgT4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum payments under the operating lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal year ending on June 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Imputed Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 631&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 490&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 142&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 688&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 710&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 936&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (389)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_WOlgde6q0U24vCIuYEIg8A_2_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">389000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_3ZgocOLZiESG4bkajDDRjA_2_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">242000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_L-fx8a_7b0WU7thZQbAUbA_2_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">631000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_5_piRl0Irka_39CwO3hfig_3_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">436000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_lsjSyc0fqkeVxZ-hUHyk8g_3_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">212000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_-7-LHk2VWEyTHlAom7t_HA_3_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">648000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_bnDWKND140y8Tx11IEBegQ_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">490000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_lRPePZXSSUG1zXdzsb253A_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">179000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_MZZXYys-aEuoBau7i09m0A_4_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">669000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_3yLfgg9mAUqMBUjq0e4ASg_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">546000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_m8VIl7YbnEGUNKarBVvRbQ_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">142000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_x0m61xy1EEeO_8m0W5vi-A_5_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">688000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_JLGS1rq2_0qarazil8WnJw_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">610000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_rK8vVSN2fE-SRbm5NukYCg_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">100000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_S41IThaLh0WTBC17hL-8qQ_6_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">710000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_LepEkuHf10mXi9Mjc-B8sQ_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1043000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_ikcXezYRcUay3WSDBvz2ig_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">61000</ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_R3jzZ4T5Lka9YFqJXKaqAg_7_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1104000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_IG9W7O0oz0uLIBU4skapew_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3514000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_L-f1GP4dKEK6hfvRWcObhg_9_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">936000</ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_cfARW3caUEGu3-Pqwy6zaA_9_9"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4450000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_EU2A7wWuBkucYE4eA-J-kQ_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">389000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_xC2C7D2J00eiri1DRKjvlw_11_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3125000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_dKrVh06lfU-auK1pgrL-Aw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17.&#160;&#160;&#160;&#160;Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Series 2022 Convertible Preferred Stock (&#x201c;Series 2022 Preferred&#x201d;)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$0.001&lt;/span&gt;&lt;span style="font-style:normal;"&gt; per share, out of the Company&#x2019;s &lt;/span&gt;&lt;span style="font-style:normal;"&gt;1&lt;/span&gt;&lt;span style="font-style:normal;"&gt; million authorized shares of preferred stock. Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (&lt;/span&gt;&lt;span style="font-style:normal;"&gt;1&lt;/span&gt;&lt;span style="font-style:normal;"&gt;:1) shares of the Common Stock on a pre-split basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#x2019;s Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued one share of a newly created Preferred Tracking Stock, in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $13 million. After giving effect to the transaction, the Company owned 99.99% and Bryan Capital owned 0.01% of iBio CDMO.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 23, 2017, the Board of Directors of the Company created the Preferred Tracking Stock out of the Company&#x2019;s 1 million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of 2% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board of Directors, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. No dividends were declared through October 31, 2021. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. No iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The number of authorized shares of the Company&#x2019;s common stock is 275 million. In addition, the Company has reserved 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#x2019;s 2020 Omnibus Incentive Plan (the &#x201c;2020 Plan&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of &lt;span style="-sec-ix-hidden:Hidden_NSsLunwOnk-e7VxuFTCjbw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-twenty-five (1:25). On September 22, 2022, the Company's Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into &lt;span style="-sec-ix-hidden:Hidden_SIzvssG14kSIBSMx9LhFKg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a &lt;span style="-sec-ix-hidden:Hidden_E34AVy54BU-rs9CUNflyRg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-twenty five (1:25) reverse stock split of the shares of the Common Stock, either issued and outstanding, effective October 7, 2022. The Company&#x2019;s common stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuances of Common Stock for the years ended June 30, 2023 and 2022 include the following:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Cantor Fitzgerald Underwriting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. ("Cantor Fitzgerald") to sell shares of Common Stock, from time to time, through an &#x201c;at the market offering&#x201d; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022 and June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 5,782,871 shares of Common Stock. The Company received net proceeds of approximately $6.4 million during the Fiscal year ended June 30, 2023 and holds a subscription receivable for $204,000 at June 30, 2023 for proceeds received on July 6, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In Fiscal year ended June 30, 2022, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 175,973 shares of Common Stock. The Company received net proceeds of approximately $1.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;RubrYc Transaction&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;On September 19, 2022, the Company issued 102,354 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Wainwright Underwriting&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On December 6, 2022, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#x201c;Offering&#x201d;) (i) 1,530,769 shares of the Company&#x2019;s Common Stock, (ii) pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to 1,834,616 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#x201c;Series A Warrants&#x201d;) to purchase up to 3,365,385 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#x201c;Series B Warrants&#x201d; and together with the Series A Warrants, the &#x201c;Common Warrants&#x201d;) to purchase up to 3,365,385 shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a &lt;span style="-sec-ix-hidden:Hidden_sSHbFN61YUW0p-uuiWxmGw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;30-day&lt;/span&gt;&lt;/span&gt; option to purchase up to an additional 504,807 shares of Common Stock and/or Common Warrants to purchase up to an additional 1,009,614 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 504,807 Series A Warrants and 504,807 Series B Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#x201c;Representative&#x2019;s Warrants&#x201d;) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 201,923 shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Vesting of Restricted Stock Units &#x201c;RSUs&#x201d;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;RSUs for 217,553 of Common Stock vested during the year ended June 30, 2023. RSUs for 8,854 of Common Stock vested during the year ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Exercise of Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;No stock options were exercised in the year ended June 30, 2023. &#160;In the year ended June 30, 2022, options for 3,380 shares of Common Stock were exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Bryan Capital&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock of the Company at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of the Warrant using the Black-Scholes model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Wainwright&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;As discussed above, the Company issued various warrants with the following terms:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Pre-Funded Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.001&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Class A Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.04&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Class B Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.04&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Representative Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended June 30, 2023, 341,300 Class A Warrants and 1,781,216 Class B Warrants were exercised. The total proceeds from Class A and B Warrants exercised during the year ended June 30, 2023 was $2,207,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;3,475,916&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of common stock and existing Series B Warrants to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;2,058,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_CLcT6POV_06On0uZXB8YcQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; prices of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.04&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share (the &#x201c;Existing Warrants&#x201d;), to lower the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_uJKhf1drZEWLizl1NaG14A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; price of the Existing Warrants to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.50&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-6"
      id="Narr_THPbiQgb-UumAregDK_Q2Q"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_-uulEswf2EOU3Yjcrnq5ZQ"
      decimals="INF"
      id="Narr_FNxMafJlhU-D6H3CN-fLdQ"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-6"
      id="Narr_pQdbo9JatkySdEtngX31eQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_m5xJ-VdP5EGewGg_SkDIbQ"
      decimals="INF"
      id="Narr_N90-dCJ5pUyBGGIGYN_gFg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_m5xJ-VdP5EGewGg_SkDIbQ"
      decimals="0"
      id="Narr_u_ZHpZw-YEur-rgS3jeFJA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_m5xJ-VdP5EGewGg_SkDIbQ"
      decimals="0"
      id="Narr_cNmRrRoPHU6M5p9-ZBedXg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">270</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_kGxSOxgACUGRePau63QWAw"
      decimals="0"
      id="Narr_BTaL7X2Fy0KQBeZZGHNogA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">40</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_sAVoKqkVwEuYlSh556L0JQ"
      decimals="INF"
      id="Narr_Bcd2OUooN0KptfUS3PPWmA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_sAVoKqkVwEuYlSh556L0JQ"
      decimals="INF"
      id="Narr_znVcJJf_aUuBcbwkaCR5LQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">29990000</ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_sAVoKqkVwEuYlSh556L0JQ"
      decimals="-6"
      id="Narr_eNK0E2hVW0qsBYyYSxsGcQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">13000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_pjd-weRrSUC1EbGtOeMjCw"
      decimals="INF"
      id="Narr_u8B8UX-Vb0ywfjLD5mlROA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.9999</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_2_23_2017_srt_CounterpartyNameAxis_ibio_EasternAffiliateMember_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_UjXKotGel0yQY9BFBXctgA"
      decimals="INF"
      id="Narr_pAiUBofNcEy6Y7PII9eKJA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0001</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-6"
      id="Narr_FwWIEJa9v0C2SMNLlbmbzg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_xoNlaRhK6ku3VdMk_jLIIA"
      decimals="INF"
      id="Narr_hwbnluXyQkC-ejEJo00cgg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.02</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_8uq-EWtWF0WoADmNPR7Tfg"
      decimals="INF"
      id="Narr_7qev4LAbiUCHVDc8u2XK8Q"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_1C24-uZb10SvLErWVqmo3w"
      decimals="INF"
      id="Narr_9269YEhegkyVGjAingJLTg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-6"
      id="Narr_1baBjGvk0EeBMwhUemt22g"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_6_30_2023_us-gaap_PlanNameAxis_ibio_OmnibusIncentivePlanMember_joWgB2aWOEyl8YJ2QrOPgA"
      decimals="INF"
      id="Narr_9_KHx4r1u0WHEye57vtPIQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ibio:AggregateCommonStockPurchased
      contextRef="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_PideCfI-jEiSzj_q8lGFBQ"
      decimals="0"
      id="Narr_fY1_pDK7AE6xkjwww1dBNA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">100000000</ibio:AggregateCommonStockPurchased>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_KNMSVlZ63keio6WMZ-FPmA"
      decimals="0"
      id="Narr_UBD8jEkPaE-n-cgIsY1-rQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">5782871</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_KNMSVlZ63keio6WMZ-FPmA"
      decimals="-5"
      id="Narr_g2TgymATj0aD9KUh_80-Qw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">6400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ibio:SubscriptionReceivableCurrent
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j4x0PspL1UuXk5bJ7v3ZFw"
      decimals="0"
      id="Narr_scOHuLkw4E21e3LT4Tot0w"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">204000</ibio:SubscriptionReceivableCurrent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j-fx3hLA50uNFaaqQkekIA"
      decimals="0"
      id="Narr_F3JVKNKUM0-35m6K4ALpvA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">175973</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_j-fx3hLA50uNFaaqQkekIA"
      decimals="-5"
      id="Narr_QvtobkQQZUuHAl2aEYoDDQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg"
      decimals="0"
      id="Narr_Cv9PGmmvqkGnVfZIFMlTCA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">102354</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg"
      decimals="0"
      id="Narr_dEqmtKqnPk2wqCpHRKBOvQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_mX_BARMd50iV5vznznteBA"
      decimals="0"
      id="Narr_QevPjssoBEaKh0_B7A1BIQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1530769</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ldHkHQ1HnEC1Bn3XAgpiXA"
      decimals="0"
      id="Narr_nLcnsbDCoE6K_L33Wxq8eQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1834616</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8w4IUbsDIki_jJ-9mVfRmA"
      decimals="0"
      id="Narr_YY0uzbu5IEq0kycrm0N8cQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3365385</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_8Im5yjRmNUarH6CaeVLVOw"
      decimals="0"
      id="Narr_nwq7-CQ5cUWWWbmTjFgSUA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3365385</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg"
      decimals="3"
      id="Narr_47G4wLodeEKK7pxMNejuKA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.070</ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering>
    <ibio:NumberOfAdditionalSharesIssued
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg"
      decimals="0"
      id="Narr__glVWIJvikK-hRGJvp_H0g"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">504807</ibio:NumberOfAdditionalSharesIssued>
    <ibio:CommonWarrantsToPurchaseAdditionalShares
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg"
      decimals="0"
      id="Narr_2Bn4LAusXUS0Stzr68_N1Q"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1009614</ibio:CommonWarrantsToPurchaseAdditionalShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_7hZGnl4YaECwuy-_woxKIA"
      decimals="0"
      id="Narr_K7qSTBhYaky6YTqHPKVApQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">504807</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_br7oNpaVRECbzfYrlkkvkw"
      decimals="0"
      id="Narr_x4Wl0_Jx-0-tUW7_uVOEYg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">504807</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ibio:PercentageOfAggregateNumberOfSharesOfCommonStock
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg"
      decimals="3"
      id="Narr_xFdrraF4GUugjViS-BVlCw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.060</ibio:PercentageOfAggregateNumberOfSharesOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_tOoXZBADJEadNjNS6JvQtQ"
      decimals="0"
      id="Narr_8EaG3wK1skCT_IKZkJ-pyg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">201923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg"
      decimals="0"
      id="Narr_MxfSfJOzJkeMtljQsXxuRA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2864000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bdlOYYhGck24BhiEx8F8Rw"
      decimals="0"
      id="Narr_6tyEW5gL1EWvcr4JHwlOnA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">217553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nKpGtSGxbEyiWH4EXHdW8g"
      decimals="0"
      id="Narr_Q3__b_Aj20yw2_FDwsg3yQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_Mw9GYinnB0a2SlCSc1kLjg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_IrnxZ9Z-GUGjvFnHipnOXg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3380</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w"
      decimals="INF"
      id="Narr_KUhSpp2yXUmuN2SxNzFOPg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">51583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Mrr0EORFykGgWwTPIQuR2w"
      decimals="2"
      id="Narr_z1o8omyLF0afPerPZawv7w"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">33.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_o77NiAlVOUOqpWUlIgvjbA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_rZ1rHQ0ZHUSWW77arLucKQ"
      decimals="2"
      id="Tc_r7V8IalV1kWwwwsbgEA0QA_1_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.23</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_8k_8F3ieCk6zFGf27VtTEg"
      decimals="0"
      id="Tc_Fd0gD6kCLkOVqmBQx-Z4Ng_2_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_M0zc34V5Q0m5WCVOKFey5g"
      decimals="1"
      id="Tc_CiCmbGtpw0K38h8xZhVAaA_3_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">136.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C3bH4V8Ib0S8XH9UELJ_gw"
      decimals="2"
      id="Tc_bEWZN6GCnkefoEvUvo8YCQ_4_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">4.95</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_i1SOU2raCEu41QFjJywLPw"
      decimals="INF"
      id="Narr_ngJDZh78p0-yNx_qECykRw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_Zw6WafGCsUCnHKMzdWedpg"
      decimals="INF"
      id="Narr_C3wAfFMKNkaoUjZDMKtSbQ"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_Zw6WafGCsUCnHKMzdWedpg"
      id="Narr_YzNJThSxhUOv3S5Bnnz_rQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_oMAsA2QZvk2xKNG3oHvjzQ"
      decimals="INF"
      id="Narr_P8g6ZmEtCUu9tWQ-t0FRMw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_oMAsA2QZvk2xKNG3oHvjzQ"
      id="Narr_Iq8Vua5JIk2zh25RMoneOw">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_m9_bmICRfkK3AwOGcAYudw"
      decimals="INF"
      id="Narr_nJgwu2P0UEiISu3SPPiNiA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">1.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_m9_bmICRfkK3AwOGcAYudw"
      id="Narr_nh_ki10qdkurLeLtZkWn9A">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ibio:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_X8mbSSFy70ubOrSPbND4oA"
      decimals="0"
      id="Narr_4yugBz_yw0CVTlaloMwyJA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">341300</ibio:StockIssuedDuringPeriodSharesWarrantsExercised>
    <ibio:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_aSOPBLDfl0qZrWSm0hH1mg"
      decimals="0"
      id="Narr_vezw9h-h5UCNkxmmwNTUqg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1781216</ibio:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_-HXRfzZt7EeeqOAod_TF_w"
      decimals="0"
      id="Narr_6XYjqe8UV0mLJyhcwPMFyg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2207000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_O9UHa1q5u0uVaR1ViiQn-g"
      decimals="INF"
      id="Narr_E0rfPNRudEOrYT0v4UqOqw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3475916</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_TBHg74MkiUewy0H-HarEhw"
      decimals="INF"
      id="Narr_iSBckdZ5f0q94U635Qp9Bw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">2058000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_iwp_hRW6o0erhC__pkGDFg"
      decimals="2"
      id="Narr_HRgpm5XqCUKOsQDfIynULw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_O9UHa1q5u0uVaR1ViiQn-g"
      decimals="2"
      id="Narr_u9o1lcb5DUyyzwoOUh91zg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_nqqeo6vCvUOM4bmFG3_fpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;18.&#160;&#160;&#160;&#160;Earnings (Loss) Per Common Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss attributable to iBio, Inc. from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,311)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,512)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Preferred stock dividends &#x2013; iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss available to iBio, Inc. stockholders from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,311)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss available to iBio, Inc. stockholders from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35,699)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,791)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss available to iBio, Inc. stockholders - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (65,010)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,391)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Per share amount - continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_VSCcaFQWPEqZ6HuNP22L4g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_szGXjMD-xEyf9K1Eh278Xw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Per share amount - discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KWCju4zEm0OFrF28ztSNUw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.92)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_g9LgYZJp_E2abMmTXdVUKg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Per share amount - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NyTbTzFAwU-jeS3gdyqc7A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.31)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_GSNMn7paDkWrRL314FWinw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.78)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;In Fiscal Years 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June&#160;30, 2023 and 2022, shares issuable which could potentially dilute future earnings included were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series 2022 Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares excluded from the calculation of diluted loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;*  Less than 1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Group_XA6L3cVMN0-FlMbM-VRE0w">The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss attributable to iBio, Inc. from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,311)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,512)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Preferred stock dividends &#x2013; iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss available to iBio, Inc. stockholders from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,311)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss available to iBio, Inc. stockholders from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35,699)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,791)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss available to iBio, Inc. stockholders - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (65,010)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,391)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Per share amount - continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_VSCcaFQWPEqZ6HuNP22L4g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_szGXjMD-xEyf9K1Eh278Xw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Per share amount - discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KWCju4zEm0OFrF28ztSNUw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.92)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_g9LgYZJp_E2abMmTXdVUKg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.39)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Per share amount - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NyTbTzFAwU-jeS3gdyqc7A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.31)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_GSNMn7paDkWrRL314FWinw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.78)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_2k6503CmK0ehwbDFIHwwUA_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29311000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_SYlBDDQmz0Kfcbr75HlGpA_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29512000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_-WTs_vNgSUOVeWUZvlomAg_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">88000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_Ol7GrSPOPUSS3Tk181kokA_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29311000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_iMG3hPyNdkubjBNVgVZFAQ_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-29600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_KPGvlq04Pkie70BDsq52lw_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-35699000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_lAI9XDLobUyUvJFrCYgIFg_10_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-20791000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc__1pAefXP_UqSLTih6TRvmw_12_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-65010000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_7Nrkm0ewlE2DYz81Qfkv0A_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-50391000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_6_2foJVt4USGLUE-lUuDIw_16_3"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">12245000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_8xBaKZRSbEqvfjh6j82-oA_16_6"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">8721000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_yiwgO4hC7EWd9Hs58c9FYA_18_3"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.39</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_UnQhKQZNJE-x-9YtxF5Wpw_18_6"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-3.39</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_OFo_RNBjs0qLGa0fybUf4Q_19_3"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.92</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_W3TDFMCtGUaNZz85qi-Osg_19_6"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-2.39</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_NoRDGRjlw0aUSa0y4joS_A_20_3"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-5.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_u0RdGmHXQUaR4RwDUVSs-A_20_6"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">-5.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_qA9ie3Sxm0O7Vrx761hMeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;In Fiscal Years 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June&#160;30, 2023 and 2022, shares issuable which could potentially dilute future earnings included were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series 2022 Preferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares excluded from the calculation of diluted loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;*  Less than 1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_vveLDkXdfkmYnuPBTD5qQw"
      decimals="-3"
      id="Tc_-3pZV8rGck6GYBT1XUHbng_4_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">292000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_OAl5YM-9vUiYev8izSQcBg"
      decimals="-3"
      id="Tc_AlTYNoBR6EO3EF0HFuUsow_4_4"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">622000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cUS-0Y50wkGSIGh6RCynOQ"
      decimals="-3"
      id="Tc_Rb8jlkfTsk6KSRnzTJpw0g_5_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">248000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_17hKRS8vdUK0th6qBY6JZg"
      decimals="-3"
      id="Tc_bK-TZlOacUKlmHbgTnwACA_5_4"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">51000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_2Unp8yCqvUWviC4g1sxLBg"
      decimals="-3"
      id="Tc_MCgAcHu21EyIoh_OvjHBXw_6_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">5871000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Ak8TEYVQm0SAkhapZ3V0_w"
      decimals="-3"
      id="Tc_SI-0nDFA9U6zD0-Ux3HVsg_6_4"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">21000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_bdhiK2hZHEubNq6Ukrfx9g_8_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">6411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_6PKLvXcBu0GgUMdGxmmNDQ_8_4"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">694000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb__QFdWjozr0WfEQRXaagocw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;19.&#160;&#160;&#160;&#160;Share-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,776&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,958&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $1,528,000 and $419,000 for the years ended June 30, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $1,500,000 for any non-executive chair of our Board of Directors should one be appointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Vesting of service awards is determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally &lt;span style="-sec-ix-hidden:Hidden_LToFWvo-BkiblBBqRkPxFg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Issuances of stock options during the year ended June 30, 2023 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal year 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Common Stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase 4,000 shares of the Common Stock at an exercise price of $6.75 per share. The option vests in equal monthly installments, over a period of 12 months, starting after the second month and expire on the tenth anniversary of the grant date. &#160;During the third quarter of Fiscal year 2023, the Company terminated the consultant&#x2019;s services. &#160;As a result, none of the 4,000 shares pursuant to the stock option agreement were exercised and as such, all 4,000 shares will be forfeited. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Issuances of stock options during the year ended June 30, 2022 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;During the first quarter of Fiscal Year 2022, the Company granted stock option agreements to various employees to purchase 165,488 shares of the Common Stock at exercise prices between $26.50 and $33.75 per share. The options vest &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal year 2022, the Company granted a stock option agreement to a new member of its Board of Directors to purchase 4,000 shares of Common Stock at an exercise price of $31.50 per share. The option vests monthly over a period of three years and expires on the tenth anniversary of the grant date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal year 2022, the Board of Directors approved an option grant award to Mr. Isett to purchase 80,000 shares of Common Stock with an exercise price of $29.25, which vests in equal monthly installments over a 36-month period following the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the second quarter of Fiscal year 2022, the Company granted a stock option agreement to a consultant to purchase 4,000 shares of Common Stock at an exercise price of $21.25 per share. The option vests over a period of eight months commencing in April 2022 and expires on the &lt;span style="-sec-ix-hidden:Hidden_0OdVFTQWiE-Lr_bsSKBPmA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;tenth&lt;/span&gt;&lt;/span&gt; anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the second quarter of Fiscal year 2022, the Company granted stock option agreements to various directors to purchase an aggregate of 34,880 shares of Common Stock at an exercise price of $17.25 per share. The options vest over a period of one year commencing in January 2022 and expire on the &lt;span style="-sec-ix-hidden:Hidden_mpImJhbCfEK69FYXeZdXCQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;tenth&lt;/span&gt;&lt;/span&gt; anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the third quarter of Fiscal year 2022, the Company granted stock option agreements to two consultants to purchase an aggregate of 1,200 shares of Common Stock at an exercise price of $13.00 per share. The options vest over a period of 12 months and expire on the &lt;span style="-sec-ix-hidden:Hidden_z9rBFPXNl0qc-K8BGo9Big;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt;th anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the third quarter of Fiscal year 2022, the Company granted a stock option agreement to various employees to purchase 24,000 shares of Common Stock at exercise prices between $8.50 and $11.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes all stock option activity during the&#160;years ended June&#160;30, 2023 and 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&#160;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of July 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 341,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,995&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 313,568&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,380)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited/expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (30,068)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of June 30, 2022, vested and expected to vest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 620,810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 197,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 307,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited/expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (637,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of June 30, 2023, vested and expected to vest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable as of June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes information about options outstanding and exercisable at June&#160;30, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:65.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&#160;and&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise prices:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$7.00 - $11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$17.35 - $26.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$26.50 - $39.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,483&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$41.25 - $61.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The total fair value of stock options that vested during 2023 and 2022 was approximately $4,828,000 and $3,334,000, respectively. The total cash received for stock options that were exercised during 2023 and 2022 was approximately $0 and $77,000, respectively. The total intrinsic value of stock options that were exercised during 2023 and 2022 was approximately $0 and $19,000, respectively. As of June&#160;30, 2023, there was approximately $2,193,000 of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of 2.3&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The weighted-average grant date fair value of stock options granted during 2023 and 2022 was $6.30 and $23.25 per share, respectively.&#160;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.21% - 3.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.80 - 2.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;115.52 - 116.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;119.16 - 120.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company&#x2019;s closing stock price of $0.61 as of June 30, 2023 and $6.50 as of June 30, 2022, which would have been received by the option holders had all option holders exercised their options as of that date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;):&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Issuances of RSUs during the year ended June 30, 2023 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 29, 2022, the Company issued RSUs to acquire 6,954 shares of common stock to various employees at a market value of $7.06 per share. &#160;The RSUs vest over a four-year period. &#160;The grant date fair value of the RSUs totaled approximately $49,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Company&#x2019;s former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 200,000 shares of Common Stock.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000. The performance conditions were not met and the RSUs did not vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 11, 2022, the Board of the Company granted Mr. Robert Lutz, the Company&#x2019;s Chief Financial and Business Officer at the time, RSUs to acquire 100,057 shares of the Company&#x2019;s Common Stock in exchange for Mr. Lutz&#x2019;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#x2019;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $175,100. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 11, 2022, the Board of the Company granted Dr. Martin Brenner, the Company&#x2019;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#x2019;s Common Stock in exchange for Mr. Brenner&#x2019;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#x2019;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $167,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire 130,000 shares of the Company&#x2019;s Common Stock, which RSUs shall vest pro rata over a 12-month period, such vesting to terminate if Dr. Brenner is no longer the Company&#x2019;s Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $91,000. Upon appointment of Dr. Brenner to permanent Chief Executive Officer on June 22, 2023, 75,833 of the RSUs terminated and did not vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 31, 2023, the Compensation Committee (the &#x201c;Committee&#x201d;) of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of 225,000 RSUs under the Company&#x2019;s 2020 Omnibus Equity Incentive Plan, as amended (the &#x201c;Plan&#x201d;), which awards included a grant of 50,000 and 37,500 restricted stock units to each of Dr. Brenner, and Felipe Duran, the Company&#x2019;s Interim, Chief Financial Officer, respectively, vesting quarterly over 12 months commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $468,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On June 26, 2023, the Board of the Company granted Dr. Brenner RSUs to acquire 75,833 shares of the Company&#x2019;s Common Stock, which RSUs shall vest pro rata over a seven-month period. &#160;The grant-date fair value of the RSUs totaled approximately $52,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Issuances of RSUs during the year ended June 30, 2022 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 23, 2021, the Company issued RSUs to acquire 4,229 shares of Common Stock to various employees at a market value of $31.50 per share. The RSUs vest over a four-year period. The grant-date fair value of the RSUs totaled approximately $133,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;As of June 30, 2023, there was approximately $445,000 of total unrecognized compensation cost related to non-vested RSUs that the Company expects to recognize over a weighted-average period of 0.8 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_itnhX5NbfUeS0IY2E6BH2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,776&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,958&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-cLI1L4-PUeoHAyAedVjig"
      decimals="-3"
      id="Tc_IULbm_8D1kOVv6AC3Iye8g_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">149000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_7JFoPwEFAEm9j_JAvuBOqw"
      decimals="-3"
      id="Tc_stEvdIgAqUyN27JNR1-DSw_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_L1pakgn-HEqXSQrFTkRD1Q"
      decimals="-3"
      id="Tc_HAUaHKc4zkChptg0xu0EcQ_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_F6t0DfzkFkyMeMWVv6D4Yg"
      decimals="-3"
      id="Tc_G3mIBZHKF0KgFhUXw1O5Xg_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3776000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_MNuJ4nqfvUC22u93Kp5mGw_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2863000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_6j5Mm8bBy0qebva1pEtoGg_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3958000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember__JoTwj7JekqGkccr8jaLLQ"
      decimals="0"
      id="Narr_bWlxFkn__EW703Oiy-vELw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_lUPOZKyWjkGiiwoG4yyWyw"
      decimals="0"
      id="Narr_3UxZH0lpqEmMAg8JlVhMBg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">419000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9KRNjiJqDUK-i_ivBqGgvw"
      decimals="INF"
      id="Narr_EyccetOkmE-sTtlw6uRPYg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1280000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9KRNjiJqDUK-i_ivBqGgvw"
      decimals="0"
      id="Narr_IL43iiEgDUWOfV3eK4PygQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">500000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HptY7B29EUeK8ToPssBmJg"
      decimals="0"
      id="Narr_U3pLdzsOZEONlTgmHQanIg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">750000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_TkpAIuZ6B0q3R1zaoy1iDg"
      decimals="0"
      id="Narr_PrmfB5nahkmjOHKb4pw3qQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1500000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_12_9_2020_To_12_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_TS5Xb__b0USUWuxhMopskw"
      id="Narr_gMZwOEgzfU-l_nuI82oxwg">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9bo96afqQUqvQatv96XUtg"
      decimals="INF"
      id="Narr_MbtPISlZwEehX0Ia8OJRhA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">303869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_xtVTtCXFJ0G4QbVCIxGD0Q"
      decimals="2"
      id="Narr_r69_6Vk8qEKwdeLVoy91PQ"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_2Y54sBBMcUylpJ4aaoVljQ"
      decimals="2"
      id="Narr_itEizcfnw0Kqga2UHTCpEg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">9.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9Cz54lZIsEqkhtb-zVdBsQ"
      decimals="INF"
      id="Narr_GE0Yc3-LwEOQKolYw6FA2Q"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9Cz54lZIsEqkhtb-zVdBsQ"
      id="Narr_pE22ZMewBEWffeEBnULK0Q">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_N5IDTAkcGkqXFW4wZwmQCA"
      id="Narr_0LHzP_1VIk-HAQlFLqKWjA">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow"
      decimals="INF"
      id="Narr_aQMKS-a1cUKkGuXWIbzRCg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow"
      decimals="2"
      id="Narr_WKUi-G2J5US8stdTlX-eTQ"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow"
      id="Narr_pGbeNi5lRk-czvmFtop12g">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow"
      decimals="INF"
      id="Narr_2f36iHzMBU-qLt5aWb74Uw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hZ69zfgV_0mPhDbVLb3gow"
      decimals="INF"
      id="Narr_ENEaA-fTBkS1TjbeQgRAHA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_YvKXv6XQlUSg6GU05Ezz1Q"
      decimals="INF"
      id="Narr_NSM-VYqW6EyFLFJzgA1UUg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">165488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_xCmsPvHt_0-4XRMWv2OvcQ"
      decimals="2"
      id="Narr_rIRFJrt_fkG2LuLlGaoq7Q"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">26.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ZsC7M5TDO06bqBrcL1vesg"
      decimals="2"
      id="Narr_hT_BckjUxkO7ewV6FKPn7A"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">33.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_YvKXv6XQlUSg6GU05Ezz1Q"
      decimals="INF"
      id="Narr_oHadQMvhwkW26SUM01rFGg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_CSnFR5tK_UmMcPFIliPY2w"
      id="Narr_Y4Ja4KXroUaKWtiaW6TCvw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_sbtMBgPfE0GQWHaJX1zw5A"
      id="Narr_Qqcp4w3SE02PhQX4MsSC3Q">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_BoardOfDirectorsOfficersAndEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_3f1m_cPO-0Ki-AKnAQsaNw"
      decimals="INF"
      id="Narr_TDsFuEzmi0epQNndyN8JIw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_BoardOfDirectorsOfficersAndEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_3f1m_cPO-0Ki-AKnAQsaNw"
      decimals="2"
      id="Narr_0jqHTIWxSEul8Af_MFOYAw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">31.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_ibio_BoardOfDirectorsOfficersAndEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_3f1m_cPO-0Ki-AKnAQsaNw"
      id="Narr_VcQhTDouFU2pWrtk5Xkm1g">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ibio_IsettMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_e88Xq6AsD0WbXCbo4ZpVbQ"
      decimals="INF"
      id="Narr_tFoiHSe6EUabRtmFWWQvpQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ibio_IsettMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_e88Xq6AsD0WbXCbo4ZpVbQ"
      decimals="2"
      id="Narr_uqMrom1y5EKq8gxgf8FScw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">29.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_CounterpartyNameAxis_ibio_IsettMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_e88Xq6AsD0WbXCbo4ZpVbQ"
      id="Narr_RnArTuqgrk2hz8jWb9EsuA">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA"
      decimals="INF"
      id="Narr_29aKQDG9Jk-9VeYaA8v7cw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA"
      decimals="2"
      id="Narr_2RCQC4nuGEWC7C8SKMS_SA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">21.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Y8w5j1LfHk6l7TxBHt2GkA"
      id="Narr_lZiIYcKuEEyAg8CasaPvlg">P8M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ"
      decimals="INF"
      id="Narr_VWpflBnKMUSOgPXIJVhq_g"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">34880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ"
      decimals="2"
      id="Narr_aIAbx8TctUaVdjmE-EzZTw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">17.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_cBcK543pEkeMLkWZv_m-yQ"
      id="Narr_UsD26BBA8EmaCR86BGGutw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ibio:NumberOfConsultantsToWhomStockOptionGranted
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw"
      decimals="INF"
      id="Narr_0yeiJg-MC0msfZdEMHbXew"
      unitRef="Unit_Standard_item_hCBMRpViQ0aEEJdOwEy49g">2</ibio:NumberOfConsultantsToWhomStockOptionGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw"
      decimals="INF"
      id="Narr_h26T-HqYTEqo72EGujYHjw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">1200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw"
      decimals="2"
      id="Narr_e5_ylYm-dUGlXaMJM_0v8g"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">13.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SoEHM9_lakC8ZKUYZLgPNw"
      id="Narr_XVpnmz7SV0eO1fNU0Arm2w">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_XbzQngOnPkuMI19LjLTR6w"
      decimals="INF"
      id="Narr_WeOZp_LLNE6qydwXb5z2FQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_9AU5LSHRJ0uhtE7EOzns8w"
      decimals="2"
      id="Narr_yg8z7m7Q6EeyvLxmCdLy7Q"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">8.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_SHgrCz-qZEG92jvNuUFSAQ"
      decimals="2"
      id="Narr_ZfaYQvD3-0m30Pq22id5Kw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">11.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_XbzQngOnPkuMI19LjLTR6w"
      decimals="INF"
      id="Narr_r3GoyThD8UawZCA2HyPs4A"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_VGPTPTFClUWUEjRTn7IMzA"
      id="Narr_L8zO6dbYwk24P3hWWFeIvg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_XZG8-Y3yAUK2kmzzd5QisA"
      id="Narr_Y3eMqsQik0St6IJ5wk0ocw">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_rRkhrEG7Aka7aIzZ5l9r7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes all stock option activity during the&#160;years ended June&#160;30, 2023 and 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&#160;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of July 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 341,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,995&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 313,568&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,380)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited/expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (30,068)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of June 30, 2022, vested and expected to vest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 620,810&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 197,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 307,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited/expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (637,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of June 30, 2023, vested and expected to vest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable as of June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag"
      decimals="INF"
      id="Tc_ERBN_qHQ9k-E8vS114Jxrg_6_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">341686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag"
      decimals="2"
      id="Tc_ZGkct8CFO06pkVqy4KuyKQ_6_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">32.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2020_To_6_30_2021_uOAx-6C-q0ysOGltI-sj8Q"
      id="Tc_emoGxMKWD0GVAnJvhg7trw_6_7">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_6_30_2021_WZ3_413Xg0yCDLuTKswhag"
      decimals="-3"
      id="Tc_Owlvj_LMvUi8K33WnE0Nbg_6_10"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="INF"
      id="Tc_MBynxYyLtEuqLLnOxOz0_A_7_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">313568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_Lk19T9tvPkGpcSXIoS6QrA_7_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">27.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="INF"
      id="Tc_xCJkdH1_B0So_SErY0O_4w_8_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3380</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_apf8MyrHo0-dtwfFVZ1xcw_8_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">22.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="INF"
      id="Tc_IRqBvUzVLUCCRbMsWKtSyg_9_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">30068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_eh3pvqQdfUWVRODnUC23QA_9_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">35.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Tc_tK6CLeS26Ui5VVUeWM38FQ_10_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">621806</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="2"
      id="Tc_BKAw1xjnDUGXWEK0TAaBSg_10_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">30.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      id="Tc_2tYJRHBDf0WpXRfqPeVydg_10_7">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Tc_LqoEhWxAXU2CKWeQEpdnYA_11_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">620810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="2"
      id="Tc_XQ0BNJgfM02zECcSpMIWvg_11_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">30.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      id="Tc_EUoTJsRwqEayRIk58lPcwQ_11_7">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Tc_Z3MQ0DrVIEO1k-Tsh2dp1w_13_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">197404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="2"
      id="Tc_RBg53GSKsE29tJf21hc5vA_13_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">29.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      id="Tc_d8KkA2Te506p9fAPCz5NEg_13_7">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="INF"
      id="Tc_fr047q7i_Uey7NUvKUxxOg_15_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">621806</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="2"
      id="Tc_gXLlHGaKOkq2ohUak0eSCQ_15_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">30.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      id="Tc_7zV6GHZMa0yMpuG8N6OcHA_15_7">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="INF"
      id="Tc_Eq_55V0TaUyX_IbBG7cCcw_16_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">307863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_n7ygtLyvLUGN-XKQKRkYyQ_16_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">7.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="INF"
      id="Tc_n9z6f4rEN0iBN59P4FKkpA_18_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">637191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_pY-07zuXEEeht_UjKqu5Yw_18_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">23.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Tc_MVXNjjlcdEicShScFag5QQ_19_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">292478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="2"
      id="Tc_oYxn1411Qk-i1a3Ejt4L4w_19_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">19.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_zdj-aMKOQkKvh5TgvmtFwA_19_7">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Tc_joScF8Lfo0yRScXqYUwWOQ_20_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">292431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="2"
      id="Tc_IeN3K9tdc02UyjjXrOY8xg_20_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">19.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_Q-AaMCCFd0OxOve6IJ36mQ_20_7">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Tc_oOGrO2pUUkmUFJ1XP6liMw_22_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">96050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="2"
      id="Tc_wR78Ngy-N0OXW2uXEjfHGw_22_5"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">29.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_A33FIJ051kK1aHLIpQlVXQ_22_7">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_NeD17pLQ-EiZLMylTbTETA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The following table summarizes information about options outstanding and exercisable at June&#160;30, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:65.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&#160;and&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise prices:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$7.00 - $11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$17.35 - $26.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,674&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$26.50 - $39.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,483&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$41.25 - $61.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,665&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:31.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_DhwMK66Jc0W1ZHFYrQtkXA"
      decimals="2"
      id="Narr_9SDSxRulPkGC7_UtMgxPzg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">7.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_DhwMK66Jc0W1ZHFYrQtkXA"
      decimals="2"
      id="Narr_68EUuno1PEy414CDiRDPxA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">11.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_ygGJi-7VwkSgwUh8hFlAmA"
      decimals="INF"
      id="Tc_2yMEQBgeUkWAvbPfrG7zTA_7_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">151309</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_DhwMK66Jc0W1ZHFYrQtkXA"
      id="Tc_7Z0kjpB3ZE6EXV-6YbvF6w_7_4">P9Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_ygGJi-7VwkSgwUh8hFlAmA"
      decimals="2"
      id="Tc_O_uUp0PYs0qj2oj2n2wo-A_7_7"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">7.51</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceOneMember_ygGJi-7VwkSgwUh8hFlAmA"
      decimals="INF"
      id="Tc_0lWFZw4CokaxAeFBxdfaww_7_9"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">6250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_sM74qrP0cUKZ4Ya1U1gVYg"
      decimals="2"
      id="Narr_2no3n3htYUeSn2TygBg-Uw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">17.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_sM74qrP0cUKZ4Ya1U1gVYg"
      decimals="2"
      id="Narr_nh2WBoCWMEmSi3er88Nf0g"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">26.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_FzOe7EM0YEaXLo9qcItmHg"
      decimals="INF"
      id="Tc_LWvao9nAR0Of-nOkwTmZEg_8_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">29674</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_sM74qrP0cUKZ4Ya1U1gVYg"
      id="Tc_psVC_i4GRUqVtmJvtaG8Ig_8_4">P7Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_FzOe7EM0YEaXLo9qcItmHg"
      decimals="2"
      id="Tc_V98zwPs-HkyvwwtodFyCvw_8_7"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">18.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceTwoMember_FzOe7EM0YEaXLo9qcItmHg"
      decimals="INF"
      id="Tc_3WGDax6I6k-1nou6-3nZKg_8_9"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">29652</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_QgG8WNbPyUmBAvmup53SMA"
      decimals="2"
      id="Narr_YvD7YObulU-KjzWbWupMnA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">26.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_QgG8WNbPyUmBAvmup53SMA"
      decimals="2"
      id="Narr_DAzSbWulAkOsvyHCVXMxwg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">39.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_E7yiwtNsC0mz-2dHsOptEA"
      decimals="INF"
      id="Tc_mczotPT4m0yWRGaRnSLW5Q_9_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">95495</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_QgG8WNbPyUmBAvmup53SMA"
      id="Tc_v_OJNkg_gE6Pg-akRemMAA_9_4">P7Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_E7yiwtNsC0mz-2dHsOptEA"
      decimals="2"
      id="Tc_fHzDLj0IuEKKkHKinBnW-g_9_7"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">33.08</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceThreeMember_E7yiwtNsC0mz-2dHsOptEA"
      decimals="INF"
      id="Tc_ltS_kvl5tU6B5JrX9qX7_g_9_9"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">47483</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_JqlBsxB3WEy25nmRrsywXw"
      decimals="2"
      id="Narr_4iOEgWOFTE2GL_am5Od3Fg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">41.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_JqlBsxB3WEy25nmRrsywXw"
      decimals="2"
      id="Narr_LoQhd_WTAES9kmmoWngahA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">61.88</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_ac-7x3LW9E6Qyh9TSY9ZPA"
      decimals="INF"
      id="Tc__PZlPt7LvEe4JW2G8gIlIQ_10_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">16000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_JqlBsxB3WEy25nmRrsywXw"
      id="Tc_6BQ6S6R_hESTLDJcza_opw_10_4">P7Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_ac-7x3LW9E6Qyh9TSY9ZPA"
      decimals="2"
      id="Tc_ydlTTwrVM0mx1bYH9meIKw_10_7"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">48.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_ibio_ExercisePriceFourMember_ac-7x3LW9E6Qyh9TSY9ZPA"
      decimals="INF"
      id="Tc_GN-0UGOr80irNQbbpkLF2g_10_9"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">12665</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Tc_icrmcFW9e0SOHltDlJrxWQ_11_2"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">292478</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc__sWmaIhvZk6_3nexmVqtDw_11_4">P8Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="2"
      id="Tc__iJ8pT_ypUC-Ek_mqBMQqA_11_7"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">28.31</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="INF"
      id="Tc_N8OAHYWaPkC05EouYIgiYw_11_9"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">96050</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr___zHDxZ8kEG63xx9Ow2zBg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">4828000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_-wJ3tnTfVEyOpF_1tjhoTA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3334000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_xoixG9m8x0uQ_FMG38ELfg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_2lLiMndb90SecinF0aDsCA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">77000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_-vv6rJoPpkCjnn6NgnJRnA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_tLDOsxCLfEqoxQx0TgZ33A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="0"
      id="Narr_3oL2yPxn9ESd7Ae48w0yYA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2193000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Narr_HuS9UCfLQUGBLHEez3MTEQ">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Narr_6aCBFiynPkqL69bcMoznlA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">6.30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Narr_OkDvYpFjukWQw-eDzuW-YA"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">23.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_5YE334tL50WGq4G_Xty22Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.21% - 3.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.80 - 2.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;115.52 - 116.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;119.16 - 120.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="4"
      id="Narr_6WXoqw_WeE6XFhmFBmLoIA"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="4"
      id="Narr_cg3Jl5dGk0mkNr6j46Q2UQ"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="4"
      id="Narr_3W0UA1FTH0Kz-S5cNDa20g"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="4"
      id="Narr_ogBG4m0WL0qcGR4M0RuECg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_8yLSlghkmUyf85KkM_iRYA_3_3"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_xIIUaULyOU2CumJm_hz1ug_3_6"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="4"
      id="Narr_-QaoIcylsUy96Hokxs2hIw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">1.1552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="4"
      id="Narr_fqBAU8ygpkKE3Zs16PtXfQ"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">1.1693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="4"
      id="Narr_q0NaTpdfyEW0-08dpF8vhQ"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">1.1916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="4"
      id="Narr_uDpawk64AUSONzNQvO8AHw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">1.2034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tc_wnI6Pc6_xkuZSyDM1S5J-g_5_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      id="Tc_2vAhQ23HCE-898FaxLyUgw_5_6">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="2"
      id="Narr_4lfSOh2Vw02OHfMWf5sbNw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.61</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="2"
      id="Narr_vQ0k7ta3lUaj6rv38uy73g"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">6.50</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg"
      decimals="INF"
      id="Narr_lVI4OJZQYUW1Ag-bs75zPA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">6954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg"
      decimals="2"
      id="Narr_Tre0-mn9B0uOLa9qj0v9MQ"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">7.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg"
      id="Narr_SrYuDQ71YEG30GVqJ1CZuw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_8_29_2022_To_8_29_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LzJ9A_RJBUa1ANn21ledAg"
      decimals="0"
      id="Narr_31xlSd400kK7hhkzl-KclQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">49000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_11_10_2022_To_11_10_2022_srt_TitleOfIndividualAxis_ibio_Mr.IsettMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lgDtxmNOk0-1j1MhUErEmg"
      decimals="INF"
      id="Narr_t42I-Z3OVUSDJGKacJVFwA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_11_10_2022_To_11_10_2022_srt_TitleOfIndividualAxis_ibio_Mr.IsettMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lgDtxmNOk0-1j1MhUErEmg"
      id="Narr_sj2ZzT8Rvkur5Q29D_4bKw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_11_10_2022_To_11_10_2022_srt_TitleOfIndividualAxis_ibio_Mr.IsettMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lgDtxmNOk0-1j1MhUErEmg"
      decimals="0"
      id="Narr_KPXY4kK_uEC7hIk270yCKA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">296000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Mr.RobertLutzMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SVjgzLilBkyuvpaaJZlWoA"
      decimals="INF"
      id="Narr_yy32pY5GREey2OSdusqm1g"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">100057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Mr.RobertLutzMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SVjgzLilBkyuvpaaJZlWoA"
      decimals="0"
      id="Narr_Jpj_Gjx5pUGDbYZE-o8RLQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">175100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dpjHIDhP7ESwXkYz03k_Zg"
      decimals="INF"
      id="Narr_r9A5R7thuUiUGj2AM_0EHw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">95348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_11_11_2022_To_11_11_2022_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dpjHIDhP7ESwXkYz03k_Zg"
      decimals="0"
      id="Narr_5sbwIn9-CE6Dwf0yuPBdUA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">167000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_igEZn9PhVEiylIxh6caSLA"
      decimals="INF"
      id="Narr_I0ePmME1tkaYReZCiPnQIA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_igEZn9PhVEiylIxh6caSLA"
      id="Narr_-7IfnQTBz0mBXIa2IwOwSg">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_igEZn9PhVEiylIxh6caSLA"
      decimals="0"
      id="Narr_vpTMGzq2Qkm0N2CQhgm0ig"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_6_22_2023_To_6_22_2023_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kqjXeqU8mEmZuO4mrfyDSA"
      decimals="INF"
      id="Narr_rgAihvdnv0mE8vulmaWjgw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">75833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HfFb1iTZDEK4b5gZPeFNew"
      decimals="INF"
      id="Narr_Y6ZoC5RPI0Ct5BCXlXo1Dg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">225000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_ibio_InterimChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HhEQxy6pnUCpQsZ0aKHI-w"
      decimals="INF"
      id="Narr_io2Aawwf2E6VOlSLyd3o9Q"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_a-ruAN-Fp0aT8KVbiaSHbg"
      decimals="INF"
      id="Narr_D7P1aspip0KhKy_QEu4Tww"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_4UJTvMaPYUmEsDKWssS5fA"
      id="Narr_frCjRRVKW0WvSLfXGsjPKg">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_4UJTvMaPYUmEsDKWssS5fA"
      decimals="0"
      id="Narr_57qAAl_-Hku-iPsox16SnA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_6_26_2023_To_6_26_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_A3-mdp0Omkera-zLt8EKJg"
      decimals="INF"
      id="Narr_O40QO3kaDk-Kk3NUfxwKtw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">75833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_26_2023_To_6_26_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_A3-mdp0Omkera-zLt8EKJg"
      id="Narr_qRJINavSGUmLlFiMliyNDw">P7M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_6_26_2023_To_6_26_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_A3-mdp0Omkera-zLt8EKJg"
      decimals="0"
      id="Narr_VnkH85yV6kKPm0rWQ2pNAw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">52000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw"
      decimals="INF"
      id="Narr_TgbuJohtVUWolagz8o0jIg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">4229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw"
      decimals="2"
      id="Narr_ln6_Vp0mbEydaJEaNDBwjw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">31.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw"
      id="Narr_MJBc0ST6fk2HaPs0peL-Ug">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trY7qAzhpU6V8JPl5DqkJw"
      decimals="0"
      id="Narr_8atN_vL9uUWCW-l1vWF6Fg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_G00b6C-z9kKKm4HpP4CcHA"
      decimals="0"
      id="Narr_HJWZsduzz0qAf9oRb--qSw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">445000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bdlOYYhGck24BhiEx8F8Rw"
      id="Narr_-4zOSdODDkKTXCduGbOKCQ">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <ibio:GainLossRelatedToLitigationSettlementTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_mN-m9je0RkyVqdbkrgQVCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;20.&#160;&#160;&#160;&#160;Fraunhofer Settlement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Fraunhofer Settlement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 4, 2021, iBio, Inc. (the &#x201c;Company&#x201d;) and Fraunhofer USA, Inc. (&#x201c;FhUSA&#x201d;) entered into a Confidential Settlement Agreement and Mutual Release (the &#x201c;Settlement Agreement&#x201d;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#x201c;Lawsuit&#x201d;). The Settlement Agreement, among other things, resolves the Company&#x2019;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The terms of the Settlement Agreement provided for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 paid no later than May 14, 2021 (which was paid 100% to cover legal fees and expenses); (ii) &lt;span style="-sec-ix-hidden:Hidden_jYLIaZRQbkaIs4FnEH9rdg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; payments &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;of $5,100,000 paid by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, &lt;span style="-sec-ix-hidden:Hidden_kXKwXnCsRkauOXx5_TATcQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; payments of $900,000 paid by March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#x2019;s aggregate net cash recovery as a result of the Settlement Agreement was approximately $10,200,000. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,000 to a Company account at Woodforest on March 24, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. The second $900,000 payment was received on February 17, 2023.&lt;/p&gt;</ibio:GainLossRelatedToLitigationSettlementTextBlock>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember__8CY_8OqkkmBwgmzP9GZVw"
      decimals="0"
      id="Narr_do_N_H7qQU-Ci-UZtZ8YTA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">28000000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_gQzJcEQS6U-ffQ0wp3xFOA"
      decimals="0"
      id="Narr_p8VyunIOW0qLZRyIYrOYdA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">16000000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:PercentageOfLegalFeesExpectedToBeReceived
      contextRef="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_49sQrs8MA0CP9gEl5c6S8w"
      decimals="INF"
      id="Narr_nKhd0JxrokSEDFgmSbXENw"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">1</ibio:PercentageOfLegalFeesExpectedToBeReceived>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Ng3EGcHwDUSSHJ0vzePC6w"
      decimals="0"
      id="Narr_nRqGWMozmEachjulhtuyAA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5100000</us-gaap:SettlementAssetsCurrent>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Fy-Gf6u-0EitjXayqqPTHw"
      decimals="0"
      id="Narr_Ou-FkWag9kevV7s8UIUdxQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_z9FbEXk9g0ql9OZ20V-ejg"
      decimals="0"
      id="Narr_G-syk2Yjh0OEJj_qB1Ybjg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10200000</us-gaap:GainContingencyUnrecordedAmount>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_xiBf2oc6W0C50iTxTcBcmw"
      decimals="0"
      id="Narr___YEvK4tIEq15q_EJCqXxQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10200000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_QFHntIxLBEO846_F3J6DgQ"
      decimals="0"
      id="Narr_nJbbQfjSWkWYL9kZ7uz90w"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5100000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_3_17_2023_To_3_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_GhYBtnMX2kWlAFeWO0dmuQ"
      decimals="0"
      id="Narr_QLSKRYbmuU6t5XLcnVvTJw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5100000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_3_24_2023_To_3_24_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_t8lePepQ2kKL5ThSHCVZjg"
      decimals="0"
      id="Narr_34Z7pfFALkqtPqFmvg3H5g"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">3000000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_2umbQoBSEk60AzYnxpGopg"
      decimals="-5"
      id="Narr_FIFQAw9oNkiPgXV1veHJMQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1800000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_2umbQoBSEk60AzYnxpGopg"
      decimals="0"
      id="Narr_myz6Xc-7FEupgUWZt-sTBw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">900000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_2_17_2023_To_2_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_KnJIktsPp0-EQ6aH9Z2wWg"
      decimals="0"
      id="Narr_siBzo90JbkeNiYXxcPAYug"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">900000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_ERjpWGp-EEWG5A7-N451yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;21.&#160;&#160;&#160;&#160;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The components of the provision (benefit) for income taxes consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current &#x2013; Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred &#x2013; Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,051)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred &#x2013; State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,051)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has deferred income taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets (liabilities):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Investment in equity security&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,520)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating and finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating and finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,555)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,765)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a valuation allowance against the full amount of its net deferred tax assets due to the uncertainty of realization of the deferred tax assets due to the operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Federal net operating losses of approximately $5.5 million were used by the Former Parent prior to June&#160;30, 2008 and are not available to the Company. The Former Parent allocated the use of the Federal net operating losses available for use on its consolidated Federal tax return on a pro rata basis based on all of the available net operating losses from all the entities included in its control group.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;U.S. federal net operating losses of approximately $202.1 million are available to the Company as of June&#160;30, 2023, of which $63.9 million will expire at various dates through 2039 and $138.2 million with no expiration date. These carryforwards could be subject to certain limitations in the event there is a change in control of the Company pursuant to Internal Revenue Code Section&#160;382, though the Company has not performed a study to determine if the loss carryforwards are subject to these Section&#160;382 limitations. The Company has a research and development credit carryforward of approximately $1.76 million at June&#160;30, 2023. In addition, the Company has net operating loss carry forwards from various states of approximately $35.2 million which expire from 2029 through 2042.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;A reconciliation of the statutory tax rate to the effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expiration and forfeiture of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change related to iBio CDMO&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company has not been audited in connection with income taxes. iBio files U.S. Federal and state income tax returns subject to varying statutes of limitations. The 2019 through 2022 tax returns generally remain open to examination by U.S. Federal authorities and by state tax authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_jdEyeQ_OD0CEjq3TDZnkiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The components of the provision (benefit) for income taxes consist of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current &#x2013; Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred &#x2013; Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,051)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred &#x2013; State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,051)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_EnnC-TXEKEie5AHRQ1d--A_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_WIRHm_Y5oEm1ZFOFFdq1rg_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_qPDmY67ouUOaGkg2CxkOng_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-12153000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_72n_7A0kAUa77giOxG0ZiQ_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-9051000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_uROYCmDzwEGjiYDgY_Iiuw_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-637000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_1rMjxdIgYEq1pvafsSpmcg_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <ibio:CurrentAndDeferredFederalAndStateTaxes
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_NoXhlz5DH0yJrdAM8WyL_g_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-12790000</ibio:CurrentAndDeferredFederalAndStateTaxes>
    <ibio:CurrentAndDeferredFederalAndStateTaxes
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_yKI-tQSZCU-mBKJEX-di-g_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">-9051000</ibio:CurrentAndDeferredFederalAndStateTaxes>
    <ibio:IncomeTaxExpenseBenefitValuationAllowance
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_ZvKY9oG7UkqaCrpUkhQlKA_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">12790000</ibio:IncomeTaxExpenseBenefitValuationAllowance>
    <ibio:IncomeTaxExpenseBenefitValuationAllowance
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_0IGO1BnbXky1R_GyjvKspg_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">9051000</ibio:IncomeTaxExpenseBenefitValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="-3"
      id="Tc_xxeaT-PJZUOnvMCejDRS_g_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="-3"
      id="Tc_YoEHXXDFW0q9pUW1MECTZg_9_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_mgMR0w6ns0KlsPDu201qig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets (liabilities):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Investment in equity security&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,520)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating and finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating and finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,555)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,765)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_VHC2Nn12e0eiHrwdRIA8tw_4_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">42951000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_Gb2IY2dS5E-kX8AIaq3wMg_4_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">35829000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_zP_yD57RMEWkR5OMmU5ELQ_5_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">883000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_2GVd_Z6LJEWUBZS_pA-vyA_5_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1248000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ibio:DeferredTaxAssetsResearchAndDevelopmentCosts
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_EX1WVGR40UeWOGRtGICxAg_6_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2775000</ibio:DeferredTaxAssetsResearchAndDevelopmentCosts>
    <ibio:DeferredTaxAssetsResearchAndDevelopmentCosts
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_740EYdsyI0ap6LCcoRllDg_6_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</ibio:DeferredTaxAssetsResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_JBvlPeWcVk2kyduLh1BGuw_7_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1764000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_TxzZgFd0NkeRNEnMWcI64Q_7_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1764000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_f0yBL0_CB0md9LbyJBa7Ag_8_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">395000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_DiXmmo2Dxk-ylvNoDK5pTg_8_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">370000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_sVxT9XMVI0u8Idfvj_UBww_9_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">121000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_ozWgzCUY0kq9mn4J9oDUuA_9_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">2520000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_t4h4YixPR0SmUT483oJQrw_10_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">42000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_mVs_pJWsMUCOaKxD6SZAxQ_10_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">71000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <ibio:DeferredTaxAssetOperatingAndFinanceLeaseLiabilities
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_UFHg9Rc-_0ajRgyCZFWsfA_11_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1363000</ibio:DeferredTaxAssetOperatingAndFinanceLeaseLiabilities>
    <ibio:DeferredTaxAssetOperatingAndFinanceLeaseLiabilities
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_-Ow-nkDm-0m-A3SgfF2l4Q_11_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</ibio:DeferredTaxAssetOperatingAndFinanceLeaseLiabilities>
    <ibio:DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_97-7CZLK-0Cuc8JljqvhhA_12_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1184000</ibio:DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets>
    <ibio:DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_GespMebEI0Wah85xU7b8tQ_12_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</ibio:DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_Xd7pqK_vDUiYN2P58bAWbA_13_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">529000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_fsl43GLag0aW4-Gdr5HtWg_13_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">145000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_8Hb69CpJIkSsgc-Mfv2PsQ_14_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">49555000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_QNJPlva8w0S7FUcyp_OeAg_14_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">36765000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-3"
      id="Tc_T-vYsgTcxUmB4RSfPd7VUg_15_3"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ"
      decimals="-3"
      id="Tc_duNYzzn1jU-75gFiwHKpwQ_15_6"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_6_30_2008_80RUzZ4LGECu9HWLvLycUA"
      decimals="-5"
      id="Narr_Dv71B3PKDEStiZsVUSDmLQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-5"
      id="Narr_rvPdv8vNgkylSb6MjvkOLg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">202100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-5"
      id="Narr_lHui_t3lIUq39La0GJHzxA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">63900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-5"
      id="Narr_pP5pOYPCn0SLjE9P_JxQUg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">138200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_AZyAVySM7UKPZ8RTjixNPg"
      decimals="-4"
      id="Narr_n3Iei2ce_kmowmQUMxIABA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1760000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw"
      decimals="-5"
      id="Narr_Pbbi-qGAtUqsQ-vqbRd2lA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">35200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_7QsEHrip7EqvPSW2SF3nww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;A reconciliation of the statutory tax rate to the effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expiration and forfeiture of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change related to iBio CDMO&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_cFnyDEDWNkqDBzyGfdhOHQ_4_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_HY0mInYwi0aWU9mFmpRLkA_4_5"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_eJ66kzGKDEiyEipphHhecA_5_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_teNfjUYUxk2XxJFK21VAoA_5_5"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ibio:EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_gdI2FNnX4UuR3sEYJGddtg_6_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">-0.02</ibio:EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions>
    <ibio:EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_2aSgw-NpuEyd_t-8lrD4vA_6_5"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</ibio:EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions>
    <ibio:EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_EMuQISJH4km3d00rDJd1pw_7_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</ibio:EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo>
    <ibio:EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_bnXPP9diG0Wkh-PdYzJN-w_7_5"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">-0.03</ibio:EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_2oHcKtF0qEuhslfZZdylTA_8_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_ZL5H2Cb5Ukm3sqyPJGq3gg_8_5"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">-0.18</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Tc_1z9Kff6iM0C2RaEuGThqsg_9_2"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="2"
      id="Tc_GFXoOW2p_kmStSm22uItsg_9_5"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_hZ1gSfx_x0m7A5ZD6fcTkg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;22.&#160;&#160;&#160;&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;CRO Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce IBIO-101 in addition to process development and GMP manufacturing of IBIO-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. The Company has incurred costs totaling approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$1,209,000&lt;/span&gt;&lt;span style="font-style:normal;"&gt; through June 30, 2023. The Company is committed to additional costs totaling approximately &lt;/span&gt;&lt;span style="font-style:normal;"&gt;$171,000&lt;/span&gt;&lt;span style="font-style:normal;"&gt; as of the date of the filing of this Annual Report.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Inflation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:normal;"&gt;Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#x2019;s operations.&lt;/span&gt;&lt;i style="font-size:12pt;"&gt; &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_olBr2CcxoUyuzZH0lS6s3w"
      decimals="0"
      id="Narr_-89H0JByMkaR1sc7pfKEYQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1209000</us-gaap:OtherResearchAndDevelopmentExpense>
    <ibio:EstimatedAdditionalCostOnDevelopment
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_Nj1rBi5mf0-4KTZgTQfTXw"
      decimals="0"
      id="Narr_-fHMdHGmr0CxMPDE6MFxpQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">171000</ibio:EstimatedAdditionalCostOnDevelopment>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_vxcma61mbUOCmvYCKO4YAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;23.&#160;&#160;&#160;&#160;Employee 401(K)&#160;Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#x201c;Plan&#x201d;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#x2019;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. Employer contributions made to the Plan totaled approximately $263,000 and $169,000 for the years ended June 30, 2023 and 2022, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $135,000 and $150,000 for the years ended June 30, 2023 and 2022, respectively,&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Narr_GmpUlCwSBEqzeFfhmLql_Q"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="2"
      id="Narr_J0Ljzb9gCEiBSKnlSP-Law"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      decimals="0"
      id="Narr_9-AmOlTVZEGzhThRl_JLPg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">263000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg"
      decimals="0"
      id="Narr_RBs9kUn5m0uBkCzByJX8eA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">169000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember__JoTwj7JekqGkccr8jaLLQ"
      decimals="0"
      id="Narr_UHpiIyRC2Uq34hrbVgsGWQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">135000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_lUPOZKyWjkGiiwoG4yyWyw"
      decimals="0"
      id="Narr_1nXBjRxg4k6m9QM4XVH2Pw"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">150000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ"
      id="Tb_AVDvHfDGWEmGGfXSv8V5qg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;24.&#160;&#160;&#160;&#160;Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Purchase and Sale Agreement with Majestic Realty Co.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 15, 2023, iBio CDMO entered into the Purchase and Sale Agreement with Majestic Realty Co., pursuant to which iBio CDMO agreed to sell to Majestic Realty for a purchase price of $17,250,000 its Facility located in Bryan, TX consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;amp;M University System (together, the &#x201c;Ground Lease&#x201d;), related to 21.401 acres in Brazos County, Texas land (the &#x201c;Land&#x201d;); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the &#x201c;Improvements&#x201d;); (iii) all iBio CDMO&#x2019;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the &#x201c;Personal Property&#x201d;); (iii) all iBio CDMO&#x2019;s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the &#x201c;Contracts&#x201d;); and (iv) all iBio CDMO&#x2019;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the &#x201c;Intangibles&#x201d;; and together with the Ground Lease, Improvements and Personal Property, collectively, the &#x201c;Property&#x201d;). The closing of the sale of the Property is to occur, with time being of the essence, on December 1, 2023 or such other date as mutually agreed. &#160;Pursuant to the terms of the Purchase and Sale Agreement , Majestic Realty deposited with a title company (the &#x201c;Escrow Agent&#x201d;) $200,000 as an earnest money deposit. Majestic Realty will also be afforded access to the Property to conduct a due diligence review of its condition. The closing is subject to certain closing conditions, including: (i) Majestic Realty&#x2019;s delivery to iBio CDMO and the Escrow Agent of written notice of its approval of the condition of the Property on or before 5:00 p.m. Central time on October 16, 2023; (ii) Majestic &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Realty obtaining the approval of The Board of Regents of the Texas A&amp;amp;M University System of Majestic Realty&#x2019;s purchase from it of the fee interest in the Land on or before 5:00 p.m. Central time on November 13, 2023; and (iii) the delivery at closing by the title company of a title policy to Majestic Realty in the amount of the Purchase Price. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Credit Agreement with Woodforest National Bank&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#x201c;Sixth Amendment&#x201d;), to amend the Credit Agreement to: (i) set the maturity date of the term loan to the&#160;&lt;i style="font-style:italic;"&gt;earlier of&lt;/i&gt;&#160;(a) December 31, 2023, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement, (ii) provided that iBio CDMO will, immediately upon receipt of the proceeds of the sale of the Property, apply the net proceeds to satisfy all outstanding obligations under the term loan, and to the extent such net proceeds are sufficient, to pay off the term loan, and (iii) change the annual filing requirement solely for the fiscal year ending June 30, 2023, such that the filing is acceptable with or without a &#x201c;going concern&#x201d; designation; provided that (y) iBio CDMO shall deliver an executed copy of the Purchase and Sale Agreement for the sale of the Facility within one business day after entry into the Sixth Amendment, and (z) if the Facility is not sold on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the maturity date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Repriced Existing Warrants issued pursuant to Wainwright Underwriting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On August 4, 2023, iBio, Inc. (the &#x201c;Company&#x201d;) agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A warrants to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;3,475,916&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of common stock and existing Series B warrants to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;2,058,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with exercise prices of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.04&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share (the &#x201c;Existing Warrants&#x201d;), to lower the exercise price of the Existing Warrants to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.50&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Lincoln Park Stock Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 4, 2023, iBio, Inc. (the &#x201c;Company&#x201d;) entered into a purchase agreement, dated as of August 4, 2023 (the &#x201c;Purchase Agreement&#x201d;), with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;), pursuant to&#160;&lt;span style="background:#ffffff;"&gt;which, under the terms and subject to the satisfaction of specified conditions set forth therein,&#160;&lt;/span&gt;the Company may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of the Company&#x2019;s Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the &#x201c;Registration Rights Agreement&#x201d;), with Lincoln Park, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), to register under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by the Company to Lincoln Park under the Purchase Agreement. The Company cannot sell any shares of Common Stock to Lincoln Park under the Purchase Agreement until such time that all of the conditions to Lincoln Park&#x2019;s purchase obligation set forth in the Purchase Agreement, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the &#x201c;Commencement Date&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company&#x2019;s discretion, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10 million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company may, at its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.15, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to 100,000 shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a &#x201c;Regular Purchase&#x201d;);&#160;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;provided&lt;/span&gt;,&#160;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;however&lt;/span&gt;, that the maximum number of shares the Company may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 150,000 shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00, and (ii) 200,000 shares, if &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;the closing sale price of the Common Stock on the applicable purchase date is not below $2.00;&#160;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;provided&lt;/span&gt;,&#160;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;however&lt;/span&gt;, that Lincoln Park&#x2019;s maximum purchase commitment in any single Regular Purchase may not exceed $500,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition, provided that the Company has directed Lincoln Park to purchase the maximum amount of shares that the Company is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.20, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an &#x201c;accelerated purchase,&#x201d; and one or more &#x201c;additional accelerated purchases&#x201d; on the business day immediately following the purchase date for such Regular Purchase,&#160;&lt;span style="background:#ffffff;"&gt;as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable,&lt;/span&gt;&#160;calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company will control the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Actual sales of shares of Common Stock to Lincoln Park will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, market prices of the Common Stock from time to time during the term of the Purchase Agreement and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of Common Stock to Lincoln Park. The Company expects that any proceeds received by the Company from such sales to Lincoln Park will be used for working capital and general corporate purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As consideration for Lincoln Park&#x2019;s commitment to purchase shares of Common Stock at the Company&#x2019;s direction pursuant to the Purchase Agreement, the Company issued 211,473 shares of Common Stock to Lincoln Park as commitment shares (the &#x201c;Initial Commitment Shares&#x201d;) and agreed to issue 211,474 additional shares of Common Stock to Lincoln Park as commitment shares (the &#x201c;Additional Commitment Shares&#x201d; and, collectively with the Initial Commitment Shares, the &#x201c;Commitment Shares&#x201d;) at such time as the Company has received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, if any, that the Company elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Under applicable rules of the NYSE American, the Company may not issue or sell to Lincoln Park under the Purchase Agreement more than&#160;&lt;/span&gt;4,474,945 shares (inclusive of the Commitment Shares), subject to adjustment as described above, of Common Stock (which is equal to approximately 19.99% of the shares of Common Stock outstanding immediately prior to the execution of the Purchase Agreement) (the &#x201c;Exchange Cap&#x201d;), unless stockholder approval is obtained to issue shares of Common Stock in excess of the Exchange Cap in accordance with the applicable rules of the NYSE American. In any event, the Company may not issue or sell any shares of Common Stock under the Purchase Agreement if such issuance or sale would breach any applicable rules or regulations of the NYSE American.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Purchase Agreement also prohibits the Company from directing Lincoln Park to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock then beneficially owned by Lincoln Park (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in Lincoln Park beneficially owning more than 4.99% of the outstanding shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or Registration Rights Agreement, other than a prohibition (with certain limited exceptions) on entering into specified &#x201c;Variable Rate Transactions&#x201d; (as such term is defined in the Purchase Agreement) for a period specified in the Purchase Agreement. Such transactions include, among others, any sale of debt or equity securities that are convertible into or exercisable for shares of Common Stock at a conversion price or exercise price that is based upon and/or varies with the trading prices of the Common Stock after the initial issuance of such securities,&#160;&lt;span style="background:#ffffff;"&gt;or effecting or entering into an agreement to effect an &#x201c;equity line of credit&#x201d; or other substantially similar continuous offering with a third party, in which we may offer, issue or sell Common Stock or any securities exercisable, exchangeable or convertible into Common Stock at a future determined price.&lt;/span&gt;&#160;During any &#x201c;suspension event&#x201d; under the Purchase Agreement, the Company may not initiate any Regular Purchase, accelerated purchase or additional accelerated purchase of Common Stock by Lincoln Park, until such suspension event is cured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Lincoln Park has agreed not to engage in or effect, directly or indirectly, for its own principal account or for the principal account of any of its affiliates, any short sales of the Common Stock or hedging transaction that establishes a net short position in the Common Stock during the term of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time with one business days&#x2019; notice, at no cost or penalty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;Between August 16, 2023 and September 15, 2023, Lincoln Park purchased pursuant to the Purchase Agreement 3,622,834 shares of Common Stock. The Company received net proceeds of approximately $1.2 million during the first quarter of Fiscal 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cantor Fitzgerald Underwriting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.34;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -0.7pt 0pt 0pt;"&gt;Between July 3 and September 26, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 3,419,795 shares of Common Stock. The Company received net proceeds of approximately $1.7 million during the first quarter of Fiscal 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Issuances of stock options during Fiscal 2024 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 58.3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In Fiscal 2024, the Company granted stock option agreements to certain officers and employees to purchase an aggregate of 473,000 shares of Common Stock at an exercise price of $0.35 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the &lt;span style="-sec-ix-hidden:Hidden_jBumV3Rkt02i3MRw82WE7Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt;th anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Vesting of RSUs during Fiscal 2024 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the first quarter of Fiscal 2024, RSUs for 33,153 shares of Common Stock were vested.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ibio:GroundLeasesAgreedToSellPruchasePrice
      contextRef="As_Of_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_ushJsRuZQEyiUOY_3efaUg"
      decimals="0"
      id="Narr_6Ic0TyLpSUe8mEuxX5hw5A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">17250000</ibio:GroundLeasesAgreedToSellPruchasePrice>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="As_Of_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_ushJsRuZQEyiUOY_3efaUg"
      decimals="3"
      id="Narr_Ae7Auo5oLke-RuRuRjx_Nw"
      unitRef="Unit_Standard_acre_scgUJO-cMUuybvEVKZVJgQ">21.401</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:EarnestMoneyDeposits
      contextRef="As_Of_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_ushJsRuZQEyiUOY_3efaUg"
      decimals="0"
      id="Narr_hXCinM0mYUSdeJ1znxERng"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">200000</us-gaap:EarnestMoneyDeposits>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_CreditAgreementWithWoodforestNationalBankMember_2dAEJVyuAUOVNF-AXyg-lA"
      decimals="0"
      id="Narr_oIktmPACckS4zuEvtjuywg"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">20000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_r68Y0EmbuEeMR0WnlD99_A"
      decimals="INF"
      id="Narr_IOGn_sg530G6Iu5eloQP7w"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3475916</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RSn4_RfPj0SPtSJMEmhzUA"
      decimals="INF"
      id="Narr_nTfEmVyiYUqc_OwQ9E75RQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">2058000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_uUlIkQW2oEq35oK92beemA"
      decimals="2"
      id="Narr_r30jz5RpW0OKuo9gGi5Dxw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_6d6Raa3cZUiRPuWmRc-WaA"
      decimals="2"
      id="Narr_mWnWKZDeqEeQM2vii6tMUw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ibio:MaximumAmountOfCommonStockAgreedToSell
      contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw"
      decimals="-5"
      id="Narr_87ZBwHpmOE-2FXi-9Wg3cA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10000000.0</ibio:MaximumAmountOfCommonStockAgreedToSell>
    <ibio:MaximumAmountOfCommonStockAgreedToSell
      contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw"
      decimals="-6"
      id="Narr_koJRXg9rv0y0aWRvZDU8mQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">10000000</ibio:MaximumAmountOfCommonStockAgreedToSell>
    <ibio:ClosingPricePerShareOfCommonStock
      contextRef="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_65MqqZL2kUWg5zU9Y4i3kQ"
      decimals="2"
      id="Narr_3vOamBgHz0WMVLVHQu2HZw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.15</ibio:ClosingPricePerShareOfCommonStock>
    <ibio:MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice
      contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw"
      decimals="INF"
      id="Narr_nwQqxTEVbU-ZHgR4WaP7_g"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">100000</ibio:MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice>
    <ibio:MaximumNumberOfCommonStockToBeSold
      contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_odmv-ki5qUWWcb8GBFn57Q"
      decimals="INF"
      id="Narr_ZRTrZT3MfEipD-WXuKfDTw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">150000</ibio:MaximumNumberOfCommonStockToBeSold>
    <ibio:ClosingPricePerShareOfCommonStock
      contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_odmv-ki5qUWWcb8GBFn57Q"
      decimals="2"
      id="Narr_QfSh401s9kqsN5K9WDBKag"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">1.00</ibio:ClosingPricePerShareOfCommonStock>
    <ibio:MaximumNumberOfCommonStockToBeSold
      contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_Dw9k-bulX0-p0mYFE2o_Ug"
      decimals="INF"
      id="Narr_e-zkYpJ0bEqF5euudb5Ezw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">200000</ibio:MaximumNumberOfCommonStockToBeSold>
    <ibio:ClosingPricePerShareOfCommonStock
      contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_Dw9k-bulX0-p0mYFE2o_Ug"
      decimals="INF"
      id="Narr_3JupPqUc0km43idjH1a-pg"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">2.00</ibio:ClosingPricePerShareOfCommonStock>
    <ibio:MaximumCommitmentInSingleRegularSaleOfCommonStock
      contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw"
      decimals="0"
      id="Narr_4nHJm4am-U26ZXq9sbSKoQ"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">500000</ibio:MaximumCommitmentInSingleRegularSaleOfCommonStock>
    <ibio:MinimumClosingPriceOfCommonStockToSellAdditionalShares
      contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw"
      decimals="2"
      id="Narr_j12UFcaZU02RE5R-E2e3bw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.20</ibio:MinimumClosingPriceOfCommonStockToSellAdditionalShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w"
      decimals="INF"
      id="Narr_bF8JjLvH802Tuo3wC7Kovg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">211473</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ibio:AdditionalSharesAgreedToIssue
      contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w"
      decimals="INF"
      id="Narr_AWhREwwQeEyWw3SqoYqwFA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">211474</ibio:AdditionalSharesAgreedToIssue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w"
      decimals="0"
      id="Narr_VCQvHDTigUaXlfwWRtTIoA"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ibio:MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican
      contextRef="As_Of_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_5SpD_RJm8Eud38J6Ztk_yw"
      decimals="INF"
      id="Narr_JSW7tgVvgUS5CNwMjo5csA"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">4474945</ibio:MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican>
    <ibio:PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican
      contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w"
      decimals="4"
      id="Narr_5FHfZLznLUy9-22SNyhgpg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.1999</ibio:PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican>
    <ibio:MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement
      contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_ktvK39VMu0KZYgJIbOUu7w"
      decimals="4"
      id="Narr_a_OrbV7adEan-yHh-TMupg"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.0499</ibio:MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_16_2023_To_9_15_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_iUI1PTAMS0mokeLZNB2Fjg"
      decimals="INF"
      id="Narr_tEkMKT3370-blvQv_-YPSQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3622834</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_HvdB1ZWYLEujtiGbTKuLOg"
      decimals="-5"
      id="Narr_nW-p1GqVAUKgEcRyqB2Z7A"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_3_2023_To_9_26_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_UNfYWTucIEGpRkg5uUnc2w"
      decimals="INF"
      id="Narr__7D4IuK5b0a6IzzsaeoUQQ"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">3419795</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_E1rZVhR8okSSqW6gfMvzJg"
      decimals="-5"
      id="Narr_AFHzA9pSakWYtPpwY5TD-Q"
      unitRef="Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA">1700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rm5qrexyo0mItmFx_ydLbg"
      decimals="INF"
      id="Narr_nxE1Q-hVjUKpNafrJCq_yg"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">473000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2023_To_6_30_2024_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rm5qrexyo0mItmFx_ydLbg"
      decimals="2"
      id="Narr_onppLtXfbkukwRnKKCfcTw"
      unitRef="Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ">0.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_G3Cg20_u1k-sLeLr-GIKSA"
      decimals="2"
      id="Narr_FrVu9AV_yEWEFRafFbTu-g"
      unitRef="Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_G3Cg20_u1k-sLeLr-GIKSA"
      id="Narr_3379tc0FGkyaH4X7Ud4PGw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Mz-O4KcM5kmuLTNfOTFLBA"
      id="Narr_dMAY3ExAD0KJCZuMC2vHQQ">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_u3o7OY19vkGgjeV5Z4Mo1A"
      decimals="INF"
      id="Narr_4aQpr-GvIUOA33hGqaVRVw"
      unitRef="Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w">33153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>141
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-)3?+!@/B)"+?-F)UIP2-RT*_ XVC'XG(%[8&IVGG\WXZ)S%PO=".N,HBH.
M\+=+ZK/-1<ML[3ZX]Y8KD7S0&9VOR9+.J?B^GG&YU,DIKA?0,/)8B#A=7+3&
MYJ>)-4P*TE_\\.@FVGN/DEUY8NPY69BZ%RTCV2+J4T<D"")?7JA-?3\AR>WX
M>PMMY>M,"O??[^C7Z<[+G7DB$;69_]-SQ>JB-6PAERY([(M[MKFAVQWJ)3R'
M^5'Z%VVRWW:[+>3$D6#!MEAN0>"%V2MYW8K8*\"XH@!O"_"[ K-J#=:VP*I;
MT-T6=%,SV:ZD'B9$D-$Y9QO$DU]+6O(FE9E6R]WWPN3_/A=<?NO).C&:,">6
M_T:!QJ&+KD+AB3<T#;/C*?F_M-'W^01]^/7C>4?(U25%'6>+OLS0N )M8O25
MA6(52:Y+W3*@([<SWUB\V]A+#!(_Q^$ILHP3A UL*3;(ALOG='V*<+^R? *7
M3Z@CUVZFY1C8&RM7;Z4\Z_^I5PG/@%TU,!DB/D5KXM"+EAP#(LI?:&OTVR]F
MW_A=)4LG;*()5A+9S45V(7HA\N%M357:X'+3:']1^0&KFOK1!"OYZ>5^>O7\
MC,,P)CZZIVO&A4H4S!$\5NFUP:JFHC3!2J+ZN:A^S0.)$WEE2P? :EDP:T'\
M2&D++&MJ2Q.L9&N0VQK4LS6CW&/)$.8B>0U2GH$P*1_7*P=VL+ZI-$VPDK1A
M+FT([NIVG+_V?(KNXN")<I4NF&$89MOJ59@"2YN:T@0KF3K+39W5,75/EUXD
MY/DHT!T)E <7S/$N/7:2;=4T=$Y5SD! 4V>:8"5GIE'$.:..-;FGC,N!*TT2
M)V@NY'F)&$<VBT/!W^2KJU1Y@#ZY4NF#BYKZTT4K"]S+PV8=@0_D%4U=.;IY
M"\_)HG#UZ7H B?MM/#@;#$WE"0L7-[:GB5:VAPM[N(Z]L>M*>G2R>X-NY>_0
MMU!]S,'(X= PT,W<1C/"GS?D3>D01#1VJ(E6=EBT!288EO_CT$Z6Y+G[P#;*
MIN  [I*_$56=#=<UEG:,#L L6@ 3#O'OI>4CWHRS%R]TU$<>S'SX4ZE-:U^@
MBU;65G0&)ASIWVN;L4C(#N$O;UU]B8")@\'0&+1-TQ@HY6GM%731RO**;L&$
M(WYZ8HXY)=6N8(!E8*4DK2V"+EI94M$DF'"VOV6./*!F*Q9"@?< Q.KUVD:_
M9RAM:>T-=-'*MHKNP(2C_8,G9&/ %LC$'YX^HCEU8BZ/,J4RF&2S()"A92Z8
M\ZS4IK51T$4K:RM:!1/.^+)?=[UPB>9OP1/SE;9@P/1R^DUI26MKH(M6OGE:
M] 883N^[HPE=O3HK$BYI94=U '3W.+\:?[VZ5]Z"U=H,Z**5C17- *[5#/Q@
MOFR;",_Z=AXIE<&D.Z:4I37[ZZ*59179']?*_C^I[[>?0QE6Y?!%(CGNNV@:
M1;%ZX#_ K-"F->[KHI6U%7$?UXK[=LQY<C,MN]^8#F8RPL;J8PTF/E)5E0U7
M-;9VC+R/B[R/:^7]:2@HSYX=)O<>R4ZCTAI,K+*F->[KHI6M%7$?UXK[Z2B&
M;-DA+1E7AHL#G#L6MHGC4(F1$#<#*NUIS?NZ:&5[1=['<%S?VIL'Q/?191S)
MKR/U^0ESJIZCP&6-91TC]^,B]V,XLF]E7064+Y/1[ ])$"O9*05K$JJ/.1A8
M^4 %KFNL[1@- "X: %SK^<!\):^BH"P84RU+:^S712O+*F(_KO6(P)8#/I=-
MYC1TZ2OZ0M7"8)1A&&87&P.L[#'AXL;6CM$&6$4;8,'I?9<TKKTH:<T?*>'@
ML[L#N+;LS-N64AM<V7B*P3%Z :OH!2PXP>>/._>]7<L/E9>  ["JYYQP66-C
MQV@(K*(AL.#P_M[8]CEQM3,8=_VH-*:U%]!%*QO;FQ$$)_>QU.5FRGRR5#J"
M 97C/ES76-,QPK]5A'^K5OC?O\5U(B^91*X+?8M%)$B8W Y2^M,9Y^TMK9?2
MDBF6+R,\Z W[W;.S\\Y+R=@Q@K]5!'^K5O"?Q4^^Y\B#BQ%EBP13&MO1&OZW
MM/Z>ZU[7Z@U-G*LNRRERO07G\7'L>H+QRKMA!\IMM@KOZ3^AYSRCV]N9TH36
M9*^+5M95)'L+#N([7=<>#]!THC0&$WIG?:4EK4%>%ZULJ0CR%IS =Y:2YQ^5
MTSEAQ WS Y?Z)^B.;M!GRB-ELK5A2F-M6B-]9V]F<M()IC.\(^0DTU"R2<KY
MI_DL\G$Z=[I3_#R;@OZ5)(UDA'RZD*7&Z4".!SR;U9TM"+9.YSD_,2%8D+Y=
M4>)2GOQ ?K]@3.P6DA7D<^M'_P)02P,$%     @ .8 [5WA)O':T!P  (2<
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M*%NE>&,0T]H">POAV3F(80=N,;W5&U;PRYE=+9JK+9\M__H7G$;O('2OY.P
M*]UCI2'ORVNFUX@U)2K<!?_2BBVK+'@-H=ZY2CM7;L5OES&-<!1%%_/M&)!O
M1TB:I6/#@V#C?;!Q,-A/7!LE"C?Y7+A0B#L'R>C1-"*)'V+P02_L\V0/(PG"
M^-AL+9#:]3(2C4TC=P9I7K1*&,'!C@_Z.W6Z)5X7X2B/D\G12?>PTB"LJZ*0
MK<.D>,'M-+JKN$T*1K&20YB"SD[%E *8NA\84K:'E 4AW;9WNE!B8W8T] 0+
M@I-Y$9 H]N==\'DOG'?Y'DT>1L.-J;B;=X=#5/3Y;B.5 PJA"SH^=;!RKZL2
M'!BLQ1[>(@CO1O$-$R7B7ZUJT5QW:4V:-5=[A+N,#@%<>#&E*3!\OAE.XL5D
MZ#@:B#4*Y^&#"-&:5R6RL@MI!D^WWMU!)'F4 ID.L*2+0'?CD1C P9A_EX95
MZ"GRJ\F^[=T<K(V4) L@5M_2)J8L$.S Z3A(H\=P1^_A(,Z$ E'Z=LEB,4UO
M>"!C'&;C&R5KH;54CZB1AH^7J9O,K"A4:P&(QG"[S@P(@OH3(XM2  5@F%(\
MC6)@:1RFZ0^BZ81AQ:UB1LI)XW.Y.F_MS6YZGZ'&EAQRY0"U=5MU<I+5+OW\
MR:92$/:I/<41@.M'4#L>N!V'R?T_&ZXLAN9^$CX(SB=EDA$"H/,-:93FTZ,V
ML#<.T_<'\=6-PO0 E=QV6"&F!\@GX9A@:)4#;$TS.HUAH&L<YNN/C6'-O>C6
MRW?,-)_+$YKG !#?,,Z3P!(:F!H_1]6=''QTG2ZUF,BK )%""\(W(P'*&N@6
MG\BWYS9I-3W5@O$&_9VJ(K#/Q5D\"8L,3$S"3/SO/8:CR3CL\>1R$"#LC.(
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M=$,8X2F@.TNGT-F<2. Z!TU3PLYC5YL#+<Q-6_*;AMS?0_ZUXB,4X OD8S]
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M;\Q?_#+WM^/X$J,00"W?FF;SX;%N"Q-_[N%%=YK0RXT)[EKQQE+$7;A.MT-
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M_,-W"S"Z?*N1?H'G\DT"V 8T(Q_)?<;S!3S?.'1 _H4;3%\M7?P?4$L#!!0
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M ,\W#CW:7K"!_I/9V7\!4$L#!!0    ( #F .U=-.G\Q- L  *PE   8
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M5UHD#JB?.]^A-1+&D D_+*O;4720,R08G> +6@\BR5!^PBX,4/2^[X.A8:;
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MOH55"0(3*PQWE@V_GOB&A".[6N4&B#3/7]AR\?OGW_WW'V"-XN:BKH+M17:
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MYD=W_$??G!879[-B?C:_.++?1<3^@O>[^-/8%_]YM7"=)2'ZKRE"R#&7T\=
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MCVU.5)[6PK6TTG-/W(WR8*MQY3'H7RRDR=[>&SN?K4+:0_7&ZHTOF,I2\$K
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M\][-G$_<L.ZJ238*T(:D-[22:H(AY[/%R)X- W$W?\8@L90$UU"K0L\U5+Q
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MI9)H]+0 [^<.WN4;4M!^&[_Z#U!+ P04    "  Y@#M7 2<"WV81   E,@
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M -1.@<Y+1:TR",[!^+]B\2]02P,$%     @ .8 [5Y7B5^9N P  " @  !D
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MQR:$E6 F%.1RYLTDR[(&:J?>D<'?#!5G<@53-PZ;HD'#PB62N_#9#WV@:OK
MI.<CFC.W7\X,4=9EFJI%Q86#K0!^]!?Y!OH';\P,P\A@7[;I'JB0HR)SA!Q3
MFR0S; @7O6XJ3BD]Y7E(QAJV>3 I"T,S@!)$9DJ]*;1SM6\N/MY^QMD(@7'%
MG<FE+.]#=0C5>SW*6/Y'"5,!G3[&V,;H.5"$.'^<O4&B*TDGJU/JQ3@H,@7A
MD &Q=*ABJF#DK(./IHC38J+=4.=W95_R;(0K-2>0X8@&Y.B@?&^TI(U%'#['
M_[&X:"E[5%ENU,3RCE\W17YK15SK3]$G&@K8-DN9S9IW0_+.$UTT1$U -L8)
M5;='N9-\5,W9'M@6LA7 H3A#Q#A@*,XE5Q8T$05.S=Q7AI#!:DJHWI%3)#(Z
M>L!>7M:CJ7/RV29/K(%QHZ$ZZ.B11V;>.\;VOM=4C3^_;_=Y[HMH*Y;X(/2X
MP#8QO*,R^L+D>S8&REP%"2U'S:L83)J[@AUH EPKG:^8.Z3\3%&)B W9'\MJ
MW+E%\R?]YT!=,S<L9E\*S&],LQ67R)?8M#>^AV&K=KO[L(%UD/]Q_*W4*CZ:
M--VI\;A8\:%W2VNQ5Q&Q?RU<FI(P47QZ6L5(%T71MAO,T$B6Y,;,9P EJ2S1
M*4%3(BQYI$4'*NJ+JB.0'172WBM?'V3 X <H"/5^"H<JM]($-,WNID:@AX2+
MQJ5B6T#$%!T-832T9Z.79M(I&M]J_D+ WGBBK8CM;&!]Z<HQ)YC1\'FFTULA
MDE.LE3,?K^4R'BVPML-@#0VQ\&%5(>^5;YJ8H34I1''3["0<3#\TS$XM,
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MP];851T/UEVS,S:9-H)G_BH:@E$TN=M('A4\9MVC)[-6A!I''[A=H6YE(-'
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MO<M))PPBU8W3N?_"--<.+X_^<B4X6H\$\'RAM:MN2$']R?'N'U!+ P04
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M/M9NE3]U@G/%7L'S(PX?1]\F<^,3KQY.C@$;3^)@#$7 GG$P[.-@=A$'"31
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;.U;^V_;.!+^5XAL=M$
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M/D4B _4ES!/GQ+\6/$MAT=#%H04#N&Y$!"U'Y#Z$(TM+&MYX"!DZ#)_ \B@
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MH^GD0&W_S$,A-_1KU(4L"IG0QS4/@#^Q 7R_E+(P#SA ]?/D%_\"4$L#!!0
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M9M/S-XFPPP <-M[T<>ALC,<(B\L&OQG(L@&^U\;X_88#''Z%+/\"4$L#!!0
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MCI8-2+\TQN\$/J#_OS#[!U!+ P04    "  Y@#M7'H32;F(1  #,-   &0
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M4QR1*NJ+A!=';+K4I.ZQ',&J]D6>6$;2PM!V%'L]A[CQ'+82LL_HN^\(";N
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MW) 2X7IW!+PA.955>DM3=/4M!JN89O5/V)I)@28"+SP-BRCEYG':4#:V57?
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M*X"X2%RKC<ZY?+K6"VK+"(JPUM_Z!MD- N!2!9=3Y]E+PD4TJ&)Z<EU3Z_D
M;CL\#2M/I^&VF83*(RW#OQ&5ODZDMP!& Z,HVV9U,P$H\G?7#*Z:FE"+[5P0
M)AO7F74F(%V;V%ZO9TQ +[?0)ACO19'3R*/95&3 @MX*(>!O;,"S?T>'X%NJ
M,VVG ET[N: >:V<B;JV%8P+2!W1E?^'VC<QRV+9];65RSQHF.-?5*,UZ\9@
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M'(R9#AFSMX#235Y8^$"+*L5-3B^0?,9@-@['P:A$$1 YB2LR^:U5.9TB](L
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M]#<]?&#O8]U"-?@LZGZ3\,@QLH^N].= 6?@Z$6O?#L[IN5*1!<<YS4HO1E]
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M3^0@JO^E;3;\]P3F34OVE']<J9R@!QZ@[Q=-T_I?,$'X"Q-O_@=02P,$%
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M<VAE971S+W-H965T,S$N>&ULQ59;;]LZ#/XKA#<,&Y#5CIU;VR1 VVTX9\"
MHNG9'H8]*#8="Y,E3Y*;]?SZ0\F.YYVZP2X/ X)(I'CY2)&BEWNE/YL"T<+7
M4DBS"@IKJ[,P-&F!)3,GJD)))[G2);-$ZEUH*HTL\TJE".,HFH4EXS)8+SWO
M6J^7JK:"2[S68.JR9/K^$H7:KX)Q<&#<\%UA'2-<+RNVPPW:?ZIK35386<EX
MB=)P)4%CO@HNQF>74R?O!=YSW)O>'EPD6Z4^.^+O;!5$#A *3*VSP&BYPRL4
MPADB&%]:FT'GTBGV]P?K;WSL%,N6&;Q2X@//;+$*%@%DF+-:V!NU_PO;>#S
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M]#V$V@G0>:ZH)5O".>B^L-;_ 5!+ P04    "  Y@#M7[V41O^,"  #F!P
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M(^;TRT#M'.@\4W3%:\4EZ'Y"\5]02P,$%     @ .8 [5^N8[ C/ @  Z08
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M+>T=B=H5V/-"*=H&;D!WZZ:_ 5!+ P04    "  Y@#M71TFRR\H$  #N#@
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MULP]O1B8_7;#5P;/JO%-C"<+(9[,X#HZ;_6,09! J T"Q;\-S"%)#!":\:W
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M/R!?C_2R=G_L!$'0B(,_P#3BQ';+_+X>-JAZV.#=/>PJCL'>,9M'];UI\?>
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MUWR?ZUC_CP2 ,C^,@^0@?\9U]/L'3Q.ZSPVH&-,?'#5@D!LPL!IP3=<T("P
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MH:@:5+=+5,@I5".GOJ\4V-$;&X@:B0)4J"UD5UNWE-$HCJR);(=H;,I;?)M
MA8I#W7=+9*M>;.R7EM#*?BG4(:I1AW2K8SK]'O(!Q)+,XU"_QLTK7R1JL#SP
M1+"H2HNI?>9KK2P4';)_8KG%V_IP;U6JM856-KB0:JC_;N'>DC3+_/(60@\5
M0@_9A5ZS<+=CP7-+O+^%TD.%TD-VI7?#% G-1DN,0W G3,M23_;H;U6UM856
M_CA?J#;OW52;UZIJ:PNM[)="M7EVU:;# K,%-1^^DA2HS8 :/.0>SP#[U*:F
M.GL;9%I:+I)]0PF2YYGN,^57\[W)RV1'[MGU*W@Q37<8"YATP_,6BP5E$H1D
MKB'=L[YN62+=0TQ/%%\EVW SKK2^30Z7! =$F 'Z_IQSM3LQ"^0[N9/_ 5!+
M P04    "  Y@#M7<4<BW=(#   A$0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U,"YX;6S-6-%RHS84_14-[722F30(,&"G-C-9IYVVDYUZXMWV8:</,ES;
MFH#DE61[\_>5P,$0,(FW/,0/-ECW'LXY7%U?/-YS\2C7  I]RU(F)]9:J<V-
M;<MX#1F1UWP#3*\LN<B(TJ=B9<N- )+D25EJNQ@'=D8HLZ)Q_MU,1&.^52EE
M,!-(;K.,B*</D/+]Q'*LYR\>Z&JMS!=V--Z0%<Q!?=[,A#ZS2Y2$9L DY0P)
M6$ZL6^=FZ@0F(8_XF\)>5HZ1D;+@_-&<_)%,+&P800JQ,A!$?^Q@"FEJD#2/
MKP=0J[RF2:P>/Z/_EHO78A9$PI2G_]!$K2?6T$()+,DV50]\_SL<!/D&+^:I
MS-_1_A"++11OI>+9(5DSR"@K/LFW@Q&5!&=P(L$])+AO3? ."5XNM&"6R[HC
MBD1CP?=(F&B-9@YR;_)LK88R<QOG2NA5JO-4-"]N'^)+-*<K1I<T)DRAVSCF
M6Z8H6Z$93VE,0:*+*9'K*V3>T:]?MW1'4F!*(L(2] !2"1HK2/+U2W1Q!XK0
M5%ZBG]'G^1VZ^/%R;"M-V%S6C@_D/A3DW!/D_MRR:^3A*^1BUVM)G[X]W:VG
MV]JFTBNW],K-\;P3>.WZKUZ*;S.D9MB7VX5>U 7\;YLE!8=!.P>SJV_DAL0P
ML?2VE2!V8$4__> $^)<V@WH"J]GEE79Y7>C1;9)0LU5)BC8@8BU=]P53:+IF
M4Z) Z(4UI(GN!MH<H9U:/.DMR1[;7"DNY>#\6J8W[2)\C?VQO:O*[23TG7('
MI=Q!I]S*'8_U'6\340 $%0V>&PXQQB]D-./\T2BHQM48^B5#OY-A69R&'X)C
M1;9Q+:#\"H>!AYTFUV:<ZP;A:;)!23;H)/N)*UT?<;[E7O+-18C7_0X:W$(_
M'#4U-./<81"Z)S6$I8:P4\,]*%WFZ*\EFNKRIDKWPD\@,G3/"4-?/D*V -':
M SIAS^T!/8'5'!B6#@S?0<L<]FE73V UNT:E7:/_VT-&C5KU</YZ4=.=%_I.
M&0X^3A6XN]746WSK3S]N4>+Z324M@7XX\$[N3J<R^SCG[L^YWIEW%%8<W8.>
M#CMW:3?ZN777%UK=B^-LX[R'X<;I=;KI"ZUNV7&^<;H'G+<4N=>H76?4\HO_
M>ER=XW$H<;JGDBG/-H0]H=E6Q&LBS4 _)2+IKNM.R+-O4D]H=0..,X_COX>Z
M[IR\SK:L)[2Z9<?)R^D>O=Y2UT%S1&UKW:^%%0SMRO.K^?/@(Q$KRB1*8:GS
M\'6H_1#%\WAQHO@F?Z1=<*4?D//#-9 $A G0ZTO.U?.)>4HN_Q6)_@-02P,$
M%     @ .8 [5XJ@?&)% @  '04  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL?51M;]HP$/XK5E9-(%4DA)>U+$2"HFF=M G!NGZ8]L&$"['JV)E]
M(>V_G^V$B&V!+['/]O-R.9^C2JH7G0$@><VYT',O0RQFOJ^3#'*J![( 8792
MJ7**)E0'7Q<*Z-Z!<NZ'03#U<\J$%T=N;:WB2);(F8"U(KK,<ZK>EL!E-?>&
MWFEAPPX9V@4_C@IZ@"W@4[%6)O);ECW+06@F!5&0SKW%<+:<V//NP \&E3Z;
M$YO)3LH7&SSNYUY@#0&'!"T#-<,1'H!S2V1L_&XXO5;2 L_G)_9/+G>3RXYJ
M>)#\F>TQFWMW'ME#2DN.&UE]AB8?9S"17+LOJ9JS@4>24J/,&[!QD#-1C_2U
M^0]G@#"\  @;0.A\UT+.Y8HBC2,E*Z+L:<-F)RY5AS;FF+!%V:(RN\S@,-[6
MQ2 R)5MV$"QE"15(%DDB2X%,',A:<I8PT*3W*(X@4*JW/NFM "GCND]N"!/D
M>R9+3<5>1SX:4Y;:3QH#R]I >,' EU(,R"BX)6$0AN1INR*]F_[?-+[)J4TL
M;!,+'>_H F]K]I9\,W?[YV*G49D[\*O+8DTU[J:R?3'3!4U@[IF+KT$=P8O?
MOQM.@X]7C(Y:HZ-K[/&&5J:@"(I1WOG_:OC4P6V/'>/1W?TT\H\=HN-6='Q5
M]-FTBBU<H60"NE.V)IB<R8Z[-2>MYN2J9EL1@A(I[]*<_)_J?1#\(^N?W7;[
M<'REZL"$)AQ2 PL&'PR+JINQ#E 6K@%V$DT[N6EFWB]0]H#93Z7$4V![JGT1
MXS]02P,$%     @ .8 [5UJH^ECZ!   >R(  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3(N>&ULS9K;;N,V$(9?A5"+(@&VT<EVXM0V$$<*-L5F$<38[<6B
M%[1%V\1*HI>D["S0AR]UL&3%#&.U<Y%<.#IP/H[^(8<:2:,=X]_%FA")GI,X
M%6-K+>7FVK;%8DT2+"[8AJ3JS)+Q!$NURU>VV'""H\(HB6W/<09V@FEJ34;%
ML4<^&;%,QC0ECQR)+$DP_SDE,=N-+=?:'WBBJ[7,#]B3T0:OR(S(+YM'KO;L
MFA+1A*2"LA1QLAQ;-^YUZ!4&18NOE.S$P3;*+V7.V/=\YSX:6T[N$8G)0N8(
MK/YMR2V)XYRD_/A10:VZS]SP<'M/ORLN7EW,' MRR^*_:"378^O*0A%9XBR6
M3VSWD507U,]Y"Q:+XA?MJK:.A1:9D"RIC)4'"4W+__BY$N+ 0''T!EYEX+TT
MZ+UBX%<&_DN#P2L&O<J@=VH/_<J@N'2[O/9"N !+/!EQMD,\;ZUH^4:A?F&M
M]*)I/E!FDJNS5-G)R1U-<;J@.$;WJ9 \4V- "H33"-UARM%7'&<$/1 L,D[R
M<^CL,^8<Y]$]1V<!D9C&XAS]CK[, G3VZ_G(ELJKG&TO*@^FI0?>*Q[XZ(&E
M<BU0F$8DTM@'9GO7,P!L)4>MB;?79.H9B3.RN4"^\P%YCN=K'+HUF_^9I4;S
MX/^9AZ>;>P8Q_'J ^ 7/?VV U,/@ [H1@E2CXQ/%<QI328G8#X\(J8G_1!89
MYS1=%:T^LY37!Z984(&^?5(=H'M)$O&W;K"4WO3TWN1I\UIL\(*,+947!>%;
M8DU^^\4=.'_H @4)"R!A(1"L%=)>'=*>B:[F_+,*%BZ#29.-BG Q[77A,)*Z
MA@,2%I2P00'+E\/MQ+T<.OG?R-X>2@W4:TOJ?BUU_W2IUR2.D%K;D< QT8EM
M9'45NW^LS\#U>D?Z!&7#_IL-PV.BW_>NAH<-6R(-:I$&1I&F&8TCE2'*S*(&
M)&=;4BY$WQY(,B=<FRF,T*YJ0<("2%@(!&M%YK*.S.6[2OZ7D"&%A 60L! (
MU@KI51W2*^-D"X6DZOY:!6R9!W>;!U>;^8V8KK&XTN089Z!)1J<V#('<:VDX
MK#4<@BV@1E)7&8='ZOB:%2\X;C88Z%9&(-]:&KI.4WDX@&NC&=95R(KV8M'3
M:7ERRQ#*P[:<!X6<:Y1SELT%^9'E-5JXS7]-:Z>9U5E-2%H 2@NA:.VH>$U4
MO'>U@E;N0 46DA: TD(H6CNP35GL&DNTR2-G"T(B@9:<)6BFLA9B2U3?RFIC
MXVM*%J]_G$INS7UWUAVT<H6BM75O:E?WC>+U8$*UYL<^W:%_T'\L*,P]=YX[
MH-4N*"V$HK5CV!3%;O]])470PAJ4%H#20BA:.[!-(>^:*_F3BPLSIW-$!II[
M-%^36(.36X90'K:5; IOUU@$=BHQS*C.8H+6S16M58OH:I80JMNVWDU5[)K+
MXE.6E0>\6"LS_K/(0^I>FVZ2-V^T0<MH4%H 2@NA:.T -B6Y.WQ?:PIH80]*
M"T!I(12M_2ZN>4S@F1\3G+RFF#E=(U+1#F_6/>T# N_X 8&V80CE7UO'YOF
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M#:"T$$J+4+2NW%KGW]8[_[<=OW^=B[MH'9LW,M0W:]#)^U":9RO2"56S!@T
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M2^/+^6XG/4DWVCS:$@#94R65G0<E8GT:AC8OH>+V4->@Z&:E3<61MF8=VMH
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M9O0C0.T<R+Y0RFXW+D'S:XE_ U!+ P04    "  Y@#M7>>%^XAT"  #^!
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M_5>"P@3H]PGG:CLQ!U_UGQ/] 5!+ P04    "  Y@#M7/0D:^JL"  !\"
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MH).BNNNJCN*E.<QG7.'58)I+_#P H0-P/.5</77T_=!\<$1_ 5!+ P04
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M\P<$S5X/]T[(\;OV^8;/?TW[?DR70G+U8OX<ZE1#% P3Z<,Z%C5.86*ITRB
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M-KK.*+YT=V)1(U9/V0_S,*C_S48/?6YFL_%Y&/7;:4C&'9+Q24A8;QI@O6G
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MRT_.J<6A0H75^2FO0)P5\_Q6LI&W;;.TH/UL5#E]EUO/&Q.H.X!2TU<&*'=
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M=F=0S4,U']4"5 M1+4(UB6HQJB6HIBC-C&Y7QW'L-903GTVB;1M4\U#-1[4
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MFJ(T\RX577%L:.]B?>>Z>[>JULNE>4K;T]/]"MPYXH2V?<=.33>J>:CFHUJ
M:B&J1:@F42U&M035%*69#P)==6SHH OK(=K[0C4/U7Q4"U M1+4(U22JQ:B6
MH)JB-#.Z7>]K:+]F5?L.C'PNYEJ7HLK%1RTV:=;[7HS6.GCWA+E<>F.?\N1
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M>?7MDV:"+WGQ:;?;5_\'4$L#!!0    ( #F .U?'D"Y:!P,  +<)   9
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M)%=S(]$5R7"6D&QUCLZF(#&AXAQ]0O=W4W3V_GS@2C6F5KI)Y3\I_8,C_GZ
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M'A/*AF2YV6GG3*I]V]RNU<D*N.Z@WB^9VBRJAAZ@/JO%?P%02P,$%     @
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M\Y'B)_$ZVS+^56P )'K*,RKFSD;*XMQU1;*!'(L!*X"J.RO&<RS5*5^[HN"
MTRHHS]S \R9NC@EU%K/JVAU?S%@I,T+ACB-1YCGFSY>0L>W<\9W=A7NRWDA]
MP5W,"KR&!Y"?BSNNSMR6DI(<J"",(@ZKN7/AG\?^2 =4*?XDL!5[QT@_RI*Q
MK_KD.IT[GBX19)!(C<#J[Q&N(,LT297C6P-UVCQUX/[QCAY7#Z\>9HD%7+'L
M+Y+*S=R9.BB%%2XS><^VOT'S0&/-2U@FJE^TK=..3AV4E$*RO E6)<@)K?_Q
M4U,1>P'!])6 H D(_A\0O!(P; *&;PT8-0&CMP:,FX#Q6P,F3<"DJONZLJJ:
M#K'$BQEG6\1U:D73!Y6N*EI5,*'ZS7J07-TE*DXN8D(Q30!]!*4'_;',R!I7
MRD]N,>=8:W^'3D*0F&3BW<R5*D\=Z28-/ZSYP2M\/T WC,J-0!%-(>T"7%78
MML3!KL27@9%XRQX'R//?H\ +?/3Y(40G/[]#F2Y_3_&NS+"+@A_"^I[2C/F]
MI ,T]"I,8,!$;\<,#9C8C'F 8H#\B:DTG9H?MN_*L.(.7^'>0X8EI.@.<_F,
M/G%,!:[;AR\?55)T+2$7__24][+FCOJYNO$\%P5.8.ZHUE$ ?P1G\<M/_L3[
MM<^H35AH$Q;9A,668!W3H];TR$1?7"0)+Y5I>%(]F #1Y]1(.-:I35A8PR85
M3/>LCXM1,!EYGC=S'_=U':;SIZ.S@W2QI<)U3(Q;$V.CB1NV)!D@MEH1U4I+
MKIIAX"C736KVK+IV*OO<&)G'NAD?5--PZI]UZRBTF6-D$Q9;@G7L35I[$Z.]
M^W+)_T[0IPUP7$ I22+>HVN:#-"7&\B7P'M;2R/S6'LV8:%-6&03%EN"=2R?
MMI9/?U"_>&K3M$U8:!,6V83%EF =T]/6]-3X/=^6^J-5K3&";R4IU Q+UB-/
M@?Y]=0AZ63/'^PUHM_6\,N9ZK#J;L,@F++8$ZZ@[:]6=&=7M)CJUKCY-9P?]
MW-0_'#5<&;,YUI5-6&03%G^W-CH6?.]EONE]9T!C'KHTX9U168\%<R[':K!*
MBZS28ENTKJ^]]0'?Z.L!$D93%&$A@5-TH0:B&5'=G7$$8V8>V[%9I856:9%5
M6FR+UG4=O+@.?M! I@';$FZ3%EJE159IL2U:5_C+@HYO7$58? "J9B89PNH+
MQVE.*!&R7O0S3OW-U*-M6UW0:6C[HZU@[!U._JWF&MNB=3V^+-?XYO6::ZH:
M9Q!R9ZU7FM4%&ZNTT#]<BIGZ?=)LYAK;HM72W+U%^!SXNMHN$2AA)97U>GQ[
MM=V2N:@V(MR7Y/5^S@WF:T*%&JNN5*@W.%5O,Z^W2.H3R8IJ27_)I&1Y=;@!
MG +7"=3]%6-R=Z(S:#>J%O\!4$L#!!0    ( #F .U<RW7ZXR0,   ,.   9
M    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;*V7;6_;-A#'O\I!*X8$6".)
M\F-F&TB<%<W0(D'2K*\9B;:(2J1'4G:S3[\C9<NRK&B9D3>V'GA_WN]T/!XG
M&ZE^Z)0Q S_S3.BIEQJSNO1]':<LI_I"KIC -PNI<FKP5BU]O5*,)LXHSWP2
M! ,_IUQXLXE[=J]F$UF8C MVKT 7>4[5RS7+Y&;JA=[NP0-?IL8^\&>3%5VR
M1V:>5O<*[_Q*)>$Y$YI+ 8HMIMY5>#D/(VO@1OS%V4;7KL&B/$OYP][<)E,O
ML!ZQC,7&2E#\6[,YRS*KA'[\O17UJCFM8?UZI_[)P2/,,]5L+K/O/#'IU!MY
MD+ %+3+S(#>?V1:H;_5BF6GW"YOMV,"#N-!&YEMC]"#GHORG/[>!J!F0Z!4#
MLC4@#8.P]XI!M#5PD?-+SQS6#35T-E%R \J.1C5[X6+CK)&&"_L9'XW"MQSM
MS.P3%U3$#+XPC 7</6=\25U\SP[?S*4V0$4"=R9E"FY%F4$X\AS.;IBA/-/G
M\!&>'F_@[,,Y?  NX%LJ"XU&>N(;]-7.Z,=;OZY+O\@K?H4$ODIA4@U_B(0E
MAP(^0E:D9$=Z33H5_RS$!43!;T "$K4X-'^[.>EP)ZH"'SF]Z#\"G[GPQAC>
MR[8HE2*]=A&[QB_UBL9LZN$BUDRMF3?[]9=P$/S>1OA.8@>\O8JWUZ4^N\JE
M,OR?,KGD A[NGH!JS4QK<I1: Z=E*]%Z1DAOXJ_K-,=C^N-Q->; R7[E9+_3
MR5MA&*(;0!_+#Y-Q^LPS;CAK];.4Z]=\Z(T;;G;.>&+0!Q7/H)/GFS0TJZ58
M&\+@"($,HP9#YRPG,@PKAF'G0IE3G<**\@2PY #-92&,QNH29P46!EMFL")!
MCHR%8KC!F.,OU[JRAN^YLMY)["! HRI H\Z/7%82+I80VU M<&?6L% RA\5!
MC9%5<6]-Y=%Q'@2C1AYT.G(BYKC"'+\!<P?373[&1RR#,&BP=,YV(DL8[+?=
MX'_0[#\-;J%QH91-XY4MF%*T[IU!RZ(E#<!N#TXEK#46X:F$ G_?0AD>5?BH
M'S8I.[TXE9+L*4DGY7?7)V(=HFNFL._%UM8VSW8UEN"XH>2(?+ 46V&[YR'P
MPJC20" OVZ(0$OK25HJZA4X-R+ZM"3N[B.. )%S'MF:#HH8U(U'+B]:@E'.%
M82T%@HM@W&\FP;MV-GZMG<Z96KI3A@9'4?:;U=/J)'/E^O?&\VM[PG%M^EZF
M/!Y]I6K)A<8@+% RN!CB4E;EB:.\,7+EFO9G:? (X"Y3/*4Q90?@^X649G=C
M)ZC.?;-_ 5!+ P04    "  Y@#M7JQTX9T4#   ##   &0   'AL+W=O<FMS
M:&5E=',O<VAE970W-BYX;6RE5FMOVC 4_2M65DVMM#9Q(($P0%I;5>O4:JB/
M[<.T#R9<P&IB9[8#[7[][! 2:!Y][ NQ$]][SK5]#G>XYN)!+@$4>HPC)D?6
M4JED8-LR7$),Y E/@.DO<RYBHO14+&R9"""S+"B.;-=Q?#LFE%GC8?9N(L9#
MGJJ(,I@()-,X)N+I%"*^'EG8VKZXH8NE,B_L\3 A"[@%=9],A)[91989C8%)
MRAD2,!]97_#@% <F(%OQ@\):[HR1*67*^8.97,Y&EF,8002A,BF(?JS@#*+(
M9-(\_N1)K0+3!.Z.M]DOLN)U,5,BX8Q'/^E,+4=6WT(SF),T4C=\_17R@CR3
M+^21S'[1.E_K6"A,I>)Q'JP9Q)1MGN0QWXB= -=M"'#S #?CO0'*6)X31<9#
MP==(F-4ZFQEDI6;1FAQEYE1NE=!?J8Y3XPO*" L!78$N#7V?1G1!LNTZO$A5
M*@!=4T;C-$83\J0/0TETSV8@D%H".B,)522B?V%6B9='Z/ <%*&1'AT@RM#=
MDJ>2L)D<VDH3-_!VF),\W9!T&TA^2]D)ZCB?D.NX'71_>XX.#X[VT]BZ[J)X
MMRC>S?)V&_+J=-TZ-ILH/XLRUWHU[N!@:*]JH#H%5.<E**\.:A/EO0:J6T!U
M7X+RZZ"Z%2BO4X_D%4A>*](=U\=O;F5V0Z+L"B3Y/:ECX%48^ &NI^ 7%/Q6
M"E<@Y4 +10@-BA(NS.6KP_8KV,=NSZT'[Q7@O79PSA;'"D2\!49\_FP[>*F(
M.E:]ZO%[#3O2+TCU6TE-!&4A3?3!_+J&> KB=QUP:P[S5S"0"0EA9&FOER!6
M8(T_?L"^\[E%=D'!,'B7[(+*9C2>$'9*?W/>);P\; \M:% >WG%3_"[MY6%[
MXFLJK70OW&Y?;Y5?GFY/?VZ#!>#2V'"[L[U:@;CJ=<T2Q*7;X7:[^W\1XJHS
M-JH0E]Z(V\WQDFE2(%6K#-MSO%.'N#1/W.Z>34K$5;?L]AHVI#1+W.Z6C4JL
MFJ#K-("5)HC;7;!1B/T*6--)EW:&V_WLS3H,*OV%WW]&PMYIZ4Q[?$W$@C*I
ML\]UD'/2TQ6(3<>YF2B>9%W>E"O=,V;#I>[209@%^ON<<[6=F,:QZ/O'_P!0
M2P,$%     @ .8 [5\6OACG. P  "Q   !D   !X;"]W;W)K<VAE971S+W-H
M965T-S<N>&ULK9=AC]HV&,>_BI5-U56:2!Q(2*^ =,=IVDEW[:FLZXMI+TQX
M *N)G3D&#FD??H^=$* -IFR\ 3O.\[=_?F+[[\%&JJ_E$D"3USP3Y=!;:EW<
M^GZ9+B%G94<6(+!E+E7.-%;5PB\+!6QF@_+,#X,@]G/&A3<:V&<O:C20*YUQ
M 2^*E*L\9VI[#YG<##WJ[1Y\XHNE-@_\T:!@"YB _ER\**SYC<J,YR!*+@51
M,!]Z=_1V3",38-_X@\.F/"@3@S*5\JNI/,Z&7F!&!!FDVD@P_%O#&++,*.$X
M_JY%O:9/$WA8WJG_:N$19LI*&,OL"Y_IY=!+/#*#.5ME^I/<_ 8UD!U@*K/2
M_I)-]6[4]TBZ*K7,ZV <0<Y%]<]>ZXDX" C#$P%A'1!^&Q"?".C6 5T+6HW,
M8CTPS48#)3=$F;=1S13LW-AHI.'"I'&B%;9RC-.CCP4HIKE8D"? V2 ?IQE?
M,#O#-Q^8,FUK>$MN'D SGI5O![[&7DVLG]8]W%<]A"=Z^"#7'1+07T@8A)1\
MGCR0FY_;9,9NF0D4'4*#8QDRUV]^HOWD_;&>CY/0S$38S$1H.^B=Z. .5P&1
M<Y*Q*6%BAL4Y3X'\<Z*/"MTI:9;@;5FP%(8>KK$2U!J\$8K%09O8N!*+K)A9
M?NL1I=VD._#7+5C=!JOKQ/H=5&ZQ3'K;$)SAER*XQY(D))="+TM'NGH-5\^I
MM?]P+5DEG&UQ:Q&:%&S+IEDKKE/U4MQ*+#[(6$3#\$3&HH8L<G^(0JQ81I O
M11;<2PD7J;*07-@]RT*VP3F%+X6KQ&AP0!=T@A-P<0,7G_D<!<,$\;Q0<@VY
M21;+\"QA(FU-EU/M4J+XNW0E-(F#=J)^0]1W$CV!UJ#,$ALKF/'6O#@5+J6X
MDM@1;-+ )D[81Z5@+5.SN'#=[<#3D^!.M4O!D^_21Y,DZ?7:\_>N07KG1'KF
M@N>KG/SY#/D4U%]M&$Z%2S&N)'8$2X/]>1\X<>]W^P=A4Z:K%8A;#9<SL[OH
M)9 Y5Z4F6V"J];!WRE\Z%V<&&YX_+^B!TZ'N1+/7LXEV2UQ,=R6U8^"]H:%N
M1_._4WU5=W-FL-$/I'KO>:C;:*"ISP /SHFNK.RC6 -::562IZ<QN4-W=Z^V
M3) Q*[C&L];Y25S5(%U+[7AB]J:)NEW3R]Y4X+[M]!*U$J7'YW\<-=MM370E
M1W5,M#=+U.V6_JL/K&6/3I.(]J+@6[PK>:H*SS^XJ9EK\C-3"RY*'/L<Y8-.
M'WM3U<VSJFA9V,O;5&J\"MKB$F_KH,P+V#Z74N\JYC[8W/]'_P)02P,$%
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M-7Q&_X8/J*9'M%$;/=)</QJV4WO34'O32>V'[]]49K8F)BNDD>.&VHZ115W
MZX=$6QM5MZ<$;I%I PD4OE]UU+D7[=IX]'?T,VY2)V @MOB8]UZ"VWMM[:[7
MV\MQ=!P-X\&#-(=[LZ= O?(3UH#W78^A9K>9XN_JV;4[7O\"?&%ZQ:4A@DLR
MC8Z'I#U=3]5Z857I)]E"69J+_C&G/Q'4[@"]7RIE[Q;.0?-O,_T-4$L#!!0
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M0BW:!$BMBRU?4MM 8FNQ6R!!$#<MBJ(/M#26B4BDEJ3LW44_OJ0D:RU'5F.
M>8A)B>?,S!ER1'*Z9_Q5; $D^I(F5,RLK939K6V+< LI%CV6 55O-HRG6*HN
MCVV1<<!1 4H3VW.<H9UB0JWYM'CVQ.=3ELN$4'CB2.1IBOG7>TC8?F:YUN'!
M,XFW4C^PY],,Q[ "^9(]<=6S:Y:(I$ %811QV,RL._<V< M ,>(/ GMQU$8Z
ME#5CK[KS*9I9CO8($@BEIL#J9P<+2!+-I/SX7)%:M4T-/&X?V#\4P:M@UEC
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ME*(;9:*%NM-ZM0E2/FFZ%Y[7\P;-'!:=X9SZAEF"-90;U<J-?J\<^)SKET>
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M9>8RP4BU.-I W5\QU>!4 _V ^B@O^!]02P,$%     @ .8 [5WS-3SUK P
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M[RAT0PRJ993F1LNV10;^MLB[V6+RXN?KP,Y5YM.KX ^]2J9_$UNG%:V7H)I
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M*"7<JA*-8:2V/#["@>*-!<5Z#UH3XP'2IW;I8ABP)/L?OZ 1^@$\1A=A@MZ
M<G&YLVH:-=+WZN4XR$%Q]JBE<;L]#L(N(!#V4$#?FJ"&1T+Y6JA=@3?F%^O=
M[[D"G[H\]54<)?AQ$$<)_A$^FVQ\-M'[[',U/[#P#_3J%@)A:ZT0:>]3:'
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M#>8LK),%-A-]+.CB_9Y$0?"M#:?SL3^G;%%M:7 P+]>%J+_[MW?;;9.S>K-
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M!.C#$P%&'6"<&V#6 >:Y <,Z8'ANP*@.&)T;,*X#QN<&3.J R;D!TSI@>F[
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M/8BL.J#\^F.:%M_>]$O_)<T^;]NX_@]02P,$%     @ .8 [5Z<H?_]-!P
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M',+4D&\O![8!(_CXP?:LSVTN_Y/8&\^#QO.@2SV8EXS)+26WR2U$P'"&Y.9
M7& !;;XK,4^+J3-H$UB^N3DTTQ7QAG#8$ X["1<0@V2,7A';P"J-X<&RE[9C
M#]TCNI:PB36TVPF]AM![+^'R7.&\TX4]=W1$=QITIG:CAFS42?9$17NY1FWE
M&DV._\R6L//E&C=0X^XMEV"R!G48;7!6XJIA9+)C81*VUFY\0M'&>AIU'G72
MH$XZ4>L30<A#%JI#MHUO\L^7HBNB C,/ND0.;*V;)T<A+8FH#M1FMNG/-[HM
M'<W/9-^NVNRK3-7T[S%;IX2C#&(I:5V-9*U8U4BK@:"%[D4K*F1GT[>)_/8
MI@+D\YA2L1^H!9JOF> O4$L#!!0    ( #F .U=OOVC#V0,  ',-   9
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M;O"K"*0QP.<K(?3SP)R[V^^LV3=02P,$%     @ .8 [5_O: 34! P  M0H
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MM8.]JX.S=G!RT"*R'&M$%?7[@B^)T-:HI@?YV>3>2!,SG<6Q$K@:HY_R+UC
M4R"W= 62''ZG0E!]KD?D< 2*QHD\(I_(W7A$#@^.R &)&;F-^%Q2%LJ^J3
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M;W)K<VAE971S+W-H965T.38N>&UL?51+C],P$/XKHXA#*T&3IMTMK-)(?8
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M"4"U5Z$-C*S\^!VDL</LEZ7]>Z!R"?;\**4Y!TZ@_Q^E?P!02P,$%     @
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MK63-V)V>?$YFEJ,)00ZQU A8?;:P@#S70(K&GP;3:D-JQ^YXC_[1:%=:UEC
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MK7F[B+ITUU67[D[,%+[]^F?J[9^;N*AFH)J):A:JV:CFH)J+:AZJ^:@6H)I
MM1#5(E2+42U!M932FOE=%^:Z<&&NBQ;F4,U -1/5+%2S4<U!-1?5/%3S42U
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M'<)H;P_5+%2S4<U!-1?5/%3S42U -8%J(:I%J!:C6H)J*:4U0[AN]XV^X5:
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M"  Y@#M7:(+GPOX&  ""0   #P   'AL+W=O<FMB;V]K+GAM;,6;2W/;-A"
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ .8 [5Y$N9I?N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M.8 [5YE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  Y@#M7?MYX!!P'  !G+P  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M.8 [5WA)O':T!P  (2<  !@              ("!7P\  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #F .U>;V,#QV@(  'L*   8
M          " @4D7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    "  Y@#M7&B%98% &  !#'P  &               @(%9&@  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ .8 [5R7XM$"/"   +D@
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M965T.2YX;6Q02P$"% ,4    "  Y@#M71+3HN.,;  "\60  &0
M    @(%-50  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M #F .U>5Q[KN<P@  "<7   9              " @6=Q  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ .8 [5P$G M]F$0  )3(  !D
M             ("!$7H  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    "  Y@#M7T/#1)V,$  !."@  &0              @(&NBP  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #F .U?="P\QIP,
M , *   9              " @4B0  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ .8 [5V89K+"4 P  8P@  !D              ("!
M)I0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  Y@#M7
ME>)7YFX#   ("   &0              @('QEP  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( #F .U<F;2MJ*00  # *   9
M      " @9:;  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ .8 [5QXT\:=:#0  PB<  !D              ("!]I\  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  Y@#M7]M!:'8D&  #F$@
M&0              @(&'K0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( #F .U?^/:N/D <  'X4   9              " @4>T  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ .8 [5P^GMSKS
M#   JR<  !D              ("!#KP  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    "  Y@#M7[ETH;#$%  "6$   &0
M@($XR0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( #F
M.U?)0SG?81   *H\   9              " @:#.  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ .8 [5QAR-VC]!0  ?@X  !D
M         ("!.-\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    "  Y@#M7#&=U"<8'  #Y%0  &0              @(%LY0  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #F .U>I[FP!X ,  )$(
M   9              " @6GM  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ .8 [5SW!JIZ0 P  .P@  !D              ("!@/$
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  Y@#M7'H32
M;F(1  #,-   &0              @(%']0  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( #F .U?^Z7?F"!T  &UB   9
M  " @> & 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M.8 [5V<CQ+J&!@  _1<  !D              ("!'R0! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    "  Y@#M7CH2+"U@#  !M"0  &0
M            @('<*@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( #F .U?O91&_XP(  .8'   9              " @6LN 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ .8 [5SHS) VT @
MZ08  !D              ("!A3$! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    "  Y@#M7)EWO68<#  "7"P  &0              @(%P
M- $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( #F .U?)
M) ]6H0(  '<&   9              " @2XX 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ .8 [5SCM5RSX @  F0<  !D
M     ("!!CL! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F .U>KXP+\9@0  !(-   9              "
M@69- 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ .8 [
M5Y/'\1F# @  @04  !D              ("! U(! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    "  Y@#M71TFRR\H$  #N#@  &0
M        @(&]5 $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( #F .U>6N,WR( 8  ,,4   9              " @;Y9 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ .8 [5U\EYAKP!   CPX
M !D              ("!%6 ! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    "  Y@#M79GI;@:4#  #P$@  &0              @($\90$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( #F .U=7T016
M\04  .@I   9              " @1AI 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ .8 [5]BS*@%?"   D2P  !D
M ("!0&\! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  Y
M@#M7)4&B/6,%  #5'0  &0              @('6=P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( #F .U=Q1R+=T@,  "$1   9
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M970U-"YX;6Q02P$"% ,4    "  Y@#M7PD81*T\#  "C#P  &0
M    @('!F0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M #F .U?[2/<DW ,  (T3   9              " @4>= 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ .8 [5W(V:HEN @  W 4  !D
M             ("!6J$! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    "  Y@#M7FDF0@E$"  !7!0  &0              @('_HP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( #F .U< 4_@B9P(
M 'D%   9              " @8>F 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ .8 [5U'*"D&^ @  9@8  !D              ("!
M):D! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  Y@#M7
M>>%^XAT"  #^!   &0              @($:K $ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( #F .U>OK<WVNP(  /,(   9
M      " @6ZN 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ .8 [5ST)&OJK @  ? @  !D              ("!8+$! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  Y@#M7L@)3G) "  #\!@
M&0              @(%"M $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( #F .U?863!4( ,  .T+   9              " @0FW 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ .8 [5YTA$ 6'
M!   Q!L  !D              ("!8+H! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    "  Y@#M7[K#O$44&  "2+P  &0
M@($>OP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( #F
M.U=:&/'CH@(  &,)   9              " @9K% 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ .8 [5Q/(7DW+ @  0@@  !D
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M=#<S+GAM;%!+ 0(4 Q0    ( #F .U=Y0"7M5P0  +0:   9
M  " @4SF 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
M.8 [5S+=?KC) P   PX  !D              ("!VNH! 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    "  Y@#M7JQTX9T4#   ##   &0
M            @(':[@$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    ( #F .U?%KX8YS@,   L0   9              " @5;R 0!X;"]W
M;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ .8 [5ZGIF$@A P
MYP@  !D              ("!6_8! 'AL+W=O<FMS:&5E=',O<VAE970W."YX
M;6Q02P$"% ,4    "  Y@#M7LJ./-60$  #/%P  &0              @(&S
M^0$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( #F .U?!
M!FR+%Q0  +([ 0 9              " @4[^ 0!X;"]W;W)K<VAE971S+W-H
M965T.# N>&UL4$L! A0#%     @ .8 [5SJ^%LSP P  %A(  !D
M     ("!G!(" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
M"  Y@#M7E6=:M.<%  "N+0  &0              @('#%@( >&PO=V]R:W-H
M965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( #F .U=9TU?Q1P0  .,0   9
M              " @>$< @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L!
M A0#%     @ .8 [5U;1(UW2 P  UA,  !D              ("!7R$" 'AL
M+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    "  Y@#M7?,U//6L#
M  #B#@  &0              @(%H)0( >&PO=V]R:W-H965T<R]S:&5E=#@U
M+GAM;%!+ 0(4 Q0    ( #F .U?:"'6U&Q(  &\= 0 9              "
M@0HI @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ .8 [
M5Z.4A08V!0  YAD  !D              ("!7#L" 'AL+W=O<FMS:&5E=',O
M<VAE970X-RYX;6Q02P$"% ,4    "  Y@#M7$WLO2 T%  !8&@  &0
M        @(')0 ( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0
M   ( #F .U=K);/7!P,  # )   9              " @0U& @!X;"]W;W)K
M<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ .8 [5S:&/6Z:"0  GX4
M !D              ("!2TD" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q0
M2P$"% ,4    "  Y@#M7IRA__TT'  "M6@  &0              @($<4P(
M>&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( #F .U>'*LDX
M]@(  -D(   9              " @:!: @!X;"]W;W)K<VAE971S+W-H965T
M.3(N>&UL4$L! A0#%     @ .8 [5V^_:,/9 P  <PT  !D
M ("!S5T" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    "  Y
M@#M7^]H!-0$#  "U"@  &0              @('=80( >&PO=V]R:W-H965T
M<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( #F .U<#!0K:"0,  %\)   9
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M;',O+G)E;'-02P$"% ,4    "  Y@#M7:(+GPOX&  ""0   #P
M    @ %3DP( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ .8 [5Z.T-3')
M @  GCD  !H              ( !?IH" 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ .8 [5V';>)%1 @  L#<  !,
M ( !?YT" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &H :@ ='0   : "
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>285</ContextCount>
  <ElementCount>595</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>124</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Financial Instruments and Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement</Role>
      <ShortName>Financial Instruments and Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Significant Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactions</Role>
      <ShortName>Significant Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Promissory Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable</Role>
      <ShortName>Promissory Note Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Investments in Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities</Role>
      <ShortName>Investments in Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Finance Lease ROU Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets</Role>
      <ShortName>Finance Lease ROU Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Operating Lease ROU Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</Role>
      <ShortName>Operating Lease ROU Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Finance Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations</Role>
      <ShortName>Finance Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Operating Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations</Role>
      <ShortName>Operating Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Earnings (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare</Role>
      <ShortName>Earnings (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Fraunhofer Settlement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFraunhoferSettlement</Role>
      <ShortName>Fraunhofer Settlement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>12101 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>12201 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>12301 - Disclosure - Employee 401(K) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEmployee401KPlan</Role>
      <ShortName>Employee 401(K) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>12401 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>20402 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Significant Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</Role>
      <ShortName>Significant Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Investments in Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</Role>
      <ShortName>Investments in Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Finance Lease ROU Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</Role>
      <ShortName>Finance Lease ROU Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Finance Lease Obligation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</Role>
      <ShortName>Finance Lease Obligation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Operating Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</Role>
      <ShortName>Operating Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>31803 - Disclosure - Earnings (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</Role>
      <ShortName>Earnings (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>31903 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>32103 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails</Role>
      <ShortName>Basis of Presentation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Discontinued Operations (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails</Role>
      <ShortName>Discontinued Operations (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails</Role>
      <ShortName>Discontinued Operations (Reconciliation and Classifications) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Summary of Significant Accounting Policies (Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Significant Transactions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails</Role>
      <ShortName>Significant Transactions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails</Role>
      <ShortName>Significant Transactions (Summary of Asset Acquisition) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails</Role>
      <ShortName>Promissory Note Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails</Role>
      <ShortName>Investments in Debt Securities (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Investments in Debt Securities (Components of Investments in Debt Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails</Role>
      <ShortName>Investments in Debt Securities (Components of Investments in Debt Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails</Role>
      <ShortName>Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Investments in Debt Securities (Realized Losses on Available-For-Sale Debt Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails</Role>
      <ShortName>Investments in Debt Securities (Realized Losses on Available-For-Sale Debt Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails</Role>
      <ShortName>Finance Lease ROU Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails</Role>
      <ShortName>Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails</Role>
      <ShortName>Operating Lease ROU Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Fixed Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails</Role>
      <ShortName>Fixed Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails</Role>
      <ShortName>Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails</Role>
      <ShortName>Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets (Estimated Annual Amortization Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Accrued Expenses (Summary of Accrued Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Summary of Accrued Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Debt (The Credit Agreement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails</Role>
      <ShortName>Debt (The Credit Agreement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Debt (Equipment Financing) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails</Role>
      <ShortName>Debt (Equipment Financing) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails</Role>
      <ShortName>Debt (Equipment Financing) (Future Minimum Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41404 - Disclosure - Debt (Note Payable - PPP Loan) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails</Role>
      <ShortName>Debt (Note Payable - PPP Loan) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Finance Lease Obligation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails</Role>
      <ShortName>Finance Lease Obligation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails</Role>
      <ShortName>Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails</Role>
      <ShortName>Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Operating Lease Obligation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails</Role>
      <ShortName>Operating Lease Obligation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails</Role>
      <ShortName>Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>41603 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails</Role>
      <ShortName>Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>41702 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>41703 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails</Role>
      <ShortName>Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>41802 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>41901 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation (Share Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>41902 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>41903 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation (Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>41904 - Disclosure - Share-Based Compensation (Options Outstanding and Exercisable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Share-Based Compensation (Options Outstanding and Exercisable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>41905 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation (Fair Value of Options Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>41906 - Disclosure - Share-Based Compensation (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails</Role>
      <ShortName>Share-Based Compensation (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>42001 - Disclosure - Fraunhofer Settlement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails</Role>
      <ShortName>Fraunhofer Settlement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFraunhoferSettlement</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>42101 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>42102 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>42103 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>42104 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>42201 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>42301 - Disclosure - Employee 401(K) Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails</Role>
      <ShortName>Employee 401(K) Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEmployee401KPlan</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="ibio-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>42401 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>98</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ibio-20230630.xsd</File>
    <File>ibio-20230630_cal.xml</File>
    <File>ibio-20230630_def.xml</File>
    <File>ibio-20230630_lab.xml</File>
    <File>ibio-20230630_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ibio-20230630x10k.htm">ibio-20230630x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ibio-20230630x10k001.jpg</File>
    <File>ibio-20230630x10k002.jpg</File>
    <File>ibio-20230630x10k003.jpg</File>
    <File>ibio-20230630x10k004.jpg</File>
    <File>ibio-20230630x10k005.jpg</File>
    <File>ibio-20230630x10k006.jpg</File>
    <File>ibio-20230630x10k007.jpg</File>
    <File>ibio-20230630x10k008.jpg</File>
    <File>ibio-20230630x10k009.jpg</File>
    <File>ibio-20230630x10k010.jpg</File>
    <File>ibio-20230630x10k011.jpg</File>
    <File>ibio-20230630x10k012.jpg</File>
    <File>ibio-20230630x10k013.jpg</File>
    <File>ibio-20230630x10k014.jpg</File>
    <File>ibio-20230630x10k015.jpg</File>
    <File>ibio-20230630x10k016.jpg</File>
    <File>ibio-20230630x10k017.jpg</File>
    <File>ibio-20230630x10k018.jpg</File>
    <File>ibio-20230630x10k019.jpg</File>
    <File>ibio-20230630x10k020.jpg</File>
    <File>ibio-20230630x10k021.jpg</File>
    <File>ibio-20230630x10k022.jpg</File>
    <File>ibio-20230630x10k023.jpg</File>
    <File>ibio-20230630x10k024.jpg</File>
    <File>ibio-20230630x10k025.jpg</File>
    <File>ibio-20230630x10k026.jpg</File>
    <File>ibio-20230630x10k027.jpg</File>
    <File>ibio-20230630x10k028.jpg</File>
    <File>ibio-20230630x10k030.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="893">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>147
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ibio-20230630x10k.htm": {
   "nsprefix": "ibio",
   "nsuri": "http://www.ibioinc.com/20230630",
   "dts": {
    "schema": {
     "local": [
      "ibio-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ibio-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ibio-20230630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ibio-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibio-20230630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ibio-20230630x10k.htm"
     ]
    }
   },
   "keyStandard": 406,
   "keyCustom": 189,
   "axisStandard": 38,
   "axisCustom": 0,
   "memberStandard": 41,
   "memberCustom": 79,
   "hidden": {
    "total": 54,
    "http://xbrl.sec.gov/dei/2023": 7,
    "http://www.ibioinc.com/20230630": 12,
    "http://fasb.org/us-gaap/2023": 35
   },
   "contextCount": 285,
   "entityCount": 1,
   "segmentCount": 124,
   "elementCount": 897,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 893,
    "http://xbrl.sec.gov/dei/2023": 35
   },
   "report": {
    "R1": {
     "role": "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "00300 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3umrq38u0aybR_OiS3qMw",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3umrq38u0aybR_OiS3qMw",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.ibioinc.com/role/DisclosureNatureOfBusiness",
     "longName": "10101 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentation",
     "longName": "10201 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations",
     "longName": "10301 - Disclosure - Discontinued Operations",
     "shortName": "Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10401 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement",
     "longName": "10501 - Disclosure - Financial Instruments and Fair Value Measurement",
     "shortName": "Financial Instruments and Fair Value Measurement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactions",
     "longName": "10601 - Disclosure - Significant Transactions",
     "shortName": "Significant Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:SignificantTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:SignificantTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable",
     "longName": "10701 - Disclosure - Promissory Note Receivable",
     "shortName": "Promissory Note Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities",
     "longName": "10801 - Disclosure - Investments in Debt Securities",
     "shortName": "Investments in Debt Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets",
     "longName": "10901 - Disclosure - Finance Lease ROU Assets",
     "shortName": "Finance Lease ROU Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets",
     "longName": "11001 - Disclosure - Operating Lease ROU Assets",
     "shortName": "Operating Lease ROU Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssets",
     "longName": "11101 - Disclosure - Fixed Assets",
     "shortName": "Fixed Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.ibioinc.com/role/DisclosureDebt",
     "longName": "11401 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations",
     "longName": "11501 - Disclosure - Finance Lease Obligations",
     "shortName": "Finance Lease Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations",
     "longName": "11601 - Disclosure - Operating Lease Obligations",
     "shortName": "Operating Lease Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquity",
     "longName": "11701 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare",
     "longName": "11801 - Disclosure - Earnings (Loss) Per Common Share",
     "shortName": "Earnings (Loss) Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensation",
     "longName": "11901 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement",
     "longName": "12001 - Disclosure - Fraunhofer Settlement",
     "shortName": "Fraunhofer Settlement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxes",
     "longName": "12101 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "12201 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlan",
     "longName": "12301 - Disclosure - Employee 401(K) Plan",
     "shortName": "Employee 401(K) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.ibioinc.com/role/DisclosureSubsequentEvents",
     "longName": "12401 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20402 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables",
     "longName": "30303 - Disclosure - Discontinued Operations (Tables)",
     "shortName": "Discontinued Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30403 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables",
     "longName": "30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)",
     "shortName": "Financial Instruments and Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
     "longName": "30603 - Disclosure - Significant Transactions (Tables)",
     "shortName": "Significant Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables",
     "longName": "30803 - Disclosure - Investments in Debt Securities (Tables)",
     "shortName": "Investments in Debt Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables",
     "longName": "30903 - Disclosure - Finance Lease ROU Assets (Tables)",
     "shortName": "Finance Lease ROU Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsTables",
     "longName": "31103 - Disclosure - Fixed Assets (Tables)",
     "shortName": "Fixed Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables",
     "longName": "31203 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ibioinc.com/role/DisclosureAccruedExpensesTables",
     "longName": "31303 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtTables",
     "longName": "31403 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables",
     "longName": "31503 - Disclosure - Finance Lease Obligation (Tables)",
     "shortName": "Finance Lease Obligation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables",
     "longName": "31603 - Disclosure - Operating Lease Obligations (Tables)",
     "shortName": "Operating Lease Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityTables",
     "longName": "31703 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables",
     "longName": "31803 - Disclosure - Earnings (Loss) Per Common Share (Tables)",
     "shortName": "Earnings (Loss) Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables",
     "longName": "31903 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesTables",
     "longName": "32103 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
     "longName": "40201 - Disclosure - Basis of Presentation (Narrative) (Details)",
     "shortName": "Basis of Presentation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "ibio:CashAndCashEquivalentsPlusDebtSecurities",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
     "longName": "40301 - Disclosure - Discontinued Operations (Narrative) (Details)",
     "shortName": "Discontinued Operations (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_11_3_2022_To_11_3_2022_hXSudI1Q50eadoT_rxmzgw",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_3_2022_x45ryYnU3UWbXnPzJBxuug",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
     "longName": "40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)",
     "shortName": "Discontinued Operations (Reconciliation and Classifications) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "ibio:PercentageOfCollateralRequired",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "ibio:PercentageOfCollateralRequired",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails",
     "longName": "40403 - Disclosure - Summary of Significant Accounting Policies (Inventory) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryWorkInProcessPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryWorkInProcessPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
     "longName": "40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)",
     "shortName": "Financial Instruments and Fair Value Measurement (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5qaPdrZ830G5d8zR_8zrkQ",
      "name": "us-gaap:ProceedsFromSaleOfBuildings",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
     "longName": "40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)",
     "shortName": "Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
     "longName": "40601 - Disclosure - Significant Transactions (Narrative) (Details)",
     "shortName": "Significant Transactions (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_hoD9xiBRdEquKTaBbRREJg",
      "name": "us-gaap:ImpairmentOfInvestments",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_zbJ3y7eLWE2lHPVwEednHA",
      "name": "ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
     "longName": "40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)",
     "shortName": "Significant Transactions (Summary of Asset Acquisition) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_8_23_2021_To_8_23_2021_s69drdBtfkiXxiX5xIaWhw",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_23_2021_To_8_23_2021_s69drdBtfkiXxiX5xIaWhw",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails",
     "longName": "40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)",
     "shortName": "Promissory Note Receivable (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XheyQ-Fl9UOlWW6gNyl5VQ",
      "name": "ibio:LoansReceivableAmountInvested",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails",
     "longName": "40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)",
     "shortName": "Investments in Debt Securities (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails",
     "longName": "40802 - Disclosure - Investments in Debt Securities (Components of Investments in Debt Securities) (Details)",
     "shortName": "Investments in Debt Securities (Components of Investments in Debt Securities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails",
     "longName": "40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)",
     "shortName": "Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails",
     "longName": "40804 - Disclosure - Investments in Debt Securities (Realized Losses on Available-For-Sale Debt Securities) (Details)",
     "shortName": "Investments in Debt Securities (Realized Losses on Available-For-Sale Debt Securities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "ibio:CostOfDebtSecurities",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
     "longName": "40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)",
     "shortName": "Finance Lease ROU Assets (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
     "longName": "40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)",
     "shortName": "Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cDhv992H80uLjlrOUmMXpA",
      "name": "ibio:FinanceLeaseRightOfUseAssetGross",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails",
     "longName": "41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)",
     "shortName": "Operating Lease ROU Assets (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_1_2021_9whzlfUgsUeBm5EBeEsgEg",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
     "longName": "41101 - Disclosure - Fixed Assets (Narrative) (Details)",
     "shortName": "Fixed Assets (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
     "longName": "41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)",
     "shortName": "Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
     "longName": "41201 - Disclosure - Intangible Assets (Narrative) (Details)",
     "shortName": "Intangible Assets (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DA4mNb1HCESUnEtjTHgS3w",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
     "longName": "41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)",
     "shortName": "Intangible Assets (Carrying Value and Accumulated Amortization) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails",
     "longName": "41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)",
     "shortName": "Intangible Assets (Estimated Annual Amortization Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
     "longName": "41301 - Disclosure - Accrued Expenses (Summary of Accrued Expenses) (Details)",
     "shortName": "Accrued Expenses (Summary of Accrued Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
     "longName": "41401 - Disclosure - Debt (The Credit Agreement) (Details)",
     "shortName": "Debt (The Credit Agreement) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_CU79tDBZJ0-os-9D7HXbbQ",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails",
     "longName": "41402 - Disclosure - Debt (Equipment Financing) (Details)",
     "shortName": "Debt (Equipment Financing) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "As_Of_10_12_2022_JPfG9ZEqqUa0LmbfHdCHIg",
      "name": "ibio:EquipmentFinancingAmountBorrowed",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_12_2022_JPfG9ZEqqUa0LmbfHdCHIg",
      "name": "ibio:EquipmentFinancingAmountBorrowed",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
     "longName": "41403 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)",
     "shortName": "Debt (Equipment Financing) (Future Minimum Payments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
     "longName": "41404 - Disclosure - Debt (Note Payable - PPP Loan) (Details)",
     "shortName": "Debt (Note Payable - PPP Loan) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:NotesPayableCurrent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_XdqoL_rkxkCM1xpi2PlAeQ",
      "name": "us-gaap:LongTermNotesPayable",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
     "longName": "41501 - Disclosure - Finance Lease Obligation (Narrative) (Details)",
     "shortName": "Finance Lease Obligation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2021_To_4_1_2021_94fR0DLTmEC12g7MPaQqxA",
      "name": "ibio:LessorFinanceLeaseMonthlyRent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
     "longName": "41502 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)",
     "shortName": "Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
     "longName": "41503 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)",
     "shortName": "Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
     "longName": "41601 - Disclosure - Operating Lease Obligation (Narrative) (Details)",
     "shortName": "Operating Lease Obligation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_Standard_sqft_uA8s2oIkbUWKT6Mf1V4mBw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_10_2021_96zK_wBSvkCjq1df9gFa9A",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails",
     "longName": "41602 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)",
     "shortName": "Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
     "longName": "41603 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)",
     "shortName": "Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "longName": "41701 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_rZ1rHQ0ZHUSWW77arLucKQ",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
     "longName": "41702 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)",
     "shortName": "Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "ibio:SubscriptionReceivableCurrent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_4HR1GiFll0CGCfdsUqANQg",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
     "longName": "41703 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)",
     "shortName": "Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bdlOYYhGck24BhiEx8F8Rw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_BeQMt5-tdEWE4-W-VcUbHg",
      "name": "ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
     "longName": "41801 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)",
     "shortName": "Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "41802 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "shortName": "Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
     "longName": "41901 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)",
     "shortName": "Share-Based Compensation (Share Based Compensation Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
     "longName": "41902 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
     "longName": "41903 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)",
     "shortName": "Share-Based Compensation (Stock Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails",
     "longName": "41904 - Disclosure - Share-Based Compensation (Options Outstanding and Exercisable) (Details)",
     "shortName": "Share-Based Compensation (Options Outstanding and Exercisable) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails",
     "longName": "41905 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)",
     "shortName": "Share-Based Compensation (Fair Value of Options Granted) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
     "longName": "41906 - Disclosure - Share-Based Compensation (RSUs) (Details)",
     "shortName": "Share-Based Compensation (RSUs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_31_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_HfFb1iTZDEK4b5gZPeFNew",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
     "longName": "42001 - Disclosure - Fraunhofer Settlement (Narrative) (Details)",
     "shortName": "Fraunhofer Settlement (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_LICZs20bO0KdobWGNuOujQ",
      "name": "us-gaap:SettlementAssetsCurrent",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_xiBf2oc6W0C50iTxTcBcmw",
      "name": "ibio:CashPaymentsReceivablesRelatedToLitigationSettlement",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails",
     "longName": "42101 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)",
     "shortName": "Income Taxes (Components of Income Tax Expense (Benefit)) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "42102 - Disclosure - Income Taxes (Deferred Tax Assets and Liabilities) (Details)",
     "shortName": "Income Taxes (Deferred Tax Assets and Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "42103 - Disclosure - Income Taxes (Narrative) (Details)",
     "shortName": "Income Taxes (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_tjyx-B23sU61-Gcfmns0pw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "42104 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)",
     "shortName": "Income Taxes (Effective Income Tax Rate Reconciliation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "longName": "42201 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_olBr2CcxoUyuzZH0lS6s3w",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_olBr2CcxoUyuzZH0lS6s3w",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_H_LlgbcY7ESYF9kylYkRIA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
     "longName": "42301 - Disclosure - Employee 401(K) Plan (Narrative) (Details)",
     "shortName": "Employee 401(K) Plan (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_q8WaOzxJ40aaTz7CjEQf3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
     "longName": "42401 - Disclosure - Subsequent Events (Narrative) (Details)",
     "shortName": "Subsequent Events (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_amJ43cfHoUK2mrzk0jFwIQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_zapKxQkUfE2jcbBL28dO0w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_6d6Raa3cZUiRPuWmRc-WaA",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_P09XWTqrjkq0BA0-6gA-OQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230630x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r780"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Noncurrent assets held for sale",
        "verboseLabel": "Total other assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r4",
      "r111",
      "r127",
      "r168",
      "r223",
      "r224"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Amount of liability for uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r501"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease obligations",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r798"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Summary of Purchase Price Allocation of Asset Acquisition",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedLabel": "Total other expenses",
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r232",
      "r233",
      "r234",
      "r267",
      "r290",
      "r291",
      "r294",
      "r296",
      "r302",
      "r303",
      "r332",
      "r355",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r394",
      "r395",
      "r398",
      "r401",
      "r408",
      "r548",
      "r625",
      "r626",
      "r627",
      "r628",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r654",
      "r675",
      "r696",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r776",
      "r802",
      "r811"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable - trade",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Number Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price - Upper range",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Share based payment award, stock options, intrinsic value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Net proceeds",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r215",
      "r283",
      "r284",
      "r309",
      "r498",
      "r512",
      "r606"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "verboseLabel": "Amortization of operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)",
        "verboseLabel": "Shares available for grant under the plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Lease Obligations",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r566",
      "r752"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Stock Options, Forfeited/expired",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sales proceeds for fixed assets",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - total",
        "verboseLabel": "Per share amount basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r287",
      "r290",
      "r294",
      "r295",
      "r296",
      "r300",
      "r535",
      "r536",
      "r588",
      "r605",
      "r728"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "ibio_CurrentAndDeferredFederalAndStateTaxes",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred - State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r862",
      "r863"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value ,Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Market price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock Options, Outstanding at end of the period",
        "periodStartLabel": "Stock Options, Outstanding at beginning of the period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average Exercise Price, Outstanding at end of the period",
        "periodStartLabel": "Weighted-average Exercise Price, Outstanding at beginning of the period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r455"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Stock Options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "verboseLabel": "Redemption of debt securities",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r815"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "verboseLabel": "Operating lease obligation - current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation settlement, amount awarded from other party",
        "terseLabel": "Settlement income",
        "documentation": "Amount awarded from other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of stock options granted",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndMaintenanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAndMaintenanceMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Maintenance [Member]",
        "documentation": "Right to use intangible asset and process of preserving asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_DividendsPreferredStockStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStockStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "ibio_NetLossAvailableToStockholdersFromContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Preferred Stock, Stock",
        "negatedLabel": "Preferred stock dividends - iBio CDMO Tracking Stock",
        "negatedNetLabel": "Preferred stock dividends - iBio CMO Preferred Tracking Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r176"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r448",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease obligation - net of current portion",
        "verboseLabel": "Long-term portion of minimum lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "verboseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r448",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "verboseLabel": "Tax credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of debt securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r255",
      "r327"
     ]
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Schedule of non-cash activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Number of shares terminated",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of premiums on debt securities",
        "verboseLabel": "Amortization of premiums on debt securities",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r98",
      "r152",
      "r386"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleGainLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sale of debt securities",
        "verboseLabel": "Proceeds from sale of debt securities",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r255",
      "r327",
      "r331"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares issued",
        "verboseLabel": "Share-based award, Number of awards issued",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Market value per share",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Investment in equity security",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r861"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "verboseLabel": "Compensation cost, not recognized",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Area of facility",
        "verboseLabel": "Area of ground lease",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Shares vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Grant date fair value",
        "verboseLabel": "Share based payment award, Grant-date fair value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CollaborationAndLicenseAgreementRoyaltyPaymentTerm",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement, royalty payment term",
        "label": "Collaboration and License Agreement, Royalty payment term",
        "terseLabel": "Collaboration and license agreement, royalty payment term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r739",
      "r830",
      "r894",
      "r895"
     ]
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedLabel": "Gain on sale of fixed assets",
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Number Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price - Lower range",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsAndSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ibio_ScenarioPlanExpectedPaymentTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ScenarioPlanExpectedPaymentTwoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan Expected Payment Two [Member].",
        "label": "Scenario Plan Expected Payment Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].",
        "label": "iBio, Inc. v. Fraunhofer USA, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease right-of-use assets, net of accumulated amortization",
        "verboseLabel": "Finance lease ROU assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Finance Lease Obligations",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Obligation, Principal"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_GainLossRelatedToLitigationSettlementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "GainLossRelatedToLitigationSettlementTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure on gain (Loss) related to litigation settlement.",
        "label": "Gain Loss Related To Litigation Settlement [Text Block]",
        "terseLabel": "Fraunhofer Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r231",
      "r267",
      "r304",
      "r312",
      "r316",
      "r332",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r521",
      "r525",
      "r548",
      "r592",
      "r666",
      "r753",
      "r766",
      "r826",
      "r827",
      "r878"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]",
        "terseLabel": "Other assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SettlementOfRevenueContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SettlementOfRevenueContract",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of revenue contract.",
        "label": "Settlement of revenue contract",
        "negatedLabel": "Settlement of revenue contract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors [Member]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r897"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized included in contract liabilities",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Annual percentage increase in base rent",
        "label": "Lessee Operating Lease, Annual percentage increase in base rent",
        "verboseLabel": "Annual percentage increase in base rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CapitalExpenditureIncurredForIntangibleAssetsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid for capital expenditures incurred for intangible assets during the previous year.",
        "label": "Capital Expenditure Incurred For Intangible Assets Paid",
        "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r195",
      "r249",
      "r308",
      "r556",
      "r681",
      "r764",
      "r898"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, Net, Current",
        "verboseLabel": "Contract assets",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r421"
     ]
    },
    "ibio_BasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "BasisOfPresentationTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ContractAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ContractAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract assets.",
        "label": "Contract Assets [Policy Text Block]",
        "terseLabel": "Contract Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_UnpaidFixedAssetsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "UnpaidFixedAssetsIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unpaid fixed assets included in accounts payable.",
        "label": "Unpaid Fixed Assets Included In Accounts Payable",
        "terseLabel": "Unpaid fixed assets included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of of total cash, cash equivalents and restricted cash",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "ibio_NetLossAvailableToStockholdersFromContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss attributable to iBio, Inc.",
        "totalLabel": "Net loss attributable to iBio, Inc. from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r148",
      "r157",
      "r277",
      "r278",
      "r279",
      "r280",
      "r292",
      "r296"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Share-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r453",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r487",
      "r488",
      "r489",
      "r490"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r193",
      "r194",
      "r252",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r290",
      "r294",
      "r295",
      "r536",
      "r588",
      "r893"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r141",
      "r142",
      "r143"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r252",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r290",
      "r294",
      "r295",
      "r296",
      "r536",
      "r588",
      "r893"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r557",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r803"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "ibio_UnconsolidatedGainLossAttributableToStockholders",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r129",
      "r224",
      "r516",
      "r602"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r132",
      "r133",
      "r190",
      "r191",
      "r271",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r557",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r803"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r447"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r291",
      "r294",
      "r295"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r74",
      "r75",
      "r98",
      "r99",
      "r101",
      "r105",
      "r173",
      "r175",
      "r271",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r557",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r803"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease ROU Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r252",
      "r291",
      "r294",
      "r295",
      "r888",
      "r893"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments in Debt Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r196",
      "r197",
      "r219",
      "r326",
      "r328",
      "r546",
      "r547"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of shares, net of issuance cost",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "positiveTerseLabel": "Number of shares to be issued upon exercise of warrants",
        "terseLabel": "Number of warrants issued",
        "verboseLabel": "Warrants to purchase shares of Common Stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses - noncurrent",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r266",
      "r393",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r410",
      "r533",
      "r699",
      "r700",
      "r716"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r539",
      "r580",
      "r733",
      "r734",
      "r740",
      "r741",
      "r742"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "verboseLabel": "Irrevocable letter of credit",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r760",
      "r761",
      "r762",
      "r763",
      "r896",
      "r900"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r807",
      "r808",
      "r869",
      "r896",
      "r900"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Deferred finance costs",
        "verboseLabel": "Cost incurred to attain debt",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r829"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after Two Years, Fair Value",
        "terseLabel": "2023",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Security deposit",
        "documentation": "The increase (decrease) during the reporting period in security deposits."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r577"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Schedule of fair value of available-for-sale debt securities, by contractual maturity",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r209"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Fair Value Measurement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Domain]",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of fixed assets",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Warrant issued for Transaction",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r73",
      "r176"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r265",
      "r364",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r387",
      "r388",
      "r390"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_PaymentsForAdvanceToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForAdvanceToAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Advance to Affiliate",
        "terseLabel": "Amount advanced",
        "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Investing noncash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ibio_CollaborationOptionAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CollaborationOptionAndLicenseAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, Option and License Agreement [Member]",
        "label": "Collaboration, Option and License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "verboseLabel": "Operating loss carryforwards, subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "verboseLabel": "Operating loss carryforwards, not subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Volatility, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "verboseLabel": "Volatility, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r677"
     ]
    },
    "ibio_StockPurchaseAgreementValueOfSharesPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockPurchaseAgreementValueOfSharesPurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, value of shares purchased",
        "label": "Stock purchase agreement, value of shares purchased"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividends Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockPurchaseAgreementNumberOfSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockPurchaseAgreementNumberOfSharesPurchased",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, number of shares purchased",
        "label": "Stock purchase agreement, number of shares purchased",
        "terseLabel": "Stock purchase agreement, number of shares purchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings (loss) Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee 401(K) Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r425",
      "r426",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r742"
     ]
    },
    "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Finished Goods and Work in Process Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_InventoryWorkInProcessPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessPolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Work in Process, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory in the course of production (work in process). If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average)."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ibio_RubrycTheraputicsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "RubrycTheraputicsInc.Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RubrYc Therapeutics, Inc. [Member]",
        "label": "RubrYc Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesReceivableMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Receivable [Member]",
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Secured term loan",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r101",
      "r365",
      "r557",
      "r733",
      "r734"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r394"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r864"
     ]
    },
    "us-gaap_IntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntellectualPropertyMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property [Member]",
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ibio_ImmuneOncologyAntibodiesRtx003Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ImmuneOncologyAntibodiesRtx003Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immune-Oncology Antibodies (RTX-003) [Member]",
        "label": "Immune-Oncology Antibodies (RTX-003) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other than Temporary Impairment Losses, Investments",
        "verboseLabel": "Impairment of investment in equity security",
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory federal income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r499",
      "r514"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss available to iBio, Inc. stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r277",
      "r278",
      "r279",
      "r280",
      "r287",
      "r288",
      "r293",
      "r296",
      "r304",
      "r311",
      "r315",
      "r317",
      "r730"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "negatedLabel": "Impairment of intangible assets",
        "verboseLabel": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r21"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation of fixed assets",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r678",
      "r679",
      "r680"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r679",
      "r680"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "verboseLabel": "General and administrative expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r899"
     ]
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r864"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property, plant and equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r861"
     ]
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "verboseLabel": "Total minimum equipment financing payments",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Personnel related costs",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ibio_SecondEasternAffiliateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SecondEasternAffiliateMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to Second Eastern Affiliate.",
        "label": "Second Eastern Affiliate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AuctionSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AuctionSaleAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the Auction Sale Agreement with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC.",
        "label": "Auction Sale Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EasternAffiliateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EasternAffiliateMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Eastern affiliate.",
        "label": "Eastern Affiliate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NetLossAvailableToStockholdersFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NetLossAvailableToStockholdersFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "ibio_UnconsolidatedGainLossAttributableToStockholders",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net loss available to stockholders from continuing operations.",
        "label": "Net Loss Available To Stockholders from Continuing Operations",
        "totalLabel": "Net loss available to iBio, Inc. stockholders from continuing operations"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ImpairmentOfIntangibleAssetsGrossOfReversals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ImpairmentOfIntangibleAssetsGrossOfReversals",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of intangible asset impairment before reversals.",
        "label": "Impairment Of Intangible Assets Gross Of Reversals",
        "negatedLabel": "Impairment of intangible assets - gross carrying value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "terseLabel": "Number of positions reduced",
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r721"
     ]
    },
    "ibio_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating lease obligations",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r752"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current",
        "terseLabel": "Term note payable - net of deferred financing costs",
        "verboseLabel": "Notes payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ibio_EstimatedAdditionalCostOnDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EstimatedAdditionalCostOnDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated additional cost on development as at end of the reporting period.",
        "label": "Estimated Additional Cost on Development",
        "terseLabel": "Additional costs committed"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_Dr.MartinBrennerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "Dr.MartinBrennerMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Dr. Martin Brenner, the Company's Chief Scientific Officer and Interim Chief Executive Officer.",
        "label": "Dr. Martin Brenner [Member]",
        "terseLabel": "Dr. Martin Brenner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_Mr.IsettMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "Mr.IsettMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Mr. Isett, Former CEO.",
        "label": "Mr. Isett [Member]",
        "terseLabel": "Mr. Isett, former CEO"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Noncurrent",
        "netLabel": "Note payable, PPP loan",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r184",
      "r621",
      "r622"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - finance lease obligation",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r752"
     ]
    },
    "ibio_TangibleAssetImpairmentChargesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "TangibleAssetImpairmentChargesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets of discontinued operations from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges, Discontinued Operations",
        "terseLabel": "Fixed assets impairments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ibio_InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "InterestMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to interest portion of the obligation.",
        "label": "Interest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "positiveLabel": "Sale of preferred stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r134",
      "r135",
      "r176",
      "r633",
      "r696",
      "r711",
      "r765"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r544"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ibio_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ReversalOfIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ReversalOfIntangibleAssetImpairment",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of intangible asset impairment.",
        "label": "Reversal Of Intangible Asset Impairment",
        "terseLabel": "Intangible asset impairment - accumulated amortization"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockholdersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockholdersEquityLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NumberOfEquipmentLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NumberOfEquipmentLeases",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equipment leases.",
        "label": "Number of Equipment Leases",
        "terseLabel": "Number of equipment leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EarningsLossPerCommonShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EarningsLossPerCommonShareTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Loss Per Common Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PreferredTrackingStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PreferredTrackingStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "iBio CMO Preferred Tracking Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AssetAcquisitionInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AssetAcquisitionInShares",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares from asset acquisition during the period.",
        "label": "Asset Acquisition (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AssetAcquisitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AssetAcquisitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of asset acquisition during the period. (Value)",
        "label": "Asset Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AggregateCommonStockPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AggregateCommonStockPurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Aggregate Common Stock Purchased",
        "verboseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ibio_PrincipalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PrincipalMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to principal portion of the obligation.",
        "label": "Principal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Fair value of Warrant using the Black-Scholes model assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ibio_ExcessAuctionProceedsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ExcessAuctionProceedsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to proceeds from auction of company assets after counterparty fees.",
        "label": "Excess Auction Proceeds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r42",
      "r176"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 27.0
      },
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Gain (Loss)",
        "negatedLabel": "Loss on sale of debt securities",
        "terseLabel": "Loss on sale of debt securities",
        "totalLabel": "Realized loss on sale of debt securities",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r368",
      "r396",
      "r574",
      "r725",
      "r727"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairmentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Asset Impairment [Abstract]",
        "terseLabel": "Impairments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ibio_Mr.RobertLutzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "Mr.RobertLutzMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Mr. Robert Lutz, the Company's Chief Financial and Business Officer.",
        "label": "Mr. Robert Lutz [Member]",
        "terseLabel": "Mr. Robert Lutz"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r134",
      "r135",
      "r176",
      "r625",
      "r696",
      "r711"
     ]
    },
    "ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reclassification adjustment for the period on gains (losses) on avaliable for sale debt securities.",
        "label": "Reclassficiation Adjustment, Gain (Loss) On Available For Sale Debt Securities",
        "terseLabel": "Reclassification adjustment for loss on available-for-sale debt securities realized in net income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Future Minimum Payments under the Operating Lease Obligation",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ibio_EarningsLossPerCommonShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EarningsLossPerCommonShareLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Loss Per Common Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Note balance and accrued interest",
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "verboseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Allocated Share-based Compensation Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r491"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets Acquired",
        "terseLabel": "Additions to licenses",
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfAuctionProceedsReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PercentageOfAuctionProceedsReceived",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of proceeds received in an auction sale of company assets.",
        "label": "Percentage Of Auction Proceeds Received",
        "terseLabel": "Percentage of excess proceeds received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from issuance of common stock",
        "terseLabel": "Gross proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from offering",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_GuaranteedAuctionProceedsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "GuaranteedAuctionProceedsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to guaranteed procedds from auction of company assets.",
        "label": "Guaranteed Auction Proceeds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Costs incurred",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains (losses) on available for sale debt securities.",
        "label": "Avaliable For Sale Debt Securities Realized Gains (Losses) [Table Text Block]",
        "terseLabel": "Schedule of realized losses on available-for-sale debt securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation.",
        "verboseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Gain (Loss) From Continuing Operations",
        "totalLabel": "Consolidated net loss from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r267",
      "r275",
      "r304",
      "r311",
      "r315",
      "r317",
      "r332",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r536",
      "r548",
      "r601",
      "r730",
      "r826"
     ]
    },
    "ibio_CroAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CroAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to CRO Agreement.",
        "label": "CRO Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockholdersEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockholdersEquityTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and Licenses [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r176"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Additions to definite lived intangible assets",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated annual amortization expenses for next five years and thereafter",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ibio_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Vesting of RSU's (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r134",
      "r135",
      "r176"
     ]
    },
    "ibio_HollandIndustrialGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "HollandIndustrialGroupMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Holland Industrial Group.",
        "label": "Holland Industrial Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Stock Options, Exercised",
        "terseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r134",
      "r135",
      "r176",
      "r459"
     ]
    },
    "ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as non current  assets attributable to disposal group held for sale or disposed of, expected to be disposed of more than one year.",
        "label": "Disposal Group, Non Current Assets, Finance Lease Right of Use Assets",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of preferred stock to common stock (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r41",
      "r74",
      "r176",
      "r381"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r96",
      "r97",
      "r320",
      "r717"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r185"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value",
        "totalLabel": "Fair value",
        "verboseLabel": "Investments in debt securities",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r96",
      "r97",
      "r320",
      "r620",
      "r717"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r345",
      "r346",
      "r718",
      "r821"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage of workforce reduction",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r485",
      "r486",
      "r633",
      "r807",
      "r808",
      "r809",
      "r869",
      "r900"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Total net intangible assets",
        "verboseLabel": "Intangible assets, net of accumulated amortization",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "presentationGuidance": "Amortization of ROU assets",
        "terseLabel": "Amortization of finance lease right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r566",
      "r752"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Total",
        "totalLabel": "Total definite lived intangible assets, net of accumulated amortization",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r585"
     ]
    },
    "us-gaap_SettledLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SettledLitigationMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settled Litigation [Member]",
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, gross carrying value",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r586"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r572"
     ]
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLegalSettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Legal Settlements",
        "terseLabel": "Settlement payment received",
        "documentation": "Cash received for the settlement of litigation during the current period."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r301",
      "r584",
      "r623",
      "r644",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r676",
      "r677",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r759"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Finance lease obligations - current portion",
        "verboseLabel": "Finance lease obligation - current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r539",
      "r578",
      "r579",
      "r580",
      "r733",
      "r734",
      "r740",
      "r741",
      "r742"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r585"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "License - indefinite lived",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Value of common stock issued",
        "verboseLabel": "Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2023 and 2022; 20,310,077 and 8,727,158 shares issued and outstanding as of June 30, 2023 and June 30, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r594",
      "r753"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of Category the gross carrying value and accumulated amortization of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r654"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r135",
      "r654",
      "r672",
      "r900",
      "r901"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "netLabel": "Long-term portion of minimum lease obligations",
        "presentationGuidance": "Finance lease obligation - non current portion",
        "terseLabel": "Finance lease obligations - net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r541",
      "r542",
      "r545"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r42",
      "r220",
      "r246",
      "r247",
      "r248",
      "r272",
      "r273",
      "r274",
      "r276",
      "r282",
      "r284",
      "r301",
      "r333",
      "r334",
      "r410",
      "r484",
      "r485",
      "r486",
      "r509",
      "r510",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r573",
      "r614",
      "r615",
      "r616",
      "r633",
      "r696"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r272",
      "r273",
      "r274",
      "r276",
      "r282",
      "r284",
      "r333",
      "r334",
      "r484",
      "r485",
      "r486",
      "r509",
      "r510",
      "r527",
      "r529",
      "r530",
      "r532",
      "r534",
      "r614",
      "r616",
      "r633",
      "r900"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r448",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r232",
      "r233",
      "r234",
      "r267",
      "r290",
      "r291",
      "r294",
      "r296",
      "r302",
      "r303",
      "r332",
      "r355",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r394",
      "r395",
      "r398",
      "r401",
      "r408",
      "r548",
      "r625",
      "r626",
      "r627",
      "r628",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r654",
      "r675",
      "r696",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r776",
      "r802",
      "r811"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r220",
      "r246",
      "r247",
      "r248",
      "r272",
      "r273",
      "r274",
      "r276",
      "r282",
      "r284",
      "r301",
      "r333",
      "r334",
      "r410",
      "r484",
      "r485",
      "r486",
      "r509",
      "r510",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r573",
      "r614",
      "r615",
      "r616",
      "r633",
      "r696"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "terseLabel": "Additions",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Net",
        "terseLabel": "Cash paid during the period for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r261",
      "r262"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r448",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtTables",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Payments Under the Finance Lease Obligation",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r96",
      "r97",
      "r320",
      "r717"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options granted",
        "verboseLabel": "Stock Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Loss [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r45",
      "r528",
      "r531",
      "r573",
      "r614",
      "r615",
      "r792",
      "r793",
      "r794",
      "r807",
      "r808",
      "r809"
     ]
    },
    "ibio_RepresentativeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "RepresentativeWarrantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to representative warrants.",
        "label": "Representative Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FixedAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FixedAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed assets held-for-sale.",
        "label": "Fixed Assets Held-for-sale",
        "terseLabel": "Fixed assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\") subsidy period.",
        "label": "Severance Benefits, Consolidated Omnibus Budget Reconciliation Act Subsidy Period",
        "terseLabel": "COBRA subsidy period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.",
        "label": "Severance Benefits, Period of Bi-Monthly Installments of target Bonus",
        "terseLabel": "Period of bi-monthly installments of target bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDeferredChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDeferredChargesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Deferred Charges [Abstract]",
        "terseLabel": "Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Amortization of Intangible Assets",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization of definite lived intangible assets",
        "verboseLabel": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r70"
     ]
    },
    "ibio_AssetAcquisitionFixedAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AssetAcquisitionFixedAssetsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Fixed Assets [Member]",
        "label": "Asset Acquisition Fixed Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property Plant And Equipment Fair Value Disclosure",
        "terseLabel": "Total Fair Value",
        "verboseLabel": "Estimated fair values"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquipmentFinancingBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquipmentFinancingBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of equipment financing balance under equipment leasing.",
        "label": "Equipment Financing Balance",
        "terseLabel": "Balance owed under financing"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ContractualObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ContractualObligationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of contractual obligation.",
        "label": "Contractual Obligation, Current",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquipmentFinancingAmountBorrowed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquipmentFinancingAmountBorrowed",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount borrowed under equipment financing as at the end of the reporting period.",
        "label": "Equipment Financing, Amount Borrowed",
        "terseLabel": "Amount borrowed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees gross pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ContractualObligationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ContractualObligationNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncurrent portion of contractual obligation.",
        "label": "Contractual Obligation, Noncurrent",
        "terseLabel": "Long-term portion of minimum equipment financing obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquipmentLeasingMonthlyInstallmentPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquipmentLeasingMonthlyInstallmentPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of monthly installment payable under equipment leasing.",
        "label": "Equipment Leasing Monthly Installment Payable",
        "terseLabel": "Monthly installment payable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AssetAcquisitionTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AssetAcquisitionTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect an asset acquisition.",
        "label": "Asset Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Total current assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r111",
      "r127",
      "r165",
      "r168",
      "r223",
      "r224"
     ]
    },
    "ibio_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement [Member]",
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\").",
        "label": "Severance Benefits, Maximum Period for Coverage of Health Insurance If Employer Elects Consolidated Omnibus Budget Reconciliation Act",
        "terseLabel": "Maximum period for coverage of health insurance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "verboseLabel": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ibio_SeparationAgreementAndGeneralReleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeparationAgreementAndGeneralReleaseMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Separation Agreement and General Release.",
        "label": "Separation Agreement and General Release [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\").",
        "label": "Severance Benefits, Number of Times on Which Lum Sum Cash Payment to be Made if Health Coverage Not Made Under Consolidated Omnibus Budget Reconciliation Act",
        "terseLabel": "Number of times on which lump sum cash payment tis o be made"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "verboseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ibio_EquipmentFinancingLeaseImputedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquipmentFinancingLeaseImputedInterestRate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of imputed interest rate on equipment financing.",
        "label": "Equipment Financing Lease, Imputed Interest Rate",
        "terseLabel": "Imputed interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "verboseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of the warrants",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "ibio_EquipmentFinancingInterestIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquipmentFinancingInterestIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest incurred under equipment financing.",
        "label": "Equipment Financing, Interest Incurred",
        "terseLabel": "Interest incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "ibio_PercentageOfAggregateNumberOfSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PercentageOfAggregateNumberOfSharesOfCommonStock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate number of shares of common stock.",
        "label": "Percentage of Aggregate Number of Shares of Common Stock",
        "terseLabel": "Percentage of number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157"
     ]
    },
    "ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.",
        "label": "Severance Benefits, Period of Bi-Monthly Installments of Current Base Salary",
        "terseLabel": "Period of bi-monthly installments of current base salary"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LeaseRentExpensePerMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LeaseRentExpensePerMonth",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of lease rent expense per month during the reporting period.",
        "label": "Lease Rent Expense Per Month",
        "terseLabel": "Monthly rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CommonWarrantsToPurchaseAdditionalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CommonWarrantsToPurchaseAdditionalShares",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common warrants to purchase additional shares.",
        "label": "Common Warrants to Purchase Additional Shares",
        "terseLabel": "Warrants to purchase additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NumberOfDaysOptionToPurchaseAdditionalShares": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NumberOfDaysOptionToPurchaseAdditionalShares",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days option to purchase additional shares.",
        "label": "Number of Days Option to Purchase Additional Shares",
        "terseLabel": "Number of days granted to purchase additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underwriting discount paid on gross proceeds of offering.",
        "label": "Percentage of Underwriting Discount Paid on Gross Proceeds of Offering",
        "terseLabel": "Percentage of underwriting discount"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeEquipmentLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeEquipmentLeaseTermOfContract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee equipment financing lease.",
        "label": "Lessee, Equipment Lease, Term of Contract",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Accounts receivable - trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NumberOfAdditionalSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NumberOfAdditionalSharesIssued",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares issued.",
        "label": "Number of Additional Shares Issued",
        "terseLabel": "Additional shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Pre Funded Warrants.",
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToMinorityShareholders",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Acquisition of noncontrolling interest",
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Uninsured Amount",
        "verboseLabel": "Amount in excess of insured limit",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average Remaining Contractual Term (in years), Exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ibio_H.c.WainwrightCo.LlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "H.c.WainwrightCo.LlcMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.",
        "label": "H.C. Wainwright &amp; Co., LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r680"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Doubtful Accounts",
        "terseLabel": "Reserve for loss on contract",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r335"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Fixed assets, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r680"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r210",
      "r213",
      "r214"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r176",
      "r596",
      "r617",
      "r619",
      "r629",
      "r655",
      "r753"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of lease",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r576"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on available-for-sale debt securities",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r817"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r752"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accrued expenses",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r753"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r185",
      "r242",
      "r244",
      "r251",
      "r587",
      "r604"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Compensation cost recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r267",
      "r305",
      "r306",
      "r310",
      "r313",
      "r314",
      "r318",
      "r319",
      "r320",
      "r332",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r548",
      "r589",
      "r826"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Life In Years",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r394"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r311",
      "r315",
      "r317",
      "r730"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset, useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Buildings and improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalty income",
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r410",
      "r807",
      "r808",
      "r809",
      "r900"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Preferred Stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r654"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r654",
      "r672",
      "r900",
      "r901"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r91",
      "r220",
      "r221",
      "r247",
      "r272",
      "r273",
      "r274",
      "r276",
      "r282",
      "r333",
      "r334",
      "r410",
      "r484",
      "r485",
      "r486",
      "r509",
      "r510",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r549",
      "r550",
      "r554",
      "r573",
      "r615",
      "r616",
      "r631",
      "r656",
      "r672",
      "r697",
      "r698",
      "r715",
      "r765",
      "r804",
      "r819",
      "r872",
      "r900"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r493",
      "r886"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Cost to raise capital",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r176"
     ]
    },
    "us-gaap_InterestPaidDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Discontinued Operations",
        "terseLabel": "Cash paid during the period for interest",
        "documentation": "The amount of cash paid during the current period for interest owed on debt associated with discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ConvertiblePromissoryNoteReceivableAndAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of convertible Promissory Note Receivable and Accrued Interest.",
        "label": "Convertible Promissory Note Receivable and Accrued Interest",
        "terseLabel": "Promissory note receivable and accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue",
        "terseLabel": "Contract liabilities",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance lease obligation",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r568"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized",
        "terseLabel": "Maximum value of all awards awarded under the Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r264"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average Remaining Contractual Term (in years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ibio_IbioInc.2020OmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IbioInc.2020OmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.",
        "label": "2020 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Increase in finance lease ROU assets for new leases",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r752"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization",
        "terseLabel": "Depreciation expense",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r783"
     ]
    },
    "ibio_LoansReceivableAmountInvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LoansReceivableAmountInvested",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the face amount of notes receivable invested.",
        "label": "Loans Receivable, Amount Invested",
        "terseLabel": "Amount invested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term (in years), Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "verboseLabel": "Security deposits",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ibio_ScenarioTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ScenarioTwoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Preferred tracking stock exchanged for units.",
        "label": "Scenario Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SubscriptionReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SubscriptionReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.",
        "label": "Subscription Receivable Current",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "ibio_NumberOfMajorCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NumberOfMajorCustomers",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to number of major customers.",
        "label": "Number of Major Customers",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Nonrecurring [Member]",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r545"
     ]
    },
    "ibio_LoansReceivableFixedRatesOfInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LoansReceivableFixedRatesOfInterest",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fixed rate of interest on notes.",
        "label": "Loans Receivable, Fixed Rates of Interest",
        "terseLabel": "Interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r226",
      "r267",
      "r332",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r522",
      "r525",
      "r526",
      "r548",
      "r753",
      "r826",
      "r878",
      "r879"
     ]
    },
    "ibio_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants [Member]",
        "label": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "ibio_CurrentAndDeferredFederalAndStateTaxes",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "verboseLabel": "Current - Federal and state",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r508",
      "r513",
      "r805"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_FinancialStandbyLetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialStandbyLetterOfCreditMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit",
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfLeasedAssetsNetOperatingLeases",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Sale of Leased Assets, Net, Operating Leases",
        "negatedLabel": "Gain on disposition of finance lease ROU assets",
        "documentation": "The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r342"
     ]
    },
    "us-gaap_ScenarioPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScenarioPlanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Plan [Member]",
        "documentation": "The scenario under which facts represent plans as distinct from actual."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r307"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r301",
      "r584",
      "r623",
      "r644",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r676",
      "r677",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r759"
     ]
    },
    "ibio_CantorFitzgeraldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CantorFitzgeraldMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cantor Fitzgerald [Member]",
        "label": "Cantor Fitzgerald [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentOperatingActivitiesDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Domain]",
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_VariousEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "VariousEmployeesMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various Employees [Member]",
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r267",
      "r332",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r522",
      "r525",
      "r526",
      "r548",
      "r653",
      "r729",
      "r766",
      "r826",
      "r878",
      "r879"
     ]
    },
    "ibio_ScenarioOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ScenarioOneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for scenario one in which the value of maximum award in calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors.",
        "label": "Scenario One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations [Member]",
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r112",
      "r113",
      "r114"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Total current liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r111",
      "r127",
      "r165",
      "r168",
      "r223",
      "r224"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r74",
      "r134",
      "r174",
      "r404"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r339",
      "r340",
      "r341",
      "r585",
      "r586"
     ]
    },
    "ibio_OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "OmnibusIncentivePlanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan [Member]",
        "label": "Omnibus Incentive (the 2020) Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CashAndCashEquivalentsPlusDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CashAndCashEquivalentsPlusDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents plus debt securities",
        "label": "Cash and cash equivalents plus debt securities",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r576"
     ]
    },
    "ibio_PppLoanCaresActMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PppLoanCaresActMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PP Loans Cares Act.",
        "label": "PPP Loan Cares Act [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarnestMoneyDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarnestMoneyDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnest Money Deposits",
        "terseLabel": "Earnest money deposit",
        "documentation": "A deposit made by a purchaser of real estate to evidence good faith. It is customary for a buyer to give the seller earnest money at the time a sales contract is signed. The earnest money generally is credited to the down payment at closing, which is applied at closing as a component of payment against the purchase price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69"
     ]
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Axis]",
        "documentation": "Information by continuing and discontinuing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r576"
     ]
    },
    "ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest receivable on convertible promissory note receivable.",
        "label": "Accrued Interest Receivable on Convertible Promissory Note Receivable",
        "negatedLabel": "Accrued interest receivable on promissory note receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r576"
     ]
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tenant Improvements",
        "verboseLabel": "Tenant improvement allowance",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Total long-term liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r4",
      "r111",
      "r127",
      "r168",
      "r223",
      "r224"
     ]
    },
    "ibio_FourCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FourCustomersMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Customers [Member]",
        "label": "Four Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent of match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r192",
      "r597",
      "r753",
      "r804",
      "r819",
      "r872"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ibio_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Sales Agreement.",
        "label": "Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r576"
     ]
    },
    "ibio_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three",
        "label": "$26.50 - $39.75 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.",
        "label": "Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]",
        "terseLabel": "Summary of the gross carrying value and accumulated amortization of finance lease ROU"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Amendment fee",
        "verboseLabel": "Fee amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Area of facility to be sold",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities With In Two Year Amortized Cost",
        "terseLabel": "2024"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ContractLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ContractLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract liabilities.",
        "label": "Contract Liabilities [Policy Text Block]",
        "terseLabel": "Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r861"
     ]
    },
    "ibio_IncomeTaxExpenseBenefitValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IncomeTaxExpenseBenefitValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in the valuation allowance of the income tax expense (benefit) reported during the period.",
        "label": "Income Tax Expense Benefit Valuation Allowance",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "verboseLabel": "Operating loss carryforwards, net",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r861"
     ]
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FinanceLeaseRightOfUseAssetDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease ROU [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "verboseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FinanceLeaseRightOfUseAssetDisclosureTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about activity in the balance of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r861"
     ]
    },
    "ibio_ScenarioPlanExpectedLegalFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ScenarioPlanExpectedLegalFeesMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan, Expected Legal Fees [Member].",
        "label": "Scenario Plan Expected Legal Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FacilityMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for facility.",
        "label": "Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CurrentAndDeferredFederalAndStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CurrentAndDeferredFederalAndStateTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the current and deferred federal income tax expense or benefit and the deferred income tax expense or benefit pertaining to pretax Income or Loss from continuing operations; income tax expense or benefit may include interest and penalties on tax uncertainties based on the entity's accounting policy.",
        "label": "Current And Deferred Federal And State Taxes",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ibio_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Basis of Presentation.",
        "label": "Basis of Presentation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One[Member]",
        "label": "$7.00 - $11.50 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockIssuedDuringPeriodValueCapitalRaise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockIssuedDuringPeriodValueCapitalRaise",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of capital raise during the period.",
        "label": "Stock Issued During Period, Value, Capital Raise",
        "terseLabel": "Capital raise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "verboseLabel": "Area of lab and office",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_RightOfUseAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "RightOfUseAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policy for right-of-use assets.",
        "label": "Right Of Use Assets Policy [Policy Text Block]",
        "terseLabel": "Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two[Member]",
        "label": "$17.35 - $26.03 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member]",
        "label": "$41.25 - $61.88 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FinanceLeaseRightOfUseAssetDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Text Block]",
        "terseLabel": "Finance Lease ROU Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IbioCdmoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IbioCdmoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Bioprocessing (iBio CDMO) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockIssuedDuringPeriodSharesCapitalRaise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockIssuedDuringPeriodSharesCapitalRaise",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares raised during the period.",
        "label": "Stock Issued During Period, Shares, Capital Raise",
        "terseLabel": "Capital raise (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r752"
     ]
    },
    "ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]",
        "label": "After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FinancingCashFlowsFromFinanceLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FinancingCashFlowsFromFinanceLeaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for finance lease obligations.",
        "label": "Financing Cash Flows From Finance Lease Obligation",
        "terseLabel": "Financing cash flows from finance lease obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r752"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r861"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r444",
      "r777",
      "r778",
      "r810"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r877"
     ]
    },
    "ibio_BoardOfDirectorsOfficersAndEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "BoardOfDirectorsOfficersAndEmployeesMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board Of Directors Officers And Employees",
        "label": "Board Of Directors and Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r366"
     ]
    },
    "ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid For Amounts Included In Measurement Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r861"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r444",
      "r777",
      "r810"
     ]
    },
    "ibio_FinanceLeaseObligationOtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FinanceLeaseObligationOtherInformationAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease Obligation, Other Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CollaborationAndLicenseAgreementAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CollaborationAndLicenseAgreementAgreementTerm",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement, agreement term",
        "label": "Collaboration and license agreement, agreement term",
        "terseLabel": "Collaboration and license agreement, agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of June 30, 2023 and 2022",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r593",
      "r753"
     ]
    },
    "ibio_FinanceLeaseRightOfUseAssetGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FinanceLeaseRightOfUseAssetGross",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.",
        "label": "Finance Lease, Right Of Use Asset, Gross",
        "terseLabel": "ROU, gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt amortization payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r106"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "verboseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r861"
     ]
    },
    "ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.",
        "label": "Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payment for RubrYc asset acquisition",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ibio_CashPaymentsReceivablesRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CashPaymentsReceivablesRelatedToLitigationSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments receivables related to litigation settlement.",
        "label": "Cash Payments Receivables Related to Litigation Settlement",
        "terseLabel": "Cash payments receivables related to litigation settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r861"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r271",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r557",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r803"
     ]
    },
    "ibio_SeriesWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeriesWarrantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series A warrants.",
        "label": "Series A warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ProceedsFromIssuanceOfPreferredAndCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ProceedsFromIssuanceOfPreferredAndCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Preferred And Common Stock",
        "terseLabel": "Proceeds from sales of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Stockholders' Equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r138",
      "r139",
      "r159",
      "r656",
      "r672",
      "r697",
      "r698",
      "r753",
      "r766",
      "r804",
      "r819",
      "r872",
      "r900"
     ]
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FinanceLeaseRightOfUseAssetDisclosureLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Principal payment",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable",
        "terseLabel": "Interest and fees related to term note payable",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r890"
     ]
    },
    "ibio_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series B warrants.",
        "label": "Series B warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventory",
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r111",
      "r127",
      "r165",
      "r168"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share based payment plan term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r798"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Purchase price allocated",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Current assets held for sale",
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r753"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditure, Discontinued Operations",
        "terseLabel": "Purchase of fixed assets",
        "documentation": "Amount of capital expenditure attributable to discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r578",
      "r579",
      "r580",
      "r733",
      "r734",
      "r740",
      "r741",
      "r742"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r449",
      "r480",
      "r481",
      "r483",
      "r747"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Liability for the assumed acquisition",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "verboseLabel": "Stock options vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r368",
      "r396",
      "r574",
      "r726",
      "r727"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fixed assets measured at fair value on a non-recurring basis",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r94",
      "r95",
      "r187"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - finance lease",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r752"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average exercise price per share, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r4",
      "r111",
      "r127",
      "r168"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r111",
      "r127",
      "r165",
      "r168"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average Exercise Price, Forfeited/expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ibio_CommonStockIssuedInRubrycTransactionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CommonStockIssuedInRubrycTransactionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common stock issued in the RubrYc transaction.",
        "label": "Common Stock Issued In RubrYc Transaction, Value",
        "verboseLabel": "RubrYc asset acquisition by issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ibio_UnconsolidatedGainLossAttributableToStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "UnconsolidatedGainLossAttributableToStockholders",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unconsolidated net gain (loss) attributable to stockholders.",
        "label": "Unconsolidated Gain (Loss) Attributable To Stockholders",
        "totalLabel": "Net loss available to iBio, Inc. stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EmployeeReductionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EmployeeReductionExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected amount of expenses to be incurred due to employee reductions.",
        "label": "Employee Reduction Expenses",
        "terseLabel": "Expected employee reduction charges"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DebtCovenantLiquidityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DebtCovenantLiquidityAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required liquidity per debt covenant.",
        "label": "Debt Covenant, Liquidity Amount",
        "terseLabel": "Liquidity covenant, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupGainOnDebtForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupGainOnDebtForgiveness",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on forgiveness of debt to discontinued operations.",
        "label": "Disposal Group, Gain On Debt Forgiveness",
        "terseLabel": "Forgiveness of note payable and accrued interest - SBA loan"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of finance lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Amortization Of Finance Lease Right Of Use Assets",
        "terseLabel": "Amortization of finance lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r384",
      "r392",
      "r735",
      "r736"
     ]
    },
    "ibio_DisposalGroupOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current operating lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r207",
      "r208",
      "r211",
      "r212"
     ]
    },
    "ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CurrentLiabilitiesRelatedToAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current liabilities related to assets held for sale.",
        "label": "Current Liabilities Related To Assets Held For Sale",
        "terseLabel": "Current liabilities related to assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DateOfAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DateOfAmendmentMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date Of Amendment [Member]",
        "label": "Date Of Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent finance lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Noncurrent Liabilities, Finance Lease Obligations",
        "terseLabel": "Finance lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Other comprehensive income (loss) - unrealized gain (loss) on debt securities",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "terseLabel": "Unrealized (gain) loss on available-for-sale debt securities",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Within Two Business Days Of Frunhofer Legal Settlement [Member]",
        "label": "Within Two Business Days Of Frunhofer Legal Settlement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IncreaseDecreaseInFinanceLeaseObligationsForNewLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in finance lease obligations for new leases incurred during the period.",
        "label": "Increase (Decrease) In Finance Lease Obligations For New Leases",
        "terseLabel": "Increase in finance lease obligation for new leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IncreaseDecreaseInInventoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IncreaseDecreaseInInventoryReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in inventory valuation reserve during the period.",
        "label": "Increase (Decrease) In Inventory Reserve",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupCurrentLiabilitiesOperatingLeaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current operating lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Current Liabilities, Operating Lease Obligations",
        "terseLabel": "Operating lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupCurrentLiabilitiesFinanceLeaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current finance lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Current Liabilities, Finance Lease Obligations",
        "terseLabel": "Finance lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Other comprehensive income - foreign currency adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ibio_DiscontinuedOperationsMiscellaneousExpensesIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DiscontinuedOperationsMiscellaneousExpensesIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous expenses (income) attributable to discontinued operations.",
        "label": "Discontinued Operations, Miscellaneous Expenses (Income)",
        "negatedLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurement",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average risk-free interest rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DiscontinuedOperationsResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses attributable to discontinued operations.",
        "label": "Discontinued Operations, Research And Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r494",
      "r500",
      "r502",
      "r506",
      "r511",
      "r515",
      "r517",
      "r518",
      "r630"
     ]
    },
    "ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent operating lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Operating Lease Right Of Use Assets, Noncurrent",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r739",
      "r830",
      "r894",
      "r895"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupNoncurrentOperatingLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupNoncurrentOperatingLeaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent operating lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Noncurrent Operating Lease Obligations",
        "terseLabel": "Operating lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_OccurrenceOfSpecificMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "OccurrenceOfSpecificMilestoneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Occurrence Of Specific Milestone [Member]",
        "label": "Occurrence Of Specific Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount inventory written down in a discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory Write down",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "UnpaidFixedAssetsAttributableToDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid fixed assets included in accounts payable, attributable to discontinued operations.",
        "label": "Unpaid Fixed Assets Attributable To Discontinued Operations",
        "terseLabel": "Unpaid fixed assets included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossRelatedToLitigationSettlementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossRelatedToLitigationSettlementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fraunhofer Settlement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FractionalShareIssuedAfterReverseStockSplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FractionalShareIssuedAfterReverseStockSplitShares",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fractional shares after reverse stock split issued during period.",
        "label": "Fractional Share Issued After Reverse Stock Split, Shares",
        "terseLabel": "Payment for fractional shares after reverse stock split (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NoncurrentLiabilitiesRelatedToAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent liabilities related to assets held for sale.",
        "label": "Noncurrent Liabilities Related To Assets Held For Sale",
        "terseLabel": "Noncurrent liabilities related to assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedLabel": "Purchase of equity security",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r258"
     ]
    },
    "ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed asset charges incurred but not yet paid attributable to discontinued operations.",
        "label": "Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current Period",
        "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of personnel cost including severance incurred in a discontinuing operation.",
        "label": "Disposal Group, Including Discontinued Operation, Personnel Costs Including Severance",
        "terseLabel": "Personnel costs including severance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r496",
      "r497",
      "r502",
      "r503",
      "r505",
      "r507",
      "r624"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "totalLabel": "Inventory total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r724",
      "r753"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.",
        "label": "Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued expenses - noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ExchangeAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement [Member]",
        "label": "Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_Series2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "Series2PreferredStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Preferred Stock [Member]",
        "label": "Series A-2 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNetAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FractionalShareIssuedAfterReverseStockSplitValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FractionalShareIssuedAfterReverseStockSplitValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of fractional shares after reverse stock split issued during period.",
        "label": "Fractional Share Issued After Reverse Stock Split, Value",
        "terseLabel": "Payment for fractional shares after reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquipmentFinancingPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquipmentFinancingPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of equipment financing payable.",
        "label": "Equipment Financing Payable, Current",
        "terseLabel": "Equipment financing payable - current portion"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued expenses - noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupInterestExpenseRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DisposalGroupInterestExpenseRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense to related party from discontinued operations.",
        "label": "Disposal Group, Interest Expense, Related Party",
        "negatedLabel": "Interest expense - related party"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquipmentFinancingPayableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquipmentFinancingPayableNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncurrent portion of equipment financing payable.",
        "label": "Equipment Financing Payable, Noncurrent",
        "terseLabel": "Equipment financing payable - net of current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r96",
      "r97",
      "r320",
      "r717",
      "r781"
     ]
    },
    "ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CostToRaiseCapitalPaidDirectlyFromGrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost incurred to raise capital directly from gross proceeds.",
        "label": "Cost to Raise Capital paid Directly from Gross Proceeds",
        "terseLabel": "Costs to raise capital paid directly from gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainContingencyUnrecordedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Contingency, Unrecorded Amount",
        "terseLabel": "Estimated net cash recovery",
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ibio_ProceedsFromEquipmentFinancingLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ProceedsFromEquipmentFinancingLoan",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from equipment financing loan.",
        "label": "Proceeds from Equipment Financing Loan",
        "terseLabel": "Proceeds from equipment financing loan"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PaymentOfEquipmentFinancingLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PaymentOfEquipmentFinancingLoan",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for equipment financing loan.",
        "label": "Payment of Equipment Financing Loan",
        "negatedLabel": "Payment of equipment financing loan"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PaymentsForFractionalSharesAfterReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PaymentsForFractionalSharesAfterReverseStockSplit",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for fractional shares after reverse stock split.",
        "label": "Payments for Fractional Shares after Reverse Stock Split",
        "negatedLabel": "Payments for fractional shares after reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "verboseLabel": "Fair value of the Warrant assumptions",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "MaximumCommitmentInSingleRegularSaleOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum commitment in single regular sale of common stock.",
        "label": "Maximum Commitment in Single Regular Sale of Common Stock",
        "terseLabel": "Maximum commitment in single regular sale of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r801",
      "r887",
      "r892"
     ]
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidTotal",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Total",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Total",
        "totalLabel": "Imputed Interest, Total"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AdditionalSharesAgreedToIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AdditionalSharesAgreedToIssue",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares agreed to issue.",
        "label": "Additional Shares Agreed to Issue",
        "terseLabel": "Additional commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NonCashSettlementOfRevenueContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NonCashSettlementOfRevenueContract",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash Settlement of revenue contract",
        "label": "Non cash Settlement of revenue contract",
        "verboseLabel": "Settlement of revenue contract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r584",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r722",
      "r738",
      "r754",
      "r785",
      "r823",
      "r824",
      "r830",
      "r894"
     ]
    },
    "ibio_SignificantTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SignificantTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions [Abstract]",
        "label": "Significant Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DeferredTaxAssetOperatingAndFinanceLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DeferredTaxAssetOperatingAndFinanceLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets from operating and finance lease liabilities.",
        "label": "Deferred Tax Asset Operating and Finance Lease Liabilities",
        "terseLabel": "Operating and finance lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r227",
      "r723"
     ]
    },
    "ibio_EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes from iBio CDMO.",
        "label": "Effective Income Tax Rate Reconciliation Change Related to iBio CDMO",
        "terseLabel": "Change related to iBio CDMO"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r18"
     ]
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearOne",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Obligation, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r20",
      "r28",
      "r111",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r128",
      "r130",
      "r131",
      "r169"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ibio_IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in ROU operating assets and liabilities for new leases from discontinued operations.",
        "label": "Increase in ROU operating assets and liabilities for new leases"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid For Amounts Included In Measurement Operating Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement lease liability:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four",
        "totalLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IssuanceOfWarrantForFinalLeaseObligationPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IssuanceOfWarrantForFinalLeaseObligationPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of warrant for final lease obligation payment from discontinued operations.",
        "label": "Issuance of warrant for final lease obligation payment"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CostOfDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CostOfDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleGainLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesRealizedLossesOnAvailableForSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cost of debt securities.",
        "label": "Cost of Debt Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital acquisition of remaining portion of affiliate.",
        "label": "Adjustments to additional paid in capital acquisition of remaining portion of affiliate",
        "negatedLabel": "Acquisition of remaining portion of iBio CDMO"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LoansReceivableRateOfInterestForSecondOneYearExtension": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LoansReceivableRateOfInterestForSecondOneYearExtension",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of rate of interest on notes receivable for second one year extension.",
        "label": "Loans Receivable, Rate of Interest for Second One Year Extension",
        "terseLabel": "Interest rate for second one year extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "verboseLabel": "Debt balance",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r191",
      "r377",
      "r391",
      "r733",
      "r734",
      "r891"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of goods sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r224"
     ]
    },
    "ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "OperatingLeaseRightOfUseAssetDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset Disclosure [Text Block]",
        "terseLabel": "Operating Lease ROU Assets"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r584",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r722",
      "r738",
      "r754",
      "r785",
      "r823",
      "r824",
      "r830",
      "r894"
     ]
    },
    "ibio_EightCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EightCustomersMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eight Customers [Member]",
        "label": "Eight Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation",
        "label": "Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]",
        "terseLabel": "Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Principal And Imputed Interest",
        "label": "Lessee Operating Lease Liability Principal And Imputed Interest",
        "totalLabel": "Principal and imputed interest, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ibio_AuctionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AuctionFee",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of auction costs incurred in a discontinuing operation.",
        "label": "Auction fee"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three",
        "totalLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_MaximumNumberOfCommonStockToBeSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "MaximumNumberOfCommonStockToBeSold",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of common stock to be sold.",
        "label": "Maximum Number of Common Stock to be Sold",
        "terseLabel": "Maximum number of common stock to be sold"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "MaximumNumberOfCommonStockToBeSoldAsPerApplicableRulesOfNyseAmerican",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of common stock to be sold as per applicable rules of the NYSE American.",
        "label": "Maximum Number of Common Stock to be Sold as per Applicable Rules of the NYSE American",
        "terseLabel": "Maximum number of common stock to be sold as per applicable rules of the nyse american"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NonCashTransactionOfSubscriptionReceivableForCapitalRaise",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Transaction of Subscription Receivable For Capital Raise",
        "label": "Non-Cash Transaction Of Subscription Receivable For Capital Raise",
        "verboseLabel": "Subscription receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement [Member]",
        "label": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "negatedLabel": "Amount released from restricted cash",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r155"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r237",
      "r267",
      "r332",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r521",
      "r525",
      "r548",
      "r753",
      "r826",
      "r827",
      "r878"
     ]
    },
    "ibio_ProceedsFromNotesPayableFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ProceedsFromNotesPayableFromDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation from discontinued operations.",
        "label": "Proceeds from Notes Payable from Discontinued Operations",
        "terseLabel": "Note payable to acquire Facility"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "MinimumClosingPriceOfCommonStockToSellAdditionalShares",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Price per share of common stock to sell additional shares.",
        "label": "Minimum Closing Price of Common Stock to Sell Additional Shares",
        "terseLabel": "Minimum Price per share of common stock to sell additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SignificantTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SignificantTransactionsTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions [Text Block]",
        "label": "Significant Transactions [Text Block]",
        "verboseLabel": "Significant Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee 401(K) Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SecuredTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SecuredTermLoanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to secured term loan.",
        "label": "Secured Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_WarrantsIssuedForFinanceLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "WarrantsIssuedForFinanceLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of warrants issued in noncash financing activities.",
        "label": "Warrants Issued for Finance Lease Payment",
        "terseLabel": "Issuance of warrant for final finance lease obligation payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CostAccruedToAmendTermNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CostAccruedToAmendTermNotePayable",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost accrued to amend the term note payable during the period.",
        "label": "Cost accrued to amend term note payable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SeveranceTransitionalPeriodDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "SeveranceTransitionalPeriodDays",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days during transitional period of severance obligations.",
        "label": "Severance Transitional Period Days"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ibio_LessorFinanceLeaseMonthlyRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LessorFinanceLeaseMonthlyRent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent receivable monthly by the lessor under the finance lease.",
        "label": "Lessor, Finance Lease Monthly Rent",
        "terseLabel": "Mobile office trailer monthly rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r78"
     ]
    },
    "ibio_OperatingCashFlowsFromOperatingLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "OperatingCashFlowsFromOperatingLeaseObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating cash flows from operating lease obligation.",
        "label": "Operating Cash Flows From Operating Lease Obligation",
        "terseLabel": "Operating cash flows from operating lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r155",
      "r263"
     ]
    },
    "ibio_EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes from the expiration and forfeiture of stock options.",
        "label": "Effective Income Tax Rate Reconciliation Expiration Forfeiture of Stock Options",
        "terseLabel": "Expiration and forfeiture of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "terseLabel": "Gross profit",
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r224"
     ]
    },
    "ibio_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum beneficial ownership considered to sale shares under agreement.",
        "label": "Maximum Beneficial Ownership Considered to Sale Shares Under Agreement",
        "terseLabel": "Maximum beneficial ownership considered to sale shares under agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_GainOnSaleOfFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "GainOnSaleOfFixedAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain or loss on the sale of fixed assets resulting from discontinued operations.",
        "label": "Gain on sale of fixed assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options Granted using the Black-Scholes Option Pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One",
        "totalLabel": "2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two",
        "totalLabel": "2024"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PercentageOfPaymentFromProceedsOfAtMarketFacility",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of payment of equity interests from proceeds of sales of equipment.",
        "label": "Percentage of Payment from Proceeds of At the Market Facility",
        "terseLabel": "Percentage of payment of equity Interests from proceeds of at-the-market facility"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DeferredTaxAssetsResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DeferredTaxAssetsResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets from research and development costs.",
        "label": "Deferred Tax Assets Research and Development Costs",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_TotalOperatingLeaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "TotalOperatingLeaseCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total operating lease costs.",
        "label": "Total Operating Lease Costs",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IsettMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IsettMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Isett [Member]",
        "label": "Isett [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted average remaining life",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_SettlementAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SettlementAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Assets, Current",
        "verboseLabel": "Settlement receivable - current portion",
        "documentation": "Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedLabel": "Interest expense - term note payable",
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r29",
      "r125"
     ]
    },
    "ibio_LesseeOperatingLeaseMonthlyRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseMonthlyRent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent payable monthly by the lessee under the operating lease.",
        "label": "Lessee, Operating Lease Monthly Rent",
        "terseLabel": "Operating lease monthly rent payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745"
     ]
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five",
        "totalLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of common stock directed to sell through written notice.",
        "label": "Maximum Number of Common Stock Directed to Sell Through Written Notice",
        "terseLabel": "Maximum number of common stock directed to sell through written notice"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five",
        "totalLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LoansReceivableRateOfInterestForFirstOneYearExtension": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LoansReceivableRateOfInterestForFirstOneYearExtension",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of rate of interest on notes receivable for first one year extension.",
        "label": "Loans Receivable, Rate of Interest for First One Year Extension",
        "terseLabel": "Interest rate for first one year extension"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PaymentsToAttainTermNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PaymentsToAttainTermNote",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred with attain term note.",
        "label": "Payments To Attain Term Note",
        "negatedLabel": "Costs to attain term note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Total operating expenses",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ibio_NumberOfConsultantsToWhomStockOptionGranted": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NumberOfConsultantsToWhomStockOptionGranted",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of consultants to whom the stock options granted.",
        "label": "Number of Consultants to Whom the Stock Option Granted",
        "terseLabel": "Number of consultants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic and diluted denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue reported in discontinued operations",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r224"
     ]
    },
    "ibio_CollegeStationInvestorsLlcAndBryanCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CollegeStationInvestorsLlcAndBryanCapitalMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to College Station Investors LLC And Bryan Capital.",
        "label": "College Station Investors LLC And Bryan Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PurchaseAndSaleAgreementWithMajesticRealtyCoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase and Sale Agreement with Majestic Realty Co.",
        "label": "Purchase and Sale Agreement with Majestic Realty Co"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of capitalized lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to capitalized lease liability recognized in statement of financial position.",
        "label": "Capitalized Lease, Liability, to be Paid, Maturity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_OperatingLeaseCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "OperatingLeaseCostsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Operating Lease Costs [Abstract]",
        "terseLabel": "Operating lease cost:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ForgivenessOfNotePayableAndAccruedInterestSbaLoan",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness of note payable and accrued interest - SBA loan",
        "label": "Forgiveness of note payable and accrued interest - SBA loan",
        "negatedLabel": "Forgiveness of note payable and accrued interest - SBA loan"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_InterimChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "InterimChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of interim chief executive officer.",
        "label": "Interim Chief Executive Officer [Member]",
        "terseLabel": "Interim Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LetterOfCreditTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LetterOfCreditTermLoanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to letter of credit term loan.",
        "label": "Letter Of Credit - Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CreditAgreementWithWoodforestNationalBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CreditAgreementWithWoodforestNationalBankMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Credit Agreement with Woodforest National Bank.",
        "label": "Credit Agreement with Woodforest National Bank"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r801"
     ]
    },
    "ibio_DeferredFinancingCostsAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DeferredFinancingCostsAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of loan and debt issuance costs.",
        "label": "Deferred Financing Costs, Amortization Expense",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfBuildings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfBuildings",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Buildings",
        "documentation": "The cash inflow from sale of buildings."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ibio_BaseRentAbatementInFirstYearPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "BaseRentAbatementInFirstYearPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base rent abatement period in the first year.",
        "label": "Base Rent Abatement In the First Year, Period",
        "terseLabel": "Base rent abatement period in the first year"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of termination of finance lease right of use asset, including issuance of warrant.",
        "label": "Termination Of Finance Lease Right Of Use Asset, Including Issuance Of Warrant",
        "terseLabel": "Termination of finance ROU assets including issuance of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PercentageOfCommonStockToBeSoldOnOutstandingCommonStockAsPerApplicableRulesOfNyseAmerican",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock to be sold on outstanding common stock as per applicable rules of the NYSE American.",
        "label": "Percentage of Common Stock to be Sold on Outstanding common Stock as per Applicable Rules of the NYSE American",
        "terseLabel": "Percentage of common stock to be sold on outstanding common stock as per applicable rules of the nyse american"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r216"
     ]
    },
    "ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]",
        "label": "Operating Lease Obligation, Imputed Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.",
        "label": "Purchase Price For Property, Termination of Sublease And Equity Interest",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "verboseLabel": "Preferential dividend rate percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r702",
      "r704",
      "r705",
      "r709"
     ]
    },
    "ibio_PercentageOfCollateralRequired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PercentageOfCollateralRequired",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of collateral required to be held by the reporting entity.",
        "label": "Percentage Of Collateral Required",
        "terseLabel": "Additional percentage of collateral held required by bank"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IncreaseDecreaseInSettlementAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IncreaseDecreaseInSettlementAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.",
        "label": "Increase (Decrease) In Settlement Assets",
        "negatedLabel": "Settlement receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745"
     ]
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Issued",
        "terseLabel": "Note payable to acquire Facility",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Premium on Purchased Options [Policy Text Block]",
        "verboseLabel": "Investments in Debt Securities",
        "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "WarrantsIssuedForFinalPaymentOfSubleaseRentValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of warrants issued for the final payment of rent due under sublease.",
        "label": "Warrants Issued for Final Payment of Sublease Rent, Value",
        "terseLabel": "Fair value of the warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AmendedCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AmendedCreditAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_GroundLeasesAgreedToSellPruchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "GroundLeasesAgreedToSellPruchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase price of land agreed to sell.",
        "label": "Ground Leases Agreed to Sell, Pruchase Price",
        "terseLabel": "Purchase price of land agreed to sell"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NoBiosimilarProductHasBeenApprovedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NoBiosimilarProductHasBeenApprovedMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Biosimilar Product has been Approved [Member]",
        "label": "No Biosimilar Product has been Approved [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LetterOfCreditSanDiegoLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LetterOfCreditSanDiegoLeaseMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to letter of credit for sandiego lease.",
        "label": "Letter Of Credit - San Diego Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ClosingPricePerShareOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ClosingPricePerShareOfCommonStock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price per share of common stock.",
        "label": "Closing Price Per Share of Common Stock",
        "terseLabel": "Closing price per share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockPurchaseAgreementTotalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockPurchaseAgreementTotalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investment under the stock purchase agreement.",
        "label": "Stock Purchase Agreement, Total Investment",
        "terseLabel": "Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_WoodforestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "WoodforestMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Woodforest [Member]",
        "label": "Woodforest [Member]",
        "terseLabel": "Woodforest Bank"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Results of operations for discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]",
        "label": "If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "ibio_CurrentAndDeferredFederalAndStateTaxes",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred - Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r862",
      "r863"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Award vested in period, fair value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "WarrantsIssuedForFinalPaymentOfSubleaseRent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued for the final payment of rent due under sublease.",
        "label": "Warrants Issued for Final Payment of Sublease Rent",
        "terseLabel": "Shares issued under the Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of finance ROU assets including issuance of warrant from discontinued operaions.",
        "label": "Termination of finance ROU assets including issuance of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r111",
      "r127",
      "r165",
      "r168"
     ]
    },
    "ibio_FairMarketValueOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "FairMarketValueOfProperty",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value of the property.",
        "label": "Fair Market Value of Property",
        "terseLabel": "Fair market value of property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ibio_CompanyPurchasingCardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CompanyPurchasingCardMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Company purchasing card.",
        "label": "Company Purchasing Card [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_BaseRentPercentageOfFairMarketValueOfProperty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "BaseRentPercentageOfFairMarketValueOfProperty",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent payable on percentage of fair Market Value of the Property.",
        "label": "Base Rent, Percentage of Fair Market Value of Property",
        "terseLabel": "Percentage of base rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfFacilityIsNotSoldOnOrBeforeDecember12023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfFacilityIsNotSoldOnOrBeforeDecember12023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the event if the Facility is not sold on or before December 1, 2023.",
        "label": "If the Facility is not sold on or before December 1, 2023,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment of term note payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ibio_IfOutstandingPrincipalAmountReducedTo10000000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfOutstandingPrincipalAmountReducedTo10000000Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If Outstanding Principal Amount Reduced to 10,000,000 [Member]",
        "label": "If Outstanding Principal Amount Reduced to 10,000,000 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AssetAcquisitionIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AssetAcquisitionIntangibleAssetsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Intangible Assets [Member]",
        "label": "Asset Acquisition Intangible Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r20",
      "r28",
      "r111",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r128",
      "r130",
      "r131",
      "r169"
     ]
    },
    "ibio_AssetAcquisitionPrepaidExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AssetAcquisitionPrepaidExpensesMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Prepaid Expenses [Member]",
        "label": "Asset Acquisition Prepaid Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the event if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00.",
        "label": "If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_MaximumAmountOfCommonStockAgreedToSell": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "MaximumAmountOfCommonStockAgreedToSell",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common stock agreed to sell",
        "label": "Maximum Amount of Common Stock Agreed to Sell",
        "terseLabel": "Maximum amount of common stock agreed to sell"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ibio_CreditAgreementThresholdLimitUnrestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "CreditAgreementThresholdLimitUnrestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold limit of unrestricted cash to be maintained.",
        "label": "Credit Agreement, Threshold Limit, Unrestricted Cash",
        "terseLabel": "Unrestricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r427",
      "r439",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]",
        "label": "If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquityAgreementWarrantsIssuedOrIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquityAgreementWarrantsIssuedOrIssuable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued or issuable under the equity agreement.",
        "label": "Equity Agreement, Warrants Issued or Issuable",
        "terseLabel": "Warrants issuable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfFacilityIsSoldOnOrBeforeJune302023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfFacilityIsSoldOnOrBeforeJune302023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If The Facility Is Sold On Or Before June 30, 2023 [Member]",
        "label": "If The Facility Is Sold On Or Before June 30, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_OperatingLeaseObligationOtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "OperatingLeaseObligationOtherInformationAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease Obligation Other Information [Abstract]",
        "verboseLabel": "Other information:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockPurchaseAgreementWithLincolnParkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "StockPurchaseAgreementWithLincolnParkMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Stock Purchase Agreement with Lincoln Park.",
        "label": "Lincoln Park Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Common Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ImpairmentOfPrepaidExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ImpairmentOfPrepaidExpensesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of current prepaid expenses.",
        "label": "Impairment Of Prepaid Expenses, Current",
        "terseLabel": "Impairment of current prepaid expense"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquityAgreementPercentageOfEquityInterestIssuedOrIssuable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity agreement, percentage of equity interest issued or issuable.",
        "label": "Equity Agreement, Percentage of Equity Interest Issued or Issuable",
        "terseLabel": "Percentage of equity interest"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the event if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00.",
        "label": "If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non controlling interest that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Non Controlling Interest Assumed",
        "terseLabel": "Acquisition of noncontrolling interest"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating and finance lease ROU assets.",
        "label": "Deferred Tax Liabilities, Operating And Finance Lease Right Of Use Assets",
        "negatedLabel": "Operating and finance lease ROU assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Gross fixed assets",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r228",
      "r600"
     ]
    },
    "ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]",
        "label": "If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_Series2022ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "Series2022ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series 2022 Convertible Preferred Stock [Member]",
        "label": "Series 2022 Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AccruedRealEstateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AccruedRealEstateTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued real estate taxes.",
        "label": "Accrued Real Estate Taxes",
        "terseLabel": "Real estate taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.",
        "label": "Threshold Period for Delivery of Executed Copy of Agreement for Sale of Facility from Amendment Date",
        "terseLabel": "Threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r210",
      "r213",
      "r598"
     ]
    },
    "ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IfFacilityIsNotSellOnOrBeforeDecember12023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If The Facility Is Not Sell On Or Before December 1, 2023 [Member]",
        "label": "If The Facility Is Not Sell On Or Before December 1, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating lease",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r568"
     ]
    },
    "ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PeriodForPaymentFromIssuanceOfAtMarketFacility",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period for the payment to counterparty of equity interests from the issuances.",
        "label": "Period for Payment from Issuance of At-the Market Facility",
        "terseLabel": "Period for payment of equity interests at-the-market facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net fixed assets",
        "verboseLabel": "Fixed assets, net of accumulated depreciation",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r590",
      "r600",
      "r753"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r787",
      "r801"
     ]
    },
    "ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DebtInstrumentAmountOfFeesToBePaidUnderAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of fees to be paid under Purchase Agreement.",
        "label": "Debt Instrument, Amount of Fees to be Paid under Agreement",
        "terseLabel": "Amount of fees to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ImpairmentOfPrepaidExpensesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ImpairmentOfPrepaidExpensesNonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of non-current prepaid expenses.",
        "label": "Impairment Of Prepaid Expenses, Non Current",
        "terseLabel": "Impairment of non-current prepaid expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment of fixed assets",
        "verboseLabel": "Fixed assets impairments",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r167"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.",
        "label": "Non Cash Transaction Increase In Right Of Use Assets And Liabilities",
        "terseLabel": "Increase in operating lease ROU assets for new lease - net of lease incentive"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of gross carrying value and accumulated depreciation of fixed assets",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ibio_DebtInstrumentPaidInKindInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "DebtInstrumentPaidInKindInterestRate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payable in-kind interest rate.",
        "label": "Debt Instrument, Paid-in Kind Interest Rate",
        "terseLabel": "Payable in-kind rate (in percent)"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IbioCmoPreferredTrackingStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "IbioCmoPreferredTrackingStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to IBio CMO Preferred Tracking Stock.",
        "label": "IBio CMO Preferred Tracking Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PercentageOfPaymentFromProceedsOfSalesOfEquipment",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of payment of equity interests from proceeds of sales of equipment.",
        "label": "Percentage of Payment from Proceeds of Sales of Equipment",
        "terseLabel": "Percentage of payment from proceeds of sales of equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "EquityAgreementConsiderationTransferredEquityInterestsAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration transferred for equity interest acquired under the equity agreement.",
        "label": "Equity Agreement, Consideration Transferred Equity Interests Acquired",
        "terseLabel": "Cash consideration for equity interest acquired"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AmountRetainedFromProceedsOfLegalSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AmountRetainedFromProceedsOfLegalSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount retained from proceeds of legal settlement.",
        "label": "Amount Retained from Proceeds of Legal Settlement",
        "terseLabel": "Amount retained"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.",
        "label": "Purchase Price For Property, Termination of Sublease And Equity Interest, Cash Payment",
        "terseLabel": "Cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Outstanding and Exercisable",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "ibio_AmountToBeReleasedFromRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "AmountToBeReleasedFromRestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount to be released from restricted cash.",
        "label": "Amount to Be Released from Restricted Cash",
        "terseLabel": "Amount to be released from restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Promissory Note Receivable",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r425",
      "r443",
      "r475",
      "r476",
      "r477",
      "r581",
      "r582",
      "r613",
      "r645",
      "r646",
      "r701",
      "r703",
      "r706",
      "r707",
      "r708",
      "r719",
      "r720",
      "r731",
      "r737",
      "r746",
      "r755",
      "r758",
      "r820",
      "r828",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office equipment and software [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Collateral held",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r227",
      "r263"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Noncurrent",
        "verboseLabel": "Prepaid expenses - noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r443",
      "r582",
      "r613",
      "r645",
      "r646",
      "r701",
      "r703",
      "r706",
      "r707",
      "r708",
      "r719",
      "r720",
      "r731",
      "r737",
      "r746",
      "r755",
      "r828",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885"
     ]
    },
    "ibio_PercentageOfLegalFeesExpectedToBeReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "PercentageOfLegalFeesExpectedToBeReceived",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of legal fees expected to be received.",
        "label": "Percentage Of Legal Fees Expected to be Received",
        "terseLabel": "Percentage of legal fees expected to be received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r425",
      "r443",
      "r475",
      "r476",
      "r477",
      "r581",
      "r582",
      "r613",
      "r645",
      "r646",
      "r701",
      "r703",
      "r706",
      "r707",
      "r708",
      "r719",
      "r720",
      "r731",
      "r737",
      "r746",
      "r755",
      "r758",
      "r820",
      "r828",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r443",
      "r582",
      "r613",
      "r645",
      "r646",
      "r701",
      "r703",
      "r706",
      "r707",
      "r708",
      "r719",
      "r720",
      "r731",
      "r737",
      "r746",
      "r755",
      "r828",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r229",
      "r599"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r320"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation expense",
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r799"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - total",
        "verboseLabel": "Per share amount diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r290",
      "r294",
      "r295",
      "r296",
      "r300",
      "r535",
      "r536",
      "r588",
      "r605",
      "r728"
     ]
    },
    "ibio_LeaseIncentiveForConstructionInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "LeaseIncentiveForConstructionInProgress",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incentive for construction in progress",
        "label": "Lease incentive for construction in progress"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Basic and diluted numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, shares received per share tendered",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r144",
      "r235",
      "r595",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Stock Options, Vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r163"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average Exercise Price, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Consolidated net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Consolidated net loss",
        "verboseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r241",
      "r243",
      "r259",
      "r267",
      "r275",
      "r283",
      "r284",
      "r304",
      "r311",
      "r315",
      "r317",
      "r332",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r520",
      "r523",
      "r524",
      "r536",
      "r548",
      "r589",
      "r603",
      "r632",
      "r674",
      "r694",
      "r695",
      "r730",
      "r750",
      "r751",
      "r765",
      "r794",
      "r826"
     ]
    },
    "ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.",
        "label": "Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock",
        "terseLabel": "Number of LLC interest units exchanged for each share of preferred tracking stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) Per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r323",
      "r324",
      "r325"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Adjusted cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r336",
      "r591"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-Lived Intangible Assets, accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r340"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of components of investments in debt securities",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ScenarioPlanExpectedPaymentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230630",
     "localname": "ScenarioPlanExpectedPaymentOneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan Expected Payment One [Member].",
        "label": "Scenario Plan Expected Payment One [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "44",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-9"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482309/360-10-15-4"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-8A"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481222/840-30-40-8"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482161/360-10-40-3A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>148
<FILENAME>0001420720-23-000045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001420720-23-000045-xbrl.zip
M4$L#!!0    ( #F .U>Y&@WEO"@  .[P 0 1    :6)I;RTR,#(S,#8S,"YX
M<V3M/6MSY+:1WU-U_X&G+[>NBM[>=7;+Z]3H9>LB[:@DK9U\2D$D9H8QAQR#
MH*3QKS\TP =(XD%RI%W,'E.51#OL;J ? !J-1N/'OS\O(^\1DS1,XH\[AWL'
M.QZ._20(X_G'G8S.=O^V\_>?_NLO/_[W[NX_3VZOO"#QLR6.J><3C"@.O*>0
M+KS[9+5"L7>-"0FCR#LA83#'GG=XL'>\=[#WWMO=_8F3.$$I0TEBC],ZVCLL
M/ISFU)+X@_=^_^B'_:.#HV/O[8>C=Q_>OO-NK@NX:]:S66@#?$Z##ZF_P$OD
M,?;B]$,4QK]_W%E0NOJPO__T]+3W_$"BO83,&?K!\3Y\?F!=V\G!4[HB)3@'
M3;&_-T\>]^$+;[( ]3-"F,#6:O#B:PWE.3)TY9]7K"]E/T)?TXW0KY%,"2T!
M9RA]X/38CS6@+-VEZQ5.VY#%EWHW68.AH:=AG%(4^[ABJRGDIV,.??C^_?M]
M_E4F'= Z:SG=M_OB8P&*G_V%6@;PI:Z*)(LIT6E"?*PAQ"CT4S4X_]24WARA
ME5)X\"$'IHC,,?V$ECA=(1_7Y!$^A$D8^WM^LN30!^^.8;A%& ;414*69WB&
MLH@)YH\,1=S.)07KE%=^JFLO#52Z8!(^W/_G]=4='QT%<$!)@WI-W>SS/GR&
M!HYV#XYWCP\+3&"I X^Y+N-L>:32^M$!TR;%<1H^1'@7P#!!E,U(Z>[17HD>
MX!7!/DP36JM\OT^2".]7D)+VX(O:]OF7FO0(GFG;>+?/OLIZT1 N/]7-B!)#
M[]G7TC@QM;')0"K9A&I#9A_J-H_G7228@Q58B%(2/F04UZPTBUMV^IR&=K/;
M;4X=@5$H0244/C>$RHGCG9@XPIV?_N)Y? 5 <9Q0;D;P4_'C:A7&LT3\PGZ#
M:>D#L'S/#-R#/S[?7FHMFLOF+$S]*$DS@N\8%P$BP20.3K.4)LO)<YB>)4L4
MQKF0TATO9,+NAU)TKNA>@&=A'')&V%1Z<.#M>A5!]H^"IL>(>H*J!V0]0=<K
M"/^XWR37:"ACJ_,T_HG_S490RJ8E+C]8DW+D',2 Z*/(SZ+^>%6WM&CYCX6Z
M-E$BDQGE\^XIFV62* S W$]0!&9YM\"XT%P'.(.ZF-ES=954V-\R(2^GY E2
MHX(L"BI_3*>SZ:I8)& L)4LFCP4L(8_X*DE-VNM!Q*C:([-JJV:\9.95#7D(
M1JG<E =MC;I7ZSY@,L+!,/V=,FZ/VI:P.4F+71RV[4*TN9&%>*>3J].CT4YZ
MS!&G*%U<1,E3U^F@@C=J^/L^(Q]H>ISHJ#JE$Y4MEXBLI[.[<!XS9])',9WX
M?+\6QO,;)E4_Q"E($?Y[_D<6/J((A,N&YRU.F6/J,Z'#MS-,41BU7:X7;\!@
M'-\SXSAJ.6BB!V -4A^\JA->T0OO#;3S5V$T4E?XE%!UAG__SGN3=^B[T;*&
M6]9E_,BDD9#U1N;3HF*QD>--;*1L;#0!BPF I%+*Y^)+ML%ZH&Q,P["BZSOL
M9X3UB(U\MM(FL5@ 6O 5V)'&/EZC":/Q_-">8"2:'M_P/5 ^8XA^>%4+;'XI
MNP*FID*4^C/:5U_[JH17_Q=S$"A!/LU0=(TH_*B;;UZ"I-%^_M:>?,QF $90
M^^&OGM2V5S0^&LMP8[G%* K_Q 'X^3B=QI-')D?T$$' [8ZY $T[Z&LYP^A;
MS.C[OF94],(3W8"#H+(CNZPGN]"5)MIH5A:SN@B?<3!A J7,B25DS7R%7U&4
M8;8.,>\A6P(O.#CC,?&0LZ6QG^&$3(9R>-A>KWA+GF@*7%[1F,=;XPN7U)XG
M-S@:@W6.H2B>PSF*59&394)H^*?)(C:D9C2+(Y4;4S37U3;D5D?;Z&D;YRD-
MEUQW<<P6<EF6Y\\K"%AU-(ONA"P6H7!,6A91-N:)UFHVX.7MC;9@L04VB$B&
M@UQ<:;G);?RN,8">V$:M'_-P:4WK.9E"F4SITNZX^7%4M=4_B.&,Z0JC%$\?
MHG#.NWZ1,:\=7[,>+;/E#5ISK^US'&"BAL]E+(747[4%B\FT7,^<I,=I>A51
M[XWHAI?WPRLZXO&>>'2!M;B29<%"Q+HU6IC2PO*CBWC>V0)T&"8K>Z56C):F
M"-251'O86E;:FAZ[96W>:&Y?T-R.OXBY'3ML;L>CN;W(^GF*5B'-PRUU')T[
M]0HM&,WL;=O,-ED_I>ZT\$?W[(O/9J\^D9F-Z]U7F<-&VU+O^-F/^!X]-X^@
M\I_S/=0)CED'J7:W/X2(R4:.#MM[/D'.X\VT3ZF*;\6NSWN3-_?=: /=;> ,
MSS A.&#_$-&421Q<A>@AC,S'"GT)6'2OB/O)NB\:X?K.HSX0]Y,:&I7>7>GG
MLQGV:?A8_7:+*+[%?A+[3)SF\.\@*A;U*XZ-9/67+<G#'AKSZJV--J"V@?R"
M5O'_D(T0TY"N+^-90I:\^[F>NT :\^ .WO-<].)*F/0G9*(+8IY$;=13GP3T
M&T38YP6F(>.H:S9Z'<FHO<.#M]U3T[TW-<KCD.N3AGI'$__W11(QCS85*3D=
M\U$5B$:5'O=)3)6)_T^>*C2J5;6:?H(,%SR=G61I&..TM4ZVOAN4Q%S?MO,K
M"(!2"A*C(E2*.$%IR(;%C<1O4Q<J$*,ZCMKJX#1 &S*542/#<VR'Y=2:]?9]
M6V_=<VA'9>HCG2&*+N.4$N[)P0[O H6$IU]<8P1@\+LZA-D-U:C6MVVUEK0]
MB3C?$@+Y/#-$:F!4KG*D5B/BGJ X13Z/S[:&I@;,J+1WBK$H#4"9T*@<E7)N
M2+(,TS0AZT\)WU;C\!&R(IO:T<(9U?-#6ST5(0\H>16I44$]<W=[I.&:U?0W
M5534E%$[JLIV7G>;9"*":#IRJX",ZGFO6YF*4[/;Z><\7CDJQG[2I56-#LRD
MG,.#MG*:YT:C>CKGD1LRP\UJ4.QMY5SO4?!=\G)MZ;9F%2CVLZTLVE$/'7)B
M+4FO9BUTR&H=E:!2 K@X3<GSWXSB5@0# &D4<?>$IHY921:[UV[?VZE%XP#H
ME0_4.:_'HB'%7EV?83/J2%/X2WV@8X0P:D6Q11_/9[JJXQR1F%EO"M=*;S Y
M39;+)+Y;(-**GQ@@C>I1;,T+4MX;(/:=Q\AY@I['"8ZJ4HX<$ TO PLI7LP/
M4A[B:*",*E)LSSF9O.BL3&A4C=(M("B+%\D,DSM,::0.\ZM@3&HY4FS,*R)>
M1674B26/RY"<9=: )=ER%+Q*\#"3A[0XQH)R%VRNQ['J,-,$:E2,8J<NT<JK
MP$G41DTI%__E*DK6&+,MX#]N(M1:2UK?C3I1[-L+ AZC\.8?;*%G1$95J),!
M'E+\1\9X/8<"58IC_\9WHRJ4!_P% 4]0&/4P/"ECL^2,+DD:1YL6PRO^&M,-
M-]#S/9SJ#M1RCFO0\?&FQ>Q$$Z.&-\W(4:NY/P&CKK4W![MGYXP:'Y*FHQG$
M1F"C)A77]'0I.Z/&AJ:&J+5F1S!J;D#]OE%_??-%3+.I&M2HL_>V&]=5<L*H
MK:Y9"CH=-0%,FCD\5&E&KDXW:J-'ZH)NPE-"&?72K1C8J)SN^0QJW:B!C*HY
M;JNF7;%KU$SO$WC[FM."->JI5YF/45]#SN35*K.!&[76JW[&.-#Z'M1K-E(Z
M.*.J?E#LH12']J..!I[>JW5EA3?J3+%[LIWDC_H;<*2O&6<F6*/>%#LHW?'^
MJ*^N9\HZ=[T)8-+,D6('5:_H,6JCWY7F3XC <O^H*[_<!<6@L>\[7WGVWI1T
MQVHKMKQE]A<_K&?;H.HI-YLJ.V(9M:DXLI;)R@_+C?K<4)_U$D20[A&A-.5!
M<_Z]EYJ[$K-HOW7"JM5^O4&18%)O<C2+%SERM0W[@52,AK!1/81Q9GB5,UF;
M'6Q"RF@,+U!%832)US&))+Z%DSG"AA]WNE[ -'0D+2:B>):GMXDD\2XIVA9.
MY&@LPT[XK6M&1S2CTGL4ZAC'_\8JK=Y%@>.JB?]'%J:\=_U4;"5C47D[!4^K
M<OF=%6C,DUH;K6!@$1?;R.Z,9]1SKR(OX^!^D?P>FV;[H!J5V[LTS*C@%U%P
MQX=[^ZN_)V&+<71Z$'CH*\"C_0Q)(.NV];,A&?7>HR#1.!ULJ,[2!VM\[:-=
M&PV+LC7;-96R)3>N!33J?UB9*MN [HIFTG*_,E;CH!Z4-FJ?F?6@1N59BE^-
MZAJ>5VIWM"WP1L5U*9DU:J]?#:=3@H.03N8$\U"A[F!,#VG4F*;>D_?F'MXC
MXP2]DN*HKP[Z@E2U%4@K#P+'<^7[8 8]]J1@T6\KIT3HMVS$*UOY3ON(V*CX
M#HJ'R! 3&$2%;E:KJP3IHI-F8(LZ6X_^"'7RL%1.$ )6-S<>$!T5-RB!O,^>
MTX!E5&6/ F_CDKGQ(Z/2KZ=)"D\T3>D"$^E-I7Y/BG:G9S$"RV:T]L)C[0LT
MRX\4></RZU"CC0R\A=!O9SITX/>J&S@._<W5RO^97ZAB _4N6ZU$J2P4R4]^
M22/H%D?PSM-]\D(OQ+YB#RRFUII>3*8F?BE>!H6Y1>YI_2$S><+Q\MYZ-!D?
MFMWP +QU?\::SF#',-I(QX*9XT2TB1)/44P3<A'2/^=L:$0!?QWZ"8Z%XCF;
M$&ZS![+VI0R"_DK?N 6+D;1S'Y1&(KKA5?WPY([P.06Z\B]?SI?X;C2N38SK
M-Q3&3,#S!6TH_5><PE_3V6V:Z0(.FY*SF$W'>WU5FVU[R9N%,YC;N\]C+&+X
M-4#YK%P/I3&4ER)K-)@!Y8&;9_#@@#1Q5DV<T8@&&]$DIF$01AE,UE5NP_FS
M'V4!#BY(L@1]9$)&E4$P(L.LZX7:LYA=:WFSFYW<,3DGI.B:-V-]\Z3.@766
M9($>)S2:XJ!KL>I?\[V+;JT;3LEH/CTJ9GMOA/4HON0MCO8PR!ZL'G,W+(N>
MVUZP5L^C1[OA  ='<;J"/R=LE_#(_,1^PUJ/;U%RC_OQO!%/M.(5S8P*'Z1P
M(<5TFM&4,K]?[#G.GS'QPQ2.M7IIORLQBRFT3MOTII"WZ$E-\NV+U.AH&(,,
MH[RJ-9WE0OZ9H)CBH)=%6*E83.%M=U.0+GDQEZ\PC+RYT0@&&8$IA&%%L*CV
M77?5CA&(@0^@6(_4N^"8]-CY@931-1M4XL:>.:@'->K-6O9F5-<+/+9B4U\?
M5*,Z^S[&,NIW^!,M-J5:X8V:[/B$RZC X0^[V.N;6."-"NSR\,NHO4U+&76K
M461\HJ='Z:E1,]TUHZ[*9X0U:.GX0%&O65LB:JS59TF7UBBG^F)2A3ZO?91[
M[_L)O:XB=$Q3;]=2,]PZ^/^QZL#_/,"-1CSSGODOE,%\W$E#YE3AG?RW!<&S
MCSN@P]VC ^:"O3L^^#=C=>]Y&14@0+ZF\><'$NTE9+[/]L#'0N=-Z>0-%R00
M\5M4GHXYC</W[]_O<RA&)&$S&AQJ[A>=W_'V7XHKIH>^7#54YR!3S$CZ,E6W
M*P=YBM!#7YX8"HY>A9T?]Y_3X -:K<)XEL!/^0]QG AKY[_!3XROA% O1DN<
MKI!?-<K[FV)_;YX\,NF'^\#ICI?Z"[Q$5XFHX"B@4QTX_,$EM,>:RCMG;K4M
MJ3"&@P(?JYM6HL"_=@N\7?AI]_!H]_BP<R]D<F_YOP+:N?T" 1I^.YCQ]\)$
M8CR'G.%NC4>$U+"@!^^!]<-WF_>CHP"D/M"-VP\HV8?Q!\9TM,O4>'RHMT ;
M)O]WVKDC,Y0^<%)9N@L,I5T&@(PT1V@E1@&.:%J2Z3<>E 0WZ@3\,K /*:&]
MVB_@1=OL7\IV<1YP!K\*IM1_GZ)52%'$,SV"D(JH:48(#BX2TKQZ?8-"1@TZ
M_7%G"&(81> +?]RA)&-SC)CM@8WPPS)A-HS(^I+B)3@JC.WL(:6,,##],TFR
M50$:,A V>_._V:0<)L$])Q1D8JM3?'L0EP,^[OC\TK!*#(*5S_&*]4^J#< X
MX?E2EW%>3S7-[S'N5(+K@[01HXA])<BG'W=F*()EIRG&!K<!?@!F3?+1"0*B
MH-!4KK0D"OWU/7ZF)U'B_R[Q;H$3[+)989?/ A]H\>FE>>['G:*V^GU#J7H0
M686L;VR78&4FH!\6[#OQLP=\V6!+</$27-UDQ%\P=Z2\$C]Y#E.))<WW8?P$
M(:.0LI^_(#]GR1*%L8FC J)I=P'_?8#1O00W97?/44HQB2>S&:_.C:_Q\@&3
M8AK5?E7.E2_&VPN-'^9/<]-.S6-( AM@=Z^C'\%3MVK=*C9[8[K&N?I9))E#
M'82[<R';*F)P0>X9Y=]9OS@+Q9"J)A CF%.SB$Y72HLT03EC?65W)W,V?\/6
M*<^LA]X74WOI9=J 7M>C%-M:JG.Q=.JRO&*U(Z\-%DAGAYJ^YRK3[ 3MC(D*
M#IM/)4GLM#\YJR>IJRK%J#\[HPEIR@YC/URAJ.X]M7]VR6V2I,Q\/)S2>N=;
MOSK9]SMX6"8P.[$6&"?Y4KBIDYSRCM[AE4 ,2\^&8V8@1\6N_"I$#TP#$*QN
M;<WK^WPCI$5K_3?U0Q65(!),9V<AP3Y-"%,(<[:9BP/9\WGN3UHWQUX83AKG
M*0328JCA<Y:[JA<X@,OK4*J#6:*8L4MU=H7^2O$WK;O47H;R&V<G.,:SD$+"
MNAAV490\B8.)QK+6 <%9KO-[&)BM8CZ>QLW(@.ZKDQ9;Z^W]4V+@1?ZZ!;PL
M"#9IIO[=?7XNDHP8V*E]=I*;2_8_I\&R86&M7YWL^PU)?(R#%.Z(7Z9I!C,%
M=S#$M,W3G,M];N7D]D-R=KZ[A6H:T]GG%,L'!QH?I2NP*VY*K?![O>]5UE'3
MP^R+Y)S/V8F!EFY[8[FBY#+HRTBFZ2DB9,V$SN_5L6$X\?ULF?&Z8Y-E0FCX
MI[CX.3/P*P((+0E]B89<$6HW:Q!QEC[VDV-L/F;LD9JAG"-XL96NZTM9ZU<G
ME[)..I!B2CTT)V-MTXS'QVH'3@LXQX+7U2SG+W"01<S)D.LH;5 Q4EVQ5C/S
M?:7&79D-[Q@"3G^#&S",\V:<3?G-R?E!]/7$Q$C[HY.<J VH65S9Y-IUPG)N
MICM%Z0(2MRX2PKR,+)93G*278CF'4B2Q*8C-R3@GF?*F /!V$25/?&^FUGC=
M'CKC.)<J5S]FAGTH#LXRD/X-)\Q]TSPI\!:%:>FL]8#?.J;Y$6;:@VLE@LF^
M.?RKKSFFSA:3=!$F"CJQJ,+Z^GSZ.$8,IQ6?5'UP<BWZE$'OIK-K])^$G&8I
M39:8E#ZG]JM!\F%,\9RM2:\L>HC/L7E_[^C@Z&"ZC,.'+,]183\RP/ 1P\7M
M=DRO!XZ3"BLLJQ7>5WUPDP-E+9L)#.\Y!SU95R#Y\SR3)T0"L=I/9V)"F&1T
MD9#P3VG^> 7"7V=+U6$!R9_4.>4]]AN9 +J/3MK#:1(_PE4H>"=(\[JU"%&Q
M1H(BQT$Z>1Z$[.I6N='3BHMIW('5,LMM4RKN.DY@UZFD7#YTQ:/$U4Q@ W)V
M5#<ZSF^#W"**^<O/=<OO!FH9\1"$9!UX=3\)16PB*M+K&^N6^INK4U6:1;0=
M?U!]<).#QAL*#39T7YWD!8Z62Z>T$?)6?G*2"]B^PY$K^S]P1A_9<("K7A&4
M]I.?=Y?#'QWA75WD<M_;X*D;(9Q4XZ_@>[/]A#J#3/O525Z@@I)/PI4(>Q<K
M3)X55ITHFH%<-;Y/20QC1WJ;A3G^2EXNV)Y7$8G9A("[?A7KZYP-M!BGS(&0
MGNYL>\]W#PA\CVJJ[8_HKA@FCRB,<MV!9U+-IS"[7B.:_^NWD"XNX_NGY%\8
MD?S,'/:=E7_V(I1<'43GS_X"=M4:GT[_V<GY[C2!7B4",J^G'@=7H<]/!]4L
M]L1QDN_\Q:P%\_56K"D?UMN].IMF$">YJFE&H9/;9(TBNLX#0/>8+)4Z[8II
M&*)%=U\]%KI<9C';V_M)E,S7\&C+0Q*PJ>66/A\<'#=BH-U@G=1L[;:>;CMI
MAG&3+WYZ?51F8-:NC\H'W#H0-[E2:J(X4A"QUM;]S+Y(7_\(2-GAO I_+R:U
M.,[FW]KFR_*//I-L$\F!^?5G-GK@IFF9 G3%/#=QLE[57&\E'O7&<B5C:#)C
M_KKZ3GOAV$'RQ><XY)E4X9*U%A29%FLX>T'QNG#Z&QOA5Z+MY 1X><*/&W_%
M),W2JDX_\(;%/2K&XF3)R/H([A^1%8P*W(C);4S%2=F()![N1TE!;/-8J2<
M]<9U=2]5'-Q"C LR$GVP>#Q'T44KC-0-U$F%J[J>*U%[E&V!W38^M5DB%E@G
M^;P1)T=HCB&9-C?!@HG[Y"0_3ZR<GCX(;IQ:7>$TQ8T'[R=QG*&HXH7-N 1^
MOXQ/>!G0:I8:C.T&\X7+;5F"^4(MK]SGR%]P%U:Z459;YINY1:_1P-??%90+
MSW1VBQ]QG.'BCGRUHS.!N!LAO1(&FQ_,0(@[84L?R7@D_#*^(0ESX*MK"]W!
MG=WFY '_#CKM!.DLGU+A,>EPHY5_;0=S+K]:T^7V71$[G"N;M$\)VQ>D;.Z,
M$-M/)0$;4+^@] 3C>+):D>2QN8WH >^DOU%?2+M?#1V YXJ*7_SF4ET67_SB
M5.?F75$ N'"0#E-=J;AFT_@B6C?]/!.0RRMYVT/5,&@&<W9%*[SJR0.S0/AT
M&5^$)*5PU"HN%Q1,=H)T(!2I&T.VVV,#\)Q;Q3M>_*JSNOE%LB[TG)-5V>G:
M[3"=%;2LI"N6LR/_/F$+4KWCD%)1;DL,WYWE"4Y.\!S?B<IQ(ITY(>E5Y+.%
M^(2L(>&?9QNU,Q7ZH3GI /*"/,O$7&M7JMUC!7622YXEQ'J,R1)RI5IE$94?
MG>2D.,',JT#!IH/1H&OH/7.6RKRY2 3&@N(F5CW+?6,JSJ;Z;\:9= ;R,J*J
M$W37:2T<-3F<#(_17R/R.R[.T O6F]Y=5R0W0K!6MGJSX,!IE["Z\I ?HH%A
MD+\IR6,N8LJN&V<Z\=F_2768L#$5=PV\P5IQ[UG<BYX27K!-NNK5'?RK!\4;
M794'8UU1'7GM1<"-(7W*]5^EN"Q8;Z'"/C\$^1Q#W]GL33&_WE$Z<#V17!WZ
M==N\$$&3J#C8+9<F.?;0#^6K6WB/[O(9>P";!9ZS?HTZN8WOM\3>0_99N@*[
M:M**':0Y\M($<2YPH(KVE6>SE\M51JL+';F!GF6M.I0;4]D*N308@20&B"=!
MS' :8Y,LK)C.#N^>W-P_)0/E(#"_&3E 5>>ADLAQOQ59P.7<@:+(4;\9282/
M0XTB1_T6),%S@C<01Q/_6Y )=X$&R*+ VRH9E)Y!^?S.) Y>QM?H2W$K_(XN
MW/5P1H:1^^8LK(?;,HS<MRTQFX,SE. W+36;*S20WK<M,XN7,)#>-RNSSN[5
M)D2_.>EM*BB793()_I.)T%IZGTP"!LX:A7ACR+J?)P/PLY(T%*>&MQA.D/DS
MQ$3\4C[*5U[L>UF:SB9A%!?/&).4,@;@=!6JGI2GL/KO[IXYU8Z(#0\-B/PH
M\(++9X/RT'695_,2E-P5U*<D]E&ZF)(;1&C^#\FJ(?\?$OV3* +6\JF ,9PM
MJ[/+#6FX*QSE*4:A_T:R0D=8=YF]PI3"]25Q.*?.U[' .)FV4^_S'8K/0CQ/
M1-*O@3DUH),<MNMW5=?PFF\<\?H$9<)GXYK/, K.KFSE6Y_EPP+\K$IZ#RI/
M^R_$T ?!6:X+S9WA0H/5[2VAP3*KL ND<Q-6^_(M+\!!H;[G+2[R8937>E6
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M+1+.*DE1Q'M1')_E;.1+(QR\K>L"Z8BRE4* -7 :@]LHO=6A8U\#[ SCMBE
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M:CIF8/=FEUI_F:K:ZWH> E8IV(ZS+9I6'/@H*DG>\@(\!D/7(S6=Z)>_'#Y
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M9F1D@WCQG-R7E DX+;!=[\1Y!>PF?]#5D-\2N(SOF.U&S"F?9Q'*O0BUG0_
MW9;AWJS"44Q:O ")O(DQP[VJL@<X6'8#G4"1VVJQNLWX+EQ>RWK9>Q=RCHT(
M.3*AX&@:2]%N>5GK([A7;,/)*$EN**)FJA^B:/H48Y(NPA4<HH=LU\<7!39?
MB&&DW4-N2LA-Z80QGT<EMZ%A%K!<&FH)#27@I!=BC0R:8ZI]<9VTB'->K2Y+
M:<+&M>*"JO*S@]L&7@YDIKVKJ/[L8+SSQWW@+?47>(E^^C]02P,$%     @
M.8 [5ZE<YC?P'   <=L! !4   !I8FEO+3(P,C,P-C,P7V-A;"YX;6SM7=UO
MXSB2?S_@_@==W\L,L.GX*[+=F-Y%XB1] 9)VD*1G]YX&BD4GO)%%KR0G\?SU
M1^K#%FU1(BG*HN1^V-F.3!9953\6R6*Q^-L_/A:.\08\'R+WZZ?NY\XG [@S
M9$/WY>NGE7]B^3,(/_WC[__Y'[_]U\G)ORX>;@T;S58+X ;&S -6 &SC'0:O
MQA-:+BW7N .>!QW'N/"@_0(,H]OYW/_<^3PV3DYB&A>6C^L@UPB)]3YW-[],
M8GK(_6*,3WO#TUZGUS?.OO3,+V>F<7^W*7B'^S>'A24=Z/[YA?SG&3=I8$9=
M_\N'#[]^>@V"Y9?3T_?W]\_O_<_(>\'U.]W3?]W=/LY>P<(Z@:X?6.X,?(IJ
M434^GCTGJ=,_3<A_2NB3#UDM=,?C\6GX*R[JPR]^V-(MFEE!*/K"%@QF"?+7
M25+LA'PZZ?9.^MW/'[Z=]&NO6P5LX%]A3OF-@+"<#>,W#SG@ <R-D+\OP7H)
MOG[RX6+I$(+AMU</S+]^@L\0G1!==<Q^AW3OOQ\#K'*"I@ER?>1 FR#@PG((
M\<=7  +_DT&H_WBXH;I#*$%W]GF&%J?D]U,>0J>5]';ST9_.ITO@A0KUSUU[
M@A9+#[P"UX=OX!;YI5@1:44IGS:F#&RYKDPL9]:3X%I!F]7K>F+YK]<.>E>F
MUA3!TKV_A/[,0?[* X^KQ<+RUM/Y(WQQL=F<66YP/INAE1M@(W^/.S*#P"=M
MD_]=_7L%WRR'= @+]P'X@0=GN)_DMTL06-#A9;?2'AQ</C?N&^X1\M;5"F&_
M&86<$N)^$(+MQKT$SP&6+Y%VL'X$LY4' Z(%/)R0&^%QK_RV6$]6#)7TH4H9
M;=NC_\*#./"L6;"RG#LK(!^EH:&DS</(X %8#OP+V,30 G_JGK_AUJUG!UPC
M[Q$/VMW>*Q>(9 <42N<:?@#['+<>8)/E>6L\>G^WG!7 0,;C>;58.<2N7P(\
M*\U@.$W)BJ%$2TK1@%=Z+Q"+N+ KYPOD!?"O4DR7;:Y"SJ_\ "["AET7#\%T
M\U<?2[)D4<6T0$L*^<6B]5; CEOP-S/6SG=9)D7)*QVS+MD'W *\Q9D^._ E
M%.7U"MM0< ==N%@M[JUU:'!^X,6GEUT^[IG(HK;:+BB44+RF=E^X.\BJ44I*
M575#=TGU]9!4O]91-[&6,(BG=[J.M,VIH@LZ8ZE^&"F>@7&7P9/UL;LIB#_'
M<\8%<,$<!O*SKU0KU?!Y">; \X"-_XC6 GC-<PNM9^B47%(+MU -?U?S.9@%
M\&W[[0$O=![ #+DSW(.2:T>Y9F).9]@"DI4E_ND6\Q5S1]HH[WI,2P]\! "/
M)'OS%0:DB4ZGV^D8)\:&'/YWFJ(1DS1BFF&G<;<=-*/(.\2GC#Q:.Z3_/F8@
M=./.+?\Y].6N_),7RUJ&[O-3X 1^\B549*C$^,,?$502HGC+!9RPJ3]V"YP>
MME_W'L(&*5C?.\2A$CD3ED1ZWT&PTUN>*G^8_5&_.^CW!IWQV< TSWK=%$LI
MA)Q[-'>6-TN:P__< PWM/H]+G/ID#4RHG4"L\J3^W$.+;-G&#:(2O" /V_"O
MG_"_5C[N(EJ2YBWGD_$.X,MK$/XBIL+]@4^^_(&A^X9[1C8UN),+Z/O(6W]'
MX2 $\(WLV:/M'%G\XPT0\/">?T=C\H2:HD?%',;:[>5I=^E!1%Q'8;$#C];=
MC2Y&Z=7'S%F1\\9O"-GOT'$8HY:G:E.T7IJG6,]]=:.XM&K32^T'THGI_(<?
M\<70:$X-FNFA.1H/M%:D*"NQ_@:ZCM/8A;J^!$OD0Y8"=THU36D\W8\5=:;1
M0*,W8'Q#+;=.T_0FSDRL15/7X7;O@:4%$Q?H=[Q'6>$=FLM>P&87;YHBA?B(
M=3C458=X&XK-B.5\\]!JB7>=T2Q.-J>('/'BE=LF;B&>[(O47()BTY"@FM48
M+".-S#8=R5"H?%;QIFE6B(]8;6-=QWA\))FK.*I,T[15W/G$?]#15D=14(V_
MW3OC756!RG*JZ*-!?AUEZ%640QXW49U:ILU*OGHSR])<C\QQ;]1 O?*SQN,9
MJG75>^[:T^ 5>#PVEJ-F._0KRRB/?ZC.X4O02H)W=^(] RK:AZ%\KKKM4+\\
MJ[H[F'8"&_/W05EEVZ%@?M9X'%'U>@R#P F/+7D,.*-T.Y0JPISNGJF(@_\!
MCAT'V'Y'P;WE!=,YM67GV1+Q$FD'"!3PS./Q4G)4^[AZ]F<>#.EO=PC9.BVN
MT&S]2?*GH<,I%=.#UQ"/ 9K]^8H<W$T_NG"1$\M17+4^7A@V)E6"5M#8' ^'
M&CA=>-61-B)%3*D/YE!Z#)QT?UWH[2RHI8]&>363?T3,RZ*8%Z:O:#J( TU2
M+#+U5UB^R9J38TY#1PM]8,H_*@OK-5F[Y9BLV,'"&)G;3J7X? #A;:@GM+?D
MS!JL@B2:K&%E_/(X4Y3H=Q.]&4T6Y&*PM0Z]];D&F*,:Q==9QQQUZUZ4"^I1
MED<- WA2G.?OF_<+-EF-@ESQ>$9J.EJ,D<=WJ$@7UEJ!>7UDGRER,*CA/F5_
M75>HSNSR[=*H (_-6>CF:S:_4HO4*\&H[N>(Y)($GSG.*$ESW#7')*BEF:KE
MY4[W8\%,)TF^8O.JM$C#PFQ6?& HNH/).4THJM,"+<KSJ>$R.+E _ #>@+LJ
ML+O9A6E6^^99MZZ+6J4'I@"#%8>PLRYBEO08B=1O@5[5\*SA>6#A"2"[H#YJ
M+7NBQLF;AGN;>R\V-"$+>0%R&27U4:"@(O8UR,N=ACZ'"5HLD%NHO]UB+5(>
M%VL:#KYSVX91+^XM:-^X<9Z@%#LLMU%A15H$ W/<-YNJ74EF-;S,GLHR&$9<
M4UF&HY0R) /E=Q!,YT_6!]MG*$*E34A0P+GZ4S<%MTX""[K OK(\%V_??"H-
MYQS.F#?EBRO2(C@S1V=UWS.25KXDL_PG=;^=[J1JJB!_DTB^];0ZF,F=>OG)
MG;;M&6AN;%LT+-<VJ#:-L%$5.\,?>"!NN_ -*XV0/@\"#SZO N*9>$)I%&3M
M#L5I'#SE3&)MKC&\,Z\4%]EQ$1+ZC.-2*J:SU)1D_V YIW O0O:2I- T;Z3W
MDZCKV"QM^YX9)B-%B>;>-$?]QBI?M10T7-1?PC=H8V/MTUO*O.5\7A7-E*]0
M=QE.3U$Y%)J D\/KG[9K'):!O^(Q84%2&AH:A&).:-M)0L_(DPS(P;UXN<+%
MF3Y5%:3U 55)U<M@2%(\S;0[FPPX]R3Q/U9H#O.,U)G5-G;44%0F, U-(.X]
M2L*$(DG$N0>8836,\DU$B#+%9@7HB,A)P[.+A-]\..R4T@\$8GK(L@[%#.HY
MYR1/*D5<%\X:V<5I?H?F8%QW*$YYA0IPJJ'!?D!KRPG64>?3PF!YHEGEVZ=:
M,58U/(6BLX/L/G66^'.8@5<\E=NG]1)\:WCB-*5%D:/OC)+Z*;?6-1BOA#2T
M\INN)Z^D%8$@*:<?!'BUD*._7.9T7'T] !]@&9%<7I?@#3@H# /.7TKGUM%8
MK;G*R3HL%F53P\W1-^!B[AWR2(>]@"[T R*+MX*]<T$MFOF1.>K5O7F2U;$,
MHQH:X3C"FV5[DY\UUINPR<WEB5]%%09L*'@JGC-\H[L?OA$U7BJ0PYB<WTYZ
M!W[,*R,<*SG 5^AZ5M[*H1==.9%K>#N!0>Y&]P1FZR?/<GUK%K+BVN%?\1BW
M_V\5N1<*8DRJ:4P_6U01]*AUXN%$J>%:)(_[W=UP:I^L J<BY'\B4[7P-%PQ
MW7MH#H,<I\6V ,W2V!P-ZKYG?P \%+#/[Y(\=$0LR4A][:!WWN#7@4CP*R%N
M1-0/GY5\)]<VG6 ?SQ'TAU3)>^!!9&-D>.2*]B6(_G^#E*N/V:OEO@#R#&WT
M."UKU73@3ASZ@!D$I,\8^22"S+Y8__#)FY:;+<HY>;4W+]$G/P$-34HM */.
MH<M)3_=G01H]X934C>STPJE,53':^P F1[ NKKXFOD#O+?,2>G&M%NNSC 0T
M7!7>+)86],AT/YUOC]^9P;;9I5NL;AG.U9]>YR<'3E:UV^SH4Y?C&>NLH5V.
M8HMQ4)5T"H^Y3\JEE2Y_^W9!ME5_A8*>SLF!?GCI:.4&]QY8P-6"82H*Z[48
M+.5D4$^RJ"1USB8?T@3Y@9_F(/L 3:PRQ;#9,4?FN"U*5R (L0=H:LA:\VIY
MX,(*SW@6A(V0(X8!R"[<8@!(,"Z6A*J&U N4 </S'M[4DBF.?K0TU_+O5CH"
M $@(@"=%59U 2&<\W'GD/<TM Q&<M8\ &F4D4?&#S(QUP346',1[6^#[TSE9
MT,9Y$DD ";T<?GRV;I&UBP$Y(BV&@D*!%+__7/?N@4YSG(/X_.@L43(MAH]2
MD20 JLJ'S'KC;O,HXW2>I.HDAW36WD%,47&:JZXY[O?;HF@IUA.%LEV,)S6?
M"CRE%T-;K]H$+YI?F.=,^95:#((2 DB@H-,E&MJ+2J^+KS[BP[-O"-GOT'&X
M?- %-(X &N7ED2!%I[LVR=V@J4OB;Z;S<):S(ZY(Y <U^[',AAB1(\"* H$D
M8&&[)VNXTW$)EAZ8P;P]:+K($6BZD-U$C]J^=KU_QIH\<L0\PA*I>@08D!9#
M@@VV7[+N5>0^:_<>P/.@7902(;\:+8V>.>ZT[DQ*2@0)(-C^R9*.!N[XE.V&
M*-,'S5FKQ7HN(X%$S6P7HW[C_IK<87L%-EGADHM%_T3>GP33: 9\/XG*84<P
MRA-L,88J$DX2_L3KKM0!7K%Q3,YU8R.).0^O#^2>@\D1.TI820LF@53^#7.]
M(!5?)EGC)3KRH0!\=BL>)52XA)# (C?2LL[S5/;2/#X($M[9Q/5H<?3-\>"L
M_9C@D4$""<[G,^OV>/G3>63VR(F@B*M<E,P1 $:)2!+\Y$=J5K3KV7\,./\1
M>C$*+8: *FDDVM?IZ?I]MAB/"G//)8SZ+<:'&EDDZ-#K8=##YJMK)RY*""(!
M1;X3M7:;L6\*19:>.U5I00S,,>&^78B0%D."!VUC//<Y2T)-_@F#U\G*#] "
M>.*S2BZ5HT2,N$02\' &?]:0JSQ;:M%5N1)7R3,(Z <9;:^2\TJ/YV)JK5?)
MK75XW?()G<^PY#S >16AL)Y^6"JIR7UHR,F *W-GG09GCRUVSAZRB.,%2#X5
M6E1GPV[MK_]6#Q<)B12:D[J=\GM,8OGA^3U8WSN6&V!K3>QSF/R4%S=, L<(
M&3%A%%Z7U\[41"^P;@?"]=MWR N4K+K'B!%N.7#=D#]\:IL9 ':8./W."F(6
MPE/,B$V2X=1R'.)K9II/%F)4T#X&1%4FIXHOX*NW1Q<K'Y*K9"!Z^C7<<42_
MV+QF*8?$,6"IK#@*;^[7;*2B<&^Y);(@&5H^ICGNUIT.OU+3(RT2GKO_M2-&
M>%W,3^$H<2(F#9ZL 'KX^3;Y3F3]?!D$] .(MGX^7NGQ9"93?]TW/0QN?']%
M,B"0H1!'^T6O 2R0F_78MS@!FO&A.38U/97D5=I.-$-Y852<.)2%@NT:*P@L
MZ#X!;T$R'V0JG%&V];H5X;MJ+QO':-Y,7QM^61E BFNU7K=R$CA8,LD8>].Y
M@%+SJ[1>HQ+LZ^C->MBX3*)<- 4QR*SB-+\C<S2N^Q4)9>J68KW0C52W3X L
M$*9AK_RK#^#-H,_V%Q75.P+ER\E +*>CZL76-?*NO>A-'<L)$Q/ZY_, >"27
MC.>#D(W'I0,SHXB%B;08! H%4NCXJ<$NI//2W7L0RV9I.0F[#)N06Z?%4)#G
MO]"?H\])YQUTPUZ$Z'Y%#NYX<9!-5B5:$&,L3+-M0) 00&$NQ[HC)"(7%%[:
MIMQ24[>4 VSCZKJ$_A+YEO/-0ZLE>6N6),4.7Y\&]O:-1@;:ZN^8?HBNWR^I
MJ5;X'Y%7_&@7Z:.#_)4''HG^O/5T_@A?7#B',^+XC^XKAF^6.7"&+4V&I/9D
M<PD""SI\KWP-.H-.SS@QMOT@3WY%72'/>J4Z8VQ[8R3=,7XA#?XM>OTKU:?P
MW=1MK\+??S5^B7OV:_U/A&&A/;XB+R".L^+G3$0('-C^QJ-CMW=XYO*\-5;5
M[Y:S8FW0N>I2XV78,<?]NB-?Q=69MD#R3.O^CM:>R90"A2"5ML%#!?N24?(U
M3RV;EZE$YX]^F?ECTVI]T\.F"WC!S[RLE"YR\/M6R9-AUOL=7B]YT')"2*^6
M2R?O'EY^-?U&;I8BZ M2$ASI;K4W3%$IDHIT2A5NL":+^=#-F*;FCQN7!&W%
MT3GI&&7RG@MR(_?_7OEML9Z8I1WNK]13Q WH&H1\N/2..F1LF\(+]4V?B%W.
MJICJ6'W&>#= ;N=B=92OGKR8XP<7E@^9;\L(DSGTBSGY'9S-5@N"4V#CW:SO
M_W#Q9MLA/2;7R"_ ''F _=R[$MKT8.P..V=U1U7)0H-Z<J<RT>@^S]"<3C)S
MPN26;2<@^%G5?B*B8XG3LU%TBWQE.?']!\$E_FA_B9\_?Y#9@_KP-R/5"2/I
M17VS3.G!H.IAUMQP\.UM%9( X,9]>D?_"RR/ G;6>6QYJOJ-]5R-;1]>K89S
MW6V["-O0G;J@"$;J"#<0214SWZ!YY"&U^@'^U,V?<$4GE8'HI))TQXCZ8R#7
MV/3H!'?IA/1IMYHNDTPUF;54Q0$1M$8O#S/OG3++T2COF2.S[G-.?N'MS!_<
M['&EO:C]5M;A[_$U5OU*N>>*N*_8K%_#C^3%'NK$(GHY,MGFII]_$;+?W>Z^
M-RILTHC:)"?#4:M&V&SHEDHU;*1;KL]&,^_9L<\"\JI@- P[@[-.WQP->IWN
M>#@<U&$&LOL7NC1$F0HKZ3?$A960.=)%6>;9!QQZZ<\:RTL'A!K!PSWUR*?H
M/5U5Y%N)H$J%(WAKJ_H)93<=6,ZLDN9:;%;I99UQ).WR3BWIYNL\5J;EA7'%
M_70E5]7#AW[CT70+W\(WIW?[QX[]SJE$ Q^/MK.ZK8*(TG9BO$7YU' RR>$B
M;_%05$T_-4NH2TCG;+:;I76&31?' 8/0\2%#1! "V\@#SFHVF+/9XY_AQ,CH
M!Q39F4()YSP^Y ,O!Z_\ "Y"6+ONRG+2X(Z?Z1)="68<.NZM!#>M&E&SU-K/
MB!NN;PU8S9HIM3<Y&YO#CE8SQK[>OV,=/[T#YPW<(3=XE5A%<!#5ST!(J%%L
M)I$4BMAAIE[+D7V6R9G;TSM2@JF8%BVU@3GJU9W'L 8HY<E"[ 2S$0C"+;,N
M1$A2^XFB0FF(91EK HZNT<I3!B-"[">*BH3!<W6S82#"9=6!")?]":(B88AE
M<M8=1&&.$:5(HBC^A!.71,02^E2_88^?'XO[[V\N!>Y\%]NE]SO=W5UZ3"_9
M?.-->NH^X.Z/-5XTV7N-+3\,.*?\P5UP&'K #^*<8G$WSEV;^=:K0$W]!G>A
MHFCOFAR'ZMWRK(COB!L2RGCE!U9 [I-DA]IEEZ1[3S(&-4(_HASQ.S@/E^EF
ML730&H '$'KON0U'8;V&JK0<?Q5GF"ZM[6GP"CS1.2*_4L/U+,&<V-ZLAGL3
M$3?W'IH#WP_[=@TX%P*,2@U7L@1SDJ_@5!CXNDVW-WUVX$M(['H5X-_N\!I_
ML5HDB=A^X#6MEUT^7I5.<'=ZW&OAO1L-,6TC)&YLJ1N_1/TQX@X928^,L$L&
M'FK,NJDE,XF$POVKX51K(['-<[0)!Y?,S#+%U6I,9KGI4.$BNJ"6?@: 5UVL
MG)6\3.I^2RZ3IWQ;GU>EQ8KF,/?:7%_;O+?-;?!9-21,?D;RHPUU :._VAA]
M=NT]LV\<W.[?DH?.=@0N8/_YJQ]ZK9_=I8*U?FXE>NB8P\ZP[B<-1)5'+?W%
M>=5],F"P5#C[%]8["LT7L'L4<T2_"7-$7W".8'@M\R&4Y#0_=^V;Q7(5A <H
MH1LVRZ\I3TN) S:K^9V6GM %N+>@_80":S> 58J&/C9!B38W#ETE<M!]ICC0
MJH>6S= <#>O:3BC#B!(12,XE-1F\!.YY1_!5-*#IF.")1)"BU9+1D@L7F2%4
M+*1Z'G44F"FDA@X/K6/!C'HA-=,&5VE^92UO^>&A:&2T=%"H& ]UFL^#S<R*
M)N4C@I%2T338HNZ'N"NF78M%%>"J@ RM[Y&)_VC\4$A)1]JBLD33*HO*OO\A
M2N8(8*14-&(6M:^119VZE2U10])UV%,!GO*IM' 8I&0C:TQ9@FF++>6\,BY+
MKOV@JD1"S5VT9MWO54V\#C,KQ%<1G1:."DH^LL:6+9RVF-NB*_#"=&AIC<W1
MH*YL'-5!2:UP&FQ;][)OJ"5=BUWEYRF?2AL'PE8VTA:5(9A6V5-F4AI!*NV'
MD$K!Z!9Z)GH;96(M81"_ND'7$;R9?;8?=E;F-DJJ7WOU:[S%W>JK* (K-.[Z
MU* 9=6H\J%%^:X&;7=VG&2[N\G*>\=0^(B PF*UXR5TY#/CS*@J1.0Y@<'$M
M>4F].7'LG&L)LY80]I^1ZTV.2=7'C%0?\ZY62/I$:.H6;?<34Q+R::YGL>I0
MHY]PDI!/Q8E[&AMG00NK6V,"<OW Q!)/Q?F!&GV@_!-/,@*23$:D Z(J/4;[
MB29Q\8@E<*WAII2R^\EMO>2E)]!YM*GV'M<.HC786=9PN>FXP,"# PVVA#5<
MR3A"'+!$H,]>[N"AY,>' OTW8;4$NAX?$)JP>SIX;-ZHAT6@G?NO4A@P)%#Q
MMJ<I^7BTY>LP.55J'0\J,M>I$X'NX4(Z7/D_&KCP($7;B"(=KC(?%U)8W.O^
M_(6.%S5'?7/4ZQT!<KBDH/O;&GK</3L:S.2S7_'&K@47:XX+* SF);=^E<6[
MWKCX8_1*V 0MEL@E/$SGF\_Q*X(7P 5S& C%M/:Z^R\71G2-L#WCEVV+Y.'"
M[6_)VX7&+W&[O]9W_84A"<;X8)1.OX_9[_;-H3E2Y-G9/K]W">8 _]N^!AAA
MX8'L8^[C=WPU:1 /S%%_5/,(%A'QCONF!,OJ7R\LC<R8&S& YE?21]ME];5O
MO24XUU#I.X(04SY?Y3:#H(0$-'PO,^$F% ,6QRUN11(2/"2. 1C2<N!Q-RB9
M\1F=^MUR5I'P'0>]DXM969,^=V5]=*U@WB_'-?_ /\0J/0$J_B-^.=U-/SPI
MND+OY:_0D];"57G4GF&YMI%JL;ZE^9XH4KWZ#HHL'J,6C:>!.1S49]<W7=SN
M.9'O3RS/6\^1]VYY-LL;*$!!OY$NHR&V19<5P<'>*]_KZ /P 9;7:SBSO0$'
M+8EG88+\(',C)U*?YI2\-SALM++5"$#CI=V&)_R/Y%L\BQ$NO3= )H#P36'+
M\?<?(N:U#Y+DVX:G@\A'_5+Q$' CSCK\_Y$V73M>0_F/KY8'+BP?V.D"9*S)
M0T^XJ2.&H1I9\1QU:0#)"?X;!M3<G=AZ ;3E4#DF((F*@>>$JVZ,7/U[!8/U
M'0A>D7WC8NL<A(<RO.!@5#\:5(CPSW.253<<[CV$%_W!^MZQ0D<1X2]<"_("
M@DG@:" A)H$8%,-#;II2?&ZV>+BCZ?1$#Z3QZ?R'#R*F"K91$A3;AH>J1!(#
M9,0$R$FM9B/%9@G;P4.%EHXY['3'C0:,2C'$(!DK! FG[X6%;?:.6I9,V_2O
M5 Z)[ZVCY^(BU?UO"-GOT GOO[N!Y;[ 9R>V?[M_"]D- ;IM0U*U@DF@Q?;K
MUCL#15TO/,T3J'D$^!!B/4$ V]U[<M 3O:OY',P"^+;]]F %X ',D#O#0K&$
MDTGVNIU!_K'>ILETT!UIU:";K>]L+ULH$^3BV62%)Y1X9D$NRZR*$#CP:.=1
M>'8< M.?7X8D/4B&YGA0MWT05W[:+BB7Q<%. GEZ?O6QA!'SU\B; TCRP$[G
MCP&:_3E=9@T(A93;@I2J1:+^/+$$8":O>%&$OV'-X+D2W>!Z$WN1><&[!+FC
M@X:('#0\\.-G\<:57YTJ;J4M(#ND>#0\V>-A^SR(@SG)3+W"?5A3A4O@K8#R
M,6),1B3\IX%9>ZC?3B/UX?\\6S[X^_\#4$L#!!0    ( #F .U?#)B.K!5T
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M?U/43"#$@B+G\TX)H3[WM*3[]9 'KQ.*(IQ- DHW<T*+A)D*O[BLO7QY4/6
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MAE:BUPPE$8H.V']Q\?'B8O1FM!N*_;G^B?T/Z8C,1_6O_*]1]1V/)^TGGFM
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M'[>#LK,TE-\Q &BBX!IVFZ8YBJYRGFNSC,PN";]'7XN?Y ;7K#.4':7%I#-
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M;7]%$Z;KB+X/"6;"[06JF])"G8CD"?H?@DVEBCT+NS$XE O<P>7>0.TF+4B
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MT]I(TP*>DQ0FV\KQ&M=@X4"L>Q2O@W!9$,TSA(G<CR([.^#'?*^1UO9Z0%Y
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M2:*'.$BDSI-A/P5HW1;JKU52E58<\*]$,Y1F%/.*0\7.ORBD,'O\HCS,:/I
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MOV\CK]:>_=;0"I3_R5!5UE/8K48+3V9+EGMN2+/5P U&4$JC== &D,T2J)F
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MC(JB\0O;[RY0(ZJQK:7JDP+WVM?!C^V%0VWK&5?_S/_#9\%__O]02P,$%
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MHI7->&XWP@B?)Z'BS<J!RT7.6#![HHUBN-T2S0D%4D>T$30J&J*56,##4#[
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M&DY6_#8>SU5?Q;2S\LM(_%7_/I43#4")\'1,@,4*3#4"8;DF)V &S*5([GZ
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M05B5U"HJ5$6\X'O[)!KG8<BO@P?Q71"%U\E%L(N*(#:*R0 ,GLA8,2.+CQ$
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M&CP%&,NRK"2N.% 4:1R1/>&5B\/@U6TH?6 R+)"1( G%CZ3!1TJ$Z.?R.5<
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M04'#BS0O<D[F$SL,A.7KU#8=?J<@]:'&<<IRJ,L@QV!$KI0<3W+?U0" L[<
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M*G>,-\$9[^-ZES*J:A;?TH1N(I>FD./1(=X1GK@$K?O"(W'AW!V>1&S_'K%
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MYFM68]AM/W3E@@'I#2QW$GN26B(!04V?16-TCW5R*9:7J NK"!1=P,P:9@.
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M]2.;.=CMBV@-0:/OE((Z/!SK$L P"TWIOWXL8L'_$%']; >#^,\U$2"4P_#
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M9^/5Z,Z[KVN:Y]9Z8QR.I#,6+-3Z8AB+IRN#1#GHR:X2&K-RD&!34'B<%-Z
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M,.L&87UO';G-1^^.0/CR:A(4;:/%&+0]&DX0MYL6O<I3Y\!8'%D8)+X2">W
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M0DZCY>:.1LDEOZ6XS;,=S<NW U;MPQ&3"RPL=%(&-&-Q$@&,Q/1C-6PX^ <
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MN?#?(#L-H=[A-.SCUSWTXL-0_W  GA,Q45T]1&\DX9NIH5C@,$,-HD[B5"+
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M(A([<$(!Q.B)GK_=,O+3P^8M@S @QD3]&>T$1]W!<:*DOO0I\I12)L:2S93
M-O&Z;KO1Y*8UN,CC&Q'83D!]NYR)(6/$J,87N&J;A."MZ"IDX:J]GMKQ1G
M((8A%\;N+%;5%6_!Z.;KT">Z2MC_K#42=89&+*7MQV"GQK8;*$[Q;1_:5)4Z
MNENK&@%HK-AHL5]*)-B'B.TV2\7!*=K%992('=(=+6C^PB,E5_MRG]-K>?#1
M[M"\\6 >( 8RW3T^>")!.CP,HE)Q=  \=4A H*K.#!4R'O42Z$B%#_WD, W_
M3=A/! 1(WN9Y(WB.;3R'48M:5QZX"J7*V[$J/9Z)Z&=XK*\+O<PV7< UJ4>*
MT*LN]<"YPJQ-/8H9]6G^PR,@(^T)26M&V!JVQ\E9"9]V01K#ELZLGIM;-I\=
M.[CY+H7*TX#$G_5Y0),(^(7FCUEX(BZ:%TA<*D]<*E#A+>?E+W8,Y$17$I''
M<YT69<[OEXLE8RA_>([2Y8[G2?R-G>2@":G(I9CZHWA/?X(KS4 13[+R>,Y]
M6BO1(.;F<*(R&:Y%">&D,.<0I402LR""',*<J2#H5!>K">5>D!<^%M=[5C6N
MSM(UKU!;+/=E44;I.DZ?(&-6(T [&)ZW<F6I[65L,"C>P8VH_GNBJFP9=,46
M@*0%N2  BVR  UF#/\&&#78>LU;A-&5D5K1??J/Y*BYZD=%!&#"3N+T9[>9U
M.X,C5OH<0*<ANE*I'J$5"%F+M%M0S-4^AXLN*(K%YD K 3H%RRZ9Q;6[J9&A
M'92F8[SZ>^=KPUFPL)P%CW1C(Y* KI@A2XXJ@K5];8T@F'<S=E:Z%S+Z\4BW
M,#:"+#E<58^ &@H]SC":):JPGG"WN8</Q@9L6?HHPMS^ZEAUW0H?P@>W+583
MZ+]%[E6-0#?*";B^BN*<O$3)GE9[Z,KW1&RYW.YF>QP$B:_%0>]XY=*M'(>U
M-380W6R %8,0M[E::H;5L^?X2(T0;2OKSM8!Q;B+SI*9]5F29"60(N)#QD?B
MAO%XRXF5B?;:H1V,LE!8J.D7U6/C/]0 ,G@Y:Q7@"^9\L_PJ+O_Y1/,H6>M=
MHVXDDG,T$UZ[1_4P/ =IHJ>?3<('DV8T=AW:N:D?4\[ZB;G<IZBDK5266\;X
M<Z2)CUD L I,N[#15(HVC48L^6PGJQ]899O!J((CT3;;I_PET4ID5,ET(K8[
MV,8E+Y&1D4=:/5!X?&/[:,)(BLNW?RD(FRB'*L:PMWY\2Z)7M!8@0R11PY!V
M-AFIP7"#6^,XRC8;RF-X.ZB]$TX,JTIK6VY:;#D$)S1P842SC$SI0EI*(/2X
MEH&JGK;]G&<%\Q2=>%#]'K'E41"?9+\?%CV#>3Y,=B-ZE><(LM#-WR"D\86^
M\K]X%KDYA VNP(V:.8?B-EW D K;J"CSNGKB"!:$H1 #9@Z9[S(HG/-BSB@9
MPZI\Q=T47QA?<T'7([A^C+3<?(4DOM><L98^?8J+%>SY;J-XO4RY@ZL<P'*S
ME,:OVI",1(C5;W@*,31=B<=@0^Q=/)[L_JK1/'9C"KUO825KB9;L&%XHS/#4
M74;9^&J50>MU/+M$VEA)A9;<2HF(C<5M2R)+V[H[[TX)4T_FK%+V*7HK1'CO
M(:N.3V?K-2^/5CV^48G"#QZYEI@/D[WR8"[ ^!6_W*DT9/.L&1*2B6!OF9&=
MQ$.B&I&,?V 7Y)J$6T!2A;:ATWS%;8-(9O:$4"]KNN_+WRV(P)7^ \_I<@[)
M%GM%$_,Z"&2W8F:DYTC4P_%=AXDN@S+U=$8&0;%]PT!V>E8O3UPA&+\72V>:
M[S++K1T/GE0)&7X["'=8K)L]3^::NSY'0,3;/R\*#58C WQU8FB0NX:1W,K;
MCU]:/(:Y5QC)YR].'W'N6$Q]1]-]JFFZ$!F((X"(BP^SRB"+"X(PXBKNE%J.
MR,WE;'I8Y.'@QB&$X,ED;#=WE[W7VNQ?[1O:4"(DD[%^^)U#O*ZMG*?7W5,#
M%-I%[2$[]EO:"B*@*]HN299[O>O6M>4OMDQ]S%M9"U=?:%E'DG$-A5%RG3)_
M3&^RHCA[+*".MNY)@68LGED8B6];@W(@BA$8*%%JB1A,OH/AWY.SLLSCQWW)
MZUO %I?7J"2_5HAF3O6S&H,/=^=1$:]XUM4Z3O80[&)+")28SO)_#\DFJGHB
M#UEK293==3@/3K)PP!**'3DSK+<P*XH ;,^11A>KK$O.,)-L;_(DM@7A^(*R
MS3'<)W#M%[69A@[:"Y#*1[&IEXAPS?@RRN%E2%UADK-E6>(L,'@FZL1,VR"-
M "CFYT!1_V&SA&D7^10+1S!KWA"V^FO?FJ;9-D['KWZ:Z$U%)1@_HU0:/=#[
M $:L.B9:09!B,XZLU*$8R_CC=_1S(DAO"C<\ZX+90[74 "3YE<,BM_8[2\N8
M:W3\0N_I:@\Y$A1:!"7[-5W#$0D*&.U%,&JYZ9G.FQK!V;=8=V:?=48\=W\$
M0;87BQFG0UEJ9N>G?Z'7 B -!%NF&$R05ODEVM)/V3:*=1UL[&"AV4>?);N2
M-S !:>HA4:[JMB  27X5L,AJ=[G=)=D;I?QHX?">V# ><=]M8Z*SY]8-QMEO
MFZG1I+#+PH#3/+^<JA"*46\.QJ"7,M'K1V< 9C$2HQ[(,<<]A=R8^HD[@05W
M&NFQY' BN<'K,^Y,E/?)Y":4SN,CMX5G_)WQ/%O."G=H6ZJ!PIGP<"$0![0Y
M&T2Y\X&APBXN/%OXX<Y3%0X3LR"_=%P]T_4>VH76FPZ:O\0KJJE<G' RN-#N
MZ"I[2N-_TK5X@G:1%66ABDG-/!?B2\HYA==Y>3G'1#@O->?CI+\MEG-Q^Y.S
M$3E=I]1X>T9FEO6< -C,*E^%$CYO&%$[<2UTS]P,KT)U(^DV1-V,$'B6Y,!(
MVQX,PU&TVDI/3S?E/60-0BJ8(.).&GZ,02<+3'"ZI0\W&0%"TB]CH,F@84$$
MF:#G&/N*SV?I^A-]H4FV RHOOX$GIL:P@1,DGKYY,-;6.@<P%-USIDM1^E%
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M;Y3]IP,4[79)O.)//-,L_4"KC>PZSND*FK7$T(PK+N,H2=X(3=@OF2*RWS/
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M]:E8^U6#3SW&AC40GVJ4?L>G!K-/'5(_SB216<IB.DP86E+ E&*<I&RE=;:
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M6ZWR?904_'_I6K]KG!Y]$.?!243DF9CEA!O[=#@!\6,2L*IIN*%5$RV(G"J
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MUR7=*B\MU./P-S4]HE4;FWH0ZN;F@ K+!@=&$S[\=-ZW,[]&BS)>::QC$*:
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M$:*H04D#R[MS ?,M<-2@U'#VSKI?M(! Z#8NRY&N8XJ,SSB%;H:IB(\R$J'
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MW"\5U(X\%;H"=P(N+&3/UZY#/HH6F_1+^$RC3Q50=B!(5T 2K;0[.7U[Q=<
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M/3KOB&T\?V+Q$8I(UC4?.#@XF):\H52#DCOP%B0EBW LZ;L!;?P\,TDI\-6
M#F6GP=9YT AJ(8(!UAQ=N#O#CA[^(H%F14SR=I#:#QHS?%SKEPA(WFZ6=Q<[
M:)CP<2TJ]B9SSE$-D\/)[@$)>!I7ND+".-Q3-<DP0+TZ$OTQ+0':[GC5H: D
M8%I+&-,$=(^:$Y]"B2!]E!!M*):V 6V5!T4M(=D8<$<))QI8>IYVZPZ^0PLX
MEE\('*=DE*!U&2 \N-EM&_TFR(J0$CF" $-]?Y1]=;,16HSVH@6E 2%$M!2&
MD:@\;TXK:]C6I1WA(9&7Y/7DZE2#(L B%Z0&[,LH_RO, 'W'F[%]C&+J0LOO
MV+)3J,KT\-(8$$C$\3^00L*9P.18HL5XVN2WS"_I6:@,"% B)9!"JO?IUN:>
MNX0!Y6[DT$!+*(A09ADB-4P+"MRSP!(ZT;N"KR$R<(X)U$3D4')]%2^",E=$
MUG^'\95CS1Y'%/DC@I]4D0VQY M%7DA, *Z<N&Z2N7OU#,='FL 0<:SH)SL&
MC @\-__8)[IE"%!*DDO5UTD5HDN%(/ >2?!7M,1WNWUD%Q)*=QH]#_NL]SS/
M@7=K^-"DI:_@I)(3Z.GX\OJZMPXXD1)((=7["%$&4=Q!.\3/4=N"*DOG6&%5
M*X,46#U/F\+CE.2W6AST!@^TMK)( =?SO"R<0N&V:5P4/T'';.=$UN96 +LT
M57>:"2N:; 1 5;8=(%38^4Q!T/-B3D6&$_ SPB!I?01 H'&:0D%XTI9NH? [
M@*LUXO'F'1G%%7@.-V_ FRU+B9!H=H*+1EZ8)Y.S<PWRF[>#37O^4^^LVAMM
M66#*KJT,B<<XJ1P/H+@DD$)*>.)LA4FER$46:A))G?$DDLI^Y3]&R7>47OPW
M*+[(T!?!9C(^OQB?75Z=GUR<GXPOU=SC[ ?[BAVE=1Q%C;2<\\V%3HE6(+,K
MZ#K:5A_9$DL(.]9=!T_"FP](BDN@]M$;%61-4M3/S"81#<K3F'\#>/4BQIF4
MF^JM1F:-5,67,#*KDS(SV5&IFBRU&ZP:V3@E!ESH4UV3JD]JG\'JEI]K8K"!
MGE4QZ3IG[9^7Q.EDK,.]OA#]MY( \;&[!L4LJ8JO;CQ8+7.P2WS$JR;Q0$4$
M"56QM"Z#52\WT\2'L2I\\WF^[]P-@BK),U_5=K!J9>>6^'95Y2GW"5F<1_3/
MVJ/MOJ'>FFQTGJ7S)BA(6:5+H^CW$1B;*8:XWJ"BXZ,*6-)D(LB_M@4>=+$7
MVPL4/B)CO'JIN5KH/5J8V!-DA?10/)X?<7VCN]##LR(>522(9_ C^A-Y16+I
M/#"(-.=9QV<'A$?*!"ZC&GF)RV-AP%)&,ZZ^P\!%>Y;URX#'!XH8^@U14>Z<
ME]'9Y.12IU)R(F#!R+.$<I.JWR@=WF?YKR[!E9H1&OXO?O\Z=?V M :U(3D,
MJ$F3A)1T8'),TXWO@^#&1!O\N");9'FKS%!EPV'@@),_0?F[["[5^NC$MI-%
MLVG; 2N7RJ*@(I1B]"OKG!+!._K;+.+/O_\ GHE65%*L,C>=8<!'+/L2RE%J
MBJ]X?@D &(7042",EW\9*;SDK%$/7IR) &VN,(\QZS=+]&%<%1)]_5#KE;@K
MX:4Q#,B(8UU8*B^=T$+>ZG 3.4Z\U&^.6B?JZLT2M@!^X$$S2&(+;WX8GA6]
M;GQPO26 05B&FC"ZPT"?7'&(RNA!<@ZKBMRG.<#VE<]GR_C? 7S+9JYJ@L=:
MHGGIGR,M%V?K8,#83!:B$H$HSV'(Y _#@GHST"X4AXT QX^TO@#Q$1N)RGN'
M)HB%N@"FNW*([J6N/CLL "N1UD!2D@PMOUWOP=RAC&0D.5&]@66Q!;\;'I)5
M$"]Y+2QPCLZP4"B&?1GI3"1=$C#PFW&:SY8+@ -##Q%@L^7-<@EMB.1=>;$@
MD/XPD-:-6%KG4NGP_A%M.VS#]Y?0A 4KGB:GGSG%%+WYVII5R&M/=4!XDR0,
M&6E:5"^D]*JMWQT/&#;\ZU X@;".\I(9!MB$<B\C;XMJ=#6M#7!Z,3DYT2 %
M5&-$U/ E*J&*7FFE>_=BH>\HDRB3%*%B(M?O'84E'@4]6.@]6)C82_7>]G*A
M4N\*TSU-#7_]8+L_]@M139:G<YXL3YCX**:N-+?3GDGVE$ZE+H>T8E=C="Z*
MTXJI>* , CPVM)#BFI+6[>Z[#]!I<9;6 ;\Q _@>[[?HS/(3RD^,R[@JN3;S
MGE5G90L@2!*"'K,I]H@WWIIJ@@=!RF3?NLK3ONJKYYQ["M\*.2:T<26.@TO^
MU15CC&1\ZKC@V9D$)52Y4K7YO2U>B-)VP*7&6N*K,Q@0-M)L4A)D+-7'1VSP
M<?(O(_;%HX.CX:QP?$CTRH#XW(K:Z1-5!;O&+RU!%DHYNAZ@@U^7/0$TIQ8X
M6_%LB:0:OV#)2(4 ,\;>GWC+XZV-V 2]3M=I#[@7:)U [C^PR2=%=/&2^41E
M(2Q&A/P$O9+7*S[V#J#1)_>9Q$NX0Y-/8!6OZ&ID(^@)O?+%]'##C>\>_=DR
MWD#<.%;TC\?-UH!>Y"E%V]@5,7*:E\PGWO)X$R*_/KVJ-TT/9PI([I20L %\
MQ[=.,R<33X[DO(&^[WJ[9S< AT:5L52M*'[B,1M_)5Z4;5,"U$"SF ):Q3$7
M1W5$M=Y")YA[8 /##=-)MZ+?)QIIAUU6@0E*4Z#3L8,>.=0JZ*HZV.@3>RVD
MUC:908?K\5TRH/B8C^05Y>ZI/\CR=<Y+:3(9GY\>);8$2*T_60R0&#U\.K\#
M\?\^.H]H#^&@[KL%4K;W7HFI^EZ?8,J J:&X-,QNT'J-?,UZPEG/K_1.GU#+
MKXD-I#7$M @'SLLW,/<?263E5]>U?D#;)@"/B\8G#O,X;"\\V<D1U  S[TV:
M+2/O>.Q)B@J/Y[SF;"Z].B*?T*0Y]!I)KW6ZA [/#^@XM()HPP$0QTOL#YH;
M.WQ,P@[,O#?IY<UX<HWBG40S(I^@RZ8O$B*]U@D,:D#7R&]"RAH-@L!.@EQQ
MBB8G!%/\7J$<3U?7_!-(V=S2G')JG3! AIT2O+E[!XDFF+9Q^]:?N*)MV.AB
M$I4F0*^M6?F@OI=J^K*='A+,3N 3? 7PM9-<ZZ0!NESYE^6 ]@?X,L4GWK#R
M=,T+[^KR^FJB'G8M=<\")D9)M(WQE7$3RNRY/6P-*D-Y&7L-&R%MA- V1%?/
MG51)%@_0@?X:6-@U@V-<?G>]/Q\=9/%-='A)'=?D-(W-"0X;>9+DTS9\MP:4
MQ4V)*E#./8 VIU9Z+9=<OB%A1;G7J$\7FA$[5C VEDW;0-U^ 9$>.5[7[<C!
M19-"V]#=&A@5,U"K@E$2M+*[ UO7AQRVJ]CQ6*'$)(>V,;=Z//LDGV82)S+W
M>3#I=ZS881&#H#)9.D('WS8\0>,-VK1TZRQ=\Y*[OKR^UB <L1L L4A"0HRK
M1/=!F2F<8BK*6UQY8\-'8=A0$260 5;8HL@XNEY/A;/C=ZGG^P\;86+$H6%@
MJ@2 I1>BO\-@/0W]P-T CQ]F5"K'"C9^H8B*8E5^,\.>!8< ,78"6J)+6A:@
MEG(1E<# 1?-#.W3%]_ "4N11"&F)-GDI\G@E,8S<4>BLF^;LQ\GY/5!\+'5X
M1H4?51' Q4DE)\^S\61\I4%F<$&P*.--A' D7T 7)W9GZ1E- "S_ >GAFQ$D
M,HB<P;'$;AQK:M@V?EE/%!D)D2)H'QE.I8E,2A(KU<[[K+CB</%FII.3S/%B
MLK%TI*:R4E1TH;BFQ*GA#\)X>'^&K(MU5=\C@UECD4B^WM8$78S9(&O['3FJ
MF,0AY:9;!Q A :.C>[";VX83H+T$GF/;3?D6@9_ D<.*3RYB$TZ]*L_P7M@?
M<*.,G4)>G"=(G.,APZRE8"3<E&NW+MZ&/L1O]T#T/#3R2"5_(14CY2%Q9'AK
M*YFVU^I:;L78Q=W:[WM<<&LI%U$W\EK>+NRS&[6]7: 0TA)M\FX7>"4AR&?1
M]G:4$"64W1O@HM$XRSC>'R1#PXY"=[-QG:AX7560$!<!+:$B2,^%6*'V<I%:
MNT?D0[5TO7]PO0<LGFB8<0&[FR7Z/'[%CL80<?JRM6%EL!DWD;S,3B?C:PW>
MUTK"DA#9#/)UVV&O^0TZT4@BN21E-FNW[E6=C@-8+60A^46:R!PE62N\/^3N
MA4;*A%/?ZS@PTD88@LHZR$^0F4R V9(#'_0NQP2.!I*0_ !,S3JTV-^MQ]F?
M:E[ND)H?!W0:24''\@IBO=YX^S:+V/+O/X!G0I_L?*SKEQ?AV>1D/&0@-1.'
M5+]VHU"6F@/6JWL3! 9T7H&WP?.%=HXJMCT.0/"+8)"^YFRYN+D'D2RWAIV*
MA6!2J'V. SW-1:%CK8$.?<JM?<G'A:^6<A'VQDOME<7]<@E,?'3X,->&LP(+
M!/V9@P6#_P\?*-X-&T0IO9!TH8DF1G1SZ%CY7V1:/CI)UND[Z&]=W["_>FZX
M13VB@C5. )T06,FS$[0](,!6_<#R:C]'&^"B4Z2?5RJ:2E:"KT+!?&HEQCE
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M5\'B2-%C=DT4QW"?U\HX;"':C#XZ^5 #QFE]59[6&:(CZ(PPV5&&KHJKW_V
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M&:LXCGZ.":N(JE)2SO&/HH>PHTVFN096:(/9DJO68+R$[BN8WAHV3H+UL@8
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M>\XE7(FJKEU:_7HE^NW+UH;!U'40F'U\68V%?<+U&HI,9E# $BJ$!&,7O4\
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MP0 \H1F#EMD@>YGMW^Z^&?_M>E/;\/V;#TA:$S@H:(4-#BV7H=&6:2)N](+
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M4T[#@585V_3ZJ_4]]886IZHIH.&4P"!!XV?G'_6E"V-OO<'#J7(V\+!*H?<
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MAO45-?;7KFT]P0T,OCN8:0^:B&'L$*@,S> A, R,".([==V-![4,Q0./BU&
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M%7[Q/T>908S247SNA+I<M/+P2'2 ?GJ!SLH&>V0@F[9P;3205?JK&C$(_\X
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M #A,,RW#@5_=G3" K9[()_8:2TGJM;)Z\U:0"CYZ1W60C0 DM;/Y 5A!Y!.
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MCOFLI_[>,->1&&;+:K=^U:(D[6-#PIX"24FM[*;HM?XAN\X4S4]T:/,BW2^
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MG?IC]&73+_SGM&M__#N447OU&H0^[JK0&-U6TOF48AR"3NUWOE!QU!SCN1G
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MO?T>%=W"F@V%MK?<>S(4TIV>YZ?_1,K1]NS==N(P:#1CG8TD53?>?3[GMKK
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M-/=R>(IO*'85!-$JT?;,#OZZ]Q%ZP"K'U YG&(CO>#^ZBE:R??L%/P]R]E7
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ML^W27L^].Q>?X3XK5[P&+8 BE)B":XC10&[=\PDE#ORGX=M>%-RMUH[WB5!
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M@(+;4B#4QI]Z/*R+#R%1!&&\E@1ED MCO3OP.:3LOR\=;GNZN,)##*,3/QW
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M=P)4YJG9UGH/RU4S,3S&&Z"-.U"\."6VI0<W]U0<C:L"30R2@FWESY@%Z#9
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M">$]Q> 1[<S=HJ&W"F";]5QK6,^)-MYTVSFC7@"I>CQTK/UPY>KC<&6O]C,
MZI2<*%H5SV3J,5=MSZUH/73Z^,-%FR'ERJ;BUK'A3;P 57MX:,\ U!(C]*9,
M\&H9=+FU8#-BQ3^L6$F.0<4I< 6A9L4:DJ1."J&3JDUI[-OSW:XU'IWPW\#I
MDJP,- LXP>ZX%;\I194LSTIZ.I86DJEAS&I'^>_![S/3_ANXCMK(>(ZOH!63
MG 5_V7> N]ZL!:K#4:$TB<AX,Y=)% :MJ2>'[QR'#[']W+P?B^_D#?5ZS,;B
MQKB7HKA8JYU+VI52?5[Z'@S_3+U^]UCY5GH=%W-$M%I(2%Q!YU.T4^N-<>=[
M\/OS]7JHN'Y6KUL)&IOD]$I.QU*4;%1C=4./? ^V?X%>#Q7?&5^#,[3Z<-CZ
MSYPY<NS)8JUA#0#'ZM@4/JJF1%_O5KKQ5B4RK7X/?^XB H0="6\4Y[VJ>UIN
MZT-I/]O:Y+VVJ3-/AII0Y63'@M188X ;#\Q82^I3>C/BYJ)!2VRVU= J@;-3
MW>V^=FRN=ZL<^=*2N./U33?!AILFLK4B'<G@S8"L$T$_'TO*H=4/X<3&5U05
M7574F_VI_&Q""DT=K3_P6/MGT5#6^9YLJ]:;=[PX!\"8IVU5JJ>E1]L:<GI^
MWU,_4!N^+UOI7P8"VX!65LU9JH]6&60CX]C^: 4#.I?(S/IUM:EG2$\T,$"Z
M=OB66M^"P9D9W@T(RTVJEQY=2]T6".2F.@@"@;RP5.@L$-[8@IKQ90<Z/@"H
M]-(3AQZ< J_6YD7VJO.82?N!6(CIXGA6&\Z+3.C,RSUP=-%#S^W4?(.T]P0P
M>>'!M@=#[[;]Z[J=7-&Q7%&=3H+",U$U,:])B;FCATZ7W6F+U W0\'4;EBB)
MC.S8M?7%';?K7[5;WDL8H )&55(O%*/U@9!E&YUAZ.*L4.Z6#\W&\=>VG(Q<
M;,NW0^\'?B/I-'IJ0\OH!;*']=0VWZU4[FY1'XQR1'R'<NN+L*J-S*#->%:I
M1>I-@TZ#)H^KIA\Z^_14&^\#/Q&_&/S;H;<) >*[(<#]P7]5BYNK)*=@Y7.Z
MYU9&.,958W(VV2&GS:?!#7%[FM *+'FYP)*W%=C3QR"&T5A5TUG+R\V*#,<G
M(C$I3>5CJ?[36#TN]K_T(+][A/N7[.!&&^)7-?-@LSVKJ7F#H@89;E@5V5DW
M"LA.5(;H--M%SA]Z6J9;+_A%/G0V)M0-5BZG]K=*8RP7^0EBO7AW80^+3=N&
MNB,KNF;U=]M6$"P9P?Q.E\"%29%SFHVQ:5.A6YZYM&W%N:G>:>&>P(A==7?]
M=MQ[-2C!?-_@W&F/Y'B1:@\5QQI'.Z$SM*%N4+)?K[';<^0&]1H$OCD6$S7#
MWE[=0LP3_ACCFEXSC3=M.F66*[5XO1=>HQ,2,3]8E"?P'6?E? __O:$W"<(7
M9SG"X'L1A*\O;@&-F5TVY-J@$--]JJ&6=&E8S(6OT4R8H4'$40QWT1&*AT/O
M5J]Q@=/*.O9A6P;;8!R256:V&/CS3A8WA)@;7F_@G(_X>G+?JE+CT!5,3@=S
MHR?V71$P9I1C .?VN;OK]R_UE&*;(X;>ZD12&8W0+E56=H!+*VNL.Y-H2^RK
MHSB7<6/I=JDZ[<AL:+%^LC/(T<G=S=>]\_8C6E%0U81;MCW@HFFA<XG2&LH4
M0E5> PK0)C)T])A@^_>K*'[QX^WWZ_T*;:4RGH[XH>X'G8"3$D+:ZX66W=<0
M8AN;'Z7$G;!Q]RU*=\3&D)B)F6AB1.!:J:1,\WFL,V^&-C1Z/&S<>)O#UO]%
M26U^:@'''6BCG7PV_(=5S<V)RN=+SNB>!YSC?B,W4P;(N5#3]B*="QW.HF:B
MM&Y1D[N:L2H9EJT@AVJ]@.L='E9WC6>^FY;45$UV M3;\-4]UB]YZ,R-ABHV
M!35'$%F"ZV8\'I2&X3-P*+.^Q\*=$XBV/+QN7>I<5=P]N']]^O,N8<[E3S\%
MN-733R#N/MKC,&2ZK?8X7<7*R2[\PJ)[/<AIR(T=9?)4.2=4CCAL%6PO PP\
MJ+:33)II*5X_=+F$-ZISCS/^.@WTU'!/#?=I&BXB$;'E08H?BXQ;ZM@N2HX^
MT]D2,1MI9,6@P]><,U21,8[A$8R(W8J#VT. WN*@ !0?"<E^5S+5)!("R4_R
MN!"0V$RN5),1+G1Z^$T.'IW<_>+7W9-G;K"@0^Z<.[#Y^UN6S9&^V:W:C,#I
M,9R>MZW9*&./0K>Z%,H:GF?9W'XF_=(#7P^&WGT=Y8[9)[Z5X4J,W$OB_GQD
M^7TP&]:#T)K;!\D^??D*S85[[>^(*T*8%9@A:+5T/UIDY6I0-#3JB:MOMD__
M76?40(?*MM03F8U4WVK'+7M>T&/%HLO8#6TZ;(7.:7PC>#\WP^^)@X1$1#:&
M:WNQU@U0A* +4]0F0(4Q/(QI4:$4[;K <YF@) ]M9Q& [^F3"GRE;<>?>I?-
MS8192M+E6"MA*.RXB-U_;?FC>N0=\]VJC;T)W],,)3#BHCUL!T/O;H:N1TD)
MR&QN7,CSG#SEY^(@7AEA]]]&^ U1\G5'2B57_1VV%16;E@%\UUB% ) ^91@I
M./L>R,I0RP8,(RRU&^SW"5]!Q"N. J\%ID4QTYQEV.2\3*8+H5N06G/[K;EO
M<7')Y.]7D9&\R2$MNV6HVSB((#?[AR[9!0&@15[<99,VA3Y<!ECH[+<:,'9.
MWFC/N^UDIJAE.!+3O<ZXTYLZ06AMRMG-"!=/^HYVA< OUA@$>9/*U'6U>F2I
M,,*ZNVR>3'>YEI[LXV,CR7=(O(&!9P>%QTH1[:N[*(9'KE=WIPK0KO>#4G3$
M+'>)+,L)HL5YPWJV+X2WA#9<?M!G=CK_"*?1(JAA ,7S96/=670=)-E-#!^G
MFJ0.NIG8**^FXE@ZM,F6#[']].P?"P.WC'IX46B7YS.,TLUA?.(TJDH-"V]5
M:6BE_>Y]D&\L[;&T0:AL0O%$F1-2%-Z?$;C[O8+=3Y?VS^Z 3$]E1WV52M^>
MD+4H"5D4Q=0$<<7WKFKP[?8@H^ADA!EHW"R13M1"*^Y[,]QM9GMFBM]J#>;D
M-H,/L#Z#X]T8B\V3>J%@1K*C2H15LJ$5^:]F_=VM.)Z0$GA-G'<BQ0S'^LEL
MLS@I!HH8AL9EV\GCB7LIM:M:=].*XIN^@:)$WAL !PUSP "!: )0#&FN\S3&
M-&*51G,+QL_S;D\?.9V!6 Q=_/S.;MX73_];Y7CW,GP[*;[MU3L/ '^CQAGU
MX]"L^M1F?%>S@.NFY,#E>VEGE< H@KYL+-,'.Q7$;]6[G3U57!HVTMJXZ'HB
MWS2#:"QAC44Q=$'8IYTJ_E9A\(<X='U"Z<L/.7^=/"4N39[N#GT<442ON<@1
M6NJM1(VLB=V19L?3'-!&XQY>B)M5-G2&(32B=I0#3U$*H2A=)176G,BKC.XF
M<-;%Z=)H-!]8K=#%AY\F%4^8'BZ7$0>1Z(=0QHKQI)=B.GD<LUTLF8IG6]UN
MZ-R<T#!_/Q:-WF2Y?%,PD=AVPSUC@'.]M*PLME/E4(&C8!LJ;_$. Y"<I8"R
MF!R![G2@A>[6L?" ZL@5W,I]>:%298.1K?7&0%*EN7PC\&F1;Y33&-T*^I@1
MNO3'6V;XO7RX7O6%L7_B.WE_/UE,8D3B?BM\[]LRI8T2]?DDK2=PT+:-:C$Z
M!WTU=  /VY:I^Z[:O(^#K:A/X]C8!AS(Z5PC$RUT.L,G!\]Q\,;K;MM^5.>=
M;M8V#- '2%-KZ*S5"=0[MN,6#04=O>D$:-/F2/-DXT*?_#@>FH;1EUKQ= '7
M*AE#SH@,GN@^6HCZ3E+=T5?_3%S>N%78ZY:Y[T-2WR?*-87M46(!4]I)N<LE
MH_CC.=P/S,&X1-RK+ZZ>F0G\K$^S8J8&*K(?HZI-.G0Q^P/UQ8UCQ WZXI[R
MZHJHH!;.S7/D16T"0O-.H+5J4['BK2CS<3?(- U1D(E^+Y4%E68C="9@4VEY
M8FKKX&5O;H_ATR6DG2/6:HN.&HA7Z*HDSS33-P],_ K631E%+A[OU-"!JX=B
MO?KV5>.;#P7+3BS1QCFSZW.@5,.;EI%*)J70N8W(3=C0[\<?=+E'P.L-_TG*
M[VF6?=*'+CZ^&OR)&Y87WP?\S$W17Q.LB%3K58:X4/&$?(DS!_/[%U$\*OJ9
M)_S?X7634NR2)9@SAX??RBH<;V6V'L%#/XDV#-M#1.-'.]M'$M-(3NRZJ9RN
M2<,\EC0;O9H92NFX[>'E#V T3G3O6@\YR=.[^;T$2J8\JNR<,RH?%IZ<&0V&
M-;,LRDXVQLJ@46SPH0NL0B\\=[$Y3^FYC?3 R#KMHU7,.\B/H6;U;)7(6AQ+
M,!;5HOLC[>'Z<7RE_)Q@SE."PB1!1WVW^*"3L8Q(6^;8J1]@TM2>%<)W)DV(
MH?\NO^NO1MZAY]-UXG9Y)#=J'-N=]]J.H>L3_>FUW,MK"17V-@F;:W07GQ2S
M,C&.^KC?D&M$0].J%A;:G'.(%,F]LF]7J8,ZD^W'(R5=$\$TP+-85G:X0>C4
M01AE\^;LI*Z736TZD@:U9LS&@3-@)6FD9U+IIVQ>RLR;=2C_&#,/93.7EXJ8
M7QB:8J:22A%.,]"]R8-S\S-E\V;LW*[2?DFTT)G&FG(OP[HB:V4+I;G:!&HX
MVT^'VF7[+.3=IZ_+UT0+=HEV:;+:F>CDK%#.4'9V,IR'KC(H]-#[-*WWF-BK
M@9$#7#A+V=,FX ""9E+JFCFVUM,+%#WE,PK=]M70>:@AAN YZCZ1>%F^6R,$
M7B0=F>7\"%%-#_/!M%AY@O!^N>I0X6^G3>B14A?-VBEUB:FQFBQ32D?4:A6_
M:=84K"F',K-[6&^R.XU[IK.HVY4]GV7+?@62:.3T:I.TN3$5M0M)L@M . L=
M/E0&%"JV; ^N;G8H*4)0K3X>L*FB7R^XTX$<NE.[/[DM%^I+1BMC7W.U15?=
M[9Y8]$W%=Y0!:I!ZL"?V@BV/-;_K!$I] !QYY'N:XN8LY>?JYS*>,KA(6<KA
MF=FPWTLUXH );V+H&(W6FVK/$.EZ*W9N5^$9\MY2+K^\J=@&Q\G-G@0(Y.W%
M>1?L' @O%(&=;P[;^:UN)*:JG!SH-1W'1F2C6<2:J4+JT:+2C^#I9A+T)HWO
M">GDS@:*-UI#[0[]'I!.:S.@[J$Y'Q28,5.K!&)L/F"LJ:KGLLE'BRW"@N97
MY'T"^2(@1[(U(J.E#0-G,VQ/=<4Q7:Z&SD&X P@?&@:)Y5G?RVZ)VXNWM=)J
M&]W1#8/C3#[/#_M1$@>:Y^"\-4]-PK=AZ +=<&:2=X,#@5:>MD<=GX/#P="O
MA,/A-Y!D(UE3N=D('<VY-E0X-<8[,AZE\0(.R"+9X6N]>>@,U0>,QM'I/B'R
M$==<KHJ523(3'W-"N\*1>%6E0?A<\_"[R6$$B1M+JH[*>#U=:\VT5G26DYOW
MKQ5Z!,H=GB^6C,T+TI01)CH['!-J+]E/R\EPM6Z^W=%:FQX4U-()G46B3M"V
M1$IL=EM699YG9KX?LJP?N6C?<(,"D4NS?O"U5,WPT0K<HDT%U"G Y6:*X:M
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MS69*&\I&00FM$Q:ZY?*OD_[H\@B7Q<K1YF\D^T7-T_J+,2S*@F]]<V;AK3:
MX_INVI%]:V#W@(-VFJ 4/7P=%WHY)GP3149FQQG9#C)*!S'D]O;H-_Z^*1>
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MV[]?P7OQX^WWZXITJINO8Q$F@F/XH(.WLJT4R(;.(=@I7_DP(;:@/4J)NVE
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MT;'8;"K=1(9)6]%P%NU^HE 33Z%^+*&FI)TEA:+F:?V%5\^BZ6TEFED<ZM4
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MM.S]B"Q=Y[TNVY>;1<4FEIJS5-_U'$TV,H[MCPX\'F3-3;"QP8P,?Z( 80
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MXP#/E(OC:0>,9^6_>%_UVW4][^;/]<Y=F/;>/DQ#O*]NV)7/UL7F)$4'N"D
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M':Z01VKM4Q36WV<P*9B&PR".L_;I_>DZ;+DH2>JP8#BYU!1#A4/>Y4.\/*2
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M>+$?,6X/9PKZ3<()\)P,?H_D%Z&@UG.*$LRH:@THGA;;A!9&YL+*O5!U*I:
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MHW ":A33S67R;YGYV-\_VWEN1*/O3O?/8.]CT_90Z>P&90GRAO:%4*4XIEY
M351KDG3%$.PWV-XI!W=5/1WZ<8^2P6#DT-?(OXA4F4G1"6+F)'22D@8[0/N6
M]DA&^'LM=?4NL2?AF/E6-:.G[*\*,?Z9Z*RI9LA)K(A!FWIKV/7HINV)-O!
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M3039V6TL]#5>LZNQ494<*N[%6V\-W29*AT<7L<F7M_!#.RX+YFLQ\FT&POB
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MEQ!FC 6#%!X7K-%>PQ03\C5($LKNOR58+EV! !=?*4I*D<*1BCTX-@*W*^<
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MF#JJJDB/MAMJ):R"*(R6_3CS5JY^*Q)1E$N7ROE9**DVN)8WKV0J(MP7=.K
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M?IA72"_O*7-#4BHEU5HXX:JM!PHLW.8$&_A(06 B%WI7PZ_[].M8?FV$#?Y
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M_B@A/0=+76<'&3A-Q)LB+>:\<B8HS$ZW>M@@2Z4_H9GC5-;@C8_9B>>8H%S
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MPZN=<07I^WN98^G>M9(.5"<E6V+'S>"Y:)J@J& :<=A9DX9:#+0@DT *^UP
MD#<@ST<6Q=V@X]C29+%7\VL65^>X$AR?&Z&;<#:ZW8J2J6A@YFTC1(D"**[D
M(0LE/>5_-B2]*7PI@/76RX,/6;;1:I]J78E72EX0EPOQYV%8<8:]0O-K#CV]
M /PKGR-'EE7'&(90R<M&^I5G9\W_I$W"D1+OV/_%=!EI)4["T;:"%6])-GA]
M<M=LR=7%*&JK6>4MTQ9;D$8CJ7-Z*H)A.C7BV;=;2Z20![<@'4+2@5M*Q *W
MK.K3M&2WFO1OQ2D*LA%:&+D+SO'3A^S.AJ$-%1L\I)N3\F(ES[UYYSD-GG,*
MEFI353EV^5TYAY?"+3*2XDM,OVU6[%[X/0Y,\2[22^2Z:;S46(5\ZE*@LYSC
MYR,UG#$>N/Z<E],3<31B14OF2T/A^&MQ*)PSR0N%.7TU%5Z507W,K!_?X60/
M#]FG7NLHTTQ6>54C]S)2@"?AV[@FQ,<$<<5!OR0H+:)#W\3PQY?'NFD'XJA*
ML*?%^,58,9)<S%R"R&E$NMF,F=@1E5Q(VD6T)/Y_9S45M3L/X(LC[R0SS$G>
M-6DJ4;2]6D39PJ%.VZ'(>E51)"E1AKNW&%[]H%:[R,K3]HQ+8"'EN+C)L@_B
M$FOF-BZ_8M/'6W!EIMN?TXIRT$O^4B!*I7%F?#+L$5+*P'')90X=S\,8RPP?
MVMD:BNP,U<2<O89I8]I-S!1?^C#,TKN2!Y0EMQ+-;1:T=V8:]<#7<=4I_Y)'
MFY<(I^.JKM%$GUPT_BQ[E*GSP^3'KH:PS40J1VL3=-_$6X4.T(J7F22HX0 P
M_]2%WYF?@U0Q"2JJALH/)1<0U!6MQ-K"@@UBFU(82X*N3HC$E/(Z/FT1,D\X
M"IK-M"I!?H557M;I!:+<4IQBKW>791].DIWX!IO?G;)\P@8%RGY?]!=JW#3R
M7@B9Z%5QKB*\JHJBND!+TIX0-V%NIKZQ/>L;DP(,<YQP?KG3S=4(;?GT$S5
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M6)W[46$KB-I"<P?%41?<[[2C&0D!1/D8.1^V$QM$R/H1V\5??GECW\NA8QE
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M[K[3QGM1<+ULN1FA<OPQ1&#9T#5!82A7WO?6Q=[6V<G]<OL4[:C+#)H.(P@
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M>BFI,,R)1H#8#[:4?8@%$X(V&"2%X5AXM.D>/ M7 2HH A[B;NWQ^0(A0HG
M;*PR,,I((*)9=G(VG=;2:KYAJ'J7*C!,&^NE&(LR7A;X/DQ^J_&9I,CLE-*G
MV(5 K]G S!P/G6O2(!JZQ@ $Q0*_Z$J!^T><,PKKSSANO\HYO]LHE@CO05?I
M(04(M+7&>X1O4#QB!JZFZ4Y/ 6J?1NC=O&,P^GZ!E8(\V.PBT,)P.RD'OP6
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M 57.#$6T.*M0'16PH@B&$>#ANF'^4'D]60U*:4(/(HJFMD"-TNE91,VD53X
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MF:6HU4L>:^;P8**)$;'IP=$;Y\P#/UE$.\#YI4,F.Y>H7A"@"OLS3FM\O61
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M59=3L<\0RYV.::VQQ"5=M8#0 ="QZ<"Y&_%']%&U=0CE:;S&#!PNB-K#C'3
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MZ( ,(.Z5A(8$JM7^?V/L"8+FZM4RJ=&LG^R+D;D'^G;';4SPH:J@XO=\@RY
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M@ZAZFNB8%(ZVRK!=HD\EYQ4,R6_.E; S\]8DXY\RZE7LU@5?K(R8>-[EQ?(
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M8'-I!GFH"(R\.E9'PK>YN5GVB/R=H&7X&!,P.=7BK?9-"W)%)],-#:#L8;E
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M,[T%4DQ+"J<\WPFU^&CC%),2RZISS^&K@'%55L[?#.&:8ZR<Z <RZ3< RM^
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M4CIM%YIE9]4*Q ^0 (=4PFZI?'1G2Q\K#B@^8<_L5=3D-$DU/;&H0KGYG+R
M/OUEW*.3B0,M;>8!;7)ERQ?'<O.VO,3_S*H2%N%'N@N<B9F"1U82(?AC2Q(8
M!_Z_I@JB35LNA-"I$BLZ>2AKB\7E@9ZU$9_B+Z1%MW52,8DY):RAOFSH-Q.8
M<K.3,Y6!7Z<[[VX *SN77DUA  DMPRY4C9YD@^Z72X-N:= ]H09=& .-.Q@N
M+_K,I.*"S4^.R;N04 ,ZL&N[K-#6U\^A/;.O.-2U^[XPRJ,YJ',SM"U=[=NF
MV:[^F#CE'P )V7!+8?/M'W\H4F_""\ER98D[+W@V@Q&E?=OLXS_$JB;7NUL>
M*]MRZHVB"_Z*<0URTZ*1UVP&>93L%B[+-B2O]B!@OT9I+,-9KDZ=3UC*NI,E
M-4< WXJNP^L?QH,BYX:$M"";G%NQ9WGGI(("N4N_-.B+)#F=CAG%@P.YA*9#
M'*VIFAIJ-YTYE:=GZN2:?'>"7F\DK*DY ^/#)SS0=[O;NHD?N/Z4AE\Z%,Z1
M*'^%^A(/KC3Y<WJ&/D5R;<W#\ E8C*'=1PIDMA-8,N3G;Y%B'!2IC=$J*H!:
MB<Z@RSD59DJ +]'F0_?2?DJ"0A',=)NJ8_?65^MFJS@ZE5MHH2O#,W(DWEU=
M(NP/;4?4*BC&<M+^ET5"<"1M5MGX5"(.X5C S:O4IW81=I7;;W6)8XO;9V35
MUKPBV1_<21=9L%J3=_=.7'3Z2M== W "E9K\'FP.HB*1OMZX#PV:$;4U'H61
M0AG<*8:90]D[-R"YF[%MF1O)3<LJO"IXP/] >T$GQXFJYLB\>["(' =_5FU6
MY:50@J$EH2<8Y?=DG.4&J2QYB'751,QK88['?;7SW@_48LA:R854CI6"LFKG
M)4:+6PNRHZG,&^E2<5L]K!";TNA5H$S72OL6O0-J[<D@9UZ-C PK76AK4B[9
M6GOC6ST'":5XG:I!!RF=F^WLMX7?/.$(IZLSCR/=3DWSU/DU?2:#YL:DI>&'
MX#V0O7@S<#?\;'1-/%,0I70\%::)<2SHB7(DK^$O<J5*+G +_YR!AU(72GXV
M7""5P)129R@N6K!D7 %<(=YO5C=DZ4+J:O'5(@C3&$C:HI3@8=- /+&,HKSY
M*RZH3DK02/J_25EA"H_!I4HJ&@43F6TB4*-4F/5 QM&&SI=&)K"6,%8GSMNZ
M@;EG%E:#\,!YQYOB1G%3^/::"(S"4;P+HK>@0_FC(X(!V20;'R=U55(U2G<U
M-_SMQJ9 9>CP>'*61S<*8A'<;7SO/**(R:2Z9RPJ9]=*CQ#'=3.W^&!EJ.\S
M]\RE]&NB/#DX;P_;L/.YYH$E5O(4_Y[HU$!Q$&!=(F I.V^S1?#HL4J_)T=,
M$#H2QR5/QU$I1THRH\W:M^KI1G1/>A82FQ>_^:A%[)2 TW8?RDVY=0?R["GB
M-SLT!02]U;@RVU'8PY/+ >=AX0W&CX8O1$=.X7+%_59JXM(,G,OK<^NRJWB9
M\?AA-VH1;N1!D=JX2#'W8+;TC:*Y*"N:KD5B-)ZZW?"B-^H3-+\+QR4#5.!I
M=!10KAK8\K5"!(=6;JN&J\WL$C<^V-1_$"(2\=QP/,FOAA\(OQ[=2WAOP')2
MA9G[/ :$!LH1=A>A]JU R'"S +#B 2Y6KY6!;AP<Y=TS<PAL?-C6L^6RMRF8
M/\6[W*YOO/&@>TK]7VKPFN6G/*%C7!1N#%_5JYKL!TVXNF1IP]'/M''+Y$>.
MO]G=3B*<&)8:R 2"*>]]!2<K08[,I^"1V5F8>*MUQT&31G.*7>Z;-?<48^Y,
M3=':[>4 .A!'A9UE,,N;U#H%W,A(4@J\+]EA9V="- K&%W2KK_?5Z@\5?8MN
M_S4GB<7J*T)4-/MG?SS1B?/&/^YZ'?_J3Z+-6RZ"_YM/]+_T?[DH1,^[WEP4
MJS_Y0Y@*N:M7W]*GM]^!R*98_>$/KU?_7A*M _UB<U,SA417;2OJGWL;>D5U
ME?_?1T8;GZCO-_^S6/VOYJKNFMK^G/Q3L?IAY_=V:W\9M_:_ORVY3/NFK)M=
MM7KS2KKC^8M)S\?QZGSK;Z2F3YBGHP<X.#WY:%_\V/@-NOJV;8:CO]]7!Q]V
MVUOZMH*@_1L)H^VE$'Y0^!K7X'_[\&3U UY;LJ3B\H]LW^(^>+>JJQC=OW^/
M^\&M":'EG6]RN9_:LNXH'\7B?%4.G?_&?W)S[;5>Q[^PP9N@WL[JE?_"T-G+
MO-H.;4,7SQ:)_G)=^B X^3>80?/:F_] P?I/MJ'&G_M#OZ7/_?'_VJ]]_\YO
M=#S"'\&F3H9!]TRNSN^^/_D_^C/QU2_>%"NZ]M:]F[JT+&/<?G3+!%SP,;)4
M\&(@.C:%'RF$[A#FOEIO_"7\#] M(>GT*\67I]_W=]5+%O657^#KAIB:7WWW
MT-62YS^C6G(&!N;>755K'P7,S3<R9]9 S53J0PGU("WP6D73.$5#PAE;T*GC
MBEE )"BT1)S<7*&ME 0[[51R$'%>]'G@K78\7:6__JD+,JC! .RO(+\YO/\H
M*2UYX,_.F07T\RFBD@%QQ4B9:A7,8MD Z@'4(:2?4XM($@8RJ%#ZK8[*L2U2
MFILOI,:)OB#?L4!BJSZ6:\\C[.PCAH&:M6R_\,""/?$G>[R1M=^#NXJZB_X'
MGF2?[5=+GVWILSWZ/EM<EH3**#D+FC:C 2KX>"BW_ET2EJC-C@ENH?A873I3
MTK6;.QS !CGT6&2%%(6ZC3@"II9FWDA*,B,S$<$*'&=/&5E1PT)!S^"6@8HK
M-Z'V,D6 /L'#V]S6Q4G[++$VPRF\G'69V&AVXA4!43?ALHOTX-.I!'Y5*,?M
M!-5DD'3F2'P@+%OZ)H#Q9/[+L^>%?U3NM@")>YI'EO%J,W24L1X@YJI[J:5G
M@YI^AR5HUAS9A1*Q?TGM</1O([RV*Q]8C\'&".FG7G9=<;-RXBT*&CWE"]M1
MWY3)]LB&_8K)&9_9,<.;A8!U9E[FAC>'-E?G855%WMXZ$RT$R,Z9)J8T1I6C
M6A!7Q.B8E9G+<R8QP>1LG<MDZ#EM0M8RM+\0WBWG\K5 6@DA< T65< N@0<-
M=_7(H'K?<-1&N7 Q'7>QG223H^"(E:40%XE9C<AOG<QJE);*41WP_I24,@(7
M.>%(V7RSPK1!R#\4 ?ZO<MZVEPN]SZ.C]YEQQ>1/:']OV_)&1C@M$.3\:#?B
MCP-@QRE0O.8S-\&[*)H>9(JF['AP)0V%/[!.Y6+2_U FK4,>2/3E3"1[5H N
M9FX4?:;5JYNRI5ZI2H'Y/#K.."[FN9CG/<WS)D1KE@M;0\;Y^;K%TA9+N[>E
M<4B(5KA$HU<.0$1.?5 HH/%,%.L[F4JCE$_4RA>C6XSN/8W.[07VB\Z0HL @
MY\%5N_-!Y,/+^-YB?<\7XWMTQD>)> 0,"!X94,][,X6^?&"FT%>U3JZ;:@TV
M5DX%PU IBEZ!>:OJE!3 5BEEU_$<I-N>R^%B@2U%H2@'FH"5.I[V&E$ /73'
M]N?@VW\(>!DMT.W+FVX ;R11O#!%BRUQ#5*\S"DV]0J*?=$AB&G-0U."BX,:
M L.C*O5#8]W_ BR/4,>)]L%QM%;092"0)\J%=2U,*F&$4J?:SW91>3YYJN@+
MZ!9NHQ3H94!/TRWQ;&PR4-X!LW#;V@KV5QCI,D[8G8A9^TO1I(A:P69?5H<N
M,@U,U]+#STI94R.NB"$^:S@@6"C;[5Y(/PY4H ;>7EK"*F!:F)<@=\8YK]3'
M'XT0YA*V/;Z3<^N4VG+K#K3/=(#L%IN>V$J/*F=8C.\)&!\\(K?!T@ .M&13
M?8^#VU8E\7]3>Z2I%Y-;3.Z>::HT-[B?D2M7J_;48ZN +*;U!$PKQ9QWK-(@
M,233:O&4!H5WE^7BOA8;>P\;,[G"H:E=3_!W[\V(>8 FET9N#$';8RSJ+N;V
M!,QMWW#N*4/WC]J EKKLX[,?UNRQ*C)2_3& #Z([&5IB=4OF]1FW?GFZI1]P
MERKN4\.N_WK!KB_8]??%KB^.>''$8[-CSJ59^;>[=R">2AOMA[;B 2H\*)-_
M3#878C6^<^ZM@62/.QQ$),QL8)AX]'[U8O6&R3WR/TRS:ZO8R'59[;%-T2J1
M;Y0'(M( EAQW0G58TJS>:XM"[HLAX?*M0E]4RH*:Z-QI:S#])BXNZKKX)*6L
M,D%"3,^XFS@V1H0HWL=T.T:,QT4)]/%E6W4?E+YWU(>_7_MOG=Q$VNG[$?+>
M/TI"[I_M]PXBV>B5UJN?(-#P PLT_.X7ZP_9>?N93W7OIF:@9)AM^?(6B,12
M*E/1@)DBR.@(!C)142 R R:7SNA1O4$=K)(YP$7#F$.EC.,>=DQ S1GJ7Z?;
MQX!$:5W(X^C':0,2?\^6,??T5_^0^V:C/6Y0_,&:_1Z+O&8<IX[U'U0HPVJD
M/U@W-KXK4;:W3&1F-N',.[<L@OK.0;N?OW7[LE/J1#=#*!OXE&X<2]]807L^
M:"">!H$>?>$Z,I,Q,UHH&Y@KMDS-Y/VC04Q.WZ\P\<!FF02Y=>L 9$ K>DA%
MC:*ZVVB@1C_>^Q<)/@VF%*I/$RU]7,9O#&44OR&'O"=:&Z.7Q>AWN[K*O8;G
M3;CEYFF=3^%<80HY6LGRNN&1<II[R\: I$T.%8'LQTM6VSDV%4V!@W'3Z>DY
M%J%C?@ ZHRBGN(TM,AZR&?S5CBB#/R ,6Z]=?^.<3C/F\BWL4,">GBY6&^2L
MSGV)>,A2+S;% ,9+*@>LLHO=#MAER,.]?OYA*<A5[&GHV?ME"SHUZ&05X5*/
M$/B>O(.5@<"[C''F6]%05]^H XADXNEHV^@ $N:9$PW*WL,CMBY]6Q,<V,)Z
M78BL!W2/@FB0X;N.:CMBU/M4+TA9!J'$U2DUVOLRW?(AO(MB8[L&.M*6BS:C
M,2<&&-%@*K>T2L)$R3&BOV;"L1^G=:SHB*&=!3$J,;;0)4P?)!46D< WL"E$
MOH%A_Y;Y&Z3 +8R[.QI"O#*J$;OQD+"EMTAG0K.Y7\BL79&_@+I,>IDBJHA$
MA@S [400K$F=W*0LR5VT.3%)#0HJ,('4H,]CLB8.F@)@BE_B P[R+27Z)Y#9
M1Q1HR-7,'GEVV?I_#HH,JO;E7']G-W6BX:AZBQ83321[;X?=S08OK&U!U82)
M%L.0M9@_[< 3D=$*O+1;FE&+I=_7TNE\RYCW*'DS$_W^DT:J1G7?*<GWEZ>:
MQX3.9:%R7%/0W.(69[X8\6+$]S-B)HB-.48"J^\V,B*C)EGZ)Q4APH()--3&
MG80(1)A^5Y*4J/?&N'6;EZ^Z*[]71!)6RRZM?%PA_WFT?TM1QCS>LE&6C7+_
M>;)IE7A32IA*06\Q2I2]::A#BMZ!=1>;3TZ#Z5_QV<@V*19F!91X$OD/#X9*
M'X6$90LL6^#^4VVAE+'9-ZSQU;'$+>6Y*=M1Y]-F40KU-\JDU\AYO;4.+9/F
M@II[L<3%$N\).Y3@ *4\[IQ45)7Q;H\FO?;%BOAB8I;IS>ZMBQVCIEW2O<7F
MWC_=D\XWA 0M.UI^>J=EX%N08T\-%?;%@@I;4&$+*FQQL1\PP!0-UU'O*>__
M6/G65.[UG@VOIP<D$Y7FT*<I+3]#:-J(-@B6X(:D<]!&(K$7UFT.%901L*3J
MT$Q-1-1VA$^ 1VC-;#JGGW70Z9V$: 1 F&+-)!WE1/C6[!B0G'$3%Y!!= T$
M8,;#P@_6MQ:Q8*"X:-WWU5N":K#ZCWOG=V2[!K1+J$15S=Y4O *+J39:$YF=
M$:#)B/V80>FD+Z[AKW^D+KP&B)M$#32#&DC$PH[^?UU1&3#$T,7JJFJY"PKF
MN97S>[0Y.;HVY%3JJT @/W.W7,MH.N'_F#88>J;>6DR09Z<'Y$+A?<LK!DIH
M4 #&K'K1="-JC3,72^@<KL%=Q:WNL %WG%TP #&JO!N@ZPR0)F42QM;PT5,'
MBF=O=$'D:4>%(ESL$QM[C"]^=.*;(;(U\Q8C0*VB_W*$^/2)&&\1OPQ!\YS1
M%/*N%=G L*![O.; B?$(^&9'V=P2:CR^4*--C%@@ACRI*&I9)EHP\4B :EHU
MYL==3%C,[_&9'P"!>K!1VNN=H42O&<[WLG42W0J<*[74M>.6F/^RGCUK=VI$
MF4\$Q+5_Y\^1QCM)<,SOTL@QO6J(GD5H%,5:.BU)58 5V-; ,1.O<C$JZ-H+
MR$T)W_M>CT41':^2LU&QC/P'';U[= Q\2RKY^#<8;ZZ [$N@=U!F?@;IWD@C
M?LM&*SB2)+@U]]&JH!R*P-*;KM]8""8Y3BWLUL0DZ5UV.5V,!2[X7/+;H+FI
MXQ3JD<:(F([KWIGK\P?)7)]GF:M.<Y2WSW)@9:&LIV$DU6 9;[,GK6RAL1#X
MMJF^W@?K&R\P DM&NC=661 UA6)4[.5.;2T&0FHED$P%^*Q/TP8SX>1?YD;3
MIQ'8&]FUB.B(J.]Q[_<CD](GH39T.72)"*,AQ3L#=I,NLR50I*>^+O<Z9U P
MT&+F$]?-?CC(D(&$/Z(QGC]T$8-ZR8+3X2]*VN<R5BP$OJIIZD@S1Y,F]RR\
MI2D(KBRIW$>3: @)>4#(,P%^[2'I;9#"O-.;*#4Y/YDC\)3;L;;*O<AJZO6)
MT<V$OI>+!;V.%+I-'Q58KR3"4+J>)IB_6"7J(/&4]R=M<QU35,L;F<@3=4.'
M04%1)ZK]58/C1"3L%,$\6G;;_1W6API*S"*U(YLLD?>^#2?$=U?UD=7RRKMY
M5/6Z)&7.N4ASD>Y;WHNE67QHQM#G/V.X;FIJ)!HP&5JJ-"^U)9G'I.H]/H1Z
MSKN*^3'3;Y@"8N=&5Y-)C+B<14JB$&:G\G#PT^LUYHMMM>+C<;LO01[:4[$+
M0QD)%B<=<O7Q&_D%<2_"='/BD$*,4E>KD0*)?XU^ISF];L+V.?059J%'DN-S
MA*;1W1?IZ$HB-&YX7H,XM(PHJ:!64%.?&J7['LQXR778%L)SHU*E#QX5L;?)
M2.NL>>D8FRQJ9F$H?5/9VYML4U 09H9AK&(1"DVF&/1()QB6U.'QI0[I-@U%
M\V2,J.HVK=/)X*WCZ$3-S.W\"2W'DZFJTP['B"2KOB-F((ZL"4^Z%)06H_VY
M1DL'\=&U@&1+)NG#@,LH8:^Z;XNQ+<;V08R-6;.RT .9LPT()T.1:79G3"1"
MOH.NSP5"UN] 1D&A:B85/KZXO_)E6QZZ6%;)2%89NTHJH9A"[U;_.!"MWRP0
MK06B]70A6O_DOO^1.7U)=A/?+S/[2H[H4\==LV%=V4@JM?,.!AP%I!7Q#@6T
MO5:AHKHA1B?_/E2=L"@P0&!+9=[>\C5Z'P^=#92B>.(]%L674.;QFO-3"66X
M#CHJ;5+5DO21B5LMX(;$M%FD8L3>SI&'-_&>1H/S/]-7UC[<005]HO;9NJ,K
M):CAMBCJ=[DB?2BM4OG#?\ .'4^3WV2D%2R#L^R<9>?\G)W#E=VJUBH?R, X
M-H?CUPEYJ58FG=64Z9']NL\CO$UO0G\U_%>N]FYE8!+QIMWXN#*T5^&'*C1S
M$C(AM-L2"&<FPX1'82HW&J=<I\/Z_@_>+3CN6<E#A<LFN-JR1].SXCNJ@6(;
M#T>GCT!9$ ]H@W:@00/3(#?GJ -F6+L>][Y?YJ >^[['=C3D0_4VU55'IM8Q
M557L9<]KKO%N 8=,"MC7.2NM-I"-5[T%\8ZVP9G;0M?6D 4:*:DOI^L(DT6*
M8G6@YPM44RF<^D@T-$%W3^#+6##ZHS0MIBY*RX3K1OZH*-+!V/YUU7.M.'1X
M!5&K'3;J7S\C(ISAH"L0"&"73;]L^@]2\6O],=CN3[&%C)->50I!H;JG^MW
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MS55S$+4]IB34462$X*#I,,T<1LGLD@*B%@WQVC-<JMB6#J"57:#X&(0&0_@
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M$U "8>[10'**<=@RL>*3?)P,Y!C=FHRSK4\,@)+N>0-_;' ^_'(C3@AD7YG
MI8;P-U>"&TRPE8>H7M58659"?K3'!M/SV>"I#MX87KOL$R%@-W.I\N_D*DH
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M'61\_;$"R4D=?%;-H>!)PM1X>5,2*)5I9^I38=U(0K1$H^#^(4A>>_5JLVG
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MA$#]Y[UTQ=!RV*@P":&.D_KG);V0Z9>CHV 22-Y$LA=9Q<Z',D[-@_)L^N^
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M);K<UP.1]OD71W*NJ%S*+03M*2-7A6^9C.0DUBD_B3QS7W&$I!,UZ].*'Z<
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M&Z(P8"H&88"S>K)K9VAZ)H(FAFXI?E%<R&/@U;1^A)Y0)W[X2.Z#JC ('"!
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M=A%<5GO V]4*TIOGWBJ>/W>(39MM'8V6^'5<K/X"K"#/U- >/+/X\0XQ<2N
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M];-S^MO%V>GY>Z?;H"@#H0F>MV]4B@XJ&Z[9&7:<Y%\KK!"  T&"-??&7$B
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MH<BX'BRPCI^XPL9ZX,M,SPQE%2DF0^)A;1\5]C&#62*TO1QGPDIAK)6C@"5
M,G/I.$@>ZJF)HQ,B^\2MS.T>+HO^2^4ZF&03*_QXR\@^):5$1<:*X9J-XR6L
M"F2'/[O%&D5DO5WQ5]Z8E\%HHX#<"4$>IUBQ.\' ^=1+U< W,BB0SI)C]B9@
MYHWAFQ&N8LI3Q)GHE".(WY!QVZE0_UZM/:NE/57?OC(!4ZMZ58!Y1WHT:R44
M5D6=4&F,3.C4_\HMTVG&8UZ"+>%QKO?&F\/IP+'K%)AY>2>BU[W_1)P ,@6@
MJ.!1GD7ZH^K(_866K).,6[036?_%$5]Y[A-/L+)_EW:OAG+'$,KPCUGG#G/X
MF-^_#I:"9EZP$!=A[&-MN0S,4,E7^0'!T\+[)R9\L]U+XGH7W'5,&B:^3VX4
MO.U@*M0J27IDTD?HRE_QEJKAI0!&QG;AP@-&*MUO@B7K_E$<)%_%NH /?61G
MABW$4@A8_)'V9VZC^&O3R3IZGA-CN0:R>Y#),/.25-0!]>JHFZ,5)D,.,M?4
M6XQ%(OG8 !IB,3Z;/2/ WO8&!MLH5C"-D(V%*'N-;\^\V_!RWB(3ZW+),SK4
M\%[M^0?A+/:T8F/7&ZTC.'WH_:D;L@%06"'\T/<6] QH%8G[SJ:16$9I()4;
MJN^'S UMI*F*7#-;8(+MQ71)-3C8&J)D%@@OPL^' 4 $%C*MV,08-O1VU\KW
M12C?=RP_BMF2*(DG2NEA+BE:,5<PRP_*K4E-S^]VI*-/]#1V6B_WTJ G V<5
MCQ]JTNQ9:BJ]KO/9\RCZ*JSOH"U0\ZU"KL/ .BQ\8&H*LAEELQI*]J2A&MAG
M$?TY"D)J#XK"">GJ!FP->)X!N6L4HM?[6ZKQ])DL:=#J#+INS\V>N@O_*O*=
MWT^_;S<SO5X#^/^&:/"Q<U@AY="J=</V=<,7L#><CWJ"7X"=P%S7@85-WI+,
M$^<88"[9D6-R&C(O![?_\T:Q?Z&YUP$/X>CP;&UC(%!-E3Q,:CW,-$)*=S,D
M[.2W"W3Q;[S)!/&;S;D@5#.&V*CC(8=L AR?4AP;0Q!8NPH2X'/5'74C4@EH
MRHP=%'D2"X)4+])K<_Z OBLV 4:7N>60!V(EQ%YE @E;W_-=W9A"526QZFRN
M0*8-P\55?3>[FY*F7?CPEE=SKI_C22A3++#R));E+Y9HH#*!1R9'P[NO,CX\
M4*HD^)6/)@$HK*@*4Y.8+?-=WY02LX40Q-9K:/QX8>S0P[JPIR[L^=["GI_4
M+JE#J ^T6'X/;SW)VS 5JPP7MOP:6P7O+BV%5@;115'+D5XT%U70HO64(34#
MTL0E9&P598!6(0XBU@]FET^P!8'5X5SAL*:<PJ2"X/> <-Z$SZ@PB,ED2L"H
M61PQ15&A(,/LKC>_ F,KO5Y(I<(BFOIS'F,94V.5R2D%7,R.A.H4E*' $)=,
M48B$"960"3VE<3D,IP&QQMX$=-!5&&DO*.K 5M4\;&*;)K#X)7/3J'F.7*HU
M6:7XYR-_BL.73H\HVA7F8H!+9/*:<VS,Q(RH,"7%9K;4M^MU9A'6(>3MX$:V
M=,08. U5)P&WF.M,I>5M8QJ0@DA/VBU>77JJ7#E8_PEK,N$%?S&O5;,"/6_]
MXV,?P-YX^N44>\Q(5G*66/Y3O/$OU%>)_U7XF!5F$LV#;+7<3OG%/MLA?PR9
M(]=,PFQ57WV.OT<A#[@F*FZ<#<\'6<6@XL@,]K5"NB8AK4/R&*FE25P.AK+'
MT3388KV6JFT-8H :> @_;N2R[Z0U&BHAXDLPOE@T8=4OJ#(MJX)!ZA=0XV0]
M)'43Z^$YHG8-HJHOI9+Y%+OV)G?<))/@6.LI+QOA$H<O)&H<.;PS/_5HS^G"
M=^"HCV-BJA<"3^0'"N84K5-A.)S4#%LU)<=P%H-;A]F-1#&GD;/.J0U3409/
M=XV%9/;KH^6EUT&L5B<-/);^IA !A1!HNJ>L482#>_$0P_ZV4D&%4.*)DVBU
MG"MJL86W +,B\#">D: 46E]M4L6U+KS3E79:LO%_$@'X%;::T5J;SGL4Z<*Z
MS8IY!A<G+W!_G.0.$ 5[VG@/&^R5FY=,V2EJ(KKA$CGSKF6X&/QU*58/P/L-
MA6"CV1'\7_79P=GGD\.7 3:55,T@A:JPZR*5(F*#6Q50V$IM)6IUUF'+"2UX
M*+'4'!/;8(+C)<=WSM4JX/E=1C[];Q.N,B8R7)Y7KN;0Q30:3.LX.BBL D7=
M48J18D#&F,:^N)R"Y"IC>(L($CI#/,<!#A)^PJLC(0%G6#&.=8W#W+D@7H]O
M@"4J\SJ]MHN)UX_+TXK'8)2NQ&+' +<6WKUH>:K;\#/U6++O>L@ZF;8X%-/Q
M%[B)"T7YJKZHO(K\7E'?HZ[X@N<-0KO<BQY)OV-)RV*4%BF4Z/6 1Q$E<$[G
MOG@2,P(F/360._&OZ!'R96+YPC#[:2;8H<OH /L;Q9ASUCQMM&Q39%;<&-'Q
MR!@G976JQ"RO!D/OKW]N=T;@G-/(X<5B%=(U&;BV:1;L2LG\9G: BK.=8R6?
M'QF\=ZQGR%9:H2!D(%_;%L:H6"W7F!4(CFE  \!RUS#V!ND-JP1%AKABI'J,
MC# -/5T7%H\CP*@]664T=-7%"15[X/D#Z4GOCM[)B%N\Y#FI'N?@Y-WYH:Z3
MQT'DJS'_*YW?F=MD N<^:B9AEW=HCB&Y@ZK6'JP1.D(!7P[.T 0.$>P:1]SQ
MKJI\@3D6[9+6K#:S8@%6I8.#A2E,?&L.D!RJ@.PV' 8/:DM>RD]_:I2EJ',S
MJ^S#TO('S5[>#<3PX[,M2P5$\Y'&:(GGZ!.L=;7<V@XA@BE5<O39V-B5,F!L
MIT4;_UDC!LV/F*@@B&^&._!M?U*#M[Y 0 SZX*=1B(T0*)IGK"$UU]#36@RS
MJ3EWS-9ZH#.(J-6CB1)>HD=F!^&2NJYXHQ$::<WX1S1O6%?0\612?U0QJ]"
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M4Y5SZ*!)EHV6A#^<T&@J,B+1G/T$ A4<G3%'_7LV -][,9+;)\XG<$7@SZJ
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M6P4$;B]QK[MMW -4BOT$I)@8CS5H?2\*=FL4K%&P5DK/@X+[2L#?JPGX_9J
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MZ$M29B\+07LU@M9L*T\#J8.M!8>#.$D=,T."P.WQ*(O_O@=IA5^3PZEN_]%
M.ZB!M@;:%ZKS7A+0;M+OZY"W7\M@C;M/@;O#;>$N %$$ +0-X-5\+&WA8WDL
M\@YKY*V1]X5JO9>$O \ VII"K<;;[\/;?KO;YR(HMSOHMBJ1AU6C#;T$@9,G
M)2G2SOMRL5^N83F)\Z'IG"9^^B,#H)XW[?K)NW-J+*VQM (:K<;2#);61&PU
MEGX?E@Z&P_Z L734<;=?TZ3Z7'$N(OB5'P'_"J3:U4% XN(>U1!80^#N%=%+
M@L#O">2._O,__^,_:CG<O1Q6&?_@/^ ?W%#3;_4Z6\>_$Z2 &4?<@M)0Q! (
M087 ;2.;_91A2?=7^J[&\?].P,GT8V_IKT!6$OFTNH.&Y0D'_(0/ ]KFOB#M
M8Y59#;U[I_)^(NB]'VD[K1IIJR%V^XBT6^M=S2!M11&V72-L[<O6FJTF'L6'
M'@UJXE&_)AXM%=::>'2K%JY;6[C5P(%]M'"W1L'/+"QG*UBO5RFSME.;M;59
M6ZNSEQXG:M<H6@VQVT<4W1)YMW&J?OGSC/Y/KL)>N,?.%??8:0@/A04,YWB9
MY.&HZRVB\&H#R.)W)B!)'F!K(#?17L*SVQ+?SQA>8WR-\;6R?:D8WZDQOBY#
M?#+0WQIO^":$_Y\HA=?WS,#^W0SB-=S6</N"]%X-MQFX[=9P6\/MD\'MUMC7
M-L$M^=&8&6,^F7-_MDJ\.7WG)#JZ\.:/B&QO!8K[-1374/P"=6(-Q1DHKBG;
M:B!^*!#W>L/. %1XRVT/W=%K6$ETA"J]U>^T$(G;K>FPW]M::>0&8O%W_D08
M7SI"^8( Y6O"<.YWU]2GPX>EEC]Y($6A\[;IO 6$#+^CXP\6(J@KXS&+-#)/
MT_)WX2]3V8%AW?A7X^[N56"-NQG<K0G;*B!R^PBR'=?MN_[6AD*?1.$LF.(\
M*T"K"S]-YXRSA(>KE#%L[F/E%D'4A]A;A=<1=L7_?G$LX,F@C$0LWSNCH^/6
MP%D#9ZW%?G+@_(Z.^<Z@EL':?WU<(+G3[8QZ%$CNN(/A<.OM\[K8&8&H/#:L
M.4O=TN PM@7Z %XX_1$!2=5S)<['CR<-\$_OX!%.O&60 E;F/D2OUCEY]^DS
M_I.N:?FYE>VNUQO2S<$R3^/\.<"Y;K)_>9KR)X+O!Z#U<,]E,%]IVVKMA5C^
ME'B]O4@S#W8N]BBM >M\''D#'/\H_FZM]_Y%X&\-MR] U;TLP!W54EA)*=Q'
MP-U:3_!)[$^#$I[R-4#;R&1LC6]+$/='%$UG40R0Z_Q&SC) \%LO_%K=?N :
M:FNH_3F4W(N"VFZKEL)*2N%FJ'U.P)0T[:\K+_9"\" ?%N:UW$$ +@*.L1_Z
MLX *C-?AF=;X+V57*]OK^X/X70-WK3)WK3)?%G"[M1164@KWT4?>6O/O1RRZ
MNH[F6.T,& 66P9<8=K'A' .V7(44GH8_TM<2:58*TZ2A0,RR1NC3WT]. (]"
M+YQ@WS FEODS-$$^!-_25>PC7N&'8J-82>3$N4(+!ZT5QM@4U^+[CS%@'NV0
M;ZV;N';(:US_.33JBV2D'=:,M'[-2%LJK#4C[58-[78-"Y6$A7TTM+?9]I^S
MES>EH[*&\2/,W\HV\-?6;VW]_AQJ[F5%M3JU%%92"O<1; =;*[4,;X(XHN@5
ME4I._47XG=B;JZP$-)UY-X#'3QF"&M0@7(-PK?Z>#H0?]=3[)\*(R]U:,'<A
MF/L/PEOJ3[R]#E+_"&XR\7]9QO[1;>PM8<M^I5?.^20K=82(.5\1'UZBD?$8
M8?$+@-MW=#INJ=&14=A:<Z:9<5OH79,*U,!=$?U8 _=]P+WOG#T_JV!6$<OY
M/]MM3"2Z0TWCTV[U6J-OB.;3K;$-$'2!T[MNT%IU>_Z1,<AM$V2V-636,%G#
M9)6UT8N'R7TGY/E9!7,_87)K3?X*)D\!PVZB"95]G,71MSM*XLHX%:PRB:-Y
M==OT:\BL(7/O--.+A\R:%:>:@EEUR&QW+<CL=-PM>Y9?KH-8YJ&0(TF8-YFO
M$N18_QB M)<-]/[@CV/B76=N]G:!=OWW$'X?)YCV!3P^"](T&:_BJ^MGXZK[
M!RP'SN7\KH16]A\_CL,U@6R-R'NF^%X\(M>T.=44S*HC<G=D(?+([6\9D8^3
MQ$_7$]49=G.WOP9\<S-/UD\AJVS4V*)P=VM'N(;=/=)N+QUV>ZW_V/MY9#^K
M;%8=>?NV+]SOM!AY>]M+L]+@SXPSG*>Q<TCJ =&"$#[E(62?)VE$@.QN .3G
MHK3KK07E>\>L/!*4\X]9CP&MT7G?-."+1^>:)Z>:@EE%:)8Y9NV6.Q@.;&@>
M*6C>6F;WBQ\O@I#KA[.<-VIT6<$['FW;.UZ;('Z&V+2IN.[6_G&-P'NDZ%Y4
M V^O9LNHIA3N)]QNC;S]8SFDMNX=LMV0+J'0>1?X5Q'\+5D&L8]-,^CZ/AE?
M>PVI-:36RNQ%0FH''Z?=?5,+8R6%<3^1=6O#N,_])(V#"0$K-?/\'F)X^=;#
M*JRU,\E:#_-EOUS#VA+G-/'3Q[<$K>56K[&VQMI:O;U(K.W66%ME8:PBUMKY
MW&'?8*T+Z+OE2BKP7+VX+&;\JQ_Z,:5&*7:LJIK?^1.;QN)YX79KM53ZJ=KJ
MJ01K:ZBMH;;*VNU%$IV/:J)SOR8Z+Q76FNA\J[9OK[9]JXP.%;9].Z2239RI
MTP+C=\L%$Y]G8'8Z'\$RA?]GLQG[P9\'2]]YMXIA36P)_]T+J;VOS?U]G>HV
MR^N5]F2E=2"IMF[W07^]K$!2S;M632FL/(J.[ B2ZH[?&HH"!D7A])Z.@%Q+
M/-<==NX+'CU9 \ VRP[U0TK>IH;;&F[W0]&]++@=U+YKE85Q/U%W:]6'%TM_
M$A 7.,HW$M&\C<)54H!<[?OU'P:YGP / 4O? HJ&X!57N1BQ!MH::/=3M[TL
MH!W60%ME8=Q/H-U:,>)S 6TFHESE.L0:9FN8W4_-]K)@]O]G[\V;5,>1/=#_
M;\3]#HXS<V]TWU?4> >J9SJ"Q>S[6O#BA</8!@S&!B\L]>F?)!L*"FH]4&6#
M(F9.%R#+4BKSEXM2*5S*+9A<&'3]2D7W-F'I[2;L3Q97?2]Z[-<[8UZI'?-F
MY-C+2=R]$G2;!7U*AE>$]1)55\^]FWM,AA/ZF"2P/L9(&# DO"E]S).8"P/)
MA4'7QS2]IX\9FOWV:[1<"^BCCRCDL@2F1=#LSN']FCK>?V,(];%'!8;$RA@K
MXQ#!X&TI8US2+9A<&$1E[)^$!\HX'B7WG>/=S2/1;ZMS[LKH:-[AE=*OA91S
M\/0"^&_>4%QX@AXH67B;]?P.^(P*.LPG+%QMCKKPM2)Z;GNO=$.53< Q&^\I
MI+P]1>^5<'T.!)-?S'B.?O?-)#CA&2OE,,'A;2EE7/@MF%P83J4<^[X*Z,.7
M#C+2::\YR<\*\^LN\O,KS^<AQ[ VQMH8XR#6QIXV9C 7!I(+@ZB-*9+EN3C0
MOK%H+,[^RYG1#$V#OQ5*A+HX\FW1ZA-7@+U(NX(ZJJ&.-. 02WYIFQ)4E+I!
MU"1KNG-^,X!Q4 '6;:6;A#L"ZT&P7_1UORW^?#A.?.$(UK-A0[C;TK,LYL)
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M%CU(<0K\TU=3>X&P71 L(2,M1L49]@[FA$J*.8>1N?E>K^ Y-'B&I'==2=9
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MS>"=0UY)EJ0I60K&JG!CU14[?AAIPHHTV%ZZ*0S"+A]V^3"$80C#$':=+I\
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M'DTK;60Z]52;CI! <,O)6K^1']EUV/1H6@G[*:<D5]:J'8FM*#G+R2W#'L$
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M(;),-E)&EI]&U)$8A>8+<T?2W.7,EX!R/);Y*PEO?%[$415L^J_K"E3DC27
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M=8B=B&\H7W"JU&V<-J1UO2F3&VL>RY74;IKJ !^!0QOOW%V,?NLT]'6" L:
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MMXP# 31W-F^9!C)CIM,*IU-"EVFML]%448@T5B*-"@]>^U4#K]H)6E(S[PA
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M)]X)9>+:SDPUG+ULZ)< .LKV:G&JNIF3]%,T,3?HUJ3=7XD,"PTF*G9L+>&
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M E^NPY?"YQ+HL0SR!?08\ 7X\CMZK/#FQ%S@"^ %^ +V6-;Y4OR,@A[+(%]
MCP%?@"^_$Q^CP*^\'%]^\R:"GY:__C41BC^AP16N$?E9Z<]-,/X&*/##":.9
MI,G/ O>/2!- "B %D/(>YN;](^7&I"(UBA7$Y(XH<%O*X\:@<T=RDF4*_*S"
MYQ&E I!RWTB1'2O^,+EZ^,^H4;KT':'%WQ>0M^:_T[(<K )+3.Y0E$ >;H<"
MMZ4E?I8'?T2: %)^ENU]1*GX6:;U$6D"2($SY?=S>3=,$\BC924VGF4 0'8
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M>PN]7!\\0/&Q]=E]5UZ#H(*@WH2@7K;Z[(,'=@*;[A2%0 $0\+MF+_3B75W
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M6R9,CEKJTS\4\406\^]^J<4CHP/&C0 %+GYQ:D*!W_)DKDT2$ J@ , "^IU
M*$ H@ ( "Q"*/Z[)>&0* "P %G"[\@]R_P +@ 50()5C!EB 4,!ID4IM BP
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M0"4S"/'B$U5(ZSD(? #D;ZHOX4,ACPF3.2&0&#'5T7VEV@E&;2]<B%<RBLY
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MVHB.)1.=7'91L&?;VW5N;&Y'X=H#O8@F_O(IZ4^'$Z!3H6CL-((^\DXJ^(Y
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M2C'KZ,0C5@1_+=>:-ZEA,Q_>BM%MOY(Q8N'U(!2G5D3R[6V(C\02#A,+*'"
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M+2"&T)_!&'[*_OGHW0U@EW>G[Y-? :;]SY$MS@%UP#1.Y_(EL 6T,6=-"+>
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M:O8(OF!08-T8BYJS3]SW;.ZF_H,;.O+ &?%NF62/"E45R%GF;"R5)L&_X#C
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MG7K)?93(=:T3V!S'\Z=D!E+3Y_P<F*.P3XZN9Q+1V59J_:$M*U.)LV5;Y8E
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MY76GRX_KP_7M*)>N1<?0\F ]T_-.;7*M;M==4I^&>,+'-Z$9MCQ8)7*[2O6
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ML8QD["*2C =  S4V:KI%O B0I7.BM+05@W %4:(,%0 + ; 0  L!L!  "Z=
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M\C<S('05!1.(CKF"0@LOM5-0PL%JC'5=IO8G<AV558P)#3)";C8]>PXE$%L
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M*Y(")4 % RH/IW@F548[]'P'G*L@Q^3M8P#?E]NEC)P<K<<]*E39LDPJT&M
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M6<@//#HG_M9 :Q9Y3X<"RE 4E-> KV! @-N!JV;RU6E*(MH3VC!WB?I?6-8
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MU&WB-S_O<^W6XK?IS.\-@3\,P9_MKX=Q_O>X\7_?+/=ZN5GVP]#A6AG<3T
MBTWPQ__W#:N*/PF-S'LSA.Q3+K=P^$P#:_H;SWW[)U"MSHE?GOZNC,%9I8"/
M,#5D/&L%*5L$QX(5!-6,GB_S$Y3U;1#I?<'W#H@$"FD0>[Y([!>)?1\2RU1>
MI^.JOH\013KBQ O\.B\';"U?-/=Z:.YOA5G\:^EQF+7&"\KY\5^BB-!L]MY
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ML]M(+L*,_L#OH3\#,>/(IJ_U _.H2;:(6!>7\UVS=AD.[K@6:-+30I%7"*X
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M*-APPX45;0!(OB\P7B_AO TP$K%.::1/LO>E5KQS'QVWQA(_;G_[)Y:YX2]
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MMCG4+JQW\DPS2Y"NQ]W&+UX0TP0\EDR+"4))XO 7%Z>Q8#/%C<>"-\8\ *#
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MH0_O;OO]S'01$ []'-]_*;1SFT5"BMV'2COV.9P@=-T;]FKHI+#<R6V3Y8G
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M1EA04V"MD%7<'\ QZO< :,5[OJ>C^U7*CJ-<.LTE1_/<MW]F(*%#YHAYFEL
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M+<(\LN-C$0;+? _D_-X (E;SU58TQL5N3K/Q"X5.YB92NBMWMM5J]29RWR^
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M!([=;C>U\OW39^] J84\6J?GD4:6(@557+ IBM='D%(7GUAYB 9.V=E.<9T
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MED.5JF13S5[3,*L@E,_GADZ_-O8AS-#7<VCNK1<_-?=P.3SP8TKA"[A#Y_"
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MSO3?;K$/4C4.:UH+*=H)Z!GT9O%8?<3,*-"-JI2N=<NKE==_)')N5-9WT=5
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M9+^TQ DI-*30X%/H@T/T[Z30;Q&8MBYX[%M[^;4N==M]A=[?%Z@Z#+!5%##
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MJ_,TPJ;X]]V\CD>?X[%+5\H]10Z>YT,G61,A/EQN<7^/H L[/^U"%F1^O%E
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MWY W!"!" 2=@DG*!F?YQGR%#+-D<^0KS2PHOFP*4;"L.HM_4(<I6EMS0(1%
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M.?K0%G<<BBJBRZR(R+Z+>7[;T''7@F+I $3=UPAO4H8PW&FZ@/>W$6692BW
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M8%'B.1&[$;9.4DW4 3?_Y;")A@34_W8;V3>+XKR5NONJB:YE"EFY-$@(5I=
MAW2Y7QZTOT:NQZ#V@^!)W?OEJFVW&OL#M=OD=:NUKU0"[<U,!K#(1+'"^%;*
MQ<]9\G,V>?M$EO>$BJ._G/-IH^3]GB<QXC+3PFJ&TR!36T\8,#=(TBH\.+\1
M>(@8EZ"-#X7+>5@852W#EP)M=9-$YBGP7!.E*7/*<12O,5>DD:F7%"3Z(9.B
M%8Y-,E7[XPS)]1OT5DX.RF1+:S1_)UAEP3F#+#H$!:#HE@A(:QIRGY#=E-D>
MECC-$M-K>'(WS>0@:L5),I)3>54KP.\:_K8,6RENHAIAXOTBO06QQ,IHEE"
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MLV7;$"D'V]-P<FWD-5AY,^40C3?<$H6;:P_8QRG46D&*YF4*&CC7!YP.7*!
MSL'^0@X,N.\QL2<G@.>"91K/LK+E96\FA5R\/T2T%/!L18 "!1=I3Q6H"+M[
M7K5K ^::*4!!6+"D GE=@$H,OA-F72%9IY("PRHH+]*EU<<;Z>9MJ&4?Q4,)
ML-4[A1ZX&*<R89X$5B#86XP@^W=4M&#N>>Y3Q;*=Q-(5+"?,$.05:$C#-<%%
M'"8K O9X"NI"6NRI/KB+*^A[N/9S]@)^"$)58$-MZ;O:2M!/65RH$[J* S&J
M2D804[J"]JP&>N%L=_!5]@N]$4A?UU]([VSZ?:YX;&S2I#!=MKCEJB4X*YH<
M<([\^33&I[7/-F]:"'IDEHQ0 14LT[9/.ERUL=,L=;21QTJS 5H2J$:Y/6-^
M_2%0XH$BCZ^3[*4YMESVG.H08! M6:)BPZR6 H5P+#F>!'3.7QSL7) Y"-SK
M+1\U47K0[RZMN;I$,PR*D#*#P([('^2C%Y8&! G/EN8F^6SM]+I.=I OHX5D
M:]S+EM:%''I0$<+/R67VA]BL'W@/TH0!7I @2^R6&9J0%TYRGT72/-E3J25;
M\292M6?Z--8$[C[YF$Y]JJ+T78QTX++<)"/APU32SF1J(N=KBW)2$,R>-K]9
M1E(<5MF(4\-#*TM9P+EB-[M@@5=%/Z9.A(Q/W;-"+V?G($#'_[WF#IA'B5]2
M?:&Q69>3J"!T-^GLG&U-B?=4CV_<V.T>L_4Y#VNIISDAF"C88W$F/>?(Z.PF
ME=1&)? J=>:,D4UODK%;7S2:X[\;S?%;+GL[R%@#/H3K!LSWQ&\(OL=P!18=
MB@12]=A&JV)J0X_,,SC07/BQWOI'(L">?E?0%#/)NYGDZI'<@L7Q44WR,FQ_
M.I78C,%5*\ 4_X$Y)>B,OXSC OOEP @,YGN  Z_MO'C-!Q_9CJ!I6]!0F$40
M8H;Y",,\YT[KJ5*NRZAB05T.\OVD-_+T5I:) ,.@U>*FR6.]DHH4F9:6KRXK
M_3GTM4D$.-'.[(AAPN31MFS\KAS?<RHJ,@F\KX>NPBO!:U#L@V)ANYJSK:I&
M-FS-/DTS(N(V&Y'T9BKW>%1OSG+C7G5,R.87"N_?%;$*K5JE@PB8R%74@COH
ME\:;=A:>?_I;6?Y4O"H8+T)6./!:,<9]<<\MA0_]"J<@!;R<XCJ4[4RZV@"1
MNJ_&H2?#AR!ZL)]->Z#17QCVAYUEWRIVP&L7L_$WPS%7-\N+PEBJ*RFMK2+B
M9J7G'7.!X?"L#QYNXHF$/-A2*\BVAYY]6/ !>S<)O_%)BYT(;Y;N&4QGIEB3
M]QO,L$0@[,ZF/5O&H$MZ^C_VKBQE[][%V( ;@0H#PQY@!57:32LVGW=J/O$I
M02K%32W#(<NJDQ+ZXW22\_YF/E\>7'O%(0O*)SN#&CJN@AV4NA^"DUPQ5]TI
M5[%U5F"0:3>C=K#N?"RUY#939/[&5<'IA?%3]1!6'?<NU]]:]1"/3/7P?5'7
M<&M$\)LK&&+[0H[=9K9CN*H,5N2@I7$=F2QP:(K=;+"OYCZ_0=+KG1K2&R[[
M).OGJ_GR1F8PCH/>$IEZ2%+'U^RB7# \P4?W5S#,ZG9S571X%$D.VK7^"F^L
MQ)NM\UBE=KX,MF&J%O"J6]4*@KE,P[0[>;+0\VT5P[]STNU7#$=V-EU+=7,-
ME!PO,Y98Q4#(*]\J)\VZ?$94Y]Q:;:0EKT?F*TTC#9.QQ/MC_EW)\"Y:KR;1
MN/6J%+=>/<FN?V^]NNTM2J)C@J92.#^93E-\DJ!HGI*F8SXYP844T(R3*7'4
M-7,SZE"Z5K QMK*84&)2D =#NP7T:OKER.70RN:+*:W$2>EAHXE5TBVST^)Q
M/OERY*RT*E?E02/)ZCA6;\PV;<4OP"ZD1\]<<4VZ8 ]&.;6Q1.5<SQ2+HB'S
MQ/$SDY,&BZWM(5@'MRD7.DPJWPKZE1X]TS'8>JW)C:L<V5"6:Z>A]C*F!T;2
M1_.L+)+S"E)'T,H0FV^L\L9>.]ZI+J1=;5PFJ-+4XA!%S;7X(D>DVW#DT3S)
M255O25K?9Y&,V4OFBDHZ.X;]2H_FZ<^4%>ZTRAE.-RJ3\;*8[&5<V /U:)[C
MKF2:77J#<+B2$HI\N8Y:E,>GCN>9\1&XF7)-%;*4N3*KBJ4)$-?J:)[ULDL:
MK3EN<7H7H0IL<N;/+0BI=S1/NTJ7S>(D1:(%RJ_.46G954TX\FB>1DV>*AJ_
M]E%\DW0EM-S2$.ED7]7!L.L@:YF><PVA7L"5^=Q:EB!@Q-$\%V2Y)SLEHL N
M!SQFX?U:LIQO@9%';V=7W8%$K\#:70/I5:>Y[JB]88"/</1VS,PTLS*M@;"Y
M.UX8@F],.+T%1AZM?3KIE'O]>HMA&[4Z.S!UI]XJP)'8T4/%;J_*KS+II:J4
MN@;GM',+WI1YZOCU2S3'$_G&0&"12:O>;:]6UDCRP,BCU^=Z\Q'']NPLVJ%K
M.I_CQVQ#@\\\?KVM>!QCS8HF5ZAOT'Z%:BO-H0R\HJ.1OF\F"8]!BVC%R&<+
M1K/DV LX\NCUJ8Z,LH6T!ZA#*1Q#B15I7FZ!D<>O3]JRD[22K0$KT#FJB'::
M,D, -8(>OY_K;H1\H4Q+ZI+CNURC4)[D, 8./=K\UMP4VVLIU^*6;".KCA"L
MBVT\./1H][WU8J#IQL1@]3K10<JFPU6P8.CQ9"6Q*XS&AIM'"W*YO1&]'J%M
MP&2QX\G.V.QXB!(-2Q5<*D.@0FV6'C)PZ-%D/1.9YI%N6V%U%NE2K5&WW!D%
M0X\FNRXO/8&K#OL<4FRT1O6V6DZE/#CT>++3/&Y0J-D?JHUINJ%TY+6<T\%C
MB1.,E:^-2()I<!S9Z29'U9+,Y5(M./1HLEB#Z%;DI"ZAKL:PP!NC2YV^#(<>
M3;8[];3\&/"Q6NB4'%-U9U2R$ P]GFS?RMG%324S95V>4/T>@==G73"#$TV8
MR\QR2@FV-605LS\@+<=.4S4&#CV:[%*2NG2FE!RSTJ2TH)WBV/3*,AQZK"I3
M3ETI4Z3&55+E<EDS<;57"IYZ/-D-PLYP.]>D55*I;7((-9>F"S#9$_I*H55
MU(+1X]P\.>3*J%9I2S(<>B0T>39;I%)>A>20J3PL3?%46Y\$3SV>0:%L3HI=
MJ\>CRDH>=OJE.FDU !^<T%GI1KK;'BT<E>U(?70X1%;4:-F"0X^,0$-H8;*+
MYPF57(RXW 9;KU6.@4./K/^(E#B4UEM+E%0I?SA8H3.\%$S@:%WI?DK5ZRLW
MRW;R[;4^FI>F7EV&0X_797;)-DE9DS4K];UJ$RC""4Z"L2>4(5!JI4)52V?9
M?F$E.%;36H@3!@X]FL& KE2(=*\[4QO)LBKF>=NIBL%3CV=0KJ9L%Y$K&HOX
M;*_"H4UD!=V:$_JPC_? FB;\1NW8RV4MM4C1%2L8>L2(7,'')SUO2JNZ.,$8
MW!C5N+8,AQXQHM_Q>1Y'<A9*2E7&=$?+;JT9//5XLO45H5!&67=0O&(@VMR4
M-F56!L'L\62]S4SE"Z5IFVLL)FFYAE47&308>C393I7K*LLYQJFX6!8F962>
ML0$)\!/*DVF8&Z51]2@6;%<[WZGU<,'VX-#CR?(+MB3IW(ID$2)=70W+_L0#
M3A..'T]V/B@O#$1/^FK!ZH\G,[0AT9P,AQY-EFX*=5M9BSZ75>R"CSG>5.>"
MIQ[K(W&4U1C$I5!)(O/Y>5IDQOU@Z--D032XQ9()[ZJ_V=M\U[/\ QW.\4M$
MB7]/D%_Z=&R<V;WJJ5:S*$Q:M=7,4_LXV>%J*&;E"_*Y3K7>P^:>ZU1KMF/D
MVRFGPG-Z36SF2QKPE?$HG(88)LM"LC*P3$ZH]!U%Z)/=[,J[SJG6F&&>3[7:
M8Z>6D9M3%BVT^D6A/ !A2"H*IUI;2W&1](@.B^+-66N0K-F=+-&ZS5.M9SG%
M^DH]]>U3K!  *,02@$^$H  G;K)'N<H:3+<Q?9IL8XM_Q1B3B$DD,<5T7FPV
M$+2B($S%8%JV4+^!,Q;=G)UWV8VNH-*B53<F?ITJE_YZ<N<E'M55#[W^7):Z
MI=(8.E\6NZ7^NL.Z&L5,^5J^,60 HQ'8^V_3;8_#[D[!?N7<ZT]CFJM;])[8
MFG5SIIOG\$7?<M340-4Q>0L&<AJC8L^:VQ\Z\GH[]OP4LLP.0 =HU"W;AVL+
M 6: N:Y9CXF2+3G??3?EA,QD(0R39"W ,OT77 LG& V9D"AJL"09.X?VQX/L
MV$R.%KWQ#9R*<O*F4NQ(),L)X[:CY_O]UFH!G. /@D5"Y*EHF><[X9I;,K_N
MLF:9.N:GV,J2DM?RE,IW1&!^<?KQ1![F88N3]X[K)^>)P&^:(ZYN6]O@$5UW
M*5LJ/MM0\_Z89FWW'7= PR/%.Y,5K8!X>_7ES!'Q]]_KA)7:)Z;'<)[ WN5Q
M1NX2P9#R4G.L.BVJI);NKC-%!R^H3/2-*$X+E5:N0)=5A.Y)0X&A5FGQ1@+<
MG\,[MV1*\7:VE4T:;H'M9]-9JE.I=?@.T+8X=LJ4OAG)?BJ"O7>NN+HYU49*
M:2A67);U&9G*"K;07&D@5 T8Y97KFQ!$'#Q>A.8+^$L,T!!:>'_G1!#[#K1.
MM#'IY;NMOL(B58L?VYU*IJDS5T'KE (/X@"M,_+I],]Z#^^XGS0YF3F'R/(R
M&"\'@*W3:'D4\"^[!$,T9%_,B)54DEBPJE2KJOW1BM<1_P9"\EY_,=4R1J7&
M=1IR<U J]V9+'J@&(OE 4??G3MPBX]R2*R&4F/&:ZHH.)_0F<YU%V,VH"SM@
MI=_O2FSOBWR3*W$[''%U-X*S<SB9R3 4JPO9-D5F"@77>>O0PZ$+418,%]K7
M%T[$!WP(?5'2R[-Q=LI62#H_'$BCR2#;BGV(=_H0?\/)^+@+\4ZG0'$DG9]E
M,[7VHJ>T4(%ERY.&Q_I)6GY-L^_A%!!;*;X]G(*.R19K-*\):I8:5;CAJ"HW
MWZZA!X(--/P+P0YZ2]2#;E>-Z=XRNV9_9NI[\R^$>W:Z8.E+2EE&:EE4MZ>C
M"5LKC@<2$%_',X\U\W->Z7INX0_E@6@XAC.<["+%Y;#++LTTSA;<^; X#WI9
MXM%/,_T0SKDESU!*\;XVU)$)5] &0JU<X]$5!1$1B,=3_'1^S_"N>>+JON&@
MMS#T3;K30Z4&-JUS*&/IN/<&/-CG/, -;67RS4%=0Y<B4J$R!9/.*-?I^2(9
MA_[?+1S*_*0'^%8)ZFHH-Y\2Z&B>?AZ,-RU#;AA-U:V5,+HZKW;;Y#5\A-T4
M;<=R YO0@$TENS/!.&D$3J-$2HW1@J]6ZRRY]"?>8)S:X'D(/O+A M5U4&]>
MYZN[0[VA&2Y5[13;9=2=.6R:;6P,F[I9#\.7J4U:3[=(5O)7U;6>G51]B'I#
M70GTYMV,=/N@-YVB;&4WR'+$%FA\OJJ[7+[#W&P2<S05AJU5CD!0G4";2QQ7
M)JD*]&4^<++WTGTR8NL7A9N %E$P_>XL1W&"-\HR>-%OVDGFRS<![VASSW43
ML%=H=IO=?%;C^AP[;W>-=*FVB4)MO4IM&N1D//14/-DD9OU^7BJMY&^^"1@S
MS-%-P,&H0"%#PF>X"J[JF\TDU5+L*##,D)!J2[NEJ&C'(4OEE*>B)CR_=<&;
M@!]$3R>W)UD)7M#+24*<%DU 1-W:J.@\[Y5:1X0"A)^XD,U.DVR/5VP&:,,5
MV/H :JL+II'1P!]_[6[^6VUU9K&%-*,*::&T&:4TVDH#6R ![;L KP1QB73)
M._UOHL5V@R;'3R=, [ PV]7!&/!(.X!N/HR3MVO=0\4-@7N#RR%[V+CAIT_M
M->%.P[VX)C+N03[E$(D/IA;^LU)L(-L:6-WO,$,#O@/QTU'B/T]I$3#Y+9&V
MV'@!D!W$Q=.$A2W]WOVP/U<();>%D8. :F((Q'8(7(<NG!>H=<?8@(ZU>^OV
M:5BX+&>R^QS(C /;M&ZI$BYN^Y0D\4CA_]BGR/9].^I<!,P.?413SQ@2Q_AU
MP??>3_M_.Y-WK'>F.!("OB3"=)=G"8LM"?!' OO9%,#01YK\V22(F0![3%(_
MG *Q&  Q('XV!; ?K@9B#H@5X?THPG\[%O20H^,-4W]9]V%I^#Y<'^HM[/'3
MNS\^>.>V(CTVM4E  !A#'O_[WW^/;XCY/TB0T^) W8U[?"T> 9$YI%%0MODD
MO^"/R>0-\<L1M>[#K;@Q)7-3TK2K*R)G6GW,#%=P.&_+X-RS%8Z<4_I9;_Q^
MW(][,+'W+#(QY[R/2+?@SOYTYR1:'/,3_%<A/ \7,\@W,DCLT_XH QW[M+%G
M$HM,S#FQ3QL[++>I:6[*HVU+NJ 88((QB\0JY5T<P^RP+ XY)O;;8NM[DW[;
MF<4C.+E_/F7ZDSCD!RK3W<W*V/K&#MII#LF"C^"%2%?08B:)M<J[>*8$6$8Q
M;$4,3Q?T!,V-O;6HV^(;.VH2^F7;^VF[:VZ+=<(V-662^!\T^.^&Z+6];'DK
MGMO-'W.\'\X)4#%NQ3;?F);![HE1NI*EA^3YIV+L76O^5\P\L=+Y(.V>.,B9
MF:XM&).77/0Y#V\LB*ILF:XQ^?T_HBA)T^E5G;Z&Z]@0\ =" 0@!X%G9U?P$
M%MSZQ\YFIR.VZIT4G,U)^_[E[7%Z #>POU[BY7HO 'G(V'QC^H3*@?']$<$G
M,6(@HWXV5W6[%=N;"?+U((7W&#O$J'Z)JM45>;:=J?/+8HM6$99:=3 L65Y;
M,E@4#GM-8 \D11Y!)MVK2'S_9;;PW%'$R/"_L5+X$M#@Q]7"64'XWJ\4/@+
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M[JXAGY2JL [3F.ZEC+?WZ$[ ^^-^C6UE@"BJ?68U;DZM0GK3A0B1.!"Q%/9
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M,-N16 1\!R=TM>SRQ79KZT:9UO8C. [;V[BBVZ&Y[+3:X@J9:I&5-D2MR[;
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M*,0SY78KPH?#D.J,$K*.,/^<I/K_"L:_\?D[Q,W^=CZ/>/F<&<_5?'HK9MN
MVUOKLME)NUWP-V>X&)\/*NVR/![&U8(<&14;Q2*_BN@SQ.>)E_#YU3EPSQ)Q
M7K#+W(_,EZ]@EC\OJ)YWU4Y_OI-3<F4Y@>^4#'M*=)V&*'Y>NXWR9#VBPY\V
M6YX79&@UT*,#)-JJF9>'B:1J]1IL:3EC<MME0YF-XV"Y1)A0)'[:%>K7M^#^
M\PQ^8^[K3?%=%W/_L6%R8>9.,FBH&7J9Z;')Y$QL;$OT2&PAYD;F2CI$QR-/
M\?:W"+^<&#"=6\SE<WRQ3XQ4OE 77#0P\]G3OR[!^3%6$>;UC,+75>Y-XM-J
M-X8Y.;_?%$H+<9B?#<<5T=K N'_\FX@F+V@87;-<N8F1CQ C9^(^GSW]OR,N
M]$H!<BPW(OK]8LM79L/"*J*MV:G1T61NAD;Z3:-$N"_.MW *K\: ^BYB[!;P
M>1_3AB!/D7 U$DA'KB'Z!(LJ?'SI*8OF07V<2_MXODSOJCJ?N4\-=O4Q'(HC
MT9YD^O1$ZO>(]GR6!?-=^/@6VWF?V,X[\?&N5@F;K<XHUPO+V5JU\!CFQ3#P
M\5\3V(&&-S.,3@?M5 G )PL'!0$XX*_PPV[QG5M\YTH=LPO:0&>\L+XC!#*.
M# B0FJ-U;9A62\G><L7F=*VWG+>D6F:<>L+Z^2LDR4UPW"(ZUR$X+FAT_8G@
MH"NE1B2K3!Z7NTA[7-HMUC5#FR'!<=;<^LKAG(H+QN @L7\_%_!3C2<?QT<1
MQ_.J!4 0UR#QWK,\^;/G>56B[6+%RB^/2V^W ML--ZNC7D-9W^>$1;[=&0,H
MT4=4*5\-Z]\X_5TY'9LUGSW/J^+TBZ6E7L[I0[50?GS,%P?T*JWU!I'[0JX[
M DY_>0;JOQB<Z-^3[GU?&G#I$P;_%)+SG(6&S':%D@\#B[=P!Y_#9Q2'8<F-
M$.Y+8_=R4&:D<0/'ZOH.41  "QL'9%/D7CC-=P09 #GU'<6+Z$,=^DT;U$0P
M-X)@]XV 1\ #(9Q&6N\X/8%8W$,,/]5IRRS:;8JF(@!U0A=S'7>'A@<0R'5W
MW)JE:ZHA& >\RJ_="S)VZP4IW'I!!I+K\[T@;231=()CDBD^.>:2-#N.1=G)
M.$4GD^-)2DC1'#M-\='I,4ZD/%P,'I5N-=?;T;N=PJRF]>IC*PA)]'Y;*$;C
ML_QP*4?XQF.J72G5TID@)%&U(D:'AK2Q:&9:F#T.:[5\0@',T1.$SMZ$DYK*
MG-<*B>%,VVA1KE6O >;H"?)EXU%K+61]N>@)D6:F>3\L=;N/F2 DT=E>RBF#
MS4;H=;+;;+NDEE?1AUD0DFBT-'K<3@;#%5UJZ+R6#Z.)3P.11&FI8PTG TXM
M,.7H/C]NSY@$KG@]1?VL&,J.?NAP/<%*)EM;8\Q/I[,@)-%6;;9-5:RRNNRL
MXB->5T?CCKP)0A)MS3.M@I(+B[W<-I-.F%,I(<QF04BBVX?2+KQO1NN]@1E?
MW0_*8V/7"D02+<0R?+S-[%.]TF.S&H_.BJN1.AM'Z--+-XQ8$_:-!DV'[[5^
M=+TJ2ZW$9AR)G%YJ5O>#EM)9K.E20M2[X5A.7X[0I<SII6(STT^D%I6'92Z<
MTHJU\/I>C:(!!.Q]M<U/LL(P.UEV^L*BVKR7ZLA:&D<"-G\_*VYCZZZV+H1'
M2[Z]$A+Y= 1=&K!3A>%8VL=FP]%2;CSP]14G-P;Q&5QZ0BB9>JI0V]4F2]K:
M-8UJNI<1^DH++O53RC@I3!*Q230Y9N.QY#C&<?PX':6%,?J4HR=3+LU.$L</
M7Y9RAE;6K-QR%<UQVF.QG1!G@1R8H)-,;*+5.@69'HZDIE@:&=-6$ ?*A7FM
MUTU.HW0XG2OUQHUB;2=F@K!\&^5N?](RY5*O47NH]M>ELL45-T%8ODRQ,Q16
MV>QV*4:7X=*RU%^/'S9!'*BN-'7!SJ?RLO'858U4MMK0K0TYMGI$KV)J4)-2
MU1(=EB96I\8U!6:Y(0??_%>.^DR#:\Q%91F>3W+#/-]]T-*!'(A$\' WR,5I
M>J4_IB.U6E4;3UKDZ(G_RGJ_EYTN9GM^61O5U(;9&>3O=;N._8@#=X7U6L^K
ME4*NVJQ8^NI^JF<#N3I7KC6F:F,:IME[V>QM4\/A;MPBQ9W^*U-TXR&VZ"/9
MQVRMA^K$5!76RI!RKJ-5:NPSF3A3-^A2KY:+%S:YQ[@>B#G<370BI5[3K!<Z
MC1S3V _N![5-BQ1B'%&_5$M9XYF\*@AF-79?I1<1@\^05._1;BZ&Y65KU4\7
MQ$2EF8W.PLMI.1,D?7J+?;C29).]Y6#:H]>;=%:AS1E)A!S-J!G-"G1M6J4'
MZPG_D%RGU<W CGP>/5-<1=.5N%8O[)(QJ6(VK+X>W01)-#;;WZ^Z[6IGV8A7
MT]*\EDUG=W88PG_EX[[4:S\,ZP^TV"D^]CFF,FS46L2-<;"1@WHK/PE#_('8
MODYZ'[ELI!$OU!(>3.@SN+[R[+Y-;Q**0=<DHYFW&#JR$F=7C>M[W$73=6K
M SCC/["Z !WG"+RO<0/W_4+@OHF[Y&7QZI[![?=<^/+]^.,@YH>F9:Y@RLB+
M^]"X[35,.7*7_M"JO2N8\XVR_XHI?UW*?FT&_7JTTT>BAUX>ZO$IL+=W@]-X
M%V#0:.JJD?&>6ZQ#!_!WQ0.]\<7U;?7K^>)/$".3L2_-%^\+"OJQ)QH")_L!
M^,I_-[G\(:(HD9B?6KKKQ;#P!%-^>B(I=K#D/1CBLZ?Z*84ZGUV=_3GS)O[
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M:NY"E":QR-R   C8&SC\\3T=HK\YY/$WE8=?BZB[O(GB,'$36#BC ! J8>
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M@U0PV9\ADD#L*> 6KF@@P!&4J'!HW'?70H5% 4E<5L*$Y-]H,FQ60SNXQ=-
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M+6@OM*ZP*TB,LTA86_P.GLL+Z+G(D$+C("_'=J5_HL#WGCF:>"V.7^V=LM\
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MD31#:X.$69!8F_$5IOB@/,9Z5CMJ%(;5$L^;,S0=B)5<")'J&CCF%BOYF^3
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M<8%"\!P)!.;!:A*,.Y+(FHH2&B?&V'7@AZ&&!^/\^:PLC$=L> $CUZR^ ]!
M@J-&4 %/T"(9.N(%M6,8W]-F@@*OE';H$QD -E4-S< $I$X6PX##T">[H_%9
MYES5"80QC!5];S@5S=XO"7P>4 U'>) E3/.E<=L(P(0'-X.3!%8'-I__XW]J
M%-Y[">",L\?_F)BG@1&9=3$,;2#]\!C_^W_Y<#]<#PGPYU3]MR-S/!.S\488
M+'YF0IC BK!3].[?K+1A=X8]T63Z+NJ(L]^NV(*5H"+T733^'\KS.ZS(R7("
MMIUGT7S8=?9M?O@ZY\-GX$WLO3%5[3<3N</<C/ZT)Q:+W"7C%]HMCY[%NO:P
M-__#4G,=%.3_Z39R@0=?X7<D<I'JDWR'7^V/D!#"*(*([T'+(5HP7%)E7T*N
M_J4.6L$+@U\B 8KD%>#50O-3HJJ13.*0],B+!B>I!C(R3N$NYZ/(K#/=CK>T
MG,S$1_G$E.LN9Q>"NSRQ&X]VU .5SC!WY\ZN>V:*A:9OKN^HQSR$@Q2!)')!
M@O+\#'+M!I69Z8( ([V>83W#&S_^;2A4@S/5B: CX8*!=QD_UBX6E%@K(^V&
MGL4ZDR2:F:5@YM <@!,D":E11?"A*<.6R:R!GD$NF+#*$G0O>IB&K%&+$ZA*
MMM((1^@(*'X'[]?^GA,,X^1QI?LF>J1B39$Q:>GP,,3'[D-XW9J!LD>:%3<1
M 71G^(B\#>M_P]*@-0A5JC?1GUL1Q/=LAR]M(HM$H"(4AR8"QB@%P-2@DD\0
MI)&)8>$N(IQJ(-(TH>$=C,4/+^R(E>>VX;UAB)\1,BZ\]$X3&M.,KD.P$A88
M0TM#]G><TU67GFUL:57*ZDR.VZJ]G;4?E6FIDS"B/BQC^A51U 9 CSOHU4B(
MY0_;;+=W=KT-V@-:'$ZERW0UN[M?LNV(P26U::TP;/WX-Q)BZ'0(Z=\ 9^-E
M>^!:>X".0AU@J+T[+P+,.@@DNZ;*H5=$*5=)!V=QQ5^U\0^+B)X5X_*4#L=J
MW=&LVYIV'U^]\:2HP.Y[PV?<E<NAA6LHGNT/WO=I^9XOEV2=SFWOF_E"XKZX
MU6#?DY$_VW72* +W.@);W/X=N1>V9#'G:-,S"K+" >P>!,?=^WM1?RCF*\I4
MPOS^>4-ZB;+)2$^T Q 0T^LBTNO0$ !]#E2BB^ V\6M!-QQP:P,:R*B63DTL
M RD;PVU'A00RLJX-V#7168X0-(J"%^BLB'O/N(#QA%M!;\GP,N=AQ#,+.3T2
M2+.FD-U:040#YJ ?E0RJ MVJ(=O.IA*_0H*V]"('IU31&Y %I*#9V>T5=()#
MKU."K$GJ3A"H#?(,D((9"*2A"8[$()$AJXCC5?RX [2W87<[X$5#MTB9+M9;
M09.W1SUGU[AKCV?-<5@F^8_AK <XO0Y-B_X-Q.3 V/&M_XJ?&CEX NOP#_S2
MBP1GKF-NUS"7KSWZ+[43EPK=7-B7;2);#_+A"H]-PB:2S+I@BCJV0++D6/^3
M7NUZR\EL(B)/>HV<O![F:HW8,'.I)@ZO\6JC9[W:@B/\8W3D9^T7^; IL>^I
MP/^H>1FXW>!C(X521:J-U7=DC!&PBB.I(Q_1@$BW:,SM[G(0H+5A!2L*=W<R
M2>HG7 64QI /\*^1?W[=404T7A%B,XYZ-(Z[$,GLCM)8R!6(&HGUXJ_A,2%H
M#JD+I*<>N5*0[*"OS"X%\A>DX4D/2&RU*Z8N3BRB2KT=CEC*8"4T;W0M.(ZX
M -+U?4'GZ@(GP+.0H<+-B4WA?9:EH3MD0<#F!E+Q^!Y)4&;F/*Q.P[:)@)ZR
MLFQ:/_(R<9LM/&SVZI/*SS6M0<85CE(YRP.[9?. ?F^OG^][08<0;6.*OSQ)
M.V&/H"1K/2FWZ60+J[U0G,[E^DH:@T<0X W\)WB72+-0D1B@(K;2P*)$%/>7
M+GCP2E?I^F(_2<]R!3';J2E2IQFNLYL?_YYVN/P/[K"D0#=4/QN[)B=RG\&Y
MQXOQ1(LGX%U,^ROD=XE3$4D6])ZPR\!^7H--A,ZN2$F ZH G.Y,]NE)F>;=;
M#A9%V&$'E^.B;:'^>/M?$UFQM]]6G3!+[TX;V9VS-H&.=CJ<D1M2MS\JE/;S
M[KPMC:OU)C1C3$0#'>V+-/G[X]3WQZU7.VNDESTE+M-6=IG;9W?5QY0 +<\2
MP>$H['0"^>TP2+4 (-7^D!->41*)U05#$VR/\(A;A& "]_9&Q5W1<(LNX R2
M2SQXP7#U55"_$Y3"(!N@"-VF9AF8.LZ)=H29&Z9RKR>?Y3US.Y0JV*&K<57M
M;A;)JK!<E98<IZ<6;+W^29S5*VMB9=?.,;U5-#;7)_V941J PHK&KX:S+KD7
M4J_9&-5V@\6R)(H;M13;[0:[-\>/_VPO(LIC=M'>SF++A)QNW<<>^V6FB51:
M)$Z_+]>&OITO^]'E+/YQ7Y/#?0L>?'KPH&--#.1!0=((^MD:I]&!3#^_+D_S
MI4%!+I6FCYUUJA]?S8A0Q'(J8SYQW1@NBUPHEO!$WO9)*.K8V;C"83DHLAYN
M'?;%B.A%*0 [@Q PF::E<SCI"N*S@^3T(8U.,LSW[ )W#J?: BN9.^0A7"#_
M\JIY?3;;^D;64*B.H)E8PU*1N-/DW 5[\"?PL=OSAA4/^4(CI 7LX14X+H+S
MH0;D^-&_QX\ [<G",\B;(7&"4VV7R7>FQY'XD6GI%Q.0_O2;+_[O;8/E!=E2
M9S$S"@]+Z:[D "VDLPAD#7*J^]1YU6A;HU9A)_8:PW%4F+*]5SLO.)M:PO5G
M=0$-P,"OYKMJ!VU!4[?PJ)JPSH'V3Z+"T=U=7>OTA)1<L+:/\?DF#EY+,L2<
M,X' Q2ZR'*9\Y%MPK%VMF=5W$'OK/L)6&*)ADIS8;^JG^ M3'"F3HR08YQRQ
M/0X8FH*=N0+R-$QJ+J OT&4"L;/(U"@\MP.!AG"2ED?T!:V[4S@8B>POZ.@M
M$YML H4<5,$P54T3)"H'5<53D7->EX'+,*DC*GWZ'20QG!<XPEM@V*&W(0Z;
M".8&"E8/#/ 3!F# ,2[![HF<4R5)F E4AQ25(M=MC2:I(M.Q7L_]PD.!6%]6
MM=N+M]'%4.)D!SN1&D./S/Q_K*S]<T\A7H 4*"Q[9V<@7J=^FNI,@&@YB9K8
MH53O?)R0:L@+ ?-";F,Y71@;W*Q7;82Y^YZUFZP+_=JH7YVUOB.[15_A==31
M$G5(*7%7];)?()=EA&3&4N-J?2F$VQ;Z;[$=/VP 4?HN1I_BN5*P\ 9A*7:O
M&HB*+,7<A6QRD(!JO*%S&(RSS_\@;K/9;6*)$A1Z&B$(E.-R*Q:RPR'(8.OJ
MF@2;0P3S$,W8@I<BZK(PF=BIXOKQRRJ>>WTO16]ED=1WN<$-]>$Z4T2@HBD)
M(3^SBP1Q$9'DU-(5D639D;]HX%(:]"+T.TQ<9B%2*>CH5U9#DV%-RQXXA,U)
M39BZ47#) $_ABBS%E':491#1!.-WPQW "AHKZG91&@Q&P45B-M/A*</_O5,E
M5>7.X@#+"6B%?D*G:=?%\_)@TYE$TY[$*];*\,@_'-5A.7L ;N;!(.QLE]#Y
MID?A8H; 687\4T(7G@S3[>N.;D=25-BI"DGF0-H-7H>K8[P$D7-&>)@AIAEQ
M_<PDT;Z@42+FQA%B%A^+)7'C'>(VC+_IG21\#.8#>J1O2O#;R4YA ^=D;CXZ
M=E_M#/P?FQ:)1"4VT+$*"IV^ZN0U4"=RCBJ.B(%D>IRE=?JZLY*[:^[010C2
M42J':#MD#PW9BVB#/#="X0K:\1#PKJNO(G98 BV=@:P!2L63P[N(9(EL(8J&
M\PO$=KNC[.R<Q\J#)R-VE5VE])3A&#HQ^7@!%T8CIK$+1;$<P/%_V%'OEA0,
M3E<WZ&GH2<X*W4S#-YN&[KDN5E?06^Y51=CER6X$JZGY8TY4[FEYV.OP0C6R
M5[:%M@(A?_J,)0CFCD()Y/E0J22X^WUW0@@XCXD&KR*BI=CI% XY((G&X52;
MXY,XY([^1IN&*W597-G%(W,3JKU!)JQ%Y#8A8@1#%*X22:K'RTJB[Z0/AYX)
MIW.<;]V;0!?B0#F<",-VZM&H79G%"Q(87SL?@IXK:KR4"R/;Z% :JD ^T?9P
M8*PXNKYF7?GE#N.$VXD4GPA0-D;%?],TI=W)=\B*!5$K$=97/27;"<+DMO)W
MYQ 8I_MZ)W 2MQ,XMQ,X?W "QWM\[NEPH!/F>T50D+D$5P2&>&PYJDY ECGU
MH%Z9\B>>)+KLG.ASPS78HQ5-MS9:$'R6O&L[OU!Z/8 9A<57U!%?Q'!T'!A7
MYK*F*[I)4<^1$0%&H_V1IDHBMPN*/=DC9&5PIDYL&1PBN:-NL<0W16]SNH T
MV7$ <:"J/-  (H\'UCX>D665Y2UN>RYNFSJ-VP)+>!;2?PX+>:1;,*J]T2Q<
M/G.\'UXSNX/O<2-@AP@1/!$^#7Z$J1(+";EI^ (97#20(-[S$N H4)**"VK@
M QO]0CQ/33_^1>)<$M'LU2E4EI,[?K*_#BY,-.(L"Q(K/R=$.(#A*+DN[_0P
MG).10)"!XY!&Q^ZPZ]8=3S!$C"<0IR*/?7PH)W+W <Q7B)S(Z"Y2'H$K^W#U
MG^;*$WQ83>"-IWPY',.0B!R#[E7N/1 X1_,QICOBY5HFG%[CL8<W021D%VL<
M@@/N'$-.& 6[@>"[F\3;\ST?SA48UG0J<B*>+QRN8V'!ID%/(W+8/JZ 5YP<
M?K&/Q'@*%@$ "A;$R8U/17 N<(H<,N2X>-2;(@^1L>$%]ARR038[;*J&X1+(
M/JG$#4<K@6C=)M^9:IOPR*IW*D:1JH"H*UZ@?XZV\.?NEV<;C3DLK:U9L/>R
M%3C+Q ?XM-U+7%QGEMZM=</A,%J  5 $S\$4M,;8T@3FU7>'#,P1(]K+OD?#
M/7JJ79EH0,S<IUR/O?S0$<'B_65M37VD_B[F6*>(8VWHYJ%\I(/L?%87U8-;
M7)DZTZL8#ZK907-K* T]BR?FS"L"3SIRM2_FJ!.!X///#X+746"@O^Q',GRF
M4.WOK$ROT7\HAC./.V3E9]Y>QS(Q*XIAZA:\O"@(&;Q3@8ZZ6EF:<C.3XY:=
MV-XJK,V%M=M@1SW83\>2"HL&5]2>G'1S@U#ZJ72_NQ[CXZJ4]^L-I;: <YX\
M5=C:";(!"[0(X5##@*H\;X)U@ S]#782D<6.A#Z$%= ]5V<_>5$"I_A_5[,K
M@4-#1E?&FJ%[J9A7;H8H?$S!']QV3\KA:.0AQ7VPE) &T3G136=CQ>5$G"#-
MB1PMA\DZ<+01N6&'7<<*AGR:/7R*%==&P.< L9KEB?/E+8VV!;KE$ ;$FS0+
MV0D<:'3!/C$(SV%)N;4DV(G:0RZ39I@[0EJV<B#)TXT]#G\M]O'<!8>$W5EM
MW/&K!Z_1TG#*,> <;N#>O% K(3V.Q/)XSVJU;6O9FQ:8!3?)UID4WZ W08HI
M!>V<';W4!NF/)3_\=<]N1=F2CS1%3F(-HS&U]Z2AMX$/#]J"3-K9L7?147HB
M-:0+\L0J"/=M>J!(^71Z[%,HE8?B*U1*X P>+'A78]I!9@_!&<HABTC@LSMG
M+O:%P3'B2J.DC(U9/$J7$A4K+DAJJYG<_/@W&HHEXZ%T)/&B$]B!.T^1/05>
M@</U*EP-O=?8 %K+_H6TEGU78FMWE-BX/6TNZ$[3[%3O"_)\W[LR8E.ZTX+<
MWXG#WHH;-S:M="$9;[>0G1.BXZD7'_=_%;$=)*\&B0;5,J2=HYJ/1:?C<#G"
M7G2+.VS9?"2.[<2=7U^08T8O'?8S1GM>!,<'F^PVT3;I]..@N](7RQ6=S=#A
MQ"P3;@26;T28<=0NP'R6;'M29=D:,&IA%8VKM30S029SYJW'E (IIV O$H[+
MN5^ZY!()I!<]2B_V\;8VH!LU2TW/2F(\OX5J[CLZ]@>D@KQV0B[^;.6Q!><+
MI$CJQE:J1^:!;0F<VG^O$5R?1@:BXB&#!)]HLVR4&_7$=M,:R&TN/&"O@ SD
M@3*HC?+"JB"T[IFU*";,^QXB _HN_B<2PR6#CRD\?7E5]JGG\:6+S%_D2-4!
MVU%2J":K+RG<KNX0M/$ <%WYQ*YPGXZCTV]TE([BU*Z%Q@:75_K?XC\8?K*M
M!T&+]:F/%'*L!FM+%2VH#:K7<]1/ITK.<]GA"1YWVXY5/RL(<(54Z"@,:Q>(
M'6H.2(@0HKFVB(9>PAH2??@0ZZ$" <?3D9 D46E=$)60 QF-=_OX-*Q36NV;
M-;%[+Q/1<XW9BP?@,!N[Y3+>.)P]69BK_;AX1\N/VU4Y5;#X:*J:&)G+L?\0
M63C^TO)IV[@A ;?&-(?M03P8;S&UJVH2'E632HZRF[(F-PIAIO@HAM.#692#
M^FGZ+B .AYA4@GWY&5";XD&>_76$=>!F8LG(B+@+V1$!2*8"N<&_O.7B!.%@
M_G$TVUW3.^J NP4E:NHIGY\'_Z-T88:,%SOU8A?SO9ZOV]ZG$'7^(A8/.H,0
M'*8 ;.#CX1I.1/J0"#HX)YB'"PY$$X:<- R\8=[T62'GL_3(XY$H. @$SQ,S
M' ZV1]+1J*\^W?=$W^6>A\^AV@GG&28[/\.#,'$=&"]9$ <&@SUA-&5<#+J#
MDBO;B<%B"A()=B;=6;83D>+.)HA\O  5'*O@[ 0()OC[W,!>\0+TI2E*=IH(
M4SC,RE/ZZ9&?1\\]+5LXY,X\LM:!"SEYM:<B[)"ALG?A#"6YEWG@ >WTV($.
M#^16R'GF_B07P(.0P))8>)#@-@^Q=PX>A(N"T0OL<FE\WM3R%@>#2H&2-0./
M@O</X^<A":#8G&2O,5YYSR+CU"'69DA[^4I:;808,MX\>I9;V_J!=HJGR<+'
MO#"+MDW!13@'2#7_,I"R>G+>";U"Q44Y1$\S,:B5-.<&V1Z<&WR1/>'9D+.B
M/4 OA"@_?1Z*&EV@#+^\!Z@\3/:D<G]BF3C_B,O,768*>0]Z^04T#-W'ZXC\
M[!L)1SB\&;I9+D&62^(#+)>E6FT_SM+ZFM[1[*"]'N5[*1G#YIRW6\YJG5!0
MM:W'HGF)X+VC.L0\YHA-<FK>X$^PQ,/9]$"V.X&/"9VBPF![!VLJQ,#24:;>
ME83>I*@O=..+%]KL_S#L%""3CZZ#BA,#SJ6PF#.0!$ S9,F T7<7#-V\.NQ\
M%?R0B-^O5J,ZL^P-9O%]+SV,B='EJS&/,#ODR';A8%%3T#NP@#ZN" P71=<-
M5L[.RGMZ<-^O]\LMBRF/<+@H<HIL% +M>U3>;5>3$-'FEX0\L@$05_B$84#"
MXM)YB*O:\.<%X,LR#UX)Z"0:/'N=QTOOR, N 74>D)U[P!L7G'/8M%;;;J$_
MZ85'Y5D[-F";R?$,PXD%%U><,7=!0H 1Y14N6!:=G'\^A)=)\@'J=B9 56 '
MB,ZAMJFX)2F(H%JV  O:5OFV]7P0B3:Q&F1T1Y1\;*/_%%@(=; >G\U"UJC[
M/O?(5T#L!)M0:,M48MP>U>8??PN(\;^Q"02_G7Q-HF:XT2"ROIP"+SM$$OK8
MM\_5C8!6T'GYP?R7"2U2"B9&C[9\40P'MI8Z7F#7>2/ OD3$$*$!M9@?DL!\
MLHC+%KE0(V?'Z#TLV% >=D@<V&JQH60T34*_3="U]OQ 95> ';."I&XB=S1]
MC2I*Y>5U>"G&5[W!@)ND2MFB$D^VWEUB==6L '5P@7)IU.[JHV[T?EH0M7QX
M\&C5IOGN4TA%9--#3C&A8\I@1]9GSQR+K5-[QOZ0=;?O(,*P]R@Z[9O0'GZ8
M@7,CR^?)\L*64VO:F<?HB)%>KHR'>"T]R&=K[ SG6T\)TJTJ_G9BB[E2^LAO
MTLOPQ)(>Z;!&R\-B@5''_F.DEQ=;0GB_'&I5>E)8%>."9?&3>&&_>>),J4=L
MG>E_]O4.,"9O!QAO!Q@_[@ C\ZH#C-$/.\#X>C/D;[4X_@J-\L9H3=72FJL>
M1R_E6%3D%^4(&];@[$.0S7'S2P-38XZCZO(4YW;7(Y \;F@TT!\E;7K@3-DM
M</^V]E>V,75H:EA1.GC![?4&*?(\*\24<E6.L7*XQR1&CZNT,>G4U-:/?^-G
M;"N2MH7S3.0,'0DZD1-A)-]T"$79M:E.,(KE0:(+=D9+@7ZWJCYC%7'O0BIQ
MI/+&_01PVCG6F%,\EK]0CD-"Y@:2?2;<0?HY>3Z$8#G!IS%$I((0W9EHSPRG
M@ ; ;W"!PR'^[SW!%! $PP$R&X;7/1OKT3-D1<[&XXYC>CAO#OT!6&Y.XF?'
M_('M5K0^(7?E)CAJ ST@$"7ATYA.T>^)TO,>+M7@8"GO5G/@(_-3K#5#%*($
MSI*<*HN7I%:^<RK6AX;N/_IYG-/D[9#P^7B\-XQW."KIAO%.\_SH3_1^,%#.
M9$//Q/4@ V7W+\%??+L<U!<3W2^.E-@ET%[CY<@;AG3#H;P*FS7!QQL6$:97
MY-A1CV;:A7@[7&"$Z 0GGIB@\ DFM:/FJ&>$T$D.%$XG(!D/![5]B5",Q_1<
MDLK3W?),L@,;#4Z2P#V93TXSDB$Y![4)/HB ZY+@!+-SS^$50;<[M?4.J?NX
MQ2LVIZJ$S&=';/I]AJD#@7:R7B^M_$0BQ!4P3^2Q7Z]3 F0&UC%!:T$RX$^O
MUQ^I(6_FR-8YS_IC[MJ>'3'Y]NEA_S1^D2(Y]S4AVYHE._1ZQ0=[H9..B@HD
M3F ?<%V"X4PI, ?GVPP9*ACA(#V>Y!,,L//D=9^JGOO.VMA;&(AI#P-8JI)#
M4MA\ P)VE2OV-A"-/5\QJ!VA$@;MM^\&TE.4E#&14DU<E'=<]_C*RD52$/5D
M?1-N6>0*+XKUIP")O#4"BV8.)5[?FDPR'.!.'O;]A36CF*)X01,(RA1+K5E=
M% CH"]39P]D[4SW*GA\5N@:4Q[D5GR&@2RCJ R?$"#G"THL7^+S\_(.Z;-*G
MW!ZZ73IU-'S6!4O$T%]H'"!_#14]BXQG:A'(%0>GQ+T1@'=-7[-7K*E\$#%/
M%N4>'*@#>Q\V R.YZ-B4X\C;[#6"FH:3*FW@.>.%V^XO-X8&P9QS1AX+76?P
M=B>^X!W'^H?06R!5(9K!:,&P;!N5P"7;+BV>S$Q0!-(I4-<@_H+Y6U,1>W]O
M1C4(FCOO0"W!^@0&E3PQ)*_Q>&:+SU:D@FB$]SPO[/UFKEW>_OZI1;<_B>O:
M=-4K=7.6YKH63??O+;HV&LZJE4FC9R7?4%GE=E6!=U?PPN:Q"&OB2F;BTB :
MPU\%^S:38JJZJ*_+*9KI6FITDTO6U#6$:2.14"P9?7$9U3&OLCY"LV_RXSHC
M28WX]!!;H\AX#Q@>#I V5M68;FYD\QYD@_WC8\_7*43&M!*,CC^8MPN;34LH
M[ :;:&>E#E>;8L8AE=.#VR_P1U]--8=1GR4<TA'>"^U]J+\[2W0G1R7.D*3I
M.>MR9"WBOO6.9F.A^RQ:T9D=][Q86[CO0+6O@=]JVD9$$=D*0*I07_E\!+Z?
M:ZW+^:XXZ[&/TG0S:)O=BHI(%S?R.],]!=GX$!5WK19LG?BHE=@K+W&)#G[^
M26P2MT@USD=^'"_EK67V+W#&OK-=]'RPB, J>2(FNB4=/ 9?L/:TYRUN1(PU
M$\0< H_\/F6IX] :A'I]1XEO9>87*#-WJI\R!C*.#GG]-FQV8^I-^P=*D&IG
MD#1G_?6LUXGG'C;W"S7.&4B"Q$#UA=*QTQ,(KOK"7JL!!P(]7JA/O_SRA1A(
M#H^XF7"N$,D"<0(Z9:*NH6G$D:CY:;?W\N01_.UA+]8;^SOHGMA+*<ONN,W.
MCM,(A*P:2N,  ^L]W_5R<O/U\(X7R]-1?:_4>[MTF&$Z#[OY#,HG(NF[=#JX
MCS=&,CASR,$#4>O/7HH0?7#P: %AU=OFX$1@_3I"UG%.8+/:X32TI4@0\<<I
M+P*K=P _Q_$WB)]Y;?KSH=I#?W<"Q7-XW;D#%B\2XZ0S,^C>]8E[&BS4GP@Z
M/BG?1?N$KFA;*OB!$*??J!8<[=9)]@"B/B<#U^$8,T31O>=(_?/XSHJ[>R;P
M!HDP1$USQ)2F<1H^L@,3B,[/I\G.;R:NP5?=:$B(VN"TL6/).[UQX.PU*7\X
M=[8?W37!G8XY$;?M(4VOCM$!H ^=)U?B-=4Z=G@E$OW)NS@3'@ "EQD.P 4Q
M+W !J>(&<8,>P8>CY @S)E8 :\#DAX9N2;B2R#>JXX'#8KJ&RDV;O(LVL>V4
MK+O4#40@NC$7M9P=Q<,'XI"H(!8"-E+=X06K#';<T"?]),L76"6\*\_#W7L+
M5$;L28WA50W!Y/Q)8N8[%)2G;@7EMX+RCRLH_[@2<5^Z'G#7D4%B&RH*-;5P
M4T! .U$XTMC21A^"M)>H&R:Z96HA0RADEU:)FA>D"%I+*JR$]9P*=0 K2R1@
M13PK(QXPSA<2P/5/0K6$;,V-=1GK6A(8/,B'"(VK#P#.90NM#FRX)X5 +&$S
M&C"6#D!AMDG<9W41TT4; G_=0U6D&YT$G4]BB)!AQ, Q4VP/GYW3+S\\R>&=
M3T$TX#=X7F_G3H7CS*F3U8>MX84)7D#(OIN0^G.M#9+#TS&RR1I:],(4\0K
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M/;KQWXG*[] _<U.6_OW_ 5!+ P04    "  Y@#M7Z,OLQ&>8 0#NJ $ &
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MVZB,ZL!^P"'EB1%_P\0(91I#W3?_##GAP9\;M-H\T4L6VQ?[66BX3S(79>&
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M]8$R1ZYV,E!EAZTS'6UDB(F^J;_47R0.E=D1>6%A=]WYV$TH]@9?N"B$IS%
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M7GV-O9."P>,)=)]4]3J1:JNV0U/*C&NU5+C1('NQ< U[3*BR6:U'8(_5>,0
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MOD9(XA:RN2AGP0*(6D#PBRUD4#+8N.Q^W?,R*SNQ*B'GO1:!; M2MV>W"3D
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MVNRT=F&X#VCCY?FEJ8&/&Q&2PWO,>#"#6&WZ\N%OSOXZTH_M4.Z[]3+WA4G
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M?JXKSPW!&A_VIK%BPFPP7>XWC-O!G:8L&-0SQQ9F,RBWL+SD,?GHN'Q@Q1G
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M64?<?:[CTHY:4?7HFEHPPY5-\4[[#S\ZZ7@P3>^^#6@$',*F&!:1!!&&<!*
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M4N6#Y#POH9ILXG2JPW@HAV-$! S>Q[=;:W &._'!.QL33(I-%O+U"JU,YD@
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MPY&;CJ,^68&U+TP>?[XDX6Z!/E%JA0\4E%'"(53.RS '1$P&:X@T;-JFG2B
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M4[R:*1^OCE#+TM,$MDP[Q>'*;58-XTQ:>JKLY2T]*@H_P-KEFG[)98&0JJ"
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MC>+2H'820'R,R-]HM@2B\4DG4N._ L.5^3Z3 !6KK]VIG(_I4FJJN<Y#)TF
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M'(-\.>XB)#D8]898>[SN?:*H@$:$M)K9HB5G0@01N?A=DV^XF&[E6P>ZO5>
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MR_=2J+'S_35'NF*JER]_0B?ON)MT6ZY?3:%FGJ_R#F[D0M?L>G;=R<4_'8=
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M&-Z_+!X0+G7RJC7Y=??B'0[6'70'%^>/^J/(SU.#NK2#>&Q4U%&SF!CS:"-
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M^#CV?S[?X>,,F5)F\-A_. M6GNW\P_G#:0STOTXJ7%#JGFTA4O0)X__2.#=
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M\$6$(>A^Y=]7,8U5IT.B<VN$LW^X)%X!WB-.9PYS+Z2N9PLB117;B&ASN+!
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MQTNRFT2MISD]LP/PNL?S>0-T*-5 V9$6,UU>]'B><T[G]4N Q[_U(7-."IJ
M/BHY,V2?7Z0$"<BES_>:/?3^:\C[&;/.]@895 PQ)A3 <=+T^&W.")QKB!^Q
M&5OD/_.>8'@@B!QRNE%*5[')NZ;DQ53R]S7SRZOR'HBH_S5S\A);$'#VYQH6
M%J,M\!LB&;7T('%?AS.F]D2;O]75BE%QJ)(MD$U_9/"]4+;2GY\.W]8D@[6/
M?HDA8B\!(.?9S/ZE*T"LD4=N8_-I2))H:U,[T7]4\?PH)#BOQYC;0,?X53%<
M<'D__8W^?]UE=N?06-F>85_3\2"-<ZOC)QUU28] /+)FGG_JHIXP"7QZ^<H[
MF;U,ZLH*O<03?(3^ZPA:U3+K'YTLEX!7*10XV:UNHF\?D(JL^U7W&]A.XR5G
MV0SM=5[;24E#)$_75_\?/%X,,4""Q4B,2A@PJEZ6$1QG>3'7^KV^L1VS<[!J
M0MDA)_9><1[&H>;=9EBM5K8M%.Z@EGY$'UHF^^ DO,>9!6D:= ;]I\>?'G4J
M@&5-""4=1;ZE/W](+[]/>K&WQL&MD6'<3UWB2Q*[!'0+8V;19_;6WM(^'?T0
M@]8G<29,[GR;K=O_5L5';N1!0="D3-I7!0/0']FTI7JK"L+<416)KU T2>K
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M8^TUXHK'K$$5KLI ,B07W[MOJ%TJPS=D_$#GNT2,ID0H**5CY;@Z%AEB3[J
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MO*- QBS5EWC?#(/DT&1CFD3K<M423V\_I%.C!H\*EN^M(B(VD'35_EH'H7A
M4\%F0_[DBWZ!>];4A^6]/:9VJA/_'RSHM!E@CXKENCQ(?20)^;!5::%])Y.U
M"3$<R L7EI<L3#&3ASXJ@0=Z__@Q@*"?4IJ;&W;!2RW=@K"5S6_< L=U3P=Z
M GVR350"!0UY)IED,)+["2PV%%FS7<N8"-SN;,?.&KI#<DQ3H8JL,2JMJ0(Y
M?3D.7K,+MT^YMPV0KY0S'+(0U]#$_+)19KM:D>W(=UAVDCG,UJJUV\-+-P'E
M\U29SE54J+?FC%FM) [('(4G)>2&ZHBR7_^]_)J#-ZOO8KCSIHPV&XEF:Z.1
M-1>60-;_YDB*MHOJ+4^4K$BX&6HTV&TS\>*JJHCQKE-(R)F=$ZFHNY-!"4AC
M[\&I/Y+HLULIVD;4W_SO I.377[IJ#D5"CG2]A,2X_JXB^D>O.@@5-9M_-7*
M9!6V?M*)&907'OJPID_<HOWIC^OON=_TTJ;VU&6\MVHW,9->'UV]$")+CEZ(
MV:X3-SI?U7=,R&ACRKQ:'2?L%G\/UY>#2YP,_HC8FCV-[+[14@4\>D5(:8S#
MS7&M!Z5 S_JL1$VG&MK=+<)3[H$>4]TJ+K[")+,J8*$S('H-\VW,8F@Z1S9+
M)? 34?:-8AJKC4=PV-M 14[E0O?R6:I5L?M'0YR":%*LH5#["[XH7E8@W1^"
M>.SN!>.)[YR%Q\7XHN\G7^BLV47S?@NZC&7)0G^6)7VU0(9TY3.IJ"^GX$[M
M%%(?2Q=\H9CTJ(W0_W7:V?<)N[G6W9]#16](])0<72PPU!*%IA#65E/D3IYG
MT$W2"Y.!2B>3 9&0['6:>6,%-6G)#F,I=/EP2(59T<=MOS^&HM_(TH3%=IRT
MK\WDUHU"[88BP\]+<_.-9Z&54W_\8A7ZC3_NA4=I2::, ETO 31_3SN20D*^
M@?-Z@\.8*[33BT&GDTW9ZI!$.:YB[^./E%0O9:R_=G,@G$KLU'(WZ,4/-%%]
MG74C<61S7,4NX\S&HA"AH*K<('TC@.1N%<XR>8_NJ_LC*IF*O00VAF2Z>9J_
MVFR0.P1,=_O5S?N$JD_9G(Y]![.14<:SWK6#*20WX>4LR@PS8[75-AJQU>#O
M <4[_]-5"20?]4G=TA-5<JT&](F4?@D0WNT#'E&W70+&9!UY_O?;>1OK9-!D
M\TZJT/^S?B=X=PMV";@S2,!?=!$N 79'$ABV"Z(EV7R?QQEG,A7#;.$0>^_Q
MF#[@CKC'ES<T#ZVSR##2): ,0C-6WQ0AO]G+>503>&0J:U"+,_FH.J*J2B&A
M>BVCZ\IPZ.[;3M"Y\R-2"18& ,.QV158Z4#;D'E?G_=HSFMNU@]E=Z_\[CKH
MKIX%JQ^*G]F@3<.J\]8[8L>*U P_2C.4U)@X"\Q?+*I732$2? Y\8S@;*URP
M;0,"4[(N';K7&"59Z.W=0GB*M]& EY^L@_"(.0I]PG$4DO&;!R=K(2XEI-^"
M^G4^S1RU CV%KZHJB@=)D4&O>BU%).?%BTD'E7U'1'6K9W6)IM:3\9H#!AZQ
M8T0"4I9H[41*.?,F40=UTGEU4$U*U6L,AK=SGD;\V/XSM"F!I]G0Y<9'46T[
MZUY,:<OD_7<ROY0:! +%-K2:JBW'>LQ7%/V\[_4D59=K/WW]02G-ZXV)XL6Z
M)MSV/K6%__OG4P55TY'#$$F"X5'B)%+@3 2B9QJ\MTZVQ%J!0,$=6;D!/OW>
M"5+&JL&^W?JOX37 OA9-68(>.I.T:=DNVI.;-!RJ7"@TJ.F/-.K6?F&LD?7&
MV3+Q;T7VTQ*.G\=_/,.6OIUA%CVE%+\4GVF$P5W&7R/>OX+Y)%6\GFC8O46^
MBT$""6>/\Y\W$J6J>71<8D)TD.+]8-$W_JVM\#D]7! FIH-!MX04O(Z.UW0,
MH<\J;2]^:]QX[V8KR]K.\E5@AR3#5^NGSQ]XS8\,(+3:@A2.;J]:@ +_.M&Q
M(SYVOH!Q;0():> Z[%J23VD+T3!:25QZ-3PAUSJ#4B0K6D6*@A)P"7A=Y4 R
M/K/? +)!7N="<PAKUI> MX_#6RIQ1.9 M&#O6)2).1_O(TT74<WDEVLTI3<J
M15713WG;/ [MC^W>?C56$QF=(F6=W?E-FNAO@DJ.0CQQOA0@M@W6DWJ3GAJ'
MY2L9;\G%;Q2BHY/QFA@0P7PY).[B.M@+_V",=V,'-# \=50$$_WH'R3./K\&
M>/V7LO.Q,>+^EYH"B?KU;X]SVB[L;VW\LOCCJRMGHL_R\^7_?/)B7]YHAY]G
M=:[XD]8O 2Y]F(ND!V+_C[%D&Q<YY&^GL*\S_JQ3Z/TE("H!\JB9X-L#DJ6S
M&1I= .=B/W],_PX=9*<3.SQ)T#]E10QMG-E?T(#K&-A)=*G07Z]D>DY]]UU&
MUA-)I1UG(F7LSSYC[)N.YPZTMIB?>)2VYJ?U(-YVB)"&<?_ED,9L9>\<#RH,
M"B/^]%W3>>-DL"6OLV.L>K41*G\Q I4E<<A\@NC353;:Q?O6;G!"+EXSU2;7
MK@%B 6O7 M3=<_M(,+8D;^Q4@RS#G=9<K7H/I<$4EF*=[.*,'BO+GBR&9.)T
M1^IY\9(>,6ZKX3^O0 J2G"5KC"E13LP][$SIF.&9\+F2>V^(G?9[UP5)#4U1
M6A563[R5"$IO\ZYKLHY8TG<Q_F51SC(&Y\=,7@*^&_;:'L!YO)SH"AZ_4@)S
M[BQ08V5>< C#VGEU+P%^UH,LF[!:CP\78[PT>X'I00(06.! 9LBZO<NS;\]7
M2V8ZVQYOZC_XE DTU[!>6]O>)UKVJ%^4XWSCX$S:[* CC#*KX%HW5'8<?]LX
M,!BE^O@NJ^"<WAT;<M4[+D_$J-SHXS<.7_NWN".3ET_3PLBK%JM6VD$5\$^=
MC >[?%[P:YTNT\3\[")_'%C3^EI.IT?,(D[U?LV)-)##:J_Q99,V<K5)@!3#
ML!5XYD)^.7W!3S*TFSSHY#;+:>6+K\]C:,A."Y=KY!#BF&=^$T +>O<DVOFS
M?3XUAZLHXA&,4Z>7]B5>#=U9Y;YUV/IR#_Z^@+I^,FAI!G[4W9[4?7S!?H&9
M>K53I:@FM:@F8-#BQOAV5J&>\=T-RG$$^!* -TWKNP3,2'9? @ 0-4)9KQS$
M$%Q_9K-U9QSR56I1OA+C*;!V'"U<0Y' 7M.U=JBC^79G'LVS!RZ-*+1IV=?S
MUN#>I:0\*SXZY=3*,8D3/]GFZS&_#>*K/^[WI;*K7YIM@E-5'4A&6&1E4_OT
ME12[,Z6G?7R?O%:H'=L10?BD'I36T^8<4R"%@:K,;.)<GH<3CHW&"S.&/PUG
M$"GY&<=:.$;TDCG/4^<?1#9G'8PP_W'[%<*-YQA1/2A_C42])^^1T&? ]1#G
M>O>M<L*9S802 S/X'DHWQPQY,9F0E:NT3R.US=ASMR?YQ@5O:9,V-YEE5)L)
MUFV,>4@(B;T$8/D(;6!! ^U[/T>I5QZJ+:[L^:F.>)W]D .\,:+\2IEHD//B
M.=PKC+6K;&LT )[!"E69O&"##L%O=[HM6'9KB^3AE"L0)KSY+%61&3?C5[)9
M]RE2C7I%V:_=#5+;=/[*1ZDI&[*<]K:#FK!-N@DK_IMM94U3)N":>MV:8S?V
M&I3E]PW-6^C(-X&CC^GK\?1.10]07TL -5W7X#H*1FJ.J*Q?\NIN]3?^KVQD
MHYV:VHKO]]:\8E6E(BC+2\K9_ZR;&+6+:_;NTX9CABB"AU)^KW\*0K=?W5#_
MG\@-Z'D?5%S"XR$<% K;UL"%(H4(#/V8H^':[2VZXFM!2PI4L5H7@4Z%3GQG
M_T!DX&:;Z/FCJ7J4Z!G<Z^$TR:;<.BH"LPHR=BJVW E']\"I=9>!L1ULA,/6
M:TFF$\\:NW9^1ON3[46)B%QM(;(1:0;G/)O6"Z3OX %'/YR0JI3B[[@$)*04
MOTH72)3OK3%P$YE_%GY*<W:%2DSY?-[_ #$(F]/HLQN)AH& 3!MV]!6A15XW
M06Y1&_UNB3JE,_(M/&DEH"S+TVG!+QFFS4W?6MNG2YZ[;'L].)LK/YA:BKX$
M@$ @XU)S'I)!2,I-JHQAW8 ;?M1Q 'C8"0B'Z=ME@3B?PY%J5> F"_LJLY%^
M-M::D>NM]USTZU.:GW0)R[GD[FO 9REQWG^0W\V)%+T!*(GWK[T-'LJG1S$H
M586CMVJ*8;_7@RX!Q7+64X^ZU9F2OXDM;LS7-!D&3L:PF98)(Z#QIU831^B&
MJ%FQ.;Q!D9#@=5F5-^_;G@4)FR9CDJ 3?)Q%I :V6'P2N@DJ;2\9%PA2B8O-
MX;X>E:8@,!?.^V%+NV'_,#P$A9B9'RS\VZ% 1"<<^%XEO=@!_ZESM/U8'<0^
MU>TKP7*2^$X.#L&S_QJDC.T>L-J<,+I@3;G F[L\2+(\9_N;-KX0@C>,0PK@
MS.G!#W3#OX&3GJ3>,06:-((2^-]B(2<UO?[1Y/M'JC?:;U=!]/QQ=+(.1'A?
MOD'0>%#[S:?(<1^WC,U'G)!Q3R;[2)!2/DK^+7C5RKO2P*A?[XH3@B"$ \9#
M//'I19Z\PMH*A#N1+HK64-&"(8'.5D_K+:)P40*G6.2^L$5# F451!_"(*R&
M'W-<&A;=6YP./S\BK-T;:SVY!#AC3L+8MMF6_Y+#"2K]IT+53A$2(4D4PB:<
M'X6$E@)H>DA<N"8BNGOD.JBV<7WW=5Y(5OO+FS6=3Y4VM(7$-('E'X%3Y]F.
M2Z9Q2LM\-;]V26[PJSOK1[;!EX"VM8&T\;J2:E;K=1%2&6S@-H\G4/0$0:*L
M>YQ:_[ZHZD6"/3U"AGC<%:&![F1%,N+#DYK>D" UK=\?0=H-G^]+D7^A?WRH
M3RI8;3=(YG:GI&RGGGO!:1[X4Y.:0&%&X.N%Q?-*-2!#\WH_5^5_>G,2]F+@
MHTPV4%>I>]^>A_@4PD90/NN9!EY[EF/5T QDJ)*1KOXHZ'^$$BE\P[Y_K*-)
M7JCX;23$<<V]A/DD[SIS*"8*RKH ML8N)4)49 JO]YX.7]2!<QC[NP79:G_^
MK600_OR.(K49U^H;Z\2>TP5C((MBU]=,6NH=Y<=[C'&/*R3UF I=*=_1S[^)
M $$_J3]I\M\KJ<$V_N/%G;H2,@_!.:Y^Y):M':FIA[,"I.Y6+E(QX+'/X<..
ME@JE=0%7.REW7^,U?) !C-:^2_1>2FX8X02ILV,.83?GP=8/ZT>7\[:L;IFT
M%!AZFG^4K(^A7@:41V88(WR^Y&:*Z/)ZXY;>-D&%2(98!&7?U[GNP.*1+P^.
M?;F8W]D,7TMEIC<@4E-HR2O87 ((51W\8(K>19$64F@%*2""HI?S;2NRU3R1
MOWFA;-$D6J%;BG(MY;>O7#/[B]^O.(\>B =J16?Q/B\GRQ#9XE_#XOPWH:)-
M4X=P>G BSS\S/SJC:C+YG*#^X4L"-17EIT(3)C^XG/ T:]N9YM)&YK]=7D=D
MMK..ER$[,B35\^A*)U>X: ;[VX<&]AOM,TZ)6-,8#HI>8W2:59_XNOK"SSSP
MAZ)Y[(4:T3H-J8(SCY]%Q V7Q;[,V'PX!E&@Q8G++"K'SX\(K_G/<34;33YC
M$\Z,-)W0ON%L<S&(^:?:4BN\3F-^I827TAG=Q[%X+EHQ-.T^"XT60MQHC\T*
M&U]]_B.->U*;!3S1HRW?2@2BSIWO[S<D<6F8@@R)W)9<GJN-23\3-S@$3O 1
M<"'QZS82!X(M^2I'KXBO3AL1E>"X?LY@1(57@?0HV53QG0V2\7ZV@)Z]05XJ
M&PT+M3 ^>P4S]L1RU4.-$0VQ)_G F9&<I_>\'O_-S6J?ZB@I]?K.G[Z%>/;.
MF+:-@9Z"5AZ.K$0EKR+QSB1KHCO.H 1+K6F-\Z7QG V)"]KD\=PB UT#S$I'
MC9M/TB2A?UU$+'2YXD7BV1%A/.*>=T;G+2?W1ZY [K828&\U'8M,8=>'6A<1
M%1L6@]RO6$60Z0LLD2M9"U&&#OXVBXPDT0AL2P>-L4RYMRKA1HI_R<*U!/0<
MIXG-9P9>Z-\;@G[SRXF'/\75Y%2+UC329LKZ&F^1[JVA+N0F#O+=405"&"72
MSIV:4&RS_5I6QN+]>>J')@T_^(\MWTD6U9%4<&GQO-+1CJ3RKW]SLF<C8E;A
M91Z\7(FO&\P;#/\X.)A*H<-_C+DI :[K#(6**FTK%E5Q;R?H\FFI=#LG3I"H
M(/)Y_;/4_YTYU3H[FG#$MI[Z+!08+"SJO.\[JP.6#=<IC7G!J9#FRPB.89QS
MS/&I=(879T1I7OE?;8%4M_HL[T<E]403MA'N)(Z]'_P57YW>NK5G)[NENLG<
MA^ O ;03>#HW/NZ%_ZSG4U))*K(=#7++7NPWXJ^WI[:8752<-QLN;Z 67LE8
M (4=8RE3-;EP:2R.I*O[/2KJ*@FR*U,O:XFNR>/&94X/*#\1D,Z;0@$J)[Y-
MM/9TT>CF*FGN(8=XXC]Q<X=XCD'1 7N4U8]C-6VYCW)89_'@02.WU#UC,ZRB
MYQ6:*'D;J?L!;08$:]&)"S[P4R3=LCD]R1^Q-F5O-%&U17<X<CH8S?U<LW]E
MS[^@M,GSIZJ2=&/EXT0SW)@^RT</L2+*\<1K$A/E%6;=!XJ __HMCUX=TV<&
M8,>SW[TN*0?\_Y#3^7^O='=EOVG;D8#NF]VI6Y;E(_'V2X.<"$&;\["7#['0
MJ=O;\\P9-[!-I8&Q/U:>G:RP.K-"9:#C?+2:G@B(<C,A)^ZU58%6K0-:JN9&
M2A,2&77%NU#'J1<S\_X#;];Z./I!OA+]DUE3T:KQD$[[('47QW[-1D?K14@*
M(0U+F73 $.G,7>^MASIF;:UN@Y4/EMEK"(!*,@2%)/08!_ 9DCG.4<Y,D)O+
MNY$7&J.:&N?EN+0;Z[4V&TZ<!?=M[53<?Z$R;@*VZ*F%) S\]"-0B7)V4C\1
M"CD24POG\XU+-<ZV67.U&'(E)')Y6!('[W6>1?WC\5M("\*%+S48.O*@M3:!
M%Z?F=%W\CB:.2N/C4F139.(!<.X?@=XAI1-2,2AM]O&R*=%)I?"G;3:V.HDS
M-G5M/D)O[AT@(%U?:L SX5Y!+LPMRG9S!DOAAP+3$&*N/1\3V?/\O:8NSG?6
M1!=N6)M/IJR*B'(,,\JW8@8]3%9?$ZZ5P /V^AN5?&<&^WB%B)AM:NQD780*
M"JI8WX"<:+"E.:$+X;#^K:,1-V2D^?I&1T])5;:[HX'<Q/V<^0ESS/WVFZ=#
M6SF^^YU_(;(X'CY\61\\IM6Y.T4/V^O$%\7H[?H57 "J!UGZ7G&LXDR]! C"
MWW_" VB)X^2'Y_F:CL1,?'!<<?NO<JPS!4E!/Y%.P;E)?'7D]577(JY:KICK
MW^7^_-.0/5T'7]*V)=)#REAXCCIV0RJ@^=&;\LXT)C!T.7$WZA+@WLD%N7+^
MY8#AUCK;*3JMWC1X&B0=;M'Q^K8.>&_VGKW4YV^W0OEO'%6[="W10@7G+\;5
MV>+K+P&Q@1#Y;&D#3XAAN$LYY?@AU^/>;9NS-HKHIJA>9;8;'>M%%.-IV^K5
M.Q:F#8,1P9@OP9MS7Q@J!^VKO'TW/]._K[=PTOWQWW7%__/Y?Y68!+P$7*<D
M6?KC1][> IU"I+7^O9 HJ#_EAFV5X[WAR(M?C!?QH'WZSA"W&)G_&CYEJ%RW
MY7YY5TN7IP_Z^K\F*-D(;(K9<6\GO=3+J7KJ#\/*"8 %_Y?FPO<[]\:!^GSR
M!]U7.S*%AYZ; :TJMV<NXDJB>@TD9TQ/^;3)3*1U'$.DW?EJX1>T9P0(1CF#
M.!C6O3FW8/B+XLH/(5'*^2@J)00QYR@3 [WK8><>=PFH?8VX"78VRQR),Q@3
MD.MQ[>::FTP9?@/@SAQ W&EMROZY:A+^87$1I]" _?A '7ZO[-H3US<;.J>Y
MIYC8(HG$NK3V^<.(3]PMVU\;#F%;=(39").^T[*4ZN>2+J7WII5340DRPA10
MX(+Y5%_H2+?YC'-?)RO">Z?:NY3P;V$":%M+YO7M]'<$]*)63L_'-L*L_R*B
M(7PE8$J4.C3RBUV2J7(_4$9L/UMK4.[BCDN&>0#HQQ#Q>XR* ?U>^(E0)HNM
M6+-AL+?U3V>"!4-\6'\F 8VZ!-"3Q35K2&@<*^)&NON1NVN6 'VIP?500$T"
M-<_'B@W4>(<8:>1,##QR]/F\0K8!QK0(XJ4D4,;6?]V&:%5X6C-&E&[@_=S!
M_;A'K*'4PA1O=9W9'I,;#1/)J8@+ZAG\L-L9]I\V@K*#6W&VFBZ$8[L\XS85
M^A&AKCVYE+WY=]P//A=T:X%&<BYH]/&.SBBH)/%&)$%YTVH4(@(A@,*^;)"B
M%OGGGL;M[#GL&773W#6G5*HC@([,B/"M]C-;C]GC6-D&! ^8H3?L=7:!\%00
M*+YC J1\/B"4TO7CBE$\_^TH7"%)[4P#HD- ;\40-[MSR^)X,;V+=SJG[HQ7
M/B3*M=@^UT^.I7T:\"3M0VI6XEJM_>VJ2C]@?0YZB1G<B<=LH7 C-T@REX#'
MXP@74WN#!F\=G5ED[8>AQFK*GRF,CTI2=1?0+&L=RLUC^/.L3J^$>@U'%[,6
M<Y[?J*#SPF_G%8%)11D?[L\-O%KS%_(0WF;9#;/>6B?2+ST^3RG)1 5(0:\:
M\@K? 7>.*@B_]#GI@#*?#QU4*SB=9VF++Y*OG!<A-1AB1"+<^Z#*35/U(-]Z
M5%[;TQ9WSRM+,3WO_'KYO(;+-=I@5B+SVXH,<X-]S@SUYA1>VAHDN4J2,S:X
MC*X4#L(-5),'8%,2E>-Z35=LQ"%,U [O[-I%\6S;<96D<!QRB;:#!:*&))7C
MN;B>M$\Q+6YN'4U;U%:(R49G2_P-[3J9# B@3(#H$OBVY<X,2 PHONMD:\*F
M"0$:#9+..1I)SGED_*4E<4''DOMY*A=WEL.?6&V+W&WD<P(*M[NU=J9/0N"
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M?32VJOZE>-3B#.'^_!7F*>P=046YEP="[I7E[?E".M^(>6(-!)E@53=@$P2
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M'F(>OH*Z8-(Z3XL[UBO1:/CS6JN7DL&=_E,CCYY]4BWO_D[[U-#P#H ZB#S
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M,7FIUN!B!E1]P=\4GM7GE])RBBJ]?_-9?Q^9;E PZ"BV!W&K70IS#?C3TUO
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M2']!\NTJIZ'#4P5?C?NIBR-KD]>N0.^@'4/1,0P)FACB[R341M6;ET4:E,8
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MO#+ZR&X%<"<0!0L87;8+P>?=3.G@C!ZX_&C#8*(-T.BK):L(7_*^YYLTY9^
MNLT!K^0!%4=OFWA\.8X<=3&-N ;<W>RQO$GD'O/<F& WP8D42R#.,B>%FWR;
M-1R":XLC\D%?F4R[EQV'2T'/RMD74;[+J5$A]/B Y<2"VUMM\O? @1M6K<ZU
M:2HE?>NS&Z;D57GK7K,O.*N'3_7^;':W'4:O8\M*,:EL;ER4M']-X>P%EL.E
MA=P[W9SY#G%8R2<I._\% ?0O0P(3WKV#L'YS720_(O*!\V76;<B-)FG=&_H+
M._,Q& S/;+QV'_/K^0U5%ENO3H(Z'KGZ4TZ/!:*(BXWVV1<[VNW,.8!1=WQS
MH],!O;\?K?_DS9@-!ZON\H*B<LG:<D+>P6=-5.UA#G.8.((:_-,6QUG40AR;
MAN[MUT35>:0ZU;4A&[VZ>I/S=<';UGW5EW)X=5/L8E&);DZ4G>M,.>Z);'3'
MG$K FPJM]:'IHPHRL3L\U&KC2O-4[_ D-B\)G-C>'+<NQ2H?=LEFYCJQWJ.K
M/,F_23=>EYSRT.^!-NPB[5@5>?' %?6>9"X:JJW%!U/M%K =M$<>7T[#SOVC
MM9\YFAZLQ7P/Q-\];>4']-U!\I6<OF)/J'.Y8._F)CVY!E#O'NT&-L>UJZ_:
M&$"YNF4@FI!Z]9LTJ<_H;H\]^'M6L_'8/#P)T]H2ZCA"H>X,*M:&X:N.NYCJ
MGXR"Q39-EDIY3.?3&&<WVA^_>"#PL;"3I9.DU8HFH:F 4J(@P;\.KRG2[J78
M6NPJZEIB-[0-W<EFNM>@E>\_>!/4$?X:,,MJ_QSI[A;*0GQ(4,!Q1[R3=UY&
MT.@X89+]9C1TM'LNOH^C7H^3\;^UL#<5O.U71RB)H%X4VY?X >.JV&_WPDII
MX4(35G&J*<TPL%POXBV3T4X^1YL&U\&"YB.&K2U</T.]N_W/;*^N+J0%W@2K
MW8,@7\?=1#.T?3V7/>WUSTGNJPR<,1QYGQ8W5#J7-T1F]=6YD)0$'H+WPF7T
MVE)B:2+:Y0K1+C.!J#A?!+TX<\C#R9*&1K](PUSW;QI5O2,\H6EZ-PQ2I9'!
M7N7:7A+)#=E9NZY^.%X=C[J "$$>IA=X]A\?GH=_=684VTA)\EK/JC@>!BT+
M9&!$.7LP"NJ]7/P_&Q/U8TWMJ <K/<:1:SRW2VD9YR4S36]S""RS>[BEP"XE
M79IS#FHK7&WY<6;1PA(_(WVK7=G(RH3W#LO>!:0S/ARF;R$-4NZWJMS,.:VR
M6V&4'_85RN1R7@F=W>Q6I,%N1HASBLC]$1\AW\EP0QNKK7II.M)'U&C\_4CQ
M!< )MM65B44"ZQ>S:\#%)CBRU/] AZ#^-".SR;_RYG;%DW*5YO<DG;=OQ>DN
MR=_XQCA2OF6'R5A+7VJ]H-1,=X>1_9";8*V>;ELZ[$(R%)F2N9)LR&G?)^UQ
MQZ\U.:]Y8#_K8[W&WMK76KX,ZVM ;VIT-C==B!Q!8O+P),ZN)X1:N^.-+ZN%
M]F#(BGW$+>N#N\4^0QI=3HDM$GO:XQD=6AFZF'4KZAI_C!0A \%P#?CS^/ :
M\++#Q^1_=L&7ZZW:EL+B.43W_B%S@9'_BQ_I=.>(>Y:9J%/PO^F1=J?@_W=Z
MI 2Y<<.4D\R^H5BN3XG3GTY*;!N><NH"_7+_V<?;LA.5Q5#9L/]%8_/_;8I!
M5YF(-2_\]C7  3E#3-1Z^#_&0C_9"?Y;"#Y/N]5+!.\T49 @-TX4 M.;8VM^
M1/W9>?IYL'PIOFM  [$O!.C9MDM=8H;? R<NPY(\( H8=M.4E_;3,R[EO]H3
MY;59#VB\IO3($&[5V?AH[$@/D%&<?*S=J,1JY^R)_^.AISBI\S344/)!B9F?
MQ9=!4D%6H:Z3*X,F=KHM.04C(.T6;-23Y1K0)=:@/5@I@$4E>?JT?%YW]V5W
M:J/8X]1J4BPL"$2.(Y8_EST8=UN4<W50*A#4FU"NO_3PER8D!R?\?J]C5X -
M70L28E6J/N:FV4)+G,?Y:MM(O:K/N0;HMWEQ,$UO6:PY_+E!5 ^\$K[Z0B0K
M[Q(E91$AM$+4*QD+#'.>9RJ3_[J;O_-%_MQ>K]23((RG7UZ*Q$H1>-'F5MO,
MCFV9$P'-AM3+K9?%5YD LT*SQ-2AD+J./ D7HC,C1+W!NO:/2C\L"F*WFL@]
MJTV\2X[Q9 4?L4+E&7'D:C'HP=X'3.E"FL7F*FIS2CQDL91D&I3)268+I]F8
MT+LN^1)CI>/M*L7_ZJ1CBZASQ1P?[MF>WP]>Q2M0UR?/VLZI$9:):X ',"KG
ML'>)$LS=$TB /YEJW$X2DHQUYSL[:W=Z-1P>IH$:H%Z$ACVWDR207Q4K<A)(
MK[XA7%&XI;C5T>'S^)=9M7_IAODP,B)2>[?+TUH#5Z'!7<MZ45QD> >^([!Z
MUX5@C--7]RP;D3YI1Z\M<ZH_9[\?"UT#(H#4C3J6J\8=6.883PFY^%<3MM:N
M]S2?U-&G[R$U^?(WBOKTK!*&\-EG3OA*+^Q,-W<#S3YWT JG?2@Y.+OWF=Z;
MLMFJDGT/@>S@/O;D*N<70]*_#\ 2PW/@GL[II294#PT7A %G#'\Z#>>Q_?5O
M"RL2[WNO13:X?=WRE<R+448CP0%J8]49UZXK85G?8M>EUY(_V$F9/[I#2H\@
M[0YOA]SG4B1766J,NNS(Y$FQ2T:M"&QYQ DWM9UU1+WU=A9M#V_E6LVR&/F/
MSLHS3QW5@=<A_WS)7(QGQG+W*3X[9O1\MX?FE'_6=]D:Z@\@L#8'WYM9;SSL
MMDNQI;W*;9#KP7[<;B)R3M&DQ";?VF&?Z*!-E+<Z;K;O]DI*_G(*^Z-'CU=1
MQC5];0N-\[$!VORP8'H#JK3B[U7J>S]G39N6,=(*%4JDL)IC?7<@7)0_[C(D
M9M4?7@SN1^M7+E=R.)0]&N 8>>^VN8G:EX."_<_R< 5[WI6+5JB 0G#=A:;(
MWN![?X4?.4RHXEB5D\HB_)L542KB? &;O&@9.$BG#CM\WF,ALC'V)ERU6'.]
M^^\1?*NGPFMK?F9>,I1"GKE<O5@=M,))/2MN81LL;#^!,7C#^_$W]DVH7V^8
MIK5CTM09UCEVR;9MAEUE(M>RK>F2L>^;N]$^O5)2@)Z E-AKFD]?C=O\IV*%
M1WX!;[K(>N1=RA(' C.AR8U-114$K4^+"^HL%B*O_ V^ASCXNE=IL&Y1!:;&
M2.B%YSCOKUPJ-_<YCB5*7%()Z-WK=:KGECKL>_KB8\UP*R?IC>&0&!5L>9?^
M=IMI 7>4.-^/<0^JQ3RW-A]E.9E?-P?I]KME>#@'(].,VY6PVBN;B7R3?-/M
M=U:&+6W4G%K:LXZU8]1;/OGXV[>^997/6"PU=+%N @K?KYT6N08X(M!BNRM(
M>#5S=T"[$TBD@(Z<$OVA'>'RD$8.()E[_(=J@<J/F_T0?FO7TJY+2&]V8'$4
M8L VE58G2RG&O^9UZR]RE7;P$*V[E\^QZ0$ZI=$:%1\F5XO5F!"?TY'3BGA.
M:2KY@^_] ZXJ7E(/:ETUF5_#WHMT>(5EX(V=&5E8#(&YT(4M[_?+YAR// :Z
M%@6U=>NPH/"$D,$A&;TH]P,XHTM!LS]*\*H(,T$Y\X!57DHJOLCU"566K-I3
M,P'@$U'.$M*-80=B7P&%/"=NM7.IT3."($ROLJ+@;! N3O^>>@L@I??V&B#%
M2UDY\]61Z_2"<U4O.H02__',$X.XLP7G#WJ>ZSSUSJ'%)6!DP)R.+,BGTIU
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M+R_%HN4E5C>BT R]X>03WT1-S(_\F3U74BL Z:>[_3^UA0Y,_OZP2DHV.PO
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M@4>R932?2EFR /LJ'12HWY']WA:)N=1"?2Z]JQ;<3A!X%6IZZ/B>(QOIWV\
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M8<G *1G(([JCLR5G2#_:$8-%>#+P9OK "O(C-(D,L"C@D*=T<V RT+9'!I+
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MP!_*WI]W3NP;[H1)$2_AWV'1'2=*77%$[<=E,%/%FNH\[21++\S7W0)G-3J
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M@8O?QVG9NSI*9*"JM6VD-262%O,HF>>5B,E',Y,A"@,./2H#@3N5/07T<=>
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MC-*8^:M-,*-4& N^;G%WEF@P!-=3=</V>Y>X*AG+<[&^>/"&(?T+Y7PTQ&0
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M&(!@"FN!C2Y"H\*$^1V6D/0NK2+N#J^-RAYS?D\X'=GPQIOGA8U!OQ+;^,F
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M!7CM*80 _-?0^MNHNSZ0O.#S%] U]IK.#FF99%UZ#OBKK]4O;-$1? [X=V-
M=__F;-#?M+B\1J5"\-3G@*4/HSZH6OC7+?A?G:+S=_M"5___(?(%B!WO"MKC
M_+<8:/ D,:O-AQ"O7@1!P/$_%J?_& /2#R$#PH3+\#TE._FYB^5FE40QJY3O
M-W8.8-X1M Y;H0H;+/I1X^XH2]?&N F_Y@> TL^W]1V0@(/G@+*[C2KJ ^BW
MB5#=Z(=;SG@=PS<;OXJ?VWF6J=LOQ>[?*_J\#-W.6/O\-0>9C++C,#I[CN_
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M$_@">NNH!,=4@&-K\:8*)W'V8 1E6X_ZG+/-Q+$ITY=GSMJH)9;\N+G#6L[
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MTPZ-M8 53-[H98[*7B/;[$QJXEQQ'R/?\T>Q277KI5MPCB;&385'8<>&B=I
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M[+&:B:7&W&\ 6GK*:7%S<OHCLY3X-(>%1J[QDT6W#_-OI>-IQX\(\H5%P3Y
M.MOBTLS&\A3JLF^/?G!'JQT@;]3YJAVYC"?)LHGF0YF.='G>DX>41A^^!,\<
M4#8:/!?GRJ-R.[)9MFV;3-V]/'V+6^1I++QNLJ 0J#KN-L=D,W[:&'I3C:];
MX>&&+Q!5Z1 Q;UVL?>W/$D?_#XV2LW2>"#;X-O/&F$/-<0Q5!G]@WD(6-^0_
M^_OZ%8I5EN_ ?'Q@BT_D-O+H\%/7+5:8C^,-6 <-K9_3O,Z/V.?J 'U]%9O<
M(^],Y/12I58XY\TAL3/[3:+'<#]Z84>6PLO8\9Z'E<IK+Y-X\[B YI6ZG\H
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MS\C @S#(-E/@2Y_X)MR]KQPYGX)O;IC<ZC\"N<%:XDS46A'!Z-5?:0SJF',
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MI,B*VCGSG>>^1YRRPT/5Q%$E)6ADWS*VSGM'X>%U+<.TV05]@1N/ >KQ"9T
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M3X1FLW]QC$]]>I2QW5+KJS2%L#9],OY3<\YR?;H&$H!U<T7M8E57,/5OTTB
MCROI5UNT43KI='<7,N]\6JMO<</P=R NN6-W6PPJINVEJ^\8K[1]4F^)RU99
MA9\!?^#B&'.WP[J1 !?LWN+M') $%ZW.<^L1X*\[7B6\[<G7NON1<YFO+[LE
MAB 6\5"[7+P8(5L!^!EB$P6^XJU$=U&E\.=IZT+TH&-J$2!Q)9KVO@P_)>,^
MQ5Q<_T>+6]JJFJT']>6( ?<4..AC:6553&GZUOX!\>,1*(QXT]NZIXEBR_=J
M:^%FTZ-G'\5$RIESXRGXW88'@H;OEL*H(*YHNJY+S_V%.C-%1Z4R'G*DUM4V
M&253%%-@ P_9*CZT79<):>,-&(0Q\&&YD7W;.4E'_..#F6E'\%F]W/,)W8G[
MY=_QN:PKSFSK;]LFB9QX#8Q8.T%FJ3SXR%)LS.,"?VMC;:43F4"JX":^0"ZM
M*R0G(S)?O0JWH"Z6^5[GE_]K!KQX2&RFYU P]2,!4C)T*R%ZF&.DY3O7@U:_
M'DM@;.Z'Z043B_E<^AL</1MOYLK5%)V@1IC>$*5K6*6I)VT3M1E4G59,9MIK
M/(:K&OUOORX%RYYQ6AZ^"%%"[T:)D@".S@9&(SM2G/>&-E'R9M%O0UHH^A/W
M0@ECC4]6WGPMUS&PR\.*';EBU.->\D^T<4Q/:S-O[#WZT2XONS?[@"+QZ_(7
M?<6X:+%\OEPVI513)^]]A_4?%27M&^G$]P=*N6BO'7Z6^  0[,*&C)Q:!5+Z
M!PE0NSPAG">N,;H[^R3!,U#Q3MK6.B&OC<5TT^B(T?M8.>I7+\@^<C>!%?U*
M[4VPRK8$F,O;$->9J4#(5KJNA4[Y.FV*\%;:E)>NKY>N&GZMS&6CH3Q+/2L1
ME'3I5=IQ%)&^$R?4B7R WC*#Z%4_:[AQ,&56Q&^BY&.3#GSCRLH_Q[F5O?JN
M\&Y>7ANS;5/K86+A1"[?>Y@NUC,@= O!U<:)?8Z2]S?H,55\WY78+7Y?9#3"
M/95@=F[SON?->F$B+]:0!.B0\"Y =+&[+W*&2F@6YW=\N"+0:7M*:]0/I5:0
MS<>&')77.C_L6,1M9YX?*P@T[^)0PS&Y .(N4Z\7E3-:HL4BG0-N.R( +RG4
MD< K3G>VUI[P'QNJBPF>(2P,Q&,O'):KIHZ\7EESR,O;=6Z:&V0E6%Z:)8CM
M;08$VL\.QK]U+['0TFZ*.NKX25DY?V\N2561E0M5/N$LH]LPZHYS$M)(N6CF
M/<F::QD5=1MP>L;0Z:MG6SJ'V+=OS?4ME:U)>WVJ7:_/K)O=:;]+Y%%JZRV3
M.QK6QG@FNEG[OTSU3"[6+'-A;,CF+#$LLC3K3]5;4 Y6>WIKY-?<%^#681YW
M&+IB>W<)>'Z3CP1X]"/4R^=;BME'&^[I\\_O6"8P"08" *\ R\P1)=BQAS^<
M#5'$59'E=@?Q3<A[H ^,*HQST "=V@VD]MZ940"A1.0-$]4>>3;0#,=;M+KM
M*G.JBO#JP:=J%T38RG=WRH)C8-)/S0-JT^M+9<0F76J0! F+6".]FO 5?L%1
ML>\PM4T0A?E$;P^8NFON^?CD#DZ81@?*&&3IY8>YC.B1ZYY8V(%GY,[!D^UL
M%7N^940L)JD"O=<#J;]6?.JU\PG@XJ@I9@,7;*W;D #<D]DIJ+6Q%3<\2)XK
MNO@^?U#YMNAV>3G/*%^&\R\1_G?]5>%(BXLV,5RY=\MG6Z[,S6^E.>\>41I=
MU1>X=&3&*W,UZ<IKBNR7V<N[_"M.8V0I^@5B__GH14W3:)V3X9ZK)&ZZ7_-:
MW#+(1_=Q9XC1^^5BU-.?)6JFO0U/=MR;G5U6K&_OY>SP>S80Q!HG1U2-X-46
M:D-.=DG&24]G+:EI791B9*GFC7YD6CV/6AL.*FMV]/U& GSYM)A' O@A3O2A
M'707N-G;:N^0 'H"_JT$N,&6J2DGF:F5-F?PV7\[++<C7K'M.=]8?IE\Q8WS
MBE69JG>Q @T,"BIEY3IN1Y7**YE;NZ<TLM;SPN0*JFSESI!KXM9</)/8PTP)
M N+4CCA,5(!2D@"A2MM\(ZA8>PYK3ZSFSQ@2X#,^("?.F 2X;>(E9VJZ3A<F
M%FWC#3.BX%D^YBIU(Y;,TV$O'/>+A>Z&G(7HE23<:=^3Q<$/!@C))(!_0_UE
M<DV9M:L60_&2+QISE[8*[I6A_.U7/5<T:6!-:M[Q%;*G00\A=+3E/<N&DZ+O
M(WFY"",^PFZA<SVL\5E<P7'&QQ=%UU;7\AT*K_N5?'!.2*#0OJZ2I$P!TU?&
M.P&\]Q!ZTTV\[R>_F%%JN:1?;Y]^L];&A*](C"&,WI5RZ?TZ>SGC5HJ(Z/GT
MBHR[XGUX4-<)Z&MAQ5.J,A=K)LN+WR7519NX&LMVG*WUKSY^I9V2]/U3;.':
M!^2P4&*M&*W*O)"KYHBPI)!DW=C.S=H@ $VBZ'FJAZVJ_-(33=3U9&98=,6H
M$X;6)P&F@^#VL/,5L2U FS+,197 $%?6,W5F*BFW<=\^O3OLL]R*_[*11;?J
MZ,U3EZ9AJQ;WY'EIW.TG<1>N'TCV$\@@!Y,99;MT;[?,N!(O7J12 V^IDO[T
MA]49HR>'*?0_=#=;>;:.VXZ7!U<_G7K,3S8\[G-^0U&KWRG.Y#W/(5Z=J4+Y
M+$3YRE1MP""430S"N*PHUCE;7D)K>7Y2C+MV(FN<Y7M#,#6K</*YZSNV^II+
M)<]<#)E1!X^I$. ZENT2M-PN2L'7JP,8Z4N91ABL-F^+\"]]D"*A,7-BU=2;
M>NWVM="7TVQ?9^]8&F'VCZRP[<ALI+/O,G(HWYDK/V^V4QAM)C+&@^Y=O>VI
MORJ>R'WVU04%]A/[.Y3T[<R[EJ*$1J*D]UB[$@<Z?S?&Y?K(P5W#"];5L<\<
M)I[<]-G./6Y^\LQEN;%O+5!6#/N$*#Q689UN/EE;<7$0N$M?9^'(NJ;KQB#Q
M$$19$J*)KF6AWTQ%T%>('::#%Q7:.,;X?,SI4(PZZ*6*(JKX?-O[&%SWDG-C
MJN8X2M%Z7%)+H--?2Q4VV2P6!JHU"L=+8<0Z37>CVZYB#<Q&:W&UF6N<2NUE
MMHGJ.:7!?(I'3<QWV[/H"D@ LKZ(LSR/;LL&O<6#T3AC;!#OBEBA_7%:;%D^
ML>SU=%?7S:Z\#J8=!QZOZY6/=<RX%#&,RS0.F8*3'EH[AL.=#.8Z:Y>HVE^9
M9>BPJMR\Q0L_D[*@]ZK9VHX;Z.9KR+_C@S.[C^GL920;&HK">2SW5X1-W+3#
ME5[F&O/;PB;Y5] J(ATV%6P]FA5IFH, 7YFH@+M.OM\:&T:?>/OV+S%_F'NT
MMV@>?^KJ=4.\+W/K"S_N9LLZWV]^6EA9V3CA^JRF)EBKI'A>G>EVL9TG_QEE
MCB1_H9U6/R(U=)GN?$ _^U17F7]A R;L<_Z>M\MMZN!OT%)QM&YZ[:]9.6LJ
MGB6 'Q6>7H>.4KO">U&SK,'[E-5:>O^1RMEOGT I\IQS7EQ+IR_@)B4G382D
M@+L+ <-@+H@8:B-3MZKSU75XV#4NYQI\M0#^,I2&&%>;H3]E/KI]>$T@!37T
MBRF3+6%%3CS<$/A8%6#VW[Q-0+$Z_&?<^N,_O<5K-TB -R<U&Y7 ]A.R9P5^
MX'OC?Q!.Z#\+V O:+M9VW*6+(]/0V4-T[)]/[Z(_D17N^$F /:H'>A8\9; K
M>"L'?D?)YB\Y)H6Z+:]58^(CI$08]73%>XA4#1_5]4MO.VD'*5X6: ;BEO>R
MZ))9CF@^UGJ7 E&&^=$.[W=,W+%'><\(4^>J!^.6@A#,/RR)[9D7)@K'#B\9
M&$_5:3_O7=,L%PT,6MDVO=*LP8IK7&]S^JD83\"<Z%61 &T@00!6!J7;N6.&
M'.X>Y%)DRR)KZ21\44/XCR0;9=8[;&S@=Y7K05LF4V :*?#;-D%G%K6QYQ8:
M'?TN==0,R]O-X3R)&4855H$ 7$GRH'_Z\G!P&P/V?;&Q(]?UT=S?!^G-YH/U
M?G#E<A>5[=)B9331SI$U(R^?C2U9-X9J#L ,K?M IH!O6$5T?^?2<6<&2X?O
M&Y\$!_2VP]OV]WT#C5PK:=N;?QEN4I3R!0I^OI3_N"5Z?S0EX2"+[B.1!MHW
M#WE! I1[POJCE/[RZ> .HAN,C"<FQ461  P'X,2#01\2H(LN"DA'I' 8L<3&
MZU6BYV7VWL?JTV4B>_49I'BK,G7N#K?ZGH.LXHSPW!,MUL58L^ZV*XV5J3V+
M'/OYM2,>U^.Y"L\ !EC5-CN!.KXAP>(='1D//S-;Y)  ^3^W?D3IQ12\RXS(
MMH3881U<D67\O71E/T=_FKX?-39UK.RPM?NX=U7A<XI!.R6'=9O0B.CV3ATK
MK<SM[C?46QQ%G+I+WA7#P!BYHU0,_]%K-%<)TLP+S5L6'V6D-:X@97>V]#&B
MV68P,R^;LAS:IO+3,AN= G[+Q8,=P%P=UL,FEEG8MYW[2"]<WY-#O/]26?R*
M.(L0W'XIV3+#O%$MO2C_187[\4A>O=G6AH?6Y7<^%4[@-]L7_;R=GVE8Q=X(
M.\_,_?AS[O3E]\SEZ7;6PM5FLYVN/(7B"GJ?4Y7R@H:7P5=D>BJND0"=EWYF
M"G'=:B,+3(ZV@S-,?[[M#?]L_3;N"Z[%_:=%>5497@6+P<QU99X;4?#X?5CX
M/KHLHWE0-)VF;G5[]&9&5X,JY7*<G,<PJT*3V]I:FJ9T^M3VC.?F;%5Z9Y_E
MKBJT ['FS[(,Y\""D0$ATG4HK6_N9>*:^FS\]B:=\AF?+SSE6?EDN#=G@G#8
M8DEFJG]]_2:?\N/B]5^)4=B&HRHT?RQ>$2<]TXV"O67P3EH;,(EARZXV#AAC
MO&O<5<C_YL9)]9UA*D6G1JP9*I[9 5CK,17L 6)&;/E:1(1D?=%SIX?,'--^
M?W+Y&A6G6[=,L$Y$7>BO*1G_]_5CWP.Z7[]1^YUG :BC8N7D5-/7$"X27>5Y
MW5PLZ^O/';T,OJYAX;6A^<';<SSAO//+/S[9$*70/&#6 %XG^"7\3>$6UR(3
MQR9XO.C!FR(KSK V@&J[.;/YBN%NM]C; (4Q(K\*NE,7PQ]7+KE[^6?B@$\Q
M%JP3=VPXSA< Z=.\+D@;U+O5[4!(-4A/S0!;XD3DO80VJULK"-R_'M2%RRIT
M15[5;O8* RR/*;U?#[B$Y;=#0J,L!3"KD\5NI4YRHWGT)YC/^9\NCM["3"\Q
MZ!Y6?#J <D%\)XGGL)VZ]6/X!YG71W^A<.=+BGX^']-OJ7H.&2Q"W/BHO),\
M7"XT20)8(]@&4&1ZZ'AOM\>W(5JL=)?6X'[Y=%G9KTPWXF=S.Y]O_)Y0P?Z"
MJ^7L[U8*TF;F+"3]:\%>SWD?/EGFAW(O;N1$[5U6_BQ6#$K[EF(D3M^S\_DS
ME$'5,B=08;_;%34@FTRDUZ6R']-Z/=W4.%Z><J.A[2E3"IX$H#"7A-;H37A\
M._3; E%OI!81G[=%Y/6MG3]DD,RR0]@A+4]4 <^,O1^IO+1J'=^M4S9PL?/0
MAFM'?<%O41ABS1&VG^Q/Z[H_E1?2+PC./]#]XL'/C-#3+"FY)"\/DT(X@.@5
MKB>)D 7Z0)?>>(^VO@FBX[852M-)/)'*0+I&9]+]>*F=/Q5<:DKD_/JMA-[K
M)0EPQ8,69'J:$*C.+=5EST4[)I7!OC9F-N*\RR!?G'3'WY%U>R'!Z-60[%+4
MB>!'RYNQ]@3#9E-0I(!HFN44&$WW@K7?H(!0)WEH)MV<0N3 #JA@"F)$:Y]$
M+:2>]7NJ',_H>P5TWQ!B=*&^>;2.M;+ASGPI;X2AVE+Q46FLT%)#N.0%W:.G
M+:>VBYHLDPVT-?$O#P1!32I<$V6V2+/=AOO2A66#GU5<YI!A2W&@]!I9O7WZ
M ^;M6ZA\-<DM55F'S[ZN;?50CR&^GP*-8[Z>?B0 V&U4?T35M_=_E#SV/UX0
M=,\O!Z*6$0AO0W_&^U.BM70,CH[68[]*G\=IZ@59#-=A;V578T^"5RKNEH3Z
MK.3Z71)JYFQ30;6I$ZI!2QE*U(2B')C%6!J(&J)\<6_KMNH'U]MWS8IZ%P_V
MJ8;NXKX^;]:=N8B$QBHPYF%A3[&1_OY%WA5ZX^P4(CMCYM#<^WNYW(S'%M&5
M7SF846UA94)CL8)Q]*GB%GIOHD(_&33BIR 00FH;-W'0]V0,XH;\66KE*>3\
M604W)U2UQ=$9LE6+C'@EU"]T^A[#'RX9SVH_):?6G#^SQ6[1OYW9?WHNC8TJ
ME_OL)<@-S!SQPBYZK#?)W!%$=Z@%CSA-3T)8MS>/3>.XKV!(@*_F0839K]_Q
M)CEM[=ALLM'_C,6A?YED=G8>M4E6JLF[0$#NU;*<D>':27;3%&!I[Q(D71SD
MTBNT=WS[[%&8( /-IMS+']"-AQ+*'+%,^1=XN"YL>V?=X#G3IPA8"V2(VFH1
M08?T*MW-N('>#:G;>:U^]V+ASV1M$B"KN"*/R IM%VQ3PM]/8QE7 #DM-5-9
M-:UWL3C&L4SUQ?NM3P<I X%&)7C*WT@$C,J=_ERD1A\<5PJ=:QQ?.R\DK[?%
M4QA$W!C@ZH _"2"[9^U< >S>-%K.ZKVS&8CXP[OHGN\5,Y)H?QH!41( S0<X
M-5H(8$/7QR\-,DRI_W!O5KSVL.YQ@HFQ<F4GZP%-UAEEH BQ%XS6J: ,&,"8
M;:4%Q7=G*LVE3*Q'TYLRR)K9#Y-)$03?2\A\?^A9EC_G9&HQ"?-A&'9XPWA?
M6$><S?A9"):]014 E0'7P;]NQ<^L+R.B%*Z/,%5&+<W_')[9L>'-[2V7!7^>
MVI+!,X0<!9$ 815H@+>!7N.^!^+"E]H;P]^/RI(9_9;7P"]%?([Q5T%+5'A>
MX.5:U\A3Y_HMPEG=:O [\Y2Z!'0O8:KW!R.8%MHNIZ0(# +6EH<H+K1'W)N<
MPPGI42+O:2@;@7[5_R/J&9WJS82O5U[3N?W]A/OOY$F^YXM1H*"<,<TQ5RFS
MBIU;U[Y5-_C *&3EGS!&X1'D$:HO5YPRM*B3W;#H>.)-N"W$87F8#B(_0@+4
M*6B5S&XT>7VXB=.>V];NS1HN>P5%3X*H2("-[ THELS@)RL*!O9IU=CC:PHU
M^\#^T&\':&S4N^P!5G-\P=_:CL<^"9 C ;*%NJ#86U]( )30H1V1O7>)!" P
M*=*1]37T=!S::8P'D@ Y$;]#6^B2 *:MH)T8,($"WHN/@Y4_)0%@T(\G9.FB
MB>\%'_!ZQY, YUB >%4@N@CO00+<,_J=H$B/S'&[C#:'\5+Q[23 Z2U?()$L
M/(=%)$!X%19$ JC2W2?O"QBQ#CC'"C^E@L:?4$T)D@##\.__NP8=_\\QAVR]
MAZXCU@(,H!VYF"D"M>7O!$>J9,9-KXX7!'%"?[Q'@?!,YE ,\VD-"7#)&@TE
M1G%%D !!(((C"%D:0.Y@Y/[ON!_\)$"9^E&/&#$(L4Q4.>R'[^_N@P3@2#WL
M%C&TXG>:I9QE$N!M+I$9& ??>(@!$FE$0=@H@LG?)_W'"N;BK%E( .5=S.]\
M0JO@D^,3V#O$W^#4^QOD :5DBO7GO+%.P! 2X.#Q 0A/30)LZ1&JHLF:P M+
M B3XOZ[ X_##_:Y_ GKK[T)H"/W;W/]<3.)T-PGP0QX/_:;4:$3T)]JMROP5
M4::_00XN ?TY][^MY,OGY)\YB: 5H'D)":!$ DCLI?^!*>A/T"LF8'_.^V]K
M67\'>G"9! #NT?W?$.*V&$("WK\B8 B.?L=IARR,E9(H\4_OQYU/Y.];/?FX
MT'*YN>?.AM,VXH]YZ -G!Y;06QC&^\"C0S)>I4)K=V.T91X6L,V<D@")GS#,
M@JH]3PY./E'AI<>@(\#?>9*"0XB2T$YG&0(9G[=P["W0,IF'XJ5@[8C36VDL
MQ'/0?\RA!BM/G@/C/?(<*HAU/EQ#H ,:X@DTL:\?OCZ&UZ$@7G. ;\3_(U&3
M"@G #D+6IQ/)L'2!\4Q 3#D)0&0?7MHE,&E?)*\;_/<.-,%SDB4Q,ANZ9/1;
M$.V I^>@$/@W62/\*33RZU\'I/Z7T4J1M>"?U;%.H!#X@9ZD&)[F]W)NDY=9
MN6(W]82*##%,%W.7#NM,1CD']#O)TSDJO#UY1K.NIV1)HX>B'T-[FDF /UH@
M"X0=VHL8Q1=&%@@PP5'Q$W2#F;!'WG.KX/V?1/XSY MJ$0?JQ-^YK,@^;BP0
M/4>6D =0E!B1A@X[!?VS ;)V()(%:N3!#SA:Z/<&J8DGG(6W@5<X2HC^H*ZE
MOR*6^P>>NR3 G_7_ND1'9/'+,CH>P(>\APX78O_=!?[G^B:\KC@Y( $8 _\
M+/ZO>#K!_]8"66U!J: ;.?9@+//OG3O32PP"(\3V+I.WDQ(,]>JO>(W\":<7
M>4O]M8$_),CO+EF=".%6B2K_AR1PX-^20(7F(_,)*3%6O \V S4'H]T*X*B<
MN%%_6[UTIN6R)UI-HQU/G=.Z^Q7*"F'&R/D508109I=\S9Y>DC,9:.FANV=?
M3FN^JE^VRF7!T)!3%68B^W#'>+OD&U&*.!C B9TH=C#MGLS^C(5VR3V7-)QM
MBWZS,E35P$M]?<7C0"'SE9MEHZK5P]*-@<ST&HF8?"KOFB[&H_OH!V!:=QA%
MMVCQY0RK$O6RNE%S@<;&)G/\WAW]"[(] (XS43L*C.@W#]#\T7A;E!!U!7\+
MYFF7%\O(_+<R!G&!Q]QG5"@HUWFFO%0=A+4="O+Y=N'K)WEF);)\Z4KN#80P
M_!E75.CXN:.64T$PU($_/!,G]WKXT_I C]M.YB<[#B--C,&1"7JX"\'<BWI;
MI^W:D<ES)=I'2HS.TC]-<YGSJLZ%NQQV(7&R7ROL<FI/?_'V:0XNV(.<]8_7
M% S!,_+M^Q ^$-TLSLQ98-?H<<HOK5WI39.0\_,FXX'4'&&/08QIT&[8C'4G
MD+DN V2:;##9(E]N,DN(QJD_:-[C3:/[!:+B3OXY/E4SHE_EL2QJ*^,/Y6PW
M+,KXY3T.JDX-?HD'+;6R?]^\:AC /'Z^V&%5)W\=5NP0+;"0B>VM%^SMCI\I
M[(0SX56=4'<^.UE>Q8BT6"I/X$'>S@5)8K] E+=7EN%26[6/JYZ.-YXL'.*]
M<-T[=G[SF'#"^Y8[9&/2!*84K4$]K4_: "L5>#A<0G[BB)CW[E'SW.D-:)E2
M1[LNA4>BS;3'L\=$#SGU<0:?S!&;OG6]&6YOKK.>2Z?((GILO'LRP&CJ]NI=
MNO9"Y'BZMLP7/57F[_\R:N)_7XQ-C]\.ON]P:((\WS?Z<+:2HDM#D\LFE*+J
MU34VLO>D,OQ0LV_FDE T2HP^XU:GG2T%V'&*1_CJM[L4"LV99S_'-/!<G;VW
M@M%"#I/5E"U;A<L*BVDWJF*VW"WPE29]UB:W_F M1P(=3Z8#1 ;9GJ/*,\68
MOJ._?G[SL(<V(KE.A:?T68K@QQM>'(83!@ZBQK'-]L%1MTK[?M^5NQ(S9A/)
M>Z\\>QS]-%P%+W#PF KDA\9ULB>G-J/7DMW72W2M&&$3]M58*#)6ZGC6^XUF
M'717Q8H!..*4E1/(FBC\D)GI9M'7ITMT'9\ 3+7_>9^52@(C]K4)VH4 ;!&O
M3CPW*95RDG7F->3\J#&\Y'12A$U>BM5%BG5E>'6RX)#CM5HG(M'TP0]E^I<W
MI2M/IPYPX%BRFC(1"PKI@#.Y@]X>77E9C:$%V;3:<ES\T-NOV\Q/)'M,9+)5
M6=A[#GN(D_8VLDBS336L#75H>DO%HWOE8C)Q;P<469'EA!D@7IC"=&'M4 '-
M:!1QV3G^[77<T[2:5Z+/V:Y#6\+:\F@(L5EGHV[]I="E@I9R/D'^>13I(O_X
MU,_=/].E2-\GKN_;C3P#A>S3P@S4=(MSHDZY1_[Y+T#<7YM-J2#J%J#O4-+F
M-.U6%@7_^$CRIGU.X/_B)?X39&]U%^N&U.7PENC>QT9W^AHV2K*_TV1*B_WT
MIM;1BC),^/)YGVZ($#@;CGX$/J%7<"8!K#2@!\H5C++O<H.3HVO&]N]6Q7X6
MR?VIB[7;#0<?Z.(ER!KW PB;!D+"VMB@(R#T,)'F&9F%.L%SX+)'A] ,PO;)
MD,^Q'=D@TQ+0 \1(LB6"H@W(K)%1'2]QW"EVRD]D(]N$1T"\MM>!WLXF"2"/
MFWXSW$SF!/^ZBWA7HQ/$8F>F_PS9(( @XF2-#T7"\$QDBM<U\O<>+0A,?K[P
M(>(1Q_ZO(0HB&PZ92B#S5EJR42N@^QV[XX\>=[=",>!>W0CB>0QG6T@%MEES
MM"XZAJFF\0L-5O$BU)VKN\I 6%M#J#\7+.%[N^LY;Y^JK%+_#I$2BAY&T,(W
M8%@[LOV]#<5(_FUT$SNNJ(*0' OC!U.:;IQSSBQ7-&(98/=F5C*_OF@Z>+;)
M^OK"M\__@5_WD,-,_2OPOVQR,K4;&&7)@95?P@TS>A?@C1T\I\\%I_JP?A*\
M&6<2N42#AE\D+A!9L>]1ER2TT)[))0AMR1C1)+^KXO=R?WVZ8162F8=9K#F=
M'V]4S(67R+VG?5*DH!]]Y##3ENJOJ$MF\N$!6%LR*2!;5Q!6@$QL(W/_AF'S
M-XN\2+9WN<R4Q=O^ H>%#27XW5T[?@5<3>#_7/W36_\Q:]GU!3)+^D-"@'^
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M#3\:W1-<H@.DD"_QH" Q5!@?TPA9,J>38)OJ>IWC24Q]^+HFWV*"EN]4(64
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MD0;*]WHO)(%"I#U=D@L:NL,"13DYELV*K;R"*.1^*VIC[^+</>RIMC4AJ1!
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M[9ZLVK!&"$_14V>Y(YD -ZB"#N4?CB"%5V./@\&?++0QD-\-MZ?; RHVB6?
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MX?X#P%9Q7I2!H[DWJ"Z!?ZB*0/JD?FT.!D'SCE26N(-07\X!8Q& 0),CN7/
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MC70\7(*T=@[2@;A0,%)>I"$2%!'I8<);EQ7+!G?@78[>+O_87>:FG&Y33@4
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MF1JD&4V" KQU"O%%T7+;_"0? XS<A[CN3 3C %UL&-/UU=3+;-JWT5+[0+G
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MF$!DCQ6&["D'$Z/ 18N[GP , /]+C/-P,1A-.A;3"09  ]0)!]%NOE0 N\V
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M(15PFG"!'B0D["HJPWZ9"KA:#@@)PPOZD[GPZE1 L3R2$L.%U^Y(2"=B8X7
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M5+RA=,<8P6,>\E6"3#L$L)9&$:NQ42-2=@?T-&Y\'RJVAG7I\*F=\M5<I_]
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M92WW,.^!6+2VPUW%,WS6;U08 4=)T8>U:A)D6Q0:O_Q62@IV%>96]CO398F
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MG2N-JP.S1N?\PK&=*U>I])Y=^T<IU[0>@;=/=?C?DOL4DJ:^CF@.NU2'65F
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M]PM]<5J%?("M]N#$;J8M@M[Z+S?I XE+3R1[VH:Y?6IIIE)3WJY1Q.JBH@'
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M6V>8.2;HG3-^,_-HAR\/\9/P\8<-:O/1Q!O_R,4E[B'7&ICR^U?>-V<'JD2
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M%I1IAR0/E*?#5OX8->7[Z 4N?7A9VRBF<&GT;=955*QL5M18HZD]1<#I#0.
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M70#NZSQOW?A? ?@_XL;-ZQQOD]TAIZ"\GE!W#W#S!@G)35*2_[*^OAMX?1]
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M;>,:4;6A[VUXPK<VK-16GZXLB=3O"!W+>.]USW!^.;-E5N@.@\_DWNR1=S$
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M\6X+08,K#LK44NQ;W'GV5UV'TTI'8""9\W6('@T&O',%J-F?D"AK/%^HN )
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M[&;@Q6EX;O!:7JVE.>E=\:R;7&5U"D52EW"%3LI'&&$/L1% 3>?%4)DGV)'
M]RMQI>41!5F)DNDNV6=T]F([Z*XIWX_1GGNG1U,B!Y3'\A?97C2QW/=$ZV):
M3!,ZTE]L*P\.5-#Y,:Q:&\VMDYY9(TP,2!U*?]XB 5!/[$.>6=)G"B)]%ZX
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MU+=G\'O/G'>WIQ'2L+.03=+;4-^T+6=,/;&2S?N5WF03+BWJ)\'B/3Y@:9/
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MY@2S-P=9U<WA\@*AC3:C"#U1"'?N9GI;;NF,(Y/)3&H> -X2?>N-"V"#\_-
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M#&UG5&;\<6T7E*\ (0&01_C PX9TAW&(F-*7&HW"OT5WSS5XWB'4>(QIR*X
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MZ\_[A^VJ5H$+K,PS$S@92,/)@<EE1(<H[;8IC;F>3T&?U+E7MR07/=4+3/\
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M"MDA;U,N J^P4B.;ZRXT-U#4 0NDQ3ME4/94_F(5__"*F(.BXR@J6QYC$%:
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MNTJ0\3[EO7ZU]1]'[HI!JZ)>VR]7QB-SIJOBV(0U@\_9+ C97]8+2MT%C7Y
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MTHZM\BYSDGM^_W]*W_^M[)F*H[9<=\I.:YY>O0E6ID"36YZN82JRFXYZ+5*
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M@B6KNT&Z\S> _IKV ^9U( N&$/.9EQLYGTGGX[2Z,5VWF!?$+%(65>75YLD
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M,RZ'VOHX?]"*3;$*-ZHKU[ZOWC%8MD3M/U!Y>T_P]*5+WI+(ZU3_M479)S>
MOXT%-X!MR3<$>?_7@DQ4[PQ:P5*:S4V&F>Z!'-]5(HS2OVH#&.)L\/IASYAI
M<%*^$0Y+GL".-K.>BJQ&I^(!(5J+><4L4;F6 1^#VA.8P'4Z5L+G%U:XOG4:
MO%X[<SJ74IN&*=!E,WKNK&?(I&#8 PJ:!'O[ J@VQ/RKQ;J)#QD'5U]@&2TX
MPM82?I]_:Z-3;-;\<?YEWB#0?2VF$::=_54Z<^E,'Z,'0K:^D]<A,&9DUHUE
M;ZB-L\U0>C;D9=4H .98)T_$JWMQZ;!7BX*I3N1,@J6?6)+&*0MS/_+2&>3F
MUA $<KBPQ*F/*GN74=X)1X[AV_B1-TQSC)]LE;)/'<C"/<<WA31K^([CX0\(
MF!+?]3$]_U-SI7ZRKZD?.&02-G1O(1D096TSB+?89+<F,A:,8 X329HJ3UI^
M?07YN_*CU'DU'XFC+4P6:9TL(-MK/#2J::G'ZCR=D";R]5UQV--KF<P]HF*/
MS<ER.FIX%K@JP<I@\*G \PI'P4^ICBQIY4+X,JEXDMRC$/R"$]T$.&T)[)H7
MX0?7UJ2MU$>((2B<?Q+8; G![R9)B;-D;*A9JF<=#CRZ[U"T Z(=7\,8;<_\
M7N0P'F_6&#8Q.O]SD=/G#K-<D8H6)+X7,33S,?S^8<,WZ]]L:XT.NCX&>1#^
MI55F$CM)[:KH0ML_:I6];+E)?4+U'J8PRRD#EW*,D#):J.\R,X-T/A95]?+9
MUY.!IZN(FII]4;AZ3<S,Z**4B6<?-6<"%[3C?5=DU#SL5SF'4#"$A[/0& 3+
M<IO9VVR10DTJHJ:7F^OJXWSR1@?+\VV-Y!;&\'9GFHHYRQ.IJ*P\W;A&:QJ+
MU>LW;IWNV]@A[)O0,11U5=;B5^A,FPX=&;-[6RNZ1<X&59[#?)[=OVM.=AV$
M&]LV/P"^BTLSMTZ)"!6.ESZ\(H -WUJ<EZ$#**9H9JV*.^8<UT']"]?<BQ *
MLE@D6$(2'/9 Z$'ZR<0Q"8^$U<@09W8+Z^1_5@8\BHIB4M:M&A?>%U2)&^V:
MF?YKD4JH1W3YG>N4LC0SVU;,/8:C)^L1EF@YK<&U%?A^XF2VFVAF>NJS*,>S
M <"^Q*93K^I*%C-6MK)E,J2UV&;1M3(R4H*O2YQ3&R_GD?R]F)_PS*TVU@D_
MVMU%X2JT>[@/+ZZ@2-,#?][89X'OE_VREU,))RN78+,VOO[,Z0+]K39[=#)\
M=4AB1VX#EZ6A1FT[;6N]B(Z:)1?DY"H G,/H#(N<6S_6UI:>P,O;UX]E[0TO
MCIH;RL"?LYK+6O?]AX<VBSUS^A8)45./VNH+M]W1=LM@P6 GUY\D%%\]..\Y
M>S[9-=E4&C\\:>#5SOKD5 "@XR3A_!,P165JV6YWD?.N+O[V%@CW(%)EMDV9
MX?Y>MD[L&7MTGDTOZ#5^UY'(\Z4EE'O[>L)RI(G.LC"*-<^\K(3G?GTBC!MQ
M"3-\2N^U"?5>(C.#IT5EU^E,7!5<LY801'BF5GU;26[*1)0<9&U67>R E1Z8
M],3V1#+8B!8_[<#[\\"7TB#?Q^+_)=2-9Q7]/#IV2O)E-S=)H QA,? OG?7L
M/O@&4%TF':E/YD#S/<W"XL_//LJKB'9EJ=J* V=$:_\W"$?YK"E0H<#VLJU>
MO#)P>8XS=4=1:/V0.+[CP,GD)<9?L_Y*+#$?H7H&7E09=F/2]]Y?71^#&(3@
MILR)'2@Q!4BKV.C7-=Y;T8@NK[>6NM\.P%FN:V0_5AF%S)67VZD\Z_6FL$+(
M#!PGW5CHQO3ZS,B0:>E'P2HO]CR'I-?K[E]U:KUK4)DS<45/=JW]^[%EQY(Y
MFID/;CVX<9;E D9)84KXM+)I7'@WC<J%:T[+EKZ/(3WI@<&3,>_Z^U +D*0.
M:6++.S8_C8'OA9]T#@+O*UZYPD(ASU"3P*DYY(0Y)JW?0EHYQWRL#*]X@7^,
MZ;5Z9J4K PF%WIP)O  %#R+HX37H%VVCA6HTQB VE:_>-"2_44^QI"%]M*C]
M1_1@^;PLTWQN78__Z'06:!9YV:[,OPL\DEV?;)'(M:4QH!&E,TM,[!W\?6QB
MDNOPXO0C@!<SY=Y&,<ZCO%PWOL?;N^$WP5(;#<&>+@4<^TG DG'WMLT%T6*]
M_&3SGBN[/=S/LY!_#^*(#IZ'O& _5E/)N$,XX>4Y(',9<8EHP2J+*4+2X1([
MRI/NK4/>^E"+7T9Y^6F?' H0SS4Z08][(C,;] !Z0YSE*G/3/X(IWZK]MXF-
M/_SI+3%A,+J.3NL[Z:NXE&[S!DF#7O\:@[W$56!8>^U8]Q*MC1\'?$^:P4.]
M3,FV6(?!?83Z(>N;9<X?^/<X-TE3KS0X>P18^-P+ 59K.%? Y3^F ^9KDSPS
MH;A,91%(:IC]5=8)<XT2)(O*))-E2,RI13]/:P(_O#2_%X3YZ;+E!!VXA&\D
MAT&DBC"JIBWCIY$O7*\U1I48SB;YGM#ZZR@MMMN>+CQ@_#QGN6ZFO>XF_DDF
M3";:$]H'#6BCPU1;U>$$J^/@[X/=C3%9.O+/%68_ 5> EOWYW-N"+?"=K*:2
M4CE^#($9W7SF7IT<WYT1[]!@64F@YSLD7]ZRH6NSUW+K]+,I'.+HI95 E>C(
MSP^!;UPR-YKEF/RZV\DA+ZV:_CRK0]?%SDAE/->C(,=-O7;).M<TB+6[5;[6
MN:\M6E$QK:"GXMS/4\1N !3 +R463D[Z<7%++OFF\<9"+JO WA)H-)-X?$^R
MI*NQ26V+?M?BB]=?[YE:.^'!S!.[\"+V(1(HH16.B'S#FO9[N\GX,6*M\5U!
M.Z.49*-M7S%N5X1F<R/XYST9=HPL<[=S]7';87-A!#?HU'4#Z/#P57Z%]GQ-
M)4+#%C?+"[Q(?Q=AS"2!(EY6*4-W][(@'LV8,U=_N,PL[":Z9QE7[$W#^G-_
MZ@J7C.'H3GK;6V"RG90]UGWYFF5.IQX/4$B[Z#LJ-VI7'X0EL+;(1FPAM.-I
M0EL$P%!^G6\6>7*+"><<,(GSYZW4BP@IPR3Q*:Z J <8AF&!3%G?[#I@R;'$
MA-IW$A+=<67/[O_H5-<70D:;X,EMQ=_JG'*PJ<'>Y W@.1HUB>L=N5V<ZA._
MKO-E:7> -#@BSX)N8SZ8[Z_=9.KHYQF^!0OJ#BRF3^<CC BE#*.C)"VB'9<J
M_#N!Y)!'UYFNC/R]ES%YOBL^O30>W^W$G'7.&+ZRULG_5N2QH02;B]G_LZWT
M_Y72!$7Y>YF GR0P*L\"391YL$<IB";<LF".;_OY]\<$'P" ./5E )$(FK%^
M?WSE!D#LV:^79E 1:?9GT[:M_Z.E"4VTOE;ECQ]%7E+V^H"8O]OF]5?F6.W
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M$#-8LQ/CG4,]$8>(=NH3'_JW_*&E^4F^<3+SWN"!B,=*'Q\'I(2SJX[,>6@
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M(:Q)*JJR/ BV+^SQMB*!#X\]3\]BL_/)@ :7=+NQ72=P&R<>@NS:QRXG]5V
M=]N81E!SR/6D%"_H/I%1>7E@>G#L[4#)H #,P=Y4E 83N@5T+]^O5LE.!--:
M;*LDB$94O%6F*FKX[Z?G)UF([E+?&>"AD5YV$\<J R0C8!Z%B+_X8F(OYT*V
M-P8HI .6Y@,P4Q<_\;-S(CPW=<<'JCC9U96^$RY'4*\\S_CU^%G*>R'5!GO
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ML#$@C:.] <PJR\RK=S,]5, ".4ZH_HY^-B3YT^E<N39D$=(G[>\9E;6IW+'
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M+Z+?4TA2D.X_^FD/L[KJ";K\\6X ?]+^J32FZKP!].B[YRS@"%Z;TNVXF+^
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M0:H]A@)#:HBI*K#B)0#X&[O?8^+#W"H^L=8XE.FZ<I/]!U4P"'#]U>0PE(%
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M",FY! PG6,JT@<^$6J^B$G@-0:T!AKU'AD_E%"*T75'WC9ZB!? R"+:2D+D
M71P:)VB<%YQ07P(^_2__=R0%.<210?OJ-D#'<\N7 #6V<[86!1_<.!@#^G7^
M\^J14PNOXIN.E_](9N"?#I3 %%=^XM6QO?-5+/Y%F.O!P>RV\2([KDF%'K^]
M5XP&3YN?O 5=@7%;AGF'=U*72[G:ME^^CEP'^:BLL6+H-;6@ST1GPLM@%+T)
M-OS*BYP.-S.6JJ_.8#T[Q4Q5^#ORG5XQ80_W9&P4MY>+<<B3(:Q7V0:0^-T
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MS X+VDT("OM)]\WSVCJN[%O2A]_(ILA9$QDCKX=P=;100]J[9%B:YM6.ZUS
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MVX[<W1-X3OXYV>3I^UZ-/J((M4?[8(GO2/A4+^O8]$-).K,BXQL+"P=RO3W
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MN6,_TK]F:+I&E-&QUD-;2*RJ<H*5)YJ'X5<%OE"\PSB,B>/C!S)64LHKZ#-
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MYIK& =C'FM'4'&9V$8G.R"PJP#IIUT[L&^B-+]7&B>PMZ\3<SW[TAKCVF0[
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MAG)##OLZM1/N8. = USCDCA<S%=AFU0#$4^^OK/?S,^D/Q;+\C">4O'_#J
MV#;G^_)\[,8P/Y_F9;'MW0C<TOI[.";YMXB7AH0-*W#2?1&'ZH)#O!:TN2=6
MOGH)<\UZ/#\6[\RI*TXHA+=LP-6)XTN"BXM'@DIRU/D%J&X:R@F<GBC17L2#
M;#S,^GNLY"MY6-*?#N\Q%[A+%@><WSM/P]48W@7<)/JC/ZS-&5^24+PU'A3S
M73D":="!3 *B%Z](?Z;77Z0?>#GU?P%02P,$%     @ .8 [5T[$RZ:PFP
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M$L-)P(GAU,*LF*\'L=#6QVE3PBJNZI7;K)J \$28]N56J3<W^C06(R<);/C
M^Q]&;4=4CF'%D.E>YJ9C75E?2V[><GP:=EOTROSS7F<#4P]8&^2DDDGFJC$O
MQY"TK_$-9'EUN<5MW02VGBE3P-!_LBKSB036X8F+S!J8DRCU;1S?UDJDQ4R]
M*3"A)0'<;];52(#1\-CZBT\67_S--'(#CEF);,@_YKNP2%D'TBN.:R8!;#Z^
MCUR52AI5I&V?*5[_CE,'X5YT1Z0!=WMX+O!HFVZI;^4M]5"6X#<+"DOSFFQG
M]&AHAN_+F@;'L08LB)24AC9XU$XDLUYKYXMX)FDH6(-=;(& R*)!^1V>6SS2
MW<-']2AUUI=)E?GK2[$7G[FZ-%X_XIZUF-\8V@$W35HU,OKH8O;:H.)-\"@9
M'5]>>FKN<'JC!9B(X1MKFWZV;2O(5"UT8]@XP(]]14X.00='FWRP&^8]UN?:
MK:D_X#*8\+U6=JR[4=6.547OS>5(+>+&]K?![>Q>GX)=);\F]'24CU3TS/KM
MQ@/'(K&H9-YHIZS5@TO=4N-F-_;T13]4F5U,>G:R=7 &<R'XO9\ L5??5/>]
MA\'FG;Z=:[)&*? @:0T=>B7Y;0ZFRW>"K 6=+S%U-PC,&!?[@$=(P.RM*8\W
MZ*+FP_$ZKM:I7X;>#^3/UO6EX&R!F'-#R3./U<)65I^PIREU -Q.(>\]C"2"
MB?+X.MO9KL,DS/OT&7I-TUYQJX1>W?ORS]>_^?L=4/;)/>W[E/,ES@TZHF]2
MGJ=T:KK!\I?J$=&=NRX\-QT>8*^.VV)'VT?.?/AZ2N/X ECDV?'+*@E6S7 &
M@N$L_>,1[1$EN3R;@^RIZ5*3J5%MYM+Y&4\[S9ZXMJXTCZ*<Q]'&0T2>[BR\
MFO:;MKUI4*W4O>"^=F3- ,M&Y(YL,\^7[Y$U"H)?VB,''QI*!"IHABH)SB).
M+*>I!). FVRHTTH0N2#I22LOB]95Y_#EV2B]M,MTCZ6M_/,/)6-S0&-U+>T5
M*L85 Q(2?D,X;Y/%0U%=Y;8D#MAY&;Y+2)65@"L"F),LILC2ZB$?.>SQGCGK
M\/6LLMY::YJ0<GMZF$:D3VXYDR.:<86U\S+U6G,?[HD"9AX49[8)+K#G<'8Y
MJ_\I7E_=YHKQ$(("4B**Y/'0NS6TPR5Q>M1LU .-7KQ9PV6TSE]2=I_K,E<2
M<IC[@SS+5JJC[90\]GC<^[:<47LYMPK)-O=39LUX=9VL.U6W)/O5U8UV3XG(
MMR6;L+%U]A3Z,?C(]Q'D0$&N)(#!_'WYS*0SFC5.-L;3[>7(1>H2I-3H1"'#
M:(;#\Y!)I^+6JT[?55BQ42ALUVQ2,WNMDW)A@6V&[:MI6^0Y9'F8L,OJ0G6P
MT*R<D'^9LVCL\<A*W^YZ^O*Y-"XR4?#AQ:B$%E@N/Z;]5LX>5%:C9MZ:7_R%
M1G>EL)[;Y8'([58$NP\,R]1**\&$SS$8%KT7UQW6[ZG6&!T!V^J]L-'&];*G
MSGIM<@.J4+P..=:":(0?]S&J?M-V<71?WR9=A@0<;V']B/5,NOWAI>?[BW(4
MV\[U;>;#B>]\SF!%9AD2R J\GRQ40UHX&Y>(D*'UV&&;G*BI=DV6-:=$P\KX
M8C55E=O43JU8J(H'&!T=[L>I[4-D'=F4ED5>BUI=&S^1?"OV>: (58 VV#0/
M'<V+#V]]%^E^MVJ(>:++N\*WQF?9D%7[XCO Q"J"%^*OOS:>T)1JVC88ZR,>
MK7Z4\7V08'@\)M.62($I#/'T/5XEU6!U/E<:;]#?;WVK/E3\^ (?3P=7FG-*
MW'4,+A(SCIYNAC+;FJ[86C(-UYYQ*EHV70RY%ZUO=G8OL<.)Y_.SL 5APE+5
M!;>8@<M%">42O![1)OU0'=3P9I'T7NQ)TRG/<!$E1O9[@DH(<2G]9QXT8?T8
M1 L)X,2S<MFX@,[8<=Z1[7KZJ8U*^.[PL^![5,+LSLR/0M1N\9:E"LM\%LY;
M\]YLBY2[26S$EQ;9]H[3BU@&-IJVICX5,QHS>9#T52-%JR(WV(17F*?OBOG;
MB !Z4[RW8+!+SXNQQ^EH&$,3FH<3$EP)<[5Y8Y4<Z/%*<Z'EO(I)C)E06[6_
MGX&ZAW@2=A4M'EFT,C:9$[%KL^M[5Z-R+_I"Y]Y9R.[]O3PZ<;]; %6Y%=1'
M"WLSV\$5YEIDV7.LNRSQ]K6OE+5,YK[9<WQT#K8DP.,*4=P&]ZP<51"8:KDX
MA&3 RV?CX4UIIX(%!FK=<R97IOA'E"YLGM[:70R_7NFMZ&EUV-#<WHE;))IJ
M=+7?1RA@HB/\?O'QQE1&NG1;MQV(C9DNCQB/<()?EC6V]K/S;W-Z/XZB3WR2
MY6F_+?A%;5V>9:;7(\FHO+BT-/!V3<!PY]KT6 OS6A[LF5J@M =$Y%7H-ATX
MWLO8!-T3C6!4<DWOSER=DAAT%9.=32B\!Q=3&;SS_<:7L )):NN]H*K% MZO
MENE?HP">>FXK_LO*'VPRJF^HA0F]HWP^,APF1+4DP>VCB84T2)ST41BHI<F%
M!)7QW&Y*3*D=*XC0ST]IV7F#''R4')_$J*44P^J6>]-8+"X)/7YX9#T3'5GN
MX*U9UB>3A^"TU9,^;=OU@,WMC<OHW4^R-&@U $ALYPZ;)7!@2]O@()?W_01E
MM/>DHJY4<DL:?PK[=^6'UQ+N\K^E*YEY2S=8#6J#OTQCKQW:V)GFL.NUL&>C
M=<V]L97?XRX5P*I-%S9Z[R1PP&W$'?DDTC-.Y66BQ#%3@OPP:E:R_]J83$](
M+<CN("A>!U<GN5!60P)NO*#8+DDP:(</BW]7F@E>(3><-G\5WG&;ZOAJUZF>
MX"F^S[I&34\^3=0??!&CG]"+>-5W\5'/E\P+3U59MA9RYC895V7E9(W'AKX/
M97>.9?5JS62%/V$W"Y#LE^0/VIFP4X1SV>.JK7$NIMWHN[3"97U/SIT[EM]_
M\M$+JCZ>04FJS]UZ);Z=MRVBX?@FK'L;_!12VL[O&,;3@JVQVJ)_U&:*+:!1
M>%U&48HF3K28^?S:A#"#127KMHK!1<F\0V4/VL84ZQ<R=59H 2(7!H]MF6P+
M*5@OKPFT/A<44$I;TW6WLWB;OVJ+_Y;3<^9,&;2IX/I)K&"3%WU%Y'N/GCNE
M ^M6%\<R%#C$K)0-.$QNQ$@(OKAWW*/%Z6#DY:X>8\M]W@^YYG:,WTS#10P_
M^S:R4UWRM%^OFHQ^=C<NUO90SOZ)N*MWVH<YT E+/&A&I3A]U0@[OFH*;=;\
M5/7@'??[MZI-KD(>][^>X!N)-'YG"RD#-?O268:#.>R>T@XP5G5I$)VB&.D>
M5:9WW$VXQ?N92KX((E LL*7=(9-UVRSF?%J#.K/1"W V%*,QA6(A 5,#\/@=
M?1) [;"*A1ZMR^WKJ?O@1/#]Q&K>;/!LYA((+VS=1 *8"-I';ZWZE83?3>/#
M[W"NQR_TZ/IW220B'R^,*=)%'-EOH8@<X#G8$1.<#3Y3L+J[AYO"AZ(AP9!C
M<\-*$A^UL^RLC<HKY1C/2FZ-^WUOHI2O7[> K[6@4XW;P!0^'(6KE9&Y*R/#
MCW7"/[ 89L$D@[5NT5Q1.+66LVYSW]#5T6A]>$\VC>7FJ3P_332"( 5IG3X0
M((J3@ :S/A) %XVM)(9"PE$8H]W#PS*O4[+1JG>/W'(>.OM:TLRP_97'-4?L
MW%1W/<#^4$P[">""+\7AR4 ^!M/\S>*1S8V^):$QY6-@BP^C-$,S?A3P)GZ"
M PG(T$-O$ECJP+]=#$75:+[+M-EA]B7; C9^CC_VF\UW?KO8C[C.&Q"9V:N_
M.Y;ZZE_+<,+1-+$3Q>%2P_5FO"<(*5)11L9ZBJUT&RVGT+G7:?6 [@U$B5YK
M!Z.)'[-'54*P*J?9ELB>XAQ3-/Y.FNP,O)WAD 1H3U4K<VCBU*.ICJ[!#TYD
MKI8K\AW4@NI) /XA/!*UHTVP( $!E9F_ =+>'MD*!]Z Z,+!M< 5# 1 S<80
M94E GR#6G7AJ*OHW2XNF)S-[#>[[_M-+$O G;AK_S><UWV6-(?]I#9DC_Y$Y
M7X36A,8R/_V'JY#_JY[JDQ&@4G.[!)173Z D <&:^'$2< W1,HT7\8+\9C$*
M[A:MJD%&P,'ZS7:5(BH,[?]WZZ6?UAX=D8'"10; KV9+_/?-SIOVZR0!'-+M
MK/:HH"F1RM"LJ--;ME$4[D]?HHP>&_+.&^_0DMV8]9/*)0$OU :>DX!?Z@1)
M@,[,K[LW]?S1[B#T8BO\I \C9FF(<-M/S"HFS&RL&?FHI2OJ>FM@W(8'517+
MEE\>.7G*Y3J5%G*S.P.F@5L=[A]$'9L&/[;6^SVNHU-R^IR[;9#C.@WK3F7>
MVC<T#K!>M/ZCTCL@BS\0)(D8.@C'RY& =6EX4\]W,F9<P41Z$G"HZWJD)T4"
M$/:;T 7[HX3;E>CHGN@_\&$'3.2%2QR=(0<  R,!8S^^W$9TD;.Q B%PD0!<
MBDI.,KRG?*]H&[3V,17%[.?SQ[7[COR>[7WX4JHF"0B$$P<T"4I$Z($@N<G/
M3). LKY=I2ZB;U$=_#7\T9UU?.;VW!]B@>9G:R"SBUOD]"I$DXDX"3AZ'_UA
M ;J][KM*:#J\D -K 2/ ?]B(EB _F?-3+'W_(W;@44-%/R$"_H^1K4HNP9\,
MPGL24#LW,\G;H4B ;>:*9Q+A$.I% BX2.S^,8S47?3?72K'ANH>0,20;_N/T
M^AFQ6LO'*7,^D:D?E;_2F_RTWV%."QRC;ZMTR^7!%*4.?&W].OW52&/WY.\;
M^Y A.FMW2R^7@EFRHRKQ &36XM>8#VY+[..0N\3[_PN ?ST M/U/JAM\^PMJ
M<>QP9#\$9WAS.@RB\EM[\B:(76#VM4(Q/L2L>]ALRL95^FJ5US.=LQR=11_&
M(J;590[ O]U )@@-P@O5IFR4SM9LSPB\6-HK\B1O:+?8/0D3573^[D2L=/,\
M_+SY,Z:"X'\T('KA/T7A)XP=I#TB 2HC4Z@OD)*/;@3]_:T?$QP_:4&>X T6
M6H\>#7"?UE0#61F1GW[4$^U5WCDQ[2.-;=GM],^PSQ/.?DISA2.4SW@:]5>A
M-O@#:LNHAT61&]_'9_4B.#HF[BY'::M4[>9$C^K,?2R]B+>8N_)E?#08(:[C
MW"$_O^6Y)W-P[&\F(V0M 5OG-D=^__&!F$C)5E#NSA+D0C%HK1*[,1I^%3/0
M=KKXJZF(?/QNQSS80&]PY*\X(/%O#@S]<  WAS/ +[LUY)"-U?YFO?!&+Z%'
M*4U;&H'I( '<&!K"A1Z.>X*)-#B7U[0C,,NT29$=T%^O[NH?U>TGN):._2K_
M(,&/%=_]*)S7/#RGG4-RP/:KAJ)5MH[GH1C!:Q"F,NJ.Z6EC<_>!9YF;Z K4
MNNQ_BVMSM-_<_,.LV_ZCN'3^K;A<?Q37/KFXKN.G/R/PAKP7.[[JX:SF%PL$
M_U[%$G]J3^X]AZ*$!Q5UY:5)L_"PS.IJAGM!92/TY^MI[[G7\T-,2W];<'LW
M"\AM@C7.$&OTO !,(6!]W2QA"U[NO+"?FS?2.<?EW+NHG)<>0CSEYS.T[<<=
M+0&1[88NM%7<_WUA%_TA8Q;$@'%%&+VV#YQ-NIXNB--G.<!:@Y3Y^9EY&O4)
MKQCP\^Z4=7DV.RS?#9L?".G%YC_Y:C++#!8M3/YKO-T(0F:1C/]_TA"&TSAC
M?'O*"R-Z3$W+ ]S=-!?_Y>BJ3(/TUZ K%F2N[/$/\C:S*P/&U! @9";_ZG@Z
M"<AFC?_56-__1P7/OY!2\X(W7$!R>Q3-.A9A16Y@0X)W]>B@4TTY$^-F*XG=
MM+I,R4/)SH/'^?RDC4<_^:LH3MZS(@I_1NU\O"X2E36I+7\I0_*6D68D^=T:
M\/DI,E/Y]!U!'"S<QI%K-\[J1X;N;9. 3,O/$+Q0#^'-! 3'32[0L80IOU82
ML/4$#D*M\<)W[$=*(?LL5PFP+64:X@JJY8"W1YW9^,73H'__(Y__[.2&MT+V
M!?S((^H3SQXQKL[%2XX0( I??4%6?X7.<V!"+(0+_NU7:<A%5&6%[#9"CJAO
M'1L3RO!7LL)U8ENK,".X^_A0-(S>#I1M7^V88EU6&\DR)C@5R'>1#Z-WRWX&
M-@;%=>#3,7/HXV]%583U9@=#ZA5DJQRR5<+IYQ4JTH6@LO)<CQ_0T4KZ!'$]
ME8R!9B#*BAKSILD1H:Q]-&.A@)N^63<B&IEO;*P:X92Z,GJO=N[[.O0B0?LH
M""FXBKSH>[L1*8MIC;/-]>#L:C!-63&UGZQI83J6,&<@&Z!U3$]_?=A?0=D9
M%X>5"R&W7,C)]]D?B@AGZ3%I<RT':3$YK[,#='*[%)6>S212W/GX:ERKH1 R
MN_GCT:(QB=D(,+O+9L0MC_,DP"BRG(>J(='KSFW;54>.VMS"<_#D<'^I;T\>
M\BJ =#'6:UII('SRC*YJN;<OM%&%!^\M\7SCR49?4,MB,O^ECK9.QL"82GD>
MD;!^R,/I,<%9]V"8"C=!'E^7;NHC\ZJ+)>AK<8[V^>)LLW9MR6N=LL5<;^BT
M=KF\ 6_CM<K#ZV,^=GCZ600'/E8'S+#*YJ"<L%X6E^_T)E= LNO[AM('OHL<
ME^F.ZYEN;XX%MH(9D6 _,LZIK/L([N=R GWTT5R^3)M-%Y>Q#C&>G@*>X\ZQ
MH[1!8P!5E<R8ASN.#:]Y'X-H\*,:J;T$0X^#: 6Z;9T_LFYS>KY6;LZQ8GCH
M2AUU!6 8*L!NSHAG8NU;IVEV"Q3URP;6:QG1TL.%]S\;BRE=?^.F&16YB_97
M@>$GL6QS;,TD(!+%Y=(#^*C%U7O)-?(P3!$5M40SWAR:KJ]W-XE^F9F5S13B
MCGK[3/?2'+1M.HP350_R1[ KR<U=G;6W\-J^_FEHATM909AUPS[IK/%VUH0A
M37R#_I7#^;C^&E@4HGBO>=(9C6@&G2&(8"M"9R<A:)48AABTM^Z#86T>:J?7
MM:MN5_RL./AIV"<FMB1'" 9'T=^QX+5MS  Y^*[AWI=]>#[:&B/L!QFCQ_C+
MZ%%!7WFZSBQWO .]5VW/SJ)B+@/TU9E_<QK38R-U\-<[-&\7+//!9QJG:E)F
MD9(5/2=-Y"RJ%V+A6^FP*^!$1+E>\^%F&)R+H./KI*@<A7 53\YI0B0*G7WV
MEJ'E]26P@6_0TRD 8XY4QK+AS-UM'S*->5>=M[%\S-@<-"&@1=N.YSZ[Y;E3
M6(I+PGMZ8WKFW,.E\W)-+ULC$XE?U2XG3EE+\5--4R>HK-A'8!Z7YRQQKKFG
M)!3L-FMEM8@G>^-T\FQ5CYT/N\%8I;54'QBW#BW4_W[7YI GOV /;$;K+=/Q
M#07#=$&'1FY_[LW/PC(D/9*.H==H "6H-'Q^';ANO>_WX!TK52Y+NB\&;A+I
M\G+G>]S=VD$KDT0N>[<[6MWY<L<B(M0(>1?I8RGG!&;"EL61"K;5.2\+=L>G
M::M7.(WRG/-LL*/3GA>O;4M5F8P\AC+Q/>OX5&%RDX(]&!;UU,Y4#Z>1G:XT
M]J@[N03)NJ<F_U#O;/_%OM0L89!-4<"I5RU:F_K=H=5[<(GM$<R:[HH;$55T
M]?6P'\<DWJS9]'@,FC:[[_&0PX-JZQ2VN+5&;9[34N]U'KZ3-P_@YK0.4^%8
M40"%184^:+.P\A5/IN_.!W&:6UR[DB@ "KB>:.G%'2"L]&A.!WS:SH\[[D;_
MPL 3:1U:[Q/W/E=OS\<\2)B?Z"D#S#QGZ!@FC&\_PN;I63SP-=IKVIZ CMLG
MC>$2OEN^B.)PO/+%.>!%>UA[A&R"(#4OB,UK6=CT0%EZ'VY\8=O(6MD:<[O-
M&&>4],KCP?ZZ8Z9VQNLU0\GJ#6WV1"[]$(TGE!XT2H;L*FSXBH6V6[7132/K
ML)P.:6.!MF#-\.0[PHJOWWVO""QS;;$8(@H@\[)7*QY_>3<D72"B\_B2]8/1
M)PW\W,'"J:BFM-TA.PA/OJNOWWBSG"7/Z]44BY:) YTV>,4) DXB=. QU*I4
M]DXA1JV2,D14[5#DP+)N9]_<^,/XP>'72[?P>N@CP>MO#&I[Q0OR[P>)"Z2H
M!3YQE!.Q<O.$OJ:SAG5'.)NG>AGNM73I7A]I677/U'4Z7T7-J$Z7)#0\O*7N
M^"KK.YUW[>"WZR52F):;1K6#NP4?%"(A-F2^2+_2?7:>R)<1)O*@\<=W*?_#
MDQX$\@C1QZ15W<]?9I.P_O#M1B7K0.M3_<%Y/YITGH:S*'L5+@\D!$R 8#9#
M^6^%?_QVU>.6B]H2K<3,,\@IPHT!Z9INF$'YP,ZA>PVJ)N%>98!D8JS&94.J
MB1AH.>)4+0\).'4X6Q2L)/N%5U?B9D"_!@_'$/! N?(Q4O%EO+PMJKQHPF,_
M6BQS8F4I(PP?V'R*/ %_<\[L0O;%B&3I^.D?%"MARICF PGH@&'(DM=?!G0D
M5/:.8>L/7&2@E-@7WX/@Q%K(RPWTKT&W+#;@:V;A).!Z%GG:PHBG+I& \WN@
MHQ!1LBK)=D<4HPAOP$V;AS2((\[=AC_E#W6C)*#](W@.'C-! B:-\:BKHV17
M,%&G,\*$@/_BI(K&MY$ @>C6:1P5D@3TNQ=&:Y!)I'KTT5.RF%=E^>IC10)B
M->=@AQ33\&7%$<U,>/O9-N)GLEA[%P;4J#/?HO@KI[E$*W2?60RR)I=% I8;
M3VWD!>')"NQL4,Y1\ [BZ++J%0XH-\JZZ)2/;V]&R<B,!ZR@DDO98##H<Z5@
M+G6$5)I43N":9]$K&1C^/"0TL^Z5;9ITOW593_N(6TG;>>7&#7"![S8:QKRL
M0M<G7N[KK%_9O]/U2$)L:/ Y(\W@W@[/ZL*Z,_&4)*94!^DA=G9$QF,P!O?&
MC*^X\O,VAS8A;[+^P:43+6VT[F"=S.J@&VI&V1^51(@\"7.P ZXRT.$>A 2<
MT20HBK1.[\C9@/<VX,3S=7%$7D/,--$?*4 "ZN^B\-_!F*VB8!*P<PPK2*0D
MY[A-9/B@U96 "% X>B]7.>,Q_=L71./=C"-12XZ]D$URO@BZWH($I;Q9U!&%
MCS8)\"^&8SLAL]^A9)&]1(O6(QPCPR1*?S=B=1]"S3O -8XAX^5_:I_0/\P#
MV4:NXWG)8&+HQ%8>T8_1'!TB2$!HYD_OMR3K:] %/%G%7H$RP6=$H81GT7A/
MXR;X 24^C@10/" !<_&^5@I$O0::LE8< 436UB&//,:)P>M4Q*,>$M#<]_,6
M10_)CR3XD+=^)Q$*P;!*$.4U?PZ"2G$J7' F<,S*VX^&S!B;2FK),N"JVW,2
MX+=( M V/V\R4@)OZO0C[]W+UHS T[*1 .ZBFWC=0TL?67S3!\WL9872;_9,
M6-[4C]?N)4(?"EY8_,;DFW?A]9>I>,]%+@E,QB,S-A8W%-6<'A.YXI1JH;.!
MV2<)MS-TCC+AK AP$O>T2,=;R<X=+ON'\ 8IPI,K$$S2OX<<.8&OW*LE[V@E
MED0NT%T5])%(X*$S%Z%K0Q,RDN=. 'V%_91T,&:MB O>._D./EU% O I1UP9
MT>M?8-L2533_6*#WOPL(NE:K<(P>B&W)JS#POD28B[S L/A4_WFMQ4:I!H'F
MRJX!1L:V9R([7S]+O(1O*?C(D#ODQ/0!K#KS'[%7W5V9)!-E-/C/S.#D$;8A
M3I!%E]3A*U^O2G@]8?[/(=Q7+?2_:WY>TS5( F;2+"7Z"=H92_T>.5<]=]53
M,V.LWMAY7L]WWMJ;'*O\A00$/,1_:<^ LMMH\_H]UK)^0/.IGNB*ZXF S.?A
MJ8A5*]"#\PJ;2[]Y\_XBSOLH0DD8([4O4[4A@!4,'=**(BY<C!E_>&]?<KLL
M30.MW7;#&7I57]UC-V^P66_,,&&T0[XS<R&NACS%/UWZW['^U\8ZS1N_?C#3
M+B@005D+FW.X,#6VJ=^[TP&[%[ F&3KIY#^N=?F $:KB0WM4)G-( D[:(V7Q
MI?D$Q4\8/T26F9TN"3@1G'EN=S=/5]0F PU\;;_$=[OUJI/E]T,3/+\)/NY0
MSN<:!A623P+*9.J,M5*&^[\IY"3S6U$YGZ9!VZ/OD@!KZ,NQO;4:+&V]&ZKT
M?>0,^(PY'GZS./#N0+FBK>#P^["-R2PF*ZYGQ64Y8H-6<5? #PG"1R5(1A_;
M$9D"P4:D>/#&MG:9_6%0567BD&[)G,M2_\?@B(>/0JADR,%F0LUD\](/RDQ3
MVB!.E=<H>]\>\K&ZGS&=O1O4R/^M<RVVVW'^0I71-SG**Y.]"ZE8",X JQ=%
ME!Q/5=0-5\<<+3;2%M'HY&DL?;#W6F1LU;^)?F?UZD2KNJ<)7AV[VF+)@Z>8
ML="<J7B3;CM-YZ.;/3'E$3Q^IP)>WN0X:ZIUZW2#B:JG0J)#[2V:8=X+1]7$
MDW@1]#4DS1#! 69?T/!43-S<K!-741KWG+N2XH;-Z$S A/-;H[9PE#TJR(\&
M7YQ#N#Q$N/$)7[@[$RF669%X=\ZS]9[V.4.AB)F ])?M?'M%T3+3HP-SL& _
ML(\NGBV3(--'T$G']UA^'G2HA3OEMG"J4F^%2#B=\<-TLUN>6-)N]?A*9A@0
M:UBX FB=;29O,P1YYO/ N8$SZI^0V'FO"8T>X^**("O$^O#-D]M7+'*-WWJ_
MND*3[L-(KN.7>,U65@3;+I1C95B!-V26WF&FN$I'\>678;H&OL=T)VU3F^C#
MJ)SVKBQ4VT)FR&5V@MRC3^#?;S<2!;S789J]CJZ9]YVR)_G/MJI)O,ZF6-#F
MGW$.[KEIWTBP/OR%H#NL= DKNW>SUT%P2 PI00(:/3.6QH*:_30J'X>7:30S
ML3T5#&E34QQN32 +:<$6V)A<"Y1)21OS'D2Q?!#2Y'NUR:VBXX/9A*Y8%W@R
M-/G$_NM8&O93>7%7N" 4*!C];714S8SWNK$^9CTDY#W&,;T ']6OJ%A>&[PR
M--UM(W7J=0(E;Q8"P?W<L@_3AEO$2V #VSC=7]2*H7>1P^7L-X:==!XIG70J
MUY'B;W]N,J1Z3K6'IA\)Q<#6,K%7=<HPG.8>-LUCL(9N:./>U?5;" F#Y!S)
MJTW.J:O;H'CK.(NB%_#',$Z;%/B:(V26(VH,3LE5BI:*;:1')#O2"( 1SHN*
MSCW2%,N(BLIU073/Z(Z/4@4FGI?+&\5L5V+;;X[/< _HGQ"]'U@6UGGZX=9-
M]<=VJ'+B!\P SAS11I2*:ZS>#-^ G1MP\95K<%_ #=RJ$:LXH=_P0&O^,XU_
M#O+8+7(._0F\6'C+2;\STWAHO=$TXSO,1I48,3/=TKR%6N[TZX 7SK^TGL0I
M*Q@SH8JCP_TD;)''L8:?HG$NPS[G8>HA+\J\=7QO#G-D/=,=BS6DCA7OO=FO
MT<(7>(67!!RR^-B/D  ;O='I)N1EK$Q=:F$I7&S0N>4^EX#.=W,E*XI0_B".
MQ0+O;!\RQZ3>Q$O.09]#2H-"@FM=16-6FFY5?X[6C>NZ?_^,=K/=DM;39NDJ
M0;YV3;L#QW^V\5F_2_!VA"T)N/^//UXH7/D,C9C>$AR#?X.1J60_7HAJ>P"W
MC>_.]=A&[^X%W?_L@MD+GF==?I)#*S;<^R@AY-G);\H7?>T7H^D\[ Y;#B8X
M+=\6EP]^W*RVI7;*.'NIIB:-Q=#P==PWXUSB-UZ&.@QLG67N\L;<HVB#6H7L
MLA=. K=]1GD_.W3MFFXC*%8J#L!A3S8W9'2OJF_)29M&)7-VR=36W&S[UDQC
MCNE*NQ.S#LV_S\_IH74!VH4?)_3D9<7;%-YL<=!K'$M,@N>:OE;Y]N2B]>=/
M]YTI/U $[H<FC*E2<P]UF]5SML8<O8ZFM#!?N1@Z4UX"4W$(EH[1.1N@8:0.
M061[]1,>8U(KBAV<LG7S/>SU!F1L92[E+,M^X.;\BD<S"%R9O4^';9>5W;G[
MG8\N@GE0Y?(2YTCP@$:8KUF30=>#Q,7; [,3N&RC<<E<AOP'\%_BU^\]+=[E
M8/:VV[-<+-K%+_N-ARCM]&[S",[Z5>5[%/8TQ80K^IINC8GDGJVMT:+*?\G#
M?.FT7 +$O8BFO^IPG7.AZU9B#ZT+=CY4C.MKE#H-5U]2,!07PK)LFM.B?&%U
M+C$030(4;P]*KZLHLB^DX638W(_3/@J=]'\@]>72R&JWWJQ$J"5GGZB+\O7E
M7=;ALG5&:=:!N8K;M.^JMNG0%B1@^\NGT<IS_HO'RW )!KJM!Q(H@ZJL<IOM
MDTJ0C\V%T!MU5V(\UTQ'6[]M1RY&L4%:^C.)[:@MAX5#^I&X9]<;!%^-/^+/
MO1HA>?"X+@PTQKGBH*GG>_7.L*.#9JB,F,&67'QEJJT3NQ::K_(+3<_KGDXY
MI^'R'4CTF'A(8:H#K+PKNNSH95MZK0[.@N/=%;GQ5+P R]@;0X91+C<]$]>\
M<P3(ZL9^Z%?[M31:WZQIV_OTZY'=K^,4Z9O%>-=<6V<NA>59!LZ1 +"9!ZJ!
MEZD4H3_H:N%],Z+%V<DE/^9EL]W'UU(78YJ.'RV=,G$+IHX801@;RE_7KTU(
MSC>SOY41)J(6D$K7;];%7:R%U>&BT>9_D!_!<)52GIHW^(VF*7!T$2^,#=B>
M$VR AZ0$YTD@"I:G1,H'8.^5'[O0&5W=:._40]JOS!^&[Q2%P!_"CUO@[6>L
M7[@JMH])K/=PC4_5YTN^-J2[/HTY&Z%9(;(A\./!CF+L"TE#?CW[TOG5W-;\
M>+?/*T(9G^G^4WKT,R,OQ/U\Y1T#QB4[BTR\_TLJXX\-(23  ?B(L@X)N-9F
M<?24]R*9O!3-@ X6/\"77J^B_NL/ECXKZQ%UX"$D8(TB%[ZLGNV>T+ "WS(C
MD/7L/?JK9(8F)D15^T<\RC^<J%/7<Q3N!%^^$Z_/1DCR1ARRDA';_T'HW0^!
M&Q!!IHIU3>2VTP4Y^F"QN$:6Q^?;,(?$!K(XU:A["L?H(_;E/L/7Y*U)0+E(
M[1%9PLY_(X+AWY3(PGZDR V^=2$$/SWO#MDS)$KTXKR$,FKY7_S1?ZTP1Y0D
M;\E/YM_^FZB=U-7,/M0\(YG-F?.3):^Z,X*=O$$,?IQ8[SY]<'.W;VEZZT0Q
M"2@DC^FEL_[B?>K,@,$]KU.F0A22&C398LS :XZO\IE4\FW29;<H'T10C"6&
M 3= UR\J"]N\H^;C+;-B+ON['^5PDX!UFD,YO#/N!88@6YWN"S$NG7CB:N]Z
M7,MYZ"X8&4)UP5?JA R6H8;<[+_C4W.@2J:^4R$?QZV_O[60%HAV?31#/(^Z
ML2%^MBQ .R?F?K",Z)8\Q1V&K+A>X^A5> 6X81,TW6'M.A=.DW:I'-E98BX$
MV=3(\BO?N.?T;4P2Y^'ZI<84IVAC7'2L2\]P#T%/ IKJ_,3A/15D3A[XR[\K
MF%T\6?2IC$D0Z<CP. .U@S?!""PD('T83*#Z3 +F7'Z^X+I"'F$+J.U5$G#.
M&CKL!.W 7T*C\.Y%+3W[N#XXYB$$GP*9G4*Q01;'U<FL_A4)0-NOZ^$=R"A!
M[2B0,>+O#B8X1O_NPCKW"-$7/I^O4AI&U&M L/S?,=<%_JNQ]W??&F_YT>&+
MB#RK6&>B;QF4P 'Z\?G3;TP_O$WD@L\4'3%\(DLW'K)ZX,K\W85#37+=(J#[
M(J!\-"H.8]T"QVQ"PQ';ZQGD1]KA6&GX3Y:/C"$PXR3@&'S)E6PVL '!3X)_
M=V%,OHAP0,;T75]K%@(B4$6$+#B]?,S).SFPD8#C5W\H3 .\*ADLDS711I4H
M?&C>6,?],S0*&O%?6GW@=+&O+B+3-?1RB]ZA9BN)I\AEL HB4DS L=60GW[O
M?*\H^X&-1;=(JR;F KY*Y-GXO.OT&5&QLCP(Q>AH T]Y-NKED[/![/$7-,*X
M+_@K  ![D;K>9]3U?7>TQ'H@)MH"1N<;WM*GAU-^-KSA8_I5]MJ;/3GA\;/5
MWX\JD:>"J(AG[E;#>U)_!*N(:N5N#@D0S]Z[%/AMB&B\Q[NN[F%,D"4C WK
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MUVYU$=8OI+1/G666^Y<_^*B<!HR-)FJ#(U%K-+XD(&O3@I<\,?C"P0>S8&*
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M9!YVFB0 8O,4O1'>$ZXV86E=4QR#I:V*I5^+X]\SY&49;1HFFLT7\:Y$Z@1
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ML5PK*>+#_JIN9_GCY?&GD@]>V5+_YAAOL O[3$Q@0[)&*,X=RE$8H5JMS:L
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M\,L98ICMO$<I603D48+8?TS[%\O^8X9%_+^R[-\-^^]V(0%J(H+KAT=$#T"
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MLSFNSN7-]PHW?T]K1+ROJ%S.FG G6Q5]33O3JUU)UYY'$RJ,H^I=D*N+[NM
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M6!#(U?(J\MP@6**F%DN#&:D[I['D'*(NASI*>%)[:PFK*.X-QD#4I,F(/F!
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MJ>8"& \,.,N)QY$IU:LU[P3[X?I*<?8]4.(Z"*56"2SG,98V/X!C(TA.ZSJ
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M 3(97QTS2#>>:(:H_D7.B:.5#-0)XT:EHW02;N2+I4,=:KY^BVAG6?*9JKZ
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MD]"RD/3;@7K>J_$1W+,TH!HHBEDS>LKNRLCQ7<7R7V'GCC:I^7.L>LZ*)]^
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MZNLZ);MVVG/61I[4"VKT64<,,;JNV).,:W\&OBLO^ZRG.R=LNO13$'4[4.K
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M<2!>O5?'KRWD&D!Z[/;IXG9O6E[K_/A4BAX8O&T:O0YIWDEI=_P.NU]'^PP
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MA!U-!&C39'P=@,E>I04\@;G@IM&HB*R:V\-?"XQQIB!%94QL/'I%XY!!'2<
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M6*QU:$%0#XA,QWPN56KLJ[#O@L8\SX33WQG:V2?GOZ# _R]2!^JM_+^N 0[
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M%U%L8O3FOS&^)U]R:OFO-55*Y-:%$0(&^(OJJE?LKQ!4\*UJ4,7;?S#<RB)
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MP/_IUU>7;X;-Z(U366*BG%B<6T(*?T=8(]']GH=YMX>%,7/PL8V \N>-W%"
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MZC;9Q!CF/.;6*ID'V$,HVG6[L4CSF<0(,X_JD&I+BP>;Z[TAVPB 5=;LKW.
MG6O$'/\(HF8?P;8V#O_LNYW.4CE2\VVGBA'2HL%!XU- _^Q3RPX:WMVW$S5'
MA^,J=RQ&<AYFESLT&;26:X?G;KOPA5,Y@9M_7 @4,XOLH(]7D,=G+XI<7S=9
M#=D2IP5VC0_9&XV_=]A\V[FF2--A<"&NS'A\Y>!2L/S ?\/#[L;?N]GW0/>W
M'=G^B^OZ[ZU?/CB4+OGU+]<1_LN;WWA\V]USP&O0=\N29RG:U[JKOQ_IGY#-
MC!F&X)(7MZ.YH!<AME9AXC=#\Y9\&#$HJ<X7Y5O60MX([99#R]37&WJ'@PG9
MQV=(J*ZFBK&N.8OHUV^\'QE2GJ?CQ),?)4BPVE@%4P1(&38N3LYUK55J$N_X
M^@F#8?6K.:Z7U8E>PR:S77^<C/FMYNGBO;6WM)8:UY1K''*&X3:N+^A-8K2*
MV!">FDH,1D\&_M@HU1DFL8U3$O*I))') B'0ES^SU_W_F2H /P?P]H:= RQ$
MS@$?QW:V&L\!?+N;Q$Z2CC6JEZ#Z>4(B&_V9+X(8:8JH7B6D],%.J4@LJ( _
MZ!UB245[_,!V'O(S_8^"8&51)S-"/59B<NP-'N;7JN,Y*!V&JK8ZL&;S_U$"
M=!+J1#TKYKI%=<>*.1UND2Z.I'RW&+VGKS%5K-Z?>4/ (4U67VVJ6&LT^U;^
M X+ 6198&K,-PBA %X5X7S0&)')LC#^T/_*I*4[K5GC[H4@2'2J38\MWU7VN
MJD4#:VJ.4^F$3 4-/QLJKL6I1,MIN#G;7.;).QF]67LVX^)?_NEG6(YU8AD,
M]L=2:XJR,S<#00J[#8MK$R1(.8ON])J\R^-L<&Q40D46#+T:7+PJ(]%2[>=@
M_+(>=9=J@-SJ"JT.+J,3=,V<P%??D*@Y A6?%<!45D$=ZOT#0S4]A*);6JX.
MO'_0_2.>3R^\XT=<L'K,J8?16.TY@,X^94.F>(F)Z8'PNHOPF\M1\FIR5]">
MP(0I^ACB[34BTR\7H;IL316EEM'>,ENW:N5\V[PY7E;RQE-ER(($'_=-7UA[
MAH4<-K'7W..Q@@A.8\:7:U&)^*MMB/=K!-$HR?B6J@'C2M*%*OI0!FFSO9C]
M_*D;Z&XB$QZ./>I^WU>V9D$Q! :Z%W5)AA0A_<7+>Y-O&[-=@-:]B9>KXHF+
M_\!W:74=RHWQ>>=U#KAJ9F?B&K7?M_UZ)DDHE5EUMU*&4+ :$Z:';UR \A#G
M>H]Z9#2AL]VPBSI]WC$_-WI8W?,^AE#.Z% B97PZR3&!Y-I-YKS=; ,AE02M
MP0/JJ(-^&5F[WP41MXV%>[[<V5U\S?#032IM)NA( 8'C;8<#L0TM$(7LCU^'
M#[C#=Z?$IJ=?"\86->3_B%NPS!',H6N0V'P/UH&G8'Z7+T36[Z9H_Q*J&QMA
M>WRUHJ:?:<8;F:SE[V%BP8K/18NPMFZL!?$,>]G67)P1*O[Q[35YV2MZ\KE@
M!3F<:R<WBV]*EPQ72L$ZLR$<A361ETB]&RS?WE2=;"I*<$I^IO9B?.5V?1N/
M;VP7B$$XB-Z^C0[O6#X-PD-Z921&N]0^RG_XY3SDQJ?RNL"*^ZX!GWMSP:76
MV Y$+13>;;=MC>U)RRMDP3DC(T5\''1O15S.LS8MOD@X)>3^"$MFER\?+")9
MR"*GU\:>TNW_VG$[6'S1,\_;?]'%(]\!@ '::+*= YYA76-NC=Q?J4X',6_"
MKQ6MZ==J0P1YXPYHBJX&A)EEA,JI2'6<)L83;X[N.RO[NK8$7IDPG6Y_#L\+
M_)SO>BV.X]*E%W#Y1PII6_[G@![@95_#I>D-(O_0_F0W9J;'PS.J\^F7#E6!
ML+K4L\M0^NMXD#8N+]O9V=]"PQ<F5'?YITC<]XMEXK8*V4D>&W?(?WK.3^5W
M'LV):]-_=_:QSU[W+&E]_S%&]MO[3,M7+%^O?%M'L&O< HSEAQ&!$[[P;@NN
M8<K(@UP9^FNFV@%%H+G'3.P-/ :O%W,^+WN]JB"[N<KX=GI!*G(+;*P =Y78
MLI>8.0D9EBJ9#!H6_9K\5/+WK5@Q!B&XQXT8C )3$$IFYUV+3\$FVUAMAHQ/
MI).+DV??(^$W28PV$X]4=)>_?'EU8<"O=XONL4+P'T_Y5(IA2GK,F=$BD>SZ
MHT7W?X.;'54;DWV(&XDK_E>V$AFQ]-LJF$:"):Y$KU:4J7HP=**#RY<V>$A2
M7H,#TJZD;S"Y/R.?IB+9&W O<2:F>7][S_6WN)SVJ3%^NE<J1:G8[$F!21CQ
M\ZCB3TKG@8 S"K<F1#3!O'RZCV^*6.(EK6=@L=Z9,AW\N-+U,1.33U;Q\/1W
MLG?@72GE57BC1#YDL?D[/\^$4,MCK.0240*:./-UTILI=*E+-P:>C@A:-4;/
M,^.'N[!=[G2MI9.SY,GE;W^V^OZHXFE+Q N<OOQ>MB$Y11D/+G6Y;<G9]B7,
M09;KPC?@NY3YDJ$VG<$6.Q>;EQ(4>I5N_+KQ)7.U$JWRC^5T1@><N@0Z;:YZ
M5EU5VT\V@>6OH48 3U@Y8G8;VQ3L3R"]\=KHPX_60CE)D]/:5F4/SWI&=HLJ
MG6L(HLY17REW:!8_5NQ,&F'DYH!X6PZIH<PZ32[MKRA>CMH8P,/&HWMN@2-C
MJU%ME^P4[H_*V7M4:/#_Y.*KKP[!:,^V9D]3@1L_O>>H".YK>-![):$NUA"8
M[]Y@O.!^HTM_3G@>&Q20TYM]^A)O(7)Q/>MWE2N$FI-NVFP44;.UW!2IGF#7
MTG-#-3;\VW?658Y]J#SE8=30 3 Z"Q5>6?';:2$B4'):N\V7NZ\Y_?><6F=8
M',U]Y_FJ2GN(C2!4K%,F,IP@M9A9"^5].?AJL.[IH9K<T >H4FE#/!R0,,A3
M?H$%W,BR J_3GAR2+FE$#+<\D4BHK%DW\C:B=>'3\*NP]#5ZZ\(^.J1"(_JP
M.:R'-VIJ!&&G36G?QJ=)^[OR#4**V4V=M\Y;E0*6=ICY!FS)&Z?-*NR[T@B\
M01RSX*[&GOT\,<@K\#*^S_YBV/E EA5JU5:GQJ.2)67=H;MZEZ "M5N#U,3'
M9\_/;&;];.KI+2_9.#2IB7HFZ.9%==//^+' *P/X,UT41TI6[RC0!FK:^WY]
M'</-K?'%9'W*[,3@?9B6ZO<$P^#,-[<&UA^Z%,;1:3.0[;0OZ0U35_A2!*/*
M_A,P100K&.&TMQ>+\%:=H!L2DW(/ \6#J'#@H.M9_)EDC4DY EDE<B+2'2MM
M)88T!?O?^H/T".98GR@@6I,XC)&GULW2R(_]-3?=PUA3@[KRLZB)!MP7,F(T
ML;V8R$T<YKHR=$#B]OZ;8+G0'X<8E$YDCXQ89J6J:B8KP^(5*2GY[X<%-/.)
MH/K]?"JP#T:$;@U([P5C0Z(U%>1?=&<<*EE%:H>,NRVW[5T\CEI/(+"=T'<
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MMA+Z8<LGQM%'[?] VAKEIA3PP:S2-\O!!RX*;G/V#,RMEZ\0-I;3E)"=SE0
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MFV#:6X ]7QBP"E];@>WJ%C"TIPID$X??LZYW'UF::6#Q2;TT-$+:_%$9U'>
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M *DE26*OB-1D@ ;VXFHQ93PA!R6B$.MT7O.3.-%DKFNDR:EY!ADLM.E*6+H
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M+T)J+2C]2%!F(W0MJ/U_ROONJ":_K<TH HH449!.$%!$FC3IQ$87$%"BM(B
ME(B(@'0B(KV#@-30D1(BTFND"PBAAR(M@'1(J %2)K_[S;UWUGSSS=R[ULQ?
M\\?)>Y+UOJ?L_>SG[)WSGG/8GP#O[5A5Y!%\'^&(_ ;IUBXVK.LU^'-H#!\T
M@R 9J'[%Z^Z90%*2"]7D&;;$COS4&+S,C')TS*1-M184(PZDG]I9E3;E;[=%
MW"P/ROB;V*/2KG^:^L5=.?5PZO,EM2JP!LPK7D5,F695]YH0*1[\-9M!>C69
MU:G6+,WL?NW1XVYG^1_W6K0'ZQ^*U-%I"<"JH"F#9 8"3SL8@TF#!%=-BZ5/
MY'_TC #(\I#V:7)+/2]^@-;D?E":AH1F<7]/OD!U9'.];H1XI5X#Y,>U+W6T
MS]@<G]E4++E"!.(LT9&A$==QXYDWFH2O^%?GT#;]N"TLE/,6%,EU5-X5 ?C1
MB.,(=2$J>69;.(R;.&#>Z8@?2IV75NFY%C\1N\/Q<G(C,:UWB,Q($+H[<G!1
MC(71<?QP*KBBJLF(6?^7<(*QII*DNLUH5O64T5W>0P3NJ-ULJ[S4^:M#,CC.
MJ04R;>SPX *Q^B*7BW$V@,4HYE9Y* [99L4](C"RCV:9F#*[][YVC5LCPT)J
MYG-BC^MD^(V&AIMGHVLBK>U+K-9OFVFPD]:[4C@8ZKQ-;]^G4SO<?NVO;_7?
MP2V6B >U1\MVU-(MUYK-*,PF2&%/(C9NEHD]+@J+O?YLAF<(:<(BZ6-<J3AW
MD2@Q1)1^+QG/U/E3">P!$#WXL6.I603C3RKZ/:O?\59S6&&0<:SD%_[&EZF!
M()AM*!1]41#NYWHR;I3#*,&EQ<16^WU//LD;6ZKY+%6A>BY^OD48?YA78G"D
M .YWI MX-G1XB[E]MH$EA#I$E]N,;B$D)<F3UN^P\N^=.SGW!4[L(_#P\ ;-
M[.BSG+9GZ>R2Q=\A)N*/QU=^N%QT,DO^%I@;+_%PJ%>/D9;AG>'B#V3/[<ED
MV5,#N=QTYYWREA9+EO$*I3<LIS)/;8=UG NSLOP-$:OY.5\$DU^R:PEGC9TJ
M$7KVNKO"M]UW6#<XKC-&Q97%%:\^$>C>2,-%"W5Q%X_-2ZE8B'^_5?7P[3U%
M;,L/_.?9RW@]"<1L'AO8:-G876DZ*_M0L![-$C P"ZP:O?)X+QDKXRGUN8X>
MOT4P?8PPR'.Z;#"36K8Z6IB8889RUV+OG EM;?_86SGSF9Z<>G4%)PP<:-+K
MM)).T6@VUW.(S[AI;[\J.\AP2F^,(V45Y.H4J+Y4T8SM>WHO^LNJUG#3E<ZY
MRJZ\$J<SV(ZZXX=#WWA2:NXA/V)?TRDW)3T2='E8M>J_P[CX34YP#3M3[6+5
MR.IW"2_>D!(FMX8UX4J:O;!(__'."I')YZC3\M*&.O?<N4<GP661$J4W>U@&
M@\@]YX(.#LMA"T?M_: %4_CAEL$?Q:6[]Y=6'-4,&[G7G -$O0*VEQX<)D>*
MG%FZ7WJ,023LV1&TA[OZ-5W,%99BI102NFWX_-AX<_B+WWNJ>^(91R 2905G
MS9?CQ/SW4^C??3N<CNC:!7IR;G7Z@CL-STU?3#VX&=)G^;!8IDB0)UM=:W]:
MX-BPA<5G5^=UUK"+Y!\N@4SZ?K8@6K=UL8D.X[=.>J]\4DUEL@33@X;U<OZD
MR.BYNLE]EQ4OZU94;*4K=\"G(S2BOM,07W/:>Z'7>MBKRPC6VY*V6:/1 YYR
MSC_XY\><0=K.DMA9'0NYRM(<HZ&[K1L;:6WZ[U8]AXI 3O4U OC\W7MYUCPO
MO-EEFK5;?QZN6<&L$+YV_'DNUZO6'[VF[]]95^M\N]):^\="0"NTJKX;J-O+
M)/S^I>. L;$9W#3@)P6PJ[O\SS7^/U&O^,0=@<S"M<RVH#=)?3:\<=4;U5O#
MX^>)[;P9KO)7MMOB]@OR$097]E2P.X%^2CB;PZ:_]D%WEIGK(I_#LT1(\*G>
MLWL?,+. T 9<GGV,(.<O\;5\\&&UN+X22Q;W8\+O;'$AO7P[E?W2,EI4AMW#
M/XTKZ134S52<$'-L>,[O9&!^<^]LLN**.D#LK_#]8\EYA^G1&O*^B.M2&8Y'
M"A'O;GCY7$7+-V)!$SL+<Q&2?D_5#JKW=+"6[]$="J>2K@W;$ZRL5HI6!EH^
M !S)MQO"T_0 7PC\J [$_XG/6R=SXY;,!BJQOJ?B-05RW_F*V9X?VSSNO7 H
MWPJ<9EEDZ6 YXR?\'4?:CL_SZ@/C.RF CP=Z?VKWRK:Y:1]9"*!GVK=_;%<?
MP+N!DT(_(/S5?4QNEK%&(QX;VDRYZPT2&V86.F>4I%6D9JT,Z<<+1U"VZ%#N
M.W#<;K?^L.VW*IQD]DE6(N_E>')<._-N5KFA21K@6-:8]$U=G"A.L,/'/AA'
M[O?#N@*NXM_ %S)5K+Q4OYR=I1-T-"F\=(WXS ?LC=O!2G6YG"5C0"QD3L)T
MMYE(E+N^FT;+Z%**015K+[?B /OQ*M>[HCJ1X6:11?O- L<RKRO8-(*"_D@U
M"ZO7]O;LJ7$U_J+LU&]5(< U3ND[S$]#[],[X5TF.0[%\$6!ZNJ.5&YK,L^?
M]'K)Q*.7U3;>RV2FK^M;?+UWQY%G.[?X!<?:7?[ TR=^QH2<(O(PD*&%VT\-
MSY^R4$<$%\WU>7@6FX??Y[SKW/>SS_G<F=_Q5EQ8U-3*HF'0/H2-0'LP(WC:
MK<Z#_Q.]L(P7-FU$("5<L)F?E>U#C2,S?&/&]J6VQ$Z%?P<,PJM [?HPHSE@
MT+Z^[./:EKK*YCN8.+0 '7U8S#M.9@WW*9%-65SM?9QE;*C MQ8OYX-3ERMZ
M_O*3OHVEJPK>+G*A*31NKCMW@?+$EZ0"=4DOST5>U(4J1,"^A1?X04W]F/R,
MPCV%Q'5PPE>_XQ=8Q0\O9#>ASP(P$$X_^WEDD#ISD$$E3JLCEG>=XQ"<UH5X
M8SI[WIG]63^O?:ENV7FN^8]*R )U6?+/+%K"#-;+3ZOD#C+/*U""W'VC('NN
M.0-SR2VL0.SHL^VB' 7 %? 3QNSGBNMKGZ4?E3OM'&E2G7V5Y,NTB-C*R%@>
M?KU];@7>/OB8O@]8HQZ+E[I+BFNRL<;S=*8I1'$#65<7#9M&7D@_^OKF4L-
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MV00[GHJN'?F,Y_GRERYF&K R=8X*'9G&+4F'J![T "H]?_");?H"K]A^JK>
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M4O!R65.0Y2NX7^T@/:_B0LK@&(B@*8Y:0Y(.'?$$G_'+NG*]AODA'^16RRB
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MP8*]JI6N>TT[=BU]ZD[<HH8&\3;/8CHXHP.>GC##"][GM?J\W:(VE6I-Y]_
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MQX6I":O:?K6I584633&H3OJ6,+STF7_ZZM5!_+1RAXZI7#&/IEIB4G*-\=3
MGN]&ZJUJSF;.G.S+E57-#?Y'6X0=N)0Q?@0K)3DYRQ 3S/@AI:KA KTKU6Y9
M5\]]:NMNY$L\&%?4.L?A]5Y,23F@$S.]U3CB^K'#UXXX;#(@''0*-/US(RXS
M>D_L Y"2JUVAW5(:J[.'-\#(?.Q5R.%CM,P_!R3+:LAYNWZ-X@]$*Q1H,^Z,
M:4F2;&OZQ/J">I=68G4$LG=)#J<7HO>0[T!<V?BB/(CC9%7\(-0E"S1QF,YD
ML/^$F ,_&Y)]%H1; Q>B;VMYY K0ENC%9,UOM48+%K__C_("SBT:6%F-6+"
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M9DYG2ZZ1C#ZDF4&=GO>-N>K^J3=&7Z(+*%=L ?<I5C-$PG[6X"XO^$:0)*;
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M3M;?F<"-*?.?DS\A"M8.]%3??+[H']DA%ET3S#S*_'08$S6]Q:2MM%DKJ R
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MT9V!468SF&T<6ANAJ^N/U_$?U?->3%F"W5V<DG?%#5]E)Q2*9Q(!K-LDRN9
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M-7U-[:0&=9C3C#HP$>UAE"G@G8#7_+22?^OH'UT&N-#%OSSBJP[(-<BV@]V
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M/ZN RQ9L\P<D; +4(W)5XST108Y7 (PXGB8-ZV^AQJ4W7O7]C=?^JRF1'0
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MK,?Q*EH>C:6@M;0BGM",QMQFBUP(E[98ME(F;Q'I%C6[C-ZZQF"@10HJ:9S
MLCOJ@G,KUWJ\Q/WMD*;UGE#?B7*.08C3]MG><JU")$$$O[>3<Z=J (8U1V(<
MGUZ>79I(/1I#Q,_TO3S5E<!*>BYR?>'B'VYBQ,/:0/0(A -1!.LO:MKPYPH
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M+AAK:\L&A@;W%K81=K(+NVMA <-(@%  WSH7Y0A1EBNYR&Z&"TX]5Y-*H<U
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MR1=0V\]B BJ<,F'UDOA%]RRZK#DQ)DG'PT\$W3U$@TUZ)=XMLC]V?I,T-O^
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M<0R]V<G1QCC7;.:&EHQX_K;,_/8,<KO$JN*C3QX)#Q-,FU:S 2N((U5<U V
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M+D3XQ(\XVV02Y<A0%>%X"[/=QT]Y'MH+:?<"[1P:% #5\O92&%YD@(>?S,C
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M9UX*K7;BVY?KFS:?X_:ZX7F-'G\%0RF5D%*Z][+ZR>)M]HU'Q7VDTJ[? 2C
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M&"'#/6755H5D=$KUAG:8E__>URN4!(,-SC4M&.!'"'^XQ\R#M 73S#5MX:J
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M,>N=5V%4\ZU17GV=-4D)F;"_ 'M^HV[<.G?@<RNF+7O"F2EK,_/E[>?!-+X
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M@C>T\8>_6XH[CVOI*?;GS^1]SA/9H-5'Z#ZDS=J-QOP:<!JB[P U,_NA6([
M@DC<JGAH:;M1O!CM);)SK7!0QB7%Y\4YB^EG@$;?T$,3'2W:I\_D&#D7A<^)
MV)OC\.3M1M]A1_8,JCH[FW<FM4,M]AC<#KN^O'D7H>%>R65FFZ&K9FR@PK*^
M, (D[WH(7KR11TOX^Y9HHW3UD)5_9GT/R0S:D\>ZTS3L28=G"@1S^#A_E9,_
M+215KN(?O =H\<;HJ'OMD_S^J(/8@2MC9A$=VLO"%CV]I#:[V4K&//#G5P7J
M*JB9G4!/$_".$'"=]KTKPX%7[R+EJ1ED"Y]+.OWZ5O&RVQSM:(B6N=: <1<%
M?0.MLN>^GJ4U2SJ2D7_6I9OY-K&2YK?9KY[1"+T$ %^+.T>"*#"ZH$%^5029
M-YA\+S"2HN!@>Q;5S!($V)>Q7.PBPQ$T>)JBD4CH0 @Y*>*(4 &P^F@T,>BW
M='AYO'5@&Y/#T][TE)*B/]NNW.Y6Z/"_EH*XHJ2B["/^>E"!ROW25X'.]>C/
MHO2(N32MU^_%/^F>Z2T"PB<I4Y[HTD%H;K]P((/K_Z2#IX-#[@ &LU4E 1W6
MIHN%*;<1(JRP1Y('\GD3$3)JPST$*UGFR3'0V=!Z(2&?A>[.%=K%K30Q@6M:
M;Z&^$3?#M*>>I$'S83-NN+M/&V/&-6Y*TD<8,Y3:2$4)=/A/4=V.!4GF/!\Z
M='WA%H(FK[HZNF<;\6:A\V_XI6 "7UX_<E@<$CK/\'<#,.<]2_#1NV% [U>9
M/7>[.*;_$\)"N6=H9FH)KE L<2VPPUZ5RWV?<A6V'/%+2G(R0%JZD*PIY_@E
M<N^W6<-\H%-KUL_&9H'4@#JFIEEK43 /SO+<4'.T&8U)+(LJGM%O%3:60M9
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M&A@HDVQS[7>=Y);36Z8O!$@%0O9V&"]V9U2">7!='SG3NXD&[,.5) "]@N8
M=PG5Z>Z"/FR8O16<;9MR9LRVCL&OF%)F9;4(&6611C4U>I6 KZU:KDT;HMPA
M9L6JQ!;[GOQ'INZ"F]O\I:;;<A]ZY +6-UFK7 7>S%2F$9JXE&YN9"HLYF]>
M*NP-4&%MW $:E 9'6*/:K#+3+D_^P)H_4("LE$R=Y$<LZ",HZBQ9( WC^">2
M$6I>0 F(&)IQ0S@AA&?N$&(5C#BDH&IJO [&E#OB2"S7_BS@U*I1EU$;35E]
M1CUE6NX8#O3>9^ N0) H(H8,ZR(PXPC):"<A#M(TCH>B*8$1?/G,R(L"N#;I
MD/JT6^:$=EVL37/SLY>#D6%%G)\? !J=':D3L'GU]0EX  _S-_^F+R_$8J9#
M60WAF07>\%M%9GWYYT$E$P$T)0Y.]0-0M6(>&*?!CVRC;.^M\@QZVZ?\RQ^&
MJ[.W;Y-A'M2?CL_W.T-[_?U-9-.)<W^[-0JRGSP;\DU O<GD,:Q%V$7(,&NP
ML3Q')J]WQW9)[;<EK++-R9M\<Z[TL%,8+RJ#*0_>3AZ_ICA\-#H< O9X\^ '
M*\BQ)'C##43]^9FTOIVR9F^8J*[AD/?K&QGXBE*O.6E!D;/QOO.W1>7,"R0?
M)SMO#[U\P6#+6B)&'D5P+R8?_ B%'Q.MH7L#W-,8XQ4D+G2I"&[M2S4&MRQ3
M2$75>''B;TNZE,BB__H>Q_@,^YI"5'Q+Q@)8RIU=ZOJ@:H2ZBLHZVWJCK2)%
M'PF\Z*C7"PA#'H#3-X ?)!@[0PU0[JE0W-K6_#N 84-8Y\T'_^]$?N\S-I3$
M_6OPN&4DFW35("RWGTO0V8AX9G--^SD(@12L*A3.6;?@&'$4P-2TW-<^UM3^
MS)POC%U*):)U4'$;B0E_ W<C[=.8/IR?T:D-%SQ<?Z:1)$&G/Z& ![",6.4W
MO6FQTTCG/%1](*JCBUW\7Y0NXQ/14@5P$Y0PJA>6? VCQ$F2?6U"D[+2;Y=/
MMYV0\E+C2SC;IF?PG@LOH!@FDO#08$J9*'Q7;2HI(C,.\(KLY5,%/$$JP">6
MCS:DLPUZN-XJ3*B#-(E44=)Y/365X8U][=:&B!.""+!=#BV=TZ;RK[YE%A)M
M58"H=!KG:]77JH GI3T '^R\AL 'YKS8XA'2FP$4$B80=P<]8KMONH%I_W5M
M5$!QS]D_$P9,W<^?B^Z?2RK;?^:D'V?.B\7[A!A;F=-'O$$/YR4^6PH14[*+
MY?W429XPT@/6-^T-2_]W!Y?^:Z.DL@G\QUH-/4E1K"'QO?LG#MR;^O%_/$1$
M[9ZRXOXSY$9JJL9PU=.>1W]49>\_U?M%1Z[,=L&>^5^XG A  :9JW"YH\"M!
M5"JM'W](_R%K-%B+R!U6''I#THW4Y%ODM/MMPA5[@ <(E)=Z9/F",^Y%FMA4
M:C@!BBI]Y;DKU=B3%W2'>(M"NE")JTOD!KQ@*#GJKV(VLFJ>Q+\O4*&IQD.I
M65[&,VOJ-DE+DWC@(A8![YJ,6_/F&$/4?$4'HZ F.4?'P*D;BW*0>;E3EA3V
MQ32?(+D:E^8PHQ=5_$E!%JZ'W5H8V;3TMR2G>8T5*SI[T125&V?NEKB5YUKL
M:D0 6AM1717@YWSLR(L89'68^ K+^ *"*_E]1>%,Y;D1B/AY!:QEE=M*PB\%
MA;6UF=+O)S/.C1)*O%8!_T$'Z:+F"A(<B'Q+K,RY<YU=!'!%5L2T)0OW1+/X
MZ:)JBH6\A\P!MW3#"GN,0=>@YHS'^7SY-$OL@_ XUN=),?M 3LSX*B?Z"PJD
M@<X1[M#Q*)RR;4'.IP80]T^N6?'+!=<'\C)&B/.%>1*ZG^]8XR%-XN7ID7MW
M  SUY8]D<K0P0J?@B^"W6D3 JGBPVL884/X'HQS79H74<+H23O@:%=9?G);
M.%$%50CIR+7&/HU8+K/A4!.#1$E^B6_1SV#'MSEY&SQI;D6=^O18\0&%O ]&
MBSY[O2XPN2WW. ?2$!7T&XL-4ZE25^4^BJ 2)LN<KS)Q7_^F/7)ZN=*,'::D
MXD^FKP;?XS_M&[*F0E\[(HC=7L(NA_XF?2EA]M"9]EB/(*+/>/]V7G.6S9A
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MYHWF0:_UG6/D(_PV#^2D918;3?FY[J8=6U-759J_E&E<1C@,WH9;6RW2+0M
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M9-3]\PT.)9/^1Y,#9)'!3$T90VTGL4=>(^GP0W!E4?HR(A8I)3P@U9K<8.%
MEM&IS$0=!RB;R=B #]X#HJ7MYTQ@>2A-KQ4MQ2S&:,<%TC&8^)LO!"N2CX_X
MI-['/$[U;<>UU#0+GK[R*8>*YN#WMG5'G^]VI!)XM?0_?Z&1'^F8@W!\G_!$
ME^%F37PSWE"K.-!E6HPUTK=+])JF%':!YU0M.E\/^G?;\_!SX4E>NG[H8_T7
M]!%(2A7BASM9DG9)F(H:(" +144@DW#SM=;NN93B&A@]-UB#P,"EH@>U%A8R
MSSR4-8,%K?_+L2XL\0,]'0."*DNBCX'6YE+>6J4WF ^<'!OYR9/B4^,)%;_*
M<]^_,\Q'!,\BN+<'(VVGSD,.D0<0>=2)'C]!DK9$867=:XEC@7YR'SRBN:^&
M]NA=5%4F1GBSWWVOR23AR[08;LFH-Z-!,\B,H^F/VM\F\F5*//_$YTZX.]=)
M^(%&D'==<2702YU:'M;#1W,WND_N 5;N?!)DP5T@84ZA%341<ES NYI!W6AY
MPL!WN<R4^WN!^E6B5*JEDT30\, 4\TKDD5/SZP<1$7-';VD?2]=40YMOOQ^=
MR+,[KS(VHP]WD*^ZQ"7\/[<5Q2L1)-@YFOI\T1FE'E+9Q:<?<+Z1P4XK]#._
M'"X).[\5>CG/%I C9-:FD;6Z([9%2W"(/F$5)@0LRY$]P5F73NH-B6OSR;$M
M0HZC.DW?9.C,]M->RK-1&2NQO_7FZM#D_A6_M1%L@!L:\<+\'A#;(5$-G;W0
MG;NA+\$&Z$7U,SAD0@IO$Y4(0$6)=%IT6LVP=<IW-)+<&GL6NZA)>J=<O!E3
M?7@CG>C8(WME=REV)5[ !YD%FF9,4F\;;U]<-U.(4]P)60^C]+A#L=K7\ 9U
MAG-'X&D$L^8W,ORXGE4><_T^%O9VM&%,A[9U_IK.I;1:HV.!J;E"-BZ'+K'!
M1,VPK<(:.WJKRCT668]=\D3[C")5V[%@L@A@L6%+V 11,7E<S';R@ LSAQ/,
M8/"2L;<*1>LC]2>/ZL:1@:PW1V((UD4_YVTNN#\HIP;ES$400MB<.L9G_.J>
MI0KC/-:<?+U %GNCB_ZVY"3/@PTO >4RSWN/*U"80B.Y:&TX6IV6!3=.HV02
M@\URU45Q>*,/;]0Q?3]-( L1I2&]_*5* :*&[I6W*$%L#LK;&%@8D>,KJ.3Z
M8I'A%S8-O3:(F,A;K^09,U@(GK0%>8G)Y' :9LT7?S&M"?=*X,W:'$<$.\C>
M;L;#7\J+![Y ,Q==1C7DV+X^^Z.ER<,@_G4SN%_W12]IO**5#J'"<]Y*\;&+
M8JPM=-HTCW8O9=_%0+Q&9$?E<TZQL"(R^1[ +O73520+<)84GDN/;;7?7*'9
M'5! ]F[Y)52LKCK7CA5-ND(^*S\1W]]U&9,0Z*$M2/U%]WA;UG$]+X$6&-CF
M$BQDVO=#BZ<Z@*4E >QGX_CKQ2(R9M/./LD)4DVXT2-H9#B?BXL):D[JX"S"
M1DX05E8V$@1NQ:[C<,2G1/9PROHO7/#A;G5_7,._8__=3;V.H8T]%.0E*QE[
MTI:P7).9$Z^DIT&Q"/OY6$=71W,?NAA,&&@7WB>1]6@[8C4?) NO0W(9UA15
M=C:$'=",$P;Z16PE_ J7"5\_6@J_%'N"@TGZ>(=WH]N0Q2R,!IO0?'+ESGH_
M(Q;1X, H1*_D]%6<. EG,$B.Y#U6"I5'3Y8H3XV^C#ZO#-##J!A2)MC3&E,:
M5=8MDJ2,.%>>MHV-I%D1#T6YK ?5QCI%/"Q6C.7B?%0[PI+Y#?^QR?]35B3C
MPBZA9X=8I-%%MTF1-R">=$^!'WM4:FSFH:>Y+K;0JSOOZ1M1=%3,#?#;GGC;
M/_(4PEV!E?V>D1^?'R5V63-.R.GR,L$-RP_$I4GB5ITE/BR9%$MHRT2\R?V:
ME3MS3'3M5 4LTEQ/5RZL;=JV"@CCGTQX3$2^4_CWJ%D$<5M]#P"<%^7,ET48
MVVXU6(JU6H__:#P!([6OSV6'+I+0C^#]"E%O00B?-+S*4J)V$*64@6R$<?K7
ML!NRSPP3&-8CB76W*)/YB8C2GC(CX.=Q7"W27.T6Q(^)T7>GY3L\&LRFW6*_
M<V6P'S=.(BV8L\TQ\B4T*86]>XS+HQ4_16K>T^EICK!Y52C080TW;E?S!,NJ
MC??XB:W/:3H_\SU[#)AU;$'0YJKCSG3BCLA>HG++2X.GNO'%M!0>F*X8'20[
M&X2)_##E^$)O(:6"I*_9IPBWE?US,  =K$=KH89B&H_D#_2FJJM(,F-8P"NO
MZ,=>%74LI<3M@K\^QZ=[*(C'OT\69O$$'1(>"/3&_^28B^H-*' 7&U]0UOKG
MX2/?*YFW?WAG=966=>!V8_T=E&$2U+A0!B:^BAAI:%1FXP&%P5Y4*40#=.1*
M<3=7#']:TG< -[2.@K7=S&:J*ZN8[<X:DR'LM:>L 7ZO!G#=.(F?U$C*X50K
MWWZ69S<[H#PP0 E1KOUN;BM0+S;;;XN>6UCB;%)+%ON9TO-VZV-C]H[DYK<K
M?!.,0=+&+>FNX9S0>KAVLX&?JX2K'KYE>ZINS4[K)'6@#3HDU.5/R9Q0X9LR
M%<?ZQIK:W'T0!U%K(7EO? ^ #<:&D^N$NZM+$LB+Z3?(%4&?[<ESS>[."XI9
MUBUW5B6+]E/)-+A=?%)PH7\8S/O0IJV2M;^MN@^L1?(6ON[YVW-Q;PI$N>P6
M-Y%\;+[QJ/1+8]LCQ]4^W]="O"SQ>0W_0B I,3H(5;]J?Y>:D$'OUE+^%P>V
M2WG+SQ&=]%'Y T+]D]'=1/9U&+Q,%/)(_$J!3(#6)*%B.E-^U"R/[RLIW?HZ
M;MY$J&1 'M.!98/J)W_'R!U=DDC]4N/]#_L9SH+?U$_S%!R=['2_H@G9$C7P
M8W]W<00*PF55T7F*:"_T0.6*KN>CXK(RC4&'V/F\RU-^L_IAG5_QQ\!QD[E@
MML!G6!%/<&EEYBQC_TLAGA/UJ:HJR@-)HUDOBN</,1'K>:_.$^2O@#J#J\<X
M;)'0!17*_NDN@N'1&N*2Q5!50. &9FQCHKIJ7]K&J0LGX]WTGUOA$Z7&.L.F
M=Q\+-?HE""K9B"A#]7*90GRI/Z+YUWT39.DQ%J.HBYD <U:UAHY$K?8OE>%K
MVM(E'- M81V)!TLIY*4 YGY<R]=FV$WEQ@6W/YENH7,N$-@I:EGM<(2*DCH2
M7XHMGCC/N6_J3@(JU.__ ]3F6@4WG!AXS>\H:<<6ZKN-]XL& !L44605@EZJ
M8"/0LZ]FSA-\^UFXXY0[8,HH@BT,+^PX&!'XI7(+].#G:Y6@!47%'JGB0$DT
M:[];3"[Y5(>2P"I7@VE90C/B'M#T6F)FD3?WMUVFF0B_S$M)V4_X)6(77S.:
M1%Y*3+IB-)!XNV\K@N0(+RJJ&:$'*EC/C=V%1F0FT.OW"L?*HX8,THE#:FK;
M&.,OJ8H 7$56N4!^K"Z&3!E;L'ZD;@FQU)\%"L "VBLMW]$FD6PBQIB0OE)L
M-"_B^9#+OM5EC_P&3HX>K7?*:#9VM[;,0^[F14R1QF/YEMQ;Q^6M3:9T*A7?
M/(P$IQ,;E["6 ]*&":*,<F"5SB2]6<'90 F*,%SB9 ^"A^1*#\D)V,+X< UB
MXY=5N$YO^M=N5_H4TB6./OA5LN:P?BEO3?LPS%+HK_=P[AV_'RXR*-\AH1+3
M/DXJO@F7>Z%G!C:@:>IV@IT2K)\BWK G6WV/A[%\P\GE>W!$';&QQNC4)5"7
M>J;993JF\CZDX=GSA/G/S^UL %9*^ZW,;;.!4IOC^ ,9AC"$10'SP#QLK0%9
MU^#1U^ZS,OSS^<1L?.+7RV\D5T^IPTOMV<*'.?Z79_6SDW@%\BX6+)%ZK5NT
MH;\7C80^"@%\B3QBW'J3.IIM=/-MJTERT@(\!>X+EK@;7B7'SKJ5N,$V^^!-
M;]LK%[)^O([%"E95$,B&*AT&^1M:4,^^M]D?&? US8$:6>^^5W^"B#+EOP=8
M>LKE:<Y5G"<(S]P#='+YRXF^P)QX0\-2U7Y2VW.6LL6>LB:LLJ'5;[CTL+[]
M\H Y6=\RB]]P*LU'D=G,TUK4N51L'L=Y3].M(05<G_$;?>]PL/;_/'F;6&).
M_F)EAP^LS*G^Q8I =,LVLI7+[AI.B(FZL$7O#I'15!6A0IO]_9UH341]]HL<
MPC2+8I7<F4)O*K[+VN)+[<:'3\I;.([^>9X5EJ;G:^%(]3U0$<M?N =+V%"(
M@IL<1S''[OOZMI%%=4T_BI= YSM\9<W)TGA JVK,Q&;^D]@ _DF>+? I]GTI
M-N\U.BK\Y+"@P4$KNY-(Q8^SHR4F5:&>L]@XTT0OENX9;L?3OY9T)I.'9:B#
M>P#)VN]DZ.2K6!(??H-Y1X9W4YJ0@$=UB+@QH?IE%0Z'6,FDS]<%AJ\_-AR5
M<M\F!RIMW :8S0?2;S++]+5]VKD# XWVN,]QN?>2)FB%8P"9^N &6URP,%5.
MGBA]-D/UH.4G"]$TO=KY&R$_#\2G*1-L]"J("92J[K%PT?NWYR]!Q@>UMXO;
MI[0[5=4_69YC@S9)+-;ZVMPBC[V>WBB4C BF-E^]J7]C\PNR:FIV6IO:KO/R
M*[5D#U['Z<F%1 L<&"AF7VKA1&,@SB%9W5UW>,*9"]WLN#:2MUUA%5LYZZQZ
M^,7!\;4(P[$\XPT-QB#&;Q-<37MP9=!=BLVB9\\PK*_+8FQX::9*("3R79E2
MBHCAV<V2 W=F#&!#5GMS+?PJ*;PA2$8/&U()K>Z]HYYFG[>>8WU-2[&'"""T
M2=S(*22+2D2H_U7B!G!YQOXARB,,)%A8F" J=\-;;HYT>>L=N6/DNVA"65>6
M;EQ7:Y^.84,0X<9GG8WI+N[,#JU21KK1].'EH0)"2/;\F>-1U%_VX-(!VDT;
MP9#4 7Y15QOKL *PMV2:P6WB>67P_E,A6=V"[WM7"0OM5M;3.GMN5:Z<+3"9
M[_:W1S4I!!3QE$7"GG1<N"E1/5TLF.JD\R,R-6S$QD>Q>\#7A2O/UV=*WBS?
M!!FTQB!GX@?)K71QE[9CN_2]M_+R@EA5R]>)L^:-\_D=<QGJUQ9Y'ADO>KQ&
M!S@S4Q(';=K50F(^^U)OE5WSF#O[FC3EEQ]D6<V+0?1UYG;3-&9HIJVN9=-D
MADCI4MHG)#VT' 66!,!YZ,G#@BHHKFKM])$;T-LW]UHE4@N[ +V;M"]JUV7L
MSI']U!%?3J?1^^-$<E,2\&<MP0-+I$KCK].^;GQC[H=J/^-8!&4%>H[+]=-<
M=^P([#44O@EE]/GPG)_T$N76=X0W]F:Z>\,"[$#O51Z"U1 = Y(X,-C#%F*?
MM"=*<+*8='$F!3Q\>#3X[&1@,DSZ9%".]2=MUC?TV($_8^?\74XY:&9UKWX<
M6*_*]HZ2$U"Q52;@[_G.:RWT3A+=D.$)U1\PP8]8,ZEIJIOGK)OF@AXB --#
M8F$-_6JK^L\.,WZ9#U?N%^(NB5D2_F;A4\E^,W-X_DC<TYC?["7C+8-5EXO9
M/0#WT^O$:U5H2=]DN )A(7:@%%O^&L.2@<JC,*4OCNREKR@,>##SU)>#FG3@
MU0]^S=2"1,UQ#P9X0I? (ECZMI"6A:VM,?9XN](-TN##]OK[&WL[VP#W=(_:
M3)ZWP\I)N;+P-BSM^D[F.L3UTJ2^8]ZNNS,!IN'FE@75J\>7>?<QG@6_$>!7
MH4 E3]17 (T-4N_#5YK]8\[G3"QF_@1Y^Z/'-7-&@_QFHGC+7B_"X[!0Z!?A
MB5A(;"X+UA9=HHJACHH2 W7PW^9FO!DH6"PG8M3E'2?AH-6+I9J5E#7\TG?-
M XT:(#](A2('00$5:V;96W!128>&-I%GH\GJ'"-<*=E0 ]LZ[O<X=7\%M0P_
M!.,Y-W<3W\BMRVGUDUO^-GF=I9%2U& K=DA3Q&)4!,%RJ"6H ZP]2(\;<)9#
M>N?1G<41^?M9@]7@C<\+5HD!6A!_K[H6R(:&,E,\@7NGDL6WK^_\[P$#)_A8
M?SEW!PQICGO(=Z2F;T"QR<H0<,LIKF6''%D?)LD6M'%@!A]D_5A[8S#'U9IZ
MBEC.(]EO>V(3H"0!N\S5X7F8*_Y7_2/<]XT%;?[=^)WPW)T Z$+"X 6HBVA:
MJ)&Q3(RQW4E[,)]Y?([JRZ?:7^-LGE1!OV=MK$W] %/X,PO=#+*$?J(^&&CW
MRX#=9$4!0_W09;]^JFT74MW,GK_^6PQ(M%OL8:#WAC9GOXEC]FW.#Y,A/[==
MGJ'3%67![<,/_H:34W>#*<K%%9S&=;0O!U?A1_S% .3F?+8>2*1=0=SG_.#,
M[D^U%Q:T@8?^3_LR*19R''$ ,B!?RH[0#GL92^NS_-6164216>R_= 00C-)K
M<+*AE:KET+2'M^C+C:18,5T*J&T?399.;9DK+>T+6ED15WO%_D\/3U^&\E?#
M*\7 [?;FO'K-L]OTRV>(S)[->,!!8G#C:<GA"3I[<RCBCA^:IH<QC&8!\G@G
MB\*;%5PC3U^N%PP0)+L '/,R<+=[J@V)I&OS340/3E6+H"M5$!^0FULF7 M?
MBX+P_5?45S'-_VQ)"@WR]'7)@-7U" :VDA=8K:_',V"8>2_TT:*4?=15E563
M!8H+NH+18C87^II.T<FRM1]A;*KT;$V$2LE@N/<8.#,0&(2C &H'J[^TT6Y?
MLV82U!$.L(/W7+D=_L7@]J[237/$]<7R=J#M# 9DA8H$TT43NE9.!,YI*2G/
M9#4.GGPJ7;6;F!FS>#,<)'X/J!<*LY]9CWN]X+W",2$C=-@.GVF$15LB^=NC
MJ^@<95ZG L8:?_HPUH!KYN1)H#P'O<VY=,W3+G]RY*_H"K+DA$6;82IQKK_J
M$L8; ,*> X'AJ.X'!PS'E=! (/ITLX^5M MI*Y[/G/3),0R40F-OM*:=.6HN
MZC(\_DPU'C*<9O5@!DNDCP&N18IFKSV IO5<K< 2B'11<D):K5D@>_)7R<;(
M5V9#8(9RO,^B'[4D8#)UH4&ZMFC#WBS?I$),O/ZJWZG9F#=SFL7.(/\()[FF
MM.K4JV%Q%HVM]0>:E4)$-^(-:$ZCH1)G..R*)*=Q3OUUEN*T;-KD+GUFDLSG
M#-PIJ>KH(WF6@^=8YTO=N2[&?4HCYWIE4+&VXT;Y6IU3-N2A;\8]P&IYPI61
M+[J?>)@^'/((^3LO<8HUFK5>(EI4EV1I'[%\%=C4YI6\ JKV]'P::40<\4U2
MY*:CAA5ZS-* TUE\-Q%,63O=R"SM1@6^2OIT;+#-/2WD[1U =W/I"&G1&U9N
MM6<_+:';,[OL5UA:O9O4B-WLRXJ*[GA3K>U)I>U7OH\9G61Z,\P6J\3V_KE
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M.69L/PCG]?OSNP"[AXH)<6K/(?7CKD.G-]621M!I:?E9M\"TK(5A;L]U*K0
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M%3>+615C])<G$]O'.*A0V1FAQ;P!C),AN:P\[9SV> <L7&ONA#MU9AK!I11
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M#W^/?<D5OIU0=QJYR_J4^MA')V-!S\P,V<?</_4T5<P[65"1VS>$?#(XJA(
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M7$'&.[+\I8W-3=;&B2\&BL_BU#EJ["$WN_(KDM4Z_\""-+K-O:&NA.JJH/_
M:)\;.<V*7KA!@D3UAS@C*:4^BU\(=393:LHDV)0<9J!1_+IUZL660S8<%)7?
MG>%:CVO,O^N%O?;+AY[)7^+F\B_^_D8F^!\=<FS@K,DD3^R9N:FIN<F0._=R
M)5OB^HY+T[$6BX<?O>2 O=#AR,:!&PO4UZ0>Z5;L!$]U3EF43#64B&2G;!N>
M>,FF1ZC848,O=CBG]\"KZ)]WN%_ZOP!02P,$%     @ .8 [5\JU;=C2'P$
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M:/>>Z@!H5*'N%W1GOW=VMB]A1R9-]>9C7!7T9@A< K*_JI=T?P3&C^<XQQI
MI %8SZ%6'V)VD-0\E5E;]C, !7ZSJCDO.!["P&OD%Q#$;AX8)N[W_.(8M8B2
MD^%9!4$G)UZ&)V'0=EUP$>#JCP532GX;*9 X9Z*LSX# %]Y[^MG2P[CKZ35;
M30X3.YGB%WN(3$B39";%LQ=OE[Y['.%(EL\._B0Z.=4[+_;ZP2<OUH$X-W>W
M0J6E39=N/9Z\VYT"M&_XZ%@J4B^<5")T&BA$UH-67XN;KKV/<:WPQ,Y#1T/1
M#X'^M'.@O%PU.FT0,1@.7O6DL6F0W&E#31<P7!_\A8XEKCQ;L_&P+(DXKFLF
MG8":^DKZ @2 (])V-KJ>'LG<-W^VC1):5OEK#7IA4C[M")XTUQMH+^L;()6E
M<8,G/O\7ZQ_%35]X?.&=$IR$$2ENWEFS*:(42SQ RT%_?,3IWA#G_-R:_QA\
M!>=#Z(@X4C#Z@#*8Z @D("2 ;&) :G.P\<_*$0XUAS5C$T'SVF43(P7Q &%H
M6RE8 V DC^.*.8[?48T^K#F$Q>CQO5DOEOP;$LT*V#CFDBS2GQ=QKT$\O%QG
MGCIK/KJ$J[/TJ:?R&1$6$B^?@&;ZP?P#Y3/SOIVRG1,.ASMKC/DF:;IMY5G<
M=\5-!-0_!N:[9A0>P.,035&)Y =_'2:S:FJ S_T.RZ/OD=6]-JG;=3Q12]<-
MV,4M9KCIQK6[3I.MZP04?XCHBDYZ@H@+]AT</-:%1Z3*% /O7F:,#ZB[O7]+
MK)0*'&$#_1O<]QG9/58GJFR*$(4?$J$0\G9FAZ%OU;2Y,++V[([,2U=CJ9CW
M.]J@X*'PZ-3==4<X((N+?Q,WR7+N$YK\]Z:L]05T@H\MH&2P=.R[L<V(8AGM
MX'2EB$[^.#P,IO0WA-<B1&98XQQ?Y,K?_5C!=N:,EMO2J[Q[6]5'YY$!MX^+
M@DOB>=?:WP/1-].^*6SG5!PYLGN/N2F%^OVN !&?\&58,9=0;3J2]Q\?UZ(T
M*(+>%1_)B%Y?%V()S[ ,0]*L=:R#!7NU?&P;P]-<)(@-<R1\=Y@BN(Z+EM@S
M<[K8$?GVX6C%"^[)0[EWJ@X*S%LO6<(M=;9L;AQWHL. E^1M+(+E WH\^CWR
MR*FYP3&/+F3<SR6D>/EOZ*4J'LV,/;6PY<XL\G!R\ F(!1EV8V2W)@0]?GG6
M:V/3;[PRT*3,VG2$S@"B%S6'V5%&29V &BN(P\<*/HM0-JH\>24].D %+]/7
M/EG$5/W.*\AKOST 7\$KUY#?YV N8&GPF,<N5(W)0*_PT.AT*7?/*2XJ)R?Y
MA3@.#EX>01FZDA2#/*Q$Y)L?_\EN@W\U7Q&&)MQ"0@C+SPGPE!,0-\K3,SP<
M6K9HOK'R)>YQDL)-M.1UEH^E,79YGXJ?/(C1XU3F(]9O]E'$D7:6:1-K"QPV
MSI\^-F?(ACU)$,HUYD\4 K7=XB]^TPR['TT'P*V/7U/U%T-;FRC,:50GOK4H
MJ:EM&?.ZNFU)D[^N85)/&UJLI+K$GK@5[E<"L*IJG A4@7UP>+. 3"83T=^.
M2[X*P;P6,C^W;BW6J>([FFR.,^VN42[6UZ#4@.>D^D3;PR&LTYJH9HK?RGCE
MRTYJ0[?>P[.A6S;TTU;,$D?W46)D6 ]F1FOQ^"!^U\*/:Q'1F+5N$S?PK6M<
ML=2..[Y1S5!VT_K3JU=3RD<.2#58(JP!'J\G0G!D5Q:"3X8H\V$/GY7#&RKP
MWZ.?>+[F;_R0>U_OU2NSN2#G(>:-.X0_-![D=C??.O3L1+W>H_>G0H7?QZY\
MY?:7$!E?(??I,H.>MU:E?'U/,!E10L@PDA"V:($>R.W6R 8[S]0^[T.O,(X:
ML#V^="?6JCN)18IG+ 9ZZY1*GH#2)*4 ZW""GP6AI#L=QFKJ,?+!O/[7-:51
MNU1K6C^;CFLH-3XGU_<%Q2/UPSH-=)P;)4*UH @DIU"UZWURN^O7=.[\:VN<
MO(GF/%?"#L<5YCY]2?NK$C3TY/?P!BS\P^IYHE_88D#OS0 B*9:'/''P]&PQ
MW1AKW9CJY9Q%-L.'.?V^4U"IJ.$H1B"'W+A W*JND*M/^C#&4]U7K=J:9XDT
M.9L[-_5B3I=GB\M0*N81HKFD6R59\NQQ$<H]H.9/H6V>=_F?*:T6H<G)T=G.
M(B6K)A.*6HP- R,>2I:S#'+6)6(2:*I34 ;:=PQ?!_L;;TEY"G,\2H[#C^@7
MF&#EPWT/;R"[XRZ5XHE0\O,0QG)'@LM]$!^7BJ^,(8R 9$H\KAA&[C$9"*CP
MT>(V8HVLE"W@Y/>9XDCFZ'29;3.4FC*NC1K(E4]$L;]!FI+",E \D41ED<N*
M$9N:R_*.G]WOV*QT_7G@J<N_S<8",XP!%YZ O! IHF&]"S.MQ*UT\DI/2Q3G
M*!5.X=6G[Y,4PYR 4MVLG6J^'@AJW3*HOI\?;/6C=(D'=Z5NF(3K0:05JP/&
M[P [!\"8['F-O-><_D\H!QE'FCV2>2#1RG.E2=(ZFZ[I*=09>>[+XK7C'"I=
M-8JU [CSUM'9]U""VNCL(X1_WAVQ_GE&]J\DI0K$HTF]Y-Y_B?DZZ2+L@2Z&
M%^_X!ZH.#"^>@$0 P3-MY)_'WWGD\"IS:6O("GL/2R9#EU<AI5P!O0B63H4%
MP)00W?M%OT.+ L%ULH_*H2<N%WTNW7=8"N,QJ=>O'75ZI\WSSIX%/SOLWSES
MI HL=--@@)-D-6&!HS[>+Y^VQ6EJ<"3M:.[Z5K;2R51::A;S?4!)9TE2ARU:
M .9IWN$77H8 X+AY.< UNF)&0HV1O-1PG%EK"0N=;%0TS6D._0C* !MF51 *
MNFO!!-,8/Y1RV<WP<-XAY;G)LG<W5YP0][[]7B[V[/JU@9,'<<4$EX)%3T!Q
MSZ,'RI'5M!Y1..V5W_HT30E9@RL6&$>OHE@)C@'B<Q:*RM^%=":>>,6>6;KD
M:;*0U\^D:DZ9)?3G48Z(;\H(M?X[.UC++X7XL.*NTN<WU"N_T;F[Q(W&(/_<
M#"/<?Q #Y3UNU(.?RLAH=J@8,J WBF-<3T8^E1KB5[DFJC&<<F/2;G]0)%_!
M\W.27G^>V6<S-OA7V!?;*%6J/%"SF)W@4)W4/)P(8>J E>'M=1W7K("D"-<*
M_ENWEL\S%OXS4:/WE+K/C3S7V0+4DFNPT:(HSK> 15\HS'],Y6H^R[*V2XZ9
M6[Z6>$4-R(BKY$8:^2A[.G>EC]OA3Z<V,+BX( Y(SXR<DGF-M[\<L0+X=]]P
M(9>M/^35TY]-^:%=RB6T:)G];I@(F6%!]ONI]$K*0M7&E/<D;GVO_2Y4O6$G
M]EKV@E;%*]@-WJ"T-9HZ,L@\>C9H/ZS%[^) [8(Y1?2RR8QF8U6'&)WPDHK+
M;',$O!<6>RC4J]T)0>_ J["G#V_!<;P634[E03Y CIV[5<VS^93\28]#M*@/
MPK1;+X!R))OVBA4-?FU&L,XNS.(=KUD97I@KETTRN-UB8)C!LW J'@2.FU]0
MS2:C!*@<3;+UF2&]GR==L\O_[%\I)FCJ,+N(9I##!>:B\($?8(TJ?97&+.G$
M])'W%2"P H$MO0?"3#4,.K(#9DG9J6,3WB-_]CLER&C5F\LZCFY#(8IU()/P
M1Z"E3?&I2JHM$.)*"2*VIJ)$WOVZY^!]N)F 1_W%"_#VYUX<LWDDHW? %'/%
MB;U7\B)Y:F.%(#;,B+0$BZS#9D1])#07;]_4OF8R$P8K_(:5H?^-T]ZO?PU[
M6(010]D#?.5_2GA1]'Z$E(".\-)I4\ZZ]L("O$N^ASFKF_&T2>#"Z>"6#GGB
MM-Y9HA_D:G.N>2UZ\,K#\MP'[(TF:3$M()&S)H\4"P <.>PZ,%[^YXE_;7BX
M.U=>G;WOQR\Y!L,:Z.(',OXV.WS=_5PZ/ 80%=JO>8%V)PL"# MA0T:<ZHD$
M.X>I-T>VB9'JWGCWO_C9FEF''Q09B<SX!'P8O[4] BW?4Y\.XX;RS]]=QX"C
MP,B+G,J"*W"*!B;5LRGO:J$:1U"?R@R_"7]L/X&%,#4%$XGB0'HNML8MD8?3
ME%<B$%#=S[Z?M3.$;.U47^'T>+-N&>NS[$DM\2KB%O85\OI:=2);>^O3)2\#
M!<1(J%LQA'-MQQ'K^>B/(;PY7+7F7HS!E:"X)\LQ5S#\0"3M/&T2P=0!H9C-
M^(IZO"384?AUHK:UX#\U?N9(%QI4,KXP>1G"\$@L5+4PF<860B[JLHGZ[H!+
M]0_^HGN3(IBI43JF4DLT\PB+2!FMW2D5,KTZ8Y2SDX0;+%P[ ?G=10N+=6\N
M@AG66R79F\+E$!)(36^[.^3::9#I!1R;$'<[V?XQ'?V%*(=_821P HK]R/2N
M/:#2%77EM#NL]VL=V%(,/R!?#!\7$'T#M$5)FTT<JJDHM!M#4A"&7J(+9H5>
M^,<\&STE>P(:,;9_8\2=))N)O$-G.A((+SV3IO#_W#N=CENBEWR.7\$VWJZ6
M')XC=9;70T]K@ZLYT/86$/UKT]&!SNN!2L7WVOIZ6;%6ISK=^8_*DC9Z=9]\
MFDURQY4O'&D3I[3O=V^RFXS]9-E%I-C"C?OQ:V:DET?A)>K="VRE\$)OFAPR
M7,;P9\HG#ZDH4$G/%\_%@BX,%S62G* C^45N,V,R+'!-U+^^"K[DO-H:N.)&
M-H]O3C);XC;4LRL&%/<-',$0+V<5RDIOM #5:J)#;^A<:D#] $=HOMKSV964
M!\;@BU>X9G#.GZ3H8T<[A9!!. 3Y%CCER?R7JMFU)B"ZI]UHVC1,./>*Q_,J
MFTM&_>2W!K*!7QHFFRXOQ':"?\((E5$RN8O7T)'0J>Y)A\/5J%O'F7N:Q8XA
MG[T"&ZKN/H]YH,:>-U5X&' 5T*WR@@AW6%,$V0<'- *XO2<=_/K0B:B4Q9:+
MUD\9Y_*6Q9=RNOH5&@#]JFFJWT^HO-SO15_1I&2F>+D:@2,=+/_PA4]B80%R
M7_4608$&$%UD$AUY?'^)DHE+")Y6OKBGDM"T]M?!H8='1:5V^WJWS 7R<'R3
M?F!? *T'PH$2"CNZ#+CV@5U<21+1??O)MRE,S=%L]WXAG*]_][!WBI65\;_Y
MA6F\WWP8/4 .NIZW^ '&/_2;,%E.7D<^=#A3XG%)H^M5I^;6PB?7;5>)FH$]
MR#3:JWVK/HP\2TK.@ JN.GS?#HDL_7/+4"[[U8J:^1D+L7"..4MLQB+HM#?=
M!8:J[%%7@/ C;Y0N.9^O2]2I./L=?G54?'8U;.I&;5" D+M-,^0^,2C#[H]6
M-R99A[GG!)0,A8QTZ%?A5_-M"U'<B2V)5IW<[J]B\Q]8J,KGWBW>6TG>5R<K
M09H.4COY[(?>.WIWRKIJUM=^Z2JQZ?SD:1>1ZI%C%LYJH"U,'\,84?7\_33>
MT#^A\5JZL/)$C.JQ OUO!+[:M!%(/3)',0+1I T+ N?UFS8VG\8]K[3^5-DL
M-VF)<_[.=/ H.:G_D@]B]@1$.,!NVNQ;4N9HU>6K3_Q^Q%<.AE3Y<!L\M?![
M5,'3GU7*W<@K<WXT?E%"T7<?GWSS$SD@>:KW! 1NAHL@535X+E;4(!]["]F2
M-])@0='^.9F;S8W"[QA-/1C2_H%)3LG8^LQB[L_DZ#B:%-7RN SE]ZYGTN%<
M7OV7K^-H>UDQSKW1G;,&+K8>G.<?LPB++,?H(X@+V#D^'*(ENF<P,\"R9:+
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M,W)RD3*UX0M4_BR6X0TGBJ:-J AC;9WXVV%JE.%\C+X=X6"3E7RTN-E2'4B
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MAAR_5ZSKZZ?3JR!EMH5%]:MIOM^AN^>>,IM\*J@*XH,74O#L@.M^6A,YJHJ
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M$WH%BWBG\-F!J:$"8W9ARQMU._$X=O4;AN;B<8*^(7W E>R6T 5R[[S 1Y1
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M[OR9"ZNOZ)(/'UT:NGAK)D3&3]QL0:U?]25,: (F!!7B\'7)K9[,2=K\N4*
M+L=G^ V\P7>$M&L2ADJV K-X"<U8<K=>2V/=Z5T!$>S.G^R[;5=3[@9Q'2<:
MC2SS"H:\<<Z^1,J 78.*D#X1=7 &9K/M0E -;+XM,BH+T]_U1JJRPJ- E^_I
MI??W.&P4O?P<V7!],II#6%3400>7FR+/4FPP75$^JJN1H[&A4N!FWI,4ER=3
MEY9"Y/_\TXC_VP&9_/*CH;::GXLW80(XI2CG]B;%#<X(OX:.5%G.@/5'0B]P
M<2>S4?#.6_7R,W#73-L3Y<)0*76[\KO5OT0&V13ZEKF#+F5<^OG6R5YF8(_
M<VQ&OM#JBY7KX5XGBTOZ4@#C>"#8[BS]TCJ8F-3.O,RO[:@+.YFX'RW8'/\L
MOO]KE> 4,YJDMCW>R9]ON<$F22/I&:88SO4X:N[5 \0NILXMAS5=_<KI>8A5
M%^JBGQ?;9KL<KC$^XFW [+QF&L;#:<>RP8I>.6V7/G%6ZV: ,C*7 E27J^=Q
M_JQHK97.>C!HSRV72>A?&H75^\0 A>D*[SPK&RR_;XG?*[]J?B>R+$$3M_MF
M\ME8W8;?[.12U_0V2*W"EOV6XKU[#[C4]R>0][79DO6K8DW(PR;BSR8;N,@#
M5<6Q[ILMM^*"GGZ)[%;5:ZNUZRV8,_ <J*XS\@QEN/F]!'"FKMJQ]3.G53D(
M8DQ-*:QI3"F(N_,;8^% -? @<0"_89G(SB864DH'4 ,,_FQ40'4CQX1=U+6+
M1BU0.[J97T8O$R)55 X'"]WG7;(0KOP%X>4<EM6D <D5Z_$@; X@-LU&9:NA
M.,$E$J;F9L$=*Y]8_E@\];0W0L87I?&"=X?>=.K@H*IU<L>S_ &O1U&HX]6$
MCQ:W^B>0X]H"=KB.Y>M%?9F<AM5.[(3/G;[N%I\J/*'2,,FO(2W/XLH,KBV_
MXH;LQ&5T++MN[Z/A(5F7I^1-N?<.W?WMBMJG_4T]X76+FTHL7VS6H  $> P
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M2>?FAM"ZC^L!;/?_5SS:JV?TD)VKE):Z5A]J2&>3<2T.JZ)N3K/^!:E"L*(
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M(<AA5\C&TN\HP+:T*P7(F^AX'6E,?H1[\>'F\P-VY?RV]#F['</378'D5(%
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M:22+VW_9!Q@C[H\1BPXS_)"#%(":P(NAW_ZTDDU-O(_+[O2*N.6F2JX&%U&
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M[KZS7REWA<UI<DP%SGG?CT_>$$A0V,[]^?.8WHB"EXU+34WT-<,31H)\AE<
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M3C$T$@;,KPK8?1UT&_V1&@BKFN@\>BTF^7/\B?OGX@!ZS]%V$-IY@4A5[9"
M0>I6%IS"-VM,.*=@=G.J/KPG#;H"@\&P6!&=>T\01TWS%Z9/DM:>Z92W^@5E
M.7.KJRB.OCY2(\1]<?[\8?\F#=494!DV'@HG<Q!+,SZ,46)V#:I0,;:J"HV*
M1UJ_\LE<6N/Y^G;Z;L#56;K7'\O;O.P;N^^[XU3X%6NWL"YJO+5POSI=-"%
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MVL<G%@4NO1>]^.?X86 D!%G+,J*)I66,D?..SQ-7M-$V1&K5=O#*"Y889(H
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M8OW*/X=3.H]&==?(M."_]P9>?2G(D C&O3GG$QKP?][M[Y/5<4"LN&)VEX+
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M]6@C.,7 O*5%IPZ+(<.7YHN+WNK(2_^U_SN[+=K:5ZA\BLP/S3PN 93?D$(
MPVK#U7-G7@SUQ? --%GR^T,'1]SBQ7SQI!NNP0^#W3\7?ZY\D_?'XYAR,B@8
M$%%^)J40Q>(%%YIM44]%7AG&C;0<C957NHXY>2>FW<KJ?$@1>VF1$12NO[.
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M@%CKK@5F1IN1-\='E-%[J4.7HO,E]60KNT%AJ5%]VLT2X&<] DEFDSTH_.#
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M*Z+TIJ+!$;=O7QJUG4>^TM5J/U/%V,SG9C1?)(AF)#D(W2B.%?<LIY_W^Y0
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M"5/G;%= -M1V>1C-Z,\P!0U7-%(AH^1NA7TPX#)8MGUW$+\%]PN)AJ>>RR.
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MZ8<D"/  8O@SD $>$E]#7?QZ,_M)XJV%XF^ONC)6T#OH!JW*EA"VH#HC7,&
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M^I:F;D!X97\FE0]<IIE@^1IKS'&";GVID6Z+PRAW9$(6K]^1SQN:CW!=8R=
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M7#NI-3*_A@/7&WPO0;9CW0C=GBDJ?@VBVU\"BGR5 8@L]H7@SU#-  *)T!9
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M2!^L/BJUW6HE.9O2::I_O+Q,8I-]V-C ]\2"C,*7<_N5"HNU=9)$D;J@G4F
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M_K:Q.\SZH@3F05C%GC;C(9N^71Z8#JU;\6!VZ/X)V_TY71%8BN>'"[</4;3
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MM1U.[ X4<BNH*W"9;:HRYN6:DKZ1SCC)]S#AR9FSIG6<&@]_ H  NSOA5D\
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M[=VO_I(SF9R7)0 .#U!9M\0N/G5*&])[2]6@I9^(NI=^^H@R#0=L&^\YU/4
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M4AE&:[L:_EM(DY2#WC<W+W*G2V=2G_MZ!7XS)V^I;S#]1N&X;< ' "C\)DD
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MD(FJ*%M3I!S(>&N9:_PX<7Y_-Z!*4K+RT#5O>5XD1-XO6#[<7//(1E;QW-&
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M/RX,I7(%:%").!;%[>=[5T :^QX/9WF_X>[Q9M>%#MKJ4J2XW.42J13%1QV
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MDTJ_>G+GSE!A4OXW>U5N2U1(.+?:TT5_T#L8E389I!4)XGX%5: W+5JR71X
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MWDH2=W"=.$YAFRYP 0AL9I,3^U&ZZZ]OI:]U/[BZFH]HGJ:UMD]V50& O "
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M[B7%BT]D'L?]O.E[&%XK<$= Z.V35.W:?1=7D.%31(PJEP5!'-O2-<(.<5Q
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M@BN6M967ZEB?!I_]LFRBJR7$ _*M>5Q<G/X7?U@[88&RK\TEW9?C7(TKG)"
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M<.PJPEL+-B:/F1QM:VKB;E@X_UR[^FEDY*0(#?9_3"?.V3!E<<,^2=O(A'1
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M:F(EV<=QX:#@4+YX@3&TR,@CL^)3*C3VY$V"=U5BI87C&WS,X]K)1J!J>MZ
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MU#$[PVO#-2TS+EYLKVLD)5_MK(O&/T1?]IXQ=>KN70*EQ&J+K?'.-[S "EX
M6JY:\8<\_=!<X%+44PWV]4 "HQV!\%]ASB6)(Q508ZQU6S-E9',+*DI(T^!^
MZD#OVB69[@/A[VBB9U @)NB3:DQ^!XAMR6&9OJPBW$S\R"&#HJD6FB2H%BR<
M;0_@8DH883LMZJB&_]P*$63*#X7RPKTS\:>354FUGS.-!H_7>:N2VS/G_-:Z
MEI,+\<:HD8^- H7FCW!FMU@+?SX)B"_660]FYY-78-N.]J>6=^)V\ .Z]I\J
M:(RUI#[5\_%K.+ I&+DS%=V8;*4/ZI/HW&AYU3+?LB;7Q4NWFT%9.UUU[B[]
MC:73]-0EI68^/VF](&(D\9/[#[Y;&[0^-^VX_.V0(T% IE1C2V,-C&K8MQUT
M&U8B6D9CVE-]ZT 8E"1Q8CVO4A1P'E$E,=>"T\)4%USE96L4+03/=WQK:M0]
M>D;]=38B(5[5EC_-3H5<]!?VS(5 <0'X7H)T);#U$&4R^&:1.=L&CEYG7EZN
M?2IWJZ<5]YVU5U8*>!.\+@#CYO"P\)8*4)3RBR<9"OA4_\+]L^DDR<H;%P"]
M'WUQ1!RX"M.RMX34I^F\3MXLHL%]ZXMYT3DTZ"'\.I@6MLA+,I!X 0@J04)C
M3D-[B-(MF(66*\!?11"+"P"YY 4@RF=*R*C21T2[%M?2< $(*-+$J+"]V=)>
M#H_DA70)7892BU2L_ 4@9N7G9A#6:&?X O @9>51<SA0Y,4^8T[X*ZI;$6]_
MNKAGO)/<MCS8FSF3WUZI6 F1</Y6SWJ:E[5S8DJ9>HUL>%)MAO0]5X:VC"Z1
MTWM5\YS%E0:^V@W$9O_GVU+[,8/*9[G]Z9,^F;==O;)ASU8\2GV?5PQZ\=$<
MFY?K*0F)OSBL3)]\B1Y$I:?H+:C/\2 _Z%IQ7X*O!@P?,;PFJ 5CS8L?^]M]
M$W"=CQ<_O17@]V3ZQLQ]3>EJK.Y=:';]E8$CH=P7"#I@#46KIPT%JB;H=P\I
M4? OC4@09 ]:8TY%EB]5W!8)7]/I=:[)5ND.QQS@G5<^4! =_]-3+BG&D FF
MYB6\5P.(S>-;M$?07P""E_",%P!UB_;ES-^,,03[O_MER?T"<(OM M =\%>7
M,^>UJJ3?]X$LC1(Q9Y1_/S^@?YL?@%\4"W+E/V:M]%_D^3L!Z]>(#_\'[?[M
M*;?_LI1U@XY+/6 N$UCLI=@/>#;4(=[_H8O=F#]_C0_>X4*@_!?C=:G]]W9K
M_X-V$6=N4 I;&]Y+!<2ZP5&7:AVEJ#/\^QG]]X'S_H=F_E6V48K:L;]O=_I/
MMOOW_ESQK+@LO#'V?N<TD0=3$^,AYF=>JPDI=G*]KFUIX/*&F:>5Z0%/[O]6
M7K$R.],GW."ME&C-O($G<QEO7S.M?EY3'WL][DETN<8+>J_]!_1*3%;YZ@!H
M^ID,; 3(>)09E1+2I1]>85\&=L,[+K2G>"9%B.ID/'["ON7UZIY9",!CT9_<
M_\  +X Y-&[.P!VV-G,V-&8\NEO#M'U/.5Y!X>Z@*7]"GV"#8Q\6%%X90XI_
M;SA3A7Y()ZHY@01'% TD_[6?*5X/  V\ %PEXE56T^&KP47NQ7@)M4GQY"[S
M0;#8?C)M-)]%'F56>4(E+4"1!*1[ 6C_B+>[ #P^;%_!"]9< % BF6WZ42OT
MS?>W?3^M,%0U<!LM]SO7&,P+?<8J$5HKWUZ1>Z?6(R^S+4W2!O^O_Q6^#$YD
MF!%BV-:E4^FY7@ Z3?W4 6X@3%8S^P5@3!E30Z2ZI)'X<"!2[:\]T=]]+J,F
MTZ798EF6QQ[P*N M<#*8C##L83=1M@%SZ6<2RBHEV].R7N:WQM^(VO'?#..Z
M8YD-T^3+4$#H_X^>Q<5*$)8(AA_I*XM= #Z"X<3;,7@#$.T%X%?&7VYT=?H"
M0%#WKN+NZC2)59[0*GL<4*&41L:3,TK1=0&HC&D[N+K=4GFPUV=GO=I$/M]^
M8CHUC:.4KC6Y,^7TP?!V4 ? A_T7>-L=0X/,H"!8C%P&Q)25"T!H(0=##SRX
M618CF(N],M#)X;D2+$VU?ZMV.H_S334DX'KLGN*K:,V7D;8ET)OXLU5@-(YU
M!D:!92FMXXZ,X!Y73XR_WB%:QT8."'!S#PP,!R03F5D[@*="&7]%-YF6"P"C
MYG^5JV%>F/3C/^C*\ ) 38/,/&?ZCZ&5XL(!?[9P4>?1C7Q8[]614(( ,I,>
M8MT^O_S]9TES<<H3K5&G# 5.,N9[_=D2O,N(AV7GF:J<%F9JS)D,!#'^N.X?
M(^=1KH?7 $+[IM\-_TD-5QI0D/W#4++_02I+-#/)EGE,JWYPV&NW <Q)>VOH
MPE7[RRZ6@'NFPYF8IXC 90HLZU[8:NHYN,V</O='_TF[;BI:G-T&:C5(OFG#
MOPH@]R.Q6D+%S!\@60.;;\';&8OQ*WKEV&M?Q7*JXZ)G;:#.VKR<AM&:M&J;
MN5@[]'U,,E(NJAA*58POTAFMZB,TI< 77S1._'85D>VIS9"S5LBB#_PGU-^J
MQLX5;@Y8;?FO9LC\#^XCVO0]0)[OTF:^4A#%MH+@_V;6R5#Y\TC"'21#1 NS
MLG$!'M[!41J%"MNSF9"N'K?F>_KBE60OP&9>KF;H-U'FR)/Y?]TQ_W$JF[VQ
M(P%0E57$PLGJ-<Q!2.42-7NEZ[7+OBKN9M>8WB9;:'C%SB?$?BQSM-6)"".R
MXM60NC'7(2UFU:-'$'9K<&I2JW@/=;AB!4_K.W#<96:S;PFR$L)[^V#%)[HX
MGBUSC--TN1?I/$S56&5;<%N,?-<B<77=?0C@^W-;]Z5$NW[4,C5^Z]OBSC+5
M3$G5@))#\XC;Z_Y&*6LE2S9R([7>WG53SP=DEQ2#C-E4"$NCAE5MREYL0V8R
M/D*>U52E2"=92 "OEZ/DAK$U#EO?LNB_*ZQ]^:EI*N*V\-3-87B7(^D-R[.W
M":/4A+WS0*!-R[P<$M@)Y-BQ4L ^2;%*]*8*,OJ]=68 >ODG(&P*VE9#T[#)
MSU1+ZPL+ )O,2.'?G"Y9H%F=[?A?QWD=P.]&?E@0J@+H.Y=LGT38CEJU22U_
MBY_-"0C[#- 59!@$\.676/8>(T;.7#\"68F<$/TV1= GC]WJFHE& 4_O_/Y!
MGC6-YHSE*?&]G\O%%=HW?.]+P:FG)'@A/2BYCP0%6,IR$RI56#UJC\@9O!@J
MP9>)OE8HTZ_SI%P]V.;A*L\+QO1/ ;"@ 6FW6S[<AFJ )'FN-.KH8=R*08T9
M.D\;Z82.EZ7-IZ"(VZ>#WD'!Z:$OL1FYJ %_76WLNU\5V8M#MN5*DDDK9I5)
MC#1DS_GGBS<>/[H*H+)EF72PXL*C';)?;-=+X()2EAV2S=L'O/AB]I(O_=+Q
MA3.[&X"50>!S"+%.+Z.2!*?]BH0_@,+8S%<B_,B5L<\CQ:3 [D=3T9_W)96[
MMZ*:."G"_V0C\S\1[T"25^%=*@P&S=-BQRKZNK+U?+O"N,,N+YR-[:W%@WD;
MOLU6:ETG?FOV^:34'XO;U49X7J1LS>KC\NJ?Y3,2Q>BD\?,]]7;V$C%KT/%>
M87&W 15-[2V!7Z2[@S'F;^_WN'/T,17'_>RU4:# (F*@0"0P8CZRQCQ]Z22B
MY/O/^G'31Y49;S63NO7,D2ZJD]]@/B:=/2WR(K*9C73O>:[B/;&:'<MT/Y_@
MEP>TQY!CE0OIXNPM,-S")G$,PLJ9?D+IUKHU,#RL!_ ?XMYCLM1S2N!;?%@X
M_KB8YJ83FM]K>"+F6\'N5N:<=P=,:@)JO"9FT35M'BD*MWE-G_F^D.SL2?78
M2] ?44G0'Z>???3$/Z\SWH,>_?/ !"0(;S-$-J;BY+"F<TD:-;I+"@>/?2X1
MO[LWS]Y:M==F<T6A^73$:Y2*X('NU-W528_=VA3."(LOG7']D?>>?\:H95V&
M&3O.(4[32U</(#QKQD"3$O"O(*):X2A+.=>YH9']06O1;B2;ZW3S<NDC9$N[
M!#GTUD2IDS([LD2I(ZE&RF<B]],MY9EN$NO)M6I][B+$/RXWJQV)R*0^@D<2
MJ>HQI2TR1[XJBV4JDUZL8BZ'W^6MF10/R\J"27_PF]JI V"/='/[K"_S114^
MU2[O 78[*?/:IF[HJSX:^^2?5QC\LZG^F$ZL5)1L1A3#VQX015<@BKH*C?>4
M.7,TE>M=5BI28Y:^=)MN+&T$XDE!+QR U(V\WR @(\Q&2/#1@C.%4;R9J_1&
MC3%9QP#Q9ST/_1[MN0@P^ ) V<B."=2K^XFQ"ZX\H#=_.;"ES_V75+]H>/*Y
MRR$CS"0S__78%",.<V'2P_NXY"E5=H(1O@@%_&!%!Z*':.HW3K^>;KZ)'S"J
MT^H?CB>_M_"54T+R=6!-@"[# 6,;P:-A]*ZTZT*(_LQZQ07@4\KNL]$+0-GX
MKD-="G??.MO[0\8*UR4TZ+MYYEX,!FPVN7_,>1"\S-/0W/!U7UQ<H(+V=^^@
MV=>8=]K\YV#O3C@ QH5OZ/*U"_-$D/V:SVC**P:#X>_M2_A?JZZ.^#=5I'EE
MT1V$&"YWK#+0:1:X$,?TI*9<O,\/I!\V'!ZDS:C_XPDO)&LKE<T-F+5'F.&/
ML-M]>1;%IY6&O[S-NXKTG5T+G5TK>EO=  K\U>3W4P@]6.7,5Y= /%!C4EP,
MJG:>B@6I3RIKHJ*42)].ODH=Y+_[REF-4YA6@?WUB,XY%)O_H1&(9>V8460-
MJ_13>:]5VY-JYW\M7O;F.A?/)YY/[T09'N.Y5QGH(=</VU)</TE'Z--8D;,J
M&IDCXE3=XU?/UUK7#UN/LAB^PFUH(KB-<<OG>:Z$>Q@]I)P>H_+N=;J*)9KW
M+0Z@SW&'6]R'((<94<P!TO53\_5?43D0I0X<#_=$QJ/[;=;7'NQKR$GN] !H
M$T9-G_]KZGB#S^Q*LF(JC]_$BG,;":4Z-]+=NJ6AM>H&JZK2<\O5<F+ABW5\
MFS/U?:\W)2'"P ON<]C2QC#_>P+5$BIC*76H5CL>R<CYA3_0LQO?0=81!$JL
MXUD"_S)TBW(1')[M/QC ?H@\S$CLABJ/-_-NG\QWX*7$V,4'&UR'O_2:@80V
MG'/06\INH@4SE0-ZX$>3TF>8(6MO5WZFH'>?NON?_^R(:U..5G^'=,,/R@#M
MHI*ES\6V\3X\+A;ZK#H?HZ4*"\0\=9;@I2$#*PQ YUIE-=;(4H13UM2;X,WQ
MK8YI\_L%=75E]<UG5V\_V -\UF%<B+VBSWZ<OP.O;*H)4_:V=BV$R*[HEXWG
M5T;[G9NPB=M.'#PMQMWOOK<B$B-Z^QD_?>-1R<(!"VR$*#"MS)C7-!66J?>Q
MS<,D<"A:^'MZ5M(832ESB+WSW/,1 =.9I-V9%<"1LZDN5FQJ$>147U\W:2T[
MH2_T!0NJ'!_B!V?&*^6\KPN>4@IYJ.[%4S ,53__T:@I$>.Y(!%R@N-82DR*
ML?;/?6'^:X9URS3#0?SY][/'>M4D7YX_NB?/G] JTY!#<,">%^,R^"?SQEP:
M[WNO^30*GDK+(KB7ZCEG*L*?I_J8L;\4E4*3NJ 8N,YN)K?!F"NG56_3-(B*
MTJ 5ERV:7CTE:YAOYX>D*BQ44J5]5-P_-?WJX&O:)L:)L@VY:SH@%"KC%X->
MDAU'$7V<XU$'?L7;-)+1"@*#0>](A+R6[4FK\ )K!XSX5?RR!-/VM+DE+@+%
M+MU;4FPC5=@N5K*I-_Q@\0+0K-#:^NM^9)H*'"41<103/2\47+*BU3(A0Q/8
MH%4=K=E8/3&]]/5@,UG)F@?R8EJJ11;BA)$CR.5"@-V*I;D_(*:F D<7 *:J
MS>)YF[X[*J?F=\68&U<_<#[6B9:*6#216>E8"<9"'9K@:,XB$ \8%^7O:>=<
MK,_YLHWY#1WZ>K-L5BS9&B M^IT]J<C,&D,8ZCPK'[-?YNCA2C'T(UU4.\/R
MSIPG>U!L>D#=H6R1"]-KG5>AH<-Z!E@@VL<5>0Y_,9&%46THZ,E?=#1![5/4
MO-@$7]5VZ=^/O79#[NIU<A1U--A.8ZSY^BS!Q8+3HDPH"OU>:D[73SJNI+?Z
MF</#^VS$,9Q_0\S*K"Y/3D;A!6#U A"P7^K*LZ7_:4@YY5."+?*#&#2">PPH
MQSGUS,\ZTH B=0=8=9PXG>JN&H-<>CR_<R,EPIZCI#5F[^3D1G$<\RSGH.6$
M3J@<20.MNAV>%->D6/W5)\_RU^%NL^C$<9VRDK*O>8ZD+LRE]+JPZ:![S*)%
M9?$ZFC1R'Y57=IX,E4!*A+[#3YA/9_DS=71O&99/W#:[K6LYPCSX.T8F=N],
M,3.1U>=/IE!I<#[&NA7$K,SI6H+GV1]Y4NNP_*)*X_"%@NX?H5A9?DW:&@99
MKGMOQ5?=NK0HB@EW\4&N6-W6:1Z!ZDM,L58?CQ*L:*(6#$)F:%E:./ =:"Q1
ME9;7QGQ<H4/#KD.EQI3OV$'G/\O2W)%SNF?C(^!C61;_8!$=&>\>&>]3NOR_
M=B:^<@LN\CS+@W<N']F9<1_+G7N\GY;L-O?'W)?B<^.GH-58R9X2G\R.D87#
MUF5I?& V1,YTM%%OU=G:7$FZ#>4LOZ#I=1['R^^B0NZ;1I]7NX(7?11Z 7A;
M9Q;Z''3-(2=AUB?*RN[,"?H< ^]9TER5^TCD D_SB&&_X]N[_UAH?WDZ[78[
MCJ^AU(L6;9UP ;C;AW[ ^_T=:.&1<+AN:+SQ&'NK-=YX''6')BCN13X]R?!*
M">P^;+I9<AQJ641PP7J'<)Q.F(XJ/ZR^4P*&B4!<OV4H/*<U]X]\!=LE";T+
M,= W (_!Y FF6,V]KC4@*\C"$K1L0;#%T.7,*X1KQKV9[E>GS26'&3T>U^[Q
M-@><Z_OKC,M/:]8%&1)W[P<PC$X%O=IAUQ+14./>_6V\AFA;TFVUXL-0? +6
M5"+87T+@;9(1!^2[RS<S=6,M[TLGL_X<M'R^V)!F\R7@R_P#1!W\%8C7[#)V
M)4,%"APP8%D<Y@_NM>="2]6BK<(++KU*G["YIXJT7ED,W_[9CVR+IF,S R\
MR'L3ME7$Z4F/;/[K'9LO=*X1=J-Z;JY'9^=Z/(] 17F=//R9XJ?"LV42=RO^
M0=)>8"([S>$UG^UNQS6K%W;H-WLSB1> *TAU%'^!>--2"ZOU!FC.#L<Y3:2
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M"9+**KW 0(XYNJW1182V$>HJVT8%@T$"A/M'8K0/&-V24$,5G#V+HI;>!:X
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M#Q<=0$_WOY?_K[AX3W"=8F"@9V#^#Q?=J:C_&O R,,J<8^(S=6"^'<(OJYG
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MY90F"P&*;/K?1/P*58"]$T;?'K[,GF))8LY&7&.X&/OS0H_0'>RGTOXP&55
M3QKC _Q)1W,3=HD##D?%VG:98NZ%>>6O-ZXI--!><; UD2>U*OX&BY\%J)UK
MD2RK_"802P>8H!^,>&,T*6J!EBNXDM)^NQ0.NYY[JY'D5%:66O]'IE.Z$?>
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M[F-@ %V?DA3!S<FJ8:B!8?FDL=::E3SXNS5/QS&._"+^&(#/3KKJ;GOC5B3
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M[F9*=V^/X "V@:<K"_LK*6(GL@&%>0/E]LK[3CNTFZ!)5K_2J6C<$X]\+IC
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MJFN"Q:\L(,:& B](;VX^J<BG;W''=Z@,H>^@%P(\P0Q,3H:Q+%B 4Y&?;-?
M!;0I[Y8GJUA6!<J)BG^/YS*RT]X;[2KA7E\1/@8"-%):RVH(@N7P/[TTJ5/_
M%,:H0/C<KWK/NTU/<#SI+3:=T?%)/S-7"<8!W$E44US.7 _^PUB@>@2[-21M
M.*[2U66U/<_J"97+TFEN8.RTT0?Z_5%L%&&(",5#,IF3VD_C%U4(H1:G&=\1
M;>X'61)XGPOHXU_K&R5=P%D0>H@66*74@U%NL'P@LM6SK92%-E^N7=7SO6Q*
M,XE=E.O!]P?O,%(A,( VAN:EL5$18T@.N#4Y9DSV)-#D"E7Y*;R9"']?7V2=
M)+SF\FY!]W;C%_U;.D)J2_O":#X:'U7M&'A82+TYU:&^L-#P=,[MTNT/*S>+
MVF+=$@.#K.ZR+5HKWQ)G%AT0'0;B#K'HA3JL7092T+^$=[]$Q-43A%YQG#T<
M'S@=<-5+UK+Q;WKT1E/Q?+76U9-.DVFCK@-I^T=LL[A[+V;S!ZL$:LW.1V(^
M#SH7/);5K>/-3F%"&]>/OX<W=<,:H=DTJ0U^WV. -4)-36V?M%H4&[US2>9>
M%M=9Z$PC]-$5)J80MY)Z6#>:9:.$:*<Q_^_?[,7)*HV=!A5^HVU[61N-$HDJ
MG0U@*$AOQ(I2.F;/O&[1/;H(Q9P($O$EN$77LF[=] &8*-APTSO55H"O7RF<
M71%0^J644/QR&II>TJ3;Q?V0IF$L3/+))JA&]$K;!3"VSRJN&.:<[\WDP20^
M#,L.@6DBHHB*B1CHXA;YQ.'TYWJ]857U:5*YS791U.'B:QF3$7K>T2I$%>9O
M,%($7,$S9>!1F3%1W2@>NTKW;Q_\_ATFX&>\IV]%WJF1&/ETY?/]1R+,TIED
MX"B(E$/0)J([8=SU*(DMY+G/C<2\FC.F7I6]4O![D0SQ'/Z]<3,C)OU<(>X#
M\= @[H<P@7:S"E]/4=+/XK*/&\1O(?*>EP?EL[75Y"[_B+\B< IYE:BI5S,"
M2X=PG-]E0G9Z,C34DA =6L21)OR@QJ>UE@GOB1\.[4$U(NGF2N+/7GY<" TI
M;MB'](^FT,2(&H0CBNX"B+H\N1_@%TXI\KM3VV299SE^L>(S$-1Y3^)?(;"+
MNHU:M*>-0WB,%<"HFR2UXG*C]V7RRQ)-39_/GB_TK^-<)8AB!@X_+^V7D@E'
M;SO.(!3!Y\2V;BA' R>];2O)S?V2_+)TTE6VS?%':C)06>J H5CG"6G\UQ?N
M0WB@OA]??ZE+#T")6#-H""A7"<3^_BN0L%=#_TLBY":,Z !+^:?49[>00GY
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MJBY3D?&R9O:"K:NA^.7UBDK7EBA;&D8O80W)GH=K ,:RQ]U^-<H 7QCJL?]
MXV: 1"P-&$)=HTG;S9)<E+]]Q>,.]TL4RJJJ4JQ(,7!I5.%S<2?)TT6&+@M1
M=7+6++:-X^'&_;-E%4RVT]R&C1=!]ZA?AQD-WH9?KJ[@ .AT6%OLU0D,<OJ&
MCN!4CKX3;8EHS3ZZ:$LQ'$JEK(;%#U(\J[,=Y!SF*N(1(#KR [<#EXO0;CB
MO#\[#M &CL7**' :C(+N<L(S>Q5HSX$W':G0C7,0!/Q*"R]IP^QE#9;2J?2;
M8OC+RDM6ZI-N#[7]SHIKX%G=56#_[_O@OP^O6 !K9Y!(#LH1-^8]"4Y:&W>/
MG[=X \%)>DI12S%S;^ D7<.DR(*7#-*J8:[[*D=%3L0U'4UQTM_(CA;#.:N
M$<U&JZ7F!C\GQ,/V12QI5%)HU,MRK)ENWV%O ;]>&MZ[6-$*;96NFZK1V!<&
MZV<GR"4GJ ]I4% U!Y@U,ZV<D(2?.U"AFF;3=NW/)=9#A0Z+]DR%\-8NO_9T
MS#/(L&I,YZU/@GWN+"KOMICY" U0.J_ U_A(MS1[%LR0<7=L8]S>/CA*[]JZ
M@D^@(Q?@I#E!WM@J[206KKI4%]8JH$7?$\S[H]I0ISO+P'YAYG<,HG(_7KO6
M,72C1Y6-95.<:F:@2]33],AVQ&:X6&W%R,Y^>/]BN,@8_IV.YJ#9<W)^YC7A
M.A.;%?TA,\?N\F(X!P/"OJ;(AD486K#CG?'-R0T,EF[J'KJI<"K+YBK+ <XK
M9T+J+$$8IM%JL.8G*_.L&C44"?!MK;P=UN6:&M'#XRDJW@<'*A?.O7P "F>_
MC  R_N__$00H?2]6H)$+MW\BNL_*OI89S=NX>U=+PB3#K;D;AL8,%]A_=3P/
M_%1%WT]Q*SH_0#ZXY!*Z]AB/Z\8\6+ IY8I(E/S=&D3N>9I] 7U/QGM*%DJ@
M.^_<4UV?ILM^5-N\JCVE3TG"8P3%#;,[Q,V?U.(#/428=A58/O]WYL7>2.DY
MSCRUS'@3\G#RVQ)9#\IR,VS6+MY'3@PHL<R4\ X'>-Z^!80# PX5J& 2V[==
MK/)['"0XR%72N4"'C_=/=WS(-$S$WK1$R><5,5V(/- O^)R#)7*>N:(V]/;_
M:I?7OF[TE.N5A^3C^SX)6CRHM!H%YEIYMG'7XT'Z[\Q&AYIW+>);RV;X3DJ)
ME*,5OP=KMP%<"_ZM"5.Z&M 5 ]Y$W?*9XD-SDQ<P\XYN2-(^G!O-3&.4WY[=
MJ9=H4@:8&WJ&6FR#B]I<=_,?*0XV"FBAJ';W','FCPK+]I9:/R[5A_,%]S#S
M& ?I)[=211!*RZVO&M7#?T:FD)%L9DX%2*W&\YKTM<,F7RA+_]AN=/4V^=%.
M;58\/Z1IF'6]_X)URS8C' >XW03)QKXO4_O/\0 1;?V%^PC_^"4_!C\CHU8-
M\ALJIGI$6(5K6DN"(3"@->BF@:?#<YAXH-LN^:5%.,?UXPBZZ&_)-PDX/=@B
M%G?.6E+JUGQ3:O;V_6'P3;U)<".GP;G#S,+<E&_=OE_YFG<2_0D.$(H#@/EE
M52VY])%.;I3Z VQ.1MN-S8R2!RPBXAO+*O23WMG,_9R&>^):T=$_D%"5L;M'
M\_O1^16L+4EK53W#=Y2)^\/5+*.L"/K78@)_/M9Z^3\!E_(,>3P8]L_[WL !
MRN4\< #E)R EV# G(PZP=M!*!(%E-.$ W[.R;D+/TW& ! T?' "4G'DE!UY+
MNYK]AR0 ZT'="&P6=!VX]ME3"]L>!]FZULKKT+BH!++SQ2->@O8R$'7]"0Z0
M10;8_]N1CO\7 2'"BIUJI3[BC*BAO';5:9!QW-VA?CZ%J+9((@DTIFT_Q1,P
M!0Y@,TR.?HU0M)8V22YU\$3(_H#%<>7361RSG2!U@;% "Q"E)ZH;'ALF?)9N
M"M^X[.RGHV3HOJ.PRJ_E8#B"-$*)6'.2^>IQX/U%8][ZV%/$C8,TN2_O OUU
M2,[*=34(]\0W-NM^;6:TUNV[U?%BW27]'_BZCV&IWCF<[C9=LO2 UV_):A?I
MS[PILF%63#!V]MQ--%;#5,D^2$Z^4_VUJFC.M/_]E/:B@6@01\<@&]8CZ<'E
M!+'*?2TFIK+9E8NV%IF5DY*4M/2%=%']08MH![97_#2BM2N5 D2!04&]QA'+
MG.?BHW<--A.[O ,F#DVU(6[TZ;DVLC3WBCOB2IYP$7&E]Q%:)6AZJ6:Y0RD@
MUG)4*RG1OD^66Z1[SJ<.G\U9^(2$K0E^LNN+,;P[YVEP+9DM1G!B]Y<\(Q[N
M01V'-,,_9G;JZN)+: SA1IILS^Z$K]$\\%"F$K-G$_\4]ZA<[^\H05#&%-HR
M7MW_?OQT<]+A.I%[T;WN^L3YV6#"(ME,!>^7UZ/IAY%B72G^O..;R1<O3"1W
M2!<6GJTT:GP9$.BT<^MQ=+YA^>J&K$=98 #9\%>L4C+TK$-KHR;;X 32YPS#
MUJNAIP+$_U6;$.2XZ+J70FGSCMR6,>=0E;E#]>!PU/];IFU!<0>6:_)5#W.&
M#-@A8WW5N8'O((L[TV7_K'16@__^[5NSBG%/'Y.R+%E-!3R,#0&]X3)YOS37
M=U-W@;OV!B8PL^7,H9.^.8Q;X<>#K+=D;G=N4R1V X3H!^>04\R;">/*=7[.
MB)LPACVBAYSGZT#^*XI,VQX_PI[8XK)<"2&)9W=:NRO0)>8'!Z@9_%=>@)*H
MS,6.UQ4E%K;^:E@8-9XOB+X3LB*C:4LR*J*_K^WH0E& 31VXT!I90NDI)/9R
MT^OIOINX1DK_[?MJHY":AIDZ__?<K+\?7Z_TZ[EB*?@.Z1->W(*D%B?\IV@6
MF:G(D7WL:@N-'Y]QI<8N<PB') ]G>RCWD42_)@J(E,%2SP.?UE1^??&S(GX]
MS/"74K*%A4SJ1Z%.MO=-+;H[.V.3N36UJ#<!CA]_NICRHE1M6P4U:9535$U>
M]%@%(H?27)Z]>,HIC /<MW#YYG&ZT8BI<0L]-SZ<64#7C6'VKZ;!8L56*0(#
M*2OK%PTB-3A ,@X07DRRU[*\15 O?1'&,SFARB9=;*Q8U4XC\(0E..SN6&Z@
M.HT?V*<=#X7B?V8B&C=-?\)J^C-<]3.&#JPM/W&5T=-]:>[6AED[BJIU^_8N
M+U(CPZM?B4BP^XN0KS%;C=F?J=4:8[YXV6R\"'S[O(%7[^$F(;RI/$B>"QD$
M[&$20ALP%-TO)Q3LWICC<6SC?LV6<(?CR9S+A;_?3+\<R>W8'];_+2]4!-HU
M]$^1:Y9*F9I*F*OM,\^P5$EJH:.1XGRGP&C]PZYX.C^WT<?4J!3%]Z4V7^=$
M'0?P%':)]=7&7UDPF8//+A@-NWU02&-:U_6L&G<.2D);7UOW12 @V!>[2ZH8
MKUWHU3VRBT$IW8JI.UX?1(0.S50?5LW^JN1_-T&3>RPGV(;]J]=68(?LR^
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MBW0(H45R&#,4VT6/!V+35.6T5B!Y+N.^%D?5VK4#FPWI^MEUM<%YCIT5LW%
MZ56WT\E6<;!#OM*F/M*L+][=_"UE5WJ.^;=;TG'2KK((DX70HSJ%D?V5<*&U
M!OV&)TYW+$'?HT2VC8!66O,)SBE&,KSK/G)^C+]_'2<VF\3W($-7_795CJP7
M.-/SW&0LFSYSW^Y=.(8Y ;_\2,-KU3 WZP1-\\Z,.S"".SDU\2NU-:8D+X?(
M8R_ZK\C.><:%N$R*P&0BQO??Z@0   0! CY>O-;=(BW0UMUCJO=?F[]:T4E
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M?(D+4/7V95MSR_X7L)HSV=\J7$S6)\/FAQ2C:>A9'" D!IF-=T>M^!]_(1P
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M+,FTF+B# ^@\8J.>U_=XO7VIQ[JZ&&*8CI=;9ZQ 4L_05Z,2 F8S!#Z7+/3
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M@7]-@3Q=@QX+=>+AVE\U\?6J53GV%^18UQZX1R6%C8YH<3BOP@$2G@ QGSY
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MJ6&Z<8!69;S*XH2N-7@>8CO*<8 L7D>WTU0:T(P^Z$@5!U!3O;K3J2:;2%*
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MP%*WC8TB"I76B1AN_YKNT=5K,':W<OQ@K3EP:PY[QAL^)AGU2_)6I>08XX>
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MJN@T^9_BD5NG8+!;Y#[C6&<\50*M<-^&EIAC;X+8K1TJ[RZKR7^YA^5+WO<
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M=*U_YV#]K;:R.,Q3A%9TSR *+#7WKWS&B?^-)!HULB\BNH3_UI^RX39G (8
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M<!*8A<,6MABQRRB87XE%%#>LX.?;UV[<H+7LEV7%K'Q9 1F) ^.M/F> ]C,
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M@I]T+C CU AMU/!2TS&*\E*<F,VXY(%5D"E>XD^+13%,J,5HV3]R)!48[ME
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MR#>Q(4\"3-C^3&1/\@ID$4 18\1/A%7DD:@/(;"E>%N/Q=)^_"P5[DR_.ER
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M6$+A*BV(<T?=$':$.O$P$P^4>"(_(N]4EB_;BEW;.7M=G9O*_;?BY%")'$P
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M$IFZQ;11A1-=:+-=W[^^7F!-]'1^3&S>E= OEAM&SO?6)Q,WKCW^KC;[YN[
M2.7<PT6[DBW98 ,5D2R?5]^ C,9?(]'!@<N564*_?#UZ?%>S'#E]H^][(D7)
M8L2+,M3\T[(M$LR&W_8P20!*^3!)TJ_PK.]5IW2[NV"8A]&0/(68,J=F9&E!
M]7L7QIGG:9=H'U0%VZBG5FFJ5EGP"G 1XR,6XP0D1+N:U<+#OFCF2@X9U.O<
M?''0^?E2.?3BP:^>CI[^K]S\U+)RW&IK.BN&U:6;Z'F-XV4NF I:<H%N^'^A
M^]@Q<E]?PV8LZT^YO-C_3+;!1W@- -FQ/< 8E@,D'J9_AOU\.YEAG^5+DMYY
M\AEP)M^FR>W[O7R\N'#MD(\IUM?2/JX^VU' ][^@W:2L9 )@ALDSL1M,+-<E
M'W=.'NKI(C;]&L/L[O7'>CQ\@/LMFC1HG9\X8(:3S/TZ.SUK8VYE/6O19U^?
M!C?!T0K1)":E*BT)<=BL9?@6^3OZ^;UR\?&QZ]YVS.#T"X[LN(VUU[U^3=K,
MZ3.S64\N YJ7='TFEY,,>4RZTZ#\?@.',!/1.-+[VNVT?G:5>);\H'JX=D9&
M(BSG96V<QAO9R$;0&SM*JS+8=)!CYY SR?CIJ*NWM3J027U@OJ>'<YJ_KE;O
MN@XF^AN ^K>)$T(L?V8MH4"ST%RS4*4:DY/6)_%;4?SJ2S?!HZ6,\8M<6*;P
M$C,[-)B_-*9W7K ]15%BZ'A=KEQ%S"'EE!!-7TZ6LU:?,FX>?U55'_&LV40O
MIA%ODF9OPZ$:G$9=#[G(!Z"'I_DR DH,;6]C]2C?14 6YVBQ9FGDOQ7R^@K
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MZN39M%GH&M+7Z222FU],-<^SD!2,F.2?-B]D_";<ZK\S]Z N)7OB5X<<:6$
M*ST6P,H+;^-^W:%6]E RE+M;P3#(K_S6W[39AW%<6D]TOQUB0H=D8 VA4=_1
M-P /8M))C[T<D/\)7F=MWT<8TG:)OLXH;^02_^/JMQ:6($VF)'C.Z0>4RU\L
M#7S^YL3JI*UUR'%'HM1/L5PM$R9KF<P[(%?))'5HQVJ59W!):6+9TX6%I_H>
M+E[\1HI[39.)H&_/0D W_+[-!8)O:LIUY]>S&1'S^_-9*79*7WZC/\&Y@Z/>
M98=\SO@C'DKZ+%WT_.TL*677FD\BY^0A4FV<0#S]2%3I-6)TV?MT.&1#7C/I
MV!M@)+\=4X$ZR*<6N^:64B?SY($4\;ZU[L[(8$P"19[]'1HVT6BE&!_R4X#=
MNRYB3Z[(X:)=3+<I#K)  ,?)4D0P@+DMD35Q6^3D?K9L_96 #.FEG]$$S8&;
M;BW")Y:87%C64W1@0041W@6[HG@CP,N-()GPC'2YMJ(N?>R@13-7P43W;_+E
M'[6'KS3_F9W[U*LR$KL=@ HIF\79]N&W?94TTEM=+QMTWTY_>''?;^'B?"/E
M#BE$AP3N76 #N.AYE888>&0E$]_V#%P?=/DGQ&P-U)*T] "-Q7.8L=F*DI;N
MCBC76^=]?[-RK56BKJ.U::):VH%B"3A5(#;[.YD#XOGCK;PH2E6-I[BG7*S7
M>.*>:?Y'_VTW#DU =\^9]Y_+.80/$?%]=8Q?BVEA)"!08.5-JE3?9SHBG22D
M^(E< @HL&\;K,<\<*MJMDG=K@F+^4N9YPZ;1H%>.+_KGRHI(<$C<-R)J6RG$
M;VE.JEM($PC (-4F&U\O&>4\RIO?&2--N!19?WS% *S!+V07ESG_^C(SW1N)
M1_6A(]JH'9U,K-%(73SSLQUC;478U;D1-]D<7Y&?>1:U13&): T#FN"I$&+:
MUSSUT4\!<_H#\U+&@;U\/W9/F%_[CRM.,$;%S<%612=G,NY4350H/%[%W= ;
M&$JA#D'$8']<3:-C'HV=@9IP?TUD[WTCAW9ZLCMIJ+BY#Y@T;H!Y(8*>6E<A
M])M4EO&UIDBS"<7#ACAX:K>X S1#F#V)U?- <S1;8";P..:F)N, ^"(25KJ)
MY2$-]'PQ?U!/*DTOT2^&36]LBHP?VKI<7'ZEC56V_ 8%'2Y;\(&[T;$P]G/M
M0O6!.=>(U,P2P%NO=8RBA&]U;=5O$_7)]]6LS&F*>%58<SEXZE=62=FV8&0Z
M6.W;>8R(Z1KA 6(> 5#)&*41)D3$=B,CFA612H#KU;:A#M$THZ(K/'MFF9&_
M)E L81<09R JMU[STL+;MIWX3Z7-!2@7XQ(/WQ\"7$Y^8:LR2[(YMIG/>%(1
MG =!JAC>28@Z_,@FL_<4W$UEA A/=8B0 QKK3H)[3@O'^C$)=03-RW<,AV^^
M6Y$J-C(4@$93!9&!@&2I(1[\WRQ"H\_^:NRT!W>8>$MK4\?X,\EK-[C$7'+-
M56DXQ5@\ILY =4D-9Z!+C::LN6%34%)->XTM'#=<CTAD4OB95IQTU4+^"4.[
M10C35!F\D\>[0PY#41Y5TF(U9"DB'(M'6]B6.#J*O8CE8>,^^O#AA2X<@)T[
MP"0214B4M"2&CU+4RHYA?[(79A[#M@5[Y$YJOWM!&OQ&7M1-[\-X*6#2;B15
M;(YR%X &%1J%5MGT>=4@ GN9I2V;$Z_,")",^>KUA04$*F@84.'8*\"Y&[*Q
M$R3[XJMY#YDAWXUDP#UYX'WQACI#^=7!O4'.DG3BY5>O05\Q(4.<0J/3-19(
M)V*F-<DTYF#(S0C06!JA60#4A\G^?"KH9ZT-$QV0DV\(ZT<1I(IOC_"(@:&X
MF=.X@VV=DX$%'DU37X+9DI&7OD7$50*/XU5;NQ&.NP]D)M@TBY^9O3"=VX#/
M='B=J%-N 2F?$FU[J?\1J:V5#A>#0LKZ]UH$+RK?7DB"-X\>R*CTM%GPN68Z
M>I6N_UY?Z?%P8^CC@/^M_ B"I!=72F3;&9@%3AS?(\, 6*DGJ@'<>P827$\S
MUHKRWS99>OC+J]C!(3K0X6A/1_V2!V*0NH[!& Q^6F !W R)29E".84>36TF
M^?P*,HT?C#@<:L631OL-Q?+]; +>K0SO/(7>K,5C:4X_4(>(]0-Y]*3G34=-
M$,E))?Y2998_!M[B;B963.K+0DNB7U[^0T5U>J"8$$&:_*4;>9<F/N'16TU8
MA4[XNR])5VYAQ L+]-_+O< ;\E[#9A=6X2"%*_K#_]RVZN7>H/#&./?@!"A7
M&--$3:.@R0;E<PLV%6%GK\M -SNF]HP>Q/!/X'3\H*2P\/'+V>+4:: >;YE)
M,C4%ZDG-," HI,"S"4TXB8<O,"-B5YK?M@WP6N-;8JV*DE]\']1F8-'&W!NC
M@H"E_L#Y6R1TKS%4/ZW?IBQF!ZE5Y!&L_]Y_^QJ]67,8J?_8;K;"#:?Z"(0)
M&]-4*7%GWV#W: MH3&B+ZFIO#T%$\,>^!0TNAZX*LYB6>%@F5?G<UXGQ&^C$
MW]4FF/[)?P!8$S0^I]G^)3?)E7OTKC*^?\)@>M6!]<<U*:;P#WZ_6T+0S&'C
MP?DQMEUI&UB:AN94N3JC);AKJTHIFW(6V\_2O@\8E(*[9MP_U[ATL\)6LT6(
MS&G&[Q'\VFO_W1A<&^#7)W3AFC'CXXZ$(8XLXS3=ET674AV/WBX+7!UKR8_O
M9-!RU\+QXW=*\'>"][OLZ<?GS(KMKFVL;A_>8--UT0],1+Y'? -IL($&>3'5
MUTLK#3TE:49H@7QB_ #7O"9QK=<TAKM-G@3)+1%D?S06L'3->D,YZDT<36W$
MZ" Z]9QNY2^GX?.[Y?CA,/8 K;<+G!*_SD"-+F.HSPW;%[5O&WFXN(^L/K"W
MYK2Q%GONO VZ$&Z_KRL;"&=-MU_[.<\!>)"J%CG?Y'$ 851V4F9X8<HP&ASK
M(RN-\6_)BJ?C74K2S5,4B]*2<HK$-9S/G!8!VJL5,?97Z#K).^T3HF:SETN]
MI\.R]'?W,(\WX?W,O2@/GDL)KT=2K5N_KA_H<IP6??D7GRYDMXB*:LN/#E.E
M&)!RAX:*LWUBO0Y:O$1BWP_Q-D6-Z2PF@(R8'/*1EI)OPU@;\KD@(HB1ITF"
MIMTV4Y'X48FQ[93E]G?WIUAOT=%JI#[BN"&6-R<U<[UB+;#E^-R^N]%<R+MU
M@+4;]^LP::3:5)@0;N;8$B)"<O;KJ5Q_M7'K6EN4M=GR6^9.M83<SELU(^2+
M8Y+UP!-"M5FCQI?@@:>D5V455IN!M6^7)X7=++AM]4!LBMX] @X)OO99!/"?
M>+Q<'$7O'[F6N-2CGH01/:ZSF_5(4?A^/+RVQ!(ZH[2N_/O7'UM='Q\V;9H'
M;*J%CRKC+H- +T""5=83QHIM:3P-.R.W2?K=7\QM3PLT69<&O;W8'_QJ"#4U
M;8G0\[FSW.K.P %RNOC]^7)2$6\%1 1Y[NBVYU0"C:^6]7HV3KDA6WJ4_-/*
MZ'I+XY[Y#]"5%[,?4@8>3I696?O=_H1.I/@2TTP ;>(U'DTXH0!O]YA5< Z.
MDXQO:(>V1NJWM;9G& 6V,GVDBQM\EO:*?:U_)[IU!.?7V\D1H/4Z[]HXQ7'I
M#!2#"TLOG[Y3TA#&P#Y2 40'VGW&=:<VB5H_+??*<\19_4>K=,154FJ]J<S-
MI4+^O&#]5"0)#G_?FS)85EF7K$W[:RH?<8\,!Z"+X"NRK?B%&*S Z*&_V$"(
M1YE>:J^I70Q8DD++V>!9O=+*PNK\$LL-2-78('4!4T+6:D/T> ^$.4?G2Z.K
MC^JL0=/T31#.(DB:Q238@6^=$D <,"=I]2]$"\DWM32BC8EMGO&!3"5OZD)+
M+R5I28.TN\S_=S=*1ZWVVV>Q%DJDAK6R+\B8$PFD[+C<><<](5&S%(^$..I^
MRRFBF&V_:T?/S8T9FQC0WD6_:-<&SWG^.WQW.UE/>S%NB+@6[9]/YT[T4)?(
M@1>O)W/)VUCWUMZ/>E_OJ']1VA!2G.V;>1/>HO0*S3&!<E4@G)HO)0A=ZWCC
MGJ<5PM4 E_1IP/&'./(D+X,$G9\$=(F&9W]7E]N^(Q&!Y5#/#W?RD=L:6BK)
M^#OWGH16M=J:EAS0VE3V7BOC/,@]'Y0-60M$W^[7[:? T>+JI[:E3:XPAF9L
M!'7?*JL8BU6P.9:2T,&_;Y9)55W/7F[(C\KGHE[R;)N,Z6''H]@08 MLCEG3
M&-(PX,Z'?_?'Y8,>JSW39]-YFL%P5SCU J;D>LDVV&RO:$WN/*714H4IBD ,
MB9V@E:"4(\?MF4U.>\[U0S=\::_D]?>P$1J?,Y#T5Q<&ZV8%+C&FJ7(*"T0I
M!Y^'#B!==E_H@\8=!5J2NFL9M46YC)!R-/U1CYI?,@>^>_QNMOD2__,@7\"V
M$HPS#!,)+1T_$4"X',#J5SK.0*JSTNVUB>TOB@.&0RSLI0&SRLT%(:3\$D*V
MFMUH[,#XGG$V/6_':JH?K]ZCR\J),6IJZZ_AD^5%N3$W(;=)T!Y^TXA.6BS'
MNKTP*;TS$NE7L#%U49?TU!+C6]+GJYC:G.)O==W*17\ZD'.M8%@J_;3R4"Y.
M2 : G8'HSD#Q2+=%^*M);^&F<7]6FJ I[K;M'H/V*UE)3F]#5^GXPW]<@/EM
MMEW.(B1*K!G]5MRT@QJWVJ59SW?7ZU[[=_N6,+K:-^S2:1Z$EW)[<N8)$1.N
MR$QK+HR9D7XNFO2$MMRR_YRB+$<K,SN.1'H*I[__HK)[MOD,])%Z,RT32U@9
M!@J"+N2,[&<XBCQW\IYE?;K6:#5)Y=H(/ ,UZ,=TA H.%:ZKOXH)+#6ZJ!"T
M+5:G]_V[?+,[G5]:W@=H^7E;UQV;[2]LKWE[GX%<Y3AF8FTNIV\7L97-Z[AI
MMX0D->K8T9+3O$"(!S/F1,6,:NX_F?WU2H-?KBSQXP9%[D'F"<;%^^%CV' 2
M;?0!ALOCY7K;<*Y7I<=>NIQ7X)549>&(VV61$1<H4O=!'T&W:!TMRMQ+'%7G
M9H]WSYFEKK?-I]OT$H#Z&OPSV">V@SLXNS2]8J,VRZFU[5)"Z:*<N(OL\8!H
M(&^?Y6? A>1#P* [)*LHCR"<OY!:>/C(ME2H5(_Y2(#X(:&";L_PIL3@E%@4
M*#4X^Y]ZW)WBR'0A?6(DGJ6:> ;2!L*=4 %NFEB1*;E&#==FUVNJJ[I/H-_1
M[SG5^G5]%<*&PD33R&Y$:$]MN4?^#)_X:<ED7_\Q9'B3<S0K0C"G#AJ>K(8I
M+B_9%@^)N=F(OGC:3!@7/\T+^+MK[SR1;0#5AS^F67ITF[7^_1D(MQ#W-XP'
MP;>_J+]U!O(IM?XS4@U$#_<;_2A^?3G['_6N<_+^1,.;A'\7[-'5 ,R )#K=
M5%5JXRG1C_>N-IZ0DDR[??J'^P[/*Z4R?:VV0HB=MV\^K1/I)5)U%#P0Z#N'
MJ'1'GBS<Y(Q]YB;^YJX<6%C$<,<B>_MZ84%[>Z([AYFN2!2'V=U+_[>"8K9E
M\#X<B/'%S#A%%.T#TN;1K>M1U]J41]1IS<6DKI^!+,>$G9FGF^#CF^E %CXQ
ML&^>K76<HD3(0=/"Q<=L0RWG<1JY45;*4XG]O/P\CLDO3.@JXQO2V"?!=RB7
MB:;=<GP(K0$A_E%%&!O"!:?Z;(I"7[VAXFM8]N!CG4&<\R"+_K_I?'B4$*&C
M'9^*Z?*9]GE(XHYXTN##C:C9DQ$RMH?'NAJ]RGR4.N=VM9WC<5QOXD?G\ ]3
MXS Z*NWF/"=)/[;#<0G&U4<8X=[,2%X?NI.7)^WEY?5,]K$J8;8W=?BG]?N\
MGO]R\9U_RNXUG.;B 4,"8]F4?PK3J.&K6'(0?5">BS\H-R'A:V3:]T@[V4+3
MD*HB6>A,:^\&K!8<J2A'/PO[R]?YUC\?;/MU7S(1;-N:2K9]79SY7N']',_I
MW^_;75_[$+HUB97 _B)F*ZL4$ROG'ZIW!H)FJS7F6->_K%JQ"XI6>8[/NG>S
M^7F"/^:CV/DT2\-M^!'Z]L",TFZDC5;]#YG2*$%LO=]E^17#P%5.FB2F>!ZG
M$1V_)P%:TZ7,YOC [L[+9Z!NMW*/I:^9,@&7R\IT1%I2R(.BSAKH#+-B\^'%
M5XM)'A4EI =G(.+/3/ZM!-.$A7JW:.QEI.IDV#6D8MN$I@CA#,0THUPLEU3E
MIQF<VJ]BR(PS$I7NODLGEA#QDMER(DS<M 3YDB2'%JD_ QF@\0+JW3AEA)/6
M^RNG]'T!;9E;4R16@G;C*%82"35E V[.6V2$@@U^C1NG64R_K JXGE*7!:KK
MYU!I#-9 <M3E$':*EF[LI-KR+S!C8OCUE!?U1-F#<IK=2B%V+13/H#'[_7:I
M] -+B (1&K%-"5VLDF,#UO"T??F\P)I-LYV.*2?.T_>NB,?E@Q.VZ@VZPD=0
M]YE!@4/,IS.0B['^0":*8:D1B"G;R+ 9BEK^G;&_>4T^*-"]F$<\YX<K3,$#
MUROT8.V+[WF@6")I?+6Q1=A^17$7C7:P,<KD-E5\%#\D9S&R(<MEF>)XH9(^
M[S]9./C%D;6BP$P-NV_"Z.N(JSD!(6')]3^4R$7R&80-MV=C1J)@@JO8H@/+
M:[/'G@]^'-+IEB*/23E? V$<9R#X&8@%<$6Q;;2IQ(@1JW_^R\W(#":/H/AF
M]6@TWD5\3%7A[/&B<7:M0IH"T.*P;]F94>?P-&R[S3!L]VS<Z+>F*N[-$5?P
M._9!43%]J:8_[SX[;$9V#7OZ)*!8&UG!87_L!?A48C$=HC7K\VQM[9\GGQ=9
M/Q$[>?C TBI_)4/94KA 5&TQ0JIU%.66SP44]6>?XZP4@@SFZ?DX+-OPA?7!
MF%ZN0Z:PH[>$N6A#3<<V313M!_/5.FBPK4/CS*\]3/@9B+$!PPT<$7:3-,UE
MBPBTQ+5X6=C]\;+._*W?C_79- Q2I**D!]R/PT$LM!(-5$;JB+W@:3$5;$,Q
M G+]*H"R7HC8OFQU>H!1/$+QK6:_%;[)(%>'D^%V+YNMTBZ* 7)5LD>"E+&M
M?V*FJ5\]5%6G*&3UQN M%F;>SJ].FBH)^@2N1_6RQF3:I&=VC\3)(V#=V5&]
MF??N3QXH3D3GB\7X1_\VE6>H$,M-X/D/4;(M.Y<;F3%3-,Q/6$L(8T9>![[A
MK0*^-6[K=P4GUN04;K;E!-7K,T\+0?,&=AO4-/,,^N$=L.GXK@Q[SM"[<"$1
MG[?_L6L@9DZ\E^<;AV>SY#M__,D_=FOV5NT+M+]ZFJ4I_Y$B,]7!6V4<0/ C
MJ*2&^EE.\##FZ@3R>!C:L_/PZQ _,D$%X2>:%.L87:&KJ,1QK8A4K7KI(IT$
M.,RUGT9B-VQV>^GGWI'3?%( V:[S4?U&#:*YAS'^5.5<)@X%FG?V\\'?F&>)
M:HFRK#A))H/'%RPUE\J4=F%-G(=]Y]W!YE4CT1RD:5LJLN?L+%WJF_PBB':L
M:+S365"YAXP:P_+)O=UU;!G%\)V!#*>VB^A]W5Y(>#Q[49P\\_+"M^/6]6QO
M](D&8JV7*D<D5Y.," \A<N,=&B_EGBLFRMTW5N?UMG"4:($X94I-7.]>R_8V
M>[F*G6(SEA)8B8G81GG"$L!7KI$:MT^GWFB*A@JE.>+A\#]>7BOO^L5"<L+Y
MI0Q,%CG8&T (C"Y196L ?P:*QI76<H57P2WGKTS*,#=0V;.IUELI(Y3&J-R$
M% 'G*PFT2D8#L'IR&T1X'K&)QR2R1FCJEO>F>#8U!P<OK..235OV=*P9!HM>
M;WQ=BK2%,6(Y$9T]\V(=)+E$ZC48HA/:$KDU:H6S9=8R:D2K:<BDY_BE0DYJ
ME5AL/&0TN#+:B@8[GZ'>Y'$2L:TDT2?C_NL?.VM),O,Y-)A07V';%[7))?8Z
MGX).>KF.:G;)Z5_R1OH7+M% V;4%L')1XE<'!P4?>NTUL8I.3_D0T7A5P&I>
M2M1</9.\4Z^,^0F!I:W>1,M5S"5^06R.I2VY=6V:)F YXA^&FFSJ3$K7%'6.
M*\4+,_V&RG\H?BW$$URQH5J\FFOBVEOD/KUX+@[MF_%W)/'$II;LN172JUS^
MH-NWN<TE;[X($II<XT-U&Z$2P8UN??%@CHVVDK7( V"+!WC%O^[0U)J;\GGL
MN<.#\/SD*_3+D?91!=01(542.(%RYW].<%-8X[<H&EJX@VU)HU&H2?@.J'M$
M;7YE.H#A5BM&F^C6[8@'Q\ZKD%#D@C:(^(FR%Y-&V,AR!>Q+6KO: 4_EXT>)
M:5-4.NMO<T5KIXRV+:?92KN)>?S$K2EH&/\OQ>L!IZ(/L2VI^.?%+[Z/%JG)
MK"Q?QAGV>2$U3I,[;BQU_N<1)DW**ZL&T -M0Y^"$[#BQJZKO%XN*??*FZR6
MZ?DD[C)P)*D-!6\@V>OS"3'Q'5#4*[FM#MWB>\6F)88@AO*HNL"UW*[:!"9H
MKOL9J#Z_=_>B%9@1T%BB'Z,PT=O:>MW32=HW&\=+GEIP2]REX^W.U),:L$&N
M;VWU_? :7<2"267Q$*:P(12[T]BA4;5;GP)BWEA0"9'.W,-KS3X$PB/GL"W\
MK243$*Z^$@"U'<8&J)'2=(%X[SROSOA\BVBCK!U]C9J+, Y_IZ,T[UL(3"&2
M^43HKQ /H$_ Q)PW="AF/7BU0+: _(UJU.*,O$)U-7&&\C<O^N'JY;3<4/%"
MU\;8N_.$@0GO#L&&>QK3[C?@579?M5;>9>KH5!KPR+ZE_Y\?/7F?@][M(.O5
M[)$WC9@D%#B,[WRY5_0J"OO\%O]X-YZ!6''VW[PS;W]ZS;.\]P%9TBHL! R%
MAG,FQO0L7%+"IKL*CS?$2]RRJ5)P%-71B3"4+/-[ZII+O#FB!U1_!-IZ'KE+
M'R32-ZCZ]_ B2Q?O91FY"3,Y)(7"QY<371.+ E@2&.I2DO5+_(:1OXV<K/JG
M(,: !I&[I[,!'>&%%44^RC[IY\-BQY[:VC25^#*79EXF6T33%08\$6:Q6HG=
M?7(&<E^(5M&B0[G ./XV826F G99L 7>0T)5:BT9 Z:WRS.NWCB>OZ71*L9R
M^&>&.ARF"?B@RGN(980GG=$4!=2+(WWM*46S"ET7J0^M3;[7;M^0U.!_<?D+
M(_ZHZUA38W'.5I?D%JL$?JO"]Z-] ZH^K%FADL!#B JS*AK0A8TH%>7F*QUL
MZ21EU(X!09\:1OZS4HEYOM16&]W%U_U[,IW+XFI$7-E. O$V8K7#5N^TC/(H
MGX,BL[C+B01/(L7]")*I4O!OA_%2'RLC_>0-K'/<*>J3QJ)D'R"+6*BFV!G5
MR75MG"+>DN/%V&=S:^+W5_!BA$NJRK2&E!OG%/+Z:9YLA^225*<@,-Z7";E#
M6ND%NZ#-\LZU\).#YOOJZHD4'LD*L;39"1N&[?;3(ZGY5W^1(WZ"NS%AUX%]
M\NNQ^ZF)C'U>)1N^(I(C8SK2+TEGH(?3NY3-SZ<E*2C/.WZ6Q+Q,!3O$O6X;
MCNP5RJ]:>E\DB;LA7K1F\GCP"/.1RHV\4D=D?=W8R>3)'6D?8_6EH[TCPX F
MS*'EF;7R\@$M;R7L8J>;#.TBK"?Q_"5/>IMK83\TF[DS&4_^:/Y\79:67*F#
M=K11K^V\/??<5+2Q/1^"O$>B?=L!)9Z0[2<U9?\YD@3[*"A7+V<#+\VNYQ;'
M>;"A)-8'AUZBBYV]NT)(0^) '.0F(KY'RX'X<R2PS#V/O2Y7-!6?Z9.E6%_K
M%#YZM\^.>+35XG_G(OY5QKP$/(JH7"9;(!#]4PZ7$GF!EY_ZT'MSQ"1]]PE;
M>4;*OH#3+ &B#&PLX?.[89R(PF'.O%VCSZD$#E1[!],-R-=DT[$.IZ]GH-JC
M"$K(XI!&+T2S[;>FTY*@S1\YMZF5W[*%J;R"]RX\KQVL8JAY4:#O[0<S@+>)
MHV/]X7-2YDU&0Q R=W-+A'9Z"H]C.(49>5H2-H+B[+A8ANI6640EF*U361^6
M?.";BAFCGIB^/4BZ0>ECX@:0?:I+U0_%79RW!L0#*UMS2"$F)/V>,Q -11V
MEB$VK?*6^OBZQLI(QIL8\AMESU(]W>0+)]T?A?WV S>M.KG/XS&,B7()"$"1
M:/&-.]5X'R[$2Q'D$;KJZ:Q$>9Q^%N?8@ZTZ6MXU4 0" _U]_GBN1F\^W1:2
MMQ+(L9\(D*+O.RR+\ZY!#NDQ?@VDGWS[M4MRN7_6-VX9H^6Z^W;A2E0>FJ1
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M4QLH]3CX?WSV^?]1@<_^_!]02P,$%     @ .8 [5RT+SJ8IL@  \L0  !@
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M@8S#DI-;/OY)B6]B65CG\IR">NTH]NWZ<0D#QWAMV=W2SG.4ZF=$A BG2OS
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MRE+YQUL/CGOO_IP@50M&Z#-T0>M*.X9+-+(88WQ^V-E4FY^1:>G@9\=!3RQ
M1R%!$K672(@BOJC",1>Y4,6J8A)1\XCN*V*+#\;)8<?^)$_J&L=%S"RZ20I5
MBTW;C-4^@'[ :FG=Z@>8G8$LBHE'DC.;[9%M_)@T/?1T9#;6#-/GAX*HA772
MI>87Y*YVL@<;MT-_5]TR%FK@OOW,D''D^70[&A0C;8(F0H"P-PF%1EJ]=-8;
MLKI87I%;EFWB,5F^'OJ$GS/\[N\8/###[\KM)R ()JW[7#-8F'D18C8)/O["
M/B#$-[P_OQ?!>6()+\'X]5Z!T%93ZW61I7/VR71VI,F"QB\X;?5?+E.^DB2T
M^.P;@5U'0_892Z O4>1?4T&13E#Y KO,6Z3GYY9#H:R&@TQ7F,?(GQ<+3%TN
M" I\4"S31BSZZ6&G<?#-VB)"G^GOR9?=0&V<%WH_T5)6+9#4%M-9=/=D& CX
M.F:N>O$ LWK%$3 20#:3US1U6-!0YQZ_:?;6K]&(TXKW9R!/C*P!X,0@LNL.
MO)S.1!^!IK.+RN20&W)E@*.>NMJ5S#5 J;]3D'\-W.2\\"S2 >Z<P,=8=409
M<T>J-+RNO7ANJ\E4_ @BL&&8\R*=M'+%34^:%7D-D&*?5B:==5[=G8 JV%#_
MUM$L,"W=BHW:OZ])!*\*$-XR]@IOH\$4C^A]JYLL(T^3^LR/H+IG]?3E"OJC
M#RWJL/.0;1Z+>U-?BNX@M6([KDBF.%INEOB@'89N_1EJ,(QSX8Z$! OU$U#.
ML76[F#0S4N!#.X,(),SW62:UM/;JHIQIY<S)@Y:)]5LB0Y0JZHT$R2'? 1;W
MH@ JJ"*FY(9-9R8:O-QMYM>3G/'(7TVC84Q@"/;6Q2F>^'F6EE=\8-)/#5N\
MXYN)Z44I[^,@N1I0&?EY4),9Z=?(+\Y+%1%86C?B.[9Q.1)+'[XQ2%?1XV<X
M[%C,Y6JC/2KV4ML$F]"$%4@8W4ZJ._P3##[^070@.TB1*?"/%G*I5.!<)[>Q
M,6( ;O)AS3#K TE+C#/MDWZNV=L8J5-?S%>1R<H9N5680]M#3(I?X>*(#^IT
MY[[HKFM$M_RZCT_8:SP6[-3:-4 @*X8U1&=&\D5OQI;5\K0^7[H&+KRZ?&.:
M[K\-YUBWK+KSL.XMDM$M%;CD1,WTR!%A!LZ9^4BZFYS*O$0JYBU#QYWW4$[S
M&X!<V-VH\^FEY@J[)8:Q@Q.P^2FKU(OJJ$$7+^=YRP]$^I:S!M]AW[1 J+H6
MONUK@)CH:DG&M;TVLWMPT<(0LY[O/8AHJUQQ:'W 68-:#N;[Q%=>X;AURU,G
M;[!AC8IX/@*XY)VH938S[X2?#[@W53=&6X=ZQ^@\>YWXRB_H44^ 'E89,X\6
M4$&3I^68>,]BJ#7&H6(%LB&D3;,3]YJL/[@]5,#/M-\,"HPR *-MD :1"3U,
M/>W=H,CSY,ZT19[.Z3,X:UUP2-VTT]SC \:/OQO%?RL)I@(71V:8V%4(J;D9
M?&?I[D3-;IJ:KK^T&'6(=UE'7VI7U68K>/L\I*[$$N)G(VD*-U6JZA)6YF&G
M_/C]#-]@G;R5L!;)78[5+O6N,)H486X/"?VUHO[H4TI4FN>WWN=G?67^#R^X
M%C#UWZ\!!F$8X8ZL^+2T0;:]+$GM--V\P5NKFK1W=:Q9X!<N$<"%4I6'!9TM
MG"[7YO57>_U3K^2X0;X6(5FF9U%.<6%5,>K03;18;R9UBP02;-(ARYBTL;,W
M? W<XBO/=V/#S*A'63NH+R_QWOZZ:RB %*""OD@:-&]KGW+WI^Y)8NI.\M4X
MO+]?EEV'0_&B1,CII@HMF8 :Y#J(_3$_N^-9GS#L*, 1PXA'_S[]%M$%)SIU
MJB(ZX*8@2C.=QG)9T4=@%?/A\BMO4Y9ZL?G=Y59OLO-[]XM];HN?5.2V$6""
MM=!RG65$6E-.QF=:MDL23J; ^"?7[#36'WC".$O:BC0X^06P(LA9\;KNA-QD
M_<64:Z"<[#6P4I/Y"[Q$?PU4IH(NN3+:Z79/$ZY(5*^!!XNKL O&[&M@W&<7
M[10H)DVRZF_3VR8X5B- WCWAT!0RZ7FJ73I(^;BR<W4VL.6,4R_:"*M^DUY[
MFH9#>DXV4LKG3=7LH*/F=S84W[ :C;4YR1_(EW>=ZJD]E+.C"(TL(G%[!95_
MRT5O]<Q$>NKGY8(EJUM/P'N,5\_5G5%I/51NIUHVANWP9FO[05K3KF+!W-!8
M7;#6I/&9ZD:&I;D\$8<X R)0CL= OTU%YWY+@V&\A8S6\PY]S<-WF:V'TU]$
MJ[]JLG:J^;NQF_ZXGV)NS6[ RACJ(^,C/;/5'GC,IS.X4O@^><7S':K+L'+Q
M*U?T!OI=I0_RB[7S!\$&YUT@G'\"9%X+>B>MC-KGNDR6OH^XD+LU[ZVK6],\
M*=*GYJ!]&KFU\07,T9")'^Y5A2WU_*BT]^X)*"/9G&?ZT*G,R4DD\O<!6&GV
M0?SV'((M0G4@-M_Z)F]!%_<W#A;;O21.A@.*H;KUF#?7 -75G3FL)BHZ- XF
M$/X6MB_S=/.9REHU97TRP9"DG^6/(VA.Q=WM!NIA5<07(=/([W"1ONY80BA?
M"]H5^^3;!7E*OF8!G*15:A.>H,KXJ#)#-'DMMH4,"#"Q#^"<.BE:3=.:$A#8
M"'SSD-_)7"G*]^$;%\S+Y #>&8'#-\V-TY #?H0"DR;??'5.7'3VAQ]L4^=#
M;0PHUL)](B1/(W*TEB)<3):YMF&TAMG!C(ZY529JZ$'DIJ45WP^S/"%7W5H7
M=@I"<Z@[^APCU2E+-WXE.(\Q7[#SA84[N3>6EGM0")W]*N[LG7(B-=,-));V
MRJ(8^0+KDKL#I2WT]MRX BL-S/2(LJN+YZ/9#V8EHG!I,69SS":@Y]LM/A>B
M4+O+#&&&%DV$)IE]&\4$OQE8YQ+"H2F83D5]YDK]@PC>6GAU6\S/3PC*&J9_
M]3W,H@Z%+,AW6"VZYR#E%RN=I'<G/L+O8XN-.*(U\SL;]QBT(JA>,KU)M*K)
MJTO&'%;E0$8[A+O.")=!_U!93'_%9HMW]$;&2_=#V9P(29[#FUZJZF^"=!+@
M%G0&IE >P:H_K]E0&:;;$C&P<I ZQ\]J^?&\:I,(73$^$GBFY3VQ.O-.9)CB
M!09<M"59N[_>UV-20=EG13M)D,]U.[8V)_R9:Q!E]'*TNQPI5H"OO=,"=PG*
MA]KLNKA9/A:\D_75=2YZ/AJ1A(Y-(V\KC(1Q4Q>9?OOMKPX$Z,U;+/7>"R7Y
M,,D9I(*,46)(*%@A@KD,^X;%M%M;1,)(L"!+9 65MZ;.V+%)G2K'9%Z<6JX<
MMRD/?52]EB'IS&LTCQJ&ARM:V@,4#,$J9=QGPGY8#:^9K+_J$X0PDZCLL9#-
M?U-F(+%0O!I=)F\!HW)/M:=GM&; TA"$)NV@@S]BW]<L  ZI[*/$959Y?23V
MXWM<XY1+'PT.2J8^1F37W\A#J'C1=#%,V;HIL8"*1D)KM9\<9V^.=A]$U0ZN
M8,(JHV@W0P@C5V-)YW8>".SS9%)L!TW[+?,&9<^[W&YD["1@K"B$O6J5ZW"%
MXJ7Z@Y2J9J#N'DEF3O1@CGT2RQI'?'M.[L O\ZD":2)C6/HZS&O^,F1S-$0!
MI1^V6I))]1E+8%D^2##84X)_;[+_UJ-IO_:6%]!RJ5&B#6-,I+Y1P2=[KR"C
M!56>R+!%#O*H/NFXV50#-%O9P_LG:GWWC86:5G_JQ1AZ;&EJ+[7K7C%[*_>F
M>G7&AE7/>5NLUIRY[:;&>__<M*B?F+H:>G"YF33^ZO.3$<&W[^I9#)@1,GXK
MIQ&RC-Z><!"9,FK>&!V"F71*@A.F['.DO.">>/7CX\$94"ZE1;1)C8G5][_O
M7C<EP*RN&V?MQ-))43Z$/"ZB[O%=\'SX-K7G?"[K4=*N.T*$Z"M).NG,#E??
M)*JVO&SE!^2*V;8IIGCIP?LMB%^1+9WGD3'>D/)>;(+38)3P]Q6DR"C<V^%Y
MY&G6=&4N1NFD5I.\;R.8+9)U)K3_8VP&ZY+B-)&^#K--*Q!@CLGMR!!%)8<*
M@ZCM-S:6GZ/YFB.9,^O"Q"B5/!-?,7P#3E_QD*BA8PH+=Z;KJS7.XSM<6+N,
MEY__4A"ZQZQ0?OC9)38_X--6!@CC;U.,E:ZQ@U*68U+)Q,R86))5(70I7D4D
ML0N,NE)Z*C][ B0M(^I?TX>Y6WS(H&E'GWY8(< 4$86<1$9[J4_D5,=__Q25
MIBMY[X_?C7NMBD" $U0/\Z4,^QJ]5(08N:-*;>]UP!B_**I(%4BK3<]E'PC@
M-CXZCSQM1Q.FW12LH=< H;3=96:VH7>:X;B34JDPCRU8.U6BKJ^-&Z-#_^ZC
M>$6R+=YN)N9^&#9#(*1]-V3D*K)B:76\'1^VD@3ZY=U&=PV4T\N=\[?[A3T'
M\HLN)\^G_6WM81ZRM9E_[NQ9-C\$W,/ .B4/PX[!QECC'>/C?7"A_'HUXYIV
M?"/PKJ],J%>."BJSPJKY9.)D?K.J9<;IJJ>P[]0'-)S,"'\>1!^SB=MF<@T$
MO8=O5^VV$W/-F'337;$$&Z34\K23*4N9R5,D]Y,1\^=.QKB,MPC(3[88\)J#
M;LIFSZ->L4QR@UYZO*YZX]'&"UWX96*]$[_8;[^K;5_@\HGM(M%05.YD$,\G
M-"P**[ R;/)THG;[=4TK^O[F[!Y'_&P[O%!O@>9CWEN<C\;M<@'4&(N^ ')8
M2,;]T=I8^IL8Z)XV;O%"V=?/",T?*EHZ%3R\98ARB4(TC!!\X7F)"4'9>]<*
MA)]E4I:=^'V FJ<.T5?-SYGZ:(CE-/U^W7&1+1G(C7>B_!)UFE:BBI^:E&SG
MQTG61M]<ITIJ,Z6&%WQ<KC38N42!5HYI4?[Z^<VTB,HS.OKI&4^$8=9;Y@3[
M)J0GLP1C1?)-Y9%Q/GSDW8Y02A29;D=(>5L;]7WP>"B0&^IEX]@]?:9PIBN
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M_QW(W\T&\FCKP_YR__?-8.&?H^]<YJF3WC,I ]0-(6?SNR:)2=/4=%QX%66
M7D[I7WUBP)D0[^J_K5;)P-OM2_UO#GMB%M[Q1CE;^!8+2]AK3&KFGW3&_DX
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MSZ>_J<OT#DUVS*:CR)C@_&DXXX_/OX4:_!<,MK @.BRU6)3<*J4F_=:$=W:
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MNL6JL*S@A#M)-*>IO>CI=-UY@M(O31+3TA<7VN%F<^!&B2UUW6F8?2MY;^>
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MK"*C[W"NBT6PYALY=2_<N4=]N 8VHVV=>++;@3*-:)P>F\_W -UP&VSR7I5
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MO>,O'&Z3/W0L EQ3;7^ "R$-YP@/[QS1NHK&%.\SNVK"#MU>%['S&[$@_[R
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M-C_15S>P9;Q_2RQPM*]@\TOTF;)$4I6TW:.J3B?\8I0$>VNW[TV#$6WZ1:_
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M1APER'N));(-IJ;9>1O0UB9W@0GGE)C);<3_6WO?'=3DN_T91,5"D:;TH("
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M="S:%MD:R7>KJNHMRBQK''HC3EN$LS1M'I:B]G&Q?!B&F7YHI&1X\NQ&>,.
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M2%L)9G_@D&B?;6]8R_7"GG=-AZF8XG4IP ?VN53C3:*VK$/[TL:2/;<.>(Q
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MD>B7-; ?@FX-YVA?JJ"Q#H<]M>/<DX&W!F9/)LOX2?18N!Q9?O[.8E2[#\U
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MJG4SSM.9D40F:=9HNKUHIML13.IYC'LZ'LEQYX<T@%:8=D61,JXCMBEI:Y+
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MZC7)O_,P;^BK%&-4!$]O=SFM1/68\Z%J&8OSFBHC8E,<:7I9A!B Z,PBUKU
MV<5'+5*!ME*VYXH/^5WL4@PNP1MQ=\K84K16<N=7K@!%!Q<_GZL_9G[4;^7:
M,EY5F>;7:.*>0B5J1'?">4 ,<.:13V<"4SUY]$F!2$_W+4 "P#V!3<SXH3+X
M83?KB0H/:VZ)*?B^Y^!/]BUFW^*5R?=9/'*</S\,L 3BWC,%\$"32:A-#.4(
MH-1931)S:&7(!4(H,#(6[=X88143PD,:K9O4-195/;=B7V1CO55GX#P_N\WP
M\K-P*>\W4VPU)^XEYP_1#6<%7\2G"W7'I<MK*-W:F\)?[V$1Z+ 7SAOHQ97
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M6@7=J_R$I\4I8MDQ22B7,!QH>6D6UI>(_,XEEU):[###^+WPY04NT>"CU_R
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MR1EVYISK\JIX2[IFQY]Q%+>#4)()N*^;,A?+.^^Y[IJP8]GWZJHRX)^ \I5
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M-K&?5V5+?$![QLM^AD9:=!;C>P4-:=O#&P9CHJ\BSV0PB-U=_0C-_C\: CS
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M0M24V$<_+>K+2Y\TI[0^6-EW#?Z@AZL)T5L ^Y=/GE$AW7.9STWGW"W ?\1
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MY_L@OM6FBA()U$3ILQ5PU![>+[4_Y8S[-!@G*97UVSXMMWRX!4*2+73XK="
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ML@I7II(KGG5-\%H^=Y/0H7G^23#YM=#0IRZ"I)DZ6YSH139<&!U[VCV^:;!
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M[H_EMF4!!<M?S65DA(5SS44Y'(/BKW-I/9 <;AB(;*VK[4D,EK6"!6RUKQ3
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M.N431Q:K;\P2#DD_L^YA.Y\THOI#M;S9;$C[=*R\H2X@H9IW]KB$QV$*__'
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MF Z+6O-)6WDA!U^F1W9,W7864.)>V(92%@@Z#-=H?.;IX^==ZH(*2. JN?#
MS/GS;)0DZO9",S=>-CI8BLQ6L.*WEPT>A-OY/[M2T-A8^6;2YN8+[!184=GW
MX7QOZ(JVX#'ZL;B 3S0+446&*CS6U[*7;0I3-YV2]M1Y>K[W $[<BP_^0*IS
M.C7]\%$=AYJ!G1Q3,K]2^L_Z*7-JF-K?3'P@F2!4?>D+/Y"RH[0T>DR=SGT
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MWB5%/VT\]'W8:"K'PMUKWMZ."V<_A6IL_6=Z.XP&/)V!X'C#T+*0KIQX2,U
MQ/$Z=:"XN9HN6^GIUJURHHU+6Q*X%)I)4)RCA^GOOC3V(\B1)KH'Z&%QVJ2=
M]FQ!-[<\H7'CYL8O3PD!"V&:TAN>_Y316QDC1L1,2'5.G!:+/76T%52+8IZY
MG>R<IE)EL/O^I!6]OWMXV"M?8= ==ND\TN^<#A"O%?QD&'@*U/8<''4I[J4]
M#HF5:Z-N,/U>FD7O_E,3"W*4U^Q ="#X]7A&B&A4D;?F@Y0'VNL975;7K\3U
M>J5S?XXOHE_?JV A/"C"A)/23(\GM/1N/K$(D\.UO%+_H+JA&>3R8FX.9^D=
M^O:)F)@8]][&/S6P-YU6RTE1'5!F)39/&W+.H9T+F*/6_1Z8=$7@M4!0)753
MFC5R;?,5U,&^A12X6TX^0Y+$1<509-U)*1T\?@*UK^IBO)2(3^*K".+LMU /
M_AEC(2J>5&X*VVBK8PX;7#-E]Q7QLH@2\4^)1$$1+)+_IU[H3Y[X"C\'Y !C
MBQBA?ZX=B6QEUP!=R3O4@QE>)]?C5.];PU!&3>>O"7OMO7G]/ZA[[ZBFOFUM
M.#1!0!"D(QU%J4I5JH@T$9#>0:2#@/0 @2!5>A,0E"Y-")$:I'<$I/=.0N\)
M-4 27CSG/7><>W[WWG'N]XWOCX\Q]C\S)'OON=9\YO.LN<KR78($=PJ_.+X]
MZ+_5NLNNH;@GXY;HY#QT",)GKR/',4,CR3U#_P-X36 9MSOSXCFEN]Z7>0/+
M F#(,DBNY@H0)2OHR'870^:;X^1GL@7-#R@^G[:>=I^9BZLYU?RWG'R>!Y(I
M G%.BO6S?;"HM0C%\"QG&MMF5L<J[0@YFA3'A+HESJ19+MM--H<CP7&RA .7
MDHX69+A[N%$_UTY?+\-,EQ-G95T=[E?S\3S>AD32L9W9!0%:_U:>,#("205W
MM,.6**YULW,+J0F&+QD8K6$2+B+,^N)=H[.V6T+E]2>V37SMM5F$2,W==%=D
M0T=V37P82 *A9F:LKBX6P+N5'_5>A>_.T3J 9% 7*T][0?SOW!M$<"FUE4UZ
M36K8NEAET4.7*FB^GF;NR>JI43-^%_TG&?1F98-S!A[.RY;*Y>INXO7XH'L!
M)AU+Q'+.%J1 'S@6,\3I4!\V(S)[0_KC+Z6V*X #Z9TX7^B8YK_5T!^P\2#?
MY76D#33X>"FV F.-$HA10AR\SCC6E!WUIS!DE[[5F>UW(?B3D@3$BF3KV-ER
M!0DMMU "W0]U#U?K1CWK!*R]=JHK'W#[&UC\?UKT^/_=!9SJ$IIM:;UF,S40
M)]7);HAL;H'QC-F :Y'#WOM]F,YG#JJPI[;"Y&\,*J>Z+:I[=M-7*&/DJ#$&
MWQVV;&?%H98YLP^=3F%?L/1:(D-],=#]H3[Y0;^W03+N<K.7;?IIYO2UJ!O9
M"(L;IL!D76<NS>C."]%Z?]4GKUL3>3@HEG/K[:+V&PE0\=>DA9IC:G54J/8*
M8+DM86RS;89WIT>@P3GQAX:W-1)["_1G?N4I\VBCJP_RK&/6TX :+?(J6S=;
M*UEG8J.A,5@M6N&N</N1R$_K3UQX=43= 4X;FK=QO\#4C7AP"^(9Q_I.#V!^
MUR)O([+GXXF9K/C7)0?Z ^;JT=LM'+\)CUJ/**6'B;>.[_1X$7HH</:31[%P
M*Y&74;('2T8E?7=@,BN/*)C9FGQTKR;EVT-7PL<Q_&YY87H$PP BD__]%B*-
M:0BY/;EE<%C@O9;AD\OH36A9V7)SVJ]J!X.^5$O2-W%%_N1Q[4V.S1+8DNMX
M%F+%:%T#G#.X0_S"YK>$'VU*2IF/3[.J+[S1Z+-$GW>)WLX (."##(9N4MML
M@#UN\<GO\CT,[PU53&E_(#5N;)$8/8)@7J#O&'-4]7>]6?_1T?C=9*2O"YME
MQHWWA)%U5IP_+V4($&>=4DXF6&]?68:%S4/7:!7D/N1&OFN9X-)/J7X7<BMV
MRK0*L?[ WQ84@;R;2S0@ \125#/+*$55J9)5A%'E)&Y4 ))RQ/)5O/T>5<ZV
MB1N_/<&VY/^3&?=(9ZO3+F1Y).H)D!1,!ES7O"V2R-0!_[GX\"T%;9$RFQ^[
MIN 3J"^4<:J9=J<^?N_/K@VLG0+7:,%6B1P83'GH4"&1=1AN>O^IJ<\ 0 $.
MGB.&M\1X9DI> =3&7?:YFJ8T(P@M;"SY)4+<YC@WU@@?LI\Q%(&DL*728BCE
M+F*589#4"N->U_BD,Z0WYU7&VUXJCK:?ER&$5"?0SYB'EP3HN79S/K0'0D9R
MO[W/Q-E/[5HH.20NV#(7&"2TO2]R%0X+^.;6+3F5B^'%1I9C)) KW8B+TYV7
MJ,7:V3+],_WZA=^I6CWO=ZWNSS^*N4N5=(>+)P-PT:^!8DTI;>YGT1@\.3]W
MWJ=6:&O;U%1H@S"ASTX5L!D8/60$(JX"P>+:)DN/K E;#',HZ,ZXA<J,&:9F
MM64U_K"^^KA;LUP](.R_"79M:SO&]2!\-R6_*T 8J. 2N-ERV\O?@@ 6LB<V
MH* *RSA5NQ2XZ6*L6AX*F"[%9AFNOA F9G5!)*;JVSRA79&$A>$>J2,LF-7]
M\]&[TT/%?.A"9K7H-),=MKTO/G$RCTICUSQ1DA(SI[7"E(.*@,#(]2 /BZ_&
M/*'-<O=+X<_Y,=99#^(58D7G^B/7+FEKTF;$./@EK%O23O.YKE%^!R_9/9=X
MS?$T>R:Y0XYV&6U1*E]@OHA^*;<'-.\3^B@9,("=^B1ZZ=6 Q^J9J& >':']
M6YXP!4\EAQ)B#Q7!9C5ZE6/DT=Y>E-0R,?5=M:7%6U5J1<^&VX1FRM>")/-%
M:'_%W*63<1K[:]GC6\%_6HCW*X?H+_^1S_5D2.S(8*_-#F5AB!3/+@))C+H*
ME2VZR98()H-JS^:T/JCD$R>5!9Z.9>;$'>,=ESLX'7TQ1?9TFV1Z=(^IYP,/
MGVRD?S&/FD3 1[?'%YZ]C6O-AZ>_H2XY%,]NI.0V: 2Z!0JCU4X#1L7LQ08D
M5+^HC97;96NB-))EUHXX^[F>5:H(WBXE =5PA#R2T?!XQO9ZQ) 5,.4BK;-L
M0>$DH<9DYBCI7+-:>IN#H)>Z 4#Y[A]3<_XW5[(H/J6".1ZJI]U<L '=MNSL
M]&(<I"B>FCH;2J]/QR#NO?L&.U^6[[)%]KYACO7SSC/6*T##SKE6EM.1I! 1
MR* *:?@C6AD=5KREM>W^JSZX VQ3LK HJM#K"QGX'?8VSC1VNYWS*5_4R= '
M'".ZE[[[5J"Z?,V B%Y2GU?SA-AXQH9RZG.=W4(23)?RK,2J<G7<>I#L9%ZC
M*YPGIM%-HG.)#BW5[1<77=J<XN3D1;2>6*1J2_*)6B]E+?E)SVNGF?]=I>MI
M9_A-0OY2P;&*KS8*5C'7?U._666' SG1^"L=]:GYJ![SN@FO!9<IQ> IC6'1
MI=TZVZ\_M"?WR<,Y8,1G7:CAC8R+8,-)P\R[-Y0(;_N'6&3)$J.-X ',IPWU
ME<BSH.H%OI?(J<B<ZIJZ46F"@&*ENN"':KW?SQ%\O@HO/3[_DH>5VQ,<\VBJ
M??I1:S+#F8%\D>? _OSCP8>Z[TDJA!N Y'@='41J%.#5ZR7/T5&)!5&\%;E*
M,"99Q@#7G0F^ FBDT>Z>K+#]J^GX?UCT*:RJ36.7.$&EI/:XE09P<30#>HB8
M0K?0?6_F^&E!'/W\H#!<O7 9E.MGYT#L8YZ_6&\$<LO]UFSJL^7#OEUK/T4(
M7OHQWK'",(?53RG]+:,8780+BX*7;4ZN-9XZ;%[ZP#2Y!LJ1)^>Z1<CJXP #
M9><I3T\:?7QT'GRH'[Y@>ODI#/PU./M:)M_:6@5ZZ/0TS,5C2TTN[7VQ0Y@X
M:)E" 6X#I[1&JZG>5-<4.[NBF:WYYCVU3VPTI47BYT O]UK-=#-FQ1*^G+RH
MAY]H65I3<A*>]R732C%.N8=,)R8F:NMZM*?=[J6)8I70+BO*)?PSURT:01&&
MHFPUD!0O+0:]G]H8%PLP7GH5/*0Q[+FT.VUN-YN;ZR7,T.TKZX+Q@1:*CM='
M:]:J;>75-1J.J_,__CRRQ";"F_0RV-WMNCDLLG!T:#-XK-!I=7W-,(BH<*O>
M^P-4GH9>TB!(J(:&7,M:Z'[1QL?E!+JG?;?SB;].;0;E$-!V@^RO $GJB(-+
MHGGPYHV&EPB<*+CW/LH'&[PO=TSPC!(M<07@CFYC.R6HN!97-\UBW99N7 %6
M$X%<N%9ON0L.OHK_(6QYF1M^\0LL^J?GP\)N&*L:\L:7B'Y1T[\_:F ];B!S
M[6KPG#RN=\SEY-[>$RUR-K.#F'BO&R4S3O7-->]'C,TV'TD&H%?JG'[2;],4
M\F4B./R53:X )KONC7I2!2RN<] AU\X=ATHZJHIGC*U/")?O&,I-S^[&IDL_
M+]ES?1M]!<BE*Z*D6()=#%$[*F-_[4U=,_L)?U4P%T;N-]3I^L4$EW!J.#L9
M9 N"HF:E%.(MH].1/?UX"Z8T8CJ?_FI0,D$\AMSJJ!Q7.CW+S&?S<>A>/T7E
M ,S?/S.'<K1,._?F6&&^MNE00R6FFHXI\Z7N)\>!/K-9M<,Q]>"H!^4AQ7QD
MW9-,ZR7P_E(+BAUQ'-L$-Y[5N,N[KN%0'TM&&Z**,1[6G,D]=S"M-$\N>JJ5
M:3$-(2 \9CB:-;.:.GCIDWQ_@E]B;X.1I9B@6U1 JAMW"SV6AS;7C+XXBRP7
MXL_6_1EB/+++VJ>B=RK,\>%M$L\0>W#'.-.%1O,=;#"(S])UA6S >ZS=&\=&
M[ZU!6]9(X%M@LG=$@B_SW&A!D)X@Y@$/E/;,!G#_H7U>D+1)F\6A)YCJ"K!+
M6W@%V+S?5-CX5]/_BBMQ_51.6M2-4R"/^<8?1%"]$A+2UA7HOH/C&<91!HX8
M^)U%BBXH=]?'QC402L(B10\H=\1?"J;.L''M3E$;S:O\(+)B2TTG!4)'QH:G
MUN5ZA!A TE78[QA5^A@!T2]F9#AJDNH]@Q?T]7WJO/UOHRXF.5PKRS[&KR$;
MD)D*"=?@!5.9@(CMW>_7'MLP*27[18U8]+RL5-IF-/2_+8]Q7'M_<07HU"3$
M<*)=+<L=C5.:(^!/.&MJJY.M]N;N3R_'WL;O_%H,(%^!*ICB<B]U,$)C0B M
M.S?$Y\F=#A>N<4XUHX60]-1;"4$10ZY/)SDK7#FF'P*^OB8NTY98$%OS!M<(
MM?=C393&<E!A^?..%^#3@GR& L.,6TEU0@_5$W^J\%@R)ZR^N ((]3E]0]NA
MG-JS&3 R@C5P%EW'>I .LR]#&S<E\YX!7GZB7KC62!L7>?DWZ]OV!)'8Y.OP
M2]]N.17=N0)<>-9![:",V$]/T [?KP#38] KP-8HHBGCOVF5,CDJ1P-\%=&F
MI\';$KZ=H=;R#)>CB7L)@'V5L^*OXUR_?V^KZ\2+/#V@QIB.5 _1S0*5QE[7
MRG+7L_.+1#QD];.S/X_<S8EW)Q9KH QQYO'*UD]2=UGUJ#_Z_.D*4'7[G/Z0
M9WZ<[@IPZYC9V?7EQ.20=T%A%_]KTP:;H?38W1[TYY/>$[&QJ7N\>G8/I=6S
MZN]5ZN\L+%ZW1,==4?O)KT7\9EG-VP:5^B9+/OX[Y^^$'VB33' IQOXY/@@/
MK?/CE@#MO)_)S2CC!SF4,F->V7?[4>Y7 -7ZFA\6Q!WO!"V;#.^J<;@0^L.<
MYTFX46.TF[I:AEK?MNY__5H^-U5PX<>5$4:OJ/KTIQD,JG9LKI:CI4C[<Y26
MMD^Z]I!;^[.U#8<U*;-##S%QB/8H$P"SAA**%)4+O0)4JT_"$#+BUVK?+Z6P
M@M X[:,HEL"H@DPNM<"WMBYIU$=W[O#SV)/UYB9TV^6+:0PO\G[L"HDGWP$U
M$/SZL93YC#KY0W)A@-901I_1%_<P1<(DMRZ0)JJC:Q&O OO=JQ/E7!COG%]>
MY6I7;-]]9F1D1TD:/HZZ><E;?Z-G8>'P9)!OGY()1(F$=E/B;S)I._I-IL#K
M!*B?"!RKG=7&K0_DDW*DJ$@-%TK&=A2S#Q-G.5K Q$,L2W:\5>$RC@@U7^.Y
MEYPJ-(YC92,=W YIV,F9>UIIK:U6L^689]@B'*M3-KZKJY@<M4,6P[@7Y/[.
MKU&QZ,V\^L489#W1PM';%S9]JZPRC@M#NPK(;8>3=*XTLYI+[UN5\B6WZW7.
M(SG\7Y4<3C>J=&;.< UG;(&,D"LOT%Z7,DZ!;*-[LVHR<JKUAFN-G$:9GT4:
M&A+[140>RQ8&20Z%A+"18&Y36NQ*L6%OITP;L"!=<:KTP7*[Q%97@#SJ!J;_
MI@14"9(OJTTG?SVG?!K[?*VQ >@Q?F:UF5\B)IP4O&ZMX?C5]-M[)I^N ?_7
MZ%@(4 7XJD<@F#CN:.]%#R=LP>/P5NF4='(/8_EL?WL)]Y9O:3^V-+#(/9UX
MWU+N>% V9-L]8'LQ)$\PWF5M58*^"I;NYMZQGMB2PP+8Y=.N*WZ="34W'=PK
MG5,<<6@P&Y*[%5Z<#WIUOC!G4!MU(2#J['.'M@O-!1>/7!:B D88CKTE\RC[
M?3]YC:"?92(@<F/'#$([)BFZ_5+DD\L*+$VALH!4SXXT.7;>2[-FHH4]+XK/
MZOT_2&"Y%4(_N]@QD'3BS9A7;H[I.7_W\0QD6A>0>D.<KXXJ<9SM.5]1V1*U
M2@(:K.,KD'HH5I.2L3!(]_KVFNJQC!P3 ,US:H!.68:&+]$Z>_8@L;@O=##&
M\'XS27.8C>M3!Q*+^?D!:=*8UJ#-9;LH+#&QV'GTI1 P'QY8BJI2^X&ZU9PH
M,S$6D*\2O+ACG+ Y]9#O7>6<^\ =(?US_')_3^@PE IC@70-!1D4 >WTI_;X
M3^;0]WX&MWU.)W]<OI$81.SX :/^X1E++.V*U6D+6F46WTFA:P3[ 2K;SKQK
M(&N7'K/:LW9P,Y@R/?;SQI/R['8P"^C62CRCHRSM,$:>(K?<D"==K-%-A0;*
M^)#C=9(5E]3-;M\N@'L@Z14@.1\=?P5X [G.X/)B>V*(Q;_81/][GFFXR(V*
MBUA&6Z:93#B+%A>^K6B:SWNTZDUX(MJ+<<COU.)JN+0>S)UDYG9893^6>DTM
M=U=?L.8)C/Z>U[HE[[$5#[V8U^CF?-[/*P!:Q4LJY983?*Z]"%V^%L4VYN;Z
MVX >Q0#2:DE6!I.)I<:%KRH#8SE-;44&KP 9LH^#GPQI=5D:T#*]]M#ZU)CD
M@WG7<B>C65S4H3XQM, E2O!@]-0B<ON3@204 8DBE]18?J2:H9.->:^537MA
MOX*[ N@WSUU"]R5.KP +8+<1+7.SE5L2"*^ECXV2LTH5-I8%U9=B#_8@$[]B
M0'-5[#P\S,"3&TWR2@#"U8L,W5+)RD^^3#"#J3%M^[<L#H."7_/[G<W*CILS
MK@"I>2.*M*->B?//TAZID@=]7M6.P>,*?N1[-^I<^ KP'.U3 -*(AV]A"QH=
MK+ZK2IH4!:^@1-4E&X)Z2;ZVNZ3Q*A%G-A!Z6)BPAC?363#"PL#O;IEY0IPZ
M:UGIQT$.3@7;WC\LMMXR>CGPPSD4DY^[O"(/9A_C#]KP .BIO2:&!8ZQ5::T
M[!'!9>ZHU:)L(?#TXR<S[Z3STA[1R1J?)W-__[U?'$/;<8-Y>G5U(Z@>&U%3
M!74T+FB)VUOTO_5LNYE)PMCJ<3C\1,7K:>"T_C,>'5&.&VVLM)$[41?;J4&R
MXF-7@.5L#Y/R+X7J*Y8\$8NC$A-OU:4AG6=;K@&D_63G7ZRBL3+3W7KQ^^,N
M:Z7#S8RX7_4:7Y87E-71<1?@.->#&A*A&41-TN0B%]$G\4>[\;]MAY)="B+?
MT=FV$M >RW %C#UC9;MDV?+.8&LGRY1L)ZJIJ$;=_TG4>#.SHKL^I56/L;<5
M0.$T[]0M9WT%.+_O!\7&2EX!<)F"?#.;_Z4 9&XHWH78U*6W*U+_.4^0X'Y%
M(Y\#]\A Z4*NR8 "!55]%\EU=\A.G ^8OM"15KL"W'&ZO$45:+_A*KL)'J/A
M8K\"-'89;*I[Z@TV7:1ML0WA\#$S?2V^^EBN\RM J\67:T)03Y'SK[<NWF=7
M*^8.?[6;^+)VDO>]TA.N1&UMUD]XA^8E^2"IT<#[/!^LL04@NZ)MG5<)T!"=
MSD31W.R4CZ\L)7A)N @&!A\/!!@53BL6;)U.OF<D%T>5J=@D?G.G>>-BRUUQ
MPIWD!-^)9Y((:W%R-KD4,D;=BP@_ *D[6);,F6PS&4:I/U=)X(T6#YVO5O2^
MD6C*^@T?3^Q,PQ[/*1H]<JU"OG0MG9+570&&;WG[EHNL*&.27.G!TX(K5X!G
MHH K0 CX4*7QFJV^^7M&F?KW,LK?SVV\?^UGIM0_YS9&P!L<Q)@CO?J_\0FT
MSCDS@_L?^ <*C.-H%H"9KGJPD=?K *(N.-L\\9HFF@I+Y/F,"( 7)&4@A^()
M3,1<=[/ P A>[)[:<?S&%8#@Z)CN;T+@7V_*1]S#2E^)B@AW%5UX?GJI4>LU
M[RJZ,U65A=\88?0Z^)O7\0FA_HDM\.L<Y:WMPB/PC&RO4.9:L>W,C_U6&0V1
M+@!H#ND]![\"Q$K[31IK[E$AH)%ILVJ,+3]6IW(/\V?=THFJ'XNVLC[:O=8#
MQU> :#!^#CH;$4"@3Y^P!;$DVFOJ@!0[%*DN/P:PL<?^'*10!!U=4J,GEX'3
M0*\3*-5 [KQ#DOFFOF1X?J'Y<X$771Z<<\^3GBT?*]LR'&1<N@?)BK+]B/@X
M&!<#"GCCM;=G?\:E J[Z0D#:]D-YPVY@.N=@(>8*0,%7@?:]9# !:G9-'3I)
MSK-R(.-G7 3*JB/Y9Y\^^UJ2-OA)-8)1'N98+K7>G)$7).N%YD)>=K3<DK./
M_WBA'.Y9[!D@<2FED;:+I..K*^D]CQ0[U@/"@EM6-W%<UV273_VZ+ZC[J_^7
MV_C3WEJ8%Q<?-355^='!E.KC$93C4U+ZV>8*$ HSM''Q]+_Y&%;3V3$UH8NS
MV^3C37;3-VF*<1Q_KZJL?XIKX+K3N4@:LL(2<WLGM7!)/LKS9_!\\9U!7>2@
MYKP.=J27.$G2P+5P2]]/+,_$<+;+P24$_\GK!UC>!=I,R=NAF6KFFCY3.(:^
M5*;,I_6UC8L'I;"MU>N'\LRT_*>38 D]\J6%>9_&]B64YU 7L?@B6F1!+,5.
M%]E[\OG;%X41*X\13@)OEY32M%"4$2 IA_59DA%SVY]:IT%WZ3C>+B2T\L7L
ML>7RY$*'SD$WD3L&V)J#$ZD] SWD%2"F#&-'&,FR%):%\J*]%*OJ3'#DHYN^
MXU>?.9!0MC/F &#+H:D.3@TB5;HL3$ULWLJA9/PO9 7#7VU_U?@)"3G)K30U
M&VS4.!X%^(#3*V2&H:.P8SWRL&S?&7[CMNKL:BT\.&=?VK/<[P0>$5%=?(PU
M[U]W1[B)(JL77I;WNWX9$?HRO-7(VS)[QV)':&B.^W!9-H&#P^U$Z@N*=GA<
MW+O"<%;!F70WG(8J[^(! ZV8@X9THNK!Q8E8 :4=$7V+A7FN(HU^>.X?MVH-
M")MT'JKL,+'?2Q\$L'Z;,',UJ4#NI\GF%L_?@WPC^[GJT7K,NGH,<'>*#7DQ
M+LO],BV0 Y;4T9$343O\#;XOP[HS5Q=1='88J#6E%"$=4*#<3S35DF1FL5Q?
MK19 A0B\@<W#:"*&HI%;2,?4M&%-B'J1*AQ876L JW@]YSJYXR989/^VZ\4[
M9L?5F*D)JP)A*2"\NU.W/8Q9Z1&Q_'$)7X-(-QQ5P\$O0ZM^SXG/:2,O?L5G
MH=*2GK:T[EJ-K# 1*7B73U:1S"0]#^5C)_K00TC0'5@CQK'UC"UKD67<:T#S
M],N8EYF"/"H!11M72O%Y-JX!?D Q&RE01_GPFI*8TP1WDIQ1/PYG;#T]F/.X
M--Y00':E1MJL^,>^7#_^YI-%J]8#&PM_6O]33:O9+%-;V#NU6TG$7*082 F?
MA%[:+&X;AY=^!X*[3K-X8$F/O>!VC2;PM<Y?"4MEBI9F?<2_9P!UF_.!05$
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M]G\9?X+*H.?<$,!&GKOFMYOI,E;/R,C=SOEX,B = ?N?[V[,-I'^'."_ K@
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M$NY57@O^+%1FCTW=8O$Z%+<X4%> #@@E8G#/R<07\X;XU&F;VJB?)53XT;Q
MYR6H()FMW<*;4L:I)1O1$K&H'Z*6 :8RA;)J1!.8>6R:!2I>!^$C:/0QY4P^
MXD85*KN+B>E/[KD1[V%3WFLG%UY8!\OR):#*%M[LHV%HXUM_DW%A+'03XQLL
M%B?'@J9XDA84#>?+ 9RRN4"M[BC?;^\F(QB2*NT[-3\SV?+9*-TZD TCE>T5
MHTE9P(*6?-8'QV&QTIJ'WTW0SSM/?/A\0!W3E M* 4<\HW64)(%]?G:A( ?7
MTJ*/)WQ[@I/G)VH!PNL/U*(+>_G/\$#=SU0MV4AO8G@W_@3H=>[F.OO@!Q[^
M&PB-_PGE(US$ ?X5 ,[S-UC*Y)^Z$Q&Z!9\-M2X;5;/XTM!</GAFX%TS,,]Y
MXI<U,IK:;#?EM10OR=,))@>^0O>W5O9".CP>_"W9;OJ:OW3I7JH]RB[NNOZQ
M/[AU#1I7@-:F/\!U!5C=1@U0.N0U6OSI_.E7@,3+UB;P__U$$ZT4*'L%&,8N
M6V"X]UO.)8-D"J/.DQ'0CX'2&"'D26$)3TPC6:"@&)D3'@.R:]S_%13F'3CK
MY]7EK=!AP4:)&<(1=?_CQP"G&7Q=+7!&]&7\.1N&[.M_>MV_H1GTGY"+.-H2
M?0+7)-N>[4=OM,+(BF;5/-]>OX_^EL^N]O30G(9(7,V.Q2V0L@?B"A"!8YD\
MH.-N&.?GJ$^Q)&3W>=9CS_W5^F*86.V/G# /0"W!K4#6:(<2M"W?\5BYG?UZ
M,,(>A'Y14>=%K9S8=).!+RME4_0U\0<,#_KQ2BDXJA+S#!U9#-1U'-ZR4JZN
M0@;$3"(;36"NZ6MO?R^D*)/--AW^658U0%Q$BYIJ9[L),JQ%KZU\2<IH3G03
M]7GK;&!NY.)9&DE^7OVH:ST(_O87I\SG@P& W\%?"IB@#W!UXA6IP!%9F:BE
M[N9;ZD:><P1N4FA'>)[GK'>89BW^-Y][<0&E$W]<=Y[]QW4QU]_\N^_P-BVH
M0&!+Y%R'<ZF%R8)Y:KH 9'<W07I*Y&F[4E""L*;[,X:G8CIP6&<#^&-J?51M
M&CAG>]:F9\;U&**N,PA+9F03??>K-22AKY/I\( >\P ]M (A=>8Q0L$^E+];
MY;T"-"!KQMVY0E(\P;6995+B%'R)PV!;S9A%NJAM&3;$>GK1O?%FSR443Y81
M-\A*@*..*+Z9R)/W6$_NS2:,!RIS.N'?V 3Q"3APR9 E37&C*L]E\@F#^D,N
M37 W3\(=F1OF_$F8G-(1L#"_7KXP+70&^JBSF1J]!S]@!6JV'Z!\-#-KX.Z*
MK:/[K[M6O\/D/09]_.)2A#JO #/)*T4Q($%G9H1W;+FH,/].X8*QN8F"NS)2
M"IN+?/KK7/-)V5;';'^2X,#NFC5T=/_B_G&+^O2V7GDNCT;F0G7##CK;8M9\
M;JFURD23I5-@5.6K9':G3D'6$RXAKC)[R:JO>.BI:WI VF([%!M(COP^H[[2
M0CY]/B;6X5#J4#S?\<[D.Q=DU8@%MPGYTC*3C6#-==M8W,'AC]_?J3_KF/V$
MP;)I<T;J>*YO#:K.E7D9[#B7)^\$^%%\10F'FBXG.YF9QU\!\&285UHZHP/H
MX?L%7@7 /"'*A5;=0@A?#\LWY^SZP_Y#CR% <L]+NV!I&WBQZ"UF'11EYRVN
MSHL$F$&XDW_Q@K"R$!/'O4C<J>QG*  ]AW3MR;HY)BV%<(I5AD_,;?E!&O5/
M*] :GG$&F9T6C4O>YV0-7 S27K1;+93-))BW:(>"></-9@DD_Z-YLP'@,OJY
M5X?*7+J!#2(H)^N&I('/:: >$QFCY%BFTUPR/,IXQ]77PMGEP-_(^"#=\AZ_
M&E1KZ07$I[\0MM:,"U2&7C.3_FM"N38BRN)J_%;6B/KWG,(5 ,PS_?AXP%>S
MAV\HDKY#7CC3H\.<QM=:,AIX,W"IM!1 _BR9K2]T]0Y3+86PFQG>-3$;NF!K
M_!\ PHSA57LJ:;7C6$XF%.5XHG\%N#6Y=;@Y]/*UN_Z[*30>G!DKU#KK4H3P
M?PB&"_[\^*5TX<5Y6MG/\Q>QR345,=_A\H-$?BG Z\2&DT$[=1B7ER]*(OEW
M+!W$1CX"_P#,\VN J1N4G) ##*!V>LS)1AJ?94D@!?*V]2OF/U*&E6?;PK_:
M[>7+I;Q_BQ+I-LCTW5R=JYSQ%;HW7-R38GC!&84"_T%..YSR%0#_Y&\<[0J0
M7"+W!_RN -<N^0^PG_BEM2=J$,U&C@']7U1N6?\[7*[*WG5J897E4"C_E26"
M%,@^-8=Z%21> 4B:QLZSU#XM79.X?,9NM]D@V<]YC29_P+ON&KS_&=<M_HMG
M*":8?0"E8[U&DK\_A_\_J._X06BS,&HUFQ9DL#S$M.U']V/6]HM=L<G"9OV[
M6HN=##T;&]]O@](5P20[SUB'_FFPAC@6-PJ^6R,7PJ017D\7Z52^(UDV%6@J
M,:7NBJ_@9".SNFNF%;?"TL ;8^5!GH!7KH"8VO.0^U"=3;B=(12>/\%_DDF(
M_HYU%?Q-;;+5=_JQGT'WS9'M"0DQ6>B[+$5_^NM0#Y6]C>[/,]F2?3R2/_G.
M>>/RA<IH[QVE2\:;E,Q\ *T%0SORLCYYPJB.:_UK"PUO?EA?63<!$B#:337(
M=H%1FZK72LQ1?R)E8]5GCSA[<GC$E/F3,8>2N!9;6],0O9/)HXK42$W+Z,Z]
MR\IP)$:L4J0\7LZ?I39087M_Z=VA)<'J$\9?8IMRI'*.:E> *',))&MJ%F6:
MR@A($_X4I,A:Y :,>U4\S-?&)'3O]4#P/KWT&R^Q\87 /C92H;>HN^YHV3D<
M+]FGQA;@/H^R\#>(</6K2H(;W(E+5#3,F?':3C]&96G1.L_&I>7\B^Q33PTD
M;V1<*'T>3M5RLL>9;Z9XQ+#=EU7A6=N9#)),8W_(;4UZ?K1\!=A3\T*Q=3=S
MC9Y04BH4.GB?&M07IG@1C:GSGT["1F?4-CB>4?U.='E=$#[9]O1&<RB7V/JL
MP>X*<D=ALL;91!,Y[FT<7NK+<C(_;#K8L*;ZJ@,@2TL>,SA23++;65DABG?D
MU;*W QW("\A;:F4R!D:=SK(XDF@4(NA'OVAF85\ED52=?J!M*)RGF5_>[W9:
M:&;$^+6@HU%6.LC.+/IDI5%.Y$E<DR78XWW\O6W3QXPDWW:U@F\@&%*D\6)B
M+UE!+*X4 ]?=O9W*7K375?'R!4P"+S1//(;([?Y:?+^MY@,JUDD^&&'4L1,;
MOCV31>12IWB&M?Y%QQ;*P79=H -+)VX7Q_YS%K_J,0/C>I#$SB^P?4NL9%$;
MENNY&9EBS>0)Q/;0!,C17.\$I.*HR=C6M].SRA:\00JX_"W2[315FHA.0WYI
M!S-XJGC&TV]NE1DJ//D9R63$:;\**%\#SAC:&'U:/F0(25#)H:1&%UV:MH2*
M9N,[U6N&L8_OG;A2@MMU_%Q=7ND8.YS7&*A\5%H2=$D.J5%12/X%54%;HOQU
M41N=!Q]Q=.,@\5E"6?K4 6>;#+A-ZNG329WUE.?/'Q[B] 9WV3X3=,F98-,#
M&=%Q^]TKVL@R>G?#>8&!RJ;.-DX;E6'V9Y<@R(^NRS)?ZYQ['@/>]18AHF;T
MG1F3+39O$QPO^EIA9R]_OT+<;N</?B\>X1+DM1XDOL6PIQWPT.$!0:LL)6[D
MS((N\)Z3.7,S<J I*R/1?-&!7FL^_5N&%-]!19^MTC.JF#KK64T6%;$I$#FZ
MZ3O(T)5)$ *O139U?RB7_53K/E]V6$GR-M'\>?KKW]R#$]P4-SPR:@IQ@]D4
MQ\Y@_<DRZ:<LJ27?%^ZM+0PTC6^:OT@;9,!#1EDSS^@2>:^%&)C #V[8-],T
M3+I4E])491LV7@8<E3X6&:JP6G37H!B7__"A"^ \HCIZ+6L%4&I=$LVDR!LP
MB,,L>?/]QJI:!ZM11.J3F%6*L%4./?\D?X(@39JAT&9!,!OH$;(HDKLJ6C-9
M?TS@P'CTQL+=^RH=[W0^)(A\:"U/UAZ#U/B31?/]"CV%_9_BKO0="O=?CR5D
M+=F&,G:5?2E\R9)L^69:[(.QI+(,91V,)=F)*-0HE*VR)6-GF :###+6(6:&
MREAGDC$R='S/>7'.BW-=O]]UG1?GQ?,'/,_GOJ_GOJ_G\]R?DZB;_39L^2D\
M2S.3P0+,2#M:]L.J>TB+][-^T;'MKL0Y>6&Y=*[)ZS8*)+:),:[\?U+?8^D_
M*(Y5M!QR4 >E5AG[$8[<LGM8N2_IIL CPM_8T4"VO_VJM&']>+TZ+7C#)K*&
MY4DP4C)2\_-[#;45R/0_Z0XR@G[V#,[9;(9I!=[LR R:C_;N^@/H14L1$%[D
M _,K4VJ.^U<G9&("BNYZ<^9^P)Z32=06\G$K+J1)];AJ9&^P?'W)'3'QPI Y
MM7*G:H42U0!00947K.@3HHBQ.=?_P/0,;?GFE__N=H-S]T.)0=OD^+XSREC'
M!="C&X0KCM.2%<LMUTXW6%T:@E@MEUX^\\AXJ;6>(SN FS*Z\5 #FY..K'NH
MD2+SSS#3M-J@3?P72$H;\GCE8T>UY+_A22F*C=O\'!D,L 3K),TJAW6K')X#
MI;$DLYO*_P!P%00;.9&]1P",LTI"CZ8@#R>[9H#R(;"(7!3 ^#V/%DU<LT^<
MK16CK%*B,BTQF(4S Q'L5FPS8M=[V8\!$*SNEL@TW8.+$LHT]2+IJBKNCLG2
M1[>>#F3T>:=<]S2^KJ8T.P'S?,];?-\B9O%3?%9T82\4Q-PW1=/F5DXP0R .
MS5&;PBY!2R_<DVK>7BTUU'=[FMU*M2<=Y!J?A%!='5\6\S7M*[T(FRX8FM9I
M/"YQUG!^L-U"5B0PY'/RC2PVC\?E3 V+L4ZSFH "L>/![]?896-#:GI'OW&=
M7#[U, $_)HAB$^\5$NLC:7"NQ<D5<[5E_HW*H[XV3]RW?\DQ=X&$/GU0UZ32
MG;B@^<\WE$Q(;(QI'D]WXX:&JZW?X]X;G[FW7#@$%=G0MQ(%=:#6_DCWRJ8J
MMQGH'"[2-U3*0E>XSF$LZX35:]'OT<'K3;1N:]H\\EA]LD^.5:ZOBYKD3_*4
MF5PR;.])@:S#Y:>O$@0Z'IA*GWL3-^?Z;@KU58MUT@O0U"D6)QL 81Q,C(:I
MY=>:9465-LQ';N@OU<:D]FQE1E?U>5&V-H(%0?QN*\A>I/?L8$CCP T'9\./
MOF:RC<G*IT.1=TKVU1%JXUL(O4@8F<]Y$V%D0ZC0^7LX"7TP[COZ,I(U^_0!
M=RX^TEB:%I1)-JQU7;)IL#5H@I3%1*\,(Z@9R>I'%!81U-0O%6BG@;),4),_
ML!H9T4XIL$X3KK+*]>8B^\X":EF!0G%XHHDB^Y-EG=N;*CU+R-U5<J<7S0HC
M;4QW?$JY%H.E^4M.%?;5SMG(B0('^-]CW-C9I!YB@!*Z;-^E90\JZWZ!<FI)
M<U!>3%0E7YKNX [/9H2'3:2JMJUPC6_$L][;PB,&7OTZ[HOK^W2?&TP<*>95
MJ,/8-+9P;-7IHE 5WT.#S*'8;IULONB-@='+_K$:C"AF3!D3!Z8[M*3*2\M\
MR!QL01=\]W.WPB>:M_%C0P'K? !K3MY5EC()+][#T!.+/I/HQY@6O[E@*ZFC
MZ5=N$+F7OAK/"YBKBZ&(9\G1N!_NC)[$<[CA*EUMPKR.,.*D/QHX;>YPP?W\
MJ#LA"+5QF6C8H?*6""S-#\F3YQ>5'\L T$%)):"=X#0T@'ZQ+9;$S$EG7<IA
M%E C+SN\M&''2V2[7(8I.G.- &1VZOX 2/&]AO491T:$94+I^&J@6]1E)YX'
M.?MMVU',!<B[U?-U-WHRGI/%1@-AB^ RM,WD@R)^XX@)V\%Y/>1K:!Q5\ _@
M&4#O[CV NDHUK2I9MX2#&3=J/K8^#1ZOY5 5&QC&L'GC"A1VO*,NK7!X9%S5
M,95VVK^"<)@P%H9;XAP::!_HY_%OS6!:!6$94E<B^;ZCMUXT%+,GAJX8U-^R
MG"_]-8#W8;9@VO6R?T6,-ZV)3(0Q<A4U#;43!S#/OED;G1 (3!#Q#/O/3!*.
M(;0.RWT"+16 YB7 .M6)Z!+*&4>UBULW"\C"4A<02\N#D3[9 (F="\,L]H.R
M8&-5)M9I;+/3 /9FUB)PM]UM:MK2,6]6^1Y/_M6S5O/E">593A^8A1BD7I8@
M,CQ3I.NO<"*4N'D'>CYLO^YB;IXVW,@1]#".#ZY"KFNI63V4'/,<;SKCSOH\
M6)9GN1#:P0M,LQA4]@=HAQ[=0;#_*6IEZ:&X)7(D]G%D'\AG/\9O+"H=UNV9
M^_G8=0@WAZKV@_'.Z$5&Y501J78Q78G6E\=L%O!#F!P@"^L"B=27YUM>^GS]
M1EIFM=7'T953?HV*KS@1+S;>E7Y=L=#KU=K\'/%1=E70Y'F]42H#PO0*)M^E
M4>#N7!FTYY(3"_-/S&+W6X!Z445MVSJ=\3$B;*2QN(7ID_/8MWA2C#W!*QVV
MXU>&#D:ID;,MKZ1%P>'=$9;?97[JUVYH, ;^&?3:U-9!XP<%'RZ@QK=\FR9:
M7%VQ]]_3!PL<(D)JN"9O:@OIUT,>,5R93K!W?H5TYL4!-VIS2O],X;/25#\W
M;7'B1HI7%R8(;#3YE9L1_D\_*5^.(!4-3%RT%J>^>\Z_;:!W-B1/_*YJ!(.3
M)*B5 ?@5-TE"ZQY4!'>JT!=P&"UF'-^K4Z.HCUT32&H!_$>;);RS-?'$$/N9
MW@]&=(]=-^X,8W:F4'^<=FI?-"[U=0>=4U/J-OJ4K13G>:<GV6R>$LDA>NIP
MN00C<XK5QHMP$E2:F?()S$U<H$;?;O1KUJND9:9KY/HH:._=5K#"WVC5,I)6
MN?6INRDG+;SCR.Q0=^-X,A9@4(_6L7#(2CB T?STBL3AFHR-+*SMFRG'NU'1
ME5W0QR/QN=_EO6_?2LMOZMO9*63$#C>"=?:>D#1DVJ0&'(83@O6!02H0,Z8H
M"<SO)PTBZ"X*86&^I>Y-AR^+P^K&YC5ERU6'76820]Q>CG%'N<7W;:6!:-5Q
M4FOHLV+Q1*$J4VE#J(YG[FS^"3%,SSQ6F3MKVE-%KQ<M23#R*5V\UXY_%IU2
M&'LRA4(,W,@5NOY@E&)P5&H0C8!L6L38=)J%DJ]=8KF(M:.E)2$>.BY2C4J3
M\;JXCKOQ;<@&4C"QR)%>DAXG2<5A:GU\*$60EK:)8KK'V2"9GGO>-[:[C39]
M;R1JX2,R]]40FF"^H]WJ&ZF76?S\V\1W/WQ$\_:VWN;V?T&L^Z#&R;8"(4N+
M2T%+0,X(\GF1GR]GVIP\.LHWU0D@D![^"9?M[3%N'PN19VRD.)V#\GJ$ 7V!
MT%.&;=Z-/EX\#49/>%"3UBX-@Q5BY&8<GIP_,>L9 A<E$%FN$V4'I29D-[WD
MD9*RNNQPJ5@/&\*!3"K14;]0T3[LL^?3,1_D-%VO)YB-B>W/A;<XTG[I><AE
MS,\ITI#.,[(WVSZUWL2X)!S!P8ZG]I4AN3M5MS; ;DH-16HO?N5U\ (6MFTC
M7]&\,:<]'!DZ8@?N H1-W+!! @+')=Y$\HR+<B9YU*ZK?#9F1SA-&)_MHQSY
M)@U^C63U,%A(K.XL<-Q%0DEPCQ?1D1UR.>\2/KK)&QZ*B=9(J@N/>2R'4:V<
MK)<^W,E]OD=HUC,8U%<^PW7L2+!:B+ YV7<48*^UMR6.0_;>I+]2\SPO?8=#
M5J2!][A1B.F/IU %]T/B[\F2)-0E.%QP1,#N6WW59*W2A. :Q- 6U>*9_18Q
M&"HC<[]3.DJ4(1"54KNOP]*9#D15VVX=GP,'5RS8QM]+\;,<K'AB*ZN@KUY#
MTK(<RN,^S0OXE2E5@6Y,_&;F@+SPA&."7>?@WKL;8KKV%KSO-0$KQT0 J_];
MHL.>. /5VI)*F4HR0AQJ@9/_ &@Y7XO,R*?@P*;Z"T8-LJB]ECT(J_8/0&E]
MM[[N'0\>@+A<(GVHNM)]"A4LZ,=PG9Z1.QQN1HU=.."RJ:__M0?CF%_5<UK;
M1R'%ASZ&#9TP4U<1PS'2F5L53,L%6-"2RGN_OZ2K0VO-R0;'Q^3:V@ND/JI-
M/#5(E[>2^<FW7+>@LI45BM0R!?%2H2A<?TQ)IK'(%TK+?L3#\ !_G]8.6E_?
M(W^Z?LEH.X\Y2@!4".09KAYQ]IH0A-YB8NF+CK2X=*4NBM37BP8DVF*:>CVJ
M6\"&SP5W:1\;'CA47FAQQ>8TZ'E6(GM37+IW5OP1.WM )[KOU6?'B3(CI=L$
MRQZH5[\/^ OE&OO26'CX.N:N0C7_39/AODK><L2+8++*9\>(5W1SRF1+^M:.
MJ+M3'W%=6KX3_?%+7=C:\S<MZ2@=79ZL\G/I%7OL+TFOC72F5U)TUO:^9 "8
MYI^@H#A]^-#<58(NWAD?$%L#<06)X4E46#-W0W' <V.\+,>N-DXR'0PR)K1.
MAU- Z<;J]$),?$+A[U7;"G]IA>D:GVGO%*#:1P??7)^S]P<4"LX^]-AO&)N>
M*O5N1)B17ZGT.9Z[6SV#?0NQTHT\?GJM5;6A%3X?K?TQ4<C[+,=V%>[0A+E&
MMR+K_E:JCXD77>BH<O9W)% E=8D(8M@? /%SD/="JBH_/.+KHZQBL;9N7F8W
MI:]O-,LHBB)?[Q==VQNM.)7O%4(HUW(S>VMUS]M!_^:=65E?G!P4,;UZ1T4'
M0NO/IX __ 'X.YO'J0;=_#ECUY%T2W;(FGOWV4\A'U-)[X)_G5S%)H"PHGPN
MAQ+E>S\O>=&!K.L7,F5),PCUZ8# *8CE3]X_@++ Q0[\=ER@SYGJ#>+?H:8@
MSJ^'!.CIN$E*Z_H&D?*;9S.)& IWA4^;Y:IS1I"NSKNG7]]<NA2B>>S>&A1T
MJ,T,8IP1=YTLL6MLF@K: /4Y+O C?RV(9.LE+JXW-(L81+J3MEO>7MA5/]L'
M0/!THXY,34<M!$=[I:A:\2$#_'%FL!2/'DZ7=[[-X;?-F3%\M?$I=6P2"F1!
MF(NE\+H1RE:OWGAS9FCU3"\,H;\&>V_=3%7L?B$<!%1\83:B/Q(*+6TM _W0
M9:-!T]'&B"#:UF,$D-SP;G[UEK_8Q3S_F_^\_BY;%#U30 569'OKGWX&V!EY
MX%:2@%9G.=-:4NYVZR&;R][B*B$0?V/9B3##ZA>J'![M>-D6JHKE<R-^4M8R
M[X$,;@\O\?LPC(T6S-(5QW6!K]BN759[34 --AU[P5+?F_JB/JX_YW/"<UO>
M>\X2# 3P;G7[@=/BM,80,3ZAKW4;/&;@QFN.!-5>#=U0*% ^:S,)M!!HY8,Z
M"%C[VQ'V!Y 25@MV(C1!JGF4)E"4[^/4PMTG6U*0@'! -D^IT$CP8V,CYI+:
M8?I;8#@,ZDB[TWB)B'Y:><U7NHJ=6%-\JS>I6F#8/GSD4L";@_P@HTAR]VFF
M$3QQUZ7$>;+3[+WB1EV%:N^%\H(U_4]M^PV- )[3/J*_3^74_W!IA-^U;:4?
M0[>I)0G[,VA-G7K9;7GZ,]_RP9[6WQ-T4Z^Z_CLIE7P,W%.7G!Y)V6:8KY%F
M>%$\TP:*/8R<XRK9#IY;/MR^L]'1')JQ2[1#L='NU-,?>3 ?D+HD35).,7'6
MM&L3[4E3T569NBI=WC'I2_+KC.O]B^B,XS:R'M"B,WUNJ8SD@U+YJ1\3M[_D
M.5_[.ID4!SS\]$0TK/&4_ O,X,%WI[%?(P&;L6^RKG/_F$X[(@PT*SHR 56-
MY[,O@@9DXB#X.S\P>F+G[IY-=@]D: 9K OED<^VE-06C:K_&+%GA'M^RGWR3
M846HJ6POL<X>(F!_ F65[71J/]G=GQ5^7)V;'?4=O4(T&2P38=NCDTJR38!A
M6ZF2Q64::3N&>$/S+ZB5<1N$TOC7>?=1E*W"8]E;:=EF^H'A,K_J[/X EC3Z
M-8 S?NT%76_]UQBO3I(DKS6GAXIVS=-7K5/,OR6?4\[?_O%M8$4+6@D_ IC/
MVMX8-P99M:%%+P-/(&X)Y-<T+KI H)MC4MA3#\O+%8^54U;HH3_8[3 E@9[3
M;ZCQIPZ5JS!"CX/KYV-;W&D[1UKBCO]]ZIW>]DMO!IQE%$X!(P"/6$;;4"=/
M>Z>()XNN>-@#87"PML1RAEF;NS6&4[KTD2F(O[NW)(,H^<K0H@.YA2GX:%9F
M?D\W7:F8 @SK?U%GL1#IZTLZP3.(,>B#ZV%C-#+_*N@@=?'UZ<6=>X25%"<6
MQ%!OMX-1N$B8$:8B2.L;X)$J7":L?A)VROP#;2'7KX):T##KQVA(*VU)\I(W
M^V*Z?H[8_]BWGNH4'5065!@A_D!79^[SD'66YI#5?2NN!'VAV6J/2028)H_Y
MJ[A%'O]NWJ]!EV"S6Z[?X[-IRM6E7=K0T$(()*%0R6H;I6:G;USI<!#A!W![
M'@/__\?D_A\7Z,_L?P!02P,$%     @ .8 [5R-.B76GF0  ,K<  !@   !I
M8FEO+3(P,C,P-C,P>#$P:S Q,RYJ<&?LO =44]VV/QH$*=)[)R!(D:+TGH!*
M%T%Z$8*"TH2@M "!T)'>/D!! 0'I1:1*BW05Z1VD!:4'$H$0) F/[[[SO^_=
M<^Z]Y]Q[WWCO/]XX*WN.9*^]]UIS[C7+;ZZU=\[GSE<!3(:Z!KH LDL  -G%
M!W"^"+@-(+]TZ<_MHE!<;)>I+U^FH+A\A8J*DIKN"AT=[15:6GH&%B9Z!F8&
M6EHF#B9F5C9V=G8Z1DXN#C8N%C9VMC\;(2._N(;B,LWERS1L]+3T;/_E<OX)
MP$Q-AB='D)-=!5QB)B-G)COO P O^+Q,]B\%\)="=NF"1THJ:IHKM!<G-#$!
M+I&1DU^B(/^3ZXNCH1?' 13,EUF$9+4I6>\_I+KZC$TN(OTMM?"M^FYVLW&,
MB/RCYY$T5S@XN;AYKHF*B4M<5U!44E915;M]1T=73]_ T-S"TLK:QM;.V>7Q
M$U<W=P]?/_^ 0%A0<%1T3&S<B_B$C,P_LK)S7K[*+2HN>5=:5EY1^:&AL:FY
MI?5C6T]O7__ X.<O7R<FIZ9G9N?F%]90ZS]^;FQN;>]@?QT>'>-.\*>__Y2+
M#$!.]K_*ORL7\X5<ER@HR"FH_I2+[%+@GR<P4UP6DJ5DT;Y/]? 9ZU6Y"&JV
M6^EOZ[MIA.7-,.R/GH]?X1!16+N&_5.T?Y'L'Q,L\K\EV;\*]G_)M0"@(R>[
M&#QR9@ 80#0O2A '_$/4Y42L1;HOZ>&"\'&8A+D='L>L-8<0*YCBT+#AU67+
M#S%27^=Y]2D.HQRXB'4$&BSMZDEJARVFO>]W8/Q!AWR9B1]&X[GHH,438VRK
MWISA,1_0#G#R5?)P<%4,?8+UM,.V])S=>$%BQ[00A N8N8LFZOQHLSE-6[W"
MAUCU^V3V7 5]GC-Z=">2KFAC/;6PI4V(*KQ)ST)9+U&]?W0MGN.KN]#4X89<
M\55NAL.FY_H/7"=K &'9]R%\88N0%H9W9S*$.WCG8G><6NA&0>VWB9V5I\G?
MZNVI=(C+,V3VFYK:VQ-5I%E@2\SH)T3B.8!.0VAM2V%8=[&/D7^D0G.A0<$J
M0ZV2"_>^V\GF1]1)L"G5_)'UEX)&/?3#]5 P"IW3/1H9QE&/U>OCKM%!$W$U
M0O;T<N3C)0NZ)F$=+CX&EVK@3/CTL[O;2#8O#6%LX-I^?+E;R_N.+Z@5FA&K
MF:GRD7DKW1_YX0]--%PIPT$5?W<X/H(3<LL2_:" 7<Y\R@FIXQ7VVS2>_" 2
M5)2[Y,CU>ROP15WZ.> )=!&"*NL;AO3EMO29T,#,>X ,';(BN+;E=BC\#"W#
MY--NI_O](Y<4F< 1V<DU]IYEPG,,QQO/M9"\ G;WL6Y4'//6R"^F&R^3(H!\
MLT(HZ*+Z:EQ4D^02V!;_JM &,O^=F(&:,8I\G."X\Y5,>'=R.5RS-.&7/61A
M:!5]DK0'%_/"\O:>" AV47M5KW4PN'R7*[QY^EQ/9R2T<K1O= &Q9M*]Y+VB
MARU(.8(R[K1<X9;:+R.NFH^_LN O7GHO3C[E5J>,K4,#,8-K,UDE.V$BV)'$
MDNV%1MT0VH_[<5E^X2Z-3^5X,;6+O6'"DW!(X=RNG>8"Q#UP7 HW*QO)<4>3
MRX5<B\?BO@Z [3\CZR_@QA/T9 UI>!G<B#F$\\W"C<I6OK!W%50O+E,_['CS
M"737:6#>29]K.*0ENDMF88F@,@Z_O^YY!^\)>LOD[C?*M*Q'OJAZ#LA^.MK(
M01 G'Q.O'D<9BVS%V9 F&TA?F$]+SP%HFA]/22>OWK2>C$A^/@>X01?R>L\!
M%"!:!\+MR92"=5K]C10NP0_35^^T2LVIBY!U"U< > "X'4G.[GSQ9FQ93&/G
M\V$4[$;-A/^O)[86WJ8^W#"5;4OOL&LPPU'S]DE7K&XB9;%;^[ZTR-1#VX<0
MZUOS]_=U 'Y_6*N6P_4Q^1F5LUUBX]7367R\R;>XNJW/XK*WEE+#IG]]7\&8
M\@Y#>Q L!X1KJRK^1/ONWSONS-O8W?0G.!8?;^V%FYV4E/LFCO2 T%0=7['!
M!<?4-0=U.ZPF.C4F8X<MT.$>3CQ#^3%%*4[(@'N0?0/9B$3+>V& :_?RUD/%
M3)JPH>]P%9YENH)(&E:IDE19%TN?9RE1=36 D!CV$0\D$T%UK4J=YI@88C1F
MO"-Y*S?YR!0JPL 90K\48D5@'?2_8D27*'6/7++X4C7C+>I=+9;[.FR _PE9
M,P;5>6;G2[O7"87<8-3:X!JW=*@U@!Q''P,$$@>":E&%'0T)I!FCH!R_YW3,
M1#<RW FSPZT/O5>'>.EBS=,\# ^'EFQ)/!T-CEUHA<CY[0U$&QB)7FX,XX%K
MYZ#HLXC?<BURS19'?PYD?.5_H__Y$94A8*^\* $@7CF3^^;=V=?L6=E[6*5Y
M9CZ.VUN]Y02/X?]0.>'&9T%XT,I  ?^%/0^#32=2:MX9H![)K,+HTME.Y8!)
M7L>C[)L\*U'%F L5$SJSTR[9*NTU^8AAV%IO;)3M%8E5.6R\OEJ/.ZD;)]Q/
M . A))JU,P&"(F:P!T%.,$/0&2Z#VNJ#! Y,<ZU_ 4-JMU#0+(8QU8%0R=5D
M:*^:R+(</B,7&D5XYH\MQ\^X$^3+MYHG0G-%.*4,,F?SM6GS7T= VHGBGTX(
M6^2'0%1!-S$$ET]\UY3* "OJ7[E_P54O6X)]=O2I>^47 2-)9^_5/4:!K%4>
MJIX;W' [XNLP,;@%-O^5OUA\AZ) 3M$V6<UKPW1;_5B'PJ0,=BT1_R]U\^7P
MP+6JQ,0Y(2Q#EA3NGG!;_(TB:>^^5<GD%0FQ^GYO";K"BL\:D?2 ,"\([*0/
MV,"()BN%PZ8U)*OPF6N#?8RT<]T5R]L!I?;),JMZW.ICZ^37U=)?M_C('XEU
M(Q:K3(AO09*+,-]/70"LSCD@)GOI1Q?6X?A]4TM3&F.64LORZ+W"WQ+<=>6O
M;M,QIV^YU_>EBUN85JI=YF(#_!8O"K]RO2:_S+6\<<C3GW[H%NE!$3<[3KG8
M"1.:;%=X*4'\K^AZ1PYNW*'?XX3YVK?"1I^&\'TJ,\Z*?H#-A6>_=.%#II!C
MLQN!W294.\NRQ.QS@,<;3L.&W$VS]MD;7:/>+P*_:CO'\(^R__:TO(,+"*2%
M;FC3'3[.EOY:32IA* T'BQ&N8>V-B6^/"^9]/SDRU4_7PO56A_IS^IA,G$6,
MG.HKK&3V;B(8-QVHPKO88)[]-6>/=MH.XJ2.C0UI7Q4W?NQH8M$0?@A=8I$K
M$^2K4_P=!2VS6QB6&EOL9_OP:S\]QO5WFBK!0]N+Y:!/7YFX)W[:U=5(=LI:
M!9?&;,:!'R'G5_IXH'%>TAJWP?'2CUNGWC;2^@NYAWGM4Z)N4E$EK.3U0^A!
ME^'>^'4J-,WJ[AMG!RS?,"BFPM%=&IZ3_>VE3>%3ICB5TUC9E"*DY;78!7%
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M7)YH.%@%[@S%;/8AFPVW5QH==NQAUR=[9J37C$(=-XQ"Y>[V=3ESF%'N;58
M7F\65G2!MPLH% KF2#8@RAT(%+.*/4Y=Z%GZ;LQG_O-#^;6SJB1G*(5OY@Q2
M%^Z%R>P&LB@,>:GW.S*/PW6</2,N=Y65#:K=)JT^5D=<N8])_+3>,[/,<PZ(
M5M<&\3>G/XDR4'L*?IR@HVIMTXRF8X0_"0<+DR1M'6$YN')\B49@*&:&6[HH
M15H.F-#".7ZGF1<<\+0CDE/=!]&9F3XUNPS$&-<Q>)"XB&]6FSJP*<GKQEPK
M=W_K;,1K]KW7AN8__+:5HM2U2L9'=^4DE8_ AJ'JFY<&]G==&=,PN%9(Z_V[
M] U[[QU-M@\95"V&.XTUHH.W)FOV%!95I*2\QO3HFZJ-^)Z5;U56 LCG3"^W
M_>F-_X>D4O<"07\5'P%Z)=66A"MP<O6+9U/P[O.Q 9KL>'[KN(_: K$L+N^V
M]4_Q7%[.9%+F_278D5AX!9P8J$4E.#MFV0-WP2NNK:0(T+=B3E[4='RVB8M$
MR<=[_>#G-SDZT(H/8X8[8C8'D)2+L-3>P+#0:J3(^]9%Z8ZH2C6<\''M0M?5
MR3W_<\!\>_\S>]N>Y@KO" IQ66@@X&!?\W=%74T7D* U0;JZ95"^/?%P@"/$
M%=P1<5;%>&$U7G"I\G<*!YQ3:[VH=<=[KW.D<G3]W*%LSS7B>:0R0G&6@):I
MDPKQHM84S%\G%'62Q%*2QO8YH ':71,R&(B+,U6BKH"Z %T+U-_KC[4XV23E
M]RKN9&T4-%I_&A;#)>$-:O"\UJT9 _S:[$4=,;<U.SYWKZ>1=_>2I7]W,:7J
M0S""5TOSI=]C6Z+-!P,A],=(!ECNAOJ39LR3M_([:A*9^WDQ:5D^<LI>)]RC
M[$A4P>)M7,Q,!Q2;>1=#%:7!'UA$4/WH+E-WK/S&)6-)&V17GD:9'EG_^1.9
M25, @NH<X'R02.+%%L2)8'.2X9=#UXQ9K\PLF$2AK0[,+;FT%5*IY^;(-\Q,
MPDP4%_"\.*,9@F3HF?:H4GO9")*EQ/4#<[^@4E#*'>)^V,D*,' B7..@OZ"E
M+HF@MPJ,LD+2=?"7[0!90"*+!AI*N27#.$GV^ 3#/6VS7A\1ER1QD1])?"I@
M+VA*%RWV)!G.B67L7F:=]"]@P*L=],D:EW;\Z@X1<;-3,H.\^$+!OMN]T7&&
M2\-K<^[U8Z)6G:8T#&IAO@/YM/+=KNO#5+K*"P\N&1@U6LMF,Y!3<JG;J]LX
M;;(/AHTXTF,+T,Y8)"JL#>[LNVXO?;L[1XT5]O5$-U2MWUO4(9[NYBI_8L82
M&5A6,!!PHH_P1B0N\Q'SC^I>.(I@<F)KFY"\CHONRW1C?LTOH0'+ D;9KAJ/
MGU>V:L8?F V=F9$F\B_AZU<A<04L<.[5=M4.ZTUJ16-1VV51(?#T.:!:G=^
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MQ\S$,$0%MY$R6A:>%%^1(9-MJS>C45$1R^][$JYJ0HWH-O!'>ZXB^SWGCRX
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MFKY: B>8 ASN(EVH0NFFKM:] -)IZ&'*+&91\FX9NW378HE:8FY>"9;O&;E
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M%/I')?A?U8HOKV?< _R8W2CH-<%+W4M]N([V["U@:51*U(^ZGT][@\6M7E9
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M_UWZR^)9]O_Y9(R$Q%^"W<L&W5]RDE5JQ)]4Z<=%!L4OR@,MI'S:4^1"+P-
M"<[#?"Z4_F8A+)=!?WFJIO0T$?ED#<F]F/],BZ$HE]\V(?9R3CE5NG;Z[>CO
MRLQI'S?9 #O_#[RL]/\%@4R()7YO="$"B6!Z?&_?[YR^8?N]<P F92M8YRA[
M)EA$?*6KO>T.R/Z.[R%WQ%)X@IQG#M9X-DGC&A9JC]U,K/$/O=V=B%(W5AK8
MU<7VU0^Z71GDR9E\1%RL>!7O'\@8"Y1@/^@2)N9HD*%2>7= ,FU-T^ACM-Y7
M3FNUL,Y0-U'F)$&7!,L'C'>=,W>M"G!N^!"Q9.M^^B)]?[* W"A[8ANB_DM
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MFO915Y)^M3N:.OW6O*W;\6=SL[=Y/:89<A8Z_D^U'[,=]%N2)HRM.Z#7[-*
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MNFE21)>S0?/^B8!7<57TBE^:G/N;\/($Z6VGXWXF,MK4"B/C]JL6#!U^3)Z
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MC;R=S4B]B:_#W_["#?V*/I/%:$?<-PDV%_/Y'-9)'BB<$8^TR?*5A[:;7\*
M$*(TQD3SLP+D+6K4Y6PK\O4K'':^33HH:.X,-6VA[3>@47=CH%5#'&#5 (K@
M$6N[ ##MJ1(U\G=)K:5=*.11&,X"EKV\4/Y)^MQ9Y8PY8O>O+:O_U?05>369
MU/:]#+K*?Q S//\?B1GY,W1M9S097,Y$",QNI@+<=?EJ)!)8.U*?+W(OGLFQ
MU: AQF_+D&,2"\+%O2 ->J4SF@PDUF@4/!-)2'=R"YY]S"BI?.NJMHI$Q[N
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MQ6)]R0!7P$ G$%8!3452A)AQ)79P@(-1XOF0A[8W13.7O4Z:YE:EW9[Y\)O
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MQ%CLU]/#?<UUO(4('SZDOPEGQC<EYRKLV1D8*__17]-\?LSYYZ-80H:_B0*
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MF2*H*^M#Y<0AE6/5B52!Y5AU:"E'VSC!IJ269_X*%3O74DR:IE=M^^X5FPL
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MSHZDQHF0[,V-@A^B"VC&3:"A?!G+$XY[-Y1B'U)Q31;!S=\M4A-?1Y]2@"\
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MM=(+-SP=(IXO+$P:6D.^*2]=M[:RV%:7-WBC)JL[&2V0["#$UQ^G61/O'_:
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M!]V_T[=7+@#,7MRJ5QEFVKD>9G4RV3$S7+_B^Q# ':1N/*#C%L&<5:711US
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MRYU/(?9A^[44!F1;V?(CB87FU3_>S#)?,@-?,X.$.OYA+U7Y]Q"@>*6%9OE
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MUK;VOOZ!P:'AD=&Q&>CL[[GY/PNP=?C&W\VM[9W=/>3)Z=GYQ27JZOH?O3
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M<$A?[2,/=_*Y5;!?IP]TH'I1V]"U]$V&>G+Y3VC"4J:4L4:CM$QNQJ[R.Y3
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MN?TOS O-><\2 Z3$D "-HPZ3N;/]#9O-#1>;7O\%"\(C;A(.IEU27UXUEE)
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M&SJIOK(U_X&ZSE8HJEA>V,8\$CQW=2TQ1<8':5( (%\[[V ?K*Y$A=@S"MX
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M!=T"606]'-H;CA[W2Y9,RL;K[ DNN"@(\7QE?Y/.?E>=8VAH5QGS%?NT(GC
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ML2%17TN7+@5Z,%^OHQRT:K:-W &S=;9GJ.V:Z,BJ+- *^^!C-FO->T9SHT>
M *D^Y/-]Y+[N?@:2QM I*[=C,*MWTY]UUCKEWZMEA_8I 9_JBO<3#M 'W?C#
M$W.*/,A/AX\[HPX(NV;YNQ49Q(C-[,[R0YI-+M#,'W]0\$^KV;%_KFO96<5D
MUZS@7ZUR-B3 M5<6- >(=,D=CP#_$MVT9686G,!SW+SDR8;3/RU2(,?BVYCZ
MMQ_2]1D:01>NW>L?X6X0)\ )OO5I]@?S"!VE)?":VI[1EOTX8I2XN79\.AAK
MT_!$'0^UZ/1+_5CO=XP'MWVGP%,HSO4QFC(%EB@7F69\EZ$ N-YD-F1B@/[X
MZBZV/J%\C8CCPLMOYV]J;R9/QRQ(./2>V3ULPUW%^]<-=&^=\W_)E4(3PU2G
M#^UU'P'.PE*SAX\ G(9),MNSWE@,YD#OYHVL6NFIDV4TM:+FZ4X&XP%[4]@M
MI]RJ6$.[\"Q. ;\ITV!-5Q>^\<NJ=V]]:\WEXWUU-S;P[&:SJ)\#1*]93[ZP
M<&D>/DOB4A&!I4REE\Z(U>C: K>C@Y47R%-E9T8D<MZG=&R45;9>/%BV]7YC
MB@R6J6>CCL^G7R0/E@)#BD V+ M)9GO(D::-#F%RAN2]@8^&F;8BG__& 3 1
M&2-=$+BBY[1YC4O1&/6N0\Y[T ?SCF:FDZ>NO93SL562>L9LSU%6 +]\3@69
M#_-KDDOG'2P"#7L4N#P/$['L@.%;O[>,7T8+WV[@^;A@?3/3,EFGVP[A9S;9
MM>>QL@[6*T#9%:<6B/VB];T-:.\-])K]BY2JZ9NSU.]$^WA,*6E3+/'65\GX
M< ^P2LM.\^B%LMRGJOF[(L]K M<?7BK+"]!HL'O.^B8:F^DCU50K1+J>-I5)
MVK<<WJI5<5+?LB<DB'Q;M^)\&,;@]';2\?0XK*$+6H*ELJ(UIQ>6B[&Z8P?Z
M&Z;80:DMOZ@\OX(OL7PG&(+O"YUG]^ 8M(;=G-S!H^S#+7PX%UM^D1H$ 6_L
M$F;<\'6J'P->EYO[]@WJ;2[UK1X!%)_:K-YS?+WK)-X2=4]QHV)"IJ@VE=VB
MJD^E5T='05Q1VU(-_Y**GN%A45GZ)>X#09"ZJ3KUT]P5@_:AKZR-L)8EY=I<
M2E4M6J,7F$Y8)'E;@ZG^%-:?OD]VPE9HVIE0W/K8>(=R7(,KCT3Y]],\VJ?/
M/?N;/Q;M;J522I;6'LRF7$K<7N6I-3.+>!:X?N:<1%3_6_QE)<T%H, 6\\\!
M1>#['1-J?>.D"(4Q4D8"8=0SY^-T:3KZ++N2'L_)B('HY=7N-\SNNB-F>J+>
M7\OJVE1J-[=D#GO:[<[I*,7J7YZ+0'N+5?G>4_0K,,ARU>G,(93.35ZBU$?2
MU("-G4R-.Q;.P?RX"S\DMII,;W*>QM4,E_ ^?U_/R$O6O0RU?TS!(3<EA/ J
M_.%;6(Q)XP[*#_'&\NF9'YQ7&#R^GSW1V,;U]#;CJ><SX9M 1AHGH88/,=U1
MZ+<4-O8PR! 7]HHI[/0XR5X"N1K[?L5X"7$^KV80KE8$L1:JZ\'J62VGH7%1
MO)K;GIY,V-#?1;Q_7'N>]^-9K52MJE?J]2TA!-(1(%2RV"7A<1.62VUD203F
M(N7\YP=*WW1;?W# 8_9-/3G#W-_OY[99"8E+R? [Z+W,C>?KC\*YWO'=?3N3
M?4&>\;V-#!6O.4@WB4X?]FY80T,?ARL.9\MV.L:&B<ANOXG64GKQ]O-VMXF-
M'DV>S YD50)?S^#[,QK5W-D_-.1=EF^:[O.L'(F%&1K<5WCY;8L8..I5FPW;
MT$_<(]VC67GR#71\N?HAQ[#E9,#%H.X"#'1ZT32;:VQ2>VN-L\YW+]7'VN5#
M1]G-+?9Z3S%5='M%E+GVB/ /__YMHX4L+]TT?UV\-8 2&B0RM+7OY-C1A%O)
MLUJ@6)R-:S<-?!J;"8]K9U;77]57)>53-8VH81231B(Y94%%I+Q70M+Z*0AS
M;OE#J=*-Y8+M,#EGYGUMQ8!5S6=F!51<@^FA1#UYHG^CC<G!%[7H>NOY2\U+
MNIR#W6]T#*;$P\ G1;_Y+?&QMG 7!T]'+*3[>$ ?1W[\'6GQ),18[F&1]KVK
M+?IW'N8/1!85SRP5=V"VB0;*89G)SQU[C3.$Q9]:54%:VDVJ9HV@R6@FG3%U
MM/!DG;D,D)VF77Z0 5=U)5U".W(G##1\4G\=77"[O$I"H&WU79[RQF#M&&DG
M:DV)82K,DT5V4AQC2IH;,_@>[?ZQ9G?./#9UV]!&=/AE&4V9;*)'GHLE'P'T
M _=(6C5\M^(LRMXGX]1NF2.^?$I7/NUI#2)[I<P0F2?G+<I=1!+ZWK7(#L^W
M-\3VU@<GO'ON=_%F?D_A>9,A(L1SJ3UISO[SG$^ *%^(H]CT0KN9CIA?<?F?
M)(V#EO)Z3X]5']8(&Y)!(YBJX?*:XH_^*"$CX:U/P)[-(PQR!E^O?&A[CMGM
M JG2^;Y\-\>[# X:-!/&U!( [O>\48(I7['8T>@KUW+R*HJ4"NAFCJL4"6/\
M'GU_2V9\G':J?LBY7!NN/H.QM(Q0KZ_HO_7%X64PO/75!>9JS;5S#,ZP%NT6
M: Z6JIB%/+&D<KD64N+1:;JZNOX2;YO=K:CW22A3\_GC[5%QUA?6QLYRX678
M67]?3T3! EUWVH$*3*(\SY?]12I&R? 0ZFL29G@4GUK=J.LN7$=<@.M1O)"D
M-(#V5\?T6]A^*:'R?B=1\G*%KF,)/HT]E&I4FN"LLY$ZE$]S&U)2FSX"G,(,
MA=;,9ZS$Y&Y-8'&CK['EPKMEFE<HWRGX3%%&#C-UJFI!,P9BAMJ)VG*Y.+J@
M+U+^/?;R!/.[BR5B^G8"_*$,2K%6]E$U<OFPE$<A+%(V5>25/])%;9Y0;NUJ
M0& TIE&,$<W[WI*0^]0XU<ZO%CNT@<@8]_G\V]E&J9'5-"XH,D"TO=^Z>$CG
MT@C"?0B%_P"5L]@)AS\E.VT:L \[XG824>W BYB25H$F>5?.99]W@$I1GK+T
MSX5[?UM8V6@W^E0$%D;3?@?<& "IYE4DP08/31ZYI&6I)[#)#R\:=.R$G)&V
M#IJ6"K3P_E!<(^7)F>GN[I[%HOH[+ACHF$@9F(M]-QU@U\KP'H4MH7'WPHT*
M8,5_C>-\LB@L:;FI%*$WMP_2TK+C9'E#F???+S\V%6?]:.0649Z1GG&Z?K,D
M>;Y#KMW.F!VJKA]Y95U$]+#G;[8V*.WZ0$(VIBA]\NFT2YBU1%^-U?3\JP$9
M \ZGB]YA]OF6XU1?2T$'H( !^P?;EQ5W,5V$5(H5:X@4#4%YW;[6[*L9Y@17
MS#LH)O%)Z4 %%3IY[Y;[%?/&J'H]>%OO<:E_2#>3)M0_/>11?8!H&2WY^*4O
MY7=96>SE2;#T:;5VD^2SI\AOI;MN%M6?DBR287D$\VOAS@@%Z>E/KQ:7%YK/
M>#X5EO_T:UF:<UU;P/Y4W)V'$#/=R6JK$GL"?;+K!L,;Q5,S2M]&Z4KY$VJ<
M?*S<]D$_4*[EM:A>&7]GX/>E1T< !OB]H;.EX])6R487GMBLN#L#=JYV^F+<
M@2PUC/;DC@8+EY WHHFDKI]:I=KR'3%]TNM^,U[2*U;*ON8P!8\7YYSC;-Y3
M?.JNI4O=:2+=H+&E_JER^#-*Z/FO0A_" _[3 L*E_[X@D]I_?I?8V*.(>-EZ
M4<$KV,\]9UBR(+_Y*NS-J-'%S\CI<=BIR!DE>XX9?D4J)9LX"C-:P3[U8&J%
M:]KRE^39(+(GU,Z]-M6^5!_J=UUKZIV^J]7CMUOB]:Y<_87<B$OD#!H[;OL#
MI2)V_V'WM+*HJ8)I?/;"=@GW6.-5'_['=Z6E[\:/ Q1<UTSKIY+!Y5>B/.N1
MZS!=\P']PIQ%E-7O94G!2"5CM=*$A 35AE.!K'SB-MM' *K@=$DX\&HVQ3IX
MQN_>6LD;P?"]WFF?6.;G7Q6J3LH_LS/(\^NW^89<;K3/IAG6#F13/PZFBU24
MQGK,;XYI\-XQ$@*C*NU:SC1TR[<V^SHR+6['5:0E;V2,<K$6[W/U1Q3Z62SN
MK"P&1-<59,+5ZBF:'U:7-3)=\G9OVX@TO<CT2@3?%C@"0,P@RBVSQ5]O))Z-
M _$8 0R5 26<Y-!&9)C**8(D:(S%N[$,T_P[R5NA>:*\T]/U5E1B; ]?;NF[
M,U, P(73OH=14$_;7 M+HC7"P5J3NPAG;8[L?"[O]"75GB S-_1!,%=^ K[O
M2"O9R5#7,4[\'I6QE>D5?J-8[>U_L2C7B;BF^"9*:X2P\_GOMUN?^P;>3(R:
M7I%J_%:C8)H"R6M:^9%=]OZ:J4K.C:LRF>H T5R!%=T%+45#@)^QKW%Z?_HG
M@#%_2&+,)@B B!)<TST$A=:"0(RU@@LZ?GW\GUI"^K@MU![9^A^_K77BW,)6
M#J@NPT)-CSTD8XEN%1]GA!/HVE.>7W;HVYG8090F^\PDRO?)M1"4PXH^J'>T
M@)E5]1%HH\>$!63,C<" -D$S!Q!T9MX=5M\'"GWIFZ&UALS*"SF(FZYK6HC<
MTX)G\VR/@SAOQO3TB56BN77L6*ZAU.\1]$ ,9Y?TKJ7[$;CS<P3IOU)]^[AM
MN=3E&/I2(5CU<^]CFT'O\>RKI)CMO)#;T:<%&0BU8O-BK%MY#%I7%_2>RY/2
M?0D\M2##/C%TK7P!NM:P9YR9\%99T:2Z#Q$,,AR_<"]ORK59L2]EX=&IGYO'
MOQ5BO/+NY+#J;_;=0P.7])1OA@@RI(N=O:ID3)<:<S<D1KK'(^?G)OO,$#EO
M@+F9\@5(#ED:9]UE'$?,5Q3[;7,#8)I-E0 $6K,'01"T8HT"_]$?JO_'#LT:
M_;$V##U4!UX^ @QM(O9NF,'K_YC9#(*3)Z1V.4VWD'/^TNKL9BT9U]B-U '_
M7Q,LX[]83Z 9_)^7;GOVN'[R)F*LOF!SF+C+_KS6\="5,US\3HUN[O7OH[J.
MG!T%12]M'?I.7/_UEL?E&2_WJG8M\K.31)NGLB->TT^D]D?T2(DSY^"XUO"&
MR',MU44M4]I7/K-&;MF:Q;W$>-O\[Y'B5I;".:RJE=RS*K(.5T:[ YOG8L_]
M&"Q7;)5)X7$=A CXMPBN+M2"IYX4VE' C5>LV4LI;$NRB556X^(@MW$=H9_*
M'Y4"64]Y"83//YYMNTJH77-9WS\":+R:^Y%J5TH174F9]F?[B;A,JG8RN-]S
M2X;'?)3I>F7XR*<OH_B.F4 -]_"^@Y#R#@D$R;.K-&]I5"/[0HK]-5V6M$5=
MR5<_&1U3WS?,U=');F D[&MWBPU6 U< &=+8,5#PC#3=>+XB\-#;J9N\*D$(
M=*?#5(I%0.'7 ,*V:95&B6RHZW6DK_4BU\/Z&V>]OJ>?%05^+'EIG/^MZ^XD
MOM%X&E[U]/MO>51\DNSAROY\B3-Z*73EA+\$^I=>@.)3:_']UIG2\COR9M*=
M-S6YC.6[YOC$>T+/WW5?LY&;'S5KLOGH^^FVH[5@K_! C6!A*V$!)RO%79-I
M;OE;IW0\1.ZR&'Y2I= Z_/ \92U,,[:86D74+5729@U="=<56%5:.#=&E83^
M70YH^/C+)%N'7=1"3J]B:PEJJ>=A9N!D\*!\H&AMM1BSLIJ5[F?Z)/W>N+2&
M5BLSHUHXSCS@,MDZ:LH?-.(PJ UAJ]BU$<E)WJ^)=NO"]\=;?D*>1U^+?SP&
M[3[&(>E_PBO^4V+KB_'*W<SARP<H%RB+&3@:Z #$6-5TM7RY >"6F)W<(P"W
MVB2*FV$R9C-7>8%5QU8-PB(AF'>G[I/1@CK@P^9>'[>- 48P+US-8"M'>>&?
M[!UA,NB?[1VWWW%TR1I])L:JZ8&\T-P.*X]#&+_D<?O,BX6@Q%C @RA?;M?#
M<D(/@2NT5G#M&,&V[M_>R0'W?3K. F-"DA<,0-TZ.2!0GS&*#BT@@CZ(H <@
M3'[NWYC\/* NR&JAIO,/L!Q'RWR]H4^'D]Q5,59'!UM652T$YE^(<I*_O&7-
M0!D2-8FZ 34Q\'6GI\S,V@7PKZ1:4:J).LMFWIY)K5C=IY\ZJJ.),5Y?'"!T
MH?I2C]&O\%BRI6/)RGMZ0DNF]=#\]<&R^=E76C+61:'$;=9*NA)W>K:S+$/7
MU,@PQ-(>^(!=/)."IH6-[AP$K8(W+<V4]UD0K=DDF[U#Y!% _?Q:$BU\:0^_
MH4B_O==&)TMIW7D.6>%4PI\'_V=7)QF2(ZV%6O-1VC4/L+EJWB";Q6(-VW2I
M'6'CJP@&*Q$.XM5V5I3D[UUO#I'7R+M'@."K)\7"I;A@W\75!L<=!4.4Y=@E
M]H8RYA%G:#QR+?YR^KV@#^GX7VV2F5^MG[4.\=MM3GW,%&GC"2S__HVA(#)=
MSY_C5L ;_91DN9-R8@W\I-(:GJE.J9^H:Q#?1Q+L/*-/A6,[.I2*W-:U_B9Z
M*<4A$KP;KQK?2?BSNKF_XS*+(_;,)?*S%$I<(KNL$'-AWBTVG-/?^FMD7BB-
M/HF\@YEGCM<JE@M^F6-GIL3L&K]DBGCN+W>?;-^LV\$BWIC(6;9H>M>Y_@3*
MX^R3BC,OWZ(K^7X6 P_/2U (JF1[O&K6L(/TY%(,A*R=/Z'M/MOD'?CRR3.V
M2LF[OFZGI0_/+>T_A!E84FM]T$NH%[V>$-"N]:]#W6^#4R?K7MX6>/%1((@
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M<S#-GRZA>_C@0T6X5?^6A )L>8U'/QQOF'9;,E'1O[C=;UT^'^&(.$T-07#
MY2F389ERX9EDS'*?M4/^"1^AV/L;EPR,<Q$)OHAF@PB402,P%+43/A'_&*D3
M]LK/$A+OERAPFG=+OGO:4I9?*L*4S&LM4H:#YJ08['MX]=Z^A>\@S@81O )L
M,.ZWU.U,[^'X5("B#CE#X_8KHK^_CG60<7_@V9D+*C<H^)9N7EBW(=4RW]P!
MA0RR+PU]5/DD:FW,;9HO],3X*]]I=?<,UIHK)"KM-(5'JXI\Y:.GP0E=])BF
MW?3*DUXITS\ZN8-7&6_%1OU6"8K6*L&H7(6;XBBXQMHK3:/-:-JU]47+P!&;
MWYGO+SQ^_C=U!ASE'6+>I&&\*,3@M0[#%T._^D3IZ!$\^K"):_IF!"M:;U'I
MW2!7UQ5B)CDQ@QQ!LD$& &!EFE"6AR/#2XF^B>_1T/8"'Y]3]W>_M6M.'O+E
M;(TA=58V,7+-&7P!LE0&&Y<35C1P'UR$KW'":O(:7KB+LGRQA?$)XVYZPI82
MOW"?LW-61:AQ>2+I"9%76R'1;HM!B;"V-2&G@[KA(K6"$?E$ J&>/"#>U[._
MU9[SH]XKWKMBSUT<;)D[5"#%)HKPMD)PO(9[DJM<N.$ <G$N>6]MFH\8L=:5
M":K82ZL2&B5FM\6L5]MS\=?>L2"RU[' RDC@9B+0/UXG0[=B, "(1UM.R)YB
M\A Q6Y>+5G2Z-\.Q>@1@"Y"!9+ H/9GRYUP]4QG?M#/7)J+]Q'3\.?#.>L#:
MO9+[U;6X;Q5^$<G9N/=GYN),SW]5;ON:J%!TO?0\RCAM:\C*M*+>\]N$3][7
M&R/U^+U2LG=D%H78Q!JJ B"_ I_%2EQ;:E1(>%];?['XYS5![0C>F/$RH/,6
M$98QE1&N!)DI&;T[./G+\BQ<,V]8+9?XJ/IE9:S0Z4]RF>+E!]"Q.G&X,^&0
M&U+'61=-W'])M!ITVOS\IR+9J\6NNTO_[7V\SB:+HGGI0*+I]YK Y8?-O T"
M_NB>F=QGE*W,T_<(1OK;$TN=5Y6)'O(O1=ESLNV. *?!/52Y:6+#BDDS-S&0
M!L; #/"#:.W*<,OD-9>7ECQ7(DXI*;GE1 >E\F^-Y"7/2 71=69)+FO(CK5,
M1(O9!G%A-.V[>,O#+X>++P,6BU<S2.)+A>"+"[[!?Q(3JX(QS;\1 5QYIIY[
M[QSYH$U[SB'%.+E$RL39R8<XGR?6>E_U :*C>3YI%O&.CU=18]8[]:Y*CW.6
M9]!._@:W#J)KQ JIXML!Y-788LC& NH3J]NKBDJKXA]IK:T[I[BWOTX=GH6;
MA,Z &YVDF[^9M^7A??OR*Q*"[B['QN=OC:'6Q-N;V]V:'B>H0V17JQ53$U+3
MM.7%%3_)[)JR7#[4?!M>L7ZY:>I$^8:UR3Z?H,%(RC19O#P-)/?(_JY\]TSJ
M('+E"CEOAS34N(2YBV_RKN-/%(ZSV31M\@8+'HQ7_LE<"S*KMW=A:YP!OI\\
M-S!%F.XC5?9--Z=5-KDZ\9POJ7A,*FY[P:._$U>?&$T,J'>U65_2/P+,^<JP
M&SV[_B^_?L H8OV-BL(1H/@B8N'1$[EEER/ ];8IX-ZZRP&?B-H^Y C0]HVZ
M=%BI>@3(O?.86%I/2Q%]AUAJJ]_T2*"/U]_H0Q)B!9UR!+A#W/Z[Z*?,;F1]
M:>%?CW[:#%LKF<W&GSS=W$Y^*_G*P#,O;O%GM;H[SIH--7-O8'7F". QJ-?=
MZ%<8.=.TEXI8_8:9.>_B,_:G,_NL\JQ+O"*\%[4AGA$DA^-3<L+@#Y?"VRH/
M,CRO=FDVV5S2I._.1S$K3F+K5P8]6J+YUBR(U_WX'3IA.)IT<>X10%V\*6-G
ME*[UF9<*$+TZ%-&#;2S"[-<1H/L(0$M4/[!A.0* CP#KIG[Z_^U!Y?XV3/]J
M^91Q@$S<. (< 43LR^<BAR(0C0J+-IO&-=I' '\,D-Q5E73 7G(9081J#I#K
M_]4PQO\_^M',9<#"ZFG2%<<=B?Y[1ROTCK3_FXY\C<TB$8V*CO2.X/]T)$J3
MKON/,VS!I6C'+=M> <T:$<?7EI#>J^7+34%2[?UU#\,-PA!KV!QP6<O_RR''
M-CX,3Y-N^;\)1_DWX6@6*B7!1X",(\#NK:!%JLON\?%Q94-;+ _&=,H25]=A
M*YBLJSYV3E^S[[6!H[39>\<?"H<-:@V_NIL:J(*=LI8^2/&L/@(P+9H.ILL/
M8BV3KXTF>O?E!YK$-NXC@CV/ *?J+BZ"F3SPX4> )F^+0JW/^]<1O=/@9?N,
M/\I?%U^0>[\L/L#.^A=UI -9N"7?8GQLH-*$!18)P9+;&QI[1IJY["?9CCW_
M_BKE(2@Q=IGNW9..X*T5J<-W4/HXHXJ:8E]DPH4I=BW9?J<C&2W5-R2%S_[8
M!\%?#0US_Z6]]P3N;2<= >[+[!+V%2"#.#HUKJMTAH/]2*Q2S9<^D[['9'Y,
M 9U. 9 U^110>_#O<27!&!W]MG9@RMHKMP=Q)<DO%K1'5%S:O$MW]'9:UDY"
M_H35&*'_>&FK(6[.J C"[Y-9FXF,CNE<%13E<.N)+[*8.S>S[!1C_NQ'!LAL
MS"8%2Z$9EH'GG$4VY>[^)K:>WY0Z03N9@O>R:,:%T02!'QXTA;1L#Z0@DM-5
M-43=9M('QM=I_!<&TC12+?R:MY;31G:0)S[\LBC,)T08P.IJXZNO455G.H4:
MK(4('F"@0UL>+$CGXPADK_\G[5N<5S;_Y]V/9@M!-D\TK^E=KGE3''FW""V
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MN T"^M+8.RV;*5>\*'XGYAJ%LX0']$+#SL?F=I<>E5YH:] Y.<9"2*Y<Q-X
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M#F5?$O%7-X"*-CBH55E3*2\^FS*&7-YC#E11)Q.@G*C:DE:37Y!$C5*/!%P
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M7>;C:0U #GO]\.X/ 8?^ E!+ P04    "  Y@#M7.8E-[Q\- 0#',0$ &
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M -GS= QL#Z'%/TZX-[XR*1O85+XRCC13B>S1O\Y<?A+533I2_M*1"%R2G2&
M\,^FCV1#^.APK1HQ#^JS;X;JY]RT]33FMLWR&H8.%VT/86O-,) (T&47]9Z+
MG<%XZ&KX*K[=3='E0ZX91W?DZ=K:RTN4@G9+7JUI5YAN?,N/_KW2T<[B8]58
MT_![(54SJ[R@8\LY8"KE3!UZUI=3QQBI0IH+M=8*XKK;UJB45NGCO?ESID7L
M#G4BY[TG.Z2QDM>;,]V0(VBWN,5>*T$,8X^%OAMJ-TJEJGU^<B-Z=UU3:H=Y
MC3)6[F=Y%ZGB4@!;=\);3B(0%@R"/<5JEI#7K%L)R>5UY6<IM^2QN@\EI+45
M]2Q2@%1@7.-M>DM\EQ(8G*WH)V^)9 R9313>]'A6$WO[EU+#G9EP_UT-&_*W
MKI_SO?-;??VL3BRG#R.M!EL%&RP(8.EW6'A?Z6+\G>!AD,1$W9DE:'.M7[K_
M6?T+Z(26H".5Q C_BXY97@4,:@I1'8XH^&@-3S_/EK0]T\0[N*6W^GK\N&-]
M'6=\_ 1[G+2T]P;ITU<0,H>#]#8J91=>/;R<J/+EF\'RF@)E]*D.V&$D(@FO
M#E*RIC5+N)H9ZG->T@*1'A9K])6W589NF-G:A\&J8D:]S)'G1:]:GV3LIM1
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MO:/:%J7]E3_;IKPY4-S*2KP-_'Y<%*+K&6KR]-QG8^@5$9CL]LA_L>PJ202
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M>25CWU$W"?HN&^0X]X[3K,DS,213VPWU8I#=A'4J>!I1MXHX4[+ ,3/2X:3
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M2]D?DS0U_!/^H1L?YON%)B*P;E1+!!#)1 #K[?F3X$ $7E<2M"48]G:)0$B
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MW8*<"%33=76CP1(PS?$VQH)%(N!H!E6:-G<LOQ;4]]9F@G)_'S(TL7*0K ]
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M1/JOY5YJ=^FR$IN6M1@JE^P-YLJ\/REA $;RI^Q<9=-]**\N1_(C(/]+U:%
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MBJOH9\-5E9M;Z8([SR@T8,U$@&P1LQ@%NHKWF("9EN&,K1HQ>$Z9XW0_N9;
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M*;AT5RL84:'KOHL5C62\!>?89%B/KQGC3>4(TM"%Q[+@4!A0&"U9=!CCWRM
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M-6L(NR8EK,<CGC>)!]9&Q+S6Q*BKE_.4UW&R8FS5*?FPHG5M=. 7MDTW+*=
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MBKG$4KJFG'T&Y #>^;P>T1<OT=5\H@$RV]V' Y%"E-#D'JF1?PPPO.JF7^,
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M]N08,FZHPDM]*;7E-/- :J<%I]PM UEY3\\0/82?&6'\B *@V_\%XFB&X/^
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MJPL8+Z36RLAIC?T@Z&TR(V^.X;T?O%E?62Q=!P'Z.!R3I(SJ?O\R7MCM<@6
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M1K;+FFK2M=0#Q*[FN!@UJ+EFD*B:HJ$A3*9CEOO1DI$$,+;J)ZM[NY%V7"3
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MK^4A4N5^_U4MU]<$]E+@@%J/-!EX01$T6[6.WU!SF;<G_O#85WO+)PU4=OW
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MNBGO'IK)5I39XC,KXWNM[6[!,05.J, (D7/!42:ZKB$YHG1#5=&V>'U2065
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MRZO;CGZ7OUJOEY]ZW^T4"*RD!ST5%]_L#N$W2NZU-$C+9^3]/4[(@MGXHSZ
M;U:#Z4B -QK%8B-=KH46K&^C'+F^JTY<V;5:+-.1B3-'$^GQ5'6X&$PB&A2=
M-\%3D=+^]D&OPR<*BXSNH:#.(*0W&QGXFWE^^] =Z--1!9%U#OX)L:_*:EAE
MWP8Z!N\;^Z:?HQ^\_/"<XE'GFBO6Y0B1!+/;$HR1/'Y)R'$61C^<MY@-MXL)
MI93IN%>.OW:OQ2M4H?29'$)V4%.F; 1"I)0[\_PCX+)G.+GLBK/Y$W!'EZ6E
M)M_T\9?DS4W!=XNO"[R-?LDN2R/*/?>F9-O,[2/40B:7>;[F1[Y6\?$85)H0
M2]">GMZ/N"3=M@'FQCTFJK&3$=N-D6?2@NLDP&R_\G@-"3 3/KT^86+2$#WC
M&6FA!F%]G*J1Z#)'3>TVY%*S@<XSF@P1\)2^H[V=.;&WZ3'^SETONC2'0,W5
M :^J08:1  [T.%^LI)$K]<P#?6U"EOT!3_O.@#;K0T[!%_MJY)H9+ ="D';J
M!:'):M2-O+WPPW.JPIS0W9GAZ=P0RY#X)$7!3[*3Z]WUHOD[Z1B7OMW7Z> :
M3-[Z&+N.A@USMV[C@X\!D& <!=9&?627R.ES#V6I2^;3<-+M73F]E6(L*%]Z
M7KUF6U7UPJ55L.I=+;7A:M.ZG7A]0+X086QGU"M]NB5ET[V'5M;=_$QD<!-Z
MF<OF?FM^H-=.C_1&M-^Y$4&WHZ$VBD[?2<;J&,Z&W%S8G5%/(H:\'PP8PL2U
MF2-"B<)0;VQ<E$>,)!@7L51LVS2Z79)U>7Y&/?-I,EVWZI^GEH2]YL0?B=:,
M9<1IU!TY_T7X[?4&0F8<^J;PF;B&;;IFWY2+%+E7QF4__D!%0'#:859TH3FT
M^EN:<2/2,T!L$E,_S#*244J>76=-B+LV<NBL;/'CH>,$H_G'19='YD_VRSER
M^7CIF49=68Y*)D:6$'1)$NT,HD$R05]^P2C/]4F GC3X=M<Y#UY\7(%C>D81
MA@X^CK&P3IYZ]C1$\LH;;,*['+E+S*V]@QK8XA[)1U 1'#\6O?<L3!T7U! D
MU#?;_4KR>%&C4<!7X&<J\SH/UW=!\;B,W%(:SSKZLCJ3>8NGVR(NLR,R$B.3
MA5@!T[E>[V/#NM3=.KI]!@E1%W;5.7N%J4+GZJCS?A*@O,W&4_Y8_?S!6UFM
M^+$W9*"\P/@%GSL="I=Q46C8C(XT)[S#W<=-7.N:(C-D(P7"YM<0?@$YG8P/
MR[2.O<<.Y\F.72>)]YT4!&HQ\,@FC9(YF*-/V;*NY-Z;9YW7VKW8NWWZ@]R[
M; C%/N[MC-.PV2'/;%?=#=JCXIY4X?[5,VA<D$AU\;PH9L;:;&YZ/AJ6,Z<T
MW#NDF_0>E&>N2[GU3HT[(GM3)_Y'S/2;O+NFT2$@$0JVQ<E9%(/"7:@<[@/F
MH..A-52Q ML3>TAXU^<L:!*EX<_OPG5NJ,5M>?,CN5#&+=%OB[0#L)JPG4?H
MN%!0=694WO3\-;E'V1JVA9;33SZ8KS?\^-QX!&I\=?FP+WBB.E2AQCB+Q?JX
M<=[9N0Q1>GZWNVEE1&\2W+$"%6+//;",<EA,U@KJNB+PL=Y5^YN]PMCTSI^:
M5'0:;ZBAE,.*?DG^[^"?B!&JH1 9BG905(L4X1OO0]TE]4.W8D>^$I"O_]M<
M!8ISL##*/W@#_+6%&TM. D3)*19"_'*[ [3TZA,VT4I^/[<U\%??RK\O*[G_
MZ-7L6W/NF@-_1(J!N5%S6;_N9,57=55%BD_^+.:"PS*ZO\%35,?)/[ WE)?R
M(UQF_+=,GZ6)SPVF)-,#Q1OOC'W[ YO^260Y=T'>; *B&_<NXXHUL RI=V-)
M *UZK1_JN\]7"H^Y! (B$+.Z5#ZALUV9+",UC5SIVJH3@C]BW?=EK@)_(>6'
M'KIEF1D'C8#A>."!@C^[BD%:AI==*9T>6-0WZ]_;\O^?-,!I*(Q^J=DN\?&Z
MQ!6XP-!3$Z,+K];(Y28!EH/W$2-I^'D2("C%P=4>Z]IA_GUT96%]0?V-6PM_
M.M=^/$SF[$8DRLID^Q?^9G.E@F)VI.!A\,;E9M8E9(\S; D<W&2V1*"<:;^+
M5H=&-:L^M?%D\V>6Z&Y[S_:80_%/E;6[BKV,6S&'67&V+3V/G2?PI@(7!$@)
M=<[SR5'V8 G-V![./4^3--8OB;UTI?#*2=F%*HY#MP.BT-HE,L9QSA1QX(&Q
M";[<R_>G]*)!(.9>FXQ];5]R^CM9FKGU>:S(?6]PA'#&Z]UA^V?(1,VQDKU7
ME",S0VSK;+9:7%>9CW_2'Q)0>#I7M,<Z42=UJ='LRPN=Y(0JD34>:)GTO18D
M!M2&#$H#;O]9W L'WG+V/!7V3'U=ZS7R/;[MD]P/P@QAN%:A!6F.[GD@HY?D
M!YV9=@PX(MR G,NSJ\]AX->)OZV%,<BN/9R9Z)Q*F<_7CUDK8Y^KW[!+V#@E
MM5*U?WC_R"J_ SDKV86B>7-D(?X;+U\RC7)RAU#=)!22 &KU\?U5_ :)03[S
M"3)DEFL11"8+J!IVH0%Y50Y4NDED&2W-2LVI5S[^4IGO:_N.*:AOBHPW5I"Q
M!P1HN0L5_^U\A+B-TS_7&%FS573G,S:T.R\ZU^#3S;$9+956OFX^7)#@+,01
MUVO1MSC./*TA>+SIY BL'HJKUHTR#^NT<-:[BBR UCD,V\TXO+_T\M':+I]>
M[+M'&6O2VTT!Y\ZXH6[BG3$\")*-\^\P3BMBVOLS4DJ3_C:_@">"3.X@R'<Q
M\@!%1AP"T[9P.XB47D0\[[/,Y-P/'NFTK[D*M+<EE_/[,WU*20  GFZ\Z3%6
MK=4+12M'7\)^Q[+!-K8-H+%W.8O'2/DJ$P\56?6R5)X^D["+7?8?^MJ440N+
M_@']&-:%OJU#7ISLN9E/S^):Z!_,"D.#?7B3U*_7<<\FLD2Y;^CHM%_CO/-K
M-#XC/CIM-5 ,ZHL%]S@[39  G2FW<AF<](=T*Y79FRLS[)T2-'C)'FC(76I%
M-XAPX&DFH-I8R9[G>%F,3J4'^^VCE_X,SP]F7)XH5>X^>.=]2UJJ&Y*("\$\
M[H%3ECB+0(V6T@<Y?FW4JKC=GXQN>5Q>>9N^G(:"(MA(^R6[BC$_?__(6=G\
M3KV>87U]4CU\P7*,*(\K-L(]^HY_E&D*6F(KKS]_ZE*TX/]^H/^.Q%L]L\JK
MLC2:2(S%<3S6OA7G2<7._Z;&BNJY[&YU@#F74%-,M O@EN$G@'SL5;7+A3Z"
MQV]Q2=@[BBR38?B[,%A>RS-O,+>6L,SV0@=LS,WR?DVV$P?KN$OUH'%?@*Q>
MC3O;<9W>EY68,#N#D1I#S#A=06YF'62H43#Y,^*FW) I+N_<$%>%3OWMO/M&
M+(!5;5AXN:5ZI+K1^=-I0=N'5SK;;K]?O/.?Y,*ZHK]789$]B3[I9G65=6-E
MKT)G^ZK)[[;?+#Z)Z+'6$._4,Q_M&,ES4<^#$&536-Z&U.L=V>_H8>_U*.)
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MT&?RNX_:\6=<ZJ(NC=FZ.4T40FS^_J!F&X1-3[2;BH&30<DOP>\$\1@8FBQ
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MYN-Z W\![A$&3?"3A2MYS+Q:6EC*]\KM,=)C/#RFZ8P7S'9;3(\G+S7S%8O
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MRP1'6_WSFCAA/9F?^#YY I.3$:EM<AKNP<+W=>FW^"YE_D>A/V(HW)Y[ZU,
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MM-# \#LS9^8Y]]Q[[G_F?IB97?76AUU5^]EO[=I[O6O5JJN9JQ4 I::JABJ
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MKGKF"@"X*;O*YE'8!2[N]6;C5G8C.\*U=ZS8;&9H=C9 2N8'0>+;N\,KP)Z
MN,Q*(=?XHLN3NKU)D^/F:B?K/\S\Z\(W+L=3 N^UL5GN6/),^BFOWMJ7UW$M
M[-P#,Z93R\S0ROR*<0XYOM%*WL&!L J3?YW-PUR448Y7W>R:N@)\:*F;VNO6
M\V;+!.B4K,(E:+''/#;K[\\"35E6I8&2G><:G4F9C_9^)TTN"M+4UH.AS18C
M#L.\D%7A*"7$WG*4VQ7@;G%8;3LM7MW* 4/NKXH;52&]:-M]"AK8V;+2]U/#
MAQ02A# >^6@MZV%)28W&1))%SL2/=&JL27V/RU(D8QT]&0J@GMO6\:C,02%C
MK^GP WZ9)ST.^^D6XI/-]J=-'K*.7Q&'\;T4<SIZTXHDR_C4YTB"RDKYO(+J
MN)04KI.7*W:&9KW^88>5CNE! '/ )#-%K/N6&\L>IQEF<5>28XYJJ-+LEM$&
MJ7EM^<"#-S0CNOJLG9_+?!6AX_59!Y=J*HY40R4K2V*S%BH#&H+FW@86RVY_
M4Z;W1YSSV@*J+ZH)$N[>3L["800@& 7,R*E^CD[;=7YWD$F<N<:K@#4-I IT
MB"7O"!!([3(-"(=[U>@'$SE[7X38\YBI]_?;R; UHN$[,XZ6CN[6&1=&PZW5
MWS'C&^"VE&K$_H$-$BP^!ZY-;U:KVQ2WN8-QFCE%T\.P/#]]ELK+MD&F:9>S
MC4"[9H"L<F:>=1W1EKE37W1.#//+;&%LB%<OQPV\]0M#6948W1[IB7B.G?L:
M)-E/U5 F+1\,;Z$YZ9'30.CBCG59SEW#%"CH2;DE929S[/I018:&*J_*0-TR
ME&Z^6FW2!IW2IH^O05\!(CR7[Q 45N7B6><(4J/3KX#1O74UX/U]H1F_" ;&
M.WULYU.<!"M\UJK530(O9K(-SA'N!T2W'KC#^F[(1;NM2&L'9;2)X(U<?K]E
MDFYH33*#^')/:UF9N<N5?'S/U\HX;;@UGZZ;VK/OPJNIU6:F.18-?3Y0WKMC
MX!\[E=)"@W/$CD3MRVNL6MWPZC.P"-3#+/ZJD*W_RND;8>S<J,94.;*JUJ?%
MLN(?E^!>8>P@M56ZD&&<I!5I\Q$_LLAEIR!=6?*N]%=\?6I3TW)1'6&$F.K+
M*N][I=FO>N6ZLWVI8!YVF\G=D[BF@A'UO#:(SGSX<X^)#^'!\F^O +=)(X6%
M8B^RY4\^WTTSV^@L86^9!OF?@[Q>4 #L%1_7U$V<F"#ZGL[83WF<']A^]5^;
MS;SK*=/STAD/MD2:LAEZZ<A_7RE[:WL@)Y@U#_J#JW8\-U%PLZL=LZ1S.C?W
M@OJ)H+74],<DAA@,,&=<]7/LN1^J%BL^?&1[#JUHC_7AZ1R)Z$+'AX',HY4G
MCN4TS*/=)M]1#8AZ?'G"<\?7J!9KX#"@2MV\<(3UIK?^5,B'3Q=ZJJ6Z/]6L
M40Z!(;6WM^>R8FEU+=0^T^JJ /[_ +K5=D1\5ZLG.K4C%MAUR5ICMJ<'R0!3
M,Z0](M6S??\W,VB4&<?'SSR1;YE9"GQ?X6/BJ%@)BLF/^YZ4)</+O^>V#W]?
M^S='WFMSQ8)P!:!5I(98LF%P.1#K/ W^;:1IQ!O^;Z-"SSH"E-U&=BS]P>>R
M>)SPYSFAB+F7RGIUV*UI[NB]A+=0F8N-O1F>B^RV29P*79=\4\S:>F5;5N+>
M6GQI%S;;-JQ0.U'7+Z7&06N++Q%TVCR1.B T? 7@PM>@.+HMK'"1=5CZ4!2_
M\)T*GTR7$726%*C3<B;F9AQZ'K_VP(-X=/, !+M$6MU!.$4KW2<-"Q6GVO'Q
M7S.-S?0T5Q%/2#JO4ZB^C1L6LZQ7 ;/>DV#^ D4H7 %63#A3X+36?.^>>GWK
M%$EAXF9C:;(:&N*5;#(13VQ-5-0))/>SP9=B75$'$2V&*ZUR7::J(0+ETO43
M^=GF39_&W8>10:%,BHT5TI<T!%N,4Y"?"B9#!;,47X9W,FS(?([VAALI/;X=
M/[3Q,N#=BF>?91JZ[7?>#^\/;/.9E0>>A2<:$H@FSO%X9O2;7&U&4\U,6N^W
MX,-B)DWGE)H-J,R@!U)[2"Q\U(^4Y_,EI2E><\JJ;L2NT#^2R[K^MS.[V,@S
MG74K);5S1?RLTGLK(KSR^6-AO+IXZWNYP69G3WIJ$;$JZ'E=]JT5UNEI<9"6
M.1M?*8^[[> ADA#/0MS=L$M2*/UDX%=>V;R."3?W&(Q#KNEXXJ^K'D:IQ^FS
M$E6+4PF>I<O4*48\D$&]GF7?R6C.C"DX^>\I5:L,#_%QGXP'1PU/=(L4"AY*
M_Q365NQ=Z)5T[F22R)0BO4(Q2'+W^1MI5@K3LZ6HCO6)#$_'109(<S-XLK)>
M01J;K4@5%2O-:\*K.7RT'E+,[N2SM&NS]RO?L[QQS0HA_ EQ$*E$AE"@Z#**
M]"T'BE/0ZFE6E<X_L$YY1_;<TN@*0-$F2###Z@15$*Q16<*=9SR?-X&-PC"G
M%(^V9!J'B F73Z=D03MS;55Y"%APJ$/VN)[/W Y03JXRE: MT!Q9)?.>ZBVO
M7LBZJW.2WD9TIH'-9$%^]3C68[D*VQJ^N[/:3^#.FQG*[\)%![(!84,<<^@'
MIB*HHV:RBZ6VR2D_E8OL%K75*T#D,E7E9^=9,/-!>/Z/FG;PU_A:_OVN!W)5
M?5Q19RY1 [:U!MZ.>\4KZ7L;GB.Q-3)&N*WGP*59!9E"IF43A4S#%KAO#@,^
M^N<RFWP@"GX3;Z:/44PJ-O9RP<T6MH7K1Z9OO?MY-T+GUU-1WQSMR>/I7BU.
MO>D 5H@DLW90L5?Z(5HP!#C)+=(AS?/%V)J,38;UE&Y>UW2\HS<Q?<,IS<S,
M#5FU:=V06"=9R9Z7>\<A)C,Q7E9KH%1N";H]K0H;GS-#WU/">>&S/#&^W:8T
M]K"BN87M*4]94-B^Q.>F<UKUE<%(XT]$NXTC)R?Q[ 3*Z19K;."K"?K%-Z,Z
M88[B&=$=HN]Y+20_T<A%C'P4L5+6FWHZ:-\K7^_DN,CBWW(%Z#]V9H5\FR[;
M>?)">'D6N-<KXF0BN?@]W7&ON=%RLR.;ZN(K0:UX86N);?*2#CSWU>@HR!EM
MXF?HDH)\P2(7VJ1H6#7/B#NP+"PE*.!3,2'HXHB3=@ >HH-]'XV6?A29U]1.
M?VC<'T&E(3CX ."S.=>6FU?$9,&L6\NB)5<$<T?6-9\T(J-66_K8#$?HM,5B
M\B9R>71[00Z@FI(%"W3ZFK/F%*)67AFGC7='YX1=DDWNR5O8DL:5>Y?K^%C7
MIW'%A,OT\VG?=.W8:(&OV@4'B!,T\?D0;Z4@08D<$ONCORFRXND33WO<5O<'
MI8:21C K[]JZ"GJ@\B0\+Z0#WN>U2IPT31Q]7 !%=FTDUWB^R"R;:-LVBCUV
MI$\'SP.7=O+5AMH4G6(_S9@_7VEEZ6&^GUM\2[B%6Z*;2,!1AN5SC*)[KRP-
MWKV23.,BHXW33P8##Y97RS<QWE[B'87O"W./DO:KIS#%^7U;X^$0GMY*/U>-
MBEP?+14"#VL=3X)KD-H[R/ZM+FP*_VV5UUVH+56IT\28UA.PZOAI>XJ6A:D3
M< #ANA$?>@6HN42LDCNQ091H!'/4VK&V$RYL4L#6KOF7.6Y,^NWCE7ZJ%]F.
M>P(!S%OL%(CL*P!P%#%2;R%Q@?&F%I61*WA0KQ#JSZ!B_X/6/X?'\L*S?<-Y
M,-J5)^KL%U@%2AJ@LN\K8>N[Q4;C>#$OSZ*%UT?S!\:W4[;H<'^V5IL\-JBI
M:3@:3>,&!#>[)F_+<-*AYU)W,U:9VIB]9$V.Y?Q!QJ-P(=/-KG$'*[OS5]2*
MJ&JO&:A3;QLZKZ8T9:PL/?D,MXW<6V0SUA;_C=&+^5-2_D2P$"&MF0[2T[(4
M]007^^NK]=!?DQ1J+_43QY:;^DG68K);2^8+$;'%!"Z]99U'CJ2?XSF__5P-
M^>)?OK-\$USSYY)ZK,+QBYHKU(Y6[\&#3[\^425,I\_EU7>M;*&R4'.+<O5C
M0IMIF=C'8G+!Q9&:O[2!)G5PQM[IS((]>]CB@?^+J">5J^O7Q^\W_C\'_BS,
M2+?.7:\1_2FW/7(KY(GO'O-;IY+Y67,!./CAR, #LG4EWI4S9@_BO+R6\7-<
M*EZW"#(M*WC0[737Q*$.B:B=2I4MT!U@_;Z2?_-M, 5C95*O%4T+#^;T9=V4
M/! M*/5RO-+&^'M+:Z,Q.CD-^,2(A^3+;<9=WL/!'Y5QV5%H ADV_V<[K;#0
MGA\W>HBSVU,RH:*>"EP/$7M9H:[WTXTD)#ZW<CQ)R[Y#;O=:P#P,I=5]1OI?
M8MH]EFDQ^%%,BO4GLM)*AHYVMDMV@C*6;BD4!6?\<S8%=V <M+-SJ\3KA_$I
M11!W\'_A+5@J :EYJWS,H6R3)2CA]5U)ZZ/]K K^2+E6_H$Y[C]+FSZ_5@1]
M;2)F;7>QF^&*C^RKMB\9I\4O E^YUEJ I\G%O?=OZWWTCQ?_:P%_T]0:N\T7
M.MQ:;.J 2S>?_J%6LEC>0E^QHO&H9)#.LN#^!GPBYDE>%."_1$4\O5>]&D8X
M_$!B*% W1'/\ _)W]OYZ7=[]G$B>3V1<QY56J.F^0!(_P^S+Y:[T@8:6*I44
M]/#^N*]<Q*I3,T^R*">MPK>['*9^L/(9D!G;!=TO+S)T:FC;D^<E0ZA8$PGC
MXYV4FN9YVH1O1:S)#R=UT-*53GT<M?5=.>'9#_W)0-C[%XY<U%K%X!00P]'/
M\'SU%&QC3&!KE%^UXQ0Y;$0GKS$^?)G&CQ^K__)R&I/=:%=I?%.D)06>$MMG
MX"9M\_9B"G!N6*[$:F\:'XV@N&OF(#("!V/47#W?!T4KLZ;-&*\",MG%,EVC
MC-ZZ.8ZIT(;]CV6KUI=D5<X26L V?[<B \&C%:L=7S:SD[)5Y!7&W9:CE4H\
M, '-35<G]%\!YE]\DG5GE5)='6UCPR>>6^$M4$,N)UI+^=Z%SSU%?P;Y#3 _
M&*JU(4KT8NIQU>O6A]G=+]NLCQO >OMF.M\6,GERT'KP/GO(_H(]WF!O:LR2
M9\4IGD%XQ7"B13G?8:1\8?M4UCWT\],7=JVVZ<^J>LO.5;M?,'TK8=$88)WJ
MN0+LD1?8IQOE*L)S=WS>E[Z5J!6S/S0K2'VI??[("R=C0I7!R=='0NFL5^5F
M;I!1ERI5VO4W5K8ZG]EO")BJFK6X5VQ4.=X*\V=O8B]5\5;9[,-7G) /R5U2
M+E,O.'C05RUMT]=AGFV,,RP&#VWL"7Y6>I2H\^:C@S_+:ELJV@RF* <5-JU"
M2GS^ O99'RKC;D56V&(^U6$\POA;GT&+V:JG^*(]-J;/+MQ.1+W9WS+ZJ@$7
M$0=NQX@SQ?(E"W0&2*-FX@F< 3/29Z^O,U8;#:&@\IJVS !JO1JZ]Y6R]DNJ
M[=(50+;W,UWOPE%"S)$%:5^?PB,+?N4<#:2$A:O>E)$J8EQ@1=<E3ZQ.7PAG
M&,-YKZ#&?<7NT5=G@P)XX,[)<JZABT#GU[]L<MN3N+G]?9RSD=:2AGV.G9-Z
M7HOE^6H&9'I*4E:KJ#!WFSX=EU.\G9)>6,99-MSW1.:-2_X!;Q_GS5;B/B5*
M 3]R)YO'B):)$Y:_;2.V1>"Q2"$A*Y(OW[\  -0F$8#[6@;.M&N926.,DP/8
MKW;:7U$'PS@+-XW%8T36@:^915Q>U*%9_)R<ZGB2N9;UB^E:R![]D!-<8!_V
MI2$V\]%7OG6; :5.'>7EJ*EQ10GP-.APWN%,M1SEC).:$%R?1+\$1KOU;EK$
M]:B34,/".K:F0B/S%K^VPT<;U])BI1M_1=</++\\KCFM!6_YL^$4J*,PR_0$
M_U9_'HT,+0RN/<]LVR>T0M(4=I$9H-+M]"CDIX?]*:\<L&Q3(=8W8LM0NY:O
M+A=Y(H--<^0DNJ5#"?L]IWF*A_K.:]<M;15EA>9%\;L.WGF2]^E_&5B*L!]]
M%'O*V$AKE5CMG%QJJF=,A_LRZ-:VQE@6U'Y&+OZ@.T"@/A&%4/!@41=*5+O)
M;?81K1 =$W+>.\(C[U:N/9!GVAK_Y"++3RP?G]2I*(^8/"YGTUMR8H*4<DFE
M#(@V751KWWKCPL^YHEKUG2"(">\EYX\.M0K/)L/2H<%[(D?4OV:AZ'2(UZD=
M/VVU9E1K@RZ2;FSPG,]$<+\:QT'5$IBW=0:[Z,UW+@*;MGA@;MNY''[@I_CV
MO88]/B$;,6X>,+QT3^F^F],-DSF=(KR9=EOPQ:Y@87^K?>%1W8+8/MAPC6B9
M1T"-)RG+/.^@<HWK6+3]/9S,:M;+U0#;'E'1DQHM#W&1@,R_^\["[Y\+%;B>
MPU\?/K\"0 L4=F:V '< K$1 XX$CN71NVS=Y47RJ_S,'^V,[*T*07P.OC-[)
M<H24^PNZS7X^-+G[F[:4X\'EJ3SHUR5S-3X(!35;L?93QN"B\[P"-9RJP&)X
M[Q!+\K2'(O-]7@6DD>94+2_-&79Z_#/0</*M-G',?GXNA'[0N\B!4J*U^Z[Z
M4LQ3537.'4L35.!LM,Z8^]Z=*X Q-B>*8 U&G5+;G[UO]J9-F7*\.>FG1BU>
MF1\*-HDX.S+K=! !IPU(#OOB-,;%R]MO0BZE&^HM]/MDB\K]FGH6(F!NU2IB
M>:9ACH:&=$_3B#=&?')12C&71!BK>'DK=W_,O!$>4L'&C<@R>STAN)</C'@$
MS9UY+A;;74?T@":[J#F>.F"H"7H0[43003G1XN-1N)I2RKD0O,O&0](=HD^'
M'>(NJE:L3G=8)J9.NZR"F:]=NDG'\=776/KF<M&Z_$H(,CIC\'N[N\9/0Y6!
MSD=E\9J.NIY.)8D^G&N!(5:,QU815@BG4 *XS&M$*T</>S_+%VR7J^Q5V63#
MDKJ+6U<CU">E.OG=GSR==)'*(3^6&^&POQ02D3<M2H5(%-RFGXRH*' 4:';1
M(2:3F#8P2$PRXN.%=48]J8C^KR:)3 Z'EU+7DO X] J >AS)C:P=_#K1D6+-
M"N8RL?5\\,G06UK>.7MR[0IPUS9C5;B7/SY*,B76&B6HI.W/HM*8(EJ]_7V@
M"9C)_E*&\=7)VK'$-@?M):/]%8"!P.&)BO4!GHP+]9^_]&"(_S!>LFDM2ZEY
M%A?V(X#-CV0L@,DA80F<?A!U0"^M.)SB4Q\A!!=,D.Y]E! 5+-+11U=AJNNS
MK:Q5DX1_>JJQ2A$'?2^U)-36"U@DOTCSB!^AT\<]TY*<7WDV65O^M@2?O6&6
M=@(;+G5U+B5S$I6Q:))$U3JNW/6 O\-,!XG'WW9(O\PM5N;RE%U?GG<R6;>C
M$!IM!%R,?9*FZ\07XVPQQ1'R^KYH!<GS;O9[4P<8ITH"?_E0\<6/N%B^AS-[
MEU.+2\=_DYH"7JQ#](>2<&'L]]OQ6<[>F"P_7G0L/S#<H"V%?P>8Y"T0/EBO
M41"23U-_P!HJ4Y8#*,;6=P32_SD3CJ\0U](^1;-.,R?MG+TZ1'2TW&'MD55_
M^EK5\'41@#S&$P[%%/_4(<&K=9SUA<%JX^O 9U-'90.E.MR3O=^'GP[)CU/O
M=WORQ(G$&%EU+<_6= ;>;U&YV>CD6@DQ#2ULK$6N39^ X6%91)PB\Q6?/Y,1
M9VL#F,HV0]-_--JZ^2!H=<TW<E5H7Q/])]!9O6Y(G.I$V[_Q+;6.S7H04P*^
MQ?I$X!G)\5J0\BC853SA7?I.XRTV=3@%WAN+U$M"U85Z5]JG9^>CH4;[Z*G.
MSOG=#0@Z41UXKY):7,5<3.:UY&G_,&)DC\HVOPMM.$40@]E/7[(C4_5;:[/>
MN8R))5OQ3OX:R*3YXDOY494_3KI)B$]K;OL*$'IY[N#/ILW^&SR5Q=BAT:LM
M*WX =EGD7^S+ ,Y-C^U\[U<DCE5&J;2'(>0F:Z=V]^'" A+^TCFBPR9V*2_=
MN&X$F$A69S/2LT;-84 =L0Q=<TYAQ1,"WYNP] G%\[,7;;Q<=TR?=-J"'EC#
M=9<R"@CV]:D&].G[(:5X/=[=PHD/^^XZ_#:8ET1?OL3U2AF^F6<E#MF^Q>H9
MJRBW?8A_UWD%T,:TM>9NG66=9)H&(%QI!5E+N;#QV4_7T: 7'JFZ$W8D41M.
MY%J\<SB+YD"@D:]S6&!,1I>K2UFB(V& ?ZBY #GIY*6*JQG?BH8%C$RGAW]V
ML[>)5IM$6' :MTY85T\H9_"7%*?HO7-A<)&<);I+BTK-I6-/Q7#JVQ<T7/9B
MX&'<4-5.E(";UVR=,@D:="1TAU]]*([!7C=H8$ "">'@@ D((SRJ,1OE%?9-
MXD-.)=M3L8 X'IV3($YODL3=2\$HY^";ZCT:%7X>]>&6&1JC?A+E^#+[VC\2
M'AE:AR^5;%,]IBDX*S5N=\9I>_UQOL\(7+JT"FVV^--D[]9'URW$VE(VU&A1
MF]CR-3W@5,!_B^> 6]"SIJH*N@*<\=-:C54?=%J'U-6-FI7PN#".&\KAM])N
MBF2?A 70.@1B(@E2XSU#WW.Z=&@L),T^!$&S.6O6-S?>>/?1'MPE^",).KZY
M&O1!%:9>@19)_4CWYI)5=;L,\)LPA<MWQ(A/[U_?9O_&X]1[!:#I^^P'S/,*
MF'\QX;X( L6!H:O5(GR/>NI]U0]E0P&2KGMQ!497@-W#<%F?P P=K$?5VKQT
M?H2Q]W->A*^B!>V#E?T#VT':OTG@(D2-S!7@\Q7@MKL.T?9'\V7SV>&J/T9G
M)N=R(HHV+OV[WKJ'J%XYC%?%D#!*)UJ>QK5HQY1VSO 2YGB*,9^Q!'*]7C S
M-T^;_I#+6!#E<=T.6<(?B.H!+ARYMX0[4R V:,*TQNPYN<.[,=[J_?,V[A']
MW%ZCP>1E"1V]SD9P1:DT@G+%GTL.3!P"[7T<PF(Q8O-&_8;\VXG\@4<'7.RT
MKCTV*70JJH);=:<'1>E[6XV+/-G:%=N3Q0S#</[#DEDA,XU%EW;_QQEZ6K"L
MN(!!%$\,0H?:?*=I;RDFE4&V-Z.$'$+_I8!RGGZ1?>.U19LC"X!:YQ4(@F7I
M..LM+[-7?(A9J[,V'RM,2)S7%:@[%5$/Y8I->_[DHPLC<; ,B9'M9A^,W4+J
M9=)+)!RQ!S0VL5Q^%3T8;/Q9JTY?)#GYW<PR[\"P%U.Q&G93Y?I!NFR<0>ZI
MLIG.8<4W1U]PI89M8?2X[_2P?'P0=J^>B2N&N>'"5,19;]GL4NYTQ_I.N6RY
M$=VZBI!9A^H@Q%<RTRG 0L8[.[6M7H:"TN\1=B3NA(-RV^=W$]WG]+@TNE!$
M;,'XKQ_03'5@OS7+(9DMXXIUJT<@=1N=%I;<LBJY,K\>F:334IW#=.0J2JJ7
MSRC-F9E>I"AAR:8'O7G4T;24@*;_D7VV-.=1[[6A_O,\L2*4W"8H6%5NJOWG
M%8#>X5(<;U?@,+=8,37WN=^SME=@<.#OSY@O9!\^>FUI4N7*R#KLM5H<C"U;
MSN]:\K5!PPKOVC0^9 [8-3"W3(J.77V_#[NW?S)MH2UGA-'I7J:Q/Y,,*E$*
M@WT0GR\'V[4'@[/-UD(G8E2M;U"_6",,C1#'J=7%D?I=H(5I\%WZ&,]N)5JP
M(G_CF+Y&>PH_OUMML)M(%^/=6PD42QY<"2._^(IC",XPO)0^)B 91C!4Y*B?
M$-\Z>#Q96;NC@-24;TT(%=EC7%@@2M)E/OZS9.0$-;/8;<KW^:LM+(9S^[K5
M4ZSD(5+J]M=@TRV7O]G$1*HRT@1\#*5;\5'K#J0S]P)V-.V=K/[505,5:TG7
MGLMN&\4MF;LR?K,559>W+O)A/JT:;[UCF&]BJ6@5>6@29@822HQ5S5I(25T2
M&G%KR1DQD\NUSXM:./P/D:"&6+O5\"[X_6U/9H_RU>6[X*;0Y@_IXT?&]5'&
M&6,)F90!B'GV9#QJ58EBZVQY+QG[T_)R9"Z^[VEZ<'*T3FOZS Q&\?WAQ*:G
MMCTQCD-G BKARRC\P?%M2TT628*Y63^[#.TQ7U>P0L]S.#Y$"U,9ZUV^PS *
M;K+-? ^);BZ]H49]O^*WUXU_XAI[Q-CBSF4Z11;"([P*2H&L2VENB0485. 5
M)\-U.<!9^5?YYD,R:$&.YM!$.Y@B2M8]O@<>$LA:*WQO)^!A+69A#A&*RZ'Q
M#[ND).+G\M93>W%KSK]YE&S!2(F)0%IJ_(<AY5)T=*T.2]2;Q(/[K+RW.<Z:
MDWE^'U(#[SU@!*YF6;^Z2(#["3JAM&[,'=PK,%&#\O60;NA\&P\V_M:_%<8C
M<=RR7.NYQX$]ZEL2&@^X/>NEHS5*H$7_.KL"6,0N(N1ZS)M>RLP5;!(3Q]B6
M$!^4\1_!>SDPNA0<YI>_Z2V%1]T$I;3PH;9H>X),.3B52GQJ2%+]D5(F)4M<
MP:H"Q'(5EWA1T$:$/_CI>05@/+X"W-H.(,/&KGDH@L*3I_R%3$000$DIJ@8[
MN:#-A"C .2Z*L(A?O0*0WL+:3O<>T.*E.@+$,%)=4)8N4?^L$PY&9?G#;=>X
M<N;>6(18KSJ'Z9D<CNFBW.ZB-(#- 90.:XUMCSB6ZWH;,&=68[K :OL^VO.A
ML6O(^"?%K_\QS4;K9Z;-^T_T4;D5D";/\+W\AHF#[S^"-1))$M'/HL;E2%^2
MG+Y[1MQ8?@S0?;VX ,MJ_GT%</>9^+X/.!N],:9""]#]5V#@=/!9F,2Y/TPU
MF2[U8[^>JE?YQ+]VYS4^?Q+5YJ5622;FO*D_&E5:#IZ:B\TO_ WD*Q$@IGX:
M>$>+AEBSKE>D/K;UR8V3_VD([[^!1.\ZYU3C 3M^;OJG(KN_-GH)?09*D3,S
M8U&Y)S%Q^%0=_4R=Z3UGXC-B+@S_X(EPE.+C&GS&RKP2M7T-7DW'"T'>G,1V
M:#&WH,)6]4&NA$2657+!NH'G9F,9^J'&X:"_$@/4LA^',5'E9R,S2M?DU=B>
M7.;R3H]Q&A*4XX'LO-N+[V@-[&ICQGQN4LTOSJ'!NT Z@[>L=CU?+_3O<;UZ
MMA1.>NOC?2992HB2)5YNU8D5B)Y?=-4;$]QWSV)6X)L:'["UATG^MA+8)4J2
M65OQ(>K57HSO$U3K'T=D@3I2F]1"3C3RHN9!*?M2*2+\I&$:>S]_JZ^G9OT&
M?5P@D\XMO1SS-/W C"OSHPN4"G,3U-82O0+H 1M:AOI1Y%UD2PG/;4?X5-59
M?D!&4B=E/LS70WU-SSUVJDZ.LP/W,E':]SWQ<*WFQB,7GB'(T<X@%@+-R@%A
M&5!!^"#8EJC.QP3PE]GEV45546[WAO#!7^R9+MZ52@9X5ZR8%68C%96Q!^I*
MV$KW[REOR[WSRE$X/]C UB@FMDKDEA3ET,@SHE7; %G%4"$X1XR\A#NJN :I
M#;L#^V61$4'\F?]S[ZRRZ+W,^,RW\1*L.4Q^SPL=LCEJL R?X.+&[CNU-8C&
M>-VPE1>_*V8RG[!PW/%B"8?.PAYCD-"ZR=-EI(7X/"Q.7MRU0OZA]M//R0IO
M/;7VO.O)A@[$"PX&AZ!"E0F##E8UO?G@,D@"V%0IV)U%0>_,;.;$PE-'S'*6
MZ5MM=,U;DT_O-!UM>S^ZD/HHA5VRCJ"NM1$$M./L.)6:KI620>+<S?GD#76P
M9LF=,K^.3RUWV65!Y"M7@!C/L;D_/C=#OD/8^28.]@Z<]/Q!>I&OP'3S+Y?<
MFKW,$^KO:$O&>,),E.QO%\>_0" )PH*]S24+%J:#18L.E//>HO,_3*Q-6-83
MAI\_$VFP67LSH>=E[+MS<IZ2ON]N#=Z<B49M<TV5-G=(YAT,\?_"6C4OSMJ?
MU?NF*-TZ8=$A\Y,=&]HKS>B22IF6$@7,VQI/!MWN=?%T3M]"!)(N.%A1'0M3
M1J+H4YC]%S._U/GU@E_94,T3OQV9,%+KBZ?:"6#&JU5NIW,)I7\U*NPB#XW<
MPZ]W/ @&(5M=Z-NI"790+(\Q$D:0<*YXU221O#HC6<AJ5&=3VW$%\ -M>'2N
MD&ZR?KD),=&,9>+34LPZLUQ.V!S-3WLO;AL7JQXXV%,>A<_T/@7SGVNQ(#%M
M[P*&F<-23F6-<@J\'JUJI>]KY$U+"(J-3+R)4A/JMWZB9Z37S2]&%&/#ZIJ+
MNA#N\P%U"T=P8*(K8\Y\%\U>?MFY+7!#TLSFAOJ<Q,/IJE?W,ZG&FZ0O923;
M(;DJ**?[YCOIPZ4.I_%O%3I-"[_:7YJE%3[\].C9:])[#2%Q,I5*?<LL!(T2
M+X[NG%E+MM91]R$&W=J:ICC?F>34WP^C.0$=7S'?L5]F5QDK300DN(=N'D\#
M<3X\D \C+C%'+1\660VEI>14CAK^+*I7@E4)4RY1("/0O*>O;/SNJK/3_= 2
M9?90=*S#F*-J+ED$5&?6<0ZM(S'[E+7;\/* ;'WE9,A^SN_^Y!O,;Y=Y#=0%
M37?=7+I#W<<MV8]1G8^?U[[ $ZV3 F]LYF1\$HDZ#J3V&N>XZ24)#32K]PU\
M].#0U.Q'VN_P(&JJV-_&GV3M)+J!V&++,0DM>F1WP(WF,23H:P_4F3V?KE/U
MA5ARJCT+!_FH(\<>Z&7I6[""(]SQ,AJY^3?;D+5+H4^_A=4F;VG_#JZE(!'*
MR^VQS.<CGK%>S6&]$L@*R9:KQE)$"M7*F4& Y!E/:O<$AAXSOR;[9N-N?KQ5
M^\938M9/"H/H"VZY5V"?JJ_F[&Q'D7+XXGZO7.2J_"E<,AR7G'1)I<!CVHQI
M1!9,FS^.M?,L4V8Q%QJWU+#X\2,O=%CCW7-&)G33%2#,B@$:\&#)P<>F;G0&
M8OI1XW%=77L4CB'VJ$Y]/3Z,B83RQ1=?%[X_$UU'E1I2/$L7T#/N0QE7@<=.
M)V!?']W8)R:F0K(NC4*Q=5^+D#[G<U)NSDL,&,1T1 LI5K@C8A!<HECJR:SQ
M$5;SH<-&;;5D+4Z!_SO6KB." "[?HB@%DF_5-8DWN94T?\XS$DE.$2-P:]JP
M-_8(3O>8[8&Z WA&:_>84I;5(\=7]<[]@ *BWF:3;<,!_N$/R-BTO5;2-]N8
M"> IJZ[LNZG=BJPM]4@)MZ@I04?T]<*L\0LS_N*FH7%(V(#"[1O5.A2%,A"D
M'92#P(:36V==7NH9U:1 UXM[PV5]$+#]"<=\K-"BACRHV"MD5XF"P ];5*MP
M&('U<*76]7?]KJ]__%S@4PP_ZIEC]_&.Y8PL*$SG7']K;$CA$/Q1 Q7AR$PV
M<;_J0_U+_@]@H]&L=2*RAG<W7Z1ON>M$I\-PQ67S7OJ=KOC$02"1DP1I:]RL
MYU>*:LJ??RMH@P/^K-V=JBW7C784;5MDPQ%\MC^N'OX>K@5WPNA(&C/\1G6;
M$UM/-.]9\B?,_H58(_]4DJ_810C+ZV,&-2:%UQM2-M:+WTM94W]Z_)$N_!V
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M#)HC=1E?94@P/&<EV/QC^GJN1>5/G8@YM3 W*T9-NXECF,=DX;EX]YM!8I(
M?UFJ RO'L6<<*3F(]MWNG!KX;A JA[P+/E2*CS?"QL*6\N&B4%&+_IDC.M>?
M>EZ;\B"X?6#52&].-+LX1F*S-SZR22W"CPXE8]V&/+Y@_MVEL%M&I)JS_IJ"
MF$<0N2QQ2I];:.(PQN4Y]<52-89-#\W]Y2;;+1)V_^U1HF> -_<_O2;KYJ!N
M?Z<4D<V.;T4',A-8L12?!?=:]-#^0#5L]I=ZYPXE[S=.@OTG?>Q_X?E7 +O
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M70YB1*NR&M;&ISU2\,!=B=+2U%(>,\N8%S+0MS\IE50?<T/;-QWGP$]1IH>
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M1X9R>:X4+(%5+\2\NZ/F=-FU+99=M_"U"O,-P&^ P9=7WPM5IVM1V^<F_,K
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MVQ))=Q 4 ,=_^#*^H]?HE97YT(U)E[,+%,"2!J<2!7"+$7N@U<0-G0^'$K:
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MF-'I.O?V$)O2N:0[M7J*F1"^U3XGH@SDL:YS9^&HI:TCA0,\#EY;/+8H"WM
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MVG*&ISJ[B^"$8DM 9/6<=61 TR'Y[6;>F;B_$,,B^-^-@0(()R[0G')9RE,
M:,-ST]3&'$\"-TBMDUJG]D>F@AWH?S.(<V[90L9TSA&D%@?EDFY]HP"F8Q1+
MC'IVP,N<W> 1M4I=2TFHHPB-PW,@O8][^QQUU*ZS9^-M76?%RO;E>Z?)@B,!
M8@NS3!TP [_4T.+)#4;:P.ET_G$#Q4G]YB.)C%6#?(3TI/?:\6<^3=EJR) *
M0_!_"@66@<1G=Q2OG@L@WDO$&_MPHM78J@1'>[61J\9E?.[@GSQ+&?HG/Q64
MJ$($-3_\A:79&H ??0:)->COPG1HR+U@:I+]G#C^ZH^K.84.CO4<2Q-.BEA_
M.F)U)YO7O/L,1@7OKG:.5L"I]>7U.9:"$<];3XZFU#8NXVY0<1(M(A7ST4^7
M!L6[2N]7?'Y9[<]WH]IPZR+SHN"Q9OECT6GZ9(*W5J;+<YA31LCQU56)>B"(
M0PJ_;XV5V"Z=G=M+-"/5Y0@Z+;E\FSVL]4>>68 &20N$#1P%$#EW832 '^I\
M>KM"$HXK VUQ7AE+]ODVK+HO-=&;R6-K:VN^DNS;Q7"4N'7%*PU>Q10O_/S6
MNV3"!]_+M+M#EVY[U?[JIQEN?+C?<BKYP]W!S3-W8F; %E"3"GGG%78[_3H+
MN 4Q:ZH<Z,33V"8Z<#E&=R%%6?#2Z!V?!W40ZQ3PNRGOT"9$8 .:H[< G)ZF
MG=C[3)%!J@41L8*K2VJ23"?*GWWJ=FG8PC;N0R-[.F<[F3ND9RV8VE^'DWB(
M.B7T  )*ZZ;/_ [#Z5T[G *=SB@C&:/VL[;)X&[LUS)KC6?6;-X7,JSC#)()
M$(U,X51MX6Z5>C=N7-E@M+&'W>(RURC&[JC:]_.2B]GZ-IE'T*D&YI<>Z&1Y
M!(7"H#_P@2NM%G+GP+'%AG.2PHVE':D<%<T'*DU)<W//FI>^T,7RI@I5?UZ_
MXB.)H@!NV(!L'W7WHEDO=V[-^7ZQ/,OI/]M)SY(OJ]O SJ$-S+2J_"=<6(>O
MHL)ONO5;@47I#R]4?%((?Y7>#+O2/MLW6L^9SM/W9UI^P([%5RU'U+Q6:3P_
M%=*]L)SN.%5@NSEWZHB<_O.JW;0/6V")D1&Y\X8\@*GKP!+4:,"G1XC( V"$
M)>NN2S/PHZ+L\/OQ@7;9Q*@RQD4#C6O)SQW8WV_$?^?[S4G.1ZN;3O'6/A97
M'V28L!:03.D03?C:Z5@8 ,I+UX* -S=TJLP>^]S?HWOW0I;!_*W.KW)Y21G<
M2(P9JM'/I"3HH?@&41SS[>2PG":\H!W,HM-1\\5GTY$.:AW;^CAM$Z4S2>Y*
M$!LY."ZIL:2&+SRL)8K9@^]NY34EK^B@I1@QI2TF;_7*:+M(YM]?)"RR(!H]
M16[:G[;_9?(^?1V_-0I<+ZBKT>!4I  $'W,',=@Z/>E?WJ.N<WJ;NGXSJL!G
MM,%W QGU9P#I*3^BTL/D[ST]ZW;L,>0I<3H.$^ET$OJQ!]K<RH5DT:<MUD8&
ML:OEF\VLP4@:>2:.YQ[/.O2#33#U_H5$':570:.O",/@\+GKT&B\:=>/3D2.
MSS=YD>6OBIW]+9,G%5F-53'$BY@7U16P!3.(L=/2+Z=]>=WB;VQC4>QP=W.[
M#F#X/DE_=\'A*(AOC,0;>#/;V*6ZR&W@6:5JD,F=8WWC5O:\Z-?ODL<L#J>F
MR7+.S\HS51ZB2XP)D=K0\.2@P4ITB\^B-A7YKK;6 ,0SR:EW3ID"*-F768N?
M6)3>@0V.+*((3D00B8'0EST=F+_1.J1A4\AM?-5?QL;5H/:[%6BG^!2,D]IL
MD;^^R-)@M !FF"5,6Q#O5]3ZITN7O:D);]HKU275*0S4+=2[Q,(O/R(+^D!5
M=XF.(MF$H/Y3.52F8O?LL]ELCA:N/S=R]UP%FWS#@0[,%K]*+%"H$@V)2N?C
MS81HJ_N].?[EB!T*0.POFHD ! ]";?GES8IYUF<)/1:1AO@7-6].N@KD."KP
M_8,H]TW(,)FQE:B B%4C"5#5*DJP/E\>=4"X+\'3R&9V?[%D"@"4(+AQI2K8
M2>5GM&(_7<]=)S:O1>;.?('41%P@L+6/?_@@G4.\AWRN(;G-R*BG?:XZCX\^
MN24[S&YN(E?'D,BR5?<&-7%3[Q,%1;ME;Y+9_5W;0P1LG\Q*1]38_]5W5G T
M(+74Z2("Q$S5PQ.2[16!A*I<R.G9>.("!4"O9I/?7N*C8V06A;!*I]Z?[/YZ
MI:I'!%,..;C?()I34RZAGV><^<)51+O2%WL\)Q5479O%-NQY2_76LXT75;_0
MH6>O1VM6]SK)&W>3".>L>#P1)"6X@6FL-K6O7D-\0XR/[=B=ZZ35 #E\H4\Z
M3JT->\?'N\6+MM4.;SEU]WV,Y%GRYJ?*#+]-:_@';5.\7?"V(FN 5<5N;>C8
M9]V1(,Y995LA@E?ZK=1+HS4ZB^!7Z\ K\^-!XFO8.Q)"IF8#FRA)Y,A!?M@U
MI\PF$JHJN<UMT JUGS>)/,6R&=]:+T@5O@E9OG(P&[<X5>4;$V:5C$8ATB?!
M0R*]\%+N9.0!!D-F)B'QCPD/%2\3WJPNJ;6+U"B=Y31T'2'$^CA=X*BEZ;6=
M'=B1RSDR3T+MT9SF!'_-*$("D$HX[\U@W)_:N/07Q6+'W7&V3:,N5WP"RX5Y
M93EA=K_NYW^9[*Q_=EO)NI877W;MH(0/88H7NJ=5H\22::5[7W?(VUKZJ#@+
M @U71*&V1VJF'7[."1!Y,=YSG4OPUBWJ%V-;#?<9X8LT%U<Y1:56-\0-92./
M=NNP^SRMY?/N?[CCD1N*?#J1U/B1!6/"7K?G_<O@"2?_Y:@X1?!#K O>N5]P
M.TJ>/WMJ/;&H-==8I0@TUY PQFA[^HOES.$4'G&0Z>CS<%0<);CV729"*]TC
M*4>QV)@]B$&_[\N*OWC94$F9_M"T$]4CL%@C'(OX&W!,!"!1I*ON]KWCZ*GC
M(-U/2S7.;-[^YU!U#470QNFP\FYQ+7!8OXPY?CTL_%=2K"KIR/8ZZL-'-Q17
M$6)0ZY;DB%98JQWD5JY*[)<0"17N0VF NZYP9,$#B^P)TW"4S"_=&PO69"Q0
M:M$\J9==T*"$'B-F$;#]KH(Q([^> OBV*USE^WW=#]%<1Q89$,?>RMV=$-7P
MZ'=BW6<^6P._MY;H6R^QX6W6B4LBJ,] 6TIE\[)7.S[,O?HPK['DLN)" 9BB
M5;=),GF.K(YKQZ8VF7TA'QG'(1X^$;)OKW6NO92]^M5C; 1=50:JPEQP"@C;
M.W\NFCA<SP7CFY[UD\@[&#9J+$-KP1[I&8Z0:M%S 6[? R0'F^X&#8.IO^]Z
M9O@9U-=&VOK_Y+82SIVX9M>U\KG/#Q3_';]UW (%FI$LQ^7E<%B:/EN]:=W=
MA0'N"IOZ/[DV$:*?F@X/N!PD=3RO])@^Q3P6_I,O*DS #+U\0C5<D#4G6&C)
MDJ-AY89,&GWR\^#>8;G,8L82BX9%"02C.I>XNVXML*TMB00'K2P_S"Q<=2 J
MD%X,>O1)*;L[2"1^6]"AD2^!!.5]-,^%?W@J<\\Z:VSC"'O+ QH& BJRJ\S[
M@S9+^L"M3"+2,<^T1^>,!?H^=\U -DN@U^U3_=S7=NU/ QB%IZ?&Y8S''[KH
M?7\#;RFK^?SN^)4Y,N.6V\7-&'W:M/A ^L5[_C<VBF#N%GPH.:S%=C)F&$.*
MMXEIW*SV)B5V!XJH_QRKCIU 8ND(@D_QU; <WUK6QA0B(8(-+K8D@%]9ZA<-
M[Y#%U/EL3[<88JNO-(" Y3F-@SF[6_5K4D99]A6I;]"-;Q.\Z0;DEYMFTEI@
MCTZ+US\X,-(Z:@WCRU[U@N9]!C;TULG X4/"8J+^2)D$?7QM]NSOY'"75\SL
MK,.^E1F?ER!J549&-?U3[PTJ @9<-GJ4E^ $7J)]@0XAE@*XMJ\^Q8RAF2 -
M:YV8!9FO9&4UC .WS(CJ/FX!RIZ[K<_&Q0=H!@I_1;8%<:<$F1FC8T2K&7VO
M+4[G!2:^S9U8"[*;V-S:DA^?(3_73$\L^LTB\6REV1+8^"O9/YY&.\OW]DJR
MEO3DU]-DHX>_QI]\J=!K,P@-3#D]]G.TWLI>KT]6^P/D#!"=;Q2<AX8$0.9I
MZ-<93;.^.<-T(A$>H4@DS>.MO8G'5)?_KA0B]'9Y6\[ES#7R57M3M>#;T:"8
MY4]SCE4^X7E[LW]/X%=D_O"R8QHH@+<.:*N($:(B9O/G3_OY/2.KNX/A'1<X
MQ_RR?=8T8060W&F,V9&.$_*D0G:K76V@"#_0 ;^,: --4<V71^(O#G<<+2QJ
M_W)2'>_[:M:]KB%0=Q)C5X'@&PFZZO-PI15>S9*NF6"SV]Y68;^Z5V$&8/*R
M9OG-?:B8<LHK^<W.S??63,U/#<]K#_CG)(0_'MYH>Q?$P+IJ^J%L*I;Z5:V=
M%.#9KZ^GZ/-];D&_+S,2$N:<K&5WMD$V956C7T@&C]>"I!7OF8,=:T'7EO&J
M/WZHX2)VV[3M0'$/L@+YMT7W3T(>@'Q7C1>!X08-NXUH$K^&56A;_4,T3D&M
MPTNWV>%'J_NMLIQD0X/8 <#6/7QUT@XX%]/$.NS)(2%.;!3N7F^1?X^$S7+R
M=+ZXSPQ,X=M=_O+H326KT]>JX-!VER./O46N'Z__F:WZOF%=33;%]6ELS5*I
M1;(&0P 3SH*WV9)YY,#I=@N'V MD%+?D^ ;RCN'L/69F]ANF)^,SZ2[N \[;
MFWS9,<_^E[^D*BM<JX$U?AGW'O\Y9_H"Q1VR\!C_ZT# YT'ID+:<8ZA[/P_A
M/BY0\OJM^'$DC@B@UG#*AZ09UOSV/F'4+@;- HS2"9?F.T/DU8H@G/=JANY3
M &&:PY.E'FFC65K5F94O:M^\Z)4,N?B#P_6OJQ+B.S*3L;--]OUI4)X#PV'<
M1J69+^:#>E.8-^>8?EL]1 >GH-G1SW!S_(/R3;Z+P7MWBJF<6U"XN!)FB?YM
M$@50!M713_9Q_.#7;DSRQB@*$Z@T\+>V,VFB*8#J>[6_[ W)6)V,UGNWXC?V
M_B:VKL'.P 3&*1M$<^(-Q<P2L_6IMR/#ZDCF#Q6:9:E_9D.HI%>H$MS 'TUK
M0P*4?VQ4K6).&0L@)<J"SXX^F'3SW"ZX?&7Z\X!;>]  N0]=I199#K5%7%V;
M$]F=28)\6+OO;'AD\F)0C/$MTB0J_N.]^0NA%L9K,L^D[();9Q12;8RC1R/%
M?5,0>,^IOLY#.>#U */=SDA/"H!=54)ZQYEW/!HY?-!\5%+T5>F.4X7:YR[F
MKM_S?S%V\UM<EN/(6KQ:M'R?3*^M$.A9PONR7+627@/<LK/8Z+WY=\D08',%
M!'33$ONT87=XW=3-,^:6MU)-M)2PJ^+8Q2V^5M1W&P771L'1D@Z[5<+ZSS!X
M!9A6"[8VRYT*$S8[1#>.:.OO@Z;T5!+G7>)JV9U'9M7JY&]LD7C95'"!]]F=
M;*K"[OASQ%J"%\NXVN#,),TFIC35SRJ[$O%3VH7K1F*J[T:/[O3<%,VA+7PI
M);;X\2G#9O$/ P#@TL]R >],!X.:5*WMQG-6^MXZ 2CT(^S#2V>]=(T"&QX&
M^JEZU))3V7@:1LD^.V93T?5_.G;VIR$0KV8Z1M(5"5;D4+Z"B;ZK["C;.)Q:
M-;3H'(X_7@*U,I]F"5HO)B8BY._BU,L.#.@(Z2:_+*0TP_:)*XN^G%%/.M=,
MX3>:V"8#1'<S6"U0;.E=S#-@;%=OFK=0;W+=ML;:ZF/!\@SKEYSCCF=IZZ2T
MA;[L+T9B)\R65\_@)#F<Q5,(K"*MG2P<9(,Y[-51#'R@O]?2%/,Q2&*MX,9U
M7H!GGY!OXA803T=F2&OA\'\=MO(J5:321%7QX'/7WO=+=5V%+_,%LF.]79X%
MKE=J;'O,41,^XZ!1B46(2(E8)Y/JGE"(U[V![5P.@[\WS]081MX&4BV!X>BJ
MB+Q2$AT!GC>)]=&RV.VKC:X><>"&+0CD+>=^K&]X1Q<_V4$CT;\!O .#7ISU
M2=A9I(HJ)?-JE\6:P:D[B\0UV*T"?*UFWA2'DQ^[6;95EHRY%8AX:RD<HYUA
M"B\[PQO*F H.)\XN[:XD>@ 9(;++*7FSL>E;C&XN@4Q?>I;459]V 3CEXC#*
MR'_&<U-37MG)$Q_9EL4V*G)O3!Z$,%G_H *1$YGZ89S6%S\*_,K0U5RP 6*0
M=U\ 1G#R$\H@)8[UC$GECI)3G@F81_666<R/:@6!]V1D3O##E;XN8N;)(RH(
MK\]G+GOW<8C=)FQ0Y$RZT6"0P;^8S[,ZE14[#Z(F=._C!MK/P M7T;>C, XY
MENO1A<4@TC$X[=ZAG-(B>PR.=&G1/=NG"M<W$*XHY$@6&R.I)@/O.J0=MZP+
MOMOK$>]X G*K0+%[E(Y;\/-+"*'RZ\&6V"+!V[.;%,"E[;Z259! #UXGVF/@
MJH\?!6 ^ML)8;Q.G"HFN89P(+?I]&=[2=(^@#RTCH P(H3AF$K1T(^AAP\A2
MTPCR?!L\7&_O5M>\RWQAZ^\\_XOYA#$&;!N0@>1)\%VT\-?]A1X1!]\@.!U,
MQXH)<AO!HG^GS"JU.G6R')89&H]N\=N70;/&#Z?W1=;'O5QT]A4WAB1B1>XZ
M,/IEAH7X"_Y*M7\W9?3A\1]I^<2.J@:EQ4RJEJF.V#S'M"X':&GOH/&SH0HQ
MV;A/UR[?5G #,R*BR@X3Z1S\>.,4>1S1-/*@/!^]_GTUUD *8")UW9K3\MD9
MMX#/)#;/?8XN9*=S''KQ4%NGW72[R%L1!76NM7OU9N_1>Q-FNF26GQ<H@'<+
M93;1_L.I65G:95[^CA(19K4%I*M!4;CSC_,:*4=TXGI9WU3_E@%9K2V.J,XL
M_)[LJA >],$L0)D0BB!$$$W. 7\8JXXW,)U$1DSKXZ.J$NYQ3PGUPX8^=;?&
MM^UG+*,2H[)X.7GQB+8)$A0O9[ K1(ZTIU,=VG0A][G(5LO7]%JY;FHN#HXV
M%.LFZ\%G2V:%TLH73DM>]L$="&KM,+7$!@F;LE7,Q6/-IL3>"+VXX%$*H/(W
ML-<(3D =^0Z72V@$J,RGU^[2Q)*/CR*2@]_4@V;K:HG)1=NN;(.CH$JQJV>9
MI#O*SE>;?0\W+%LM/98>"3ETI$\B-S:&,K;J]1T?[?USD3JCBV>@\TKSW).?
MB<_P[5^"($IT=$[0VZ["0E_/EA1&]PI"+7]8>N,+<*59\KLD*=B+[,[V*;&S
M6M51JJLR'RD P\YZ=45##ID!QQ&"%OZB2'30U9'#O,1-S(N;4JFE01#_,+EW
M<6?,K*^M65JG1@Q7,7;D%WH:Y3Z9\?2ZYA'_M63'_[>-Z@^6P38)ZI(8X<CM
MBIY,>,R\")<"_3'"7/J.2%(4I "ZS@+^J5>PAFZ9GFYZ,&PN UM;*8#@H/?[
MNV@.,#XHRI0ON\%Z4![8P<E>L<NT=6D^WNYI?'4/@L["W!1RMYGK&L+@:6\9
MM^^4A>;-QRQ;EMLR%QNXCN"QK^I1NPRU$<#-.9G/)E1JJ*^)52W/W]N*%5%]
M\/6/&.I:O-I8\$Q;58&U2\+!:66T34#8IOI9DOC7DQA^[N"LC[!MA*]>@>0A
MLN' 97=M3RJK(M;F5# =XQ3P6GAG,WU6DD8'^6R+%.\[5_<CP.<+?!-.1Q"^
M,+UEZM0*?5CZ5D/'-V\#NO?@,=K 7X5A?X?$!:WN/+L-I('NZIX[]/:A<_Z.
MW1*E )0C6[$D>@LHWA,]9DT!@*R/T7LBDR++X,03H)(N6)$":)$BOH .XG:/
M*8 K3&"2!7 WGCP"/) .4*  FE4P% "3VK_VI'F'_A8$^AMX125@WQHW,*4'
M8G2@Q?I4-8O9K[;-\=1D/HD :^=N"ZTJ"\LM-X59-%]=H+9.OGH5DE7&HSF>
MG$*$MMZ5WCM\@2]ZY=-YE/7\2V3U;O[_:.\M@^)\MG[1!P_!">X!0@@:/#@D
MP4.0X&Y! X3@3B"X!1)<!G=W)[@EN/N@P1ED&&"8N62_<O;=^_]:W5/W5-VZ
M'_K#3+7\UNKN)4_W6AV[*YLAM^A 3=V1C0(_6#CH[Z  ),1\-,XEY_RSCI"
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M$^@<M]HI56Z?4],0L4J"C2M/1.(&F#Q<[U/UL&R'+G4FCJX5#O:7B7];W0K
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MW1F@7\P^%]"\^[$J0L8$>BNI%F$#P4^?D)=9-C)*'A@3;4T1]3H5==\(D/@
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M0;^-GY A9?JO+KQ(4,+FD, S7MB]WC:Y5VR+EU>LO]FW0>&=J'#3#96E4/!
MKRB>Q#.QIWE[-:\\O>8>%#RELR0W%8UQCS(AFGM161P*:!MZ/I/-R!RYM"29
M>JM]S/GG_ [\O^%\#5.POIA1B124)!R7*8A?+?S&D5;GHR350MDORQTBXI?O
M8T=Y^U^_#SGI$+6L^_VWK!*4@<\L&5@IF:$E6B5SWWQ+WH1!PLQ-HPA.Z)UO
M"/K#YVY?;@YB71'1C" F#CO?[IY>E;:S(4AWWA[JL>9D9?TG7^K0N)XE&A,J
M$O4<!F"B="VZNS#5VVJ9,:@0RK\\6G' 9D#YUCI7;G._E4A)?W8_B#2I_DWB
M^K0J]R-#DW^]"O3];9:ENBA^#Z34! - "1!!4=-;NB9*/V>B'5TM*"AQS"$^
MOE=?Q7^E+/Y=:<AI3H*GP:CF# N)= 91H)%REB\\>4L$,B<@8S];>ZFWL^J1
MEM$L2V<I&C4(!D);V@=$>4M6%:L>3)WM@'$)% FT9=J(6EG#V72-1Z*3H90%
M>BPC+EC%E)+1ZO.&"D4Y$7%_N2.T4X>%03\I8QPRS3ZNW?GWEZDI"S8\TF;S
M3-*"B^!\IQ^@Q[MV@4=+4/^VLB^!?6N1'.XY%3#+37RP:Z! -2A.89DQM:QE
M9Z;(EE5UUCFMPB%YN/L)(2>9K_P@09JXIC-;<V#W%QY7E$7=?^5<_6\JN.T.
MDVA4!OP\E+W5GY]I+F-"^N7+%0=FZTXGY5QW1RF-!,YFM8A Z9\T?.W, AZ6
M^HHR<JC1KXV<%=Y*E,/\@W7B9<(IE\$:%JFE9K$L!RG?\VI<7OKM0^F-]?)7
MXF\?+?W@S-:9CB=Q-8]7*2ZVSBG\%/B?(?J:CNHK_LPZ"U><%R&NI!MOO9'X
M> NC][3._JK]YK)\^-???0S0TP T=48,5FKI+WE\2H]7QL!3YX4KBA/]I)*S
MPHN=QGKQK%]X2KBE>#1KFAK-?_]',_IWA43 7KKLL6%#$KGW&0\JYM* GPP5
M 3R0LVGI[(*)8@M:7%G)>?18P@?2TT3881X\!/WU*MO\EF6)HG]U_E+B.XKX
MWD_;H-(JO73<AY^1@*=74!1C(EQ9I\2;F?F_=);_7RRXE83Z1LMZ:%8<K.82
MYAP3?"%=Z.8V6(T==H]NK7J5<O&DRDL?J_I45H_M6J3[_MQI?<CVS5K98&?+
MUW6G3BFX)E&86M1,0<,"-WH@G:#2JZ8E,V\Q4M<WD?: XNM0BEC'6YY6![XC
M?1=U^RK%?MJ&XF*#NU*RN,*%Y5Q'XHI#W/@4XV0OHME2$*$MF@Q52M7=@NJJ
ME,*;Y71SRY](X+(TKR"%!%4)P'J7^3W$U-B.*OI+8AC4AGO1@#'Y=07A33/.
M6:RSHJNO@JNT*?0%O(<^^0FJ"OM>YY\A_6S)EIK(+K!2?0&31=N;Z*VKN">I
M3/J"LS9:&MJ;,&SC9%^V-C_FSB29)'4JYP>;*[<A$6H\70/8C2PMMI6^CA@S
M>=4& ;.'A1Y/T>B-IE'"W3?P7H[B/-/K'>1*T=1BW;9\<_7QT?;!J*V"0,9+
M<3U.R<.PR<%@^ PQ1=)\QS):UT;9[QNN-&OUXQ^MI8\UG3Z=9:L[]^L$C7E-
M"*E&?G9X+RULN"'>X[:\^>(@U@OHK9^]Q&D=&7&MDU^<!F=J)MP[5<MFR0X9
M)6T23SO29-+>47F7J1'C$N".B)I E5.$?[F2J&()N6ZPWRKA*#54<25QE%0/
MD)0S.ASOD[-A^5P4%\ZZ4ONJK_8NY"J()!)GQ>48^'M"U_T$VF4 $_T#D>C1
M7&?+AK :*10;9ETMP;$K@PKJTR).N)*_<X'!&F<0L]OA\(0"22F[/6*?9,2J
M061.609P)J=CZ6R8+'=<4K%4"LPVDR^PT99<E4HQ\)Y9.TI+L]=:'-Z?!HD1
M,S<HT#ZB7[7/(AAM*/K;0L/7UYBMN/"U>9_VEIOFWAL^Y37L;5T21L.7>YJ)
MZ?5N&^*Z[%ZM1TOLY,S*457_\_&"G#KFL=><#&?;N^^\LO$DHM]K@NIN8A7Q
MVI1Y?YJ]8HO"?AC]P\NRF+_EX:HE;6:CD[.[J'+^,O-7L%C15C1T-QV4;)*:
M2$_ZRMF1LU?K6QL1'T<\9J0MZ>V/#+A9 QFSEN6#[+030F%)/5L]:1IEJE=4
M_0L<GZ6PQ#\]$_JHV"^6R=D8T<6=N6A1^_'AZ!CAJ\QDT=N=O"8(O]LW:1*H
M.Y&"Z(=PRAQ,V?Z/$GYVRF7K'NAXZ)9$4;*J]A1[ XJZCT.T93TF%OD2.+(2
M)'(GO_[\MI&L=?=!N6P#DN3UPXASV]>I\T4.P3T\9_$VK=HA,?H#<ZVP&E]9
M!/N[][6CW^S#"_I)3X7,YR\+G]3Q#)XQR]=(KIEDD=UD7J#$$D265W ^:8G
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M_5%&^]9K%73G8/3*Y,]5OK6Z+8*UA3T%4K&^'X)E'_ Q##P=GUW3R[\++[0
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M2@#WH>O_^47]/\KL@%SXOP!02P,$%     @ .8 [5\Q\;1?UN0  T\\  !@
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MG;1"-Q]B.*P]1NDXA>50(MB_5/N;9O\UQ=[^MS3[9\7^MUXS  ,Y&>GFD;,
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M')B4'V:IM2B^IL-8CYUOH6_[YO(TV>-:J6SPPE/36Q7.W.?%1,!1/"MD2.6
M9;=?U3_!/:<*<,3+G>=I7(6]7M;(P70O0R+4P,_+G4UJ+!V:C\/L/VZ].@K
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MJ[,N,[#"NLA2;]T@6TX_!S F$7 4DLXQW:JDR@(71YABX9^IFKENX-%=48,
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M;DRK-##^.]HX7/OMD1+A<?K"K2++I[>67C^=;_E2Y3J;9R9NF07MA$1"+VJ
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MFU!]TRC'G#JNK9/\#2[34W@\0?#)HN5K]]<N9;_Z)19W/STSQU9!<4Z[;XG
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M$9UFX/9?E>GL4JVN)CH(Q[IB(?EX=7=!QZ3QH6#Z6]$L&1610>2^@&.1#R3
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MY"@ITW[1J#SC26Q;L'_U<AH6-B&N(W'LB.EFGBINMH)DPKK"L@DT=C<1R=;
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M5.VR4F>.=^Z?K/J8_RS>78O[&T,7J'.>J<UNGH,$[SJT.#QH;2-N=%211V'
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MFB,:K..PQ]HND&12V:($24.5&Q;WPNHHT5SGS\+"CFVM)ZFB*/,#_](Q#T>
M5-=DQ!6H,'+?O7<H@)6 \9%@AL3JZ!N;-J1+S0750L75-,IB!PB3&:<(W*GB
MC\P:MM7X8$M.D;_"-=^6<P/%MD.FK+O'77,Z:FSB-$B"K#VNJ!48<O5]8D<2
M143P#*"[B=#%V2</M8P+*^\TO&2L(JBE!-NH,X:4&8S4#]0>"X<\[_6!>[WK
M1-4^[SO6/"?S,YDZSE]CC\/_WBJ136Y!Q40DWGI<PG\4>@8(>)@S#A>- J%3
M'/2<^7[YWLSJ-51IK47XWYNLEVWZ4/4IKR;EIGQO7T[&GLR*G6BQ33H88]R4
M0"/?W!:C%+!'?CVD/?%\H"A=8G]RN[JPT3@35+CFMU;B,HGQ/.W+95!CLO$M
MK;KU\DVI%&.13"7AT-32]GZ,JI'SI[SZ(:WH3$+P8Q6Q]D&/(:;P@R20]]PY
M=<6TS8Z>S$CA2E][F.=49=1 Q. S1%+(WA)Z6GMK]6LL>?,T\S_Z%C D%\\E
MU^F!&#4QEH;G^PN8SY@TF 6T"K:,$:'S<B?FO%%@79?9-[^W$^E!,9<YIA3V
M+P_7W08>(>&%J^=V+[ W]E\N\0#*P))]AVL*B=<4$U*+;?US2PTFJRVIQ'_^
M$DF[\83U_=;.;JA'\"-N3&XZT5G-J477^F'W==<02<IHZ\1.[OC+\<%D+BM+
M?>XOB[/M/Y*N ]YJ4[D'(IVIT".4NR2_%P1E[+WL(^E@KM\Z!WVUIFQG 'OG
MWWEQDO81HM_#!Z44,3_;:@][):+@S-X25&NM+,2AJ""=HMY%^4*(OIAQY*))
MO&4_78JF")5 3L!Q5/L\[=X.(XD-WQG0EKQH!OV3C3>"S+S810FE:R*-AG>_
MZ$D>^0/L6E^?5K8RD?B^9_,0],\ D>2;GYW9!Q998LIK6J1N^NO>=.DS^O%Y
M8<%SR^IWS@)PA*)5BX3_&*,[ X#/R5Z^P*;>PPPS;<H"Q43&=,S ^\1.@=?B
M#'#;%/+E-6QW5/\<*SQ+CB4-E><P!(D3Q=?E=2(R>MD"FQ-B:5HMT&H:%5RF
M";:O<IWKP^0KMUFHCI>;=Z8-SI>'K T'83T17E,KE.ZP;1OJ?SYKB$OE2@H*
M*#K6^ZY#?4+_.''NN$!+Z_>?1&@ \D.K[@@X-M%8Z&52I0B -MAI Z/F,'K_
M#V7S-5PW5GK.-:F@WDT"O=UC)_"N\T47T%FCCYPRJ&Y@+]2LZR_U8]=IW75
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MYV:;/M&NOJSC/G(@#^T?')RO483I44:SX@2RZO<_2$4C[B:B"E;@#*3S@S;
MT5%D>K^49?8;+1'=!5^XTB Z5%4HHRR.$),UTWI)FQD-Y7N\G"R*#[;I7P3R
MWG?4_ZM9,O4M"$.FN\G'N!U17EB\MNG!'5=$B8H\?43>:$:)GMB.U$+$GSG]
MBD$WGBLYY9DP. -]0*:[H(;C[0_Q84JQ),KMS_CH]T)N,N<H0DN+9$X>JEK8
MM,AFA@F?KO]S*Z,$*13G<V:76_0U]LAX[]]__URX<NEZ -<\R;Z( ]<RL@1-
M'SGLSBZ07=F3"3?!&"9W3K?457*EO;]EW_!(03*[D+!A\8\20034B/,I[QG
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MFEP^,02]!-P]<$?_'= HFB)KCM6*NW>CQ7%'A:,RECS\^#Z,XTO'IJD_%6<
MS<&1Y?N+GN\A>WQ4'%LF6WL;>I9Q&=%NMI&!J?3*E3VL^;=>L@FDWKKF-7T^
M9-RF[6_R$!'>I<9%DF@_[HW>(3/:"D5^*OQ5-)CDNILFV>OK9@9P^S[7HO?&
MLSY]'_ZNE8[4N*A&X\(K.$)6PGE^@?AZ@F<LK$EAMH+\&M<4+:_+*[_7A&SF
M<,",>GMY62;(*L4Q#%DE%GU.'K>#$7^:4E[+V8?Y%\#XVJ?].N=IG%LY1Y_F
M/AL5YZ^JN]%ZN(LW_-;8G,E0$ZCC)_SB[N!]9M"S(ZV>=+7NG"LND\E@DE+'
MX0,LMKVPQ'+C;R6]=)B,."6N(^Q[\IKIMB-I@K <3*772*B/0"U,0"-S(/4V
M#?9TK*^H9S9G;TUK>F9K!-,OYL2E:T4J^^/:KJ"-L:Y-_1&/Z@'Y)=2"RGDY
M'Y@?*"6/?2G'<^8;N9?)Z7XUD,C5V['.27^0__9+5!FW!@M>9D*V9G-_PE\I
M=TG?<I&Q.XL+RM;KN8"@>XO[)H\JGX6%!5<)1-W2U*\7]'=2Z'UN[L?'$7)W
M!FMI>0;HH,9-T7=9>/?Q0ZI39F#=]BN;\YWQ]9_W457E9;=:ZU.QRQS;MU)T
M=5A*.*UX/X>WLZR^C)WF6(R4CKTS+LI_A_;S-0!@E=J_S; 3+K(<F&/=!5<@
M6*.VM(B7-Q;!X<J,9P#:0\TH4Z(5^XTI_?OU4AUA[-Z>MT]4'PM=Y: )$YN!
M5ZO*G0&&<Q:&R'>VU8[86L#=\*O2?)RPE8[L>^/40P?UD3;F]ZX9N\5SLD.@
M5D&S(&L_CWM;KSX6>S*SB[887/:X<QQY\TCMP?&VP-%0VFN?G?CTJ'@9((/6
M0@ZM^'86E+X?V19]_Y)!%1M +#@-*9M)837"]/"Q;V^C32["^#K6L3RWK%(Q
MVX TR;33^6.)@>^][A!LZXT@?7!L^K6F&L4 ,\L8"VEPG9820?MV!_R;N^J&
MUX ?2[ Z/3GG8[ ?$WFEUY,,)'T3@+G!<5<('7THE[^NIC^FR3BD//XOIU5P
MQNW*GLO^Y;[X@W>D3Y<_0#-PD[$C_KY5K[G&3RI5MW+Y7FU5K(SQM\ZG&=2D
M[]YL%/^"7 <\-:YYB7Y)>%+_/)M4_#-,\?G^-;E=&HPGWV 0D."TJ-4-C_V%
MLH:I=Z2S14[K'_[>MLOI,K[DHDOS UC]H(<CP,LF%Q7TE+2_ *9UY>HI6VB[
M[/K K'NYH193KHRAHHHXD;VZW&*,PW18T^"",3'WI1^_$<3L7Q[?41V1^ZB\
M#.!!!^6^3[%<Q'0/R.%4,PKU_;F]9M=!3T8G.=V-L+)OI/1^D$7?8DLB&2(Y
M*<O*K2#?$Q3T>_KODM^(Q>:C*?#.[-\R^T5$SQ9[!SLO?\;W$$;DX$U@'<=7
M(GW?A_*YWW0'X)8AW4)/8@9>OW8HPA8*@&G71Y\!\+\1UZV8V+>[<M#GEO4(
M)K\S$$R=!TXPUJMMIHT527#H>A,#2IJ*NJ;2;=GMFQGUE@P8)UOBYZ-MQ(E1
M,=)E IKO+U':+8,?&@96[78*6_<YC]$-\6S,N[9D9T$*[\5!W.BK?BZ#KO=<
M5\HN]1S/L:C\_PXB\%3C0//!\0@J*Y=CV]!UIEE+K#K]S(?(5Y$.R;\20[5-
M9^(7%A;PL5M%GQGO$E*C%A$1X"NU_F7>\LKJBVG9?TT0CZO09E]="C[ELZT]
M+ +<)[N+*GJS_@7V[$3S<:%#6AF!3$&7)LCB^2[3H]B^(I>F4HO^N#C_1"KJ
MIIUVB<,FQI[6S;QN%P/WS'%\TWA/[9W%N[KQ!T@7\E X6>Y$AY3<D4T3+,I4
MNJ9H@_ ZH(N;)SV5$$R?U/2,_O3Q->.GYYI:1$:+H?&0.R2;#:,T"C,,#46Y
MFNZBI<K+OF"END4U#F)N_+S"JMOU])U]Q'+K,$:5F02Q&?8IX]<3KJV9E,"/
M[R24EB)D.G2XW_:M(&WCN7U9-G;>A5P?WRF'NM>(^6^7.Z6NFYO5V9B[193&
M^Z\/7^ \.%Q&'^'NZJ_7;/DYKG[:]Y:/XXNRP2,>8G4EC9+79V(M6N9*T8A$
MM-B))DR]^SCU2Q[)M[<KO9:26IG1+,;(,*><6H*7W#',N6/[8[\\$K_X+*G
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M_PRP*P,(CDI_".:%=V2?EJNM5I+@9X +[.=(M>@,$*%R8@4?L2>< 2@7)<X
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MJ*;8:I;>@2:AK/>M\M7/:TVMS;A34#O;XLP3HFJ:=]*Z:5\]Y)OD$Z1 *)7
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M0$M.T$=40D3 "Q#2$A#1$N#[ >[K<9(0_*L _U8("*_'2$I&3G&#\OJ&AIL
M(0$1$2$QT3^COFX-OFX'B&E)Z&Y)J)'2&[TDX_5DD'R;G$O.]Z"FA_'))(I?
MZI57&,4-)F865C:!VX)W[MZ3EI&5NR^OH/Y00U-+6^?14^-G)J9FYA:V=O8.
MCD[.+MX^OG[^D(# \'<1D5'OHV-24C^DI6=\_)29EU]06%1<4EI66U??T-C4
MW-+:V]<_,#CT?7AD:GIF=FY^87$)CD!N_MKZO;VSBSXZ/OE[>H8YO_@'%P%
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MP8DVW"'$&$LXKNLEXG(,U.^&<+,(9O)M;?I6%SEE3"U=\JC4/^V9J;Q@TR,
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MDA_)E%=Z\.8XVEJGS4S5MK><L83D?ZMS7+<PKW _&J89.*XR$3/I*N7W[/"
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MVY:TD'+,G\W1^^';V@VWU\E7T]M.1%4/S7[RECPS"@6Z"5M M%!V%"CV+_A
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M!5.$H87^A%K$\P:VESP84;'%/@.,5(!L?@#\2CFNT1_QDOJ@HM<O2SXO&5A
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M HY"]G2AJJ *2Z#DS8]KO;*?FB^W7@=$ZN,<#A9_R_Q:IX4*%&/83V.O4I3
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MF*^L!^0]@*; CGFAMT^\0$9I3[N4)G</#J$8CY!]=XJGB8]WL"",V#_O#CR
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ME\] -]<X00<5J*HBGYWOQG):OV0 #7QQ/>L=QHUA48;L3N<[<Y&O[_J4R[9
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M6R/.A[7WGS09?F-["?@^I@E2(/!?E'KX>D:#&$Z,XQ5F V@P:-M,/=B<K&$
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M'SASB,!I^M3S<]G*?$Y/4<8)G5Y2:M5CMCP_?JRH@%6LIJA,0QW*?[,UOQD
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M.5CV8#W<.-2\2?Q[9@L?@]1!%QK @V[T3REST6=2=3ZG"OEV]# [^JHMII4
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MJI\\)D XS 63B@PP][>:XMW'5M0CWJ+_9PN/_G\"M/O9_P502P,$%     @
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M^Z#I%<BF;.JRF'>H*CMF[-S=*0;.B3YF0>Z*I7S*Y?B(!B@/;@!2-= !HL>
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MXCL3L!:]L15\\;O4=T77G _6&GG-&ZP6 5'D!Z*=%@7W/L?N?S"^-ZV]Y35
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MU;>M95I\3/?A3<)%ZSB1D7'TS?O1-_M3_1XY]WQ@?XC;?O4E;8U$=J$A,N;
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MVI 16C0WZTC)K7-_]ZQ0:%-[G>3]^+!X[)Z5!<9&)\C*6]J&H87"/95B!QK
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M9R>4E7\;7T.]UC5L&(V,AN6D&T8I\\CCI!FVS\ENRCW$)7&O![@&(_?.6[&
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MD:? V:N+3D9=;>3&1:S3_F,DETH@:^1 P_$!0]B'.]P< AM51/?POGXE=9@
MV99'8O@G#J0U7(@GJ 6=&VN;QSV?PJ8O?BB2>1S/ .B>/+8 A2M+9K3X7,M
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MZ1$R.ZSY?O'.A05C:VO"5J?)YO>J^<4Y<T7R/M[F$>&8LH(GB-)^ G(20MS
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MLN+A!ZMG$Z!I@6'T'0,K\3R0@.PA2>CO] %!6UDK1N^M+UB WV+C[A.\#_!
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M_J-0SOJO#0'X%X"RJ=&WE?'S]ID%^.==Y%?W85A 2 X6,)!HAEF$0[<?@[$
M:#K:[A\%\"\LX%^:PE\;X58W%L &17!B ;\B)U%03 @8NEP$/5Z;!M55+UT1
MF& !2QM_GH3R3](QZ&]L_\;V;VS_QO9O;/_&]O\E;,%"AHD*4S8QQIXT.?5Q
M5,;+C00KVJ_>^QIF_M72_QNLI,"4E&1VI^]-E5%+9?(<>RJ0QX?'S4?VS)?7
M5CU")$%J3GQ,&;>T" !\,9W\_SOV\S>[_!O?O_']&]^_\?UOC*\%\-K*(<T0
M>A]F'7)X/P^S ">963< (8];@F':_PS 1-I2!1;0T63ZD3.Q,WY3D:4_O)SC
M-:V6?+O+*Z/I!+X:"5W7F,:ZKC^G/^ #W'_0OA5-$!79[8,GI[9\H#J E1^8
MMV[Z"?YY#:;'MQ;=9>UD64&PNUUC5M%HL9"F#X\&LS2'>]_%Z44Y.5L%6_*@
M;YH$1\OUJD@>74_%*J'H>_Y/T@-I#*QX7Y8BJ=:$(!HZ&MTA3V3'&5;>AFT*
MH<[1X,U=?I_L&BLZ/:OM-M9O*'#IBS\RM=P;%U@%<S@/W7" 6F"_'HR#7=,*
MT0/5O,;:!\6_7#KS=1%MX;T1U@W-3:D<7E$AK!OZ\GU7GQ/'86 ZS:6H/)R4
M_:0> D568*;XL!PHG+VV(+X,G#NR\.9-FVCO+JT63:#(CLG=?6]?F>JYCGHS
M5:ED<1#LS0CB)'A]@?E2^6!;R[1ME&ZJ*ESXVHAG=E$U_? ^R8,JMT#$V698
MJ5[&6\-X%N/QQ7?J!VZP>8]ES,=B:6I']A_)4E$]1\^JM6 AAGC29ST.ASEW
M!+O>-["(.8V<6&\PND')7N7/B];Y>CR*JNQCI9EXO&)HSY;M()D2P&/2%/.$
MJ#19$[>;QO8/]R!O-Y_S>[$!.E-C S2#%4)I@A7M7IQLRZY:$[G/[+V!=O9L
MX'"RU#BB$+V0@)^8U*%.R17]5I6YY);@-?$;D.0X)Z]A?J)F97WLJVJ-/,^'
MAWTG^-+OW+A'I4E7>R-?QFHV-?(Z]]7.UV^8 1M-=^ [%J#E8IMKJN'U0=XG
MW-F%XF<'YLR-7#KZEAFBQM0ROUZ[HD[+,O09)3@2Z6G#$C@RPRYVUOV@X8?D
MG7J-<++@ZH_T R\\ +5L\J?.@8D'YIH^CA1+=^%'UF&]?HZ;EI5;$G>L5O$G
M$K*6#?-VIA$.:2\7YNJ3:3](_C@5.1 ;;A@9YM+QL/GU^VT#S'M5.[Q9H$@D
M ;9*+*75K$_RNJ%>[QVI8@@XOWS@"/7D/1 Q^GP9B$J=PP+V)W=M/HJOE4CJ
M>JE9(BTW/:V>J)")T<JD8@&4;;JG0AAJPZ!;2NH\UH80^/-@"G,+O-N!HDGY
M=A2Z;>YTZ"@$M'V$$G*B6=$R>KI]]*9EPE0]^,ZOL@M<5@'SO"UZRL^GJP63
M@0203L7F:9@G([/1R+>=3OTFM3SYS#=SSZ/<(V_[J;<,<0#^.1.91NK4]+KW
MC7KXP>!M[S[K_<^46_P8+YPHW]]?#J,MVU1]/"\:X?7ZNR!D5TF['.5UT2FY
M6)BW^VB5>T%T4T,CU4PPKZC;R)F!21X&G;RBKJOVOJ0Z>R!EC@&N!PY!.W81
MP!OB63',/4[4+>LG+/D)/16S6T+19*]9)BT"4(_72*-G-1<+5Q;871R=;!_!
M7\#9K/[@HN$?5!%GGARYBQFQD$1B$F;+$G.B>:1[(B2V/CTV7M"BM9Y7/B;H
MI8JK?,'@,F0RM?3&@I"D+N5Z[&K@GY6HH/G*<6Z'JH5<Z/(;:'R@.LITF33!
MWUJVCB3S:Y7FM_E8&7G.))9G+^0?DZQ*+$\8MN$V@ZV6C=#6?*&/$2<_ZU@.
M&$W)'LTR%$D09@G%0&<^2AU?.P6:>Y$66QTYVU[DGK7]9VB^15Q$'*'URV?L
M&FUR&B;*"S7L'N/=S;,.-\OZ)%L#YVP'T:BF#39R4S74M35%'5EF<(L]=5N
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MF4@N4/BQ1IYN,1'KZOH%3-)?::K>:94R<M6#W!6_1E-4^S>^A/Q90"=O<[A
MWHVEOKO]!MQ3P&U(J.TM+6W>1?T,KF_GX&$@7+4$1_F NI-KVU"C90X]81E;
M$[KT<(M&B8J$U%=U7?<EG[@D8UQA;55"XXTT@G#AVJYZ'NEC$S35J3]LPW((
M&^IS0+%JT9\CP(Z:I80=-0<[*A3%"<7#ZK\,.Z\+]Z"!0'@!"CNG3YIB,8 W
M(6C*(^@.9 Y% D2 ]GUQ0(OV[ESHH' >#.!JXM\FO7&A[)Q. (8B@!Q@@_.6
M/+C])<&Y*OHJ&U(= R!(_P8[YMH$(:^G+\I=4)_" !B "?IT@?__)A,%] O4
M"T[Z'XG^(]%_)/J/1/^1Z#\2_4>B?TNB5.KV,KP^3MDTUF&&6?_"]_%=S LD
M%; _N?PU2 7;FP:11>S0>K.;=0R!X0.CQR?D4G;Y"_1O<4T)Y@+O,WA^R:Z-
MM9LEWAAJ 1?0*7U\M#MPFL2!K\CU73QV%0.@UZW*6"8V6XM]>9FQ;)FYL45*
M'^E\2<+%<;PQ.;L\;[>RUVOKEV[8R&72Z1:E@PS6B5E2)S+?>FR08I)6V6_5
M=.?S&.L-"]'>[AMW;M^43-U>SSO@1SP3K:31_XH*!6N?:FQ96;E,[Y@9</E5
MD/OKO'#9C/!QUF_.O^$7Y;LG&4_<=@\A%**3Q47T2/3A-_RY@MFMM?'6PZW[
M];I,?+9&S@%^2$:0:*P7==,PG?)*>3BRGYGH:"CHC<'TNS7".R O'-KCSAQW
M[U.RF1F!(_FA9YV.3AY]KFFX!PS=UDRJ:18Q7)$UO4XF+V[L3_AIY#B#E7.<
M,V!#4_IOJY)T'XMPJN&SJ((>(CKX]?2T4M\*J4F;?FG8>UU ? 2C!3TS8:NZ
MINJ9?L!;Z>WP?8-W!N[@\R7%:]C^^#C5I-;O<1KSBZ*!A\9'.'N/.WRVXLL*
MXE)J(0^6;8LE)Z)G#!,3GESGC7E$HOKL];T2!KZ^K%OTEHIWOQLVWB@P^6"@
M'Z+VIE0(9SQTK;*?4<^*+G@R1N0!(_]%W]MK*RY=>^R-?JQ]B_;<Q3*O\GAQ
M172$.=)JUG-MG)^Z5R9O6SZ.EE8IXKP5I++BFVH3/="@GV<36W$S*/3UM6[Y
M&NZ(AM/21)DD]\KW/%]GNVP0!=I"+O0!)(4$YXRR7N85N9<KCDN?1CD$L^01
M8D]\)Z\L 'E5M_7.O?-:SQ<"<E,+1-C%9!S#XL^%<2,1?B?Y%;/,%C]2'9P/
M.[Q>G.2YE_ O;F]*M25L(MY-7Y2^%4WO]:T\=LG<M1A!)5-J\*<N#VP7'5Z@
M"5@P +:KT!UJ>PR@'+R)LFT2?&7")%SV%F2M.KG>-L^( 5B&:_.0*)G16TTI
M9RDCNA1-'^V8X$PUHB*RK5ZRB=2S4)]EP1Y8\Z6DS< *Q=<1X(/.P ;NQ7U\
M8HCF\/%%#Y2^WXVWQ@RL9)+38#QQ,F$0>-Q5LO_.2 PNLR*ZXT97%>F1S_9F
M6"EI7B&N\8-+DVP$O;9QZMJ]E8MQ$ 9 LHI,@:ZN/\6:>RS6FEMK?=FP"<"/
M$&P:P8;BFH^#\Q7M^M2A4W]4<Y(8S*QU=D3>=C=?;F[B=W?% (BM1;GG)]*_
MT9E'VQ5XY=;Q)5@T$R5K/K1M6QGG6H!06E'#OJZ'[P@VNBF4C^R9U]>'5S,G
M!:ZV\E%&:)K-2*>V&ZKV_+!10C/T'(#2CU/)T\\]0(MR*+'$)5]G1"HYZ.00
MVE(H^)#7/[A*3^#<I?K,9CU_))_]\.BD%G]G?4F9E=1OCFG08L2;C:2(YUU&
M@Y(JE;PV5:!M5:):PQZ1 XBN/DOIYQN:4Q:M7CT8P,U-;6TCJJ$?L07NGA<:
M-J0/9*+?-?B]$0LP%;H-_[D)\5,9GC,;P>@Y50R 7 H#\'="J0CW_7CGN.T$
M128Y%?G'Y0@:LLYB (0XJ50S<:=4D/>^U^%N@4WWH2T<-B;%$W/NP<JB/L'O
MF#WF]@1#$FS2Y$V.5OP]3;7'\@Y,6F/1?51&#(,GRD*J!W&2-ZO ]=%^5O?T
M\ZR*956HI-XZ\,;&<)&C&?H.0&A?%U74C=^5X89";:0CR: M.3T\KWVG-8?G
MORJI0TA1:/-#;R,XKA$STJIH8]<LSUJ2_0 OO019T%V8FXHPT^F5CHS6>SR4
MEAZ=V;,$#HP9;]URG;XYL,$H4!U%*]?%TC<L6)?N0>'?5!F _>UK/T_E!8FR
MH7'3X5D_IT3L=R%0RLJ'ER ?Y)D@DLT^RBCX" /0PP ^]OKVSW' M2,/F%JI
M]8S2J1+%10W@6\^1"0@0JVZ2 'U)EP:3@UO\#.]4(TRIJ7*X@>51QF(ZK?O+
M[FY[H-''2A_K(4KJL2?">CK+9XY^"8N.-42A1\X8 .XJ,NWW24!J=8$6TN>I
MS8?N#F6/"N0-&W\LO5=A4\6;70RPP+''?8/G4S!6X%\D:6;H?;(_/\+&R>^V
M+J8:!".3I)F26L*#+UO660N%[#_8NSO*%C%I\9GMX7)O^'N9\-:7"V'C;!G(
M8;E&N&2:-TX94KKY0,ZK0*ELPN8+<]E#CX^?I@P58NXRCJK5=#*>)$ 74F#D
MD?JI-R_M5'_Z+BQ0TOYN-91"S:SSU1 )K_UY:!3,T>LH6=2BO810YC)U7+9\
MK**FDK9!,%=?V;J UBWY0D-50IXI/[ +@<M8V5CJ/BT]X@HAJV[% *B0<JU)
ML>YI6^M:=6,OPV,075FJS&VZ\I8=-)1&"J5,_S@CO\,"N"G*!CP^Q"*3YTU]
M3'&E[?&V/>Q%(^%\RM'^Y%&[*"00S84,!H^6NK2$9&UUS"DL0<J5G)[SXLK2
MM#X\DQ5U-&JT.>A1/*!*7)PFMCZ5BF'0;Z;N*TW_*DW?57C-S,_0?]7@A2T.
M@V]\X'_A@^=W?/P72%'*MMJE5RO.5K4@:"!J__"!<X:0&W\)?+X-&'AN\<8E
M/: Z[6[ZSJDOHY?8],8H29(@;<L,?7"LR.SMT)N, 3DZ<&!DA1((!\47K'E@
M'QCY]CB25-EFR99DETR_)ZBW7D.2\';,HT F?+::4JZ_<07-A4I(Y/G9[WIX
M#5W^;28P@+8QTBUBP=U3M\VF:FAD]_?@'>"T",^D4%L:)?PT!*5YWJHW95U-
M9Y^8,0/ICL[6\/CH>L2@J][] N_.L63E3A*T;3XX 4K1(%>(#%(E 1*]EQ#]
ML?5CW&QQ1) RCL\P=]3 0_K26(WRRUQ-)-*-IPUK"CRB=S& ZC^X,_+,8Q $
M9\;&/C9ZN7@5JT+ZKK:7CRZ:+A53\E545+R2T P'9-.64R6Y@<N1>)MI/! R
M0X/MI-(\"F62+--F&CJB D8U@P"ZA?70R!9&?GA: 7Q9&MZ44[;QQ5HO*'*I
M1-".F:!J;%R(6JVQ/B5RENOMR[PP@EX,(!C+5!A >C@Y-@+Z25Y_TPP4A$4(
M"(N0EIS^JQC ZN'<I9C@J4WF&<$Q<%H,ANL^_"T)$KY_G+Z[3_0M;P*IJCA8
M)IC2#NL/9#[*KIK+,3?X&GR;:AD_=+4"2NLM.N8*NN[.WT87'@)/*%HH$E.Z
ME&66\1+;M@DQES4)*^);E<< ;&7,,8"?FG!$QV8Z#E]B57$@@%5-TS^X%<[G
MS;,P^^E])>@(. ,F,N7-CNQ?V">37IK5)*9_.KXO+H<(H$1]GN)!*'84X%H;
M/;JFR?,C] KS6L&&D00\[[V@?7 3];#MJ]6A!JDB9*1"T]#]+T(3N_O,D=WQ
M?'R?^#Q"W5L"#&I_HV\).Q?IDUK0(K@",H&_A%64('LE Y?VT/$%,N#ZGNT^
M+?,S_SQ\>UK<R(ZXIHS7R[H>-BM#%Z5L.X+6T-%B#[GV?3++KRCCP>,2HG9@
M((J#.S?22C0?(O$BVGL[F*G C63R^&I3W%@3"Q)'%]FW. N6&:LP!+56,;(W
MID/\]RV2O?@[[X3"Y9W7I/T+*7R&QQI&,(!O(FBVV+ZQ4.CN*JPE]E>RM='(
MQ<M^V?AU4/!T[]+S/)%#+48IW:0 2(:ZCP$0N2A=/VFD4IJHF"=\:NMZ@Q\/
M*4B8^)$%A\VZB,-.F(@+Z^:L^MQ:Z:H[^DFWWN=/VXB:2%F?EU0EKU:\7GCV
M+(HY^@WS&9]4A\-C":Z\O\%&M1_E_3?W@DS"1Y$G+KG34(O> ?YTO:%:#P4*
MG0M[RI;M#Z\KOF7IS35$%BWU/?+Q[#C$ -HE;XXUT:;?G)S1W1 U_$HX<7SB
MH.M02/NHC.3&66TI8KTSZ6H_EG_:T22C.ZL':?$>V>UY,F25I0G5]!]-6\+8
M#<Q4'(/Z]8X@/RUIX>\._V^&M7]V]IL='0@FNU-3 NTJC@]17DW9<P$*SLGG
M%NW]U]SS-. =.<NTQR(LPRCC8FG;JC'!B+F^3R 3CUN V>N)5EW]S\['? .6
MIKEYEJD#2GU9D&4MDFPZ)?8)<\N*H2#.H<4XPM<UKLHY3B0S =4B@M*_.-['
MOZ$'Y^KZ4YSA72QX0PK7FJWCS6P$AY7F[:91G9[ 'Z_3>)'?%OOHQML2'\5:
M$BX30FYT)TRE4-^<$Q\G=J4-)V'2M%*7CGJ\X;%IQ'TA9#-EEVRV_.[EJ$ J
M:2=U IR84&ML4+E!)RXY\)J?5G0B#3/8&O33T;S! ")3_\&0DY<\L(SW3N[2
M.QU>%/@,EZ,[J;BR>G%X^+NU)H6!YJE0$Q5R_/&PM^'!+=<2MU;1X/ ',N_*
MQUXE<2DIO)2Y/)=ARI#Q7G:</C(),%0-]GV ) &2AV2,"-A2X1YDGVK(6#D0
M$<$FOK:,7W>0!,?Y#1!WSC4L_ 2I+]NMR(J-#\<7"AC DN7?2>;OLNGT;Y';
MUFUKV;>TP5[L[W^$,*"D,FR@ /$KN'0=[R_+35\$7_#('<X:W;63?K;"[CXC
MU-W=YM]YKQ*VD (\A&!#XAT<1PP@RSC[-R3^O6\DN-KW>_I7U3 T/DJ][@ /
M]BB5)2S)M,J:F_7!Q>2R<8>H,3%-F H9C6A<P:AR/?I>@49,%KLL6+(G,Y1K
M@127/3,4\,\*Y]MS1*JM=X+&O'[G:PS@-54</BC(1F@)/XR[X=K"+-BH[DZG
MQ157:93](/7!RVN^K[;.3]#5Q3/6X^,:??G]'!_7Y]SPV$ <NQ$3FZ& 2[G,
MVL@@/NL8E#A\>5LF(G_L9K(_!N!>-3@^G^MS9"CQWUQ _K\OE"OI%>NH6"_H
M!='F_+E&_+;KGRHVS.;W76!M,'X8-@/WRD&SG*55B*H_WI3Q6+\"MVB_U+!5
M77K0]/7@-G5,.QU.\Y6Z2V6G!/"15:+Z[.,+UG=[^.,C0!.CC(/WW\KGD,-Z
M(Z\0]1(]^&^(^&\Z1F\;1(0O$/9)V\P!OSQ1G7&\Z, IQ;<^*\C[T3_]\##R
M<W F*E*Q(F5FLO71U7K9LG*)&X#ED^*"'96"C/F)IQNQZ7R"71>?JAZ?WXK\
MD3/&,ZXP?.O.K1#(*\7:#=XP-$"+AZ#G3OG-]E<1B(W"'7K2.SOSN9PE3@8Q
M,T>[TJUT::FB,BQ%\I"]"I PZ%UI<C/C[33"C_M[)6&O DRO&HF W-$&OH(3
MJ4]T<F4>E=]Y]:;P"O/)CON^05Z8X*4B/\(+]W!G53G7L,9IODWB2U(R2T$U
M?T)@3S_Y-ZHF7">6T:^?-$SL3$3.8)*@*X8LY1Z!N7+$Y!:6.&42,A[/>!^D
M6K8!#(C;+ HZ%8])<6E5@[F-M#H.]V,W=)9QABG8'!4?Z=$]"OB>=$9A<IJ!
MG?CK&EDIOJ;C[Y6X5+F^[S;.ON?WC/$<_[PY#K4>L9NB"?&#=+F9 SW<OY_@
M H>^G$"#$X2@@D4^04_0]?'ETPSYUHLWV/<\T%&)9-8)[ZWJ=UFU)L#Y(NOP
M#IO98\N\FG&!XTK(<7R*_/7;G#A'L;L5T<AQ^D](OO'6ZHY#I2PNSK@GS>RT
MM]-+/,%^QUS#^7I;3Z1LKW+QQ&@FN/<_5GT51;JH-QC@)(=G_"Y05&7?U=1S
M[[VO*:1<^.5V3+$'O==5'RO!;Y<Y+$WA0#ZCA_PFR#L:A+$GS>KHT\KGGT?N
M#>T^*&4A6?F:*1O S13=PK[7-BZ]V,BH3[-6WS@U%3])S/L\F@;X6A !&8GQ
M&A_Z-L7Y#!74 *ZTHK_7$-LR?^C4)(H!?'Z4BIIK=&J(_*6B#IY^S?[GO1R#
M8I]AOW^2< IE+Q,_:OG3Z>+_M[(@*;Z%O@.?;X&0;S?1CM@>SSZ7^UPS$K]7
MXCL0<Y]7/(BO/I&^RB_E8%/']PJRQ-%^<??E=)L;=Y&-'DF 3=G\[+3>.Z8$
MKL#402;ESC5UN^:5H\X2@.<LY=%:P<5+RW,7NMQ/393CI2X,C!*BAJJ:02RF
M5=15\+[KA*E#MU5I7GQ:%A'7KO<=3DAPV'KD&1PH6 2DU)^?LD*@&3@C'=U8
M>NWOL]#JE!)(\_,RVQZF"[<#O,PH%X?1(P^E!$MCYDC',(!%GF0=PULHT 5,
M5"1I3"D[JFDWB#64^NZWSFXY-2M8A44;D K)I@Z/'G(5 Q%94@>Y-HW;[R1M
M77\ <T-86DRU=H<^&0K@$>;,:@1XI5(N8.=@E]1UX<K217T)D\:!86EJ:6?.
MSO 0>QA?U[4L.5SC=)?VJ>4[?FGRG;0Y8]!7V#[36$<$SHXOLG*M/$.M1",*
MO[9_G5J) T-X7I]J6A#\^/3&><,29]XR>UOI3U>>@=-1]@<^G6_%"1U9XCJF
MSA%25L3?::G.<!ORAE]R54LT,VQ;"^3H95MUOK913"G2#!?>ZW^<60L)HI[J
M*%CP>7!AT#(_*VLQ66TE/Q%+5WTA1; ^+]A8;*UN.:6\ER'Y[-%G\?V(>BTE
MX(#F2$">$!YB0.ONSMK"7&<W!E 5W :2W%>&NV:GWQ=N; 1@ +>^AY N)J"T
M&Y(1/D@O;&Y/O62>:B7@=3S-CYCN/69_:ZQZT>=WW.?8=/] 8CP,I51@DUB2
M_/YLZC7NY8#O5N2+&F"@3_(%B[<X!O!6:7%A[$'F9+[-JP<DB]W-PB'06PG8
MH%?;W*+&S\^OG?NO]Q?\#^5M("W;U3=4H>TCWKHF+SH$3'X>CI_@Z!Q9L,&%
M!Z'>TA"Q'+O^_.M-G<B.$JGR7!K/6'!EQ%+H(FCQ_B@4AG6MOOT__R1TP[SH
M\@)Z@8!VI#,)G.>H,M5GUJ@BE00A^],8P'SYSYUBW4+LP_/HR_2#K.C@44X/
MAEG*EE]JT61]X L$!G"Z@P&$WPZ3+'C^?6^CE/R7:B \P1HV7XT!P"Q0EBO&
M)XII<FXR#D5+L^HZ9+8S.-T[3*#P5Q/NW4,^!2[$*<'UA\$;(RET]W2LH\&5
M/X)"7SG=+Z2EX4M[>SO45:K[_^3J%NK&_07I]\FVR92<*1OPEN1"G]GQQ$9=
MW_5K=W+>$,T&6NL:T90:O_0GR\L_8<LS@4@QL("?UZ1^C]=9U8RL<^XJ]GG>
M7.69LSL[W2^J*GE]2G;D!>"'V/%M\&UX(CAB?73Q:/*YM2"P+F9S\Y)_C1J^
M>QXD;74_EE6\\QMSVKKDR2 2\B11U5\A]S%+W$*!>&%$P';2";%^<UW\6T=1
MBD;B.Y&WKA+$-K^4D/#A^.(-JJM($VHTBQG59[FEVA_QY@+,,[J6UEEY61#L
M")/X<6]>*MVP\=[4<Z(O3X=D>].93!?6IV>\QAYEO1CJY,Y!$<3*.K2H$)E>
M8 !,<XUU-%G^ O*C)N'4UH5A5S1SX;,16<6M7BR?:QH(;DG?+NAPD-^0[UHK
MU7$94G*FTZTHZ%:QF=U<<>>N#A#85N@])2,<8\;5_4Z0-4&2FS<J&'A86ER2
M>>?H5M1M3H3PN1<X'YGX[762;%6384SWJ<-9()G$-WUA,YSA-U#1I56X3%:O
M:9!Y!%-7N*R*PCIMJ96ZR^S''8W.UEO7A%T?BG.9,'04W^$M?_*]W?_+%0<\
M^HC+:ZY6BY4)6U/ "@.\&$TU)WI FGMGKD?!<2K!N PY'V_\-*#<=3D%(+$]
MX U:3"[A1(QKP1+H*8)D>_F7'9^\M9"L!>78J+S/'Y)?:%].H$J.C4^MX!7H
M![2;%?0XLO1/96IR$-01=RO@QDY7<67W>GH3O*^=K'F*P\W$V.PF6,[7M<14
MK51^IK!V_D(#U.P*;3TJ#9:#S]"9YJZ!;7H0-#8?Y>YXLF]D38!+Z'CSLB0Y
MJTPT8 VG1^SN%JWE&4$8@.93_0K#S]-WN_4#1M;KTW:1!)L;F07U:2_ T4A]
MM JX$X+ &X8ECY?^Z;LO^4()&GA9QY81B.2"!F, =B';<>I8_*;])?8#IR+S
MEJ:0X*5'D8O)J1)OJ==XCL<<*&X09BYXR>?GH>L(=D]>AQ>S!NY1C>9)D\GW
M4A.UXC">"39LC.1FKC2QN-B*\O_VP<$-6"'WIL1;T45!<")PJFNE?)>5Q7O9
MRC?59H@B"! 0Y8$+7I,Y#;!WJ=\NDI"5?[7B#PY$K9]]**)D9N\2:?>9OY!$
M-KO#%G/3C,!IVRHXJFFZU%;1@W)]$0W^HL/NGE_R=LVHLF;L G5:I[JYY6HW
M!=1EG#_\;^_#I$D3@C=("L&-8(O3']/FYL'#>P)GK&%FT6;A6?<EFE^-)R$[
M$1ZQD#3P8(.^S^((;& 1CBC^K)\-LZU\[Q[FWWGJ=.5^ED,_Z;"?AN_85"#Z
M(YP4DJSL5=%@4_*(0O\&ZN,*F375QF 6EAY=S0TP@$JC6POI8;[L<)#? U=;
MQF&UA)YV(Y9@F0&7<//%2L)&UJ=!S]V'W_98N-S'%6%SV,)QN')\;7UG/U-U
M,9)J0\W(0&\"Z;^LFAH/8)W1D[:AL*S=(IAB=;Y<5EA6G3SO:4_C&/56LB^9
MVZ1#'5F=:H-?;Y0@.';)E@1?Y 63,HSD=SM&N=]K.)6[_"3N421MLNB<-37A
M7JXVGBQ?.5I)PUQ=8:G=.UO10776YB<5)C>S$!!:!E]>@H0)J(:+K@4NZ;^G
MWWZ/ 5!.699+9!?;+H59.AER/<W;XV]0JB5U\CQXS!B^")L\9.!O%X6&NMK?
M--SV90G6$BUIWXDJ5A*A<M:3(_C$9FH96PL@4R)36"M#F2%%O Z,AO2%Q76]
M/FV.5Y%;><;'.3##9_5[PB>T+V*N1 %3\,09N0*!MQOTE_KI#=WY6S]O/A)-
MMM$KJ="+/S /O+^3,,)[721&V^O3HX WMT(V=4 4**D#@OXV#( D5GWD.%NU
M?+NG8'HSIF?5Z+HMK1_NBXPI?/SX5^=J^(:%OCV!*%6+8LLFGOHA[6$U6PU"
MD1*R+9::1VJZV<'.5WNCI0YC![YWEK(G([3*)3F:1KA/UBJ'!1GDK4_'E'*;
MCQ0<= 3J']!0A3,[UB;B[S_$M8C@;TVG$W<K1++N80 M<,O7GG(! L2/EA#3
MX)KH-5CT\80] Y7J@M3M0G_9'VNS:6]'W\]/L76"/:'O&\SR=*S4D#RMX#K/
MRIP!:-7L-T<K"\<[_;/AR]3NM#^6:I9+ #YR,G=$?KT#AU02673P!!+\99I9
MU'Z*I59#>VU)BK+!0OB;A)+;U*>DP^,!R3O>>J[I&L\9$^A[=?9-'NJE./'B
MSR?F'<0SCAY+S"5:0 4;JA]]GE&R:U_T,"$R>?E0<3VC2+C=,\XQNO6;E_ #
MWWU(S7'^TG*P/\+!X')^PSW8'\V!_";^/,]2="\NN33GEGT"?F4TW@UFG#CO
M*VETC8E:-D^']J90'57WJ/D_JMR4J]B;W0U;*Z'$IZ7MO/?5VW 1V:"[:&CQ
M].,4NZL81W'J>&'Q.[7HXUF#FM#/)2SL4G(#:VU:@58<3P@D@U=3@!6DS0AD
M716>H;<[SZXO!!'P)$U7>:)KW2T1/<8?>JDW'%ZNHT_/1%O!RQ/S\B+YX:/E
M:9IVJ!@C.[QO/L!;H<C=2R.LTRO'4,G8X2WT]BLUM'O_,J0"^AF_G?] %6$"
M;Z@F]YA*>U>2.4?F,8N':WKYDC=I520RR_)?)/A_%*Y>7ZXMSSBZ^/B2G-XO
M^A779ID,@L2^]'FZ.C"*!5E5;KL&T;+:E[M(#:]+V%AKKXWL?1.DZZIT_D'^
M?#3Z=8@9SJ#QU3CKI%K0]AH0T0;6<U%6?NXV.8+-5[[ZCU[5G9._H/KAA ZK
M ::ZYN&70_SVO5Q117"1]%UEB/B,,C:"8D>/C<+6*[!1T@I8Y_Q!#MG>HZWE
M(9$K]MT9H=V(U],,*=.P:?K'*.4;W[9=D?C5D&X8SD?TZ"@&L%XQ?[JB ;7>
M!A[-V5_ N8H3Y49>&/;9KO% .4YO(34=)B &*3)6["=6OH]!HCQX97\T3\ .
MB6W>@!US00,#L+'& (ZF["\.N8J2%4>X$YVG/E*/4<U'MB3C)4-?0]VL-V!S
M'W: )=2!?^\AD:ZT9,X*MO_]TU9=M=4:RIAR9,:J&I%WFE"Z?;FA<J!DG[-%
M+<WQ:K#L--<V/4^/A]!H&T[Z"A;OB\]Q652, ?1[@/;[@%-UM1I$Y;<1AS*N
M_%;CB,[3A)B'.X,,R\=Y[=G6_*4K58?CZ&3)(2C!;^WML.VOD5ZQGJHPXOCL
MMV=.52YV/^JK,>GW-A\1G!PO&8^(8 M7FR4) 0/]!I,?() 6B,FM3(6!*Z&R
MM-B]YHRC3X'+DMN#;5<$ V">FT>WBKJAXW(\9_]<X[+Z6^S(QX=54!UD"?)Q
M6SJ'@B0.G.9 4VU$5E%3$V.:M#4E][+7..6-ZL"*UFOX7!;IH_.>SSO5#XO0
M692#@^#^>Q[JO8*)[^[0M@<.(,S#L,'7,R'1-NG3.JZ')T$N]NN&6I1&@PAJ
MC@[ZW+D^5C]/VDCFI_1G=$Y;8K0$&XD+N:^7YFGZ]78X+-<-@RUF5K NR)XA
M.#$30K5CP(G.'K]QP*/QOE7/P"TI,7A8I;H^]87M,V%CZQU?76;"0>>1\?*7
M!=MT$FFPG%FL7C==S9QI0W5,:8GR\HO>;A[QV-!W%C3>\.(,5:[WL/P!DD?Z
MKOT8:)S-++P7GS $Z$7Y[.YNC^>XO/8E&RXQ)>LB-U(!K98,>P3#\?V0!$>@
MX//V]99(2CGXA5&-1T51&"RX4B1R7FILLO]TO#J_S+RH3%&3I3N][D39%3)V
MF194DZ21!_(X8BOT&3^!F=\!N.1DAJZ(//E)@W_*[_^2\#<2L7W3Q^:P+JK2
MA'!M#( 4/4L^CK7;HW[Q/ULR' .8<K&ZN7E.V=?]>53C]</N\ #*.LHD\T[H
MB27U9:Y>CBW<K;U)=&1'L(S,IF/<VW'V0U:/1$7XD8=CQAG8 L>CB]F\"F4+
M[]0Y2&PW%%-KU,F!HU3)7@AQ$$$:S;BVF>=TA-$TC=L3-G,)W(N?CPL&8YS*
M;?=MC@T;^IUTJH,R5%)IV;@>S2%@,M.]J'@,P#]BRKUZ4:[#/%*IJ7;8FZ-,
MCV6U7J^TMY>O/$L>3\GNRD%TZW@I!O#MGAU*RC'36T[HI8?+C0>[9OY+3KUT
MVR8A3V+'5VY9P,MT+\O1=_0@!GKN#S>3?+/([M36)B FS0\G4CAS?3>;NYA&
MP'(7=.Z'RA#ID8:'4SXYJ4UQ7WKLQAYM$U Z21$5=>R4&9TLJ61OB?7-CQSD
MB?3-V>WWGBN&LN??^7<X\A]+SP%;4,4\M15/KC4BQ.OE83O_DY6%!HW[7](D
M&"C0E/TV0+P&AM+6DG:WS"=@W;I0-+QME]8F?X13)4>>XP[ >]O?\8=-9>8;
M\1/?J^YWO=G10-%'VT+U= '/QLGH8UWP<-&^N^@7M_'Z540=M98O4\6OX 5Z
MY<AEX 8A]KB?>+3WPBR]\H=?&GC45X=</:AA3'$I4\3VAEA> /JMPYM2/X53
M2%GDJ;*,9@^HWC-H%WC[D9D<;[[VE*$MMEX<430&Q/>^F[LY919')^ KFU*M
M9-\D]QI2P:';]5+AY4)*C,):O2([3I]K^N3P(KJ1)=;0\L;7J1\,XJU$AW*W
M$? P&8KN8MS"K#= <<?AT(U]23IW+'DJC5=L'G\PZC%,M1.D\2!TO)=MF;UP
M$!C$VWDJXW*L=O4GWO^B2 [1H<''P&@, *Z1/KFO#^_OI.^GMZ(3[.L/;E"@
M<.Z1*)89HV]7B^$RR5TH;$[+3CK'1]^0@>^WI]V$ \,J;9VZEY4'3][7OQXN
MV8O*DC>1U64A\ "L4DL@+L#*%ZHHFY$34O)PZM;S9.E,O3MD_9;-Q4>,.G;'
M1G@2SD9%%\S(??V#/']7FI./1OL7HILO_/>DCD0IB"O2+J#YV4G6&P6R:G9\
MVI:GBNR9'^_^.RL2!FME&,#=<@S J <#R$C:V$[!.IF51]#M2>@QO\+.CQ10
MAXP,A3;^"_6QOYX\=P4;G@+/H9?>I)?7B@H9N.(A2 Q@& /87H!N<!NJ;>K+
MF23>:O"Y5L9\F0=:29[& "8L5#" H;@R_;]6*3WX/>=/,L, ?EL&& M69&=@
M+Q-?H/K34A\)9$GHS2O?>TASGP?P"CY_ELKZR!#N7",-&8EWH ^E;HMLD665
M(CSB'$L.56B>P6;=3IGZ]YD&<ELT)I)!C9P-ZTOSK=.-/O=1<HN=^JK4&VU=
M%CQ2#NGMN&F%K8>"&\9;LMF^95J3$ND6:-6R^8%C=LUP^4NCHJ]>DOVH= @L
M8V,$S (?7B+.:[,G84&QCU5'\_HC.E28JU+=38U/-K>X2DI%XU85[<BU+9<+
M5#1S%P7-_4/9BWM;_C]D3LZ$RL)O&5;4=?&#T[96.#/R<F9:]Z%28)M49'"Q
MI2BUWTG//(61M/$B<I>9NIJ\:E0^-&H&+7P^@+_.6%NBM,1S<RNIP<W6XD&&
M,\M(E5MMVNC[*L?^/B!C"GAR_BLX@!4^WMI52;C+OND95.2XSO?Q;<8B@?C7
M8M#;U7?]XN/=Z==>-5&@S)&?Q,4RO!_K?]=*DB\NY38B?%\S'I.O[^\@TODJ
MZ9*ZJCIB:$[86":"?>3>O;!K:@\!**ZD-$:!W%6\(1]1:/,9XQJ/4$E$:T<$
M*V]<EHW*6&I"@JW^1VC(HY*LI]C,V26-YI\?CL?JT0[@_B73U&"4 5B0WMHL
M*6&X8]3B>B?-N&KV:'<[Q8=+ML'B.5P69G9@Q*TR-)E7E:ZN5%F/:RO?C1L-
MK#F3OK(=;2B9<Y#W9/B$@UOK0>E22+>",ZY7M+RPL,3!K@YG%4PR*2T;KF*0
MKNU]&FHW"]1T\9P//U8EF<EIRBJ0LA4C.GLUX[?E<^V5_DRGZU5EHO?W-=A-
M742(2!ULUBZ=6T^38"&NQ$[]&E_KA^U,8XSO)\J_*7J1_\+WA1IQ3:X^LES[
MZW#Q<9^05@*Q9#N1HX+=H[->G7(0DYB4F*8GT6FQT=WV)K,\Z>$(9;H!_PR-
MPPOP)%1?9P<E?>!E--!@#'WYBGMNZD:OE=T9V/(@FG7O@]ULT6"#V+(RJ(V1
MWM 4-,G]S2Q.Y<F'5!5:!83@8C5:Q,=<2>?D\D&GCF7B59V)5J=NT2@Y6L2F
MX5B&<89[SV)% B--C?^4&(=)K8U'\HL9DJ6OZQ>3XFD+&GGJU:RIJ/<=+PJ&
M ]E'<A?V8F-&]6W.+SNSK'SO#@LVSK]H\M^V5R?WE[$$=_-NNC71UC]-,;0Z
M?\<JGRLL=R<%52S\ D1W6A:8]K#VP/R]Z/PUH3&^,[+O 5?5-/FJQ,A(F4:T
MXXJ.FG2Y^&.!\3[:266*W@,^*D,)44EZ6^)_.06SF(?!_:,X[<*NA8'+T;7
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M]?M.WV5\-EZ#9-U#8P M>LH=!>32^0IV06;& ?4,\KMI-:<EV3+A6IK7M&@
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M@8M\G2YO.^,J*YSOI-\I9JY>QQ=>RSE@Z[2G\>8;;&*Q$IV>1":V)ST3=1@
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MLPO2HI2*9[Y)C'8$X][,:K]QESGQM=.Z1!"@'?!Z]"@X0@<4)OA:@U:Y]45
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M)>'7$%(JFI/GACZ'S6V?6^OG5^G=PUA-$6?DOU"G-M^0:U[)U<JS\#*%%OU
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M!ER.Z4<_V,'.0V@<ROB S; 9;VI8KH5<O5I!;%N>BDNL^].(*K,FSF$9M8(
ME\4K?&6YX1Y).!,;/\?LYW%1%FIY5$*X>.D >X;:-M6;G-G2K-!(%7AM9M9"
M<)6]63XJSV)F;P3*MY?H$@B*(<!G[]D31V;HQ_?2&L4(_-!C..<*%_T2.,YE
MKKQQR([M44YH3BR'_O+64[\'IL'?: 84DY3"!5QQ2=VSHQF9YBR":M/\;.Y
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MT);?EV]S\G,A9UF8MLC^DHBU'#0=HC)(&ND8 5,G#QI#[&:LDR_97VMJ+;"
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M!*%@IRVRC!ON-!+^')J/\S+DW1HHBU+)>^L6P33A=M"4\W8\L=LTP\O(R^K
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M2IS,QEN'KLSYB^A*_!I3IJMJ56X$R@HIDD1((G)OD0#:AP$$I.Z\=>+<-B%
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M6,\-7)+SF2<!NMP9H'G=\U*1OOHBO$..6J]..=W^\"QFY[]$_=QA\"8!F$D
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M@=T!X!@?*U5[S4F)6AO)PP<2+1N9WW4*-$9+&:\C$H@B.#"H$0?&'.AB^KK
MG(;Y_X.V]XYJZ@NW18,HJ/0.(D3IBH!2I49%F@@("H$@1 2D29$:(!!Z+X("
M"D) >HUTJ9'>I)?02U!Z2:B!!/+XW7O&.V^<>\Y][YQ[WA_?&!D9&1GK6WO/
M^<VYUK?7AC$?ZZ+3M-&U ;/0F9 WW9$KC'M9?S\ONG4Z5!)H<%Y=IW*_E(%Z
M%X8YWY#@7.17<_PB<6"^<V#E592=R7+88TG-HE=,K0?KCX!ZP^:6Q(>P? @^
MOE4,:("G_^[A:)(*RVNR96:1[3&A9'W$>E-D#8#2_3][_/SC'IT8*\6^7&L
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MO&S>K6'CA;;\TJC/=SQ"]\:_?!B47U49/Q!_B.(B6) !PMSX^/,F:=#9I8T
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M77T$?+ORXQ7'\T$5Q:%F?K@+H:V$X/7"3%O'5MHX9).[4^Z>EPFG!_7/[4?
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M^G1"YK%R> >=I&^T0.H> R?!M>WY#X<@]:/(TFR#W6_+GK!,!IJS3'>_:V2
M;9U>&Q%-/[GI)<>HE=?\^?0Z:EI5#KGJER?U\$OSI>UNI0-43>-+'(LZ8751
MCV:&I#LZOVI>'BB0ZJ=PI*W%_.Z1D+[ O3JC/Y+!5?M044+Q,D_/6;;XKI).
M 1V-7GE3%(W9=4Q'BB?+]VR>$>XKHSUUDBZ/:-V&;A!WGXU9CE=M.DP:V&(S
M'O")M>NP!C EU'%>RI^,B0+L[3*=]X$8X'HY_7ESZYAADXJ9J_Q5X^)OB%RU
MG)&EO0_WC.DW@WQ7&A@ND1[BR(#6^,L=2X.TDV?!VC5@:U5^S9WMQ(&=]LI*
M7FUFK;**_T*O6W;A9JIG])^+*8+.&)\,\$=OL]SSG1FRVK//)0,B^:+>55?H
M;=,LRD?Q[W7M\KOKGYY>#W]8.E5E.Y:>&A>/TD._G4 5J^7,A%O;O7.K$&'9
MU9P+N,#@^(JY)"%W"1FFT!]B+D3G@>71.$ZXND3[D79)??^80\G*;6QBK%D@
MJG<]+Q1C.O'G;+J/$V03?!;2);;#(7#,5X=@)-&-*7EA>43-QPX]JS/FQG-"
ME_>Y/LLN @;&3FF)B0Y!Q<5FD&"M8_MU_[N[>P_+98IZT[)3^N]XI)<UL1>1
M >.G_-6X^6B56A^/].<G:=VVF,NB%,<N#$]YFO2$&B#VXAW7Y7]U*#0L7;EB
M]?I685?2%59](]O_+AG%&I[5!8&H=C_,9(A7LB/JD(P)C_$H?=S%K+:!:.WK
MQ4@I'!##+7.1BA'KII@J;?8EE^7CX%7:JWTNX%"9"XQS2MNIB/@/U*?"\MO$
M\AW -]QFA<.18'['1?4'OVS"--L#?@!B6TP?*H%_(QF;>=664)$@-DP7M#*O
M$I_V$J]S4C<$U\Z?>NS-#*D228 T5CQT -U):K;F.?9DVX1,I!61;I]%PQ]D
M$=HTRO$VT5L'?7XJW'[JVEH6<:1"8R^9L4CN$ZNBLZV:>:E4P#YP4G>S\Y0Z
M+G_$49H8O4LQ/Q/HX>=U44.K2_!/KAKN[PK?I2R/$3&DE_Q%"FLJZCH2&Q9K
MYB,T='BIR.*=OC??DQ*OSC%[_<M1XC9L7B:TG/&C>A3!D/Y!X$3=[F1>GQY.
MIJ;PNSW[]M(%6]B_O89YWEP[M"WX<XK;.Y;6QZZO,^=LG4I=72'UM"Q *7I1
M8FLJDT1A!M&1 T\T/D84=#C:'Y_^;=61]JSI-IB?D^4+B,@)[-0ST#'\-WZE
MZ<O!O^MA]H#QZ"ID^(456MAB*E-;X3%WHU4K8V;JE I:\*[CU#^)6E\F?*F-
MY)Y>7V(:NR]7J\5QV>9C0W>96E3.QK-$QU[9YGA4]Y+Q-'W)6MYLMD-.SK9?
MO?'V.E=0D!;@PMV7<1(J3O==','/1U\<!UTK@^($1,[H8,A.,H!Q<T)%$C<&
M,6_R+C"67U#B,.K(2C\.K.IDO<,I''"MH#2B\*K;RYR_QQ+]7S$=AOGT]M+6
M<C-J)Y5K=B0SMM^ESMF/IOM[TTN&9&_%D &U$G/ QY^VU?+#<AOKXO9-TYUW
M7NQ$S7&P#_%VO#I;(0/LZ@XNA>.-TG*G@FJ.'YBJWW_P#M^9/>0$N#[@S+IQ
MSE?3&9RC0_M^1N<H-^(%PR[?WN"6)N4FQ-5L/KMA>W1G<Y]$/VEA UXHVFE>
M0^W[U^YIT.%%E]FKEP8C3\&A[D1?F:H&XPG32->18'ZVWL5%2ZY5>92&=J =
M\]HI7Z1-S%O3\)-$9N][JX1O>YZ'PF577$=MS;FJ\>))-E@ZJ$9PN]R5C)')
M_AO0UTCLW1UXUX5^O$(YW<0^T$NG,O>F)O)6J \?[?4)QDI79S"!-]9^PR56
M1."S3^X[TCP*NL\W<M!=5>Q\5W+@MU>/Z+>J&)]RE6K7J.?[D&]O_U5/"-G^
ME[KF_]_BY-/1RD3F:..#)5$VW$ "5N>E_E@&S>,R>SEVHX]OV>VX4JEHM1Z]
M8C 0[4(O(M4[V[!B.#TJF$-;?YDM3;%)<V#1@EF/,W7ZCYE9O^\V1N]C9SY+
MC#3W$-)Q;BU0KH-B1ZG.>>YRO%AH53/\/K333!\?VW;9+:J;8$&4@TL2'A29
MV:M<Q9DG+15O%C1^S?\1DJU@HZ@E@$\%' 3?2*9]-*O >]A.>D68640$^3BF
M'\<VJCEFFIIK_S&MVM@949%T*2B9I$S\$" O /X O>^/0=*2'+! %MC+#EXF
MW)\,<2)=<G;NK%WRL<M,-](^I+.24O1NDH$W8)7G"L#7)N;\ 4%B:3<P&Q^'
MQG+K@-H,2AS9,[4U$\.):9<N#>C"KE\KE: CC*H2 I=HG!EAOB^#C89169*F
M\Z8U!FHMAW^ +[S9]L*C5)A)6J/-+' YW&%*L+A,\4*XEX('\6HUM_N-SC$^
MXZ7Y-@=U74D"=;47Z,H_>YTL=FA*]U)N"%XN@L14<E:S;Y"*::L=HM934?<(
MT[#]8S1]E=AHTP3P7*CPE2#=$>-/( . '!<Z<1W[[/!L<P.D<&*Z*+PUA^K"
M]>GJ:&"A[6@&LVME<L:"VU6/J;\1%,W'$A*",4T>[*!*FYB4=I^&.=)[_+ZM
MXTWH%+ZC8.;:, X^*)WVG%'W0=P8Q<H"[@5#E#D+P:,0Q@/7*(R6:TI:#M7G
MZCX)'UCT&^/I]UD(KP9=AZY-J!H0XC.KOT9RO=]"94;=9+RZ[ 7"W=*!H=OU
M",(#U?A@/5P6?K ]UKE].BY)[/>HEK<7T].W#!\M.G[P4SOAIJBI+U4)GWTZ
M?_C8FE86Q%TM\MRE/1"B*1MV+?P7.\++2\]^!6:OZ^2DT$0ZTS!Z67IUI%A8
M1.S[S ?SA"8TY=JV:.<"?=73#E047"4VAHO[5>BW^.?)Z]LC/YTCH36#+0NA
M*G>'E$!EL,ZAA4UQ=JIR,D KZI;NT$@],_]E_"=2\8#*-3@%X5,AHE7;&D^)
M1<99-HWNAK#70MRF59W=V&=W=8Z^6F1(Z9.>D %!/G8+S,U","@4T^B%]7O7
MI1ZFKH5R*FV>8B4&JUN*VC,6*'W\M3]2KU9^4$! +88!XCG7+C-=7"F6APA"
M$74'XG)&QH,AAK/VQ7]>]-3BC+9&1ZJ+&9O [?"2BO8/9)$KLY"E>Q5*'9_8
MX3TQBW$*1NK%1%'2.V^A\P'"0JEZF$G,$^_2GJM6O$8?;,:$5'V7;[Z@SH;5
M'DT3Y!=1D:ER@1X27!"$HWW@<P/3\],)L05W;<F_C!E3H-?@BXK=BL'I7EBQ
M:W&!2.*U%C*@ ]R>P7$6HJ2%U9NF\T!$J8AC#ANVI72UTX7;4_7#0$)Z#\*3
M?T^TF 2L7M&5,K\8L]Y4>/L>CQ219IDC%CL#B_4[VFR0JI^AAL4[(AG2?PK'
M55%L(G'5)!8R0#4LD P(?@@B%.U?*%<GAN#D!2Y^PKMSL5HR("1PU.4GI>SM
M\H8^.:ZI!IYZSP$'#O!9"LGIM.9"]'=".?*^35N8LM755TF6'IG2W6:'/;!T
MILRH_G.*)+&@VX^!3"E=0W#UIHN_ZA=;C%)^9V*Q'\@HV?>K>N9WFNPW*W%U
MMT? "\G>.H'3.Z._07U.^\^,%X#82(R@E0]#()P--1G !N6?]A]$\C2"\,#6
M"9_=#C2S_3S7F$VR:)V[/D7BN*&<J&)U'BM+H'D3=O B\4J8ZXF2/#Z^Z[[#
M^R_5G_0;*FW9*E0(IDH),0>9-*<2V]4X-RBALH"D6(5/RC\ZBZK4NH<4S$XB
M=G]")GRQR00]Q^3^VR$5K[RZN*^\3=:!;.YHWK4,1;P@,J(L)!)+9[CC&-O?
M^IES#S'L>>>>O, E];LD,J"BJV/_79!$;/U:W91;7:JO7T-,D2/^/'Q(HU&N
MV/+B;ABVQ**#-)<[;U ,YN7_DZ3YAT70#'AQH=V9>[.9;;C1X>UT7ISFU[+(
MH&N/'@K=@=+<HHXI1%W!YV]M$Y_ #-^,.39+;-9W9D@L1IF**:D*#@>N7O^=
MO?7E1+]"[W&0PQ"<GPRX?(#S"H!KE<"0;>92^)IXK/)K%F\_MNTLNTC%N,?5
MM]67D9^O TXIS]G10=>Z2$(*_Y)M804<@E/2KZR-<0<4T;"<Y3, /,[OXH:)
MXJ2G%Y<2J!=!LL7KD02_:^K\:5W!;+T/>KRR!2W?N9RW6+<;@]??0%<LM$?*
MF%9:X+/;-_-D#J@N__Q9+4GSF%W8J"-#J4WXKH_CYB.>U5_(Z>4EU#9/"2SZ
M.4Z]7.QL/OR6:5+&5!9]SL<*=;WY)Z]B#I=S?67\/=;(@!\,'=# 4VBD3'PX
MDCE_N)I[C>XOR<>A,/G(*D)V'/ANY]QIG!,H2<3,0:^OCN_XWX0YF?EN V?T
M\EN=5<;2!/<]Z8B=5/1N"5& C8+_=+W]&!/S@KH7716_+85%4TYN\@)'#L9Q
M86B>+5&',O,^1P]+F32%G0_\]^.FW^8LB;?;^BJ"JTCW*R>4G'$.3\*QALGQ
MQ1O'$ZI$W7G6*.S ^T^U@?6RO=O"3F!/3WS4'R5%(A]!L0U]HQH=><<-X5VP
M@;:5LCM^0E4KY/[JL]35]HJLJ[)=_!7BNN,W+3&-<DOIPBW3@C7Q678U]>I)
M]IR/K:T9HS@#W[;?I6>UCORUG KHP&FT@BA)TE+(:S#08UR;WGEU5:PL]TMA
M8@<K"P$#%HBD?;_3PJ2N_> 7Y5BJAPN:!ZY81&A8'(P]T*%E*=FX(3-7^L5H
M^CF*Y2[MT9\X6TJW5G,E'"9^JTR<] !+)]%N]/'9Q-Y@KKF&:T*W0K8D,R6#
MJKDCKNU<5VX9>.9CBSB],@[3V'+#S73T77!9_T[*]PWTM:5ZW'EHMFE/D6W/
MS=@"R$S%ZX&:W4"^H">[2BJNUSK<>2D)4+P1- [*LAR,W3H"WW',.<%L+SE(
MB@=JIV?>.5$?\-\UFSU@!0S.;!X9.T_+;OZJ[+(H,I--^"!NJI.DP5#YU^.-
M"_U"LX+E?'/JR#V/,SFMBLHX95G.[45-0XB)U5VV1RT/N=8G&A%&!&O\#IWO
MT["V9;[7ZR^U;HTY6>&:@IKJKTYFJ0W^U@Y]N79-N1AH2O C/IL1CM+]BC<8
MV2YUQ#JRZBQM7B:^SY'[4K%/_''U.>^)2E(\_XICS]3!EE?C<^7/=SH_OP0W
M5C<<-M1D:'DCGT0C&#7O8Z;AO.NV.PB3*_ 6XLOS"SX[%R9I$GR+"-18^[4;
M0DD?T/JU^^:C=K,,J4R4UYI?@!TRSE=R\!Q!(/L9T]+'[HB(4\<#ID&^Z<93
MMIAWQJ$U!^^X3K20QU:>T-0Z,H!&@ZB/:)T>)0EC%R*2?721!=-F9J;028+/
MP")2,*#MZ'68:I#O-_=B?<W5)#LM2 \\9;7N\! 56K5IE^P5,C>+TMJ9RW/Q
M>_SV ^%M]>:J,R=<BG"6OU8J%^[_H*MHP__],[&=Q@>6U[VM?R74VA08:/)T
MYVT@Z/Q!;5A3;E]@#-.L;:*I[K&<*\R^Q3K*HK97[?D>]TK/=N"K[]D5?!["
M^O-.?X <((L%&KCYV7<E0;SS"XR'K[+>8T8RH+UY*J4'V>N*)W6MZ&H-S&>/
M-"=07FI^ZDSE/X%\6^E!",T]R]TVW.$_[RB?N4D&V%[O9O#8TU9!- )V7]>4
M+53GAS9J+*UY#/+8_5CS22ZD2A?[FQ=JHU1^37":^\UV#+,>I?3OP3J'O_$L
M#-/@<VX)M?,>(I!TAT%0!8/D=YH%2GDB?%=6N3_LG5=/VD.OG\NHY;_NL<;7
ME4FPR][O$ Z]QV:&WPMR^R7,-MB#VSR*-J-LJ\SO2/,<WQ&L,8-,$EQ_:=C&
MQBMU3IWTNE4AV)77*-=]1/_Z[E*<C^+G?B>C64JL:V^$)&CPK[$#JC/#79^I
M^Y^D_!6==#/W72X@ ]X[7R%X'D.<N6R/V3V-L%B_5)E/#RGXQ=G @C\Z'P$V
MJWR&J+,(ED>YA-B2\RE(;:LO.NPE!"8^P@XCJ1N8M5^F%11'>.JG_06X9:SF
M^NF94R[MAB.X9$HI=<8$" OW)+P<6;<Y2'Q&H-M6M!K"-0Y4$N'HJ@1<1K6;
M<(>I(?ZRE&Z]1P3N,# *>Q_A/G!1_8P]> HHURNA8G#.8;2=(G0ZO+/67VG,
M49B@QX<^>O6@\<H'Y)SWL^S?!E1>SILG^B4PFJ/TP/P;SNV;HIG2A-R(ODQC
MH<V*7UI,!X\:(IP(;+\OJMK9CZT_/Q6\XJI,?R;,\NOD&&=9T5]*E!K+TU56
M%Z'<ZK4JZN>^[!CWF*+\&Q!RXKLX$(SOPNJUI8M"Q_WOUR04S'XU\!7 I2<8
MS\M#)"DL$U5>KS8[N XN(;MZE%2+'[OA8_F&L5'\ENX9G#\D=?\ [TNN_@6$
MMNQ^>L0)K-AMB8]#,_@_@#^=:!:$/X:R$%Z^3(K[9'%4*#25TEN1#;A]'2D^
MOGA>?:@,KP8&H.TJ+;(UR0#6>QVS(Z_IGC!E&CO6JC'\^2Q_$LWXE:<6^&S5
M68F?^*;+F=L4MJN1;$G[?FU:.>+2DQ(SMXS H #?/Z<OJ"</P$'^O2HBA+3B
M:5B;%B'?UQF!6CN-FLDYJK%SYHK]Y-+94MW@*CJ_]M_1Q?&O)Z1L:JL!X+O$
M%R1_/+1UV^T1;C>HZNS&J@FZHFE<*.WU_G,:9P?>8S6FCUZUC_0HA\81P/-1
MR!\H]3FW0S/SJ/0?O'#<CECI^U&PI$QN=G=H^C>-L#?W'P%B,![XKB,WW'&7
M\U9=M;*VR= AG9(V*R0LW/U6>E:29Q\-<\GUAXLQ-D,3PI$(*Q0=++X-M];6
MSBLT6K*E4[R&[3U[M;9[R1%<T\N3&ZA8:R--L<@!K.V*DSAPT#Z3:)OGC;%-
M]3H*C\RN]Q[\=F5AZJO852)ZOF]UI G= JSBB"*!B5IF!-[CUO(U%8[S]AOI
MH7_;-P7[=XP9[E]^RR3_BU;NIDU45H%_RP*#Q/LJ;DT42=7".7\F6KN]>NS2
M!<S45DXZG/;"_:U.(LV:TT4G+ @:WV=(+VKQ8WINO(5426?Q-Z\O=S,ZS:J\
MMO'B<7O$DS3>.CVC+;7ZWO[U\A MIA==209L6V,7(A?8[KF;(=2'2PZ 3) %
M\S54?E7>RN6:+^U]+L;;;R>[[U(I@,?+HODD[].6W'^\([I*!M#Z=S0SX9RJ
M2^Q3Y2+@+RV\O&@GCAAXOZ,O9MM$J<=H:*O7R:FAUL5%A#(T^*@-[P9W=@2>
M,VV+;[9(;6+,;U3%3>6<C_D66.PKM1I'')6?/%FT+)191U0*=PZRDBS3NH8)
MJ+:)<\[&(8^\T>^C;S_K".AOT5ZNH+H[.*CH<D=:;XJFI1[8$=$(2PUK</-F
MZ[-G6O>2RRHQ.,QF:AJ*MU6Q%%E=Z73]8'8<H,)J!Z3W0+)O^%AA7 >QCIH;
M*=%NMZRUGH6V J@X*+/Z 9Y)2\BJXTX4"UQ,[^K:.5W%2!E< ZO=4[J8!F'F
M-F87B2DSL;P=>>O-&_PW3!TFE>1$8,@BN8]4]3F^?#'N;CHGOE3VWD.'?5'5
MS6DK%^@@^:/MSJT_+Z@8@IL5'?PES])*_/GLS%G\H.T<LD(669#7 O:C08;A
M7V\#;MU*U'MX*%-(E(2_F%!Y0.+ D0'1,D1M4SK(V<U!1VOD75FP:*A XH>X
MIHW=P&9J.Q#]5DG5'-!H(GMHZR K5RU'VY-W3%Q+BDWTTYV>/AM<*3(407N
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M7$NHW@)FP KZ1&(-8RX_-U\.>CI+BM:N)0)#$+ESWSDGCVB#S=C<WI;>?1O
M._I/<Z_%NYKY&?YR4^^FJ1,?JL "88!SGKN&Y7KWJUR^:.TBZLYZ7)AV'=)=
MSCX/&328R8*&:7+=#=MZ'-_Q6.A1;<47O6N]SI<-7I"B#NDE__&=-=9-SY]#
MF>E9Y]8EK DRD)BPJ M#N)/WTUY78.R&>PN!_[S%&MTV6Z'DP&CG?^+^.M\E
M()M0> HG.@7#G;'S,GGUK?N+KW$^8A\860].5UOBHH:VE)!!/H%"<W6SLE"M
M'?@T]APP)8%=#2UV\4]SM1<;5Q)07Y$1KF\:?Y#P<\6A9_:-8(B0-=Z+93JD
M@_<K.MY=/.LIR]+#9X?2=7<N?GBGB4Q9H7C:M^BX2+G?=-]+HV:< ^0:)_B:
M$E:"),[2X9*XA7![ 8+=-B9Q@Y?]<[_K\.SE;]^H.T<8S]TV9.8YP!45ALE$
M$B]B=HZQG#]P R)\7E%H6T)8[M%I'*#G-QIZN[=\/H/%E?PRB<,7[F;(9NJ_
M.U%VC.DV0][2V(%'D]GAS),4#AR,W;?)C-!%91@[Y!Z= 8\@91C1MZ(,9$4%
MWWDN\!QP'++$4$0+?/<[,%GAAZ\QQAI/0K._F]36CLT*=GEQ5(TF5W6]+(@H
MPV?&@SM?NC[]:K#?,B0\@7!$7-@28H:K+99$VZ"VW:Z\KZ]Q3*?[/KZ\ZX:Z
M"\,M.M7!W0B@SE8MHL2GPQ;MW9>-A#^M;E'6?ZYK+G&_-5_VV)0<+BP\'8 N
M?#^D^)!_'R7-GP/&-'-TSK[#V7*?^?;U& 64/>[O3DJ+U678""G?/P=H$B[8
M>O$O6_[;:.;2+NGUBT2^6*.NXR>2-&[\J5G]K@J)HGQR0_"HTZBH2>[M1WP>
MA1/]3S?U7#@.R-P',PP!^D;<V;$OC7LE ,^=]\IENQ:N5 MQ4!X1UN)@KUKL
MH-J1N&I])P8ZIO1=N]RD?4%<4Y]DLI+XE14NIW. F;@$UWMX RXK-!79C<0<
M/YJL 3,9.V!!]-:WHTWJ/]W9Y.(1OY].:3>0H%Z\ YL1Q3XN(IK9D!P<H#_F
MH;P/_4O*"R=#(IZ[?:BZ*US8IAEO>.K)[J TP^^E;_YIE,21<D)547FZG,<C
M$]7["2Y_%JM)2^CO8?5-Y?$*]#&OO?QFQKJ9?!_#Z+#,S?^Q34(5;P8W_4N>
M.(B@;E/2UW*O>*:M%(;*S5WM9N75Y?=GB^V7ENI[ E9;^O[Z=7T<PF5PM^Y7
MO)M96EJ:613)F!#>B;K<?*>1-@R;J0&^.R"68L;CF/Q@XGL\(IL&TV1]J]QJ
M\*G8FHKWG[1W/B]TV,VO_H^DL5XB[2=%,$=M)J;GJTM1;=;;.N_\36'JH[9K
M I[#,9/UW'G_I+F5R,V%LIOHZWVACIX#V-=()H1R*OG1%0CK)G.J4_S%F.J4
M=QE%'ZE#TJ2GD& AAC(J*UQCK%K, 9CMZ55D5]$_.X>2;Q*D$+0^E$O@V! =
MO6=(3?%LT*XBZK*+*;2.->$KV;;WE=HQ#:/D[-9?_E/\O_(?G6/HOKK$CK9>
M*_* VMS1RG ."/[T6H43Q4K1*/T">M4R2AU$SOR)TA5'W&9'SW]=.P?P UE<
M%O@T&3Q^V-?7-.GN;\O6[BB/??R@OY/[MK,>F&W):/=]]^V\,V.!?$%$"<$U
M*S$PR";KB[FE%5$""XEL98/"\GU3'B7^WH\HOR<->PMJX<_@#O 2:"L'7VED
MV;SSM B=7SR:^,5^P/6;92.UN_5Z,U&BMXSW].K,=JJ( <+SUGJ.@\AM8.D@
MX%3(<)_E$D4-#0\Z9LFSTC\-S&;R*:QD=7-MH)$WB&%&??BM>1%ZX'/D3/+"
M#H4CF&^$/'"N;ZF';]99TG-Z-YB$Q:))]YWILQ-"FB2\7?/H[@2-8M[ ]3B=
MW__DYOWFJS&>ZE$'+;/!Y_>/_=AZ\%&'W9*',LNQO] 50Z$E[?Z%NTCO[R&=
M]C>3M5BZKZ(V)W5QF/6X+D&ZHV/D#\E(TL2B?JLXY0X1%"YFVX*/R7S@8_4%
M%AM>[\@Q'5I8-&&(8*P.BJ?4V;_&?/GB6#ZDZ]^F!@A)M=Y;F([N3:3HD;BP
M DX;=9"S&.NY_5^IUU_"R8G?*=#QDLPR%<-W!=)C%>G_+$EP#?]74UND G%M
M>_KO80N+$$5K&F'Y!,!/[V7/5OAB[JG33K4!09@!?ZM%R[\DAQD$A?*!N>%&
ME:18G)V0SL^1&M3VV2WU$U/UBR>_+J6(NBXO1>$[S9 R+L/N1'S )GX8D^ZT
M>R>0Q;;R+!/(OS'/A=94@V*-- )9;+XZ_253SL_6'-4NQ<XZC+R5!'<)T3;S
MX3)8'HP<VM$S#"@\]%T>P\^E2S?I*O_@?OZ8EG^UYJ_2X(?0L; +O&OS?=^Y
M%OMD]E;=[3/\26\=.JJ-P-6+"/\;!$IT;^#2N#D%ZY8(3FB '\KOXWBH\'7:
MPJ+5KJ;!O3&?\OCG+7KEC:QP@[,LJA#<OJFVB0@+DU:*;O*:$>A,B;O7,#CZ
MJ^WKD1J'9QOD,H65T$$]/>YHY:\>WH$YZ)?SHM\REQSKT@D[3)D#54E;BRQA
MF%)>Y\AFJ_S7IY\6Y6ULC</;%Z]?\0[9?"L92AHAZVPTPMI1/+[1V.,(Q3('
MB^%/1J(/=?YX*-0#[EZB24CWM.Y0+:Z(%5OI.["9L3QV-W]J)2[PAKHT1G$@
MC'6"KLF\3XN_YG)MT]-%163G]XK3%3H]76[1K#+I^$X(XT:K"HH86IO$:"^.
M^F!CNWDA#9X0\T)_4(,YI 8^)X$/]"J /R8Y_H!LGDKQ.I7D=GLB#<1>:37O
MZ?*P"TP93W-S:T$AV"$\U,%E22C2 L+:;)"SWA@47\H@(*7N9ZH._W=C>VA5
M<76^4K8O\O!N7X_<9_RW2,GK$T8KIYE+/^"B!$28&T7[2D:V=?L5E"2X^&';
MKQ3WZ5E;.=&,WH^]2D,DKB,GD@,!W06:R>0GA,:E%<=L-UQ>EELK;]N^'\1=
MMD]$M+^$L/2> ^B44VVZA/;HNQ:C!^]U.?]0$WZ)A&9=:U;!HJZYJ L6E&*L
MMGA+V"LJDQ\9O=6]@&DYC5I:[2KIV3NN6[ )\I9K,;9H3/<N(<O"I28IK^!F
M 8LMZH%O^B2@P?R2OT"1.4P5\0W\Z+SYC:/3V)A)'SFIVBK=EXFB;8ZBESSP
MX,;&L!Z,372DZ541TSTCR<OF)N.)OA>;M[3/<ENY?;.Z)']L!*F.()4L$=+2
MH\MP_'KI6^XSNJ(6_\W3WWH3,Y20XR0[.Q2-[L)B_$=\D)#QXNMF+?=,]A3Q
M@[;=E=K'8(TZ+\'J78Z_Y!,42Y%PP)9Y=B;[QT6_C!8HJ_Y1=;&P;6IQQUYU
M<?P<< THZZN M;UFC!NZ[G)Z?=#C^EQ_.,+VUF_1!8Y?%&/2S*NL"Q2#I?@+
M6^K>/]^4"=H$?(O(%%ZJDM$#]EZIR:]0\$B$6>9,HH,"^Z(*,:ZGJ*[-($$*
M-\&R(T-YM;<C4Z!ZI&Q'5V)/V_F+OT*%E%XM5*\-Q0Q7(8P9UX]1%/)T<JV&
M-&S[V:6Z%&./TU8ERN!;BR",2@]0F/2#4/"@);F3#.JR9MODPDI[5WQQ7^'S
MZ5/E][3'YL+]27[EI%8PPS/?3L-&XB5W!V6Y6::5WJ>T.:SK=$IY_MS?E/-G
MD25SVQCT#C_V*:SL4#%(A")!B._.N*.ET=W(45L#Y8/%/*)O=MLLSY6G7FG8
MI0_Z<PY@A+,4SD#6@U@JQF!NBP&OUT)S%U;J;[2+M[X)]E-3VABW%(-.Q/B)
M*J= FWAN#\B8'VAN47FVL N4&\,D,RIK (2D]Z.)_-Y;8WFJ:DUCOTGMUV&9
M;(00K28/$:Q?-Z;Y%$LV?CDX<W;_SU7?^MZ^S0?,6DS>[TWPFW-&&7/0)F8_
M^V-59-@YX(HF!R%N- !QE>0]I&- 7&V^5YWH4*5QO2O F:.?%'YD1-+#(5D-
MREV#:,<*QO,0\@;LOWE_S9=&M1L<_EIM\8Z"LEH9#!C/[>SL*)FZS*EXQJ&!
MUWQ5NCZ_?N(J*%2=RD2ODV8<>2%6^MG[6\7W"MU;Z4DWC\V)G#F@</QR"Y%1
MR&GBILQ)8SRY;/^M*CX*OU[TM%B:/6MAGW+(I9EB%CD>1$^2L"#HQ(?L4$ P
M4%BIH5)MYB!9],Z[^AM5[<?(:V=Y0$:X-M&[I:#_!\FS0U"3T-(LHEJMY7_A
MTE$NHZ,,C22'*K\[A2G02,=-C\LBYF2LE7RRN[]OG4)?&=*Z]@=46;>]AA,*
MSY1&:SKBF@2XM,=E%VV,[%BTA=:/$F@R6^A IH'&@5HZ')DBS40EK=SCFWD&
MYBF*__[+\;S[?UD[2XM)^L;Z:YK5K-"'4$3U0H_;B[ E)ZGW]?''YC>/A#("
M\GS!;1^/8+$( 6E()*)6VJE]JR8;UX)I(J*ZZ[X@#K[ ;)9.9'__^]#Q"NV@
M4)WE-OD<P-"_B/]SZH7ZCHL%*!UEFL-'"X6:PZF7<N+?2NZK'(%)":44:=(A
MUEA/W^!F0$G7V,Z;-M &JV&[H+R6WU %!SE8UQ_=3A4F"H7#N8C]YD254$TV
M;(;*D[K&]RH/P$R*I<R"CY(^.:FM !0O'$<SE7:6T[&CGZSW==[1O:K5;3*L
MI%W^VC_H']&[T4WOL_JU+-^%1#7KFR2^I;WY 0@CI4LUW\!!*M;E^&YI@O*-
M-8WX$BTV-XZ$+Z4?BN$:\0J+9OT.>1LJE@DSOM:JHIFG'>/RLZXJKQQCN\(3
M&_"VTE'G@ X_(O/U!76H.OGQPN&&TUW0Q<.##36Q4_2X@P?'VY\%CV7G:V:V
M$/NFJ^.G;]Q%\CG9-[K)DTV!".S8ZGC8X""3^BB?S3/3>0P'';^)S(2. $"@
M^,6XB0Z\TV<B2W'NT#F*VL\]0D$0X^_9B]2BDS?%MB\5U5-K#MS@2V2-HGK2
M/K%R!33!L/6L?J->9R!0P&YJ80G2&$]-C"VA(,1/V)463BXNG /0=* #-D@F
MJDJB,\.S6UTP#U% <6DB,)7ZC_=A%*\7EW8!C9[_0@44&)ZQ-]09-?F]^%]H
M>\^H)MNH73"(@M(BO1,5%)7>D185Z2_2I)>H2&\B(#U!>@=!0%% >B>TT F=
MB$A'0B^AET B$"*$,+RS9LY:<[XS9]:<[SL_]EK/CZP\=W+?S[6O:^]G[YW,
MS!-K$"*_',_U%T?N E,_SR>LYB[)_,@8F?=Y-#+4ZJN[B)CXT&>4^[S@WNQ&
MXS-"A[K+TXI7G/=._N@=*FUV*BQFX.8(T_@VJ$13XM2A17W<&;]A^VU&-&UR
ME1]WM0;$.6X5A)7#QZT4)^1.]"<MMY8K[EX ZK8EU*2L;'0X;PE).XF:AJ&O
M().)Q3A@%XA3.M -W,>EL$AK/.?FQ?UY,]R6PYS]6R!/DO,ZF0V*6J(C,^Z6
M5CJ>_G.260_9\9!13&_R"Q[E 03C,[<2Q6X(&9=S#PA4NDG/% <K'=G'5@H>
MZ%K/3BD!5T'A2JIX6D(W;C^CB)BYVV4QO\BK]6;2>_TNYF5!"T73V^<:%KEG
MYG[\?7QLXU!&1^J^#.@M_%-GR0JN]>4Y(6UU_6_IVQ/MP1%>N+@>4QAS95OP
MW0I4;SJA:/A17T\X8_:BS?O4@U@]4! (-]);:?IDTF?.O$JT7C$)82YM"N30
M4M8T.@RF9SF\W^U=?_*Z562/_![=I,&4FO2FU4?%\SRL_H>,M4X_4@!/!8>5
M!:FSJ_>\T/DC1?/@K_9J:HH"/O;WQ 5@_;9I!T$T:=UF,S>(%0>/1-[90<I.
MB C6H66>S?C9-GO2+6X(8T>0#_V0C'[NH)@_?N=N]GQW R$U]1< 1YC8X-&?
MPT858H6S[8/A2NW,68/&_ F]9\_*U7X:[E>\_V2@YE=\\S\S?LZ0+S(]^>@[
M,%.%)K62/ KFE1F .MWY+2+]>6[L=E3QAEI@I9_IWNY94@R$M_+K^6LBHO#1
M+B+O*NSAB<5!_P6 :]'@ C!NT.Z1M-8AP&*@]I:#Y=B-KP=2G8(RJFF8="TX
M(Z ]A6L:?YLQVGA>.JU&7 X6<TB^:2TV-(S]G/ISY-QKH?$(;I27-?R3X]=S
M3IFG%=^S"6[0?TJ+M]FXGG_+#$Y+0V2%/E!#-$88WFKJX@;T7X>SUXUYU(/X
MG%ODP@["#718:C[?3<M]L'Y](%IEJD?]GBK+5S-7^X1(5LT3A?5*$C4]/.$-
MGL4WQ3]%2SK)7=_M?$WBV6-EV'ILXR0:RM225U1PY.(V$4PO/IUDOSE\X(.V
M1&9< "2!@ ',A[M[*OS,V'BQ%#1CIP[S-XR9&34/0TG4KG6$FH_/M8CZ1CDI
M-3</IHP4IV]W[B16_'H+X"MJT^G/0=C'K9R_WM0>.RHE/?&BO<;<IU#!Q$/Y
M2:BI:;.$0[D\I>*\8+XB(V5ZM13L)"AT=[MF_T5^),CBCT<XB*G-:77!?F\7
MRL(E&GUKZ1HZXP[S/77VS;.9JT>4''"SBO@1MO/X)(+)5[Q8CVITO0<'1(/I
M N C,+L, P\CX^'?.MZL$I(X26];](XEB=W&5MX_^RG.7;9F#U"P-JV31LS'
M=A@&O/O=0(VU\^7M;0@-B95HN>+!2SPAQ':@CRQU+3;0!DV-C8$E/7\IXBOZ
MI$XL'W:(K[U&[E;0@SIM>'"DT]Y9]QA;6]&:VQGZ?K=IW+]MBMQ3P:\='U>1
M9 5W<-^,#X3<UO8]GL/K#'4J.Z0.Y0S)4TWG24A>2OFDGAIB]HK'>K-ZRJ(*
M[+V=\5H1!L6'/%YR5&'(Z85Q*%&*1/7"(M[N-OC>\+0#AN^]:4C'W'KB^+F_
M5>OA=1JB<O#N/E9N!1[A#:/562D78]AN((,R/%/_T7ESIKB_7ONY:\B>*+B<
M$4+F61H,7H'?V+:0V0LIM[*8>S@0-DFU0UT-?VU>SV/G6'^Y1D+KTJF#;5]1
M5@9T0>]R>7JX8=3J4K\$/LW[-YKK/+.O[6ENGFR.K%([R7UF?16IX N7PY4[
MPG'4A#@/!BH(\.N9;7'D\#,^%]?=D>=?-CG@HTM<05PX<*_NT]FS7B3K.*)\
M#LK?U-9@^E;JFT,I'^I.-)2.R+:D\[M^.H@_OZ]XYQ<<YL*;*>Q[%[KM0TG-
M6\:?::B-U3[(T-EJMIB;ZC;[7.EZ&N 8Y,4>X>VFNGJR]Y=W*M7N;<8B3Z).
M8?J"V?.!Z],C'P]9.[N4)2Q UU38_"Q1.3<[''4N.;-C0R:BKY(T:HF8?$5*
M7GSU^LM991KHWXWLU8M$LNJ::DZB>TX#=KB>@1TF]M5:_J;7K'+S@[LEIE_,
M@D/:%%=V$VR"Y=1J:[Z:PF3/E\,?M+A#G:Z?H5+14S79=G[R_=LS8J3,"T!Z
MN-+S=.L.RYQK?JHKY^AX\*M $1>=19\#&N?#G71)05$VN6N3P::"?'GM4@2S
MIDF88T[<*;R?_OU,;MTXEG^\_C-WFI8VI53BPO0%H!-5& COA42@&W*H?7*N
MD\1KQX/DO((26%Z&7;T9PR#PEE%O*'XUL:D2'@JC$U$!!DF-DD2<#69_4A!B
MDCV%AWXE$;.S.TW2:O!97 E!AJF-/NSEEZ3GEU=5X0V95O=%K7U_"':GI?D\
MYQBX-_:HCET?YA@':R=8KT(]YXJ"RY-&#\!V#Y0DEJ<+(+3UZ\ML@^LYB!LX
M,#J-&WEB?0$0A=&<8C9FN0?];V4+9'*RE*/N1)I0E]PZ9NW:@M0=],#H7%8M
MQMN8\\QV8N>F-KAEZ!)VVC^= ZH4Y)N>1M5F2#HU-%O#H1OZY:P,IC[NJ+X+
M ,?RY @V#,ZK:H;+CN[O%]O[0O*T=Q>VH,^/KI4M=_ 5_(LI)<*Z18J"Q(@K
M%=-^(]V9Y*\^1?6F ;X1KS(Y;C5?9?5)^'3_JONZ%K4@ZTEQ(I3=3P=C72_N
M5]S3\KZ51U BN &P ;:NG(12I?2L.(1+=]P868G3H]].7P1E:0\5:[B6TWT_
MGF_ZV\&%-2\PEM=(6WA7C*C(N:0H5V=>9SPTP1)!3$%R9I:K<ITUGH)I%+CP
M;HUAV2KTP,AXC0J[,Y2=:( O[WE_*C(2 ;U+]'HQ]4:'=AK;O<OE6M'+YB[Y
M>.3JNIY!&"30G"2,B\PIV<X@+')/W&Z;N"7;8%18&]48O7D_BD=,,#8WEP3$
M44>V/2??&6^[G3_MXJ[#/2W"^N;J,?]HCD$LGX.VU4#?3+GE<^SI\1;(/*Y]
M8HYTN;?[U'?28X4V@?+_R_-+\C6HNRX #9 XU[NW;^.?1UPC\24(T"-0:+=+
MC@W'NKWR7*'MN$8RKHX>$(L0Z^QXP=,>/ZT%;5I&UTQ#+'?>RYZDIU00,A@K
M1G\6WQZ+?)%4<J<5KT)Z,&5MG%/A3:KP,%J,=UCW:"5?B]G*BUT6ER09E(BF
MKE2:''\0\G 1"']P"U?<M 9EQ?%%COLEF=?4)A).AENR#%Y-&LO<?S<T(>GV
M14.Y0.;T1J75S,S6R<0.-[2+A>&$NU\CG27]QT&_R^'7Y0L U@=7I)=D(DL@
M4TT>8>_MG.R=0DM]2F/"&880 K)G5"PIX/@TJII2=5;7]9:]65*2#O5GC/A#
M@[S?A2V?; 6P"UHRAXB1L5U:O6JS.<N@\"XFM3/$;,?##YT#G:M%SN:VYGE^
M2W>MM;_QO'7J?9D<$!8K9)>[";'\%A4%9=N"LDUA$2*/!&,J*[F&.?ATMV)'
MVK]F^S)/IEH'LY@@'@Z7;Y3L#Y8:^D"D%Z:-[GUQ6_&WBM"<;&6>IDC5@]\[
M+VKSD0M#<EC/.G4.P'>'6YY_I7DW)-SQ@'_KAO36A$^9^K> 6$:OE-@'T/YD
M9/EWXES?L#P>&.U^+Z:CG<7A=4YA,+,5K%OL2A]N8J4QJDWF)@@O5J^YQD\L
MZ+>Z "P]0[^R>%WV$%$HCYT8<^RX4C:@[589FI+>1DN8'_60.?C ONLBT^9I
ML6BY8*WA69G /?R!ASW!??!A[R_Y:XE"GWZ<_!I';R[MZ> .(:F8+GQ4E* E
MZ)I2Q@/_8L$D]EY=#\[XZV[K-X1C.J!6XH\ +U,AWS\!#*R2^G0]^E1 ../C
MS3#O0!$/B&X>=[ VSF+NEN!&B@:X.U_@PP"*=;4#"'.V-C4YSU*RQ;/W<JGD
MB(Q$%K9&0>.D(U&&?_R8'H_3S]'RO-G,[9*F.(I@/?3M LT6'5A/!)E>"CIM
M$>IN4XNK[S-2%J<7-*?4%S<D!/R= ':>6<4URD(S2!#)! ?KLU0LAU_W2]7%
M\[:71Q>G/F]BBOX<'S*]Y?F8UYK%X/&U_XS=YF2IUZ?^10:"<%'D:3"3M\-/
M58RNZ(A5 S5Q5F)=)ZDW\\0"#YIMF-4#$/,[0>PB^;; */CSG(I/G()Z37_-
MDVIK1D@T[66+&*%6O^)0M4Q.?:5WMW_X\-\*VWHRY(MI)TY4M)2#S;;_FI.&
M8Y%_XL_@@T^U[Y=E-A13Q1590^9KS$3RG:P2FWBCFK>):(IA+?]@CV++^A-3
M1LNG[6^^=)>0=%\_P3/WL$O]E=AM4/]GF?(>!=BH+V@=L\2^PR<QN;A/4*T3
M_-E(O181"% .UC,R<\@$G#TP4X@TY-3\<6N-$6NN<@_O_G%Y3E/4IWSKB.A^
M]V;WFZM?K(Z, 4RZ0:QX$&$$#;TQ)!;:!G+VZ6"!J,==9>X=[WO])[C_&<_
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M:M",_Y4@C;/R8%FQ/H<.6,3[13JBEQ=F$@^.D_[R2:.XQR5W=[M@SC]%4W9
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MNTVOO/7_<2=$)>"2EK[K\G?#0)CZW):_6O-K)O;V>%8!J6#=8.E&(>^N.Q>
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M:=6[KR4]OH]? M4?="]V_*&9@AUQW*><*?D?)K7JCJVMO0]$[Z_*R=5YTK>
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M)8,@C 6IVI834S%)O4!>1/B@<F5B7;F B=.=;^5*LF.]=V\=QL@!G4_H@-H
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M[]R*$PGK4<1JK\EF87(ZI!IBQ%1M&W].KH.A^_4'%B/%+=7D>1Z4M32EPFH
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M,6>%EL:F\@+(?P>P8STZVEY,"QVW4T*;%69/J%Y$+QG;9WS2[R<:D;56YO*
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MZ#:_"P5W&M&>W]-Q_1;V=5=;I<Y^YT2C236-JX60M#;V0S9[L@KI9+1--C!
M53WVA]&X[2NCWZVJ?F[-<<I* ^BT1X(DVD7W/$'V"C(O*ES<?CU[S[(6++#W
MLICQ4EF6^M*/GF,8WOU2X_LV@DGJ[[ MA\E=LJ6,+3(T0D_-NDN7N#^RVKKD
M;1\H9LG>]/V21G4(NGI<6X31FC)<T.#=6Y  96G<BC\HBZ2/7_J=Q_KN^60E
MFM%)REG\9>1/>7E&ZKIJI)-W:H< $1W?P0X:]X5SBC"2=<)DAM8MB4-'Y2XL
M-1V&F=J8@3F*(U)'JA 2J:5!Z86RDSVJ03D](I)\SOQD8MO;\[$"8]<DH^PG
MX>DL274&O;D??<J>$5"IG)3N<.CTKG=\5IH[1G$R**,O2V"^LG[TK 3?TZT=
M^;C3/K?H#=K#MDYF9C_2QM[]#I)*KQP[.&KSTFAIA:B8(_2'NJ/F0<3+^ULI
M;/)+7B,*&0F@&=F4A.Q;/9G++DR2_8J#T+<FE#9@=6XAC^(#O,N?/_ ]'.HY
M'V.2 *$A*1W:7Y#F3.L"T%A8ZC&P5%@@V"9)BNL->92)&PI5/3\MWF29:%#'
M$>QX#9#[_IVT[F'8DUMN9'=D>-3>1E<.+N[=(5U]ETG5,N4_%7<[A>[[X'?Y
M1S3$0;)T%+$L5@F"N=.+I J_#!J832P:$"D9BBH?Y[[B[GVZT/QHK#WWO9C
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MD'2E\($>V%1J4%C&R8&(2O9V<B9QFI!.3=9<JN;>-Q1+2M*DD62.##N\MY@
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M4E-4%#A,41T>:/*9MT$N%"9G[!F"W,WFNK9ILE!H($+3..YS+H$J\/.F#W#
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M+.GN6<E5:Y1SD_B.2;G[4Y>^BXGW-3P;_^CC8R#(I@<X_.VHRL>V>W@D*RC
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M1@T=Q()$1-W-K^_OZI4;B(9O*TF>R[BDKU/(,H-T@PIM4)A SVPHNWY4I8>
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MY#LMVMQ!0D_!&+6X/-H-L8IIS8*-X)\QG&'CGA\_L]E1)ZW$"%"O7A%:TJ0
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M-\]UN#$OS56X=!6APB8]LK/FH(.3 WD?[@Q0*7!9I%]2N@1.\U9,U4(87#B
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M3K1U$F#I<3[J/[B5Y/)Y+Z/D#8*)>!G3ZD]HX0M$QT,T4LDHZ6I/PD10D*X
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M%B2%[=\8:BHBV%* >#TH!8 D9QSK\7D7_K_C@K7W%3G_GXIIDAF/[(@]TAQ
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MTY;X[_ 7YJ76*M8.']V0%D:MHVJM#=IZMFX8<T!7G] "L39 .N8@&9>-M:0
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M"V5#+T*?U\>;;E\2$TI?N>EWKE%02!!^4TE^SG2I6<L\9=M:2Z1]J,/7)?[
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MV>6?Z?Y7IM2'>9+1+,>^(Y4; XV'X\\7$&\_OC64")'=> A2&X3P#IR8P"G
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MC"(BO?<2Z4B+=.F@ @(B($TZ"M*+2@L0JM)""1T! 94N0B@)H29T1$0Z2(>
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M^P<)CPEEU7._#)4E/XGG.F<WLQT1OV+^K'PXXP <?1>[HIC+%H39BP2RN$L
MSN*?,B>)UXNT!^IQ/!+C$ L??[R/;9)?OI7UK<=6YN\I^2*CIAL458YZ *$D
M6F!, IJ;:%"#._]QRMIC&WQF^K3 ]"JJM)LD;?>\$C8Y(7T*Z=&'Z^I=DY/
MAW=KQK$#IX/MR2X!UUQ)QEWA3#ZQA8Q]B>;#$-.IY A/8E?@>7;)'N-N[Q#A
M> -%5K9B+0VYBV_N[0D#$>)JR$C.0/I;EX"(\6N;IA8)A ?+B]VSEP#:F2$X
MQ&SJJ[_V4/X-JROY@^[UG2KN)!\,,1)5"(7.?O#M<&CNX:^L0_[6?=DVT''
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MPW[%_@D["C"$#&I>B]L2]A*0;E,"ZQV*MA/!95P]ND/4+[+[D\LPP#0SXD/
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MD-"W'$XB#R_394&5Z'ZI_B+9D63JT/L%H(RJ7B.[USE,5DR4)I@LA[^]X.0
M1LLBQ\2IDE1R4G]G!3W[79RF(S@/"WAAX#^Q8APV#;PAU-S<8 A58Y>QUO 6
M!/K8W.!^%2S%#A3I/ZKZ=*9'E/")35CYM-)&1S H^<MJ>F;T=\9F98"D G()
MH)'9T>#)U@K*O1@#4LQV!* E+@'OSC3MJ>=^3(ZX^P17DF=<?^Q4D Q0O]-1
M38L%[?3C^CK#J2QZ<X'QLG#&7_GFU"()(6U1"H'7!HC%27'Z2\D:'VD_BWQ1
MXJEWP4KP#)B.[?(WU[7$.\> D\U&8C3)1N%&9%E$N_.<"R#$=P)19=C+H=7[
M*;RD%S\]Y%,^9R4KVB?QEA(N/%EN>=$?3O65>"UT:6A;.2__YM\-GURQMJ>;
M08Z--IY9=PH>"'@V+A51A<EMRQJ1,>/JE_:BU:A=IY1\HOW6ZJ&; <W-!5BL
M?EY"!>RFKG-JSGP-H%^5- #Q[WR$YS4^X0B"4^][?_ .7YHM7RR;8Q7"3WIP
M5$59 ZB14OJP1!-B3I-TQDN4&('P5A.>JZB_#OGLH:W0VC#NKU]99Z5F/%*2
MFBMO\LWI]EI;%A2P/Q0-O*;"BK-%*K9*E1HP'Y5^GVI..E^=0@5R:M.IC,DH
MFG&1_B0K">;^WY2>ZN9:K:C=!AO:3B*\3 F!W1;!=G#9F\J:_.4-T/MWV2*B
M:Q?A5C,9_$_=I=.23MLP)%:O3-(22WSD S3? C1O /7>&HU+(/(H\V:G5Y#U
M#4FEN4'O1;6AY,XO@@'7!*8RB+179&[Q.D&T[Q'>,&'77ZR%_5'TMB"/2=>'
M+XW@8Z<WM*I2MHO=(>1(P]@+@3K4R#*>:4K)OUNLV,9@M2^D69Y'7QT7^W/N
M:- #6O0DVM*DQ-A N+FML*#T/=2HR+CSPWC:9O/Y>C88N-+7(;9C;3LA>T?<
MKTK_3-[+>?/(@,&:'+[]F;.X*6E!P"-NJD+$NERU1Q^WB$5UJ,?EMBW&$A5I
M\GB*X!I3]<_L7*6?R5?2=;A)R8I( JC(>[=)TGL@&XZ?P$,6(X>A9%U*K-UB
M@]=4.+].S[F%T\EFN/G%+_PH9CD-71%)<W:993>3+ $(-EOXNX 2U.YB.@9!
M71>4>-9H.)&]X6+?[HI.".8C& 3?SL;1L[]+]TG3;!2Z.:'HG?G-EZ<#K]Z+
M(5-C]3 N9)UU;<BMFD_-G#T#[LA(?  _$.B]][[ONI/D<2=-SI:Y9)@D41"&
M9<E>KI"C%K)G<%Z8&4S[UL]ER!>4A4N(B)$->-#$OT!^@TZ1'5^8W+P(^Y@\
MT*$T%2MGH!?J^R0+2$]8;U]@+%BMB@P@,41QYF=9D-;M]AA).93$]83'G3XI
MJ28DM ?3OB.28-LH;$EL1_806X%UP%^!1X]J]AK1Z8 ^<7JQ<AT?*2>HRLUO
M[60-X, 5ET[50/-QOWP9\U'(O-#/[6^#KL]19[(2"7 A<TVNU"(JW=_U@.!)
MR4Q\X-*3DJ+-"VFD%SW?F%H_\_Q<L]B# )(4B>M%]P53%"E_>Y(%W%S(7+X*
M]&1IV8D/\,B=J9@PH,<1:U8!&_XF+/"?.S-\?[)*GT&[CM@!IFGZL:;BIBEF
M<2_>5\NK1R](%';-C.>:P_"43W&7@)SEMR&5X*CV/JR^B8LR8G'ZFX8X+R<;
M7=F:F_Q)QK5#,WB?>A2:8D2B5??Y/]T>MTST/=7K$3DL?]TD]M?%4W18/ZBD
MYI^->W[[*2TS^>?B.JXLWO_*D9A+/ZAT*Q ?DRAJ;> 5KAWG?_S>1523M$'1
MYD ,0?\7>I+0I12 7 Z//EW(J0 _P%*ZJ=V>E'.NPWOG. "[A[5 &9M3=-O2
M=_(GQL!FG7T\N*8;_G1@CQ50C+JS1XC0&.+$:T=%@OL]KC3)1Z[AJ^ M.M+&
MY*?7*/>E/^\*2%?TWXQ0'<":[74MQJ))$89,;DK!A#><[[V^'HR/AHW'!'@^
M3)DM]LJ: U,@9U5+"LK<?-:M^L1O%]?VJ?"O\I,^F03>X0J!$@]Q+AWA] 28
M;5,=!I?5?,&>T%/ -8XX2#= CU45::27;(]HR0[Q 1Z&#-0(Q\S(I",F"YD/
MX3?!]IW-H%@5MU)P7E<S,,X+A.1L?!E%+FF#G=-Z-=A@[M^OPTXB]DW%B&QV
M9B_J(#]$&SVV,&=9M?B^=ZW[E@O4XFFIZZIQ9CI9+-?4D!I=,T$.Q_@4/86T
M9['Q:/XQ)>WV>F%AH]/2\>RVT',J\YIK<3^2UGZP[C&PUTG9JF_O%&\TL!3<
ML:<$Z_2@&4:=HN:T"^X$I3HWT]>D]/A(219#/JW^G/+6?J7[UYY\H3ELP(YF
MN 2WF+"@WZ9L-.8/H@-+SWO[&R@;62X.18YY*)W4Q0[X?>.,^R9[;?M*N=0$
MB3Q-J!K<X"4@K@K1CQQX6=!G-#(RLI.%RTA>]BZZW[!F[BE6+_DW9%_[[9DP
MV$6OH3'YV'3\,+L54]^&#HF.$FRV-@?=H.:2XKO5E;]]/>J'V@M?Z$EM&#?A
M$J!%,,':7]^TNSZ^BF=-:E7XM''$L&&>MRW^,D:&LOAOE#D)W2SOW*LG.\6Y
MIV(KBUW*A7$7:@3'T@5+]V!8#&^H)M+8366X\U?]\UL?>K_KY<@O,4:]UN#!
MB='VALF-7  )8:$>MBUG//F4?+(%UHISV_0:9C?2+".6+#H4PBE4/);L :XH
M\\DPX?IT8]R8</S,NDF.<(O3^$[4;+Q@RHU&#T=1[6M/-=M5)ONZN'D,V0EG
MW0N<N+T8HD$I06VHVZU"+J9.4&C$ZV!XY+ZYMB/+63S_<W;%SO1(#: OP:6[
MV2<1HOZ\:H.5;_\Q.MH%U6@F*O!@>"DB7"G!$A^0N7QNH3.&I"RLM]D<DT,6
M'"@+9O"&YM5&=(LY\#2VPX<6J0BL6.'(L'_VT0 /&>!)#Z:,7$<Y\RQYQM%I
M]:)SKB.EA_1S%2<-%=3W?-^F0N=Q'VH6P*P]#4J",<B20H+EJ3\J]F#'69=C
M;233RS;U08NL.^L/KYP3TP^15U'AQ>>4I\/_KYLYD$'#9CCDB["TT[%]1QSF
MA?Y?W!F?E4-_?F?)=7N42</,FG6/+-*.'<^*M6LZTX8(CZHQ@1\LPY,E?.3H
M7WI4N%_P#A>/>7K>3BS26]-]W81^+%JN"$=5T/I4 <+<(>ZU>$0AKH$H2 /#
MYO.L;0>Q< #?$3GJ^^#=M>76E?E:J=D?WGS*2'2@FBSK+KQ!*-/$DT4<4#.,
MAH3X) 0+)B=4:8F^+T&DC8OI\_-VW.B6YYKZ@W$_8>RY!/Q-L;\6_@MH=,68
M14B^A8' )F:$T!4,ZT8!Y7"K8^FFPI3\@DZ,"VYF"\V-EVR'UN5 6JU26/-_
MRJ_('6!V#(3CTX_\41ZTY-8>2N59_7#Q;(.+499;MZ0-N&LN 38C_F;K9<&G
MMT)G5$5(_AYWVW'C8<G^5T86_$&^0!D?VO!IF4U\1R[4IW/]\9EIA5^B8PQI
MO*69CL:*"I>3Q6<(&$>6(#?$3'R .TI?GG==(!2US_BC\P*]'':\Q+-692?W
MY.5[5Z]?;Y &PS&Q)IH;&L!<^0OZR3!>K#5G>'SNQ-K;96[MD6P;W!R'5MM;
M572'<\MS\T;!V.O2I@Y<^_8^%X-J# D=F.NMC*5)@GXA[_WR_ MFM[&L%K>D
MN1RXUJN#X(9[^AK _'#<.P^.PAY]$+6[&L7D[^0I[+O3GFX4Q^,DIZ,T[37%
MARUZTJLT1"Y3>R8B/9:6!&)/P/A4A'<&N9426MS&>'&PF-OC.\AGCS5)*_6&
M,2G?W]SM,:71"DNDR: IC5"71U(#>Q=N8%IPK<TZ":UW. E6DYV]7B2=M5L<
M6:T+NC<7ULX&7+%_^V=1MP#]@[8XM4BL^BTWS$WO0W4R0L8=G&3%1SW^T9=9
M^M9]OQG\S7XXK.S1P_3.V9@"/]+&$N_@@M> Y&'? _;!2B^]^/ZZ'8JLCOWT
MG&M_<A)IGY*].W^^]0,2A"OJM=+I'K3HJ=DH$!HARA03-<;A@HW#LF:M33&*
MGQ)U JGKB\B-Z-KK[O K,I_:ZRY$J"L057%E9GCMEB+".U<UZ4E$FP66M.3@
M.$QX] 72 P&='Y_/>X0UH?">47AT38#$UG"'&G?<3;X"2FRNSELV>/JWZTRG
MRRHM2=DPB'I48W,,H5=TG/CQ#:L0^IC;@"?C6O:RUXLKY^UK,/XQ9FV&L](O
MA[<U\F/.-?:NWG9F'Z-@\ZK_G.%>?Y'X=$2#'"JEKP40$NF18 *\+_D,!3PV
MCOSG@FA,^O*YPOV0M;'M3_4**.I W]7J17EG@ SJ[*%(_QYT^',$(]-5Q,]>
MP(^;3,>>,^SI3!YLV5KKM3S@.@I,)7^1&<IN>/,+&-0>QD/P+Z(6[E*2*X@M
M(W,S:,NX+^>B^FRE$F@RQ-RF!7 BE'5:@9(.E/,Y[4=WY))$5Z_)E6S??[1(
MQG_[^,9UVA=BH*Y%2A7>965;T5D=W%I^:4=)O\"D\:SUESB!%+I=S,Y= 99-
MW\GF+_]]_N-R^K\ 4$L#!!0    ( #F .U>U]Y?"R$X! 'R# 0 8    :6)I
M;RTR,#(S,#8S,'@Q,&LP,C(N:G!G[+L)/)1OOS]^6Z(2DS4B4R$D5$C9)LF6
M)/M6)BW$)+*O,TF(,"&4,&4)68;LPM@52?8US(Q]G;&,8;;_])SG^YSG^YSG
M_,XYO]?O_/^O_WG];G-[S7W?U^>Z/MMU?3[ON:\/8X0Q#1R^IF>H!["P @ +
M\P]@C ,Z !LKZ^\/\V!G?O;MW[>/G7W?04Y.COV'#AXZQ'60BXN;A^\P-P\O
M#Q?78:'#O/P"@H*"AT!'A(4$A/D$! 5^=\+"QJ1AWW=@W[X# MQ<W +_Y8/1
M"/#N9REBRV-C.0FP\K*P\;(P6@$PD\]]+'\Y@+\>+*Q,'CDX]Q\XR,5L4'$8
M8&5A8V-E9_O--?-I"/,YP,Z[C^_$.6T.?E-'SI-/!,Z'QG_8+W&EM$G0K)<@
MJ737\]F!@T)'A$6.2IV2EI$]K:QR0?7B)36=J[IZ^@:&U\PM+*VL;6SM[MU_
MX.3\T,75R]O'U\\_(##L>7A$Y(NHZ(3$UTG)*6_>IF9F9>=\S,W+__2YK+RB
MLJJZIK:YI;6MO>/KM\Z^_H'!H>&1T3$L#C\S.S>_L+A$W-C<VB;MD'?W?LO%
M K"Q_''\4[EXF7*QLK.SL7/^EHN%U>]W U[V?2?.<?!IFW(Z/N$_>3YTO\"5
M^ ^E30<DE,P(@G<]>P\*22ICI8B_1?N+9/\YP9[];TGV-\'^5:XQX! ;"]-X
M;+P !*"9%\--7F@)1^O%4O6S"_)/=PX36?=//U.UVEV$OH!?8 #Q.P["PO2^
MZE4&8&Q7=Z;_?(!GF.G<',;^$;R@,5C0).;3W1-F7W)67CO$U^^BY[Z JUB7
M^%CX/G"^TCFHU0^B;IM0%JPS;%A(HH\Y]]XP@"U>J\O"BPZYE1M:/+:!+ZM4
MI_V@+I'TP%S:EBR\]\B_M.<!.K2-0BU7H7?%]R'.C=,R%7>74#L_LU9Y$3U7
M&4!#^)/+3VX ]W+$^[]"S:#??1$/7](#I6E;,I2KT,U>R/J'6P_%^AM%%O7+
M-Z278+MQF)Z_/M_$,X",EPP@Y.!,":>KQ[+)&-?2RYJA@%[F+82:Q@*S;TRZ
MYZ=+N7E98_S;EA.+U'^Y)>Z-F(+^J/EDVH>ZV%#X)5TZ%<6\1JI F,^\&I\8
MF:2A"HKG=>:D=U(VL[Z;K"O.VPCGXN(\0YZM/0Z(HF%W>^L1=1"UUF,NC5XF
M;QS:_"[XH7<BY_6VZ03JLI2^\M*E*)*#T\??EPN3F$EPNE/1)5VQ9A+<*0Z[
M!%%3!9E:R+;DJ"=^O3VAJ2OR*2Q'9OD&;E;>*6: K4C#)W-F)%'9W,6ZZ!Q/
M9K3,85-= >!Y.'OB4_74EZNO$#T/&<!ZZ:VJ-IQ^\Y30*P_$Y[4 \'9W :$R
MQ&[+^/@1\^ES#" YHNX1_"[!+,9"$:$.CZ$I/B>K:1A?*7*YJXF2N#91-UR+
MV=3K6)\:/\Y4(%-;4W>1E=H,0#.+J9XV.(" 33* G@D&L$/HI:&#& #$B]FF
MQ0%*6L',#].-&0! 09/#!1C PB4&,%W! +I 4PS@7[L /PJC!^DSK1!-!>C#
M]0P 5</D&IM%<=BAP^<9 "8"N3J*Z$%3W]$!1*M,+@/0[F$ ^]!T&S@#H'T&
M[:Z":209RGWPYAB$LF(]S4FJ7Z?2F$T0W."Q'<SF#H1&548\[J*'(&:F"&ST
M$[J0/1X$61ZQT;+# /ZF)?U_E0\#0"K6$?-K" KYX9\X\H5N+C. 4PS@*9AX
M4)8!_&2*V@1CJA",80!_$T-KE)-*0M(I@F26OU.(_M^Q-?Z9V2=T5Y4*,( 7
MIB;T,!2="THMH3& /\0P)7V%S)<C=D;0C>!5V-0NY1V=CB)F4>R8.IG[#W02
M\F]U B)5, ?O9@YN0O[I V-*J?A7IOYF) A.P)P!O&<J_-DP S@#033\50R!
M/_J3(W#^JTT2_[\T#^(/\[C\G:%^I5#W&, WS#0G]4HT8DN, 1#L&,!LY#H#
M^(]=MX\!P"91NT$H.OTHI.H! ]#";+B361C X4P4C1-"%<+L.E)H?Q@EZV]L
M09]"_B*$*E,(U/\$;P.M!C&][2]J^#^DVMX_L?7O^QO]W_H;V]\[V=_X^O?,
MPP#^F7W^YF0J=ULLZV C++5I82=G B*'_JG;,AG6V2$<UM,_F5S3$RE&A1"&
M$>3D<<1"17%<0[%BJBSJJ57NBFMG^KK3\(2 J:[IB]]+KAF?P/TTD+G1+?=V
M)60X_+1$&"T=0G_J*JU@4..KYC$ +W40<'_LE$2['5?V3UV S5V%0GZ<K5M]
MYY/'/AT&<$"<J4>(/%2R;+$"P10W$4'*W9*LDVQIOJ%X-A#1G\-<14VFD/]T
M$>5D ,^1IDR3)V?1^33UZ7 [%&F+ <PS7;P10S%#X/@=F6NQHR)5 +/K0B'^
M,YTQ[1N_!-G<&$ TZ^<Q[=AE2JN'[&YA"(KT <C_F_0@7E=INH,=<G61V0M3
MZ% $Z0/3Z.] #$#G &+ZOZ:&_]O+?T<O[_U?FD(VF*9V-Z&'*%*Y&$ %B/R<
MC-@3-F+.)T6Z'9SZ3P(2A"H9B*12*\!_.,J?J$?^QU,;NN&X=A^?U*NY6]C(
MJ]/SL8+$I&)E!HAKR.?5 2J";S01B\P).YN[WEGR@/VP]H*NX#RB+%]Z&M*R
M82A-X>E/9 "WDJ/W:KU(KV(H!:B>D0G( -'28Q@CF>8^^6-8\_ 6NA4BBOA*
M02-&KC%37WT5^*1X$CD2[[X+]EFG'+B%6)A#Q^+<(U(*:*!%138&@'R#B "G
M(8?M061B)0,H9J:&"R<+T=>*F--5_,+4=CN$QFX9WXC.T<?QD]\0^Y(_:VCB
M5D%M+P.]C9U:;(14N5V\'RF8N9]\0.EMZ/,MV=(8JK>-72_!]F6H6<$KBETF
MC_8I;-^VVYLR[C^#4[KE</NK1+0 6[*3!B!#8$8F[Q[!A4J[AM@\>]?:VS-7
M8$%=AE?CKT=FR?'L_ZCC2E+6M_-?OG[,!5_$7CI0,/0T9J3Y7,]UMFZNH;SO
MGMNY1<?UYV<>HWXIDWM1ZI;O:+VI]R\\2PHT.ZS=Q Z^(CMNJW^Z94GF:FE+
MCOSQ12.+RWL^%S)8'DWSQU6+O'_ZN]>SS[)9]VL]OYMMZ30C*S%P,/OR[+*1
MP?NU=IZ0<]T7"Q0MY;:%/^H(NG09WS313O7\:73LQC'9<FQ?7L1%[YQC+IS7
M3(>>"1.',M3Z.7\S&J&6%-AGAK;+%%Z2R0S=)V!Z62RRC0'L2F7(,X 2RQ[Z
M2U?JR6JFUJ,@DRJ4+T0$W=#Y)6)%D!DF,\<P^XLA>)S)3FRP;P#5)E!I3[\9
MLR-F3<;O\O;J"FXZKV)U!6ZR_''>1C6A.>RH.N1\+)1[LO.G[5+@\PO]:F)G
MKTQ= .4#H6NPF *[&P5^'UQ]4V/#6\:@=M?*FC2<N47S.TNTWH=:<KQ.3*B]
M1#R<;Q:#O7;KLTLV1?TA77]P4HN6=Z9!C*H]I"'XD2I/>$GF-ZQ),0XYN7,#
M_+#:0HJKCEKBJ><5AH27_U)M/:K:"'[J($JDATVO'KE)M(YU7[=3+S*;F-3.
M'F\[Q<XKAZKSGTG;_N'?+DH?6PP) +]040R'\PQ0 \2"]%_,5[E]QWI(^<.7
M(0V(YAJ32$R%% ,(IT+R_6&M&4(_J4^P1N-5F*-Z.:#DY++2+N5#83MW9JCO
M[]S'BUS:_N7OI;JJ/FX2Z4YVNP"Y%&<:1>*-;E9Q!C^LSZ$5O48/C5?(=?ZP
M*ONYC1E=QMU $C=)200C5S@KX4<\@CMV8TG)=BS4/>]B>+3&J\.FOGBT9-KF
M3YYAO/,*Q9&HCXMLZ>$HR@C_2&Y6M]T&"T+)9FU%*UG]8?G1NF9:+OLGWL?,
MQ(\+3IO2AX=K$:U0'G^D/L$D4ME8O864(N2KIO+\U,7FZ^&WOAW?G=@PT7#6
M\#1L&\"X3HE,D(-:A(:.F"VDDL)AI]+!+Y27\R6^5']VYJG<V'R6=P6_N&Y5
MJJSY+ER_NXA406( \K2@M.WSUWOQCE%-'2,Y/!9I-37VI-3ZM:3AVF)T%RPO
M@YG260>?Z== 0)IA$.[1Q2D>;T/O=]D1"'[9_@_:_'E7DSIG##I5][F_2]U0
M'%LG>?72#Y*C'BMS>^DF&B6Y91J+:UZ?<.55ORPRZRUQ\L(=@TL+7;>LVZ;&
MU-N@(E0YK#%_ZY'S$Z?"N4YD&$7&KTO=H]?>GFKG%-DJ%FUW4!W6.KZ,+B1'
MWDPT'YB\B(-%6>H(ZNX/FP4\WH.::TH%%RSF9^.*AX*\!TB?;^4J-Q6J%=G]
MC"PW0[8%_2#Z+>=:?]K]$J3_'+XO6.LG7-C?JQTJ4&?_::$+Y_?&10T>>;_L
MZ\FH2HU-H6D%@]W+/_:W>X76$^Q)^KUP69#P\E#MCRJ<(L="%=ZD1 O<WZO"
M;?B5NUI?/3S6TM9P(J#'%1_,0KD!YB&#C G(Z#K>]V0&8- ['Q0K"6,9,CKE
M5?/Z/.HMEU<Y,Q<%>CCI_</BXJBV9+N4L&!((=FH->4N'=_B8#YN-WX#X[/:
M>6&!<'']E6RSC07^>WE5^OKC>GGXUQY>':W7,(JLBK3\,6Q75W?FL]Y\SX>[
MV4GKQ=TAW-CUT;[Q:6\&P.^]"Z;8FPQH*#KGNZSGC67^LI];-<4E>3;=-V\Z
M[>&I]1K#CW%2/$#5(R<1D:W6J1_SW13B\W/J E4CE,EK3I7(E?CJZ@2QB(??
MOC8?FA'+J-YE&C-AKL6*&/+C[?0JEUX9D0/%\8[$K6$H9M7;=MRC)<'V&_B<
M9HA<;A_&[4N]7'O#26(@,[==:9 >0!\EC5LXO3%^V+[O^<?IEN](KO38T 23
MCVKU#;QMVD6*\[3U30WII"?[U#ZW-AL//*GHC_Y"&XJ]T$>V<X/6WB!Y8QQ#
M>""'@UWK2BAB@6%&'Y:X!)3T"D6HA8K<C9?: J$MH&=VULW@*"]_!\T 'Y"X
M/M9^N=YWTDU-[ITHGR//JU-TN^N\R8O(VR/BJI2S_F,MS1D:0U3=3V2T(>'7
M0++YN.S@HV)GP^[&T[.ZU9U)RSUBP_6+J"-4*3>A=UYY5"L"O (G=^Q4"*\/
M)9;?TBA_];[Q%Z>QZE=H)PVZLU(X"=ZI,53K_FG<1+.[; H=$O@Y.QM[45?Y
M@W2 E)SZ1CD._<G*#Q:D[ U7(-PNKB&LWRHIZ3\S1-_$8B+X)E[P&J3:SMP>
M[6!/.!\XS(\W(4O7%[_$QOHHK^JWRN.XQ=O0HC<QI1&:IVB]?AHWS]?$V^?M
MB[A8$(AL<^>:>NBGYHT0UI!^N/GPZ..G53<74G/?\MD:](AU);5OV,?WAQH3
MYUM!$=##WD4V4_Y=V &'4X,?#D^2HQ5YEC[Z'6>9D[S_*$XG-!F<Y&/LN*08
MV#V^F\#$7 "AI*^[)/%:6-K=63]*?E>V4)61L53F<)=3&?Q0,"O9BT#I8  '
M'8G.+Q5[D"KHS[ +>Q9V@4:YA9['>K65Q/VTSF4\W1:>H781FX57Z>?(DQ>S
M;#*-78E6RC<_9?UX!' "UB,._.3A:7>0'?FNFWX'!A1LA -S7TE.?8S)(_M9
M'#EWN>[TL2SVT.:JQ]4_#,GC^'W;'PN(ZJU5)+6<X@JWH""IL<E1G3-GO]Y7
M'SEIM/F42W"W!E='-<L]>BY6W;UWUV>0 <1O4R$:#QZU%]VRAK3 .N45HS"^
MQ-BDU-YE3'X',\[-H#+#F7%SWQ^G33\&3Y^BURIN?MJ^=X,9.BF(O07,CU=#
M\^N*+<A=:?I19F1UJZ*_M%M83B,_80"2#* %2N)F)C.]L-O'X#DFT\@/5,%8
M!A!00)?>+<F,EM.)D<F,!N1BR=^8K=%M"!(WB@%<5AFU%B4FT@VAT0Q@190)
MY&!'IUI2LC3/5-'V(IE!.(N0RTQ]D:.8228C?_NV^P@N@ BTHI^IMS'5%70Z
M\4=XAEK3FQD :$5\N15SV&>*NPL7(J<;)7^G_VZ9JE[ [)T#O*N7QG(U-6&S
M![=IG*1THM^S!F&7!FY";&N&H%%0OL*:C_QYG,&:NT@MYZ5&MA+!P? TV8'Y
M_/Y-K2#-EKNEU:KAS0_G^AZ3ROT"BWPJRH?->^M,*#*G/E!NPB8%@K*PZUP=
M[J=JAR/$RB^H^[W*_Q7Q)&ZD>!+$%BR92')KB&S).#ZPS<VZWC:4/%P;\2&W
M37#UU6F+U8M-YBV^TUO= 7STT8:S;G[-@:N#Z<D?BA\FF[E460_GS+I9C=*W
M_( ,>%9J& ZR>BU#F>SL-^TFT:C&^5S9_N4,!C*J!SW[52FA+4[TTA8^]/92
ML9#8!M)^#74[Q=U\)C=EOCHR,O?V%_V$M?.Q]4.[V6LU[UR[[7N+:1<J*"+?
ML&^"KZAHFN%DQ^W#= ES$I;&NCG'=[^;&#2G)=0O5Q&'J?Q[P]J$C"^GWH8P
MAR_B^_G+,"#?5EO\+:+\01^']7E6CB?57M$$%)@^('Z.')KKSS>VY%V9V'SN
M?7D&7UM.DL%)ZV_M*Z>1-^3NX3A7]3F16YJ&"EIB9*?AUM3,O 8B.TSNQHI:
MW4/[1X^"XH=/Y:(XUQ6@Q@Q@>IL:FW$D*BWOVY!] TRFO+#/OB(KVFUL;6/<
MJ5X*<Q\2:434OTQ0I)ZR^SFD4+Z^:I2=,,G.4W2TW)? Y]%7*HT6%C1J0I3Z
MIN.86:^#2GGT>BL3\,;Y/]0K<O7^BAM<>_ $)2OAN__<<,!%"7;K=%=(>0\S
M^K?)U-TK)DOK#/5ZCY3W?W00.7HV+SKSZJ,U0RUHG=I]7.4#6IG/+_WVC!,#
MV^[<#_>J(K>[;!ZMU:D_F0L0OR7!*YBHWH)<=T9UIF9PU]_+H9(J4W;?=G&U
MQH=_,*V<+IXZE3!WX]:7VQN_Y$;E5583*3?@/\"$3$5ON7=&[Q:]8UV%DH55
M'IK)C3N;;^J?SA+\^O42)Z?*,I@)?.Z,0_G)7"UVE35^.),J<C2+%WNMU&N^
MT<7>J@E8<GR+6 S?X2=[P]T8P09)^V"#H=6UE6#%;/*U]C%>=BNU:PU]G$3U
M<U+CM&*YGU1%BI46:IHFJDM4#-6 X%VV9(PKDQ % 1]6<:NBGTKX9%9X($4/
M;OA#W:1E*/6J#$".S@D_'1&\L70XRWPGO\'OX>38^*KG8@YM-9@4L@^]XNQ3
M9/M2'FR:L=.:ZA[5$[G]Q2)&V8J8^+HF)NZ:&WO:#J[6A!7>E@J*4:R[]\EN
MR>'DL(9\YI*^8?G+*Y7/C"B+%J#SVG/G,]M!-^9WR</-)F/ZK1B.;1/!R84G
M]M)4R0L)]D:@[Z6-W>F?]5BF/^)C]@90!QG PR TX.]G01@JP_Y2;8<?&5#0
M74EU^M@GG>+!H=$:O_^!I(<^XL<G_F8'C=YU1#^=)\(_39'7<]"BP&&BKO+:
MVNJEA3'#HJQU>=&AO0P,9,7P ]D/!XHJQ_#Y%]SLK]/,)0?[1TQNG^DMOFK?
M6>[9EJ#ZK/!L;F+T*OP E8/\!&L29<=1YEBX%+@>46>(?3G>Q3[@3;Y>^IFU
M+.#ES\-GK=F*]6MVNQ$N<N]N0]N' Q'ARK=/CK>.69,,2_L'<1%#D/7CW[H"
M$P>8Z_1!^N 8)MQ- \RN=NPYOB70>"[Q0( DQ_UJRH^1!?U'5B5%SY_WFX[N
M[C  B3#^9"+'R>?Y/PK\8E-W^,C'INRU@N17Z\O5D/ST;BWN,O*!)T3^Z\/!
MV@5&<IT$44TM63>WQA37%I^*JJL4 RED)XA-PWE.;8<;3'J?TH(ZZ />[Z+%
M];-\G*;75C[>[3MA4#9QV:9T\NU(GZ?>Y@^U>]&$S6]HR.%%HZ2^533Z^]Y*
M1H960I&8E_MD<-$8M5X+3/8;98:/6[F]?PLDQ@\8 /@5H@&2KF-NB^B8 :\C
MY\WEWQ8IXO0'P=68LESJ*_=(!D!B8R:#O4:ZX'^\ 4=%T-DUC\P@#LQ#-Y3:
M$,/,Z+%X?4NG#W.8ZL94PEH] W"40]+$!BG^@=8X<"QF)F08LR+%#$E9J0WZ
M40U''=!;D _!(+J6(UT8[@FY_0B";Q^G5S.C]OOHC?4QY%5R8G&PZ& B5J]\
M3#&F*$/]B]?18DIVS)J_X)O#A7AAZ6=Z_4^]'++^!,W[&E(5AIRQ@UG=W?S$
M1"QG^ZK7]'R,(EV>?+YM^NH;>ZH.071-FTOD[/"Y$[-WG:4Y"_GX(F=\>I93
M6I#1\*/D(@+E!C$WTD=FK9QKX="RQO,3D>Y3AIR$\X=UV/K%WZAL8E99**!O
M>'2,FF)K3^18461XG;9D,XC7WN%*#^R37<FXK/=-'?43,IW^'GH&$M*X=[%^
MYN1SA Y2%=D/FWYE#G1H<:RBJ#[-Z<IUWJZ F:_O&4"%$"_2([/V46[IC+2&
MNJN]>"3E>C#"?8S26MN.O%=DA$6/;C9]EF^OQ[$+AUC=](AOS:7=^\):TC8Q
M.Q[:P<3/39H^D!>3ZN]N$HURJ2>A^^17>9*P[@<$N)/TA5$!HF\CNQNNP/U\
M@3M/.LBJI'T0@3HPX8:L#_E, Z_MPZ&]'SE8BL>R3YZK9_'N U^PG/L^\R>7
MKII]NM0-#W51L\P(SQES&?,IO'!!*/Z,$&EH@>]BEFFX+MM[X.[KU&M?9<W3
M<GO.CRP[Z%-LJ,ZUY'T$T5;ZN?YIHUBK(>5G;5(B)EK6O%EGUU@>X1O..52K
M#:?1>R$<17 MZC$B.'3M,;QU[#7;RDZ0WWYI/9!H_ 2':?QB:K?=7KJ/8N>N
MG]9-@C25?]V:7#.=#ND \\(5R;WT$S"K;WDY[>G^?).-7S_T"N[_UBAQXAK+
M3QXE.P9P3 -&]"(YTM*I)Z9-\4BR$5W*/]>&WE9"/%/R*,A&]$/7_2^AH?4U
M^[ZLLL_[2^-V5AT)]YJ%,H !+7:DV)*:A=R]7/_D3@9 $WKXVBTVNX,38$FX
M.>W),E<[%8TH0[>#QL"D1S\16"5,KS<ZIE8HBU;V42M]PSZ+U;=)[E#>(SY5
M!0M'3Y-3E<OY\POX-6FO0TP+*?EP<8NHQ"KB_6*+&J3?\U^HD5]6*9CP.?Z>
M-O>=F#Z#KW+%0J;?^]GEAKEKL3QL4"/'%RZ2UA*U<6"^A]JK.:]!BL'-,F3)
M^_BX0'SJ.FB5EP)UM3M*=AHG(9 FQ#"9*@3_Q.W\_L%:D6;^LBG1KZ15:XR+
MR>ARQY1H\ ,*!!VM 8'A+BIO2L(5:OI*SF"G2M1E/$4YV0EJ8:$QYM8-V15'
MA-Z_G46563,#\8LJ<!EZE6-2B.A;@3/A7O!="Y;&N?,F"C:I"S<,OR)<%FFZ
MR'E,*7I#<8324;E(T0D^CL2N(S7,"V&U(XET?GM%WEMW!^,\N\3QE)8JR1!\
MVIWYZ)U?7*1'Y'9,&:0-\31QT>NEJ&B6%U;^L0O>1D747?E2I>0%BTK.2>!^
MI7^QD399AXC 0Z+HW ^/0%E6M?CLR'Q+(NY4LR\GE0KOL)4!0K]B1_9M=%QB
MS6OOT=E*::]2RT&%^7R)Y98(N2LGFUUF"U]\?4(6]0B'4<5,HS"B\+-48_*N
M^[Z=F#H=W"_P2LIY_\_]-B]"D-??*.U/_A7&FW"Y_6=]^WX1= W"M8?3OP '
M6F$ >#>V)K,W=?J(N\3QTUVSRF\ARH[D,5M/I8SMW;<?X#V0<H<PJ88< HH9
M:^!\FI5)0NG%7"&NYQ1*L!&[=PVO89'2,:$C>]]]E3^-)4#N?GSK-AT 7<M,
M?A3(D@A-A[,2.*,1TUGBJD14%-417^37 N96UC0SEC,@K$<^9N>PNJ*=<$5;
MI)$]X< \&V ].<F:O'.3(![A$Q1RA5M[Y9Y1=<6#V,=UC1^@W;P)[Z+8J75>
M4+[%#$[R*H4W6(_XA.PW?8+HCHV,4D29(4TJJC?0RKMO$O1%)/)%QAICO$\^
M5TL7'=E"1F+V:5A3A!8;U(@GR*@"_QYL<7JV48 SMMLM>/E%[DV3O0FL=>X$
MFV;CLH,FP9ID091>+9U>H)^AVI/?XMX9;@\EW);0(]!&GDV9/#_'%7Y'W_0G
M2[]D FR<SF]"Q.,IY/8IW'R8-X89/WBV8\^MR"N?2NP>2!KAG4OFS-589\ME
MJP\ M1PS(J728LI=&L3&J)(0)KA]< 8U$CB4$C![_FKKJ\^ <.C4H8*P-+[3
M,;>K%KP1 G !ZE5:.N(N W@9"*\BFIL1T\N%*.5R;Y.RZDJ?\[:8? G0:IR^
M%U>-?L< [BF^V$O',(-+^)A["R9*ZQQQ(+"B5.MLGTJ\W.@(<5-0L:G#J4/\
M8T,.T3D2\A 5"_YLTG8,@@-%>!<@^):98:OU94N@D>+8':3$CF?EZO,=$;=?
M7HNW((WKHVB<_@J6:-^XMQZI(>L_*4*TCL3W41US1^OLM[I>[=_L3!%I:@FN
M60AQ>;7S<QHQG0,I!T5IG?ZU/,E)1FAD-6L=.."#<[.:-#]JZ/%=\#B/VJKT
M^R5XTIXZP?@7'426RG9R=A/ZF7S74+K3P5!E=Y?813\0BB:;8_U>@IG3+O@V
M+D3'K/:(F?]MC3QY]*T:J6S1QKLUDOQ07WHW'1AH$ [F(R CMF/U&(#Y0&&A
MA.W<0)KRUQG6>Y)\9U'>GOX"&6UZ.P-;M1Z+QKD\KX4Z>%YG%1U?O*;V4T=<
MK;_#[LZRR3&75QUF:+MKELL6.L>8@.YX9K0,VRLRAHD8R]HPI(,US)S #2I+
MY:>%P07\*5AH1)WVIU%7=-Z2D(O&JE#F0@[R%G 17:"ER "^G2'ZT9X5([;L
MK54IBHAOK 1]6M@]NN7L8,Z-2H5S^:+%UIA/6CLLR+8'$Q"S8KZ"Y^D/"]I&
MQQ/LQ&\S_6>2?(X!:!WMH'.#J3(,(-(]6)@!H+CO,0 .)%UP6TH0,U RM;D:
MTI%(+W=&;(F8,P!6YRX$874]#+R)+41,]S* 9B39=Z<)N4L8@A >,@ LU+17
M_U^HFOZ>"/7?0=37NWU&E4J!>B"*1*9H'!8,H/'MQA15/6BZ@TJ&@<G*"$(6
M_5@]X1X]6 5)/0HA6^=3+<E1!?[ZK8&:L>EMR>EN3[BZYQW&NB#C4GPG7]J0
M>"M&SEUJ$4^[<W13%(.DJ]Y6-Z[MQY15!'S4\EFM+TXY2^]F -:U!T:SQ4YM
MU@Q[Q7@= YNU('HJ=CCW>M,9P,\')M0#\8B6JH9#B)Z(4@80IL],>"'8\2D.
MR'R+#3-Z93&GC2;$!212U6PB0'ZQ. 0=JU3+MJK,DX=V\E8.>4Y!+$6KI>R/
MLWYXP?F9"&ZO-Y;L?;P55=@WMJG_TKSB\Y>2M)X" \HFN\W<J9N?/"SBZQX#
M7O]$>8+_H7V5,>5'8HHJN 5L+Z!P;EHZ8BG#@;Y)Y_4/!SA:1749MBB^F18
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MI3).,X 2;P:PQU((0_ XQ&Q]GMI9 N.1<\@4+1"]"7%0PX_0U0(_/OBHPGK
M1U0EP_>EJ;=91S$@9NWXC_(.89RF=D]H[6?VZ(JPV_HTW3)-Z,OB6"Q*,9%8
M5HJ3_.$R9_-&YXCRZ[F$N2"O_W"*R!0C\QTQ\V,4I 3MX0\&L' ^E\[>D\QL
M^;^>D-F9?Z4+^[]D_Y?L_U=D7E!^R!W0\PP0V0N7[F?R>9#9Y'K?&EI^S-AP
M]&I\Z_?L&,_SG((D8X^I8XB9:'\*O?'(U-Z)Y:,C9\[GG,HO0NGT=5U,4<M0
M>R[U\MV-)Q236EGX#WT(BQ88O!=JRQPW)Q,YVD$WD&Z9HK#\RW4M8:HQ,I.*
M1/W S#A',P T<S7I>[N0FP,_01ZGZ_\*HC=;@_<N%9 (_V8313"2/UBY'KJ
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MYU_MY@DK?E/L''DQ$\-A^HS;1VV]^5W0;423EK26QN=RQ &[D#@L_3MR/CM
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M^:&864^I'ET-GK[!FZE,)3[RK?&-!DYTR]3H,[RC08.SM?IBX6GB]GJ%2._
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M>'[H5TB<2<C#S?K'6ER_&MZS\%4"O#YG^!/-5]5)2GS\-:R!$XO[*8_6MF<
M6+=IC9]6**=U(8]50M<@D-JJUP#D)_, 0:NVI=PJ-US*[DAUM]J@79'!E-YX
MZ5DUZ@FH+(8M"^IV<W)&UO1:1=MF=E$G1B>I6EO&=Z=_[#J_RW^JAOMK/6P7
M+IT%K/#N?-E,B8G)AW1W6-T?+OG2 -]NGW1R\#WLHF;ZC1O]EC(V1 ;9> TX
M41X_)K5>#$IG+@CT*M*R\?%YEDRC3Y.(C#!Z/-N=Q*9()_?9N/\\.4Q X6[M
M+AT2AC^M$(XPVZJI@4VC^@5B;%P>1.Y2WK;GX*-+X_2:S,H"-E>FBEK30U4Q
M>HO[P<TT* >X I.S\420\/=Q ;?L>OJ24VTD9X8*1??#QJB*56*%'6C#RP?\
M<6BCHA/AZ7O6X9Z82(-:C$A J8I$Y<L09>J,;^V_+.];>IRQQS;[6G@N<+_N
M! 06+ [2SD(JW+R$Y*2+-W"UFP.D%@P_Z%I]/4IE*O&FV]$!5KMLU^=L3 M>
M8HV,91*2OLGU.=A_R?_\->XN#NL]J1]XQ^)HLH+2>>T2YPS*YDGA(Q#!]@+%
MOEB3@5Y- X2)U>14Q;G2042@1&)578H6S[[)HV/AUA4#EG&T>F:?R)E&X>Z$
M$!14R.<X,3T6(J@N0 +M"E%[L?>9:3-$M%<,9_/<H<N%/]V@5<;HRY=M&>YR
M9+'T/FMY\QLC+26"1YL*M+L>\\*X\MM#E9U0GJ6R, 5Z=#B\Q=[-V&S47&_,
M'2ON+7 J:@EN5@V3]::3\I3BO/0><!XH0Y)ZM_O1U^Z,>@3Z^Z1;FUGOI-V8
M9N6'$']]^U0E(>]//UR@Z\5$@(NXB*(\IZ%->C=$ N"]&](DWJMW.@>7IT6S
M]K\[Z/U]^YND[GLIPW(9-A;, INZ=7$->"S_W!IC< 2+W;*S/GC0?@V @\[U
M>8,&0 =*"LS7@"FBP3_J6ZI_V_'M+W5=M'?9&1WR'T;"G_>_UQ2YL2V)W5=P
MY\M&>7XTL&OA0&%[X82B[L9"]EMS="R0"AN?LPPUX]^$W0^N 20@:9;2&A;T
M\@T,6=A< X943*T2S=JOY-Q:MJ-@YP3%_"/-B:Y!;* /,4R\3OB:9I7WI%X5
MP!-:1S)D#+@B_DDLCFSP/*NJA.*)PC!I_]&)3TU.VTHD/GQ'N7E6"<,DD$TM
M=1G]<7*%=.T"7<7_0J,B<GG_D1%A,S-;D3X=,^?1I!"3K0,0'$1]S +4>KXX
M>"=['G-J?B:8LY3T4QA9%S^$,RKOXKT,ZFP O;VB,\_DW))9/;Q,TQQ!KFD5
M#1(!KC:VM&VAQ!@UG\4-CT8P\D-8WG+_J[/I=S,O6:V*/5BRRVK]D0A]0ZYC
M?YW!XIV6_J.+P:(^SRK/IZ#J<O1:A&_!S: (<]:W[*GM^OE&S,W<65C$[Y"H
MC9J%OD)+9E:]SC LD97TZP(_&<M$#<[+WY#K)C(3>SL4ZS*GIJDWD3E6>'8-
M6-2_!HA*=IPE[OO#,-PQUP!6B,EE)C3@YM:-=H(PQ+>%L:+K,2T;]9"":P#.
MLS+?/VE 4)'>X37@1]Z5K0+/KX:;1P'O)NQ< =Z<3UC #1/3@*EN#BQ !?R]
MW]U]Y9(9 4/=(SK]:K@-WA*#7@-0O+ 4X0A1A:.;K]HL5XIG95VP.U"O)0]B
M9W]$=Y<UG?-'LQ\#)[[^4%&M!]US3_=3XT^$,-+(LK"@>V/B0/(M8R^5$HV3
MR$"B9W75>.L!P0JF#/5EMYKCLK.EB'01]+U-$N--EZ9-[OS=+QY.?W=3;QNG
M?^E,'EGEJY7$7UJ[D%W1]/-^=A,'<D#Y/]5+6O+\9W"L8[FX^3LQ=OAXZ!H0
MYUYP"8NYBN48V\B.V%=XK,GK> ,E27'!= +#K92]_"5>A;._U@% ?>W7X1_D
M E$G.Q:F\T[?7+YIL,4]2_7OIVQ^8))$:P,7':3NA[JA$R;/!T_P*,Y\DS"B
MPIS:W**A.W>DCL^-/V[)(-*#%6QB.20_E7<0V'0I/-\\S@+F-3Y8 $(MY2N=
MSHWB)I-\U^9I[;[!I9^_C:)2-'[;RD'<S3/1P$2C- J5+.A^GKMY,FV7\)K7
MPX&HDWYE9>DI3F\9_)4'%6?]NV)3V=_SJGZ<;Q>+F(B68PKWY%VV/7 A,5<4
M922FS@)?N'UF^,C>C"VUZ"DRC,&WZ9/LB;X^U) "^(],^#;EU2!L.=2(-I"*
M<$DU-I:VY?I4[:JJ6Z0.'4GGKH#'?>)CY72L,>EEFTFXN/)-3DG, I5)!.]V
M.^Y) EG?V23I?ID](FR@XQE%0-1V\6DB.3!.7UN7[GNL3:RFWTWJ2:I3CPPZ
M[=O_;",;8'LQV7$-H,!Z!'CD0Y35QN74+BN+-OH%.^+D$*PU*;E&)M#VOJKG
M#WX1 N)PD(TIRUQT5M,L!@DK8+&(!&>N8FWW$<U3E^RFI()MHZ7/#AEU>66#
M+'>PRD-8,/IG.])NO<,'E7J9+=DR[ .6ZRFN=%&F+!1IY(033C]E5E5UV1U\
MER$R<?/$GATSN;1WMP^>%''4*/DF\WJ[/[!)9X+\>3$1:SE6_+6V]OA*C=DF
M8:QOS"+]R+B^.M,.%C$W/C$W/&%EJ6;C)-[17T.KE^M[I/L0ENC-3!>F?@3)
M3_>=LZRT_ 74'6&:PN(88OD&HS)WB^QR2KUA0O;=CI2D/.L'95BR4@<>J>Z1
M>C#!'Q4+_Y9QYN]IG[G?EFT$5A;^N_I>Y\8_I^'9CV87K'Y&\U\=SX6MOU@7
MS"Q:#.3?ZFNP;:I.G=?[M*8:W?R6')8.35S>O7.H!7<AS $Y5B0(?%$3R"(O
ME5>B!67F ;R-,W@:ZSS9V">HI1\K$C)_3FU% ]MW.9!C)P]=K!WA%YKQN^1S
M4SWL*1^CY)103Y[7]:E5URU&I'G*=Z];UK;ODUINI7XVZJ6CG(^EX.WA2SG[
M?($3CPD8PA]I)L5X+ &)(-S"P(T@^E&Q!2"8_+78QFYB=IHG7HHR[IK(H, 9
MS_<R3O1^L!S38CJ^<0TJ^:VKF$I3B]ZK5PF$5'%\\&]\,J'AS]L (I/B1YP/
M$(TBG2RST8^$ATB(^L:A3%G;(4J%&Q,TS3;XWO+UY?:X@'6Z =E)56:O CU-
M2[QCM>YK '#_53@FN'QV.K"&\\.I^0<\-3;UV2P F<QB(9;?N&-24F(2;;:9
M5/%HF/7R2,_N-^R='\X06?/QKL.BT+NEM+XF\_9S6U'KVO-B\XP73S+3Z.30
MPSKX3T8V0< R<0QGQI;PCH;>">W$@O-/4".EE,$,1ZA5YY,G/ H^M9EGS-IF
MU#P%QZ>?/<)VD1Y XB8KT^@=UP\G4H^*$CZ"?\WN+GJ_L3K,<M8HWICPB^U>
MR2T/X>"1]>H27<A[R4R&<J6A=SMN1GQA\+1C8'8R:?PT0.;=)?^-S*6^IB;B
MY_Q]UB@5$LV[=_WO,Q7WE>EI*5<"M4<?I]^8J&69G].)^R>^Z=X^WWI7N@:_
M^?W8M&(IPX3N^CW<,GM;_G@0+LE4*/+#XL9?1_MG=O '?)"3]1*0C#/O)I\3
MT+S#;;4%UL,8#RK(?0ROC*3%];8E 5X#++V0YD8?3E)N$V@^+)KT4%;=[O W
MRG.28S_7>J!TN<A ^V9#?=\"OU._?<F]IH0HLWP=\,R&@VJM59^@9X^4A>HH
M,AJT)%2![F*>*VGE(R-Q@'MM8HN[.N:&TPY@L>?NVGU@ED>2\U[8X1._?]5:
M%:/Y6Z=;HE])[51Y4%MC5%?M*!CF%,3\[%C:PY;O(*!_2Z$U;;3JQ$75.&(U
M$:^7O X1.K/#\<Z;X@T;H^"U&-P;-^;_/]P8K%W^)B:*+/C?;NPG?^9_>;$=
M&((N\[_\)@M6=/)_>$KARR\*9)!M#93B*+B#A0:SMFR2XIHU$I9)K#C@3V>-
MH?*?_)U@9/AR2YQU,<WXZBASR^\9I/M!VPLG) ^MALK\_$""AUNU;OUD=6:J
MW,))(,8/@17&6.=NT%_5"M46*J;8>R<&,\>R;1GZVUX#^";_5I0Y-?FO*K.O
M3Y>UR#:[;1$89B8!2XL@#Q)+%^^![/@*#<N?YUS9_Q?4RV# 4%W2K#C\K68S
M@C\7K0/K#@*@]F]"M=D-YOLC@CY-[,MWM,QS9[\SAN&]+)%]P KO^AY#&C2P
M0";'MKC=0NRD0%E>,[2W;IZ69K_ 5I=H\K Q3I;&%X_DGLU(TYV] V("^H"4
MG-IW04=Q=88L^I!"M^I(XCY3(;=]M_7:*(J#;KZ*^[@\G(Q$@%6H!LK\QY70
M^-JX.(S4Q&J+<AJ1,$GRSLR1.E3 HRIZD9Q@[K--Q,P0E/H+YB;2-&@:J>H1
M<*^6U!#F>DON8*L;8;Z1131>W1!R/BT;Z913%Z+TG>M#*#]05PWO:9QZN>K
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M/3'+W>U./GV7U'*PI;#Q$NJ,O0[GDZM71"V0^OV?R\W^?F5PGS.L^')F]#6
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M/NWNGM=DW\LI:(!]?0"0THF^]&WJ7%*QG5^.G.JKL6=U:K6.Z'2DHN]NM_0
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MN9A9?9R70PV-^X QZ(JKB=#^^I7"@\D@<\X'M%M*N'G0"P0D?&D_!N0(>VL
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M?)X/C*%^MX<%FK:VE7(427)_C<[#<M+R?IHFO^I[F&?*ZOEC6E5-4FQZH+M
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MDV=$50Z/'IZ+]!V0XI8HN<K\#)6:4%VT_U"K&/# ,'?JP/[+G1B5=!VIT\E
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M[4:1L9+]DQKY]O"R.6R.4)^1&8H/L#_[D70=\"^=%\*K'"Y]5^S5CSAV1C&
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M]VVR/\2S_8=PL_^-KBJ6[LJ_!#ETQ0N^WKF#)0O#3NRY/R:V?^>\]QU>J5O
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M+20#B&7%:X$HV:-?OQHK>*Y=I-*O\U</EH[R[\_IE6'E:6RV<T=<+N\I$ ,
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M 3"+? ,;OK.$1-X9EM/O7T2O.#Y<?5?Q)T9EH!M5#XO[8$36NF5>,;^>,V,
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MO:&K'-D'<]9S#^V-,EX=DZ]->FS/+7 0?F:Q%N+X3?5-TTT<E) ?\:GF63.
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M//UP^Z ; -_VR$S!&]NSQ*C,3-14^RSK<,5*':4_71V%1X3@,S-^TM3'N&N
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M!Z?CWFHXQ9 (6F?@2A)E6B5.RB:&V!5O\P2$?1K)<$TQJHNYJ+Y)'8:'_^B
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M!J)$U5<EGNV=#;R<6F\7>"(<+(#QCAV+?-=YA#;RL ,$F8/TW@<U/@ELKSO
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M< Z,F$E-F<=-Z+)+U/LMVO)YKBF""O#F<@1B"\6G6E$$SAV-RTK[_]['PQI
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M2W5Y<$N/T0"N"&UC*$0^50<F79F'9_Y]0JIF\4([.3X_5PSK0125V\9TV4&
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M.66NK!Y@T?NIBI,*^QX])8:JL*L-.Q*LE2?1.3N:%K#EZ*1:(U^>9\%K\A'
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MCBQA%SL>]BHY7@QT8/X@$FZGMOV:MM_:M6=N_SY7XQJ?'U6:FY=V_U[]_YL
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M<HP[_9M]0-SQ@LCA^6 ]QF2N^5R34]*-.6\^>I+S+G 'D9ZG$6>'D<)3#5>
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M@$J93D>LR A[O5)82[,#=<.BT"[=,I0V1+!^<VMK0[Q;N>SR T3MX0^[. G
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M]R4-<>R?-(C.FLG.S5[^^A4!8GX<33,"%^QGM%6]]BIL)'8HEU."IM8/>YJ
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M=1$B%![;B.,H)^TZ&WNCV+C-1?4Z>>N3VT%#WX)!W:<%=)X(0UZ,<TMY\+X
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M=J6[PSTMXU8)I0VZ(6[XR>X/M[-$?=T5W%@5=/O*=MFO\%@OAC"2BM]O,SO
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M^#2.45K#98B[RZ$4C,QE BH^%J95[N ==HG8Z9?R=<TG9G()" ?C)4\ /PV
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MML%\[ZMY0\:@"'%B2VD[]\-?M>-YVY$O!Z7V+.X!BM0X9VL#08@)#13=T#T
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M@V#M!%/ NN<8P'@ND :FC4XR/6!<B\3*0I"D')?$*XR]@X,&,YN>>'(9O][
M=W#CR$>6Q%-J G]EK V,>??I8?*K]OY6N2GX$"TX[(G7&4?J\Q'8DE0/^*4&
MEGZG::V F6%B-PYB9?H0:2&>>DBXU<GA7]N!INJCDA'Z5Z>JG/1?RK3=FC\L
M:SUJM8RX!S321771K_Y!6$9Z!A%B3'7;FMI:,@*<S%.<MRB>$WV ;MC)G/WP
MTI5^/XGK>0]8^">_/@?AKS7'NCHWLCQ (D1IL_%T$&I@W!?RM0TV0YP/B%-<
MJMS=QOPWH4#)F+1^N27&%MN0X;M?=*6'O+?U9"^ZU\37_<B/8KTJH6>](-8V
M5(.T6=NL08F:4_3BPTG11QPJ:2,$UMJMMYN<"7U$3G\6&]O%,I"+0GE)EP2_
M8AWK:M(?2:>,RV.?XNYH$06.,#;%5QQ,6B"@2FHL%FI30HW.:4X5 AY)2CB0
MIXE#M0,NF/C>>P#].1N>*L0#><!D*@N:XV>"8!3/?7=;LQ[@Y_)MM35-/EJ(
M[.':.J^2(PQ<3,N82RG?GS>XH\O@-RI^5@C.2!G=5U(03F%\F;1B9=8D^7@7
M@,ZX7'N R1VL4_/+D9X4BR5;X52%7Y"*ZHO^6&KK1[Y1,K0THY&-=P2<Q8?X
MU?033["85'?310C"$82@*:<@!J>7ZT3 <&,&!9%ZF^_C&U/!U3>]W;ABN810
MY,$ +:*DW,WWHXT@Y.,DO=)9<G M?X#($+KZKX;2ZLM2KP2UK=+T/8K5A4$_
M,E\66:<(U-I@ /_ )6)F#^%="^'YYGQ%?EM>HN$0'PPU\-HM=02@CTPOY7\'
M+A8=2$M&NG@>!<X8Y=QM-;:+=QYR9V^HTDFM,$F\]K/QK$[;,#P<\4&E#?QE
M[2R%5MSH!-6J@:N6'$7%$K4ZL3\FA?#3(HF9F5%.HC_N 4WBN5%BG;3_%/IK
M:<'92+^_C5E7#/Y<GX7%N2S3KB(Y3N$#/O<  $@\J'<?-7!T,9[)&EVQL$(O
MY(DY#OT1J[)"=0(@SR9P]AY_BCOK\-_8ZTCQ>\"G-3*88856N5,@#FJPMFR9
M><PGJ'!I0B#W1.8)+UI\87'1=&^NU@31P]+8P$?Y\H-\1-1+ ,X/W.F2@F"0
MZ6T-4!0=TK\JB**"\FJJG1"#VXKAOY<-,B*;<U2QO9+J.<8K>.!Q7"]>]G7#
M7V,H^TUR[!/I!D-6:G31W*/3%T$E/'F#.U<Z-\PCE\/=@<2OA!AIN41"FKU7
M^<\ODW$GM?'[<G'NZ+ VTR!QQS237L<VBQ+/@X9V-&OEDXZ9:I\(4'_DXZ_X
M+QZF?<1YD:,ZYC??PR+:WV9XQ(+F8Z-Q:@*QSW;7-J32F02F.W,2?D-U&:>J
MYW0<8_G_9.'\MX.1_U@*7F#20T%JU!!0_?G4S_ROMPK5DKU",.Z*[B_59((I
MC $\NB^ZEBG:A*\*N,B]GOKMM&?TH,/#NC<X9VC>9QYFI-1'1_-_%_GP3:&'
MLRWA[??C*L4W:0C3;#&[QF+)X^Z>\Z#=;8^823%_-;G'F-P?&2EM8X6KNP8S
M2%>ZD91[ "PZYOV0A!'%ST@J^@'?B9Z (&1@&MI 0W+(4#H&Q)+!'^%Y<D2/
M?)>AZ+6 6S8*^C&4G(0#1+9/4!]0.68\S(UFKX/"7F_(I#K= #S8HQWH=,A/
M<%FYM4Z<8^(:U]; ",-8++#\J=HH<<NTT58LRE]$)4;*@/EQ7X(O39@H"5JW
M.*I4(LM'=5&B36VTIM(^/&YT5[>#[UG+S\S.Y+JTK^W5:[Y-9&"GR"GQFWL
MZ?[C/R#.]+?336-RANQ\J^@[^(\-.]RR/YB?5SJ(D(Q5*CUE&!]?M,:--VW4
MTTJQ_^_LKNI6J^^O=]W^5=/'%>D! :+I/"O.!!R.6WH P4D4(%X=K91<M8]H
M2K,N6UIQE%9/' ARH?Y4U.2CP,$?UY]/(AMK!5-#GT%QE>M2Y]723']?\"\T
M',EHQND\SMDXE0<3/*%X9[[X_6/%1\(?(!V4QZ7XU-UCF"[:,G9FH.TDHKI#
M561Y=>]O<\)<KTW Y B]_D,3]K>\P&<#?A,Q=XQ[H!>H6>G7LH-)@D*4IX-G
M&F[4EX8$ ZE&(W@VE.[T-.]_$; GRC/GE*+U!BU8HN8U9[$T]L*1C3*S==/L
M,Q>)W-F++U0%JD\;WJ*J5*EH?]G+/=7H7P>#[P$46,72 []'L<AX$E-P6EM3
MH6",WH*CU?[*E*!-[IBNM?(!PZNJ"@4IO"BX#TK7Q6HHL&8S_O$^XQ:=CH61
M$]\<2K7T;=0?8'K2$UH&&Z^/^SU]CZ&XI)V89_[E0Z5FRYA_O*![T$2W<T=J
M:%MBS8,?W)^0KJ[&H.SZ8*M9*H\LN8_U9:X%NB;:D_!\JX&1TR2]FG+SUXVZ
MA](O0O/"#P_IK7ECF,\^]6$*-TL:2Z"F_7?LTS IZS)C!T0#PF3(IURVH]F%
M_LV#Y]^[S'<]*&M8<"9>UKR9[*!SRH>&&\\5MK:T=/TN;(K;^F4(.=9)40&0
M4'4D_[5J^;=;8(PWW-CXJM6 DO&9_F8+]N^-GVJ9&BJ_GGTR2XU33OR*&_/%
MM3"8%$(+^S!UQS94L(2)8AKVRGZ+4 N=:1A5K5EY\Q8N]R+_6@\ZRFS__<CL
M^K8$^+0Y4"0R9E4K7&PIP$BSD#\(KY:0NN<6*:E4[+>C?X>JWC5#R89'B!_(
MFB"-IY%S/W=Z:"5P2#RN_4<VRT[3V&(_7K+5\X8<SBA2-N7[\"0&IJ%4!7\\
M_&DZ\&"(9Q)W$.]Q5]\@YG<[$6 ! T&[@-CW"Q; @[W/&F3ES)J%A7:?N7.1
M,L7 X$S*(2/C_E:=9!T3&Z6]$I@ 9*S2GA >P@K<U&:15;V]8[29!#8;]OXT
M^K8"<!@BOO?U?SR!KIK@/Y4!^,_A]C,1T;G_2\#P_Q9\Y,_$P-$^ Q8LMT58
MTO4CW/XV9K2C"TE:#GW25.!DD^F"F?FH^S2Y,%N[D;4B]_)W*8:E3#3N4-M5
M9)<4C&7F0CB\[2KT\*A#Q]/JMQ=_-._G7==L:!Y'GTS+,NA#JS)N%NM3W+VI
M_XQ )KTRD. LHP;L\V_+/8*IH+?6*&TI'#V<[)!@:VGSP85UOO:F4'98.LN0
MF8?%R#V T++_E0B0P2:P+4ZN^/U!K]!:$N24QO["UWVV\Y;-WUN6(YESKF,9
M4XI4& ?2E.+$E1K@W@-L:]A1N?WW #8+[)NX!4<YB*]0<<R>X4/.9C;_K56J
MC\1QY%)#G2_GOM2T78M?%_PI-7^KK:7%N[N]%:"CZ$9<!E-(>3GE2?"O*3"D
M!R:^D\G%F%#&)\)>X-\DC6OM:-\#^*9D#KMKTA6>5:ZN-M\#."?K]5TO1OFE
M@"7IJG(.3QZIDF/Q;.:'&9^@;4\&O"V/6G=G>3M3)1I;6I,/?:7,'K( CD[O
M:$X,5FG1_2_H$1.O4LCU[Z9;(LE_6T<J8)V>:19.9W17SF#O 0_V>SW%/KH<
MS(UJR5K>J9U)+YT\!B;YBFBVF32KI%&N_/LS;.ED@BQ[.YJ5.S/.D.U_YKK(
M0M0C";\ZSIB(FC\;A$WW'XV NF\=CP7@0*^2H;H9)51Q74X!?_F\G)GBV$<3
M2-C=TQXTS0G+MSQ*L9UGC5(:802#@'WE@'9W_O'^=;>7I?A'K=0F+MS^-=OM
MB-MIY<3HXG1D0$9AI*=545;A0[1RE2W/B?V:FK=LG\;4T?G8$3V8-_G6MA_>
MI@J"WTJ3O^TTL\Q$$]_!L/\!#CYL6->P9"3%GM-&XD5KJ]R-9J=#K]B\P+O$
M-2*W8E8C?LZ&@BZ7>$U,0:!01[0MEU9[$,+"ETG]M#;^Y!&G7%_,;D[*_J,9
M9,CMT>O>/W)[V0W7V!&YGXTZ6KZF)_\^A7[RRM*)+%'9/< 5O.9Z0[=T%+B8
M%9 [;BD*RO3(6*\^#XJ<X>&<$_,"Y;7%3PO<-6YQ;ES%N8+X!5=V$L6:00ZQ
M%^E& X0:G6\JW@1[Q'V#4X-KHBQ]L$RT7^GZ[TXP$J"\KEF7\S^PI6\&W']$
M?\?GL:A>TH3*'OI5Y3<2(K_/3![3S@Q7<I76NN70W>:4=A=[S-T!9CN&MUIF
M/(DCM3_8M/IGIN'>[A&*6UD20#^1_V4.I*YC6V54:P_ZTZ.; H+? RQ?"&G"
MDY31T6\RAVJAKU:)E^!*;\YHG:"_CRZMN:/#ULF+?;S.2$ TF!3PS:N%?=T>
M+U \=33N*J(_T=07S_8K#Y3A;Z[?7[^*JG(9?ZZYC)4UW0IIU]4Q4XV 5]_$
M7BR_0;^-%G!]/KS)'O_JV07S&7>#L$!LXV/;.&FB71=N[_>(MX=;7I"0._*Y
MQDXY@[9)../Q$,A@H3?_'N"K3!I7*#Z[L)>:8>.<ZOT=4<B<$O8\.->"/P1-
M/O0?\>Y^;Y,W!3OV+8-[R/BM>%Y<J1ZYX.KC/KVFV4VP8/&9CB9A#_,=1\OS
MZS J&EW/,GW=K^896M:_>G?2!5R,I_KF8HKQ[9(7CWV[(^\!=MVXT/%_9Y)?
M6'/)/0#LF+$8T93O7MLYEAX#^XQXU1J!.\%R(+UY:81*&8]ES;I"S'&&(;E;
MZ-1V=NS)3K+35UH>O!RJK>;?E!R08X;J(64/YTQ^I;*2S3PLR]A4GX$WOA1<
M6=IEC&)X^(M/24+L-8MJ538O<BU>K$P0:!^$'/;2H#P8$"YH#F=3"Y6;&CTR
M_&R$YI2.S\Q>/*^1OR W"+^T00']"&:VZI-V3H[8P-*_*NF6%CMZGEB^9'^B
M1J;__IV+WK_B+&IPA]QX*GQD?Y7M^30BD^S)S.F%7O,#]"^OJF60/D,LC@P-
MEM10F7X*C0V;SL]S=[WFO-;]\3SS&0?CST24%]5U3GVE:'9S^&X+0+P8D7N
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M0&?2YXSV^#_CXA:BBNF]TO$?5^K3Q<_I/>&CINH$EN^M"W_$<-ADG)H]9%J
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M7$!/NK10-+\LMR/J._]^H.9OY+QC>DU_%7?%32(_Z?!KY\#-=2'!%[Z>1_=
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MK\<.L;9V?M!#O__1]G;/FEZ.;XF7XMXG69ZNG)JL]*@VWB1F"UR9P4RE,/=
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MT.'\(EA))_*E;5NXQHS*TBX W;"L\$(* KHNO.$'U[A% RFNY(02/N#440G
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MOKCCE:B++TU&8H^GKQ]W7PJQ_5"HP/INC*3$- MI!F %%X!5ZD+20OWJM(E
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MH&AP#^[N6EQ2$BS!/:%("@$NYUM7SSGW6]]=]]_\>M_US#PS>^^9/?/@GQ)
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MR($3M]0:M3-F4P@&J"G-U0>( #ZTD^'EUM^1]]>)E/]3\5E#TW);6-B*[@_
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M4+@I)6M<(&B",0!CA>0?"B1BB_;\Y175F"$L^>;"\-,88ZS)\QS(39]@:V*
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ML$=N08A,%R,N?C'0%:V! C&?F;(\#)#(]#T@0>NA48I^:"G.R6)8OMX#T-L
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MLVRTV6K3HG%1Z_=SFH8)ED]68"J<7"9N3SU=>Q(39B\G!-;%>-IH@(]%S4/
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MAOBZ.E5Z+&F/_VC0M^ 8^RO-F4G48"VIF&SB?@WF"<W9IL(<KYDV3?)=9EJ
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M7<L?J)>?BPC'JGJM(]B)@I.J$H3W^H1:=]]J0H!N5QXH$L0G<2<,TCG?)G@
M=U/!M7W]O606P]_73.:HMV1MNRG7A+;7 (UW55GHEJG_7IV,Z^6RR1+,NI:C
M,.622OG-_"8@E$2=WIRF$    6KV&'_+70KA=BN+EV0J/2M08^[2ZFN\U#S,
MSC6*G)*]VQ#]9,!I+D9^NQ<+3' 0F,5^:Z&3#!>M]'G2-LE;\,7Q1]\7QGU(
M$)I32L;5Q.S^B)#]@$9]F?E]00" 2EW(HY"T_0^ *YP;YSO +K.@;+DR1O?<
M4-%(;LZ@8G^**25:A]KB\X_$JWF0BN7[8W4Z+3/C*M*KAAA<;A)8?-4PA*@'
M &+,[\#P_Z>',_W_,)(#JIUQ/&P@$H";2.R2P.UOGLT/@6^WYUBYS<BTS9:W
MM;2EC-PYO58SX*!)J]T8S>N"ZDJ00'?VWQF\%?+JF<"T+!?0D0"YW_D>*3\/
M<^]FLV1K0OT8<HNAS@D,I]11 %L-2N>=3\'1#V893VN=(+,I_6W\DNO"C-3&
MWX?)H_UGDD?!I+CI)8U@996/URMX#XH_6 T@Y$>4LEM_<C9SIKU0A9.L<X$C
MA<=]<0=7S0@X5X3&&C%YYMV<D]DP<2)__B/^76;"VF(+6)7@=L1R8#0 0TMC
M+>IQ>S8M4[4R/33+7HT. HE'J:KX\HX$6T,O.A7B[[5T-]Z#YW*_.,]2(IJQ
M/0D.8'SBRS^ %<[.!EMO2?>$3=[&@4X-&5/1J1%V8[F&3,VG86=YTZK R3R%
M*;BWRIS*@*;-H)]U?\H#T ]*U1J2+76N]TO@BP:$,+1X=<B!/\+ME^&,C"/M
MPF:.HE:F5K'M>Z5AL3TDW2<1F5BL:A>I9"Q%9!YZV#56_@[%6SD5*9$LO'N?
M&@UA0M]>[@] +T;T<HJN/Q,UV'"Z9(?%W,EF?RI5$>R0$O#AY_P3@#$ <_7>
M_N^>GO9?F-J?A7\#4$L#!!0    ( #F .U?\X\,6E+0   #1   8    :6)I
M;RTR,#(S,#8S,'@Q,&LP,C0N:G!G[+MW/)S?MR_^((@Z:G0C41,M>LDP1+0(
M(D6-DD@(@NB#883H+4A(B)(((GJ/.A@E(7J+.F9T@AD1'@RNSWG]?O=WSOE^
MS_><>^Z]?]S?/7N>]U][S[/7VF6M]7[VVJ<_3^<!IILZ^CH &3D D)W]@--I
M0 N@("?_ZSDKY\X>RO.4E.?.4=)24U.=IZ>EIZ>CI:-C8&1A8F!D9J2C8[K
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MT0C*W2&P/_(<HKT@)(\3)OZEVC]I]A]3+/0_I=E_5^S_TVL*H*<@.YL\"F8
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MKEJFYL<*YS6/DK[%/2_5.W<EZT<'Q<9MDN%Q80LKDG?TV3.8_4(?5*NY.<Z
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MG@MI0#&<]JUE K-?_MY6]@'*>G)M]Z[)^ WZ3[+EWP06F8U**4;_A7*J0]J
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MU SBR5=EDF7BDI]3N1S2@ZXXGFT*4,EH6 '.[*PN/OKAULSZ82Z%0D=DZC.
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M.WVM*/"GI.O".UE]7Z_W%'$$\0&KO3O$E78(A,1*9*R85VX1[\8=-9ON=]A
M1J8NGU/B^"2K3ZOG:[!DQTC:74@'CM(TP6/"1*>2K^F44B)2Y<M X'-)R=RJ
M4=SK/AE#O/Q4M]?FRM,5]F$G&T7"26/)^J%Z1HDY=KU!17OT64DI^U*UE)+
M&\T>%A7@#_O!NR\D'B(D[!1P/ 7B@U7'FKC1YQ4,Q3M]6Z0)>>&8&]_/)26F
MRN]\?]""S]"A6FE=LWURTHFF4Y"F('%Q3T1';/. X\O&S!N5;S T!0?)TK>9
M:4.:HR^%*+N@03&UFKH.N@P?T+]8GS \T:'57@5NNN7NV*-GV!(%>>(>1E'^
M)K7"K1-<?NN<19.1G>,C-:@7EPD[>X8<M\%0Y,TL9=8N^=V1*9_W6RM^Z8ID
M=84KT_"\5KO;Y$/_X"/=PBE0C=TD/P6JRD*]CWVA] _ VO53X$[8K3"CF@8#
M/W]A(2FN%WRHS$=(EN/BW5,@>DZ82/VRR0079(;+CO>^]C#([R/X8@%CF9*H
MKO)ZTYLZ%$'R[X8?!8)RG<%704=</B$RPAUF4>@4+%0YFFU4\=B"7^QME5T%
M@/JST0%S)\ 71#<-BY':Q*ZR^1K01;Z%-073<"$\Z+.NY-AON4@ON>YV0?I\
MR'[C;PVH]5-T#4<[E+E_T G%0A)'J1[4QV!-P[',A4Z,@Y/MGX6RWE(U^((%
M\TOEA.,UHD[2GC&37OD::U"E6GI8>4^Q*+Q)E#I\X"8HCJMK1[$BRA96VN)O
M!/?70>EVX0QK:98VC87*-72>F\_LVYAK5VXM1MKI2P5]KS^Z@(2.^=A.47<H
M'B9\N%!&.,(Q?@C,1]P3Z*&+39MK?8^+NW+S%*@T!(($C[2"QSC0YV$//R*N
MM6>1CP8+@I@[-1DFKK)=6]?NUU7';G\;5A94>]Y,"'JQ:_L"R^F=F BEES?F
M7BT?<'$JU.DL<8L0KDLR+TYJN59$K@:69:.<H!#P"+>]R7,6T\2<L!+X/Q!9
M;Z5@)FR@32.[T4P/IK^M>-]QM>]A>:ZW%C-TG&AE <K@RBB1(D2J,.\YB=%G
MVTW:16I%159.M+^?"+ZIZI5YGB/E3UW>!_A"J]&;"F5(2@2/+FA= L[UB.LK
M,!C?"\5)%#^3'-EVR]*X_TE0.<[3PZ:",-WM"V<E4>8@JFXE/'VF$"M6]C !
MY_LM9B.S6$W72+GLW2G@Q@/G0K30(/F\" ';>#_,IE%W4'-WY-8/U?"$_.);
MKB(/(.);[^=W57;5NG\-+4!8$?;Z!-MV%*?YG+.Z[#!)@6^OZHO.[6D+TI'
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M(B^-3.A4'F>K"UO8V PL)/* "5L#'6;N@6?$S$E+PB]1R%/GA]DS$<X]@&I
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MSXF:XV2 UNQ\2SV2)EF,=!=NVF9]98R[H8X,9%Z_5?I28-CI>8P[Z3Z>5!^
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M^T([B(Z3O0V-<7TN+=#=* 5JH7 NR3%%D5UXD59?(?ZL/%=(ZY+2R[B4.#+
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M*OE#%DH$@%2E TDAYXLA:;/=TM*BB( *,<R:OCG?**Y-8GDE45)3HHSNBJP
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MP]>2:P-WPEO503$UEK^'NF-ST/TBX'FSD@L99 C^S>JY^!6J\X$E80WL64X
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M/LA*>J/#=&U_HM^%\M([1TZ)?2'I _\M#^+Y_A[NSD?*,QG-]RJX9U)YN@1
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MV8J\/#HO7_= HF>$.<Q,,!IT$V+7F;SU5<U-/ YUK9-MPLM/LW@;=CP4B"4
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M*8WXZOPJ;NZKK7UZF.S[DX3115;JP*+L__<FF?^OEM ]WRF;J9-C)J29!QC
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MZ+CT+93$$L.$G/]0."T\6.$N=$)%IRXD>M,L5B8SZK-^_X.*UNO]-/()4,V
MP0OMA"R_F\C2O-""OJ*MR-<O(]8=897W179W6W0P/\G[?W-C@>_OC%E6=&:@
M2Z @C(Q; 0*=-]1A?&^/UM[W<3%O?[\:(% !>*S& XQK05ARI\6U16^^#G@0
M H9"S*>;1!>5L^KLUZ[;RK_BH!Y) ?=GM3S  :'?O.6PP>5T.&#!$X[QS,G
MDKLM&GU*%25#)QTN$-([U<3RW8HN%?&6 8787\7%-C<G<.^@G<Z'3Y4941D8
M^956''#,ZYV,O:S& 2O5PYL92%T8Z4XZ-0I<#PJ5Z/,1EUZ**]FG! 9Y/ZDT
M6I@7M--^.RW97JOKO>$A8& ODJ_"VBQO8[>TJ9GRUE.S$9PY5D:5E^$FS7*_
M:^B<<K(=C]&ZF4$TN6@WTM.?"(RB9IKG@MGA$$9C+R=>M3G4YS*ZJGN-<-#&
M16,\%N_S=ZTXT <)]?N3SMG.KA>C>$R]AI"ZHK^"X@#"O9W!-=NI,J9!RRFO
ML_(C(3^%&E1Y^,%!N9]4R186!$(&VK^9OU.8U>,[TF2U1%Y,EH50-!KT\F T
M6]P[",2P%]G5X@!&NK8>/F19*DUH-7O C1J]K*X%AX^2GU['Z,]0W&T76V$!
M_D 6<Q%XX)X"*X8M^C<[HT6QY&R+,(8=I'TZ]["S/'=^/QOVCF]:OYA9-L$G
M-A=NZ5_@JK>5LDT2J<-!A?)R/X^O6 X62'.0K['4)DVD+Y/ MU+633B?"?/4
M?%01/FI26_0+7OVH5W6H_ PU6,TM[LO[^:-<9,B<?/'$35_Z$P72Y7?&-!Z7
MUACFFNJDQ^C83(W?.6$CFW3SOZR:YET0L4MQ575X,A$2D@DN+9 66;#_'2H/
M>&\&G0RHKUPI,>, ,)XDO(<?*JA0V%4[CE6'7]N2]2'7]9^V86>>%378=LS7
M0.T].$U"R^6;*CG2=+C0["E&I68G*?2L%,I/EDY9*A:8*GDXBIF;:4<*&:B\
M+0M^>4^AE22(O,YW3'CO^4K 5GE_0Z(5>-Q"H,._X)X0'DP5Y^(!E1"?HD'N
MPS1B[<\$+V0-"@M'TAX2,^C]4Q@D_E GN'VCK6U1\-^>!6T;7 UCBO+J6MU3
MX[4!RYP5^!A,MI[F7OYE]KDNX696!,"/E[LT&J9*(^^Y?,,;Q\KUI'RK%"F\
M"C*:->:V^0Y,.6_4&NC5:L0UI$0W&(5]?#2^WL+_WD\!Q8V.OWGF_>ZI1Y!9
M39<^'T3 PNE8!H'-#++\/*ZC5UD[]MK9R7G%I/15=':2U&5)\/,@M+'RW4--
MB_1U@UBQ4;=$)'76 C5&.YTN;;H)4K"?JI26^B:DH;G,G\2+KZ+;X:3W7'^H
MJX6^<=C#A6@[0'+X1=-PKHEXM*F6"N=AT!<SSX.6T-47DXS;EL!5MA_C,@T%
M8M:A1?B/^Y[> ZHQNFW=,EZ#CX)):SJZJJ5.D6U/71 JPF>C 4,;DT-C@R'>
MHJ[55^[G')7*KB!D4P [GF>=+<$QK/AYVJF' RC:EQ:N:"S9\!RS!(0Q]($;
MEV)B]VVAU?F8O@,Y7\'V%D[L- X@#[AE:8J8\PZ]M'(,%B/XKGJZ&/G-;X^%
M,R!XO1Z$]BYO$SW?*<<!B^E05-D7&W1]F=U(@F54[[,B6D\WJ,_Q%>,1+QS#
MH+FX&V_EN/=JX)[.5]<<#6:%4);58T801MYXB1ES@N>X2!U1]#CLU8KDJ=CE
MEY;:4#R<C#P 9V2U/,>'I@@,%PY(3\$!6+)5/#H;1L7N+2%7VDQ50T]X8HW'
M2ZN+K;T(JJJ?WL^TJH-)3%)]4I'9>F;8NLS/*U U:YPB]T,WR=I0M^W=T6ZU
M[?"8<0\>V2@A,5&QU-XYL7HN+CB@NP!_E4]H0FP(' _4%A7@>$17YFSD3W-1
MGXJ_;^(M*SL:@JMPM _->\BF&4H'2SB# U#;Q[$?836D[=!P5L.!Z8DE9$?-
MX;F._3);F).-_$NQZ%6QHS%6(UL)OP2QMG:$T7>>QJG37L%@_)0[0LY@\2Y2
MXJ\U3X,5B$5#(53P31AR"$NUB*?WA1PNX\4X@/ORZZR6F%G'H5HKM[)0?S=
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M? /MBQZ6D<,.#!6X<4 MR"0*!\11TV!;C#"%],/*C/-^7_24&8#_HA ,_*\
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MM_VYA-_E2B.0U['A^FA5D[&2)H\L[RXLE!2Z,SGA*4LWDT$*??Q4V4E$_8A
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MU E.;U<E5J?U*NXI6*AHDYBHZO,3EF?5EU_'J".[8YU/&J$TCDF^S5WAOHB
M;/:2U.C2MJO-C.'07/>O>,7_S'OG.. TZ:J8Y^K+2?.U'5/DG>8R;]:+NY J
M>=6LS@TJD8>_^!/OD4SH:WL1'J+2/Q,<$S-N9)#"[41#X1S'>H7>])VFL# N
M0RJA&^HURY2G24SM^98K6Y:A_UCKNC79,73.%\"'S]@V0]@(AQ68C<ZY%(P
M!TQ)0([OE/4MVV(2X/3XJAB>02I+N,)_YF-2X>]QP"YKQ@6],2$.\(,NP5+
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M)=#^RN8/(ES.E\^N/3@8%.SFA:*5L4+<5W.03J9Y,U^**89$B''8#QQ08]5
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M(#H"_7H$W:.R]T*YNH^A0U!!2PL?A<5/11J<0\7/2NL;*D5V*PE&/T ?!O2
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M1_J==_&"#VGLLS^3F-98^)WX$-O2^O)>E@Z,? .&L(.N;H4<DJG)RV1_]P1
M]8SP50K@>RY*S2^#* -KAY_P;E-#",LB!9 XD05!UDE$>^O'!4#_$-6*\=%M
M$VM?--/34[I]BW_"#Q-L--Y'__8^^+SZ'G6K8%:5=!5:.AVY,$--4K<>R<DG
MN\CN/C)H:10:0TS*(+Z-]Y'<U!XZ^#-]<F$<:PXW%U)+D>7ETOP.2M.W35KM
MJ49O=>37&V(T/SY/NQ9B C8C0'$V\SB+NJNP=_-.LG8)RH[*-@3_Z6PGGHE!
M>!6P=YX#O]_1.%"'52>T![!)0EB=<?R/TZV@,N99D*493:_4HT?[FP]@6=[Z
M?\!HLRB/(.#G-6QWL0XH=@F)54[%??_ R^$$@70KU&9<:&,W2E$PL\=HX!SQ
M82A@8@AP#!$$]$!-YXB<X!:ML3,!"PVI79@?6DG\YQ1Z[IZ? U@_-4.NS]=
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MN6OD&\UU[:"JP3!%,51\!<NJ?C76)&9L1SJ9U.)!-S^Y\SQXR^A6Y%0 S_.
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MIN5Y_K\6+BEY9FZ%2)#'<[FQG&U =@B863I+5\>T+I(_97R#>6ZZ(.ER@9\
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MPENY\,]^=O%=QS)6Y*:%]/$F?'6O#QSW;. XA[ZXSW+_S)G%W'=GIH9L+R\
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MK:, W/QA*U!G$GQ@&IX!<CJ6A/6.-];W4HG!()A]>_'GUB)0S=%)OGECIC2
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M)Y4(M!BNSII5GYLP&GM<;@^Y':KURMYFCY875]IWP'8&ZT0%+_$AP''D<\9
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M\\Q<UWW-W',_-J2+N+>$NS @5!G+IY<.=CZ2NS"I;/)G\]!3.Z_@"4E+,LN
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MP>E)S:HTF,K7"%SPPM,Q[P:&IT,66A%ZC7*=AWRO[@D^C;L?+Q,=0OWACSM
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MY?O<F@G7K,1HL9M,W/<I,L#%!?+*:T-R?8NI9*GUWE<N9<%SYV@YC)\K1[>
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MQCN52VMHT+]$2I8/?%D&?"UD,4U+Q%UB/X6CG: U3%]6.2C\4@M*!M0+[?Y
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M(J:BY-BP^S'! 5_T)?NC:.:T0[1^(O[!=N*EO5V_H]%]_#S6!MYW&X6)1%%
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MEZ?%&N%(Z/N"7SQ6@SH-RX/>6JAAN#HOPV-Y<X.$'Z'$Y -B6HPTOR5+*3Q
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MP)D0$0OL2.)UI*70@>Y"C<FO'S[L3#L2,DF;%O0\<20"13[8B?4[/!&F\42
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MJVW<:F:&4[=-TSXV/+LU=GWSPV<IO, KP>5%EM ^$+.J%E(W%_>@;@K+%'.
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MA?&_5KR]A=^ELFK2B%Y)T:2:W<=6NG)QGW&KS3J4DL(+D]-:GS,Q_-6VIO3
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MF4WX):#QL_H-L?45Q;M,G<\()NU\=E!OQ3.RYHP+;@-*C"1K.!_%B;$W@G2
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MB+30*3=(NZUL.+Y+JT-0N!NQ&CP?B:O?_95K^-,WN/6D7I^J[H4FQ/FGI]S
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M_[6LC,YG]\+W=MYQA*_6&7K[G$=/OZ*(GL!+!3U7G?!K,E'>X&HK0E(+73%
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M^)T30_/'O'>F3V(]IISI)F$7#.@U*=)  VDX%%GH;]P@DST49Z!]1#LOQVG
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M,88[7425-*Z(%R/&4/L)_:]L"=:],7%? +.^I9FQ+16KTIE<D6<L=LL#S-U
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MY@QM;E O 1K$V8=WF8_08=UZK&T<#0.ZW71!7-?F?\Q4P%*;S4MGU7+$$"Z
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M)OS>\%[-\PW#:A0WBV"[<XHM_P\<HR1#!!8_EHQ?[U!RXXVT_;J6-/9 B-?
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M)./AY)0.P('X!D"<$+DQO-5@[':NB%KD)UNJM!LG;MSR-NX=</@SA/&<=!6
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MD"+J?!A.91;#JZXOY&[TS+-!#%Y-KZ=J74$_.<M:$<OKDQEK=GLN(,Z$R.E
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M^7OGI"]?V5N/MD[JZ.54YIMM?FG"?HH=:@&BZ&4V2>)]R-PLL#$%:&CPA;'
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M?'FD:<E_E&<1@Q^994>NR-,O_(842Q6-!9S=PB%[ C5T41^$I8$X=8C>\M3
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M:%$\>E48=8&BCVJI^;2+F+^N*CM-MY2O.Y! $D4Z;?T3ZO!0KC&=.IF["VG
M<1'A@*<.^0W=J>$]_&@@K'037OG5'CR\SBK5.]1-L;(P/B7%H2YI+ND\ZU;<
MIQC0G+LETU"ACI':7>?() \7OZI[^??UAUP2_J_@] LJ)\;3_>:'...LY%I0
M$08$#0C7]=6B7.13A/SJ"846J$H']^'G4_+UN>JJH[\1\]NOR<KS-Y$<:S-7
M!SQ[O1>.RRKM/@R3#N^_I_V3?[E:>( Q+/ F):X2=9)\'<#B_!JT[#T@,6Y;
MV[*Y,0(\LG>:2X2YDL34"]X1H&2N7=,1#6ZR5/E0H&%6\\(V:$JQ4#DUXV-U
MJOW>O?;4&X\_B-P0GD,YDZ[//BII&+GR_'Q35>K1+VFHBW#^T!VAK:0'+VNQ
M NM&T[[A^A5#.2/+(X6XX:?]*7[B*R7?V-FMTEE%5.D4F10H0.)QGL2V@H4!
MM_EGY;BT'@R7)25# A\;5K37N?=G34E5M$ORO+ RS[)%^(8\8:%]3(1EH.$1
M(?GN:* LCNWVS#*T/%;7]T]-C(10X#+_Q3=1QW8Y_$G&\^#WBF!V@,MDS)-?
M88H$G-]U61C9;O]<&![EEOZ&\X7__'=G,+^:&,Y%=&:Y74,*3WSM7G;A1;)J
MX:4X_17^\\^>?/!KQIY_]DK#CB"Y<0Z]'GP6:,_6F2]2NJSF,<\2]&Q2N^I#
MI$G43FS_3^CW^49P"[+\5 %N-K8NMXW)J_Y&X;::K!MNOUS72K=,.^U>Z/N.
MX=6Q*BJ$.EA%E]TR#>?8WWOAZGL-VI57$0X:E05%1:EMVA:VHF$7W7](78N_
M41R.B^WP;7#X!C0=F$?T:%7BM_*NH!0G&DZ=,KEK>]F;F>?^%N4[PR)'S&SY
M!IP!\P1R!N"P^@CDVHSL+]<.INE6OUCW49C*G'NC/;WC#QN%ET&;^35 @:?Q
MXZ&W0[[+'%\W^A2;:IFBX<2DKM>%Q5GGAFO( 7P=G.)UX*@*MJ?*<9EFI2.X
M3WP,%[7'U%[WJ=_(G)VG=SPW19(+.X> (]>ZLMZ29FY[7LMP=U/^ZS(=QMP<
MD%]_.VIBV0AX3[H=> 4(=RF8G)CPO?73H2Q)PNF*\K(0OS![XWJ?!.5#TX45
MC\#'&'QRS)Z+F#&AJI0WBW%* 57YX[QIZU1?O-V9WYV,,:-[Z/"F2[Z0]G)G
M=\<,J4$O/\^?E%H9K]/?E&K6EUQLR_G5@Z18()$SIT:\!C,G?7MNU8ZQ0AQY
MSZR]:%A2<PC^,3$5X[%Z"RP&&!!Y@30\#3375([#</@>M! G^^H+E7+SG:I%
MP(\J]#*EJS=668X;W<0WH.X]M*03C^H^A7$N^<V>-2,V:4P$@B^N5*I_DI=V
M]KE8DO%N2ZE=8I0GN+NI'9_<YL;L2]I$XJ-]DW4)C+]F>VJH/4T1RUUN6TT=
M-Z%CY; %6.O!N)N"T4(L^SF;G[RUI=31D+ZW[#G#WK!SNT.O-.P'D(_/Z;31
MK255PI+\@)#MOQT=Z*/@PZ=:G.AXH;K<MS:R)VKA!6/QK;F%F5S@ @D<J(-W
MBZDPV.8'8G'$K[A- 6^L2R9P94RH?OX4YY^4K)_/56YHI8^7^N82/PYX0B*K
M9D!530/+(\453E[\=C5CHI$'ZZ@KIVQT9ZY.K,>\0'P;U)!ZM IG4T!S^Y(>
MX@]"!>?/.\1YO5LLA8GC;&M<OM) S*#ME4+9F]@,P5&R2L;Y,L*I9)^O&L?7
M7MAT$'L37K]G<%F[M3Z6#P3,(T/(UH4SJX+@"$]K6],R&B@V38CM]N5OX90]
M,_%@A6/#@_^[M=VB\M6BMK-W)B973!:*3[=[-+'BM=/FY$ZN!O,-OQUR\O?*
MG[Q]!?73.XHU$,L@B=)?3?T:O*^;T-6@3-)P:N)J+(O!TON_B'!)2FX%OM59
M7P%@ZN_:^9(X?X+ U=FIPO\#I(6C@>CB'/][_U,U02["?L#S4#P-BI^N0Y$-
M-B;*6T(UQ3(7-V-T[&RNJO#O?_L>_5 7I@(-QS IR(52?8CR-LII]DZ/9YT_
MZ9'JD?(]6 ;43!4T6!5F\S=(IO-[T7\A':?Z;6>8(F<1I_C]6WWW&8O\D.&5
M%16#9*>%%&R7EUJD"W7D#(.P+PWD=Y"Z&BRY[K$JPET3TTE7 OT//(<W?JPO
M=7N' ,>AN$<P&^'JVM% @3D6S7KH*]G?<^MIB,#'RJ0=%W*OST.]VSL35 /8
MD7"ET,NRU<-&SE4(4\,-R= F\ H1QE*UGTFZ.Z:CX?FV\_"(5PQ?W!2?U'"C
M=R0A[7?&QZ=9/#P#ES(CWKR)N/2/F%ZL;OQ.\"D-X<8JHQ1FWMB)<+%#6+SU
M]%;U<.75:W]4=M43F\S K]&>:-$QS[>E8U[6EW_P[C[S1?X.SL*[+=_B'2K\
M&_M^-7=X\*)8_ZM/=D=H< ]/R;=7,O^(VEB@[5? F?'QV+._&RCWW@_[=]4%
M&X<L,GRG@<8K,$?'_CZ+/5HFO_("'Q&3::!;BB^ ./K?$AS$"6T)XI)J%-^
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MX_D$%%.J?Y*FRJ8_17,7B]$>KNJ.&?Z8(WSZX;KR%0I4/@OLWZ/__K\X_LO
MILCTS/(Z8QR\B9=([/E]DH_5AL6%]S49%QVF8DA 7D</0>K/I=QC]4FYX[N0
M S0T%M"K#*1=TDC)F@4GWY3F>ACSN&.07&R.B-K-=C(,9V]XLT),![E!W0^C
M@ _?];8EEC22P =LOPNAL%+(RC+X& ?I#BDRI>@?$R!.@3!8J6UJN'TTT;>
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M+BK[5/-<[*C=I>M;S&EJNQ"60?/&8+E]5B%L<C;'\5TYL@D:390BPR"E[I@
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M*?*,Y%7O1/7V3W%YF>U-<>QN<(=^XX[3)ZSMXS]9&Q2R>/LL"=CB*):Z!IL
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MF3TBU 0QKY( >L_Y"%G3K78'OXR^*>-;HOG.??4)%;W<@*LU*"AS?Q?2J<R
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M%.LY+>6#G><@[OO_U.S.E\F_]Z :ZV?V!6=91DS/M'N)DAH;::[%'UB$YY*
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M[)1' X9OS/-6=END?-05[F72M5?<AZ'<;!?RWX,H+31XJHVUH<,&TGKU#%0
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MZ&+T<[DQWKBGXD(K'B3WC,//QSV*:(\S*:^:\&T:C_S99B$BH/O%\7+!: G
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MB#]F6Y@H/%X,,R$6(RWLB<K--UD2G7]H>QJ%ESZ8Q(GKK%^0^7$2 .^)$?O
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M20!,;R\)ADB?V-SHXRIG,'"J']W?39Y_T7;V43)0/ZR6;PS\+6 05@&.D"(
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MTBN,:^_(<O3%AED6Z%TF=3X1MY^H3_^9P/@'M[>_]'-L\V].'D3<+MR<+A8
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M \O:S$E2SX4'\<\U5B O+WS?\M.HQ#[F$K: 5[Y[[6?Z9.IJC>L:!7:/ ,B
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M&,,0)*XV@X;CW*J; 3@)U$*DE33V"UAC(GMTW:YJV.,#48A\_WCP\H,VME=
M*?5";HCEN.R38ZJ>C."-:>T7" 0"QPD2W.F[E:/UN?"5>*-)G]6%#\PZ;@EV
M?1KGA;F[)*RP*Z:'?OEE#"L0P\2Z5U(ZMAC8=R@</,M!NP,YMFAGB\TNPH U
MFL=WKB<56DZKBHY'R(MK_:#,6]1D+(DT/ZC@Z,.J)]4[BGI:Z<6W(YD8^Y)U
MNG;@]__*#R<-Q*1"5K;89(B\NF'JA__GES#T"O"+FXS@SO3ND1(3DFXU('O%
M9:5JLUEA9,$$57*D3S6K%F1?N^[#V7<>>3#3\-'!XXN!,N\KBIZ+"#60VLQ]
MSDL>1;3C?\1PYO\U3OAQ% P1\-,,&1.U2EX'J/K-S6 Z!%KAL6YKDMVB!AWU
MJ$F+@340^*:>HGH\-4SH?#RK35<#FS4S]'_7?['E_]GTGV'[?N>MX.L./R U
M,8G%C/Q>& L*#F->O$AP+6.1L8\A\YVK:DJ;0]S6S2ZU/6MP<^4_Y9!9HCW?
M5_AF2;/8'[ER>=FQ^LY55RZ:I3E?\8UV]P3V8H7_3;F\V*F^]S^#8<@JEWEA
MB< >W$(K&?8?3_X<_Q'LW_[V_,>3/_L_K Y-TG,KD#/_*/0C^-"M:2O<GC<I
M/U5X]4E.T'UG$FNA>)WTO,,'[TE^T+*TFK?=H.N;Z^LFG^U%=='M3^.V/_)O
MNV:GEJL3$W-'1RQ\XCV)\+R;,RU#<_H:'GQ\&7R[@NW2_6.%/SK7J<UZ)&VV
MI4W2(,CVC.2=PKG'&6JUUTG,*FB;_?[SRW_I-BM.!7VZ_>?<I'L<;Q/Z)":X
MBV0)"KHQK9!@J!-5%0F?4-ZJ*"EAJYFQ@$?7_D"=]*72E:7=^OPORV9M6="^
MK^F<R<S-U_78_+++NK26:GI'6G>J;./26+0D.:4WM7=B6V@CB]RC/5'_&3PS
MQ(,OSE;R3K<+M+]K;R3X9_6MU^S!'UJ7K5S=Z_ADFJ7->LVI'(=YG@@?#W20
MX9M8^>TWA_HQR>D\MA(%[L^C-&-%VP^_EF;;<=/VL,HF2:9)!DN^,G?ML%',
ML'^ZYCXP6W,Q/ L")M9=@@^C _\SZ*J" OGZX;#34'8 F]*5EU&/'1KJ9>:#
M5%=<5)0_]I]A*4/:\JP-4TLR#?D?UU^:9_+B^$=3!O ,KTWDBG_*_@*,=RXP
M'0\*#G6ZO (E>0&+8[V[>HK;\]5[=U?_RHU_&A4:[;<IUNYJ0M@=<9NWW/<O
M%#J(92#=^)D,ZA'YA9L<%K!]-5DP<I7:ZW#>';9G36YIPI+2K"WGYBW_<=;@
M94=][ZHK$\W2O(%)2=W#&>@#Z2_+YHJ!;DB5_[(JN--FS2%@X7W=H42B_\_6
M^DLS:FPY_S-,6_\K=-5$<66+\\*OO]T3_?!OZ9I[Q=F)>=^--%X=='/J+[,(
M?.=:N>:6WN(E-3J7_AA=$OGHWJU7=[98J_;)O)>SHD_:OYT3E__WP]8W=GH_
M,K,?O>;VUGROUG7)^G7USD>A07IBZO>4\EUU!.9_+[RWS)Y_[?UCM]([ENZ>
MEKP\ZCSKWM4K;FSR.KDOY^O=K6;\:?E1;Y9W+O<#:OU[VO]X\;R2=/6GV^_O
MO/CR5HU4V/S<U&RIP]FY0H=%LB\*.G"Q7V#T^E6[9I));[ZP=6FRA,H_B]4B
MX1/+J^>^]NU:N^S6I@FZCX+< Z6>U$W]-+^K1O[1_M8ZFRU[VWZY[=LY^^1E
M&X_DOW=?ICTZ'1 J\7S1Z7Z?_PR;OVY5#+CK5OTYKHU?6D=YVIR3[^9__<_
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M_TA]SUE_P?W(_!]6\_]D?(NP__GK/\,'^7\W;*<)_ZO;_P=HXC;;:OOX4SU
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MOT!?A]'$'G 4G;8:2J'SS <+Y S]GBFV*T-DX0CF#"YTU@<.@T]8?L] :TN
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M(D'^++!OI6]H.I28REQ9<'KDM^4A1^!=P>T@PZ.Q'ITAUGU5ZSQW?]8'"!;
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MGO[0[LIX>\,'9T&7U5^46CVZ1GR<?O:\/$H5B%]\'E@9S_*T[!Y+MU]7)<]
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M8L]T+ES=LRHOLSZ:^DIQQ(>N],LUQ/W,=8*;;&Y)0/9@3XFR;1.=F;5&WHG
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M-=RHJ-T#X)V*/&EHW7_CB&CD#0J(&\2Z]F.YT3X?R_XM*?V(-O]'-$[M 11
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M69RBM,5W^D[S2Z_N9RS/J8+?98'.R<:E$RL[N0KYQ-F4E68(_<.4&3UP/[_
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MU7;_D.S@2$Q>\TOLK;XX)1QFM'8,(CX9N/[:=+33C82D/JZN@6W4O%^S(U@
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M-3;:78M;4WCG1])<L^V?HUB-8*  6*$X55?\:B0'2]H/Y[^(%F0;D:P'K*.
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MNLEKZ6CC57T?0(=$ KBNQF3./O<5?!<@H'3\9'BY.X+$]1*"2_F)4V=MUUY
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M> FZ(RS%_+1G-4YPB#<C[1(RH(L<DF0)[IDCO4X+3GL6-;4IG_IU&Y+C)C
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M\$52CX1B%WJ'1U)0R71GDJC\QI?CCK<928,*H4['='=UL?N.'E%(-6ZUA77
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M4?BM1[P?= \*AU7UZ+E\<%ID[DAE'O72IYVJ$OQ>]2 /&>I@_K#ID3P%4<+
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MTA/^='0W@ZRQ+CDOG7RV%4QI[Z6"X&A+9?&3F<U>KWJCJYQ[40H65,J-*)C
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M_>)1V]*O#C<Z/#7<]MI<:470-(J"%QHWBH7<"I5G6*:^%3BR&<($,CDG/L9
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MCVHOL7'71ZI[+N<K3$*MPFPCGKPVK'ZI\=31YS)]L]"HFQ&*8[&??%9A>*_
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MDZG!5*,=L]U:3CKC50^V)ROHCU5>/RP@>OXN/.<[:XN/- ?"-=#9QB1X0IH
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MVN$#N<[!<D0#WNO7P^WED[5CU2R+T#V\=K2+D;?!B3YR\YDL*M;#ZG;_W O
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M22KHN+GQ-FWD_H^>/?S3Q/7U"&K]RE@$^:A^V;"=D*?PR$H9I+2;L13\,4*
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M-C[WG#R:60COW^1)&)<4*?I?[7UG5%3;LNXB2\XYB2 @3<Y*!DDBDB6#DH.
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M#PDG1^?K?[A^\"W [J<K+0JAI++*C ,>Z_RJ>A!2N>?P7R+__K<^_S104B?
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M%VB I4V5%NKF*LI(%RCC5I5/K.5+#'<N;5_>JB_'UWFMW T55LKX<;%1+9"
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MB"JM=(29(WA-C?'9KEZD<11N$HNZ2RMM]PJ#LC62?PL-G9C :PF*6D6!E=%
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MSLP$ 2P/]'-4J&+)A>I;>0@ W\JY^?N)0D#WWL["@M+>Y'K.S22_R*\B-[J
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MHJ/.K5H#T0(0*(%00**96L.*-\G$+87F5;_?Y]:[:>2I.$&Q2RGW0E/Q+6D
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M_"(-#ZC+&I;\]1(RD]1WP5*Y3Z#<OS'IO>^A>P1Z\D IL&H(5]#ZY4SV@HY
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MC&F,..)BS[F+E[(VM%..,^+#;K,)U19RR]-,&<)]T[SG,$OJ6OTB=717I:#
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M>#OK--P-N34KX9\#3'-L.DYXC$);43Q1?&BN7^O%N&<I?DQX(R?DSHDOUY%
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M.TA*9/O/'!2K\ME-GX5G(O.4&?_Y@#*I/*>O -P!KV_!_8[&!UK7[UA)2+H
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MY%,$8R_@E#H,7>=O+\>EF.]LU-53+A>@[QZ_"0RPEMO.VK#%@2 73B8<L$+
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MV&#YO1KHI9O3D8V+&:)USNU7BQ\ZFDEM?B?^_58;#?.--UH2HE=E1O]J_CY
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MA+#. 3HAL[S=2P&C'N+%R[\)O0#1N,!8BUL>:A9,3)J&?;@=@[(*5%P]+SY
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M>5:,-XE7&QK..F5[ ;HN \%IC7<2KL78*=^L@GY:Y;4)D.(38'6-N:G7JY[
M_1W,]\G'_#N=>C%>&3M7;HD>H-(4#%6\Y\TS4&(S_KZIO=;D]8]R,Q.!)WS1
MTPD&DIVFT(S9?4DD#*/;"J/&D1,\9R4E7M>[J18[P&!*D[6^;,&O]HT;Z_:(
MII1(T[M(SL!XP2#=06=J^@WJ@@Z/*#.97+A3<(DHY1Z]:%1;F:*/P_PDKV2X
MQG/+'$]OT/7/ <0Q(';-'"0-;A^;CM/J'G*>[KLBM$.W<K=W]I6[5^*RQFA
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MJ]%<GX!7YNK,#AN.N0!KFC(S6&8__&O87]^)-FPP,'02=F("E<8"$9J8FU@
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MF\-FY@4J'RR_)[R!3TUNFQ)K6_7Z__JGAO]%!0^[^#\ 4$L#!!0    ( #F
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M,D:A/>*Q VVYB\U5[Z_^8D:O+NI^)V<+EC,R*A-2,P"9K(!N#-F$U'% )U?
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M.\#8!6I$LFHS1W)SN[6=?Q$=!*$^'L6E$P&^HV;P[J+@5@&("OXU-Y,(H%Y
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MO5JB[6^!E]"O@9>_HMY^&1FP2X35#K4297&^Z_/]%X^UY"SH+S\S\/Q:PXX
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MPPMJ%4D,SZ&H"/&-8*3<_5[/]EO;?%+07).BBM<8YKW(T=]02P,$%     @
M.8 [5^9Y"C%N"0  "5$  !@   !I8FEO+3(P,C,P-C,P>&5X,S%D,BYH=&WM
M7&U3VSH6_BM:.O<69I(X+X5"H,Q0"'/9;4N'IK-[/\JV'&N1+5])3LC^^CU'
MLA,': DMY";4?  L'1T=R=*C1X]E'_VCV1RD,4T#%I(_AA\_D% &><)20P+%
MJ('4"3<Q&<HLHRGYR)3B0I#WBH<C1LA!J_.FU6X=[#6;QT?@ZK0H(],^.?"Z
M;[UNN]LC[=U^=Z_?V2.?/Y+MK\/3'6M]=GDZ_//SP-7Z^>O[#Q>G9*OI>?_N
MG7K>V?#,98#[#ADJFFINN$RI\+S!IRVR%1N3]3UO,IFT)KV65"-O>.7%)A%O
M/"&E9JW0A%O'1Y@"OQD-CX\29B@)8JHT,^^VO@[/F_M@8;@1[/C(*_\Z6U^&
MT^.CD(^)-E/!WFTE5(UXVC0RZ_?:F3F$DAYDW[*Y:4YX:.)^I]W^[3"C8<C3
M45.PR$!*J[<[3U-\%,\3I6M<7S%!#1\S]%[Q&PA&5=^7)CZ\7<5]);.R7"13
MTXQHPL6T_WK($Z;))S8A5S*AZ>N&2X&_FBD>O3ZTUIK_CX%K:*!A-Z9)!1^!
M<PSVT/5 OVB\OU#)A-GV^%*$D#FXB;G/#>EU6MTCSX>>RIXJJL4@,'/!K37<
M@\PQUQ""X&;:CWD8LA3,?W^UWVWW#H\\-'W*H"I=%<#,8>H1?74ZN!I>G%^<
MG@PO+C_!-+CZ\O7DTY ,+VW'?:_DD:^.'S3Z,CBUCGOM+KD\?QJ?PS\&Y,O)
MU?N33X,OS<O_?!C\24Y.A^">=-OMI[[AE;[];ZX-CZ:+G7O1(.=,\(R1LQQ0
MHD$"IM"*F)B:_OJ./)S>MEGOMA ?$(BH+UCITY<J9*H92"%HIEF__*<:%=86
MNSN#L!! #HR^1=C!<!<Q!U,J"((5J[+6PEO'M=&$9?H8^S2@HK@1 (*%BU[K
M[6_5GBFJ*GNI@F$5UQ+<14).ROXIKYL31;.^#TO(=7,"[7\0%V?YU-=2Y(8=
M(CS?;: #ZN*W"5]XRV"H:%BKWVUUMQYLY4&WM;N_B>WTC,*!^Q2W\AG@X?=7
MG;WVH9WG3S3>GB'(3FLAP"<=-BO"?A+3,2.*C3F; .LT,=?D)$US*L@5RZ0R
M0$3)N50)Z;2;_R(R(OP]EPURD08M$DD%)1B)N(8VDBEP+,+2$/S\,T\9K)@-
M@NRU<AN+07=K0O1:O:?"RU]U*-X3Y 8.Q]NMJ#'J.7JYN_&P]9YJNT4FR91<
MIW(B&.RE&PZ]E(.M4$*-J81-.+BF/"4TG9(\-2I'A@A;;+M#!SRC)($KQ0'
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MEA@*J,ZI8S(HIMQ7+:XH%FXMDKK%8,&THGS;3<M-T: L5QD@N;;B3Q!(%=H
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M%MO#TLOK.G=T\5EH- ^YD4K/I!2; "Z3A!O#V'<V'KZDRK+[D$-\ULDVK![
M\S7N(^ O*O3EDL?^RCF$;Y>W/ WLD9F=^HGINLR]^HEI_<1T38;B9CXQ/1&"
MH/K- =GQ4 @>- DX R@N!)C9D\L)H]>HJ#CUV6HJ5C>WI\/+XX2/ OCB(:,[
MIG,/<:<A%-1LQMN_N1@4:CL4 427"M8B*^MHW2 Z3Z"]T!VV,<5^Z=Z#EYO+
MZ3=UQM2233U87O@CS9-T2B(%Y+0!8,<LGP:XM*^P%+C:<,(&3\=2C!FJ&RD=
M%6_BJ(*"LR03<LH@=Q)+Q[OI FH#RCZ)]--:X3OV/\=E//MB>_GV[NI>QN_@
MF\J_U-OX>^U-?)5[*5@[.'BI3=O=T+8]9CO]_8'Y#)!P!I#=)U_P;$7B X!V
MW[J7N1^YF'[_SJSHK:5I_W%1NP%50)8OC9%)O]/:S0 B\6 B>=6V/W][PSSM
M+7RZY<>4FE4,K6=@Q^LQMGXD\(?P:C61WQDXJZGV-.8L(N<S.G;I9-;U';KU
M.%UA_VY_=D?W8&#<&2)6U)CGG\S/^Q4&.W\K;5Z6U5=80#PCJCX-KD<*VA,B
M19:J7RXQE0_7+6843*8+@0B>LF9Q72Y*"Y_,*Y(6OIA7I,V^QI?!1JSI6 ^-
M8 ?5IV/)PW+K?M#JS19$E]2VE,9]Y,]^-?#X_U!+ P04    "  Y@#M7R^:2
MT-\%  !=(@  &    &EB:6\M,C R,S V,S!X97@S,F0Q+FAT;>U:>U/;.!#_
M*GMTVL),_$H@$"=E)H0PY:X0AIBYNS]E6XYUE26?K!!RG_Y6MA,2>CV@ Q1*
MF9"'M-J75[N_M=7[Q;*&(B4BHC%\#$X^02RC:4:%ADA1HG%TQG0*@<QS(N"$
M*L4XAP/%X@D%Z-C>MNW:G;9E[?>0U:!>(X4/':>YZS3=9@O<';_9]EMM.#N!
MS8M@L%52'XX&P9]GPTKJV<7!I^,!;%B.\WMKX#B'P6$U@>P]"!01!=-,"L(=
M9WBZ 1NIUKGO.+/9S)ZU;*DF3G#NI#KCVPZ7LJ!VK..-_9X9P7=*XOU>1C6!
M*"6JH/K#QD5P9.TAA6::T_V>L_BL:$,9S_=[,;N$0L\Y_;"1$35APM(R]UMN
MKKNXTL'I&S17UHS%.O4]UWW;S4D<,S&Q.$TTCMBMG>LQQ2;I]:"LC/,5Y42S
M2VJXK_"-."7*#Z5.NS=%_-?*?+$ND4);"<D8G_OO Y;1 D[I#,YE1L3[1C6"
MGP55+'G?+:D+]@]%UFB@IE?:(IQ-D+E1MEMYP*^-#]>$S&AI3RAYC)/#JY2%
M3$.K:7L])T1/Y0^EU;H29G+!]I(5*)0S/?=3%L=4(,&[-WM-M]7M.8;P(=58
M<4Z$>X6J>WAG,#P/CH^.!_W@>'2*@7\^ONB?!A",2E?]W\I>J/9O)?+VX,(>
MVP,;WKWQVKM=K[7C-AZ&=7\,_</163 \?'BUQ\.!\8?1V>UVW#:,CB#X.(1Q
M__R@?SH<6Z,_/@W_A/X@,#--UVW^\)'UU[30+)FO:W8L())"T,AL^RHWZY1"
M7X@IX7!.<ZDTR 38 9,-.!:1#9N&8" S3.#S+4S-<"15!IYK_0:)5.7RA!41
M+I]CG@$J8LS@OTX%A9;;@#*#DP))^*(8F!5C&DT5YAXTCH@8AE>86,6DE).Q
MHC#*X<M0QE@1(*6*HE:E*L9W3;=;Z5K^\+I;J&L#3HC23&!UH6BA:L @931!
MWBC+)#<8)0F+J"HE5G/CB.'^8SB\G$0Q*P8W ,>,&QN03U4Q)7A=M83K73*N
M75GN$V,HB65N:M@J>4UT'9VUD#%1(1&TL$97G,ZA'Y6^-]'9P'E2KLWF\%G(
M&7IO0OT?+V"_KL8*H8>S=]3*U+TR_C]LF,)I*C0).5TP#:6*J;(BR3G)"^HO
MOJRJU49I:95=3+W$_:(Q2-;KL=%WO1B;D972:@2KA=2:FU<9J>.EITULX<ZI
M=RRB@YK%MMW9>[OJFUJ6^0ZNO6?>J_\;M7Y%DD3N"9>SA;L6OZV9(KD?(M3Z
M;,W0';?BA^4\"0O)IYIV#8SYTMX*T-3O.KZ3H4V[TWD5AG::B$1?OJ6.5B:P
M'R&('R&=5/FV3 N/$X^/H+-GWTO?>X;5TX", $M;#262*>=SA!Q9SDVM7]9_
M1?^>,D5-IUB8FK=6(;W6)D&DH<#;V8RWEL7R&C(LX4)=,;U.:[MKROJU[UY4
MH'ZE[K7O7O9>3'P_G:G/<FL\D/DO*KI?8AIN_B!IF GLT3)2MB@&R!(FL#=A
M56NUR-&$*4S2N:*%2<<-,TTX!UR&<K&OPXD<\W/1J)L]041DQI%A7,*(LJ-"
MJBFOLKG,J2IE%C?:*?M&"#LE.%\@C.?94;R2=NM5]5<[[LN'XJ_$S/N4NOO8
M^PC[:4QS3;.0*FCN5G>^[E5$C/;U_@FEUC+S/=LHC/YB,;QQR[_O:9]3.#?N
ML7T;(GGZRW1;J?P&B/+\C/AY:6XUXNG4_I9[SY6IL/;Q\S)^U\NX>:88@MT<
MT>X7UW+K)YA]W@^[^E#@G#E/@! 2NQ9>=2.L@)EB&D$G:H$]3GE<H;XA%4,X
M7S[3N=.3&DA) 2%%9KF2E\P\_-)R]?F9V?$S<^HAQ-YIJ@0KTHKFKL_!%#!L
MJU#5)(%ICB-&5UKHNIE: 4SI$A&')/H\47(J8H/%I?(7\&'E,,#Z1 WZFN@Y
MCDVB5?]> (ZU8PCUT-HIA)LG''(RH58%$$F"C:1/+B6+ZZV]V[%;2[!3#;DE
M^JL.3I0G,?;_!5!+ P04    "  Y@#M7@^<@U=4%  !*'P  &    &EB:6\M
M,C R,S V,S!X97@S,F0R+FAT;>U9;5/;.!#^*WMT>H69^"TI+W'2S(00IMRU
MA"%F[OI1MN585]GRR3(A]^MOY9>0T.L1&-H&IDRP$VDE/;M:/;N2^K\8QCB-
M21K0$-Y['S] *((BH:F"0%*BL'3.5 R>R#*2PD<J)>,<CB4+9Q2@:SIO3=OL
M'AC&H(]=C>HV(G6A:[4/K;;=[H"][[8/W,XA7'R$W2MOM%=*GTQ&WJ>+<37J
MQ=7QA[,1[!B6]4=G9%DGWDE5@=T[X$F2YDPQD1)N6>/S'=B)E<I<RYK/Y^:\
M8PHYL[Q+*U8)?VMQ(7)JABK<&?1U"3XI"0?]A"H"04QD3M6[G2OOU#A""<44
MIX.^U;PK65^$BT$_9->0JP6G[W82(F<L-93(W(Z=J1ZVM+#ZCLR-,6>ABEW'
MME_W,A*&+)T9G$8*2\S._FV99+/XME!4RKF2<J+8-=6]K_0;<$JDZPL5]^X.
M\5\MLZ9=)%)E1"1A?.&^\5A"<SBG<[@4"4G?M*H2?.=4LNA-KY3.V3\4NT8%
M%;U1!N%LAIUKL+W* FZMO+\VR)R6^OB"AU@YOHF9SQ1TVF:[;_EHJ>RI4*V#
MT)5-M]<LQT$Y4PLW9F%(4Q3X]=51V^[T^I86?$H8*\8)<*U0^0#KC,:7WMGI
MV6CHG4W.T?$OIU?#<P^\26FJ_VO9]^7@7B'G"*[,J3DR83H>E4,XG7V[]32=
M#Z<P/)E<>..3IP?>P.W:!S Y!>_]&*;#R^/A^7AJ3/[\,/X$PY&G:]JV_?+=
MZJ\B5RQ:K",[2R$0:4H#O>8K8E8QA6&:%H3#)<V$5" B8,=,M. L#4S8U0(C
MD2![+_:0E^%4R 0<V_@=(B'+YA'+ VR^0)(!FH9(W[\5*86.W8*2ODF.(KR)
M!+K%E :%1.)!Y4@:PO@&636=E>,D+,\U./QHR1## <144D150M&V:]N]"FOY
MP^GM(=86G%+.,@HG!9)]"^6< [LWBAF-X)2E&* 88IQ$$0NHU#JNZ-4"+-/6
M:D%6R+P@.'U*P,I*J"U6K@2M#PE%IN/4JG@M5 VLG; >9$JD3U*:&Y,;3A<P
M#$H3:R=L83TIVR8+^)R*.1II1MV7YY=?A[$BZ&#MAJAT;"O=_-V.#HXZ"A.?
MTZ937\B02B,0G),LIV[S9176 8X65_RA8R(N"X5$O!YS-=[U@*M+5L*G'AB9
M285+JVH_PL50+T*,]K7XOMD]?+UJA[I?_1UL\T@_J_^GB\!K5J_<LK2>I<*-
M,'=,>_^'8G;,!^'MZD3R>P.^CW(]9(":6*."\P42<))QS7Q+-I3T[X))JI/F
M7%/#&I$XG5V"O"O!V=\-]Y:<<DN@2_*LB<7I=M[V-*W>VLXJG?29..IC6.K9
M>/2W5&XKW?_1"C\KGWV.Y-I^(>3*4LQ#$U+F9SJ*$Y9B8L:J]+%A7L(D4F\F
M::Y)MJ6K">> S7!<S NQ(D/6S5MU0MODB]AA6&Z0RSP5I0I><;3(J"S'S._D
MDN8=%[;*S*39[&]G.K4E1+>=QMFJ7+,9M>[-J93<A"+MS=?NRLG1RC@"^XZX
MF#?&:GX;<TDRUY>4?#;F:(Q[3Z.6]<3/!2\4[>E#L2^UK59,_=R0I5Z"F@^*
M? _0]QLLKRG%77#BXX:Z?5AM]A\44S3Z>OWX0BF1N(ZI :.]6 BO[/+O1^IG
MY=;:L<(CTY/O/DGWQ<U'Y"O;I\3/B;E'B>\'^VO';)4ZZZ^?4_5-IVH-X^Z%
M9#@C&4[)EY.C,]K;^F$0B")5B*<1V/N9R6X5JOL<<@@YUNG+4\P?<;9YM3-A
M.<PE4YAQ(@K<[Y1WL_614PC^8GFXO=&1-<0D!Y]B9YD4UTP?]BNQ>E^@O6JN
MKWA]W$<5,F5Y7,EL>NXO@>$6"Z%&$109EFBL-%?UQFHE6XJ7Z;!/@L\SB?X;
MZD1<2+?)'59N/M<KZHROC9;CN&$TZM]-MK%VYUH7K5VYWKW.S<B,&E5V2"+<
M5+KD6K"P7O>'7;.SS'2J(KM,_:I;XO+:>? O4$L! A0#%     @ .8 [5[D:
M#>6\*   [O ! !$              ( !     &EB:6\M,C R,S V,S N>'-D
M4$L! A0#%     @ .8 [5ZE<YC?P'   <=L! !4              ( !ZR@
M &EB:6\M,C R,S V,S!?8V%L+GAM;%!+ 0(4 Q0    ( #F .U?#)B.K!5T
M "0 !@ 5              "  0Y&  !I8FEO+3(P,C,P-C,P7V1E9BYX;6Q0
M2P$"% ,4    "  Y@#M7)@@<)4/=   MPPP %0              @ %&HP
M:6)I;RTR,#(S,#8S,%]L86(N>&UL4$L! A0#%     @ .8 [5SXA[F;EH
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M,RYJ<&=02P$"% ,4    "  Y@#M7NK$9",'[  "N"@$ &
M@ $.5@H :6)I;RTR,#(S,#8S,'@Q,&LP,#0N:G!G4$L! A0#%     @ .8 [
M5T[$RZ:PFP  5-@  !@              ( !!5(+ &EB:6\M,C R,S V,S!X
M,3!K,# U+FIP9U!+ 0(4 Q0    ( #F .U=X,TCL#S$! *!+ 0 8
M      "  >OM"P!I8FEO+3(P,C,P-C,P>#$P:S P-BYJ<&=02P$"% ,4
M"  Y@#M74?HED!<_ 0!W30$ &               @ $P'PT :6)I;RTR,#(S
M,#8S,'@Q,&LP,#<N:G!G4$L! A0#%     @ .8 [5\JU;=C2'P$ CC@! !@
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M,BYJ<&=02P$"% ,4    "  Y@#M7(TZ)=:>9   RMP  &
M@ & MQ( :6)I;RTR,#(S,#8S,'@Q,&LP,3,N:G!G4$L! A0#%     @ .8 [
M5YG%Y0%%#@$ 2"<! !@              ( !75$3 &EB:6\M,C R,S V,S!X
M,3!K,#$T+FIP9U!+ 0(4 Q0    ( #F .U<YB4WO'PT! ,<Q 0 8
M      "  =A?% !I8FEO+3(P,C,P-C,P>#$P:S Q-2YJ<&=02P$"% ,4
M"  Y@#M7XS7$^^FY  !3S0  &               @ $M;14 :6)I;RTR,#(S
M,#8S,'@Q,&LP,38N:G!G4$L! A0#%     @ .8 [5\Q\;1?UN0  T\\  !@
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M,2YJ<&=02P$"% ,4    "  Y@#M7M?>7PLA. 0!\@P$ &
M@ %U3QH :6)I;RTR,#(S,#8S,'@Q,&LP,C(N:G!G4$L! A0#%     @ .8 [
M5TA2>J*S(0$ MR\! !@              ( !<YX; &EB:6\M,C R,S V,S!X
M,3!K,#(S+FIP9U!+ 0(4 Q0    ( #F .U?\X\,6E+0   #1   8
M      "  5S ' !I8FEO+3(P,C,P-C,P>#$P:S R-"YJ<&=02P$"% ,4
M"  Y@#M7$]./'5_T  ";(0$ &               @ $F=1T :6)I;RTR,#(S
M,#8S,'@Q,&LP,C4N:G!G4$L! A0#%     @ .8 [5X5 ?F[,#@$ RS@! !@
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M,2YH=&U02P$"% ,4    "  Y@#M7FAPO_Y@%  #K&0  &
M@ %IM2$ :6)I;RTR,#(S,#8S,'AE>#(S9#$N:'1M4$L! A0#%     @ .8 [
M5^9Y"C%N"0  "5$  !@              ( !-[LA &EB:6\M,C R,S V,S!X
M97@S,60R+FAT;5!+ 0(4 Q0    ( #F .U?+YI+0WP4  %TB   8
M      "  =O$(0!I8FEO+3(P,C,P-C,P>&5X,S)D,2YH=&U02P$"% ,4
M"  Y@#M7@^<@U=4%  !*'P  &               @ 'PRB$ :6)I;RTR,#(S
E,#8S,'AE>#,R9#(N:'1M4$L%!@     H "@ V@H  /O0(0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
